amlodipine has been researched along with Hypertension in 2089 studies
Amlodipine: A long-acting dihydropyridine calcium channel blocker. It is effective in the treatment of ANGINA PECTORIS and HYPERTENSION.
amlodipine : A fully substituted dialkyl 1,4-dihydropyridine-3,5-dicarboxylate derivative, which is used for the treatment of hypertension, chronic stable angina and confirmed or suspected vasospastic angina.
Hypertension: Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is currently defined as when SYSTOLIC PRESSURE is consistently greater than 140 mm Hg or when DIASTOLIC PRESSURE is consistently 90 mm Hg or more.
| Excerpt | Relevance | Reference |
|---|---|---|
| "2 years) with uncontrolled essential hypertension were randomly assigned to receive olmesartan, an angiotensin II type 1 receptor blocker (ARB) (N = 23), or amlodipine, a calcium channel blocker (CCB) (N = 22), for 6 months." | 9.69 | Effects of olmesartan and amlodipine on blood pressure, endothelial function, and vascular inflammation. ( Abe, T; Bekki, M; Fukumoto, Y; Honda, A; Igata, S; Kurata, S; Maeda-Ogata, S; Matsui, T; Nishino, Y; Sugiyama, Y; Tahara, A; Tahara, N; Yamagishi, SI, 2023) |
| " However, there are few studies on the regulation and efficacy of atorvastatin combined with amlodipine on Th17/Treg balance in hypertension combined with carotid atherosclerosis." | 9.69 | Effects of amlodipine combined with atorvastatin on Th17/Treg imbalance and vascular microcirculation in hypertensive patients with atherosclerosis: A double-blind, single-center randomized controlled trial. ( Qiu, Y; Yang, G, 2023) |
| "Allisartan isoproxil is a selective nonpeptide angiotensin II (AT1) receptor blocker developed by China, this study aimed to assess its clinical efficacy for essential hypertension (EH)." | 9.69 | Efficacy of Allisartan Isoproxil in the Treatment of Mild-to-Moderate Essential Hypertension. ( Chen, Y; Lu, X; Sun, N; Wang, H; Wang, L; Xi, Y; Yang, F, 2023) |
| "We aimed to determine the efficacy and tolerability of a fixed-dose SPC consisting of 5 mg amlodipine, 100 mg losartan, 20 mg rosuvastatin, and 10 mg ezetimibe (A/L/R/E) in patients with concomitant hypertension and dyslipidemia." | 9.69 | A Randomized, Multicenter, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of a Quadruple Combination of Amlodipine, Losartan, Rosuvastatin, and Ezetimibe in Patients with Concomitant Essential Hypertension and Dyslipidemia. ( Ahn, Y; Chae, IH; Hong, SJ; Hong, TJ; Kang, DH; Kim, BK; Kim, H; Kim, HS; Kim, MC; Kim, MH; Kim, SH; Kim, SY; Kim, W; Rhee, MY, 2023) |
| "Hyperhomocysteinemia with hypertension can synergistically increase the risk of stroke." | 9.69 | Combined use of amlodipine and folic acid are significantly more efficacious than amlodipine alone in lowering plasma homocysteine and blood pressure among hypertensive patients with hyperhomocysteinemia and intolerance to ACEI: A multicenter, randomized, ( Bao, H; Chen, G; Cheng, X; Cheng, Z; Cui, Y; Ding, C; Hu, L; Huang, X; Huo, Y; Li, P; Qin, X; Sheng, C; Song, D; Tang, G; Wang, J; Wang, X; Wang, Z; Yao, C; Zhang, J, 2023) |
| "To compare the effects of chlortalidone plus amiloride and amlodipine on blood pressure (BP) variability in patients with hypertension and obstructive sleep apnea syndrome (OSA)." | 9.69 | Effects of chlorthalidone plus amiloride compared with amlodipine on short-term blood pressure variability in individuals with hypertension and obstructive sleep apnea: a randomized controlled trial. ( Borges, RB; Cichelero, FT; Fuchs, FD; Fuchs, SC; Hirakata, VN; Jorge, JA; Lucca, MB; Martinez, D, 2023) |
| "The aim of the study was to evaluate the efficacy and safety of fixed-dose combination (FDC) of metoprolol, telmisartan, and chlorthalidone in patients with essential hypertension and stable coronary artery disease (CAD) who showed inadequate response to dual therapy." | 9.51 | Fixed-dose Combination of Metoprolol, Telmisartan, and Chlorthalidone for Essential Hypertension in Adults with Stable Coronary Artery Disease: Phase III Study. ( Agrawal, S; Anand, J; Bachani, D; Doshi, M; Gaikwad, VB; Halder, SK; Kinholkar, B; Kumar, DA; Kumbhar, A; Mathur, R; Mehta, S; Sarkar, G; Sharma, A, 2022) |
| "Hypertension and hyperhomocysteinemia (HHcy) have long been associated with adverse cardiovascular and cerebrovascular health outcomes." | 9.51 | Effects of individualized administration of folic acid on prothrombotic state and vascular endothelial function with H-type hypertension: A double-blinded, randomized clinical cohort study. ( He, H; Hou, A; Luo, M; Ran, S; Song, D; Tang, J; Tang, Y; Wang, H; Wang, T; Yan, X; Yang, R; Yu, B; Zhang, S, 2022) |
| "This study was to study the efficacy of rosuvastatin, amlodipine, and aspirin in the treatment of hypertension with coronary heart disease and its effect on platelet aggregation." | 9.51 | The Efficacy of Rosuvastatin, Amlodipine, and Aspirin in the Treatment of Hypertension with Coronary Heart Disease and Its Effect on Platelet Aggregation. ( Fu, J; Li, B; Wang, T; Zhao, N, 2022) |
| "This was a pragmatic comparative effectiveness study carried out at 110 centers across China in outpatients with primary hypertension treated with levoamlodipine maleate or amlodipine besylate, with 24 months of follow-up." | 9.41 | Effectiveness of Levoamlodipine Maleate for Hypertension Compared with Amlodipine Besylate: a Pragmatic Comparative Effectiveness Study. ( Chen, P; Cui, L; Cui, W; Dang, A; Dong, Y; Du, X; Duan, C; Gao, P; Hua, Q; Huo, Y; Jiang, Y; Li, J; Ma, W; Qi, X; Qu, P; Sun, N; Sun, Y; Wu, G; Xie, J; Zhao, L, 2021) |
| "This multicenter, randomized, double-blind, parallel-group phase III clinical trial aimed to investigate the efficacy and safety of a rosuvastatin + amlodipine combination compared with that of rosuvastatin or amlodipine monotherapy in hypertensive patients with dyslipidemia." | 9.34 | A randomized, double-blind clinical trial to evaluate the efficacy and safety of a fixed-dose combination of amlodipine/rosuvastatin in patients with dyslipidemia and hypertension. ( Ahn, JC; Ahn, YK; Chang, K; Cho, EJ; Cho, KI; Kang, DH; Kim, M; Kim, SJ; Kim, SY; Kim, U; Kim, W; Kim, YJ; Lee, CH; Lee, SH; Park, CG; Shin, JH; Yu, CW, 2020) |
| "Background Amlodipine is a widely used antihypertensive agent for the treatment of paediatric hypertension, but the commercially available tablets are not suitable to treat young patients, who need lower, flexible dosages and a liquid formulation." | 9.34 | Use of amlodipine oral solution for the treatment of hypertension in children. ( Cransberg, K; de Winter, BCM; Hanff, LM; Schreuder, MF; van der Vossen, AC; van Rooij-Kouwenhoven, RWG; Vulto, AG, 2020) |
| "In this prospective open-label study, 92 patients with essential hypertension were randomized to treatment with a TFC of perindopril/indapamide/amlodipine at different doses or a triple free combination therapy (FCT) including ACEI/diuretic/CCB." | 9.30 | Long-term effect of the perindopril/indapamide/amlodipine single-pill combination on left ventricular hypertrophy in outpatient hypertensive subjects. ( Lenti, S; Mazza, A; Rigatelli, G; Rossetti, C; Rubello, D; Schiavon, L; Torin, G; Townsend, DM, 2019) |
| "Fixed-dose combination therapy with telmisartan, amlodipine, and rosuvastatin is needed in patients with hypertension and dyslipidemia for better adherence and cost-effectiveness than free-equivalent combination therapies." | 9.30 | Efficacy and Safety of Triple Therapy With Telmisartan, Amlodipine, and Rosuvastatin in Patients With Dyslipidemia and Hypertension: The Jeil Telmisartan, Amlodipine, and Rosuvastatin Randomized Clinical Trial. ( Ahn, Y; Chang, K; Cho, JM; Hong, SJ; Hyon, MS; Jeong, HS; Kang, WC; Kim, HS; Lee, JH; Pyun, WB, 2019) |
| "To study the effect and molecular mechanisms of amlodipine besylate combined with acupoint application of traditional Chinese medicine nursing on the treatment methods of renal failure and hypertension." | 9.30 | Effect of amlodipine besylate combined with acupoint application of traditional Chinese medicine nursing on the treatment of renal failure and hypertension by the PI3K/AKT pathway. ( Chi, R; Feng, L; Liang, W; Lv, S; Su, J; Zhu, Q, 2019) |
| "This randomized trial evaluated the blood pressure (BP)-lowering efficacy of four incremental doses of perindopril/amlodipine SPC in adults with mild-to-severe hypertension." | 9.30 | Efficacy and Safety of Incremental Dosing of a New Single-Pill Formulation of Perindopril and Amlodipine in the Management of Hypertension. ( Dolan, E; Gupta, AK; O'Brien, E; Poulter, NR; Sever, PS; Whitehouse, A, 2019) |
| "In a multicenter, randomized trial, we investigated whether the long half-time dihydropyridine calcium channel blocker amlodipine was more efficacious than the gastrointestinal therapeutic system (GITS) formulation of nifedipine in lowering ambulatory blood pressure (BP) in sustained hypertension (clinic systolic/diastolic BP 140-179/90-109 mm Hg and 24-hour systolic/diastolic BP ≥ 130/80 mm Hg)." | 9.30 | A randomized controlled trial on the blood pressure-lowering effect of amlodipine and nifedipine-GITS in sustained hypertension. ( Dou, Y; Huang, QF; Li, Y; Sheng, CS; Wang, JG; Zheng, MS; Zhu, ZM, 2019) |
| "Type 2 diabetic subjects with hypertension 30 to 80 years of age who were not taking antihypertensive drugs were randomized into either valsartan (n = 33) or amlodipine (n = 35) groups and treated for 24 weeks." | 9.24 | Effects of valsartan and amlodipine on oxidative stress in type 2 diabetic patients with hypertension: a randomized, multicenter study. ( Ahn, YB; Choi, SH; Han, SJ; Jang, HC; Kim, DJ; Kim, HJ; Kim, HY; Kim, NH; Kim, SH; Kim, TH; Kim, YH; Ko, SH; Lee, KW; Lim, S; Seo, JA; Shin, DH, 2017) |
| "Aliskiren penetrates adipose and skeletal muscle in hypertensive patients with abdominal obesity and reduces renin-angiotensin-aldosterone system activity." | 9.24 | Systemic and tissue-specific effects of aliskiren on the RAAS and carbohydrate/lipid metabolism in obese patients with hypertension. ( Boschmann, M; Dahlke, M; Danser, AHJ; Dole, WP; Engeli, S; Jordan, J; May, M; Nussberger, J; Pal, P; Prescott, MF; Stitah, S, 2017) |
| "To examine the antihypertensive efficacy and safety of indapamide sustained-release (SR)/amlodipine compared with enalapril/amlodipine in patients 65 years and older with uncontrolled blood pressure (BP) on monotherapy, a post hoc analysis of the NESTOR trial (Natrilix SR vs Enalapril in Hypertensive Type 2 Diabetics With Microalbuminuria) was conducted." | 9.24 | Blood pressure-lowering efficacy of indapamide SR/amlodipine combination in older patients with hypertension: A post hoc analysis of the NESTOR trial (Natrilix SR vs Enalapril in Hypertensive Type 2 Diabetics With Microalbuminuria). ( Boully, C; Caillard, L; Chaussade, E; Hanon, O; Hernandorena, I, 2017) |
| "The goal of this study was to compare the efficacy and safety of fixed-dose combinations of amlodipine/losartan potassium/chlorthalidone (A/L/C) and A/L in Korean patients with stage 2 hypertension inadequately controlled by A/L." | 9.24 | Comparison of Fixed-dose Combinations of Amlodipine/Losartan Potassium/Chlorthalidone and Amlodipine/Losartan Potassium in Patients With Stage 2 Hypertension Inadequately Controlled With Amlodipine/Losartan Potassium: A Randomized, Double-blind, Multicent ( Chae, JK; Chae, SC; Chang, KY; Cho, JR; Choi, JH; Choi, YJ; Chun, KJ; Han, KR; Han, SH; Heo, JH; Hong, BK; Hong, SJ; Jeong, HS; Jeong, MH; Jung, J; Kang, HJ; Kang, SM; Kim, CH; Kim, DW; Kim, JJ; Kim, KS; Kim, SH; Kim, WS; Kim, YD; Kwan, J; Lee, BK; Lee, SK; Lee, SU; Park, CG; Park, SH; Shin, DG; Shin, JH; Won, KH, 2017) |
| "A single-blind randomized clinical study was used; fifty patients newly diagnosed with mild to moderate hypertension (aged 33 to 60 years) were recruited and divided into two groups: amlodipine or hydrochlorothiazide each comprising of 25 subjects." | 9.24 | Monotherapy with amlodipine or hydrochlorothiazide in patients with mild to moderate hypertension: Comparison of their efficacy and effects on electrolytes. ( Agu, PU; Aneke, EI; Azubike, NC; Eze, AA; Nwachukwu, DC; Nwachukwu, NZ; Obika, LF; Okoye, OI, 2017) |
| "The objective of this study is to evaluate the efficacy and safety of sacubitril/valsartan (LCZ696, an angiotensin receptor and neprilysin inhibitor) add-on to amlodipine compared with amlodipine monotherapy in Asian patients with systolic hypertension uncontrolled with amlodipine." | 9.24 | Efficacy and safety of sacubitril/valsartan (LCZ696) add-on to amlodipine in Asian patients with systolic hypertension uncontrolled with amlodipine monotherapy. ( Hafeez, K; Jia, Y; Sibulo, A; Wang, JG; Yukisada, K; Zhang, J, 2017) |
| "Chlorthalidone is a very effective antihypertensive drug, but it has not been studied prospectively in kidney transplant recipients with hypertension." | 9.24 | Chlorthalidone Versus Amlodipine for Hypertension in Kidney Transplant Recipients Treated With Tacrolimus: A Randomized Crossover Trial. ( Hesselink, DA; Hoorn, EJ; Moes, AD; van den Meiracker, AH; Zietse, R, 2017) |
| "The single-pill combination (SPC) of perindopril (PER)/indapamide (IND)/amlodipine (AML) is a valuable and convenient treatment option for patients with hypertension controlled with two-drug SPC of PER/IND + AML given as two separate pills at the same dose level." | 9.22 | Perindopril/Indapamide/Amlodipine in Hypertension: A Profile of Its Use. ( Syed, YY, 2022) |
| "There is a lack of sufficient evidence regarding efficacy and safety of amlodipine on treating hypertension during pregnancy." | 9.22 | Nifedipine or amlodipine? The choice for hypertension during pregnancy: a systematic review and meta-analysis. ( Du, P; Mei, Z; Qin, S; Shi, S; Yin, J, 2022) |
| "This narrative review evaluates recent evidence from four studies which explore the efficacy, safety, and adherence of FDC bisoprolol and amlodipine in patients with hypertension: one observational study; two randomized clinical trials (RCTs); and one indirect comparison analysis." | 9.22 | A growing evidence base for the fixed-dose combination of bisoprolol and amlodipine to manage hypertension. ( Gaciong, Z; Hostalek-Gottwald, U, 2022) |
| "The aim of this study was to compare the efficacy and safety of telmisartan plus amlodipine with telmisartan plus hydrochlorothiazide for the treatment of uncontrolled hypertension." | 9.22 | Comparison of telmisartan/amlodipine and telmisartan/hydrochlorothiazide in the treatment of Japanese patients with uncontrolled hypertension: the TAT-Kobe study. ( Hirata, K; Ishida, T; Kondo, K; Mori, K; Toh, R; Yasuda, T, 2016) |
| "Long-term therapy with a combination of perindopril and amlodipine has shown a beneficial effect on the morbidity and mortality of patients with stable coronary artery disease (SCAD) and hypertension." | 9.22 | Short-Term Cardioprotective Effects of the Original Perindopril/Amlodipine Fixed-Dose Combination in Patients with Stable Coronary Artery Disease: Results of the PAPA-CAD Study. ( Dézsi, CA; Forster, T, 2016) |
| "The goal of this study was to evaluate whether the blood pressure-lowering efficacy of fimasartan/amlodipine combination therapy was superior to that of fimasartan monotherapy after 8 weeks of treatment in patients with hypertension who had failed to respond adequately to fimasartan monotherapy." | 9.22 | A Randomized, Double-blind, Multicenter, Phase III Study to Evaluate the Efficacy and Safety of Fimasartan/Amlodipine Combined Therapy Versus Fimasartan Monotherapy in Patients With Essential Hypertension Unresponsive to Fimasartan Monotherapy. ( Cha, KS; Chae, SC; Chun, KJ; Ihm, SH; Il Kim, D; Jeong, JO; Joo, SJ; Kim, CH; Kim, DS; Kim, JJ; Kim, KH; Kim, KI; Kim, MH; Kim, YJ; Nam, CW; Park, S; Park, SM; Rhee, MY; Seo, HS; Shin, ES; Shin, J; Shin, MS; Sung, KC; Yoo, BS; Youn, HJ, 2016) |
| "In hypertensive patients not controlled on prior BB and ACEI/ARB therapy, addition of (S)-amlodipine besylate at half the dose of conventional amlodipine provides better tolerability with reduced incidence of peripheral edema, and equal antihypertensive efficacy compared to amlodipine given at usual doses." | 9.22 | Leg edema with (S)-amlodipine vs conventional amlodipine given in triple therapy for hypertension: a randomized double blind controlled clinical trial. ( Ekanayaka, RA; Galappatthy, GK; Galappatthy, P; Sabeer, MI; Waniganayake, YC; Wijethunga, TJ, 2016) |
| "Japanese patients with uncontrolled essential hypertension received single-blind losartan 50 mg/hydrochlorothiazide 12." | 9.20 | Efficacy and safety of fixed-dose losartan/hydrochlorothiazide/amlodipine combination versus losartan/hydrochlorothiazide combination in Japanese patients with essential hypertension. ( Azuma, K; Fujita, KP; Nishida, C; Numaguchi, H; Rakugi, H; Shimada, K; Shirakawa, M; Tsuchihashi, T; Yamaguchi, H, 2015) |
| "An international double-blind, parallel-group, randomized controlled trial was performed to determine the efficacy and safety of a new first-line strategy in mild to moderate hypertension based on a single-pill combination of perindopril/amlodipine versus a validated stepped-care strategy (initiation with valsartan monotherapy, up-titrating to valsartan/amlodipine after 2 months)." | 9.20 | Comparison of single-pill strategies first line in hypertension: perindopril/amlodipine versus valsartan/amlodipine. ( Amodeo, C; Asmar, R; Chazova, IE; Gamba, MA; Mancia, G; Mourad, JJ; Puig, JG; Taddei, S, 2015) |
| "The aim of this study was to compare the efficacy and safety of lercanidipine and amlodipine in the treatment of hypertensive patients with acute cerebral ischemic stroke." | 9.20 | Effects of lercanidipine versus amlodipine in hypertensive patients with cerebral ischemic stroke. ( Cao, TS; Huynh, VM; Tran, VH, 2015) |
| "Hypertensive diabetic patients with microalbuminuria were included in this retrospective, post-hoc analysis of the Natrilix SR Versus Enalapril Study in Hypertensive Type 2 Diabetics With MicrOalbuminuRia (NESTOR) trial if they were uncontrolled on monotherapy (indapamide slow release (SR) 1." | 9.20 | Treatment of Hypertensive Patients With Diabetes and Microalbuminuria With Combination Indapamide SR/Amlodipine: Retrospective Analysis of NESTOR. ( Boully, C; Caillard, L; Chaussade, E; Cochiello, S; Hanon, O; Labourée, F, 2015) |
| "5)/amlodipine 5 mg (A5) versus co-administration of L50 plus A5 (L50+A5) in Japanese subjects with uncontrolled essential hypertension." | 9.20 | Add-on effect of hydrochlorothiazide 12.5 mg in Japanese subjects with essential hypertension uncontrolled with losartan 50 mg and amlodipine 5 mg. ( Azuma, K; Fujita, KP; Nishida, C; Numaguchi, H; Rakugi, H; Shimada, K; Shirakawa, M; Tsuchihashi, T; Yamaguchi, H, 2015) |
| "This paper aims to research the clinical effect and security of using amlodipine and enalapril together to cure hypertension of aged people." | 9.20 | Curative effect of amlodipine combined with enalapril in curing hypertension of the aged. ( Jian, L; Li, L; Li, X; Niu, S; Zhang, L, 2015) |
| "The objective of this study was to evaluate the efficacy and safety of a fimasartan/amlodipine combination in patients with hypertension and to determine the optimal composition for a future single-pill combination formulation." | 9.20 | A Randomized, Multicenter, Double-blind, Placebo-controlled, 3 × 3 Factorial Design, Phase II Study to Evaluate the Efficacy and Safety of the Combination of Fimasartan/Amlodipine in Patients With Essential Hypertension. ( Ahn, T; Ahn, Y; Bae Park, J; Cho, EJ; Choi, DJ; Chull Chae, S; Chun, KJ; Han, KR; Hyon, MS; Jeon, ES; Jeong, JO; Joo, SJ; Kim, DI; Kim, DS; Kim, JJ; Kim, KS; Kim, YJ; Kwan, J; Lee, HY; Oh, SK; Park, JS; Rhee, MY; Seog Seo, H; Shin, JH; Sung, KC; Yoo, BS; Youn, HJ, 2015) |
| "gov identifier: NCT00923091) to measure changes in the health-related quality of life (HRQoL) of 2,690 patients aged ≥18 with moderate-to-severe hypertension who received one of six doses of olmesartan/amlodipine/hydrochlorothiazide (OLM/AML/HCTZ), using the MINICHAL and EQ-5D instruments." | 9.20 | Health-related quality of life impact of a triple combination of olmesartan medoxomil, amlodipine besylate and hydrochlorotiazide in subjects with hypertension. ( Brazier, JE; Guest, JF; Haag, U; Marques da Silva, P; Soro, M, 2015) |
| "Twenty-four patients with essential hypertension received amlodipine and S(-)-amlodipine for 6 weeks in a randomized, crossover study." | 9.19 | The effects of amlodipine and S(-)-amlodipine on vascular endothelial function in patients with hypertension. ( Ding, M; He, Y; Li, B; Ni, L; Si, D; Yang, C; Yang, P, 2014) |
| " The aim of this study was to evaluate the effects of a fixed-dose olmesartan/amlodipine combination on blood pressure control, lipid profile, insulin sensitivity, and inflammation compared to singles monotherapies." | 9.19 | Results from a 12 months, randomized, clinical trial comparing an olmesartan/amlodipine single pill combination to olmesartan and amlodipine monotherapies on blood pressure and inflammation. ( Carbone, A; Cicero, AF; D'Angelo, A; Derosa, G; Fogari, E; Maffioli, P; Querci, F, 2014) |
| "Amlodipine, not aliskiren, effectively reduces BP in CKD patients with refractory hypertension undergoing HD." | 9.19 | Effect of aliskiren in chronic kidney disease patients with refractory hypertension undergoing hemodialysis: a randomized controlled multicenter study. ( Hara, Y; Hosoya, T; Kuriyama, S; Sugano, N; Yokoo, T; Yokoyama, K, 2014) |
| "The objective of this study was to investigate the efficacy of the fixed-dose combination olmesartan/amlodipine 40/10 mg in patients with moderate essential hypertension not controlled on candesartan 32 mg." | 9.19 | Daytime systolic ambulatory blood pressure with a two-step switch from candesartan to olmesartan monotherapy and the fixed-dose combination of olmesartan/amlodipine in patients with uncontrolled essential hypertension (SEVICONTROL-2). ( Bramlage, P; Fimmers, R; Gansz, A; Lüders, S; Nadal, J; Schmieder, RE; Schrader, J; Sturm, CD; Zemmrich, C, 2014) |
| "To assess the efficacy and safety of once daily olmesartan medoxomil (OM)/amlodipine besylate (AM)/hydrochlorothiazide (HCTZ) 40/10/25 mg in patients with hypertension not at goal with mono, dual or triple drug therapy." | 9.19 | Efficacy and safety of olmesartan/amlodipine/hydrochlorothiazide in patients with hypertension not at goal with mono, dual or triple drug therapy: results of the CHAMPiOn study. ( Punzi, HA, 2014) |
| "Evaluate efficacy/safety of olmesartan medoxomil (OM)/amlodipine (AML)/ hydrochlorothiazide (HCTZ) in Hispanic/Latino adults with hypertension." | 9.19 | Triple-combination treatment with olmesartan medoxomil/amlodipine/ hydrochlorothiazide in Hispanic/Latino patients with hypertension: the TRINITY study. ( Chrysant, SG; Fernandez, V; Izzo, JL; Kereiakes, DJ; Lee, J; Lewin, AJ; Melino, M; Oparil, S, 2014) |
| " The EFFICIENT study examines the efficacy and acceptability of a single-pill combination of sustained-release (SR) indapamide, a thiazide-like diuretic, and amlodipine, a calcium channel blocker (CCB), in the management of hypertension." | 9.19 | Blood pressure control with a single-pill combination of indapamide sustained-release and amlodipine in patients with hypertension: the EFFICIENT study. ( Gujral, VK; Hiremath, J; Jadhav, U; Namjoshi, DJ; Safar, M; Shamanna, P; Siraj, M; Tripathi, KK, 2014) |
| "The objective of this study was to compare the efficacy and tolerability of the FDC of azilsartan (AZI) and amlodipine besylate (AML) with those of AZI monotherapy and AML monotherapy in Japanese patients with grade 1 to 2 essential hypertension." | 9.19 | Evaluation of the efficacy and tolerability of fixed-dose combination therapy of azilsartan and amlodipine besylate in Japanese patients with grade I to II essential hypertension. ( Kagawa, T; Nakata, E; Rakugi, H; Sasaki, E, 2014) |
| "An open-label extension of a 10-week double-blind study assessed the long-term efficacy and safety of olmesartan/amlodipine/hydrochlorothiazide (OLM/AML/HCTZ) triple combination treatment in 2,509 patients with Grade 2-3 hypertension." | 9.19 | Open-label study assessing the long-term efficacy and safety of triple olmesartan/amlodipine/hydrochlorothiazide combination therapy for hypertension. ( Ammentorp, B; de la Sierra, A; Laeis, P; Volpe, M, 2014) |
| "5 mg hydrochorothiazide + 5 mg amlodipine, 86 patients with resistant hypertension were randomized to the add-on 25 mg spironolactone (MRB group, n = 46) or 5 mg ramipril (RASB group, n = 40) groups for 12 weeks." | 9.19 | Greater efficacy of aldosterone blockade and diuretic reinforcement vs. dual renin-angiotensin blockade for left ventricular mass regression in patients with resistant hypertension. ( Azizi, M; Bobrie, G; Chatellier, G; Frank, M; Ménard, J; Perdrix, L; Plouin, PF, 2014) |
| "The present study failed to demonstrate the non-inferiority of the antialbuminuric effect of benidipine relative to that of hydrochlorothiazide in RAS inhibitor-treated hypertensive patients with macroalbuminuria." | 9.19 | Comparison of the antialbuminuric effects of benidipine and hydrochlorothiazide in Renin-Angiotensin System (RAS) inhibitor-treated hypertensive patients with albuminuria: the COSMO-CKD (COmbination Strategy on Renal Function of Benidipine or Diuretics Tr ( Ando, K; Fujita, T; Isshiki, M; Kashihara, N; Nakanishi, T; Nangaku, M; Nishizawa, Y; Nitta, K; Rakugi, H; Shimosawa, T; Takahashi, K; Tomita, K; Yokoyama, H, 2014) |
| "of the study was to assess efficacy of the use of fixed combination of nebivolol and amlodipine in patients with moderate and high degree of arterial hypertension (AH)." | 9.19 | [Postregistration study of comparative assessment efficacy of the use of fixed combination of nebivolol and amlodipine for the treatment of patients with moderate and high degree of arterial hypertension]. ( Barbarash, OL; Evdokimov, DO; Klimenkova, AV; Pecherina, TB; Vedernikova, AG, 2014) |
| "This prespecified subgroup analysis of a phase III study examined the effect of adding hydrochlorothiazide (HCTZ) to olmesartan (OLM)/amlodipine (AML) in patients with moderate to severe hypertension stratified by age, sex, body mass index, and hypertension severity." | 9.19 | Efficacy and tolerability of triple-combination therapy with olmesartan, amlodipine, and hydrochlorothiazide: a subgroup analysis of patients stratified by hypertension severity, age, sex, and obesity. ( Ammentorp, B; de la Sierra, A; Kreutz, R; Laeis, P, 2014) |
| "To investigate the effect of ARB-H on ECF in patients with uncontrolled hypertension despite the use of amlodipine (2." | 9.19 | Fixed-dose combination of losartan and hydrochlorothiazide significantly improves endothelial function in uncontrolled hypertension by low-dose amlodipine: a randomized study. ( Nagata, M; Takase, B, 2014) |
| "Being safe, the fixed-dose lisinopril and amlodipine combination is effective in lowering blood pressure in patients with hypertensive disease (HD) concurrent with coronary heart disease (CHD) or atherosclerotic changes in the carotid artery." | 9.19 | [A fixed-dose lisinopril and amlodipine combination in conjunction with rosuvastatin in patients with hypertensive disease and coronary heart disease]. ( Galeeva, ZM; Galiavich, AS, 2014) |
| "This prespecified subgroup analysis assessed the efficacy and safety of an olmesartan medoxomil (OM) 40 mg/amlodipine besylate (AML) 10 mg/hydrochlorothiazide (HCTZ) 25 mg triple-combination treatment compared with the 3 components as dual-combination treatments in participants with hypertension who were <65 and ≥ 65 years of age." | 9.17 | Combined olmesartan, amlodipine, and hydrochlorothiazide therapy in randomized patients with hypertension: a subgroup analysis of the TRINITY study by age. ( Fernandez, V; Heyrman, R; Izzo, JL; Lee, J; Lewin, AJ; Melino, M, 2013) |
| "Combination therapy with benazepril 40 mg and amlodipine 10 mg (B+A) has been shown to be more effective than benazepril 40 mg and hydrochlorothiazide (HCTZ) 25 mg (B+H) in reducing cardiovascular (CV) events in high-risk patients with stage 2 hypertension with similar blood pressure reductions." | 9.17 | Comparison of benazepril plus amlodipine or hydrochlorothiazide in high-risk patients with hypertension and coronary artery disease. ( Bakris, G; Briasoulis, A; Dahlof, B; Hester, A; Hua, T; Jamerson, K; Kelly, RY; Pitt, B; Weber, MA; Zappe, D, 2013) |
| " We enrolled 141 patients and evaluated the efficacy and safety between a fixed dose of olmesartan/amlodipine (OA) and a double dose of amlodipine (DA) for treating mild to moderate hypertension after amlodipine monotherapy failure." | 9.17 | Efficacy and tolerability between an olmesartan/amlodipine fixed-dose combination and an amlodipine double dose in mild to moderate hypertension. ( Hou, CJ; Hsia, CH; Lai, WT; Lin, TH; Pan, JP; Tsai, CD; Tsai, JP, 2013) |
| "To compare the antihypertensive efficacy and safety of once-daily triple therapy with amlodipine (Aml) 10 mg, valsartan (Val) 320 mg, and hydrochlorothiazide (HCTZ) 25 mg versus dual-therapy combinations of these components in patients with moderate to severe hypertension." | 9.17 | Effects of demographics on the antihypertensive efficacy of triple therapy with amlodipine, valsartan, and hydrochlorothiazide for moderate to severe hypertension. ( Calhoun, DA; Crikelair, N; Glazer, RD; Jia, Y; Lacourcière, Y, 2013) |
| "The purpose of this post hoc subgroup analysis was to compare the incidence of major adverse cardiovascular events (MACE) of patients treated with candesartan and amlodipine with that of those with candesartan and non-amlodipine CCBs in hypertensive patients with coronary artery disease (CAD)." | 9.17 | Efficacy of the combination of amlodipine and candesartan in hypertensive patients with coronary artery disease: a subanalysis of the HIJ-CREATE study. ( Hagiwara, N; Haruta, S; Kawada-Watanabe, E; Koyanagi, R; Ogawa, H; Takagi, A; Yamaguchi, J, 2013) |
| "To evaluate the effectiveness and safety of L-amlodipine besylate for blood pressure control in patients with mild to moderate essential hypertension." | 9.17 | [The effectiveness and safety of L-amlodipine besylate for blood pressure control in patients with mild to moderate essential hypertension]. ( Hu, DY; Jia, T; Yu, JM; Zhan, YQ; Zhang, LJ, 2013) |
| "In this multicenter, open-label, active-controlled, parallel-group study, 564 patients with hypertension not adequately controlled by prior monotherapy were randomized to receive valsartan/amlodipine 80/5 mg or nifedipine GITS 30 mg once daily for 12 weeks." | 9.17 | Valsartan/amlodipine compared to nifedipine GITS in patients with hypertension inadequately controlled by monotherapy. ( Chen, LL; He, YS; Li, Y; Li, ZP; Wang, JG; Wei, M; Zeng, WF; Zhang, BW, 2013) |
| "A direct switch of candesartan to the fixed-dose combination olmesartan/amlodipine in uncontrolled hypertension is a frequent clinical requirement but is not covered by current labeling." | 9.17 | Daytime systolic ambulatory blood pressure with a direct switch between candesartan monotherapy and the fixed-dose combination olmesartan/amlodipine in patients with uncontrolled essential hypertension (SEVICONTROL-1). ( Bramlage, P; Fimmers, R; Gansz, A; Lüders, S; Nadal, J; Schmieder, RE; Schrader, J; Sturm, CD; Zemmrich, C, 2013) |
| "This study was conducted to compare the BP-lowering and diurnal BP variation effects of amlodipine and losartan on acute stroke patients." | 9.17 | Comparison of the effects of amlodipine and losartan on blood pressure and diurnal variation in hypertensive stroke patients: a prospective, randomized, double-blind, comparative parallel study. ( Hong, YH; Kwon, HM; Lee, YS; Lim, JS; Nam, H; Shin, JW, 2013) |
| "We compared effects of racemic amlodipine and S-amlodipine in 127 patients with 1-2 degree arterial hypertension (AH) on structural-functional parameters of the left ventricle and brachial artery as well as on characteristics of carbohydrate, lipid, electrolyte, and purine metabolism." | 9.17 | [Organoprotective and metabolic effects of S-amlodipine in patients with arterial hypertension]. ( Iskenderov, BG; Saushkina, SV, 2013) |
| "To estimate effectiveness and safety of losartan and its combination with amlodipine in therapy of arterial hypertension." | 9.17 | [Effectiveness and safety of losartan and its combination with amlodipine in therapy of arterial hypertension]. ( Bazaeva, EV; Boitsov, SA; Drapkina, OM; Luk'ianov, MM; Panov, AV; Shchukina, GN; Terent'ev, BP; Tiurin, VP, 2013) |
| " In this study the effects of fixed combination of valsartan with either amlodipine (V-A) or hydrochlorothiazide (V-H) on low-density-lipoprotein (LDL) and high-density-lipoprotein (HDL) subfraction profile of patients with stage 2 or 3 hypertension were assessed." | 9.17 | Distinct effects of fixed combinations of valsartan with either amlodipine or hydrochlorothiazide on lipoprotein subfraction profile in patients with hypertension. ( Christogiannis, LG; Elisaf, MS; Kostapanos, MS; Milionis, HJ; Tellis, CC; Tselepis, AD, 2013) |
| " We conducted an open-label, randomized trial to compare the effects of cilnidipine against those of amlodipine on blood pressure (BP), albuminuria, and plasma aldosterone concentration in hypertensive patients with mild- to moderate-stage chronic kidney disease." | 9.17 | L/N-type calcium channel blocker cilnidipine reduces plasma aldosterone, albuminuria, and urinary liver-type fatty acid binding protein in patients with chronic kidney disease. ( Abe, M; Inoshita, A; Maruyama, N; Okada, K; Soma, M; Suzuki, H; Yoshida, Y, 2013) |
| " This study evaluated the effects of an olmesartan/amlodipine single pill combination compared to olmesartan or amlodipine monotherapies on BP, lipid profile, insulin resistance, and insulin sensitivity parameters." | 9.17 | Olmesartan/amlodipine combination versus olmesartan or amlodipine monotherapies on blood pressure and insulin resistance in a sample of hypertensive patients. ( Carbone, A; Cicero, AF; D'Angelo, A; Derosa, G; Fogari, E; Maffioli, P; Querci, F, 2013) |
| "In accordance with experimental data after antihypertensive treatment of 4 weeks, intraglomerular pressure was significantly lower with the CCB manidipine than with amlodipine, resulting and explaining their disparate effects on albuminuria." | 9.17 | Effects of manidipine vs. amlodipine on intrarenal haemodynamics in patients with arterial hypertension. ( Alberici, M; Ott, C; Raff, U; Ritt, M; Schmieder, RE; Schneider, MP; Striepe, K, 2013) |
| " The efficacy and safety of 20-week treatment with an amlodipine (AML)/olmesartan medoxomil (OM)±hydrochlorothiazide (HCTZ) algorithm were assessed in patients with hypertension and type 2 diabetes mellitus (T2DM) who were uncontrolled by antihypertensive monotherapy." | 9.17 | Efficacy of an amlodipine/olmesartan treatment algorithm in patients with or without type 2 diabetes and hypertension (a secondary analysis of the BP-CRUSH study). ( Maa, JF; Nesbitt, SD; Shojaee, A; Weir, MR, 2013) |
| " In present study, we aimed to investigate the effects of valsartan as an angiotensin II receptor antagonist and amlodipine as a calcium channel blocker on the vWf levels and N/L ratio in patients with essential hypertension." | 9.17 | The comparative effects of valsartan and amlodipine on vWf levels and N/L ratio in patients with newly diagnosed hypertension. ( Arslan, Z; Balta, S; Bozoglu, E; Bulucu, F; Cakar, M; Celik, T; Demirbas, S; Demirkol, S; Karaman, M; Kocak, N; Kurt, O; Naharci, I; Sarlak, H; Seyit Ahmet, AY, 2013) |
| " Hypertensive patients with type 2 diabetes mellitus and albuminuria (≥30 mg g(-1) creatinine) were enroled in the study, and were either started on or switched to candesartan (8 mg per day) monotherapy." | 9.16 | Effects of up-titration of candesartan versus candesartan plus amlodipine on kidney function in type 2 diabetic patients with albuminuria. ( Dohi, Y; Ichikawa, T; Ito, M; Kato, T; Kimura, G; Kojima, M; Komada, T; Machida, H; Miyazaki, T; Nakatani, K; Ninomiya, T; Okura, T; Sugiyama, M; Watanabe, Y, 2012) |
| "The aim of this study was to determine the dose-response relationship and assess the efficacy and safety of amlodipine or losartan monotherapy and amlodipine camsylate/losartan combination therapy in patients with essential hypertension." | 9.16 | Evaluation of the dose-response relationship of amlodipine and losartan combination in patients with essential hypertension: an 8-week, randomized, double-blind, factorial, phase II, multicenter study. ( Chae, SC; Cho, SY; Choi, YJ; Hong, BK; Hong, TJ; Jeong, JW; Kim, CH; Kim, JJ; Kim, MH; Kwan, J; Park, CG; Park, SH; Yang, JY; Youn, HJ, 2012) |
| "This 8-week, randomized, double-blind, controlled study compared efficacy and tolerability of telmisartan/amlodipine (T/A) single-pill combination (SPC) vs the respective monotherapies in 858 patients with severe hypertension (systolic/diastolic blood pressure [SBP/DBP] ≥180/95 mm Hg)." | 9.16 | Single-pill combination of telmisartan/amlodipine in patients with severe hypertension: results from the TEAMSTA severe HTN study. ( Black, HR; Dahlöf, B; Defeo, H; Ley, L; Mancia, G; Neutel, JM; Vinisko, R, 2012) |
| "The objective of this study was to compare valsartan or ramipril addition to amlodipine + hydrochlorothiazide (HCTZ) on blood pressure (BP) and left ventricular hypertrophy (LVH) in hypertensive diabetic patients with LVH." | 9.16 | Effects of valsartan or ramipril addition to amlodipine/hydrochlorothiazide combination on left ventricular mass in diabetic hypertensive patients with left ventricular hypertrophy. ( Derosa, G; Fogari, R; Maffioli, P; Mugellini, A; Preti, P; Zoppi, A, 2012) |
| "We examined blood pressure reduction and metabolic alterations after amlodipine/benazepril and valsartan/hydrochlorothiazide treatment in patients with type 2 diabetes mellitus and hypertension and microalbuminuria." | 9.16 | Comparison of the efficacy and safety profiles of two fixed-dose combinations of antihypertensive agents, amlodipine/benazepril versus valsartan/hydrochlorothiazide, in patients with type 2 diabetes mellitus and hypertension: a 16-week, multicenter, rando ( Chen, JF; Hung, YJ; Lee, IT; Lee, WJ; Sheu, WH; Wang, CY, 2012) |
| "To evaluate the clinic and ambulatory blood pressure (BP)-lowering efficacy and safety of an aliskiren/amlodipine/hydrochlorothiazide (HCT) triple combination compared with the component dual combinations, in patients with moderate-to-severe hypertension." | 9.16 | Clinic and ambulatory blood pressure lowering effect of aliskiren/amlodipine/hydrochlorothiazide combination in patients with moderate-to-severe hypertension: a randomized active-controlled trial. ( Fang, H; Konis, G; Lacourcière, Y; Severin, T; Taddei, S; Zhang, J, 2012) |
| "This exploratory study compared the amount of pedal edema experienced by female Korean patients with mild to moderate hypertension when receiving S(-)-amlodipine nicotinate compared with amlodipine besylate." | 9.16 | Quantification of pedal edema during treatment with S(-)-amlodipine nicotinate versus amlodipine besylate in female Korean patients with mild to moderate hypertension: a 12-week, multicenter, randomized, double-blind, active-controlled, phase IV clinical ( Choi, DJ; Kang, HJ; Lee, HY; Oh, BH; Oh, GC; Zo, JH, 2012) |
| " This 28- to 54-week, open-label, multicenter study evaluated the safety and efficacy of a triple combination, aliskiren with amlodipine and hydrochlorothiazide (HCTZ), in patients with moderate to severe hypertension." | 9.16 | Safety and efficacy of aliskiren/amlodipine/hydrochlorothiazide triple combination in patients with moderate to severe hypertension: a 54-week, open-label study. ( Garcia-Puig, J; Koenig, W; Murray, AV; Patel, S; Uddin, A; Zhang, J, 2012) |
| "We hypothesized that atorvastatin combined with amlodipine has additive beneficial vascular and metabolic effects that are superior to monotherapy in patients with hypertension." | 9.15 | Additive beneficial effects of atorvastatin combined with amlodipine in patients with mild-to-moderate hypertension. ( Han, SH; Kim, SJ; Koh, KK; Koh, Y; Lee, Y; Park, JB; Quon, MJ; Shin, EK, 2011) |
| " The aim of this study was to clarify the effect of angiotensin II receptor blockade with valsartan on plasma OPN levels in patients with essential hypertension (EHT)." | 9.15 | Angiotensin II receptor blockade with valsartan decreases plasma osteopontin levels in patients with essential hypertension. ( Desilva, VR; Enomoto, D; Higaki, J; Irita, J; Jotoku, M; Kurata, M; Miyoshi, K; Nagao, T; Okura, T, 2011) |
| " The objective of this analysis was to determine the efficacy of olmesartan/amlodipine in age, severity and gender-based subgroups of patients with moderate-to-severe hypertension uncontrolled by amlodipine monotherapy." | 9.15 | Efficacy and safety of olmesartan medoxomil plus amlodipine in age, gender and hypertension severity defined subgroups of hypertensive patients. ( Böhm, M; Schmieder, RE, 2011) |
| "The steady-state pharmacokinetic (PK) interaction potential between amlodipine (10 mg), valsartan (320 mg), and hydrochlorothiazide (HCTZ; 25 mg) was evaluated in patients with hypertension in a multicenter, multiple-dose, open-label, 4-cohort, parallel-group study." | 9.15 | Evaluation of pharmacokinetic interactions between amlodipine, valsartan, and hydrochlorothiazide in patients with hypertension. ( Ayalasomayajula, S; Bhad, P; Jarugula, V; Karan, R; Leon, S; Riviere, GJ; Sunkara, G, 2011) |
| "We studied the effects of treatment with olmesartan/amlodipine and olmesartan/hydrochlorothiazide on inflammatory and metabolic parameters (including new-onset diabetes as a secondary endpoint) in non-diabetic hypertensive patients with metabolic syndrome (MetS)." | 9.15 | Olmesartan/amlodipine vs olmesartan/hydrochlorothiazide in hypertensive patients with metabolic syndrome: the OLAS study. ( Comi-Diaz, C; Martinez-Martin, FJ; Pedrianes-Martin, P; Peiro-Martinez, I; Rodriguez-Rosas, H; Soriano-Perera, P, 2011) |
| "This study was a prospective, randomized, open, blinded endpoint study to assess the effects of angiotensin II type 1 receptor blocker, losartan, compared with calcium channel blocker, amlodipine, on left ventricular (LV) diastolic function and atherosclerosis of the carotid artery in Japanese patients with mild-to-moderate hypertension, LV hypertrophy, diastolic dysfunction and preserved systolic function." | 9.15 | The effect of losartan and amlodipine on left ventricular diastolic function and atherosclerosis in Japanese patients with mild-to-moderate hypertension (J-ELAN) study. ( Akehi, N; Ebisuno, S; Fukui, S; Hori, M; Horiguchi, Y; Katsube, Y; Kobayashi, K; Kodama, M; Ohtsu, H; Ota, M; Ozaki, H; Sakai, A; Shimonagata, T; Takayasu, K; Yamamoto, K; Yamazaki, T, 2011) |
| " In this study, we conducted an open-label and randomized trial to compare the effects of benidipine with those of amlodipine on blood pressure (BP), albuminuria and aldosterone concentration in hypertensive patients with mild-to-moderate stage chronic kidney disease (CKD)." | 9.15 | Benidipine reduces albuminuria and plasma aldosterone in mild-to-moderate stage chronic kidney disease with albuminuria. ( Abe, M; Fujita, T; Maruyama, N; Maruyama, T; Matsumoto, K; Matsumoto, S; Okada, K; Soma, M, 2011) |
| " The objective of this study (the MARCADOR study) was to compare the effects of manidipine 20 mg with the extemporary combination of manidipine 10 mg/lisinopril 10 mg, amlodipine 10 mg and telmisartan 80 mg on insulin sensitivity, as well as metabolic, inflammatory and prothrombotic markers, in hypertensive non-diabetic patients with metabolic syndrome." | 9.15 | Effects of manidipine and its combination with an ACE inhibitor on insulin sensitivity and metabolic, inflammatory and prothrombotic markers in hypertensive patients with metabolic syndrome: the MARCADOR study. ( Comi-Diaz, C; Macias-Batista, A; Martinez-Martin, FJ; Pedrianes-Martin, P; Rodriguez-Rosas, H; Soriano-Perera, P, 2011) |
| "The aim of our study was to evaluate the safety and effectiveness of the free combination of amlodipine/valsartan in patients with arterial hypertension in a real-life setting." | 9.15 | Real-life safety and effectiveness of amlodipine/valsartan combination in the treatment of hypertension. ( Chazova, IE; Dongre, N; Vigdorchik, AV, 2011) |
| "The GIFU substudy of the Candesartan Antihypertensive Survival Evaluation in Japan (CASE-J) trial was conducted to compare the long-term effects of candesartan and amlodipine on office- and home-measured blood pressure (BP), QTc dispersion and left ventricular mass index (LVMI) in high-risk Japanese patients with hypertension." | 9.15 | Effects of candesartan versus amlodipine on home-measured blood pressure, QT dispersion and left ventricular hypertrophy in high-risk hypertensive patients. ( Fujiwara, H; Matsuno, Y; Minatoguchi, S, 2011) |
| "To determine the effectiveness and safety of once-daily combination therapy with amlodipine, valsartan and hydrochlorothiazide for reducing ambulatory blood pressure (ABP) in patients with moderate to severe hypertension, a multicenter, double-blind study was performed (N=2271) that included ABP monitoring in a 283-patient subset." | 9.15 | 24-Hour ambulatory blood pressure control with triple-therapy amlodipine, valsartan and hydrochlorothiazide in patients with moderate to severe hypertension. ( Calhoun, DA; Crikelair, N; Glazer, RD; Lacourcière, Y; Yen, J, 2011) |
| "Twelve weeks of treatment with losartan significantly reduced proteinuria compared with placebo/amlodipine: losartan -14." | 9.15 | Efficacy and safety of losartan in children with Alport syndrome--results from a subgroup analysis of a prospective, randomized, placebo- or amlodipine-controlled trial. ( Gleim, GW; Lam, C; Le Bailly De Tilleghem, C; Shahinfar, S; Strehlau, J; Webb, NJ; Wells, TG, 2011) |
| "To evaluate the efficacy and tolerability of the fixed combination of amlodipine 5 mg/benazepril 10 mg once-daily therapy, compared with benazepril, 10 mg, monotherapy in patients with mild and moderate hypertension, and to evaluate the 24 h antihypertensive efficacy and the duration of action by ambulatory blood pressure monitoring." | 9.15 | [Comparison of benazepril monotherapy to amlodipine plus benazepril in the treatment of patients with mild and moderate hypertension: a multicentre, randomized, double-blind, parallel-controlled study]. ( Fan, CM; Gao, MM; Li, CX; Li, YQ; Li, YS; Lu, XL; Pang, HM; Tao, YK; Wang, L; Wang, XW; Wang, YN; Yan, LR, 2011) |
| "The safety and efficacy of an amlodipine/olmesartan medoxomil (OM)-based titration regimen was assessed in patients with type 2 diabetes mellitus and hypertension." | 9.15 | Management of hypertension in patients with diabetes using an amlodipine-, olmesartan medoxomil-, and hydrochlorothiazide-based titration regimen. ( Littlejohn, T; Neutel, JM; Qian, C; Ram, CV; Sachson, R; Shojaee, A; Stoakes, KA, 2011) |
| "After 4-week placebo, 120 outpatients with grade 1 - 2 hypertension were randomized to amlodipine 10 mg or aliskiren 300 mg or their combination for 8 weeks in three crossover periods." | 9.15 | Effect of aliskiren addition to amlodipine on ankle edema in hypertensive patients: a three-way crossover study. ( Derosa, G; Fogari, R; Lazzari, P; Maffioli, P; Monti, C; Mugellini, A; Zoppi, A, 2011) |
| " The authors report on an 8-week double-blind, randomized study of African American patients with stage 2 hypertension that compared brachial and central BP responses (substudy of 53 patients) to combination aliskiren/hydrochlorthiazide (HCTZ) and amlodipine monotherapy." | 9.15 | Peripheral and central blood pressure responses of combination aliskiren/hydrochlorothiazide and amlodipine monotherapy in African American patients with stage 2 hypertension: the ATLAAST trial. ( Ferdinand, KC; Pool, J; Purkayastha, D; Townsend, R; Weitzman, R, 2011) |
| "An 8-week, randomized, double-blind, controlled study with single-pill combinations of telmisartan 40 mg or 80 mg/amlodipine 5 mg (T40/A5 or T80/A5) vs monotherapy with amlodipine 5 mg or 10 mg (A10) in 1097 patients with uncontrolled hypertension (diastolic blood pressure [BP] ≥ 90 mm Hg)." | 9.15 | Telmisartan and amlodipine single-pill combinations vs amlodipine monotherapy for superior blood pressure lowering and improved tolerability in patients with uncontrolled hypertension: results of the TEAMSTA-5 study. ( Jones, R; Lang, M; Neldam, S, 2011) |
| "This study compared the efficacy and safety of combination angiotensin-receptor blocker (ARB)/calcium-channel blocker (CCB) with hydrochlorothiazide (valsartan/amlodipine/HCTZ 160/5/2mg) vs maximal available combination doses of an ARB with HCTZ (losartan/HCTZ 100/25 mg) in the management of stage 2 hypertension." | 9.15 | Combination angiotensin-receptor blocker (ARB)/calcium channel blocker with HCTZ vs the maximal recommended dose of an ARB with HCTZ in patients with stage 2 hypertension: the exforge as compared to losartan treatment in stage 2 systolic hypertension (EXA ( Duprez, D; Ferdinand, KC; Purkayastha, D; Samuel, R; Wright, RF, 2011) |
| "Seventeen non-diabetic patients with essential hypertension who had controlled blood pressure levels using amlodipine (5 mg/day) were enrolled in this study." | 9.15 | Effects of calcium channel blockers on glucose tolerance, inflammatory state, and circulating progenitor cells in non-diabetic patients with essential hypertension: a comparative study between azelnidipine and amlodipine on glucose tolerance and endotheli ( Daida, H; Fukao, K; Hiki, M; Hirose, K; Kiyanagi, T; Kume, A; Kurata, T; Matsumori, R; Miyazaki, T; Ohsaka, H; Shimada, K, 2011) |
| "The objective of this research was to evaluate the effect of telmisartan addition to amlodipine, on peripheral edema in hypertensive patients." | 9.15 | Effect of telmisartan addition to amlodipine on ankle edema development in treating hypertensive patients. ( Derosa, G; Fogari, R; Lazzari, P; Maffioli, P; Mugellini, A; Zoppi, A, 2011) |
| "In many countries, combination therapy with amlodipine and atorvastatin is indicated for the treatment of patients with hypertension and hypercholesterolemia." | 9.15 | Impact of combination therapy with amlodipine and atorvastatin on plasma adiponectin levels in hypertensive patients with coronary artery disease: combination therapy and adiponectin. ( Cheung, BM; Lam, KS; Li, M; Tse, HF; Xu, A, 2011) |
| "FDCs of metoprolol and amlodipine are effective and safe in mild to moderate hypertension." | 9.15 | Effect of fixed dose combinations of metoprolol and amlodipine in essential hypertension: MARS--a randomized controlled trial. ( Bosco, B; Devi, P; Ds, C; Gupta, R; Hiremath, J; Joshi, S; Mehta, K; Murthy, S; Nambiar, A; Pais, P; Pandey, S; Sharma, K; Sigamani, A; Singh, G; Thomas, T; Xavier, D, 2011) |
| "Losartan, enalapril and amlodipine reduced the number of premature ventricular contractions (PVCs) in patients with essential hypertension as well as blood pressure." | 9.14 | Losartan decreased premature ventricular contractions in patients with hypertension. ( Kuroyanagi, A; Matsubara, H; Sakamoto, T; Shiraishi, H; Shirayama, T, 2009) |
| "During an initial 8-week, double-blind phase, patients with concomitant hypertension and dyslipidemia were randomized into four treatment groups (placebo, amlodipine 5 mg, atorvastatin 10 mg, or coadministered amlodipine 5 mg and atorvastatin 10 mg)." | 9.14 | Coadministered amlodipine and atorvastatin produces early improvements in arterial wall compliance in hypertensive patients with dyslipidemia. ( Cohn, JN; Grimm, R; Houston, M; Neutel, J; Smith, DH; Sun, W; Weinberger, MH; Wilson, DJ, 2009) |
| " The objective of this randomized, double-blind, parallel-group, multicentre study was to determine the efficacy and safety of olmesartan medoxomil/amlodipine combination therapy in patients with moderate to severe hypertension who had failed to respond to treatment with 8 weeks of open-label amlodipine." | 9.14 | Efficacy and tolerability of olmesartan medoxomil combined with amlodipine in patients with moderate to severe hypertension after amlodipine monotherapy: a randomized, double-blind, parallel-group, multicentre study. ( Brommer, P; Haag, U; Miele, C; Volpe, M, 2009) |
| "The objective of this Phase III double-blind parallel-group controlled study was to examine the superiority of amlodipine 10 mg once daily (the amlodipine 10 mg group) to amlodipine 5 mg once daily (the amlodipine 5 mg group) in 305 Japanese outpatients with essential hypertension whose systolic blood pressure (SBP) had not reached the therapeutic target levels (<130-140/80-90 mm Hg) when treated with amlodipine 5 mg once daily." | 9.14 | The Phase III, double-blind, parallel-group controlled study of amlodipine 10 mg once daily in Japanese patients with essential hypertension who insufficiently responded to amlodipine 5 mg once daily. ( Buch, J; Fujiwara, T; Hatsuzawa, J; Ii, Y; Kimura, N; Murakami, M; Murase, H; Saruta, T; Tsuchihashi, T; Watanabe, T, 2009) |
| "To demonstrate the benefit of the combination amlodipine/valsartan 5/160 mg over amlodipine 10 mg, in producing a lower incidence of peripheral oedema for a comparable mean sitting systolic blood pressure (MSSBP) reduction." | 9.14 | The combination of amlodipine/valsartan 5/160 mg produces less peripheral oedema than amlodipine 10 mg in hypertensive patients not adequately controlled with amlodipine 5 mg. ( Akpinar, E; Brunel, P; Calvo, C; Keeling, L; Salvetti, A; Schrader, J; Weisskopf, M, 2009) |
| "Patients with Stage 1 or 2 hypertension were randomized to telmisartan 0, 20, 40, or 80 mg plus amlodipine 0, 2." | 9.14 | Telmisartan plus amlodipine in patients with moderate or severe hypertension: results from a subgroup analysis of a randomized, placebo-controlled, parallel-group, 4 x 4 factorial study. ( Guthrie, R; Kobe, M; Littlejohn, TW; Majul, CR; Oigman, W; Olvera, R; Seeber, M, 2009) |
| "This multicenter, double-blind, parallel group, forced-titration study of individuals with stage 2 hypertension, compared the efficacy of valsartan and amlodipine in combination with HCTZ on ABP reduction." | 9.14 | Effects of force-titrated valsartan/hydrochlorothiazide versus amlodipine/hydrochlorothiazide on ambulatory blood pressure in patients with stage 2 hypertension: the EVALUATE study. ( Black, HR; Lacourcière, Y; Purkayastha, D; Samuel, R; Wright, JT; Zappe, D, 2009) |
| "To evaluate the efficacy and tolerability of the fixed combination: amlodipine + enalapril, when compared to amlodipine in the normalization of the diastolic arterial pressure (DAP) (<85 mmHg), in pts with CAD and systemic arterial hypertension (SAH)." | 9.14 | Combination of amlodipine and enalapril in hypertensive patients with coronary disease. ( Armagnajian, D; César, LA; Ferreira, JF; Gomes, EP; Mansur, Ade P; Moretti, MA; Nogueira, PR; Ramires, JA; Rienzo, M; Saraiva, JF, 2009) |
| "Patients with moderate-to-severe hypertension who were inadequately controlled with amlodipine 5 mg/day monotherapy and who subsequently completed 16 weeks of double-blind combination treatment with olmesartan and amlodipine entered a 28-week open-label phase in which all patients initially received olmesartan/amlodipine 40/5 mg/day." | 9.14 | Efficacy and safety of a stepped-care regimen using olmesartan medoxomil, amlodipine and hydrochlorothiazide in patients with moderate-to-severe hypertension: an open-label, long-term study. ( Haag, U; Miele, C; Volpe, M, 2009) |
| "The STRONG (SafeTy & efficacy analysis of coveRsyl amlodipine in uncOntrolled and Newly diaGnosed hypertension) study was a prospective, observational, multicenter trial." | 9.14 | Management of hypertension with the fixed combination of perindopril and amlodipine in daily clinical practice: results from the STRONG prospective, observational, multicenter study. ( Bahl, VK; Jadhav, UM; Thacker, HP, 2009) |
| "This prospective randomized double-blinded clinical trial was designed to explore the effects of amlodipine and the combination of amlodipine with terazosin in improving postvoid residual (PVR) in patients with lower urinary tract symptoms (LUTS) and concomitant hypertension." | 9.14 | [Amlodipine combined with terazosin reduces postvoid residual and the risk of acute urinary retention]. ( Fang, J; Li, YL; Liu, HP; Qin, XH; Xu, XP; Yang, C; Zhang, X, 2009) |
| "To evaluate the effects of manidipine versus amlodipine on blood pressure, albuminuria, insulin sensitivity, adiponectin, TNF-alpha and C-reactive protein in nondiabetic subjects with metabolic syndrome (ATP-III definition), including impaired fasting glucose (>5." | 9.14 | Manidipine in hypertensive patients with metabolic syndrome: the MARIMBA study. ( Martínez Martín, FJ, 2009) |
| " The aim of the present study was to examine the effect of a novel ARB, olmesartan, on myocardial function of the left ventricle in patients with mildto-moderate hypertension." | 9.14 | Olmesartan ameliorates myocardial function independent of blood pressure control in patients with mild-to-moderate hypertension. ( Futai, R; Ito, T; Kawanishi, Y; Kitaura, Y; Terasaki, F, 2009) |
| "Double-blind, controlled trial, designed to investigate the effects of 2-months treatment with amlodipine and olmesartan on oxidized non-esterified fatty acids (ox-NEFA), and lipopolysaccharide-stimulated cytokine production in whole blood among 23 hypertensive subjects with the metabolic syndrome." | 9.14 | Treatment of hypertension in metabolic syndrome subjects with amlodipine and olmesartan-effects on oxidized non-esterified free fatty acids and cytokine production. ( Rosenson, RS, 2009) |
| "This report includes a prespecified secondary analysis of the COACH study (Combination of Olmesartan medoxomil and Amlodipine besylate in Controlling High blood pressure) based on baseline hypertension severity and prior antihypertensive medication use and a post hoc efficacy analysis of the subset of patients with baseline mean seated systolic blood pressure (SeSBP) > or =180 mm Hg." | 9.14 | Subgroup analyses of an efficacy and safety study of concomitant administration of amlodipine besylate and olmesartan medoxomil: evaluation by baseline hypertension stage and prior antihypertensive medication use. ( Karki, S; Lee, J; Melino, M; Oparil, S, 2009) |
| "Forty type 2 diabetic patients with hypertension and nephropathy receiving angiotensin receptor II blockers were enrolled and randomly divided into two groups: the efonidipine group was administered efonidipine hydrochloride ethanolate 40 mg/day and the amlodipine group was admin-istered amlodipine besilate 5 mg/day for 12 months." | 9.14 | Protective effects of efonidipine, a T- and L-type calcium channel blocker, on renal function and arterial stiffness in type 2 diabetic patients with hypertension and nephropathy. ( Ban, N; Endo, K; Kawana, H; Miyashita, Y; Nagayama, D; Ohhira, M; Oyama, T; Saiki, A; Sasaki, H; Shirai, K; Yamaguchi, T, 2009) |
| "This multicentre, double-blind, trial in subjects with severe hypertension compared the efficacy and tolerability of two parallel drug regimens: A/B (amlodipine/benazepril: 5/20 or 10/40 mg daily, if necessary) with A (amlodipine: 5 or 10 mg daily, if necessary)." | 9.14 | Comparative efficacy and safety of amlodipine/benazepril combination therapy and amlodipine monotherapy in severe hypertension. ( Hall, D; Hilkert, RJ; Izzo, JL; Purkayastha, D, 2010) |
| "Amlodipine-based antihypertensive combination regimens achieved satisfactory blood pressure control rate in patients with essential hypertension in this patient cohort." | 9.14 | [Effects of amlodipine plus telmisartan or amlodipine plus amiloride regimen on blood pressure control in hypertensive patients: preliminary report of Chinese Hypertension Intervention Efficacy (CHIEF) trial]. ( Deng, Q; Huang, J; Li, W; Lin, SG; Liu, LS; Liu, MB; Ma, LY; Wang, W; Zhang, YQ; Zhu, DL, 2009) |
| "An 8-week trial of amlodipine/valsartan/hydrochlorothiazide (Aml/Val/HCTZ) for moderate or severe hypertension demonstrated more-pronounced blood pressure (BP)-lowering effects compared with dual-component therapies." | 9.14 | Amlodipine/valsartan/hydrochlorothiazide triple combination therapy in moderate/severe hypertension: Secondary analyses evaluating efficacy and safety. ( Calhoun, DA; Crikelair, NA; Glazer, RD; Yen, J, 2009) |
| "Twelve weeks of treatment with losartan significantly reduced proteinuria compared with amlodipine/placebo: losartan -35." | 9.14 | Randomized, double-blind, controlled study of losartan in children with proteinuria. ( Gleim, GW; Lam, C; Loeys, T; Manas, D; Santoro, E; Shahinfar, S; Strehlau, J; Webb, NJ; Wells, TG, 2010) |
| "To investigate the effect of perindopril, amlodipine and telmisartan on improving the artery stiffness in patients with hypertension." | 9.14 | [Perindopril, amlodipine and telmisartan improve arterial stiffness in patients with hypertension]. ( Cheng, XM; Chu, WW; Du, M; Li, Y; Ma, SM, 2009) |
| " Serum insulin, glucose, C-reactive protein (CRP), lipids, uric acid, YKL-40 and blood pressure were measured and insulin sensitivity was calculated (HOMA) at the beginning and end of each study phase." | 9.14 | Effect of moxonidine and amlodipine on serum YKL-40, plasma lipids and insulin sensitivity in insulin-resistant hypertensive patients-a randomized, crossover trial. ( Majer, J; Masajtis-Zagajewska, A; Nowicki, M, 2010) |
| "The objective of this study was to compare the effect on ankle edema of adding valsartan (V) or olmesartan (O) to amlodipine (A) in the treatment of hypertension." | 9.14 | Effect of valsartan or olmesartan addition to amlodipine on ankle edema in hypertensive patients. ( Corradi, L; Derosa, G; Fogari, R; Malamani, G; Mugellini, A; Preti, P; Zoppi, A, 2010) |
| " We studied the effects of combining telmisartan and amlodipine on ambulatory BP in patients with stages 1-2 hypertension." | 9.14 | Effects of telmisartan and amlodipine in combination on ambulatory blood pressure in stages 1-2 hypertension. ( Littlejohn, TW; Majul, CR; Mancia, G; Oigman, W; Olvera, R; Schumacher, H; Seeber, M; White, WB, 2010) |
| "The objective of our study was to compare the effects of a combination therapy with amlodipine and fosinopril administered concomitantly or at different times on blood pressure and circadian blood pressure pattern in subjects with essential hypertension." | 9.14 | Effects of combination therapy with amlodipine and fosinopril administered at different times on blood pressure and circadian blood pressure pattern in patients with essential hypertension. ( Liang, X; Meng, Y; Qi, G; Wu, C; Zhang, Z, 2010) |
| "The aim of this study was to determine whether a triple combination of olmesartan medoxomil (OM), amlodipine besylate (AML), and hydrochlorothiazide (HCTZ) had a clinically significant benefit compared with dual combinations of the individual components in patients with moderate to severe hypertension." | 9.14 | Triple therapy with olmesartan medoxomil, amlodipine besylate, and hydrochlorothiazide in adult patients with hypertension: The TRINITY multicenter, randomized, double-blind, 12-week, parallel-group study. ( Fernandez, V; Heyrman, R; Lee, J; Melino, M; Oparil, S, 2010) |
| "To evaluate the impact of age on the pharmacokinetics and blood pressure (BP) responses of a dihydropyridine (DHP) with large versus small first-pass metabolism in hypertensive subjects, younger (n = 28) and older (n = 35) patients with hypertension were randomized to placebo, felodipine-ER 5 mg/d, or amlodipine 5 mg/d." | 9.14 | Pharmacokinetic and antihypertensive profile of amlodipine and felodipine-ER in younger versus older patients with hypertension. ( Coletta, E; Leenen, FH, 2010) |
| " In a 10-week study of stage 2 hypertension, 320/25 mg valsartan/hydrochlorothiazide (HCTZ) reduced ambulatory BP (ABP) significantly more effectively than 10/25 mg amlodipine/HCTZ." | 9.14 | 24-Hour ambulatory blood pressure response to combination valsartan/hydrochlorothiazide and amlodipine/hydrochlorothiazide in stage 2 hypertension by ethnicity: the EVALUATE study. ( Black, HR; Lacourcière, Y; Purkayastha, D; Samuel, R; Wright, JT; Zappe, D, 2010) |
| "Amlodipine (10 mg daily for 8 weeks) or placebo was given to each 45 patients with mild to moderate hypertension in a randomized, double-blind, placebo-controlled, and parallel study." | 9.14 | Amlodipine improves endothelial function and metabolic parameters in patients with hypertension. ( Ahn, JY; Chung, WJ; Han, SH; Koh, KK; Lee, Y; Shin, EK, 2009) |
| "The present study was conducted to compare the renal and vascular protective effects of telmisartan and amlodipine in untreated hypertensive chronic kidney disease (CKD) patients with moderate renal insufficiency." | 9.13 | Comparison of renal and vascular protective effects between telmisartan and amlodipine in hypertensive patients with chronic kidney disease with mild renal insufficiency. ( Inoue, T; Kawagoe, Y; Koide, H; Nakamura, T; Node, K; Suzuki, T; Ueda, Y, 2008) |
| "The ADHT (Amlodipine Diabetic Hypertension Efficacy Response Evaluation Trial) evaluated the efficacy and safety of adding amlodipine to the treatment regimen of patients with hypertension and diabetes who were already receiving either quinapril or losartan as monotherapy." | 9.13 | Blood pressure control with amlodipine add-on therapy in patients with hypertension and diabetes: results of the Amlodipine Diabetic Hypertension Efficacy Response Evaluation Trial. ( Gregg, AM; Kloner, RA; Neutel, J; Roth, EM; Schwartz, B; Shi, H; Thakker, KM; Weinberger, MH; Weiss, R, 2008) |
| "In this population of patients with essential hypertension, the amlodipine/ramipril FDC was associated with significantly reduced ambulatory and office-measured BP compared with amlodipine monotherapy, with the exception of office DBP." | 9.13 | An 18-week, prospective, randomized, double-blind, multicenter study of amlodipine/ramipril combination versus amlodipine monotherapy in the treatment of hypertension: the assessment of combination therapy of amlodipine/ramipril (ATAR) study. ( Amodeo, C; Filho, BL; Gomes, MA; Kohlmann, O; Mion, D; Miranda, RD; Rocha, JC; Saraiva, JF, 2008) |
| "The aim of the study was to evaluate the effect of valsartan/amlodipine combination on insulin sensitivity in overweight-obese hypertensive patients." | 9.13 | Effect of valsartan addition to amlodipine on insulin sensitivity in overweight-obese hypertensive patients. ( Corradi, L; Derosa, G; Fogari, R; Lazzari, P; Mugellini, A; Preti, P; Santoro, T; Zoppi, A, 2008) |
| "The aim of this study was to compare the efficacy and safety of adding manidipine 20 mg versus amlodipine 10 mg to the treatment of diabetic patients with uncontrolled hypertension and microalbuminuria despite full-dose treatment with a renin-angiotensin system blocker for at least 6 months." | 9.13 | Add-on manidipine versus amlodipine in diabetic patients with hypertension and microalbuminuria: the AMANDHA study. ( Martinez-Martin, FJ; Saiz-Satjes, M, 2008) |
| "In a randomized, double-blind trial, we assigned 11,506 patients with hypertension who were at high risk for cardiovascular events to receive treatment with either benazepril plus amlodipine or benazepril plus hydrochlorothiazide." | 9.13 | Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. ( Bakris, GL; Dahlöf, B; Gatlin, M; Gupte, J; Hester, A; Jamerson, K; Pitt, B; Shi, V; Velazquez, EJ; Weber, MA, 2008) |
| "To study effects of calcium antagonist amlodipine (normodipine) on blood pressure, heart rate variability (HRV) and carbohydrate metabolism in patients with metabolic syndrome (MS)." | 9.13 | [Effects of amlodipine on blood pressure. Results of cardiovascular tests and heart rate variability in patients with metabolic syndrome]. ( Praskurnichiĭ, EA; Savel'eva, SA; Shevchenko, OP, 2008) |
| "This multicenter, open-label, single-arm trial assessed the efficacy of the combination of amlodipine 10 mg and valsartan 160 mg to provide additional blood pressure reduction and tolerability in patients with moderate hypertension not adequately responding to the combination of ramipril 5 mg and felodipine 5 mg." | 9.13 | Combination of amlodipine 10 mg and valsartan 160 mg lowers blood pressure in patients with hypertension not controlled by an ACE inhibitor/CCB combination. ( Borbas, E; Handrock, R; Klebs, S; Schaetzl, R; Trenkwalder, P, 2008) |
| "The TOlerabilidad de LERcanidipino 20 mg frente a Amlodipino y Nifedipino en CondicionEs normales de uso study was aimed to compare the tolerability of high doses of lercanidipine with amlodipine and nifedipine gastro-intestinal therapeutic system (GITS) in the treatment of hypertension in daily clinical practice." | 9.13 | High doses of lercanidipine are better tolerated than other dihydropyridines in hypertensive patients with metabolic syndrome: results from the TOLERANCE study. ( Barrios, V; Calderón, A; de la Figuera, M; Escobar, C; Honorato, J; Llisterri, JL; Segura, J, 2008) |
| "The aim of this study was to compare the effect of valsartan/amlodipine and atenolol/amlodipine combination in preventing the recurrence of atrial fibrillation (AF) in hypertensive diabetic patients with a history of recent paroxysmal atrial fibrillation." | 9.13 | Comparative evaluation of effect of valsartan/amlodipine and atenolol/amlodipine combinations on atrial fibrillation recurrence in hypertensive patients with type 2 diabetes mellitus. ( Corradi, L; Derosa, G; Fogari, R; Lazzari, P; Mugellini, A; Preti, P; Zoppi, A, 2008) |
| "Our aim in this study was to investigate the changes of serum high-sensitive C-reactive protein (hs-CRP) and uric acid (UA), and evaluate the synergistic effect of amlodipine and atorvastatin on blood pressure and left ventricular remodeling in hypertensive patients with primary hypercholesterolemia." | 9.13 | Synergistic effect of amlodipine and atorvastatin on blood pressure, left ventricular remodeling, and C-reactive protein in hypertensive patients with primary hypercholesterolemia. ( Chen, YD; Ge, CJ; Hu, SJ; Ji, Y; Lu, SZ; Wu, XF, 2008) |
| " The aim of the present study was to evaluate whether endothelial function and oxidative stress differ following long-term antihypertensive treatment with an angiotensin type 1 receptor blocker, valsartan, or a calcium channel blocker, amlodipine, in patients with essential hypertension." | 9.13 | Effects of valsartan or amlodipine on endothelial function and oxidative stress after one year follow-up in patients with essential hypertension. ( Hirooka, Y; Ito, K; Kimura, Y; Sagara, Y; Sunagawa, K, 2008) |
| "In moderate hypertension BP normalized in 40 and 44% on monotherapy with lisinopril or amlodipine, respectively, and in 78% patients given lisinopril+amlodipine." | 9.13 | [Efficacy of combined antihypertensive treatment with amlodipine and lisinopril in metabolic syndrome]. ( Praskurnichiĭ, EA; Savel'eva, SA; Shevchenko, OP, 2008) |
| " This study evaluated the effect of a calcium channel blocker, amlodipine, on LV hypertrophy in patients with hypertension." | 9.12 | Effect of amlodipine on ventricular hypertrophy in hypertension patients: a systematic review and meta-analysis. ( Gao, Y; Yang, P; Zhou, D, 2021) |
| "The Effect of Losartan and Amlodipine on Left Ventricular Diastolic Function in Patients With Mild-to-Moderate Hypertension (J-ELAN) study is a multicenter, prospective, randomized trial designed to assess the effects of losartan and amlodipine on LV diastolic function in hypertensive patients with LV diastolic dysfunction in the absence of systolic dysfunction." | 9.12 | Effect of losartan and amlodipine on left ventricular diastolic function in patients with mild-to-moderate hypertension (J-ELAN): rationale and design. ( , 2006) |
| "The aim of the study was to evaluate the effect of losartan as compared with amlodipine, both associated with amiodarone, in preventing the recurrence of atrial fibrillation (AF) in hypertensive patients with a history of recent paroxysmal atrial fibrillation." | 9.12 | Losartan and prevention of atrial fibrillation recurrence in hypertensive patients. ( Corradi, L; Destro, M; Fogari, E; Fogari, R; Mugellini, A; Rinaldi, A; Zoppi, A, 2006) |
| " Patients with systolic-diastolic or isolated systolic hypertension (n = 1758) received indapamide (1." | 9.12 | Indapamide SR versus candesartan and amlodipine in hypertension: the X-CELLENT Study. ( Asmar, R; Calvo, C; London, G; Schmieder, R, 2006) |
| "The purpose of this study was to compare the efficacy and tolerability of amlodipine orotate with those of amlodipine besylate in Korean patients with mild to moderate hypertension." | 9.12 | Comparison of efficacy and tolerability of amlodipine orotate versus amlodipine besylate in adult patients with mild to moderate hypertension: a multicenter, randomized, double-blind, placebo-controlled, parallel-group, 8-week follow-up, noninferiority tr ( Ahn, TH; Baek, SH; Cho, WH; Hong, SJ; Jeon, HK; Kwan, J; Kyun, J; Lee, KJ; Lim, DS; Yoon, MH, 2006) |
| "To compare the efficacy of amlodipine and valsartan in African-American patients with hypertension using ambulatory blood pressure monitoring (ABPM)." | 9.12 | Randomized, double-blind, crossover comparison of amlodipine and valsartan in african-americans with hypertension using 24-hour ambulatory blood pressure monitoring. ( Aryana, A; Hilleman, DE; Maciejewski, S; Mohiuddin, SM; Mooss, AN; Packard, KA; Reyes, AP, 2006) |
| "To assess antihypertensive efficacy of a low-dose combination of amlodipin with lisinopril in the treatment of patients with arterial hypertension (AH) of the second degree." | 9.12 | [Combined therapy with amlodipin and lisinopril in arterial hypertension: efficacy of a low-dose combination]. ( Davidovich, IM; Petrichko, TA, 2006) |
| "The AVALON study was a randomized, multicenter trial to assess the efficacy and safety of coadministered amlodipine and atorvastatin in patients with hypertension and dyslipidemia." | 9.12 | Efficacy and safety of coadministered amlodipine and atorvastatin in patients with hypertension and dyslipidemia: results of the AVALON trial. ( Bakris, GL; Ferrera, D; Flack, JM; Houston, MC; Lee, E; Messerli, FH; Neutel, JM; Petrella, RJ; Sun, W, 2006) |
| "The objective of this study was to assess the effect of amlodipine-atorvastatin combination on plasma interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-alpha) and insulin sensitivity in normocholesterolemic obese hypertensive patients." | 9.12 | Effects of amlodipine-atorvastatin combination on inflammation markers and insulin sensitivity in normocholesterolemic obese hypertensive patients. ( Ciccarelli, L; Corradi, L; Derosa, G; Fogari, E; Fogari, R; Lazzari, P; Preti, P; Zoppi, A, 2006) |
| " Forty-three patients with untreated essential hypertension were randomized to receive amlodipine (n=22) or telmisartan (n=21), which were respectively administered at doses of 5 mg and 40 mg once daily in the morning for 24 weeks." | 9.12 | Renal and vascular protective effects of telmisartan in patients with essential hypertension. ( Maki, K; Morimoto, S; Sawada, K; Yano, Y, 2006) |
| "Fourteen patients with primary hypertension participated in a double-blind, cross-over study comparing the effects of 6 weeks of treatment with mibefradil 100 mg daily and amlodipine 10 mg daily." | 9.12 | Long-term calcium antagonist treatment of human hypertension with mibefradil or amlodipine increases sympathetic nerve activity. ( Ekholm, M; Hjemdahl, P; Kahan, T; Lindqvist, M; Melcher, A, 2007) |
| "Patients with essential hypertension (EHT) were randomized to treatment prospectively with losartan (50-100 mg/d) or amlodipine (5-10 mg/d) for 3 months." | 9.12 | The effect of losartan and amlodipine on serum adiponectin in Japanese adults with essential hypertension. ( Fukuoka, T; Higaki, J; Irita, J; Kurata, M; Manabe, S; Miyoshi, K; Murakami, K; Okura, T; Watanabe, S, 2006) |
| "5 mg/day and potassium chloride was compared with that of enalapril 10 mg/day and amlodipine 5 mg/day in patients with mild to moderate primary hypertension." | 9.12 | Efficacy and safety of 24 weeks of therapy with bendroflumethiazide 1.25 mg/day or 2.5 mg/day and potassium chloride compared with enalapril 10 mg/day and amlodipine 5 mg/day in patients with mild to moderate primary hypertension : a multicentre, randomis ( Borrild, N; Rasmussen, S; Vang Andersen, J, 2006) |
| "The aim of this study was to assess the effect of valsartan addition to amlodipine on ankle foot volume (AFV) and pretibial subcutaneous tissue pressure (PSTP), two objective measures of ankle oedema." | 9.12 | Effect of valsartan addition to amlodipine on ankle oedema and subcutaneous tissue pressure in hypertensive patients. ( Derosa, G; Fogari, E; Fogari, R; Lazzari, P; Mugellini, A; Preti, P; Rinaldi, A; Zoppi, A, 2007) |
| " In this study, we compared the efficacy of azelnidipine to that of amlodipine in lowering morning BP and reducing PR in outpatients with essential hypertension." | 9.12 | Efficacy of azelnidipine on home blood pressure and pulse rate in patients with essential hypertension: comparison with amlodipine. ( Yamagishi, T, 2006) |
| "This study aimed to clarify the impact of telmisartan on fat distribution and insulin sensitivity in the metabolic syndrome." | 9.12 | Effects of telmisartan on fat distribution in individuals with the metabolic syndrome. ( Shimabukuro, M; Shimabukuro, T; Tanaka, H, 2007) |
| "Forty-nine patients with untreated mild to moderate essential hypertension were recruited in a randomized double-blind study to receive a daily dose either of 8 mg candesartan or 5 mg amlodipine for 16 weeks." | 9.12 | Effects of amlodipine and candesartan on oxidized LDL level in patients with mild to moderate essential hypertension. ( Fischer, K; Kampus, P; Muda, P; Ristimäe, T; Teesalu, R; Zilmer, K; Zilmer, M, 2006) |
| "Aim of this study was to evaluate the effect of the telmisartan-amlodipine combination at different doses on urinary albumin excretion rate (UAER) in hypertensive diabetic patients with microalbuminuria." | 9.12 | Effect of telmisartan-amlodipine combination at different doses on urinary albumin excretion in hypertensive diabetic patients with microalbuminuria. ( Derosa, G; Destro, M; Fogari, E; Fogari, R; Lazzari, P; Mugellini, A; Preti, P; Rinaldi, A; Zoppi, A, 2007) |
| "We evaluated the long-term efficacy of losartan and low-dose hydrochlorothiazide combination therapy in the treatment of hypertension." | 9.12 | Long-term efficacy of combination therapy with losartan and low-dose hydrochlorothiazide in patients with uncontrolled hypertension. ( Abe, C; Akashiba, A; Ishimitsu, T; Kameda, T; Matsuoka, H; Minami, J; Takahashi, T, 2007) |
| "This study evaluated the overall safety profile of combination therapy with amlodipine plus valsartan compared with a combination of lisinopril plus hydrochlorothiazide (HCTZ) in patients with stage 2 hypertension (mean sitting diastolic BP [MSDBP] >or=110 and <120 mm Hg) over the short term (6 weeks)." | 9.12 | Tolerability and blood pressure-lowering efficacy of the combination of amlodipine plus valsartan compared with lisinopril plus hydrochlorothiazide in adult patients with stage 2 hypertension. ( Chiang, YT; Fomina, I; Gamboa, R; Glazes, R; Kaczor, J; Kargiannis, S; Poldermans, D; Wernsing, M; Yen, J, 2007) |
| "To assess whether treatment with a dihydropyridine calcium antagonist can prevent the development of hypertension and renal dysfunction after heart transplantation, 38 patients receiving cyclosporine for immunosuppression were randomized shortly after cardiac transplantation to placebo or amlodipine 2." | 9.12 | Prevention of renal dysfunction and hypertension by amlodipine after heart transplant. ( Coletta, E; Davies, RA; Leenen, FH, 2007) |
| "Fifty patients with untreated essential hypertension were randomized to receive 5 mg of amlodipine (n = 25) or 10 mg of cilnidipine (n = 25) once daily in the morning for 24 weeks." | 9.12 | Renal and vascular protective effects of cilnidipine in patients with essential hypertension. ( Iwasaka, T; Maki, K; Morimoto, S; Yano, Y, 2007) |
| "5 mg was compared with that of amlodipine, in a multicentre, double-blind, randomised, parallel-group study in patients with mild-to-moderate essential hypertension inadequately controlled by monotherapy." | 9.12 | Efficacy and tolerability of candesartan cilexetil/hydrochlorothiazide and amlodipine in patients with poorly controlled mild-to-moderate essential hypertension. ( Derosa, G; Fogari, R; Mugellini, A, 2007) |
| "Amlodipine and nifedipine CR were administered to 41 patients with essential hypertension for more than 6 weeks each in a randomized open-label crossover study." | 9.12 | Crossover study of amlodipine versus nifedipine CR with home blood pressure monitoring via cellular phone: internet-mediated open-label crossover trial of calcium channel blockers for hypertension (i-TECHO trial). ( Itagaki, K; Nakajima, S; Nakamoto, H; Nishida, E; Ryuzaki, M; Sone, M; Suzuki, Y; Yoshimoto, M, 2007) |
| "Amlodipine besylate has been used in Korea for the treatment of hypertension for >17 years, with well-established efficacy and tolerability." | 9.12 | Results of a phase III, 8-week, multicenter, prospective, randomized, double-blind, parallel-group clinical trial to assess the effects of amlodipine camsylate versus amlodipine besylate in Korean adults with mild to moderate hypertension. ( Ahn, YK; Chung, WS; Kim, HS; Kim, IJ; Kim, JJ; Kim, SH; Kim, YD; Lee, JW; Lim, DS; On, YK; Park, JB; Seo, HS; Shin, EK; Yang, JY; Yoon, MH, 2007) |
| " The Respond trial assessed whether combining amlodipine to treat hypertension and atorvastatin to treat dyslipidemia affected the action of either monotherapy." | 9.12 | A randomized, placebo-controlled trial to evaluate the efficacy, safety, and pharmacodynamic interaction of coadministered amlodipine and atorvastatin in 1660 patients with concomitant hypertension and dyslipidemia: the respond trial. ( Dykstra, G; Gillen, D; Harvey, P; Herfert, O; Jukema, JW; Preston, RA; Sun, F, 2007) |
| "The aim of this study was to compare the time-effect profiles of a once-daily administration of valsartan and amlodipine, each given alone or in combination with hydrochlorothiazide, in terms of ambulatory blood pressure (BP) and heart rate in elderly patients with isolated systolic hypertension." | 9.11 | Comparison of the effects on 24-h ambulatory blood pressure of valsartan and amlodipine, alone or in combination with a low-dose diuretic, in elderly patients with isolated systolic hypertension (Val-syst Study). ( Ambrosia, GB; Caiazza, A; Malacco, E; Mugellini, A; Palatini, P; Santonastaso, M; Spagnuolo, V, 2004) |
| "To compare the effects of the angiotensin receptor blocker (ARB) valsartan versus the calcium channel blocker amlodipine, reactive oxygen species (ROS) formation by monocytes, C-reactive protein (CRP), and left ventricular (LV) mass were studied in 104 hypertensive patients with left ventricular hypertrophy (LVH)." | 9.11 | Comparative effects of valsartan versus amlodipine on left ventricular mass and reactive oxygen species formation by monocytes in hypertensive patients with left ventricular hypertrophy. ( Asada, A; Maeda, K; Nakamura, M; Watanabe, T; Yasunari, K; Yoshikawa, J, 2004) |
| "To demonstrate that calcium channel blockers can improve insulin resistance clinically, we investigated the effects of the calcium channel blockers, amlodipine, manidipine and cilnidipine on serum levels of steroid hormones and insulin." | 9.11 | Effects of the long-acting calcium channel blockers, amlodipine, manidipine and cilnidipine on steroid hormones and insulin resistance in hypertensive obese patients. ( Miyachi, Y; Ueshiba, H, 2004) |
| "Amlodipine increased NO production, at least in the pulmonary circulation, in patients with essential hypertension." | 9.11 | Amlodipine increases nitric oxide production in exhaled air during exercise in patients with essential hypertension. ( Hirata, Y; Hirose, K; Iwasawa, K; Kato, M; Matsumoto, A; Nagai, R; Nakajima, T; Sugiura, S; Takenaka, K; Yamashita, H, 2004) |
| "The aim of this study was to evaluate the effect of the amlodipine-atorvastatin combination on plasma tissue plasminogen activator (t-PA) and plasminogen activator inhibitor type 1 (PAI-1) activity in hypercholesterolemic, hypertensive patients with insulin resistance." | 9.11 | Effect of amlodipine-atorvastatin combination on fibrinolysis in hypertensive hypercholesterolemic patients with insulin resistance. ( Derosa, G; Fogari, E; Fogari, R; Lazzari, P; Mugellini, A; Rinaldi, A; Zoppi, A, 2004) |
| "The aim of the study was to compare the antihypertensive effects and the duration of action of telmisartan, amlodipine and ramipril in patients with mild-to-moderate hypertension using ambulatory blood pressure (ABP) monitoring." | 9.11 | A comparison of the efficacy and duration of action of telmisartan, amlodipine and ramipril in patients with confirmed ambulatory hypertension. ( de Champlain, J; Lacourcière, Y; Lamarre-Cliche, M; Larochelle, P; Poirier, L, 2004) |
| "This study compared the efficacy, tolerability, and duration of antihypertensive effect of amlodipine besylate and enalapril in Chinese patients with hypertension, including elderly patients with isolated systolic hypertension." | 9.11 | Randomized, controlled, parallel-group comparison of ambulatory and clinic blood pressure responses to amlodipine or enalapril during and after treatment in adult chinese patients with hypertension. ( Chau, YM; Critchley, JA; Thomas, GN; Tomlinson, B; Woo, J, 2004) |
| "Treatment of uncomplicated essential hypertension using amlodipine-based anti-hypertensive therapy results in a reversal of the platelet morphology abnormalities and indices of platelet activation." | 9.11 | Platelet morphology and plasma indices of platelet activation in essential hypertension: effects of amlodipine-based antihypertensive therapy. ( Blann, AD; Lip, GY; Nadar, S, 2004) |
| "5 mg of S-Amlodipine with 5 mg of Amlodipine in the treatment of mild to moderate hypertension in a double blind, double dummy, randomized, comparative clinical trial." | 9.11 | Multicentric, clinical trial of S-Amlodipine 2.5 mg versus Amlodipine 5 mg in the treatment of mild to moderate hypertension--a randomized, double-blind clinical trial. ( Kerkar, PG; Manade, VG; Pathak, L, 2004) |
| "Forty-nine middle-aged patients with untreated stage I-II essential hypertension were recruited in a randomized double-blind double-dummy study to receive a daily dose either of 8 mg candesartan (n = 25) or 5 mg amlodipine (n = 24) for 16 weeks." | 9.11 | Effect of antihypertensive treatment with candesartan or amlodipine on glutathione and its redox status, homocysteine and vitamin concentrations in patients with essential hypertension. ( Fischer, K; Kairane, C; Kampus, P; Muda, P; Ristimäe, T; Teesalu, R; Zilmer, K; Zilmer, M, 2005) |
| "In order to evaluate therapeutic effects of amlodipine on intravascular thrombocyte activity (ITA) in patients having arterial hypertension (AH) with metabolic syndrome (MS), 20 patients were treated with amlodipine for 1 month." | 9.11 | [Effect of amlodipine on intravascular thrombocyte activity in patients with arterial hypertension and metabolic syndrome]. ( Gromnatskiĭ, NI; Medvedev, IN, 2005) |
| "To estimate the influence of therapy with amlodipine (A) or lacidipine (L) on heart rate variability (HRV) time and frequency domain parameters in hypertensive patients with stable angina pectoris and isolated left ventricular diastolic dysfunction." | 9.11 | Effects of amlodipine and lacidipine on heart rate variability in hypertensive patients with stable angina pectoris and isolated left ventricular diastolic dysfunction. ( Brazdzionyte, J; Jurkevicius, R; Zabiela, V; Zaliūnas, R, 2005) |
| "Fifty-nine hypertensive patients with associated coronary artery disease (stable angina pectoris) and isolated diastolic dysfunction were randomized to receive amlodipine (30 patients) or lacidipine (29 patients) for 4 weeks." | 9.11 | Effect of amlodipine and lacidipine on left ventricular diastolic and long axis functions in arterial hypertension and stable angina pectoris. ( Brazdzionyte, J; Jurkevicus, R; Zabiela, V; Zaliunas, R, 2005) |
| "The goal of this study was to compare the antihypertensive effect and tolerability of amlodipine adipate with those of amlodipine besylate in patients with mild to moderate hypertension." | 9.11 | Clinic blood pressure responses to two amlodipine salt formulations, adipate and besylate, in adult Korean patients with mild to moderate hypertension: a multicenter, randomized, double-blind, parallel-group, 8-week comparison. ( Chong-Yun, R; Heung-Sun, K; Jin-Ok, J; Joo, SJ; Joon-Han, S; Ju, AK; Kang, HJ; Kang, JH; Kim, KS; Kim, MH; Koo, BK; Lee, HY; Lim, DK; Oh, BH; Park, KM; Park, SH; Park, SY; Ro, YM; Seo, HS; Woong, CJ; Yeon, KJ; Yoon, J, 2005) |
| "The antihypertensive efficacy of nebivolol and amlodipine and their tolerability were compared in a multicentre, randomized, active-controlled, double-blind parallel-group trial in elderly patients with mild to moderate essential arterial hypertension." | 9.10 | Nebivolol vs amlodipine as first-line treatment of essential arterial hypertension in the elderly. ( Gil-Extremera, B; Maldonato, A; Mazza, A; Pessina, AC; Toutouzas, T, 2002) |
| "Three hundred thirty-two patients with type 2 diabetes and microalbuminuria, with or without hypertension, were randomly assigned to 80 mg/d valsartan or 5 mg/d amlodipine for 24 weeks." | 9.10 | Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect. ( Viberti, G; Wheeldon, NM, 2002) |
| " The patients in the hypertension group were treated with amlodipine, then examined again." | 9.10 | Improvement of endothelial function by amlodipine and vitamin C in essential hypertension. ( Choi, YS; Kim, CH; Lee, MM; Oh, BH; On, YK; Park, YB; Sohn, DW, 2002) |
| "We selected 453 hypertensive patients with type 2 diabetes and microalbuminuria and randomized them to amlodipine (5 to 15 mg/day), fosinopril (10 to 30 mg/day), or amlodipine plus fosinopril (5/10 to 15/30 mg/day) for a 3-month titration period." | 9.10 | Effects of amlodipine fosinopril combination on microalbuminuria in hypertensive type 2 diabetic patients. ( Corradi, L; Derosa, G; Fogari, R; Lazzari, P; Marasi, G; Mugellini, A; Pasotti, C; Poletti, L; Preti, P; Rinaldi, A; Voglini, C; Zoppi, A, 2002) |
| "The efficacy and safety of nisoldipine-extended release (ER) and amlodipine were compared in a 6-week multicenter, randomized, double-blind, double-dummy, parallel group, titration-to-effect trial in patients with stage 1 to 2 systemic hypertension (90 to 109 mm Hg diastolic blood pressure [BP]) and chronic stable angina pectoris." | 9.10 | Comparison of effects of nisoldipine-extended release and amlodipine in patients with systemic hypertension and chronic stable angina pectoris. ( Bittar, N; Cooper-DeHoff, RM; Hutchinson, HG; Koren, M; Michelson, EL; Minkwitz, MC; Pepine, CJ; Thadani, U; Weiss, RJ, 2003) |
| "To evaluate the effect of losartan and amilodipine on the platelet activation and renal function, and to study the relationship between the platelet activation and hypertensive renal damage in patients with mild and moderate hypertension." | 9.10 | [Effect of losartan and amilodipine on the platelet activation and renal function in patients with mild and moderate hypertension]. ( Xie, XM; Yu, GL; Zhou, P, 2002) |
| "The aim of this study was to evaluate the effect of benazepril addition to amlodipine antihypertensive treatment on ankle-foot volume (AFV) and pretibial subcutaneous tissue pressure (PSTP), two objective measures of ankle oedema." | 9.10 | Effect of benazepril addition to amlodipine on ankle oedema and subcutaneous tissue pressure in hypertensive patients. ( Fogari, R; Malamani, GD; Mugellini, A; Preti, P; Rinaldi, A; Vanasia, A; Zoppi, A, 2003) |
| "Eplerenone is a highly selective aldosterone blocker, which is under development for the treatment of hypertension and heart failure." | 9.10 | Effects of the selective aldosterone blocker eplerenone versus the calcium antagonist amlodipine in systolic hypertension. ( Duprez, D; Krause, S; Kuse-Hamilton, J; Roniker, B; St Hillaire, R; Weber, MA; White, WB, 2003) |
| "A 90-day, multicenter, randomized, double-blind, parallel-group study was conducted to compare the efficacy of amlodipine (once a day) with nicardipine (two to three times a day), in the treatment of isolated systolic hypertension (ISH) in the elderly." | 9.10 | Randomized, comparative, double-blind study of amlodipine vs. nicardipine as a treatment of isolated systolic hypertension in the elderly. ( Bernaud, C; Carre, A; Clerson, P; Emeriau, JP; Jaboureck, O; Mounier-Véhier, C, 2002) |
| "In postmenopausal females with mild to moderate hypertension the oedema formation of Lercanidipine was significantly less than that of Amlodipine, despite no significant differences in the antihypertensive effect." | 9.10 | Quantification of leg oedema in postmenopausal hypertensive patients treated with lercanidipine or amlodipine. ( Helberg, S; Istad, H; Lund-Johansen, P; Madsbu, S; Risberg, K; Rønnevik, PK; Stranden, E; Wessel-Aas, T, 2003) |
| " The aim of the present study was to compare the effects of losartan and amlodipine on proteinuria, as well as on serum and urine TGF-beta1 levels in IgA nephropathy patients with hypertension and proteinuria." | 9.10 | Effect of losartan and amlodipine on proteinuria and transforming growth factor-beta1 in patients with IgA nephropathy. ( Choi, KH; Choi, S; Goo, YS; Ha, SK; Han, DS; Kang, SW; Lee, HY; Park, HC; Xu, ZG, 2003) |
| " This randomized, double-blind study compared the antihypertensive efficacy of the starting dose of olmesartan medoxomil with that of the calcium channel blocker amlodipine besylate (amlodipine) in subjects with mild-to-moderate hypertension." | 9.10 | Antihypertensive efficacy and safety of olmesartan medoxomil compared with amlodipine for mild-to-moderate hypertension. ( Chrysant, SG; Marbury, TC; Robinson, TD, 2003) |
| "One hundred eighteen patients with mild-to-moderate essential arterial hypertension were randomized to treatment with 10 mg/d of amlodipine (group 1), 20 mg/d of quinapril (group 2), or 2 x 50 mg/d of losartan (group 3)." | 9.10 | Effect of amlodipine, quinapril, and losartan on pulse wave velocity and plasma collagen markers in patients with mild-to-moderate arterial hypertension. ( Kawecka-Jaszcz, K; Klocek, M; Rajzer, M, 2003) |
| "To compare the effectiveness, safety and tolerability of once-daily nifedipine and amlodipine treatment in patients with mild-to-moderate essential hypertension." | 9.10 | Treatment of mild-to-moderate hypertension with calcium channel blockers: a multicentre comparison of once-daily nifedipine GITS with once-daily amlodipine. ( Caglar, N; Canberk, A; Deger, N; Demirtas, M; Dortlemez, H; Kes, S; Kiliccioglu, B; Kozan, O; Ovunc, K; Turkoglu, C, 2003) |
| "The long-term effects of amlodipine, a calcium channel blocker, were examined in patients with moderate to severe hypertension." | 9.10 | Amlodipine improves vascular function in patients with moderate to severe hypertension. ( Ohtsuka, S; Oyake, Y; Yamaguchi, I; Yamazaki, A, 2003) |
| "This study evaluates the efficacy of the new dihydropyridine calcium antagonist nisoldipine extended-release (ER) compared to amlodipine on ambulatory and clinic blood pressures (BP) and heart rates in African American patients with hypertension." | 9.10 | Comparative efficacy and safety of nisoldipine extended-release (ER) and amlodipine (CESNA-III study) in African American patients with hypertension. ( Ferdinand, K; Noveck, RJ; Saunders, E; White, WB, 2003) |
| "To compare the effect of amlodipine, a prototype dihydropyridine calcium-channel blocker with lercanidipine, a newer dihydropyridine compound with lipophilic properties, on dependent oedema generation and interference with skin blood flow vasomotion in hypertensive patients." | 9.10 | Heterogeneous effect of calcium antagonists on leg oedema: a comparison of amlodipine versus lercanidipine in hypertensive patients. ( Balbarini, A; Dell'Omo, G; Mariani, M; Menegato, A; Nuti, M; Pedrinelli, R, 2003) |
| " This study compared LVH regression during treatment with the selective aldosterone blocker eplerenone, enalapril, and their combination in patients with hypertension." | 9.10 | Effects of eplerenone, enalapril, and eplerenone/enalapril in patients with essential hypertension and left ventricular hypertrophy: the 4E-left ventricular hypertrophy study. ( Burns, D; Kleiman, J; Krause, S; Phillips, RA; Pitt, B; Reichek, N; Roniker, B; Willenbrock, R; Williams, GH; Zannad, F, 2003) |
| "The aim of this study was to comparatively assess the effects of irbesartan and amlodipine monotherapies on left ventricular mass index (LVMI) in patients with mild to moderate untreated hypertension and echocardiographically determined left ventricular hypertrophy (LVH)." | 9.10 | Comparative effects of irbesartan versus amlodipine on left ventricular mass index in hypertensive patients with left ventricular hypertrophy. ( Fedele, F; Fera, MS; Ferri, FM; Gaudio, C; Giovannini, M; Pannarale, G; Puddu, PE; Vittore, A; Vizza, CD, 2003) |
| "0 years) with mild to moderate essential hypertension were included in a randomized, double-blind study to receive either valsartan (80 to 160 mg) or amlodipine (5 to 10 mg)." | 9.10 | Direct comparison of the effects of valsartan and amlodipine on renal hemodynamics in human essential hypertension. ( Delles, C; Handrock, R; Klingbeil, AU; Schmieder, RE; Schneider, MP; Weidinger, G, 2003) |
| "This study compared the risk/benefit profiles of valsartan and amlodipine in elderly patients who have isolated systolic hypertension (ISH)." | 9.10 | A randomized, double-blind, active-controlled, parallel-group comparison of valsartan and amlodipine in the treatment of isolated systolic hypertension in elderly patients: the Val-Syst study. ( Borgnino, C; Capuano, V; Malacco, E; Palatini, P; Spagnuolo, V; Varì, N, 2003) |
| "The study was to compare the effects of amlodipine (calcium channel antagonist), chlorthalidone (diuretic), and placebo in adults more than 50 years of age with stage 1 isolated systolic hypertension (ISH)." | 9.10 | Amlodipine versus chlorthalidone versus placebo in the treatment of stage I isolated systolic hypertension. ( Black, H; Ghadanfar, M; Grimm, RH; Lewin, A; Rowen, R; Shi, H, 2002) |
| " Thirty chronically hemodialyzed uremic patients with hypertension were randomly assigned to receive the AT1-R antagonist losartan (n = 10), the angiotensin-converting enzyme (ACD) inhibitor enalapril (n = 10), or calcium antagonist amlodipine (n = 10)." | 9.10 | Angiotensin II type 1 receptor antagonist, losartan, causes regression of left ventricular hypertrophy in end-stage renal disease. ( Iwasaka, T; Masaki, H; Matsubara, H; Nishikawa, M; Nishiue, T; Shibasaki, Y, 2002) |
| "Of the 310 randomized outpatients with uncomplicated mild-to-moderate primary hypertension, 259 (133 on valsartan/hydrochlorothiazide, 126 on amlodipine) were eligible for analysis." | 9.10 | Trough:peak ratio and smoothness index in the evaluation of 24-h blood pressure control in hypertension: a comparative study between valsartan/hydrochlorothiazide combination and amlodipine. ( Bertocchi, F; Carretta, R; Di, SS; Dorigatti, F; Malacco, E; Mann, J; Palatini, P, 2002) |
| "This study assessed the effects of calcium channel blocker Amlodipine on the cerebral circulation in patients with essential hypertension." | 9.09 | The effects of amlodipine on cerebral circulatory values in patients with essential hypertension. ( Alizade, IG; Karayeva, NT, 2001) |
| "To evaluate the appropriate dosing of amlodipine when converting patients from nifedipine extended-release (nifedipine ER) to amlodipine in the treatment of hypertension." | 9.09 | Evaluation of amlodipine dosing for conversion of nifedipine extended-release to amlodipine in the treatment of hypertension. ( Enlow, AM; Halverson, VJ; Kilpatrick, DM; Lower, DL; Montopoli, G; Yamreudeewong, W, 1999) |
| "To compare the therapeutic coverage and safety of amlodipine and perindopril in patients with mild to moderate hypertension (diastolic blood pressure > or = 90 mmHg and < or = 109 mmHg)." | 9.09 | Double-blind, randomized, multicentre comparison of the effects of amlodipine and perindopril on 24 h therapeutic coverage and beyond in patients with mild to moderate hypertension. General Physicians Investigators' Group. ( Bernaud, CM; Fay, R; Zannad, F, 1999) |
| "This study compares the effects of a calcium channel blocker (amlodipine) and an angiotensin converting enzyme inhibitor (enalapril) on in vivo insulin sensitivity in patients with essential hypertension." | 9.09 | A double blind comparison of the effects of amlodipine and enalapril on insulin sensitivity in hypertensive patients. ( Arauz-Pacheco, C; Breen, L; Lender, D; Mora-Mora, P; Ramirez, LC; Raskin, P, 1999) |
| "Amlodipine, a dihydropyrimidine calcium antagonist, is effective in the treatment of patients with mild to moderate hypertension at doses of 5-10 mg daily." | 9.09 | Is initial dose titration of amlodipine worthwhile in patients with mild to moderate hypertension? ( Adamczak, M; Hayduk, K; Nowitzki, G, 1999) |
| " The purpose of this study was to assess the effects of amlodipine and cilnidipine on the cardiac sympathetic nervous system and the neurohormonal status of essential hypertension." | 9.09 | Effects of amlodipine and cilnidipine on cardiac sympathetic nervous system and neurohormonal status in essential hypertension. ( Miho, N; Nawada, R; Obayashi, K; Sakata, K; Shirotani, M; Togi, K; Yoshida, H, 1999) |
| "Out of 245 randomized outpatients (90 men, 155 women) with uncomplicated mild-to-moderate primary hypertension and mean sitting diastolic blood pressure (DBP) 95-115 mmHg inclusive, 212 (102 on felodipine-metoprolol, 110 on amlodipine) were eligible for analysis." | 9.09 | Ambulatory 24-h blood pressure assessment of the felodipine-metoprolol combination versus amlodipine in mild to moderate hypertension. Lorraine General Physician Investigators Group. ( Boivin, JM; Zannad, F, 1999) |
| "The aim of this study was to compare the effect of amlodipine and enalapril on platelet aggregation, and platelet production of malondialdehyde in patients with mild to moderate arterial hypertension." | 9.09 | Effects of amlodipine and enalapril on platelet function in patients with mild to moderate hypertension. ( Armas de Hernández, MJ; Armas-Padilla, MC; Carvajal, AR; Guerrero-Pajuelo, J; Hernández-Hernández, R; Pacheco, B; Velasco, M, 1999) |
| " To evaluate the dose-response relation between this pharmacological interference and dependent edema, a frequent side effect of CCBs during antihypertensive treatment, skin blood flow (laser Doppler flowmetry) at the dorsum of the foot, both supine and with the limb passively placed 50 cm below the heart level, and leg weight (Archimedes principle) were measured at baseline, during increasing doses of the dihydropyridine amlodipine (5 and 10 mg UID each for 2 weeks), and after drug withdrawal in 10 hypertensive men." | 9.09 | Amlodipine, enalapril, and dependent leg edema in essential hypertension. ( Dell'Omo, G; Mariani, M; Melillo, E; Pedrinelli, R, 2000) |
| " After a 4-week placebo run-in period, 25 patients with mild-to-moderate essential hypertension were randomly allocated to active treatment with Losartan 50 mg titrated to Losartan 50 mg/hydrochlorothiazide (HCT) 12." | 9.09 | Effects of losartan titrated to Losartan/Hydrochlorothiazide and amlodipine on left ventricular mass in patients with mild-to-moderate hypertension. A double-blind randomized controlled study. ( Battegay, E; Dieterle, T; Martina, B; Weinbacher, M, 1999) |
| " Doxazosin and amlodipine, alone and in combination, were compared for efficacy in reducing blood pressure (BP) in 75 patients with predominantly moderate (Stage 2) hypertension." | 9.09 | Clinically additive effect between doxazosin and amlodipine in the treatment of essential hypertension. ( Nalbantgil, I; Nalbantgil, S; Onder, R, 2000) |
| "The safety and efficacy of Amlodipine (AML) for mild to moderate hypertension was evaluated in a "real life" setting." | 9.09 | [Multicenter community-based trial of amlodipine in hypertension in Israel]. ( Leshem, Y; Rav-Hon, Y; Rosenberg, GI; Viskoper, JR; Yaskil, E; Yosefy, C, 1999) |
| "This multicenter study evaluated the efficacy of candesartan cilexetil, an angiotensin II type 1 receptor antagonist, used alone or in combination with amlodipine or in combination with amlodipine and hydrochlorothiazide in the treatment of patients with moderate-to-severe essential hypertension." | 9.09 | Efficacy of candesartan cilexetil alone or in combination with amlodipine and hydrochlorothiazide in moderate-to-severe hypertension. UK and Israel Candesartan Investigators. ( Antonios, TF; He, FJ; MacGregor, GA; Viskoper, JR, 2000) |
| "25 mg (n = 84) to amlodipine 5 mg (n = 80) in isolated systolic hypertension in patients older than 60 years." | 9.09 | Efficacy, safety, and effects on quality of life of bisoprolol/hydrochlorothiazide versus amlodipine in elderly patients with systolic hypertension. ( Benetos, A; Consoli, S; Dubanchet, A; Safar, M; Safavian, A, 2000) |
| "This study was undertaken to assess the efficacy and tolerability of amlodipine, a long-acting calcium channel blocker, in elderly (> or =65 years of age) patients with mild to moderate hypertension (diastolic blood pressure 95 to 114 mm Hg)." | 9.09 | Treatment of hypertension in patients > or =65 years of age: experience with amlodipine. ( Langdon, C, 2000) |
| "To compare in the non-blind randomised parallel study the efficiency of quadropril and amlodipine in the treatment of mild to moderate arterial hypertension." | 9.09 | [Comparative study of spirapril (quadropril) and amlodipine efficacy. Results of randomized trial in patients with mild to moderate arterial hypertension]. ( Alimova, EV; Deev, AD; Koniakhina, IP; Kukushkin, SK; Kutishenko, NP; Lebedev, AV; Manoshkina, EM; Martsevich, SIu; Semenova, IuE; Shal'nova, SA; Zagrebel'nyĭ, AV, 2000) |
| "The comparative antihypertensive efficacy and tolerability of the angiotensin II receptor blocker candesartan cilexetil and the calcium channel blocker amlodipine were evaluated in an 8-week, multicenter, double-blind, randomized, parallel-group, forced-titration study in 251 adult patients (45% women, 16% black) with mild hypertension (stage 1)." | 9.09 | Comparative effects of candesartan cilexetil and amlodipine in patients with mild systemic hypertension. Comparison of Candesartan and Amlodipine for Safety, Tolerability and Efficacy (CASTLE) Study Investigators. ( Chrysant, SG; Harris, SM; Kloner, RA; Leidy, NK; Michelson, EL; Pool, JL; Prasad, R; Weinberger, M; Zyczynski, TM, 2001) |
| "A comparison of treatment costs and cost effectiveness was performed retrospectively by using patient-level data from a randomized, controlled, one-year clinical trial of amlodipine and enalapril in the treatment of mild-to-moderate hypertension." | 9.09 | A retrospective analysis comparing the costs and cost effectiveness of amlodipine and enalapril in the treatment of hypertension. ( Arikian, S; Arocho, R; Casciano, J; Casciano, R; Doyle, J; Gonzalez, MA; Omvik, P, 2001) |
| "All studies suggesting a lower incidence of edema on lacidipine than on amlodipine are based on subjective scoring." | 9.09 | Ankle edema formation during treatment with the calcium channel blockers lacidipine and amlodipine: a single-centre study. ( Andrésdóttir, MB; Huysmans, FT; Valk, IM; van de Bosch, WJ; van Hamersvelt, HW; van Helden, MJ, 2000) |
| "To investigate the effect of amlodipine on baroreflex sensitivity and sympathetic system activity, 36 patients with essential hypertension were randomized to once-daily, double-blind treatment with amlodipine 5 mg or placebo 5 mg for 60 days." | 9.09 | Effects of amlodipine on baroreflex and sympathetic nervous system activity in mild-to-moderate hypertension. ( Baguet, JP; de Gaudemaris, R; Fagret, D; Mallion, JM; Siché, JP; Trémel, F, 2001) |
| "Ramipril, compared with amlodipine, retards renal disease progression in patients with hypertensive renal disease and proteinuria and may offer benefit to patients without proteinuria." | 9.09 | Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial. ( Agodoa, LY; Appel, L; Bakris, GL; Beck, G; Bourgoignie, J; Briggs, JP; Charleston, J; Cheek, D; Cleveland, W; Douglas, JG; Douglas, M; Dowie, D; Faulkner, M; Gabriel, A; Gassman, J; Greene, T; Hall, Y; Hebert, L; Hiremath, L; Jamerson, K; Johnson, CJ; Kopple, J; Kusek, J; Lash, J; Lea, J; Lewis, JB; Lipkowitz, M; Massry, S; Middleton, J; Miller, ER; Norris, K; O'Connor, D; Ojo, A; Phillips, RA; Pogue, V; Rahman, M; Randall, OS; Rostand, S; Schulman, G; Smith, W; Thornley-Brown, D; Tisher, CC; Toto, RD; Wright, JT; Xu, S, 2001) |
| "A total of 530 patients between 21 and 80 years of age with essential hypertension were screened for the study, and 454 were randomised to treatment with amlodipine 5 mg/benazepril 10 mg, amlodipine 5 mg, benazepril 10 mg, or placebo for 8 weeks." | 9.09 | Once-daily treatment of patients with hypertension: a placebo-controlled study of amlodipine and benazepril vs amlodipine or benazepril alone. ( Ginsberg, D; Glazer, R; Kaihlanen, P; Lewis, G; Messerli, FH; Oparil, S; Pool, J, 2001) |
| "In this multicentre, double-blind trial in 176 patients with mild or moderate essential hypertension were randomized to amlodipine or enalapril monotherapy after 2-week period of placebo." | 9.09 | [The comparison of hypotensive efficiency and tolerability of amlodipine and enalapril in patients with essential hypertension]. ( Gryglas, P, 2001) |
| "In this 1-year clinical study, we compared the efficacy and tolerability of amlodipine and nifedipine retard in 64 Chinese Type 2 diabetic patients with hypertension." | 9.09 | Blood pressure reduction and tolerability of amlodipine versus nifedipine retard in Chinese patients with type 2 diabetes mellitus and hypertension: a randomized 1-year clinical trial. ( Chan, CH; Chan, HC; Ko, GT, 2001) |
| "To compare the antihypertensive efficacy and tolerability of a once-daily fixed valsartan/hydrochlorothiazide (HCTZ) combination and amlodipine in subjects with mild-to-moderate hypertension." | 9.09 | A multicenter, randomized double-blind study of valsartan/hydrochlorothiazide combination versus amlodipine in patients with mild to moderate hypertension. ( Bertocchi, F; Bonaduce, D; Carretta, R; Condorelli, M; Fogari, R; Malacco, E; Mann, J; Palatini, P, 2001) |
| "This was a 20-week, open-label, uncontrolled clinical investigation of the long-acting calcium antagonist amlodipine in 33 male or female patients with essential hypertension and left ventricular hypertrophy (LVH)." | 9.09 | Amlodipine: effective for treatment of mild to moderate essential hypertension and left ventricular hypertrophy. ( Ebanks, M; Ihenacho, HN; Islim, IF; Singh, SP; Watson, RD, 2001) |
| "This double-blind, multicenter trial compared antihypertensive efficacy, tolerability, and impact on quality of life of manidipine and amlodipine in patients with mild-to-moderate essential hypertension." | 9.09 | Efficacy, tolerability, and impact on quality of life of long-term treatment with manidipine or amlodipine in patients with essential hypertension. ( De Cesaris, R; La Commare, P; Omboni, S; Palatini, P; Zanchetti, A, 2001) |
| "The main purpose of this study was to compare efficacy, tolerability and influence on quality of life (QOL) of nifedipine gastrointestinal therapeutic system (NI) 30-60 mg once a day vs amlodipine (AM) 5-10 mg once a day in elderly patients with mild-moderate hypertension." | 9.09 | Efficacy, tolerability and influence on "quality of life" of nifedipine GITS versus amlodipine in elderly patients with mild-moderate hypertension. ( Boari, L; De Dominicis, E; Giusti, C; Kilama, MO; Marchesi, M; Marelli, G; Mattarei, M; Mos, L; Novo, S; Pessina, AC; Pirrelli, A; Santini, M; Santonastaso, M; Semeraro, S; Uslenghi, E, 2001) |
| "To compare 24-hour blood pressure control and adverse effects in patients with essential hypertension who were switched from amlodipine to nisoldipine." | 9.09 | Comparison of 24-hour blood pressure profiles in patients with hypertension who were switched from amlodipine to nisoldipine. ( Hilleman, DE; Lenz, TL; Wurdeman, RL, 2001) |
| " We here compared the effects of the N-type calcium channel blockers cilnidipine and amlodipine on the sympathetic nervous system and platelet function in hypertension under resting and stressed conditions." | 9.09 | Cilnidipine more highly attenuates cold pressor stress-induced platelet activation in hypertension than does amlodipine. ( Doba, N; Kimura, Y; Kinouchi, T; Kuwabara, Y; Kuwata, S; Maruyama, C; Tomiyama, H; Yoshida, H; Yoshida, Y, 2001) |
| "The efficacy and safety of the novel calcium antagonist Amlodipine (Pfizer Laboratories, New York, New York) and hydrochlorothiazide were evaluated and compared in a randomized, single-blind, parallel group study in black Africans with essential hypertension." | 9.08 | The efficacy and tolerability of amlodipine and hydrochlorothiazide in Nigerians with essential hypertension. ( Ajayi, AA; Akintomide, AO, 1995) |
| "In this multicentre, double-blind trial in 461 patients with essential hypertension, amlodipine (5-10 mg once daily) and enalapril (10-40 mg once daily) were compared in terms of quality of life, efficacy and tolerability after 1 year of treatment (part 1)." | 9.08 | Evaluation and quality-of-life assessment of amlodipine and enalapril in patients with hypertension. ( Eide, I; Herland, OB; Midha, R; Omvik, P; Thaulow, E; Turner, RR, 1995) |
| "The anti-hypertensive efficacy and safety of extended-release (ER) felodipine (5, 10 or 20 mg) and amlodipine (5 or 10 mg) once daily were compared in patients with mild to moderate essential hypertension in a double-blind, double-dummy, randomised, comparative study." | 9.08 | Comparative effects of amlodipine and felodipine ER on office and ambulatory blood pressure in patients with mild to moderate hypertension. Danish Multicentre Group. ( Høegholm, A; Nielsen, PE; Rasmussen, E; Wiinberg, N, 1995) |
| "The effect of calcium channel blocker (CCB), amlodipine (5-10 mg/day) and angiotensin-converting enzyme (ACE) inhibitor, quinapril (10-40 mg/day) on ambulatory blood pressure (ABP), rheological and platelet function in hypertension were compared in this randomised double-blind placebo-controlled cross-over study." | 9.08 | Comparison of amlodipine and quinapril on ambulatory blood pressure and platelet function in hypertension. ( Chang, SM; Chou, TC; Ding, YA, 1995) |
| "5 mg daily, low-dose benazepril 10 mg daily, and the combination of the two drugs at the same doses used once daily in patients (n = 401) with mild to moderate (stages I and II) systemic hypertension." | 9.08 | Comparison of amlodipine and benazepril monotherapy to amlodipine plus benazepril in patients with systemic hypertension: a randomized, double-blind, placebo-controlled, parallel-group study. The Benazepril/Amlodipine Study Group. ( Chrysant, SG; Frishman, WH; Graff, A; Hsu, H; Kupiec, JW; McMahon, FG; RAM, CV, 1995) |
| "The present study aimed to assess the efficacy and tolerance of amlodipine (Norvasc-Pfizer) in the treatment of 152 patients with mild and moderate essential hypertension." | 9.08 | -Efficacy and safety of using amlodipine in treatment of mild and moderate essential hypertension-. ( Kokot, F; Kokot, M; Raszewska, J; Rychlik, G; Witkowicz, J, 1995) |
| "One hundred sixty-eight adult outpatients with mild to moderate hypertension were randomly allocated in double-blind fashion and equal number to receive 80 mg valsartan or 5 mg amlodipine for 12 weeks." | 9.08 | Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: a comparative study of the efficacy and safety against amlodipine. ( Bodin, F; Cardoni, O; Corea, L; Fogari, R; Innocenti, P; Meilenbrock, S; Porcellati, C; Provvidenza, M; Sullivan, J, 1996) |
| "The objectives of this study were to evaluate the effects of an ACE inhibitor (fosinopril) and a calcium antagonist (amlodipine) on the urinary albumin and transferrin excretion and their relationship to the blood pressure in essential hypertension." | 9.08 | Albuminuria and transferrinuria in essential hypertension. Effects of antihypertensive therapy. ( Agrati, AM; Alli, C; Cassani, M; Granata, S; Lombardo, M; Zanni, D, 1996) |
| " The objective of the present 32-week double-blind study was to compare the effects of hydrochlorothiazide (HCTZ) and amlodipine (AML) in elderly patients with confirmed ambulatory hypertension." | 9.08 | Antihypertensive effects of amlodipine and hydrochlorothiazide in elderly patients with ambulatory hypertension. ( Archambault, F; Boileau, G; Cléroux, J; Lacourcière, Y; Lefebvre, J; Poirier, L, 1995) |
| "Amlodipine has a beneficial effect on LVH and also is an effective and safe drug to treat mild to moderate hypertension." | 9.08 | [Effect of the treatment with amlodipine on left ventricular hypertrophy in hypertensive patients]. ( Hoyos, M; Justo, E; Moreno, R; Oliván, J; Pérez Cano, R; Pizarro, JL; Ramos, E; Rodríguez, A, 1996) |
| "The purpose of the study was to compare the antianginal and hypotensive efficacy and tolerability of 8 weeks of treatment with amlodipine taken once daily and nifedipine taken twice daily in patients with stable exertional angina pectoris and mild-to-moderate hypertension." | 9.08 | [Comparative study to assess the efficacy and adverse effects of amlodipine and nifedipine retard in patients with stable exertional angina and hypertension]. ( Hlawaty, M; Kubler, G; Negrusz-Kawecka, M; Olszowska, M; Salamon, P; Tracz, W; Witkowska, M, 1997) |
| "Thirty patients (17 females, median age 55 years) with mild/moderate hypertension (sitting diastolic blood pressure 95-110 mmHg over 2 consecutive weeks) participated in a study of the efficacy and tolerability of once-daily diltiazem "controlled delivery" 180 mg-360 mg and amlodipine 5-10 mg compared with placebo (using clinic and 24-h ambulatory blood pressure measurement (Accutraker II)." | 9.08 | A placebo-controlled comparison of diltiazem and amlodipine monotherapy in essential hypertension using 24-h ambulatory monitoring. ( Watts, RW; Wing, LM, 1998) |
| " The primary aim of the Fosinopril Versus Amlodipine Cardiovascular Events Randomized Trial (FACET) was to compare the effects of fosinopril and amlodipine on serum lipids and diabetes control in NIDDM patients with hypertension." | 9.08 | Outcome results of the Fosinopril Versus Amlodipine Cardiovascular Events Randomized Trial (FACET) in patients with hypertension and NIDDM. ( Byington, RP; Di Mauro, P; Guarisco, R; Pahor, M; Strollo, F; Strollo, G; Tatti, P, 1998) |
| "To evaluate the 24 h antihypertensive efficacy and duration of action of felodipine extended release (ER) in comparison with two other long acting dihydropyridine calcium antagonists, amlodipine and nifedipine gastrointestinal therapeutic system (GITS), in patients with mild to moderate essential hypertension substantiated by ambulatory blood pressure (BP) monitoring." | 9.08 | Comparative effects of felodipine ER, amlodipine and nifedipine GITS on 24 h blood pressure control and trough to peak ratios in mild to moderate ambulatory hypertension: a forced titration study. ( Archambault, F; Jewell, D; Lacourcière, Y; Lefebvre, J; Poirier, L; Reed, CV, 1998) |
| "The aim of the study was to compare the effects of two long-acting antihypertensive agents, the calcium-antagonist amlodipine and the ACE inhibitor lisinopril, on left ventricular mass and diastolic filling in patients with mild to moderate diastolic hypertension from primary care centres." | 9.08 | Effects of amlodipine and lisinopril on left ventricular mass and diastolic function in previously untreated patients with mild to moderate diastolic hypertension. ( Beltman, FW; de Graeff, PA; Havinga, TK; Heesen, WF; Lie, KI; May, JF; Meyboom-de Jong, B; Schuurman, FH; Smit, AJ; van der Veur, E, 1998) |
| "To measure the effects of losartan and amlodipine on peripheral capillary microcirculation in hypertension." | 9.08 | Effects of losartan titrated to losartan/hydrochlorothiazide and amlodipine on blood pressure and peripheral capillary microcirculation in patients with mild-to-moderate hypertension. ( Drewe, J; Gasser, P; Martina, B; Weinbacher, M, 1998) |
| "To compare the blood pressure effects of two dihydropyridine calcium channel blockers, amlodipine and nitrendipine, in 488 patients with essential hypertension." | 9.08 | Parallel comparative trial of amlodipine and nitrendipine monotherapy in patients with essential hypertension. ( Gong, L; Guo, J; Liu, Y; Wang, X; Yang, P; Ye, X; Zhang, G, 1998) |
| "To investigate the effect of amlodipine, nifedipine and perindopril on insulin sensitivity(IS) and blood lipid of patients with essential hypertension(EH)." | 9.08 | [The effect of amlodipine, nifedipine and perindopril on insulin sensitivity and blood lipid of patients with essential hypertension]. ( Chen, D; Lin, J; Wu, K, 1998) |
| "1 We have utilised a non-imaging echo-Doppler cardiac output device, using the principle of attenuated compensation volume flow (ACVF), to assess the cardiovascular effects of amlodipine and atenolol over 3 months in 24 patients with essential hypertension." | 9.07 | Haemodynamic comparison of amlodipine and atenolol in essential hypertension using the quantascope. ( Guy, S; Herity, N; Silke, B; Tham, TC, 1993) |
| " twice-daily oral doses of captopril (25-50 mg twice daily) in adult patients with mild or moderate essential hypertension (supine diastolic blood pressure of 95-115 mm Hg) was undertaken in two hospital centers." | 9.07 | A double-blind, parallel, comparative evaluation of amlodipine vs. captopril in the monotherapeutic treatment of mild and moderate essential hypertension. ( Fonseca, R; Guevara, J; Hernandez, R; Pieretti, OH; Silva, H; Urbina, A; Velasco, M, 1991) |
| "The efficacy and safety of the dihydropyridine calcium antagonists amlodipine and nitrendipine as single-agent therapy of mild to moderate hypertension were compared in an open, parallel-group study." | 9.07 | An open, parallel, comparative evaluation of amlodipine and nitrendipine in the monotherapeutic treatment of mild and moderate essential hypertension. ( Beressem, P; Englert, R; Kramar, M; Stafunsky, S; von Manteuffel, E, 1991) |
| "The antihypertensive efficacy and safety of once-daily amlodipine (5-10 mg) were studied in patients with essential hypertension." | 9.07 | Amlodipine in hypertension: its effects on platelet aggregation and dynamic exercise. ( Armas-de Hernande, MJ; Armas-Padilla, MC; Barragan, O; Carvajal, AR; Guerrero-Pajuelo, J; Hernández, R; Machado-de Alvarado, I, 1991) |
| "The antihypertensive efficacy and safety of amlodipine (5-10 mg once daily for 10 weeks) was assessed in elderly patients with primary systolic hypertension (average sitting and standing systolic blood pressure > or = 160 mm Hg and diastolic blood pressure < or = 95 mm Hg)." | 9.07 | Open evaluation of amlodipine in the monotherapeutic treatment of systolic hypertension in the elderly. ( Lambert, M; Vandewoude, MF; Vryens, R, 1991) |
| "We compared the antihypertensive efficacy of once-daily amlodipine (AM) versus nitrendipine (NTR) by 24-h ambulatory blood pressure monitoring (24-h ABPM) in 32 patients with mild to moderate essential hypertension (EH)." | 9.07 | Comparative evaluation of the antihypertensive efficacy of once-daily amlodipine versus nitrendipine with 24-hour ambulatory blood pressure monitoring in essential hypertension. ( Aguilera, MT; Coca, A; De la Sierra, A; Lluch, MM; Picado, MJ; Sánchez, M; Urbano-Márquez, A, 1993) |
| "The nitric oxide (NO) system is abnormal in essential hypertension and the response of the forearm vascular bed to local intra-arterial infusions of NG-monomethyl-L-arginine (L-NMMA) is diminished in patients with untreated essential hypertension." | 9.07 | The effect of antihypertensive therapy on responsiveness to local intra-arterial NG-monomethyl-L-arginine in patients with essential hypertension. ( Benjamin, N; Lyons, D; Webster, J, 1994) |
| "This study was designed to compare the efficacy and tolerability of amlodipine (AML) and ramipril (RAM) administered once a day in patients affected by mild to moderate primary systemic hypertension." | 9.07 | Amlodipine versus ramipril in the treatment of mild to moderate hypertension: evaluation by 24-hour ambulatory blood pressure monitoring. ( Ceravolo, R; Mattioli, PL; Perticone, F; Pugliese, F, 1994) |
| " The metabolic and renal effects of long-term (8 months) therapy with amlodipine, 5 to 10 mg daily, were studied in 15 hypertensive patients with uncomplicated diabetes mellitus as compared with 15 patients with essential hypertension." | 9.07 | Calcium antagonists for treatment of diabetes-associated hypertension. Metabolic and renal effects of amlodipine. ( Beretta-Piccoli, C; Heinen, G; Pingitore, R; Riesen, W; Zanetti-Elshater, F, 1994) |
| "5 to 10 mg) once daily was compared with that of hydrochlorothiazide (HCTZ) (25 to 100 mg) daily in 139 patients with mild-to-moderate hypertension." | 9.07 | Long-term open evaluation of amlodipine vs hydrochlorothiazide in patients with essential hypertension. ( Adolphe, AB; Brescia, D; Rofman, BA; Vlachakis, ND; Zellner, SR, 1993) |
| "The authors studied the efficacy and safety of a long half-life dihydropyridine calcium-antagonist--amlodipine--in a single daily dose in the treatment of isolated systolic hypertension in the elderly." | 9.07 | [Amlodipine in isolated systolic hypertension in the aged]. ( Cosentino, N; Mariani, L; Marino, M; Torrisi, G, 1993) |
| "A double-blind multicenter study involving 89 patients with mild-to-moderate essential hypertension was performed to compare the efficacy and tolerability of amlodipine and enalapril." | 9.07 | [Monotherapy of mild to moderate hypertension. Double-blind comparative study: amlodipine versus enalapril]. ( Görne, RC; Mehmel, HC, 1993) |
| "In an open, non-comparative, variable-dose study, 20 outpatients with mild to moderate essential hypertension were treated with 5-10 mg amlodipine once daily for 4 weeks, after their blood pressures had stabilized on placebo." | 9.07 | Amlodipine in mild and moderate hypertension: initial Indian experience. ( Ailiani, R; Bajan, KD; Chawla, KP; Chopra, P; Joseph, TA; Karnik, ND; Khokhani, RC; Waknis, SS, 1993) |
| "5-10 mg) once daily was compared with atenolol (50-100 mg) once daily in patients with mild-to-moderate essential hypertension in a randomized, double-blind, parallel, placebo-controlled study." | 9.07 | Amlodipine versus atenolol in essential hypertension. ( Brobyn, R; Brown, RD; Frishman, WH; Johnson, BF; Reeves, RL; Wombolt, DG, 1994) |
| "This study was conducted to assess the therapeutic utility of combining amlodipine with captopril in patients with moderate-to-severe hypertension." | 9.07 | Combination therapy with amlodipine and captopril for resistant systemic hypertension. ( Maclean, D, 1994) |
| "Nifedipine is an effective compound for the treatment of hypertension." | 9.07 | Double-blind comparison between nifedipine and amlodipine for the treatment of essential hypertension. ( Cappuccio, FP; Carney, C; Crane, M; MacGregor, GA; Markandu, ND; Singer, DR, 1993) |
| "To determine the dose-response efficacy of once-daily administration of placebo or a new long-acting calcium channel blocker amlodipine in patients with mild to moderate hypertension, a randomized, multicenter, placebo-controlled, double-blind trial was conducted." | 9.07 | Double-blind evaluation of the dose-response relationship of amlodipine in essential hypertension. ( Garland, WT; Gradman, AH; Lopez, LM; Mehta, JL; Nash, DT; O'Connell, MT; Pickering, BI; Vlachakis, ND, 1993) |
| " The safety and efficacy of amlodipine vs enalapril as monotherapy was evaluated in patients with moderate/severe hypertension (supine DBP 105-125 mm Hg, SBP 140-220 mm Hg)." | 9.07 | A comparison of amlodipine with enalapril in the treatment of moderate/severe hypertension. ( Cornish, R; Crichton, WA; Fowler, G; Jeffers, TA; Lyons, D; Petrie, JC; Sanghera, SS; Webster, J; Wickham, EA; Witte, K, 1993) |
| " The safety and efficacy of amlodipine and enalapril were compared in patients with isolated systolic hypertension (supine DBP < 95 mm Hg and supine SBP 160-200 mm Hg)." | 9.07 | A comparison of amlodipine with enalapril in the treatment of isolated systolic hypertension. ( Cornish, R; Crichton, WA; Fowler, G; Jeffers, TA; Lyons, D; Petrie, JC; Sanghera, SS; Webster, J; Wickham, EA; Witte, K, 1993) |
| "An interim analysis of patient compliance is reported in 234 hypertension outpatients who were entered into a large-scale, open, crossover, comparative study between a new-generation calcium antagonist, amlodipine (5 mg, once daily), and nifedipine SR (20 mg, twice daily)." | 9.07 | Patient compliance and therapeutic coverage: amlodipine versus nifedipine SR in the treatment of hypertension and angina: interim results. Steering Committee and Cardiologists and General Practitioners involved in the Belgium Multicentre Study on Patient ( Detry, JM, 1994) |
| "5 mg, 5 mg, or 10 mg) once daily was compared with atenolol (50 mg to 100 mg) once daily in patients with mild-to-moderate essential hypertension in a randomized, double-blind, parallel, placebo-controlled study." | 9.07 | A randomized, placebo-controlled, double-blind comparison of amlodipine and atenolol in patients with essential hypertension. ( Brobyn, R; Brown, RD; Frishman, WH; Johnson, BF; Reeves, RL; Wombolt, DG, 1992) |
| "The efficacy and safety of amlodipine in the long term treatment of outpatients with mild to moderate hypertension were examined in an open, non-comparative study." | 9.07 | [Effectiveness and tolerance of amlodipine in treatment of patients with mild to moderate hypertension. Results of a long-term study with a new calcium antagonist]. ( Ganzinger, U; Habeler, G; Lenzhofer, R; Pall, H; Tomaschek, A; Ziebart-Schroth, A; Zirm, B, 1992) |
| "Amlodipine, a novel dihydropyridine calcium-antagonist, was compared to slow-release nifedipine in a short-term study on 40 patients with mild to moderate essential hypertension, in order to assess the efficacy and tolerability of two different dihydropyridine calcium-antagonists with short and long half-life." | 9.07 | [A comparison between amlodipine and nifedipine retard in patients with essential arterial hypertension]. ( Bruzzone, F; Canale, C; Caponnetto, S; Lonati, A; Malvestiti, FM; Masperone, MA; Terrachini, V, 1992) |
| "The frequency and severity of adverse effects during the first 14 days of treatment with amlodipine (5 mg once daily), nifedipine retard (20 mg twice daily) or placebo were compared in a multicentre, three-way, cross-over study involving 97 patients with mild-to-moderate hypertension." | 9.07 | Comparison of early side effects with amlodipine and nifedipine retard in hypertension. ( Bremner, AD; Fell, PJ; Hosie, J; James, IG; Saul, PA; Taylor, SH, 1992) |
| "Amlodipine (once daily) and captopril (twice daily) had comparable efficacy and safety in reducing the blood pressure of patients with mild and moderate essential hypertension." | 9.07 | A double-blind, parallel, comparative evaluation of amlodipine against captopril in the monotherapeutic treatment of mild and moderate essential hypertension: interim results. ( Guevara, J; Hernández, O; Hernández, R; Urbina, A; Velasco, M, 1991) |
| "This study compared the efficacy and safety of 8 weeks of open treatment with the dihydropyridine calcium antagonists amlodipine and nitrendipine in mild-to-moderate hypertension." | 9.07 | Amlodipine compared to nitrendipine for the treatment of mild-to-moderate hypertension. ( Beressem, P; Englert, R; Kramar, M; Stafunsky, M; von Manteuffel, E, 1991) |
| "Twenty-one subjects with mild or moderate systemic hypertension were treated for 12 weeks with amlodipine, a new calcium antagonist of the dihydropyridine group." | 9.07 | Efficacy and tolerability of amlodipine in patients with mild-to-moderate hypertension. ( Meaney, E; Moguel, R; Olvera, R; Samaniego, V, 1991) |
| "The antihypertensive efficacy of amlodipine was studied in 22 patients (16 female, six male) with mild-to-moderate hypertension." | 9.07 | Clinical evaluation of amlodipine, a new long-acting calcium antagonist, in mild and moderate hypertension. ( Escudero, J; Hernandez, H, 1991) |
| "The long-term haemodynamic responses to amlodipine, a new long-acting calcium antagonist, were studied both at rest and during exercise in 18 patients (mean age 43 years) with essential hypertension." | 9.06 | Long-term haemodynamic effects of amlodipine at rest and during exercise in essential hypertension. ( Digranes, O; Helland, B; Jordal, O; Lund-Johansen, P; Omvik, P; Stray, T; White, W, 1990) |
| "The arterial vasodilator properties of the dihydropyridine calcium antagonist amlodipine were compared with the effects of vascular muscle cyclic guanosine monophosphate production by sodium nitroprusside and with the effects of a combined infusion of amlodipine and the nondihydropyridine calcium antagonist verapamil in 8 untreated patients with primary hypertension." | 9.06 | Arterial vasodilator effects of the dihydropyridine calcium antagonist amlodipine alone and in combination with verapamil in systemic hypertension. ( Bühler, FR; Erne, P; Kiowski, W; Linder, L, 1990) |
| "Once-daily administration of amlodipine, a long-acting dihydropyridine calcium-channel blocker, and atenolol, a cardioselective beta-adrenoceptor blocking agent, were compared in patients with mild to moderate hypertension in a multicenter placebo-controlled trial." | 9.06 | Multicenter placebo-controlled comparison of amlodipine and atenolol in mild to moderate hypertension. ( Cocco, G; de Bruijn, B; Tyler, HM, 1988) |
| "Amlodipine, a new long-acting dihydropyridine calcium antagonist, was compared with placebo and atenolol in 125 patients with mild to moderate systemic hypertension [supine diastolic blood pressure (DBP) 90-114 mm Hg]." | 9.06 | A randomized placebo-controlled comparison of amlodipine and atenolol in mild to moderate systemic hypertension. ( Brobyn, R; Brown, RD; Frishman, WH; Johnson, BF; Reeves, RL; Wombolt, DG, 1988) |
| "The antihypertensive efficacy of once-daily amlodipine was studied in a group of 30 patients with mild to moderate hypertension in a double-blind, placebo-controlled, parallel-group study." | 9.06 | Once-daily amlodipine in the treatment of mild to moderate hypertension. ( Jeffers, TA; Petrie, JC; Robb, OJ; Scott, AK; Webster, J, 1988) |
| "A multicenter, placebo-controlled trial assessed the antihypertensive efficacy and safety of different doses of amlodipine in patients with mild to moderate hypertension." | 9.06 | Amlodipine: a double-blind evaluation of the dose-response relationship in mild to moderate hypertension. ( Frick, MH; McGibney, D; Tyler, HM, 1988) |
| "Amlodipine 10 mg once daily added to captopril 25 mg twice daily for 4 weeks in patients with moderate to severe hypertension significantly improved blood pressure control (by -18/-12 and -20/-12 mm Hg for supine and standing systolic/diastolic pressures respectively, p less than 0." | 9.06 | A double-blind crossover comparison of amlodipine and placebo added to captopril in moderate to severe hypertension. ( Maclean, D; Mitchell, ET; Tyler, HM; Walker, P; Wilcox, RG, 1988) |
| "One hundred sixty patients with mild to moderate essential hypertension entered this double-blind parallel group comparison of amlodipine, verapamil, and placebo." | 9.06 | Comparison of amlodipine and verapamil in the treatment of mild to moderate hypertension. ( Lorimer, AR; Smedsrud, T; Tyler, HM; Walker, P, 1988) |
| "Amlodipine, a new long-acting dihydropyridine calcium antagonist, was compared with hydrochlorothiazie (HCTZ) in 145 patients with mild to moderate hypertension." | 9.06 | Double-blind comparison of amlodipine and hydrochlorothiazide in patients with mild to moderate hypertension. ( Ames, RP; Applegate, WB; Burris, JF; Davidov, ME; Mroczek, WJ; Ram, CV, 1988) |
| "The antihypertensive efficacy and suitability for once daily dosing of amlodipine, a new calcium antagonist, was studied in a series of 205 patients with mild to moderate hypertension." | 9.06 | A dose-response study of amlodipine in mild to moderate hypertension. ( Frick, MH; McGibney, D; Tyler, HM, 1989) |
| "This is a double blind parallel group comparison in patients with mild-moderate hypertension, of amlodipine, verapamil and placebo." | 9.06 | A comparison of amlodipine, verapamil and placebo in the treatment of mild to moderate hypertension. Amlodipine Study Group. ( Lorimer, AR; Smedsrud, T; Tyler, HM; Walker, P, 1989) |
| " The antihypertensive efficacy of once-daily amlodipine was studied in a group of 30 patients with mild to moderate hypertension in a double-blind, placebo controlled parallel group study." | 9.06 | Once daily amlodipine in the treatment of mild to moderate hypertension. ( Jeffers, TA; Petrie, JC; Robb, OJ; Scott, AK; Towler, HM; Webster, J, 1987) |
| "The US Food and Drug Administration recently granted an approved indication for the first fixed-dose combination antihypertensive (amlodipine) and nonsteroidal anti-inflammatory drug (celecoxib) for treatment of comorbid hypertension and osteoarthritis." | 9.01 | Fixed-Dose Combination Amlodipine/Celecoxib (Consensi) for Hypertension and Osteoarthritis. ( Cooper-DeHoff, RM; Smith, SM, 2019) |
| "Use of amlodipine for treatment of arterial hypertension and stable coronary artery disease (CAD) is sometimes limited by occurrence of peripheral edema and headache." | 9.01 | Peripheral edema and headache associated with amlodipine treatment: a meta-analysis of randomized, placebo-controlled trials. ( Böhm, M; Mahfoud, F; Messerli, FH; Scholz, SS; Vukadinović, D; Weber, MA; Williams, B, 2019) |
| "Aliskiren, a direct renin inhibitor, is effective for reducing blood pressure (BP) in patients with hypertension when combined with amlodipine or hydrochlorothiazide (HCTZ)." | 8.90 | Aliskiren/amlodipine vs. aliskiren/hydrochlorothiazide in hypertension: indirect meta-analysis of trials comparing the two combinations vs. monotherapy. ( Cao, C; Dong, X; Gao, D; Liu, Y; Niu, X; Song, A; Wei, J; Yan, R, 2014) |
| "This review summarizes the current data on the triple combination therapy of aliskiren with amlodipine and hydrochlorothiazide, and discusses the clinical use of single pill triple combination of aliskiren, amlodipine and hydrochlorothiazide in the treatment of hypertension and associated cardiovascular conditions." | 8.88 | The single pill triple combination of aliskiren, amlodipine, and hydrochlorothiazide in the treatment of hypertension. ( Huan, Y; Townsend, R, 2012) |
| "A systematic literature search is undertaken for supporting the pharmacological proprieties and clinical efficacy of perindopril in the treatment of hypertension." | 8.87 | Perindopril for the treatment of hypertension. ( Ghiadoni, L, 2011) |
| "This study aimed to estimate the efficacy and tolerability of the combination of amlodipine and angiotensin-converting enzyme inhibitors as compared with amlodipine monotherapy in the treatment of hypertension." | 8.86 | Amlodipine and angiotensin-converting enzyme inhibitor combination versus amlodipine monotherapy in hypertension: a meta-analysis of randomized controlled trials. ( Chen, GM; Fang, WW; Jia, HX; Lv, Y; Zhong, J; Zou, Z, 2010) |
| " In particular, evidence suggests that fixed-dose perindopril/amlodipine effectively decreases BP and currently is the only RAS inhibitor/CCB combination proven to decrease all-cause and cardiovascular mortality as well as major cardiovascular events, and thus is a valuable option for the management of hypertension, especially in high-risk patients." | 8.86 | Combinations of inhibitors of the renin-angiotensin system with calcium channel blockers for the treatment of hypertension: focus on perindopril/amlodipine. ( Gaudouen, Y; Le Jeune, S; Lopez-Sublet, M; Mourad, C; Mourad, JJ; Pirollo, A, 2010) |
| "Telmisartan/amlodipine is a single-pill combination of telmisartan, an angiotensin II receptor antagonist, and amlodipine, a dihydropyridine calcium channel antagonist, which is taken orally once daily for the treatment of hypertension." | 8.86 | Telmisartan/amlodipine: single-pill combination in hypertension. ( Moen, MD, 2010) |
| "Single-pill combinations of the dihydropyridine calcium channel blocker (CCB) amlodipine and the angiotensin II receptor blocker valsartan (amlodipine/valsartan) [Exforge] are available in the US for the treatment of patients with hypertension." | 8.85 | Amlodipine/valsartan single-pill combination: a review of its use in the management of hypertension. ( Frampton, JE; Scott, LJ, 2009) |
| "A literature search was performed in PubMed/MEDLINE to identify articles published in English between 1988 and March 2008 describing clinical trials, particularly outcome trials, or mechanisms of therapeutic action relevant to the use of combination therapy in patients with hypertension or stable coronary artery disease with an ACE inhibitor (perindopril) and a calcium channel blocker (amlodipine)." | 8.84 | Optimizing the treatment of hypertension and stable coronary artery disease: clinical evidence for fixed-combination perindopril/amlodipine. ( Ferrari, R, 2008) |
| "In the present quantitative overview of outcome trials, we investigated the efficacy of amlodipine or angiotensin receptor blockers in the prevention of stroke and myocardial infarction in patients with hypertension, coronary artery disease, or diabetic nephropathy." | 8.84 | Prevention of stroke and myocardial infarction by amlodipine and Angiotensin receptor blockers: a quantitative overview. ( Franklin, SS; Li, Y; Safar, M; Wang, JG, 2007) |
| "Single-pill amlodipine besylate/atorvastatin calcium (Caduet), Pfizer Inc, NY, USA) is the first therapy aimed at the simultaneous treatment of hypertension (HTN) and dyslipidaemia (DYS)." | 8.82 | Simultaneous treatment of hypertension and dyslipidaemia may help to reduce overall cardiovascular risk: focus on amlodipine/atorvastatin single-pill therapy. ( Cowie, MR, 2005) |
| "These findings suggest that 5-ALA-HCl does not affect the antihypertensive agents-induced hypotensive effect, but enhances the bupivacaine-induced hypotensive effect, especially in SHRs, indicating that 5-ALA may contribute to anesthesia-induced hypotension via suppression of sympathetic nerve activity in patients with hypertension." | 8.31 | 5-Aminolevulinic acid hydrochloride enhances bupivacaine-induced hypotension in spontaneously hypertensive rats. ( Abe, M; Fukuda, N; Hara, T; Ishizuka, M; Ito, H; Katakawa, M; Otsuka, N, 2023) |
| "To observe the effect of amlodipine besylate combined with metoprolol in treating hypertension and heart failure." | 8.31 | Improvement in hemodynamics of amlodipine besylate combined with metoprolol in patients with hypertension complicated by heart failure. ( Chen, C; Jiao, D; Shen, J; Zhang, W; Zhang, X; Zhu, G, 2023) |
| "This prospective, multicenter observational study assessed the real-world safety and effectiveness of an SPC containing olmesartan, amlodipine, and hydrochlorothiazide (O/A/H) in South Korean patients with hypertension and cardiovascular risk factors." | 8.31 | Real-World Effectiveness and Safety of a Single-Pill Combination of Olmesartan/Amlodipine/Hydrochlorothiazide in Korean Patients with Hypertension and Cardiovascular Risk Factors. ( Hong, JH; Hyun, D; Kim, GH; Kim, HL; Kim, W; Lim, S; Min, KW; Oh, J; Park, SD; Shin, J, 2023) |
| "To describe a case of angioedema associated with increasing the dose of HMG-CoA reductase inhibitor (atorvastatin) from 20 to 40 mg daily in a patient previously stable on angiotensin II receptor blocker (losartan) and calcium channel blocker (amlodipine) as antihypertensive agents." | 8.12 | Dose-dependent atorvastatin associated with angioedema. ( Al-Mohammadi, OS; Al-Qaaneh, AM; Mustafa, SM; Obaid, WT; Rabaan, AA, 2022) |
| "The aim of this report is to document the case of a dog that developed pleural effusion as a potential side-effect to the administration of a high-dose of amlodipine." | 8.12 | Unusual case of pleural effusion caused by amlodipine in a dog with systemic hypertension. ( An, JH; Chae, HK; Choi, M; Hwang, SY; Jang, HW; Kang, K; Oh, YI; Park, SM; Youn, HY, 2022) |
| "Although amlodipine is recommended as the first-line therapy for the treatment of hypertension, its use is limited by its potential side effects." | 8.12 | Ambulatory blood pressure response to S-amlodipine in Korean adult patients with uncontrolled essential hypertension: A prospective, observational study. ( Ahn, JH; Ahn, KT; Choi, WG; Jung, IH; Kang, SH; Kim, DK; Kim, SS; Lee, JH; Lee, KH; Na, JO; Park, SD; Seo, J, 2022) |
| "This study evaluated the effectiveness of treatment with an indapamide/amlodipine single-pill combination (SPC) in outpatients with uncontrolled isolated systolic hypertension (ISH) aged over 55 years in real-life clinical practice." | 8.12 | Effectiveness of indapamide/amlodipine single-pill combination in patients with isolated systolic hypertension: post-hoc analysis of the ARBALET study. ( Goreva, LA; Karapetyan, LV; Kobalava, ZD; Kolesnik, EL; Shavarova, EK, 2022) |
| "Activity of the circulating renin-angiotensin-aldosterone system (RAAS) has not been comprehensively characterized in cats with systemic hypertension (SH) or cardiomyopathy (CM), and the effects of furosemide or amlodipine treatment on the RAAS have not been fully evaluated in cats." | 8.12 | Circulating renin-angiotensin-aldosterone system activity in cats with systemic hypertension or cardiomyopathy. ( Domenig, O; Guillot, E; Mochel, JP; Ward, JL; Ware, WA; Yuan, L, 2022) |
| "A total of 198 patients with hypertension in ambulatory care who had been on fixed-dose combination of perindopril arginine, indapamide, and amlodipine for at least 4 weeks were included." | 8.12 | Use of Perindopril Arginine/Indapamide/Amlodipine in the Management of Hypertension in Two Sub-Saharan African Island Countries of Madagascar and Mauritius. ( Ackbarkhan, A; Mbanya, A; Mbanya, JC; Mittoo, MY; Ramamonjisoa, HA; Ramilitiana, B; Ranivoharisoa, EM; Ratsimbazafy, SJN, 2022) |
| "Conclusions: The use of quercetin (Corvitin, Quertin) in combination therapy with the combined antihypertensive drug containing ramipril/amlodipine (Egis-Hungary) significantly reduces the levels of nitric oxide, CRP, IL-1, and blood lipid spectrum, which reduces the incidence of complications and progression of hypertension." | 8.12 | INDICATORS OF ENDOTHELIAL DYSFUNCTION, MARKERS OF INFLAMMATION AND LIPID METABOLISM IN PATIENTS WITH HYPERTENSION WITH THE ADMINISTRATION OF QUERCETIN. ( Prokosa, MI, 2022) |
| "Objective: This study describes the single nucleotide polymorphisms (SNPs) in amlodipine-associated genes and assesses their correlation with blood pressure control among South African adults with hypertension." | 8.12 | Single Nucleotide Polymorphisms in Amlodipine-Associated Genes and Their Correlation with Blood Pressure Control among South African Adults with Hypertension. ( Adeniyi, OV; Benjeddou, M; Masilela, C, 2022) |
| "The aim: To analyze the dynamics of daily monitoring of blood pressure, intracardiac (according to echocardiography), peripheral hemodynamics (according to ultrasound of the vessels of the lower extremity), the thickness of the intima-media complex (according to carotid sonography) in patients with hypertension the effect of treatment with a combination of lisinopril and amlodipine." | 8.12 | EFFECTIVENESS OF LISINOPRIL AND AMLODIPINE COMBINATION AT HYPERTENSION WITH COMORBIDITY OF ARTERIOSCLEROSIS OBLITERANS IN GENERAL PRACTICE. ( Babinets, LS; Halabitska, IM; Kryskiv, OI; Levchuk, RD, 2022) |
| "A total of 44,715 patients who had hypertension and received a telmisartan/S-amlodipine single-pill combination at least once were included for safety and efficacy evaluation from 2852 primary to tertiary hospitals in Korea from August 2013 to December 2019." | 8.02 | Telmisartan Plus S-Amlodipine Single-Pill Combination Therapy is Safe and Effective in Patients with Hypertension from Large-Scale Nationwide Surveillance Data in Korea (NOVEL) Study. ( Hong, GR; Jo, SH; Kim, SW; Park, CG; Park, SJ, 2021) |
| "We examined the effects of a fixed-dose single-pill combination of cilnidipine (10 mg), an L-/N-type calcium channel blocker, and valsartan (80 mg) (SPC of Cil/Val) on the day-by-day variability of morning home systolic blood pressure (MHSBP) in 616 patients with treated hypertension for 12 months as a sub-analysis of the HOPE-Combi survey, multicentral, post-marketing, and prospective observational survey." | 8.02 | Single-pill combination of cilnidipine, an l-/n-type calcium channel blocker, and valsartan reduces the day-by-day variability of morning home systolic blood pressure in patients with treated hypertension: A sub-analysis of the HOPE-combi survey. ( Kario, K; Kurose, Y; Matsuda, S; Nagahama, S; Sugii, H; Suzuki, N; Teshima, T, 2021) |
| "Aim To study the psychological continuum in elderly patients with arterial hypertension associated with metabolic syndrome during the chronotherapy with a fixed combination (FC) of amlodipine, lisinopril, and rosuvastatin." | 8.02 | Psychological Continuum of Elderly Patients Suffering from Arterial Hypertension with Metabolic Syndrome, Against the Background of Chronotherapy with a Fixed Combination of Amlodipine, Lisinopril and Rosuvastatin. ( Agarkov, NM; Kolomiets, VI; Korneeva, SI; Markelova, AM; Markelova, EA; Moskalev, AA; Moskaleva, EO; Okhotnikov, OI, 2021) |
| "The home blood pressure (BP) control by a single-pill combination of cilnidipine (an L-/N-type calcium channel blocker; CCB) and valsartan (HOPE-Combi) survey is a multicenter, post-marketing, prospective observational study of a single-pill combination of cilnidipine 10 mg and valsartan 80 mg (SPC of Cil/Val) in patients with uncontrolled hypertension." | 7.96 | Single-pill combination of cilnidipine, an L-/N-type calcium channel blocker, and valsartan effectively reduces home pulse pressure in patients with uncontrolled hypertension and sympathetic hyperactivity: The HOPE-Combi survey. ( Kario, K; Kurose, Y; Matsuda, S; Nagahama, S; Sugii, H; Suzuki, N; Teshima, T, 2020) |
| "Methyldopa and amlodipine are associated with the least side effects in pregnant women treated for chronic hypertension." | 7.96 | The comparison of side effects of methyldopa, amlodipine, and metoprolol in pregnant women with chronic hypertension. ( Ghafarzadeh, M; Namdari, P; Shakarami, A; Yari, F, 2020) |
| "In this case report, we describe a rare case of amlodipine induced massive ascites in a 30-year-old male with renal transplantation." | 7.96 | Amlodipine Induced Massive Ascites, a Rare Clinical Case. ( Arasan, SN; Cevher, SK; Dede, F; Yenigun, EC, 2020) |
| "S-amlodipine has been broadly used to treat hypertension, but its protective effects and underlying mechanism remain controversial." | 7.91 | S-amlodipine improves endothelial dysfunction via the RANK/RANKL/OPG system by regulating microRNA-155 in hypertension. ( He, C; Si, D; Yang, J; Yang, P; Zhao, Y, 2019) |
| "Background Amlodipine is used for the treatment of hypertension, but reports on its use in early pregnancy are limited." | 7.91 | Safety of Amlodipine in Early Pregnancy. ( Arata, N; Ito, S; Kamiya, CA; Mikami, M; Mito, A; Miyasato-Isoda, M; Murashima, A; Suzuki, T; Wada, Y; Waguri, M; Watanabe, O; Yakuwa, N; Yoshimatsu, J, 2019) |
| "We conducted a prospective, non-interventional, multicenter study to examine the effect of a fixed-dose combination of perindopril/amlodipine in patients with arterial hypertension." | 7.88 | Effectiveness of a Fixed-Dose, Single-Pill Combination of Perindopril and Amlodipine in Patients with Hypertension: A Non-Interventional Study. ( Fleig, SV; Haller, H; Limbourg, FP; Weger, B, 2018) |
| "Compared with amlodipine, fimasartan increased late-phase glucose-stimulated insulin secretion in patients with type 2 diabetes and hypertension." | 7.88 | Fimasartan increases glucose-stimulated insulin secretion in patients with type 2 diabetes and hypertension compared with amlodipine. ( Ahn, CH; Cho, YM; Jung, HS; Kim, S; Kwak, SH; Lee, SO; Lim, MH; Mari, A; Park, KS; Roh, E; Yang, YS, 2018) |
| "to assess in patients with arterial hypertension and type 2 diabetes the effect of perindopril / amlodipine fixed combination on arterial wall stiffness (AWF) and microcirculation, and relationship between AWF parameters and the state microcirculation." | 7.88 | [Influence of Therapy With Fixed Combination of Perindopril and Amlodipine on Parameters of Elasticity of Main Vessels and Microcirculation in Patients With Arterial Hypertension and Type 2 Diabetes Mellitus]. ( Statsenko, ME; Titarenko, MN; Turkina, SV, 2018) |
| " Supportive medical therapy was carried out and persistent systemic hypertension was managed using telmisartan." | 7.88 | Successful management of proteinuria and systemic hypertension in a dog with renal cell carcinoma with surgery, telmisartan, and amlodipine. ( Kang, SS; Kim, HJ; Kwon, YJ; Suh, GH, 2018) |
| "Amlodipine (AMLO) and ramipril (RAMI) belong to the most prescribed drugs in patients with hypertension, a condition also encountered in depression." | 7.88 | How to Treat Hypertension in Venlafaxine-Medicated Patients-Pharmacokinetic Considerations in Prescribing Amlodipine and Ramipril. ( Augustin, M; Gründer, G; Haen, E; Paulzen, M; Schoretsanitis, G, 2018) |
| "- The aim was to evaluate the efficacy of a single-pill combination of atorvastatin/amlodipine in patients with arterial hypertension, dyslipidemia and moderate to high cardiovascular risk." | 7.88 | EFFICACY AND SAFETY OF A SINGLE-PILL COMBINATION OF ATORVASTATIN/AMLODIPINE IN PATIENTS WITH ARTERIAL HYPERTENSION AND DYSLIPIDEMIA. ( Georgieva Torbova-Gigova, S; Ivanov Manov, E; Margaritov Runev, N; Naydenov Naydenov, S, 2018) |
| "This study assessed adherence to and the safety, tolerance, and effectiveness of the perindopril/amlodipine FDC in Greek patients with hypertension and stable coronary artery disease (CAD) over a 4-month period." | 7.85 | Adherence to Treatment, Safety, Tolerance, and Effectiveness of Perindopril/Amlodipine Fixed-Dose Combination in Greek Patients with Hypertension and Stable Coronary Artery Disease: A Pan-Hellenic Prospective Observational Study of Daily Clinical Practice ( Kotsis, VT; Liakos, CI; Papadopoulos, DP, 2017) |
| "The aim of the study was to assess the possibility of fixed combination perindopril+amlodipine to improve arterial elesticity in patients with hypertension and high pulse wave velocity, despite previous combination antihypertensive therapy." | 7.85 | [Optimization of BP Control and Arterial Elasticity With Fixed Combination Therapy Perindopril and Amlodipine In Patients With Arterial Hypertension and Increased Pulse Wave Velocity]. ( Chumachek, EV; Judina, JS; Khripaeva, VJ; Konradi, AO; Ledyaeva, AA; Nedogoda, SV; Palashkin, RV; Salasyuk, AS; Smirnova, VO; Tsoma, VV; Zvartau, NE, 2017) |
| "There is a significant difference between the one year persistence of ramipril and ramipril/amlodipine fixed dose combination therapy in hypertension." | 7.85 | [One year adherence of ramipril versus ramipril/amlodipine fixed dose combination therapy in hypertension]. ( Ferenci, T; Simonyi, G, 2017) |
| "An open, non-comparative, prospective clinical study was conducted to evaluate the antihypertensive efficacy and tolerability of amlodipine, a calcium antagonist, in patients with arterial hypertension (AH) I-II stages, depending on the genotype for the polymorphic marker C3435T of the ABCB1 gene." | 7.85 | [Pharmacogenetic approaches to predicting the efficiency and safety of amlodipine in patients with arterial hypertension]. ( Kalle, EG; Morozova, TE; Ryzhikova, KA; Shih, NV; Sychev, DA, 2017) |
| "This short-term, open-label study examined whether statin therapy had a synergistic effect on the BP-lowering efficacy of perindopril/amlodipine in a subgroup of patients in the PERSPECTIVA study with concomitant hypertension and hypercholesterolemia, with or without statin at baseline." | 7.85 | Impact of Statin Therapy on the Blood Pressure-Lowering Efficacy of a Single-Pill Perindopril/Amlodipine Combination in Hypertensive Patients with Hypercholesterolemia. ( Radchenko, G; Sirenko, Y, 2017) |
| " Aim of this subanalysis was to assess efficacy and tolerability of a fixed-dose perindopril/amlodipine combination (FDPAC) in patients with arterial hypertension (AP) uncontrolled on previous treatment with angiotensin receptor blockers (ARBs)." | 7.85 | [Efficacy and Safety of a Fixed Combination of Perindopril Arginine and Amlodipine in Patients With Hypertension Uncontrolled by Treatment With Angiotensin II Receptor Blockers in Real Clinical Practice. Results of the PREVOSHODSTVO (SUPERIORITY) Program] ( Ostroumova, OD, 2017) |
| "In newly diagnosed patients with hypertension, lercanidipine was superior to nifedipine in the six-year period when the analyzed endpoint was stroke." | 7.85 | Long-term outcomes of lercanidipine versus other calcium channel blockers in newly diagnosed hypertension: a nationwide cohort study. ( Cheng, KC; Cheng, KH; Cheng, KY; Lai, WT; Lee, CW; Yang, YH, 2017) |
| "This study was performed to evaluate the possible protective effect of two calcium channel blocker's "lacidipine (LAC) and amlodipine (AML)" on bone metabolism in an experimental ovariectomized and inflammation-induced osteoporosis rat model (OVXinf)." | 7.83 | Effects of Administration of Amlodipine and Lacidipine on Inflammation-Induced Bone Loss in the Ovariectomized Rat. ( Albayrak, A; Ayan, AK; Aydin, A; Bayir, Y; Cadirci, E; Demirci, E; Halici, Z; Karakus, E; Ozturk-Karagoz, B; Sahin, A; Unal, D, 2016) |
| "The current study investigated the efficacy of losartan and amlodipine in protecting spontaneously hypertensive stroke-prone (SHRSP) rats against the risk of stroke." | 7.83 | Prehypertensive treatment with losartan, however not amlodipine, leads to long-term effects on blood pressure and reduces the risk of stroke in spontaneously hypertensive stroke-prone rats. ( He, D; Lin, J; Zhang, L, 2016) |
| "The present study aims to study the role of receptor activator of nuclear factor kappa B ligand/receptor activator of nuclear factor kappa B/osteoprotegerin (RANKL/RANK/OPG) system in cardiac hypertrophy in a spontaneous hypertension rat (SHR) model and the effects of amlodipine and atorvastatin intervention." | 7.83 | Amlodipine and atorvastatin improved hypertensive cardiac hypertrophy through regulation of receptor activator of nuclear factor kappa B ligand/receptor activator of nuclear factor kappa B/osteoprotegerin system in spontaneous hypertension rats. ( Cui, W; Du, H; Hao, J; Liu, D; Liu, F; Lu, J; Yang, X, 2016) |
| "We evaluated the safety and efficacy of hypertension management with Coveram (perindopril/amlodipine combination) in patients with uncontrolled blood pressure (BP)." | 7.83 | Efficacy and Safety Assessment of Hypertension Management with Coveram (Perindopril/Amlodipine Fixed Combination) in Patients with Previous Angiotensin Receptor Blocker (ARB) Treatment: Arabian Gulf STRONG Study. ( Ahmed, M; Al-Wahshi, Y; Al-Zakwani, I; Alanbaei, M; El Tamimi, H, 2016) |
| "A total of 108 mild-to-moderate essential hypertension patients in Chinese Han nationality were treated with amlodipine for 8 weeks at a dosage of 5 mg/d." | 7.83 | [Association between gene polymorphism of calcium/calmodulin-dependent kinase 4 and efficacy of amlodipine in the treatment of hypertension in Chinese Han nationality]. ( Chen, Y; Liu, L; Liu, Y; Luo, Y; Yang, L; Yao, J; Zhong, G, 2016) |
| "Treatment with candesartan cilexetil reduced the level of ADMA in hypertensive patients in the chronic stage of cerebral infarction." | 7.83 | Effects of Candesartan Cilexetil Compared with Amlodipine on Serum Asymmetric Dimethylarginine Levels in the Chronic Stage of Cerebral Infarction: A Preliminary Study. ( Katayama, Y; Nishiyama, Y; Nomura, K; Sunami, E, 2016) |
| "to compare efficacy of verapamil and amlodipine in treatment of chronic heart failure (CHF) with preserved left ventricular (LV) ejection fraction (EF) in patients with hypertensive disease (HD)." | 7.83 | [Comparison of Verapamil and Amlodipine for Treatment of Chronic Heart Failure With Preserved Left Ventricular Ejection Fraction in Patients With Hypertensive Disease]. ( Kanorskii, SG; Sereda, AF, 2016) |
| " FC, two extreme approaches are presented: with difference in effectiveness due to improved adherence to the treatment estimated from published studies on other molecules used in hypertension such as SPCs and FCs - the base-case approach (1); and assuming no difference of effectiveness or adherence between SPC and FC of indapamide and amlodipine - the conservative approach (2)." | 7.81 | Economic evaluation of single-pill combination of indapamide and amlodipine in the treatment of arterial hypertension in the Polish setting. ( Borowiec, Ł; Filipiak, KJ; Holko, P; Kawalec, P; Stawowczyk, E, 2015) |
| "to study effectiveness of a fixed combination of perindopril arginine and amlodipine besylate for the treatment of arterial hypertension with concomitant chronic cardiac insufficiency and signs of chronic kidney disease Materials and methods: 53 (44." | 7.81 | [EFFECTIVENESS OF FIXED COMBINATION OF PERINDOPRILARGININE AND AMLODIPINE FOR THE TREATMENT OF ARTERIAL HYPERTENSION WITH CONCOMITANT CHRONIC CARDIAC INSUFFICIENCY AND SIGNS OF CHRONIC KIDNEY DISEASE]. ( Borovkova, NY; Kuznetsova, TE, 2015) |
| "to assess efficacy of a fixed combination of perindopril arginine and amlodipine besylate in the treatment of hypertensive patients with chronic heart failure (CHF) and signs of chronic kidney disease (CKD)." | 7.81 | [Therapy of Arterial Hypertension in Patients With Chronic Heart Failure and Signs of Chronic Kidney Disease With Fixed Perindopril/Amlodipine Combination]. ( Borovkov, NN; Borovkova, NJ; Kovaleva, GV; Kuznecova, TE, 2015) |
| "7 years, 19 men) with uncomplicated hypertension without diabetes were given bisoprolol 5-10 mg." | 7.81 | [The Fixed Combination of Amlodipine and Bisoprolol Eliminates the Effect of -Blockers on Central Pulse Wave in Patients With Arterial Hypertension]. ( Bogomaz, AV; Kobalava, ZD; Kotovskaya, YV, 2015) |
| " We have previously shown that in salt-sensitive hypertension either a statin or the calcium channel blocker amlodipine (Aml) have vasoprotective effects." | 7.80 | Combination therapy of amlodipine and atorvastatin has more beneficial vascular effects than monotherapy in salt-sensitive hypertension. ( Jaimes, EA; Raij, L; Tian, R; Zhou, MS, 2014) |
| "Hydralazine is a medication that has been used to manage hypertension and heart failure." | 7.80 | Hydralazine associated pauci-immune glomerulonephritis. ( Baiswar, S; Suneja, M; Vogelgesang, SA, 2014) |
| "EXCITE (clinical EXperienCe of amlodIpine and valsarTan in hypErtension) evaluated the real-life effectiveness, safety, and tolerability of single-pill combinations (SPCs) of amlodipine/valsartan (Aml/Val) and amlodipine/valsartan/hydrochlorothiazide (Aml/Val/HCTZ) in patients with hypertension from 13 countries in the Middle East and Asia." | 7.80 | Real-life effectiveness, safety, and tolerability of amlodipine/valsartan or amlodipine/valsartan/hydrochlorothiazide single-pill combination in patients with hypertension from Pakistan. ( Abid, R; Afzal, J; Iktidar, S; Khan, W; Kumar, K; Maheshwary, N; Moin, N; Qadir, M; Sakrani, J; Siddiqi, A, 2014) |
| "This study evaluated the efficacy as well as the safety and tolerability profile of low-dose valsartan/amlodipine (Val/Amlo) single-pill combination (SPC) (160/5 mg) in patients with essential hypertension in Turkey." | 7.80 | Efficacy and safety of valsartan/amlodipine single-pill combination in patients with essential hypertension (PEAK LOW). ( Ar, I; Ilerigelen, B; Kızılırmak, P, 2014) |
| "The EXCITE (clinical EXperienCe of amlodIpine and valsarTan in hypErtension) study was designed to evaluate the effectiveness, tolerability and adherence of amlodipine/valsartan (Aml/Val) and amlodipine/valsartan/hydrochlorothiazide (Aml/Val/HCT) single-pill combination therapies in patients with hypertension from the Middle East and Asia studied in routine clinical practice." | 7.80 | Real-world clinical experience of amlodipine/valsartan and amlodipine/valsartan/hydrochlorothiazide in hypertension: the EXCITE study. ( Assaad-Khalil, SH; Cho, B; Kitchlew, AR; Knap, D; Najem, R; Shete, A; Sison, J; Ueng, KC, 2014) |
| " Our study evaluated the efficacy of triple therapy with perindopril, amlodipine, and indapamide sustained release (SR) in patients with uncontrolled hypertension on previous antihypertensive therapy." | 7.80 | Triple combination therapy in hypertension: the antihypertensive efficacy of treatment with perindopril, amlodipine, and indapamide SR. ( Páll, D; Szabó, Z; Szántó, I, 2014) |
| "This is a case report of a 71-year-old male with known diabetes, hypertension and diabetic nephropaty who over the course of one year developed an unrecognized myopathy due to concomitant treatment with high-dose simvastatin and amlodipin." | 7.80 | [Myopathy and rhabdomyolysis after treatment with simvastatin, amlodipine, and roxithromycin]. ( Lindelof, M; Skovbølling, SL, 2014) |
| "To evaluate the efficacy and safety of a fixed-term combination of β-blocker bisoprolol and the calcium antagonist amlodipine in the outpatient treatment of patients with arterial hypertension (AH) and coronary heart disease (CHD)." | 7.80 | [Evaluating the effectiveness of a fixed combination of amlodipine and bisoprolol in ambulatory patients with arterial hypertension and ischemic heart disease]. ( Chesnikova, AI; Kolomatskaia, OE; Safronenko, VA, 2014) |
| "Triplixam is a fixed dose combination of three well known antihypertensive agents, with complementary activities, to control blood pressure in patients with arterial hypertension: perindopril, an angiotensin converting enzyme inhibitor, indapamide, a diuretic whith thiazide-like effects but also specific properties, and amlodipine, a long-acting calcium antagonist of the dihydropyridine family." | 7.80 | [Fixed dose combination perindopril-indapamide-amlodipine (Triplixam) for the treatment of arterial hypertension]. ( Krzesinski, JM; Lancellotti, P; Scheen, AJ, 2014) |
| "To estimate effect of combined perindopril/amlodipine therapy on structural and functional characteristics of the heart and blood vessels, intrarenal hemodynamics in patients with essential arterial hypertension (AH) depending on the degree of renal dysfunction." | 7.79 | [Organoprotective effects of the combination of perindopril and amlodipine depending on the renal functional state in patients with arterial hypertension]. ( Budagovskaia, ZM; Iskenderov, BG; Sisina, ON, 2013) |
| "amlodipine, is a milestone in the effort to test whether newer compounds offer a better reduction of the cardiovascular consequences of hypertension, as well as good BP control." | 7.79 | Long-term potential of angiotensin receptor blockade for cardiovascular protection in hypertension: the VALUE trial. Valsartan Antihypertensive Long-term Use Evaluation. ( Julius, S, 1999) |
| "Amlodipine is a dihydropyridine calcium channel blocker that is used in the management of both hypertension and angina." | 7.78 | Amlodipine-induced gingival hyperplasia in chronic renal failure: a case report. ( Aldemir, NM; Begenik, H; Emre, H; Erdur, FM; Soyoral, Y, 2012) |
| " Patients received amlodipine 5 mg daily for grade ≥ 2 bevacizumab-induced hypertension." | 7.78 | Treatment of bevacizumab-induced hypertension by amlodipine. ( Billemont, B; Blanchet, B; Cabanes, L; Camps, S; Coriat, R; Goldwasser, F; Knebelmann, B; Mir, O; Ropert, S, 2012) |
| "This prospective, open-label, postmarketing surveillance study enrolled adults with arterial hypertension (systolic BP >140 mmHg and/or diastolic BP >90 mmHg) who were prescribed antihypertensive therapy with single-pill combination amlodipine/valsartan 5/80, 5/160, or 10/160 mg once daily." | 7.78 | Amlodipine/valsartan single-pill combination: a prospective, observational evaluation of the real-life safety and effectiveness in the routine treatment of hypertension. ( Dongre, N; Karpov, Y; Sastravaha, K; Vigdorchik, A, 2012) |
| "The present study had the objective to estimate the antihypertensive efficacy of a low-dose combination of amlodipine (5 mg) and lisinopril (equator, Gedeon Richter, Hungary; 10 mg) as well as its influence on the diastolic left ventricular function in the women presenting with arterial hypertension in the postmenopausal period A total of 60 postmenopausal women with grade II arterial hypertension available for the examination were allocated to two groups to be maintained on different therapeutic regimens." | 7.78 | [Antihypertensive efficacy of a low-dose combination of amlodipine and lisinopril in the treatment of arterial hypertension in postmenopausal women]. ( Bakhshaliev, AB; Gabieva, NN, 2012) |
| "To describe the case of treatment with amlodipine in a poorly controlled hypertension in a pediatric patient diagnosed with tricodistrofia." | 7.78 | Amlodipine in pediatric patient with uncontrolled multifactorial hypertension. Formulation of amlodipine oral suspension. ( Arias Santos, I; Lago Rivero, N; Paradela Carreiro, A, 2012) |
| " To confirm and support previous findings, the SEVITENSION study will assess the effects on CABP of treatment with the high dose combination of perindopril plus amlodipine as used in ASCOT-CAFE compared with the high dose combination of olmesartan/amlodipine in patients with moderate-to-severe hypertension uncontrolled on amlodipine monotherapy." | 7.77 | Efficacy of Sevikar® compared to the combination of perindopril plus amlodipine on central arterial blood pressure in patients with moderate-to-severe hypertension: Rationale and design of the SEVITENSION study. ( Ruilope, LM; Schaefer, A, 2011) |
| "To describe the occurrence of systemic hypertension in dogs with acute kidney injury and the efficacy of amlodipine besylate for its treatment." | 7.77 | Occurrence of systemic hypertension in dogs with acute kidney injury and treatment with amlodipine besylate. ( Doherr, M; Francey, T; Geigy, CA; Schweighauser, A, 2011) |
| "The results of observational investigation by prescription of the fixed combination perindopril + amlodipin produced by to the uncontrollable hypertension patients by the previous therapy are described in the given article." | 7.77 | [Estimation of antihypertension efficiency and use of fixed combination perindopril+amlodipin by uncontrollable hypertension patients within the limits of routine treatment]. ( Ishmurzin, GP, 2011) |
| "We assessed effect of 6-weeks therapy with atorvastatin on parameters of lipid metabolism and some hemorheological characteristics in 27 patients with arterial hypertension (AH) and dyslipoproteinemia (DLP)." | 7.76 | [Effect of atorvastatin on hemorheological parameters in patients with arterial hypertension with dyslipidemia]. ( Abrashkina, ED; Nazarova, OA; Pakhrova, OA; Shaalali, N; Shutemova, EA, 2010) |
| "In this study, animals were divided into six groups as follows: control (Group 1), hypertension (Group 2), ovariectomy (Group 3), ovariectomy and hypertension (Group 4), ovariectomy, hypertension and amlodipine-treated (Group 5), and ovariectomy, hypertension and lacidipine-treated (Group 6)." | 7.76 | Effects of hypertension and ovariectomy on rat hepatocytes. Are amlodipine and lacidipine protective? (A stereological and histological study). ( Albayrak, F; Altunkaynak, ZB; Bayram, E; Beyzagül, P; Dursun, H; Halici, Z; Keleş, NO; Okçu, N; Süleyman, H; Ünal, B; Uyanik, A, 2010) |
| "Overall, 556 patients with hypertension (msDBP > or =95-<110 mmHg) received open-label aliskiren/amlodipine 150/5 mg for 2 weeks, followed by forced titration to aliskiren/amlodipine 300/10 mg for 52 weeks." | 7.75 | Long-term safety, tolerability and efficacy of combination therapy with aliskiren and amlodipine in patients with hypertension. ( Hollanders, G; Liao, W; Littlejohn, TW; Trenkwalder, P; Zhao, Y, 2009) |
| "Changes in HBP and urinary albumin excretion (UAE) were investigated in 47 benidipine and 37 amlodipine recipients with essential hypertension and albuminuria between January 2007 and December 2007." | 7.75 | Effects of benidipine, a long-acting T-type calcium channel blocker, on home blood pressure and renal function in patients with essential hypertension: a retrospective, 'real-world' comparison with amlodipine. ( Hoshino, C; Kikuchi, A; Kuriyama, C; Ohta, M; Sato, N; Sugawara, S, 2009) |
| " This subanalysis of the Clinical Utility of Caduet in Simultaneously Achieving Blood Pressure and Lipid End Points (CAPABLE) trial studied attainment of the Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 7) and the National Cholesterol Education Program Adult Treatment Panel III (NCEP ATP III) blood pressure (BP) and low-density lipoprotein cholesterol (LDL-C) goals by 8 flexibly titrated doses (5/10-10/80 mg) of amlodipine/atorvastatin single pill in 494 African Americans with hypertension and dyslipidemia, according to the presence of diabetes +/- the metabolic syndrome." | 7.75 | Amlodipine/Atorvastatin single-pill therapy for blood pressure and lipid goals in African Americans: influence of the metabolic syndrome and type 2 diabetes mellitus. ( Ferdinand, KC; Flack, JM; Jamieson, MJ; Kursun, A; Saunders, E; Shi, H; Victor, R; Watson, K, 2009) |
| "The study was based on a treatment regimen that was similar to the therapeutic approach in daily clinical practice and showed that the use of olmesartan medoxomil in monotherapy or in association with hydrochlorothiazide and amlodipine was effective in the attainment of the recommended goals for hypertension stage 1 and 2 hypertensive individuals." | 7.74 | Based treatment algorithm for essencial hypertension with olmesartan medoxomil. ( Amodeo, C; Brandão, AA; Feitosa, AD; Gomes, MA; Moriguchi, EH; Oigman, W; Précoma, DB; Ribeiro, AB; Ribeiro, JM; Saraiva, JF, 2008) |
| " In this sub-analysis of the Candesartan Antihypertensive Survival Evaluation in Japan (CASE-J) trial, we aimed to compare the effects of candesartan and amlodipine on cardiovascular mortality and morbidity in Japanese elderly patients with high-risk hypertension and to determine their optimal target blood pressures (BPs)." | 7.74 | The optimal target blood pressure for antihypertensive treatment in Japanese elderly patients with high-risk hypertension: a subanalysis of the Candesartan Antihypertensive Survival Evaluation in Japan (CASE-J) trial. ( Fujimoto, A; Fukiyama, K; Fukui, T; Matsuoka, H; Nakao, K; Oba, K; Ogihara, T; Saruta, T; Shimamoto, K; Ueshima, K, 2008) |
| "To report a case of bilateral upper extremity edema associated with amlodipine use in a child." | 7.74 | Amlodipine-induced bilateral upper extremity edema. ( Ganeshalingham, A; Wong, W, 2007) |
| "The clinical efficacy of amlodipine in improving hemodynamic variables and reducing cardiovascular events in isolated systolic hypertension could be explained by its beneficial effect on vascular calcification." | 7.74 | Distinct effects of amlodipine treatment on vascular elastocalcinosis and stiffness in a rat model of isolated systolic hypertension. ( Bouvet, C; Essalihi, R; Gilbert, LA; Lenoël, C; McKee, MD; Moreau, P; Moreau, S; Nekka, F; Zandvliet, ML, 2007) |
| "We conducted a subgroup analysis of the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) to compare metabolic, cardiovascular, and renal outcomes in individuals assigned to initial hypertension treatment with a thiazide-like diuretic (chlorthalidone), a calcium channel blocker (CCB; amlodipine), or an ACE inhibitor (lisinopril) in nondiabetic individuals with or without metabolic syndrome." | 7.74 | Metabolic and clinical outcomes in nondiabetic individuals with the metabolic syndrome assigned to chlorthalidone, amlodipine, or lisinopril as initial treatment for hypertension: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent ( Baimbridge, C; Barzilay, J; Basile, J; Black, HR; Dart, RA; Davis, B; Marginean, H; Nwachuku, C; Thadani, U; Whelton, P; Wong, ND; Wright, JT, 2008) |
| " The aim of this study was to clarify the add-on effects of bedtime dosing of the alpha(1)-adrenergic receptor antagonist doxazosin on morning blood pressure in patients with essential hypertension who were under long-acting calcium channel blocker amlodipine monotherapy." | 7.74 | Add-on effect of bedtime dosing of the alpha(1)-adrenergic receptor antagonist doxazosin on morning hypertension and left ventricular hypertrophy in patients undergoing long-term amlodipine monotherapy. ( Gomi, T; Ikeda, T; Matsuda, N; Shibuya, Y; Shinozaki, S; Suzuki, Y, 2007) |
| "To report a case of anasarca edema associated with amlodipine use." | 7.73 | Anasarca edema with amlodipine treatment. ( Arioğul, S; Cankurtaran, M; Halil, M; Sener, D; Yavuz, BB, 2005) |
| "we observe the efficacy of verapamil and amlodipine administered simultaneously in the medical treatment of endogenous hyperinsulinemic hypoglycemia." | 7.73 | [Successful pharmacological treatment of hyperinsulinemic hypoglycemia with verapamil and amlodipine--case report]. ( Owecki, M; Sowiński, J, 2005) |
| " Combination therapy of valsartan with either amlodipine or verapamil was equally effective in reducing blood pressure to valsartan monotherapy (valsartan + amlodipine 129 +/- 4 valsartan + verapamil 133 +/- 6 mmHg;) but was not as effective at reducing albuminuria." | 7.72 | Disparate effects of angiotensin II antagonists and calcium channel blockers on albuminuria in experimental diabetes and hypertension: potential role of nephrin. ( Allen, TJ; Cao, Z; Cooper, ME; Davis, BJ; de Gasparo, M; Kawachi, H, 2003) |
| "Amlodipine is a potent peripheral and coronary vasodilator with high selectivity for vascular smooth muscle, and is widely used in mild to moderate hypertension, chronic stable angina and vasospastic angina." | 7.72 | Amlodipine associated hyperpigmentation. ( Erbagci, Z, 2004) |
| "The present study assessed the cost effectiveness of irbesartan, an angiotensin II receptor antagonist, and amlodipine, a calcium channel blocker, in the treatment of Canadian patients with diabetic nephropathy and hypertension." | 7.72 | Economic evaluation of the use of irbesartan and amlodipine in the treatment of diabetic nephropathy in patients with hypertension in Canada. ( Coyle, D; Rodby, RA, 2004) |
| "In the current study we examined the effect of amlodipine (AMLOD) on oxidative stress-induced hypertension in Sprague-Dawley rats administered buthionine-sulfoximine (BSO), a glutathione (GSH) synthase inhibitor, in the drinking water." | 7.72 | Amlodipine attenuates oxidative stress-induced hypertension. ( Abukhalaf, IK; Bayorh, MA; Eatman, D; Ganafa, AA; Walton, M, 2004) |
| "A hundred and thirty-six patients with mild and moderate arterial hypertension (AH) who had received angiotensin-converting enzyme inhibitors (ACEIs) (enalapril and lisinopril) and the calcium channel blocker amlodipine were examined." | 7.72 | [Effect of enalapril, lisinopril, and amlodipine on the course of chronic gastrititis in patients with arterial hypertension]. ( Alekseenko, SA; Avilova, AA; Fleĭshman, MIu; Lamekhova, VG; Timoshin, SS, 2004) |
| " The present study compared the effects of prolonged treatment with the Ca2+-channel blocker amlodipine and the ACE inhibitor enalapril, respectively, in TGR(mREN2)27 rats (TGR), an animal model of renin-dependent hypertension." | 7.71 | Normalisation of blood pressure in hypertensive TGR(mREN2)27 rats by amlodipine vs. enalapril: effects on cardiac hypertrophy and signal transduction pathways. ( Heckmann, M; Huser, L; Knotter, B; Lemmer, B; Schiffer, S; Witte, K, 2001) |
| "We investigated the effects of the calcium channel blocker amlodipine besilate on serum levels of adrenal androgens and insulin in 20 men with essential hypertension and obesity (age: 51." | 7.71 | Effects of amlodipine on serum levels of adrenal androgens and insulin in hypertensive men with obesity. ( Miyachi, Y; Tsuboi, K; Ueshiba, H, 2001) |
| "The objective of the present study was to evaluate the efficacy and safety of a therapeutic interchange between high-dose calcium channel blocker therapy and a fixed-dose combination of amlodipine/ benazepril (Lotrel; Novartis Pharmaceuticals, USA) in patients with moderate to severe hypertension." | 7.71 | Efficacy and safety of a therapeutic interchange from high-dose calcium channel blockers to a fixed-dose combination of amlodipine/benazepril in patients with moderate-to-severe hypertension. ( Faulkner, M; Hilleman, DE; Reyes, AP; Wurdeman, RL, 2001) |
| "OBJECTIVES; We assessed the effects of long-term amlodipine administration in a diastolic heart failure (DHF) rat model with preserved systolic function as well as the relationship between changes in left ventricular (LV) myocardial stiffening and alterations in extracellular matrix." | 7.71 | Long-term administration of amlodipine prevents decompensation to diastolic heart failure in hypertensive rats. ( Hori, M; Mano, T; Masuyama, T; Miwa, T; Nishikawa, N; Sakata, Y; Sugawara, M; Yamamoto, K, 2001) |
| "These findings suggest that the ACE inhibitor imidapril augments RH after 12 weeks of treatment in patients with essential hypertension and that this ACE inhibitor-induced augmentation of RH may be due to an increase in NO." | 7.71 | Effect of the angiotensin-converting enzyme inhibitor imidapril on reactive hyperemia in patients with essential hypertension: relationship between treatment periods and resistance artery endothelial function. ( Higashi, Y; Kajiyama, G; Matsuura, H; Nakagawa, K; Oshima, T; Sasaki, S, 2001) |
| "Patients with moderate primary hypertension over 21 years of age who were given amlodipine (n:10) and captopril (n:10) for 8 weeks, plus normal controls (n:10)." | 7.71 | Normal erythrocyte calpain I activity on membrane proteins under near-physiological conditions in patients with essential hypertension. ( Barretto, OC; Dantas de Medeiros, TM; Mion, D; Nonoyama, K; Ortega, KC, 2002) |
| "The present study was performed to compare cardioprotective effects of an angiotensin-converting-enzyme inhibitor, imidapril, and of a Ca2+ channel antagonist, amlodipine, against the cardiac hypertrophy in male spontaneously hypertensive rats (SHRs) at the established stage of hypertension." | 7.70 | Cardioprotective effects of an angiotensin-converting-enzyme inhibitor, imidapril, and Ca2+ channel antagonist, amlodipine, in spontaneously hypertensive rats at established stage of hypertension. ( Adachi, T; Naito, Y; Narita, H; Ohara, N; Yokota, S; Yoshida, H, 1998) |
| "The study illustrates the antihypertensive properties of amlodipine once-daily in paediatric hypertension." | 7.70 | Amlodipine once-daily in systemic hypertension. ( Bianchetti, MG; Busch, K; Clericetti-Affolter, C; Laux-End, R; Pfammatter, JP; Truttmann, AC, 1998) |
| "The objective of this investigation was to compare changes in antioxidant status (together with other metabolites relevant to hypertension) in plasma and cardiac tissue from spontaneously hypertensive rats (SHR) and normotensive Wistar Kyoto rats (WKY), following 8 weeks of treatment with lisinopril (angiotensin converting enzyme inhibitor) or amlodipine (Ca(2+) channel antagonist) respectively." | 7.70 | Effects of lisinopril and amlodipine on antioxidant status in experimental hypertension. ( Ahmed, S; MacNee, W; Mantle, D; Patel, VB; Preedy, VR; Rahman, I; Richardson, PJ; Wassif, WS; Why, HJ, 2000) |
| "An open, multicenter study was conducted to investigate the antihypertensive efficacy and safety of amlodipine in the long-term treatment of patients with mild to moderate essential hypertension of a period of 178 weeks (3." | 7.69 | [Amlodipine in long-term treatment of mild and moderate hypertension. A multicenter study]. ( Anlauf, M; Sauerbrey-Wullkopf, N, 1995) |
| "To clarify whether the long-acting calcium-channel blocker amlodipine restores insulin insensitivity in essential hypertension, insulin sensitivity tests were performed at the physiological steady-state insulin level (45 to 55 microU/mL) before and after amlodipine (2." | 7.69 | Improvement of insulin sensitivity for glucose metabolism with the long-acting Ca-channel blocker amlodipine in essential hypertensive subjects. ( Asakura, Y; Harano, Y; Hirose, J; Ikebuchi, M; Kageyama, A; Omae, T; Suzuki, M; Yokota, T, 1995) |
| "Pharmacokinetic and pharmacodynamic data were compared between elderly and young patients with hypertension who received single intravenous doses of amlodipine, a dihydropyridine calcium antagonist, followed by oral administration of amlodipine up to 10 mg once daily for 12 weeks." | 7.69 | An overview of the pharmacokinetics and pharmacodynamics of amlodipine in elderly persons with systemic hypertension. ( Abernethy, DR, 1994) |
| "In a 3-month, open-label study, 54 consecutive black patients with very severe hypertension were treated with amlodipine." | 7.69 | Effects of amlodipine on 24-hour ambulatory blood pressure profiles, electrocardiographic monitoring, and left ventricular mass and function in black patients with very severe hypertension. ( Chautsane, Z; Chopamba, A; Lee, A; Reddy, K; Sareli, P; Skoularigis, J; Strugo, V; Weinberg, J, 1995) |
| "The dihydropyridine calcium channel blocking agent amlodipine is an effective anti-hypertensive agent and its use (in doses of 5 or 10 mg/day/kg body weight) was investigated in male Wistar rats with hypertension induced by aortic constriction." | 7.69 | Effects of the dihydropyridine calcium channel blocker amlodipine on ventricular and atrial protein synthesis in an aortic constriction model of hypertension and, following chronic treatment, in the left ventricle of SHR rats. ( Patel, VB; Preedy, VR; Richardson, PJ; Sherwood, R; Siddiq, T, 1997) |
| "Twenty two patients having mild to moderate hypertension were treated with a single daily dose of amlodipine for 4 weeks." | 7.69 | Evaluation of amlodipine in mild to moderate hypertension--a clinical report. ( Acharya, HK; Vatsaraj, DJ; Yajnik, NV; Yajnik, VH, 1995) |
| "The effects of amlodipine on ambulatory blood pressure and on diurnal variations in plasma noradrenaline and renin activity were examined 1, 4, and 7 days after the start of amlodipine administration in eight inpatients with essential hypertension." | 7.69 | Amlodipine lowers blood pressure without increasing sympathetic activity or activating the renin-angiotensin system in patients with essential hypertension. ( Arakawa, K; Ideishi, M; Kinoshita, A; Koga, M; Matsumoto, N; Noda, K; Sasaguri, M, 1997) |
| "The authors report the results of therapy with amlodipine in 20 patients with mild or moderate hypertension (diastolic pressure between 95 and 115 mmHg)." | 7.68 | [Experience with amlodipine (Norvasc) in the management of arterial hypertension]. ( Domínguez, B; Rodríguez, N, 1993) |
| "To evaluate the effects of long-term treatment antihypertensive with the dihydropyridine calcium antagonist amlodipine on insulin sensitivity, plasma insulin, and lipoprotein metabolism in obese hypertensive patients." | 7.68 | Lack of effect of long-term amlodipine on insulin sensitivity and plasma insulin in obese patients with essential hypertension. ( Böhlen, L; de Courten, M; Ferrari, P; Heynen, G; Riesen, W; Schneider, M; Shaw, S; Weidmann, P, 1993) |
| " The pressor response to norepinephrine and angiotensin II, as well as several other blood pressure modulating factors, were studied in normal subjects (n = 9) and patients with essential hypertension (n = 10) before and after 8 weeks of treatment with the long-acting dihydropyridine amlodipine." | 7.68 | Antihypertensive mechanism of amlodipine in essential hypertension: role of pressor reactivity to norepinephrine and angiotensin II. ( Beretta-Piccoli, C; Bühler, FR; Donati, L; Heinen, G; Kusch, F, 1992) |
| "Haemodynamic responses at rest and during exercise were studied in 18 patients with essential hypertension following long-term treatment with amlodipine." | 7.68 | Long-term haemodynamic effects of amlodipine at rest and during exercise in essential hypertension. ( Digranes, O; Helland, B; Jordal, O; Lund-Johansen, P; Omvik, P; Stray, T; White, W, 1992) |
| "Amlodipine administered once daily (5-10 mg) lowered blood pressure and reduced total peripheral resistance in patients with mild-to-severe essential hypertension without any reflex tachycardia." | 7.68 | Long-term haemodynamic effects of amlodipine at rest and during exercise in essential hypertension. ( Digranes, O; Helland, B; Jordal, O; Lund-Johansen, P; Omvik, P; Stray, T; White, W, 1991) |
| "Pharmacodynamics and disposition of amlodipine, a dihydropyridine calcium antagonist, were compared between elderly and young patients with hypertension." | 7.68 | Effects of amlodipine, a long-acting dihydropyridine calcium antagonist in aging hypertension: pharmacodynamics in relation to disposition. ( Abernethy, DR; Gutkowska, J; Winterbottom, LM, 1990) |
| " There was no significant difference in the adverse events rates between RSV 10 mg/AML 5 mg, RSV 20 mg/AML 5 mg, and ATV 20 mg/AML 5 mg." | 7.30 | Randomized, multicenter, parallel, open, phase 4 study to compare the efficacy and safety of rosuvastatin/amlodipine polypill versus atorvastatin/amlodipine polypill in hypertension patient with dyslipidemia. ( Bae, HJ; Cho, EJ; Choi, JY; Han, KR; Hong, BK; Hong, SP; Hyon, MS; Jin, HY; Jung, HW; Kim, CY; Kim, KS; Kim, SY; Kim, U; Lee, JB; Lee, KH; Lee, KJ; Lee, SR; Lee, SY; Nam, CW; Park, CG; Park, SJ; Park, TH; Rhee, MY; Ryu, JK; Seol, SH; Shin, JH; Yang, DH; Yu, GW, 2023) |
| " There are no serious adverse event and no one discontinued medication due to adverse event." | 7.30 | Efficacy and safety of standard dose triple combination of telmisartan 80 mg/amlodipine 5 mg/chlorthalidone 25 mg in primary hypertension: A randomized, double-blind, active-controlled, multicenter phase 3 trial. ( Ahn, Y; Cha, KS; Chang, K; Cho, EJ; Choi, DJ; Choi, SY; Doh, JH; Hong, SJ; Hong, SP; Hwang, JY; Hyon, MS; Ihm, SH; Kang, WC; Kim, HS; Kim, MH; Kim, SH; Kim, WS; Kim, YH; Kwon, K; Lee, JH; Lee, N; Lim, SW; Rhee, MY; Shin, J; Son, JW; Yoo, BS, 2023) |
| " Adverse events and laboratory test results will be monitored throughout the trial." | 7.11 | Efficacy and safety of Tengfu Jiangya tablet combined with valsartan/amlodipine in the treatment of stage 2 hypertension: study protocol for a randomized controlled trial. ( Chen, W; Hua, Z; Li, Y; Wang, Y; Zhu, Y, 2022) |
| " The availability of OM combined with HCTZ, AML or both at different dosages makes it a valuable option to customize therapy based on the levels of BP and the clinical characteristics of hypertensive patients." | 7.01 | Single-Pill Combination with Three Antihypertensive Agents to Improve Blood Pressure Control in Hypertension: Focus on Olmesartan-Based Combinations. ( Burnier, M; Redon, J; Volpe, M, 2023) |
| "Amlodipine has low renal clearance (7 mL/min/mg) and long half-life (35-50 h) and duration of action, which allows it to sustain its anti-hypertensive effect for more than 24 h following a single dose." | 7.01 | Amlodipine in the current management of hypertension. ( Palmer, BF; Sever, P; Vogel Anderson, K; Wang, JG, 2023) |
| " If BP is not at goal during 4 week's visit, dosage of antihypertensive agents will be doubled." | 6.94 | A comparative study for the effects of nifedipine GITS and amlodipine besylate administrated in daytime or at nighttime on recovery of blood pressure rhythm and arterial stiffness in the young and middle-aged subjects with non-dipper hypertension (NARRAS) ( Liu, J, 2020) |
| " The secondary efficacy variables were changes in MSSBP, mean sitting diastolic blood pressure (MSDBP), LDL cholesterol and other lipid levels at 4 weeks and 8 weeks, as well as observed adverse events during follow-up." | 6.94 | Efficacy and safety of co-administered telmisartan/amlodipine and rosuvastatin in subjects with hypertension and dyslipidemia. ( Ahn, JC; Chae, IH; Cho, EJ; Cho, JM; Cho, Y; Choi, SY; Han, KH; Hong, SJ; Hong, SP; Hwang, J; Hyon, MS; Jin, X; Kim, H; Kim, HS; Kim, JH; Kim, MH; Kim, PJ; Kim, WS; Kwon, K; Lee, H; Lee, HC; Lee, JH; Lee, K; Lee, SH; Park, CG; Rhee, MY; Seo, JS; Shin, JH; Sung, JH; Sung, KC; Yoo, BS, 2020) |
| " The adverse events (AEs) during both treatment periods were generally mild." | 6.84 | The efficacy and long-term safety of a triple combination of 80 mg telmisartan, 5 mg amlodipine and 12.5 mg hydrochlorothiazide in Japanese patients with essential hypertension: a randomized, double-blind study with open-label extension. ( Higaki, J; Ikeda, H; Komuro, I; Kuroki, D; Nishimura, S; Ogihara, T; Shiki, K; Taniguchi, A; Ugai, H, 2017) |
| "Hypertension is classified into two types which are primary or essential hypertension and secondary hypertension." | 6.82 | Evaluation of the Safety and Efficacy of Dual Therapy Perindopril/Amlodipine in the Management of Hypertension. A Systematic Review and Meta-Analysis. ( Elmoursi, A; Kamel, IS; Kassem, A; Khalil, F; Mancy, IME; Mohamed, SED; Mostafa, S; Ramadan, IG; Shabana, H; Zedan, HA, 2022) |
| " The study aimed to evaluate the feasibility of different doses of DXM combined with standard AM treatment in clinical hypertension." | 6.82 | Combination With Low-dose Dextromethorphan Improves the Effect of Amlodipine Monotherapy in Clinical Hypertension: A First-in-human, Concept-proven, Prospective, Dose-escalation, Multicenter Study. ( Chen, JW; Chen, P; Cheng, SM; Hung, YJ; Tseng, WK; Wang, KY; Wen, MS; Wu, CC; Wu, TC; Yeh, HI; Yin, WH, 2016) |
| "0001), and a lower incidence of pedal edema and adverse events compared with amlodipine." | 6.80 | Efficacy and safety of perindopril arginine + amlodipine in hypertension. ( Bakris, GL; Elliott, WJ; Feldstein, JD; Whitmore, J, 2015) |
| " Overall, the olmesartan/amlodipine FDC was well tolerated, and there were no serious adverse events associated with medication." | 6.80 | A multicenter, non-comparative study to evaluate the efficacy and safety of fixed-dose olmesartan/amlodipine in Korean patients with hypertension who are naïve or non-responders to anti-hypertensive monotherapy (ACE-HY study). ( Ahn, Y; Bae, JH; Jung, HW; Kang, DH; Kim, CH; Kim, KI; Park, CG, 2015) |
| " Population pharmacokinetic analyses were performed on data which were collected prospectively from 60 Chinese patients with mild to moderate essential hypertension [age range 40-74 years, males (n = 31), females (n = 29)] receiving oral racemic amlodipine for 4 weeks." | 6.79 | ABCB1 polymorphism and gender affect the pharmacokinetics of amlodipine in Chinese patients with essential hypertension: a population analysis. ( Barrett, JS; Guo, CX; Hua, Y; Huang, ZJ; Pei, Q; Wang, JL; Yang, GP; Yuan, H; Zhang, WL; Zhou, HH; Zuo, XC, 2014) |
| "Azelnidipine has beneficial effects on LV mass regression, transmitral flow, tissue Doppler, and LV longitudinal strain that are comparable to those of amlodipine on the same parameters." | 6.79 | Impact of azelnidipine and amlodipine on left ventricular mass and longitudinal function in hypertensive patients with left ventricular hypertrophy. ( Ikeda, U; Izawa, A; Koyama, J; Miyashita, Y; Motoki, H; Takahashi, M; Tomita, T, 2014) |
| "The current study addresses the 24-h antihypertensive efficacy and safety of arotinolol combined with a different calcium channel blocker." | 6.79 | The efficacy and safety of arotinolol combined with a different calcium channel blocker in the treatment of Chinese patients with essential hypertension: a one-year follow-up study. ( Chen, W; Fang, H; Liu, X; Xu, W, 2014) |
| " There were no differences between 4 dosing regimens in laboratory and clinical parameters of safety and tolerability." | 6.79 | [Fixed irbesartan/amlodipine combination: efficacy and safety of the use of four dosing regimens in patients with arterial hypertension]. ( Kobalava, ZhD, 2014) |
| "Amlodipine was added if target BP was not achieved at 1 month, and doxazosin was added if target BP was not achieved after 3 months." | 6.78 | Comparative effectiveness of a fixed-dose combination of losartan + HCTZ versus bisoprolol + HCTZ in patients with moderate-to-severe hypertension: results of the 6-month ELIZA trial. ( Dobrokhod, AS; Kushnir, SM; Radchenko, GD; Sirenko, YM; Torbas, OO, 2013) |
| "Candesartan or amlodipine was added when BP did not fall lower than 135/85 mmHg." | 6.78 | Comparative effect of candesartan and amlodipine, and effect of switching from valsartan, losartan, telmisartan and olmesartan to candesartan, on early morning hypertension and heart rate. ( Aoyama, T; Goto, M; Goto, N; Hiei, K; Iwasa, M; Kawai, N; Kida, K; Kobayashi, H; Kojima, S; Minagawa, T; Minatoguchi, S; Oda, M; Sugishita, F; Takai, K; Tanaka, R; Watanabe, I; Yamamoto, N; Yasue, T, 2013) |
| " Adverse events occurred at 11." | 6.77 | Efficacy and safety of aranidipine enteric-coated tablets compared with amlodipine in Chinese patients with mild to moderate essential hypertension: a multicenter, randomized, double-blind, parallel-controlled clinical trial. ( Chen, GL; Fan, CM; Li, HM; Li, YS; Lin, YZ; Pang, HM; Wang, L; Wu, SY; Yan, LR; Yu, J; Zhao, RP, 2012) |
| "Telmisartan was more effective than amlodipine in preventing AF recurrences in hypertensive patients with paroxysmal AF." | 6.77 | Effect of telmisartan on paroxysmal atrial fibrillation recurrence in hypertensive patients with normal or increased left atrial size. ( Derosa, G; Fogari, R; Maffioli, P; Mugellini, A; Perrone, T; Preti, P; Zoppi, A, 2012) |
| "In this first randomized trial evaluating the effects of intensive versus moderate dosing of the combination of amlodipine/valsartan, our data suggest that ABPM was a better method for assessing between-treatment differences than clinic or home BP recordings, although measurement of home BP as a single recording was a limitation of our trial." | 6.76 | The role of ambulatory blood pressure monitoring compared with clinic and home blood pressure measures in evaluating moderate versus intensive treatment of hypertension with amlodipine/valsartan for patients uncontrolled on angiotensin receptor blocker mo ( Giles, TD; Hilkert, R; Ofili, EO; Oparil, S; Pitt, B; Purkayastha, D; Samuel, R; Sowers, JR, 2011) |
| " Both treatment groups had similar adverse event rates (35." | 6.76 | Comparative efficacy and safety of combination aliskiren/amlodipine and amlodipine monotherapy in African Americans with stage 2 hypertension. ( Black, HR; Hilkert, R; Israel, M; Izzo, J; Lee, J; Purkayastha, D; Sridharan, K; Weinberger, MH, 2011) |
| " The present study was designed to investigate whether calcium channel blockers (CCBs) in combination with an ARB differentially affect kidney function." | 6.75 | Renoprotective effect of calcium channel blockers in combination with an angiotensin receptor blocker in elderly patients with hypertension. A randomized crossover trial between benidipine and amlodipine. ( Dohi, Y; Kimura, G; Miyagawa, K; Nakazawa, A; Sato, K; Sugiura, T; Yamashita, S, 2010) |
| "Hypertension is particularly prevalent in patients aged ≥65 years, those with a body mass index ≥30 kg m(-2), Blacks and those with type II diabetes." | 6.75 | Efficacy and tolerability of amlodipine plus olmesartan medoxomil in patients with difficult-to-treat hypertension. ( Chrysant, SG; Heyrman, R; Karki, S; Lee, J; Melino, M, 2010) |
| "The aim of the present study was to use ambulatory blood pressure (BP) monitoring (ABPM) to determine the efficacy of a fixed-dose combination of amlodipine (AML) and olmesartan medoxomil (OM) over the 24-hour dosing interval." | 6.75 | Efficacy of amlodipine and olmesartan medoxomil in patients with hypertension: the AZOR Trial Evaluating Blood Pressure Reductions and Control (AZTEC) study. ( Dubiel, R; Kereiakes, DJ; Maa, JF; Neutel, JM; Punzi, H; Shojaee, A; Waverczak, WF, 2010) |
| "Amlodipine, however, has been shown to be effective in reducing BP throughout the day and night, independent of dosing time." | 6.75 | Chronotherapy with valsartan/amlodipine fixed combination: improved blood pressure control of essential hypertension with bedtime dosing. ( Ayala, DE; Fernández, JR; Fontao, MJ; Hermida, RC; Mojón, A, 2010) |
| "Atorvastatin treatment is associated with less augmentation of the carotid BP waveform and less wave reflection from the body." | 6.74 | Atorvastatin treatment is associated with less augmentation of the carotid pressure waveform in hypertension: a substudy of the Anglo-Scandinavian Cardiac Outcome Trial (ASCOT). ( Hughes, AD; Manisty, C; Mayet, J; McG Thom, SA; Poulter, N; Sever, PS; Tapp, RJ, 2009) |
| "In olmesartan-treated patients, CBF significantly increased in the affected and unaffected hemispheres, and CRC increased significantly in the affected hemisphere." | 6.74 | Benefits of the angiotensin II receptor antagonist olmesartan in controlling hypertension and cerebral hemodynamics after stroke. ( Kawahira, K; Matsumoto, S; Miyata, R; Shimodozono, M, 2009) |
| "Seventy type 2 diabetes mellitus patients with hypertension were enrolled and randomly divided into two groups." | 6.74 | Effects of olmesartan, an angiotensin II receptor blocker, and amlodipine, a calcium channel blocker, on Cardio-Ankle Vascular Index (CAVI) in type 2 diabetic patients with hypertension. ( Ban, N; Endo, K; Kawana, H; Miyashita, Y; Nagayama, D; Ohira, M; Oyama, T; Saiki, A; Shirai, K; Yamaguchi, T, 2009) |
| "To show that rapid successful treatment of hypertension leads to improvement in cardiac morphology and function regardless of the pharmacological agents used." | 6.74 | Successful treatment of hypertension accounts for improvements in markers of diastolic function - a pilot study comparing hydrochlorothiazide-based and amlodipine-based treatment strategies. ( Day, AG; Ogunyankin, KO, 2009) |
| "Hypertension is most important risk factor in coronary heart disease and cerebrovascular accidents." | 6.74 | Treatment of hypertension: postmarketing surveillance study results of telmisartan monotherapy, fixed dose combination of telmisartan + hydrochlorothiazide/amlodipine. ( Arif, AF; Joshi, C; Kadam, GG, 2009) |
| " Safety and tolerability evaluations were based on adverse events, ECG and laboratory tests, and clinically relevant reports of abnormalities." | 6.73 | Antihypertensive efficacy and safety of manidipine versus amlodipine in elderly subjects with isolated systolic hypertension: MAISH study. ( Alberici, M; Lembo, G; Payeras, AC; Sladek, K, 2007) |
| "Amlodipine was well tolerated, with just 6 children withdrawn from treatment because of drug-related adverse events." | 6.71 | A randomized, placebo-controlled trial of amlodipine in children with hypertension. ( Daniels, SR; Flynn, JT; Hogg, RJ; Newburger, JW; Portman, RJ; Sanders, SP; Saul, JP, 2004) |
| " In addition to recommending lifestyle modifications, eight dosage strengths of amlodipine/atorvastatin single pill (5/10, 5/20, 5/40, 5/80, 10/10, 10/20, 10/40, and 10/80 mg) were electively titrated to improve blood pressure and lipid control." | 6.71 | Single-pill therapy in the treatment of concomitant hypertension and dyslipidemia (the amlodipine/atorvastatin gemini study). ( Blank, R; LaSalle, J; Maroni, J; Reeves, R; Sun, F; Tarasenko, L, 2005) |
| "Simvastatin is an HMG-CoA reductase inhibitor that is metabolized by the cytochrome P450 (CYP) 3A4." | 6.71 | Interaction between amlodipine and simvastatin in patients with hypercholesterolemia and hypertension. ( Hayashi, H; Kosuge, K; Nishio, S; Ohashi, K; Uchida, S; Watanabe, H, 2005) |
| "Primary aldosteronism is a specifically treatable and potentially curable form of secondary hypertension." | 6.70 | Drug effects on aldosterone/plasma renin activity ratio in primary aldosteronism. ( Chiandussi, L; Milan, A; Morello, F; Mulatero, P; Paglieri, C; Rabbia, F; Veglio, F, 2002) |
| "In losartan-treated patients, both cardiomyocyte and noncardiomyocyte apoptosis decreased (P<0." | 6.70 | Stimulation of cardiac apoptosis in essential hypertension: potential role of angiotensin II. ( Díez, J; Fortuño, MA; González, A; Larman, M; López, B; Querejeta, R; Ravassa, S, 2002) |
| " Amlodipine seems to be more effective than felodipine when the drugs are compared in the same dose, with regard to the effect on clinic BP 24 h after dosing and to ambulatory BP during the night." | 6.69 | Effect of amlodipine versus felodipine extended release on 24-hour ambulatory blood pressure in hypertension. ( Brodin, U; Isaksson, H; Ohman, KP; Ostergren, J; Schwan, A, 1998) |
| " Of all ongoing mortality and morbidity trials in systemic hypertension, VALUE (Valsartan Antihypertensive Long-term Use Evaluation) is the only one comparing an angiotensin II antagonist (valsartan) with a third-generation calcium channel blocker (amlodipine)." | 6.69 | The Valsartan Antihypertensive Long-term Use Evaluation (VALUE) trial of cardiovascular events in hypertension. Rationale and design. ( Julius, S; Mann, J, 1998) |
| "High blood pressure is about twice as common in persons with diabetes mellitus as in those without." | 6.69 | Comorbidity of hypertension and diabetes: the fosinopril versus amlodipine cardiovascular events trial (FACET) ( Sowers, JR, 1998) |
| "Amlodipine was an effective once daily antihypertensive agent with an acceptable safety profile." | 6.69 | Efficacy of amlodipine in pediatric patients with hypertension. ( Hayes, JR; Mahan, JD; Mentser, MI; Nahata, MC; Tallian, KB; Turman, MA, 1999) |
| " Earlier studies combining short acting drugs from these classes require multiple dosing and were associated with poor compliance." | 6.69 | Evaluation of amlodipine, lisinopril, and a combination in the treatment of essential hypertension. ( Naidu, MU; Rao, TR; Shobha, JC; Usha, PR, 2000) |
| "Amlodipine has potential advantages in children since it can be dissolved into a liquid preparation and has a long elimination half-life, allowing for once-daily administration." | 6.69 | A randomized prospective crossover trial of amlodipine in pediatric hypertension. ( Arbus, GS; Blowey, D; Khattak, S; Koren, G; Lyszkiewicz, DA; Rogan, JW, 2000) |
| "Arthritis and hypertension are frequent comorbidities in the elderly hypertensive population." | 6.69 | Effect of indomethacin on blood pressure in elderly people with essential hypertension well controlled on amlodipine or enalapril. ( Anderson, A; Bertram, D; Morgan, TO, 2000) |
| "Amlodipine was better tolerated than nifedipine slow release." | 6.68 | Patient compliance and therapeutic coverage: comparison of amlodipine and slow release nifedipine in the treatment of hypertension. The Belgian Collaborative Study Group. ( Block, P; De Backer, G; Degaute, JP; Detry, JM, 1995) |
| " Newer calcium channel blockers of the dihydropyridine group have longer elimination half-lives (t1/2) that permit once-daily dosage and are generally better tolerated than their parent compound." | 6.68 | Relative efficacy and tolerability of lacidipine and amlodipine in patients with mild-to-moderate hypertension: a randomized double-blind study. ( Cheung, BM; Lau, CP, 1996) |
| "Amlodipine treatment produced significant falls in blood pressure (-23." | 6.67 | The efficacy and safety of amlodipine in the treatment of mild and moderate essential hypertension in general practice. ( Varrone, J, 1991) |
| " In contrast, however, the effects of captopril were no longer evident during the final 3 h of the dosing interval." | 6.67 | Comparison of amlodipine and captopril in hypertension based on 24-hour ambulatory monitoring. ( Lacourcière, Y; Poirier, L; Provencher, P, 1993) |
| " Blood pressure measurements were taken at the end of the dosing interval to assess the antihypertensive efficacy of the two drugs." | 6.67 | At equipotent doses, isradipine is better tolerated than amlodipine in patients with mild-to-moderate hypertension: a double-blind, randomized, parallel-group study. ( De Keyser, P; Deblander, A; Hermans, L; Lesaffre, E; Scheys, I; Westelinck, KJ, 1994) |
| "Amlodipine treatment did not appear to produce clinically significant changes in blood lipids; HCTZ, however, produced an increase in total plasma cholesterol (delta 22." | 6.67 | Double-blind comparison of amlodipine and hydrochlorothiazide in patients with mild to moderate hypertension. ( Ames, RP; Applegate, WB; Burris, JF; Davidov, ME; Mroczek, WJ; Ram, CV, 1994) |
| "Amlodipine was considered effective and well tolerated and the majority of patients needed only 5mg daily and no reflex tachycardia was observed." | 6.67 | [Circadian rhythm of arterial pressure and use of amlodipine in primary hypertension]. ( Spritzer, N, 1993) |
| " Most adverse events were mild or moderate and the investigators' overall evaluation of tolerability was excellent or good for 91% of patients." | 6.67 | A study of the efficacy and safety of amlodipine for the treatment of hypertension in general practice. ( Varrone, J, 1991) |
| " Thus amlodipine administered once daily is an effective and safe agent for second-step therapy in mild to moderate essential hypertension." | 6.66 | Safety and efficacy of amlodipine added to hydrochlorothiazide therapy in essential hypertension. ( Chrysant, SG; Glasser, SP; Graves, J; Koehn, DK; Rofman, B, 1989) |
| " A systematic review of the literature revealed its most common adverse effects as: peripheral edema (depending on the dose of amlodipine, but attenuated by perindopril), cough, dizziness and hypotension." | 6.58 | Perindopril arginine and amlodipine besylate for hypertension: a safety evaluation. ( Bistrika, EA; Elliott, WJ, 2018) |
| "Patients with osteoarthritis are often affected by a number of cardiovascular comorbidities, including hypertension, which is present in about 40% of cases." | 6.58 | Amlodipine and celecoxib for treatment of hypertension and osteoarthritis pain. ( Angeli, F; Reboldi, G; Signorotti, S; Trapasso, M; Verdecchia, P, 2018) |
| "Given that hypertension affects ∼60% of patients with diabetes, effective blood pressure (BP) management is important in this high-risk population." | 6.50 | Uptitrating amlodipine significantly reduces blood pressure in diabetic patients with hypertension: a retrospective, pooled analysis. ( Bhambri, R; Jeffers, BW; Robbins, J, 2014) |
| "Aliskiren is a novel renin-angiotensin aldosterone system (RAAS) inhibitor, the combination therapy of aliskiren and amlodipine for blood pressure control have been reported recently." | 6.49 | Aliskiren and amlodipine in the management of essential hypertension: meta-analysis of randomized controlled trials. ( Chen, K; Han, Y; Kou, X; Liu, Y; Zeng, C; Zhou, L, 2013) |
| "The prevalence of hypertension is high in patients with diabetes mellitus (DM), chronic kidney disease (CKD) and chronic cardiovascular disease (CVD), as well as in black and elderly subjects." | 6.49 | Effectiveness of the fixed-dose combination of olmesartan/amlodipine/hydrochlorothiazide for the treatment of hypertension in patients stratified by age, race and diabetes, CKD and chronic CVD. ( Chrysant, SG, 2013) |
| "Hypertension is one of the most prevalent disorders and the largest contributor to global mortality." | 6.48 | Fixed-dose combination therapy of candesartan cilexetil and amlodipine besilate for the treatment of hypertension in Japan. ( Fujimoto, A; Kuwahara, K; Nakagawa, Y; Ueshima, K; Yasuno, S, 2012) |
| "Amlodipine has an inherently long pharmacokinetic half-life, whereas, in contrast, nifedipine has an inherently short half-life but in the GITS formulation the sophisticated delivery system allows for once-daily dosing." | 6.48 | Long-acting dihydropyridine calcium-channel blockers and sympathetic nervous system activity in hypertension: a literature review comparing amlodipine and nifedipine GITS. ( Elliott, HL; Meredith, PA; Toal, CB, 2012) |
| "Hypertension is an increasingly prevalent cardiovascular risk factor associated with high rates of morbidity and mortality." | 6.47 | Olmesartan medoxomil, amlodipine besylate and hydrochlorothiazide triple combination for hypertension. ( Ram, CV, 2011) |
| "Olmesartan/amlodipine was generally well tolerated over the short- and long-term, with a lower frequency of peripheral edema with olmesartan/amlodipine 40/10 mg than with amlodipine 10 mg monotherapy." | 6.47 | Olmesartan/amlodipine: a review of its use in the management of hypertension. ( Kreutz, R, 2011) |
| "Hypertension is a major risk factor for cardiovascular, renal and stroke complications." | 6.47 | Triple-drug, fixed-dose combinations for the treatment of hypertension: focus on olmesartan/amlodipine/hydrochlorothiazide combination. ( Chrysant, SG, 2011) |
| "Hypertension is characterized by endothelial dysfunction and increased risk for adverse cardiovascular outcomes." | 6.46 | Improving vascular function in hypertension: potential benefits of combination therapy with amlodipine and renin-angiotensin-aldosterone system blockers. ( Siragy, HM, 2010) |
| " The bioavailability of amlodipine and atorvastatin with a single-tablet, fixed-dose amlodipine/atorvastatin combination was not significantly different to that with coadministered separate amlodipine and atorvastatin tablets." | 6.46 | Amlodipine/Atorvastatin: a review of its use in the treatment of hypertension and dyslipidaemia and the prevention of cardiovascular disease. ( Curran, MP, 2010) |
| " In particular, mean 24-h BP and BP variability both correlate closely with hypertension end-organ damage and rate of CV events, which suggests that antihypertensive therapy should provide smooth BP control over the full 24-h dosing interval." | 6.46 | Efficacy and tolerability of olmesartan/amlodipine combination therapy in patients with mild-to-severe hypertension: focus on 24-h blood pressure control. ( Bilo, G; Hoshide, S; Lonati, L; Ochoa, JE; Parati, G; Ramos, C, 2010) |
| "Hypertension is a highly prevalent disease and one of the most important modifiable risk factors for cardiovascular disease." | 6.45 | Olmesartan/Amlodipine: combination therapy for the treatment of hypertension [corrected]. ( Pimenta, E, 2009) |
| "Hypertension is a common treatable risk factor for cardiovascular disease." | 6.44 | [A first drug combination for the treatment of arterial hypertension with a calcium channel antagonist (amlodipine besylate) and an angiotensin receptor blocker (valsartan): Exforge]. ( Krzesinski, JM; Scheen, AJ, 2007) |
| "Amlodipine/valsartan was generally well tolerated in clinical trials." | 6.44 | Amlodipine/Valsartan: fixed-dose combination in hypertension. ( Plosker, GL; Robinson, DM, 2008) |
| "Eplerenone is a newer aldosterone antagonist that is much more selective, with minimal affinity for progesterone and androgenic receptors; therefore, there are very few reports of adverse sexual effects." | 6.42 | Eplerenone in hypertension. ( Burgess, E, 2004) |
| " Ambulatory monitoring studies have confirmed that once-daily dosing provides 24-h control of blood pressure." | 6.38 | Amlodipine in the treatment of hypertension. ( Kaplan, NM, 1991) |
| " Blood pressure control shows a smooth profile over 24 h with once-daily dosing, and there is no tolerance with long-term administration of the drug." | 6.37 | Amlodipine in hypertension: an overview of the clinical dossier. ( Julius, S, 1988) |
| "Amlodipine is a dihydropyridine calcium antagonist which can be used once daily in hypertension." | 6.16 | Amlodipine: an effective once-daily antihypertensive agent. ( Tyler, HM, 1991) |
| "2 years) with uncontrolled essential hypertension were randomly assigned to receive olmesartan, an angiotensin II type 1 receptor blocker (ARB) (N = 23), or amlodipine, a calcium channel blocker (CCB) (N = 22), for 6 months." | 5.69 | Effects of olmesartan and amlodipine on blood pressure, endothelial function, and vascular inflammation. ( Abe, T; Bekki, M; Fukumoto, Y; Honda, A; Igata, S; Kurata, S; Maeda-Ogata, S; Matsui, T; Nishino, Y; Sugiyama, Y; Tahara, A; Tahara, N; Yamagishi, SI, 2023) |
| " However, there are few studies on the regulation and efficacy of atorvastatin combined with amlodipine on Th17/Treg balance in hypertension combined with carotid atherosclerosis." | 5.69 | Effects of amlodipine combined with atorvastatin on Th17/Treg imbalance and vascular microcirculation in hypertensive patients with atherosclerosis: A double-blind, single-center randomized controlled trial. ( Qiu, Y; Yang, G, 2023) |
| "Allisartan isoproxil is a selective nonpeptide angiotensin II (AT1) receptor blocker developed by China, this study aimed to assess its clinical efficacy for essential hypertension (EH)." | 5.69 | Efficacy of Allisartan Isoproxil in the Treatment of Mild-to-Moderate Essential Hypertension. ( Chen, Y; Lu, X; Sun, N; Wang, H; Wang, L; Xi, Y; Yang, F, 2023) |
| "We aimed to determine the efficacy and tolerability of a fixed-dose SPC consisting of 5 mg amlodipine, 100 mg losartan, 20 mg rosuvastatin, and 10 mg ezetimibe (A/L/R/E) in patients with concomitant hypertension and dyslipidemia." | 5.69 | A Randomized, Multicenter, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of a Quadruple Combination of Amlodipine, Losartan, Rosuvastatin, and Ezetimibe in Patients with Concomitant Essential Hypertension and Dyslipidemia. ( Ahn, Y; Chae, IH; Hong, SJ; Hong, TJ; Kang, DH; Kim, BK; Kim, H; Kim, HS; Kim, MC; Kim, MH; Kim, SH; Kim, SY; Kim, W; Rhee, MY, 2023) |
| "Hyperhomocysteinemia with hypertension can synergistically increase the risk of stroke." | 5.69 | Combined use of amlodipine and folic acid are significantly more efficacious than amlodipine alone in lowering plasma homocysteine and blood pressure among hypertensive patients with hyperhomocysteinemia and intolerance to ACEI: A multicenter, randomized, ( Bao, H; Chen, G; Cheng, X; Cheng, Z; Cui, Y; Ding, C; Hu, L; Huang, X; Huo, Y; Li, P; Qin, X; Sheng, C; Song, D; Tang, G; Wang, J; Wang, X; Wang, Z; Yao, C; Zhang, J, 2023) |
| "To compare the effects of chlortalidone plus amiloride and amlodipine on blood pressure (BP) variability in patients with hypertension and obstructive sleep apnea syndrome (OSA)." | 5.69 | Effects of chlorthalidone plus amiloride compared with amlodipine on short-term blood pressure variability in individuals with hypertension and obstructive sleep apnea: a randomized controlled trial. ( Borges, RB; Cichelero, FT; Fuchs, FD; Fuchs, SC; Hirakata, VN; Jorge, JA; Lucca, MB; Martinez, D, 2023) |
| "Hypertension is a chronic condition that requires lifelong therapeutic management." | 5.62 | Long-acting tunable release of amlodipine loaded PEG-PCL micelles for tailored treatment of chronic hypertension. ( Chua, CYX; Di Trani, N; Grattoni, A; Liu, HC; Liu, X; Qi, R; Viswanath, DI, 2021) |
| "Amlodipine is a general antihypertensive drug used in combination with various other antihypertensive agents." | 5.62 | Effect of Co-Administration of Curcumin with Amlodipine in Hypertension. ( Choi, HY; Jo, C; Lee, K; Lee, S, 2021) |
| "Hypertension and dyslipidemia are important risk factors for cardiovascular disease." | 5.56 | Fixed-dose combination of amlodipine and atorvastatin improves clinical outcomes in patients with concomitant hypertension and dyslipidemia. ( Chu, PH; Chu, YC; Hsiao, FC; Kao, YW; Lin, CP; Lin, YS; Tung, YC; Yang, CH, 2020) |
| "The aim of the study was to evaluate the efficacy and safety of fixed-dose combination (FDC) of metoprolol, telmisartan, and chlorthalidone in patients with essential hypertension and stable coronary artery disease (CAD) who showed inadequate response to dual therapy." | 5.51 | Fixed-dose Combination of Metoprolol, Telmisartan, and Chlorthalidone for Essential Hypertension in Adults with Stable Coronary Artery Disease: Phase III Study. ( Agrawal, S; Anand, J; Bachani, D; Doshi, M; Gaikwad, VB; Halder, SK; Kinholkar, B; Kumar, DA; Kumbhar, A; Mathur, R; Mehta, S; Sarkar, G; Sharma, A, 2022) |
| "Cilnidipine therapy is an effective and safe alternative in the treatment of essential hypertension." | 5.51 | A Randomized Open-Label Parallel-Group Study Comparing the Efficacy and Safety of Cilnidipine and Amlodipine in Hypertensive Adults. ( D, DC; Jj, NK; Kavitha, R, 2022) |
| "Hypertension and hyperhomocysteinemia (HHcy) have long been associated with adverse cardiovascular and cerebrovascular health outcomes." | 5.51 | Effects of individualized administration of folic acid on prothrombotic state and vascular endothelial function with H-type hypertension: A double-blinded, randomized clinical cohort study. ( He, H; Hou, A; Luo, M; Ran, S; Song, D; Tang, J; Tang, Y; Wang, H; Wang, T; Yan, X; Yang, R; Yu, B; Zhang, S, 2022) |
| "There is lacking evidence that telmisartan can improve insulin resistance in patients on high-intensity statins." | 5.51 | Effects of high-intensity statin combined with telmisartan versus amlodipine on glucose metabolism in hypertensive atherosclerotic cardiovascular disease patients with impaired fasting glucose: A randomized multicenter trial. ( Kang, TS; Kim, BK; Kim, JY; Lee, CJ; Lee, SH; Park, S; Sung, JH, 2022) |
| "The aim of this clinical trial was to assess the efficacy and safety of low-dose triple combinations of amlodipine, telmisartan, and chlorthalidone in patients with essential hypertension." | 5.51 | Efficacy and safety of low-dose antihypertensive combination of amlodipine, telmisartan, and chlorthalidone: A randomized, double-blind, parallel, phase II trial. ( Ahn, JC; Cho, EJ; Han, SH; Kang, SM; Kim, KH; Kim, KI; Kim, SY; Kim, W; Kim, YJ; Park, CG; Park, SJ; Park, SM; Shin, J; Shin, JH; Sohn, IS; Sung, JH; Sung, KC, 2022) |
| "This study was to study the efficacy of rosuvastatin, amlodipine, and aspirin in the treatment of hypertension with coronary heart disease and its effect on platelet aggregation." | 5.51 | The Efficacy of Rosuvastatin, Amlodipine, and Aspirin in the Treatment of Hypertension with Coronary Heart Disease and Its Effect on Platelet Aggregation. ( Fu, J; Li, B; Wang, T; Zhao, N, 2022) |
| "Hypertension is currently one of the greatest global health care challenges." | 5.46 | Management of Hypertension With a Fixed-Dose (Single-Pill) Combination of Bisoprolol and Amlodipine. ( Barho, C; Gottwald-Hostalek, U; Hildemann, S; Sun, N, 2017) |
| "Our data show a potential pharmacokinetic interaction, most likely via CYP3A4 between amlodipine and RIS, reflected in significantly different C/Ds for RIS, 9-OH-RIS and AM." | 5.43 | Pharmacokinetic considerations in the treatment of hypertension in risperidone-medicated patients - thinking of clinically relevant CYP2D6 interactions. ( Gründer, G; Haen, E; Lammertz, SE; Paulzen, M; Schoretsanitis, G; Schruers, KR; Stegmann, B; Walther, S, 2016) |
| "BACKGROUND Is the timing of dosing for amlodipine and atorvastatin important with regard to therapeutic efficacy? To answer this question, we designed an outpatient, practice-based, case-control study lasting 8 weeks." | 5.43 | Is Time an Important Problem in Management of Hypertension and Hypercholesterolemia by Using an Amlodipine-Atorvastatin Single Pill Combination? ( Wang, M; Zeng, R; Zhang, L, 2016) |
| "Gingival overgrowth is a common feature of periodontal diseases." | 5.43 | Amlodipine-Induced Gingival Overgrowth. ( Jayanthi, R; Rajan, PB, 2016) |
| "Hypertension is considered to be the most important risk factor for stroke, and all forms of hypertension are associated with an increased risk of both ischemic and haemorrhagic stroke." | 5.43 | Significance of BP Control in Reducing Stroke Events: Role of Amlodipine in an Indian Perspective. ( Muruganathan, A; Tiwaskar, M, 2016) |
| "Pedal oedema is a well-known adverse effect of amlodipine, but significantly less frequent if only half of the maximum recommended dosage is used." | 5.41 | ( Christensen, B; Helgestad, OK; Henriksen, JN; Oxlund, CS; Skovbjerg, BK, 2023) |
| "PubMed/MEDLINE, Google Scholar, PROQUEST, and International Clinical Trial Registry Platform (ICTRP) were searched for published articles to evaluate the clinical efficacy of azelnidipine in the management of hypertension patients." | 5.41 | Efficacy and Safety of Azelnidipine as an Antihypertensive Compared to Amlodipine: A Systematic Review and Meta-analysis. ( Maiti, R; Maji, S; Pal, D, 2023) |
| "This was a pragmatic comparative effectiveness study carried out at 110 centers across China in outpatients with primary hypertension treated with levoamlodipine maleate or amlodipine besylate, with 24 months of follow-up." | 5.41 | Effectiveness of Levoamlodipine Maleate for Hypertension Compared with Amlodipine Besylate: a Pragmatic Comparative Effectiveness Study. ( Chen, P; Cui, L; Cui, W; Dang, A; Dong, Y; Du, X; Duan, C; Gao, P; Hua, Q; Huo, Y; Jiang, Y; Li, J; Ma, W; Qi, X; Qu, P; Sun, N; Sun, Y; Wu, G; Xie, J; Zhao, L, 2021) |
| "In a substudy of a randomized controlled trial, we investigated the effects of the valsartan/amlodipine single-pill combination and nifedipine gastrointestinal therapeutic system (GITS) monotherapy on brachial pulse pressure (bPP) and radial augmentation index (rAI) in patients with previously uncontrolled hypertension." | 5.41 | Effects of the valsartan/amlodipine combination and nifedipine gastrointestinal therapeutic system monotherapy on brachial pulse pressure and radial augmentation index in hypertensive patients. ( Chen, LL; Li, Y; Wang, JG; Xie, JH; Xu, SK; Zeng, WF, 2021) |
| "Prehypertension has been associated with adverse cerebrovascular events and brain damage." | 5.40 | Long-term prehypertension treatment with losartan effectively prevents brain damage and stroke in stroke-prone spontaneously hypertensive rats. ( He, DH; Lin, JX; Lin, LM; Ning, RB; Wang, HJ; Xu, CS; Zhang, LM, 2014) |
| "Amlodipine therapy was discontinued and oedema diminished markedly within 72 hours." | 5.39 | Generalised peripheral oedema associated with amlodipine therapy in two dogs. ( Creevy, KE; Ellis, AE; Scuderi, MA, 2013) |
| "Candesartan treatment may suppress all-cause death and reduce the incidence of new-onset diabetes in patients with obesity." | 5.36 | Role of diabetes and obesity in outcomes of the candesartan antihypertensive survival evaluation in Japan (CASE-J) trial. ( Fujimoto, A; Hirata, M; Nakao, K; Oba, K; Ogihara, T; Saruta, T; Ueshima, K; Yasuno, S, 2010) |
| "Compared with the placebo-treated group, proteinuria was significantly lower in the irbesartan- and efonidipine-treated groups, but not in the amlodipine-treated group." | 5.36 | Combination therapy with irbesartan and efonidipine for attenuation of proteinuria in Dahl salt-sensitive rats. ( Jin, D; Miyazaki, M; Sakonjo, H; Takai, S, 2010) |
| "High blood pressure is a major risk factor for cardiovascular disease worldwide." | 5.35 | Aliskiren for hypertension in adults. ( , 2008) |
| "She had been suffering from migraine from her 30's." | 5.35 | [Migraine improved by amlodipine medication in a case with hypertension]. ( Igase, M; Kawajiri, M; Kohara, K; Miki, T; Nagai, T, 2008) |
| " Tolerability was assessed by treatment-emergent adverse events." | 5.35 | Evaluation of safety and efficacy of telmisartan-amlodipine combination in treating hypertension. ( Faruqui, AA, 2008) |
| "Although hypertension is common (30% of adults in the USA), its control to recommended blood pressure levels of under 140/90 mmHg remains low, at 36." | 5.35 | Amlodipine besylate/olmesartan medoximil fixed combination for the treatment of hypertension. ( Chrysant, SG, 2009) |
| "Treatment with amlodipine + valsartan + HCTZ for up to 8 weeks was generally well tolerated in the large, phase III trial, with most adverse events being transient and of mild to moderate severity." | 5.35 | Amlodipine/valsartan/hydrochlorothiazide: fixed-dose combination in hypertension. ( Deeks, ED, 2009) |
| "Salt-sensitive (SS) hypertension is a vascular diathesis characterized by reduced cardiovascular and renal nitric oxide bioavailability and local upregulation of ANG II." | 5.35 | Upregulation of cortical COX-2 in salt-sensitive hypertension: role of angiotensin II and reactive oxygen species. ( Jaimes, EA; Pearse, DD; Puzis, L; Raij, L; Zhou, MS, 2008) |
| "This multicenter, randomized, double-blind, parallel-group phase III clinical trial aimed to investigate the efficacy and safety of a rosuvastatin + amlodipine combination compared with that of rosuvastatin or amlodipine monotherapy in hypertensive patients with dyslipidemia." | 5.34 | A randomized, double-blind clinical trial to evaluate the efficacy and safety of a fixed-dose combination of amlodipine/rosuvastatin in patients with dyslipidemia and hypertension. ( Ahn, JC; Ahn, YK; Chang, K; Cho, EJ; Cho, KI; Kang, DH; Kim, M; Kim, SJ; Kim, SY; Kim, U; Kim, W; Kim, YJ; Lee, CH; Lee, SH; Park, CG; Shin, JH; Yu, CW, 2020) |
| "Background Amlodipine is a widely used antihypertensive agent for the treatment of paediatric hypertension, but the commercially available tablets are not suitable to treat young patients, who need lower, flexible dosages and a liquid formulation." | 5.34 | Use of amlodipine oral solution for the treatment of hypertension in children. ( Cransberg, K; de Winter, BCM; Hanff, LM; Schreuder, MF; van der Vossen, AC; van Rooij-Kouwenhoven, RWG; Vulto, AG, 2020) |
| "825), high-dose CCBs combined with ARBs controlled hypertension without elevation of serum uric acid." | 5.34 | Assessment of suitable antihypertensive therapies: Combination with high-dose amlodipine/irbesartan vs triple combination with amlodipine/irbesartan/indapamide (ASAHI-AI study). ( Hasebe, N; Koyama, S; Maruyama, J; Morimoto, H; Nakagawa, N; Nakamura, Y; Ogawa, Y; Ohta, T; Saijo, Y; Sato, N; Takeuchi, T; Uekita, K, 2020) |
| "This study showed the clinical efficacy, safety and acceptability of the perindopril/indapamide/amlodipine SPC in patients with grade 2/3 hypertension inadequately controlled with two-drug therapy." | 5.34 | Blood-pressure Lowering Efficacy and Safety of Perindopril / Indapamide / Amlodipine Single-pill Combination in Hypertensive Patients: Phase III Trial in India. ( Chaudhary, G; Joseph, S; Konda Reddy, KM; Murthy, LS; Nikam, P; Rajarshi, M; Sawhney, JP; Shah, S; Thacker, H, 2020) |
| "Drug induced gingival hyperplasia is an uncommon entity." | 5.34 | Amlodipine induced gingival hyperplasia: a rare entity. ( Bhatia, V; Kaul, U; Mittal, A; Parida, AK; Talwar, R, 2007) |
| "Amlodipine orotate was prepared by reacting orotic acid and amlodipine to increase the dissolution rate at higher gastric pH conditions." | 5.33 | Effects of amlodipine orotate on hypertension-related complications in spontaneously hypertensive rats. ( Ahn, BO; Choi, SM; Kim, JE; Kwon, JW, 2006) |
| "Aliskiren is a novel, orally active direct renin inhibitor that lowers blood pressure alone and in combination with existing antihypertensive agents." | 5.33 | Lack of pharmacokinetic interactions of aliskiren, a novel direct renin inhibitor for the treatment of hypertension, with the antihypertensives amlodipine, valsartan, hydrochlorothiazide (HCTZ) and ramipril in healthy volunteers. ( Bizot, MN; Denouel, J; Dieterich, HA; Dole, WP; Kemp, C; Vaidyanathan, S; Valencia, J; Yeh, CM; Zhao, C, 2006) |
| "Body weight was measured weekly in all the groups, and arterial blood pressure was also measured in all the 10-, 15-, 20-, and 25-week-old SHR by the tail cuff method." | 5.32 | Effect of dietary calcium supplements and amlodipine on growth, arterial blood pressure, and cardiac hypertrophy of spontaneously hypertensive rats. ( Aleixandre, A; Civantos, B, 2003) |
| "Oral treatment with amlodipine (n=7), initiated at day 0, reduced systolic blood pressure, reversed cerebral edema and restored blood-brain barrier integrity." | 5.31 | Reduction of cerebral injury in stroke-prone spontaneously hypertensive rats by amlodipine. ( Blezer, E; Goldschmeding, R; Joles, J; Koomans, H; Nicolay, K, 2002) |
| "Treatment with doxazosin positively influenced the metabolic profile." | 5.31 | [Hypertension and metabolic syndrome in population of one company. Monotherapy with amlodipine and doxazosin]. ( Ceremuzyński, L; Cybulski, J, 2002) |
| "In this prospective open-label study, 92 patients with essential hypertension were randomized to treatment with a TFC of perindopril/indapamide/amlodipine at different doses or a triple free combination therapy (FCT) including ACEI/diuretic/CCB." | 5.30 | Long-term effect of the perindopril/indapamide/amlodipine single-pill combination on left ventricular hypertrophy in outpatient hypertensive subjects. ( Lenti, S; Mazza, A; Rigatelli, G; Rossetti, C; Rubello, D; Schiavon, L; Torin, G; Townsend, DM, 2019) |
| "Fixed-dose combination therapy with telmisartan, amlodipine, and rosuvastatin is needed in patients with hypertension and dyslipidemia for better adherence and cost-effectiveness than free-equivalent combination therapies." | 5.30 | Efficacy and Safety of Triple Therapy With Telmisartan, Amlodipine, and Rosuvastatin in Patients With Dyslipidemia and Hypertension: The Jeil Telmisartan, Amlodipine, and Rosuvastatin Randomized Clinical Trial. ( Ahn, Y; Chang, K; Cho, JM; Hong, SJ; Hyon, MS; Jeong, HS; Kang, WC; Kim, HS; Lee, JH; Pyun, WB, 2019) |
| "To study the effect and molecular mechanisms of amlodipine besylate combined with acupoint application of traditional Chinese medicine nursing on the treatment methods of renal failure and hypertension." | 5.30 | Effect of amlodipine besylate combined with acupoint application of traditional Chinese medicine nursing on the treatment of renal failure and hypertension by the PI3K/AKT pathway. ( Chi, R; Feng, L; Liang, W; Lv, S; Su, J; Zhu, Q, 2019) |
| "In this randomized, single-blind, three-group trial conducted in six countries in sub-Saharan Africa, we randomly assigned 728 black patients with uncontrolled hypertension (≥140/90 mm Hg while the patient was not being treated or was taking only one antihypertensive drug) to receive a daily regimen of 5 mg of amlodipine plus 12." | 5.30 | Comparison of Dual Therapies for Lowering Blood Pressure in Black Africans. ( Badri, M; Barasa, F; Cornelius, V; Damasceno, A; Dzudie, A; Francis, V; Jones, E; Kramer, N; Mayosi, B; Mondo, C; Ogah, O; Ogola, E; Ojji, DB; Okpechi, IG; Poulter, N; Rayner, B; Sani, MU; Shedul, G; Shedul, GL; Sliwa, K; Smythe, W, 2019) |
| " This study was conducted to compare the efficacy and tolerability of the combination therapies telmisartan/amlodipine + rosuvastatin, telmisartan/amlodipine, and telmisartan + rosuvastatin in patients with hypercholesterolemia and hypertension." | 5.30 | Efficacy and Tolerability of Telmisartan/Amlodipine and Rosuvastatin Coadministration in Hypertensive Patients with Hyperlipidemia: A Phase III, Multicenter, Randomized, Double-blind Study. ( Ahn, JC; Cha, DH; Cho, SK; Jeon, DW; Kim, KH; Kim, SY; Kim, TS; Kim, WS; Kim, YJ; Lee, HC; Oh, YS; Park, DG; Park, SH; Rha, SW; Rhee, MY; Sung, KC; Yoo, BS; Yoo, KD; Yoon, MH; Yoon, YW, 2019) |
| "This randomized trial evaluated the blood pressure (BP)-lowering efficacy of four incremental doses of perindopril/amlodipine SPC in adults with mild-to-severe hypertension." | 5.30 | Efficacy and Safety of Incremental Dosing of a New Single-Pill Formulation of Perindopril and Amlodipine in the Management of Hypertension. ( Dolan, E; Gupta, AK; O'Brien, E; Poulter, NR; Sever, PS; Whitehouse, A, 2019) |
| "In a multicenter, randomized trial, we investigated whether the long half-time dihydropyridine calcium channel blocker amlodipine was more efficacious than the gastrointestinal therapeutic system (GITS) formulation of nifedipine in lowering ambulatory blood pressure (BP) in sustained hypertension (clinic systolic/diastolic BP 140-179/90-109 mm Hg and 24-hour systolic/diastolic BP ≥ 130/80 mm Hg)." | 5.30 | A randomized controlled trial on the blood pressure-lowering effect of amlodipine and nifedipine-GITS in sustained hypertension. ( Dou, Y; Huang, QF; Li, Y; Sheng, CS; Wang, JG; Zheng, MS; Zhu, ZM, 2019) |
| "Amlodipine, valsartan, and rosuvastatin are among the medications widely coadministered for the treatment of hyperlipidemia accompanied by hypertension." | 5.30 | Pharmacokinetic Drug Interactions Between Amlodipine, Valsartan, and Rosuvastatin in Healthy Volunteers. ( Cho, S; Gwon, MR; Kang, WY; Kim, BK; Lee, HW; Ohk, B; Seong, SJ; Yang, DH; Yoon, YR, 2019) |
| "Amlodipine was found to inhibit growth and bFGF-induced DNA synthesis in a concentration-dependent manner." | 5.30 | Amlodipine and vascular hypertrophy. ( Herembert, T; Iouzalen, L; Marche, P; Stepien, O; Zhu, DL, 1997) |
| "Hypertension is due to disturbance of the complex interplay between numerous known and unknown mechanisms that normally control blood pressure." | 5.29 | Long-term hemodynamic effects at rest and during exercise of newer antihypertensive agents and salt restriction in essential hypertension: review of epanolol, doxazosin, amlodipine, felodipine, diltiazem, lisinopril, dilevalol, carvedilol, and ketanserin. ( Lund-Johansen, P; Omvik, P, 1993) |
| " We plan to compare the efficacy and safety of S-amlodipine (CCB) plus chlorthalidone versus S-amlodipine plus telmisartan (ARB) combinations among hypertension patients unresponsive to amlodipine monotherapy." | 5.27 | S-amlodipine plus chlorthalidone vs. S-amlodipine plus telmisartan in hypertensive patients unresponsive to amlodipine monotherapy: study protocol for a randomized controlled trial. ( Cho, HJ; Choi, DJ; Han, KR; Jo, SH; Kim, EJ; Kim, SJ; Park, JJ; Park, SJ; Shin, J; Shin, JH; Song, JM, 2018) |
| "Amlodipine is a long-acting dihydropyridine-based calcium antagonist developed for use on a once-a-day basis." | 5.27 | The effect of amlodipine on hypertension-induced cardiac hypertrophy and reperfusion-induced calcium overload. ( Nayler, WG, 1988) |
| "A total of 33,357 patients (aged ≥ 55 years) with hypertension and at least 1 other coronary heart disease (CHD) risk factor were randomized to chlorthalidone, amlodipine, or lisinopril." | 5.24 | Electrocardiographic Left Ventricular Hypertrophy Predicts Cardiovascular Morbidity and Mortality in Hypertensive Patients: The ALLHAT Study. ( Bang, CN; Davis, BR; Devereux, RB; Okin, PM; Simpson, LM; Soliman, EZ, 2017) |
| " We conducted a multicenter randomized clinical trial to compare the efficacy of switching from the daily administration of a single-pill fixed-dose combination of irbesartan (100 mg) and amlodipine (5 mg) to irbesartan (100 mg) with an increased dose of amlodipine (10 mg) (HD group, n=62) or irbesartan (100 mg) and amlodipine (5 mg) with 1 mg of indapamide (D group, n=63) in patients with poorly controlled hypertension." | 5.24 | The effects of increasing calcium channel blocker dose vs. adding a diuretic to treatment regimens for patients with uncontrolled hypertension. ( Asayama, K; Harasawa, S; Hirayama, A; Kushiro, T; Ohkubo, T; Oiwa, K; Okubo, K; Takahashi, A; Tanabe, A; Tani, S, 2017) |
| "Type 2 diabetic subjects with hypertension 30 to 80 years of age who were not taking antihypertensive drugs were randomized into either valsartan (n = 33) or amlodipine (n = 35) groups and treated for 24 weeks." | 5.24 | Effects of valsartan and amlodipine on oxidative stress in type 2 diabetic patients with hypertension: a randomized, multicenter study. ( Ahn, YB; Choi, SH; Han, SJ; Jang, HC; Kim, DJ; Kim, HJ; Kim, HY; Kim, NH; Kim, SH; Kim, TH; Kim, YH; Ko, SH; Lee, KW; Lim, S; Seo, JA; Shin, DH, 2017) |
| "Aliskiren penetrates adipose and skeletal muscle in hypertensive patients with abdominal obesity and reduces renin-angiotensin-aldosterone system activity." | 5.24 | Systemic and tissue-specific effects of aliskiren on the RAAS and carbohydrate/lipid metabolism in obese patients with hypertension. ( Boschmann, M; Dahlke, M; Danser, AHJ; Dole, WP; Engeli, S; Jordan, J; May, M; Nussberger, J; Pal, P; Prescott, MF; Stitah, S, 2017) |
| "To examine the antihypertensive efficacy and safety of indapamide sustained-release (SR)/amlodipine compared with enalapril/amlodipine in patients 65 years and older with uncontrolled blood pressure (BP) on monotherapy, a post hoc analysis of the NESTOR trial (Natrilix SR vs Enalapril in Hypertensive Type 2 Diabetics With Microalbuminuria) was conducted." | 5.24 | Blood pressure-lowering efficacy of indapamide SR/amlodipine combination in older patients with hypertension: A post hoc analysis of the NESTOR trial (Natrilix SR vs Enalapril in Hypertensive Type 2 Diabetics With Microalbuminuria). ( Boully, C; Caillard, L; Chaussade, E; Hanon, O; Hernandorena, I, 2017) |
| " A total of 74 patients with T2D and microalbuminuria treated with renin-angiotensin system (RAS) blockers were randomized to a cilnidipine 10 mg treatment (n=38) or amlodipine 5 mg treatment (n=36)." | 5.24 | Reduction in microalbuminuria by calcium channel blockers in patients with type 2 diabetes mellitus and hypertension-A randomized, open-label, active-controlled, superiority, parallel-group clinical trial. ( Cha, BS; Chung, CH; Hwang, YC; Jang, HC; Lee, KW; Lee, MK; Min, KW; Yoon, KH, 2017) |
| "The goal of this study was to compare the efficacy and safety of fixed-dose combinations of amlodipine/losartan potassium/chlorthalidone (A/L/C) and A/L in Korean patients with stage 2 hypertension inadequately controlled by A/L." | 5.24 | Comparison of Fixed-dose Combinations of Amlodipine/Losartan Potassium/Chlorthalidone and Amlodipine/Losartan Potassium in Patients With Stage 2 Hypertension Inadequately Controlled With Amlodipine/Losartan Potassium: A Randomized, Double-blind, Multicent ( Chae, JK; Chae, SC; Chang, KY; Cho, JR; Choi, JH; Choi, YJ; Chun, KJ; Han, KR; Han, SH; Heo, JH; Hong, BK; Hong, SJ; Jeong, HS; Jeong, MH; Jung, J; Kang, HJ; Kang, SM; Kim, CH; Kim, DW; Kim, JJ; Kim, KS; Kim, SH; Kim, WS; Kim, YD; Kwan, J; Lee, BK; Lee, SK; Lee, SU; Park, CG; Park, SH; Shin, DG; Shin, JH; Won, KH, 2017) |
| "A single-blind randomized clinical study was used; fifty patients newly diagnosed with mild to moderate hypertension (aged 33 to 60 years) were recruited and divided into two groups: amlodipine or hydrochlorothiazide each comprising of 25 subjects." | 5.24 | Monotherapy with amlodipine or hydrochlorothiazide in patients with mild to moderate hypertension: Comparison of their efficacy and effects on electrolytes. ( Agu, PU; Aneke, EI; Azubike, NC; Eze, AA; Nwachukwu, DC; Nwachukwu, NZ; Obika, LF; Okoye, OI, 2017) |
| " We sought to determine whether randomization to lisinopril reduces incident AF or atrial flutter (AFL) compared with chlorthalidone in a large clinical trial cohort with extended post-trial surveillance." | 5.24 | Pharmacologic Prevention of Incident Atrial Fibrillation: Long-Term Results From the ALLHAT (Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial). ( Albert, CM; Alonso, A; Davis, BR; Dewland, TA; Haywood, LJ; Marcus, GM; Simpson, LM; Soliman, EZ; Yamal, JM, 2017) |
| "In AMANDHA trial, the addition of manidipine, but not amlodipine, in diabetic patients with uncontrolled hypertension, microalbuminuria and preserved renal function resulted in a large decrease of urinary albumin excretion (UAE) despite similar blood pressure (BP) reductions." | 5.24 | Factors associated with the reduction of albumin excretion in diabetic hypertensive patients: differential effect of manidipine versus amlodipine. ( Martinez-Martin, FJ; Roca-Cusachs, A; Saiz-Satjes, M, 2017) |
| "In this study, which titrated medications to a goal, participants assigned to chlorthalidone were less likely to develop treatment-resistant hypertension." | 5.24 | Treatment-Resistant Hypertension and Outcomes Based on Randomized Treatment Group in ALLHAT. ( Bangalore, S; Black, HR; Calhoun, DA; Cushman, WC; Davis, BR; Kostis, JB; Muntner, PM; Pressel, SL; Probstfield, JL; Rahman, M; Whelton, PK, 2017) |
| "The objective of this study is to evaluate the efficacy and safety of sacubitril/valsartan (LCZ696, an angiotensin receptor and neprilysin inhibitor) add-on to amlodipine compared with amlodipine monotherapy in Asian patients with systolic hypertension uncontrolled with amlodipine." | 5.24 | Efficacy and safety of sacubitril/valsartan (LCZ696) add-on to amlodipine in Asian patients with systolic hypertension uncontrolled with amlodipine monotherapy. ( Hafeez, K; Jia, Y; Sibulo, A; Wang, JG; Yukisada, K; Zhang, J, 2017) |
| "Chlorthalidone is a very effective antihypertensive drug, but it has not been studied prospectively in kidney transplant recipients with hypertension." | 5.24 | Chlorthalidone Versus Amlodipine for Hypertension in Kidney Transplant Recipients Treated With Tacrolimus: A Randomized Crossover Trial. ( Hesselink, DA; Hoorn, EJ; Moes, AD; van den Meiracker, AH; Zietse, R, 2017) |
| "0% male) with uncontrolled essential hypertension (office systolic BP ≥ 140 or diastolic BP ≥ 90 mmHg) previously treated with a renin-angiotensin-aldosterone system (RAAS) inhibitor plus hydrochlorothiazide were switched to once-daily FDTC therapy with perindopril/indapamide/amlodipine (5-10/1." | 5.24 | Fixed-Dose Triple Combination of Antihypertensive Drugs Improves Blood Pressure Control: From Clinical Trials to Clinical Practice. ( Dell'Avvocata, F; Lenti, S; Mazza, A; Ramazzina, E; Rigatelli, G; Sacco, AP; Schiavon, L, 2017) |
| "The single-pill combination (SPC) of perindopril (PER)/indapamide (IND)/amlodipine (AML) is a valuable and convenient treatment option for patients with hypertension controlled with two-drug SPC of PER/IND + AML given as two separate pills at the same dose level." | 5.22 | Perindopril/Indapamide/Amlodipine in Hypertension: A Profile of Its Use. ( Syed, YY, 2022) |
| "There is a lack of sufficient evidence regarding efficacy and safety of amlodipine on treating hypertension during pregnancy." | 5.22 | Nifedipine or amlodipine? The choice for hypertension during pregnancy: a systematic review and meta-analysis. ( Du, P; Mei, Z; Qin, S; Shi, S; Yin, J, 2022) |
| "To evaluate the efficacy of perindopril/indapamide/amlodipine single-pill combination in patients with uncontrolled hypertension." | 5.22 | Efficacy of Single-Pill, Triple Antihypertensive Therapy in Patients with Uncontrolled Hypertension: A Systematic Review and Meta-analysis. ( Abdelsattar, AT; Cherfaoui, O; Elmoursi, A; Farhat, AM; Habboush, S; Masoud, AT; Sofy, AA, 2022) |
| "This narrative review evaluates recent evidence from four studies which explore the efficacy, safety, and adherence of FDC bisoprolol and amlodipine in patients with hypertension: one observational study; two randomized clinical trials (RCTs); and one indirect comparison analysis." | 5.22 | A growing evidence base for the fixed-dose combination of bisoprolol and amlodipine to manage hypertension. ( Gaciong, Z; Hostalek-Gottwald, U, 2022) |
| "A single-pill fixed-dose combination therapy with irbesartan 100 mg/day and amlodipine 5 mg/day was superior to the combination of valsartan 80 mg/day and amlodipine 5 mg/day with respect to significant decreases in BP, serum UA and TG in patients with hypertension." | 5.22 | Efficacy and safety of two single-pill fixed-dose combinations of angiotensin II receptor blockers/calcium channel blockers in hypertensive patients (EXAMINER study). ( Adachi, S; Fujisawa, K; Inoue, T; Kusumoto, T; Miura, S; Motozato, K; Saku, K; Shiga, Y, 2016) |
| "This post hoc analysis from the Sevikar Compared to the Combination of Perindopril Plus Amlodipine on Central Arterial Blood Pressure in Patients With Moderate-to-Severe Hypertension (SEVITENSION) study assessed the efficacy and tolerability of olmesartan (OLM) and amlodipine (AML) in reducing central systolic blood pressure (CSBP) compared with perindopril (PER) plus AML in hypertensive patients with type 2 diabetes." | 5.22 | Fixed-Combination Olmesartan/Amlodipine Was Superior to Perindopril + Amlodipine in Reducing Central Systolic Blood Pressure in Hypertensive Patients With Diabetes. ( Ruilope, LM, 2016) |
| "The aim of this study was to compare the efficacy and safety of telmisartan plus amlodipine with telmisartan plus hydrochlorothiazide for the treatment of uncontrolled hypertension." | 5.22 | Comparison of telmisartan/amlodipine and telmisartan/hydrochlorothiazide in the treatment of Japanese patients with uncontrolled hypertension: the TAT-Kobe study. ( Hirata, K; Ishida, T; Kondo, K; Mori, K; Toh, R; Yasuda, T, 2016) |
| "To assess the blood pressure-lowering efficacy and tolerability of perindopril/amlodipine fixed-dose combinations in Chinese patients with mild-to-moderate essential hypertension not adequately controlled with monotherapy alone." | 5.22 | Efficacy and Safety of Fixed-Dose Perindopril Arginine/Amlodipine in Hypertensive Patients Not Adequately Controlled with Amlodipine 5 mg or Perindopril tert-Butylamine 4 mg Monotherapy. ( Hu, D; Huang, J; Liao, Y; Sun, Y; Yang, K; Zhao, R, 2016) |
| "The combination olmesartan/amlodipine is safe, well tolerated, and as effective as the combination of perindopril/amlodipine in the control of essential hypertension in patients with diabetes mellitus." | 5.22 | Comparative study of the efficacy of olmesartan/amlodipine vs. perindopril/amlodipine in peripheral blood pressure after missed dose in type 2 diabetes. ( Pichler, G; Redon, J, 2016) |
| "Long-term therapy with a combination of perindopril and amlodipine has shown a beneficial effect on the morbidity and mortality of patients with stable coronary artery disease (SCAD) and hypertension." | 5.22 | Short-Term Cardioprotective Effects of the Original Perindopril/Amlodipine Fixed-Dose Combination in Patients with Stable Coronary Artery Disease: Results of the PAPA-CAD Study. ( Dézsi, CA; Forster, T, 2016) |
| "The goal of this study was to evaluate whether the blood pressure-lowering efficacy of fimasartan/amlodipine combination therapy was superior to that of fimasartan monotherapy after 8 weeks of treatment in patients with hypertension who had failed to respond adequately to fimasartan monotherapy." | 5.22 | A Randomized, Double-blind, Multicenter, Phase III Study to Evaluate the Efficacy and Safety of Fimasartan/Amlodipine Combined Therapy Versus Fimasartan Monotherapy in Patients With Essential Hypertension Unresponsive to Fimasartan Monotherapy. ( Cha, KS; Chae, SC; Chun, KJ; Ihm, SH; Il Kim, D; Jeong, JO; Joo, SJ; Kim, CH; Kim, DS; Kim, JJ; Kim, KH; Kim, KI; Kim, MH; Kim, YJ; Nam, CW; Park, S; Park, SM; Rhee, MY; Seo, HS; Shin, ES; Shin, J; Shin, MS; Sung, KC; Yoo, BS; Youn, HJ, 2016) |
| "In hypertensive patients not controlled on prior BB and ACEI/ARB therapy, addition of (S)-amlodipine besylate at half the dose of conventional amlodipine provides better tolerability with reduced incidence of peripheral edema, and equal antihypertensive efficacy compared to amlodipine given at usual doses." | 5.22 | Leg edema with (S)-amlodipine vs conventional amlodipine given in triple therapy for hypertension: a randomized double blind controlled clinical trial. ( Ekanayaka, RA; Galappatthy, GK; Galappatthy, P; Sabeer, MI; Waniganayake, YC; Wijethunga, TJ, 2016) |
| "The objective of this study was to evaluate the efficacy and safety of the fixed-dose combination S-amlodipine plus telmisartan (S-AM/TEL) compared with TEL monotherapy in patients with hypertension inadequately controlled by TEL monotherapy." | 5.22 | Comparison of the Efficacy and Safety of Fixed-dose S-Amlodipine/Telmisartan and Telmisartan in Hypertensive Patients Inadequately Controlled with Telmisartan: A Randomized, Double-blind, Multicenter Study. ( Ahn, TH; Cho, EJ; Doh, JH; Ha, JW; Han, GR; Hyeon, MS; Im, SJ; Im, SW; Jae, JG; Kim, CH; Kim, HS; Kim, W; Lee, MM; Park, CG; Pyeon, WB; Ryu, JG; Tak, SJ; Yang, JY, 2016) |
| "The aim of the present study was to compare the effects of the combination of lercanidipine/enalapril versus amlodipine/enalapril and hydrochlorothiazide/enalapril on blood pressure, target organ damage and sympathetic activation in patients with grade 2 essential hypertension." | 5.22 | Differential effects of lercanidipine/enalapril versus amlodipine/enalapril and hydrochlorothiazide/enalapril on target organ damage and sympathetic activation in non-obese essential hypertensive subjects. ( Dimitriadis, K; Mani, I; Mantzouranis, E; Tousoulis, D; Tsioufis, C; Tsioufis, K, 2016) |
| "Albuminuria was significantly reduced, compared with baseline values, with the lercanidipine + enalapril combination over the entire study period; at month 3, month 6 and month 12, changes from baseline were: -162." | 5.22 | Lercanidipine valuable effect on urine protein losses: the RED LEVEL study. ( Calvo, C; Espinel, E; Esteban, R; Macias, JF; Mateos, L; Robles, NR; Sobrino, J, 2016) |
| "The aim of this study was to compare the effects of a dihidropiridin calcium channel blocker amlodipin and a non-dihidropiridin calcium channel blocker verapamil on nephropathy and serum pigment epithelium-derived factor (PEDF) levels of type 2 diabetic patients with hypertension." | 5.20 | The effects of calcium channel blockers on nephropathy and pigment epithelium-derived factor in the treatment of hypertensive patients with type 2 diabetes mellitus. ( Çelik, H; Korkmaz, H; Oğuz, E; Sabuncu, T; Tabur, S, 2015) |
| " Patients with mild-to-moderate essential hypertension received once-daily placebo (n=53), ACT-280778 10 mg (n=52) or amlodipine 10 mg (n=54) for 4 weeks." | 5.20 | Efficacy and safety of the dual L- and T-type calcium channel blocker, ACT-280778: a proof-of-concept study in patients with mild-to-moderate essential hypertension. ( Dingemanse, J; Klainman, E; Kracker, H; Mueller, MS; Otasevic, P; Putnikovic, B; Shakeri-Nejad, K; Zimlichman, R, 2015) |
| "Japanese patients with uncontrolled essential hypertension received single-blind losartan 50 mg/hydrochlorothiazide 12." | 5.20 | Efficacy and safety of fixed-dose losartan/hydrochlorothiazide/amlodipine combination versus losartan/hydrochlorothiazide combination in Japanese patients with essential hypertension. ( Azuma, K; Fujita, KP; Nishida, C; Numaguchi, H; Rakugi, H; Shimada, K; Shirakawa, M; Tsuchihashi, T; Yamaguchi, H, 2015) |
| "An international double-blind, parallel-group, randomized controlled trial was performed to determine the efficacy and safety of a new first-line strategy in mild to moderate hypertension based on a single-pill combination of perindopril/amlodipine versus a validated stepped-care strategy (initiation with valsartan monotherapy, up-titrating to valsartan/amlodipine after 2 months)." | 5.20 | Comparison of single-pill strategies first line in hypertension: perindopril/amlodipine versus valsartan/amlodipine. ( Amodeo, C; Asmar, R; Chazova, IE; Gamba, MA; Mancia, G; Mourad, JJ; Puig, JG; Taddei, S, 2015) |
| "The aim of this study was to compare the efficacy and safety of lercanidipine and amlodipine in the treatment of hypertensive patients with acute cerebral ischemic stroke." | 5.20 | Effects of lercanidipine versus amlodipine in hypertensive patients with cerebral ischemic stroke. ( Cao, TS; Huynh, VM; Tran, VH, 2015) |
| " The Avoiding Cardiovascular Events Through Combination Therapy in Patients Living With Systolic Hypertension (ACCOMPLISH) trial showed that the combination of benazepril+amlodipine (B+A) is superior to benazepril+hydrochlorothiazide (B+H) in reducing CV events." | 5.20 | Amlodipine+benazepril is superior to hydrochlorothiazide+benazepril irrespective of baseline pulse pressure: subanalysis of the ACCOMPLISH trial. ( Asp, J; Dahlöf, B; Jamerson, KA; Jia, Y; Kjeldsen, SE; Östergren, J; Skoglund, PH; Svensson, P; Weber, MA; Zappe, DH, 2015) |
| " The Genetics of Drug Responsiveness in Essential Hypertension (GENRES) study is a double-blind, placebo-controlled cross-over study where each subject received amlodipine, bisoprolol,hydrochlorothiazide, and losartan, each as a monotherapy, in a randomized order." | 5.20 | Pharmacogenomics of hypertension: a genome‐wide, placebo‐controlled cross‐over study, using four classes of antihypertensive drugs. ( Boerwinkle, E; Chapman, AB; Cooper-DeHoff, RM; Donner, KM; Frau, F; Glorioso, N; Glorioso, V; Gong, Y; Gums, JG; Hiltunen, TP; Johnson, JA; Kontula, KK; Ripatti, S; Saarela, J; Salvi, E; Sarin, AP; Turner, ST; Zaninello, R, 2015) |
| "Hypertensive diabetic patients with microalbuminuria were included in this retrospective, post-hoc analysis of the Natrilix SR Versus Enalapril Study in Hypertensive Type 2 Diabetics With MicrOalbuminuRia (NESTOR) trial if they were uncontrolled on monotherapy (indapamide slow release (SR) 1." | 5.20 | Treatment of Hypertensive Patients With Diabetes and Microalbuminuria With Combination Indapamide SR/Amlodipine: Retrospective Analysis of NESTOR. ( Boully, C; Caillard, L; Chaussade, E; Cochiello, S; Hanon, O; Labourée, F, 2015) |
| "5)/amlodipine 5 mg (A5) versus co-administration of L50 plus A5 (L50+A5) in Japanese subjects with uncontrolled essential hypertension." | 5.20 | Add-on effect of hydrochlorothiazide 12.5 mg in Japanese subjects with essential hypertension uncontrolled with losartan 50 mg and amlodipine 5 mg. ( Azuma, K; Fujita, KP; Nishida, C; Numaguchi, H; Rakugi, H; Shimada, K; Shirakawa, M; Tsuchihashi, T; Yamaguchi, H, 2015) |
| "This paper aims to research the clinical effect and security of using amlodipine and enalapril together to cure hypertension of aged people." | 5.20 | Curative effect of amlodipine combined with enalapril in curing hypertension of the aged. ( Jian, L; Li, L; Li, X; Niu, S; Zhang, L, 2015) |
| "The objective of this study was to evaluate the efficacy and safety of a fimasartan/amlodipine combination in patients with hypertension and to determine the optimal composition for a future single-pill combination formulation." | 5.20 | A Randomized, Multicenter, Double-blind, Placebo-controlled, 3 × 3 Factorial Design, Phase II Study to Evaluate the Efficacy and Safety of the Combination of Fimasartan/Amlodipine in Patients With Essential Hypertension. ( Ahn, T; Ahn, Y; Bae Park, J; Cho, EJ; Choi, DJ; Chull Chae, S; Chun, KJ; Han, KR; Hyon, MS; Jeon, ES; Jeong, JO; Joo, SJ; Kim, DI; Kim, DS; Kim, JJ; Kim, KS; Kim, YJ; Kwan, J; Lee, HY; Oh, SK; Park, JS; Rhee, MY; Seog Seo, H; Shin, JH; Sung, KC; Yoo, BS; Youn, HJ, 2015) |
| "gov identifier: NCT00923091) to measure changes in the health-related quality of life (HRQoL) of 2,690 patients aged ≥18 with moderate-to-severe hypertension who received one of six doses of olmesartan/amlodipine/hydrochlorothiazide (OLM/AML/HCTZ), using the MINICHAL and EQ-5D instruments." | 5.20 | Health-related quality of life impact of a triple combination of olmesartan medoxomil, amlodipine besylate and hydrochlorotiazide in subjects with hypertension. ( Brazier, JE; Guest, JF; Haag, U; Marques da Silva, P; Soro, M, 2015) |
| "Associations between ADRB polymorphisms and blood pressure response to ramipril were analyzed in the African American Study of Kidney Disease and Hypertension, a randomized clinical trial." | 5.20 | Association of the ADRB2 (rs2053044) polymorphism and angiotensin-converting enzyme-inhibitor blood pressure response in the African American Study of Kidney Disease and Hypertension. ( Anthony, EG; Bhatnagar, V; Lipkowitz, MS; Richard, E, 2015) |
| "213 patients with type 2 diabetes mellitus and hypertension were randomized to amlodipine 5 mg, or amlodipine 5 mg + ASA 100 mg for 3 months (Phase A); then, if adequate blood pressure control was reached patients terminated the study; otherwise, amlodipine was up-titrated to 10 mg/day for further 3 months and compared to amlodipine 10 mg + ASA 100 mg (Phase B)." | 5.20 | A study about the relevance of adding acetylsalicylic acid in primary prevention in subjects with type 2 diabetes mellitus: effects on some new emerging biomarkers of cardiovascular risk. ( D'Angelo, A; Derosa, G; Maffioli, P; Mugellini, A; Pesce, RM, 2015) |
| "Patients with diabetes and hypertension with office systolic blood pressure ≥ 130 mmHg and/or diastolic blood pressure ≥ 80 mmHg had their antihypertensive medications replaced by amlodipine during 6 weeks." | 5.20 | Renin-Angiotensin System Blockade Associated with Statin Improves Endothelial Function in Diabetics. ( Bedirian, R; Gismondi, RA; Ladeira, MC; Neves, MF; Oigman, W; Pozzobon, CR, 2015) |
| "Twenty-four patients with essential hypertension received amlodipine and S(-)-amlodipine for 6 weeks in a randomized, crossover study." | 5.19 | The effects of amlodipine and S(-)-amlodipine on vascular endothelial function in patients with hypertension. ( Ding, M; He, Y; Li, B; Ni, L; Si, D; Yang, C; Yang, P, 2014) |
| " The aim of this study was to evaluate the effects of a fixed-dose olmesartan/amlodipine combination on blood pressure control, lipid profile, insulin sensitivity, and inflammation compared to singles monotherapies." | 5.19 | Results from a 12 months, randomized, clinical trial comparing an olmesartan/amlodipine single pill combination to olmesartan and amlodipine monotherapies on blood pressure and inflammation. ( Carbone, A; Cicero, AF; D'Angelo, A; Derosa, G; Fogari, E; Maffioli, P; Querci, F, 2014) |
| "A total of 48 patients with untreated hypertension were randomly assigned to irbesartan (ARB group, n=26) and amlodipine (CCB group, n=22)." | 5.19 | Long-term effects of irbesartan on plasma aldosterone concentration and left atrial volume in hypertensive patients. ( Fujiwara, S; Fukui, M; Goda, A; Hirotani, S; Komamura, K; Koshiba, M; Lee-Kawabata, M; Masaki, M; Masuyama, T; Nakabo, A; Otsuka, M; Sugahara, M; Tsujino, T, 2014) |
| "Amlodipine, not aliskiren, effectively reduces BP in CKD patients with refractory hypertension undergoing HD." | 5.19 | Effect of aliskiren in chronic kidney disease patients with refractory hypertension undergoing hemodialysis: a randomized controlled multicenter study. ( Hara, Y; Hosoya, T; Kuriyama, S; Sugano, N; Yokoo, T; Yokoyama, K, 2014) |
| "This is a randomized double-blind clinical trial, comparing the use of chlorthalidone with amiloride versus amlodipine as a first drug option in patients older than 40 years of age with stage I hypertension (140 to 159/90 to 99 mmHg) and moderate OSA (15 to 30 apneas/hour of sleep)." | 5.19 | The effect of antihypertensive agents on sleep apnea: protocol for a randomized controlled trial. ( Cichelero, FT; Fuchs, FD; Fuchs, SC; Gus, M; Martinez, D; Moreira, LB, 2014) |
| "To investigate the efficacy and safety of telmisartan 80 mg/amlodipine 5 mg (T80/A5) single-pill combination versus A5 in patients with essential hypertension not adequately controlled on A5 monotherapy." | 5.19 | A randomized, double-blind study to evaluate the efficacy and safety of a single-pill combination of telmisartan 80 mg/amlodipine 5 mg versus amlodipine 5 mg in hypertensive Asian patients. ( Gao, P; Holtbruegge, W; Huang, C; Zhu, D, 2014) |
| "The objective of this study was to investigate the efficacy of the fixed-dose combination olmesartan/amlodipine 40/10 mg in patients with moderate essential hypertension not controlled on candesartan 32 mg." | 5.19 | Daytime systolic ambulatory blood pressure with a two-step switch from candesartan to olmesartan monotherapy and the fixed-dose combination of olmesartan/amlodipine in patients with uncontrolled essential hypertension (SEVICONTROL-2). ( Bramlage, P; Fimmers, R; Gansz, A; Lüders, S; Nadal, J; Schmieder, RE; Schrader, J; Sturm, CD; Zemmrich, C, 2014) |
| "To assess the efficacy and safety of once daily olmesartan medoxomil (OM)/amlodipine besylate (AM)/hydrochlorothiazide (HCTZ) 40/10/25 mg in patients with hypertension not at goal with mono, dual or triple drug therapy." | 5.19 | Efficacy and safety of olmesartan/amlodipine/hydrochlorothiazide in patients with hypertension not at goal with mono, dual or triple drug therapy: results of the CHAMPiOn study. ( Punzi, HA, 2014) |
| "Evaluate efficacy/safety of olmesartan medoxomil (OM)/amlodipine (AML)/ hydrochlorothiazide (HCTZ) in Hispanic/Latino adults with hypertension." | 5.19 | Triple-combination treatment with olmesartan medoxomil/amlodipine/ hydrochlorothiazide in Hispanic/Latino patients with hypertension: the TRINITY study. ( Chrysant, SG; Fernandez, V; Izzo, JL; Kereiakes, DJ; Lee, J; Lewin, AJ; Melino, M; Oparil, S, 2014) |
| " The EFFICIENT study examines the efficacy and acceptability of a single-pill combination of sustained-release (SR) indapamide, a thiazide-like diuretic, and amlodipine, a calcium channel blocker (CCB), in the management of hypertension." | 5.19 | Blood pressure control with a single-pill combination of indapamide sustained-release and amlodipine in patients with hypertension: the EFFICIENT study. ( Gujral, VK; Hiremath, J; Jadhav, U; Namjoshi, DJ; Safar, M; Shamanna, P; Siraj, M; Tripathi, KK, 2014) |
| "The objective of this study was to compare the efficacy and tolerability of the FDC of azilsartan (AZI) and amlodipine besylate (AML) with those of AZI monotherapy and AML monotherapy in Japanese patients with grade 1 to 2 essential hypertension." | 5.19 | Evaluation of the efficacy and tolerability of fixed-dose combination therapy of azilsartan and amlodipine besylate in Japanese patients with grade I to II essential hypertension. ( Kagawa, T; Nakata, E; Rakugi, H; Sasaki, E, 2014) |
| "An open-label extension of a 10-week double-blind study assessed the long-term efficacy and safety of olmesartan/amlodipine/hydrochlorothiazide (OLM/AML/HCTZ) triple combination treatment in 2,509 patients with Grade 2-3 hypertension." | 5.19 | Open-label study assessing the long-term efficacy and safety of triple olmesartan/amlodipine/hydrochlorothiazide combination therapy for hypertension. ( Ammentorp, B; de la Sierra, A; Laeis, P; Volpe, M, 2014) |
| " We prospectively examined randomization to first-step chlorthalidone, a thiazide-type diuretic; amlodipine, a calcium-channel blocker; and lisinopril, an angiotensin-converting enzyme inhibitor, on BP control and cardiovascular outcomes in a hypertensive cohort stratified by baseline BMI [kg/m(2); normal weight (BMI <25), overweight (BMI = 25-29." | 5.19 | Blood pressure control and cardiovascular outcomes in normal-weight, overweight, and obese hypertensive patients treated with three different antihypertensives in ALLHAT. ( Barzilay, JI; Dart, RA; Davis, BR; Einhorn, PT; Graves, JW; Pressel, SL; Reisin, E; Retta, TM; Saklayen, MG; Yamal, JM, 2014) |
| "5 mg hydrochorothiazide + 5 mg amlodipine, 86 patients with resistant hypertension were randomized to the add-on 25 mg spironolactone (MRB group, n = 46) or 5 mg ramipril (RASB group, n = 40) groups for 12 weeks." | 5.19 | Greater efficacy of aldosterone blockade and diuretic reinforcement vs. dual renin-angiotensin blockade for left ventricular mass regression in patients with resistant hypertension. ( Azizi, M; Bobrie, G; Chatellier, G; Frank, M; Ménard, J; Perdrix, L; Plouin, PF, 2014) |
| "The present study failed to demonstrate the non-inferiority of the antialbuminuric effect of benidipine relative to that of hydrochlorothiazide in RAS inhibitor-treated hypertensive patients with macroalbuminuria." | 5.19 | Comparison of the antialbuminuric effects of benidipine and hydrochlorothiazide in Renin-Angiotensin System (RAS) inhibitor-treated hypertensive patients with albuminuria: the COSMO-CKD (COmbination Strategy on Renal Function of Benidipine or Diuretics Tr ( Ando, K; Fujita, T; Isshiki, M; Kashihara, N; Nakanishi, T; Nangaku, M; Nishizawa, Y; Nitta, K; Rakugi, H; Shimosawa, T; Takahashi, K; Tomita, K; Yokoyama, H, 2014) |
| "Patients with a previous diagnosis of hypertension and type 2 diabetes mellitus were randomly divided into 2 groups and evaluated after 6 weeks of treatment with amlodipine (5 mg/day) or losartan (100 mg/day)." | 5.19 | Functional vascular study in hypertensive subjects with type 2 diabetes using losartan or amlodipine. ( Bedirian, R; Gismondi, RA; Ladeira, MC; Neves, MF; Oigman, W; Pozzobon, CR, 2014) |
| "Male and female patients aged ≥ 18 years with hypertension despite 4-week, stable treatment with losartan 100-mg/d monotherapy were eligible for inclusion in this multicenter, randomized, double-blind study." | 5.19 | Efficacy and tolerability of amlodipine camsylate/losartan 5/100-mg versus losartan/hydrochlorothiazide 100/12.5-mg fixed-dose combination in hypertensive patients nonresponsive to losartan 100-mg monotherapy. ( Ahn, T; Bae, JH; Han, KR; Hyon, MS; Kim, WH; Kim, YK; Lee, SU; Lim, DS; Park, HK; Suh, SY, 2014) |
| "of the study was to assess efficacy of the use of fixed combination of nebivolol and amlodipine in patients with moderate and high degree of arterial hypertension (AH)." | 5.19 | [Postregistration study of comparative assessment efficacy of the use of fixed combination of nebivolol and amlodipine for the treatment of patients with moderate and high degree of arterial hypertension]. ( Barbarash, OL; Evdokimov, DO; Klimenkova, AV; Pecherina, TB; Vedernikova, AG, 2014) |
| "This prespecified subgroup analysis of a phase III study examined the effect of adding hydrochlorothiazide (HCTZ) to olmesartan (OLM)/amlodipine (AML) in patients with moderate to severe hypertension stratified by age, sex, body mass index, and hypertension severity." | 5.19 | Efficacy and tolerability of triple-combination therapy with olmesartan, amlodipine, and hydrochlorothiazide: a subgroup analysis of patients stratified by hypertension severity, age, sex, and obesity. ( Ammentorp, B; de la Sierra, A; Kreutz, R; Laeis, P, 2014) |
| "The clinical data of 24 patients with ischemic stroke in our intensive care unit were analyzed, and received amlodipine or metoprolol for more than 14 days with 24-hour ambulatory blood pressure monitoring." | 5.19 | Effects of different antihypertensive drugs on blood pressure variability in patients with ischemic stroke. ( Hu, WL; Ji, M; Li, SJ, 2014) |
| "To evaluate the impact of 6-month antihypertensive therapy with the combined drug amlodipine + lisinopril (ekvator) on endothelial dysfunction (ED) and carbohydrate metabolic parameters in patients with hypertension and type 2 diabetes mellitus (DM)." | 5.19 | [Correction of endothelial dysfunction in hypertensive patients with type 2 diabetes mellitus during combined antihypertensive therapy]. ( Derevianchenko, MV; Statsenko, ME, 2014) |
| "To investigate the effect of ARB-H on ECF in patients with uncontrolled hypertension despite the use of amlodipine (2." | 5.19 | Fixed-dose combination of losartan and hydrochlorothiazide significantly improves endothelial function in uncontrolled hypertension by low-dose amlodipine: a randomized study. ( Nagata, M; Takase, B, 2014) |
| "Being safe, the fixed-dose lisinopril and amlodipine combination is effective in lowering blood pressure in patients with hypertensive disease (HD) concurrent with coronary heart disease (CHD) or atherosclerotic changes in the carotid artery." | 5.19 | [A fixed-dose lisinopril and amlodipine combination in conjunction with rosuvastatin in patients with hypertensive disease and coronary heart disease]. ( Galeeva, ZM; Galiavich, AS, 2014) |
| "To study effect of combined therapy with amlodipine with ramipril on the circadian profile of arterial pressure in patients with arterial hypertension in the Far North depending on the shiftwork regime." | 5.19 | [The influence of combined therapy with calcium antagonist and angiotensin-converting enzyme inhibitor on the circadian profile of arterial pressure in patients with arterial hypertension in the Far North]. ( Avtandilov, AG; Zapesochnaia, IL, 2014) |
| "The aim of this research was the study of efficiency and endurance antihypertensive therapy on the basis of fixed combination of enalapril and hydrochlorothiazide (HCTZ) and enalapril and HCTZ in combination with amlodipine according to the twenty-four-hour (? day-and-night) monitoring of blood pressure (? 24H BPM) of patients with arterial hypertension (AH) 2-3 severity." | 5.19 | [Changes of twenty-four-hour profile blood pressure and its correction of patients with arterial hypertension on the background of combined antihypertensive therapy application]. ( Bedzaĭ, AO; Prots'ko, VV; Slaba, NA; Solomennchuk, TM, 2014) |
| "Baseline low-grade inflammation in patients with hypertension was associated with a poor ambulatory BP response, especially with losartan/HCTZ treatment." | 5.17 | Low-grade inflammation and ambulatory blood pressure response to antihypertensive treatment: the ALPHABET study. ( Eguchi, K; Fukutomi, M; Hoshide, S; Kario, K; Watanabe, T, 2013) |
| "A proactive, multifactorial intervention strategy incorporating single-pill amlodipine/atorvastatin (SPAA) (5-10/10 mg up-titrated to 5-10/20 mg, where approved) is more effective than physician's usual care (UC) for reducing calculated 10 year coronary heart disease (CHD) risk, in patients with hypertension and additional risk factors (CRUCIAL trial: Curr Med Res Opin 2011;27:821--33)." | 5.17 | Post hoc analysis of the Cluster Randomized Usual Care versus Caduet Investigation Assessing Long-term risk (CRUCIAL) trial. ( Hradec, J; Sutradhar, S; Zamorano, J, 2013) |
| "This prespecified subgroup analysis assessed the efficacy and safety of an olmesartan medoxomil (OM) 40 mg/amlodipine besylate (AML) 10 mg/hydrochlorothiazide (HCTZ) 25 mg triple-combination treatment compared with the 3 components as dual-combination treatments in participants with hypertension who were <65 and ≥ 65 years of age." | 5.17 | Combined olmesartan, amlodipine, and hydrochlorothiazide therapy in randomized patients with hypertension: a subgroup analysis of the TRINITY study by age. ( Fernandez, V; Heyrman, R; Izzo, JL; Lee, J; Lewin, AJ; Melino, M, 2013) |
| "In this secondary analysis of a dose-titration study of patients with hypertension uncontrolled on prior monotherapy, blacks (n=234) and non-blacks (n=765) were switched to amlodipine (AML)/olmesartan medoxomil (OM) 5/20 mg, with uptitration every 4 weeks to AML/OM 5/40 mg and then AML/OM 10/40 mg to achieve a seated cuff blood pressure (SeBP) of <120/70 mm Hg." | 5.17 | Efficacy/safety of a fixed-dose amlodipine/olmesartan medoxomil-based treatment regimen in hypertensive blacks and non-blacks with uncontrolled BP on prior antihypertensive monotherapy. ( Maa, JF; Nesbitt, S; Shojaee, A, 2013) |
| "Combination therapy with benazepril 40 mg and amlodipine 10 mg (B+A) has been shown to be more effective than benazepril 40 mg and hydrochlorothiazide (HCTZ) 25 mg (B+H) in reducing cardiovascular (CV) events in high-risk patients with stage 2 hypertension with similar blood pressure reductions." | 5.17 | Comparison of benazepril plus amlodipine or hydrochlorothiazide in high-risk patients with hypertension and coronary artery disease. ( Bakris, G; Briasoulis, A; Dahlof, B; Hester, A; Hua, T; Jamerson, K; Kelly, RY; Pitt, B; Weber, MA; Zappe, D, 2013) |
| " We enrolled 141 patients and evaluated the efficacy and safety between a fixed dose of olmesartan/amlodipine (OA) and a double dose of amlodipine (DA) for treating mild to moderate hypertension after amlodipine monotherapy failure." | 5.17 | Efficacy and tolerability between an olmesartan/amlodipine fixed-dose combination and an amlodipine double dose in mild to moderate hypertension. ( Hou, CJ; Hsia, CH; Lai, WT; Lin, TH; Pan, JP; Tsai, CD; Tsai, JP, 2013) |
| "Forty-four patients with hypertension and severe OSA (apnea/hypopnea index > 30) received stepped dose titration of antihypertensive treatment, consisting of valsartan 160 mg + amlodipine 5-10 mg + hydrochlorothiazide 25 mg." | 5.17 | Effects of CPAP on "vascular" risk factors in patients with obstructive sleep apnea and arterial hypertension. ( Aksenova, AV; Chazova, IE; Elfimova, EM; Galitsin, PV; Litvin, AY; Rogoza, AN; Sukmarova, ZN, 2013) |
| "To compare the antihypertensive efficacy and safety of once-daily triple therapy with amlodipine (Aml) 10 mg, valsartan (Val) 320 mg, and hydrochlorothiazide (HCTZ) 25 mg versus dual-therapy combinations of these components in patients with moderate to severe hypertension." | 5.17 | Effects of demographics on the antihypertensive efficacy of triple therapy with amlodipine, valsartan, and hydrochlorothiazide for moderate to severe hypertension. ( Calhoun, DA; Crikelair, N; Glazer, RD; Jia, Y; Lacourcière, Y, 2013) |
| "We analyzed 145 out-patients with essential hypertension in primary prevention enrolled in the Natrilix SR Versus Candesartan and Amlodipine in the Reduction of Systolic Blood Pressure in Hypertensive Patients (X-CELLENT) study, a multicenter, randomized, double-blinded, placebo-controlled trial." | 5.17 | Effects of antihypertensive drugs on central blood pressure in humans: a preliminary observation. ( Agnoletti, D; Blacher, J; Borghi, C; Safar, ME; Zhang, Y, 2013) |
| "The purpose of this post hoc subgroup analysis was to compare the incidence of major adverse cardiovascular events (MACE) of patients treated with candesartan and amlodipine with that of those with candesartan and non-amlodipine CCBs in hypertensive patients with coronary artery disease (CAD)." | 5.17 | Efficacy of the combination of amlodipine and candesartan in hypertensive patients with coronary artery disease: a subanalysis of the HIJ-CREATE study. ( Hagiwara, N; Haruta, S; Kawada-Watanabe, E; Koyanagi, R; Ogawa, H; Takagi, A; Yamaguchi, J, 2013) |
| "To evaluate the safety and efficacy of a fixed olmesartan/amlodipine (Olme/Amlo) combination in improving blood pressure control, lipid profile, insulin sensitivity and some inflammatory and insulin resistance markers." | 5.17 | Evaluation of safety and efficacy of a fixed olmesartan/amlodipine combination therapy compared to single monotherapies. ( Carbone, A; Cicero, AF; D'Angelo, A; Derosa, G; Fogari, E; Maffioli, P; Querci, F, 2013) |
| "To evaluate the effectiveness and safety of L-amlodipine besylate for blood pressure control in patients with mild to moderate essential hypertension." | 5.17 | [The effectiveness and safety of L-amlodipine besylate for blood pressure control in patients with mild to moderate essential hypertension]. ( Hu, DY; Jia, T; Yu, JM; Zhan, YQ; Zhang, LJ, 2013) |
| "In this prospective, multicenter, open-labeled, randomized trial, the antialbuminuric effects of cilnidipine and amlodipine were examined in renin-angiotensin system (RAS) inhibitor-treated patients with hypertension (blood pressure [BP]: 130-180/80-110 mmHg), type 2 diabetes, and microalbuminuria (urinary albumin to creatinine [Cr] ratio [UACR]: 30-300 mg/g)." | 5.17 | Comparison of the antialbuminuric effects of L-/N-type and L-type calcium channel blockers in hypertensive patients with diabetes and microalbuminuria: the study of assessment for kidney function by urinary microalbumin in randomized (SAKURA) trial. ( Ando, K; Fujita, T; Kosugi, S; Matsuoka, H; Nakao, K; Sato, T; Tanaka, S; Ueshima, K, 2013) |
| "In this multicenter, open-label, active-controlled, parallel-group study, 564 patients with hypertension not adequately controlled by prior monotherapy were randomized to receive valsartan/amlodipine 80/5 mg or nifedipine GITS 30 mg once daily for 12 weeks." | 5.17 | Valsartan/amlodipine compared to nifedipine GITS in patients with hypertension inadequately controlled by monotherapy. ( Chen, LL; He, YS; Li, Y; Li, ZP; Wang, JG; Wei, M; Zeng, WF; Zhang, BW, 2013) |
| "Administering amlodipine in 2 divided doses was not associated with increased trough plasma amlodipine concentrations, reduced arterial stiffness, or improved BP control over a 24-hour period in patients with essential hypertension." | 5.17 | Effects of dividing amlodipine daily doses on trough drug concentrations and blood pressure control over a 24-hour period. ( Higaki, J; Irita, J; Masanori, J; Miyoshi, K; Nagao, T; Okura, T, 2013) |
| "We conducted a quasi-experimental, validation study in which patients with primary, uncomplicated hypertension received open-label, fixed combination therapy with amlodipine/losartan 5/50 mg or 5/100 mg according to their baseline blood pressure (BP)." | 5.17 | Echocardiographic changes and treatment goal rates after a 6-month combined treatment with amlodipine and losartan: a validation study in Andean countries (METAL study). ( Pérez Carreño, JG; Romero, JD; Villar Centeno, JC, 2013) |
| "A direct switch of candesartan to the fixed-dose combination olmesartan/amlodipine in uncontrolled hypertension is a frequent clinical requirement but is not covered by current labeling." | 5.17 | Daytime systolic ambulatory blood pressure with a direct switch between candesartan monotherapy and the fixed-dose combination olmesartan/amlodipine in patients with uncontrolled essential hypertension (SEVICONTROL-1). ( Bramlage, P; Fimmers, R; Gansz, A; Lüders, S; Nadal, J; Schmieder, RE; Schrader, J; Sturm, CD; Zemmrich, C, 2013) |
| "A total of 108 individuals with hypertension (grade 2 or above) were randomized to receive telmisartan and amlodipine in one of the following four therapeutic schemes: Group A (26 cases): both medications taken on the morning; Group B (28 cases): both medication taken at bedtime; Group C (27 cases): telmisartan on the morning and amlodipine at bedtime; or Group D (27 cases): amlodipine on the morning and telmisartan at bedtime." | 5.17 | [Blood pressure lowering efficacy of telmisartan and amlodipine taking on the morning or at bedtime: ABPM results]. ( Chen, JF; Huang, JX; Peng, GC; Sai, SQ; Wang, YF; Xiao, Y; Yang, Y; Ye, YL, 2013) |
| "To evaluate the impact of combination antihypertensive therapy with lisinopril + amlodipine (Ekvator) on endothelial dysfunction in patients with hypertension and concurrent type 2 diabetes mellitus (T2DM)." | 5.17 | [Endothelial dysfunction is a target for combination antihypertensive therapy in hypertensive patients with type 2 diabetes mellitus]. ( Bondarev, AM; Derevianchenko, MV; Ostrovskiĭ, OV; Shvets, MK; Statsenko, ME; Titarenko, MN, 2013) |
| "This study was conducted to compare the BP-lowering and diurnal BP variation effects of amlodipine and losartan on acute stroke patients." | 5.17 | Comparison of the effects of amlodipine and losartan on blood pressure and diurnal variation in hypertensive stroke patients: a prospective, randomized, double-blind, comparative parallel study. ( Hong, YH; Kwon, HM; Lee, YS; Lim, JS; Nam, H; Shin, JW, 2013) |
| "To evaluate the efficiency and safety of two treatment regimens using ramipril or losartan in combination with hydrochlorothiazide (HCT) and amlodipine in grade 1-2 arterial hypertension (AH)." | 5.17 | [Possibilities of rational combination antihypertensive therapy: results of HEMERA international clinical trial]. ( Chazova, IE; Martyniuk, TV, 2013) |
| "We compared effects of racemic amlodipine and S-amlodipine in 127 patients with 1-2 degree arterial hypertension (AH) on structural-functional parameters of the left ventricle and brachial artery as well as on characteristics of carbohydrate, lipid, electrolyte, and purine metabolism." | 5.17 | [Organoprotective and metabolic effects of S-amlodipine in patients with arterial hypertension]. ( Iskenderov, BG; Saushkina, SV, 2013) |
| "To estimate effectiveness and safety of losartan and its combination with amlodipine in therapy of arterial hypertension." | 5.17 | [Effectiveness and safety of losartan and its combination with amlodipine in therapy of arterial hypertension]. ( Bazaeva, EV; Boitsov, SA; Drapkina, OM; Luk'ianov, MM; Panov, AV; Shchukina, GN; Terent'ev, BP; Tiurin, VP, 2013) |
| " In this study the effects of fixed combination of valsartan with either amlodipine (V-A) or hydrochlorothiazide (V-H) on low-density-lipoprotein (LDL) and high-density-lipoprotein (HDL) subfraction profile of patients with stage 2 or 3 hypertension were assessed." | 5.17 | Distinct effects of fixed combinations of valsartan with either amlodipine or hydrochlorothiazide on lipoprotein subfraction profile in patients with hypertension. ( Christogiannis, LG; Elisaf, MS; Kostapanos, MS; Milionis, HJ; Tellis, CC; Tselepis, AD, 2013) |
| "In this multicentre study (24 centres), adults with stage 1 or 2 hypertension not adequately controlled with valsartan monotherapy were randomised to receive double-blind amlodipine/valsartan 5/160 mg SPC or valsartan 160 mg once daily for 8 weeks." | 5.17 | Amlodipine/valsartan 5/160 mg versus valsartan 160 mg in Chinese hypertensives. ( Gao, P; Grosso, A; Sun, N; Wang, R; Yang, K; Zhang, Y; Zhu, D, 2013) |
| " We conducted an open-label, randomized trial to compare the effects of cilnidipine against those of amlodipine on blood pressure (BP), albuminuria, and plasma aldosterone concentration in hypertensive patients with mild- to moderate-stage chronic kidney disease." | 5.17 | L/N-type calcium channel blocker cilnidipine reduces plasma aldosterone, albuminuria, and urinary liver-type fatty acid binding protein in patients with chronic kidney disease. ( Abe, M; Inoshita, A; Maruyama, N; Okada, K; Soma, M; Suzuki, H; Yoshida, Y, 2013) |
| " This study evaluated the effects of an olmesartan/amlodipine single pill combination compared to olmesartan or amlodipine monotherapies on BP, lipid profile, insulin resistance, and insulin sensitivity parameters." | 5.17 | Olmesartan/amlodipine combination versus olmesartan or amlodipine monotherapies on blood pressure and insulin resistance in a sample of hypertensive patients. ( Carbone, A; Cicero, AF; D'Angelo, A; Derosa, G; Fogari, E; Maffioli, P; Querci, F, 2013) |
| "Hypertensive patients with type 2 diabetes mellitus and microalbuminuria under treatment with a combination of a standard dose of telmisartan (40 mg/day) and trichlormethiazide (1 mg/day) were randomly assigned to receive either an increased dose of telmisartan (80 mg/day) combined with trichlormethiazide [increased dose angiotensin receptor blocker (ARB) group, n = 20] or a combination consisting of telmisartan (40 mg/day), trichlormethiazide, and amlodipine (5 mg/day) (triple combination group, n = 20) for 6 months." | 5.17 | Titration of telmisartan, but not addition of amlodipine, reduces urine albumin in diabetic patients treated with telmisartan-diuretic. ( Dohi, Y; Kimura, G; Kojima, M; Ohashi, M, 2013) |
| " We aimed to investigate the effects of valsartan and amlodipine on the PTX3 and C-reactive protein (CRP) levels in patients with essential hypertension." | 5.17 | The comparative effects of valsartan and amlodipine on vascular microinflammation in newly diagnosed hypertensive patients. ( Arslan, E; Ay, SA; Balta, S; Bulucu, F; Cakar, M; Celik, T; Demirbas, S; Demirkol, S; Karaman, M; Sağlam, K; Turker, T; Unlu, M; Yaman, H, 2013) |
| " In this study, we investigated the effects of valsartan and amlodipine on the lipid profile in patients with newly diagnosed essential hypertension." | 5.17 | An additional LDL-lowering effect of amlodipine; not only an antihypertensive? ( Akhan, M; Arslan, E; Arslan, Z; Ay, SA; Balta, S; Bulucu, F; Cakar, M; Celik, T; Demirbas, S; Demirkol, S; Karaman, M; Saglam, K; Sarlak, H, 2013) |
| "In accordance with experimental data after antihypertensive treatment of 4 weeks, intraglomerular pressure was significantly lower with the CCB manidipine than with amlodipine, resulting and explaining their disparate effects on albuminuria." | 5.17 | Effects of manidipine vs. amlodipine on intrarenal haemodynamics in patients with arterial hypertension. ( Alberici, M; Ott, C; Raff, U; Ritt, M; Schmieder, RE; Schneider, MP; Striepe, K, 2013) |
| " The efficacy and safety of 20-week treatment with an amlodipine (AML)/olmesartan medoxomil (OM)±hydrochlorothiazide (HCTZ) algorithm were assessed in patients with hypertension and type 2 diabetes mellitus (T2DM) who were uncontrolled by antihypertensive monotherapy." | 5.17 | Efficacy of an amlodipine/olmesartan treatment algorithm in patients with or without type 2 diabetes and hypertension (a secondary analysis of the BP-CRUSH study). ( Maa, JF; Nesbitt, SD; Shojaee, A; Weir, MR, 2013) |
| " In present study, we aimed to investigate the effects of valsartan as an angiotensin II receptor antagonist and amlodipine as a calcium channel blocker on the vWf levels and N/L ratio in patients with essential hypertension." | 5.17 | The comparative effects of valsartan and amlodipine on vWf levels and N/L ratio in patients with newly diagnosed hypertension. ( Arslan, Z; Balta, S; Bozoglu, E; Bulucu, F; Cakar, M; Celik, T; Demirbas, S; Demirkol, S; Karaman, M; Kocak, N; Kurt, O; Naharci, I; Sarlak, H; Seyit Ahmet, AY, 2013) |
| "Single-pill amlodipine/atorvastatin was associated with significant improvements in BP, LDL-C target attainment, and 10-year CV risk in patients with uncontrolled hypertension in Slovakia." | 5.17 | Slovak trial on cardiovascular risk reduction following national guidelines with CaDUET® (the STRONG DUET study). ( Fedacko, J; Janicko, M; Jarcuska, P; Jedlickova, L; Kmec, J; Lopuchovsky, T; Merkovska, L; Pella, D; Sabol, F; Sajty, M, 2013) |
| " Hypertensive patients with type 2 diabetes mellitus and albuminuria (≥30 mg g(-1) creatinine) were enroled in the study, and were either started on or switched to candesartan (8 mg per day) monotherapy." | 5.16 | Effects of up-titration of candesartan versus candesartan plus amlodipine on kidney function in type 2 diabetic patients with albuminuria. ( Dohi, Y; Ichikawa, T; Ito, M; Kato, T; Kimura, G; Kojima, M; Komada, T; Machida, H; Miyazaki, T; Nakatani, K; Ninomiya, T; Okura, T; Sugiyama, M; Watanabe, Y, 2012) |
| "To compare the effects of losartan and amlodipine on myocardial structure and function in hypertensive patients with Type 2 diabetes and left ventricular hypertrophy." | 5.16 | Losartan and amlodipine on myocardial structure and function: a prospective, randomized, clinical trial. ( Corradi, L; Derosa, G; Destro, M; Fogari, R; Lazzari, P; Mugellini, A; Preti, P; Zoppi, A, 2012) |
| "The ACCOMPLISH Trial investigated intensive antihypertensive combination treatment with benazepril + amlodipine (B+A) or benazepril + hydrochlorothiazide (B+H) on cardiovascular outcomes in patients with systolic hypertension." | 5.16 | Predictors of systolic BP <140 mmHg and systolic BP level by randomly assigned treatment group (benazepril plus amlodipine or hydrochlorothiazide) in the ACCOMPLISH Study. ( Bakris, GL; Dahlöf, B; Hester, A; Hua, TA; Ibsen, H; Jamerson, KA; Kelly, RY; Kjeldsen, SE; Ostergren, J; Pitt, B; Tuomilehto, J; Velazquez, EJ; Weber, M; Zappe, D, 2012) |
| "A total of 170 outpatients aged 50-75 years with mild to moderate hypertension (SBP >130 and <180 mmHg and DBP >80 and <100 mmHg) and type 2 diabetes were randomly treated with aliskiren 300 mg or amlodipine 10 mg, both given once daily for 24 weeks, according to a prospective, open label, blinded-end point, parallel group design." | 5.16 | Effects of aliskiren on QT duration and dispersion in hypertensive patients with type 2 diabetes mellitus. ( Derosa, G; Fogari, R; Lazzari, P; Maffioli, P; Monti, C; Mugellini, A; Zoppi, A, 2012) |
| " The aim of this study was to evaluate the effects of losartan or amlodipine alone or combined with simvastatin on hepatic steatosis degree, and on insulin sensitivity in normocholesterolemic, hypertensive patients with nonalcoholic hepatic steatosis." | 5.16 | Effects of losartan and amlodipine alone or combined with simvastatin in hypertensive patients with nonalcoholic hepatic steatosis. ( Derosa, G; Fogari, R; Lazzari, P; Maffioli, P; Mugellini, A; Zoppi, A, 2012) |
| " Therefore, we designed a randomized controlled trial using amlodipine as the base drug of a multi-drug regimen, the Optimal Combination of Effective ANtihypertensives (OCEAN) Study, to determine the drug combination that is most efficacious in the prevention of cardiovascular events, such as stroke." | 5.16 | Optimal Combination of Effective ANtihypertensives (OCEAN) study: a prospective, randomized, open-label, blinded endpoint trial--rationale, design and results of a pilot study in Japan. ( Kageyama, S; Miyakawa, M; Mochizuki, K; Nakayama, M; Ohashi, Y; Saito, I; Saruta, T; Sugawara, M; Ueda, S, 2012) |
| "The ACCOMPLISH trial (Avoiding Cardiovascular events through Combination therapy in Patients Living with Systolic Hypertension) was a 3-year multicenter, event-driven trial involving patients with high cardiovascular risk who were randomized in a double-blinded manner to benazepril plus either hydrochlorothiazide or amlodipine and titrated in parallel to reach recommended blood pressure goals." | 5.16 | Renal outcomes in hypertensive Black patients at high cardiovascular risk. ( Bakris, GL; Dahlof, B; Devereux, RB; Hester, RA; Hua, TA; Jamerson, KA; Kelly, RY; Kjeldsen, SE; Pitt, B; Velazquez, E; Weber, MA; Weir, MR; Wright, JT, 2012) |
| "The aim of this study was to determine the dose-response relationship and assess the efficacy and safety of amlodipine or losartan monotherapy and amlodipine camsylate/losartan combination therapy in patients with essential hypertension." | 5.16 | Evaluation of the dose-response relationship of amlodipine and losartan combination in patients with essential hypertension: an 8-week, randomized, double-blind, factorial, phase II, multicenter study. ( Chae, SC; Cho, SY; Choi, YJ; Hong, BK; Hong, TJ; Jeong, JW; Kim, CH; Kim, JJ; Kim, MH; Kwan, J; Park, CG; Park, SH; Yang, JY; Youn, HJ, 2012) |
| "Fifty-one hypertensive patients with coronary artery stenosis but without coronary artery spasm, treated with a sirolimus-eluting stent, were randomly assigned to either the telmisartan (25 cases) or amlodipine (26 cases) treatment groups." | 5.16 | Protective effect of telmisartan against endothelial dysfunction after coronary drug-eluting stent implantation in hypertensive patients. ( Ehara, M; Habara, M; Ito, T; Kaneda, H; Kimura, M; Kinoshita, Y; Matsuo, H; Nasu, K; Rathore, S; Suzuki, T; Suzuki, Y; Tanaka, N; Terashima, M, 2012) |
| "The objective of this study was to assess the effects of valsartan or olmesartan addition to dual therapy with amlodipine + hydrochlorothiazide (HCTZ) in the treatment of stage 2 hypertension." | 5.16 | Effects of valsartan versus olmesartan addition to amlodipine/hydrochlorothiazide combination in treating stage 2 hypertensive patients. ( Derosa, G; Fogari, R; Maffioli, P; Mugellini, A; Perrone, T; Preti, P; Zoppi, A, 2012) |
| "The aim of the study was to investigate whether the single-pill combination of telmisartan and amlodipine was superior to amlodipine alone as initial antihypertensive therapy in patients with diabetes and hypertension." | 5.16 | Single-pill combination of telmisartan/amlodipine versus amlodipine monotherapy in diabetic hypertensive patients: an 8-week randomized, parallel-group, double-blind trial. ( Bakris, G; Kobe, M; Ley, L; Littlejohn, TW; Neutel, JM; Sharma, AM; Ting, N, 2012) |
| "This 8-week, randomized, double-blind, controlled study compared efficacy and tolerability of telmisartan/amlodipine (T/A) single-pill combination (SPC) vs the respective monotherapies in 858 patients with severe hypertension (systolic/diastolic blood pressure [SBP/DBP] ≥180/95 mm Hg)." | 5.16 | Single-pill combination of telmisartan/amlodipine in patients with severe hypertension: results from the TEAMSTA severe HTN study. ( Black, HR; Dahlöf, B; Defeo, H; Ley, L; Mancia, G; Neutel, JM; Vinisko, R, 2012) |
| " Korean patients with essential hypertension inadequately controlled on losartan 100 mg were administered amlodipine/losartan 5 mg/100 mg combination versus losartan 100 mg." | 5.16 | Comparison of the efficacy and safety of fixed-dose amlodipine/losartan and losartan in hypertensive patients inadequately controlled with losartan: a randomized, double-blind, multicenter study. ( Cho, SY; Choi, YJ; Hong, BK; Kim, KS; Park, CG; Yang, JY; Yoon, HJ; Yoon, JH; Yoon, MH, 2012) |
| "A total of 61 elderly patients with grade 2 or 3 hypertension were randomized into valsartan + amlodipine (the amlodipine group, n = 31) or valsartan + hydrochlorothiazide (the hydrochlorothiazide group, n = 30) group." | 5.16 | [Effects of valsartan combined with amlodipine or hydrochlorothiazide regimen on blood pressure variation in elderly hypertensive patients]. ( Sun, CX; Tao, CW; Wu, ZB; Yu, QG; Zhang, Y, 2012) |
| "The objective of this study was to compare valsartan or ramipril addition to amlodipine + hydrochlorothiazide (HCTZ) on blood pressure (BP) and left ventricular hypertrophy (LVH) in hypertensive diabetic patients with LVH." | 5.16 | Effects of valsartan or ramipril addition to amlodipine/hydrochlorothiazide combination on left ventricular mass in diabetic hypertensive patients with left ventricular hypertrophy. ( Derosa, G; Fogari, R; Maffioli, P; Mugellini, A; Preti, P; Zoppi, A, 2012) |
| "We examined blood pressure reduction and metabolic alterations after amlodipine/benazepril and valsartan/hydrochlorothiazide treatment in patients with type 2 diabetes mellitus and hypertension and microalbuminuria." | 5.16 | Comparison of the efficacy and safety profiles of two fixed-dose combinations of antihypertensive agents, amlodipine/benazepril versus valsartan/hydrochlorothiazide, in patients with type 2 diabetes mellitus and hypertension: a 16-week, multicenter, rando ( Chen, JF; Hung, YJ; Lee, IT; Lee, WJ; Sheu, WH; Wang, CY, 2012) |
| "A total of 263 type 2 diabetes with hypertension refractory to standard dose of ARB were randomized to increased ARB regimen (n=132) or amlodipine combination regimen (n=131)." | 5.16 | Management of home blood pressure by amlodipine combined with angiotensin II receptor blocker in type 2 diabetes. ( Choi, JB; Daida, H; Hayashi, D; Ikeda, S; Imai, Y; Kawamori, R; Kishimoto, J; Kitagawa, A; Miyauchi, K; Murayama, F; Ono, Y; Suwa, S; Tanaka, Y; Watada, H; Yamazaki, T, 2012) |
| "To evaluate the clinic and ambulatory blood pressure (BP)-lowering efficacy and safety of an aliskiren/amlodipine/hydrochlorothiazide (HCT) triple combination compared with the component dual combinations, in patients with moderate-to-severe hypertension." | 5.16 | Clinic and ambulatory blood pressure lowering effect of aliskiren/amlodipine/hydrochlorothiazide combination in patients with moderate-to-severe hypertension: a randomized active-controlled trial. ( Fang, H; Konis, G; Lacourcière, Y; Severin, T; Taddei, S; Zhang, J, 2012) |
| "This study in patients with moderate-to-severe hypertension assessed the efficacy and safety of adding hydrochlorothiazide (HCTZ) 12." | 5.16 | Efficacy and safety of triple antihypertensive therapy with the olmesartan/amlodipine/hydrochlorothiazide combination. ( Ammentorp, B; Christian Rump, L; Laeis, P; Volpe, M, 2012) |
| "This exploratory study compared the amount of pedal edema experienced by female Korean patients with mild to moderate hypertension when receiving S(-)-amlodipine nicotinate compared with amlodipine besylate." | 5.16 | Quantification of pedal edema during treatment with S(-)-amlodipine nicotinate versus amlodipine besylate in female Korean patients with mild to moderate hypertension: a 12-week, multicenter, randomized, double-blind, active-controlled, phase IV clinical ( Choi, DJ; Kang, HJ; Lee, HY; Oh, BH; Oh, GC; Zo, JH, 2012) |
| "The aim of this work was a detailed study of questions connected with the peculiarities of circadian blood pressure profile, efficiency of amlodipine in elderly patients with gout and arterial hypertension." | 5.16 | [Possibilities of pharmacological correction of the arterial hypertension in elderly patients with gout]. ( Andrianova, MA; Kunitskaia, NA, 2012) |
| " This 28- to 54-week, open-label, multicenter study evaluated the safety and efficacy of a triple combination, aliskiren with amlodipine and hydrochlorothiazide (HCTZ), in patients with moderate to severe hypertension." | 5.16 | Safety and efficacy of aliskiren/amlodipine/hydrochlorothiazide triple combination in patients with moderate to severe hypertension: a 54-week, open-label study. ( Garcia-Puig, J; Koenig, W; Murray, AV; Patel, S; Uddin, A; Zhang, J, 2012) |
| "A total of 48 patients with probable AD and essential hypertension were randomly assigned into telmisartan group (n = 24, 40 - 80 mg qd) or amlodipine group (n = 24, 5 - 10 mg qd) for 6 months at Henan Provincial People's Hospital during 2008 - 2011." | 5.16 | [Effects of telmisartan on the level of Aβ1-42, interleukin-1β, tumor necrosis factor α and cognition in hypertensive patients with Alzheimer's disease]. ( Bai, YY; Li, W; Liu, HQ; Lu, F; Ma, MM; Suo, AQ; Wang, JQ; Zhang, JW, 2012) |
| "We hypothesized that atorvastatin combined with amlodipine has additive beneficial vascular and metabolic effects that are superior to monotherapy in patients with hypertension." | 5.15 | Additive beneficial effects of atorvastatin combined with amlodipine in patients with mild-to-moderate hypertension. ( Han, SH; Kim, SJ; Koh, KK; Koh, Y; Lee, Y; Park, JB; Quon, MJ; Shin, EK, 2011) |
| "The Chinese Hypertension Intervention Efficacy Study (CHIEF) is a multi-centre randomized controlled clinical trial comparing the effects of amlodipine+angiotensin II receptor blocker and amlodipine+diuretics on the incidence of cardiovascular events, represented as a composite of non-fatal stroke, non-fatal myocardial infarction and cardiovascular death events in high-risk Chinese hypertensive patients." | 5.15 | The combination of amlodipine and angiotensin receptor blocker or diuretics in high-risk hypertensive patients: rationale, design and baseline characteristics. ( Deng, Q; Liu, L; Liu, M; Ma, L; Wang, W; Zhang, Y, 2011) |
| " The aim of this study was to clarify the effect of angiotensin II receptor blockade with valsartan on plasma OPN levels in patients with essential hypertension (EHT)." | 5.15 | Angiotensin II receptor blockade with valsartan decreases plasma osteopontin levels in patients with essential hypertension. ( Desilva, VR; Enomoto, D; Higaki, J; Irita, J; Jotoku, M; Kurata, M; Miyoshi, K; Nagao, T; Okura, T, 2011) |
| " The objective of this analysis was to determine the efficacy of olmesartan/amlodipine in age, severity and gender-based subgroups of patients with moderate-to-severe hypertension uncontrolled by amlodipine monotherapy." | 5.15 | Efficacy and safety of olmesartan medoxomil plus amlodipine in age, gender and hypertension severity defined subgroups of hypertensive patients. ( Böhm, M; Schmieder, RE, 2011) |
| "The steady-state pharmacokinetic (PK) interaction potential between amlodipine (10 mg), valsartan (320 mg), and hydrochlorothiazide (HCTZ; 25 mg) was evaluated in patients with hypertension in a multicenter, multiple-dose, open-label, 4-cohort, parallel-group study." | 5.15 | Evaluation of pharmacokinetic interactions between amlodipine, valsartan, and hydrochlorothiazide in patients with hypertension. ( Ayalasomayajula, S; Bhad, P; Jarugula, V; Karan, R; Leon, S; Riviere, GJ; Sunkara, G, 2011) |
| "We evaluated ROCK activity in peripheral leukocytes by Western blot analysis in 651 patients with hypertension treated with antihypertensive agents, 28 untreated hypertensive patients and 28 healthy individuals, and the effects of treatment with amlodipine or losartan for 12 weeks on ROCK activity in 28 untreated hypertensive patients who were randomly divided into an amlodipine group (n = 14) and a losartan group (n = 14)." | 5.15 | Calcium channel blocker and Rho-associated kinase activity in patients with hypertension. ( Chayama, K; Fujii, Y; Fujimura, N; Hata, T; Hidaka, T; Higashi, Y; Idei, N; Kato, H; Kihara, Y; Liao, JK; Maruhashi, T; Mikami, S; Noma, K; Soga, J, 2011) |
| "We studied the effects of treatment with olmesartan/amlodipine and olmesartan/hydrochlorothiazide on inflammatory and metabolic parameters (including new-onset diabetes as a secondary endpoint) in non-diabetic hypertensive patients with metabolic syndrome (MetS)." | 5.15 | Olmesartan/amlodipine vs olmesartan/hydrochlorothiazide in hypertensive patients with metabolic syndrome: the OLAS study. ( Comi-Diaz, C; Martinez-Martin, FJ; Pedrianes-Martin, P; Peiro-Martinez, I; Rodriguez-Rosas, H; Soriano-Perera, P, 2011) |
| "In this open-label, single-arm switch study reflecting clinical practice, patients with moderate hypertension not controlled by the free combination of CAN 32 + HCT 25 achieved a clinically and statistically significant reduction of blood pressure from the single pill combination of ALIS 300/HCT 25, and the optional addition of amlodipine." | 5.15 | Efficacy and tolerability of aliskiren 300 mg/hydrochlorothiazide 25 mg (± amlodipine 5 mg) in hypertensive patients not controlled by candesartan 32 mg plus HCT 25 mg. ( Benduhn, H; Klebs, S; Schweizer, J; Ulmer, HJ, 2011) |
| "This study was a prospective, randomized, open, blinded endpoint study to assess the effects of angiotensin II type 1 receptor blocker, losartan, compared with calcium channel blocker, amlodipine, on left ventricular (LV) diastolic function and atherosclerosis of the carotid artery in Japanese patients with mild-to-moderate hypertension, LV hypertrophy, diastolic dysfunction and preserved systolic function." | 5.15 | The effect of losartan and amlodipine on left ventricular diastolic function and atherosclerosis in Japanese patients with mild-to-moderate hypertension (J-ELAN) study. ( Akehi, N; Ebisuno, S; Fukui, S; Hori, M; Horiguchi, Y; Katsube, Y; Kobayashi, K; Kodama, M; Ohtsu, H; Ota, M; Ozaki, H; Sakai, A; Shimonagata, T; Takayasu, K; Yamamoto, K; Yamazaki, T, 2011) |
| " In this study, we conducted an open-label and randomized trial to compare the effects of benidipine with those of amlodipine on blood pressure (BP), albuminuria and aldosterone concentration in hypertensive patients with mild-to-moderate stage chronic kidney disease (CKD)." | 5.15 | Benidipine reduces albuminuria and plasma aldosterone in mild-to-moderate stage chronic kidney disease with albuminuria. ( Abe, M; Fujita, T; Maruyama, N; Maruyama, T; Matsumoto, K; Matsumoto, S; Okada, K; Soma, M, 2011) |
| "The Japanese Rhythm Management Trial II for Atrial Fibrillation (J-RHYTHM II study) is an open-label randomized comparison between an ARB (candesartan) and a CCB (amlodipine) in the treatment of paroxysmal AF associated with hypertension." | 5.15 | Randomized trial of angiotensin II-receptor blocker vs. dihydropiridine calcium channel blocker in the treatment of paroxysmal atrial fibrillation with hypertension (J-RHYTHM II study). ( Aizawa, Y; Atarashi, H; Fukatani, M; Hirai, M; Hirayama, A; Inoue, H; Kamakura, S; Kato, T; Kodama, I; Koretsune, Y; Kumagai, K; Kurachi, Y; Mitamura, H; Nakaya, H; Ogawa, S; Ohe, T; Ohtsu, H; Okumura, K; Saikawa, T; Sakurai, M; Sato, T; Sugi, K; Watanabe, E; Yamashita, T; Yamazaki, T, 2011) |
| " The objective of this study (the MARCADOR study) was to compare the effects of manidipine 20 mg with the extemporary combination of manidipine 10 mg/lisinopril 10 mg, amlodipine 10 mg and telmisartan 80 mg on insulin sensitivity, as well as metabolic, inflammatory and prothrombotic markers, in hypertensive non-diabetic patients with metabolic syndrome." | 5.15 | Effects of manidipine and its combination with an ACE inhibitor on insulin sensitivity and metabolic, inflammatory and prothrombotic markers in hypertensive patients with metabolic syndrome: the MARCADOR study. ( Comi-Diaz, C; Macias-Batista, A; Martinez-Martin, FJ; Pedrianes-Martin, P; Rodriguez-Rosas, H; Soriano-Perera, P, 2011) |
| "The aim of our study was to evaluate the safety and effectiveness of the free combination of amlodipine/valsartan in patients with arterial hypertension in a real-life setting." | 5.15 | Real-life safety and effectiveness of amlodipine/valsartan combination in the treatment of hypertension. ( Chazova, IE; Dongre, N; Vigdorchik, AV, 2011) |
| "The GIFU substudy of the Candesartan Antihypertensive Survival Evaluation in Japan (CASE-J) trial was conducted to compare the long-term effects of candesartan and amlodipine on office- and home-measured blood pressure (BP), QTc dispersion and left ventricular mass index (LVMI) in high-risk Japanese patients with hypertension." | 5.15 | Effects of candesartan versus amlodipine on home-measured blood pressure, QT dispersion and left ventricular hypertrophy in high-risk hypertensive patients. ( Fujiwara, H; Matsuno, Y; Minatoguchi, S, 2011) |
| "To determine the effectiveness and safety of once-daily combination therapy with amlodipine, valsartan and hydrochlorothiazide for reducing ambulatory blood pressure (ABP) in patients with moderate to severe hypertension, a multicenter, double-blind study was performed (N=2271) that included ABP monitoring in a 283-patient subset." | 5.15 | 24-Hour ambulatory blood pressure control with triple-therapy amlodipine, valsartan and hydrochlorothiazide in patients with moderate to severe hypertension. ( Calhoun, DA; Crikelair, N; Glazer, RD; Lacourcière, Y; Yen, J, 2011) |
| "Twelve weeks of treatment with losartan significantly reduced proteinuria compared with placebo/amlodipine: losartan -14." | 5.15 | Efficacy and safety of losartan in children with Alport syndrome--results from a subgroup analysis of a prospective, randomized, placebo- or amlodipine-controlled trial. ( Gleim, GW; Lam, C; Le Bailly De Tilleghem, C; Shahinfar, S; Strehlau, J; Webb, NJ; Wells, TG, 2011) |
| " Patients with essential hypertension, who's ambulatory BP was uncontrolled after 4 weeks on amlodipine (5 mg) were randomized to receive amlodipine/valsartan (5/160 mg) for 8 weeks in the morning or evening (n=231, 232, respectively), with optional uptitration up to 10/160 mg after 4 weeks if the office BP was uncontrolled." | 5.15 | Efficacy of morning and evening dosing of amlodipine/valsartan combination in hypertensive patients uncontrolled by 5 mg of amlodipine. ( Achouba, A; Asmar, R; Gosse, P; Queré, S, 2011) |
| "To evaluate the efficacy and tolerability of the fixed combination of amlodipine 5 mg/benazepril 10 mg once-daily therapy, compared with benazepril, 10 mg, monotherapy in patients with mild and moderate hypertension, and to evaluate the 24 h antihypertensive efficacy and the duration of action by ambulatory blood pressure monitoring." | 5.15 | [Comparison of benazepril monotherapy to amlodipine plus benazepril in the treatment of patients with mild and moderate hypertension: a multicentre, randomized, double-blind, parallel-controlled study]. ( Fan, CM; Gao, MM; Li, CX; Li, YQ; Li, YS; Lu, XL; Pang, HM; Tao, YK; Wang, L; Wang, XW; Wang, YN; Yan, LR, 2011) |
| "The Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT-BPLA) showed that an amlodipine-based regimen prevented more cardiovascular events than an atenolol-based regimen in patients at high risk of hypertension." | 5.15 | Natriuretic peptides and collagen biomarkers in patients with medical treatment for hypertension. ( Peuhkurinen, K; Peuhkurinen, S; Risteli, J; Uusimaa, P; Vuolteenaho, O; Ylitalo, A, 2011) |
| "This randomized, double-blind study evaluated efficacy of a single-pill combination of amlodipine/valsartan (Aml/Val) in Asian patients with hypertension not responding to Val 80 mg." | 5.15 | Efficacy and tolerability of a single-pill combination of amlodipine/valsartan in Asian hypertensive patients not adequately controlled with valsartan monotherapy. ( Curt, V; Hao, YM; Huang, J; Sun, NL; Tu, Y; Zhang, Y; Zhu, JR, 2011) |
| "A previous study reported that amlodipine retarded coronary plaque progression in patients with coronary artery disease." | 5.15 | Azelnidipine and amlodipine anti-coronary atherosclerosis trial in hypertensive patients undergoing coronary intervention by serial volumetric intravascular ultrasound analysis in Juntendo University (ALPS-J). ( Daida, H; Fujiwara, Y; Hiro, T; Inoue, K; Kawamura, M; Kojima, T; Komiyama, N; Kurata, T; Miyauchi, K; Nakazato, Y; Okazaki, S; Sumiyoshi, M; Suwa, S; Tamura, H; Tanimoto, K; Yamagami, S; Yokoyama, K; Yokoyama, T, 2011) |
| "The safety and efficacy of an amlodipine/olmesartan medoxomil (OM)-based titration regimen was assessed in patients with type 2 diabetes mellitus and hypertension." | 5.15 | Management of hypertension in patients with diabetes using an amlodipine-, olmesartan medoxomil-, and hydrochlorothiazide-based titration regimen. ( Littlejohn, T; Neutel, JM; Qian, C; Ram, CV; Sachson, R; Shojaee, A; Stoakes, KA, 2011) |
| "After 4-week placebo, 120 outpatients with grade 1 - 2 hypertension were randomized to amlodipine 10 mg or aliskiren 300 mg or their combination for 8 weeks in three crossover periods." | 5.15 | Effect of aliskiren addition to amlodipine on ankle edema in hypertensive patients: a three-way crossover study. ( Derosa, G; Fogari, R; Lazzari, P; Maffioli, P; Monti, C; Mugellini, A; Zoppi, A, 2011) |
| " The authors report on an 8-week double-blind, randomized study of African American patients with stage 2 hypertension that compared brachial and central BP responses (substudy of 53 patients) to combination aliskiren/hydrochlorthiazide (HCTZ) and amlodipine monotherapy." | 5.15 | Peripheral and central blood pressure responses of combination aliskiren/hydrochlorothiazide and amlodipine monotherapy in African American patients with stage 2 hypertension: the ATLAAST trial. ( Ferdinand, KC; Pool, J; Purkayastha, D; Townsend, R; Weitzman, R, 2011) |
| "5-5 mg/day) in olmesartan-treated hypertensive (blood pressure 130-180/80-110 mmHg) patients with type 2 diabetes (fasting blood sugar ≥126 mg/dL or treatment with antidiabetic agents) and albuminuria (urinary albumin/creatinine ratio ≥30 mg/g)." | 5.15 | Design and rationale of Japanese evaluation between Formula of Azelnidipine and amlodipine add on olmesartan to Get antialbuminuric effect study (J-FLAG) : evaluation of the antialbuminuric effects between calcium channel blocker with sympatholytic action ( Ando, K; Fujita, T; Haneda, M; Ito, S; Kashihara, N; Kishimoto, J; Nangaku, M; Node, K; Shimosawa, T, 2011) |
| " To elucidate our hypothesis, we designed a multi-center, open-labeled, randomized trial to compare the antialbuminuric effect between cilnidipine and amlodipine in RAS inhibitor-treated hypertensive (blood pressure [BP]: 130-180/80-110 mmHg) patients with type 2 diabetes and microalbuminuria (urinary albumin/creatinine [Cr] ratio: 30-300 mg/g)." | 5.15 | Design and rationale of the study of assessment for kidney function by urinary microalbumin in randomized (SAKURA) trial. ( Ando, K; Babazono, T; Fujita, T; Kario, K; Matsuoka, H; Nakao, K; Tanaka, S; Ueshima, K, 2011) |
| "This was a prospective trial of amlodipine 10 mg/day administered for 1 month in primary-care patients with hypertension (n = 28), 46% of whom were obese and 57% of whom displayed the metabolic syndrome." | 5.15 | Blood pressure-lowering response to amlodipine as a determinant of the antioxidative activity of small, dense HDL3. ( Bittar, R; Bonnefont-Rousselot, D; Bruckert, E; Chantepie, S; Chapman, MJ; Girerd, X; Hansel, B; Kontush, A; Orsoni, A, 2011) |
| "An 8-week, randomized, double-blind, controlled study with single-pill combinations of telmisartan 40 mg or 80 mg/amlodipine 5 mg (T40/A5 or T80/A5) vs monotherapy with amlodipine 5 mg or 10 mg (A10) in 1097 patients with uncontrolled hypertension (diastolic blood pressure [BP] ≥ 90 mm Hg)." | 5.15 | Telmisartan and amlodipine single-pill combinations vs amlodipine monotherapy for superior blood pressure lowering and improved tolerability in patients with uncontrolled hypertension: results of the TEAMSTA-5 study. ( Jones, R; Lang, M; Neldam, S, 2011) |
| "This study compared the efficacy and safety of combination angiotensin-receptor blocker (ARB)/calcium-channel blocker (CCB) with hydrochlorothiazide (valsartan/amlodipine/HCTZ 160/5/2mg) vs maximal available combination doses of an ARB with HCTZ (losartan/HCTZ 100/25 mg) in the management of stage 2 hypertension." | 5.15 | Combination angiotensin-receptor blocker (ARB)/calcium channel blocker with HCTZ vs the maximal recommended dose of an ARB with HCTZ in patients with stage 2 hypertension: the exforge as compared to losartan treatment in stage 2 systolic hypertension (EXA ( Duprez, D; Ferdinand, KC; Purkayastha, D; Samuel, R; Wright, RF, 2011) |
| " The aim of this sub-analysis was to determine the efficacy and safety of telmisartan 40 or 80 mg plus amlodipine 5 or 10 mg in patients with hypertension, stratified according to certain criteria such as type 2 diabetes mellitus and metabolic syndrome." | 5.15 | Efficacy and tolerability of telmisartan plus amlodipine in added-risk hypertensive patients. ( Dahlöf, B; Guthrie, RM; Jamerson, KA; Oigman, W; Olvera, R; Schumacher, H; Seeber, M, 2011) |
| "Seventeen non-diabetic patients with essential hypertension who had controlled blood pressure levels using amlodipine (5 mg/day) were enrolled in this study." | 5.15 | Effects of calcium channel blockers on glucose tolerance, inflammatory state, and circulating progenitor cells in non-diabetic patients with essential hypertension: a comparative study between azelnidipine and amlodipine on glucose tolerance and endotheli ( Daida, H; Fukao, K; Hiki, M; Hirose, K; Kiyanagi, T; Kume, A; Kurata, T; Matsumori, R; Miyazaki, T; Ohsaka, H; Shimada, K, 2011) |
| "The objective of this research was to evaluate the effect of telmisartan addition to amlodipine, on peripheral edema in hypertensive patients." | 5.15 | Effect of telmisartan addition to amlodipine on ankle edema development in treating hypertensive patients. ( Derosa, G; Fogari, R; Lazzari, P; Maffioli, P; Mugellini, A; Zoppi, A, 2011) |
| "In many countries, combination therapy with amlodipine and atorvastatin is indicated for the treatment of patients with hypertension and hypercholesterolemia." | 5.15 | Impact of combination therapy with amlodipine and atorvastatin on plasma adiponectin levels in hypertensive patients with coronary artery disease: combination therapy and adiponectin. ( Cheung, BM; Lam, KS; Li, M; Tse, HF; Xu, A, 2011) |
| "This 12-week, multicenter, randomized, double-blinded, 4-arm study in 440 patients with moderate to severe hypertension compared ambulatory blood pressure (ABP) responses with a triple-combination regimen (olmesartan medoxomil [OM] 40 mg, amlodipine besylate [AML] 10 mg, and hydrochlorothiazide [HCTZ] 25 mg) and its component dual-combination regimens at similar doses." | 5.15 | 24-hour efficacy and safety of Triple-Combination Therapy With Olmesartan, Amlodipine, and Hydrochlorothiazide: the TRINITY ambulatory blood pressure substudy. ( Chrysant, SG; Fernandez, V; Heyrman, R; Izzo, JL; Kereiakes, DJ; Lee, J; Littlejohn Iii, T; Melino, M; Oparil, S, 2011) |
| "The EXforge As compared to Losartan Treatment ABPM substudy was a randomized, double-blind, parallel-group, active-control, forced-titration study of patients with Stage 2 hypertension that compared the efficacy of initial treatment with valsartan/amlodipine 160/5 mg (n = 48) or losartan 100 mg (n = 36)." | 5.15 | Ambulatory blood pressure response to triple therapy with an angiotensin-receptor blocker (ARB), calcium-channel blocker (CCB), and HCTZ versus dual therapy with an ARB and HCTZ. ( Duprez, D; Ferdinand, K; Purkayastha, D; Samuel, R; Wright, R, 2011) |
| "FDCs of metoprolol and amlodipine are effective and safe in mild to moderate hypertension." | 5.15 | Effect of fixed dose combinations of metoprolol and amlodipine in essential hypertension: MARS--a randomized controlled trial. ( Bosco, B; Devi, P; Ds, C; Gupta, R; Hiremath, J; Joshi, S; Mehta, K; Murthy, S; Nambiar, A; Pais, P; Pandey, S; Sharma, K; Sigamani, A; Singh, G; Thomas, T; Xavier, D, 2011) |
| "The Gemini-AALA (Australia, Asia, Latin America, Africa/Middle East) study evaluated the efficacy and safety of single-pill amlodipine/atorvastatin (Caduet) for the treatment of patients of diverse ethnicity with concomitant hypertension and dyslipidaemia." | 5.14 | Single-pill amlodipine/atorvastatin helps patients of diverse ethnicity attain recommended goals for blood pressure and lipids (the Gemini-AALA study). ( Aguilar-Salinas, CA; Chaves, H; Chopra, P; Erdine, S; Guindy, R; Howes, LG; Moller, RA; Ro, YM; Schou, IM; Tse, HF, 2009) |
| "Losartan, enalapril and amlodipine reduced the number of premature ventricular contractions (PVCs) in patients with essential hypertension as well as blood pressure." | 5.14 | Losartan decreased premature ventricular contractions in patients with hypertension. ( Kuroyanagi, A; Matsubara, H; Sakamoto, T; Shiraishi, H; Shirayama, T, 2009) |
| "During an initial 8-week, double-blind phase, patients with concomitant hypertension and dyslipidemia were randomized into four treatment groups (placebo, amlodipine 5 mg, atorvastatin 10 mg, or coadministered amlodipine 5 mg and atorvastatin 10 mg)." | 5.14 | Coadministered amlodipine and atorvastatin produces early improvements in arterial wall compliance in hypertensive patients with dyslipidemia. ( Cohn, JN; Grimm, R; Houston, M; Neutel, J; Smith, DH; Sun, W; Weinberger, MH; Wilson, DJ, 2009) |
| " The objective of this randomized, double-blind, parallel-group, multicentre study was to determine the efficacy and safety of olmesartan medoxomil/amlodipine combination therapy in patients with moderate to severe hypertension who had failed to respond to treatment with 8 weeks of open-label amlodipine." | 5.14 | Efficacy and tolerability of olmesartan medoxomil combined with amlodipine in patients with moderate to severe hypertension after amlodipine monotherapy: a randomized, double-blind, parallel-group, multicentre study. ( Brommer, P; Haag, U; Miele, C; Volpe, M, 2009) |
| "The objective of this Phase III double-blind parallel-group controlled study was to examine the superiority of amlodipine 10 mg once daily (the amlodipine 10 mg group) to amlodipine 5 mg once daily (the amlodipine 5 mg group) in 305 Japanese outpatients with essential hypertension whose systolic blood pressure (SBP) had not reached the therapeutic target levels (<130-140/80-90 mm Hg) when treated with amlodipine 5 mg once daily." | 5.14 | The Phase III, double-blind, parallel-group controlled study of amlodipine 10 mg once daily in Japanese patients with essential hypertension who insufficiently responded to amlodipine 5 mg once daily. ( Buch, J; Fujiwara, T; Hatsuzawa, J; Ii, Y; Kimura, N; Murakami, M; Murase, H; Saruta, T; Tsuchihashi, T; Watanabe, T, 2009) |
| "To demonstrate the benefit of the combination amlodipine/valsartan 5/160 mg over amlodipine 10 mg, in producing a lower incidence of peripheral oedema for a comparable mean sitting systolic blood pressure (MSSBP) reduction." | 5.14 | The combination of amlodipine/valsartan 5/160 mg produces less peripheral oedema than amlodipine 10 mg in hypertensive patients not adequately controlled with amlodipine 5 mg. ( Akpinar, E; Brunel, P; Calvo, C; Keeling, L; Salvetti, A; Schrader, J; Weisskopf, M, 2009) |
| "This was a 54-week, multicenter, open-label extension study in patients with mild-to-moderate essential hypertension selected after successfully completing a core study during which they received either placebo, amlodipine, valsartan or combination therapy." | 5.14 | Long-term tolerability and efficacy of the combination of amlodipine/valsartan in hypertensive patients: a 54-week, open-label extension study. ( Glazer, RD; Philipp, T; Pospiech, R; Zhao, Y, 2009) |
| "We have reported the benefits of atorvastatin and of an amlodipine-based regimen on coronary heart disease (CHD) events in hypertensive patients in the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT)." | 5.14 | Coronary heart disease benefits from blood pressure and lipid-lowering. ( Chang, CL; Dahlof, B; Mastorantonakis, S; Poulter, NR; Sever, PS; Wedel, H, 2009) |
| "Patients with Stage 1 or 2 hypertension were randomized to telmisartan 0, 20, 40, or 80 mg plus amlodipine 0, 2." | 5.14 | Telmisartan plus amlodipine in patients with moderate or severe hypertension: results from a subgroup analysis of a randomized, placebo-controlled, parallel-group, 4 x 4 factorial study. ( Guthrie, R; Kobe, M; Littlejohn, TW; Majul, CR; Oigman, W; Olvera, R; Seeber, M, 2009) |
| "Stroke: common 'GG' homozygotes had higher risk on lisinopril versus amlodipine [hazard ratio (HR)=1." | 5.14 | Antihypertensive pharmacogenetic effect of fibrinogen-beta variant -455G>A on cardiovascular disease, end-stage renal disease, and mortality: the GenHAT study. ( Arnett, DK; Boerwinkle, E; Davis, BR; Eckfeldt, JH; Ford, CE; Leiendecker-Foster, C; Lynch, AI, 2009) |
| "To investigate the therapeutic efficacy and safety of Amlodipine alone or in combination with terazosin for the presence of lower urinary tract symptoms (LUTS) and hypertension." | 5.14 | Efficacy of combined amlodipine/terazosin therapy in male hypertensive patients with lower urinary tract symptoms: a randomized, double-blind clinical trial. ( Chen, G; Liu, H; Liu, P; Liu, Z; Mao, G; Na, Y; Qin, X; Wang, B; Wang, X; Xu, X, 2009) |
| "The aim of this study was to compare the effects of nifedipine coat-core (once daily formulation) and amlodipine on systemic arterial stiffness in patients with hypertension." | 5.14 | Influence of nifedipine coat-core and amlodipine on systemic arterial stiffness modulated by sympathetic and parasympathetic activity in hypertensive patients. ( Fukuda, M; Ishii, A; Izumi, T; Masuda, T; Moriya, T; Noda, C; Ogura, MN; Tanaka, K; Yamamoto, K; Yonezawa, R, 2009) |
| "This multicenter, double-blind, parallel group, forced-titration study of individuals with stage 2 hypertension, compared the efficacy of valsartan and amlodipine in combination with HCTZ on ABP reduction." | 5.14 | Effects of force-titrated valsartan/hydrochlorothiazide versus amlodipine/hydrochlorothiazide on ambulatory blood pressure in patients with stage 2 hypertension: the EVALUATE study. ( Black, HR; Lacourcière, Y; Purkayastha, D; Samuel, R; Wright, JT; Zappe, D, 2009) |
| "To evaluate the efficacy and tolerability of the fixed combination: amlodipine + enalapril, when compared to amlodipine in the normalization of the diastolic arterial pressure (DAP) (<85 mmHg), in pts with CAD and systemic arterial hypertension (SAH)." | 5.14 | Combination of amlodipine and enalapril in hypertensive patients with coronary disease. ( Armagnajian, D; César, LA; Ferreira, JF; Gomes, EP; Mansur, Ade P; Moretti, MA; Nogueira, PR; Ramires, JA; Rienzo, M; Saraiva, JF, 2009) |
| "Single-pill amlodipine/atorvastatin targets the two most common modifiable cardiovascular risk factors, hypertension and dyslipidaemia." | 5.14 | International open-label studies to assess the efficacy and safety of single-pill amlodipine/atorvastatin in attaining blood pressure and lipid targets recommended by country-specific guidelines: the JEWEL programme. ( Bauer, B; da Silva, PM; Feldman, RD; Genest, J; Gensini, G; Harvey, P; Jenssen, TG; John Mancini, GB; Manolis, AJ; Richard Hobbs, FD, 2009) |
| "Patients with moderate-to-severe hypertension who were inadequately controlled with amlodipine 5 mg/day monotherapy and who subsequently completed 16 weeks of double-blind combination treatment with olmesartan and amlodipine entered a 28-week open-label phase in which all patients initially received olmesartan/amlodipine 40/5 mg/day." | 5.14 | Efficacy and safety of a stepped-care regimen using olmesartan medoxomil, amlodipine and hydrochlorothiazide in patients with moderate-to-severe hypertension: an open-label, long-term study. ( Haag, U; Miele, C; Volpe, M, 2009) |
| "The STRONG (SafeTy & efficacy analysis of coveRsyl amlodipine in uncOntrolled and Newly diaGnosed hypertension) study was a prospective, observational, multicenter trial." | 5.14 | Management of hypertension with the fixed combination of perindopril and amlodipine in daily clinical practice: results from the STRONG prospective, observational, multicenter study. ( Bahl, VK; Jadhav, UM; Thacker, HP, 2009) |
| "Hypotensive and cardioprotective effects of amlodipine (normodipine) were evaluated in 65 patients (35 men and 30 women) with grade II essential arterial hypertension treated with regard for calcium-controlling parathyroid function." | 5.14 | [Efficacy of calcium antagonists depending on the functional state of parathyroid glands in patients with hypertensive disease]. ( Burmistrova, LF; Iskenderov, BG; Lokhina, TV; Sisina, ON, 2009) |
| "This prospective randomized double-blinded clinical trial was designed to explore the effects of amlodipine and the combination of amlodipine with terazosin in improving postvoid residual (PVR) in patients with lower urinary tract symptoms (LUTS) and concomitant hypertension." | 5.14 | [Amlodipine combined with terazosin reduces postvoid residual and the risk of acute urinary retention]. ( Fang, J; Li, YL; Liu, HP; Qin, XH; Xu, XP; Yang, C; Zhang, X, 2009) |
| "To evaluate the effects of manidipine versus amlodipine on blood pressure, albuminuria, insulin sensitivity, adiponectin, TNF-alpha and C-reactive protein in nondiabetic subjects with metabolic syndrome (ATP-III definition), including impaired fasting glucose (>5." | 5.14 | Manidipine in hypertensive patients with metabolic syndrome: the MARIMBA study. ( Martínez Martín, FJ, 2009) |
| " The aim of the present study was to examine the effect of a novel ARB, olmesartan, on myocardial function of the left ventricle in patients with mildto-moderate hypertension." | 5.14 | Olmesartan ameliorates myocardial function independent of blood pressure control in patients with mild-to-moderate hypertension. ( Futai, R; Ito, T; Kawanishi, Y; Kitaura, Y; Terasaki, F, 2009) |
| "Double-blind, controlled trial, designed to investigate the effects of 2-months treatment with amlodipine and olmesartan on oxidized non-esterified fatty acids (ox-NEFA), and lipopolysaccharide-stimulated cytokine production in whole blood among 23 hypertensive subjects with the metabolic syndrome." | 5.14 | Treatment of hypertension in metabolic syndrome subjects with amlodipine and olmesartan-effects on oxidized non-esterified free fatty acids and cytokine production. ( Rosenson, RS, 2009) |
| "This report includes a prespecified secondary analysis of the COACH study (Combination of Olmesartan medoxomil and Amlodipine besylate in Controlling High blood pressure) based on baseline hypertension severity and prior antihypertensive medication use and a post hoc efficacy analysis of the subset of patients with baseline mean seated systolic blood pressure (SeSBP) > or =180 mm Hg." | 5.14 | Subgroup analyses of an efficacy and safety study of concomitant administration of amlodipine besylate and olmesartan medoxomil: evaluation by baseline hypertension stage and prior antihypertensive medication use. ( Karki, S; Lee, J; Melino, M; Oparil, S, 2009) |
| "Forty type 2 diabetic patients with hypertension and nephropathy receiving angiotensin receptor II blockers were enrolled and randomly divided into two groups: the efonidipine group was administered efonidipine hydrochloride ethanolate 40 mg/day and the amlodipine group was admin-istered amlodipine besilate 5 mg/day for 12 months." | 5.14 | Protective effects of efonidipine, a T- and L-type calcium channel blocker, on renal function and arterial stiffness in type 2 diabetic patients with hypertension and nephropathy. ( Ban, N; Endo, K; Kawana, H; Miyashita, Y; Nagayama, D; Ohhira, M; Oyama, T; Saiki, A; Sasaki, H; Shirai, K; Yamaguchi, T, 2009) |
| "The aim of this study was to evaluate the effect of baseline heart rate on the efficacy of atenolol-based compared with amlodipine-based therapy in patients with hypertension uncomplicated by coronary heart disease in the ASCOT-BPLA (Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm)." | 5.14 | Baseline heart rate, antihypertensive treatment, and prevention of cardiovascular outcomes in ASCOT (Anglo-Scandinavian Cardiac Outcomes Trial). ( Campbell, NR; Dahlöf, B; Dobson, JE; Poulter, NR; Sever, PS; Wedel, H, 2009) |
| " Patients with essential hypertension and a blood pressure > 140/90 mmHg on ARB monotherapy (losartan 50 mg/day or candesartan 8 mg/day) were randomly assigned to a nifedipine controlled release (CR) group (n = 15) or amlodipine group (n = 11)." | 5.14 | Additive antihypertensive and antihypertrophic effects of long-acting Ca blockers in uncontrolled hypertensive patients with angiotensin-receptor blocker based treatment. ( Ando, C; Inoue, Y; Kodama, S; Mihara, H; Miyoshi, K; Niimura, H; Okamura, K; Sumi, S; Tojyo, H; Tsuchiya, Y; Urata, H; Yamanouchi, Y, 2009) |
| "To assess clinical, hemodynamic efficacy and tolerability of a Fixed Atenolol Amlodipine Combination (FAAC) in patients with arterial 1-3 degree arterial hypertension as mono- or combination therapy." | 5.14 | [An experience of the use of a fixed atenolol amlodipine combination in real clinical practice: results of multicenter Russian study]. ( Andrushchishina, TB; Morozova, TE, 2009) |
| "This multicentre, double-blind, trial in subjects with severe hypertension compared the efficacy and tolerability of two parallel drug regimens: A/B (amlodipine/benazepril: 5/20 or 10/40 mg daily, if necessary) with A (amlodipine: 5 or 10 mg daily, if necessary)." | 5.14 | Comparative efficacy and safety of amlodipine/benazepril combination therapy and amlodipine monotherapy in severe hypertension. ( Hall, D; Hilkert, RJ; Izzo, JL; Purkayastha, D, 2010) |
| "This randomized, double-blind, 14-week study was conducted to compare the efficacy and tolerability of various doses of valsartan +/- hydrochlorothiazide (HCTZ) versus amlodipine +/- HCTZ for maximizing BP control in 1,285 patients with uncontrolled hypertension." | 5.14 | Randomized study to compare valsartan +/- HCTZ versus amlodipine +/- HCTZ strategies to maximize blood pressure control. ( Ferber, P; Papst, CC; Zappe, D, 2009) |
| "To explore the association between CYP3A4 and CYP3A5 gene polymorphisms and blood pressure response to amlodipine among participants from the African-American Study of Kidney Disease and Hypertension Trial randomized to amlodipine (n = 164)." | 5.14 | CYP3A4 and CYP3A5 polymorphisms and blood pressure response to amlodipine among African-American men and women with early hypertensive renal disease. ( Alcaraz, J; Appel, LJ; Bakris, GL; Bhatnagar, V; Brophy, VH; Contreras, G; Garcia, EP; Hiremath, L; Lipkowitz, MS; Middleton, JP; Norris, KC; O'Connor, DT; Richard, E; Wright, J, 2010) |
| "Amlodipine-based antihypertensive combination regimens achieved satisfactory blood pressure control rate in patients with essential hypertension in this patient cohort." | 5.14 | [Effects of amlodipine plus telmisartan or amlodipine plus amiloride regimen on blood pressure control in hypertensive patients: preliminary report of Chinese Hypertension Intervention Efficacy (CHIEF) trial]. ( Deng, Q; Huang, J; Li, W; Lin, SG; Liu, LS; Liu, MB; Ma, LY; Wang, W; Zhang, YQ; Zhu, DL, 2009) |
| "An 8-week trial of amlodipine/valsartan/hydrochlorothiazide (Aml/Val/HCTZ) for moderate or severe hypertension demonstrated more-pronounced blood pressure (BP)-lowering effects compared with dual-component therapies." | 5.14 | Amlodipine/valsartan/hydrochlorothiazide triple combination therapy in moderate/severe hypertension: Secondary analyses evaluating efficacy and safety. ( Calhoun, DA; Crikelair, NA; Glazer, RD; Yen, J, 2009) |
| "Twelve weeks of treatment with losartan significantly reduced proteinuria compared with amlodipine/placebo: losartan -35." | 5.14 | Randomized, double-blind, controlled study of losartan in children with proteinuria. ( Gleim, GW; Lam, C; Loeys, T; Manas, D; Santoro, E; Shahinfar, S; Strehlau, J; Webb, NJ; Wells, TG, 2010) |
| "Our results showed that valsartan/amlodipine 80/5 mg was superior to amlodipine 5 mg or valsartan 80 mg alone in lowering blood pressure and BP control in patients with mild to moderate hypertension not adequately controlled with amlodipine 5 mg or valsartan 80 mg monotherapy." | 5.14 | [Efficacy and safety of the single pill combination of valsartan 80 mg plus amlodipine 5 mg in mild to moderate essential hypertensive patients without adequate blood pressure control by monotherapy]. ( Huang, J; Ke, YN; Zhu, JR, 2009) |
| "To investigate the effect of perindopril, amlodipine and telmisartan on improving the artery stiffness in patients with hypertension." | 5.14 | [Perindopril, amlodipine and telmisartan improve arterial stiffness in patients with hypertension]. ( Cheng, XM; Chu, WW; Du, M; Li, Y; Ma, SM, 2009) |
| " Serum insulin, glucose, C-reactive protein (CRP), lipids, uric acid, YKL-40 and blood pressure were measured and insulin sensitivity was calculated (HOMA) at the beginning and end of each study phase." | 5.14 | Effect of moxonidine and amlodipine on serum YKL-40, plasma lipids and insulin sensitivity in insulin-resistant hypertensive patients-a randomized, crossover trial. ( Majer, J; Masajtis-Zagajewska, A; Nowicki, M, 2010) |
| "The Avoiding Cardiovascular Events through Combination Therapy in Patients Living with Systolic Hypertension (ACCOMPLISH) trial showed that initial antihypertensive therapy with benazepril plus amlodipine was superior to benazepril plus hydrochlorothiazide in reducing cardiovascular morbidity and mortality." | 5.14 | Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial. ( Bakris, GL; Chiang, YT; Dahlöf, B; Jamerson, K; Kelly, RY; Pitt, B; Sarafidis, PA; Shi, V; Staikos-Byrne, L; Velazquez, EJ; Weber, MA; Weir, MR, 2010) |
| "The objective of this study was to compare the effect on ankle edema of adding valsartan (V) or olmesartan (O) to amlodipine (A) in the treatment of hypertension." | 5.14 | Effect of valsartan or olmesartan addition to amlodipine on ankle edema in hypertensive patients. ( Corradi, L; Derosa, G; Fogari, R; Malamani, G; Mugellini, A; Preti, P; Zoppi, A, 2010) |
| "The Anglo-Scandinavian Cardiac Outcomes Trial Blood Pressure Lowering Arm (ASCOT-BPLA) compared amlodipine-based regimens with atenolol-based regimens in 19 257 patients with hypertension and other vascular risk factors and the Medical Research Council (MRC) trial compared atenolol-based and diuretic-based regimens versus placebo in 4396 hypertensive patients aged 65-74 years." | 5.14 | Effects of beta blockers and calcium-channel blockers on within-individual variability in blood pressure and risk of stroke. ( Dahlöf, B; Dobson, JE; Dolan, E; Howard, SC; O'Brien, E; Poulter, NR; Rothwell, PM; Sever, PS, 2010) |
| "We examined blood pressure (BP) and medication over 5 years in 80 hypertensive patients who participated in the Hypertension Control Based on home systolic pressure (HOSP) study that compares effects of strict and mild control of morning home systolic blood pressure (SBP) as well as amlodipine- and losartan-based regimens." | 5.14 | Blood pressure and medication during long-term antihypertensive therapy based on morning home SBP in hypertensive patients: Hypertension Control Based on Home Systolic Pressure (HOSP) substudy. ( Horio, T; Iwashima, Y; Kamide, K; Kawano, Y; Nakamura, S; Yoshihara, F, 2010) |
| " We studied the effects of combining telmisartan and amlodipine on ambulatory BP in patients with stages 1-2 hypertension." | 5.14 | Effects of telmisartan and amlodipine in combination on ambulatory blood pressure in stages 1-2 hypertension. ( Littlejohn, TW; Majul, CR; Mancia, G; Oigman, W; Olvera, R; Schumacher, H; Seeber, M; White, WB, 2010) |
| "The ACCOMPLISH (Avoiding Cardiovascular Events Through COMbination Therapy in Patients Living With Systolic Hypertension) trial compared the outcomes effects of a renin-angiotensin system blocker, benazepril, combined with amlodipine (B+A) or hydrochlorothiazide (B+H)." | 5.14 | Cardiovascular events during differing hypertension therapies in patients with diabetes. ( Bakris, GL; Dahlöf, B; Devereux, RB; Hester, A; Hua, TA; Jamerson, K; Kelly, RY; Kjeldsen, SE; Pitt, B; Velazquez, EJ; Weber, MA; Weir, M, 2010) |
| "To explore if non-concurrent amlodipine dosing results in less drug interaction, the pharmacokinetic profiles, safety and efficacy endpoints were assessed following repeated doses of simvastatin, co-administered concurrently or non-concurrently with amlodipine in patients with coexisting hypertension and hyperlipidemia." | 5.14 | Non-concurrent dosing attenuates the pharmacokinetic interaction between amlodipine and simvastatin. ( Choi, JW; Kim, SH; Lee, H; Lee, SJ; Lim, HE; Park, CG, 2010) |
| "The objective of our study was to compare the effects of a combination therapy with amlodipine and fosinopril administered concomitantly or at different times on blood pressure and circadian blood pressure pattern in subjects with essential hypertension." | 5.14 | Effects of combination therapy with amlodipine and fosinopril administered at different times on blood pressure and circadian blood pressure pattern in patients with essential hypertension. ( Liang, X; Meng, Y; Qi, G; Wu, C; Zhang, Z, 2010) |
| "The aim of this study was to determine whether a triple combination of olmesartan medoxomil (OM), amlodipine besylate (AML), and hydrochlorothiazide (HCTZ) had a clinically significant benefit compared with dual combinations of the individual components in patients with moderate to severe hypertension." | 5.14 | Triple therapy with olmesartan medoxomil, amlodipine besylate, and hydrochlorothiazide in adult patients with hypertension: The TRINITY multicenter, randomized, double-blind, 12-week, parallel-group study. ( Fernandez, V; Heyrman, R; Lee, J; Melino, M; Oparil, S, 2010) |
| "BP control with ramipril or amlodipine could not provide adequate protection for development or progression of atherosclerosis and eccentric type of LVH in nondiabetic HD patients." | 5.14 | Impact of amlodipine or ramipril treatment on left ventricular mass and carotid intima-media thickness in nondiabetic hemodialysis patients. ( Akinci, D; Altun, B; Kahraman, S; Ozer, N; Turgan, C; Yilmaz, R, 2010) |
| "To evaluate the impact of age on the pharmacokinetics and blood pressure (BP) responses of a dihydropyridine (DHP) with large versus small first-pass metabolism in hypertensive subjects, younger (n = 28) and older (n = 35) patients with hypertension were randomized to placebo, felodipine-ER 5 mg/d, or amlodipine 5 mg/d." | 5.14 | Pharmacokinetic and antihypertensive profile of amlodipine and felodipine-ER in younger versus older patients with hypertension. ( Coletta, E; Leenen, FH, 2010) |
| " Nine subjects with hypertension were recruited into a double-blind placebo-controlled randomized three-way crossover study to compare the hemodynamic effects of 7 days of treatment with placebo, amlodipine, or lisinopril." | 5.14 | Carotid artery hemodynamics: observing patient-specific changes with amlodipine and lisinopril by using MR imaging computation fluid dynamics. ( Ariff, BB; Crowe, L; Firmin, DN; Glor, FP; Hughes, AD; Thom, SM; Vennart, W; Xu, XY, 2010) |
| " In a 10-week study of stage 2 hypertension, 320/25 mg valsartan/hydrochlorothiazide (HCTZ) reduced ambulatory BP (ABP) significantly more effectively than 10/25 mg amlodipine/HCTZ." | 5.14 | 24-Hour ambulatory blood pressure response to combination valsartan/hydrochlorothiazide and amlodipine/hydrochlorothiazide in stage 2 hypertension by ethnicity: the EVALUATE study. ( Black, HR; Lacourcière, Y; Purkayastha, D; Samuel, R; Wright, JT; Zappe, D, 2010) |
| "5%) and none of lercanidipine group developed edema; p = 0." | 5.14 | Comparison of changes of body water measured by using bioelectrical impedance analysis between lercanidipine and amlodipine therapy in hypertensive outpatients. ( Sansanayudh, N; Veerayuthvilai, S; Wongwiwatthananukit, S, 2010) |
| "Amlodipine (10 mg daily for 8 weeks) or placebo was given to each 45 patients with mild to moderate hypertension in a randomized, double-blind, placebo-controlled, and parallel study." | 5.14 | Amlodipine improves endothelial function and metabolic parameters in patients with hypertension. ( Ahn, JY; Chung, WJ; Han, SH; Koh, KK; Lee, Y; Shin, EK, 2009) |
| "Twenty-five patients (17 men, age range 24-71 years) with untreated hypertension were randomized to treatment with an amlodipine-based (n = 12) or lisinopril-based (n = 13) regimen in a double-blind, prospective parallel limb trial for 52 weeks." | 5.13 | Effect of antihypertensive treatment on retinal microvascular changes in hypertension. ( Chapman, N; Hughes, AD; Jabbar, AS; Martinez-Perez, ME; McG Thom, SA; Stanton, AV, 2008) |
| "The present study was conducted to compare the renal and vascular protective effects of telmisartan and amlodipine in untreated hypertensive chronic kidney disease (CKD) patients with moderate renal insufficiency." | 5.13 | Comparison of renal and vascular protective effects between telmisartan and amlodipine in hypertensive patients with chronic kidney disease with mild renal insufficiency. ( Inoue, T; Kawagoe, Y; Koide, H; Nakamura, T; Node, K; Suzuki, T; Ueda, Y, 2008) |
| " In this study, we administered amlodipine 5 mg or 10 mg to patients with hypertension in order to compare the efficacy and tolerability of low and high doses, and measured two surrogate markers of hypertensive target organ damage, i." | 5.13 | Effects of strict blood pressure control by a long-acting calcium channel blocker on brain natriuretic peptide and urinary albumin excretion rate in Japanese hypertensive patients. ( Hoshide, S; Ishikawa, J; Ishikawa, S; Kabutoya, T; Kario, K; Shimada, K; Uno, H, 2008) |
| "The ADHT (Amlodipine Diabetic Hypertension Efficacy Response Evaluation Trial) evaluated the efficacy and safety of adding amlodipine to the treatment regimen of patients with hypertension and diabetes who were already receiving either quinapril or losartan as monotherapy." | 5.13 | Blood pressure control with amlodipine add-on therapy in patients with hypertension and diabetes: results of the Amlodipine Diabetic Hypertension Efficacy Response Evaluation Trial. ( Gregg, AM; Kloner, RA; Neutel, J; Roth, EM; Schwartz, B; Shi, H; Thakker, KM; Weinberger, MH; Weiss, R, 2008) |
| "In this population of patients with essential hypertension, the amlodipine/ramipril FDC was associated with significantly reduced ambulatory and office-measured BP compared with amlodipine monotherapy, with the exception of office DBP." | 5.13 | An 18-week, prospective, randomized, double-blind, multicenter study of amlodipine/ramipril combination versus amlodipine monotherapy in the treatment of hypertension: the assessment of combination therapy of amlodipine/ramipril (ATAR) study. ( Amodeo, C; Filho, BL; Gomes, MA; Kohlmann, O; Mion, D; Miranda, RD; Rocha, JC; Saraiva, JF, 2008) |
| "The trial was terminated early due to significant benefits on mortality and stroke associated with the amlodipine-based regimen." | 5.13 | The Anglo-Scandinavian Cardiac Outcomes Trial: blood pressure-lowering limb: effects in patients with type II diabetes. ( Beevers, G; Caulfield, M; Collins, R; Dahlöf, B; Kjeldsen, SE; Kristinsson, A; McInnes, GT; Mehlsen, J; Nieminen, M; O'Brien, E; Ostergren, J; Poulter, NR; Sever, PS; Wedel, H, 2008) |
| " In the present study, we evaluated the effect of treatment with the calcium channel blocker amlodipine or the angiotensin I-converting enzyme inhibitor perindopril on vascular endothelial function and arteriosclerosis in patients with essential hypertension who had already been receiving angiotensin receptor blocker monotherapy." | 5.13 | Beneficial effects of combination therapy with angiotensin II receptor blocker and angiotensin-converting enzyme inhibitor on vascular endothelial function. ( Aota, Y; Iwasaka, T; Maki, K; Morimoto, S; Sakuma, T, 2008) |
| "The aim of the study was to evaluate the effect of valsartan/amlodipine combination on insulin sensitivity in overweight-obese hypertensive patients." | 5.13 | Effect of valsartan addition to amlodipine on insulin sensitivity in overweight-obese hypertensive patients. ( Corradi, L; Derosa, G; Fogari, R; Lazzari, P; Mugellini, A; Preti, P; Santoro, T; Zoppi, A, 2008) |
| "The aim of this study was to compare the efficacy and safety of adding manidipine 20 mg versus amlodipine 10 mg to the treatment of diabetic patients with uncontrolled hypertension and microalbuminuria despite full-dose treatment with a renin-angiotensin system blocker for at least 6 months." | 5.13 | Add-on manidipine versus amlodipine in diabetic patients with hypertension and microalbuminuria: the AMANDHA study. ( Martinez-Martin, FJ; Saiz-Satjes, M, 2008) |
| "Since previous studies have reported a beneficial effect of amlodipine and atorvastatin treatment in experimental atherosclerosis, we aimed to investigate the effect of the combination of both drugs on blood and plaque inflammation in patients with carotid stenosis." | 5.13 | Treatment with amlodipine and atorvastatin has additive effect on blood and plaque inflammation in hypertensive patients with carotid atherosclerosis. ( Blanco-Colio, LM; Egido, J; Madrigal-Matute, J; Martín-Conejero, A; Martín-Ventura, JL; Muñoz-Garcia, B; Ortega, L; Serrano, J; Vega, M, 2008) |
| "The Avoiding Cardiovascular Events Through Combination Therapy in Patients Living With Systolic Hypertension (ACCOMPLISH) trial is the first cardiovascular outcome trial designed to compare initial use of 2 different fixed-dose antihypertensive regimens, benazepril plus hydrochlorothiazide vs benazepril plus amlodipine, on cardiovascular end points in hypertensive patients at high cardiovascular risk secondary to previous major events or presence of diabetes mellitus (DM)." | 5.13 | The diabetes subgroup baseline characteristics of the Avoiding Cardiovascular Events Through Combination Therapy in Patients Living With Systolic Hypertension (ACCOMPLISH) trial. ( Bakris, G; Dahlof, B; Hester, A; Jamerson, K; Pitt, B; Shi, V; Staikos-Byrne, L; Velasquez, E; Weber, M, 2008) |
| "In a randomized, double-blind trial, we assigned 11,506 patients with hypertension who were at high risk for cardiovascular events to receive treatment with either benazepril plus amlodipine or benazepril plus hydrochlorothiazide." | 5.13 | Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. ( Bakris, GL; Dahlöf, B; Gatlin, M; Gupte, J; Hester, A; Jamerson, K; Pitt, B; Shi, V; Velazquez, EJ; Weber, MA, 2008) |
| "Based on results of large-scale controlled trials of irbesartan (I), valsartan (V) and amlodipine (A) (PRIME and MARVAL) we carried out the Markov s modeling of their pharmacoeconomic parameters in arterial hypertension (AH) combined with diabetes mellitus type 2 (DM 2) and microalbuminuria (MAU) projected for 8-years perspective." | 5.13 | [Economics of nephroprotection in arterial hypertension and type 2 diabetes mellitus]. ( Belousov, DIu; Belousov, IuB; Shestakova, MV, 2008) |
| "5-10 mg/d (n=9048), or lisinopril 10-40 mg/d (n=9054) in a randomized double-blind hypertension trial." | 5.13 | Blood pressure control by drug group in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). ( Basile, JN; Bastien, A; Courtney, DL; Cushman, WC; Davis, BR; Einhorn, PT; Ford, CE; Hamilton, BP; Kirchner, K; Louis, GT; Preston, RA; Retta, TM; Vidt, DG; Weiss, RJ; Whelton, PK; Wright, JT, 2008) |
| "To study effects of calcium antagonist amlodipine (normodipine) on blood pressure, heart rate variability (HRV) and carbohydrate metabolism in patients with metabolic syndrome (MS)." | 5.13 | [Effects of amlodipine on blood pressure. Results of cardiovascular tests and heart rate variability in patients with metabolic syndrome]. ( Praskurnichiĭ, EA; Savel'eva, SA; Shevchenko, OP, 2008) |
| "This multicenter, open-label, single-arm trial assessed the efficacy of the combination of amlodipine 10 mg and valsartan 160 mg to provide additional blood pressure reduction and tolerability in patients with moderate hypertension not adequately responding to the combination of ramipril 5 mg and felodipine 5 mg." | 5.13 | Combination of amlodipine 10 mg and valsartan 160 mg lowers blood pressure in patients with hypertension not controlled by an ACE inhibitor/CCB combination. ( Borbas, E; Handrock, R; Klebs, S; Schaetzl, R; Trenkwalder, P, 2008) |
| "To compare the cost effectiveness of an amlodipine-based strategy and an atenolol-based strategy in the treatment of hypertension in the UK and Sweden." | 5.13 | Economic evaluation of ASCOT-BPLA: antihypertensive treatment with an amlodipine-based regimen is cost effective compared with an atenolol-based regimen. ( Buxton, M; Dahlöf, B; Jönsson, B; Kahan, T; Lindgren, P; Poulter, NR; Sever, PS; Wedel, H, 2008) |
| "To investigate the efficacy and safety of single-pill amlodipine/atorvastatin therapy for the simultaneous treatment of hypertension (HTN) and dyslipidemia in African Americans." | 5.13 | Improved attainment of blood pressure and cholesterol goals using single-pill amlodipine/atorvastatin in African Americans: the CAPABLE trial. ( Bruschi, P; Ferdinand, KC; Flack, JM; Jamieson, MJ; Saunders, E; Shi, H; Tarasenko, L; Victor, R; Watson, K, 2008) |
| "The TOlerabilidad de LERcanidipino 20 mg frente a Amlodipino y Nifedipino en CondicionEs normales de uso study was aimed to compare the tolerability of high doses of lercanidipine with amlodipine and nifedipine gastro-intestinal therapeutic system (GITS) in the treatment of hypertension in daily clinical practice." | 5.13 | High doses of lercanidipine are better tolerated than other dihydropyridines in hypertensive patients with metabolic syndrome: results from the TOLERANCE study. ( Barrios, V; Calderón, A; de la Figuera, M; Escobar, C; Honorato, J; Llisterri, JL; Segura, J, 2008) |
| "The aim of this study was to compare the effect of valsartan/amlodipine and atenolol/amlodipine combination in preventing the recurrence of atrial fibrillation (AF) in hypertensive diabetic patients with a history of recent paroxysmal atrial fibrillation." | 5.13 | Comparative evaluation of effect of valsartan/amlodipine and atenolol/amlodipine combinations on atrial fibrillation recurrence in hypertensive patients with type 2 diabetes mellitus. ( Corradi, L; Derosa, G; Fogari, R; Lazzari, P; Mugellini, A; Preti, P; Zoppi, A, 2008) |
| "Our aim in this study was to investigate the changes of serum high-sensitive C-reactive protein (hs-CRP) and uric acid (UA), and evaluate the synergistic effect of amlodipine and atorvastatin on blood pressure and left ventricular remodeling in hypertensive patients with primary hypercholesterolemia." | 5.13 | Synergistic effect of amlodipine and atorvastatin on blood pressure, left ventricular remodeling, and C-reactive protein in hypertensive patients with primary hypercholesterolemia. ( Chen, YD; Ge, CJ; Hu, SJ; Ji, Y; Lu, SZ; Wu, XF, 2008) |
| " The aim of the present study was to evaluate whether endothelial function and oxidative stress differ following long-term antihypertensive treatment with an angiotensin type 1 receptor blocker, valsartan, or a calcium channel blocker, amlodipine, in patients with essential hypertension." | 5.13 | Effects of valsartan or amlodipine on endothelial function and oxidative stress after one year follow-up in patients with essential hypertension. ( Hirooka, Y; Ito, K; Kimura, Y; Sagara, Y; Sunagawa, K, 2008) |
| "The TOLERANCE study was aimed to compare the tolerability of high doses of lercanidipine (20 mg) with that of other frequently used dihydropyridines (amlodipine 10 mg/nifedipine GITS 60 mg) in the treatment of essential hypertension in daily clinical practice." | 5.13 | Tolerability of high doses of lercanidipine versus high doses of other dihydropyridines in daily clinical practice: the TOLERANCE Study. ( Barrios, V; Calderón, A; de la Figuera, M; Escobar, C; Honorato, J; Llisterri, JL; Segura, J, 2008) |
| "In the GENRES study, 208 Finnish men aged 35-60 years with moderate hypertension used amlodipine 5 mg, bisoprolol 5 mg, hydrochlorothiazide 25 mg and losartan 50 mg daily, each for 4 weeks as a monotherapy in a double-blind, randomized, placebo-controlled crossover study; that is, each subject received each type of monotherapy in a random order." | 5.13 | Laboratory tests as predictors of the antihypertensive effects of amlodipine, bisoprolol, hydrochlorothiazide and losartan in men: results from the randomized, double-blind, crossover GENRES Study. ( Donner, K; Hannila-Handelberg, T; Hiltunen, TP; Kontula, K; Miettinen, HE; Paavonen, KJ; Pentikäinen, PJ; Strandberg, T; Suonsyrjä, T; Tikkanen, I; Tilvis, R, 2008) |
| "Population pharmacokinetic models for amlodipine and olmesartan were developed using data collected from 4 phase I studies in healthy volunteers and 1 phase III study in subjects with mild to severe hypertension." | 5.13 | Evaluation of population pharmacokinetics and exposure-response relationship with coadministration of amlodipine besylate and olmesartan medoxomil. ( Carrothers, TJ; Khariton, T; Kshirsagar, S; Lee, J; Rohatagi, S; Salazar, D, 2008) |
| "In moderate hypertension BP normalized in 40 and 44% on monotherapy with lisinopril or amlodipine, respectively, and in 78% patients given lisinopril+amlodipine." | 5.13 | [Efficacy of combined antihypertensive treatment with amlodipine and lisinopril in metabolic syndrome]. ( Praskurnichiĭ, EA; Savel'eva, SA; Shevchenko, OP, 2008) |
| "The aim of this study was to compare the efficacy and tolerability of combinations of olmesartan medoxomil (OM) and amlodipine besylate with those of the component monotherapies in patients with mild to severe hypertension." | 5.13 | The combination of olmesartan medoxomil and amlodipine besylate in controlling high blood pressure: COACH, a randomized, double-blind, placebo-controlled, 8-week factorial efficacy and safety study. ( Chrysant, SG; Heyrman, R; Karki, S; Lee, J; Melino, M, 2008) |
| " This study evaluated the effect of a calcium channel blocker, amlodipine, on LV hypertrophy in patients with hypertension." | 5.12 | Effect of amlodipine on ventricular hypertrophy in hypertension patients: a systematic review and meta-analysis. ( Gao, Y; Yang, P; Zhou, D, 2021) |
| "The Effect of Losartan and Amlodipine on Left Ventricular Diastolic Function in Patients With Mild-to-Moderate Hypertension (J-ELAN) study is a multicenter, prospective, randomized trial designed to assess the effects of losartan and amlodipine on LV diastolic function in hypertensive patients with LV diastolic dysfunction in the absence of systolic dysfunction." | 5.12 | Effect of losartan and amlodipine on left ventricular diastolic function in patients with mild-to-moderate hypertension (J-ELAN): rationale and design. ( , 2006) |
| "The aim of the study was to evaluate the effect of losartan as compared with amlodipine, both associated with amiodarone, in preventing the recurrence of atrial fibrillation (AF) in hypertensive patients with a history of recent paroxysmal atrial fibrillation." | 5.12 | Losartan and prevention of atrial fibrillation recurrence in hypertensive patients. ( Corradi, L; Destro, M; Fogari, E; Fogari, R; Mugellini, A; Rinaldi, A; Zoppi, A, 2006) |
| " Patients with systolic-diastolic or isolated systolic hypertension (n = 1758) received indapamide (1." | 5.12 | Indapamide SR versus candesartan and amlodipine in hypertension: the X-CELLENT Study. ( Asmar, R; Calvo, C; London, G; Schmieder, R, 2006) |
| "To compare rates of coronary heart disease (CHD) and end-stage renal disease (ESRD) events; to determine whether glomerular filtration rate (GFR) independently predicts risk for CHD; and to report the efficacy of first-step treatment with a calcium-channel blocker (amlodipine) or an angiotensin-converting enzyme inhibitor (lisinopril), each compared with a diuretic (chlorthalidone), in modifying cardiovascular disease (CVD) outcomes in high-risk patients with hypertension stratified by GFR." | 5.12 | Cardiovascular outcomes in high-risk hypertensive patients stratified by baseline glomerular filtration rate. ( Barzilay, J; Batuman, V; Davis, BR; Eckfeldt, JH; Farber, MA; Franklin, S; Henriquez, M; Kopyt, N; Louis, GT; Nwachuku, C; Pressel, S; Rahman, M; Saklayen, M; Stanford, C; Walworth, C; Ward, H; Whelton, PK; Wiegmann, T; Wright, JT, 2006) |
| "Olmesartan medoxomil is an angiotensin II receptor blocker with similar antihypertensive efficacy as the calcium channel blocker amlodipine besylate in patients with mild-to-moderate hypertension." | 5.12 | Use of 24-h ambulatory blood pressure monitoring to assess blood pressure control: a comparison of olmesartan medoxomil and amlodipine besylate. ( Chrysant, SG; Marbury, TC; Silfani, TN, 2006) |
| "The African American Study of Kidney Disease and Hypertension was a multicenter trial comparing the effects of 2 levels of blood pressure control (usual or low goal) and initial therapy with metoprolol, ramipril, or amlodipine." | 5.12 | Quality of life in the African American Study of Kidney Disease and Hypertension: effects of blood pressure management. ( Gadegbeku, CA; Greene, T; Hall, Y; Jones, K; Kusek, JW; Lash, JP; Sika, M; Unruh, M; Wang, X, 2006) |
| "The purpose of this study was to compare the efficacy and tolerability of amlodipine orotate with those of amlodipine besylate in Korean patients with mild to moderate hypertension." | 5.12 | Comparison of efficacy and tolerability of amlodipine orotate versus amlodipine besylate in adult patients with mild to moderate hypertension: a multicenter, randomized, double-blind, placebo-controlled, parallel-group, 8-week follow-up, noninferiority tr ( Ahn, TH; Baek, SH; Cho, WH; Hong, SJ; Jeon, HK; Kwan, J; Kyun, J; Lee, KJ; Lim, DS; Yoon, MH, 2006) |
| "To compare the efficacy of amlodipine and valsartan in African-American patients with hypertension using ambulatory blood pressure monitoring (ABPM)." | 5.12 | Randomized, double-blind, crossover comparison of amlodipine and valsartan in african-americans with hypertension using 24-hour ambulatory blood pressure monitoring. ( Aryana, A; Hilleman, DE; Maciejewski, S; Mohiuddin, SM; Mooss, AN; Packard, KA; Reyes, AP, 2006) |
| "To assess antihypertensive efficacy of a low-dose combination of amlodipin with lisinopril in the treatment of patients with arterial hypertension (AH) of the second degree." | 5.12 | [Combined therapy with amlodipin and lisinopril in arterial hypertension: efficacy of a low-dose combination]. ( Davidovich, IM; Petrichko, TA, 2006) |
| "The AVALON study was a randomized, multicenter trial to assess the efficacy and safety of coadministered amlodipine and atorvastatin in patients with hypertension and dyslipidemia." | 5.12 | Efficacy and safety of coadministered amlodipine and atorvastatin in patients with hypertension and dyslipidemia: results of the AVALON trial. ( Bakris, GL; Ferrera, D; Flack, JM; Houston, MC; Lee, E; Messerli, FH; Neutel, JM; Petrella, RJ; Sun, W, 2006) |
| "The objective of this study was to assess the effect of amlodipine-atorvastatin combination on plasma interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-alpha) and insulin sensitivity in normocholesterolemic obese hypertensive patients." | 5.12 | Effects of amlodipine-atorvastatin combination on inflammation markers and insulin sensitivity in normocholesterolemic obese hypertensive patients. ( Ciccarelli, L; Corradi, L; Derosa, G; Fogari, E; Fogari, R; Lazzari, P; Preti, P; Zoppi, A, 2006) |
| "The Japanese Rhythm Management Trial II for Atrial Fibrillation (J-RHYTHM II study) is a randomized comparative evaluation of an angiotensin II type 1 blocker (candesartan) and a dihydropiridine calcium blocker (amlodipine), both combined with antithrombotic therapy, as an antiarrhythmic therapy for the treatment of paroxysmal AF (PAF) associated with hypertension." | 5.12 | Randomized study of angiotensin II type 1 receptor blocker vs dihydropiridine calcium antagonist for the treatment of paroxysmal atrial fibrillation in patients with hypertension. ( Aizawa, Y; Atarashi, H; Fukatani, M; Hirai, M; Hirayama, A; Inoue, H; Kamakura, S; Kato, T; Kodama, I; Koretsune, Y; Kumagai, K; Kurachi, Y; Mitamura, H; Nakaya, H; Ogawa, S; Ohe, T; Ohtsu, H; Okumura, K; Saikawa, T; Sakurai, M; Sugi, K; Watanabe, E; Yamashita, T; Yamazaki, T, 2006) |
| " Forty-three patients with untreated essential hypertension were randomized to receive amlodipine (n=22) or telmisartan (n=21), which were respectively administered at doses of 5 mg and 40 mg once daily in the morning for 24 weeks." | 5.12 | Renal and vascular protective effects of telmisartan in patients with essential hypertension. ( Maki, K; Morimoto, S; Sawada, K; Yano, Y, 2006) |
| "Fourteen patients with primary hypertension participated in a double-blind, cross-over study comparing the effects of 6 weeks of treatment with mibefradil 100 mg daily and amlodipine 10 mg daily." | 5.12 | Long-term calcium antagonist treatment of human hypertension with mibefradil or amlodipine increases sympathetic nerve activity. ( Ekholm, M; Hjemdahl, P; Kahan, T; Lindqvist, M; Melcher, A, 2007) |
| "Patients with essential hypertension (EHT) were randomized to treatment prospectively with losartan (50-100 mg/d) or amlodipine (5-10 mg/d) for 3 months." | 5.12 | The effect of losartan and amlodipine on serum adiponectin in Japanese adults with essential hypertension. ( Fukuoka, T; Higaki, J; Irita, J; Kurata, M; Manabe, S; Miyoshi, K; Murakami, K; Okura, T; Watanabe, S, 2006) |
| "5 mg/day and potassium chloride was compared with that of enalapril 10 mg/day and amlodipine 5 mg/day in patients with mild to moderate primary hypertension." | 5.12 | Efficacy and safety of 24 weeks of therapy with bendroflumethiazide 1.25 mg/day or 2.5 mg/day and potassium chloride compared with enalapril 10 mg/day and amlodipine 5 mg/day in patients with mild to moderate primary hypertension : a multicentre, randomis ( Borrild, N; Rasmussen, S; Vang Andersen, J, 2006) |
| "Amlodipine, a dihydropyridine calcium channel antagonist, is prescribed for the management of angina and hypertension." | 5.12 | Pharmacokinetic and pharmacodynamic characteristics of a new S-amlodipine formulation in healthy Korean male subjects: a randomized, open-label, two-period, comparative, crossover study. ( Ha, MC; Kang, SW; Kim, JS; Kim, KA; Lee, GH; Lee, KR; Lee, OJ; Park, JY; Park, PW; Ryu, JH, 2006) |
| "The aim of this study was to assess the effect of valsartan addition to amlodipine on ankle foot volume (AFV) and pretibial subcutaneous tissue pressure (PSTP), two objective measures of ankle oedema." | 5.12 | Effect of valsartan addition to amlodipine on ankle oedema and subcutaneous tissue pressure in hypertensive patients. ( Derosa, G; Fogari, E; Fogari, R; Lazzari, P; Mugellini, A; Preti, P; Rinaldi, A; Zoppi, A, 2007) |
| "The hypotensive and antiischemic activity of combined therapy with dihydropyridine group (amlodipine) and non-dihydropyridine group (verapamil retard) calcium antagonists (CA) as well as tolerance to this therapy were studied in 43 patients suffering from coronary heart disease (CAD) with II-III functional class exertional angina and II degree essential hypertension during 24 weeks." | 5.12 | [Evaluation of hypotensive and antiischemic effects of a combination of dihydropyridine and non-dihydropyridine calcium antagonists in patients suffering from coronary artery disease with arterial hypertension]. ( Abramova, GN; Berenshteĭn, NV; Burmistrova, LF; Iskendeerov, BG; Lokhina, TV; Shibaeva, TM, 2006) |
| " In this study, we compared the efficacy of azelnidipine to that of amlodipine in lowering morning BP and reducing PR in outpatients with essential hypertension." | 5.12 | Efficacy of azelnidipine on home blood pressure and pulse rate in patients with essential hypertension: comparison with amlodipine. ( Yamagishi, T, 2006) |
| "We compared the effects of nilvadipine and amlodipine on the cognitive function and regional cerebral blood flow (rCBF) in patients with mild cognitive impairment (MCI) and hypertension." | 5.12 | Favourable effects of nilvadipine on cognitive function and regional cerebral blood flow on SPECT in hypertensive patients with mild cognitive impairment. ( Abe, K; Hanyu, H; Hirao, K; Iwamoto, T; Koizumi, K; Shimizu, S, 2007) |
| "To compare the effects of valsartan and amlodipine alone or in combination on plasma norepinephrine (NE) at rest and standing for 10 minutes in patients with hypertension, 47 patients with a sitting diastolic blood pressure (BP) (DBP)>95 mm Hg and<110 mm Hg were randomized in a double-blind fashion to either valsartan or amlodipine." | 5.12 | Effects of valsartan or amlodipine alone or in combination on plasma catecholamine levels at rest and during standing in hypertensive patients. ( Assouline, L; de Champlain, J; Dubé, B; Karas, M; Larochelle, P; LeBlanc, AR; Nadeau, R, 2007) |
| "This study aimed to clarify the impact of telmisartan on fat distribution and insulin sensitivity in the metabolic syndrome." | 5.12 | Effects of telmisartan on fat distribution in individuals with the metabolic syndrome. ( Shimabukuro, M; Shimabukuro, T; Tanaka, H, 2007) |
| "We evaluated whether the changes in the insulin sensitivity observed in hypertensive patients following treatment with an angiotensin II receptor blocker (candesartan) or calcium-channel antagonist (amlodipine) might be related to improvement of the endothelial function (END) and/or plasma level of high-sensitive C-reactive protein (CRP) following such treatment." | 5.12 | Discrepancy between improvement of insulin sensitivity and that of arterial endothelial function in patients receiving antihypertensive medication. ( Koji, Y; Motobe, K; Shiina, K; Tomiyama, H; Yamada, J; Yamashina, A; Yambe, M; Yoshida, M, 2007) |
| "Forty-nine patients with untreated mild to moderate essential hypertension were recruited in a randomized double-blind study to receive a daily dose either of 8 mg candesartan or 5 mg amlodipine for 16 weeks." | 5.12 | Effects of amlodipine and candesartan on oxidized LDL level in patients with mild to moderate essential hypertension. ( Fischer, K; Kampus, P; Muda, P; Ristimäe, T; Teesalu, R; Zilmer, K; Zilmer, M, 2006) |
| "Aim of this study was to evaluate the effect of the telmisartan-amlodipine combination at different doses on urinary albumin excretion rate (UAER) in hypertensive diabetic patients with microalbuminuria." | 5.12 | Effect of telmisartan-amlodipine combination at different doses on urinary albumin excretion in hypertensive diabetic patients with microalbuminuria. ( Derosa, G; Destro, M; Fogari, E; Fogari, R; Lazzari, P; Mugellini, A; Preti, P; Rinaldi, A; Zoppi, A, 2007) |
| "We evaluated the long-term efficacy of losartan and low-dose hydrochlorothiazide combination therapy in the treatment of hypertension." | 5.12 | Long-term efficacy of combination therapy with losartan and low-dose hydrochlorothiazide in patients with uncontrolled hypertension. ( Abe, C; Akashiba, A; Ishimitsu, T; Kameda, T; Matsuoka, H; Minami, J; Takahashi, T, 2007) |
| "This study evaluated the overall safety profile of combination therapy with amlodipine plus valsartan compared with a combination of lisinopril plus hydrochlorothiazide (HCTZ) in patients with stage 2 hypertension (mean sitting diastolic BP [MSDBP] >or=110 and <120 mm Hg) over the short term (6 weeks)." | 5.12 | Tolerability and blood pressure-lowering efficacy of the combination of amlodipine plus valsartan compared with lisinopril plus hydrochlorothiazide in adult patients with stage 2 hypertension. ( Chiang, YT; Fomina, I; Gamboa, R; Glazes, R; Kaczor, J; Kargiannis, S; Poldermans, D; Wernsing, M; Yen, J, 2007) |
| " We studied the effect of a new CCB, azelnidipine, compared with amlodipine, on BRS and ambulatory blood pressure (BP) in newly diagnosed untreated hypertension." | 5.12 | Effects of new calcium channel blocker, azelnidipine, and amlodipine on baroreflex sensitivity and ambulatory blood pressure. ( Eguchi, K; Fukuda, T; Hoshide, S; Ishikawa, J; Kario, K; Numao, T; Shimada, K; Tomizawa, H, 2007) |
| "Two studies were conducted to compare the efficacy of various combinations of amlodipine and valsartan administered once daily with their individual components and placebo in patients with mild to moderate essential hypertension (mean sitting diastolic blood pressure [MSDBP] >/=95 and < 110 mm Hg)." | 5.12 | Two multicenter, 8-week, randomized, double-blind, placebo-controlled, parallel-group studies evaluating the efficacy and tolerability of amlodipine and valsartan in combination and as monotherapy in adult patients with mild to moderate essential hyperten ( Glazer, R; Jin, J; Philipp, T; Pospiech, R; Schneider, H; Smith, TR; Wernsing, M; Yen, J, 2007) |
| "To assess whether treatment with a dihydropyridine calcium antagonist can prevent the development of hypertension and renal dysfunction after heart transplantation, 38 patients receiving cyclosporine for immunosuppression were randomized shortly after cardiac transplantation to placebo or amlodipine 2." | 5.12 | Prevention of renal dysfunction and hypertension by amlodipine after heart transplant. ( Coletta, E; Davies, RA; Leenen, FH, 2007) |
| "Fifty patients with untreated essential hypertension were randomized to receive 5 mg of amlodipine (n = 25) or 10 mg of cilnidipine (n = 25) once daily in the morning for 24 weeks." | 5.12 | Renal and vascular protective effects of cilnidipine in patients with essential hypertension. ( Iwasaka, T; Maki, K; Morimoto, S; Yano, Y, 2007) |
| "5 mg was compared with that of amlodipine, in a multicentre, double-blind, randomised, parallel-group study in patients with mild-to-moderate essential hypertension inadequately controlled by monotherapy." | 5.12 | Efficacy and tolerability of candesartan cilexetil/hydrochlorothiazide and amlodipine in patients with poorly controlled mild-to-moderate essential hypertension. ( Derosa, G; Fogari, R; Mugellini, A, 2007) |
| "Amlodipine and nifedipine CR were administered to 41 patients with essential hypertension for more than 6 weeks each in a randomized open-label crossover study." | 5.12 | Crossover study of amlodipine versus nifedipine CR with home blood pressure monitoring via cellular phone: internet-mediated open-label crossover trial of calcium channel blockers for hypertension (i-TECHO trial). ( Itagaki, K; Nakajima, S; Nakamoto, H; Nishida, E; Ryuzaki, M; Sone, M; Suzuki, Y; Yoshimoto, M, 2007) |
| "The aim of this randomized, double-blind, multicenter 12-week study was to compare the efficacy, safety, and tolerability of a combination of olmesartan medoxomil/hydrochlorothiazide (HCTZ) with that of benazepril plus amlodipine besylate in patients with stage 2 hypertension." | 5.12 | Efficacy and safety of olmesartan medoxomil and hydrochlorothiazide compared with benazepril and amlodipine besylate. ( Dubiel, R; Kereiakes, DJ; Lipka, LJ; Neutel, JM; Punzi, HA; Xu, J, 2007) |
| "Amlodipine besylate has been used in Korea for the treatment of hypertension for >17 years, with well-established efficacy and tolerability." | 5.12 | Results of a phase III, 8-week, multicenter, prospective, randomized, double-blind, parallel-group clinical trial to assess the effects of amlodipine camsylate versus amlodipine besylate in Korean adults with mild to moderate hypertension. ( Ahn, YK; Chung, WS; Kim, HS; Kim, IJ; Kim, JJ; Kim, SH; Kim, YD; Lee, JW; Lim, DS; On, YK; Park, JB; Seo, HS; Shin, EK; Yang, JY; Yoon, MH, 2007) |
| " The Respond trial assessed whether combining amlodipine to treat hypertension and atorvastatin to treat dyslipidemia affected the action of either monotherapy." | 5.12 | A randomized, placebo-controlled trial to evaluate the efficacy, safety, and pharmacodynamic interaction of coadministered amlodipine and atorvastatin in 1660 patients with concomitant hypertension and dyslipidemia: the respond trial. ( Dykstra, G; Gillen, D; Harvey, P; Herfert, O; Jukema, JW; Preston, RA; Sun, F, 2007) |
| "The aim of this study was to evaluate the efficacy and tolerability of a new fixed-dose combination (FDC) of telmisartan 40 mg + amlodipine 5 mg (T+A) compared with amlodipine 5-mg monotherapy (A) in adult Indian patients with stage II hypertension." | 5.12 | Results of a comparative, phase III, 12-week, multicenter, prospective, randomized, double-blind assessment of the efficacy and tolerability of a fixed-dose combination of telmisartan and amlodipine versus amlodipine monotherapy in Indian adults with stag ( Bagchi, A; Baliga, VP; Bollmall, C; Kinagi, SB; Sharma, A; Sharma, YK, 2007) |
| "Amlodipine is an effective treatment for hypertension." | 5.11 | Hemodynamic effects of amlodipine, bisoprolol, and lisinopril in hypertensive patients after liver transplantation. ( Alexander, GJ; Brown, MJ; Byrne, CD; Neal, DA; Wilkinson, IB, 2004) |
| "The aim of this study was to compare the time-effect profiles of a once-daily administration of valsartan and amlodipine, each given alone or in combination with hydrochlorothiazide, in terms of ambulatory blood pressure (BP) and heart rate in elderly patients with isolated systolic hypertension." | 5.11 | Comparison of the effects on 24-h ambulatory blood pressure of valsartan and amlodipine, alone or in combination with a low-dose diuretic, in elderly patients with isolated systolic hypertension (Val-syst Study). ( Ambrosia, GB; Caiazza, A; Malacco, E; Mugellini, A; Palatini, P; Santonastaso, M; Spagnuolo, V, 2004) |
| "In the treatment of hypertension in subjects of African origins, although hydrochlorothiazide (HCTZ) is not as effective as calcium channel blockers, indapamide is superior to HCTZ." | 5.11 | Effect of slow-release indapamide and perindopril compared with amlodipine on 24-hour blood pressure and left ventricular mass in hypertensive patients of African ancestry. ( Candy, GP; Essop, MR; Hlatshwayo, NM; Kachope, J; Libhaber, CD; Libhaber, EN; Norton, GR; Puane, MO; Sareli, P; Sliwa, K; Woodiwiss, AJ, 2004) |
| " Using treatment-specific probabilities derived from the Irbesartan in Diabetic Nephropathy Trial (IDNT), the cost effectiveness of treating patients with hypertension, type II diabetes and nephropathy with irbesartan, amlodipine or control was calculated using a Markov model." | 5.11 | An economic evaluation of the Irbesartan in Diabetic Nephropathy Trial (IDNT) in a UK setting. ( Annemans, L; Bilous, RW; Lamotte, M; Palmer, AJ; Rodby, RA; Roze, S, 2004) |
| "To compare the effects of the angiotensin receptor blocker (ARB) valsartan versus the calcium channel blocker amlodipine, reactive oxygen species (ROS) formation by monocytes, C-reactive protein (CRP), and left ventricular (LV) mass were studied in 104 hypertensive patients with left ventricular hypertrophy (LVH)." | 5.11 | Comparative effects of valsartan versus amlodipine on left ventricular mass and reactive oxygen species formation by monocytes in hypertensive patients with left ventricular hypertrophy. ( Asada, A; Maeda, K; Nakamura, M; Watanabe, T; Yasunari, K; Yoshikawa, J, 2004) |
| "This multicenter, double-blind, 12-week study randomized 364 patients with stage 2 hypertension to fixed-dose combination therapy with amlodipine besylate/benazepril HCl (5/20 mg/d titrated to 10/20 mg/d) or amlodipine besylate monotherapy (5 mg/d titrated to 10 mg/d)." | 5.11 | Initial angiotensin-converting enzyme inhibitor/calcium channel blocker combination therapy achieves superior blood pressure control compared with calcium channel blocker monotherapy in patients with stage 2 hypertension. ( Baron, M; Jamerson, KA; Jean-Louis, L; Nwose, O; Purkayastha, D; Schofield, L, 2004) |
| "15?245 patients, aged 50 years or older with treated or untreated hypertension and high risk of cardiac events participated in a randomised, double-blind, parallel-group comparison of therapy based on valsartan or amlodipine." | 5.11 | Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. ( Brunner, HR; Ekman, S; Hansson, L; Hua, T; Julius, S; Kjeldsen, SE; Laragh, J; McInnes, GT; Mitchell, L; Plat, F; Schork, A; Smith, B; Weber, M; Zanchetti, A, 2004) |
| "To demonstrate that calcium channel blockers can improve insulin resistance clinically, we investigated the effects of the calcium channel blockers, amlodipine, manidipine and cilnidipine on serum levels of steroid hormones and insulin." | 5.11 | Effects of the long-acting calcium channel blockers, amlodipine, manidipine and cilnidipine on steroid hormones and insulin resistance in hypertensive obese patients. ( Miyachi, Y; Ueshiba, H, 2004) |
| "Amlodipine increased NO production, at least in the pulmonary circulation, in patients with essential hypertension." | 5.11 | Amlodipine increases nitric oxide production in exhaled air during exercise in patients with essential hypertension. ( Hirata, Y; Hirose, K; Iwasawa, K; Kato, M; Matsumoto, A; Nagai, R; Nakajima, T; Sugiura, S; Takenaka, K; Yamashita, H, 2004) |
| "The effect of a once daily night-time (10 pm) graded-release diltiazem (GRD) on early morning blood pressure (BP), heart rate (HR), and rate-pressure product (RPP) were compared with the effect of morning (8 am) amlodipine in 262 African American individuals with hypertension." | 5.11 | Antihypertensive efficacy of night-time graded-release diltiazem versus morning amlodipine in African Americans. ( Albert, KS; Bohannon, K; Gana, TJ; Pascual, LG; Sica, DA; Wright, JT, 2004) |
| "The aim of this study was to evaluate the effect of the amlodipine-atorvastatin combination on plasma tissue plasminogen activator (t-PA) and plasminogen activator inhibitor type 1 (PAI-1) activity in hypercholesterolemic, hypertensive patients with insulin resistance." | 5.11 | Effect of amlodipine-atorvastatin combination on fibrinolysis in hypertensive hypercholesterolemic patients with insulin resistance. ( Derosa, G; Fogari, E; Fogari, R; Lazzari, P; Mugellini, A; Rinaldi, A; Zoppi, A, 2004) |
| " A new clinical trial, GUARD (Gauging Albuminuria Reduction With Lotrel in Diabetic Patients With Hypertension), is designed to compare the change in urinary albumin to creatinine ratio after 1 year of initial treatment with either amlodipine besylate/benazepril HCl or benazepril HCl/hydrochlorothiazide." | 5.11 | Rationale and design of a study comparing two fixed-dose combination regimens to reduce albuminuria in patients with type II diabetes and hypertension. ( Bakris, GL; McCullough, PA; Toto, RD, 2005) |
| "The aim of the study was to compare the antihypertensive effects and the duration of action of telmisartan, amlodipine and ramipril in patients with mild-to-moderate hypertension using ambulatory blood pressure (ABP) monitoring." | 5.11 | A comparison of the efficacy and duration of action of telmisartan, amlodipine and ramipril in patients with confirmed ambulatory hypertension. ( de Champlain, J; Lacourcière, Y; Lamarre-Cliche, M; Larochelle, P; Poirier, L, 2004) |
| "This study compared the efficacy, tolerability, and duration of antihypertensive effect of amlodipine besylate and enalapril in Chinese patients with hypertension, including elderly patients with isolated systolic hypertension." | 5.11 | Randomized, controlled, parallel-group comparison of ambulatory and clinic blood pressure responses to amlodipine or enalapril during and after treatment in adult chinese patients with hypertension. ( Chau, YM; Critchley, JA; Thomas, GN; Tomlinson, B; Woo, J, 2004) |
| "Treatment of uncomplicated essential hypertension using amlodipine-based anti-hypertensive therapy results in a reversal of the platelet morphology abnormalities and indices of platelet activation." | 5.11 | Platelet morphology and plasma indices of platelet activation in essential hypertension: effects of amlodipine-based antihypertensive therapy. ( Blann, AD; Lip, GY; Nadar, S, 2004) |
| "The aim of this study was to determine whether the use of clinic BP in the Valsartan and Amlodipine for the Treatment of Isolated Systolic Hypertension in the Elderly (Val-Syst) study accurately identified those elderly outpatients with systolic hypertension who had true 24-hour elevations in BP, as well as those who required dose increases in antihypertensive therapy during follow-up." | 5.11 | Ambulatory versus clinic blood pressure for the assessment of anti hypertensive efficacy in clinical trials: insights from the Val-Syst Study. ( Bertocchi, F; Dorigatti, F; Ferrara, R; Mugellini, A; Palatini, P; Spagnuolo, V; Varì, N, 2004) |
| "The aim of this study was to follow up the effect of an 8-week treatment with amlodipine given alone or in combination with hormone replacement therapy (HRT) on blood pressure and active renin in postmenopausal women with mild to moderate arterial hypertension using both conventional clinical blood pressure measurements and ambulatory blood pressure monitoring." | 5.11 | Ambulatory blood pressure monitoring and active renin in menopausal women treated with amlodipine and hormone replacement therapy. ( Atanassova, I; Borissova, AM; Doncheva, N; Genov, N; Kamenov, Z; Nachev, E; Orbetzova, M; Shigarminova, R; Stoynev, A; Zacharieva, S; Zingilev, D, 2004) |
| "5 mg of S-Amlodipine with 5 mg of Amlodipine in the treatment of mild to moderate hypertension in a double blind, double dummy, randomized, comparative clinical trial." | 5.11 | Multicentric, clinical trial of S-Amlodipine 2.5 mg versus Amlodipine 5 mg in the treatment of mild to moderate hypertension--a randomized, double-blind clinical trial. ( Kerkar, PG; Manade, VG; Pathak, L, 2004) |
| "Forty-nine middle-aged patients with untreated stage I-II essential hypertension were recruited in a randomized double-blind double-dummy study to receive a daily dose either of 8 mg candesartan (n = 25) or 5 mg amlodipine (n = 24) for 16 weeks." | 5.11 | Effect of antihypertensive treatment with candesartan or amlodipine on glutathione and its redox status, homocysteine and vitamin concentrations in patients with essential hypertension. ( Fischer, K; Kairane, C; Kampus, P; Muda, P; Ristimäe, T; Teesalu, R; Zilmer, K; Zilmer, M, 2005) |
| "Associations between baseline proteinuria and proteinuria reduction by either irbesartan, amlodipine, or control for similar decrements in blood pressure and the cumulative incidence of renal end points were examined using the Kaplan-Meier method in patients enrolled in the Irbesartan Diabetic Nephropathy Trial." | 5.11 | Proteinuria reduction and progression to renal failure in patients with type 2 diabetes mellitus and overt nephropathy. ( Atkins, RC; Braden, G; Briganti, EM; Champion de Crespigny, PJ; DeFerrari, G; Drury, P; Hunsicker, LG; Lewis, EJ; Lewis, JB; Locatelli, F; Wiegmann, TB, 2005) |
| "Renin, aldosterone, and their interrelation are influenced by circadian rhythms, telmisartan, ramipril, and amlodipine in patients with essential hypertension." | 5.11 | Effects of circadian rhythms, posture, and medication on renin-aldosterone interrelations in essential hypertensives. ( de Champlain, J; Karas, M; Lacourcière, Y; Lamarre-Cliche, M; Larochelle, P; Poirier, L, 2005) |
| "In order to evaluate therapeutic effects of amlodipine on intravascular thrombocyte activity (ITA) in patients having arterial hypertension (AH) with metabolic syndrome (MS), 20 patients were treated with amlodipine for 1 month." | 5.11 | [Effect of amlodipine on intravascular thrombocyte activity in patients with arterial hypertension and metabolic syndrome]. ( Gromnatskiĭ, NI; Medvedev, IN, 2005) |
| " Hypertensive participants 55 years or older with at least 1 other coronary heart disease risk factor were randomized to receive chlorthalidone, amlodipine, or lisinopril for a mean of 4." | 5.11 | Renal outcomes in high-risk hypertensive patients treated with an angiotensin-converting enzyme inhibitor or a calcium channel blocker vs a diuretic: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). ( Barzilay, J; Batuman, V; Davis, BR; Eckfeldt, JH; Farber, M; Henriquez, M; Kopyt, N; Louis, GT; Nwachuku, C; Pressel, S; Rahman, M; Saklayen, M; Stanford, C; Walworth, C; Ward, H; Whelton, PK; Wiegmann, T; Wright, JT, 2005) |
| "An open-label drug substitution study showed that controlled-release isradipine (Dynacirc-CR) can be safely substituted for amlodipine on a mg-for-mg basis in patients with mild-to-moderate hypertension." | 5.11 | Comparison of blood pressure control with amlodipine and controlled-release isradipine: an open-label, drug substitution study. ( Ganz, M; Mokabberi, R; Sica, DA, 2005) |
| "Over the course of the long-term, 12-month follow-up study, indapamide SR was shown to be an effective and well tolerated antihypertensive therapy, even after a switch from amlodipine or hydrochlorothiazide, in patients aged 65 years-80 years with systolo-diastolic hypertension (SDH) or ISH." | 5.11 | Evaluation of long-term efficacy and acceptability of indapamide SR in elderly hypertensive patients. ( Abate, G; Calvo-Gomez, C; Emeriau, JP; Knauf, H; Leonetti, G; Pujadas, JO, 2005) |
| "The African American Study of Kidney Disease and Hypertension examined the effect on renal function decline of 2 blood pressure (BP) goals (low mean arterial pressure [MAP] < or =92 versus usual MAP 102 to 107 mm Hg) and 3 antihypertensives (ramipril versus amlodipine versus metoprolol)." | 5.11 | Blood pressure control, drug therapy, and kidney disease. ( Agodoa, LY; Cheek, D; Contreras, G; Dowie, D; Greene, T; Junco, G; Lash, J; Lipkowitz, M; Miller, ER; Ojo, A; Sika, M; Toto, RD; Wilkening, B, 2005) |
| "To estimate the influence of therapy with amlodipine (A) or lacidipine (L) on heart rate variability (HRV) time and frequency domain parameters in hypertensive patients with stable angina pectoris and isolated left ventricular diastolic dysfunction." | 5.11 | Effects of amlodipine and lacidipine on heart rate variability in hypertensive patients with stable angina pectoris and isolated left ventricular diastolic dysfunction. ( Brazdzionyte, J; Jurkevicius, R; Zabiela, V; Zaliūnas, R, 2005) |
| "The aim of this study was to compare the efficacy and tolerability of amlodipine maleate with those of amlodipine besylate in Korean patients with mild to moderate hypertension." | 5.11 | Results of a multicenter, 8-week, parallel-group, randomized,double-blind, double-dummy, Phase III clinical trial to evaluate the efficacy and tolerability of amlodipine maleate versus amlodipine besylate in Korean patients with mild to moderate hypertens ( Chung, N; Han, DS; Kim, HS; Kim, YJ; Kwon, J; Park, S; Yoon, JH, 2005) |
| "The primary objective of this study was to determine whether combination therapy with valsartan 160 mg plus hydrochlorothiazide (HCTZ) 25 mg OD would be more effective than monotherapy with amlodipine 10 mg OD in reducing systolic blood pressure (SBP) in patients with moderate (stage II) hypertension and > or =1 other cardiovascular risk factor or concomitant condition." | 5.11 | Efficacy and tolerability of combination therapy with valsartan plus hydrochlorothiazide compared with amlodipine monotherapy in hypertensive patients with other cardiovascular risk factors: the VAST study. ( Bönner, G; Heintz, D; Kandra, A; Khder, Y; Malacco, E; Ruilope, LM, 2005) |
| "Fifty-nine hypertensive patients with associated coronary artery disease (stable angina pectoris) and isolated diastolic dysfunction were randomized to receive amlodipine (30 patients) or lacidipine (29 patients) for 4 weeks." | 5.11 | Effect of amlodipine and lacidipine on left ventricular diastolic and long axis functions in arterial hypertension and stable angina pectoris. ( Brazdzionyte, J; Jurkevicus, R; Zabiela, V; Zaliunas, R, 2005) |
| "These results suggest that in type 2 diabetes with overt nephropathy, 24-h blood pressure regulation alone is inadequate to reduce macroalbuminuria and additional effects of losartan are crucial for antiproteinuric action." | 5.11 | Effects of losartan and amlodipine on urinary albumin excretion and ambulatory blood pressure in hypertensive type 2 diabetic patients with overt nephropathy. ( Ando, D; Hirawa, N; Tochikubo, O; Umemura, S; Yasuda, G, 2005) |
| "The goal of this study was to compare the antihypertensive effect and tolerability of amlodipine adipate with those of amlodipine besylate in patients with mild to moderate hypertension." | 5.11 | Clinic blood pressure responses to two amlodipine salt formulations, adipate and besylate, in adult Korean patients with mild to moderate hypertension: a multicenter, randomized, double-blind, parallel-group, 8-week comparison. ( Chong-Yun, R; Heung-Sun, K; Jin-Ok, J; Joo, SJ; Joon-Han, S; Ju, AK; Kang, HJ; Kang, JH; Kim, KS; Kim, MH; Koo, BK; Lee, HY; Lim, DK; Oh, BH; Park, KM; Park, SH; Park, SY; Ro, YM; Seo, HS; Woong, CJ; Yeon, KJ; Yoon, J, 2005) |
| "The antihypertensive efficacy of nebivolol and amlodipine and their tolerability were compared in a multicentre, randomized, active-controlled, double-blind parallel-group trial in elderly patients with mild to moderate essential arterial hypertension." | 5.10 | Nebivolol vs amlodipine as first-line treatment of essential arterial hypertension in the elderly. ( Gil-Extremera, B; Maldonato, A; Mazza, A; Pessina, AC; Toutouzas, T, 2002) |
| "We studied differences in the effects of a long-acting angiotensin-converting enzyme (ACE) inhibitor (temocapril) and a long-acting calcium channel blocker (amlodipine) on ventricular ectopic beats (VEB) in relation to sympathetic nerve activity in 46 patients with essential hypertension." | 5.10 | Differential effects of a long-acting angiotensin converting enzyme inhibitor (temocapril) and a long-acting calcium antagonist (amlodipine) on ventricular ectopic beats in older hypertensive patients. ( Eguchi, K; Kario, K; Shimada, K, 2002) |
| "Three hundred thirty-two patients with type 2 diabetes and microalbuminuria, with or without hypertension, were randomly assigned to 80 mg/d valsartan or 5 mg/d amlodipine for 24 weeks." | 5.10 | Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect. ( Viberti, G; Wheeldon, NM, 2002) |
| " The patients in the hypertension group were treated with amlodipine, then examined again." | 5.10 | Improvement of endothelial function by amlodipine and vitamin C in essential hypertension. ( Choi, YS; Kim, CH; Lee, MM; Oh, BH; On, YK; Park, YB; Sohn, DW, 2002) |
| "The present study was conducted among 719 patients enrolled by 109 doctors to evaluate the efficacy and tolerability of the combination of losartan potassium and amlodipine besylate in Indian patients with mild to moderate hypertension." | 5.10 | Efficacy and safety of losartan-amplodipine combination--an Indian postmarketing surveillance experience. ( Gokhale, N; Pawar, D; Shahani, S, 2002) |
| "We selected 453 hypertensive patients with type 2 diabetes and microalbuminuria and randomized them to amlodipine (5 to 15 mg/day), fosinopril (10 to 30 mg/day), or amlodipine plus fosinopril (5/10 to 15/30 mg/day) for a 3-month titration period." | 5.10 | Effects of amlodipine fosinopril combination on microalbuminuria in hypertensive type 2 diabetic patients. ( Corradi, L; Derosa, G; Fogari, R; Lazzari, P; Marasi, G; Mugellini, A; Pasotti, C; Poletti, L; Preti, P; Rinaldi, A; Voglini, C; Zoppi, A, 2002) |
| "The efficacy and safety of nisoldipine-extended release (ER) and amlodipine were compared in a 6-week multicenter, randomized, double-blind, double-dummy, parallel group, titration-to-effect trial in patients with stage 1 to 2 systemic hypertension (90 to 109 mm Hg diastolic blood pressure [BP]) and chronic stable angina pectoris." | 5.10 | Comparison of effects of nisoldipine-extended release and amlodipine in patients with systemic hypertension and chronic stable angina pectoris. ( Bittar, N; Cooper-DeHoff, RM; Hutchinson, HG; Koren, M; Michelson, EL; Minkwitz, MC; Pepine, CJ; Thadani, U; Weiss, RJ, 2003) |
| "To evaluate the effect of losartan and amilodipine on the platelet activation and renal function, and to study the relationship between the platelet activation and hypertensive renal damage in patients with mild and moderate hypertension." | 5.10 | [Effect of losartan and amilodipine on the platelet activation and renal function in patients with mild and moderate hypertension]. ( Xie, XM; Yu, GL; Zhou, P, 2002) |
| "The aim of this study was to evaluate the effect of benazepril addition to amlodipine antihypertensive treatment on ankle-foot volume (AFV) and pretibial subcutaneous tissue pressure (PSTP), two objective measures of ankle oedema." | 5.10 | Effect of benazepril addition to amlodipine on ankle oedema and subcutaneous tissue pressure in hypertensive patients. ( Fogari, R; Malamani, GD; Mugellini, A; Preti, P; Rinaldi, A; Vanasia, A; Zoppi, A, 2003) |
| "Eplerenone is a highly selective aldosterone blocker, which is under development for the treatment of hypertension and heart failure." | 5.10 | Effects of the selective aldosterone blocker eplerenone versus the calcium antagonist amlodipine in systolic hypertension. ( Duprez, D; Krause, S; Kuse-Hamilton, J; Roniker, B; St Hillaire, R; Weber, MA; White, WB, 2003) |
| "High-dose losartan increases rHuEPO requirement and should be reserved for dialysis patients with hypertension uncontrollable with other antihypertensive medications." | 5.10 | The effect of high dose losartan on erythropoietin resistance in patients undergoing haemodialysis. ( Bilen, H; Cetinkaya, R; Keles, S; Odabas, AR; Selcuk, Y, 2003) |
| "A 90-day, multicenter, randomized, double-blind, parallel-group study was conducted to compare the efficacy of amlodipine (once a day) with nicardipine (two to three times a day), in the treatment of isolated systolic hypertension (ISH) in the elderly." | 5.10 | Randomized, comparative, double-blind study of amlodipine vs. nicardipine as a treatment of isolated systolic hypertension in the elderly. ( Bernaud, C; Carre, A; Clerson, P; Emeriau, JP; Jaboureck, O; Mounier-Véhier, C, 2002) |
| "In postmenopausal females with mild to moderate hypertension the oedema formation of Lercanidipine was significantly less than that of Amlodipine, despite no significant differences in the antihypertensive effect." | 5.10 | Quantification of leg oedema in postmenopausal hypertensive patients treated with lercanidipine or amlodipine. ( Helberg, S; Istad, H; Lund-Johansen, P; Madsbu, S; Risberg, K; Rønnevik, PK; Stranden, E; Wessel-Aas, T, 2003) |
| "The aim of this study was to observe the effect of an 8-week treatment with amlodipine, alone or in combination with hormone replacement therapy (HRT), on blood pressure (BP), serum osteocalcin, bone-specific alkaline phosphatase (B-ALP) and urine deoxypiridinoline in postmenopausal osteoporotic women with mild-to-moderate arterial hypertension." | 5.10 | Effect of amlodipine and hormone replacement therapy on blood pressure and bone markers in menopause. ( Atanassova, I; Borissova, AM; Doncheva, N; Kamenov, Z; Nachev, E; Orbetzova, M; Shigarminova, R; Stoynev, A; Zacharieva, S, 2003) |
| " The aim of the present study was to compare the effects of losartan and amlodipine on proteinuria, as well as on serum and urine TGF-beta1 levels in IgA nephropathy patients with hypertension and proteinuria." | 5.10 | Effect of losartan and amlodipine on proteinuria and transforming growth factor-beta1 in patients with IgA nephropathy. ( Choi, KH; Choi, S; Goo, YS; Ha, SK; Han, DS; Kang, SW; Lee, HY; Park, HC; Xu, ZG, 2003) |
| " This randomized, double-blind study compared the antihypertensive efficacy of the starting dose of olmesartan medoxomil with that of the calcium channel blocker amlodipine besylate (amlodipine) in subjects with mild-to-moderate hypertension." | 5.10 | Antihypertensive efficacy and safety of olmesartan medoxomil compared with amlodipine for mild-to-moderate hypertension. ( Chrysant, SG; Marbury, TC; Robinson, TD, 2003) |
| "One hundred eighteen patients with mild-to-moderate essential arterial hypertension were randomized to treatment with 10 mg/d of amlodipine (group 1), 20 mg/d of quinapril (group 2), or 2 x 50 mg/d of losartan (group 3)." | 5.10 | Effect of amlodipine, quinapril, and losartan on pulse wave velocity and plasma collagen markers in patients with mild-to-moderate arterial hypertension. ( Kawecka-Jaszcz, K; Klocek, M; Rajzer, M, 2003) |
| "To compare the effectiveness, safety and tolerability of once-daily nifedipine and amlodipine treatment in patients with mild-to-moderate essential hypertension." | 5.10 | Treatment of mild-to-moderate hypertension with calcium channel blockers: a multicentre comparison of once-daily nifedipine GITS with once-daily amlodipine. ( Caglar, N; Canberk, A; Deger, N; Demirtas, M; Dortlemez, H; Kes, S; Kiliccioglu, B; Kozan, O; Ovunc, K; Turkoglu, C, 2003) |
| "In patients aged > or =65 years with hypertension in long-term care facilities, a change from high-dose CCB monotherapy or CCB/ACE-inhibitor dual therapy to fixed-dose combination amlodipine/benazepril therapy significantly reduced drug costs and the incidence of adverse events and maintained blood-pressure control." | 5.10 | Results of a pilot pharmacotherapy quality improvement program using fixed-dose, combination amlodipine/benazepril antihypertensive therapy in a long-term care setting. ( DiCesare, J; Doan, QD; Floyd, K; Sacco, P; Sapienza, S, 2003) |
| " We sought to compare the magnitude of the distress induced by a widely used calcium channel blocking agent, amlodipine, and a new aldosterone antagonist, eplerenone, in patients treated for systolic hypertension." | 5.10 | Symptoms and the distress they cause: comparison of an aldosterone antagonist and a calcium channel blocking agent in patients with systolic hypertension. ( Akhras, KS; Anderson, R; Bittman, RM; Hollenberg, NK; Krause, SL; Williams, GH, 2003) |
| "The long-term effects of amlodipine, a calcium channel blocker, were examined in patients with moderate to severe hypertension." | 5.10 | Amlodipine improves vascular function in patients with moderate to severe hypertension. ( Ohtsuka, S; Oyake, Y; Yamaguchi, I; Yamazaki, A, 2003) |
| "This study evaluates the efficacy of the new dihydropyridine calcium antagonist nisoldipine extended-release (ER) compared to amlodipine on ambulatory and clinic blood pressures (BP) and heart rates in African American patients with hypertension." | 5.10 | Comparative efficacy and safety of nisoldipine extended-release (ER) and amlodipine (CESNA-III study) in African American patients with hypertension. ( Ferdinand, K; Noveck, RJ; Saunders, E; White, WB, 2003) |
| "After confirming hypertension in the absence of antihypertensive treatment, blood pressure control was achieved by administration of amlodipine at individually adjusted doses." | 5.10 | One year follow-up of hormone replacement therapy with percutaneous estradiol and low-dose vaginal natural progesterone in women with mild to moderate hypertension. ( Castro, I; Reis, FM; Ruschel, S; Spritzer, PM; Vilodre, LC; Vitola, D; Wender, MC, 2003) |
| "Amlodipine could be more appropriate than tertatolol for CsA-induced hypertension and hyperuricaemia in renal transplant recipients." | 5.10 | Amlodipine reduces cyclosporin-induced hyperuricaemia in hypertensive renal transplant recipients. ( Bernaud, C; Chanard, J; Hurault de Ligny, B; Lavaud, S; Moulin, B; Toupance, O, 2003) |
| "To compare the effect of amlodipine, a prototype dihydropyridine calcium-channel blocker with lercanidipine, a newer dihydropyridine compound with lipophilic properties, on dependent oedema generation and interference with skin blood flow vasomotion in hypertensive patients." | 5.10 | Heterogeneous effect of calcium antagonists on leg oedema: a comparison of amlodipine versus lercanidipine in hypertensive patients. ( Balbarini, A; Dell'Omo, G; Mariani, M; Menegato, A; Nuti, M; Pedrinelli, R, 2003) |
| " This study compared LVH regression during treatment with the selective aldosterone blocker eplerenone, enalapril, and their combination in patients with hypertension." | 5.10 | Effects of eplerenone, enalapril, and eplerenone/enalapril in patients with essential hypertension and left ventricular hypertrophy: the 4E-left ventricular hypertrophy study. ( Burns, D; Kleiman, J; Krause, S; Phillips, RA; Pitt, B; Reichek, N; Roniker, B; Willenbrock, R; Williams, GH; Zannad, F, 2003) |
| "The aim of this study was to comparatively assess the effects of irbesartan and amlodipine monotherapies on left ventricular mass index (LVMI) in patients with mild to moderate untreated hypertension and echocardiographically determined left ventricular hypertrophy (LVH)." | 5.10 | Comparative effects of irbesartan versus amlodipine on left ventricular mass index in hypertensive patients with left ventricular hypertrophy. ( Fedele, F; Fera, MS; Ferri, FM; Gaudio, C; Giovannini, M; Pannarale, G; Puddu, PE; Vittore, A; Vizza, CD, 2003) |
| "0 years) with mild to moderate essential hypertension were included in a randomized, double-blind study to receive either valsartan (80 to 160 mg) or amlodipine (5 to 10 mg)." | 5.10 | Direct comparison of the effects of valsartan and amlodipine on renal hemodynamics in human essential hypertension. ( Delles, C; Handrock, R; Klingbeil, AU; Schmieder, RE; Schneider, MP; Weidinger, G, 2003) |
| " Patients with essential hypertension were randomly assigned to receive either amlodipine, cilnidipine or nifedipine CR (which does not block N-type calcium channels) for 6 months." | 5.10 | Effects of calcium channel antagonists on left ventricular hypertrophy and diastolic function in patients with essential hypertension. ( Shigematsu, M; Takami, T, 2003) |
| "This study compared the risk/benefit profiles of valsartan and amlodipine in elderly patients who have isolated systolic hypertension (ISH)." | 5.10 | A randomized, double-blind, active-controlled, parallel-group comparison of valsartan and amlodipine in the treatment of isolated systolic hypertension in elderly patients: the Val-Syst study. ( Borgnino, C; Capuano, V; Malacco, E; Palatini, P; Spagnuolo, V; Varì, N, 2003) |
| " We investigated the effects on 24-h ambulatory blood pressure (ABP) of the angiotensin-receptor blocker, valsartan, in combination with hydrochlorothiazide (HCTZ), compared with the calcium-channel blocker amlodipine in a Brazilian population in a multicentre, double-blind, double-dummy, parallel group, controlled study in 373 patients with essential hypertension." | 5.10 | Efficacy and tolerability of the combination valsartan/hydrochlorothiazide compared with amlodipine in a mild-to-moderately hypertensive Brazilian population. ( Franco, RJ; Goldflus, S; McQuitty, M; Oigman, W, 2003) |
| "Participants with hypertension and type 2 diabetes mellitus (n=96, 51% black) were randomized after an initial 4 weeks of placebo to double-blind 20 or 40 mg fosinopril or 5 or 10 mg amlodipine daily for 4 weeks in a fixed-dose regimen." | 5.10 | Fosinopril versus amlodipine comparative treatments study: a randomized trial to assess effects on plasminogen activator inhibitor-1. ( Applegate, WB; Cushman, WC; Deitcher, SR; Franse, LV; Johnson, KC; Kottke-Marchant, K; Pahor, M; Shorr, RI; Somes, GW; Tracy, RP, 2002) |
| "The study was to compare the effects of amlodipine (calcium channel antagonist), chlorthalidone (diuretic), and placebo in adults more than 50 years of age with stage 1 isolated systolic hypertension (ISH)." | 5.10 | Amlodipine versus chlorthalidone versus placebo in the treatment of stage I isolated systolic hypertension. ( Black, H; Ghadanfar, M; Grimm, RH; Lewin, A; Rowen, R; Shi, H, 2002) |
| " Thirty chronically hemodialyzed uremic patients with hypertension were randomly assigned to receive the AT1-R antagonist losartan (n = 10), the angiotensin-converting enzyme (ACD) inhibitor enalapril (n = 10), or calcium antagonist amlodipine (n = 10)." | 5.10 | Angiotensin II type 1 receptor antagonist, losartan, causes regression of left ventricular hypertrophy in end-stage renal disease. ( Iwasaka, T; Masaki, H; Matsubara, H; Nishikawa, M; Nishiue, T; Shibasaki, Y, 2002) |
| "Of the 310 randomized outpatients with uncomplicated mild-to-moderate primary hypertension, 259 (133 on valsartan/hydrochlorothiazide, 126 on amlodipine) were eligible for analysis." | 5.10 | Trough:peak ratio and smoothness index in the evaluation of 24-h blood pressure control in hypertension: a comparative study between valsartan/hydrochlorothiazide combination and amlodipine. ( Bertocchi, F; Carretta, R; Di, SS; Dorigatti, F; Malacco, E; Mann, J; Palatini, P, 2002) |
| " Forearm blood flow (FBF) was measured in 69 patients with essential hypertension (mild, n = 23; moderate, n = 29; and severe, n = 17 randomly assigned to treatment with either imidapril or amlodipine for 24 weeks in a double-blind fashion during reactive hyperemia and after sublingual administration of nitroglycerin." | 5.10 | Severity of hypertension affects improved resistance artery endothelial function by angiotensin-converting enzyme inhibition. ( Chayama, K; Goto, C; Hara, K; Higashi, Y; Kimura, M; Matsuura, H; Nakagawa, K; Noma, K; Oshima, T; Sasaki, S, 2002) |
| "Hypertensive patients currently taking amlodipine were selected based on one of two criteria: inadequate blood pressure (BP) control on amlodipine (diastolic BP [DBP] > or = 90 mm Hg; group 1), or inability to tolerate amlodipine (DBP < or = 90 mm Hg, but with edema; group 2)." | 5.10 | Combination therapy of amlodipine/benazepril versus monotherapy of amlodipine in a practice-based setting. ( Messerli, FH; Neutel, JM; Weir, MR, 2002) |
| "This study assessed the effects of calcium channel blocker Amlodipine on the cerebral circulation in patients with essential hypertension." | 5.09 | The effects of amlodipine on cerebral circulatory values in patients with essential hypertension. ( Alizade, IG; Karayeva, NT, 2001) |
| "Amlodipine, a dihydropyridine calcium channel blocker (CCB), with a long duration of action, has been the subject of numerous controlled studies which showed its effectiveness and good tolerance in arterial hypertension in once-daily doses." | 5.09 | [Validation of the therapeutic role of amlodipine in 31,946 French hypertensive patients]. ( Bernaud, C; Diévart, F; Grolleau-Raoux, R; Pasquié, JL, 2000) |
| "Two hundred and ninety-two patients with mild to moderate hypertension were divided into 4 groups at random and treated with compound Lingjiao Jiangya Pill, benazepril, amlodipine and indapamide respectively with a therapeutic course of 6 weeks." | 5.09 | [CEA comprehensive evaluation for Western and traditional Chinese hypotensive drugs]. ( He, BR; Li, L; Wang, Y, 2001) |
| "To evaluate the appropriate dosing of amlodipine when converting patients from nifedipine extended-release (nifedipine ER) to amlodipine in the treatment of hypertension." | 5.09 | Evaluation of amlodipine dosing for conversion of nifedipine extended-release to amlodipine in the treatment of hypertension. ( Enlow, AM; Halverson, VJ; Kilpatrick, DM; Lower, DL; Montopoli, G; Yamreudeewong, W, 1999) |
| " The hemodynamic effects of sildenafil were also evaluated in a second placebo-controlled crossover study in men with hypertension who were taking the calcium antagonist amlodipine, which has a mechanism of action that does not involve the cGMP pathway." | 5.09 | Sildenafil citrate and blood-pressure-lowering drugs: results of drug interaction studies with an organic nitrate and a calcium antagonist. ( Allen, MJ; Freestone, S; Muirhead, GJ; Webb, DJ, 1999) |
| "To compare the therapeutic coverage and safety of amlodipine and perindopril in patients with mild to moderate hypertension (diastolic blood pressure > or = 90 mmHg and < or = 109 mmHg)." | 5.09 | Double-blind, randomized, multicentre comparison of the effects of amlodipine and perindopril on 24 h therapeutic coverage and beyond in patients with mild to moderate hypertension. General Physicians Investigators' Group. ( Bernaud, CM; Fay, R; Zannad, F, 1999) |
| "This study compares the effects of a calcium channel blocker (amlodipine) and an angiotensin converting enzyme inhibitor (enalapril) on in vivo insulin sensitivity in patients with essential hypertension." | 5.09 | A double blind comparison of the effects of amlodipine and enalapril on insulin sensitivity in hypertensive patients. ( Arauz-Pacheco, C; Breen, L; Lender, D; Mora-Mora, P; Ramirez, LC; Raskin, P, 1999) |
| "Amlodipine, a dihydropyrimidine calcium antagonist, is effective in the treatment of patients with mild to moderate hypertension at doses of 5-10 mg daily." | 5.09 | Is initial dose titration of amlodipine worthwhile in patients with mild to moderate hypertension? ( Adamczak, M; Hayduk, K; Nowitzki, G, 1999) |
| "We studied muscle sympathetic-nerve activity in 14 patients with hypertension, chronic renal failure, and increased plasma renin activity before, during, and after administration of the ACE inhibitor enalapril." | 5.09 | Reduction of sympathetic hyperactivity by enalapril in patients with chronic renal failure. ( Blankestijn, PJ; Boomsma, F; Dijkhorst-Oei, LT; Klein, IH; Koomans, HA; Ligtenberg, G; Oey, PL; van Huffelen, AC; Wieneke, GH, 1999) |
| " The purpose of this study was to assess the effects of amlodipine and cilnidipine on the cardiac sympathetic nervous system and the neurohormonal status of essential hypertension." | 5.09 | Effects of amlodipine and cilnidipine on cardiac sympathetic nervous system and neurohormonal status in essential hypertension. ( Miho, N; Nawada, R; Obayashi, K; Sakata, K; Shirotani, M; Togi, K; Yoshida, H, 1999) |
| " Patients with essential hypertension, nine men and 13 women aged 61 +/- 2 years, were treated with amlodipine or nitrendipine in a random cross-over design for 12-16 weeks each." | 5.09 | Amlodipine, a long-acting calcium channel blocker, attenuates morning blood pressure rise in hypertensive patients. ( Ishimitsu, T; Kawano, Y; Matsuoka, H; Minami, J; Numabe, A; Takishita, S, 1999) |
| "Out of 245 randomized outpatients (90 men, 155 women) with uncomplicated mild-to-moderate primary hypertension and mean sitting diastolic blood pressure (DBP) 95-115 mmHg inclusive, 212 (102 on felodipine-metoprolol, 110 on amlodipine) were eligible for analysis." | 5.09 | Ambulatory 24-h blood pressure assessment of the felodipine-metoprolol combination versus amlodipine in mild to moderate hypertension. Lorraine General Physician Investigators Group. ( Boivin, JM; Zannad, F, 1999) |
| "The aim of this study was to compare the effect of amlodipine and enalapril on platelet aggregation, and platelet production of malondialdehyde in patients with mild to moderate arterial hypertension." | 5.09 | Effects of amlodipine and enalapril on platelet function in patients with mild to moderate hypertension. ( Armas de Hernández, MJ; Armas-Padilla, MC; Carvajal, AR; Guerrero-Pajuelo, J; Hernández-Hernández, R; Pacheco, B; Velasco, M, 1999) |
| "To evaluate the effect of amlodipine on blood pressure and cerebral blood flow in elderly subjects with mild to moderate hypertension." | 5.09 | Amlodipine lowers blood pressure without affecting cerebral blood flow as measured by single photon emission computed tomography in elderly hypertensive subjects. ( Clarke, SE; Pandita-Gunawardena, ND, 1999) |
| " To evaluate the dose-response relation between this pharmacological interference and dependent edema, a frequent side effect of CCBs during antihypertensive treatment, skin blood flow (laser Doppler flowmetry) at the dorsum of the foot, both supine and with the limb passively placed 50 cm below the heart level, and leg weight (Archimedes principle) were measured at baseline, during increasing doses of the dihydropyridine amlodipine (5 and 10 mg UID each for 2 weeks), and after drug withdrawal in 10 hypertensive men." | 5.09 | Amlodipine, enalapril, and dependent leg edema in essential hypertension. ( Dell'Omo, G; Mariani, M; Melillo, E; Pedrinelli, R, 2000) |
| " After a 4-week placebo run-in period, 25 patients with mild-to-moderate essential hypertension were randomly allocated to active treatment with Losartan 50 mg titrated to Losartan 50 mg/hydrochlorothiazide (HCT) 12." | 5.09 | Effects of losartan titrated to Losartan/Hydrochlorothiazide and amlodipine on left ventricular mass in patients with mild-to-moderate hypertension. A double-blind randomized controlled study. ( Battegay, E; Dieterle, T; Martina, B; Weinbacher, M, 1999) |
| "To compare the effect of doxazosin, an alpha-blocker, with chlorthalidone, a diuretic, on incidence of CVD in patients with hypertension as part of a study of 4 types of antihypertensive drugs: chlorthalidone, doxazosin, amlodipine, and lisinopril." | 5.09 | Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). ALLHAT Collaborative Research Group. ( , 2000) |
| "We compared the effects of atenolol (50 mg), amlodipine (5 mg), enalapril (20 mg), hydrochlorothiazide (25 mg), and losartan (50 mg) given in once-daily oral doses on office and ambulatory blood pressures (BPs) in patients with hypertension and obstructive sleep apnea (OSA)." | 5.09 | Comparison of atenolol, amlodipine, enalapril, hydrochlorothiazide, and losartan for antihypertensive treatment in patients with obstructive sleep apnea. ( Grote, L; Hedner, J; Kraiczi, H; Peker, Y, 2000) |
| " We studied 24 patients with mild-to-moderate hypertension in a double-blind random-sequence crossover study comparing placebo with amlodipine titrated up from 5 to 10 mg daily." | 5.09 | Effect of amlodipine on hemodynamic and endocrine responses to mental stress. ( Huff, MW; Munoz, C; Spence, JD; Tokmakjian, S, 2000) |
| "Four hundred seventy-five patients with angina pectoris were randomized to double-blind treatment with PPR (physiological pattern release) verapamil hydrochloride, amlodipine besylate, amlodipineatenolol combination, or placebo." | 5.09 | Medical therapy, symptoms, and the distress the cause: relation to quality of life in patients with angina pectoris and/or hypertension. ( Anderson, R; Hollenberg, NK; Williams, GH, 2000) |
| " Doxazosin and amlodipine, alone and in combination, were compared for efficacy in reducing blood pressure (BP) in 75 patients with predominantly moderate (Stage 2) hypertension." | 5.09 | Clinically additive effect between doxazosin and amlodipine in the treatment of essential hypertension. ( Nalbantgil, I; Nalbantgil, S; Onder, R, 2000) |
| "The safety and efficacy of Amlodipine (AML) for mild to moderate hypertension was evaluated in a "real life" setting." | 5.09 | [Multicenter community-based trial of amlodipine in hypertension in Israel]. ( Leshem, Y; Rav-Hon, Y; Rosenberg, GI; Viskoper, JR; Yaskil, E; Yosefy, C, 1999) |
| " Our aim was to prospectively compare the effects of amlodipine and ACEI (enalapril) on renal function in hypertensive patients with renal impairment due to chronic glomerulonephritis and essential hypertension." | 5.09 | Amlodipine is comparable to angiotensin-converting enzyme inhibitor for long-term renoprotection in hypertensive patients with renal dysfunction: a one-year, prospective, randomized study. ( Hayashi, K; Kumagai, H; Kumamaru, H; Saruta, T, 2000) |
| "This multicenter study evaluated the efficacy of candesartan cilexetil, an angiotensin II type 1 receptor antagonist, used alone or in combination with amlodipine or in combination with amlodipine and hydrochlorothiazide in the treatment of patients with moderate-to-severe essential hypertension." | 5.09 | Efficacy of candesartan cilexetil alone or in combination with amlodipine and hydrochlorothiazide in moderate-to-severe hypertension. UK and Israel Candesartan Investigators. ( Antonios, TF; He, FJ; MacGregor, GA; Viskoper, JR, 2000) |
| "25 mg (n = 84) to amlodipine 5 mg (n = 80) in isolated systolic hypertension in patients older than 60 years." | 5.09 | Efficacy, safety, and effects on quality of life of bisoprolol/hydrochlorothiazide versus amlodipine in elderly patients with systolic hypertension. ( Benetos, A; Consoli, S; Dubanchet, A; Safar, M; Safavian, A, 2000) |
| "To assess drug prescription patterns and medical resource consumption in an elderly population in Quebec receiving amlodipine or felodipine for the treatment of hypertension." | 5.09 | Patterns of amlodipine and felodipine use in an elderly Quebec population. ( LeLorier, J; Sheehy, O, 2000) |
| "The aim of this study was to compare the chronic effects of four dihydropyridine calcium antagonists with different pharmacologic characteristics, amlodipine, felodipine, lacidipine and manidipine,on blood pressure (BP), heart rate (HR) and plasma norepinephrine (NE) levels in patients with mild to moderate essential hypertension." | 5.09 | Effects of different dihydropyridine calcium antagonists on plasma norepinephrine in essential hypertension. ( Corradi, L; Fogari, R; Malalamani, GD; Mugellini, A; Preti, P; Zoppi, A, 2000) |
| "This study was undertaken to assess the efficacy and tolerability of amlodipine, a long-acting calcium channel blocker, in elderly (> or =65 years of age) patients with mild to moderate hypertension (diastolic blood pressure 95 to 114 mm Hg)." | 5.09 | Treatment of hypertension in patients > or =65 years of age: experience with amlodipine. ( Langdon, C, 2000) |
| "5 mg shows similar antihypertensive efficacy to amlodipine 5 mg and hydrochlorothiazide 25 mg in elderly hypertensive patients, while in patients with isolated systolic hypertension, indapamide SR 1." | 5.09 | A comparison of indapamide SR 1.5 mg with both amlodipine 5 mg and hydrochlorothiazide 25 mg in elderly hypertensive patients: a randomized double-blind controlled study. ( Abate, G; Calvo-Gomez, C; Chastang, C; Emeriau, JP; Knauf, H; Leonetti, G; Pujadas, JO, 2001) |
| "To compare in the non-blind randomised parallel study the efficiency of quadropril and amlodipine in the treatment of mild to moderate arterial hypertension." | 5.09 | [Comparative study of spirapril (quadropril) and amlodipine efficacy. Results of randomized trial in patients with mild to moderate arterial hypertension]. ( Alimova, EV; Deev, AD; Koniakhina, IP; Kukushkin, SK; Kutishenko, NP; Lebedev, AV; Manoshkina, EM; Martsevich, SIu; Semenova, IuE; Shal'nova, SA; Zagrebel'nyĭ, AV, 2000) |
| "The comparative antihypertensive efficacy and tolerability of the angiotensin II receptor blocker candesartan cilexetil and the calcium channel blocker amlodipine were evaluated in an 8-week, multicenter, double-blind, randomized, parallel-group, forced-titration study in 251 adult patients (45% women, 16% black) with mild hypertension (stage 1)." | 5.09 | Comparative effects of candesartan cilexetil and amlodipine in patients with mild systemic hypertension. Comparison of Candesartan and Amlodipine for Safety, Tolerability and Efficacy (CASTLE) Study Investigators. ( Chrysant, SG; Harris, SM; Kloner, RA; Leidy, NK; Michelson, EL; Pool, JL; Prasad, R; Weinberger, M; Zyczynski, TM, 2001) |
| "A comparison of treatment costs and cost effectiveness was performed retrospectively by using patient-level data from a randomized, controlled, one-year clinical trial of amlodipine and enalapril in the treatment of mild-to-moderate hypertension." | 5.09 | A retrospective analysis comparing the costs and cost effectiveness of amlodipine and enalapril in the treatment of hypertension. ( Arikian, S; Arocho, R; Casciano, J; Casciano, R; Doyle, J; Gonzalez, MA; Omvik, P, 2001) |
| "The Antihypertensive and Lipid-Lowering high-risk hypertensive participants, ages > or = 55 years, designed to determine whether the incidence of fatal and nonfatal coronary heart disease (CHD) and combined cardiovascular events (fatal and nonfatal CHD, revascularization surgery, angina pectoris, congestive heart failure, and stroke) differs between diuretic (chlorthalidone) treatment and three alternative antihypertensive therapies: a calcium channel blocker (amlodipine), an ACE inhibitor (lisinopril), and an alpha-adrenergic blocker (doxazosin)." | 5.09 | Baseline characteristics of the diabetic participants in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). ( Barzilay, JI; Basile, JN; Ciocon, JO; Davis, BR; Goff, DC; Jones, CL; Randall, OS; Sweeney, ME, 2001) |
| "All studies suggesting a lower incidence of edema on lacidipine than on amlodipine are based on subjective scoring." | 5.09 | Ankle edema formation during treatment with the calcium channel blockers lacidipine and amlodipine: a single-centre study. ( Andrésdóttir, MB; Huysmans, FT; Valk, IM; van de Bosch, WJ; van Hamersvelt, HW; van Helden, MJ, 2000) |
| "To investigate the effect of amlodipine on baroreflex sensitivity and sympathetic system activity, 36 patients with essential hypertension were randomized to once-daily, double-blind treatment with amlodipine 5 mg or placebo 5 mg for 60 days." | 5.09 | Effects of amlodipine on baroreflex and sympathetic nervous system activity in mild-to-moderate hypertension. ( Baguet, JP; de Gaudemaris, R; Fagret, D; Mallion, JM; Siché, JP; Trémel, F, 2001) |
| "Ramipril, compared with amlodipine, retards renal disease progression in patients with hypertensive renal disease and proteinuria and may offer benefit to patients without proteinuria." | 5.09 | Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial. ( Agodoa, LY; Appel, L; Bakris, GL; Beck, G; Bourgoignie, J; Briggs, JP; Charleston, J; Cheek, D; Cleveland, W; Douglas, JG; Douglas, M; Dowie, D; Faulkner, M; Gabriel, A; Gassman, J; Greene, T; Hall, Y; Hebert, L; Hiremath, L; Jamerson, K; Johnson, CJ; Kopple, J; Kusek, J; Lash, J; Lea, J; Lewis, JB; Lipkowitz, M; Massry, S; Middleton, J; Miller, ER; Norris, K; O'Connor, D; Ojo, A; Phillips, RA; Pogue, V; Rahman, M; Randall, OS; Rostand, S; Schulman, G; Smith, W; Thornley-Brown, D; Tisher, CC; Toto, RD; Wright, JT; Xu, S, 2001) |
| "A total of 530 patients between 21 and 80 years of age with essential hypertension were screened for the study, and 454 were randomised to treatment with amlodipine 5 mg/benazepril 10 mg, amlodipine 5 mg, benazepril 10 mg, or placebo for 8 weeks." | 5.09 | Once-daily treatment of patients with hypertension: a placebo-controlled study of amlodipine and benazepril vs amlodipine or benazepril alone. ( Ginsberg, D; Glazer, R; Kaihlanen, P; Lewis, G; Messerli, FH; Oparil, S; Pool, J, 2001) |
| "We compared the effects of amlodipine and verapamil slow release on autonomic responses to a 5-min mental arithmetic test (MST) in patients with mild to moderate hypertension." | 5.09 | Less adrenergic response to mental task during verapamil compared to amlodipine treatment in hypertensive subjects. ( Eide, I; Lefrandt, JD; Rostrup, M; Sevre, K; Smit, AJ, 2001) |
| "In this multicentre, double-blind trial in 176 patients with mild or moderate essential hypertension were randomized to amlodipine or enalapril monotherapy after 2-week period of placebo." | 5.09 | [The comparison of hypotensive efficiency and tolerability of amlodipine and enalapril in patients with essential hypertension]. ( Gryglas, P, 2001) |
| "In this 1-year clinical study, we compared the efficacy and tolerability of amlodipine and nifedipine retard in 64 Chinese Type 2 diabetic patients with hypertension." | 5.09 | Blood pressure reduction and tolerability of amlodipine versus nifedipine retard in Chinese patients with type 2 diabetes mellitus and hypertension: a randomized 1-year clinical trial. ( Chan, CH; Chan, HC; Ko, GT, 2001) |
| "To compare the antihypertensive efficacy and tolerability of a once-daily fixed valsartan/hydrochlorothiazide (HCTZ) combination and amlodipine in subjects with mild-to-moderate hypertension." | 5.09 | A multicenter, randomized double-blind study of valsartan/hydrochlorothiazide combination versus amlodipine in patients with mild to moderate hypertension. ( Bertocchi, F; Bonaduce, D; Carretta, R; Condorelli, M; Fogari, R; Malacco, E; Mann, J; Palatini, P, 2001) |
| "This was a 20-week, open-label, uncontrolled clinical investigation of the long-acting calcium antagonist amlodipine in 33 male or female patients with essential hypertension and left ventricular hypertrophy (LVH)." | 5.09 | Amlodipine: effective for treatment of mild to moderate essential hypertension and left ventricular hypertrophy. ( Ebanks, M; Ihenacho, HN; Islim, IF; Singh, SP; Watson, RD, 2001) |
| "This double-blind, multicenter trial compared antihypertensive efficacy, tolerability, and impact on quality of life of manidipine and amlodipine in patients with mild-to-moderate essential hypertension." | 5.09 | Efficacy, tolerability, and impact on quality of life of long-term treatment with manidipine or amlodipine in patients with essential hypertension. ( De Cesaris, R; La Commare, P; Omboni, S; Palatini, P; Zanchetti, A, 2001) |
| " In this double-blind parallel-group clinical trial, 69 previously untreated patients with hypertension were allocated randomly to 1 year of treatment with either amlodipine (5-10 mg daily) or lisinopril (5-20 mg daily)." | 5.09 | Effects of blood pressure lowering with amlodipine or lisinopril on vascular structure of the common carotid artery. ( Chapman, JN; Hughes, AD; Mayet, J; Poulter, NR; Sever, PS; Stanton, AV; Thom, SA, 2001) |
| "The main purpose of this study was to compare efficacy, tolerability and influence on quality of life (QOL) of nifedipine gastrointestinal therapeutic system (NI) 30-60 mg once a day vs amlodipine (AM) 5-10 mg once a day in elderly patients with mild-moderate hypertension." | 5.09 | Efficacy, tolerability and influence on "quality of life" of nifedipine GITS versus amlodipine in elderly patients with mild-moderate hypertension. ( Boari, L; De Dominicis, E; Giusti, C; Kilama, MO; Marchesi, M; Marelli, G; Mattarei, M; Mos, L; Novo, S; Pessina, AC; Pirrelli, A; Santini, M; Santonastaso, M; Semeraro, S; Uslenghi, E, 2001) |
| "To compare 24-hour blood pressure control and adverse effects in patients with essential hypertension who were switched from amlodipine to nisoldipine." | 5.09 | Comparison of 24-hour blood pressure profiles in patients with hypertension who were switched from amlodipine to nisoldipine. ( Hilleman, DE; Lenz, TL; Wurdeman, RL, 2001) |
| "The aim of the present study was to compare the effects of a long-acting dihydropyridine (amlodipine) and a nondihydropyridine (verapamil) on autonomic function in patients with mild to moderate hypertension." | 5.09 | The effects of dihydropyridine and phenylalkylamine calcium antagonist classes on autonomic function in hypertension: the VAMPHYRE study. ( Agabiti-Rosei, E; Castellano, M; de Kam, PJ; Fallon, M; Fluckiger, L; Hausberg, M; Heitmann, J; Lefrandt, JD; Murphy, M; Rahn, KH; Rostrup, M; Sevre, K; Smit, AJ; Urbigkeit, A; van Roon, AM; Zannad, F, 2001) |
| " We here compared the effects of the N-type calcium channel blockers cilnidipine and amlodipine on the sympathetic nervous system and platelet function in hypertension under resting and stressed conditions." | 5.09 | Cilnidipine more highly attenuates cold pressor stress-induced platelet activation in hypertension than does amlodipine. ( Doba, N; Kimura, Y; Kinouchi, T; Kuwabara, Y; Kuwata, S; Maruyama, C; Tomiyama, H; Yoshida, H; Yoshida, Y, 2001) |
| "Each treatment was taken for 1 month, preceded by a 2-week single-blind run-in period, in which the patients received a low dose of doxazosin (study A) or enalapril (study B) to enable recruitment of patients with moderate or severe hypertension." | 5.08 | Alpha-blockade and calcium antagonism: an effective and well-tolerated combination for the treatment of resistant hypertension. ( Brown, MJ; Dickerson, JE, 1995) |
| "The efficacy and safety of the novel calcium antagonist Amlodipine (Pfizer Laboratories, New York, New York) and hydrochlorothiazide were evaluated and compared in a randomized, single-blind, parallel group study in black Africans with essential hypertension." | 5.08 | The efficacy and tolerability of amlodipine and hydrochlorothiazide in Nigerians with essential hypertension. ( Ajayi, AA; Akintomide, AO, 1995) |
| "The objective of this study was to compare the antihypertensive efficacy and influence on renal function of perindopril and amlodipine in cyclosporine-treated renal allograft recipients with mild to moderate hypertension." | 5.08 | Comparison of perindopril and amlodipine in cyclosporine-treated renal allograft recipients. ( Lamote, J; Sennesael, J; Tasse, S; Verbeelen, D; Violet, I, 1995) |
| "In this multicentre, double-blind trial in 461 patients with essential hypertension, amlodipine (5-10 mg once daily) and enalapril (10-40 mg once daily) were compared in terms of quality of life, efficacy and tolerability after 1 year of treatment (part 1)." | 5.08 | Evaluation and quality-of-life assessment of amlodipine and enalapril in patients with hypertension. ( Eide, I; Herland, OB; Midha, R; Omvik, P; Thaulow, E; Turner, RR, 1995) |
| "The anti-hypertensive efficacy and safety of extended-release (ER) felodipine (5, 10 or 20 mg) and amlodipine (5 or 10 mg) once daily were compared in patients with mild to moderate essential hypertension in a double-blind, double-dummy, randomised, comparative study." | 5.08 | Comparative effects of amlodipine and felodipine ER on office and ambulatory blood pressure in patients with mild to moderate hypertension. Danish Multicentre Group. ( Høegholm, A; Nielsen, PE; Rasmussen, E; Wiinberg, N, 1995) |
| "The anti-hypertensive efficacy and safety of extended-release (ER) felodipine (5, 10 or 20 mg) and amlodipine (5 or 10 mg) once daily were compared in patients with mild-to-moderate essential hypertension in a double-blind, double-dummy, randomised, comparative study." | 5.08 | Office and ambulatory blood pressure: a comparison between amlodipine and felodipine ER. Danish Multicentre Group. ( Høegholm, A; Nielsen, PE; Rasmussen, E; Wiinberg, N, 1995) |
| "The effect of calcium channel blocker (CCB), amlodipine (5-10 mg/day) and angiotensin-converting enzyme (ACE) inhibitor, quinapril (10-40 mg/day) on ambulatory blood pressure (ABP), rheological and platelet function in hypertension were compared in this randomised double-blind placebo-controlled cross-over study." | 5.08 | Comparison of amlodipine and quinapril on ambulatory blood pressure and platelet function in hypertension. ( Chang, SM; Chou, TC; Ding, YA, 1995) |
| " In the hypertensive patients with coronary disease the authors also evaluated sympathetic activation after double-blind, placebo-controlled administration of metoprolol (100 mg/day), followed by amlodipine (10 mg/day), quinapril (20 mg/day), and amlodipine (5 mg/day) plus quinapril (10 mg/day)." | 5.08 | Power spectral analysis of heart rate in elderly hypertensive subjects with or without silent coronary disease. ( Bucca, C; Cacciafesta, M; Di Gioacchino, C; Durante, M; Fimognari, FL; Lo Verde, A; Marigliano, V; Monteforte, G; Munizzi, MR; Piccirillo, G; Santagada, E; Tarantini, S; Viola, E, 1996) |
| "As part of the Amlodipine Cardiovascular Community Trial (ACCT), which was a large multicenter study designed to assess the effects of the calcium channel blocker amlodipine besylate (Norvasc) as monotherapy for treatment of mild to moderate hypertension, we sought to determine the effects of amlodipine on regression of left ventricular (LV) hypertrophy (LVH)." | 5.08 | Effect of amlodipine on left ventricular mass in the Amlodipine Cardiovascular Community Trial. ( DiBona, GF; Gaffney, M; Kloner, RA; Sowers, JR; Wein, M, 1995) |
| "Eighty-one adult Nigerians with essential hypertension were randomly allocated to receive doxazosin, hydrochlorothiazide/amloride, or amlodipine." | 5.08 | Relationship between body mass index (BMI) and changes in plasma total and HDL-cholesterol levels during treatment of hypertension in African patients. ( Agbedana, OE; Ahaneku, JE; Taylor, OG, 1995) |
| "5 mg daily, low-dose benazepril 10 mg daily, and the combination of the two drugs at the same doses used once daily in patients (n = 401) with mild to moderate (stages I and II) systemic hypertension." | 5.08 | Comparison of amlodipine and benazepril monotherapy to amlodipine plus benazepril in patients with systemic hypertension: a randomized, double-blind, placebo-controlled, parallel-group study. The Benazepril/Amlodipine Study Group. ( Chrysant, SG; Frishman, WH; Graff, A; Hsu, H; Kupiec, JW; McMahon, FG; RAM, CV, 1995) |
| "This community-based study assessed whether there were age, sex, or racial differences in response to amlodipine 5 to 10 mg once daily in patients with mild to moderate essential hypertension." | 5.08 | Sex- and age-related antihypertensive effects of amlodipine. The Amlodipine Cardiovascular Community Trial Study Group. ( DiBona, GF; Gaffney, M; Kloner, RA; Sowers, JR; Wein, M, 1996) |
| "Calcium channel blockers (CCB) are considered the agents of choice to treat hypertension in cyclosporine (CsA)-treated renal transplant patients." | 5.08 | Amlodipine increases cyclosporine levels in hypertensive renal transplant patients: results of a prospective study. ( Curtis, JJ; Jones, PA; Julian, BA; Pesavento, TE, 1996) |
| "The present study aimed to assess the efficacy and tolerance of amlodipine (Norvasc-Pfizer) in the treatment of 152 patients with mild and moderate essential hypertension." | 5.08 | -Efficacy and safety of using amlodipine in treatment of mild and moderate essential hypertension-. ( Kokot, F; Kokot, M; Raszewska, J; Rychlik, G; Witkowicz, J, 1995) |
| "One hundred sixty-eight adult outpatients with mild to moderate hypertension were randomly allocated in double-blind fashion and equal number to receive 80 mg valsartan or 5 mg amlodipine for 12 weeks." | 5.08 | Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: a comparative study of the efficacy and safety against amlodipine. ( Bodin, F; Cardoni, O; Corea, L; Fogari, R; Innocenti, P; Meilenbrock, S; Porcellati, C; Provvidenza, M; Sullivan, J, 1996) |
| "The objectives of this study were to evaluate the effects of an ACE inhibitor (fosinopril) and a calcium antagonist (amlodipine) on the urinary albumin and transferrin excretion and their relationship to the blood pressure in essential hypertension." | 5.08 | Albuminuria and transferrinuria in essential hypertension. Effects of antihypertensive therapy. ( Agrati, AM; Alli, C; Cassani, M; Granata, S; Lombardo, M; Zanni, D, 1996) |
| " The objective of the present 32-week double-blind study was to compare the effects of hydrochlorothiazide (HCTZ) and amlodipine (AML) in elderly patients with confirmed ambulatory hypertension." | 5.08 | Antihypertensive effects of amlodipine and hydrochlorothiazide in elderly patients with ambulatory hypertension. ( Archambault, F; Boileau, G; Cléroux, J; Lacourcière, Y; Lefebvre, J; Poirier, L, 1995) |
| "Amlodipine has a beneficial effect on LVH and also is an effective and safe drug to treat mild to moderate hypertension." | 5.08 | [Effect of the treatment with amlodipine on left ventricular hypertrophy in hypertensive patients]. ( Hoyos, M; Justo, E; Moreno, R; Oliván, J; Pérez Cano, R; Pizarro, JL; Ramos, E; Rodríguez, A, 1996) |
| "To compare the efficacy and tolerability of mibefradil and amlodipine in patients with uncomplicated mild-to-moderate essential hypertension." | 5.08 | A randomised, double-blind trial comparing mibefradil and amlodipine: two long-acting calcium antagonists with similar efficacy but different tolerability profiles. Mibefradil International Study Group. ( Bernink, PJ; Kantola, IM; Kobrin, I; Ribeiro, AB; Schelling, A; Viskoper, RJ; Wilkins, MR, 1997) |
| "The safety and tolerability of mibefradil, a selective T-type calcium channel antagonist, were evaluated in 3,430 patients with essential hypertension and chronic stable angina pectoris treated in 15 double-blind placebo and active-controlled clinical trials and 2 open-label, long-term safety studies." | 5.08 | Safety of mibefradil, a new once-a-day, selective T-type calcium channel antagonist. ( Charlon, V; Kobrin, I; Lindberg, E; Pordy, R, 1997) |
| "To compare the effects of chronic antihypertensive treatment on left and right ventricular structure and function, 24 patients with mild to moderate, never-treated hypertension were randomized to receive fosinopril (20 mg daily) or amlodipine (10 mg daily) for 12 months." | 5.08 | Long-term effects of angiotensin-converting enzyme inhibitors and calcium antagonists on the right and left ventricles in essential hypertension. ( Alli, C; Broccolino, M; Ferrari, S; Lombardo, M; Montemurro, L; Zaini, G; Zanni, D, 1997) |
| "The purpose of the study was to compare the antianginal and hypotensive efficacy and tolerability of 8 weeks of treatment with amlodipine taken once daily and nifedipine taken twice daily in patients with stable exertional angina pectoris and mild-to-moderate hypertension." | 5.08 | [Comparative study to assess the efficacy and adverse effects of amlodipine and nifedipine retard in patients with stable exertional angina and hypertension]. ( Hlawaty, M; Kubler, G; Negrusz-Kawecka, M; Olszowska, M; Salamon, P; Tracz, W; Witkowska, M, 1997) |
| "To compare two losartan regimens (with and without hydrochlorothiazide) and amlodipine in treating mild-to-moderate hypertension regarding their blood-pressure-lowering effect, drug tolerability and quality of life." | 5.08 | Main results of the losartan versus amlodipine (LOA) study on drug tolerability and psychological general well-being. LOA Study Group. ( Carney, S; Dahlöf, B; Lindholm, LH; Ostergren, J; Pentikäinen, PJ, 1997) |
| "Administration of amlodipine did not induce an increase in sympathetic nerve activity in essential hypertensive patients during the chronic period, suggesting that beneficial effects on essential hypertension can be expected after its long-term administration." | 5.08 | Evaluation of changes in sympathetic nerve activity and heart rate in essential hypertensive patients induced by amlodipine and nifedipine. ( Fujimoto, Y; Hamada, T; Hisatome, I; Kaneda, T; Kinugawa, T; Ohtahara, A; Shigemasa, C; Watanabe, M; Yoshida, A, 1998) |
| "Thirty patients (17 females, median age 55 years) with mild/moderate hypertension (sitting diastolic blood pressure 95-110 mmHg over 2 consecutive weeks) participated in a study of the efficacy and tolerability of once-daily diltiazem "controlled delivery" 180 mg-360 mg and amlodipine 5-10 mg compared with placebo (using clinic and 24-h ambulatory blood pressure measurement (Accutraker II)." | 5.08 | A placebo-controlled comparison of diltiazem and amlodipine monotherapy in essential hypertension using 24-h ambulatory monitoring. ( Watts, RW; Wing, LM, 1998) |
| " The primary aim of the Fosinopril Versus Amlodipine Cardiovascular Events Randomized Trial (FACET) was to compare the effects of fosinopril and amlodipine on serum lipids and diabetes control in NIDDM patients with hypertension." | 5.08 | Outcome results of the Fosinopril Versus Amlodipine Cardiovascular Events Randomized Trial (FACET) in patients with hypertension and NIDDM. ( Byington, RP; Di Mauro, P; Guarisco, R; Pahor, M; Strollo, F; Strollo, G; Tatti, P, 1998) |
| " The compliance, efficacy, and safety of amlodipine and nifedipine slow-release (SR) were compared in patients with mild-to-moderate essential hypertension recruited among 24 centers in France." | 5.08 | Compliance and antihypertensive efficacy of amlodipine compared with nifedipine slow-release. ( Bernaud, C; Carré, A; Charpentier, JC; Hotton, JM; Lequeuche, B; Mounier-Vehier, C, 1998) |
| "To evaluate the 24 h antihypertensive efficacy and duration of action of felodipine extended release (ER) in comparison with two other long acting dihydropyridine calcium antagonists, amlodipine and nifedipine gastrointestinal therapeutic system (GITS), in patients with mild to moderate essential hypertension substantiated by ambulatory blood pressure (BP) monitoring." | 5.08 | Comparative effects of felodipine ER, amlodipine and nifedipine GITS on 24 h blood pressure control and trough to peak ratios in mild to moderate ambulatory hypertension: a forced titration study. ( Archambault, F; Jewell, D; Lacourcière, Y; Lefebvre, J; Poirier, L; Reed, CV, 1998) |
| "The aim of the study was to compare the effects of two long-acting antihypertensive agents, the calcium-antagonist amlodipine and the ACE inhibitor lisinopril, on left ventricular mass and diastolic filling in patients with mild to moderate diastolic hypertension from primary care centres." | 5.08 | Effects of amlodipine and lisinopril on left ventricular mass and diastolic function in previously untreated patients with mild to moderate diastolic hypertension. ( Beltman, FW; de Graeff, PA; Havinga, TK; Heesen, WF; Lie, KI; May, JF; Meyboom-de Jong, B; Schuurman, FH; Smit, AJ; van der Veur, E, 1998) |
| "To measure the effects of losartan and amlodipine on peripheral capillary microcirculation in hypertension." | 5.08 | Effects of losartan titrated to losartan/hydrochlorothiazide and amlodipine on blood pressure and peripheral capillary microcirculation in patients with mild-to-moderate hypertension. ( Drewe, J; Gasser, P; Martina, B; Weinbacher, M, 1998) |
| "To compare the acute and chronic effects of nifedipine retard (NPA), nifedipine gastrointestinal therapeutic system (NGITS) and amlodipine at trough and peak plasma concentrations of drug on blood pressure and heart rate, and on plasma norepinephrine and epinephrine levels in patients with mild-to-moderate hypertension (diastolic blood pressure 95-115 mmHg)." | 5.08 | Different effects of nifedipine and amlodipine on circulating catecholamine levels in essential hypertensive patients. ( Cartier, P; de Champlain, J; Karas, M; Larochelle, P; Nadeau, R; Nguyen, P; Toal, CB; Wistaff, R, 1998) |
| "To compare the blood pressure effects of two dihydropyridine calcium channel blockers, amlodipine and nitrendipine, in 488 patients with essential hypertension." | 5.08 | Parallel comparative trial of amlodipine and nitrendipine monotherapy in patients with essential hypertension. ( Gong, L; Guo, J; Liu, Y; Wang, X; Yang, P; Ye, X; Zhang, G, 1998) |
| "To compare the acute and chronic effects of nifedipine retard (NPA), nifedipine gastrointestinal therapeutic system (NGITS) and amlodipine at trough and peak plasma concentrations of drug on blood pressure and heart rate, and on plasma norepinephrine and epinephrine levels in patients with mild-to-moderate hypertension (diastolic blood pressure 95-115 mmHg)." | 5.08 | Different effects of nifedipine and amlodipine on circulating catecholamine levels in essential hypertensive patients. ( Cartier, P; de Champlain, J; Karas, M; Larochelle, P; Nadeau, R; Nguyen, P; Toal, CB; Wistaff, R, 1998) |
| "To compare the effects of two antihypertensive agents, amlodipine and lisinopril, on left ventricular mass and diastolic filling in patients from primary care centers with mild to moderate diastolic hypertension." | 5.08 | Two-year follow-up study to evaluate the reduction of left ventricular mass and diastolic function in mild to moderate diastolic hypertensive patients. ( Beltman, F; de Graeff, P; Havinga, T; Heesen, W; Lie, K; May, J; Meyboom-de Jong, B; Schuurman, F; Smit, A; van der Veur, E, 1998) |
| "The objective of this study was to examine the effects of angiotensin II receptor blocker losartan versus the calcium channel blocker amlodipine on proteinuria, renal haemodynamics, glomerular sieving and tubular function in hypertensive patients with non-diabetic nephropathy." | 5.08 | Renal effects of losartan and amlodipine in hypertensive patients with non-diabetic nephropathy. ( Berg, KJ; Fauchald, P; Hartmann, A; Holdaas, H; Lund, K, 1998) |
| "Amlodipine as a monotherapy was evaluated in 20 patients with mild, moderate, and severe hypertension over a 10 week period." | 5.08 | Amlodipine as monotherapy in hypertensive Africans: clinical efficacy and safety studies. ( Salako, LA; Sowunmi, A; Walker, O, 1996) |
| "To investigate the effect of amlodipine, nifedipine and perindopril on insulin sensitivity(IS) and blood lipid of patients with essential hypertension(EH)." | 5.08 | [The effect of amlodipine, nifedipine and perindopril on insulin sensitivity and blood lipid of patients with essential hypertension]. ( Chen, D; Lin, J; Wu, K, 1998) |
| "1 We have utilised a non-imaging echo-Doppler cardiac output device, using the principle of attenuated compensation volume flow (ACVF), to assess the cardiovascular effects of amlodipine and atenolol over 3 months in 24 patients with essential hypertension." | 5.07 | Haemodynamic comparison of amlodipine and atenolol in essential hypertension using the quantascope. ( Guy, S; Herity, N; Silke, B; Tham, TC, 1993) |
| "The efficacy and toleration of once-daily amlodipine (5-10 mg) was studied in 11 patients with mild to moderate hypertension." | 5.07 | 24-hour blood pressure control with the once-daily calcium antagonist amlodipine. ( Al-Khawaja, I; Brigden, G; Heber, ME; Raftery, EB, 1991) |
| " twice-daily oral doses of captopril (25-50 mg twice daily) in adult patients with mild or moderate essential hypertension (supine diastolic blood pressure of 95-115 mm Hg) was undertaken in two hospital centers." | 5.07 | A double-blind, parallel, comparative evaluation of amlodipine vs. captopril in the monotherapeutic treatment of mild and moderate essential hypertension. ( Fonseca, R; Guevara, J; Hernandez, R; Pieretti, OH; Silva, H; Urbina, A; Velasco, M, 1991) |
| "The efficacy and safety of the dihydropyridine calcium antagonists amlodipine and nitrendipine as single-agent therapy of mild to moderate hypertension were compared in an open, parallel-group study." | 5.07 | An open, parallel, comparative evaluation of amlodipine and nitrendipine in the monotherapeutic treatment of mild and moderate essential hypertension. ( Beressem, P; Englert, R; Kramar, M; Stafunsky, S; von Manteuffel, E, 1991) |
| "The antihypertensive efficacy and safety of once-daily amlodipine (5-10 mg) were studied in patients with essential hypertension." | 5.07 | Amlodipine in hypertension: its effects on platelet aggregation and dynamic exercise. ( Armas-de Hernande, MJ; Armas-Padilla, MC; Barragan, O; Carvajal, AR; Guerrero-Pajuelo, J; Hernández, R; Machado-de Alvarado, I, 1991) |
| "The antihypertensive efficacy and safety of amlodipine (5-10 mg once daily for 10 weeks) was assessed in elderly patients with primary systolic hypertension (average sitting and standing systolic blood pressure > or = 160 mm Hg and diastolic blood pressure < or = 95 mm Hg)." | 5.07 | Open evaluation of amlodipine in the monotherapeutic treatment of systolic hypertension in the elderly. ( Lambert, M; Vandewoude, MF; Vryens, R, 1991) |
| "We compared the antihypertensive efficacy of once-daily amlodipine (AM) versus nitrendipine (NTR) by 24-h ambulatory blood pressure monitoring (24-h ABPM) in 32 patients with mild to moderate essential hypertension (EH)." | 5.07 | Comparative evaluation of the antihypertensive efficacy of once-daily amlodipine versus nitrendipine with 24-hour ambulatory blood pressure monitoring in essential hypertension. ( Aguilera, MT; Coca, A; De la Sierra, A; Lluch, MM; Picado, MJ; Sánchez, M; Urbano-Márquez, A, 1993) |
| "The efficacy and tolerability of amlodipine (5 mg, once daily), nifedipine retard (20 mg, twice daily), and placebo were compared in a multicenter, three-way, crossover study involving 97 patients with mild-to-moderate hypertension." | 5.07 | Side effects of dihydropyridine therapy: comparison of amlodipine and nifedipine retard. ( Bremner, AD; Fell, PJ; Hosie, J; James, GV; Saul, PA; Taylor, SH, 1993) |
| "The nitric oxide (NO) system is abnormal in essential hypertension and the response of the forearm vascular bed to local intra-arterial infusions of NG-monomethyl-L-arginine (L-NMMA) is diminished in patients with untreated essential hypertension." | 5.07 | The effect of antihypertensive therapy on responsiveness to local intra-arterial NG-monomethyl-L-arginine in patients with essential hypertension. ( Benjamin, N; Lyons, D; Webster, J, 1994) |
| "This study was designed to compare the efficacy and tolerability of amlodipine (AML) and ramipril (RAM) administered once a day in patients affected by mild to moderate primary systemic hypertension." | 5.07 | Amlodipine versus ramipril in the treatment of mild to moderate hypertension: evaluation by 24-hour ambulatory blood pressure monitoring. ( Ceravolo, R; Mattioli, PL; Perticone, F; Pugliese, F, 1994) |
| " The metabolic and renal effects of long-term (8 months) therapy with amlodipine, 5 to 10 mg daily, were studied in 15 hypertensive patients with uncomplicated diabetes mellitus as compared with 15 patients with essential hypertension." | 5.07 | Calcium antagonists for treatment of diabetes-associated hypertension. Metabolic and renal effects of amlodipine. ( Beretta-Piccoli, C; Heinen, G; Pingitore, R; Riesen, W; Zanetti-Elshater, F, 1994) |
| "5 to 10 mg) once daily was compared with that of hydrochlorothiazide (HCTZ) (25 to 100 mg) daily in 139 patients with mild-to-moderate hypertension." | 5.07 | Long-term open evaluation of amlodipine vs hydrochlorothiazide in patients with essential hypertension. ( Adolphe, AB; Brescia, D; Rofman, BA; Vlachakis, ND; Zellner, SR, 1993) |
| "The authors studied the efficacy and safety of a long half-life dihydropyridine calcium-antagonist--amlodipine--in a single daily dose in the treatment of isolated systolic hypertension in the elderly." | 5.07 | [Amlodipine in isolated systolic hypertension in the aged]. ( Cosentino, N; Mariani, L; Marino, M; Torrisi, G, 1993) |
| "A double-blind multicenter study involving 89 patients with mild-to-moderate essential hypertension was performed to compare the efficacy and tolerability of amlodipine and enalapril." | 5.07 | [Monotherapy of mild to moderate hypertension. Double-blind comparative study: amlodipine versus enalapril]. ( Görne, RC; Mehmel, HC, 1993) |
| "In an open, non-comparative, variable-dose study, 20 outpatients with mild to moderate essential hypertension were treated with 5-10 mg amlodipine once daily for 4 weeks, after their blood pressures had stabilized on placebo." | 5.07 | Amlodipine in mild and moderate hypertension: initial Indian experience. ( Ailiani, R; Bajan, KD; Chawla, KP; Chopra, P; Joseph, TA; Karnik, ND; Khokhani, RC; Waknis, SS, 1993) |
| "5-10 mg) once daily was compared with atenolol (50-100 mg) once daily in patients with mild-to-moderate essential hypertension in a randomized, double-blind, parallel, placebo-controlled study." | 5.07 | Amlodipine versus atenolol in essential hypertension. ( Brobyn, R; Brown, RD; Frishman, WH; Johnson, BF; Reeves, RL; Wombolt, DG, 1994) |
| "This study was conducted to assess the therapeutic utility of combining amlodipine with captopril in patients with moderate-to-severe hypertension." | 5.07 | Combination therapy with amlodipine and captopril for resistant systemic hypertension. ( Maclean, D, 1994) |
| "To compare tolerance, antihypertensive efficacy and impact on quality of life of amlodipine and enalapril in patients with mild or moderate hypertension." | 5.07 | Double-blind, parallel, comparative study on quality of life during treatment with amlodipine or enalapril in mild or moderate hypertensive patients: a multicentre study. ( Eide, I; Herland, OB; Midha, R; Omvik, P; Thaulow, E; Turner, RR, 1993) |
| "Nifedipine is an effective compound for the treatment of hypertension." | 5.07 | Double-blind comparison between nifedipine and amlodipine for the treatment of essential hypertension. ( Cappuccio, FP; Carney, C; Crane, M; MacGregor, GA; Markandu, ND; Singer, DR, 1993) |
| "In a multicentre crossover study of 97 patients with mild hypertension, the incidence and severity of adverse effects were observed during the first 14 days of treatment with amlodipine, nifedipine retard or placebo." | 5.07 | Early side-effects of antihypertensive therapy: comparison of amlodipine and nifedipine retard. ( Bremner, AD; Fell, PJ; Hosie, J; James, IG; Saul, PA; Taylor, SH, 1993) |
| "To determine the dose-response efficacy of once-daily administration of placebo or a new long-acting calcium channel blocker amlodipine in patients with mild to moderate hypertension, a randomized, multicenter, placebo-controlled, double-blind trial was conducted." | 5.07 | Double-blind evaluation of the dose-response relationship of amlodipine in essential hypertension. ( Garland, WT; Gradman, AH; Lopez, LM; Mehta, JL; Nash, DT; O'Connell, MT; Pickering, BI; Vlachakis, ND, 1993) |
| " The safety and efficacy of amlodipine vs enalapril as monotherapy was evaluated in patients with moderate/severe hypertension (supine DBP 105-125 mm Hg, SBP 140-220 mm Hg)." | 5.07 | A comparison of amlodipine with enalapril in the treatment of moderate/severe hypertension. ( Cornish, R; Crichton, WA; Fowler, G; Jeffers, TA; Lyons, D; Petrie, JC; Sanghera, SS; Webster, J; Wickham, EA; Witte, K, 1993) |
| " The safety and efficacy of amlodipine and enalapril were compared in patients with isolated systolic hypertension (supine DBP < 95 mm Hg and supine SBP 160-200 mm Hg)." | 5.07 | A comparison of amlodipine with enalapril in the treatment of isolated systolic hypertension. ( Cornish, R; Crichton, WA; Fowler, G; Jeffers, TA; Lyons, D; Petrie, JC; Sanghera, SS; Webster, J; Wickham, EA; Witte, K, 1993) |
| "An interim analysis of patient compliance is reported in 234 hypertension outpatients who were entered into a large-scale, open, crossover, comparative study between a new-generation calcium antagonist, amlodipine (5 mg, once daily), and nifedipine SR (20 mg, twice daily)." | 5.07 | Patient compliance and therapeutic coverage: amlodipine versus nifedipine SR in the treatment of hypertension and angina: interim results. Steering Committee and Cardiologists and General Practitioners involved in the Belgium Multicentre Study on Patient ( Detry, JM, 1994) |
| "Forty-one patients with mild to moderate essential hypertension (sitting diastolic blood pressure (DBP) 95-114 mmHg) were randomised in a double-blind fashion to treatment with either amlodipine 5-10 mg once daily (n = 21) or captopril 25-50 mg twice daily (n = 20) over a period of 8 weeks." | 5.07 | Comparison of the effects of amlodipine and captopril on clinic and ambulatory blood pressure. ( Lacourcière, Y; Poirier, L; Provencher, P, 1992) |
| "5 mg, 5 mg, or 10 mg) once daily was compared with atenolol (50 mg to 100 mg) once daily in patients with mild-to-moderate essential hypertension in a randomized, double-blind, parallel, placebo-controlled study." | 5.07 | A randomized, placebo-controlled, double-blind comparison of amlodipine and atenolol in patients with essential hypertension. ( Brobyn, R; Brown, RD; Frishman, WH; Johnson, BF; Reeves, RL; Wombolt, DG, 1992) |
| "The efficacy and safety of amlodipine in the long term treatment of outpatients with mild to moderate hypertension were examined in an open, non-comparative study." | 5.07 | [Effectiveness and tolerance of amlodipine in treatment of patients with mild to moderate hypertension. Results of a long-term study with a new calcium antagonist]. ( Ganzinger, U; Habeler, G; Lenzhofer, R; Pall, H; Tomaschek, A; Ziebart-Schroth, A; Zirm, B, 1992) |
| "Amlodipine, a novel dihydropyridine calcium-antagonist, was compared to slow-release nifedipine in a short-term study on 40 patients with mild to moderate essential hypertension, in order to assess the efficacy and tolerability of two different dihydropyridine calcium-antagonists with short and long half-life." | 5.07 | [A comparison between amlodipine and nifedipine retard in patients with essential arterial hypertension]. ( Bruzzone, F; Canale, C; Caponnetto, S; Lonati, A; Malvestiti, FM; Masperone, MA; Terrachini, V, 1992) |
| "The frequency and severity of adverse effects during the first 14 days of treatment with amlodipine (5 mg once daily), nifedipine retard (20 mg twice daily) or placebo were compared in a multicentre, three-way, cross-over study involving 97 patients with mild-to-moderate hypertension." | 5.07 | Comparison of early side effects with amlodipine and nifedipine retard in hypertension. ( Bremner, AD; Fell, PJ; Hosie, J; James, IG; Saul, PA; Taylor, SH, 1992) |
| "Twelve patients with essential hypertension who were already on treatment with the long-acting calcium antagonist amlodipine (5 mg once daily) were entered into a double-blind, randomized crossover study of the addition of one month's treatment with either bendrofluazide (5 mg once daily) or matching placebo." | 5.07 | A double-blind crossover study of the effect of concomitant diuretic therapy in hypertensive patients treated with amlodipine. ( Buckley, MG; Cappuccio, FP; MacGregor, GA; Markandu, ND; Miller, MA; Sagnella, GA; Singer, DR, 1991) |
| "The effects of amlodipine on ambulatory blood pressure were investigated in patients with mild-to-moderate hypertension." | 5.07 | A double-blind evaluation of the effect of amlodipine on ambulatory blood pressure. ( Burris, JF; Klein, J; Mroczek, WJ, 1991) |
| "Amlodipine (once daily) and captopril (twice daily) had comparable efficacy and safety in reducing the blood pressure of patients with mild and moderate essential hypertension." | 5.07 | A double-blind, parallel, comparative evaluation of amlodipine against captopril in the monotherapeutic treatment of mild and moderate essential hypertension: interim results. ( Guevara, J; Hernández, O; Hernández, R; Urbina, A; Velasco, M, 1991) |
| "This study compared the efficacy and safety of 8 weeks of open treatment with the dihydropyridine calcium antagonists amlodipine and nitrendipine in mild-to-moderate hypertension." | 5.07 | Amlodipine compared to nitrendipine for the treatment of mild-to-moderate hypertension. ( Beressem, P; Englert, R; Kramar, M; Stafunsky, M; von Manteuffel, E, 1991) |
| "Twenty-one subjects with mild or moderate systemic hypertension were treated for 12 weeks with amlodipine, a new calcium antagonist of the dihydropyridine group." | 5.07 | Efficacy and tolerability of amlodipine in patients with mild-to-moderate hypertension. ( Meaney, E; Moguel, R; Olvera, R; Samaniego, V, 1991) |
| "The antihypertensive efficacy of amlodipine was studied in 22 patients (16 female, six male) with mild-to-moderate hypertension." | 5.07 | Clinical evaluation of amlodipine, a new long-acting calcium antagonist, in mild and moderate hypertension. ( Escudero, J; Hernandez, H, 1991) |
| "The long-term haemodynamic responses to amlodipine, a new long-acting calcium antagonist, were studied both at rest and during exercise in 18 patients (mean age 43 years) with essential hypertension." | 5.06 | Long-term haemodynamic effects of amlodipine at rest and during exercise in essential hypertension. ( Digranes, O; Helland, B; Jordal, O; Lund-Johansen, P; Omvik, P; Stray, T; White, W, 1990) |
| "The arterial vasodilator properties of the dihydropyridine calcium antagonist amlodipine were compared with the effects of vascular muscle cyclic guanosine monophosphate production by sodium nitroprusside and with the effects of a combined infusion of amlodipine and the nondihydropyridine calcium antagonist verapamil in 8 untreated patients with primary hypertension." | 5.06 | Arterial vasodilator effects of the dihydropyridine calcium antagonist amlodipine alone and in combination with verapamil in systemic hypertension. ( Bühler, FR; Erne, P; Kiowski, W; Linder, L, 1990) |
| "Once-daily administration of amlodipine, a long-acting dihydropyridine calcium-channel blocker, and atenolol, a cardioselective beta-adrenoceptor blocking agent, were compared in patients with mild to moderate hypertension in a multicenter placebo-controlled trial." | 5.06 | Multicenter placebo-controlled comparison of amlodipine and atenolol in mild to moderate hypertension. ( Cocco, G; de Bruijn, B; Tyler, HM, 1988) |
| "Amlodipine, a new long-acting dihydropyridine calcium antagonist, was compared with placebo and atenolol in 125 patients with mild to moderate systemic hypertension [supine diastolic blood pressure (DBP) 90-114 mm Hg]." | 5.06 | A randomized placebo-controlled comparison of amlodipine and atenolol in mild to moderate systemic hypertension. ( Brobyn, R; Brown, RD; Frishman, WH; Johnson, BF; Reeves, RL; Wombolt, DG, 1988) |
| "The antihypertensive efficacy of once-daily amlodipine was studied in a group of 30 patients with mild to moderate hypertension in a double-blind, placebo-controlled, parallel-group study." | 5.06 | Once-daily amlodipine in the treatment of mild to moderate hypertension. ( Jeffers, TA; Petrie, JC; Robb, OJ; Scott, AK; Webster, J, 1988) |
| "A multicenter, placebo-controlled trial assessed the antihypertensive efficacy and safety of different doses of amlodipine in patients with mild to moderate hypertension." | 5.06 | Amlodipine: a double-blind evaluation of the dose-response relationship in mild to moderate hypertension. ( Frick, MH; McGibney, D; Tyler, HM, 1988) |
| "Amlodipine 10 mg once daily added to captopril 25 mg twice daily for 4 weeks in patients with moderate to severe hypertension significantly improved blood pressure control (by -18/-12 and -20/-12 mm Hg for supine and standing systolic/diastolic pressures respectively, p less than 0." | 5.06 | A double-blind crossover comparison of amlodipine and placebo added to captopril in moderate to severe hypertension. ( Maclean, D; Mitchell, ET; Tyler, HM; Walker, P; Wilcox, RG, 1988) |
| "One hundred sixty patients with mild to moderate essential hypertension entered this double-blind parallel group comparison of amlodipine, verapamil, and placebo." | 5.06 | Comparison of amlodipine and verapamil in the treatment of mild to moderate hypertension. ( Lorimer, AR; Smedsrud, T; Tyler, HM; Walker, P, 1988) |
| "Amlodipine, a new long-acting dihydropyridine calcium antagonist, was compared with hydrochlorothiazie (HCTZ) in 145 patients with mild to moderate hypertension." | 5.06 | Double-blind comparison of amlodipine and hydrochlorothiazide in patients with mild to moderate hypertension. ( Ames, RP; Applegate, WB; Burris, JF; Davidov, ME; Mroczek, WJ; Ram, CV, 1988) |
| "The antihypertensive efficacy and suitability for once daily dosing of amlodipine, a new calcium antagonist, was studied in a series of 205 patients with mild to moderate hypertension." | 5.06 | A dose-response study of amlodipine in mild to moderate hypertension. ( Frick, MH; McGibney, D; Tyler, HM, 1989) |
| "This is a double blind parallel group comparison in patients with mild-moderate hypertension, of amlodipine, verapamil and placebo." | 5.06 | A comparison of amlodipine, verapamil and placebo in the treatment of mild to moderate hypertension. Amlodipine Study Group. ( Lorimer, AR; Smedsrud, T; Tyler, HM; Walker, P, 1989) |
| " The antihypertensive efficacy of once-daily amlodipine was studied in a group of 30 patients with mild to moderate hypertension in a double-blind, placebo controlled parallel group study." | 5.06 | Once daily amlodipine in the treatment of mild to moderate hypertension. ( Jeffers, TA; Petrie, JC; Robb, OJ; Scott, AK; Towler, HM; Webster, J, 1987) |
| " The incidence of severe hypertension was significantly lower when nifedipine (odds ratio, 0." | 5.05 | Comparative efficacy and safety of oral antihypertensive agents in pregnant women with chronic hypertension: a network metaanalysis. ( Bellos, I; Daskalakis, G; Loutradis, D; Papapanagiotou, A; Pergialiotis, V, 2020) |
| "The US Food and Drug Administration recently granted an approved indication for the first fixed-dose combination antihypertensive (amlodipine) and nonsteroidal anti-inflammatory drug (celecoxib) for treatment of comorbid hypertension and osteoarthritis." | 5.01 | Fixed-Dose Combination Amlodipine/Celecoxib (Consensi) for Hypertension and Osteoarthritis. ( Cooper-DeHoff, RM; Smith, SM, 2019) |
| "Use of amlodipine for treatment of arterial hypertension and stable coronary artery disease (CAD) is sometimes limited by occurrence of peripheral edema and headache." | 5.01 | Peripheral edema and headache associated with amlodipine treatment: a meta-analysis of randomized, placebo-controlled trials. ( Böhm, M; Mahfoud, F; Messerli, FH; Scholz, SS; Vukadinović, D; Weber, MA; Williams, B, 2019) |
| " Long-acting dihydropyridine agent amlodipine is widely used for monotherapy and combination therapy for hypertension in clinical practice, while intermediate-acting dihydropyridine agents have shown inconsistent results in randomized clinical trials (RCTs)." | 4.98 | Effects of Long- and Intermediate-Acting Dihydropyridine Calcium Channel Blockers in Hypertension: A Systematic Review and Meta-Analysis of 18 Prospective, Randomized, Actively Controlled Trials. ( Arima, H; Chaugai, S; Kerman, SRJ; Sepehry, AA; Sherpa, LY, 2018) |
| "We are presenting a current view on a fixed-dose combination of amlodipine and candesartan in the treatment of hypertension." | 4.93 | [What are the effects of fixed-dose combination of candesartan and amlodipine]. ( Špinar, J; Vítovec, J, 2016) |
| "Aliskiren, a direct renin inhibitor, is effective for reducing blood pressure (BP) in patients with hypertension when combined with amlodipine or hydrochlorothiazide (HCTZ)." | 4.90 | Aliskiren/amlodipine vs. aliskiren/hydrochlorothiazide in hypertension: indirect meta-analysis of trials comparing the two combinations vs. monotherapy. ( Cao, C; Dong, X; Gao, D; Liu, Y; Niu, X; Song, A; Wei, J; Yan, R, 2014) |
| "The risk of myocardial infarction was significantly decreased with an amlodipine-based regimen compared with a non-CCB-based regimen (odds ratio [OR], 0." | 4.90 | Amlodipine and cardiovascular outcomes in hypertensive patients: meta-analysis comparing amlodipine-based versus other antihypertensive therapy. ( Choi, HM; Ko, SK; Lee, HY; Lee, SA; Park, HJ, 2014) |
| "Treatment of hypertension with CCBs should take into consideration the special effects of each single agent at different levels; lercanidipine for example may play a useful role in the management not only of hypertension but also in renal protection of hypertensive patients." | 4.89 | Renal protection with calcium antagonists: the role of lercanidipine. ( Burnier, M, 2013) |
| " This article considers the evidence supporting telmisartan/amlodipine combination therapy for the treatment of hypertension in patients with metabolic risk factors." | 4.89 | Telmisartan plus amlodipine single-pill combination for the management of hypertensive patients with a metabolic risk profile (added-risk patients). ( Ley, L; Schumacher, H, 2013) |
| "This review summarizes the current data on the triple combination therapy of aliskiren with amlodipine and hydrochlorothiazide, and discusses the clinical use of single pill triple combination of aliskiren, amlodipine and hydrochlorothiazide in the treatment of hypertension and associated cardiovascular conditions." | 4.88 | The single pill triple combination of aliskiren, amlodipine, and hydrochlorothiazide in the treatment of hypertension. ( Huan, Y; Townsend, R, 2012) |
| "A systematic literature search is undertaken for supporting the pharmacological proprieties and clinical efficacy of perindopril in the treatment of hypertension." | 4.87 | Perindopril for the treatment of hypertension. ( Ghiadoni, L, 2011) |
| "This study aimed to estimate the efficacy and tolerability of the combination of amlodipine and angiotensin-converting enzyme inhibitors as compared with amlodipine monotherapy in the treatment of hypertension." | 4.86 | Amlodipine and angiotensin-converting enzyme inhibitor combination versus amlodipine monotherapy in hypertension: a meta-analysis of randomized controlled trials. ( Chen, GM; Fang, WW; Jia, HX; Lv, Y; Zhong, J; Zou, Z, 2010) |
| " In particular, evidence suggests that fixed-dose perindopril/amlodipine effectively decreases BP and currently is the only RAS inhibitor/CCB combination proven to decrease all-cause and cardiovascular mortality as well as major cardiovascular events, and thus is a valuable option for the management of hypertension, especially in high-risk patients." | 4.86 | Combinations of inhibitors of the renin-angiotensin system with calcium channel blockers for the treatment of hypertension: focus on perindopril/amlodipine. ( Gaudouen, Y; Le Jeune, S; Lopez-Sublet, M; Mourad, C; Mourad, JJ; Pirollo, A, 2010) |
| "Telmisartan/amlodipine is a single-pill combination of telmisartan, an angiotensin II receptor antagonist, and amlodipine, a dihydropyridine calcium channel antagonist, which is taken orally once daily for the treatment of hypertension." | 4.86 | Telmisartan/amlodipine: single-pill combination in hypertension. ( Moen, MD, 2010) |
| " These concerns are illustrated by using the calcium antagonist amlodipine besylate (innovator drug) versus amlodipine maleate (generic), indicated for the treatment of hypertension and angina pectoris, as an example." | 4.85 | Potential concerns about generic substitution: bioequivalence versus therapeutic equivalence of different amlodipine salt forms. ( Meredith, PA, 2009) |
| "Single-pill combinations of the dihydropyridine calcium channel blocker (CCB) amlodipine and the angiotensin II receptor blocker valsartan (amlodipine/valsartan) [Exforge] are available in the US for the treatment of patients with hypertension." | 4.85 | Amlodipine/valsartan single-pill combination: a review of its use in the management of hypertension. ( Frampton, JE; Scott, LJ, 2009) |
| "A literature search was performed in PubMed/MEDLINE to identify articles published in English between 1988 and March 2008 describing clinical trials, particularly outcome trials, or mechanisms of therapeutic action relevant to the use of combination therapy in patients with hypertension or stable coronary artery disease with an ACE inhibitor (perindopril) and a calcium channel blocker (amlodipine)." | 4.84 | Optimizing the treatment of hypertension and stable coronary artery disease: clinical evidence for fixed-combination perindopril/amlodipine. ( Ferrari, R, 2008) |
| "In the present quantitative overview of outcome trials, we investigated the efficacy of amlodipine or angiotensin receptor blockers in the prevention of stroke and myocardial infarction in patients with hypertension, coronary artery disease, or diabetic nephropathy." | 4.84 | Prevention of stroke and myocardial infarction by amlodipine and Angiotensin receptor blockers: a quantitative overview. ( Franklin, SS; Li, Y; Safar, M; Wang, JG, 2007) |
| " Parallel-group, randomized, controlled trials that included at least 10 adults with baseline hypertension (SBP>or=140 mm Hg, DBP>or=90 mm Hg, or both), included at least 1 arm randomized to initial treatment with amlodipine monotherapy, had a minimum treatment duration of 8 weeks, and reported baseline and end-point blood pressure were included." | 4.82 | Effect of amlodipine on systolic blood pressure. ( Connelly, JE; Estok, RP; Fahrbach, KR; Frame, D; Levine, CB; Ludensky, V; Stone, LR, 2003) |
| "Calcium channel blockers (CCBs), which include both dihydropyridines such as nifedipine and amlodipine and non-dihydropyridines (verapamil and diltiazem), are among the most widely prescribed agents for the management of essential hypertension." | 4.82 | The role of existing and newer calcium channel blockers in the treatment of hypertension. ( Basile, J, 2004) |
| "Single-pill amlodipine besylate/atorvastatin calcium (Caduet), Pfizer Inc, NY, USA) is the first therapy aimed at the simultaneous treatment of hypertension (HTN) and dyslipidaemia (DYS)." | 4.82 | Simultaneous treatment of hypertension and dyslipidaemia may help to reduce overall cardiovascular risk: focus on amlodipine/atorvastatin single-pill therapy. ( Cowie, MR, 2005) |
| "SEVERAL MECHANISMS: The progression in renal failure first implies hemodynamic mechanisms and among which angiotensin II has a central role, but also an increase in proteinuria and the induction of many inflammatory and mitogenic mediators that enhance fibrosis (TGF-beta), an effect stimulating the thrombotic mechanism." | 4.81 | [The effect of angiotensin-converting enzyme inhibitors on the progression of chronic renal failure]. ( Bernadet-Monrozies, P; Durand, D; Kamar, N; Rostaing, L, 2002) |
| " hypertension clinical trial databases for amlodipine (Norvasc) and nifedipine in the gastrointestinal therapeutic system (GITS) formulation (Procardia XL)." | 4.80 | Safety of long-acting dihydropyridine calcium channel blockers in hypertensive patients. ( Kloner, RA; Levenstein, M; Materson, BJ; Vetrovec, GW, 1998) |
| " Seven trials (six of them still ongoing) have provided insight into the effects of the third-generation calcium antagonist, amlodipine, on mortality and end-organ damage in patients with hypertension or other forms of cardiovascular disease." | 4.80 | Long-term morbidity and mortality trials with amlodipine. ( Oparil, S, 1999) |
| "The study evaluated the effect of two nebivolol/valsartan on 24 hour ambulatory blood pressure versus amlodipine/valsartan in grade II or III hypertension patients or having uncontrolled BP despite treatment." | 4.31 | Effect of Fixed-dose Combination Amlodipine/Valsartan in Comparison to Two Drug Combination Nebivolol/Valsartan on 24-Hour Ambulatory Blood Pressure. ( Abdelrahim, MEA; Hanna, SM; Mahmoud, HB; Rabea, HM, 2023) |
| "These findings suggest that 5-ALA-HCl does not affect the antihypertensive agents-induced hypotensive effect, but enhances the bupivacaine-induced hypotensive effect, especially in SHRs, indicating that 5-ALA may contribute to anesthesia-induced hypotension via suppression of sympathetic nerve activity in patients with hypertension." | 4.31 | 5-Aminolevulinic acid hydrochloride enhances bupivacaine-induced hypotension in spontaneously hypertensive rats. ( Abe, M; Fukuda, N; Hara, T; Ishizuka, M; Ito, H; Katakawa, M; Otsuka, N, 2023) |
| "To investigate the actions of amlodipine-folic acid (amlodipine-FA) preparation on hypertension and cardiovascular in renal hypertensive rats with hyperhomocysteinemia (HHcy), so as to provide experimental basis for clinical research of amlodipine folic acid tablets." | 4.31 | Folic acid enhances the cardiovascular protective effect of amlodipine in renal hypertensive rats with elevated homocysteine. ( Chen, GL; Li, L; Liu, H; Lv, L; Ma, Z; Tong, X, 2023) |
| " The prevalence of hypertension in COPD patients ranges from 39-51%, and β-blockers and amlodipine are commonly used drugs for these patients." | 4.31 | Impact of bisoprolol and amlodipine on cardiopulmonary responses and symptoms during exercise in patients with chronic obstructive pulmonary disease. ( Hsieh, PC; Lan, CC; Su, WL; Tzeng, IS; Wu, CW; Wu, YK; Yang, MC, 2023) |
| " The swelling was caused by the antihypertensive amlodipine, which he used because of arterial hypertension due to a chronic kidney disease." | 4.31 | [Swelling of the labial gingiva of the teeth]. ( de Visscher, JGAM; Raaff, PI; van der Meij, EH, 2023) |
| " The medical records of diabetic cats were searched for the keywords 'hypertension', 'blood pressure', 'amlodipine', 'benazepril' and 'telmisartan' to identify cats with SH, which was defined as systemic arterial blood pressure (SABP) ⩾160 mmHg, documented at least twice, over several days." | 4.31 | Concurrent disorders of cats with diabetes mellitus and arterial systolic hypertension. ( Hess, RS; Williams, JG, 2023) |
| "To observe the effect of amlodipine besylate combined with metoprolol in treating hypertension and heart failure." | 4.31 | Improvement in hemodynamics of amlodipine besylate combined with metoprolol in patients with hypertension complicated by heart failure. ( Chen, C; Jiao, D; Shen, J; Zhang, W; Zhang, X; Zhu, G, 2023) |
| "This prospective, multicenter observational study assessed the real-world safety and effectiveness of an SPC containing olmesartan, amlodipine, and hydrochlorothiazide (O/A/H) in South Korean patients with hypertension and cardiovascular risk factors." | 4.31 | Real-World Effectiveness and Safety of a Single-Pill Combination of Olmesartan/Amlodipine/Hydrochlorothiazide in Korean Patients with Hypertension and Cardiovascular Risk Factors. ( Hong, JH; Hyun, D; Kim, GH; Kim, HL; Kim, W; Lim, S; Min, KW; Oh, J; Park, SD; Shin, J, 2023) |
| "To describe a case of angioedema associated with increasing the dose of HMG-CoA reductase inhibitor (atorvastatin) from 20 to 40 mg daily in a patient previously stable on angiotensin II receptor blocker (losartan) and calcium channel blocker (amlodipine) as antihypertensive agents." | 4.12 | Dose-dependent atorvastatin associated with angioedema. ( Al-Mohammadi, OS; Al-Qaaneh, AM; Mustafa, SM; Obaid, WT; Rabaan, AA, 2022) |
| "The aim of this report is to document the case of a dog that developed pleural effusion as a potential side-effect to the administration of a high-dose of amlodipine." | 4.12 | Unusual case of pleural effusion caused by amlodipine in a dog with systemic hypertension. ( An, JH; Chae, HK; Choi, M; Hwang, SY; Jang, HW; Kang, K; Oh, YI; Park, SM; Youn, HY, 2022) |
| "Although amlodipine is recommended as the first-line therapy for the treatment of hypertension, its use is limited by its potential side effects." | 4.12 | Ambulatory blood pressure response to S-amlodipine in Korean adult patients with uncontrolled essential hypertension: A prospective, observational study. ( Ahn, JH; Ahn, KT; Choi, WG; Jung, IH; Kang, SH; Kim, DK; Kim, SS; Lee, JH; Lee, KH; Na, JO; Park, SD; Seo, J, 2022) |
| "This study evaluated the effectiveness of treatment with an indapamide/amlodipine single-pill combination (SPC) in outpatients with uncontrolled isolated systolic hypertension (ISH) aged over 55 years in real-life clinical practice." | 4.12 | Effectiveness of indapamide/amlodipine single-pill combination in patients with isolated systolic hypertension: post-hoc analysis of the ARBALET study. ( Goreva, LA; Karapetyan, LV; Kobalava, ZD; Kolesnik, EL; Shavarova, EK, 2022) |
| "Activity of the circulating renin-angiotensin-aldosterone system (RAAS) has not been comprehensively characterized in cats with systemic hypertension (SH) or cardiomyopathy (CM), and the effects of furosemide or amlodipine treatment on the RAAS have not been fully evaluated in cats." | 4.12 | Circulating renin-angiotensin-aldosterone system activity in cats with systemic hypertension or cardiomyopathy. ( Domenig, O; Guillot, E; Mochel, JP; Ward, JL; Ware, WA; Yuan, L, 2022) |
| "A total of 198 patients with hypertension in ambulatory care who had been on fixed-dose combination of perindopril arginine, indapamide, and amlodipine for at least 4 weeks were included." | 4.12 | Use of Perindopril Arginine/Indapamide/Amlodipine in the Management of Hypertension in Two Sub-Saharan African Island Countries of Madagascar and Mauritius. ( Ackbarkhan, A; Mbanya, A; Mbanya, JC; Mittoo, MY; Ramamonjisoa, HA; Ramilitiana, B; Ranivoharisoa, EM; Ratsimbazafy, SJN, 2022) |
| " In this paper, we report the case of a late 80's female patient with hypertension who experienced amlodipine-induced gingival enlargement." | 4.12 | Gingival enlargement improvement following medication change from amlodipine to benidipine and periodontal therapy. ( Furui, M; Inagaki, K; Kamei, H; Matsubara, T, 2022) |
| "Conclusions: The use of quercetin (Corvitin, Quertin) in combination therapy with the combined antihypertensive drug containing ramipril/amlodipine (Egis-Hungary) significantly reduces the levels of nitric oxide, CRP, IL-1, and blood lipid spectrum, which reduces the incidence of complications and progression of hypertension." | 4.12 | INDICATORS OF ENDOTHELIAL DYSFUNCTION, MARKERS OF INFLAMMATION AND LIPID METABOLISM IN PATIENTS WITH HYPERTENSION WITH THE ADMINISTRATION OF QUERCETIN. ( Prokosa, MI, 2022) |
| "Objective: This study describes the single nucleotide polymorphisms (SNPs) in amlodipine-associated genes and assesses their correlation with blood pressure control among South African adults with hypertension." | 4.12 | Single Nucleotide Polymorphisms in Amlodipine-Associated Genes and Their Correlation with Blood Pressure Control among South African Adults with Hypertension. ( Adeniyi, OV; Benjeddou, M; Masilela, C, 2022) |
| "Antihypertensive treatment with Amlodipine in addition to standard diabetes therapy improves glycemic control in patients with T2DM and may be an appropriate option in people with diabetes and concomitant hypertension to help maintain euglycemia." | 4.12 | Antihypertensive treatment improves glycemic control in patients with newly diagnosed type 2 diabetes mellitus: A prospective cohort study. ( Cheng, PC; Huang, CN; Jian, LF; Li, JC; Lin, CL; Wu, YS, 2022) |
| "This study aimed to evaluate the effect of 24 weeks of S-amlodipine besylate therapy on cognitive function in patients with hypertension and cerebrovascular disease." | 4.12 | Relationship Between Calcium Channel Blockers Therapy and Cognitive Function Improvement in Cognitive Decline Patients with Cerebrovascular Disease. ( Jeong, HT; Lee, JH; Park, KY; Sung, HH; Youn, YC, 2022) |
| "The aim: To analyze the dynamics of daily monitoring of blood pressure, intracardiac (according to echocardiography), peripheral hemodynamics (according to ultrasound of the vessels of the lower extremity), the thickness of the intima-media complex (according to carotid sonography) in patients with hypertension the effect of treatment with a combination of lisinopril and amlodipine." | 4.12 | EFFECTIVENESS OF LISINOPRIL AND AMLODIPINE COMBINATION AT HYPERTENSION WITH COMORBIDITY OF ARTERIOSCLEROSIS OBLITERANS IN GENERAL PRACTICE. ( Babinets, LS; Halabitska, IM; Kryskiv, OI; Levchuk, RD, 2022) |
| "Aim To study the condition of coronary vasculature by data of coronarography (CG) in patients with chronic ischemic heart disease (IHD) and arterial hypertension (AH) associated with stage 2-4 chronic kidney disease (CKD) and to evaluate the effect of a 12-week complex treatment with perindopril or with a combination of perindopril/amlodipine on changes in vascular wall stiffness, endothelial function, and structure and function parameters in this patient category after coronary stenting." | 4.02 | [Vasoprotective effects hypotensive therapy in patients with coronary heart disease combined with chronic kidney disease stage 2-3 after coronary stenting]. ( Barbashina, TA; Gavriljuk, EV; Mal, GS; Pribylov, CA; Pribylov, VS; Pribylova, NN; Yakovleva, MV, 2021) |
| "In patients with hypertension and dementia, nifedipine was associated with increased mortality risk (aHR 1." | 4.02 | Calcium channel blockers, survival and ischaemic stroke in patients with dementia: a Swedish registry study. ( Eriksdotter, M; Garcia-Ptacek, S; Kalar, I; Kramberger, MG; Schwertner, E; Secnik, J; von Euler, M; Winblad, B; Xu, H, 2021) |
| "A total of 44,715 patients who had hypertension and received a telmisartan/S-amlodipine single-pill combination at least once were included for safety and efficacy evaluation from 2852 primary to tertiary hospitals in Korea from August 2013 to December 2019." | 4.02 | Telmisartan Plus S-Amlodipine Single-Pill Combination Therapy is Safe and Effective in Patients with Hypertension from Large-Scale Nationwide Surveillance Data in Korea (NOVEL) Study. ( Hong, GR; Jo, SH; Kim, SW; Park, CG; Park, SJ, 2021) |
| "We examined the effects of a fixed-dose single-pill combination of cilnidipine (10 mg), an L-/N-type calcium channel blocker, and valsartan (80 mg) (SPC of Cil/Val) on the day-by-day variability of morning home systolic blood pressure (MHSBP) in 616 patients with treated hypertension for 12 months as a sub-analysis of the HOPE-Combi survey, multicentral, post-marketing, and prospective observational survey." | 4.02 | Single-pill combination of cilnidipine, an l-/n-type calcium channel blocker, and valsartan reduces the day-by-day variability of morning home systolic blood pressure in patients with treated hypertension: A sub-analysis of the HOPE-combi survey. ( Kario, K; Kurose, Y; Matsuda, S; Nagahama, S; Sugii, H; Suzuki, N; Teshima, T, 2021) |
| "To determine the prevalence of ocular fundus abnormalities in cats with a diagnosis of systemic hypertension, to characterize the abnormalities observed, and to evaluate ophthalmoscopic evolution during treatment with amlodipine besylate." | 4.02 | Ocular fundus abnormalities in cats affected by systemic hypertension: Prevalence, characterization, and outcome of treatment. ( Andreani, V; Barsotti, G; Cirla, A; Drigo, M, 2021) |
| "Aim To study the psychological continuum in elderly patients with arterial hypertension associated with metabolic syndrome during the chronotherapy with a fixed combination (FC) of amlodipine, lisinopril, and rosuvastatin." | 4.02 | Psychological Continuum of Elderly Patients Suffering from Arterial Hypertension with Metabolic Syndrome, Against the Background of Chronotherapy with a Fixed Combination of Amlodipine, Lisinopril and Rosuvastatin. ( Agarkov, NM; Kolomiets, VI; Korneeva, SI; Markelova, AM; Markelova, EA; Moskalev, AA; Moskaleva, EO; Okhotnikov, OI, 2021) |
| "An amlodipine-based BP regimen reduced the long-term incidence of stroke compared with an atenolol-based regimen but had no measurable effect on dementia." | 4.02 | Long-Term Incidence of Stroke and Dementia in ASCOT. ( Godec, T; Gupta, AK; Mackay, J; Rostamian, S; Sever, PS; Whitehouse, A; Whiteley, WN, 2021) |
| "Patients ≥65years-old with a diagnosis of hypertension and/or dyslipidaemia receiving treatment with Enalapril and/or Amlodipine and/or Simvastatin." | 3.96 | [Effects of changing the appearance of medications in safety and adherence in chronic patients over 65 years of age in primary care. CAMBIMED Study]. ( Arancón-Monge, JM; Campos-Díaz, L; de Castro-Cuenca, A; Del Cura-González, I; Rodríguez Barrientos, R; Serrano-Vázquez, Á, 2020) |
| "Amlodipine lowered long-term gout risk compared with lisinopril or chlorthalidone." | 3.96 | The effects of antihypertensive class on gout in older adults: secondary analysis of the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. ( Beach, JL; Davis, BR; Ishak, A; Juraschek, SP; Mukamal, KJ; Shmerling, RH; Simpson, LM, 2020) |
| "The home blood pressure (BP) control by a single-pill combination of cilnidipine (an L-/N-type calcium channel blocker; CCB) and valsartan (HOPE-Combi) survey is a multicenter, post-marketing, prospective observational study of a single-pill combination of cilnidipine 10 mg and valsartan 80 mg (SPC of Cil/Val) in patients with uncontrolled hypertension." | 3.96 | Single-pill combination of cilnidipine, an L-/N-type calcium channel blocker, and valsartan effectively reduces home pulse pressure in patients with uncontrolled hypertension and sympathetic hyperactivity: The HOPE-Combi survey. ( Kario, K; Kurose, Y; Matsuda, S; Nagahama, S; Sugii, H; Suzuki, N; Teshima, T, 2020) |
| "Methyldopa and amlodipine are associated with the least side effects in pregnant women treated for chronic hypertension." | 3.96 | The comparison of side effects of methyldopa, amlodipine, and metoprolol in pregnant women with chronic hypertension. ( Ghafarzadeh, M; Namdari, P; Shakarami, A; Yari, F, 2020) |
| " His background history included chronic essential hypertension which was well-controlled with amlodipine 10mg daily." | 3.96 | Resistant hypertension during antituberculosis treatment: how is rifampicin implicated? ( Chai, ST; Lee, SL; Lim, WJ, 2020) |
| "In this case report, we describe a rare case of amlodipine induced massive ascites in a 30-year-old male with renal transplantation." | 3.96 | Amlodipine Induced Massive Ascites, a Rare Clinical Case. ( Arasan, SN; Cevher, SK; Dede, F; Yenigun, EC, 2020) |
| "Participants with untreated hypertension were enrolled from four centres in the community of western Sydney, NSW, Australia, mainly by general practitioners." | 3.94 | Quarter-dose quadruple combination therapy for initial treatment of hypertension: placebo-controlled, crossover, randomised trial and systematic review. ( Atkins, E; Bennett, A; Burke, M; Chalmers, J; Chou, M; Chow, CK; Dehbi, HM; Hillis, G; Hilmer, S; Krum, H; Neal, B; Nelson, M; Patel, A; Peiris, D; Reid, CM; Rodgers, A; Rogers, K; Salam, A; Thakkar, J; Thom, S; Usherwood, T; Vo, K; Webster, R; Woodward, M, 2017) |
| "In a group of 32 patients with combined ischemic heart disease (IHD) and arterial hypertension (AH) we studied dynamics of parameters of blood pressure and ECG 24-hour monitoring, as well as ultrasound structural and functional parameters of left and right ventricles during 3-month therapy with fixed dose combination of perindopril arginine (10." | 3.91 | ( Drobotya, NV; Guseynova, ES; Morgunov, MN; Torosyan, SS, 2019) |
| "S-amlodipine has been broadly used to treat hypertension, but its protective effects and underlying mechanism remain controversial." | 3.91 | S-amlodipine improves endothelial dysfunction via the RANK/RANKL/OPG system by regulating microRNA-155 in hypertension. ( He, C; Si, D; Yang, J; Yang, P; Zhao, Y, 2019) |
| "Background Amlodipine is used for the treatment of hypertension, but reports on its use in early pregnancy are limited." | 3.91 | Safety of Amlodipine in Early Pregnancy. ( Arata, N; Ito, S; Kamiya, CA; Mikami, M; Mito, A; Miyasato-Isoda, M; Murashima, A; Suzuki, T; Wada, Y; Waguri, M; Watanabe, O; Yakuwa, N; Yoshimatsu, J, 2019) |
| "Although both regimens were effective for reducing BP, increasing amlodipine to 10 mg daily controlled hypertension without elevation of serum uric acid." | 3.88 | Prospective direct comparison of antihypertensive effect and safety between high-dose amlodipine or indapamide in hypertensive patients uncontrolled by standard doses of angiotensin receptor blockers and amlodipine. ( Okamura, K; Okuda, T; Shirai, K; Totake, N; Urata, H, 2018) |
| "Study on the Effect of Irbesartan on Atrial Fibrillation Recurrence in Kumamoto (SILK study) is a prospective, multicenter, randomized, and open-label comparative evaluation of the effects of irbesartan and amlodipine on AF recurrence in hypertensive patients with AF who are scheduled to undergo catheter ablation or electrical cardioversion of AF." | 3.88 | Study on the Effect of Irbesartan on Atrial Fibrillation Recurrence in Kumamoto: Atrial Fibrillation Suppression Trial (SILK study). ( Fujimoto, K; Iwasa, A; Kaikita, K; Kajiwara, I; Koyama, J; Matsui, K; Matsumura, T; Morihisa, K; Morikami, Y; Ogawa, H; Tsujita, K; Tsunoda, R; Uemura, T; Yamabe, H, 2018) |
| "The ACCOMPLISH (Avoiding Cardiovascular Events Through Combination Therapy in Patients Living with Systolic Hypertension) trial demonstrated that combination therapy using amlodipine, rather than hydrochlorothiazide, in conjunction with benazepril provided greater cardiovascular risk reduction among high-risk hypertensive patients." | 3.88 | Prior Medications and the Cardiovascular Benefits From Combination Angiotensin-Converting Enzyme Inhibition Plus Calcium Channel Blockade Among High-Risk Hypertensive Patients. ( Bakris, G; Brook, RD; Dahlöf, B; Hau, T; Jamerson, KA; Kaciroti, N; Pitt, B; Velazquez, E; Weber, M; Zappe, DH, 2018) |
| " amlodipine in patients with hypertension and different risks of cardiovascular events, followed for a mean of 4." | 3.88 | Blood pressure variability and risk of cardiovascular events and death in patients with hypertension and different baseline risks. ( Berge, E; Hua, TA; Julius, S; Kjeldsen, SE; Liestøl, K; Mancia, G; Mehlum, MH; Parati, G; Rothwell, PM; Weber, MA, 2018) |
| "We conducted a prospective, non-interventional, multicenter study to examine the effect of a fixed-dose combination of perindopril/amlodipine in patients with arterial hypertension." | 3.88 | Effectiveness of a Fixed-Dose, Single-Pill Combination of Perindopril and Amlodipine in Patients with Hypertension: A Non-Interventional Study. ( Fleig, SV; Haller, H; Limbourg, FP; Weger, B, 2018) |
| "Compared with amlodipine, fimasartan increased late-phase glucose-stimulated insulin secretion in patients with type 2 diabetes and hypertension." | 3.88 | Fimasartan increases glucose-stimulated insulin secretion in patients with type 2 diabetes and hypertension compared with amlodipine. ( Ahn, CH; Cho, YM; Jung, HS; Kim, S; Kwak, SH; Lee, SO; Lim, MH; Mari, A; Park, KS; Roh, E; Yang, YS, 2018) |
| "The aim of the current study was to assess the association between 3 different calcium channel blockers (CCBs) (nifedipine, amlodipine and felodipine) and gingival overgrowth in patients with a diagnosis of severe refractory hypertension." | 3.88 | Influence of 3 calcium channel blockers on gingival overgrowth in a population of severe refractory hypertensive patients. ( de Souza, RC; Ferreira, DC; Fischer, RG; Gonçalves, LS; Vidal, F, 2018) |
| "During the Candesartan Antihypertensive Survival Evaluation in Japan (CASE-J) trial, patients with hypertension who received amlodipine had similar cardiovascular risks as those who received candesartan." | 3.88 | Long-term effects of antihypertensive therapy on cardiovascular events and new-onset diabetes mellitus in high-risk hypertensive patients in Japan. ( Ichihara, C; Kitao, H; Konda, M; Kuwabara, Y; Liu, J; Oba, K; Ueshima, K; Yasuno, S, 2018) |
| "to assess in patients with arterial hypertension and type 2 diabetes the effect of perindopril / amlodipine fixed combination on arterial wall stiffness (AWF) and microcirculation, and relationship between AWF parameters and the state microcirculation." | 3.88 | [Influence of Therapy With Fixed Combination of Perindopril and Amlodipine on Parameters of Elasticity of Main Vessels and Microcirculation in Patients With Arterial Hypertension and Type 2 Diabetes Mellitus]. ( Statsenko, ME; Titarenko, MN; Turkina, SV, 2018) |
| " Supportive medical therapy was carried out and persistent systemic hypertension was managed using telmisartan." | 3.88 | Successful management of proteinuria and systemic hypertension in a dog with renal cell carcinoma with surgery, telmisartan, and amlodipine. ( Kang, SS; Kim, HJ; Kwon, YJ; Suh, GH, 2018) |
| "Amlodipine (AMLO) and ramipril (RAMI) belong to the most prescribed drugs in patients with hypertension, a condition also encountered in depression." | 3.88 | How to Treat Hypertension in Venlafaxine-Medicated Patients-Pharmacokinetic Considerations in Prescribing Amlodipine and Ramipril. ( Augustin, M; Gründer, G; Haen, E; Paulzen, M; Schoretsanitis, G, 2018) |
| "Purpose - studying of clinical efficiensy of the combined therapy (Amlodipin with Valsartan and fibrates) in hypertensive patients with dyslipidemia." | 3.88 | [THE COMBINED THERAPY IN HYPERTENSIVE PATIENTS WITH DYSLIPIDEMIA]. ( Gegeshidze, N; Kapetivadze, V; Lazashvili, T; Maglapheridze, Z; Tabukashvili, R; Tchaava, K, 2018) |
| "- The aim was to evaluate the efficacy of a single-pill combination of atorvastatin/amlodipine in patients with arterial hypertension, dyslipidemia and moderate to high cardiovascular risk." | 3.88 | EFFICACY AND SAFETY OF A SINGLE-PILL COMBINATION OF ATORVASTATIN/AMLODIPINE IN PATIENTS WITH ARTERIAL HYPERTENSION AND DYSLIPIDEMIA. ( Georgieva Torbova-Gigova, S; Ivanov Manov, E; Margaritov Runev, N; Naydenov Naydenov, S, 2018) |
| "Hereby, we report four paediatric cases with amlodipine-related generalised oedema." | 3.85 | Amlodipine: The double edged sword. ( Al-Nabhani, D; El-Naggari, M; Rabah, F, 2017) |
| "This study assessed adherence to and the safety, tolerance, and effectiveness of the perindopril/amlodipine FDC in Greek patients with hypertension and stable coronary artery disease (CAD) over a 4-month period." | 3.85 | Adherence to Treatment, Safety, Tolerance, and Effectiveness of Perindopril/Amlodipine Fixed-Dose Combination in Greek Patients with Hypertension and Stable Coronary Artery Disease: A Pan-Hellenic Prospective Observational Study of Daily Clinical Practice ( Kotsis, VT; Liakos, CI; Papadopoulos, DP, 2017) |
| "The aim of the study was to assess the possibility of fixed combination perindopril+amlodipine to improve arterial elesticity in patients with hypertension and high pulse wave velocity, despite previous combination antihypertensive therapy." | 3.85 | [Optimization of BP Control and Arterial Elasticity With Fixed Combination Therapy Perindopril and Amlodipine In Patients With Arterial Hypertension and Increased Pulse Wave Velocity]. ( Chumachek, EV; Judina, JS; Khripaeva, VJ; Konradi, AO; Ledyaeva, AA; Nedogoda, SV; Palashkin, RV; Salasyuk, AS; Smirnova, VO; Tsoma, VV; Zvartau, NE, 2017) |
| "To evaluate the persistence of one-year treatment of free and fixed-dose combination of perindopril/amlodipine in hypertension." | 3.85 | [One year persistence of free and fixed dose combinations of perindopril/amlodipine]. ( Ferenci, T; Finta, E; Gasparics, R; Medvegy, M; Simonyi, G, 2017) |
| "There is a significant difference between the one year persistence of ramipril and ramipril/amlodipine fixed dose combination therapy in hypertension." | 3.85 | [One year adherence of ramipril versus ramipril/amlodipine fixed dose combination therapy in hypertension]. ( Ferenci, T; Simonyi, G, 2017) |
| "An open, non-comparative, prospective clinical study was conducted to evaluate the antihypertensive efficacy and tolerability of amlodipine, a calcium antagonist, in patients with arterial hypertension (AH) I-II stages, depending on the genotype for the polymorphic marker C3435T of the ABCB1 gene." | 3.85 | [Pharmacogenetic approaches to predicting the efficiency and safety of amlodipine in patients with arterial hypertension]. ( Kalle, EG; Morozova, TE; Ryzhikova, KA; Shih, NV; Sychev, DA, 2017) |
| " The fixed combination of rosuvastatin with ACE inhibitor lisinopril and calcium antagonist amlodipine allows to control effectively two main cardiovascular risk factors: hypercholesterolemia and arterial hypertension." | 3.85 | [Lisinopril, Amlodipine, Rosuvastatin as a Novel Fixed Combination in the Fight Against Cardiovascular Disease]. ( Semenova, AE; Sergienko, IV, 2017) |
| "In 1710 mild to moderate hypertension patients switching treatment from amlodipine or lercanidipine to barnidipine monotherapy or in combination with other antihypertensive drug classes, mean blood pressure decreased during 3-month follow-up." | 3.85 | Replacement of Amlodipine and Lercanidipine by Barnidipine: Tolerability and Effectiveness in a Real-Life Study. ( de Vries, C; Haerden, Y; Lins, R, 2017) |
| "This short-term, open-label study examined whether statin therapy had a synergistic effect on the BP-lowering efficacy of perindopril/amlodipine in a subgroup of patients in the PERSPECTIVA study with concomitant hypertension and hypercholesterolemia, with or without statin at baseline." | 3.85 | Impact of Statin Therapy on the Blood Pressure-Lowering Efficacy of a Single-Pill Perindopril/Amlodipine Combination in Hypertensive Patients with Hypercholesterolemia. ( Radchenko, G; Sirenko, Y, 2017) |
| " Aim of this subanalysis was to assess efficacy and tolerability of a fixed-dose perindopril/amlodipine combination (FDPAC) in patients with arterial hypertension (AP) uncontrolled on previous treatment with angiotensin receptor blockers (ARBs)." | 3.85 | [Efficacy and Safety of a Fixed Combination of Perindopril Arginine and Amlodipine in Patients With Hypertension Uncontrolled by Treatment With Angiotensin II Receptor Blockers in Real Clinical Practice. Results of the PREVOSHODSTVO (SUPERIORITY) Program] ( Ostroumova, OD, 2017) |
| "In newly diagnosed patients with hypertension, lercanidipine was superior to nifedipine in the six-year period when the analyzed endpoint was stroke." | 3.85 | Long-term outcomes of lercanidipine versus other calcium channel blockers in newly diagnosed hypertension: a nationwide cohort study. ( Cheng, KC; Cheng, KH; Cheng, KY; Lai, WT; Lee, CW; Yang, YH, 2017) |
| "This study was performed to evaluate the possible protective effect of two calcium channel blocker's "lacidipine (LAC) and amlodipine (AML)" on bone metabolism in an experimental ovariectomized and inflammation-induced osteoporosis rat model (OVXinf)." | 3.83 | Effects of Administration of Amlodipine and Lacidipine on Inflammation-Induced Bone Loss in the Ovariectomized Rat. ( Albayrak, A; Ayan, AK; Aydin, A; Bayir, Y; Cadirci, E; Demirci, E; Halici, Z; Karakus, E; Ozturk-Karagoz, B; Sahin, A; Unal, D, 2016) |
| "Telmisartan (TL), Hydrochlorothiazide (HZ) and Amlodipine besylate (AM) are co-formulated together for hypertension management." | 3.83 | Application and validation of superior spectrophotometric methods for simultaneous determination of ternary mixture used for hypertension management. ( Lamie, NT; Mohamed, HM, 2016) |
| "The current study investigated the efficacy of losartan and amlodipine in protecting spontaneously hypertensive stroke-prone (SHRSP) rats against the risk of stroke." | 3.83 | Prehypertensive treatment with losartan, however not amlodipine, leads to long-term effects on blood pressure and reduces the risk of stroke in spontaneously hypertensive stroke-prone rats. ( He, D; Lin, J; Zhang, L, 2016) |
| " The authors identified patients who filled prescriptions for fixed dose combinations of ramipril and amlodipine, and lisinopril and amlodipine prescribed for the first time, for the therapeutic indication of hypertension." | 3.83 | [Ramipril plus amlodipine and lisinopril plus amlodipine fixed dose combinations and patient's adherence]. ( Ferenci, T; Simonyi, G, 2016) |
| "This study was designed to quantitatively evaluate the efficacy and tolerability of a fixed dose combination of perindopril and amlodipine in the Kingdom of Saudi Arabia on a population of patients with essential hypertension, as well as to identify the predictors of BP control in this population." | 3.83 | The Efficacy of Perindopril/Amlodipine in Reaching Blood Pressure Targets: Results of the CONTROL Study. ( Abdelhady, A; Albow, A; Khader, S; Sinnuqrut, S, 2016) |
| "The present study aims to study the role of receptor activator of nuclear factor kappa B ligand/receptor activator of nuclear factor kappa B/osteoprotegerin (RANKL/RANK/OPG) system in cardiac hypertrophy in a spontaneous hypertension rat (SHR) model and the effects of amlodipine and atorvastatin intervention." | 3.83 | Amlodipine and atorvastatin improved hypertensive cardiac hypertrophy through regulation of receptor activator of nuclear factor kappa B ligand/receptor activator of nuclear factor kappa B/osteoprotegerin system in spontaneous hypertension rats. ( Cui, W; Du, H; Hao, J; Liu, D; Liu, F; Lu, J; Yang, X, 2016) |
| " Patients aged > 17 years, affected by hypertension and treated with the FDC or extemporaneous combination of olmesartan/amlodipine, were identified." | 3.83 | Patient Adherence to Olmesartan/Amlodipine Combinations: Fixed Versus Extemporaneous Combinations. ( Cricelli, C; Cricelli, I; Lapi, F; Levi, M; Parretti, D; Pasqua, A; Piccinni, C, 2016) |
| "Patients with mild/moderate hypertension and hypercholesterolemia, at high-/very high-CV risk, received lisinopril-amlodipine (10/5, 20/5 or 20/10 mg/day) plus rosuvastatin (10 or 20 mg/day)." | 3.83 | Safety and effectiveness of combined antihypertensive and cholesterol-lowering therapy in high-/very high-risk patients. ( Gaszner, B; Hild, G; Kónyi, A; Sárszegi, Z, 2016) |
| "Objective To compare 1-year treatment adherence of ramipril + amlodipine and ramipril +hydroclorothiazide fixed-dose combination therapies in patients with hypertension." | 3.83 | Ramipril + amlodipine and ramipril + hydrochlorothiazide fixed-dose combinations in relation to patient adherence. ( Alföldi, S; Farsang, C; Ferenci, T; Simonyi, G, 2016) |
| " We used pupillometry to evaluate the effects of the calcium channel blockers azelnidipine (AZ) and amlodipine (AM) on changes in autonomic nervous activity induced by isometric exercise in patients with hypertension." | 3.83 | Effects of azelnidipine and amlodipine on exercise-induced sympathoexcitation assessed by pupillometry in hypertensive patients. ( Hano, T; Iwane, N; Kawabe, T; Koike, Y; Nishihara, K, 2016) |
| "We evaluated the safety and efficacy of hypertension management with Coveram (perindopril/amlodipine combination) in patients with uncontrolled blood pressure (BP)." | 3.83 | Efficacy and Safety Assessment of Hypertension Management with Coveram (Perindopril/Amlodipine Fixed Combination) in Patients with Previous Angiotensin Receptor Blocker (ARB) Treatment: Arabian Gulf STRONG Study. ( Ahmed, M; Al-Wahshi, Y; Al-Zakwani, I; Alanbaei, M; El Tamimi, H, 2016) |
| "A total of 108 mild-to-moderate essential hypertension patients in Chinese Han nationality were treated with amlodipine for 8 weeks at a dosage of 5 mg/d." | 3.83 | [Association between gene polymorphism of calcium/calmodulin-dependent kinase 4 and efficacy of amlodipine in the treatment of hypertension in Chinese Han nationality]. ( Chen, Y; Liu, L; Liu, Y; Luo, Y; Yang, L; Yao, J; Zhong, G, 2016) |
| "Cats that required a greater dose of amlodipine had significantly higher SBP at diagnosis of hypertension (A: (median [25th, 75th percentile]) 182 [175,192] mmHg; B: 207 [194,217] mmHg, P < ." | 3.83 | Factors Influencing the Relationship Between the Dose of Amlodipine Required for Blood Pressure Control and Change in Blood Pressure in Hypertensive Cats. ( Bijsmans, ES; Doig, M; Elliott, J; Jepson, RE; Pelligand, L; Syme, HM, 2016) |
| "5 mg/day, and amlodipine 5 mg/day (baseline), 166 patients were classified as having resistant hypertension (n = 140) or CBP (n = 26) by ambulatory BP monitoring." | 3.83 | Copeptin is increased in resistant hypertension. ( Azizi, M; Bergerot, D; Blanchard, A; Bobrie, G; Courand, PY; Dubourg, J; Forni, V; Frank, M; Menard, J; Mendes, M, 2016) |
| "Treatment with candesartan cilexetil reduced the level of ADMA in hypertensive patients in the chronic stage of cerebral infarction." | 3.83 | Effects of Candesartan Cilexetil Compared with Amlodipine on Serum Asymmetric Dimethylarginine Levels in the Chronic Stage of Cerebral Infarction: A Preliminary Study. ( Katayama, Y; Nishiyama, Y; Nomura, K; Sunami, E, 2016) |
| "to compare efficacy of verapamil and amlodipine in treatment of chronic heart failure (CHF) with preserved left ventricular (LV) ejection fraction (EF) in patients with hypertensive disease (HD)." | 3.83 | [Comparison of Verapamil and Amlodipine for Treatment of Chronic Heart Failure With Preserved Left Ventricular Ejection Fraction in Patients With Hypertensive Disease]. ( Kanorskii, SG; Sereda, AF, 2016) |
| "Hypertension is a highly prevalent disease and a strong risk factor for cardiovascular disease in industrialized countries in Europe and North America." | 3.83 | [Combined antihypertensive and antilipemic therapy as one of the pillars in the poly-pharmacologic preventive strategy for patients with high cardiovascular risk]. ( Kékes, E, 2008) |
| " Amlodipine was started for steroid-induced hypertension; 11 days after its initiation, alanine aminotransferase and aspartate aminotransferase peaked at 630 and 421 IU/L, respectively." | 3.81 | Possible amlodipine-induced hepatotoxicity after stem cell transplant. ( Hammerstrom, AE, 2015) |
| "Spontaneously hypertensive rats (SHR) was used to study left ventricular hypertrophy (LVH) and its dynamic change after the interventions with Telmisartan and Amlodipine." | 3.81 | TRPC1, CaN and NFATC3 signaling pathway in the pathogenesis and progression of left ventricular hypertrophy in spontaneously hypertensive rats. ( Chen, L; Hong, H; Lin, X; Shi, X; Wu, Y; Zou, G, 2015) |
| "This retrospective claims database analysis compared two strategies of hypertension treatment in outpatient, emergency, and inpatient departments: a fixed-dose combination (FDC) of amlodipine/valsartan vs free combinations of angiotensin receptor blockers (ARBs) and calcium channel blockers (CCBs) (ARB+CCB group)." | 3.81 | Clinical outcomes and healthcare costs in hypertensive patients treated with a fixed-dose combination of amlodipine/valsartan. ( Chang, CJ; Chu, PH; Lin, YS; Tung, YC; Wu, LS, 2015) |
| " The aim of this study was to document the safety and effectiveness of the FDC olmesartan/amlodipine/hydrochlorothiazide in patients with essential hypertension in clinical practice." | 3.81 | Safety and effectiveness of a fixed-dose combination of olmesartan, amlodipine, and hydrochlorothiazide in clinical practice. ( Bramlage, P; Fronk, EM; Schmieder, RE; Smolnik, R; Sutton, G; Wolf, WP, 2015) |
| "The clinical EXCITE (EXperienCe of amlodIpine and valsarTan in hypErtension) study reported clinically relevant blood pressure (BP) reductions across all doses of amlodipine/valsartan (Aml/Val) and Aml/Val/hydrochlorothiazide (HCT) single-pill combinations." | 3.81 | Real-world effectiveness of amlodipine/valsartan and amlodipine/valsartan/hydrochlorothiazide in high-risk patients and other subgroups. ( Assaad-Khalil, SH; Cho, B; DiTommaso, S; Kitchlew, AR; Najem, R; Shete, A; Sison, J; Ueng, KC, 2015) |
| " This study aims to investigate whether calcium channel blockers plus low dosage aspirin therapy can reduce the incidence of complications during pregnancy with chronic hypertension and improve the prognosis of neonates." | 3.81 | The effect of calcium channel blockers on prevention of preeclampsia in pregnant women with chronic hypertension. ( Jiang, N; Liu, L; Liu, Q; Yang, WW; Zeng, Y, 2015) |
| "Pupillometry was used to evaluate the effects of the calcium channel blockers cilnidipine (CL) and amlodipine (AM) on changes in autonomic nervous activity induced by isometric exercise in patients with hypertension." | 3.81 | Cilnidipine but not amlodipine suppresses sympathetic activation elicited by isometric exercise in hypertensive patients. ( Hano, T; Iwane, N; Kawabe, T; Koike, Y; Nishihara, K, 2015) |
| " The PARTNER (Practical combination therapy of Amlodin and angiotensin II Receptor blocker; Safety and efficacy in paTieNts with hypERtension) study is a prospective specific clinical use survey examining the efficacy and safety of 12-week treatment with amlodipine (AML) and Angiotensin II Receptor Blocker (ARB) in 5900 hypertensive patients." | 3.81 | The therapeutic advantage of combination antihypertensive drug therapy using amlodipine and irbesartan in hypertensive patients: Analysis of the post-marketing survey data from PARTNER (Practical combination therapy of Amlodin and angiotensin II Receptor ( Fukuda, H; Ishibashi, K; Ishimitsu, T; Nagao, M; Nukui, K; Sato, F; Uchida, M, 2015) |
| " FC, two extreme approaches are presented: with difference in effectiveness due to improved adherence to the treatment estimated from published studies on other molecules used in hypertension such as SPCs and FCs - the base-case approach (1); and assuming no difference of effectiveness or adherence between SPC and FC of indapamide and amlodipine - the conservative approach (2)." | 3.81 | Economic evaluation of single-pill combination of indapamide and amlodipine in the treatment of arterial hypertension in the Polish setting. ( Borowiec, Ł; Filipiak, KJ; Holko, P; Kawalec, P; Stawowczyk, E, 2015) |
| "A 53-year-old female patient with schizophrenia and hypertension was on paliperidone 12 mg/day and amlodipine 5 mg/day." | 3.81 | Multiple inductive effects of carbamazepine on combined therapy with paliperidone and amlodipine. ( Akamine, Y; Miura, M; Uehara, H; Uno, T; Yasui-Furukori, N, 2015) |
| "This Russian study examined the effect on blood pressure (BP) of substituting current ineffective antihypertensive treatment with FDC perindopril/amlodipine in patients with uncontrolled hypertension." | 3.81 | Effectiveness of Fixed-Dose Perindopril/Amlodipine on Clinic, Ambulatory and Self-Monitored Blood Pressure and Blood Pressure Variability: An Open-Label, Non Comparative Study in the General Practice. ( Deev, AD; Gorbunov, VM; Karpov, YA, 2015) |
| "The aim of the work was to study dynamics of daily arterial pressure profile during combined antihypertensive therapy starting from calcium and angiotensin II antagonists (amlodipine-valsartan) in Far North employees suffering arterial hypertension engaged on different working schedules." | 3.81 | [DYNAMICS OF THE CIRCADIAN BLOOD PRESSURE PROFILE DURING COMBINED AMLODIPINE-VALSARTAN THERAPY IN FAR NORTH RESIDENTS]. ( Avtandilov, AG; Zapesochnaya, IL, 2015) |
| "Aim of the METR study - to assess effect of antihypertensive therapy with fixed combination of angiotensin converting enzyme inhibitor lisinopril (10 mg) and calcium antagonist amlodipine (5 mg) on parameters of arterial wall stiffness and central hemodynamics in patients with stage I-II essential hypertension (EH) and functional class II-III ischemic heart disease." | 3.81 | [Stiffness of the Arterial Wall and Central Hemodynamics During Long-Term Combination Antihypertensive Therapy]. ( Glezer, MG; Prokofieva, EB, 2015) |
| "the Indonesian subset of the EXCITE (clinical EXperience of amlodIpine and valsarTan in hypErtension) study, which was a multinational, prospective, observational, open study in hypertensive patients treated with Aml/Val SPC for 26 weeks." | 3.81 | Clinical Effectiveness, Safety and Tolerability of Amlodipine/Valsartan in Hypertensive Patients: the Indonesian Subset of the EXCITE Study. ( Abdillah, A; Kalim, H; Setiawati, A, 2015) |
| "to study effectiveness of a fixed combination of perindopril arginine and amlodipine besylate for the treatment of arterial hypertension with concomitant chronic cardiac insufficiency and signs of chronic kidney disease Materials and methods: 53 (44." | 3.81 | [EFFECTIVENESS OF FIXED COMBINATION OF PERINDOPRILARGININE AND AMLODIPINE FOR THE TREATMENT OF ARTERIAL HYPERTENSION WITH CONCOMITANT CHRONIC CARDIAC INSUFFICIENCY AND SIGNS OF CHRONIC KIDNEY DISEASE]. ( Borovkova, NY; Kuznetsova, TE, 2015) |
| "to assess efficacy of a fixed combination of perindopril arginine and amlodipine besylate in the treatment of hypertensive patients with chronic heart failure (CHF) and signs of chronic kidney disease (CKD)." | 3.81 | [Therapy of Arterial Hypertension in Patients With Chronic Heart Failure and Signs of Chronic Kidney Disease With Fixed Perindopril/Amlodipine Combination]. ( Borovkov, NN; Borovkova, NJ; Kovaleva, GV; Kuznecova, TE, 2015) |
| " Because of interaction between amlodipine and simvastatin, in combination with physical activity, the patient reported: muscle pain, weakness of the muscles, dizziness, and confusion." | 3.81 | [Drug interaction in 63-year-old male sportsman--a case report]. ( Foerster, J; Schetz, D; Sein Anand, J, 2015) |
| "To assess the possibility of a fixed combination of perindopril arginine and amlodipine in the correction of endothelial dysfunction (ED) in patients with arterial hypertension (AH)." | 3.81 | [The Possibilities of Pharmacological Correction of Endothelial Dysfunction in Patients With Arterial Hypertension]. ( Filippov, EV; Yakushin, SS, 2015) |
| "7 years, 19 men) with uncomplicated hypertension without diabetes were given bisoprolol 5-10 mg." | 3.81 | [The Fixed Combination of Amlodipine and Bisoprolol Eliminates the Effect of -Blockers on Central Pulse Wave in Patients With Arterial Hypertension]. ( Bogomaz, AV; Kobalava, ZD; Kotovskaya, YV, 2015) |
| "Aim of the postmarketing obsevational program POTENTIAL () was to assess in real clinical practice efficacy and safety of therapy with fixed perindopril A/amlodipine combination (FP/AC) in patients with artrial hypertension uncontrolled by preceeding therapy." | 3.81 | [The Use of Fixed Perindopril A/Amlodipine Combination Provides High Compliance to Therapy, Effective and Safe Arterial Pressure Lowering in Patients With Previous Inefferctive Therapy. The POTENTIAL Program]. ( Glezer On Behalf Of Program Participants, MG, 2015) |
| " We have previously shown that in salt-sensitive hypertension either a statin or the calcium channel blocker amlodipine (Aml) have vasoprotective effects." | 3.80 | Combination therapy of amlodipine and atorvastatin has more beneficial vascular effects than monotherapy in salt-sensitive hypertension. ( Jaimes, EA; Raij, L; Tian, R; Zhou, MS, 2014) |
| "Telmisartan exerted anti-obesity effects and restored leptin sensitivity, given as a treatment to rats with obesity." | 3.80 | Chronic blockade of angiotensin AT₁ receptors improves cardinal symptoms of metabolic syndrome in diet-induced obesity in rats. ( Barkhausen, J; Hübel, N; Mildner, M; Müller-Fielitz, H; Raasch, W; Vogt, FM, 2014) |
| "Hydralazine is a medication that has been used to manage hypertension and heart failure." | 3.80 | Hydralazine associated pauci-immune glomerulonephritis. ( Baiswar, S; Suneja, M; Vogelgesang, SA, 2014) |
| "EXCITE (clinical EXperienCe of amlodIpine and valsarTan in hypErtension) evaluated the real-life effectiveness, safety, and tolerability of single-pill combinations (SPCs) of amlodipine/valsartan (Aml/Val) and amlodipine/valsartan/hydrochlorothiazide (Aml/Val/HCTZ) in patients with hypertension from 13 countries in the Middle East and Asia." | 3.80 | Real-life effectiveness, safety, and tolerability of amlodipine/valsartan or amlodipine/valsartan/hydrochlorothiazide single-pill combination in patients with hypertension from Pakistan. ( Abid, R; Afzal, J; Iktidar, S; Khan, W; Kumar, K; Maheshwary, N; Moin, N; Qadir, M; Sakrani, J; Siddiqi, A, 2014) |
| "A total of 4,731 patients at high or very high cardiovascular risk with hypertension that was not properly controlled [ , and for [corrected] whom study treatment (fixed-dose perindopril 10 mg/indapamide 2." | 3.80 | Antihypertensive efficacy of triple combination perindopril/indapamide plus amlodipine in high-risk hypertensives: results of the PIANIST study (Perindopril-Indapamide plus AmlodipiNe in high rISk hyperTensive patients). ( Tóth, K, 2014) |
| "A European multi-center, prospective, 24-week, non-interventional study was conducted including 14,979 patients with essential hypertension and new treatment with olmesartan, amlodipine and hydrochlorothiazide as an FDC." | 3.80 | Clinical impact of patient adherence to a fixed-dose combination of olmesartan, amlodipine and hydrochlorothiazide. ( Bramlage, P; Fronk, EM; Ketelhut, R; Schmieder, RE; Smolnik, R; Wolf, WP; Zemmrich, C, 2014) |
| "This study evaluated the efficacy as well as the safety and tolerability profile of low-dose valsartan/amlodipine (Val/Amlo) single-pill combination (SPC) (160/5 mg) in patients with essential hypertension in Turkey." | 3.80 | Efficacy and safety of valsartan/amlodipine single-pill combination in patients with essential hypertension (PEAK LOW). ( Ar, I; Ilerigelen, B; Kızılırmak, P, 2014) |
| "The EXCITE (clinical EXperienCe of amlodIpine and valsarTan in hypErtension) study was designed to evaluate the effectiveness, tolerability and adherence of amlodipine/valsartan (Aml/Val) and amlodipine/valsartan/hydrochlorothiazide (Aml/Val/HCT) single-pill combination therapies in patients with hypertension from the Middle East and Asia studied in routine clinical practice." | 3.80 | Real-world clinical experience of amlodipine/valsartan and amlodipine/valsartan/hydrochlorothiazide in hypertension: the EXCITE study. ( Assaad-Khalil, SH; Cho, B; Kitchlew, AR; Knap, D; Najem, R; Shete, A; Sison, J; Ueng, KC, 2014) |
| " Our study evaluated the efficacy of triple therapy with perindopril, amlodipine, and indapamide sustained release (SR) in patients with uncontrolled hypertension on previous antihypertensive therapy." | 3.80 | Triple combination therapy in hypertension: the antihypertensive efficacy of treatment with perindopril, amlodipine, and indapamide SR. ( Páll, D; Szabó, Z; Szántó, I, 2014) |
| "Cyclosporine (CsA) is frequently responsible for hypertension in bone marrow transplant children." | 3.80 | Pharmacokinetic drug-drug interaction of calcium channel blockers with cyclosporine in hematopoietic stem cell transplant children. ( Bernard, E; Bertrand, Y; Bleyzac, N; Goutelle, S, 2014) |
| "This is a case report of a 71-year-old male with known diabetes, hypertension and diabetic nephropaty who over the course of one year developed an unrecognized myopathy due to concomitant treatment with high-dose simvastatin and amlodipin." | 3.80 | [Myopathy and rhabdomyolysis after treatment with simvastatin, amlodipine, and roxithromycin]. ( Lindelof, M; Skovbølling, SL, 2014) |
| "The aim of the study was to evaluate the persistence on one-year treatment with the free or fixed combination of ramipril and amlodipine, administered for the indication of hypertension." | 3.80 | [Medication adherence with the fixed combination of ramipril and amlodipine]. ( Ferenci, T; Simonyi, G, 2014) |
| "To evaluate the efficacy and safety of a fixed-term combination of β-blocker bisoprolol and the calcium antagonist amlodipine in the outpatient treatment of patients with arterial hypertension (AH) and coronary heart disease (CHD)." | 3.80 | [Evaluating the effectiveness of a fixed combination of amlodipine and bisoprolol in ambulatory patients with arterial hypertension and ischemic heart disease]. ( Chesnikova, AI; Kolomatskaia, OE; Safronenko, VA, 2014) |
| "Triplixam is a fixed dose combination of three well known antihypertensive agents, with complementary activities, to control blood pressure in patients with arterial hypertension: perindopril, an angiotensin converting enzyme inhibitor, indapamide, a diuretic whith thiazide-like effects but also specific properties, and amlodipine, a long-acting calcium antagonist of the dihydropyridine family." | 3.80 | [Fixed dose combination perindopril-indapamide-amlodipine (Triplixam) for the treatment of arterial hypertension]. ( Krzesinski, JM; Lancellotti, P; Scheen, AJ, 2014) |
| "To assess effect of combined antihypertensive therapy with lisinopril and amlodipine on circadian blood pressure (BP), insulin resistance (IR), carbohydrate and lipid metabolism in patients with arterial hypertension (AH) and type 2 diabetes mellitus (DM)." | 3.80 | [Effect of combination antihypertensive therapy on circadian blood pressure and metabolic parameters in patients with type 2 diabetes mellitus]. ( Derevianchenko, MV; Pastukhova, OR; Statsenko, ME, 2014) |
| " The patient had been treated with amlodipine (Amlor(®)) and a combination of bisoprolol and hydrochlorothiazide (Lodoz(®)) for 5years for essential hypertension." | 3.79 | [Telangiectasia during amlodipine therapy]. ( Dussouil, AS; Gaudy-Marqueste, C; Grob, JJ; Mallet, S; Monestier, S; Richard, MA; Tasei, AM, 2013) |
| "PEARL was a 3-month observational study with a perindopril/amlodipine fixed-dose combination for treatment of outpatients with essential hypertension uncontrolled by prior treatment (office BP ≥140/90 mmHg or ≥130/80 mmHg in those at high/very high cardiovascular risk)." | 3.79 | Twenty-four-hour ambulatory blood pressure reduction with a perindopril/amlodipine fixed-dose combination. ( Nagy, VL, 2013) |
| "To investigate the effects of losartan and amlodipine on cell apoptosis in the cerebral cortex of stroke-prone spontaneously hypertensive rats (SHRSP) from the onset of prehypertension or hypertension." | 3.79 | Differential effects of antihypertensive treatments on apoptosis, oxidative stress, and expression of angiotensin receptors in the cerebral cortex from the onset of prehypertension and hypertension in stroke-prone spontaneous hypertensive rats. ( He, DH; Lin, JX; Ning, RB; Wang, HJ; Xu, CS; Zhang, LM, 2013) |
| "In the observation program AESCULAP using the fixed-dose combination of amlodipine/valsartan as different dosage regimens (5/160 and 10/160 mg) and/or a diuretic, there was a marked antihypertensive effect in different subgroups of patients with previously uncontrolled hypertension and the BP goals being achieved in 79." | 3.79 | [On the way to achieve hypertension treatment goals: results of the open observational program AESCULAP (exforge--clinical safety and efficiency of using a double combination of antihypertensive drugs in patients with uncontrolled blood pressure)]. ( Chazova, IE; Martynyuk, TV, 2013) |
| "To estimate effect of combined perindopril/amlodipine therapy on structural and functional characteristics of the heart and blood vessels, intrarenal hemodynamics in patients with essential arterial hypertension (AH) depending on the degree of renal dysfunction." | 3.79 | [Organoprotective effects of the combination of perindopril and amlodipine depending on the renal functional state in patients with arterial hypertension]. ( Budagovskaia, ZM; Iskenderov, BG; Sisina, ON, 2013) |
| "The results of this study suggested that the L/N-type CCB, cilnidipine, had additive antihypertensive and proteinuria-lowering effects when administered in combination with an ARB, even in type-1 diabetic rats, and that the L-type CCB, amlodipine, did not." | 3.79 | Additive effects of cilnidipine and angiotensin II receptor blocker in preventing the progression of diabetic nephropathy in diabetic spontaneously hypertensive rats. ( Aritomi, S; Konda, T; Niinuma, K; Nitta, K; Ogawa, T, 2013) |
| "We enrolled 196 patients with hypertension who were already being treated with free-drug combinations of angiotensin-II receptor blocker (ARB) and amlodipine." | 3.79 | Improving drug adherence using fixed combinations caused beneficial treatment outcomes and decreased health-care costs in patients with hypertension. ( Dohi, K; Hiraoka, N; Hoshino, K; Ito, M; Kitai, T; Kumagai, N; Nakamori, S; Nakamura, M; Okamoto, S; Onishi, K; Oota, M; Ueda, Y; Yamada, T; Yazu, T, 2013) |
| "Since treatment regimen type can influence adherence and other outcomes, this study examined adherence, cardiovascular events, and economic outcomes in patients with hypertension treated with fixed-dose combination (FDC) amlodipine/olmesartan (AML/OM), FDC AML/benazepril (AML/BEN), and loose-dose combination AML plus angiotensin II receptor blockers (LDC AML/ARBs)." | 3.79 | Clinical and economic outcomes associated with amlodipine/renin-angiotensin system blocker combinations. ( Buzinec, P; Ferrario, CM; Panjabi, S; Swindle, JP, 2013) |
| "amlodipine, is a milestone in the effort to test whether newer compounds offer a better reduction of the cardiovascular consequences of hypertension, as well as good BP control." | 3.79 | Long-term potential of angiotensin receptor blockade for cardiovascular protection in hypertension: the VALUE trial. Valsartan Antihypertensive Long-term Use Evaluation. ( Julius, S, 1999) |
| "Amlodipine is a dihydropyridine calcium channel blocker that is used in the management of both hypertension and angina." | 3.78 | Amlodipine-induced gingival hyperplasia in chronic renal failure: a case report. ( Aldemir, NM; Begenik, H; Emre, H; Erdur, FM; Soyoral, Y, 2012) |
| " Patients received amlodipine 5 mg daily for grade ≥ 2 bevacizumab-induced hypertension." | 3.78 | Treatment of bevacizumab-induced hypertension by amlodipine. ( Billemont, B; Blanchet, B; Cabanes, L; Camps, S; Coriat, R; Goldwasser, F; Knebelmann, B; Mir, O; Ropert, S, 2012) |
| "This prospective, open-label, postmarketing surveillance study enrolled adults with arterial hypertension (systolic BP >140 mmHg and/or diastolic BP >90 mmHg) who were prescribed antihypertensive therapy with single-pill combination amlodipine/valsartan 5/80, 5/160, or 10/160 mg once daily." | 3.78 | Amlodipine/valsartan single-pill combination: a prospective, observational evaluation of the real-life safety and effectiveness in the routine treatment of hypertension. ( Dongre, N; Karpov, Y; Sastravaha, K; Vigdorchik, A, 2012) |
| "The present study had the objective to estimate the antihypertensive efficacy of a low-dose combination of amlodipine (5 mg) and lisinopril (equator, Gedeon Richter, Hungary; 10 mg) as well as its influence on the diastolic left ventricular function in the women presenting with arterial hypertension in the postmenopausal period A total of 60 postmenopausal women with grade II arterial hypertension available for the examination were allocated to two groups to be maintained on different therapeutic regimens." | 3.78 | [Antihypertensive efficacy of a low-dose combination of amlodipine and lisinopril in the treatment of arterial hypertension in postmenopausal women]. ( Bakhshaliev, AB; Gabieva, NN, 2012) |
| "Switching to a fixed-dose combination of AML/OM ± hydrochlorothiazide provided significant BP lowering and effectively controlled BP in a large proportion of Hispanic and non-Hispanic patients with hypertension uncontrolled on previous monotherapy." | 3.78 | Efficacy and tolerability of fixed-dose amlodipine/olmesartan medoxomil with or without hydrochlorothiazide in Hispanic and non-Hispanic patients whose blood pressure is uncontrolled on antihypertensive monotherapy. ( Maa, JF; Punzi, H; Shojaee, A, 2012) |
| "To describe the case of treatment with amlodipine in a poorly controlled hypertension in a pediatric patient diagnosed with tricodistrofia." | 3.78 | Amlodipine in pediatric patient with uncontrolled multifactorial hypertension. Formulation of amlodipine oral suspension. ( Arias Santos, I; Lago Rivero, N; Paradela Carreiro, A, 2012) |
| " The results suggest that the negative consequences of partial compliance for blood pressure control can be offset by choosing agents with a duration of action well beyond the dosing interval." | 3.78 | Patterns of compliance with once versus twice daily antihypertensive drug therapy in primary care: a randomized clinical trial using electronic monitoring. ( Boileau, G; Bolli, P; Handa, SP; Larochelle, P; Leenen, FH; Myers, M; Tanner, J; Wilson, TW, 1997) |
| "Hypertension is a major risk factor for renal disease and is common in people with diabetes mellitus." | 3.78 | Renoprotection and renin-angiotensin system blockade in diabetes mellitus. ( Ruilope, LM, 1997) |
| " This study was undertaken to compare the efficacy of amlodipine (an inhibitor of L-type calcium channels) and cilnidipine (an inhibitor of both L-type and N-type calcium channels) in patients with hypertension and type II diabetes mellitus." | 3.77 | Beneficial effects of L- and N-type calcium channel blocker on glucose and lipid metabolism and renal function in patients with hypertension and type II diabetes mellitus. ( Aiba, N; Hara, M; Izumi, T; Kutsuna, T; Masuda, T; Matsumoto, T; Moriya, T; Noda, C; Ogura, MN; Takahira, N, 2011) |
| "To report a case of conjunctival chemosis and bipedal edema associated with amlodipine besylate antihypertensive medication." | 3.77 | Chronic conjunctival chemosis from amlodipine besylate (Norvasc). ( Bianciotto, C; Say, EA; Shields, CL; Shields, JA, 2011) |
| "An eight-year-old boy with Burkitt lymphoma developed severe macroglossia and angioedema when treated with nicardipine." | 3.77 | Angioedema associated with dihydropyridine calcium-channel blockers in a child with Burkitt lymphoma. ( Gordon, CJ; Hederman, AD; Herrington, B; Ostrenga, AR; Pierce, WA, 2011) |
| "Outpatients with mild hypertension treated with a low dose of amlodipine." | 3.77 | The correlation between the clinical laboratory data and the telomere length in peripheral blood leukocytes of Japanese female patients with hypertension. ( Arima, T; Maeda, T; Makino, N; Oyama, JI; Sasaki, M, 2011) |
| " To confirm and support previous findings, the SEVITENSION study will assess the effects on CABP of treatment with the high dose combination of perindopril plus amlodipine as used in ASCOT-CAFE compared with the high dose combination of olmesartan/amlodipine in patients with moderate-to-severe hypertension uncontrolled on amlodipine monotherapy." | 3.77 | Efficacy of Sevikar® compared to the combination of perindopril plus amlodipine on central arterial blood pressure in patients with moderate-to-severe hypertension: Rationale and design of the SEVITENSION study. ( Ruilope, LM; Schaefer, A, 2011) |
| "A prospective (90 days), multicenter, multilevel pharmacoepidemiologic study was conducted in 3546 patients with hypertension treated with SPC amlodipine/valsartan by 698 general practitioners." | 3.77 | Effectiveness of amlodipine-valsartan single-pill combinations: hierarchical modeling of blood pressure and total cardiovascular disease risk outcomes (the EXCELLENT study). ( Abraham, I; Aerts, A; Brié, H; Coen, N; Hermans, C; Lee, C; Lins, R; MacDonald, K; Mecum, N; Shen, YM; Vancayzeele, S, 2011) |
| "To describe the occurrence of systemic hypertension in dogs with acute kidney injury and the efficacy of amlodipine besylate for its treatment." | 3.77 | Occurrence of systemic hypertension in dogs with acute kidney injury and treatment with amlodipine besylate. ( Doherr, M; Francey, T; Geigy, CA; Schweighauser, A, 2011) |
| "The real-world use of valsartan/amlodipine SPC was associated with better adherence and persistence relative to ARB + CCB FC therapy among patients with hypertension." | 3.77 | Comparison of real-world adherence, healthcare resource utilization and costs for newly initiated valsartan/amlodipine single-pill combination versus angiotensin receptor blocker/calcium channel blocker free-combination therapy. ( Andrews, LM; Baser, O; Wang, L; Xie, L, 2011) |
| "We examined a novel therapeutic approach for hypertension, a small-molecule direct inhibitor of smooth muscle myosin, CK-2018448 (CK-448), which is an N,N'-alkylurea (U." | 3.77 | Inhibition of smooth muscle myosin as a novel therapeutic target for hypertension. ( Abarzúa, P; Dhar, SK; Ho, D; Jia, Z; Malik, FI; Morgans, DJ; Pannirselvam, M; Vatner, SF; Wang, X; Zhao, X, 2011) |
| "The results of observational investigation by prescription of the fixed combination perindopril + amlodipin produced by to the uncontrollable hypertension patients by the previous therapy are described in the given article." | 3.77 | [Estimation of antihypertension efficiency and use of fixed combination perindopril+amlodipin by uncontrollable hypertension patients within the limits of routine treatment]. ( Ishmurzin, GP, 2011) |
| "Study subjects were patients receiving treatment for the first time with amlodipine ODT for hypertension under routine care." | 3.77 | Efficacy, safety, and palatability of RACTAB(®) formulation amlodipine orally disintegrating tablets. ( Fukui-Soubou, M; Kawashima, K; Terada, T; Terashima, H; Utsunomiya, O, 2011) |
| "Two hundred eighty-six outpatients prescribed three different CCBs (benidipine [CAS 91599-74-5], amlodipine [CAS 111470-99-6] and controlled release nifedipine (nifedipine CR) [CAS 21829-25-4]) for hypertension in combination with ARBs during a 4-year period were registered in a retrospective comparative study." | 3.76 | Effects of combination therapy with angiotensin II type I receptor blockers and calcium channel blockers on renal function in hypertensive patients/a retrospective, "real-world" comparative study. ( Futenma, A; Imai, H; Kimura, Y; Maeda, K; Miura, N; Suga, N; Yamada, H, 2010) |
| "We assessed effect of 6-weeks therapy with atorvastatin on parameters of lipid metabolism and some hemorheological characteristics in 27 patients with arterial hypertension (AH) and dyslipoproteinemia (DLP)." | 3.76 | [Effect of atorvastatin on hemorheological parameters in patients with arterial hypertension with dyslipidemia]. ( Abrashkina, ED; Nazarova, OA; Pakhrova, OA; Shaalali, N; Shutemova, EA, 2010) |
| "In this study, animals were divided into six groups as follows: control (Group 1), hypertension (Group 2), ovariectomy (Group 3), ovariectomy and hypertension (Group 4), ovariectomy, hypertension and amlodipine-treated (Group 5), and ovariectomy, hypertension and lacidipine-treated (Group 6)." | 3.76 | Effects of hypertension and ovariectomy on rat hepatocytes. Are amlodipine and lacidipine protective? (A stereological and histological study). ( Albayrak, F; Altunkaynak, ZB; Bayram, E; Beyzagül, P; Dursun, H; Halici, Z; Keleş, NO; Okçu, N; Süleyman, H; Ünal, B; Uyanik, A, 2010) |
| "Overall, 556 patients with hypertension (msDBP > or =95-<110 mmHg) received open-label aliskiren/amlodipine 150/5 mg for 2 weeks, followed by forced titration to aliskiren/amlodipine 300/10 mg for 52 weeks." | 3.75 | Long-term safety, tolerability and efficacy of combination therapy with aliskiren and amlodipine in patients with hypertension. ( Hollanders, G; Liao, W; Littlejohn, TW; Trenkwalder, P; Zhao, Y, 2009) |
| "To assess the cost effectiveness of four alternative treatment strategies in patients with hypertension and three or more cardiovascular risk factors in the UK (from the UK NHS perspective) or Sweden (from the societal perspective): amlodipine-based plus atorvastatin, atenolol-based plus atorvastatin, amlodipine-based alone and atenolol-based alone." | 3.75 | The lifetime cost effectiveness of amlodipine-based therapy plus atorvastatin compared with atenolol plus atorvastatin, amlodipine-based therapy alone and atenolol-based therapy alone: results from ASCOT1. ( Buxton, M; Dahlöf, B; Jönsson, B; Kahan, T; Lindgren, P; Poulter, NR; Sever, PS; Wedel, H, 2009) |
| "Goal of this study was to compare the efficacy and safety of amlodipine with enalaprile in case of patients with moderate essential arterial hypertension." | 3.75 | [Comparative evaluation of the antihypertensive efficacy of amlodipine versus enalapril]. ( Alicajić, F, 2009) |
| " Thus, we characterized the antihypertensive effect of the combination of telmisartan and low-dose hydrochlorothiazide in patients with hypertension that was not controlled by amlodipine, which is the most common CCB." | 3.75 | Effect of switching from amlodipine to combination therapy with telmisartan and low-dose hydrochlorothiazide. ( Ando, K; Isshiki, M; Takahashi, K, 2009) |
| "Changes in HBP and urinary albumin excretion (UAE) were investigated in 47 benidipine and 37 amlodipine recipients with essential hypertension and albuminuria between January 2007 and December 2007." | 3.75 | Effects of benidipine, a long-acting T-type calcium channel blocker, on home blood pressure and renal function in patients with essential hypertension: a retrospective, 'real-world' comparison with amlodipine. ( Hoshino, C; Kikuchi, A; Kuriyama, C; Ohta, M; Sato, N; Sugawara, S, 2009) |
| " This subanalysis of the Clinical Utility of Caduet in Simultaneously Achieving Blood Pressure and Lipid End Points (CAPABLE) trial studied attainment of the Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 7) and the National Cholesterol Education Program Adult Treatment Panel III (NCEP ATP III) blood pressure (BP) and low-density lipoprotein cholesterol (LDL-C) goals by 8 flexibly titrated doses (5/10-10/80 mg) of amlodipine/atorvastatin single pill in 494 African Americans with hypertension and dyslipidemia, according to the presence of diabetes +/- the metabolic syndrome." | 3.75 | Amlodipine/Atorvastatin single-pill therapy for blood pressure and lipid goals in African Americans: influence of the metabolic syndrome and type 2 diabetes mellitus. ( Ferdinand, KC; Flack, JM; Jamieson, MJ; Kursun, A; Saunders, E; Shi, H; Victor, R; Watson, K, 2009) |
| "The study was based on a treatment regimen that was similar to the therapeutic approach in daily clinical practice and showed that the use of olmesartan medoxomil in monotherapy or in association with hydrochlorothiazide and amlodipine was effective in the attainment of the recommended goals for hypertension stage 1 and 2 hypertensive individuals." | 3.74 | Based treatment algorithm for essencial hypertension with olmesartan medoxomil. ( Amodeo, C; Brandão, AA; Feitosa, AD; Gomes, MA; Moriguchi, EH; Oigman, W; Précoma, DB; Ribeiro, AB; Ribeiro, JM; Saraiva, JF, 2008) |
| " In this sub-analysis of the Candesartan Antihypertensive Survival Evaluation in Japan (CASE-J) trial, we aimed to compare the effects of candesartan and amlodipine on cardiovascular mortality and morbidity in Japanese elderly patients with high-risk hypertension and to determine their optimal target blood pressures (BPs)." | 3.74 | The optimal target blood pressure for antihypertensive treatment in Japanese elderly patients with high-risk hypertension: a subanalysis of the Candesartan Antihypertensive Survival Evaluation in Japan (CASE-J) trial. ( Fujimoto, A; Fukiyama, K; Fukui, T; Matsuoka, H; Nakao, K; Oba, K; Ogihara, T; Saruta, T; Shimamoto, K; Ueshima, K, 2008) |
| "Adding amlodipine to valsartan for treatment of hypertension results in clinically meaningful reductions in blood pressure, on an overall basis and in high-risk subgroups who may benefit the most from blood pressure control." | 3.74 | Effectiveness of add-on therapy with amlodipine in hypertensive patients receiving valsartan. ( Edelsberg, J; Kartashov, A; Keskinaslan, A; Levy, DG; Oster, G; Weycker, D, 2008) |
| "ALLHAT, a randomized, double-blind, active-controlled hypertension treatment trial in 42,418 patients, reported that a thiazide-type diuretic (chlorthalidone) was superior to a calcium channel blocker (amlodipine), an angiotensin-converting enzyme inhibitor (lisinopril), and an alpha1-blocker (doxazosin) in preventing the new onset of heart failure (HF)." | 3.74 | The Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) Heart Failure Validation Study: diagnosis and prognosis. ( Black, HR; Cushman, WC; Davis, BR; Einhorn, PT; Levy, D; Massie, BM; Nwachuku, CE; Piller, LB; Simpson, LM, 2007) |
| "To report a case of bilateral upper extremity edema associated with amlodipine use in a child." | 3.74 | Amlodipine-induced bilateral upper extremity edema. ( Ganeshalingham, A; Wong, W, 2007) |
| "The clinical efficacy of amlodipine in improving hemodynamic variables and reducing cardiovascular events in isolated systolic hypertension could be explained by its beneficial effect on vascular calcification." | 3.74 | Distinct effects of amlodipine treatment on vascular elastocalcinosis and stiffness in a rat model of isolated systolic hypertension. ( Bouvet, C; Essalihi, R; Gilbert, LA; Lenoël, C; McKee, MD; Moreau, P; Moreau, S; Nekka, F; Zandvliet, ML, 2007) |
| "We aimed to compare the effects of the angiotensin II receptor blocker (ARB) olmesartan versus the calcium channel blocker (CCB) amlodipine on coronary endothelial dysfunction in patients with hypertension." | 3.74 | Olmesartan, but not amlodipine, improves endothelium-dependent coronary dilation in hypertensive patients. ( Fujii, S; Furumoto, T; Katoh, C; Morita, K; Naya, M; Tamaki, N; Tsukamoto, T; Tsutsui, H, 2007) |
| "We conducted a subgroup analysis of the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) to compare metabolic, cardiovascular, and renal outcomes in individuals assigned to initial hypertension treatment with a thiazide-like diuretic (chlorthalidone), a calcium channel blocker (CCB; amlodipine), or an ACE inhibitor (lisinopril) in nondiabetic individuals with or without metabolic syndrome." | 3.74 | Metabolic and clinical outcomes in nondiabetic individuals with the metabolic syndrome assigned to chlorthalidone, amlodipine, or lisinopril as initial treatment for hypertension: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent ( Baimbridge, C; Barzilay, J; Basile, J; Black, HR; Dart, RA; Davis, B; Marginean, H; Nwachuku, C; Thadani, U; Whelton, P; Wong, ND; Wright, JT, 2008) |
| " The aim of this study was to clarify the add-on effects of bedtime dosing of the alpha(1)-adrenergic receptor antagonist doxazosin on morning blood pressure in patients with essential hypertension who were under long-acting calcium channel blocker amlodipine monotherapy." | 3.74 | Add-on effect of bedtime dosing of the alpha(1)-adrenergic receptor antagonist doxazosin on morning hypertension and left ventricular hypertrophy in patients undergoing long-term amlodipine monotherapy. ( Gomi, T; Ikeda, T; Matsuda, N; Shibuya, Y; Shinozaki, S; Suzuki, Y, 2007) |
| "The present study examined the levels of Angiotensin II type 1 receptor (AT(1)) and type 2 receptor (AT(2)) in the brain stem and cerebral cortex of the stroke-prone spontaneously hypertensive rat (SHR-sp) after long-term treatment with three types of antihypertensive drugs: valsartan, enalapril, and amlodipine." | 3.74 | Decreased expression of angiotensin II type 1 and type 2 receptors in the brain after long-term administration of antihypertensive drugs in stroke-prone spontaneously hypertensive rat. ( Asai, S; Ishikawa, K; Nishida, Y; Sugahara-Kobayashi, M; Takahashi, Y, 2008) |
| "To report a case of anasarca edema associated with amlodipine use." | 3.73 | Anasarca edema with amlodipine treatment. ( Arioğul, S; Cankurtaran, M; Halil, M; Sener, D; Yavuz, BB, 2005) |
| " The Avoiding Cardiovascular events through COMbination therapy in Patients Living with Systolic Hypertension (ACCOMPLISH) trial compares regimens of benazepril plus amlodipine versus benazepril plus hydrochlorothiazide, force-titrated to 40/10 and 40/25mg, respectively." | 3.73 | The Avoiding Cardiovascular events through COMbination therapy in Patients Living with Systolic Hypertension (ACCOMPLISH) trial: a comparison of first-line combination therapies. ( Weder, AB, 2005) |
| "we observe the efficacy of verapamil and amlodipine administered simultaneously in the medical treatment of endogenous hyperinsulinemic hypoglycemia." | 3.73 | [Successful pharmacological treatment of hyperinsulinemic hypoglycemia with verapamil and amlodipine--case report]. ( Owecki, M; Sowiński, J, 2005) |
| "The irbesartan in Diabetic Nephropathy Trial (IDNT) demonstrated that treatment of patients with type 2 diabetes, hypertension and nephropathy with irbesartan resulted in a 20% relative reduction of the composite endpoint of doubling serum creatinine, end-stage renal disease or death as compared with amlodipine and placebo (antihypertensive standard therapy)." | 3.73 | [Health economic consequences of the use of irbesartan in patients with type 2 diabetes, hypertension and nephropathy in Switzerland]. ( Burnier, M; Frei, A; Hess, B; Palmer, AJ, 2006) |
| " report increased expression of connective tissue growth factor and transforming growth factor-beta and worsening of remodeling in subcutaneous arterioles of patients with essential hypertension during amlodipine treatment." | 3.73 | Arteriolar remodeling in essential hypertension: are connective tissue growth factor and transforming growth factor involved? ( Rodriguez-Iturbe, B, 2006) |
| "Azelnidipine suppressed cardiac hypertrophy, fibrosis, NADPH oxidase and superoxide in spSHRs more potently than amlodipine, and was associated with lower heart rates than amlodipine." | 3.73 | Enhancement of cardiac oxidative stress by tachycardia and its critical role in cardiac hypertrophy and fibrosis. ( Ito, T; Kataoka, K; Kim-Mitsuyama, S; Lai, ZF; Ogawa, H; Tanaka, T; Tokutomi, Y; Yamamoto, E; Yamashita, T, 2006) |
| "This is a case report on a 45-year old African-American female with newly diagnosed hypertension, who was started on a combination pill of amlodipine/benazapril 10/5 mg." | 3.73 | Angiotensin-converting enzyme (ACE) inhibitor-associated angioedema of the stomach and small intestine: a case report. ( Blatt, C; Korsten, MA; Motwani, P; Shahzad, G, 2006) |
| " Combination therapy of valsartan with either amlodipine or verapamil was equally effective in reducing blood pressure to valsartan monotherapy (valsartan + amlodipine 129 +/- 4 valsartan + verapamil 133 +/- 6 mmHg;) but was not as effective at reducing albuminuria." | 3.72 | Disparate effects of angiotensin II antagonists and calcium channel blockers on albuminuria in experimental diabetes and hypertension: potential role of nephrin. ( Allen, TJ; Cao, Z; Cooper, ME; Davis, BJ; de Gasparo, M; Kawachi, H, 2003) |
| "Blood pressure (BP) decay data obtained from homeBP measurements in six patients with uncomplicated essential hypertension treated with a calcium blocker, amlodipine, were fitted to an exponential-exponential cosine function to determine the characteristic BP-lowering effects of amlodipine." | 3.72 | Exponential-exponential cosine fitting of blood pressure decay induced by a long-acting calcium blocker, amlodipine, using home blood pressure measurement. ( Kusachi, S; Mashima, K; Mayumi, E; Mitsuda, T; Murakami, T; Nakatsu, T; Tominaga, Y; Tsuji, T; Uesugi, T; Yamane, S, 2003) |
| "We estimated the cost-effectiveness of irbesartan compared with placebo or amlodipine in the treatment of patients with type 2 diabetes mellitus, hypertension, and overt nephropathy." | 3.72 | The cost-effectiveness of irbesartan in the treatment of hypertensive patients with type 2 diabetic nephropathy. ( Annemans, L; Borenstein, J; Chen, RS; Chiou, CF; Lewis, EJ; Palmer, AJ; Rodby, RA; Roze, S; Sengupta, N; Simon, TA; Smitten, A, 2003) |
| "Two hundred eighty-three men who were taking amlodipine to manage hypertension." | 3.72 | Evaluation of a therapeutic conversion from amlodipine to felodipine. ( Manzo, BA; Matalka, MS; Ravnan, SL, 2003) |
| "The "Irbesartan in Diabetic Nephropathy Trial" (IDNT), demonstrated a reduction in the combined endpoint of doubling of serum creatinine, end-stage renal disease (ESRD) or death compared to control or amlodipine arms in patients with hypertension, type 2 diabetes and overt nephropathy when treated with irbesartan." | 3.72 | [Health economic consequences of the use of irbesartan in patients in Germany with type 2 diabetes, nephropathy and hypertension]. ( Annemans, L; Lamotte, M; Palmer, AJ; Ritz, E; Rodby, RA; Roze, S, 2004) |
| "We studied the early pathophysiological response of lenticulostriate arterioles in rats in three models of human conditions associated with stroke: (a) chronic angiotensin II-hypertension; (b) chronic nicotine administration; (c) oxidative endothelial injury." | 3.72 | Early pathophysiological changes in cerebral vessels predisposing to stroke. ( Gerzanich, V; Ivanova, S; Simard, JM, 2003) |
| "Amlodipine is a potent peripheral and coronary vasodilator with high selectivity for vascular smooth muscle, and is widely used in mild to moderate hypertension, chronic stable angina and vasospastic angina." | 3.72 | Amlodipine associated hyperpigmentation. ( Erbagci, Z, 2004) |
| "The present study assessed the cost effectiveness of irbesartan, an angiotensin II receptor antagonist, and amlodipine, a calcium channel blocker, in the treatment of Canadian patients with diabetic nephropathy and hypertension." | 3.72 | Economic evaluation of the use of irbesartan and amlodipine in the treatment of diabetic nephropathy in patients with hypertension in Canada. ( Coyle, D; Rodby, RA, 2004) |
| "Our objective was to examine the effect of chronic treatment with amlodipine on blood pressure, left ventricular hypertrophy, and fibrosis in spontaneously hypertensive rats and the persistence of such an effect after drug withdrawal." | 3.72 | Amlodipine decreases fibrosis and cardiac hypertrophy in spontaneously hypertensive rats: persistent effects after withdrawal. ( Ardanaz, N; Arévalo, MA; Carrón, R; Guerrero, EI; Montero, MJ; San Román, L; Sevilla, MA; Voces, F, 2004) |
| "The Valsartan Antihypertensive Long-term Use Evaluation (VALUE) trial was designed to test whether, for the same achieved blood pressures, regimens based on valsartan or amlodipine would have differing effects on cardiovascular endpoints in high risk hypertension." | 3.72 | Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE Trial. ( Brunner, HR; Ekman, S; Hansson, L; Hua, T; Julius, S; Kjeldsen, SE; Laragh, JH; McInnes, GT; Mitchell, L; Plat, F; Schork, MA; Smith, B; Weber, MA; Zanchetti, A, 2004) |
| "In the current study we examined the effect of amlodipine (AMLOD) on oxidative stress-induced hypertension in Sprague-Dawley rats administered buthionine-sulfoximine (BSO), a glutathione (GSH) synthase inhibitor, in the drinking water." | 3.72 | Amlodipine attenuates oxidative stress-induced hypertension. ( Abukhalaf, IK; Bayorh, MA; Eatman, D; Ganafa, AA; Walton, M, 2004) |
| "A hundred and thirty-six patients with mild and moderate arterial hypertension (AH) who had received angiotensin-converting enzyme inhibitors (ACEIs) (enalapril and lisinopril) and the calcium channel blocker amlodipine were examined." | 3.72 | [Effect of enalapril, lisinopril, and amlodipine on the course of chronic gastrititis in patients with arterial hypertension]. ( Alekseenko, SA; Avilova, AA; Fleĭshman, MIu; Lamekhova, VG; Timoshin, SS, 2004) |
| "The aim of this study was to compare the effect of amlodipine and angiotensin-converting enzyme (ACE) inhibitors and angiotensin II receptor blockers (ARBs) in the treatment of essential hypertension in elderly patients (>60 years) in an actual practice setting." | 3.71 | A retrospective electronic chart review of blood pressure changes in elderly patients treated with amlodipine or an angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker. ( Arocho, R; Brown, C; Dollar, A; McLaughlin, T; Okamoto, L; Putnam, D, 2002) |
| "An elderly patient who developed marked symptoms of parkinsonism in response to amlodipine for the treatment of arterial systemic hypertension is described." | 3.71 | Parkinsonian syndrome induced by amlodipine: case report. ( Germiniani, FM; Teive, HA; Werneck, LC, 2002) |
| " The present study compared the effects of prolonged treatment with the Ca2+-channel blocker amlodipine and the ACE inhibitor enalapril, respectively, in TGR(mREN2)27 rats (TGR), an animal model of renin-dependent hypertension." | 3.71 | Normalisation of blood pressure in hypertensive TGR(mREN2)27 rats by amlodipine vs. enalapril: effects on cardiac hypertrophy and signal transduction pathways. ( Heckmann, M; Huser, L; Knotter, B; Lemmer, B; Schiffer, S; Witte, K, 2001) |
| "We investigated the effects of the calcium channel blocker amlodipine besilate on serum levels of adrenal androgens and insulin in 20 men with essential hypertension and obesity (age: 51." | 3.71 | Effects of amlodipine on serum levels of adrenal androgens and insulin in hypertensive men with obesity. ( Miyachi, Y; Tsuboi, K; Ueshiba, H, 2001) |
| " Each of five groups of obese hypertensives were treated with the long-acting calcium channel blocker (CCB) amlodipine, the angiotensin converting enzyme (ACE) inhibitor enalapril with or without a weight reduction program, or a weight reduction program alone." | 3.71 | Weight reduction and pharmacologic treatment in obese hypertensives. ( Masuo, K; Mikami, H; Ogihara, T; Tuck, ML, 2001) |
| "The objective of the present study was to evaluate the efficacy and safety of a therapeutic interchange between high-dose calcium channel blocker therapy and a fixed-dose combination of amlodipine/ benazepril (Lotrel; Novartis Pharmaceuticals, USA) in patients with moderate to severe hypertension." | 3.71 | Efficacy and safety of a therapeutic interchange from high-dose calcium channel blockers to a fixed-dose combination of amlodipine/benazepril in patients with moderate-to-severe hypertension. ( Faulkner, M; Hilleman, DE; Reyes, AP; Wurdeman, RL, 2001) |
| "OBJECTIVES; We assessed the effects of long-term amlodipine administration in a diastolic heart failure (DHF) rat model with preserved systolic function as well as the relationship between changes in left ventricular (LV) myocardial stiffening and alterations in extracellular matrix." | 3.71 | Long-term administration of amlodipine prevents decompensation to diastolic heart failure in hypertensive rats. ( Hori, M; Mano, T; Masuyama, T; Miwa, T; Nishikawa, N; Sakata, Y; Sugawara, M; Yamamoto, K, 2001) |
| "These findings suggest that the ACE inhibitor imidapril augments RH after 12 weeks of treatment in patients with essential hypertension and that this ACE inhibitor-induced augmentation of RH may be due to an increase in NO." | 3.71 | Effect of the angiotensin-converting enzyme inhibitor imidapril on reactive hyperemia in patients with essential hypertension: relationship between treatment periods and resistance artery endothelial function. ( Higashi, Y; Kajiyama, G; Matsuura, H; Nakagawa, K; Oshima, T; Sasaki, S, 2001) |
| " The lowest dosage of lacidipine (but not of amlodipine) restored the physiological downregulation of renin production by high salt and reduced left ventricular hypertrophy and mRNA levels of atrial natriuretic factor and transforming growth factor-beta1." | 3.71 | Effects of amlodipine and lacidipine on cardiac remodelling and renin production in salt-loaded stroke-prone hypertensive rats. ( Godfraind, T; Krenek, P; Kyselovic, J; Wibo, M, 2001) |
| "To determine the effects of the angiotensin II receptor antagonist irbesartan, the calcium-channel blocker amlodipine, and hydrochlorothiazide/hydralazine on superoxide, NAD(P)H oxidase and nitric oxide bioavailability in spontaneously hypertensive stroke-prone rats (SHRSP)." | 3.71 | Irbesartan lowers superoxide levels and increases nitric oxide bioavailability in blood vessels from spontaneously hypertensive stroke-prone rats. ( Brosnan, MJ; Dominiczak, AF; Graham, D; Hamilton, CA; Jardine, E; Lygate, CA, 2002) |
| "Patients with moderate primary hypertension over 21 years of age who were given amlodipine (n:10) and captopril (n:10) for 8 weeks, plus normal controls (n:10)." | 3.71 | Normal erythrocyte calpain I activity on membrane proteins under near-physiological conditions in patients with essential hypertension. ( Barretto, OC; Dantas de Medeiros, TM; Mion, D; Nonoyama, K; Ortega, KC, 2002) |
| "This study investigated the comparative effects of losartan and amlodipine on the activation of the sympathetic nervous system, renin-angiotensin-aldosterone system (R-A-A system) and brain natriuretic peptide (BNP) in patients with essential hypertension." | 3.71 | [Comparative effects of losartan and amlodipine on activities of sympathetic nerve, renin-angiotensin-aldosterone system and brain natriuretic peptide in the elderly hypertensive patients]. ( Kinoshita, M; Mabuchi, N; Maeda, K; Ohnishi, M; Tsutamoto, T; Tsutsui, T, 2002) |
| "The effects of amlodipine on blood pressure profiles, cardiac hypertrophy, and beta-adrenergic signal transduction were studied in transgenic hypertensive TGR(mREN2)27 rats (TGRs), which are characterized by an inverse circadian blood pressure rhythm." | 3.70 | Effects of amlodipine once or twice daily on circadian blood pressure profile, myocardial hypertrophy, and beta-adrenergic signaling in transgenic hypertensive TGR(mREN2)27 rats. ( Lemmer, B; Schmidt, T; Schnecko, A; Voll, C; Witte, K, 1998) |
| "The present study was performed to compare cardioprotective effects of an angiotensin-converting-enzyme inhibitor, imidapril, and of a Ca2+ channel antagonist, amlodipine, against the cardiac hypertrophy in male spontaneously hypertensive rats (SHRs) at the established stage of hypertension." | 3.70 | Cardioprotective effects of an angiotensin-converting-enzyme inhibitor, imidapril, and Ca2+ channel antagonist, amlodipine, in spontaneously hypertensive rats at established stage of hypertension. ( Adachi, T; Naito, Y; Narita, H; Ohara, N; Yokota, S; Yoshida, H, 1998) |
| "The study illustrates the antihypertensive properties of amlodipine once-daily in paediatric hypertension." | 3.70 | Amlodipine once-daily in systemic hypertension. ( Bianchetti, MG; Busch, K; Clericetti-Affolter, C; Laux-End, R; Pfammatter, JP; Truttmann, AC, 1998) |
| "To document a case of severe, progressive myopathy, myalgias, arthralgias, and weakness possibly caused by amlodipine in a patient with benign essential hypertension." | 3.70 | Severe neuromuscular complications possibly associated with amlodipine. ( Muller, BA; Phillips, BB, 1998) |
| " Candesartan cilexetil is a novel AIIRA that has demonstrated clinical efficacy superior to losartan, has a sustained duration of action over 24 hours (trough:peak ratio close to 100%) and is well tolerated in patients with essential hypertension." | 3.70 | Key features of candesartan cilexetil and a comparison with other angiotensin II receptor antagonists. ( Sever, PS, 1999) |
| " Perindopril, candesartan cilexetil, or amlodipine alone or the combination of low doses of each agent was administered orally to stroke-prone spontaneously hypertensive rats (SHRSP) for 4 weeks to compare the hypotensive or cardiovascular effects." | 3.70 | Cardiovascular effects of combination of perindopril, candesartan, and amlodipine in hypertensive rats. ( Iwao, H; Izumi, Y; Kim, S; Zhan, Y, 2000) |
| "Two groups of drugs commonly used for the treatment of hypertension are atenolol and amlodipine." | 3.70 | A study of pulmonary profile of hypertensive patients--comparison of atenolol vs amlodipine. ( Chaswal, M; Shankar, N; Singh, S; Tandon, OP, 1998) |
| "The objective of this investigation was to compare changes in antioxidant status (together with other metabolites relevant to hypertension) in plasma and cardiac tissue from spontaneously hypertensive rats (SHR) and normotensive Wistar Kyoto rats (WKY), following 8 weeks of treatment with lisinopril (angiotensin converting enzyme inhibitor) or amlodipine (Ca(2+) channel antagonist) respectively." | 3.70 | Effects of lisinopril and amlodipine on antioxidant status in experimental hypertension. ( Ahmed, S; MacNee, W; Mantle, D; Patel, VB; Preedy, VR; Rahman, I; Richardson, PJ; Wassif, WS; Why, HJ, 2000) |
| " The independent contribution of hypertension and the overactive renin-angiotensin system to soluble guanylyl cyclase subsensitivity was assessed after normalization of TGR's blood pressure by the Ca(2+)-channel blocker amlodipine or the angiotensin converting enzyme-inhibitor enalapril." | 3.70 | Contribution of the renin-angiotensin system to subsensitivity of soluble guanylyl cyclase in TGR(mREN2)27 rats. ( Behrends, S; Huser, L; Jacke, K; Lemmer, B; Witte, K, 2000) |
| "One hundred patients with hypertension who were receiving amlodipine." | 3.70 | Retrospective evaluation of the conversion of amlodipine to alternative calcium channel blockers. ( Beckey, NP; Korman, L; Parra, D, 2000) |
| "Using digitized M-mode echocardiograms and 24-hour noninvasive ambulatory blood pressure monitoring, we evaluated the effects of 1 year treatment with amlodipine on left ventricular morphology and function in 10 hypertensives with left ventricular hypertrophy." | 3.69 | One-year antihypertensive treatment with amlodipine: effects on 24-hour blood pressure and left ventricular anatomy and function. ( Bignotti, M; Gaudio, G; Grandi, AM; Guasti, L; Venco, A, 1995) |
| "An open, multicenter study was conducted to investigate the antihypertensive efficacy and safety of amlodipine in the long-term treatment of patients with mild to moderate essential hypertension of a period of 178 weeks (3." | 3.69 | [Amlodipine in long-term treatment of mild and moderate hypertension. A multicenter study]. ( Anlauf, M; Sauerbrey-Wullkopf, N, 1995) |
| "To clarify whether the long-acting calcium-channel blocker amlodipine restores insulin insensitivity in essential hypertension, insulin sensitivity tests were performed at the physiological steady-state insulin level (45 to 55 microU/mL) before and after amlodipine (2." | 3.69 | Improvement of insulin sensitivity for glucose metabolism with the long-acting Ca-channel blocker amlodipine in essential hypertensive subjects. ( Asakura, Y; Harano, Y; Hirose, J; Ikebuchi, M; Kageyama, A; Omae, T; Suzuki, M; Yokota, T, 1995) |
| "Pharmacokinetic and pharmacodynamic data were compared between elderly and young patients with hypertension who received single intravenous doses of amlodipine, a dihydropyridine calcium antagonist, followed by oral administration of amlodipine up to 10 mg once daily for 12 weeks." | 3.69 | An overview of the pharmacokinetics and pharmacodynamics of amlodipine in elderly persons with systemic hypertension. ( Abernethy, DR, 1994) |
| "In a 3-month, open-label study, 54 consecutive black patients with very severe hypertension were treated with amlodipine." | 3.69 | Effects of amlodipine on 24-hour ambulatory blood pressure profiles, electrocardiographic monitoring, and left ventricular mass and function in black patients with very severe hypertension. ( Chautsane, Z; Chopamba, A; Lee, A; Reddy, K; Sareli, P; Skoularigis, J; Strugo, V; Weinberg, J, 1995) |
| "Fasting blood glucose was determined in 27 adults with essential hypertension at four different periods during a 12-month treatment with doxazosin, an alpha-adrenoceptor antagonist, and in another set of 20 adult hypertensive patients, after 3 months treatment with amlodipine, a calcium antagonist." | 3.69 | Blood glucose levels in hypertensive patients during treatment with different antihypertensive agents. ( Ahaneku, JE, 1996) |
| "The dihydropyridine calcium channel blocking agent amlodipine is an effective anti-hypertensive agent and its use (in doses of 5 or 10 mg/day/kg body weight) was investigated in male Wistar rats with hypertension induced by aortic constriction." | 3.69 | Effects of the dihydropyridine calcium channel blocker amlodipine on ventricular and atrial protein synthesis in an aortic constriction model of hypertension and, following chronic treatment, in the left ventricle of SHR rats. ( Patel, VB; Preedy, VR; Richardson, PJ; Sherwood, R; Siddiq, T, 1997) |
| "Twenty two patients having mild to moderate hypertension were treated with a single daily dose of amlodipine for 4 weeks." | 3.69 | Evaluation of amlodipine in mild to moderate hypertension--a clinical report. ( Acharya, HK; Vatsaraj, DJ; Yajnik, NV; Yajnik, VH, 1995) |
| "The effects of amlodipine on ambulatory blood pressure and on diurnal variations in plasma noradrenaline and renin activity were examined 1, 4, and 7 days after the start of amlodipine administration in eight inpatients with essential hypertension." | 3.69 | Amlodipine lowers blood pressure without increasing sympathetic activity or activating the renin-angiotensin system in patients with essential hypertension. ( Arakawa, K; Ideishi, M; Kinoshita, A; Koga, M; Matsumoto, N; Noda, K; Sasaguri, M, 1997) |
| "The effect of anti-hypertensive drug amlodipine on regression of cardiovascular hypertrophy due to hypertension was studied by using cultured smooth muscle cells derived from arteries of spontaneously hypertensive rats (SHR) and measuring [3H]-TdR and [3H]-Leucine binding." | 3.69 | Effect of amlodipine on the growth of vascular smooth muscle cells of spontaneously hypertensive rats. ( Liu, Z; Ren, D; Tang, J; Wu, C, 1997) |
| "The authors report the results of therapy with amlodipine in 20 patients with mild or moderate hypertension (diastolic pressure between 95 and 115 mmHg)." | 3.68 | [Experience with amlodipine (Norvasc) in the management of arterial hypertension]. ( Domínguez, B; Rodríguez, N, 1993) |
| "To evaluate the effects of long-term treatment antihypertensive with the dihydropyridine calcium antagonist amlodipine on insulin sensitivity, plasma insulin, and lipoprotein metabolism in obese hypertensive patients." | 3.68 | Lack of effect of long-term amlodipine on insulin sensitivity and plasma insulin in obese patients with essential hypertension. ( Böhlen, L; de Courten, M; Ferrari, P; Heynen, G; Riesen, W; Schneider, M; Shaw, S; Weidmann, P, 1993) |
| " The pressor response to norepinephrine and angiotensin II, as well as several other blood pressure modulating factors, were studied in normal subjects (n = 9) and patients with essential hypertension (n = 10) before and after 8 weeks of treatment with the long-acting dihydropyridine amlodipine." | 3.68 | Antihypertensive mechanism of amlodipine in essential hypertension: role of pressor reactivity to norepinephrine and angiotensin II. ( Beretta-Piccoli, C; Bühler, FR; Donati, L; Heinen, G; Kusch, F, 1992) |
| " With this end in mind, 21 patients with ischemic heart disease and arterial hypertension were divided into three groups of seven subjects each and submitted to different drug treatments with single daily doses: group 1 received isosorbide-5-mononitrate (60 mg), group 2 amlodipine (10 mg), and group 3 a combination of both drugs at the same dosage, for four weeks." | 3.68 | [The association of amlodipine with isosorbide-5-mononitrate in the treatment of ischemic-hypertensive cardiopathy]. ( D'Aprile, N; Faglia, S; Kristodhullo, A; Mondillo, S; Palazzuoli, V, 1992) |
| "Haemodynamic responses at rest and during exercise were studied in 18 patients with essential hypertension following long-term treatment with amlodipine." | 3.68 | Long-term haemodynamic effects of amlodipine at rest and during exercise in essential hypertension. ( Digranes, O; Helland, B; Jordal, O; Lund-Johansen, P; Omvik, P; Stray, T; White, W, 1992) |
| "Amlodipine administered once daily (5-10 mg) lowered blood pressure and reduced total peripheral resistance in patients with mild-to-severe essential hypertension without any reflex tachycardia." | 3.68 | Long-term haemodynamic effects of amlodipine at rest and during exercise in essential hypertension. ( Digranes, O; Helland, B; Jordal, O; Lund-Johansen, P; Omvik, P; Stray, T; White, W, 1991) |
| "Pharmacodynamics and disposition of amlodipine, a dihydropyridine calcium antagonist, were compared between elderly and young patients with hypertension." | 3.68 | Effects of amlodipine, a long-acting dihydropyridine calcium antagonist in aging hypertension: pharmacodynamics in relation to disposition. ( Abernethy, DR; Gutkowska, J; Winterbottom, LM, 1990) |
| " We prospectively studied the effects of amlodipine, a once-a-day dihydropyridine calcium channel antagonist, in 19 patients with essential hypertension." | 3.67 | Amlodipine therapy corrects renal abnormalities encountered in the hypertensive state. ( Bauer, JH; Hamory, A; Lau, A; Reams, GP, 1987) |
| "Hypertension is the leading risk factor for premature death worldwide." | 3.30 | Heterogeneity in Blood Pressure Response to 4 Antihypertensive Drugs: A Randomized Clinical Trial. ( Hagström, E; Held, C; Lind, L; Lytsy, P; Marttala, K; Neal, B; Nowrouzi, S; Östlund, O; Sundström, J, 2023) |
| " Third-standard-dose triple antihypertensive combination therapy demonstrated early effective BP control compared to third-standard-dose dual combination therapies, without increasing adverse drug reactions in patients with mild-to-moderate hypertension." | 3.30 | Comparison of efficacy and safety between third-dose triple and third-dose dual antihypertensive combination therapies in patients with hypertension. ( Cho, DK; Cho, GY; Cho, JM; Heo, JH; Hong, SJ; Jeong, MH; Jung, JA; Kim, DH; Kim, SH; Kim, SY; Kim, W; Kwon, K; Lee, HY; Lee, JB; Lim, SW; Park, K; Park, S; Pyun, WB; Rha, SW; Rhee, MY; Shin, J; Sung, KC, 2023) |
| " There was no significant difference in the adverse events rates between RSV 10 mg/AML 5 mg, RSV 20 mg/AML 5 mg, and ATV 20 mg/AML 5 mg." | 3.30 | Randomized, multicenter, parallel, open, phase 4 study to compare the efficacy and safety of rosuvastatin/amlodipine polypill versus atorvastatin/amlodipine polypill in hypertension patient with dyslipidemia. ( Bae, HJ; Cho, EJ; Choi, JY; Han, KR; Hong, BK; Hong, SP; Hyon, MS; Jin, HY; Jung, HW; Kim, CY; Kim, KS; Kim, SY; Kim, U; Lee, JB; Lee, KH; Lee, KJ; Lee, SR; Lee, SY; Nam, CW; Park, CG; Park, SJ; Park, TH; Rhee, MY; Ryu, JK; Seol, SH; Shin, JH; Yang, DH; Yu, GW, 2023) |
| " There are no serious adverse event and no one discontinued medication due to adverse event." | 3.30 | Efficacy and safety of standard dose triple combination of telmisartan 80 mg/amlodipine 5 mg/chlorthalidone 25 mg in primary hypertension: A randomized, double-blind, active-controlled, multicenter phase 3 trial. ( Ahn, Y; Cha, KS; Chang, K; Cho, EJ; Choi, DJ; Choi, SY; Doh, JH; Hong, SJ; Hong, SP; Hwang, JY; Hyon, MS; Ihm, SH; Kang, WC; Kim, HS; Kim, MH; Kim, SH; Kim, WS; Kim, YH; Kwon, K; Lee, JH; Lee, N; Lim, SW; Rhee, MY; Shin, J; Son, JW; Yoo, BS, 2023) |
| " Adverse events and laboratory test results will be monitored throughout the trial." | 3.11 | Efficacy and safety of Tengfu Jiangya tablet combined with valsartan/amlodipine in the treatment of stage 2 hypertension: study protocol for a randomized controlled trial. ( Chen, W; Hua, Z; Li, Y; Wang, Y; Zhu, Y, 2022) |
| " The availability of OM combined with HCTZ, AML or both at different dosages makes it a valuable option to customize therapy based on the levels of BP and the clinical characteristics of hypertensive patients." | 3.01 | Single-Pill Combination with Three Antihypertensive Agents to Improve Blood Pressure Control in Hypertension: Focus on Olmesartan-Based Combinations. ( Burnier, M; Redon, J; Volpe, M, 2023) |
| "Amlodipine has low renal clearance (7 mL/min/mg) and long half-life (35-50 h) and duration of action, which allows it to sustain its anti-hypertensive effect for more than 24 h following a single dose." | 3.01 | Amlodipine in the current management of hypertension. ( Palmer, BF; Sever, P; Vogel Anderson, K; Wang, JG, 2023) |
| "The Quadruple UltrA-low-dose tReaTment for hypErTension (QUARTET) double-blind, active-controlled, randomized clinical trial will examine whether ultra-low-dose quadruple combination therapy is more effective than guideline-recommended standard care in lowering blood pressure." | 3.01 | Ultra-low-dose quadruple combination blood pressure-lowering therapy in patients with hypertension: The QUARTET randomized controlled trial protocol. ( Atkins, ER; Billot, L; Chalmers, J; Chow, CK; Hay, P; Hillis, GS; Neal, B; Nelson, M; Patel, A; Reid, CM; Rodgers, A; Schlaich, M; Usherwood, T; Webster, R, 2021) |
| " The former dosage of ACEis/ARBs was continued in one group while in another group, the ACEis/ARBs were replaced by amlodipine ± carvedilol according to the dose equivalents." | 3.01 | Effects of Renin-Angiotensin-Aldosterone Inhibitors on Early Outcomes of Hypertensive COVID-19 Patients: A Randomized Triple-Blind Clinical Trial. ( Ashraf, H; Bahreini, M; Ghoghaei, M; Najmeddin, F; Rasooli, F; Salehi, M; Soleimani, A; Solhjoo, M, 2021) |
| "Valsartan has a beneficial effect on LV deformation and function presented in GLS." | 2.94 | Valsartan Versus Amlodipine Effect on Left Ventricular Multidirectional Deformation and Adipocytokines Levels in Hypertensive Patients: Speckle Tracking Echocardiography. ( Khairat, I; Khedr, L; Werida, R, 2020) |
| " If BP is not at goal during 4 week's visit, dosage of antihypertensive agents will be doubled." | 2.94 | A comparative study for the effects of nifedipine GITS and amlodipine besylate administrated in daytime or at nighttime on recovery of blood pressure rhythm and arterial stiffness in the young and middle-aged subjects with non-dipper hypertension (NARRAS) ( Liu, J, 2020) |
| " The secondary efficacy variables were changes in MSSBP, mean sitting diastolic blood pressure (MSDBP), LDL cholesterol and other lipid levels at 4 weeks and 8 weeks, as well as observed adverse events during follow-up." | 2.94 | Efficacy and safety of co-administered telmisartan/amlodipine and rosuvastatin in subjects with hypertension and dyslipidemia. ( Ahn, JC; Chae, IH; Cho, EJ; Cho, JM; Cho, Y; Choi, SY; Han, KH; Hong, SJ; Hong, SP; Hwang, J; Hyon, MS; Jin, X; Kim, H; Kim, HS; Kim, JH; Kim, MH; Kim, PJ; Kim, WS; Kwon, K; Lee, H; Lee, HC; Lee, JH; Lee, K; Lee, SH; Park, CG; Rhee, MY; Seo, JS; Shin, JH; Sung, JH; Sung, KC; Yoo, BS, 2020) |
| "Hydrochlorothiazide-based therapy was associated with a lower number of endothelial microparticles throughout the study, whereas a higher number of platelet microparticles was observed after rosuvastatin withdrawal in the amlodipine arm." | 2.90 | Circulating microparticles and central blood pressure according to antihypertensive strategy. ( Bianco, HT; Ferreira, CES; Figueiredo Neto, AM; Fonseca, FAH; França, CN; Izar, MCO; Kato, JT; Massunaga, ND; Póvoa, RMS, 2019) |
| "The Precision HYpertenSIon Care (PHYSIC) study aims to investigate if there is a consistent between-person variation in blood pressure response to the common blood pressure-lowering drug classes of a clinically relevant magnitude, given the within-person variation in blood pressure." | 2.90 | The Precision HYpertenSIon Care (PHYSIC) study: a double-blind, randomized, repeated cross-over study. ( Ekman, I; Lind, L; Lytsy, P; Marttala, K; Nowrouzi, S; Öhagen, P; Östlund, O; Sundström, J, 2019) |
| "Background Hypertension is a known risk factor for heart failure ( HF ), possibly via the mechanism of cardiac remodeling and left ventricular hypertrophy ( LVH )." | 2.90 | Prevention of Heart Failure in Hypertension-Disentangling the Role of Evolving Left Ventricular Hypertrophy and Blood Pressure Lowering: The ALLHAT Study. ( Davis, BR; Johnson, K; Oparil, S; Tereshchenko, LG, 2019) |
| " For safety assessments, all adverse events and abnormal laboratory findings were recorded." | 2.87 | Efficacy and Safety of S-Amlodipine 2.5 and 5 mg/d in Hypertensive Patients Who Were Treatment-Naive or Previously Received Antihypertensive Monotherapy. ( Demir, M; Şen, S; Üresin, AY; Yiğit, Z, 2018) |
| "Poorly controlled hypertension is a leading global public health problem requiring new treatment strategies." | 2.87 | Fixed Low-Dose Triple Combination Antihypertensive Medication vs Usual Care for Blood Pressure Control in Patients With Mild to Moderate Hypertension in Sri Lanka: A Randomized Clinical Trial. ( Amarasekara, S; Amarasena, N; Billot, L; de Silva, AP; de Silva, HA; Fernando, M; Guggilla, R; Jan, S; Jayawardena, J; Maulik, PK; Mendis, S; Munasinghe, J; Naik, N; Patel, A; Prabhakaran, D; Rajapakse, S; Ranasinghe, G; Rodgers, A; Salam, A; Selak, V; Senaratne, V; Stepien, S; Thom, S; Tisserra, N; Webster, R; Wijekoon, S; Wijeyasingam, S, 2018) |
| "Although orthostatic hypotension (OH) is often considered a contraindication to blood pressure (BP) treatment, evidence is lacking." | 2.87 | Hypertension Treatment Effects on Orthostatic Hypotension and Its Relationship With Cardiovascular Disease. ( Appel, LJ; Juraschek, SP; Lipsitz, LA; Miller, ER; Mukamal, KJ, 2018) |
| " Single oral dose of amlodipine was administered to the hypertensive/normotensive subjects either morning or evening to assess the pharmacokinetic profile after morning dosing or evening dosing, respectively." | 2.84 | Evaluation of the effect of time dependent dosing on pharmacokinetic and pharmacodynamics of amlodipine in normotensive and hypertensive human subjects. ( Hs, S; Khodadoustan, S; Kumar, C; Nasri Ashrafi, I; S, C; Vanaja Satheesh, K, 2017) |
| "An amlodipine-based regimen was a negative predictor of high systolic BPV, vs." | 2.84 | Relationship Between Visit-to-Visit Blood Pressure Variability (BPV) and Kidney Function in Patients with Hypertension. ( Jeffers, BW; Zhou, D, 2017) |
| " The adverse events (AEs) during both treatment periods were generally mild." | 2.84 | The efficacy and long-term safety of a triple combination of 80 mg telmisartan, 5 mg amlodipine and 12.5 mg hydrochlorothiazide in Japanese patients with essential hypertension: a randomized, double-blind study with open-label extension. ( Higaki, J; Ikeda, H; Komuro, I; Kuroki, D; Nishimura, S; Ogihara, T; Shiki, K; Taniguchi, A; Ugai, H, 2017) |
| "Amlodipine was more effective than losartan in reducing patients' 24-h ambulatory blood pressure at the steady-state sampling time." | 2.84 | The effects of missed doses of amlodipine and losartan on blood pressure in older hypertensive patients. ( de Leeuw, PW; Fagard, R; Kroon, AA, 2017) |
| "Hypertension is classified into two types which are primary or essential hypertension and secondary hypertension." | 2.82 | Evaluation of the Safety and Efficacy of Dual Therapy Perindopril/Amlodipine in the Management of Hypertension. A Systematic Review and Meta-Analysis. ( Elmoursi, A; Kamel, IS; Kassem, A; Khalil, F; Mancy, IME; Mohamed, SED; Mostafa, S; Ramadan, IG; Shabana, H; Zedan, HA, 2022) |
| " In the prospective Valsartan Antihypertensive Long-term Use Evaluation (VALUE) trial, patients were randomized to valsartan or amlodipine regimens and followed for 4." | 2.82 | No evidence for a J-shaped curve in treated hypertensive patients with increased cardiovascular risk: The VALUE trial. ( Bangalore, S; Berge, E; Holzhauer, B; Hua, TA; Julius, S; Kjeldsen, SE; Mancia, G; Messerli, FH; Weber, MA; Zanchetti, A; Zappe, D, 2016) |
| "Hypertensive patients who had not achieved their target blood pressure with at least 4 weeks of ARB therapy were randomly assigned to receive either a fixed-dose combination of losartan and HCTZ (losartan/HCTZ; n=110) or a combination of amlodipine and a typical ARB dosage (CCB/ARB; n=121) and followed for 24 weeks." | 2.82 | Effect of Diuretic or Calcium-Channel Blocker Plus Angiotensin-Receptor Blocker on Diastolic Function in Hypertensive Patients. ( Ishii, K; Ito, H; Iwakura, K; Kihara, H; Toh, N; Watanabe, H; Yoshikawa, J, 2016) |
| " We aimed to investigate whether baseline predictors of cardiac morbidity, the major constituent of the primary endpoint in the Valsartan Antihypertensive Long-term Use Evaluation (VALUE) trial, were different in patients with diabetes and new-onset diabetes compared to patients without diabetes." | 2.82 | Predictors of cardiac morbidity in diabetic, new-onset diabetic and non-diabetic high-risk hypertensive patients: The Valsartan Antihypertensive Long-term Use Evaluation (VALUE) trial. ( Aksnes, TA; Holzhauer, B; Hua, TA; Julius, S; Kjeldsen, SE; Rostrup, M, 2016) |
| "We studied 62 patients with untreated hypertension, randomly assigned to cilnidipine or amlodipine for 48 weeks." | 2.82 | Long-term effects of L- and N-type calcium channel blocker on uric acid levels and left atrial volume in hypertensive patients. ( Eguchi, A; Fujiwara, S; Hirotani, S; Komamura, K; Koshiba, M; Mano, T; Masaki, M; Masuyama, T; Sugahara, M; Tsujino, T, 2016) |
| " The study aimed to evaluate the feasibility of different doses of DXM combined with standard AM treatment in clinical hypertension." | 2.82 | Combination With Low-dose Dextromethorphan Improves the Effect of Amlodipine Monotherapy in Clinical Hypertension: A First-in-human, Concept-proven, Prospective, Dose-escalation, Multicenter Study. ( Chen, JW; Chen, P; Cheng, SM; Hung, YJ; Tseng, WK; Wang, KY; Wen, MS; Wu, CC; Wu, TC; Yeh, HI; Yin, WH, 2016) |
| "Amlodipine blunted the increase in diastolic BP that occurred during the second and third sets of exercise at 40% of 1RM (+75 ± 6 vs." | 2.80 | Amlodipine reduces blood pressure during dynamic resistance exercise in hypertensive patients. ( Barros, S; Costa, LA; Forjaz, CL; Gomides, RS; Mion, D; Ortega, KC; Queiroz, AC; Souza, DR; Tinucci, T, 2015) |
| " We investigated the relevant impact of different dosing times of antihypertensive drugs beyond CPAP application." | 2.80 | Evening versus morning dosing of antihypertensive drugs in hypertensive patients with sleep apnoea: a cross-over study. ( Andrikou, I; Aragiannis, D; Bilo, G; Dimitriadis, K; Filis, K; Kasiakogias, A; Parati, G; Sideris, S; Stefanadis, C; Thomopoulos, C; Tsiachris, D; Tsioufis, C, 2015) |
| "0001), and a lower incidence of pedal edema and adverse events compared with amlodipine." | 2.80 | Efficacy and safety of perindopril arginine + amlodipine in hypertension. ( Bakris, GL; Elliott, WJ; Feldstein, JD; Whitmore, J, 2015) |
| " Overall, the olmesartan/amlodipine FDC was well tolerated, and there were no serious adverse events associated with medication." | 2.80 | A multicenter, non-comparative study to evaluate the efficacy and safety of fixed-dose olmesartan/amlodipine in Korean patients with hypertension who are naïve or non-responders to anti-hypertensive monotherapy (ACE-HY study). ( Ahn, Y; Bae, JH; Jung, HW; Kang, DH; Kim, CH; Kim, KI; Park, CG, 2015) |
| "Hypertension and obesity are two major threats for public health." | 2.80 | The Effects of Valsartan and Amlodipine on the Levels of Irisin, Adropin, and Perilipin. ( Akkaya, N; Cakmak, M; Çelik, HT; Demircelik, B; Erdamar, H; Gok, S; Kazanci, F; Yigitoglu, R, 2015) |
| " The final population pharmacokinetic model shows that the elimination rate constant for simvastatin acid, the active form by hydrolysis of its lactone prodrug (i." | 2.79 | Genetic algorithm guided population pharmacokinetic model development for simvastatin, concurrently or non-concurrently co-administered with amlodipine. ( Chaturvedula, A; Lee, H; Sale, ME, 2014) |
| " Population pharmacokinetic analyses were performed on data which were collected prospectively from 60 Chinese patients with mild to moderate essential hypertension [age range 40-74 years, males (n = 31), females (n = 29)] receiving oral racemic amlodipine for 4 weeks." | 2.79 | ABCB1 polymorphism and gender affect the pharmacokinetics of amlodipine in Chinese patients with essential hypertension: a population analysis. ( Barrett, JS; Guo, CX; Hua, Y; Huang, ZJ; Pei, Q; Wang, JL; Yang, GP; Yuan, H; Zhang, WL; Zhou, HH; Zuo, XC, 2014) |
| "Azelnidipine has beneficial effects on LV mass regression, transmitral flow, tissue Doppler, and LV longitudinal strain that are comparable to those of amlodipine on the same parameters." | 2.79 | Impact of azelnidipine and amlodipine on left ventricular mass and longitudinal function in hypertensive patients with left ventricular hypertrophy. ( Ikeda, U; Izawa, A; Koyama, J; Miyashita, Y; Motoki, H; Takahashi, M; Tomita, T, 2014) |
| "The current study addresses the 24-h antihypertensive efficacy and safety of arotinolol combined with a different calcium channel blocker." | 2.79 | The efficacy and safety of arotinolol combined with a different calcium channel blocker in the treatment of Chinese patients with essential hypertension: a one-year follow-up study. ( Chen, W; Fang, H; Liu, X; Xu, W, 2014) |
| "Hypertension is a major risk factor for peripheral artery disease (PAD)." | 2.79 | Characteristics and long-term follow-up of participants with peripheral arterial disease during ALLHAT. ( Baraniuk, S; Basile, JN; Dart, RA; Davis, BR; Ellsworth, AJ; Fendley, H; Habib, GB; Piller, LB; Probstfield, JL; Rahman, M; Simpson, LM; Whelton, PK, 2014) |
| " The incidence of drug-related adverse effects did not differ significantly between the groups." | 2.79 | Efficacy and safety of olmesartan medoxomil/amlodipine fixed-dose combination for hypertensive patients uncontrolled with monotherapy. ( Gao, PJ; Zhang, SY; Zhu, JR, 2014) |
| " There were no differences between 4 dosing regimens in laboratory and clinical parameters of safety and tolerability." | 2.79 | [Fixed irbesartan/amlodipine combination: efficacy and safety of the use of four dosing regimens in patients with arterial hypertension]. ( Kobalava, ZhD, 2014) |
| "Test and reference formulations gave a mean Cmax of 5." | 2.78 | A comparative pharmacokinetic study of a fixed dose combination for essential hypertensive patients: a randomized crossover study in healthy human volunteers. ( Biswas, E; Choudhury, H; Ghosh, B; Gorain, B; Halder, D; Pal, TK; Sarkar, AK; Sarkar, P, 2013) |
| "5 mg) (ARB+D; n = 72) or a combination of amlodipine (5 mg) and the typical dosage of ARBs (ARB+C; n = 68) to evaluate the change in the BP, laboratory values and cognitive function." | 2.78 | Combination of antihypertensive therapy in the elderly, multicenter investigation (CAMUI) trial: results after 1 year. ( Hasebe, N; Kikuchi, K; Koyama, S; Maruyama, J; Morimoto, H; Morita, K; Saijo, Y; Sano, H; Sasagawa, Y; Sato, N; Sumitomo, K; Takehara, N; Takeuchi, T, 2013) |
| "Treatment with olmesartan/azelnidipine for 2 years resulted in greater improvements in CBP, LVMI, and LV diastolic function, and arterial stiffness compared with olmesartan/amlodipine." | 2.78 | Azelnidipine plus olmesartan versus amlodipine plus olmesartan on arterial stiffness and cardiac function in hypertensive patients: a randomized trial. ( Saito, Y; Takami, T, 2013) |
| "7%) patients experienced a total of 174 adverse events (AEs)." | 2.78 | Efficacy and safety of valsartan and amlodipine single-pill combination in hypertensive patients (PEAK study). ( Berktaş, M; Boyacı, B; Kızılırmak, P; Yalçın, MR, 2013) |
| "Seventy-six patients with type 2 diabetes and DKD (all with albuminuria and serum creatinine <1." | 2.78 | Effect of renin-angiotensin system blockade on soluble Klotho in patients with type 2 diabetes, systolic hypertension, and albuminuria. ( Gnudi, L; Hill, B; Karalliedde, J; Maltese, G; Viberti, G, 2013) |
| "The primary composite outcomes were sudden cardiac death, acute myocardial infarction, stroke, coronary revascularization, or hospitalization for heart failure." | 2.78 | Effects of valsartan versus amlodipine in diabetic hypertensive patients with or without previous cardiovascular disease. ( Kondo, T; Maeda, K; Matsushita, K; Muramatsu, T; Murohara, T; Nagahiro, T; Shintani, S; Yamashita, K, 2013) |
| "Amlodipine was added if target BP was not achieved at 1 month, and doxazosin was added if target BP was not achieved after 3 months." | 2.78 | Comparative effectiveness of a fixed-dose combination of losartan + HCTZ versus bisoprolol + HCTZ in patients with moderate-to-severe hypertension: results of the 6-month ELIZA trial. ( Dobrokhod, AS; Kushnir, SM; Radchenko, GD; Sirenko, YM; Torbas, OO, 2013) |
| "Candesartan or amlodipine was added when BP did not fall lower than 135/85 mmHg." | 2.78 | Comparative effect of candesartan and amlodipine, and effect of switching from valsartan, losartan, telmisartan and olmesartan to candesartan, on early morning hypertension and heart rate. ( Aoyama, T; Goto, M; Goto, N; Hiei, K; Iwasa, M; Kawai, N; Kida, K; Kobayashi, H; Kojima, S; Minagawa, T; Minatoguchi, S; Oda, M; Sugishita, F; Takai, K; Tanaka, R; Watanabe, I; Yamamoto, N; Yasue, T, 2013) |
| "If hypertension was not controlled they were switched to the SPC ALIS 300/AMLO 10 (4-week Phase 2)." | 2.77 | Efficacy and tolerability of the single-pill combination of aliskiren 300 mg/amlodipine 10 mg in hypertensive patients not controlled by olmesartan 40 mg/amlodipine 10 mg. ( Axthelm, C; Kaiser, E; Meister, F; Sieder, C, 2012) |
| " The participants were 15,193 patients with hypertension enrolled in the Valsartan Antihypertensive Long-term Use Evaluation (VALUE) trial and followed up for 5 years." | 2.77 | Usefulness of heart rate to predict cardiac events in treated patients with high-risk systemic hypertension. ( Brunner, HR; Holzhauer, B; Hua, TA; Jamerson, K; Julius, S; Kjeldsen, SE; Koylan, N; Majahalme, S; Mancia, G; McInnes, GT; Palatini, P; Schork, MA; Weber, MA; Zanchetti, A; Zappe, D, 2012) |
| "Antihypertensive therapy is effective in reducing the risk of major adverse cardiovascular events." | 2.77 | Combination of amlodipine plus angiotensin receptor blocker or diuretics in high-risk hypertensive patients: a 96-week efficacy and safety study. ( Deng, Q; Liu, L; Liu, M; Ma, L; Sun, H; Wang, J; Wang, W; Zhang, Y; Zhao, Y, 2012) |
| "Hyperkalemia was associated with increased risk of combined cardiovascular disease (hazard ratio, 1." | 2.77 | Clinical significance of incident hypokalemia and hyperkalemia in treated hypertensive patients in the antihypertensive and lipid-lowering treatment to prevent heart attack trial. ( Alderman, MH; Calhoun, DA; Cushman, WC; Davis, BR; Eckfeldt, JH; Einhorn, PT; Ford, CE; Franklin, SS; Furberg, CD; Ong, ST; Oparil, S; Papademetriou, V; Piller, LB; Probstfield, JL, 2012) |
| " Adverse events occurred at 11." | 2.77 | Efficacy and safety of aranidipine enteric-coated tablets compared with amlodipine in Chinese patients with mild to moderate essential hypertension: a multicenter, randomized, double-blind, parallel-controlled clinical trial. ( Chen, GL; Fan, CM; Li, HM; Li, YS; Lin, YZ; Pang, HM; Wang, L; Wu, SY; Yan, LR; Yu, J; Zhao, RP, 2012) |
| "Telmisartan was more effective than amlodipine in preventing AF recurrences in hypertensive patients with paroxysmal AF." | 2.77 | Effect of telmisartan on paroxysmal atrial fibrillation recurrence in hypertensive patients with normal or increased left atrial size. ( Derosa, G; Fogari, R; Maffioli, P; Mugellini, A; Perrone, T; Preti, P; Zoppi, A, 2012) |
| "We compared the effects of exercise alone and in combination with a calcium channel blocker (amlodipine) or an angiotensin receptor blocker (valsartan) in hypertensive patients." | 2.77 | Effects of exercise therapy alone and in combination with a calcium channel blocker or an angiotensin receptor blocker in hypertensive patients. ( Ikeda, M; Ohta, M; Tajiri, Y; Yamato, H, 2012) |
| " Safety profile was assessed by recording adverse events reported by patients or observed by the investigator." | 2.77 | I-ADD study: assessment of efficacy and safety profile of irbesartan/amlodipine fixed-dose combination therapy compared with irbesartan monotherapy in hypertensive patients uncontrolled with irbesartan 150 mg monotherapy: a multicenter, phase III, prospec ( Bobrie, G, 2012) |
| " Safety profile was assessed by recording adverse events reported by patients or observed by the investigator." | 2.77 | I-COMBINE study: assessment of efficacy and safety profile of irbesartan/amlodipine fixed-dose combination therapy compared with amlodipine monotherapy in hypertensive patients uncontrolled with amlodipine 5 mg monotherapy: a multicenter, phase III, prosp ( Bobrie, G, 2012) |
| "Twenty patients with untreated essential hypertension (M/F = 13/7, aged 55." | 2.77 | Olmesartan improves coronary flow reserve of hypertensive patients using coronary magnetic resonance imaging compared with amlodipine. ( Adachi, H; Hoshizaki, H; Kasama, S; Kawaguchi, R; Koyama, K; Murakami, J; Oshima, S; Sato, C; Toyama, T; Yamashita, E, 2012) |
| "To investigate the effects and safety of Western medicine combined with Chinese medicine (CM) based on syndrome differentiation in the treatment of elderly polarized hypertension (PHPT), or isolated systolic hypertension with low diastolic blood pressure (DBP)." | 2.77 | Clinical study of western medicine combined with Chinese medicine based on syndrome differentiation in the patients with polarized hypertension. ( Chen, SL; Chen, XL; Liu, XY; Mei, WY; Xu, WM, 2012) |
| "Reasonable sampling scheme is the important basis for establishing reliable population pharmacokinetic model." | 2.77 | [Modeling and simulation activities to design sampling scheme for population pharmacokinetic study on amlodipine]. ( Barrett, JS; Di, W; Guo, R; Huang, ZJ; Jing, NN; Ng, CM; Pei, Q; Yang, GP; Yuan, H; Zhang, BK; Zhou, YN; Zuo, XC, 2012) |
| "Amlodipine was associated with a higher incidence of peripheral edema compared with the valsartan group (77% vs 14%, P<." | 2.77 | Changes in aortic pulse wave velocity in hypertensive postmenopausal women: comparison between a calcium channel blocker vs angiotensin receptor blocker regimen. ( Baek, I; Haesler, E; Hayoz, D; Joly, MP; Kandra, A; Mazzolai, L; Meyer, MA; Periard, D; Zappe, DH, 2012) |
| "In this first randomized trial evaluating the effects of intensive versus moderate dosing of the combination of amlodipine/valsartan, our data suggest that ABPM was a better method for assessing between-treatment differences than clinic or home BP recordings, although measurement of home BP as a single recording was a limitation of our trial." | 2.76 | The role of ambulatory blood pressure monitoring compared with clinic and home blood pressure measures in evaluating moderate versus intensive treatment of hypertension with amlodipine/valsartan for patients uncontrolled on angiotensin receptor blocker mo ( Giles, TD; Hilkert, R; Ofili, EO; Oparil, S; Pitt, B; Purkayastha, D; Samuel, R; Sowers, JR, 2011) |
| "Proteinuria was positively correlated with circulating AGE and sRAGE levels in our subjects." | 2.76 | Calcium channel blocker inhibition of AGE and RAGE axis limits renal injury in nondiabetic patients with stage I or II chronic kidney disease. ( Fujiwara, N; Kawagoe, Y; Koide, H; Nakamura, T; Sato, E; Takeuchi, M; Ueda, Y; Yamagishi, S, 2011) |
| " Both treatment groups had similar adverse event rates (35." | 2.76 | Comparative efficacy and safety of combination aliskiren/amlodipine and amlodipine monotherapy in African Americans with stage 2 hypertension. ( Black, HR; Hilkert, R; Israel, M; Izzo, J; Lee, J; Purkayastha, D; Sridharan, K; Weinberger, MH, 2011) |
| " The primary objective of the study was to determine the effect of once-daily dosing of a combination therapy for blood pressure (BP) and dyslipidemia using home BP monitoring on reaching clinical BP and the effect of daily dosing of combination therapy on reaching lipid goals." | 2.76 | Improving adherence with amlodipine/atorvastatin therapy: IMPACT study. ( Crabbe, A; Delkhah, Y; Jones, J; Leonard, D; Nesbitt, S; Oliver, S, 2011) |
| "Aliskiren was then force-titrated to 300 mg once daily for another 6 weeks." | 2.76 | Aliskiren as add-on therapy in the treatment of hypertensive diabetic patients inadequately controlled with valsartan/HCT combination: a placebo-controlled study. ( Baek, I; Drummond, W; Keefe, DL; Ramos, E; Sirenko, YM, 2011) |
| "Resistant hypertension is a well recognized clinical entity, which has been inadequately researched to date." | 2.76 | Baseline predictors of resistant hypertension in the Anglo-Scandinavian Cardiac Outcome Trial (ASCOT): a risk score to identify those at high-risk. ( Chang, CL; Dahlöf, B; Gupta, AK; Nasothimiou, EG; Poulter, NR; Sever, PS, 2011) |
| " There were 38 adverse events in 20 patients (21." | 2.76 | Comparative efficacy and safety profile of amlodipine 5 mg/losartan 50 mg fixed-dose combination and amlodipine 10 mg monotherapy in hypertensive patients who respond poorly to amlodipine 5 mg monotherapy: an 8-week, multicenter, randomized, double-blind ( Chae, SC; Cho, SY; Hong, TJ; Jeong, JW; Jung, JW; Kang, SM; Kim, CH; Kim, JJ; Kim, MH; Kwon, J; Park, CG; Park, SH; Shin, DG; Yang, JY; Yoon, JH; Youn, JC, 2011) |
| " The present study was designed to investigate whether calcium channel blockers (CCBs) in combination with an ARB differentially affect kidney function." | 2.75 | Renoprotective effect of calcium channel blockers in combination with an angiotensin receptor blocker in elderly patients with hypertension. A randomized crossover trial between benidipine and amlodipine. ( Dohi, Y; Kimura, G; Miyagawa, K; Nakazawa, A; Sato, K; Sugiura, T; Yamashita, S, 2010) |
| "Hypertension is particularly prevalent in patients aged ≥65 years, those with a body mass index ≥30 kg m(-2), Blacks and those with type II diabetes." | 2.75 | Efficacy and tolerability of amlodipine plus olmesartan medoxomil in patients with difficult-to-treat hypertension. ( Chrysant, SG; Heyrman, R; Karki, S; Lee, J; Melino, M, 2010) |
"Eligible patients had treated or untreated hypertension, >or=3 additional cardiovascular risk factors, and baseline total cholesterol| 2.75 | Design and rationale of a real-life study to compare treatment strategies for cardiovascular risk factors: the CRUCIAL study. ( Al Khadra, A; Erdine, S; Kim, JH; Lopez, AP; Sutradhar, S; Westergaard, M; Yunis, C; Zamorano, J, 2010) | |
| " Safety assessments included monitoring and recording of adverse events (AEs)." | 2.75 | Efficacy and safety of a single-pill combination of amlodipine/valsartan in Asian hypertensive patients inadequately controlled with amlodipine monotherapy. ( Cardenas, P; Hong, H; Ke, Y; Wang, R; Zhang, Y; Zhu, D; Zhu, J, 2010) |
| "Atorvastatin was as potent an anti-ischaemic agent as amlodipine." | 2.75 | Potent anti-ischaemic effects of statins in chronic stable angina: incremental benefit beyond lipid lowering? ( Beckerman, B; Buch, J; Bultas, J; Deanfield, JE; Sellier, P; Shi, H; Thaulow, E; Yunis, C, 2010) |
| "The aim of the present study was to use ambulatory blood pressure (BP) monitoring (ABPM) to determine the efficacy of a fixed-dose combination of amlodipine (AML) and olmesartan medoxomil (OM) over the 24-hour dosing interval." | 2.75 | Efficacy of amlodipine and olmesartan medoxomil in patients with hypertension: the AZOR Trial Evaluating Blood Pressure Reductions and Control (AZTEC) study. ( Dubiel, R; Kereiakes, DJ; Maa, JF; Neutel, JM; Punzi, H; Shojaee, A; Waverczak, WF, 2010) |
| "chlorthalidone treatment with fasting glucose (P < 0." | 2.75 | Pharmacogenetic association of hypertension candidate genes with fasting glucose in the GenHAT Study. ( Arnett, DK; Barzilay, JI; Boerwinkle, E; Davis, BR; Eckfeldt, JH; Ford, CE; Irvin, MR; Kabagambe, EK; Lynch, AI; Tiwari, HK, 2010) |
| "Amlodipine, however, has been shown to be effective in reducing BP throughout the day and night, independent of dosing time." | 2.75 | Chronotherapy with valsartan/amlodipine fixed combination: improved blood pressure control of essential hypertension with bedtime dosing. ( Ayala, DE; Fernández, JR; Fontao, MJ; Hermida, RC; Mojón, A, 2010) |
| "Sustained proteinuria is an important risk factor for not only renal but also cardiovascular morbidity and mortality." | 2.75 | Antiproteinuric effect of cilnidipine in hypertensive Japanese treated with renin-angiotensin-system inhibitors - a multicenter, open, randomized trial using 24-hour urine collection. ( Kawano, Y; Matsuoka, H; Miwa, Y; Ohta, Y; Sasaguri, T; Tominaga, M; Tsuchihashi, T; Ueno, M, 2010) |
| " The bedtime dosing of amlodipine and olmesartan seems more apt than the morning dose to obtain the therapeutic goal." | 2.75 | The bedtime administration ameliorates blood pressure variability and reduces urinary albumin excretion in amlodipine-olmesartan combination therapy. ( Hoshino, A; Matsubara, H; Nakamura, T, 2010) |
| " Adverse events occurred at 7." | 2.75 | Azelnidipine and amlodipine: a comparison of their effects and safety in a randomized double-blinded clinical trial in Chinese essential hypertensive patients. ( Cao, B; Jia, S; Li, H; Lin, Y; Qu, P; Wang, M; Wu, F; Zhao, X, 2010) |
| " The combination of A 10 + Val 160 was well tolerated, and the observed adverse events (15." | 2.74 | Efficacy and safety of the single pill combination of amlodipine 10 mg plus valsartan 160 mg in hypertensive patients not controlled by amlodipine 10 mg plus olmesartan 20 mg in free combination. ( Ansari, A; Braun, N; Handrock, R; Klebs, S; Ulmer, HJ, 2009) |
| " After a 4-week wash-out period, 209 patients were randomized to either CC 8 mg or AML 5 mg once daily for a minimum of 1 month, after which, if BP was not normalized, the dosage was doubled, followed by the addition of hydrochlorothiazide 12." | 2.74 | Effects of candesartan cilexetil on carotid remodeling in hypertensive diabetic patients: the MITEC study. ( Asmar, R; Baguet, JP; Mallion, JM; Nisse-Durgeat, S; Valensi, P, 2009) |
| "Amlodipine-based treatment was associated with a smaller arteriolar length:diameter ratio than atenolol-based treatment (13." | 2.74 | Differential effects of antihypertensive treatment on the retinal microcirculation: an anglo-scandinavian cardiac outcomes trial substudy. ( Allemann, S; Chaturvedi, N; Hughes, A; Mayet, J; O'Brien, E; Poulter, N; Sever, P; Stanton, A; Stettler, C; Tapp, R; Thom, S; Witt, N, 2009) |
| "Left ventricular hypertrophy was present among <4% of the enrolled patients." | 2.74 | EXCEED: Exforge-intensive control of hypertension to evaluate efficacy in diastolic dysfunction: study rationale, design, and participant characteristics. ( Desai, A; Hassanein, A; Hilkert, R; Izzo, J; Oparil, S; Pitt, B; Rocha, R; Seifu, Y; Solomon, S; Verma, A, 2009) |
| "The Assessment of Lotrel in Left Ventricular Hypertrophy and Hypertension Study compared a single-pill combination of amlodipine/benazepril at doses 5." | 2.74 | Magnetic resonance imaging left ventricular mass reduction with fixed-dose angiotensin-converting enzyme inhibitor-based regimens in patients with high-risk hypertension. ( Devereux, RB; Hall, D; Hilkert, R; Pitt, B; Purkayastha, D; Reichek, N; Rocha, RA, 2009) |
| "Atorvastatin treatment is associated with less augmentation of the carotid BP waveform and less wave reflection from the body." | 2.74 | Atorvastatin treatment is associated with less augmentation of the carotid pressure waveform in hypertension: a substudy of the Anglo-Scandinavian Cardiac Outcome Trial (ASCOT). ( Hughes, AD; Manisty, C; Mayet, J; McG Thom, SA; Poulter, N; Sever, PS; Tapp, RJ, 2009) |
| "In olmesartan-treated patients, CBF significantly increased in the affected and unaffected hemispheres, and CRC increased significantly in the affected hemisphere." | 2.74 | Benefits of the angiotensin II receptor antagonist olmesartan in controlling hypertension and cerebral hemodynamics after stroke. ( Kawahira, K; Matsumoto, S; Miyata, R; Shimodozono, M, 2009) |
| "Seventy type 2 diabetes mellitus patients with hypertension were enrolled and randomly divided into two groups." | 2.74 | Effects of olmesartan, an angiotensin II receptor blocker, and amlodipine, a calcium channel blocker, on Cardio-Ankle Vascular Index (CAVI) in type 2 diabetic patients with hypertension. ( Ban, N; Endo, K; Kawana, H; Miyashita, Y; Nagayama, D; Ohira, M; Oyama, T; Saiki, A; Shirai, K; Yamaguchi, T, 2009) |
| "To show that rapid successful treatment of hypertension leads to improvement in cardiac morphology and function regardless of the pharmacological agents used." | 2.74 | Successful treatment of hypertension accounts for improvements in markers of diastolic function - a pilot study comparing hydrochlorothiazide-based and amlodipine-based treatment strategies. ( Day, AG; Ogunyankin, KO, 2009) |
| "Hypertension is most important risk factor in coronary heart disease and cerebrovascular accidents." | 2.74 | Treatment of hypertension: postmarketing surveillance study results of telmisartan monotherapy, fixed dose combination of telmisartan + hydrochlorothiazide/amlodipine. ( Arif, AF; Joshi, C; Kadam, GG, 2009) |
| "New-onset diabetes mellitus was defined from adverse event reports, information about new antidiabetic medication and/or a fasting glucose >or=7." | 2.73 | Predictors of new-onset diabetes mellitus in hypertensive patients: the VALUE trial. ( Aksnes, TA; Hua, TA; Julius, S; Kjeldsen, SE; Rostrup, M; Störset, O, 2008) |
| "In 404 patients with left ventricular hypertrophy, a significantly larger decrease in left ventricular mass index 3 years after enrollment was observed in candesartan-based (n = 205) than amlodipine-based (n = 199) regimens (-22." | 2.73 | ARB candesartan and CCB amlodipine in hypertensive patients: the CASE-J trial. ( Fujimoto, A; Nakao, K; Ogihara, T; Saruta, T, 2008) |
| "5 mg; n=22), captopril (50 mg twice daily; n=22) or a capsule containing each of the 4 above at one-quarter dosage (n=22) in a parallel group design for 4 weeks." | 2.73 | Low-dose quadruple antihypertensive combination: more efficacious than individual agents--a preliminary report. ( Feely, J; Mahmud, A, 2007) |
| " However, during the first 7 h after dosing, ABP was lower on VAL, whereas AML exerted a significantly stronger effect during the last 4 h of the dosing interval--possibly influencing the differences in office BP found in the main study." | 2.73 | Ambulatory blood pressure monitoring after 1 year on valsartan or amlodipine-based treatment: a VALUE substudy. ( Høegholm, A; Julius, S; Kjeldsen, SE; Mancia, G; Nielsen, ES; Pedersen, OL; Pickering, T; Refsgaard, J; Weber, M, 2007) |
| "Insulin resistance was measured by homeostasis assessment index (HOMA)." | 2.73 | Effect of antihypertensive agents on plasma adiponectin levels in hypertensive patients with metabolic syndrome. ( Acikel, C; Caglar, K; Celik, T; Eyileten, T; Oguz, Y; Sonmez, A; Vural, A; Yavuz, I; Yenicesu, M; Yilmaz, MI, 2007) |
| "Treatment with amlodipine/benazepril 10/40 mg/day and 10/20 mg/day resulted in a decrease of mean sitting systolic and mean sitting diastolic BP by 13." | 2.73 | The effects of high-dose amlodipine/benazepril combination therapies on blood pressure reduction in patients not adequately controlled with amlodipine monotherapy. ( Arora, V; Chrysant, SG; Khan, M; Lefkowitz, M; Salko, T; Shi, V; Sugimoto, DH, 2007) |
| " Safety and tolerability evaluations were based on adverse events, ECG and laboratory tests, and clinically relevant reports of abnormalities." | 2.73 | Antihypertensive efficacy and safety of manidipine versus amlodipine in elderly subjects with isolated systolic hypertension: MAISH study. ( Alberici, M; Lembo, G; Payeras, AC; Sladek, K, 2007) |
| "Valsartan-based treatment reduced the development of new-onset AF, particularly sustained AF in hypertensive patients, compared with amlodipine-based therapy." | 2.73 | Reduced incidence of new-onset atrial fibrillation with angiotensin II receptor blockade: the VALUE trial. ( Hua, TA; Julius, S; Kjeldsen, SE; McInnes, GT; Schmieder, RE; Zanchetti, A, 2008) |
| "The addition of an angiotensin II receptor blocker to calcium channel blocker-based antihypertensive therapy may be associated with enhanced efficacy and reduced risk of adverse events." | 2.73 | Effective and safe reduction of blood pressure with the combination of amlodipine 5 mg and valsartan 160 mg in hypertensive patients not controlled by calcium channel blocker monotherapy. ( Ansari, A; Brachmann, J; Handrock, R; Klebs, S; Mahla, G, 2008) |
| "Hypertension is a condition in which blood pressure is elevated to an extent where benefit is obtained from blood pressure lowering." | 2.72 | Analytical and Bioanalytical Techniques for the Quantification of the Calcium Channel Blocker - Amlodipine: A Critical Review. ( Kavitha, J; Kokilambigai, KS; Lakshmi, KS; Sai Susmitha, A; Seetharaman, R, 2021) |
| "Hypertension is the most prevalent and potentially modifiable risk factor for AF." | 2.72 | Angiotensin Receptor Blocker and Calcium Channel Blocker Preventing Atrial Fibrillation Recurrence in Patients with Hypertension and Atrial Fibrillation: A Meta-analysis. ( Feng, J; Gan, Y; Jiang, H; Ma, H, 2021) |
| " Amlodipine did not affect cardiac function in the young, and with chronic dosing decreased the heart rate by 3-5 bpm and the cardiac index by 0." | 2.72 | Sympatho-excitatory responses to once-daily dihydropyridines in young versus older hypertensive patients: amlodipine versus felodipine extended release. ( Coletta, E; Leenen, FH; White, R, 2006) |
| "Amlodipine and ramipril were added to their previous antihypertensive treatment for 12 weeks." | 2.72 | Urinary TGF-beta1 reduction related to a decrease of systolic blood pressure in patients with type 2 diabetes and clinical diabetic nephropathy. ( Bertoluci, MC; Oliveira, FR; Schmid, H; Schmidt, A; Thomazelli, FC; Uebel, D, 2006) |
| "Hypertension is a major cause of heart failure (HF) and is antecedent in 91% of cases." | 2.72 | Role of diuretics in the prevention of heart failure: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. ( Colon, P; Crow, R; Cutler, JA; Davis, BR; Dunn, K; Ellsworth, A; Franklin, S; Furberg, C; Goff, D; Golden, J; Leenen, F; Mohiuddin, S; Papademetriou, V; Piller, LB; Proschan, M, 2006) |
| "Amlodipine was used as the control drug." | 2.72 | Selective imidazoline agonist moxonidine in obese hypertensive patients. ( de Abreu, VG; Francischetti, EA; Sanjuliani, AF, 2006) |
| "Type 2 diabetes is emerging as a major health problem, which tends to cluster with hypertension in individuals at high risk of cardiovascular disease." | 2.72 | Effects of valsartan compared to amlodipine on preventing type 2 diabetes in high-risk hypertensive patients: the VALUE trial. ( Coca, A; Ekman, S; Girerd, X; Hua, T; Jamerson, K; Julius, S; Kjeldsen, SE; Larochelle, P; MacDonald, TM; Mancia, G; McInnes, GT; Schmieder, RE; Schork, MA; Stolt, P; Viskoper, R; Weber, MA; Widimský, J; Zanchetti, A, 2006) |
| "A population pharmacokinetic study was conducted in 74 hypertensive children (mean age 10." | 2.72 | Population pharmacokinetics of amlodipine in hypertensive children and adolescents. ( Flynn, JT; Mahan, JD; Nahata, MC; Portman, RJ, 2006) |
| "In the main Valsartan Antihypertensive Long-Term Use Evaluation (VALUE) report, we investigated outcomes in 15 245 high-risk hypertensive subjects treated with valsartan- or amlodipine-based regimens." | 2.72 | The Valsartan Antihypertensive Long-Term Use Evaluation (VALUE) trial: outcomes in patients receiving monotherapy. ( Amerena, J; Balazovjech, I; Brunner, HR; Cassel, G; Herczeg, B; Hua, TA; Julius, S; Kjeldsen, SE; Koylan, N; Laragh, J; Magometschnigg, D; Majahalme, S; Martinez, F; McInnes, GT; Oigman, W; Schork, MA; Seabra Gomes, R; Weber, MA; Zanchetti, A; Zhu, JR, 2006) |
| "Angioedema is a rare, potentially life-threatening condition that has been associated with angiotensin-converting enzyme inhibitors since their introduction in the 1980s." | 2.72 | Incidence and predictors of angioedema in elderly hypertensive patients at high risk for cardiovascular disease: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). ( Black, HR; Davis, BR; Ford, CE; Nwachuku, C; Oparil, S; Piller, LB; Probstfield, JL; Retta, TM, 2006) |
| "The coexistence of type 2 diabetes mellitus and hypertension increases the risk of cardiovascular diseases." | 2.72 | Amlodipine versus angiotensin II receptor blocker; control of blood pressure evaluation trial in diabetics (ADVANCED-J). ( Daida, H; Hayashi, D; Ikeda, S; Imai, Y; Kawamori, R; Kishimoto, J; Kitagawa, A; Miyauchi, K; Tanaka, Y; Yamazaki, T, 2006) |
| "In the Valsartan Antihypertensive Long-term Use Evaluation (VALUE) trial the primary outcome (cardiac morbidity and mortality) did not differ between valsartan and amlodipine-based treatment groups, although systolic blood pressure (SBP) and diastolic blood pressure reductions were significantly more pronounced with amlodipine." | 2.72 | Outcomes in subgroups of hypertensive patients treated with regimens based on valsartan and amlodipine: An analysis of findings from the VALUE trial. ( Battegay, E; Calvo-Vargas, C; Cieśliński, A; Degaute, JP; Holwerda, NJ; Hua, T; Julius, S; Kjeldsen, S; Kobalava, J; Laragh, JH; McInnes, GT; Pedersen, OL; Plat, F; Rudyatmoko, FP; Siamopoulos, KC; Störset, O; Weber, M; Zanchetti, A, 2006) |
| "Hypertension in type 2 diabetes represents a strong risk factor for cardiovascular events." | 2.72 | The effects of telmisartan and amlodipine on metabolic parameters and blood pressure in type 2 diabetic, hypertensive patients. ( Hassan, H; Negro, R, 2006) |
| "The primary outcomes of the Irbesartan Diabetic Nephropathy Trial were doubling of serum creatinine levels, end-stage renal disease, and death from any cause." | 2.71 | Cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial of patients with type 2 diabetes and overt nephropathy. ( Berl, T; Drury, PL; Esmatjes, E; Goldhaber, SZ; Hricik, D; Hunsicker, LG; Lewis, EJ; Lewis, JB; Locatelli, F; Parikh, CR; Pfeffer, MA; Porush, JG; Raz, I; Rouleau, JL; Vanhille, P; Wiegmann, TB; Wolfe, BM, 2003) |
| " The pharmacokinetic results indicated that the plasma half-life (t1/2) of amlodipine was 38." | 2.71 | Azelnidipine and amlodipine: a comparison of their pharmacokinetics and effects on ambulatory blood pressure. ( Hirai, A; Ichikawa, S; Kanada, S; Kuramoto, K; Nakachi, T; Ogihara, T, 2003) |
| "Chlorthalidone was at least equivalent to amlodipine and lisinopril in all of the outcomes measured, and was better in some, notably heart failure." | 2.71 | The ALLHAT Trial. Diuretics are still the preferred initial drugs for high blood pressure. ( Vidt, DG, 2003) |
| " at the same dosage for 6 weeks in three crossover periods each separated by a 2-week placebo wash-out period (3x3 latin square)." | 2.71 | Effect of benazepril amlodipine combination on fibrinolysis in hypertensive diabetic patients. ( Corradi, L; Fogari, E; Fogari, R; Lazzari, P; Mugellini, A; Preti, P; Zoppi, A, 2003) |
| "Amlodipine is a calcium antagonist of the dihydropyridine class." | 2.71 | Pharmacokinetics of amlodipine in hypertensive patients undergoing haemodialysis. ( Kungys, G; Naujoks, H; Wanner, C, 2003) |
| "The Valsartan Antihypertensive Long-term Use Evaluation (VALUE) study compares cardiovascular outcomes in 15,314 eligible patients from 31 countries randomized to valsartan or amlodipine-based treatment." | 2.71 | VALUE trial: Long-term blood pressure trends in 13,449 patients with hypertension and high cardiovascular risk. ( Brunner, H; Ekman, S; Hansson, L; Julius, S; Kjeldsen, SE; Laragh, JH; McInnes, G; Platt, F; Schork, AM; Smith, B; Weber, M; Zanchetti, A, 2003) |
| " The dosage was doubled if necessary." | 2.71 | Better renoprotective effect of angiotensin II antagonist compared to dihydropyridine calcium channel blocker in childhood. ( Bianchetti, MG; Edefonti, A; Fossali, E; Gartenmann, AC; Schmidtko, J; Simonetti, GD; von Vigier, RO, 2003) |
| "Amlodipine monotherapy was more effective than valsartan monotherapy in controlling 24-h ambulatory BP and morning BP in hypertensive patients." | 2.71 | Comparison of valsartan and amlodipine on ambulatory and morning blood pressure in hypertensive patients. ( Eguchi, K; Hoshide, S; Hoshide, Y; Ishikawa, J; Ishikawa, S; Kario, K; Morinari, M; Shimada, K, 2004) |
| "Amlodipine was well tolerated, with just 6 children withdrawn from treatment because of drug-related adverse events." | 2.71 | A randomized, placebo-controlled trial of amlodipine in children with hypertension. ( Daniels, SR; Flynn, JT; Hogg, RJ; Newburger, JW; Portman, RJ; Sanders, SP; Saul, JP, 2004) |
| " In addition to recommending lifestyle modifications, eight dosage strengths of amlodipine/atorvastatin single pill (5/10, 5/20, 5/40, 5/80, 10/10, 10/20, 10/40, and 10/80 mg) were electively titrated to improve blood pressure and lipid control." | 2.71 | Single-pill therapy in the treatment of concomitant hypertension and dyslipidemia (the amlodipine/atorvastatin gemini study). ( Blank, R; LaSalle, J; Maroni, J; Reeves, R; Sun, F; Tarasenko, L, 2005) |
| "Twenty-eight patients who had type 1 diabetes and known diabetic renal disease and had a persistently elevated albumin creatinine ratio (ACR) > 10 mg/mmol despite office BP recordings < or = 140/80 mmHg on maximal recommended dose of the ACEI lisinopril were studied." | 2.71 | Targeting albumin excretion rate in the treatment of the hypertensive diabetic patient with renal disease. ( Bilous, R; Karalliedde, J; Krimholtz, MJ; Thomas, S; Viberti, G, 2005) |
| " We evaluated potential bidirectional pharmacokinetic interactions between calcium channel blockers and coadministered indinavir and ritonavir." | 2.71 | Pharmacokinetic interactions between indinavir plus ritonavir and calcium channel blockers. ( Aberg, JA; Fichtenbaum, CJ; Gerber, JG; Glesby, MJ; Grosskopf, N; Hafner, R; Hall, S; Kendall, MA; Zolopa, AR, 2005) |
| "Simvastatin is an HMG-CoA reductase inhibitor that is metabolized by the cytochrome P450 (CYP) 3A4." | 2.71 | Interaction between amlodipine and simvastatin in patients with hypercholesterolemia and hypertension. ( Hayashi, H; Kosuge, K; Nishio, S; Ohashi, K; Uchida, S; Watanabe, H, 2005) |
| " The adverse events related with the treatment were significantly less frequent with E/N than with a (19." | 2.71 | [Double blind study of the efficacy and safety of the fixed dose combination of enalapril 10 mg/nitrendipine 20 mg versus the increase of amlopidine dose in essential hypertensive patients not controlled with amlodipine 5 mg]. ( de la Figuera-von Wichman, M; de la Sierra-Iserte, A; Delgadillo-Duarte, J; Luque-Otero, M; Marín-Iranzo, R; Oliván-Martínez, J; Pontes-García, C; Redón-Mas, J; Roca-Cusachs, A, 2005) |
| " Evaluation of safety of the trial was based on the evaluation of a physician, standard laboratory evaluation, adverse effects." | 2.71 | Clinical study on safety and efficacy of the administration of amlodipine in a combination with lisinopril in hypertensive patients. ( Arslanagic, A; Bajraktarevic, A; Zulic, I, 2005) |
| "Systolic hypertension is predominant among patients over 50 years of age, is a more important cardiovascular risk factor than diastolic blood pressure, and is more difficult to control than diastolic blood pressure." | 2.71 | Efficacy of combination therapy for systolic blood pressure in patients with severe systolic hypertension: the Systolic Evaluation of Lotrel Efficacy and Comparative Therapies (SELECT) study. ( Gatlin, M; Neutel, JM; Purkayastha, D; Schofield, L; Smith, DH; Weber, MA, 2005) |
| "Cilnidipine is a novel and unique 1,4-dydropyridine derivative calcium antagonist that exerts potent inhibitory actions not only on L-type but also on N-type voltage-dependent calcium channels." | 2.71 | Comparison of the effects of cilnidipine and amlodipine on ambulatory blood pressure. ( Eguchi, K; Hoshide, S; Ishikawa, J; Kario, K; Shimada, K, 2005) |
| "Essential hypertension is associated with alterations in endothelial function." | 2.70 | Effects of angiotensin converting enzyme inhibitor and calcium antagonist on endothelial function in patients with essential hypertension. ( Kim, CH; Lee, MM; Oh, BH; On, YK; Park, YB, 2002) |
| "Hypertension is a leading cause of end-stage renal disease (ESRD) in the United States, with no known treatment to prevent progressive declines leading to ESRD." | 2.70 | Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. ( Agodoa, LY; Appel, LJ; Bakris, G; Charleston, J; Cheek, D; Douglas-Baltimore, JG; Gassman, J; Glassock, R; Greene, T; Hebert, L; Jamerson, K; Lewis, J; Middleton, JP; Phillips, RA; Rostand, SG; Toto, RD; Wright, JT, 2002) |
| "Primary aldosteronism is a specifically treatable and potentially curable form of secondary hypertension." | 2.70 | Drug effects on aldosterone/plasma renin activity ratio in primary aldosteronism. ( Chiandussi, L; Milan, A; Morello, F; Mulatero, P; Paglieri, C; Rabbia, F; Veglio, F, 2002) |
| "In losartan-treated patients, CVF decreased from 5." | 2.70 | Usefulness of serum carboxy-terminal propeptide of procollagen type I in assessment of the cardioreparative ability of antihypertensive treatment in hypertensive patients. ( Díez, J; González, A; Larman, M; López, B; Martínez Ubago, JL; Querejeta, R; Varo, N, 2001) |
| " Blood samples were collected after administration of amlodipine and AUC, Cmax, and tmax were determined." | 2.70 | Comparative pharmacokinetics and pharmacodynamics of amlodipine in hypertensive patients with and without type II diabetes mellitus. ( Alonso, A; Baltodano, NM; Chung, M; Epstein, M; Gaffney, M; Preston, RA, 2001) |
| "In losartan-treated patients, both cardiomyocyte and noncardiomyocyte apoptosis decreased (P<0." | 2.70 | Stimulation of cardiac apoptosis in essential hypertension: potential role of angiotensin II. ( Díez, J; Fortuño, MA; González, A; Larman, M; López, B; Querejeta, R; Ravassa, S, 2002) |
| "In conclusion, left ventricular hypertrophy, a major cardiovascular risk factor, was decreased to a significantly greater extent by rigorous than standard BP control." | 2.70 | Cardiac and renal effects of standard versus rigorous blood pressure control in autosomal-dominant polycystic kidney disease: results of a seven-year prospective randomized study. ( Brosnahan, G; Chapman, A; Ecder, T; Edelstein, C; Johnson, A; McFann, K; Schrier, R; Tison, L, 2002) |
| " Amlodipine seems to be more effective than felodipine when the drugs are compared in the same dose, with regard to the effect on clinic BP 24 h after dosing and to ambulatory BP during the night." | 2.69 | Effect of amlodipine versus felodipine extended release on 24-hour ambulatory blood pressure in hypertension. ( Brodin, U; Isaksson, H; Ohman, KP; Ostergren, J; Schwan, A, 1998) |
| "Losartan potassium is a recently marketed angiotensin II receptor antagonist." | 2.69 | The antihypertensive efficacy of losartan and amlodipine assessed with office and ambulatory blood pressure monitoring. Canadian Cozaar Hyzaar Amlodipine Trial Study Group. ( Barnes, CC; Lacourcière, Y; Wilson, TW, 1998) |
| " Of all ongoing mortality and morbidity trials in systemic hypertension, VALUE (Valsartan Antihypertensive Long-term Use Evaluation) is the only one comparing an angiotensin II antagonist (valsartan) with a third-generation calcium channel blocker (amlodipine)." | 2.69 | The Valsartan Antihypertensive Long-term Use Evaluation (VALUE) trial of cardiovascular events in hypertension. Rationale and design. ( Julius, S; Mann, J, 1998) |
| "Hypertension is a prevalent disease among African Americans, and successful treatment rates are low." | 2.69 | Comparison of the efficacy of dihydropyridine calcium channel blockers in African American patients with hypertension. ISHIB Investigators Group. International Society on Hypertension in Blacks. ( Flack, JM; Hall, WD; Preisser, J; Reed, JW; Yunis, C, 1998) |
| "High blood pressure is about twice as common in persons with diabetes mellitus as in those without." | 2.69 | Comorbidity of hypertension and diabetes: the fosinopril versus amlodipine cardiovascular events trial (FACET) ( Sowers, JR, 1998) |
| "The primary aim of this double-blind, parallel group trial was to compare incidence of newly occurring vasodilatory adverse events in elderly patients treated with recommended once-daily doses of felodipine extended release (ER) or amlodipine." | 2.69 | Improved tolerability of felodipine compared with amlodipine in elderly hypertensives: a randomised, double-blind study in 535 patients, focusing on vasodilatory adverse events. The International Study Group. ( Aldons, PM; Burgess, ED; Girerd, X; Morgan, TO; Rehn, L; Schaefer, RM; Singh, GP; Tilvis, R, 1998) |
| "Amlodipine was an effective once daily antihypertensive agent with an acceptable safety profile." | 2.69 | Efficacy of amlodipine in pediatric patients with hypertension. ( Hayes, JR; Mahan, JD; Mentser, MI; Nahata, MC; Tallian, KB; Turman, MA, 1999) |
| "Although proteinuria has been considered a surrogate of renal disease progression, further studies will be necessary to confirm this hypothesis in ADPKD, because after 5 years, no differences in renal function were observed between the enalapril and amlodipine groups." | 2.69 | Effect of antihypertensive therapy on renal function and urinary albumin excretion in hypertensive patients with autosomal dominant polycystic kidney disease. ( Brosnahan, GM; Chapman, AB; Ecder, T; Edelstein, CL; Johnson, AM; Schrier, RW, 2000) |
| " Earlier studies combining short acting drugs from these classes require multiple dosing and were associated with poor compliance." | 2.69 | Evaluation of amlodipine, lisinopril, and a combination in the treatment of essential hypertension. ( Naidu, MU; Rao, TR; Shobha, JC; Usha, PR, 2000) |
| "Amlodipine has potential advantages in children since it can be dissolved into a liquid preparation and has a long elimination half-life, allowing for once-daily administration." | 2.69 | A randomized prospective crossover trial of amlodipine in pediatric hypertension. ( Arbus, GS; Blowey, D; Khattak, S; Koren, G; Lyszkiewicz, DA; Rogan, JW, 2000) |
| "Arthritis and hypertension are frequent comorbidities in the elderly hypertensive population." | 2.69 | Effect of indomethacin on blood pressure in elderly people with essential hypertension well controlled on amlodipine or enalapril. ( Anderson, A; Bertram, D; Morgan, TO, 2000) |
| "Forty-nine hypertensive IgA nephropathy (IgAN) patients (39 +/- 7 years old, serum creatinine 1." | 2.69 | Blood pressure reduction associated with preservation of renal function in hypertensive patients with IgA nephropathy: a 3-year follow-up. ( Kanno, Y; Okada, H; Saruta, T; Suzuki, H, 2000) |
| "01), although the once-daily dosing of enalapril and the maximum dose of 20 mg might not have been optimal for this agent." | 2.68 | Low-dose drug combination therapy: an alternative first-line approach to hypertension treatment. ( Adegbile, IA; Alemayehu, D; Carr, AA; Lefkowitz, MP; Papademetriou, V; Prisant, LM; Weber, MA; Weir, MR, 1995) |
| "Amlodipine was better tolerated than nifedipine slow release." | 2.68 | Patient compliance and therapeutic coverage: comparison of amlodipine and slow release nifedipine in the treatment of hypertension. The Belgian Collaborative Study Group. ( Block, P; De Backer, G; Degaute, JP; Detry, JM, 1995) |
| "Amlodipine (10 mg) was more effective than the same dose of lisinopril in controlling hypertension (mean 24-hour arterial pressure, 111 +/- 9 and 115 +/- 9 mm Hg, respectively; P < ." | 2.68 | Hypertension after renal transplantation. Calcium channel or converting enzyme blockade? ( Blankestijn, PJ; Floor, M; Hené, RJ; Koomans, HA; van der Schaaf, MR, 1995) |
| "Of the hypertensive NIDDM patients attending the outpatient's clinic of the internal medicine departments of the University of Padova and Sassari, 44 participated in the present study." | 2.68 | Effects of cilazapril and amlodipine on kidney function in hypertensive NIDDM patients. ( Brocco, E; Carraro, A; Cernigoi, AM; Fioretto, P; Fresu, P; Frigato, F; Maioli, M; Muollo, B; Nosadini, R; Tonolo, G; Velussi, M; Zolli, M, 1996) |
| "Twenty patients with previously untreated hypertension who consecutively attended our outpatient hypertension clinic were included in this prospective, open, cross-over study." | 2.68 | Decreased blood viscosity and serum levels of erythropoietin after anti-hypertensive treatment with amlodipine or metoprolol: results of a cross-over study. ( Danielson, BG; Hägg, A; Linde, T; Mörlin, C; Sandhagen, B, 1996) |
| " Newer calcium channel blockers of the dihydropyridine group have longer elimination half-lives (t1/2) that permit once-daily dosage and are generally better tolerated than their parent compound." | 2.68 | Relative efficacy and tolerability of lacidipine and amlodipine in patients with mild-to-moderate hypertension: a randomized double-blind study. ( Cheung, BM; Lau, CP, 1996) |
| "Doxazosin therapy was characterized by significant increase in the levels of mean plasma total protein and albumin, while moduretic therapy showed significant reduction in the mean values of plasma creatinine and calcium." | 2.68 | Biochemical changes during a cross-over treatment of doxazosin, moduretic and amlodipine in hypertensive patients. ( Agbedana, EO; Ahaneku, JE; Salako, LA; Sowunmi, A; Taylor, GO; Walker, O, 1996) |
| "4." | 2.68 | [The role of calcium inhibitors in the treatment of arterial hypertension]. ( Hrnciar, J; Hrnciarová, M; Jakubíková, K, 1997) |
| "Reversal of left ventricular hypertrophy has been shown to improve left ventricular diastolic function in elderly patients with hypertension, but little is known about whether this affects physical performance." | 2.68 | Physical performance is preserved after regression of left ventricular hypertrophy. ( Cléroux, J; Lacourcière, Y; Poirier, L, 1997) |
| " Significant differences were found between all principal pharmacokinetic variables, when comparing the 2 treatments after both single and repeated dosing." | 2.68 | Crossover comparison of the pharmacokinetics of amlodipine and felodipine ER in hypertensive patients. ( Jacobsen, IA; Videbaek, LM, 1997) |
| "Amlodipine treatment significantly reduced ambulatory blood pressure without altering the normal circadian variation throughout the monitoring period." | 2.67 | Effect of amlodipine on 24-hour ambulatory blood pressure in hypertensive patients. ( Allenby, KS; Burris, JF; Mroczek, WJ, 1991) |
| "Amlodipine treatment produced significant falls in blood pressure (-23." | 2.67 | The efficacy and safety of amlodipine in the treatment of mild and moderate essential hypertension in general practice. ( Varrone, J, 1991) |
| " Apart from class-typical effects, such as edema for calcium antagonists, and cough for angiotensin-converting enzyme inhibitors, both drugs were equally well tolerated, with few adverse effects of clinical significance." | 2.67 | A double-blind, long-term, comparative study on quality of life, safety, and efficacy during treatment with amlodipine or enalapril in mild or moderate hypertensive patients: a multicenter study. ( Eide, I; Herland, OB; Midha, R; Omvik, P; Thaulow, E; Turner, RR, 1993) |
| " In contrast, however, the effects of captopril were no longer evident during the final 3 h of the dosing interval." | 2.67 | Comparison of amlodipine and captopril in hypertension based on 24-hour ambulatory monitoring. ( Lacourcière, Y; Poirier, L; Provencher, P, 1993) |
| " Adverse events were reported in 28% of patients treated with lacidipine and in 48% of patients receiving amlodipine." | 2.67 | Efficacy and safety evaluation of lacidipine compared with amlodipine in mild-to-moderate hypertensive patients. ( Lombardo, D; Raimondi, F, 1994) |
| " Blood pressure measurements were taken at the end of the dosing interval to assess the antihypertensive efficacy of the two drugs." | 2.67 | At equipotent doses, isradipine is better tolerated than amlodipine in patients with mild-to-moderate hypertension: a double-blind, randomized, parallel-group study. ( De Keyser, P; Deblander, A; Hermans, L; Lesaffre, E; Scheys, I; Westelinck, KJ, 1994) |
| "Treatment with diltiazem resulted in a significant lengthening of sinus cycle length (SCL, p < 0." | 2.67 | Electrophysiologic effects of amlodipine vs. diltiazem in patients with coronary artery disease and beta-blocking therapy. ( Biscione, F; Lanza, GA; Manzoli, A; Natale, A; Santarelli, P, 1994) |
| " About 8% of patients had a low compliance rate, irrespective of the dosage regimen." | 2.67 | [Time of drug intake in hypertension and angina pectoris. A controlled monitoring study]. ( Erne, P; Heynen, G; Saxenhofer, H; Waeber, B, 1994) |
| "Amlodipine treatment did not appear to produce clinically significant changes in blood lipids; HCTZ, however, produced an increase in total plasma cholesterol (delta 22." | 2.67 | Double-blind comparison of amlodipine and hydrochlorothiazide in patients with mild to moderate hypertension. ( Ames, RP; Applegate, WB; Burris, JF; Davidov, ME; Mroczek, WJ; Ram, CV, 1994) |
| " A side effect of mild headache was reported by one patient (2." | 2.67 | Efficacy and safety of amlodipine in hypertensive patients with renal dysfunction. ( Abe, K; Iimura, I; Ishii, M; Saruta, T, 1994) |
| " The number of days with missed medication was thus significantly higher for the evening dosing regimen." | 2.67 | The use of self-measured blood pressure determinations in assessing dynamics of drug compliance in a study with amlodipine once a day, morning versus evening. ( Binswanger, B; Mengden, T; Spühler, T; Vetter, W; Weisser, B, 1993) |
| "Amlodipine was considered effective and well tolerated and the majority of patients needed only 5mg daily and no reflex tachycardia was observed." | 2.67 | [Circadian rhythm of arterial pressure and use of amlodipine in primary hypertension]. ( Spritzer, N, 1993) |
| "The distinctive pharmacokinetic characteristics of amlodipine, particularly the long half-life, are presumed to translate directly to a prolonged duration of action, but the concentration-effect relationship for the antihypertensive response has not been clearly established." | 2.67 | Pharmacodynamic modeling of the antihypertensive response to amlodipine. ( Donnelly, R; Elliott, HL; Howie, CA; Meredith, PA; Miller, SH, 1993) |
| "Amlodipine treatment 1) lowered fasting serum insulin (from 273 +/- 19 to 200 +/- 17 pmol/L; P < 0." | 2.67 | The calcium channel blocker amlodipine raises serum dehydroepiandrosterone sulfate and androstenedione, but lowers serum cortisol, in insulin-resistant obese and hypertensive men. ( Beer, NA; Beer, RM; Jakubowicz, DJ; Nestler, JE, 1993) |
| " The overall incidence of adverse effects were temporary and extremely limited (2%)." | 2.67 | Middle term evaluation of amlodipine vs nitrendipine: efficacy, safety and metabolic effects in elderly hypertensive patients. ( Feraco, E; Grandinetti, O, 1993) |
| "Amlodipine is a dihydropyridine calcium antagonist with a long elimination half life making it suitable for once-daily dosing." | 2.67 | Intra-arterial monitoring of the antihypertensive effects of once-daily amlodipine. ( al-Khawaja, I; Brigden, G; Broadhurst, P; Heber, ME; Raftery, EB, 1992) |
| "Amlodipine was associated with a significantly lower incidence of vasodilator-related adverse effects at initiation of therapy (headache, flushing, tachycardia) compared with nitrendipine, which may reflect its slower onset of action." | 2.67 | Amlodipine compared to nitrendipine in hypertensive patients: the effects on toleration in relationship to the onset of action. ( Borges, ET; Christeler, P; Guillaume-Gentil, M; Hollenstein, U; Mannhart, M; Waeber, B, 1992) |
| " Most adverse events were mild or moderate and the investigators' overall evaluation of tolerability was excellent or good for 91% of patients." | 2.67 | A study of the efficacy and safety of amlodipine for the treatment of hypertension in general practice. ( Varrone, J, 1991) |
| "Amlodipine is a new long-acting calcium antagonist that has a long half-life and appears to be suitable for once-daily administration." | 2.66 | A double-blind evaluation of the effect of amlodipine on ambulatory blood pressure in hypertensive patients. ( Allenby, KS; Burris, JF; Mroczek, WJ, 1988) |
| " Thus amlodipine administered once daily is an effective and safe agent for second-step therapy in mild to moderate essential hypertension." | 2.66 | Safety and efficacy of amlodipine added to hydrochlorothiazide therapy in essential hypertension. ( Chrysant, SG; Glasser, SP; Graves, J; Koehn, DK; Rofman, B, 1989) |
| "Amlodipine treated patients had lower arterial pressures in both the supine and upright positions (P less than ." | 2.66 | Antihypertensive effectiveness of amlodipine in combination with hydrochlorothiazide. ( Chrysant, C; Chrysant, SG; Hitchcock, A; Trus, J, 1989) |
| "Amlodipine treatment was associated with a slightly higher incidence of side effects compared with placebo, but most of this difference was the result of edema, which was usually well tolerated." | 2.66 | The safety of amlodipine. ( Osterloh, I, 1989) |
| "Arterial hypertension is a highly manageable disorder due to a variety of drugs available for its treatment." | 2.58 | Noncholestatic acute hepatocellular injury following candesartan administration. ( DeObeso-Gonzalez, E; Flores-Villalba, E; Lammel-Lindemann, JA; Martagón, AJ; Puente-Gallegos, F, 2018) |
| " A systematic review of the literature revealed its most common adverse effects as: peripheral edema (depending on the dose of amlodipine, but attenuated by perindopril), cough, dizziness and hypotension." | 2.58 | Perindopril arginine and amlodipine besylate for hypertension: a safety evaluation. ( Bistrika, EA; Elliott, WJ, 2018) |
| "Amlodipine is a classical drug with varied properties extending from control of blood pressure to as an antianginal and anti atherosclerotic agent." | 2.58 | Amlodipine in the Era of New Generation Calcium Channel Blockers. ( Kashyap, R; Langote, A; Tiwaskar, M; Toppo, A, 2018) |
| "Patients with osteoarthritis are often affected by a number of cardiovascular comorbidities, including hypertension, which is present in about 40% of cases." | 2.58 | Amlodipine and celecoxib for treatment of hypertension and osteoarthritis pain. ( Angeli, F; Reboldi, G; Signorotti, S; Trapasso, M; Verdecchia, P, 2018) |
| " The smoothness index (SI) provides a useful measure of antihypertensive treatment efficacy over the 24 h dosing period, its values being highest with antihypertensive agents that have large and consistent effects across 24 h." | 2.50 | Blood pressure variability over 24 h: prognostic implications and treatment perspectives. An assessment using the smoothness index with telmisartan-amlodipine monotherapy and combination. ( Parati, G; Schumacher, H, 2014) |
| "Given that hypertension affects ∼60% of patients with diabetes, effective blood pressure (BP) management is important in this high-risk population." | 2.50 | Uptitrating amlodipine significantly reduces blood pressure in diabetic patients with hypertension: a retrospective, pooled analysis. ( Bhambri, R; Jeffers, BW; Robbins, J, 2014) |
| "Aliskiren is a novel renin-angiotensin aldosterone system (RAAS) inhibitor, the combination therapy of aliskiren and amlodipine for blood pressure control have been reported recently." | 2.49 | Aliskiren and amlodipine in the management of essential hypertension: meta-analysis of randomized controlled trials. ( Chen, K; Han, Y; Kou, X; Liu, Y; Zeng, C; Zhou, L, 2013) |
| "The prevalence of hypertension is high in patients with diabetes mellitus (DM), chronic kidney disease (CKD) and chronic cardiovascular disease (CVD), as well as in black and elderly subjects." | 2.49 | Effectiveness of the fixed-dose combination of olmesartan/amlodipine/hydrochlorothiazide for the treatment of hypertension in patients stratified by age, race and diabetes, CKD and chronic CVD. ( Chrysant, SG, 2013) |
| "Hypertension is one of the most frequent chronic disease in Hungary and one of the most important cardiovascular risk factor." | 2.49 | [Advantages of ramipril/amlodipin fixed combination therapy. When should we use it?]. ( Simonyi, G, 2013) |
| "Hypertension is one of the most prevalent disorders and the largest contributor to global mortality." | 2.48 | Fixed-dose combination therapy of candesartan cilexetil and amlodipine besilate for the treatment of hypertension in Japan. ( Fujimoto, A; Kuwahara, K; Nakagawa, Y; Ueshima, K; Yasuno, S, 2012) |
| "Amlodipine has an inherently long pharmacokinetic half-life, whereas, in contrast, nifedipine has an inherently short half-life but in the GITS formulation the sophisticated delivery system allows for once-daily dosing." | 2.48 | Long-acting dihydropyridine calcium-channel blockers and sympathetic nervous system activity in hypertension: a literature review comparing amlodipine and nifedipine GITS. ( Elliott, HL; Meredith, PA; Toal, CB, 2012) |
| "Effective treatment of hypertension is a key strategy for preventing and reducing the burden of hypertension-related cardiovascular diseases." | 2.48 | Triple combination therapy to improve blood pressure control: experience with olmesartan-amlodipine-hydrochlorothiazide therapy. ( Paneni, F; Passerini, J; Tocci, G; Volpe, M, 2012) |
| " Head-to-head randomized controlled trials (RCTs) of 12 months minimum duration reporting comparative efficacy (changes in systolic and diastolic blood pressure) and safety (total adverse events and ankle oedema), were included." | 2.47 | Efficacy and safety profiles of manidipine compared with amlodipine: a meta-analysis of head-to-head trials. ( Laurent, S; Richy, FF, 2011) |
| "Hypertension is an increasingly prevalent cardiovascular risk factor associated with high rates of morbidity and mortality." | 2.47 | Olmesartan medoxomil, amlodipine besylate and hydrochlorothiazide triple combination for hypertension. ( Ram, CV, 2011) |
| "Olmesartan/amlodipine was generally well tolerated over the short- and long-term, with a lower frequency of peripheral edema with olmesartan/amlodipine 40/10 mg than with amlodipine 10 mg monotherapy." | 2.47 | Olmesartan/amlodipine: a review of its use in the management of hypertension. ( Kreutz, R, 2011) |
| "Hypertension is a major risk factor for cardiovascular, renal and stroke complications." | 2.47 | Triple-drug, fixed-dose combinations for the treatment of hypertension: focus on olmesartan/amlodipine/hydrochlorothiazide combination. ( Chrysant, SG, 2011) |
| "Hypertension is characterized by endothelial dysfunction and increased risk for adverse cardiovascular outcomes." | 2.46 | Improving vascular function in hypertension: potential benefits of combination therapy with amlodipine and renin-angiotensin-aldosterone system blockers. ( Siragy, HM, 2010) |
| " The bioavailability of amlodipine and atorvastatin with a single-tablet, fixed-dose amlodipine/atorvastatin combination was not significantly different to that with coadministered separate amlodipine and atorvastatin tablets." | 2.46 | Amlodipine/Atorvastatin: a review of its use in the treatment of hypertension and dyslipidaemia and the prevention of cardiovascular disease. ( Curran, MP, 2010) |
| " In particular, mean 24-h BP and BP variability both correlate closely with hypertension end-organ damage and rate of CV events, which suggests that antihypertensive therapy should provide smooth BP control over the full 24-h dosing interval." | 2.46 | Efficacy and tolerability of olmesartan/amlodipine combination therapy in patients with mild-to-severe hypertension: focus on 24-h blood pressure control. ( Bilo, G; Hoshide, S; Lonati, L; Ochoa, JE; Parati, G; Ramos, C, 2010) |
| "Triple therapy is recommended in the treatment of hypertension in those patients not adequately controlled with two antihypertensive drugs." | 2.46 | Valsartan-amlodipine-hydrochlorothiazide: the definitive fixed combination? ( Barrios, V; Escobar, C, 2010) |
| "Hypertension is a highly prevalent disease and one of the most important modifiable risk factors for cardiovascular disease." | 2.45 | Olmesartan/Amlodipine: combination therapy for the treatment of hypertension [corrected]. ( Pimenta, E, 2009) |
| "CCB-induced oedema is caused by increased capillary hydrostatic pressure that results from preferential dilation of pre-capillary vessels." | 2.45 | Mitigation of calcium channel blocker-related oedema in hypertension by antagonists of the renin-angiotensin system. ( de la Sierra, A, 2009) |
| "Hypertension affects approximately 73 million individuals in the United States." | 2.45 | Complementary mechanisms of angiotensin receptor blockers and calcium channel blockers in managing hypertension. ( Neutel, JM, 2009) |
| " black triangle In the comparison with amlodipine monotherapy, >70% of olmesartan medoxomil/amlodipine recipients, some requiring upwards dosage adjustment, met BP goals." | 2.45 | Olmesartan medoxomil/amlodipine. ( Keam, SJ; Sanford, M, 2009) |
| "Pharmacological treatment of hypertension is effective in preventing cardiovascular and renal complications." | 2.45 | Amlodipine and valsartan as components of a rational and effective fixed-dose combination. ( Ruilope, LM; Waeber, B, 2009) |
| "Hypertension and dyslipidemia are two of the most commonly co-occurring cardiovascular risk factors which together cause an increase in coronary heart disease-related events that is more than simply additive for anticipated event rates with each condition." | 2.45 | Fixed combination of amlodipine and atorvastatin in cardiovascular risk management: patient perspectives. ( Bangalore, S; Devabhaktuni, M, 2009) |
| "Less than 10% of parathyroid carcinomas are non-functional, and as such, they have been rarely reported in the literature." | 2.45 | Non-functional parathyroid carcinoma: a review of the literature and report of a case requiring extensive surgery. ( Lewis, JS; Wilkins, BJ, 2009) |
| " Although the overall goal of these drugs remains the blockade of RAS activation, their individual targets in this system vary and may substantially influence the clinical benefit derived from the long term use of these substances." | 2.45 | Angiotensin II type 1 receptor blockade: high hopes sent back to reality? ( Divchev, D; Grothusen, A; Luchtefeld, M; Schieffer, B, 2009) |
| " Likewise, few studies have directly compared more than two agents or ARB/hydrochlorothiazide fixed-dose combinations, and most ARBs have not been compared across their full recommended dosage ranges." | 2.44 | Comparison of angiotensin II type 1 receptor antagonists in the treatment of essential hypertension. ( Smith, DH, 2008) |
| "Amlodipine is a highly effective and safe antihypertensive dihydropyridine calcium channel blocker." | 2.44 | Combination therapy with renin-angiotensin system blockers: will amlodipine replace hydrochlorothiazide? ( Fornoni, A; Lenz, O; Materson, BJ; Tejada, T, 2007) |
| "Hypertension is a common treatable risk factor for cardiovascular disease." | 2.44 | [A first drug combination for the treatment of arterial hypertension with a calcium channel antagonist (amlodipine besylate) and an angiotensin receptor blocker (valsartan): Exforge]. ( Krzesinski, JM; Scheen, AJ, 2007) |
| "Amlodipine/valsartan was generally well tolerated in clinical trials." | 2.44 | Amlodipine/Valsartan: fixed-dose combination in hypertension. ( Plosker, GL; Robinson, DM, 2008) |
| "Hypertension is the second leading attributable cause of end-stage renal disease in the United States today." | 2.43 | Lessons from the African-American Study of Kidney Disease and Hypertension: an update. ( Toto, RD, 2006) |
| "Proteinuria was reduced on average by 33% in the irbesartan group as compared with 6% in the amlodipine group and 10% in the placebo group." | 2.42 | Treatment of diabetic nephropathy with angiotensin II receptor antagonist. ( Lewis, EJ; Lewis, JB, 2003) |
| "One of the current challenges in the treatment of hypertension is the variation in the incidence and morbidity among ethnic populations." | 2.42 | Recommendations for the management of special populations: racial and ethnic populations. ( Ferdinand, KC, 2003) |
| "The Valsartan Antihypertensive Long-Term Use Evaluation (VALUE) Trial compared coronary heart disease outcome in two anti-hypertensive treatment strategies based on either an angiotensin receptor blocker, valsartan, or a calcium channel blocker (CCB), amlodipine." | 2.42 | The VALUE trial: a commentary. ( Sever, P, 2004) |
| "Eplerenone is a newer aldosterone antagonist that is much more selective, with minimal affinity for progesterone and androgenic receptors; therefore, there are very few reports of adverse sexual effects." | 2.42 | Eplerenone in hypertension. ( Burgess, E, 2004) |
| " Angiotensin II receptor antagonists provide adequate 24-hour blood pressure control, as measured by ambulatory blood pressure monitoring, and have a side-effect profile similar to placebo." | 2.40 | Safety and efficacy of angiotensin II receptor antagonists. ( Neutel, JM, 1999) |
| "Amlodipine is an intrinsically long-acting, vasoselective calcium antagonist structurally related to nifedipine, but with unique binding and pharmacologic properties that distinguish it from other agents of this class." | 2.39 | Unique pharmacologic properties of amlodipine. ( Burges, R; Moisey, D, 1994) |
| "Felodipine is a highly vascular selective calcium entry blocker, with a vascular selectivity ratio greater than 100, as shown experimentally." | 2.39 | Vascular selective calcium entry blockers in the treatment of cardiovascular disorders: focus on felodipine. ( Cheng, CP; Elvelin, L; Little, WC; Nordlander, M, 1995) |
| "Amlodipine, a third-generation dihydropyridine calcium antagonist, has a mode of action and pharmacodynamic profile which are comparable to those of conventional compounds in this series, such as nifedipine." | 2.39 | Amlodipine: an overview of its pharmacodynamic and pharmacokinetic properties. ( van Zwieten, PA, 1994) |
| "Amlodipine was not associated with adverse effects on hematologic or biochemical safety parameters nor on serum cholesterol or triglyceride levels." | 2.38 | An update on the safety of amlodipine. ( Osterloh, IH, 1991) |
| " In studies with hypertensive patients in which pharmacokinetic and pharmacodynamic indices have been integrated, we have demonstrated that the intersubject variability in the pharmacokinetics of verapamil, nifedipine, enalapril, and amlodipine is directly related to the variability in blood pressure response at steady state." | 2.38 | Amlodipine; clinical relevance of a unique pharmacokinetic profile. ( Elliott, HL; Meredith, PA, 1993) |
| "Amlodipine is a dihydropyridine calcium antagonist drug with distinctive pharmacokinetic characteristics which appear to be attributable to a high degree of ionisation." | 2.38 | Clinical pharmacokinetics of amlodipine. ( Elliott, HL; Meredith, PA, 1992) |
| " Ambulatory monitoring studies have confirmed that once-daily dosing provides 24-h control of blood pressure." | 2.38 | Amlodipine in the treatment of hypertension. ( Kaplan, NM, 1991) |
| " Blood pressure control shows a smooth profile over 24 h with once-daily dosing, and there is no tolerance with long-term administration of the drug." | 2.37 | Amlodipine in hypertension: an overview of the clinical dossier. ( Julius, S, 1988) |
| "Hypertension is the leading single preventable risk factor for cardiovascular disease." | 1.91 | The India Hypertension Control Initiative-early outcomes in 26 districts across five states of India, 2018-2020. ( Bhargava, B; Durgad, K; Gupta, S; Kaur, P; Kunwar, A; Sharma, M, 2023) |
| "Hypertension is a major public health challenge in low- and middle-income countries (LMICs) and calls for large-scale effective hypertension control programs." | 1.91 | Financial implications of protocol-based hypertension treatment: an insight into medication costs in public and private health sectors in India. ( Cazabon, D; Hering, D; Krishna, A; Moran, AE; Pathni, AK; Sahoo, SK; Sharma, B, 2023) |
| "50%) were the most frequent adverse events." | 1.91 | Efficacy and safety of single pill combination of amlodipine and valsartan in hypertensive Saudi patients. ( Ahmad, A; Alama, MN; Alharthi, TS; Alkreathy, HM; Alluhabi, SI; Alqarni, F; Alrafiah, AR; Damanhouri, ZA, 2023) |
| "Midlife hypertension is an important risk factor for cognitive impairment and dementia, including Alzheimer's disease." | 1.91 | Effect of long-term antihypertensive treatment on cerebrovascular structure and function in hypertensive rats. ( Bakker, ENTP; Coolen, BF; de Vos, J; Heijst, JA; Jongenelen, CAM; Naessens, DMP; Richard, E; Scholl, ER; Strijkers, GJ; Teunissen, CE; van der Wel, NN; VanBavel, E; Wilhelmus, MMM, 2023) |
| " Therefore, the results of valsartan and amlodipine tablets combined with alpha-lipoic acid on total antioxidant capacity (T-AOC) need to be investigated." | 1.91 | Effects of Valsartan and Amlodipine Tablets Combined with α-Lipoic Acid on T-AOC, IL-6 and β2-MG Levels in Patients with Diabetic Nephropathy. ( Su, F; Xia, Q, 2023) |
| "Patients with hypertension have a higher risk of developing stroke as well as experiencing a decline in cognitive functions and dementia." | 1.91 | In the prevention of dementia, the focus should be on early and consistent treatment of hypertension. ( Souček, M, 2023) |
| " This study aimed to investigate whether long-term use of valsartan increases cancer risk." | 1.72 | Cancer Risk of Angiotensin II Receptor Blocker Valsartan: A Population-based Study. ( Chan, TH; Tsoi, MF; Yung Cheung, BM, 2022) |
| "Uncontrolled hypertension is an important cardiovascular risk factor and therefore requires effective approaches to patient management." | 1.72 | Management of American Heart Association/American College of Cardiology-Defined Stage 2 Hypertension by Cardiologists in India. ( Abdullakutty, J; Abhyankar, M; Dalal, J; Das, MK; Fulwani, M; Guha, S; Gupta, R; Kahali, D; Mohan, JC; Mohanan, PP; Nair, T; Narasimhan, C; Ram, CVS; Ray, S; Revankar, S; Roy, DG, 2022) |
| "Hypertension is a key risk factor for ischemic heart disease and atherosclerosis." | 1.72 | Different Approaches in Manipulating Ratio Spectra for Analyzing Amlodipine Besylate and Irbesartan Combination. ( El Mously, DA; El-Sayed, GM; Hassan, NY; Mostafa, NM, 2022) |
| "Amlodipine was the most common first-line agent (n=10), followed by hydralazine (n=4) and hypertonic saline (n=1)." | 1.72 | Evaluation of presentation, treatment and outcome in hypertensive emergency in dogs and cats: 15 cases (2003-2019). ( Beeston, D; Cortellini, S; Jepson, R, 2022) |
| "Arterial hypertension is among factors with the potential for increasing the risk of cognitive impairment in elderly subjects." | 1.72 | Delayed Decline of Cognitive Function by Antihypertensive Agents: A Cohort Study Linked with Genotype Data. ( Hojnacki, D; Podolsky, R; Schaller, B; Sternberg, Z; Tian, M; Yu, J, 2022) |
| "Amlodipine was started on day +36 for HTN." | 1.72 | Platelet Dysfunction Because of Amlodipine in Bone Marrow Transplant Recipient. ( Gözmen, S; Gözmen, ŞK, 2022) |
| "Galangin is a natural flavonoid isolated from ginger, honey and propolis." | 1.62 | Galangin alleviates vascular dysfunction and remodelling through modulation of the TNF-R1, p-NF-κB and VCAM-1 pathways in hypertensive rats. ( Bunbupha, S; Chaihongsa, N; Maneesai, P; Pakdeechote, P; Potue, P; Sangartit, W, 2021) |
| "Nifedipine was resumed during periodontal treatment when the patient's hypertension worsened." | 1.62 | Treatment of calcium channel blocker-induced gingival overgrowth without modifying medication. ( Miyashita, Y; Morikawa, S; Nakagawa, T; Nasu, M, 2021) |
| "Hypertension is a chronic condition that requires lifelong therapeutic management." | 1.62 | Long-acting tunable release of amlodipine loaded PEG-PCL micelles for tailored treatment of chronic hypertension. ( Chua, CYX; Di Trani, N; Grattoni, A; Liu, HC; Liu, X; Qi, R; Viswanath, DI, 2021) |
| "Amlodipine is a calcium channel blocker shown to be effective in lowering blood pressure with minimal adverse effects in mammals." | 1.62 | Use of Amlodipine in Psittacine Birds: 5 Cases (2010-2018). ( Fink, DM; Mans, C, 2021) |
| "Hypertension is the major risk factor for SVDs, but how hypertension damages the brain microcirculation is unclear." | 1.62 | Differential restoration of functional hyperemia by antihypertensive drug classes in hypertension-related cerebral small vessel disease. ( Dabertrand, F; Ferris, HR; Greenstein, AS; Harraz, OF; Hill-Eubanks, DC; Koide, M; Longden, TA; Nelson, MT; Wellman, GC, 2021) |
| " These herbs also influenced the Cmax, AUC0-t, and Tmax of amlodipine." | 1.62 | Effect of Hibiscus sabdariffa and Zingiber officinale on pharmacokinetics and pharmacodynamics of amlodipine. ( Ahad, A; Al-Jenoobi, FI; Al-Mohizea, AM; Alam, MA; Alzenaidy, B; Bin Jardan, YA; Raish, M, 2021) |
| "Amlodipine is a general antihypertensive drug used in combination with various other antihypertensive agents." | 1.62 | Effect of Co-Administration of Curcumin with Amlodipine in Hypertension. ( Choi, HY; Jo, C; Lee, K; Lee, S, 2021) |
| " Repeat dose pharmacokinetic and pharmacodynamic study of the nano-fixed dose combination (FDC) was done in dexamethasone-induced animal model." | 1.56 | Pharmacokinetic and pharmacodynamic evaluation of nano-fixed dose combination for hypertension. ( Bhandari, RK; Bhatia, A; Kaur, N; Malhotra, S; Pandey, AK; Rather, IIG; Shafiq, N; Sharma, S, 2020) |
| " There was no remarkable effect of any of these two herbs on Cmax, AUC0-t, Kel, and terminal elimination half-life of amlodipine, but fenugreek altered the Tmax of amlodipine significantly, from 2 ± 1." | 1.56 | Effect of Nigella sativa and Fenugreek on the Pharmacokinetics and Pharmacodynamics of Amlodipine in Hypertensive Rats. ( Ahad, A; Al-Jenoobi, FI; Al-Mohizea, AM; Alam, MA; Bin Jardan, YA; Raish, M, 2020) |
| "Hypertension and dyslipidemia are important risk factors for cardiovascular disease." | 1.56 | Fixed-dose combination of amlodipine and atorvastatin improves clinical outcomes in patients with concomitant hypertension and dyslipidemia. ( Chu, PH; Chu, YC; Hsiao, FC; Kao, YW; Lin, CP; Lin, YS; Tung, YC; Yang, CH, 2020) |
| "Arterial hypertension was treated with amlodipine but remained greater than the upper limit for 51 days until the dog recovered ambulation." | 1.56 | Acute idiopathic polyradiculoneuritis with secondary arterial hypertension in a 5-year-old male Siberian Husky. ( Baisan, AR; Henea, M; Hrițcu, LD; Mocanu, D; Musteata, M; Pașca, SA; Solcan, G; Ștefănescu, R, 2020) |
| "5%) were adherent to the therapy (PDC ≥ 80%); among them, a small percentage required dosage modification." | 1.51 | Treatment with Free Triple Combination Therapy of Atorvastatin, Perindopril, Amlodipine in Hypertensive Patients: A Real-World Population Study in Italy. ( Degli Esposti, L; Gambera, M; Nati, G; Perone, F; Perrone, V; Tagliabue, PF; Veronesi, C; Volpe, M, 2019) |
| "Secondary hypertension was suspected and autoimmune workup was positive for anticardiolipin IgG and lupus anticoagulant." | 1.51 | Chronic thrombotic microangiopathy secondary to antiphospholipid syndrome, presenting with severe hypertension and chronic renal impairment. ( Angkodjojo, S; Tan, PH; Yee, Y, 2019) |
| "Enalapril was the most commonly prescribed drug." | 1.48 | Drug utilization among hypertensive patients in the outpatient department of medicine in a tertiary care hospital: A cross-sectional study. ( Paradkar, SG; Sinha, SR, 2018) |
| "Ischemic optic neuropathy is a well-recognized cause of blindness in humans and should be included as a differential diagnosis for acute prechiasmatic blindness in dogs." | 1.48 | Ischemic Optic Neuropathy in a Dog with Acute Bilateral Blindness and Primary Systemic Hypertension. ( De Risio, L; Dominguez, E; Mari, L; Oliver, J; Premont, J; Stavinohova, R, 2018) |
| "Cilnidipine has a similar capacity as amlodipine in reducing home BP variability, but the underlying mechanisms in reducing BP variability may differ." | 1.48 | Comparison between L-type and N/L-type calcium channel blockers in the regulation of home blood-pressure variability in elderly hypertensive patients. ( Akasaka, H; Hongyo, K; Ito, N; Nozato, S; Nozato, Y; Rakugi, H; Sugimoto, K; Takami, Y; Takeda, M; Takeya, M; Takeya, Y; Yamamoto, K, 2018) |
| "amlodipine was associated with lower BPV than other CCBs for both hypertensive patients and hypertensive patients with comorbidity." | 1.48 | Comparison of amlodipine versus other calcium channel blockers on blood pressure variability in hypertensive patients in China: a retrospective propensity score-matched analysis. ( Dong, P; Li, L; Lin, Y; Liu, D; Xie, X; Yang, J; Zhang, L, 2018) |
| "Drug induced linear IgA bullous dermatosis (LABD) is a rare blistering disease that has been shown to be associated with the use of various medications." | 1.48 | Diffuse vesiculobullous eruption with systemic findings. ( Falkner, RC; Helmandollar, KJ; Hoverson, KR; Meyerle, JH, 2018) |
| " Multiple blood and milk samples were obtained from the mothers over a 24 hours dosing interval." | 1.48 | Low Levels of Amlodipine in Breast Milk and Plasma. ( Aoki, H; Ito, N; Ito, S; Kaniwa, N; Murashima, A; Nakajima, K; Okamoto, A; Sago, H; Saito, Y; Wada, Y, 2018) |
| "Treatment with carvedilol or amlodipine completely prevented left ventricular collagen deposition and morphometric alterations in aorta." | 1.46 | Effects of carvedilol or amlodipine on target organ damage in L-NAME hypertensive rats: their relationship with blood pressure variability. ( Berg, G; Bertera, FM; Carranza, A; Chiappetta, DA; Del Mauro, JS; Donato, M; Fernandez Machulsky, N; Gelpi, RJ; González, GE; Gorzalczany, SB; Höcht, C; Morales, C; Morettón, MA; Prince, PD; Taira, CA, 2017) |
| " The primary objective of the PETRA study was to evaluate the efficacy of blood pressure (BP) control with once daily administration of the different dosage strengths of the once-daily, triple fixed combination of perindopril, indapamide, and amlodipine." | 1.46 | The Antihypertensive Efficacy of the Triple Fixed Combination of Perindopril, Indapamide, and Amlodipine: The Results of the PETRA Study. ( Ábrahám, G; Dézsi, CA, 2017) |
| " Here, we hypothesized different efficacy of morning versus evening dosing of VA in spontaneously hypertensive rats (SHR) and the involvement of circadian clock genes Bmal1 and Per2." | 1.46 | mRNA levels of circadian clock components Bmal1 and Per2 alter independently from dosing time-dependent efficacy of combination treatment with valsartan and amlodipine in spontaneously hypertensive rats. ( Doka, G; Klimas, J; Kralova, E; Krenek, P; Potucek, P; Radik, M, 2017) |
| "Hypertension is currently one of the greatest global health care challenges." | 1.46 | Management of Hypertension With a Fixed-Dose (Single-Pill) Combination of Bisoprolol and Amlodipine. ( Barho, C; Gottwald-Hostalek, U; Hildemann, S; Sun, N, 2017) |
| "Amlodipine could suppress Ang-II-induced endothelial dysfunction and apoptosis through diminishing ROCK1 expression." | 1.43 | Amlodipine suppresses Ang-II-induced endothelium dysfunction by diminishing ROCK1 expression. ( Cai, A; Feng, Y; Li, L; Mai, W; Qiu, R; Xu, R; Zheng, D; Zhou, Y, 2016) |
| "Aggressive treatment of hypertension resulted in complete resolution of the clinical and radiologic features of the syndrome." | 1.43 | Does this patient have hypertensive encephalopathy? ( Argyropoulou, MI; Christopoulou, F; Elisaf, M; Kosta, P; Rizos, EC, 2016) |
| "The composite outcome included incident ESRD after assessment of SD of systolic BP or ≥50% decline in eGFR between 24 months and 48 or 72 months after randomization." | 1.43 | Visit-to-Visit Variability of BP and CKD Outcomes: Results from the ALLHAT. ( Davis, BR; Lynch, AI; Muntner, P; Oparil, S; Rahman, M; Simpson, LM; Tanner, RM; Whelton, PK; Whittle, J, 2016) |
| "Treatment with amlodipine, candesartan, or indapamide did not significantly affect plasma visfatin levels." | 1.43 | Effects of antihypertensive treatment on plasma apelin, resistin, and visfatin concentrations. ( Piecha, G; Skoczylas, A; Więcek, A, 2016) |
| "Our data show a potential pharmacokinetic interaction, most likely via CYP3A4 between amlodipine and RIS, reflected in significantly different C/Ds for RIS, 9-OH-RIS and AM." | 1.43 | Pharmacokinetic considerations in the treatment of hypertension in risperidone-medicated patients - thinking of clinically relevant CYP2D6 interactions. ( Gründer, G; Haen, E; Lammertz, SE; Paulzen, M; Schoretsanitis, G; Schruers, KR; Stegmann, B; Walther, S, 2016) |
| "Treatment with Amlodipine alone or combination with atorvastatin significantly decreased blood pressure, left ventricle mass index in SHR rats (P < 0." | 1.43 | Amlodipine and Atorvastatin Improved Hypertensive Cardiac Remodeling through Regulation of MMPs/TIMPs in SHR Rats. ( Cui, W; Du, H; Hao, J; Li, Y; Lu, J; Xiao, B; Yang, X, 2016) |
| "The aims of this study are to find the prevalence of potential drug-drug interactions (DDIs) in patients with Hemodialysis and identify factors associated with these interactions if present." | 1.43 | Evaluation of potential drug- drug interactions among Palestinian hemodialysis patients. ( Abu-Ghazaleh, D; Al-Ramahi, R; Bsharat, A; Raddad, AR; Rashed, AO; Shehab, O; Yasin, E, 2016) |
| "BACKGROUND Is the timing of dosing for amlodipine and atorvastatin important with regard to therapeutic efficacy? To answer this question, we designed an outpatient, practice-based, case-control study lasting 8 weeks." | 1.43 | Is Time an Important Problem in Management of Hypertension and Hypercholesterolemia by Using an Amlodipine-Atorvastatin Single Pill Combination? ( Wang, M; Zeng, R; Zhang, L, 2016) |
| "Amlodipine was more effective in promoting beneficial autonomic cardiovascular adaptations in sedentary animals." | 1.43 | Amlodipine and enalapril promote distinct effects on cardiovascular autonomic control in spontaneously hypertensive rats: the role of aerobic physical training. ( Bezerra, VB; De Araujo, JE; de Souza, HC; Gastaldi, AC; Maida, KD; Vieira, S, 2016) |
| "Gingival overgrowth is a common feature of periodontal diseases." | 1.43 | Amlodipine-Induced Gingival Overgrowth. ( Jayanthi, R; Rajan, PB, 2016) |
| "Cilnidipine has an advantage of causing less reflex tachycardia, less pedal edema and better control of proteinuria in comparison to L-type CCB." | 1.43 | Cilnidipine: Next Generation Calcium Channel Blocker. ( Shete, MM, 2016) |
| "Hypertension is considered to be the most important risk factor for stroke, and all forms of hypertension are associated with an increased risk of both ischemic and haemorrhagic stroke." | 1.43 | Significance of BP Control in Reducing Stroke Events: Role of Amlodipine in an Indian Perspective. ( Muruganathan, A; Tiwaskar, M, 2016) |
| " We have now compared the effects of the ARB valsartan combined with cilnidipine or amlodipine on cardiac pathophysiology in DS rats." | 1.42 | Comparative effects of valsartan in combination with cilnidipine or amlodipine on cardiac remodeling and diastolic dysfunction in Dahl salt-sensitive rats. ( Harada, E; Hattori, T; Matsuura, N; Murohara, T; Nagasawa, K; Nagata, K; Niinuma, K; Takahashi, K; Takatsu, M; Watanabe, S, 2015) |
| "Amlodipine was the most commonly prescribed CCB in combination with simvastatin (70%) and the most common CCB prescribed against-label (67%)." | 1.42 | Simvastatin prescribing patterns before and after FDA dosing restrictions: a retrospective analysis of a large healthcare claims database. ( Ghushchyan, V; Nair, K; Saseen, JJ; Tuchscherer, RM, 2015) |
| "Telmisartan treatment appears to be more efficient than amlodipine treatment." | 1.42 | Long-term use of angiotensin II receptor antagonists and calcium-channel antagonists in Algerian hypertensive patients: effects on metabolic and oxidative parameters. ( El Hassar, C; Malti, N; Merzouk, H; Merzouk, SA; Meziane, A; Narce, M, 2015) |
| " Efficacy was assessed in accordance with the Austrian hypertension guidelines while tolerability was evaluated on the basis of adverse events." | 1.42 | Efficacy, safety, and tolerability of antihypertensive therapy with aliskiren/amlodipine in clinical practice in Austria. The RALLY (Rasilamlo long lasting efficacy) study. ( Ratzinger, M; Rosenkranz, AR, 2015) |
| " In this study, we elucidated the effect of amlodipine on nitric oxide (NO) bioavailability and cytotoxic peroxynitrite (ONOO(-)) and blood pressure (BP)." | 1.40 | Amlodipine increased endothelial nitric oxide and decreased nitroxidative stress disproportionately to blood pressure changes. ( Corbalan, JJ; Jacob, RF; Kaliszan, R; Malinski, T; Mason, RP, 2014) |
| "Prehypertension has been associated with adverse cerebrovascular events and brain damage." | 1.40 | Long-term prehypertension treatment with losartan effectively prevents brain damage and stroke in stroke-prone spontaneously hypertensive rats. ( He, DH; Lin, JX; Lin, LM; Ning, RB; Wang, HJ; Xu, CS; Zhang, LM, 2014) |
| "Hypertension is a major modifiable risk for the development of cardiovascular, cerebrovascular and renal diseases." | 1.40 | ARB-based single-pill platform to guide a practical therapeutic approach to hypertensive patients. ( de la Sierra, A; Kreutz, R; Laurent, S; Manolis, AJ; Volpe, M, 2014) |
| "Adrenal hyperplasia was apparent on post-mortem histopathology." | 1.40 | Hypokalaemia in a hyperthyroid domestic shorthair cat with adrenal hyperplasia. ( Elwood, C; Fryers, A, 2014) |
| " This study was performed to determine the pharmacokinetic (PK) interaction between RG and amlodipine, an antihypertensive drug." | 1.40 | Negligible pharmacokinetic interaction of red ginseng and antihypertensive agent amlodipine in Sprague-Dawley rats. ( Cho, YB; Jeong, WS; Kim, JW; Kim, KB; Kim, YG; Kim, YS; Lee, HK; Lee, SH; Ryu, SH, 2014) |
| "Hypertension is a condition which in many cases is treated with more than one drug." | 1.39 | Pill burden in hypertensive patients treated with single-pill combination therapy--an observational study. ( Freytag, S; Hagendorff, A; Klebs, S; Müller, A, 2013) |
| "Hypertension is a major challenge for public health." | 1.39 | Amlodipine increases vitamin D levels more than valsartan in newly diagnosed hypertensive patients: pointing to an additional effect on bone metabolism or a novel marker of inflammation? ( Arslan, E; Ay, SA; Balta, S; Bozoglu, E; Bulucu, F; Cakar, M; Celik, T; Demirbas, S; Demirkol, S; Karaman, M; Kurt, O; Naharci, MI, 2013) |
| "Amlodipine's effect was similar to control." | 1.39 | Telmisartan exerts pleiotropic effects in endothelial cells and promotes endothelial cell quiescence and survival. ( Sessa, WC; Siragusa, M, 2013) |
| "Cardiovascular diseases are the leading cause of death worldwide." | 1.39 | Fixed combination of amlodipine/atorvastatin: from mechanisms to trials. ( Ivanovic, B; Tadic, M, 2013) |
| "Amlodipine therapy was discontinued and oedema diminished markedly within 72 hours." | 1.39 | Generalised peripheral oedema associated with amlodipine therapy in two dogs. ( Creevy, KE; Ellis, AE; Scuderi, MA, 2013) |
| "Hypertension is associated with fibrinolysis abnormality." | 1.39 | Thrombin activatable fibrinolysis inhibitor (TAFI) levels in hypertensive patients and a comparison of the effects of amlodipine and ramipril on TAFI levels. ( Bektaş, O; Karahan, SC; Kaynar, K; Menteşe, A; Ozkan, G; Sönmez, M; Ulusoy, S, 2013) |
| "Olmesartan has been also widely examined in combination of either hydrochlorothiazide or amlodipine, as well as with both drugs in a single-pill triple combination, showing improvements in antihypertensive efficacy without significant effects on tolerability." | 1.39 | Olmesartan-based therapies: an effective way to improve blood pressure control and cardiovascular protection. ( de la Sierra, A; Volpe, M, 2013) |
| "Hypertension is a major issue in public health, and the financial costs associated with hypertension continue to increase." | 1.38 | An economic evaluation of antihypertensive therapies based on clinical trials. ( Berwanger, O; Mion Júnior, D; Ortega, KC; Silva, GV; Tsuji, RL, 2012) |
| "Amiloride treatment also reduced high blood pressure caused by the high-salt diet in these mice." | 1.38 | Impaired sodium excretion and salt-sensitive hypertension in corin-deficient mice. ( Chen, S; Cui, Y; Jiang, J; Peng, J; Shen, J; Wang, W; Wu, Q, 2012) |
| "Amlodipine treatment reduced the contractions and improved relaxation to ACh." | 1.37 | Amlodipine ameliorates endothelial dysfunction in mesenteric arteries from spontaneously hypertensive rats. ( Cheng, G; He, X; Jiang, HK; Li, DL; Sun, L; Yang, JL; Yu, XJ; Zang, WJ; Zhang, HL; Zhao, M; Zhao, Q, 2011) |
| "Systemic hypertension is one of the most common preexisting conditions." | 1.37 | Recurrent vestibular paroxysms associated with systemic hypertension in a dog. ( Bentley, RT; March, PA, 2011) |
| "Pioglitazone improved endothelial function in hypertensive patients with IGT through an increase in nitric oxide bioavailability by, in part, a decrease in oxidative stress." | 1.36 | Pioglitazone improves endothelium-dependent vasodilation in hypertensive patients with impaired glucose tolerance in part through a decrease in oxidative stress. ( Chayama, K; Fujii, Y; Fujimura, N; Goto, C; Hata, T; Hidaka, T; Higashi, Y; Idei, N; Kihara, Y; Nakagawa, K; Soga, J, 2010) |
| "Candesartan treatment may suppress all-cause death and reduce the incidence of new-onset diabetes in patients with obesity." | 1.36 | Role of diabetes and obesity in outcomes of the candesartan antihypertensive survival evaluation in Japan (CASE-J) trial. ( Fujimoto, A; Hirata, M; Nakao, K; Oba, K; Ogihara, T; Saruta, T; Ueshima, K; Yasuno, S, 2010) |
| "Compared with the placebo-treated group, proteinuria was significantly lower in the irbesartan- and efonidipine-treated groups, but not in the amlodipine-treated group." | 1.36 | Combination therapy with irbesartan and efonidipine for attenuation of proteinuria in Dahl salt-sensitive rats. ( Jin, D; Miyazaki, M; Sakonjo, H; Takai, S, 2010) |
| "Hypertension and dyslipidemia are highly co-prevalent, but often poorly controlled, coronary heart disease (CHD) risk factors." | 1.36 | Predicted coronary heart disease risk reduction and dual blood pressure/cholesterol goal attainment in patients with hypertension treated in real-world clinical practice. ( Chen, L; Eaddy, M; Jackson, JH; Kean, AJ; Lunacsek, OE; Neutel, JM; Roberts, C, 2010) |
| "Hypertension was induced by 4-weeks treatment with N(omega)-nitro-l-arginine-methyl ester (l-NAME)." | 1.35 | Sildenafil augments the beneficial hemodynamic and histopathological effects of amlodipine in nitric oxide-deficient hypertensive rats: role of nitric oxide-cyclic GMP pathway. ( Aboutabl, ME; El Din, AG; Kenawy, SA; Maklad, YA; Raafat, M, 2008) |
| "High blood pressure is a major risk factor for cardiovascular disease worldwide." | 1.35 | Aliskiren for hypertension in adults. ( , 2008) |
| "Rosiglitazone-treated rats had restored systolic blood pressure (BP) and normalized plasma insulin level during oral glucose tolerance tests, whereas amlodipine-treated rats restored only systolic BP." | 1.35 | Myocardial heat shock protein 60 expression in insulin-resistant and diabetic rats. ( Chen, HS; Juan, CC; Lin, HD; Wu, TE, 2009) |
| "She had been suffering from migraine from her 30's." | 1.35 | [Migraine improved by amlodipine medication in a case with hypertension]. ( Igase, M; Kawajiri, M; Kohara, K; Miki, T; Nagai, T, 2008) |
| "Cardiac complications were defined as left ventricular hypertrophy (LVH) and ischemic heart disease (IHD)." | 1.35 | Effects of cardiac complications on cardiovascular events in Japanese high-risk hypertensive patients: subanalysis of the CASE-J trial. ( Fujimoto, A; Nakao, K; Oba, K; Ogihara, T; Saruta, T; Ueshima, K; Yasuno, S, 2009) |
| "Arterial hypertension is an important cardiovascular risk factor." | 1.35 | [Clinical study of the month. The ACCOMPLISH study: challenging the choice of antihypertensive medications in systolic hypertensive patients with high cardiovascular risk]. ( Krzesinski, JM; Scheen, AJ, 2009) |
| " Tolerability was assessed by treatment-emergent adverse events." | 1.35 | Evaluation of safety and efficacy of telmisartan-amlodipine combination in treating hypertension. ( Faruqui, AA, 2008) |
| "Although hypertension is common (30% of adults in the USA), its control to recommended blood pressure levels of under 140/90 mmHg remains low, at 36." | 1.35 | Amlodipine besylate/olmesartan medoximil fixed combination for the treatment of hypertension. ( Chrysant, SG, 2009) |
| "Treatment with amlodipine + valsartan + HCTZ for up to 8 weeks was generally well tolerated in the large, phase III trial, with most adverse events being transient and of mild to moderate severity." | 1.35 | Amlodipine/valsartan/hydrochlorothiazide: fixed-dose combination in hypertension. ( Deeks, ED, 2009) |
| "Salt-sensitive (SS) hypertension is a vascular diathesis characterized by reduced cardiovascular and renal nitric oxide bioavailability and local upregulation of ANG II." | 1.35 | Upregulation of cortical COX-2 in salt-sensitive hypertension: role of angiotensin II and reactive oxygen species. ( Jaimes, EA; Pearse, DD; Puzis, L; Raij, L; Zhou, MS, 2008) |
| "Treatment regimens that require fewer dosage units and less frequent dosing to decrease the complexity and cost of care are among the strategies recommended to improve compliance with antihypertensive therapy." | 1.35 | Compliance with antihypertensive therapy in the elderly: a comparison of fixed-dose combination amlodipine/benazepril versus component-based free-combination therapy. ( Dickson, M; Plauschinat, CA, 2008) |
| "Drug induced gingival hyperplasia is an uncommon entity." | 1.34 | Amlodipine induced gingival hyperplasia: a rare entity. ( Bhatia, V; Kaul, U; Mittal, A; Parida, AK; Talwar, R, 2007) |
| "In the Valsartan Antihypertensive Long-Term Use Evaluation (VALUE) trial, the risk of new-onset diabetes was reported to be 23% lower among patients initiating therapy with valsartan versus amlodipine." | 1.34 | Risk of diabetes in a real-world setting among patients initiating antihypertensive therapy with valsartan or amlodipine. ( Edelsberg, J; Jamerson, K; Khan, ZM; Kjeldsen, SE; Oster, G; Vincze, G; Weycker, D, 2007) |
| " Long-term administration of normodipin is able to stabilize the achieved effect." | 1.34 | [Correction of primary hemostasis in patients suffering from arterial hypertension with metabolic syndrome]. ( Medvedev, IN, 2007) |
| "Hypertension is present in nearly 80% of dialysis patients yet adequately controlled in less than half." | 1.34 | ACE inhibitor-based, directly observed therapy for hypertension in hemodialysis patients. ( Coyne, DW; Nath, V; Zheng, S, 2007) |
| "Heart failure was two times more prevalent in obese patients." | 1.34 | [Overweight and obesity in hypertensive Spanish patients. The CORONARIA study]. ( Aguilar Llopis, A; Arístegui Urrestarazu, R; Armada Peláez, B; Cosín Aguilar, J; Hernándiz Martínez, A; Masramón Morell, X; Rodríguez Padial, L; Zamorano Gómez, JL, 2007) |
| "Amlodipine orotate was prepared by reacting orotic acid and amlodipine to increase the dissolution rate at higher gastric pH conditions." | 1.33 | Effects of amlodipine orotate on hypertension-related complications in spontaneously hypertensive rats. ( Ahn, BO; Choi, SM; Kim, JE; Kwon, JW, 2006) |
| "It is predicted that future treatment of hypertension will be increasingly tailored to the epidemiologic profiles and medical costs of individual communities." | 1.33 | Comparison of health costs associated with treatment of hypertension with a calcium channel blocker and angiotensin-converting enzyme inhibitor in the United States and Japan. ( Ikeda, S; Ikegami, N; Sakamaki, Y; Saruta, T; Sasamura, H, 2006) |
| "Amlodipine was measured by liquid chromatography-atmospheric pressure photoionization-mass spectrometry." | 1.33 | Two cases of fatal amlodipine overdose. ( Aronica-Pollack, PA; Fowler, D; Ingwersen, KM; Levine, B; Sklerov, JH, 2006) |
| "Atenolol presented lower LF and higher HF of PI." | 1.33 | Antihypertensive agents have different ability to modulate arterial pressure and heart rate variability in 2K1C rats. ( Coelho, EB; da Silva, CA; Fazan, R; Nobre, F; Salgado, HC, 2006) |
| "Aliskiren is a novel, orally active direct renin inhibitor that lowers blood pressure alone and in combination with existing antihypertensive agents." | 1.33 | Lack of pharmacokinetic interactions of aliskiren, a novel direct renin inhibitor for the treatment of hypertension, with the antihypertensives amlodipine, valsartan, hydrochlorothiazide (HCTZ) and ramipril in healthy volunteers. ( Bizot, MN; Denouel, J; Dieterich, HA; Dole, WP; Kemp, C; Vaidyanathan, S; Valencia, J; Yeh, CM; Zhao, C, 2006) |
| "Heart failure was four times more frequent in these patients with renal disease than in other hypertensives." | 1.33 | [Coronary disease risk and prevalence of heart disease in primary care patients with hypertension and renal disease]. ( Aguilar-Llopis, A; Arístegui-Urrestarazu, R; Cosín-Aguilar, J; Hernándiz-Martínez, A; Masramón-Morell, X; Rodríguez-Padial, L; Zamorano-Gómez, JL, 2006) |
| "Amlodipine was shown to be a well tolerated and effective drug in one in three patients, and achieved the therapeutic goal in a higher proportion of patients at specialised-care centres compared with those in primary care, and in those receiving combined therapy compared with monotherapy." | 1.33 | Efficacy and safety of amlodipine: a comparative study of hypertensive patients treated at primary- and specialised-care centres. ( Arístegui, R; Gil, A; Hernández, V; Jiménez, R; Valcárcel, Y, 2006) |
| "Body weight was measured weekly in all the groups, and arterial blood pressure was also measured in all the 10-, 15-, 20-, and 25-week-old SHR by the tail cuff method." | 1.32 | Effect of dietary calcium supplements and amlodipine on growth, arterial blood pressure, and cardiac hypertrophy of spontaneously hypertensive rats. ( Aleixandre, A; Civantos, B, 2003) |
| "Amlodipine has antihypertensive and antioxidant activity in vivo, which effectively inhibits many of the oxidative stress-dependent mechanisms involved in Ang II-mediated cardiovascular injury." | 1.32 | Inhibition of oxidative stress and improvement of endothelial function by amlodipine in angiotensin II-infused rats. ( Jaimes, EA; Raij, L; Zhou, MS, 2004) |
| "Amlodipine treatment reduced left ventricle, aortic and mesenteric artery weight." | 1.32 | Comparative study of the antihypertensive activity of Marrubium vulgare and of the dihydropyridine calcium antagonist amlodipine in spontaneously hypertensive rat. ( El Bardai, S; Lyoussi, B; Morel, N; Wibo, M, 2004) |
| " Adverse events were reported by only 1." | 1.32 | [Safety and antihypertensive efficacy of the dihydropyridine calcium antagonist Amlodipine besylate--results from an observational study in 9,672 patients]. ( Clemens, A; Keck, M; Regourd, E; Sauerbrey-Wullkopf, N, 2004) |
| "To investigate the effects of the mixed endothelin receptor antagonist, bosentan, combined with the long-acting calcium channel blocker, amlodipine, compared to the angiotensin-converting enzyme inhibitor, cilazapril, on the progressive renal injury in spontaneous hypertensive rats (SHR) with diabetes." | 1.31 | Endothelin receptor antagonist combined with a calcium channel blocker attenuates renal injury in spontaneous hypertensive rats with diabetes. ( Chen, J; Gu, Y; Lin, F; Lin, S; Ma, J; Yang, H; Zhu, W, 2002) |
| "Oral treatment with amlodipine (n=7), initiated at day 0, reduced systolic blood pressure, reversed cerebral edema and restored blood-brain barrier integrity." | 1.31 | Reduction of cerebral injury in stroke-prone spontaneously hypertensive rats by amlodipine. ( Blezer, E; Goldschmeding, R; Joles, J; Koomans, H; Nicolay, K, 2002) |
| "Treatment with doxazosin positively influenced the metabolic profile." | 1.31 | [Hypertension and metabolic syndrome in population of one company. Monotherapy with amlodipine and doxazosin]. ( Ceremuzyński, L; Cybulski, J, 2002) |
| "The transgenics developed left ventricular hypertrophy along with perivascular and interstitial fibrosis which became progressively worse up to 24 weeks of age." | 1.31 | Raised blood pressure, not renin-angiotensin systems, causes cardiac fibrosis in TGR m(Ren2)27 rats. ( Bishop, JE; Gohlke, P; Kiernan, LA; McEwan, JR; Montgomery, HE, 2000) |
| "Mean amlodipine dose was 0." | 1.31 | Treatment of hypertensive children with amlodipine. ( Bunchman, TE; Flynn, JT; Smoyer, WE, 2000) |
| "Systolic hypertension was diagnosed in 30 cats." | 1.31 | Feline hypertension: clinical findings and response to antihypertensive treatment in 30 cases. ( Barber, PJ; Elliott, J; Markwell, PJ; Rawlings, JM; Syme, HM, 2001) |
| "Amlodipine treatment reduced the level of adrenocortical angiotensin II type 2 receptor (AT2R) mRNA in SHR from 8 weeks of age." | 1.31 | Chronic treatment with amlodipine modulates adrenocortical angiotensin II receptors in spontaneously hypertensive rats. ( Kataoka, H; Kishida, M; Makino, H; Mimura, Y; Nakamura, Y; Ogura, T; Otsuka, F; Takahashi, M; Yamauchi, T; Yokota, K, 2001) |
| " A possible use of the technique is shown using the example of the effect of varying the drug dosage on the contraction of the arteriole muscle." | 1.31 | A rapid procedure for initial drug evaluation. ( Macpherson, AK; Macpherson, PA; Neti, S, 2001) |
| "The cost of treating hypertension represents a substantial percentage of total pharmacy expenditures at medical centers and by managed care organizations in the United States." | 1.31 | Pharmacist-managed hypertension therapy conversion. ( Yanchick, JK, 2001) |
| "Forearm vasodilatory response to reactive hyperemia was improved by temocapril (102 +/- 20% to 168 +/- 25%, P < ." | 1.30 | Converting enzyme inhibitor improves forearm reactive hyperemia in essential hypertension. ( Hata, T; Higaki, J; Iwatsubo, H; Kumamoto, K; Morita, R; Nagano, M; Ogihara, T; Sakai, T, 1997) |
| " The chronic administration of benazepril (5-10 mg/d) for 20 weeks improved insulin sensitivity, endothelial function (6." | 1.30 | Relationship between endothelial function and fibrinolysis in early hypertension. ( Doba, N; Kimura, Y; Kinouchi, T; Kushiro, T; Mitsuhashi, H; Tomiyama, H; Yoshida, H, 1998) |
| "The calcium antagonist amlodipine may have the potential for expanded use in children owing to its physiochemistry and pharmacokinetic profile that facilitates once-daily dosing in a liquid formulation." | 1.30 | Efficacy of amlodipine in pediatric bone marrow transplant patients. ( Arbus, GS; Khattak, S; Koren, G; Rogan, JW; Saunders, EF; Theis, JG, 1998) |
| "Amlodipine was found to inhibit growth and bFGF-induced DNA synthesis in a concentration-dependent manner." | 1.30 | Amlodipine and vascular hypertrophy. ( Herembert, T; Iouzalen, L; Marche, P; Stepien, O; Zhu, DL, 1997) |
| "To compare the effects of chronic administration of two dihydropyridines, nifedipine and amlodipine, and the non-dihydropyridine Ca2+ antagonist mibefradil on fluid filtration of large arteries and extravasation of albumin in spontaneously hypertensive rats." | 1.30 | Different effects of calcium antagonists on fluid filtration of large arteries and albumin permeability in spontaneously hypertensive rats. ( Koen, R; Lacolley, P; Levy, BI; Poitevin, P, 1998) |
| "Subcutaneous fat necrosis of the newborn (SCFN) is a relatively uncommon condition of the skin which is said to be benign and painless." | 1.30 | Painful subcutaneous fat necrosis of the newborn associated with intra-partum use of a calcium channel blocker. ( Haque, KN; Holden, CA; Johnson, A; Rosbotham, JL, 1998) |
| "Amlodipine was injected intraperitoneally in a dose of 5 mg/kg/day, either once daily at 8." | 1.30 | Cardiovascular risk, renal hypertensive damage, and effects of amlodipine treatment in transgenic TGR(mREN2)27 rats. ( Kränzlin, B; Lemmer, B; Schmidt, T; Schnecko, A; Voll, C; Witte, K, 1999) |
| "Arterial hypertension is a cardinal precursor of congestive heart failure, and diastolic dysfunction is the most frequent mechanism for it." | 1.30 | [Arterial hypertension and systolic left ventricular dysfunction: therapeutic approach]. ( Anguita Sánchez, M, 1999) |
| "Hypertension is a complex disease, the treatment of which should not only lower systolic and diastolic blood pressure but also attenuate the secondary consequences of the disease." | 1.29 | End-organ involvement and calcium antagonist therapy: animal studies. ( Nayler, WG, 1994) |
| " Therefore, the new once-daily calcium antagonist amlodipine is safe and efficacious in non-hypertensive patients with coronary artery disease." | 1.29 | Safety and efficacy of amlodipine. A new once-daily calcium antagonist in non-hypertensive patients with coronary artery disease. ( Ogawa, T; Sugishita, Y; Tomizawa, T; Yasui, K, 1993) |
| "Amlodipine was well tolerated." | 1.29 | Measurement of long-term hemodynamic changes and the use of 24-hour blood pressure monitoring to evaluate treatment. ( Lund-Johansen, P; Omvik, P; White, W, 1994) |
| "Hypertension is due to disturbance of the complex interplay between numerous known and unknown mechanisms that normally control blood pressure." | 1.29 | Long-term hemodynamic effects at rest and during exercise of newer antihypertensive agents and salt restriction in essential hypertension: review of epanolol, doxazosin, amlodipine, felodipine, diltiazem, lisinopril, dilevalol, carvedilol, and ketanserin. ( Lund-Johansen, P; Omvik, P, 1993) |
| "Amlodipine was analysed in plasma and GCF of four patients undergoing amlodipine therapy for cardiovascular disorders, three of whom had significant gingival overgrowth." | 1.29 | Automated gas chromatographic assay for amlodipine in plasma and gingival crevicular fluid. ( Cholerton, S; Ellis, JS; Idle, JR; Monkman, SC; Seymour, RA; Thomason, JM, 1996) |
| "Patients with previously untreated diastolic hypertension were treated with antihypertensive drugs for one year; these were withdrawn in patients with well controlled blood pressure, who were then followed for one year." | 1.29 | Predictive value of ambulatory blood pressure shortly after withdrawal of antihypertensive drugs in primary care patients. ( Beltman, FW; de Graeff, PA; Havinga, TK; Heesen, WF; Kok, RH; Lie, KI; May, JF; Meyboom-de Jong, B; Schuurman, FH; Smit, AJ; van der Veur, E, 1996) |
| "Amlodipine is a dihydropyridine calcium antagonist with prolonged duration of action." | 1.29 | Hemodynamic and 24-h blood pressure profile of amlodipine monotherapy. ( el-Boghdadly, B; Ibrahim, MM; Zaghloul, SS, 1996) |
| "Amlodipine is a low-clearance, dihydropyridine calcium antagonist." | 1.28 | Pharmacokinetics and pharmacodynamics of amlodipine. ( Abernethy, DR, 1992) |
| "Concomitantly, cardiac hypertrophy was attenuated in the treated group compared with the placebo group (heart-to-body weight ratios of 4." | 1.28 | Vascular injury: mechanisms and manifestations. ( Nayler, WG, 1991) |
| "2 mg/kg/day for 20 days) chronically receiving AML, there was an enhancement of the antihypertensive effect of AML within a few days after starting chronic dosing, and thereafter a significant reduction of BP at 24 hr after dosing and constant effects of AML during subsequent treatment." | 1.28 | [Antihypertensive effects of amlodipine, a new calcium antagonist]. ( Ishiko, J; Munehasu, S; Suzuki, M; Yamanaka, K, 1991) |
| "Amlodipine is a long-acting dihydropyridine-based calcium antagonist developed for use on a once-a-day basis." | 1.27 | The effect of amlodipine on hypertension-induced cardiac hypertrophy and reperfusion-induced calcium overload. ( Nayler, WG, 1988) |
| " amlodipine, clearance tended to be decreased in elderly as compared with young patients with resulting prolongation in elimination half-life (64 +/- 20 vs." | 1.27 | Amlodipine in elderly hypertensive patients: pharmacokinetics and pharmacodynamics. ( Abernethy, DR; Gutkowska, J; Lambert, MD, 1988) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 22 (1.05) | 18.7374 |
| 1990's | 300 (14.36) | 18.2507 |
| 2000's | 730 (34.94) | 29.6817 |
| 2010's | 854 (40.88) | 24.3611 |
| 2020's | 183 (8.76) | 2.80 |
| Authors | Studies |
|---|---|
| Rovnyak, GC | 1 |
| Atwal, KS | 1 |
| Hedberg, A | 1 |
| Kimball, SD | 1 |
| Moreland, S | 1 |
| Gougoutas, JZ | 1 |
| O'Reilly, BC | 1 |
| Schwartz, J | 1 |
| Malley, MF | 1 |
| Chow, CK | 4 |
| Atkins, ER | 2 |
| Hillis, GS | 3 |
| Nelson, MR | 2 |
| Reid, CM | 4 |
| Schlaich, MP | 2 |
| Hay, P | 3 |
| Rogers, K | 2 |
| Billot, L | 5 |
| Burke, M | 3 |
| Chalmers, J | 4 |
| Neal, B | 4 |
| Patel, A | 8 |
| Usherwood, T | 4 |
| Webster, R | 8 |
| Rodgers, A | 9 |
| Pearlman, B | 1 |
| Lodebo, BT | 1 |
| Chaihongsa, N | 1 |
| Maneesai, P | 1 |
| Sangartit, W | 1 |
| Potue, P | 1 |
| Bunbupha, S | 1 |
| Pakdeechote, P | 1 |
| Pribylova, NN | 1 |
| Yakovleva, MV | 1 |
| Pribylov, CA | 1 |
| Barbashina, TA | 1 |
| Gavriljuk, EV | 1 |
| Mal, GS | 1 |
| Pribylov, VS | 1 |
| Li, Y | 14 |
| Narisawa, M | 1 |
| Huang, Z | 2 |
| Meng, X | 1 |
| Wang, H | 5 |
| Jin, X | 2 |
| Shen, X | 1 |
| Cheng, XW | 1 |
| Zhang, D | 1 |
| Huang, QF | 3 |
| Sheng, CS | 2 |
| Wang, JG | 10 |
| Lee, J | 15 |
| Choi, J | 1 |
| Yum, Y | 1 |
| Joo, HJ | 1 |
| Kim, YH | 3 |
| An, H | 1 |
| Kim, EJ | 2 |
| Gao, Y | 1 |
| Zhou, D | 3 |
| Yang, P | 4 |
| Al-Qaaneh, AM | 2 |
| Obaid, WT | 1 |
| Al-Mohammadi, OS | 1 |
| Rabaan, AA | 1 |
| Mustafa, SM | 1 |
| J, S | 1 |
| Bennur, S | 1 |
| Taneja, NS | 1 |
| Du, XL | 1 |
| Simpson, LM | 12 |
| Tandy, BC | 1 |
| Bettencourt, JL | 1 |
| Davis, BR | 44 |
| Wei, Q | 1 |
| Jing, Z | 1 |
| Zhi-Ye, H | 1 |
| Sarkar, G | 1 |
| Gaikwad, VB | 1 |
| Sharma, A | 3 |
| Halder, SK | 1 |
| Kumar, DA | 1 |
| Anand, J | 1 |
| Agrawal, S | 1 |
| Kumbhar, A | 1 |
| Kinholkar, B | 1 |
| Mathur, R | 1 |
| Doshi, M | 1 |
| Bachani, D | 1 |
| Mehta, S | 1 |
| Youssef, AM | 1 |
| Elghoneimy, HA | 1 |
| Helmy, MW | 1 |
| Abdelazeem, AM | 1 |
| El-Khodary, NM | 1 |
| Leopold, S | 1 |
| Touyz, R | 1 |
| Dominiczak, AF | 3 |
| Flynn, JT | 4 |
| Szyndler, A | 1 |
| Zachariah, JP | 1 |
| Behera, G | 1 |
| Nagaraj, GA | 1 |
| Thirunavukarasu, SC | 1 |
| Jayaraman, R | 1 |
| Murugesan, R | 1 |
| Subramanian, A | 1 |
| Loas, G | 1 |
| Le Corre, P | 1 |
| Brown, K | 2 |
| Donato Md, AA | 1 |
| Chan, TH | 1 |
| Tsoi, MF | 1 |
| Yung Cheung, BM | 1 |
| Ram, CVS | 2 |
| Dalal, J | 1 |
| Kahali, D | 1 |
| Mohanan, PP | 1 |
| Das, MK | 1 |
| Guha, S | 1 |
| Nair, T | 1 |
| Narasimhan, C | 1 |
| Roy, DG | 1 |
| Abdullakutty, J | 1 |
| Ray, S | 2 |
| Fulwani, M | 1 |
| Mohan, JC | 1 |
| Gupta, R | 2 |
| Abhyankar, M | 1 |
| Revankar, S | 1 |
| Foch, C | 1 |
| Feifel, J | 1 |
| Gottwald-Hostalek, U | 3 |
| Jj, NK | 1 |
| D, DC | 1 |
| Kavitha, R | 1 |
| Zhang, S | 1 |
| Wang, T | 3 |
| Tang, J | 3 |
| Hou, A | 1 |
| Yan, X | 1 |
| Yu, B | 1 |
| Ran, S | 1 |
| Luo, M | 1 |
| Tang, Y | 1 |
| Yang, R | 1 |
| Song, D | 2 |
| He, H | 4 |
| Muppalla, BS | 1 |
| Parthasaradhi, SV | 1 |
| Kumar, GP | 1 |
| Jadhav, U | 2 |
| Sawhney, JPS | 1 |
| Unni, G | 1 |
| Desai, N | 1 |
| Brewster, LM | 1 |
| Boermeester, AS | 1 |
| Seedat, YK | 1 |
| Van Montfrans, GA | 2 |
| Jang, HW | 1 |
| Park, SM | 3 |
| Hwang, SY | 1 |
| Kang, K | 1 |
| Choi, M | 1 |
| An, JH | 1 |
| Chae, HK | 1 |
| Oh, YI | 1 |
| Youn, HY | 1 |
| Ojji, DB | 4 |
| Shedul, GL | 3 |
| Sani, M | 1 |
| Ogah, OS | 1 |
| Dzudie, A | 4 |
| Barasa, F | 4 |
| Mondo, C | 4 |
| Ingabire, PM | 2 |
| Jones, ESW | 1 |
| Rayner, B | 3 |
| Albertino, D | 1 |
| Ogola, E | 3 |
| Smythe, W | 4 |
| Hickman, N | 2 |
| Francis, V | 4 |
| Shahiemah, P | 1 |
| Shedul, G | 5 |
| Aje, A | 2 |
| Sliwa, K | 5 |
| Stewart, S | 1 |
| Kim, DK | 2 |
| Ahn, JH | 1 |
| Lee, KH | 2 |
| Kang, SH | 1 |
| Kim, SS | 1 |
| Na, JO | 1 |
| Park, SD | 2 |
| Ahn, KT | 2 |
| Lee, JH | 5 |
| Jung, IH | 1 |
| Seo, J | 1 |
| Choi, WG | 1 |
| Wang, Y | 2 |
| Hua, Z | 1 |
| Chen, W | 3 |
| Zhu, Y | 1 |
| Kobalava, ZD | 5 |
| Kolesnik, EL | 1 |
| Shavarova, EK | 1 |
| Goreva, LA | 1 |
| Karapetyan, LV | 1 |
| Syed, YY | 1 |
| Ward, JL | 1 |
| Guillot, E | 1 |
| Domenig, O | 1 |
| Ware, WA | 1 |
| Yuan, L | 1 |
| Mochel, JP | 1 |
| Yin, J | 2 |
| Mei, Z | 1 |
| Shi, S | 1 |
| Du, P | 1 |
| Qin, S | 1 |
| Habboush, S | 1 |
| Sofy, AA | 2 |
| Masoud, AT | 2 |
| Cherfaoui, O | 1 |
| Farhat, AM | 1 |
| Abdelsattar, AT | 2 |
| Elmoursi, A | 2 |
| Ghazi, L | 1 |
| Li, F | 1 |
| Chen, X | 4 |
| Simonov, M | 1 |
| Yamamoto, Y | 1 |
| Biswas, A | 1 |
| Hanna, J | 1 |
| Shah, T | 1 |
| Peixoto, AJ | 1 |
| Wilson, FP | 1 |
| Gnanenthiran, SR | 2 |
| Wang, N | 2 |
| Di Tanna, GL | 1 |
| Salam, A | 6 |
| de Silva, HA | 2 |
| Guggilla, R | 4 |
| Jan, S | 4 |
| Maulik, PK | 5 |
| Naik, N | 4 |
| Selak, V | 5 |
| Thom, S | 7 |
| Prabhakaran, D | 4 |
| Schutte, AE | 2 |
| Mbanya, A | 1 |
| Ackbarkhan, A | 1 |
| Mittoo, MY | 1 |
| Ramamonjisoa, HA | 1 |
| Ramilitiana, B | 1 |
| Ranivoharisoa, EM | 1 |
| Ratsimbazafy, SJN | 1 |
| Mbanya, JC | 2 |
| Hostalek-Gottwald, U | 1 |
| Gaciong, Z | 1 |
| Czech, M | 1 |
| Boguslawski, S | 1 |
| Smaga, A | 1 |
| Filipiak, KJ | 2 |
| Kamei, H | 1 |
| Furui, M | 1 |
| Matsubara, T | 1 |
| Inagaki, K | 1 |
| Colbourne, L | 1 |
| Harrison, PJ | 1 |
| Lee, HW | 2 |
| Huang, CC | 1 |
| Leu, HB | 2 |
| Lin, YJ | 1 |
| El Mously, DA | 1 |
| Mostafa, NM | 1 |
| Hassan, NY | 1 |
| El-Sayed, GM | 1 |
| Kikuchi, D | 1 |
| Obara, T | 2 |
| Miura, R | 1 |
| Suzuki, N | 3 |
| Hirakawa, H | 1 |
| Josaka, R | 1 |
| Ito, M | 3 |
| Tokunaga, M | 1 |
| Usui, K | 1 |
| Okada, K | 4 |
| El-Hanboushy, S | 1 |
| Marzouk, HM | 1 |
| Fayez, YM | 1 |
| Abdelkawy, M | 1 |
| Lotfy, HM | 1 |
| Beeston, D | 1 |
| Jepson, R | 1 |
| Cortellini, S | 1 |
| Cicero, AFG | 2 |
| Fogacci, F | 1 |
| Rizzoli, E | 1 |
| Giovannini, M | 2 |
| D'Addato, S | 1 |
| Borghi, C | 6 |
| Mistry, RP | 1 |
| Shah, C | 1 |
| Jat, R | 1 |
| Wang, SY | 2 |
| Hanna, JM | 1 |
| Gongal, P | 1 |
| Onuma, OK | 1 |
| Nanna, MG | 1 |
| Kaur, P | 1 |
| Kunwar, A | 1 |
| Sharma, M | 1 |
| Durgad, K | 1 |
| Gupta, S | 1 |
| Bhargava, B | 1 |
| Hollingworth, SA | 1 |
| Ankrah, D | 1 |
| Uzochukwu, BSC | 1 |
| Okeke, CC | 1 |
| Ruiz, F | 1 |
| Thacher, E | 1 |
| Prokosa, MI | 1 |
| Masilela, C | 1 |
| Adeniyi, OV | 1 |
| Benjeddou, M | 2 |
| Cornelius, V | 2 |
| Partington, G | 1 |
| Pandie, S | 1 |
| Damasceno, A | 3 |
| Jones, E | 3 |
| Ogah, O | 3 |
| Sani, MU | 3 |
| Poulter, N | 7 |
| Lee, CJ | 1 |
| Sung, JH | 3 |
| Kang, TS | 1 |
| Park, S | 8 |
| Lee, SH | 4 |
| Kim, JY | 1 |
| Kim, BK | 3 |
| Sung, KC | 9 |
| Cho, EJ | 10 |
| Ahn, JC | 4 |
| Han, SH | 5 |
| Kim, W | 7 |
| Kim, KH | 3 |
| Sohn, IS | 4 |
| Shin, J | 9 |
| Kim, SY | 7 |
| Kim, KI | 3 |
| Kang, SM | 3 |
| Park, SJ | 4 |
| Kim, YJ | 8 |
| Shin, JH | 7 |
| Park, CG | 16 |
| Chou, CL | 1 |
| Li, CH | 1 |
| Fang, TC | 1 |
| Li, JC | 1 |
| Cheng, PC | 1 |
| Huang, CN | 1 |
| Jian, LF | 1 |
| Wu, YS | 1 |
| Lin, CL | 1 |
| Jeong, HT | 1 |
| Sung, HH | 1 |
| Park, KY | 1 |
| Youn, YC | 1 |
| Silva, A | 1 |
| Guggilla, RK | 1 |
| Sahoo, SK | 1 |
| Pathni, AK | 1 |
| Krishna, A | 1 |
| Sharma, B | 1 |
| Cazabon, D | 1 |
| Moran, AE | 1 |
| Hering, D | 1 |
| Sternberg, Z | 1 |
| Podolsky, R | 1 |
| Yu, J | 3 |
| Tian, M | 1 |
| Hojnacki, D | 1 |
| Schaller, B | 1 |
| Fu, J | 1 |
| Li, B | 2 |
| Zhao, N | 1 |
| Mostafa, S | 1 |
| Shabana, H | 1 |
| Khalil, F | 1 |
| Mancy, IME | 1 |
| Zedan, HA | 1 |
| Ramadan, IG | 1 |
| Mohamed, SED | 1 |
| Kassem, A | 1 |
| Kamel, IS | 1 |
| Babinets, LS | 2 |
| Levchuk, RD | 2 |
| Halabitska, IM | 2 |
| Kryskiv, OI | 2 |
| Burnier, M | 4 |
| Redon, J | 4 |
| Volpe, M | 11 |
| Alluhabi, SI | 1 |
| Alkreathy, HM | 1 |
| Alharthi, TS | 1 |
| Alqarni, F | 1 |
| Alama, MN | 1 |
| Ahmad, A | 1 |
| Alrafiah, AR | 1 |
| Damanhouri, ZA | 1 |
| Honda, A | 1 |
| Tahara, N | 1 |
| Tahara, A | 1 |
| Bekki, M | 1 |
| Maeda-Ogata, S | 1 |
| Sugiyama, Y | 2 |
| Igata, S | 1 |
| Nishino, Y | 1 |
| Matsui, T | 1 |
| Kurata, S | 1 |
| Abe, T | 1 |
| Yamagishi, SI | 1 |
| Fukumoto, Y | 1 |
| Yang, G | 3 |
| Qiu, Y | 1 |
| Jayagopal, PB | 2 |
| Konradi, A | 1 |
| Bortolotto, LA | 2 |
| Degli Esposti, L | 4 |
| Perrone, V | 4 |
| Snyman, JR | 2 |
| Naessens, DMP | 1 |
| de Vos, J | 1 |
| Richard, E | 3 |
| Wilhelmus, MMM | 1 |
| Jongenelen, CAM | 1 |
| Scholl, ER | 1 |
| van der Wel, NN | 1 |
| Heijst, JA | 1 |
| Teunissen, CE | 1 |
| Strijkers, GJ | 1 |
| Coolen, BF | 1 |
| VanBavel, E | 1 |
| Bakker, ENTP | 1 |
| Schmieder, RE | 14 |
| Wassmann, S | 1 |
| Predel, HG | 1 |
| Weisser, B | 2 |
| Blettenberg, J | 1 |
| Gillessen, A | 1 |
| Randerath, O | 1 |
| Mevius, A | 1 |
| Wilke, T | 1 |
| Böhm, M | 4 |
| Hanna, SM | 1 |
| Rabea, HM | 1 |
| Abdelrahim, MEA | 1 |
| Mahmoud, HB | 1 |
| Hohl, M | 1 |
| Lauder, L | 2 |
| Sevimli, Ö | 1 |
| Tokcan, M | 1 |
| Wagmann, L | 2 |
| Götzinger, F | 1 |
| Schneider, C | 1 |
| Hübner, U | 1 |
| Lehnert, U | 1 |
| Meyer, MR | 2 |
| Mahfoud, F | 3 |
| Gallo, G | 1 |
| Sarzani, R | 1 |
| Genovese, S | 1 |
| Pirro, M | 1 |
| Gallelli, L | 1 |
| Faggiano, A | 1 |
| Su, F | 1 |
| Xia, Q | 1 |
| Sundström, J | 2 |
| Lind, L | 2 |
| Nowrouzi, S | 2 |
| Hagström, E | 1 |
| Held, C | 1 |
| Lytsy, P | 2 |
| Marttala, K | 2 |
| Östlund, O | 2 |
| Fukuda, N | 2 |
| Katakawa, M | 1 |
| Ito, H | 2 |
| Hara, T | 1 |
| Otsuka, N | 1 |
| Ishizuka, M | 1 |
| Abe, M | 4 |
| Kerkhofs, D | 1 |
| Helgers, R | 1 |
| Hermes, D | 1 |
| Steinbusch, HPJ | 1 |
| Van Essen, H | 1 |
| Leenders, P | 1 |
| Prickaerts, J | 1 |
| Staals, J | 1 |
| Biessen, EA | 1 |
| Van Oostenbrugge, RJ | 1 |
| Foulquier, S | 1 |
| Hong, SJ | 10 |
| Rhee, MY | 9 |
| Jeong, MH | 2 |
| Kim, DH | 1 |
| Lim, SW | 3 |
| Park, K | 1 |
| Lee, JB | 2 |
| Cho, JM | 3 |
| Cho, GY | 1 |
| Heo, JH | 2 |
| Kim, SH | 7 |
| Lee, HY | 8 |
| Cho, DK | 1 |
| Pyun, WB | 2 |
| Kwon, K | 3 |
| Rha, SW | 2 |
| Jung, JA | 1 |
| Skovbjerg, BK | 1 |
| Helgestad, OK | 1 |
| Oxlund, CS | 1 |
| Christensen, B | 1 |
| Henriksen, JN | 1 |
| Li, L | 5 |
| Tong, X | 1 |
| Ma, Z | 1 |
| Lv, L | 1 |
| Liu, H | 3 |
| Chen, GL | 2 |
| Tayag, JCS | 1 |
| Ishii, T | 1 |
| Kokuba, S | 1 |
| Hirata, T | 1 |
| Shiohira, H | 1 |
| Nakamura, K | 2 |
| Bush, BR | 1 |
| Bryant, SM | 1 |
| Lan, CC | 1 |
| Hsieh, PC | 1 |
| Tzeng, IS | 1 |
| Yang, MC | 1 |
| Wu, CW | 1 |
| Su, WL | 1 |
| Wu, YK | 1 |
| Zhao, X | 5 |
| Chen, Y | 3 |
| Li, X | 3 |
| Tang, X | 1 |
| Yang, Q | 1 |
| Peng, L | 1 |
| Li, J | 3 |
| Liang, Z | 1 |
| Li, A | 1 |
| Wang, W | 7 |
| Huang, M | 1 |
| Liu, T | 2 |
| Jiang, W | 1 |
| Xi, Y | 1 |
| Wang, L | 5 |
| Yang, F | 1 |
| Lu, X | 2 |
| Sun, N | 4 |
| Kim, MC | 1 |
| Ahn, Y | 5 |
| Kim, MH | 7 |
| Hong, TJ | 6 |
| Kim, H | 2 |
| Chae, IH | 2 |
| Kang, DH | 3 |
| Kim, HS | 7 |
| Raaff, PI | 1 |
| van der Meij, EH | 1 |
| de Visscher, JGAM | 1 |
| Xie, M | 1 |
| Tang, T | 1 |
| Liang, H | 1 |
| Rea, F | 1 |
| Morabito, G | 1 |
| Savaré, L | 1 |
| Pathak, A | 1 |
| Corrao, G | 1 |
| Mancia, G | 14 |
| Bao, H | 1 |
| Huang, X | 1 |
| Li, P | 1 |
| Sheng, C | 1 |
| Zhang, J | 11 |
| Wang, Z | 2 |
| Hu, L | 1 |
| Ding, C | 1 |
| Cheng, Z | 1 |
| Yao, C | 1 |
| Chen, G | 2 |
| Cui, Y | 2 |
| Qin, X | 2 |
| Tang, G | 1 |
| Wang, X | 8 |
| Huo, Y | 2 |
| Cheng, X | 1 |
| Wang, J | 6 |
| Lucca, MB | 1 |
| Jorge, JA | 1 |
| Cichelero, FT | 2 |
| Martinez, D | 2 |
| Borges, RB | 1 |
| Hirakata, VN | 1 |
| Fuchs, FD | 2 |
| Fuchs, SC | 2 |
| Souček, M | 1 |
| Williams, JG | 1 |
| Hess, RS | 1 |
| Nolde, JM | 1 |
| Atkins, E | 2 |
| Marschner, S | 1 |
| Jansen, S | 1 |
| Palmer, BF | 1 |
| Vogel Anderson, K | 1 |
| Sever, P | 5 |
| Jung, HW | 2 |
| Kim, CY | 1 |
| Hong, SP | 3 |
| Bae, HJ | 1 |
| Choi, JY | 1 |
| Ryu, JK | 1 |
| Han, KR | 5 |
| Yang, DH | 2 |
| Yu, GW | 1 |
| Hyon, MS | 6 |
| Hong, BK | 4 |
| Jin, HY | 1 |
| Lee, SY | 2 |
| Seol, SH | 1 |
| Lee, SR | 1 |
| Lee, KJ | 2 |
| Nam, CW | 2 |
| Park, TH | 1 |
| Kim, U | 2 |
| Kim, KS | 5 |
| Chen, C | 1 |
| Zhang, W | 3 |
| Jiao, D | 1 |
| Shen, J | 2 |
| Zhu, G | 1 |
| Zhang, X | 3 |
| Chang, K | 3 |
| Choi, DJ | 6 |
| Kang, WC | 2 |
| Lee, N | 1 |
| Son, JW | 1 |
| Doh, JH | 2 |
| Kim, WS | 4 |
| Choi, SY | 2 |
| Hwang, JY | 1 |
| Cha, KS | 2 |
| Ihm, SH | 2 |
| Yoo, BS | 7 |
| Ahmed-Farid, OA | 1 |
| Abdelrazek, AM | 1 |
| Elwakel, H | 1 |
| Mohamed, MM | 1 |
| Oh, J | 1 |
| Kim, GH | 1 |
| Kim, HL | 1 |
| Min, KW | 2 |
| Hyun, D | 1 |
| Hong, JH | 1 |
| Lim, S | 2 |
| Konradi, AO | 2 |
| Pal, D | 1 |
| Maji, S | 1 |
| Maiti, R | 1 |
| Bird, GS | 1 |
| D'Agostin, D | 1 |
| Alsanosi, S | 1 |
| Lip, S | 1 |
| Padmanabhan, S | 3 |
| Parekh, AB | 1 |
| Zidek, W | 5 |
| Veronesi, C | 2 |
| Gambera, M | 2 |
| Nati, G | 2 |
| Perone, F | 2 |
| Tagliabue, PF | 2 |
| Juraschek, SP | 3 |
| Beach, JL | 2 |
| Ishak, A | 2 |
| Mukamal, KJ | 3 |
| Arancón-Monge, JM | 1 |
| de Castro-Cuenca, A | 1 |
| Serrano-Vázquez, Á | 1 |
| Campos-Díaz, L | 1 |
| Rodríguez Barrientos, R | 1 |
| Del Cura-González, I | 1 |
| Taguchi, R | 2 |
| Naito, T | 2 |
| Kubono, N | 1 |
| Ogawa, N | 1 |
| Itoh, H | 4 |
| Kawakami, J | 2 |
| Yee, Y | 1 |
| Angkodjojo, S | 1 |
| Tan, PH | 1 |
| Yavas Abali, Z | 1 |
| Yesil, G | 1 |
| Kirkgoz, T | 1 |
| Cicek, N | 1 |
| Alpay, H | 1 |
| Turan, S | 1 |
| Bereket, A | 1 |
| Guran, T | 1 |
| Muñoz, D | 1 |
| Uzoije, P | 1 |
| Reynolds, C | 1 |
| Miller, R | 1 |
| Walkley, D | 1 |
| Pappalardo, S | 1 |
| Tousey, P | 1 |
| Munro, H | 1 |
| Gonzales, H | 1 |
| Song, W | 1 |
| White, C | 1 |
| Blot, WJ | 1 |
| Wang, TJ | 1 |
| Glezer, MG | 3 |
| Onakpoya, I | 1 |
| Mazza, A | 3 |
| Townsend, DM | 1 |
| Schiavon, L | 2 |
| Torin, G | 1 |
| Lenti, S | 2 |
| Rossetti, C | 1 |
| Rigatelli, G | 2 |
| Rubello, D | 1 |
| Morselli, F | 1 |
| Fang, L | 1 |
| Ambrosini, I | 1 |
| Chowienczyk, PJ | 2 |
| Faconti, L | 2 |
| Massunaga, ND | 1 |
| França, CN | 1 |
| Bianco, HT | 1 |
| Ferreira, CES | 1 |
| Kato, JT | 1 |
| Póvoa, RMS | 1 |
| Figueiredo Neto, AM | 1 |
| Izar, MCO | 1 |
| Fonseca, FAH | 1 |
| Zhao, M | 2 |
| Jiang, X | 1 |
| Wang, M | 3 |
| Zhao, C | 2 |
| Okamura, K | 3 |
| Yano, Y | 4 |
| Takamiya, Y | 1 |
| Shirai, K | 4 |
| Urata, H | 3 |
| Roffey, E | 1 |
| Bhurawala, H | 1 |
| Lu, Y | 2 |
| Wu, X | 1 |
| Fan, Y | 1 |
| Liu, F | 2 |
| Liu, HC | 2 |
| Zhou, XT | 1 |
| Zheng, YS | 1 |
| Liu, XQ | 1 |
| Jafari, R | 1 |
| Rostami, Z | 1 |
| Nikpoor, M | 1 |
| Javanbakht, M | 1 |
| Ghahroudi, MS | 1 |
| Hosseini, MS | 1 |
| Einollahi, B | 1 |
| Taddei, S | 3 |
| Shmerling, RH | 1 |
| Sofogianni, A | 1 |
| Tziomalos, K | 1 |
| Yu, CW | 1 |
| Cho, KI | 1 |
| Kim, SJ | 4 |
| Ahn, YK | 4 |
| Lee, CH | 1 |
| Kim, M | 1 |
| Tůmová, E | 1 |
| Vrablík, M | 1 |
| Argyris, AA | 1 |
| Samara, S | 1 |
| Protogerou, AD | 1 |
| Bellos, I | 1 |
| Pergialiotis, V | 1 |
| Papapanagiotou, A | 1 |
| Loutradis, D | 1 |
| Daskalakis, G | 1 |
| Kario, K | 22 |
| Matsuda, S | 2 |
| Nagahama, S | 2 |
| Kurose, Y | 2 |
| Sugii, H | 2 |
| Teshima, T | 2 |
| Naseratun, N | 1 |
| Kobara, M | 3 |
| Watanabe, Y | 5 |
| Toba, H | 3 |
| Nakata, T | 3 |
| Pandey, AK | 1 |
| Shafiq, N | 2 |
| Bhandari, RK | 1 |
| Rather, IIG | 1 |
| Kaur, N | 1 |
| Bhatia, A | 1 |
| Sharma, S | 3 |
| Malhotra, S | 2 |
| van der Vossen, AC | 1 |
| Cransberg, K | 1 |
| de Winter, BCM | 1 |
| Schreuder, MF | 1 |
| van Rooij-Kouwenhoven, RWG | 1 |
| Vulto, AG | 1 |
| Hanff, LM | 1 |
| Skibitskiy, VV | 2 |
| Gutova, SR | 1 |
| Fendrikova, AV | 3 |
| Skibitskiy, AV | 2 |
| Alam, MA | 2 |
| Bin Jardan, YA | 2 |
| Raish, M | 2 |
| Al-Mohizea, AM | 2 |
| Ahad, A | 2 |
| Al-Jenoobi, FI | 2 |
| Ghafarzadeh, M | 1 |
| Shakarami, A | 1 |
| Yari, F | 1 |
| Namdari, P | 1 |
| Yin, T | 1 |
| Alquist, CR | 1 |
| Kokilambigai, KS | 1 |
| Kavitha, J | 1 |
| Seetharaman, R | 1 |
| Lakshmi, KS | 1 |
| Sai Susmitha, A | 1 |
| Mareev, VY | 1 |
| Minina, YV | 1 |
| Begrambekova, YL | 1 |
| Levin, AM | 1 |
| Yolcu, A | 1 |
| Aydogdu, I | 1 |
| Khairat, I | 1 |
| Khedr, L | 1 |
| Werida, R | 1 |
| de Silva, A | 1 |
| Stepien, S | 2 |
| Mysore, J | 1 |
| Liu, J | 3 |
| Nakagawa, N | 1 |
| Sato, N | 4 |
| Saijo, Y | 3 |
| Morimoto, H | 3 |
| Koyama, S | 3 |
| Ogawa, Y | 1 |
| Uekita, K | 1 |
| Maruyama, J | 3 |
| Ohta, T | 1 |
| Nakamura, Y | 4 |
| Takeuchi, T | 3 |
| Hasebe, N | 3 |
| Kalar, I | 1 |
| Xu, H | 1 |
| Secnik, J | 1 |
| Schwertner, E | 1 |
| Kramberger, MG | 1 |
| Winblad, B | 1 |
| von Euler, M | 1 |
| Eriksdotter, M | 1 |
| Garcia-Ptacek, S | 1 |
| Lin, CP | 1 |
| Tung, YC | 2 |
| Hsiao, FC | 1 |
| Yang, CH | 1 |
| Kao, YW | 1 |
| Lin, YS | 2 |
| Chu, YC | 1 |
| Chu, PH | 2 |
| Musteata, M | 1 |
| Ștefănescu, R | 1 |
| Baisan, AR | 1 |
| Mocanu, D | 1 |
| Pașca, SA | 1 |
| Hrițcu, LD | 1 |
| Henea, M | 1 |
| Solcan, G | 1 |
| Ma, W | 1 |
| Duan, C | 1 |
| Zhao, L | 2 |
| Hua, Q | 1 |
| Sun, Y | 2 |
| Dang, A | 1 |
| Gao, P | 3 |
| Qu, P | 2 |
| Cui, W | 3 |
| Dong, Y | 1 |
| Cui, L | 1 |
| Qi, X | 1 |
| Jiang, Y | 1 |
| Xie, J | 2 |
| Wu, G | 2 |
| Du, X | 1 |
| Chen, P | 2 |
| Lee, SL | 1 |
| Lim, WJ | 1 |
| Chai, ST | 1 |
| Han, KH | 1 |
| Lee, HC | 2 |
| Lee, K | 3 |
| Kim, JH | 6 |
| Kim, PJ | 1 |
| Hwang, J | 1 |
| Seo, JS | 1 |
| Lee, H | 3 |
| Cho, Y | 1 |
| Thacker, H | 1 |
| Konda Reddy, KM | 1 |
| Murthy, LS | 1 |
| Sawhney, JP | 1 |
| Chaudhary, G | 1 |
| Shah, S | 1 |
| Joseph, S | 1 |
| Rajarshi, M | 1 |
| Nikam, P | 1 |
| Mohammed, OM | 1 |
| Shareef, MA | 1 |
| Alamodi, AA | 1 |
| Nso, N | 1 |
| Payton, M | 1 |
| Wang, KL | 1 |
| Yu, WC | 1 |
| Lu, TM | 1 |
| Chen, LC | 1 |
| Chiang, CE | 1 |
| Nelson, M | 2 |
| Schlaich, M | 1 |
| de la Sierra, A | 9 |
| Mateu, A | 1 |
| Gorostidi, M | 2 |
| Vinyoles, E | 2 |
| Segura, J | 5 |
| Ruilope, LM | 10 |
| Jo, SH | 2 |
| Hong, GR | 1 |
| Kim, SW | 1 |
| Khayyat-Kholghi, M | 1 |
| Oparil, S | 27 |
| Tereshchenko, LG | 2 |
| Petrova, MM | 1 |
| Moskaleva, PV | 1 |
| Shnayder, NA | 1 |
| Nasyrova, RF | 1 |
| Groenland, EH | 1 |
| van Kleef, MEAM | 1 |
| Bots, ML | 1 |
| Visseren, FLJ | 1 |
| van der Elst, KCM | 1 |
| Spiering, W | 1 |
| Arasan, SN | 1 |
| Yenigun, EC | 1 |
| Cevher, SK | 1 |
| Dede, F | 1 |
| Kim, HY | 2 |
| Morikawa, S | 1 |
| Nasu, M | 1 |
| Miyashita, Y | 4 |
| Nakagawa, T | 1 |
| Sung, J | 1 |
| Cho, BR | 1 |
| Kim, BJ | 1 |
| Park, JI | 1 |
| Lee, WS | 1 |
| Cirla, A | 1 |
| Drigo, M | 1 |
| Andreani, V | 1 |
| Barsotti, G | 1 |
| Lancellotti, P | 2 |
| Ancion, A | 1 |
| Scheen, AJ | 6 |
| Pathak, AS | 1 |
| Rojas, M | 1 |
| Stouffer, GA | 1 |
| Nouri-Vaskeh, M | 1 |
| Kalami, N | 1 |
| Zand, R | 1 |
| Soroureddin, Z | 1 |
| Varshochi, M | 1 |
| Ansarin, K | 1 |
| Rezaee, H | 1 |
| Taghizadieh, A | 1 |
| Sadeghi, A | 1 |
| Ahangari Maleki, M | 1 |
| Esmailnajad, A | 1 |
| Saleh, P | 1 |
| Haghdoost, M | 1 |
| Maleki, M | 1 |
| Sharifi, A | 1 |
| Xu, SK | 2 |
| Zeng, WF | 2 |
| Chen, LL | 2 |
| Xie, JH | 1 |
| Vollmer, AC | 1 |
| Agarkov, NM | 1 |
| Okhotnikov, OI | 1 |
| Korneeva, SI | 1 |
| Moskaleva, EO | 1 |
| Moskalev, AA | 1 |
| Kolomiets, VI | 1 |
| Markelova, AM | 1 |
| Markelova, EA | 1 |
| Stone, IB | 1 |
| Green, JAEM | 1 |
| Koefoed, AW | 1 |
| Hornik, ES | 1 |
| Williams, JS | 1 |
| Adler, GK | 1 |
| Williams, GH | 4 |
| Piszczatoski, CR | 1 |
| Smith, SM | 2 |
| Ivashchuk, Y | 1 |
| Cheung, DWS | 1 |
| Koon, JCM | 1 |
| Wong, PH | 1 |
| Yau, KC | 1 |
| Wat, ECL | 1 |
| Chan, JYW | 1 |
| Lau, VKM | 1 |
| Ko, ECH | 1 |
| Waye, MMY | 1 |
| Fung, KP | 1 |
| Vakil, D | 1 |
| Zinonos, S | 1 |
| Kostis, JB | 5 |
| Dobrzynski, JM | 1 |
| Cosgrove, NM | 1 |
| Moreyra, AE | 1 |
| Kostis, WJ | 1 |
| Reid, HW | 1 |
| Moorthy, G | 1 |
| Clark, D | 1 |
| Cannon, L | 1 |
| Ming, DY | 1 |
| Aung, TKK | 1 |
| Chuah, TY | 1 |
| Chua, MWJ | 1 |
| Ma, H | 1 |
| Jiang, H | 1 |
| Feng, J | 1 |
| Gan, Y | 1 |
| Di Trani, N | 1 |
| Qi, R | 1 |
| Viswanath, DI | 1 |
| Liu, X | 2 |
| Chua, CYX | 1 |
| Grattoni, A | 1 |
| Whiteley, WN | 1 |
| Gupta, AK | 7 |
| Godec, T | 2 |
| Rostamian, S | 1 |
| Whitehouse, A | 3 |
| Mackay, J | 2 |
| Sever, PS | 16 |
| Gözmen, S | 1 |
| Gözmen, ŞK | 1 |
| Polychronopoulou, E | 1 |
| Ehret, G | 1 |
| Schoenenberger-Berzins, R | 1 |
| Berney, M | 1 |
| Ponte, B | 1 |
| Erne, P | 4 |
| Bochud, M | 1 |
| Pechère-Bertschi, A | 1 |
| Wuerzner, G | 1 |
| Fink, DM | 1 |
| Mans, C | 1 |
| Najmeddin, F | 1 |
| Solhjoo, M | 1 |
| Ashraf, H | 1 |
| Salehi, M | 1 |
| Rasooli, F | 1 |
| Ghoghaei, M | 1 |
| Soleimani, A | 1 |
| Bahreini, M | 1 |
| Koide, M | 1 |
| Harraz, OF | 1 |
| Dabertrand, F | 1 |
| Longden, TA | 1 |
| Ferris, HR | 1 |
| Wellman, GC | 1 |
| Hill-Eubanks, DC | 1 |
| Greenstein, AS | 1 |
| Nelson, MT | 1 |
| Alzenaidy, B | 1 |
| Ostroumova, OD | 7 |
| Kochetkov, AI | 3 |
| Arablincky, NA | 1 |
| Shatalova, NA | 1 |
| Romanovsky, RR | 1 |
| Kirichenko, AA | 1 |
| Lawson, JS | 1 |
| Jepson, RE | 2 |
| Peri-Okonny, PA | 1 |
| Velasco, A | 1 |
| Lodhi, H | 1 |
| Arbique, D | 1 |
| Adams-Huet, B | 1 |
| Iwamoto, G | 1 |
| Mitchell, JH | 1 |
| Mizuno, M | 1 |
| Smith, S | 1 |
| Vongpatanasin, W | 1 |
| Lee, S | 1 |
| Jo, C | 1 |
| Choi, HY | 1 |
| Tomitani, N | 2 |
| Kanegae, H | 1 |
| Ishii, H | 1 |
| Uchiyama, K | 2 |
| Yamagiwa, K | 1 |
| Shiraiwa, T | 1 |
| Katsuya, T | 3 |
| Yoshida, T | 3 |
| Kanda, K | 1 |
| Hasegawa, S | 1 |
| Hoshide, S | 16 |
| Rabah, F | 1 |
| El-Naggari, M | 1 |
| Al-Nabhani, D | 1 |
| Yousefpour, A | 1 |
| Modarress, H | 1 |
| Goharpey, F | 1 |
| Amjad-Iranagh, S | 1 |
| Bang, CN | 1 |
| Soliman, EZ | 4 |
| Devereux, RB | 4 |
| Okin, PM | 2 |
| Buendia, R | 1 |
| Zambrano, M | 1 |
| Tani, S | 1 |
| Asayama, K | 1 |
| Oiwa, K | 1 |
| Harasawa, S | 2 |
| Okubo, K | 2 |
| Takahashi, A | 1 |
| Tanabe, A | 1 |
| Ohkubo, T | 3 |
| Hirayama, A | 4 |
| Kushiro, T | 3 |
| Calvet, D | 1 |
| Amar, L | 1 |
| Rossi, GP | 1 |
| Laurent, S | 6 |
| Turc, G | 1 |
| Barigou, M | 1 |
| Jennings, G | 1 |
| Guzik, T | 1 |
| Touyz, RM | 1 |
| Sethi, BK | 1 |
| Baruah, MP | 1 |
| Kumar, AS | 1 |
| Liakos, CI | 1 |
| Papadopoulos, DP | 1 |
| Kotsis, VT | 1 |
| Moon, JS | 1 |
| Won, KC | 1 |
| Kim, HJ | 2 |
| Han, SJ | 1 |
| Kim, DJ | 1 |
| Jang, HC | 2 |
| Choi, SH | 1 |
| Shin, DH | 1 |
| Kim, TH | 1 |
| Ahn, YB | 1 |
| Ko, SH | 1 |
| Kim, NH | 1 |
| Seo, JA | 1 |
| Lee, KW | 2 |
| Mizuno, H | 4 |
| Dhruva, SS | 1 |
| Huang, C | 2 |
| Spatz, ES | 1 |
| Coppi, AC | 1 |
| Warner, F | 1 |
| Li, SX | 1 |
| Lin, H | 1 |
| Xu, X | 2 |
| Furberg, CD | 7 |
| Pressel, SL | 6 |
| Coifman, RR | 1 |
| Krumholz, HM | 1 |
| Chen, Q | 1 |
| Kang, YY | 1 |
| Liu, CY | 1 |
| Del Mauro, JS | 1 |
| Prince, PD | 1 |
| Donato, M | 1 |
| Fernandez Machulsky, N | 1 |
| Morettón, MA | 1 |
| González, GE | 1 |
| Bertera, FM | 1 |
| Carranza, A | 1 |
| Gorzalczany, SB | 1 |
| Chiappetta, DA | 1 |
| Berg, G | 1 |
| Morales, C | 1 |
| Gelpi, RJ | 1 |
| Taira, CA | 1 |
| Höcht, C | 1 |
| Khodadoustan, S | 1 |
| Nasri Ashrafi, I | 1 |
| Vanaja Satheesh, K | 1 |
| Kumar, C | 1 |
| Hs, S | 1 |
| S, C | 1 |
| Jeffers, BW | 6 |
| Ábrahám, G | 1 |
| Dézsi, CA | 4 |
| Potucek, P | 1 |
| Radik, M | 1 |
| Doka, G | 1 |
| Kralova, E | 1 |
| Krenek, P | 2 |
| Klimas, J | 1 |
| Engeli, S | 5 |
| May, M | 3 |
| Nussberger, J | 2 |
| Danser, AHJ | 1 |
| Dole, WP | 2 |
| Prescott, MF | 2 |
| Dahlke, M | 2 |
| Stitah, S | 1 |
| Pal, P | 2 |
| Boschmann, M | 2 |
| Jordan, J | 5 |
| Totake, N | 1 |
| Okuda, T | 1 |
| Uniyal, R | 1 |
| Paliwal, VK | 1 |
| Kumar, N | 1 |
| Malhotra, HS | 1 |
| Garg, RK | 1 |
| Neyaz, Z | 1 |
| Hanon, O | 2 |
| Caillard, L | 2 |
| Chaussade, E | 2 |
| Hernandorena, I | 1 |
| Boully, C | 2 |
| Kobalava, Z | 2 |
| Troitskaya, E | 1 |
| Ezhova, N | 1 |
| Nedogoda, SV | 2 |
| Zvartau, NE | 1 |
| Chumachek, EV | 1 |
| Ledyaeva, AA | 1 |
| Tsoma, VV | 1 |
| Salasyuk, AS | 1 |
| Judina, JS | 1 |
| Smirnova, VO | 1 |
| Khripaeva, VJ | 1 |
| Palashkin, RV | 1 |
| Simons, LA | 1 |
| Chung, E | 1 |
| Ortiz, M | 1 |
| Paradkar, SG | 1 |
| Sinha, SR | 1 |
| Kreutz, R | 4 |
| Scholze, J | 2 |
| Douros, A | 1 |
| Hwang, YC | 1 |
| Yoon, KH | 1 |
| Cha, BS | 1 |
| Chung, CH | 1 |
| Lee, MK | 1 |
| Lammel-Lindemann, JA | 1 |
| Flores-Villalba, E | 1 |
| Martagón, AJ | 1 |
| DeObeso-Gonzalez, E | 1 |
| Puente-Gallegos, F | 1 |
| Simonyi, G | 8 |
| Ferenci, T | 6 |
| Medvegy, M | 1 |
| Gasparics, R | 1 |
| Finta, E | 1 |
| Yamabe, H | 1 |
| Kaikita, K | 1 |
| Matsumura, T | 1 |
| Iwasa, A | 1 |
| Koyama, J | 2 |
| Uemura, T | 1 |
| Morikami, Y | 1 |
| Tsunoda, R | 1 |
| Morihisa, K | 1 |
| Fujimoto, K | 1 |
| Kajiwara, I | 1 |
| Matsui, K | 3 |
| Tsujita, K | 1 |
| Ogawa, H | 9 |
| Radermecker, RP | 1 |
| Jeong, HS | 2 |
| Chang, KY | 1 |
| Lee, BK | 1 |
| Chae, SC | 6 |
| Lee, SU | 2 |
| Kim, YD | 2 |
| Choi, JH | 1 |
| Kang, HJ | 3 |
| Kim, JJ | 6 |
| Choi, YJ | 4 |
| Chun, KJ | 3 |
| Shin, DG | 2 |
| Park, SH | 6 |
| Kwan, J | 4 |
| Chae, JK | 1 |
| Kim, DW | 1 |
| Cho, JR | 1 |
| Won, KH | 1 |
| Lee, SK | 1 |
| Jung, J | 1 |
| Kim, CH | 8 |
| Bartlett, LE | 1 |
| Pratt, N | 1 |
| Roughead, EE | 1 |
| Kollias, A | 1 |
| Stergiou, GS | 2 |
| Kyriakoulis, KG | 1 |
| Bilo, G | 4 |
| Parati, G | 8 |
| Nwachukwu, DC | 1 |
| Eze, AA | 1 |
| Nwachukwu, NZ | 1 |
| Aneke, EI | 1 |
| Agu, PU | 1 |
| Azubike, NC | 1 |
| Obika, LF | 1 |
| Okoye, OI | 1 |
| Sato, H | 1 |
| Kobalava, DZ | 1 |
| Shavarova, KE | 1 |
| Elliott, WJ | 3 |
| Bistrika, EA | 1 |
| Schaffer, AL | 1 |
| Buckley, NA | 1 |
| Pearson, SA | 1 |
| Sychev, DA | 1 |
| Shih, NV | 1 |
| Kalle, EG | 1 |
| Ryzhikova, KA | 1 |
| Morozova, TE | 2 |
| Mari, L | 1 |
| Stavinohova, R | 1 |
| Dominguez, E | 1 |
| Premont, J | 1 |
| Oliver, J | 1 |
| De Risio, L | 1 |
| Adejare, AA | 1 |
| Sofola, OA | 1 |
| MacDonald, TM | 5 |
| Williams, B | 3 |
| Webb, DJ | 3 |
| Morant, S | 1 |
| Caulfield, M | 5 |
| Cruickshank, JK | 2 |
| Ford, I | 1 |
| Mackenzie, IS | 1 |
| McCann, GP | 1 |
| Salsbury, J | 1 |
| McInnes, G | 3 |
| Brown, MJ | 6 |
| Al Dhabyi, O | 1 |
| Bakris, GL | 21 |
| Stinkens, R | 2 |
| Heise, T | 2 |
| Goossens, GH | 2 |
| Blaak, EE | 2 |
| Havekes, B | 2 |
| Jax, T | 2 |
| Albrecht, D | 2 |
| Tegtbur, U | 1 |
| Haufe, S | 1 |
| Langenickel, TH | 2 |
| Dewland, TA | 1 |
| Yamal, JM | 4 |
| Alonso, A | 2 |
| Albert, CM | 1 |
| Haywood, LJ | 7 |
| Marcus, GM | 1 |
| Nelson, JW | 1 |
| Ferdaus, MZ | 1 |
| McCormick, JA | 1 |
| Minnier, J | 1 |
| Kaul, S | 1 |
| Ellison, DH | 1 |
| Barnes, AP | 1 |
| Hejazi, MM | 1 |
| Bacha, AO | 1 |
| Kaleemuddin, M | 1 |
| Al-Abassi, FA | 1 |
| Al-Alsieni, AI | 1 |
| Kazmi, I | 1 |
| Anwar, F | 1 |
| Borisova, EV | 3 |
| Pavleeva, EE | 1 |
| Tkachyeva, ON | 1 |
| Kotovskaya, YV | 4 |
| Dudinskaya, EN | 1 |
| Semenova, AE | 1 |
| Sergienko, IV | 1 |
| Brook, RD | 1 |
| Kaciroti, N | 1 |
| Bakris, G | 7 |
| Dahlöf, B | 28 |
| Pitt, B | 17 |
| Velazquez, E | 4 |
| Weber, M | 9 |
| Zappe, DH | 7 |
| Hau, T | 1 |
| Jamerson, KA | 9 |
| Mehlum, MH | 1 |
| Liestøl, K | 1 |
| Kjeldsen, SE | 27 |
| Julius, S | 18 |
| Hua, TA | 13 |
| Rothwell, PM | 2 |
| Weber, MA | 25 |
| Berge, E | 2 |
| Buda, S | 1 |
| Nozato, S | 1 |
| Yamamoto, K | 9 |
| Nozato, Y | 1 |
| Takeda, M | 1 |
| Hongyo, K | 1 |
| Takeya, M | 1 |
| Akasaka, H | 2 |
| Takami, Y | 1 |
| Takeya, Y | 1 |
| Sugimoto, K | 1 |
| Ito, N | 3 |
| Rakugi, H | 9 |
| Bramlage, P | 8 |
| Schmidt, S | 1 |
| Sims, H | 1 |
| Ostroumova, TM | 1 |
| Fleig, SV | 1 |
| Weger, B | 1 |
| Haller, H | 1 |
| Limbourg, FP | 1 |
| van der Kolk, BW | 1 |
| Jocken, JW | 1 |
| Schindler, C | 1 |
| Schaper, N | 1 |
| Kaiser, S | 1 |
| Hartmann, N | 1 |
| Letzkus, M | 1 |
| Yang, YS | 1 |
| Lim, MH | 1 |
| Lee, SO | 1 |
| Roh, E | 1 |
| Ahn, CH | 1 |
| Kwak, SH | 1 |
| Cho, YM | 1 |
| Kim, S | 2 |
| Mari, A | 1 |
| Park, KS | 1 |
| Jung, HS | 1 |
| Armario, P | 1 |
| Oliveras, A | 1 |
| Banegas, JR | 1 |
| de la Cruz, JJ | 1 |
| Şen, S | 1 |
| Demir, M | 1 |
| Yiğit, Z | 1 |
| Üresin, AY | 1 |
| Young, WM | 1 |
| Zheng, C | 1 |
| Davidson, MG | 1 |
| Westermeyer, HD | 1 |
| Vidal, F | 1 |
| de Souza, RC | 1 |
| Ferreira, DC | 1 |
| Fischer, RG | 1 |
| Gonçalves, LS | 1 |
| Gupta, B | 1 |
| Kerai, S | 1 |
| Chaugai, S | 1 |
| Sherpa, LY | 1 |
| Sepehry, AA | 1 |
| Kerman, SRJ | 1 |
| Arima, H | 1 |
| Yasuno, S | 8 |
| Oba, K | 8 |
| Konda, M | 1 |
| Ichihara, C | 1 |
| Kitao, H | 1 |
| Kuwabara, Y | 5 |
| Ueshima, K | 14 |
| Shen, T | 1 |
| Yu, Y | 1 |
| Bezuglova, EI | 1 |
| Luneva, YV | 1 |
| Kornilov, AA | 1 |
| Povetkin, SV | 2 |
| Kramer, N | 2 |
| Badri, M | 2 |
| Kana, SS | 1 |
| Mntla, P | 1 |
| Ogola, EN | 1 |
| Ogunbanjo, G | 1 |
| Okpechi, I | 1 |
| Mayosi, BM | 1 |
| Statsenko, ME | 7 |
| Turkina, SV | 1 |
| Titarenko, MN | 3 |
| Zhang, L | 4 |
| Yang, J | 3 |
| Liu, D | 4 |
| Xie, X | 1 |
| Dong, P | 1 |
| Lin, Y | 2 |
| Zivna, H | 1 |
| Gradošová, I | 1 |
| Zivny, P | 1 |
| Cermakova, E | 1 |
| Palicka, V | 1 |
| Ayyagari, R | 1 |
| Cheng, D | 1 |
| Wu, EQ | 1 |
| Huang, XY | 1 |
| Chen, S | 2 |
| Cho, HJ | 1 |
| Song, JM | 1 |
| Park, JJ | 1 |
| Jin, H | 1 |
| Liu, ZJ | 1 |
| Yan, CL | 1 |
| Liu, FL | 1 |
| Chen, L | 3 |
| Zhang, QJ | 1 |
| Xu, HQ | 1 |
| Hu, JH | 1 |
| Dou, RH | 1 |
| Wen, XY | 1 |
| Shi, J | 1 |
| Yuan, Y | 1 |
| Deng, X | 1 |
| Pan, Y | 1 |
| He, M | 1 |
| Liu, G | 1 |
| Sun, D | 1 |
| Kwon, YJ | 1 |
| Suh, GH | 1 |
| Kang, SS | 1 |
| Mukhtar, O | 1 |
| Cheriyan, J | 1 |
| Cockcroft, JR | 1 |
| Collier, D | 4 |
| Coulson, JM | 1 |
| Dasgupta, I | 1 |
| Glover, M | 1 |
| Heagerty, AM | 1 |
| Khong, TK | 1 |
| Lip, GYH | 1 |
| Mander, AP | 1 |
| Marchong, MN | 1 |
| Martin, U | 1 |
| McDonnell, BJ | 1 |
| McEniery, CM | 1 |
| Saxena, M | 1 |
| Sever, PJ | 1 |
| Shiel, JI | 1 |
| Wych, J | 1 |
| Wilkinson, IB | 2 |
| Augustin, M | 1 |
| Schoretsanitis, G | 2 |
| Gründer, G | 2 |
| Haen, E | 2 |
| Paulzen, M | 2 |
| Rajapakse, S | 1 |
| Amarasekara, S | 1 |
| Amarasena, N | 1 |
| de Silva, AP | 1 |
| Fernando, M | 1 |
| Jayawardena, J | 1 |
| Mendis, S | 2 |
| Munasinghe, J | 1 |
| Ranasinghe, G | 1 |
| Tisserra, N | 1 |
| Senaratne, V | 1 |
| Wijekoon, S | 1 |
| Wijeyasingam, S | 1 |
| Piller, LB | 9 |
| Ghosh, A | 2 |
| Einhorn, PT | 10 |
| Ford, CE | 19 |
| Probstfield, JL | 10 |
| Wright, JT | 18 |
| Guseva, TF | 1 |
| Temirbulatov, II | 1 |
| Helmandollar, KJ | 1 |
| Hoverson, KR | 1 |
| Falkner, RC | 1 |
| Meyerle, JH | 1 |
| Gupta, A | 1 |
| Collier, T | 1 |
| Pocock, S | 1 |
| Cooper-DeHoff, RM | 3 |
| Ekman, I | 1 |
| Öhagen, P | 1 |
| Aoki, H | 2 |
| Kaniwa, N | 1 |
| Saito, Y | 3 |
| Wada, Y | 3 |
| Nakajima, K | 1 |
| Sago, H | 1 |
| Murashima, A | 2 |
| Okamoto, A | 1 |
| Ito, S | 3 |
| Lichtenstein, SJ | 1 |
| Herring, MJ | 1 |
| Baxi, PV | 1 |
| Abrams, RI | 1 |
| Korbet, SM | 1 |
| Troitskaya, EA | 1 |
| Tolkacheva, VV | 1 |
| Tiwaskar, M | 2 |
| Langote, A | 1 |
| Kashyap, R | 1 |
| Toppo, A | 1 |
| Appel, LJ | 4 |
| Miller, ER | 3 |
| Lipsitz, LA | 1 |
| Tabukashvili, R | 1 |
| Kapetivadze, V | 1 |
| Tchaava, K | 1 |
| Gegeshidze, N | 1 |
| Lazashvili, T | 1 |
| Maglapheridze, Z | 1 |
| Angeli, F | 1 |
| Trapasso, M | 1 |
| Signorotti, S | 1 |
| Verdecchia, P | 2 |
| Reboldi, G | 1 |
| Johannsen, JO | 1 |
| Reuter, H | 1 |
| Hoffmann, F | 1 |
| Blaich, C | 1 |
| Wiesen, MHJ | 1 |
| Streichert, T | 1 |
| Müller, C | 1 |
| Presta, V | 1 |
| Tocci, G | 2 |
| Georgianos, PI | 1 |
| Liakopoulos, V | 1 |
| Zebekakis, PE | 1 |
| Barzilay, JI | 6 |
| Lai, D | 1 |
| Pressel, S | 4 |
| Previn, HE | 1 |
| Arnett, DK | 8 |
| Jeon, SY | 1 |
| Lee, NR | 1 |
| Yim, CY | 1 |
| Privalova, EV | 2 |
| Lishuta, AS | 1 |
| Johnson, R | 2 |
| Dludla, P | 1 |
| Mabhida, S | 1 |
| Louw, J | 1 |
| February, F | 1 |
| Drobotya, NV | 1 |
| Torosyan, SS | 1 |
| Guseynova, ES | 1 |
| Morgunov, MN | 1 |
| Tsioufis, K | 3 |
| Douma, S | 1 |
| Kallistratos, MS | 1 |
| Manolis, AJ | 4 |
| Feng, L | 1 |
| Su, J | 1 |
| Chi, R | 1 |
| Zhu, Q | 1 |
| Lv, S | 1 |
| Liang, W | 1 |
| Samuel, JP | 1 |
| Tyson, JE | 1 |
| Green, C | 1 |
| Bell, CS | 1 |
| Pedroza, C | 1 |
| Molony, D | 1 |
| Samuels, J | 1 |
| Mayosi, B | 1 |
| Okpechi, IG | 1 |
| Shukla, AK | 1 |
| Jhaj, R | 1 |
| Kim, TS | 1 |
| Park, DG | 1 |
| Yoon, MH | 4 |
| Cha, DH | 1 |
| Yoo, KD | 1 |
| Jeon, DW | 1 |
| Yoon, YW | 1 |
| Cho, SK | 1 |
| Oh, YS | 1 |
| Poulter, NR | 15 |
| Dolan, E | 4 |
| O'Brien, E | 7 |
| Johnson, K | 1 |
| Si, D | 2 |
| Zhao, Y | 4 |
| He, C | 1 |
| Dou, Y | 1 |
| Zheng, MS | 1 |
| Zhu, ZM | 1 |
| Ha, JW | 3 |
| Kim, SK | 2 |
| Chung, WJ | 3 |
| Youn, HJ | 5 |
| Cho, MC | 2 |
| Kim, CJ | 3 |
| Vukadinović, D | 1 |
| Scholz, SS | 1 |
| Messerli, FH | 9 |
| Seong, SJ | 1 |
| Ohk, B | 1 |
| Kang, WY | 1 |
| Gwon, MR | 1 |
| Cho, S | 1 |
| Yoon, YR | 1 |
| Naydenov Naydenov, S | 1 |
| Margaritov Runev, N | 1 |
| Ivanov Manov, E | 1 |
| Georgieva Torbova-Gigova, S | 1 |
| van der Merwe, WM | 1 |
| Sobngwi, E | 1 |
| Mfeukeu-Kuate, L | 1 |
| Kouam, M | 1 |
| Tankeu, AT | 1 |
| Nganou-Gnindjio, CN | 1 |
| Hamadou, B | 1 |
| Etoa, M | 1 |
| Ngassam, E | 1 |
| Nkamgna, A | 1 |
| Dehayem, MY | 1 |
| Kaze, FF | 1 |
| Kengne, AP | 1 |
| Simon, A | 2 |
| Donato, A | 1 |
| Topouchian, J | 1 |
| Mourad, JJ | 5 |
| De Champvallins, M | 1 |
| Feldmann, L | 1 |
| Asmar, R | 5 |
| Luo, Y | 3 |
| Ren, L | 1 |
| Jiang, M | 1 |
| Chu, Y | 1 |
| Mito, A | 1 |
| Miyasato-Isoda, M | 1 |
| Kamiya, CA | 1 |
| Waguri, M | 1 |
| Yoshimatsu, J | 1 |
| Yakuwa, N | 1 |
| Watanabe, O | 1 |
| Suzuki, T | 4 |
| Arata, N | 1 |
| Mikami, M | 1 |
| Malha, L | 1 |
| August, P | 1 |
| Ohishi, M | 2 |
| Kawai, T | 1 |
| Hayashi, N | 2 |
| Kitano, S | 1 |
| Nagano, M | 2 |
| Hirotani, A | 1 |
| Kamide, K | 3 |
| Fukutomi, M | 4 |
| Eguchi, K | 8 |
| Watanabe, T | 4 |
| Turtle, EJ | 1 |
| Sule, AA | 1 |
| Bath, LE | 1 |
| Denvir, MA | 1 |
| Gebbie, A | 1 |
| Mirsadraee, S | 1 |
| Hradec, J | 1 |
| Zamorano, J | 5 |
| Sutradhar, S | 7 |
| Dussouil, AS | 1 |
| Gaudy-Marqueste, C | 1 |
| Tasei, AM | 1 |
| Monestier, S | 1 |
| Mallet, S | 1 |
| Grob, JJ | 1 |
| Richard, MA | 1 |
| Gorain, B | 1 |
| Choudhury, H | 1 |
| Halder, D | 1 |
| Sarkar, AK | 1 |
| Sarkar, P | 1 |
| Biswas, E | 1 |
| Ghosh, B | 1 |
| Pal, TK | 1 |
| Sasagawa, Y | 2 |
| Sano, H | 2 |
| Takehara, N | 2 |
| Morita, K | 3 |
| Sumitomo, K | 2 |
| Kikuchi, K | 2 |
| Iyalomhe, GB | 1 |
| Omogbai, EK | 1 |
| Isah, AO | 1 |
| Iyalomhe, OO | 1 |
| Dada, FL | 1 |
| Iyalomhe, SI | 1 |
| Aldemir, NM | 1 |
| Begenik, H | 1 |
| Emre, H | 1 |
| Erdur, FM | 1 |
| Soyoral, Y | 1 |
| Garnock-Jones, KP | 1 |
| Cushman, WC | 13 |
| Habib, GB | 4 |
| Margolis, K | 1 |
| Whelton, PK | 14 |
| Ohta, Y | 3 |
| Kawano, Y | 5 |
| Iwashima, Y | 3 |
| Hayashi, S | 1 |
| Yoshihara, F | 2 |
| Matayoshi, T | 1 |
| Takiuchi, S | 1 |
| Nakamura, S | 2 |
| Horio, T | 2 |
| Hagendorff, A | 1 |
| Freytag, S | 1 |
| Müller, A | 2 |
| Klebs, S | 5 |
| Nishida, M | 1 |
| Ishikawa, T | 2 |
| Saiki, S | 1 |
| Sunggip, C | 1 |
| Aritomi, S | 3 |
| Harada, E | 2 |
| Kuwahara, K | 2 |
| Hirano, K | 1 |
| Mori, Y | 1 |
| Kim-Mitsuyama, S | 7 |
| Lewin, AJ | 2 |
| Izzo, JL | 10 |
| Melino, M | 12 |
| Fernandez, V | 8 |
| Heyrman, R | 10 |
| Nesbitt, S | 3 |
| Shojaee, A | 10 |
| Maa, JF | 8 |
| Kikuya, M | 1 |
| Kobayashi, Y | 2 |
| Ishikura, K | 1 |
| Ikeda, U | 2 |
| Ishikuro, M | 1 |
| Metoki, H | 1 |
| Mano, N | 1 |
| Kuriyama, S | 4 |
| Imai, Y | 3 |
| Ay, SA | 4 |
| Karaman, M | 6 |
| Cakar, M | 5 |
| Balta, S | 6 |
| Arslan, E | 4 |
| Bulucu, F | 5 |
| Demirbas, S | 4 |
| Celik, T | 7 |
| Naharci, MI | 1 |
| Demirkol, S | 6 |
| Kurt, O | 3 |
| Bozoglu, E | 2 |
| Briasoulis, A | 1 |
| Jamerson, K | 16 |
| Kelly, RY | 5 |
| Hester, A | 8 |
| Hua, T | 5 |
| Zappe, D | 8 |
| Lin, TH | 2 |
| Tsai, CD | 1 |
| Pan, JP | 1 |
| Hou, CJ | 1 |
| Hsia, CH | 1 |
| Tsai, JP | 1 |
| Lai, WT | 3 |
| Rozza, F | 1 |
| Trimarco, V | 1 |
| Izzo, R | 2 |
| Santoro, M | 1 |
| Manzi, MV | 1 |
| Marino, M | 2 |
| Di Renzo, G | 1 |
| Trimarco, B | 4 |
| Maruf, FA | 2 |
| Akinpelu, AO | 2 |
| Salako, BL | 2 |
| Takami, T | 3 |
| Billecke, SS | 2 |
| Marcovitz, PA | 2 |
| Nagy, VL | 1 |
| Litvin, AY | 1 |
| Sukmarova, ZN | 1 |
| Elfimova, EM | 1 |
| Aksenova, AV | 1 |
| Galitsin, PV | 1 |
| Rogoza, AN | 2 |
| Chazova, IE | 5 |
| Siragusa, M | 1 |
| Sessa, WC | 1 |
| Eckert, S | 1 |
| Freytag, SB | 1 |
| Klebs, SH | 1 |
| Calhoun, DA | 8 |
| Lacourcière, Y | 16 |
| Crikelair, N | 3 |
| Jia, Y | 4 |
| Glazer, RD | 8 |
| Agnoletti, D | 2 |
| Zhang, Y | 11 |
| Blacher, J | 2 |
| Safar, ME | 4 |
| Koyanagi, R | 2 |
| Hagiwara, N | 2 |
| Yamaguchi, J | 2 |
| Kawada-Watanabe, E | 1 |
| Haruta, S | 1 |
| Takagi, A | 2 |
| Ferdinand, KC | 8 |
| Nasser, SA | 1 |
| M'Buyamba-Kabangu, JR | 3 |
| Anisiuba, BC | 3 |
| Ndiaye, MB | 3 |
| Lemogoum, D | 3 |
| Jacobs, L | 1 |
| Ijoma, CK | 3 |
| Thijs, L | 3 |
| Boombhi, HJ | 3 |
| Kaptue, J | 3 |
| Kolo, PM | 3 |
| Mipinda, JB | 2 |
| Osakwe, CE | 1 |
| Odili, A | 1 |
| Ezeala-Adikaibe, B | 2 |
| Kingue, S | 3 |
| Omotoso, BA | 3 |
| Ba, SA | 3 |
| Ulasi, II | 3 |
| Staessen, JA | 5 |
| Derosa, G | 28 |
| Cicero, AF | 6 |
| Carbone, A | 5 |
| Querci, F | 5 |
| Fogari, E | 11 |
| D'Angelo, A | 8 |
| Maffioli, P | 15 |
| Weir, MR | 12 |
| Iskenderov, BG | 6 |
| Budagovskaya, ZM | 1 |
| Sisina, ON | 5 |
| Ivanovic, B | 1 |
| Tadic, M | 1 |
| Creevy, KE | 1 |
| Scuderi, MA | 1 |
| Ellis, AE | 1 |
| Mori, M | 1 |
| Takahashi, S | 1 |
| Yan, P | 3 |
| Fan, W | 1 |
| Zhang, YP | 1 |
| Zuo, XC | 3 |
| Huang, ZJ | 3 |
| Cai, JJ | 1 |
| Wen, J | 3 |
| Duan, DD | 1 |
| Yuan, H | 5 |
| Roth, EM | 2 |
| Jia, T | 1 |
| Zhang, LJ | 1 |
| Zhan, YQ | 1 |
| Yu, JM | 1 |
| Hu, DY | 1 |
| Kızılırmak, P | 3 |
| Berktaş, M | 1 |
| Yalçın, MR | 1 |
| Boyacı, B | 1 |
| Liu, Y | 4 |
| Chen, K | 1 |
| Kou, X | 1 |
| Han, Y | 1 |
| Zhou, L | 1 |
| Zeng, C | 2 |
| Karalliedde, J | 3 |
| Maltese, G | 1 |
| Hill, B | 1 |
| Viberti, G | 4 |
| Gnudi, L | 1 |
| Ando, K | 5 |
| Tanaka, S | 4 |
| Kosugi, S | 1 |
| Sato, T | 5 |
| Matsuoka, H | 8 |
| Nakao, K | 13 |
| Fujita, T | 6 |
| Wierzbicki, AS | 1 |
| Ferro, A | 1 |
| Neldam, S | 3 |
| Oigman, W | 14 |
| Schumacher, H | 7 |
| Kobalava, ZhD | 7 |
| Kotovskaia, IuV | 6 |
| Luk'ianova, EA | 2 |
| Puzyrenko, AM | 1 |
| Chekman, IS | 1 |
| Kuftyreva, TP | 1 |
| Horchakova, NO | 1 |
| He, Y | 1 |
| Yang, C | 3 |
| Ni, L | 1 |
| Ding, M | 1 |
| He, YS | 1 |
| Wei, M | 1 |
| Li, ZP | 1 |
| Zhang, BW | 1 |
| Miyoshi, K | 4 |
| Okura, T | 6 |
| Nagao, T | 2 |
| Masanori, J | 1 |
| Irita, J | 3 |
| Higaki, J | 8 |
| Bakkour, W | 1 |
| Haylett, AK | 1 |
| Gibbs, NK | 1 |
| Chalmers, RJ | 1 |
| Rhodes, LE | 1 |
| Takagi, H | 5 |
| Umemoto, T | 4 |
| He, DH | 2 |
| Zhang, LM | 2 |
| Ning, RB | 2 |
| Wang, HJ | 2 |
| Xu, CS | 2 |
| Lin, JX | 2 |
| Yamashita, K | 2 |
| Kondo, T | 3 |
| Muramatsu, T | 3 |
| Matsushita, K | 3 |
| Nagahiro, T | 1 |
| Maeda, K | 7 |
| Shintani, S | 3 |
| Murohara, T | 4 |
| Piekarska, A | 1 |
| Niklas, A | 1 |
| Stryczyński, L | 1 |
| Juszkat, R | 1 |
| Tykarski, A | 1 |
| Masaki, M | 2 |
| Komamura, K | 2 |
| Goda, A | 2 |
| Hirotani, S | 3 |
| Otsuka, M | 2 |
| Nakabo, A | 1 |
| Fukui, M | 1 |
| Fujiwara, S | 2 |
| Sugahara, M | 2 |
| Lee-Kawabata, M | 2 |
| Tsujino, T | 3 |
| Koshiba, M | 2 |
| Masuyama, T | 4 |
| Chrysant, SG | 22 |
| Pérez Carreño, JG | 1 |
| Romero, JD | 1 |
| Villar Centeno, JC | 1 |
| Zemmrich, C | 3 |
| Lüders, S | 2 |
| Gansz, A | 2 |
| Sturm, CD | 2 |
| Fimmers, R | 2 |
| Nadal, J | 2 |
| Schrader, J | 4 |
| Yoshida, H | 7 |
| Saitoh, S | 1 |
| Shimamoto, K | 3 |
| Miura, T | 2 |
| Radchenko, GD | 1 |
| Sirenko, YM | 2 |
| Kushnir, SM | 1 |
| Torbas, OO | 1 |
| Dobrokhod, AS | 1 |
| Peng, GC | 1 |
| Wang, YF | 1 |
| Xiao, Y | 1 |
| Chen, JF | 2 |
| Yang, Y | 1 |
| Ye, YL | 1 |
| Sai, SQ | 1 |
| Huang, JX | 1 |
| Chaturvedula, A | 1 |
| Sale, ME | 1 |
| Carter, JM | 1 |
| Irving, AC | 1 |
| Bridges, JP | 1 |
| Jones, BR | 1 |
| Mason, RP | 1 |
| Jacob, RF | 1 |
| Corbalan, JJ | 1 |
| Kaliszan, R | 1 |
| Malinski, T | 1 |
| Dressler, D | 1 |
| Robbins, J | 2 |
| Cooper, CJ | 1 |
| Murphy, TP | 1 |
| Cutlip, DE | 1 |
| Henrich, W | 1 |
| Reid, DM | 1 |
| Cohen, DJ | 1 |
| Matsumoto, AH | 1 |
| Steffes, M | 1 |
| Jaff, MR | 1 |
| Prince, MR | 1 |
| Lewis, EF | 1 |
| Tuttle, KR | 1 |
| Shapiro, JI | 1 |
| Rundback, JH | 1 |
| Massaro, JM | 1 |
| D'Agostino, RB | 1 |
| Dworkin, LD | 1 |
| Yokoyama, K | 3 |
| Hara, Y | 2 |
| Sugano, N | 1 |
| Yokoo, T | 1 |
| Hosoya, T | 3 |
| Souza, DR | 1 |
| Gomides, RS | 1 |
| Costa, LA | 1 |
| Queiroz, AC | 1 |
| Barros, S | 1 |
| Ortega, KC | 4 |
| Mion, D | 5 |
| Tinucci, T | 1 |
| Forjaz, CL | 1 |
| Martynyuk, TV | 1 |
| Derevianchenko, MV | 4 |
| Ostrovskiĭ, OV | 1 |
| Shvets, MK | 1 |
| Bondarev, AM | 1 |
| Phillips, W | 1 |
| Williamson, JD | 2 |
| Whittle, J | 4 |
| Jafri, SZ | 3 |
| Grimm, RH | 7 |
| Alderman, MH | 5 |
| Ruilope, L | 2 |
| Schaefer, A | 2 |
| Kwon, HM | 1 |
| Shin, JW | 1 |
| Lim, JS | 1 |
| Hong, YH | 1 |
| Lee, YS | 1 |
| Nam, H | 1 |
| Handler, J | 1 |
| Yan, R | 1 |
| Song, A | 1 |
| Niu, X | 1 |
| Cao, C | 2 |
| Wei, J | 1 |
| Dong, X | 1 |
| Gao, D | 1 |
| Lin, LM | 1 |
| Gus, M | 1 |
| Moreira, LB | 1 |
| Zhu, D | 3 |
| Holtbruegge, W | 1 |
| Fogari, R | 30 |
| Zoppi, A | 26 |
| Lazzari, P | 14 |
| Mugellini, A | 29 |
| Zhou, MS | 4 |
| Tian, R | 1 |
| Jaimes, EA | 5 |
| Raij, L | 6 |
| Martyniuk, TV | 1 |
| Singh, K | 1 |
| Kallakuri, S | 1 |
| White, WB | 8 |
| Sica, D | 1 |
| Roberts, A | 1 |
| Kupfer, S | 1 |
| Andreadis, EA | 1 |
| Angelopoulos, ET | 1 |
| Kolyvas, GN | 1 |
| Agaliotis, GD | 1 |
| Mousoulis, CG | 1 |
| Mousoulis, GP | 1 |
| Lawrence Gould, A | 1 |
| Unniachan, S | 2 |
| Wu, D | 2 |
| Byrd, JB | 1 |
| Müller-Fielitz, H | 1 |
| Hübel, N | 1 |
| Mildner, M | 1 |
| Vogt, FM | 1 |
| Barkhausen, J | 1 |
| Raasch, W | 1 |
| Punzi, HA | 3 |
| Zhang, WL | 1 |
| Barrett, JS | 2 |
| Hua, Y | 1 |
| Zhou, HH | 1 |
| Pei, Q | 2 |
| Guo, CX | 1 |
| Wang, JL | 1 |
| Yang, GP | 3 |
| Suneja, M | 1 |
| Baiswar, S | 1 |
| Vogelgesang, SA | 1 |
| Khan, W | 1 |
| Moin, N | 1 |
| Iktidar, S | 1 |
| Sakrani, J | 1 |
| Abid, R | 1 |
| Afzal, J | 1 |
| Maheshwary, N | 1 |
| Kumar, K | 1 |
| Siddiqi, A | 1 |
| Qadir, M | 1 |
| Tóth, K | 1 |
| Demirci, H | 1 |
| Polat, Z | 1 |
| Kantarcioglu, M | 1 |
| Kekilli, M | 1 |
| Uygun, A | 1 |
| Bagci, S | 1 |
| Jinnouchi, T | 2 |
| Jinnouchi, H | 2 |
| Arakawa, K | 4 |
| Teo, KK | 1 |
| Pfeffer, M | 1 |
| O'Donnell, M | 1 |
| Dagenais, G | 1 |
| Diaz, R | 1 |
| Dans, A | 1 |
| Liu, L | 5 |
| Bosch, J | 1 |
| Joseph, P | 1 |
| Copland, I | 1 |
| Jung, H | 1 |
| Pogue, J | 1 |
| Yusuf, S | 1 |
| Kereiakes, DJ | 7 |
| Fryers, A | 1 |
| Elwood, C | 1 |
| Mihaleva, AV | 1 |
| Saushkina, SV | 1 |
| Motoki, H | 1 |
| Izawa, A | 1 |
| Tomita, T | 1 |
| Takahashi, M | 2 |
| Fang, H | 2 |
| Xu, W | 1 |
| Yunis, C | 9 |
| Westergaard, M | 3 |
| Hiremath, J | 2 |
| Namjoshi, DJ | 1 |
| Gujral, VK | 1 |
| Tripathi, KK | 1 |
| Siraj, M | 1 |
| Shamanna, P | 1 |
| Safar, M | 3 |
| Ketelhut, R | 3 |
| Fronk, EM | 4 |
| Wolf, WP | 4 |
| Smolnik, R | 2 |
| Muntner, P | 2 |
| Levitan, EB | 1 |
| Lynch, AI | 8 |
| Nakata, E | 1 |
| Sasaki, E | 1 |
| Kagawa, T | 1 |
| Ley, L | 4 |
| Ammentorp, B | 4 |
| Laeis, P | 4 |
| Azushima, K | 2 |
| Uneda, K | 1 |
| Tamura, K | 2 |
| Wakui, H | 2 |
| Ohsawa, M | 2 |
| Kobayashi, R | 1 |
| Dejima, T | 2 |
| Kanaoka, T | 2 |
| Maeda, A | 3 |
| Toya, Y | 2 |
| Umemura, S | 3 |
| Reisin, E | 3 |
| Graves, JW | 1 |
| Dart, RA | 3 |
| Retta, TM | 3 |
| Saklayen, MG | 1 |
| Lee, SA | 1 |
| Choi, HM | 1 |
| Park, HJ | 1 |
| Ko, SK | 1 |
| Troitskaia, EA | 1 |
| Dmitrova, TB | 1 |
| Ar, I | 1 |
| Ilerigelen, B | 1 |
| Koch, W | 1 |
| Griffin, KA | 1 |
| Polichnowski, A | 1 |
| Litbarg, N | 1 |
| Picken, M | 1 |
| Venkatachalam, MA | 1 |
| Bidani, AK | 1 |
| Snelder, N | 1 |
| Ploeger, BA | 1 |
| Luttringer, O | 1 |
| Rigel, DF | 1 |
| Fu, F | 1 |
| Beil, M | 1 |
| Stanski, DR | 1 |
| Danhof, M | 1 |
| Inomata, J | 1 |
| Murai, H | 2 |
| Kaneko, S | 1 |
| Hamaoka, T | 1 |
| Ikeda, T | 3 |
| Kobayashi, D | 1 |
| Usui, S | 1 |
| Furusho, H | 1 |
| Takata, S | 1 |
| Takamura, M | 1 |
| Azizi, M | 2 |
| Perdrix, L | 1 |
| Bobrie, G | 4 |
| Frank, M | 2 |
| Chatellier, G | 1 |
| Ménard, J | 3 |
| Plouin, PF | 1 |
| Baraniuk, S | 1 |
| Rahman, M | 8 |
| Basile, JN | 6 |
| Ellsworth, AJ | 1 |
| Fendley, H | 1 |
| Sison, J | 2 |
| Assaad-Khalil, SH | 2 |
| Najem, R | 2 |
| Kitchlew, AR | 2 |
| Cho, B | 2 |
| Ueng, KC | 4 |
| Shete, A | 2 |
| Knap, D | 1 |
| Nitta, K | 3 |
| Nishizawa, Y | 1 |
| Yokoyama, H | 1 |
| Nakanishi, T | 1 |
| Kashihara, N | 2 |
| Tomita, K | 1 |
| Nangaku, M | 2 |
| Takahashi, K | 3 |
| Isshiki, M | 2 |
| Shimosawa, T | 3 |
| Pozzobon, CR | 2 |
| Gismondi, RA | 3 |
| Bedirian, R | 2 |
| Ladeira, MC | 2 |
| Neves, MF | 3 |
| Trenson, S | 1 |
| de Ceuninck, M | 1 |
| Tabur, S | 1 |
| Oğuz, E | 1 |
| Sabuncu, T | 1 |
| Korkmaz, H | 1 |
| Çelik, H | 1 |
| Zhu, JR | 4 |
| Zhang, SY | 1 |
| Gao, PJ | 1 |
| Grassi, G | 2 |
| Rajagopalan, S | 1 |
| Hanson, ME | 1 |
| Fujita, KP | 3 |
| Kartashova, EA | 1 |
| Romantsov, MG | 1 |
| Sarvilina, IV | 1 |
| Vygodin, VA | 1 |
| Avakian, AA | 1 |
| Prokof'eva, EB | 1 |
| Kato, H | 2 |
| Shiraishi, T | 1 |
| Ueda, S | 2 |
| Kubo, E | 1 |
| Shima, T | 1 |
| Nagura, M | 1 |
| Yano, H | 1 |
| Izumikawa, Y | 1 |
| Shimada, M | 1 |
| Tomioka, S | 1 |
| Nosaka, H | 1 |
| Kojima, K | 1 |
| Tanemoto, M | 1 |
| Uchida, S | 2 |
| Suh, SY | 1 |
| Ahn, T | 2 |
| Bae, JH | 2 |
| Lim, DS | 3 |
| Kim, YK | 1 |
| Kim, WH | 1 |
| Park, HK | 1 |
| Lobzhanidze, TV | 1 |
| Kravtsova, OA | 1 |
| Pecherina, TB | 1 |
| Vedernikova, AG | 1 |
| Evdokimov, DO | 1 |
| Klimenkova, AV | 1 |
| Barbarash, OL | 1 |
| Lankhorst, S | 1 |
| Kappers, MH | 1 |
| van Esch, JH | 1 |
| Smedts, FM | 1 |
| Sleijfer, S | 1 |
| Mathijssen, RH | 1 |
| Baelde, HJ | 1 |
| Danser, AH | 2 |
| van den Meiracker, AH | 3 |
| Nagasawa, K | 1 |
| Matsuura, N | 1 |
| Takatsu, M | 1 |
| Hattori, T | 1 |
| Watanabe, S | 2 |
| Niinuma, K | 2 |
| Nagata, K | 1 |
| Páll, D | 2 |
| Szántó, I | 1 |
| Szabó, Z | 1 |
| Xie, L | 2 |
| Frech-Tamas, F | 1 |
| Marrett, E | 1 |
| Baser, O | 2 |
| Dingemanse, J | 1 |
| Otasevic, P | 1 |
| Shakeri-Nejad, K | 1 |
| Klainman, E | 1 |
| Putnikovic, B | 1 |
| Kracker, H | 1 |
| Mueller, MS | 1 |
| Zimlichman, R | 2 |
| Hammerstrom, AE | 1 |
| Singh, GJ | 1 |
| Jackson, A | 1 |
| D'Avolio, A | 1 |
| Else, L | 1 |
| De Nicolò, A | 1 |
| Bonora, S | 1 |
| Di Perri, G | 1 |
| Khoo, S | 1 |
| Back, D | 1 |
| Moyle, G | 1 |
| Boffito, M | 1 |
| Ji, M | 1 |
| Li, SJ | 1 |
| Hu, WL | 1 |
| Ripley, DP | 1 |
| Negrou, K | 1 |
| Oliver, JJ | 2 |
| Worthy, G | 1 |
| Struthers, AD | 2 |
| Plein, S | 1 |
| Greenwood, JP | 1 |
| Zou, G | 1 |
| Hong, H | 2 |
| Lin, X | 1 |
| Shi, X | 1 |
| Wu, Y | 1 |
| Tsuchihashi, T | 4 |
| Shimada, K | 12 |
| Numaguchi, H | 2 |
| Nishida, C | 2 |
| Yamaguchi, H | 2 |
| Shirakawa, M | 2 |
| Azuma, K | 2 |
| Bernard, E | 1 |
| Goutelle, S | 1 |
| Bertrand, Y | 1 |
| Bleyzac, N | 1 |
| Kasiakogias, A | 1 |
| Tsioufis, C | 3 |
| Thomopoulos, C | 2 |
| Andrikou, I | 1 |
| Aragiannis, D | 1 |
| Dimitriadis, K | 2 |
| Tsiachris, D | 1 |
| Sideris, S | 1 |
| Filis, K | 1 |
| Stefanadis, C | 3 |
| Skovbølling, SL | 1 |
| Lindelof, M | 1 |
| Takase, B | 2 |
| Nagata, M | 1 |
| Ryu, SH | 1 |
| Kim, JW | 1 |
| Kim, YS | 1 |
| Cho, YB | 1 |
| Lee, HK | 1 |
| Kim, YG | 1 |
| Jeong, WS | 1 |
| Kim, KB | 1 |
| Tuchscherer, RM | 1 |
| Nair, K | 1 |
| Ghushchyan, V | 1 |
| Saseen, JJ | 1 |
| Amodeo, C | 3 |
| Gamba, MA | 1 |
| Puig, JG | 1 |
| Ahmet Ay, S | 1 |
| Ozturk, C | 1 |
| Dınc, M | 1 |
| Unal, HU | 1 |
| Yılmaz, MI | 3 |
| Kılıc, S | 1 |
| Kurt, G | 1 |
| Tas, A | 1 |
| Iyısoy, A | 1 |
| Quartı-Trevano, F | 1 |
| Fıcı, F | 1 |
| Cao, TS | 1 |
| Huynh, VM | 1 |
| Tran, VH | 1 |
| Olszanecka-Glinianowicz, M | 1 |
| Smertka, M | 1 |
| Almgren-Rachtan, A | 1 |
| Chudek, J | 1 |
| Fendley, HF | 1 |
| Franklin, SS | 4 |
| Sastrasinh, S | 1 |
| Wu, LS | 1 |
| Chang, CJ | 1 |
| Chazova, I | 1 |
| Sirenko, Y | 2 |
| Erglis, A | 1 |
| Laucevicius, A | 1 |
| Farsang, C | 3 |
| Bhambri, R | 1 |
| Angeloni, E | 1 |
| Vitaterna, A | 1 |
| Lombardo, P | 1 |
| Pirelli, M | 1 |
| Refice, S | 1 |
| El Hassar, C | 1 |
| Merzouk, H | 1 |
| Merzouk, SA | 1 |
| Malti, N | 1 |
| Meziane, A | 1 |
| Narce, M | 1 |
| Galeeva, ZM | 1 |
| Galiavich, AS | 1 |
| Skoglund, PH | 1 |
| Svensson, P | 1 |
| Asp, J | 1 |
| Östergren, J | 8 |
| Sutton, G | 1 |
| Morbini, M | 1 |
| Hiltunen, TP | 5 |
| Donner, KM | 2 |
| Sarin, AP | 1 |
| Saarela, J | 1 |
| Ripatti, S | 1 |
| Chapman, AB | 2 |
| Gums, JG | 1 |
| Gong, Y | 1 |
| Frau, F | 1 |
| Glorioso, V | 1 |
| Zaninello, R | 1 |
| Salvi, E | 1 |
| Glorioso, N | 2 |
| Boerwinkle, E | 8 |
| Turner, ST | 1 |
| Johnson, JA | 1 |
| Kontula, KK | 1 |
| Labourée, F | 1 |
| Cochiello, S | 1 |
| DiTommaso, S | 1 |
| Furuhashi, M | 1 |
| Mita, T | 1 |
| Moniwa, N | 1 |
| Hoshina, K | 1 |
| Ishimura, S | 1 |
| Fuseya, T | 1 |
| Semagina, IM | 1 |
| Bogomaz, AV | 2 |
| Chesnikova, AI | 1 |
| Safronenko, VA | 1 |
| Kolomatskaia, OE | 1 |
| Budagovskaia, ZM | 1 |
| Boitsov, SA | 1 |
| Bazaeva, EV | 1 |
| Luk'ianov, MM | 1 |
| Drapkina, OM | 1 |
| Panov, AV | 2 |
| Terent'ev, BP | 1 |
| Tiurin, VP | 1 |
| Shchukina, GN | 1 |
| Rosenkranz, AR | 1 |
| Ratzinger, M | 1 |
| Schlimpert, V | 1 |
| Czarnecka, D | 1 |
| Koch, EM | 1 |
| Zapesochnaia, IL | 1 |
| Avtandilov, AG | 2 |
| Jian, L | 1 |
| Niu, S | 1 |
| Krzesinski, JM | 5 |
| Solomennchuk, TM | 1 |
| Slaba, NA | 1 |
| Prots'ko, VV | 1 |
| Bedzaĭ, AO | 1 |
| Zaremba, IeKh | 1 |
| Zaremba-Fedchyshyn, OV | 1 |
| Virna, MM | 1 |
| Bula, MS | 1 |
| Zaremba, OV | 1 |
| Poteshkina, NG | 1 |
| Khashieva, FM | 1 |
| Whitmore, J | 1 |
| Feldstein, JD | 1 |
| Chull Chae, S | 1 |
| Seog Seo, H | 1 |
| Park, JS | 1 |
| Oh, SK | 1 |
| Kim, DS | 2 |
| Bae Park, J | 1 |
| Jeong, JO | 2 |
| Kim, DI | 1 |
| Joo, SJ | 3 |
| Jeon, ES | 1 |
| Jiang, N | 1 |
| Liu, Q | 2 |
| Yang, WW | 1 |
| Zeng, Y | 1 |
| Villevalde, SV | 1 |
| Tigai, ZG | 1 |
| Marques da Silva, P | 1 |
| Haag, U | 4 |
| Guest, JF | 1 |
| Brazier, JE | 1 |
| Soro, M | 1 |
| Pastukhova, OR | 1 |
| Ongen, Z | 1 |
| Koike, Y | 2 |
| Kawabe, T | 2 |
| Nishihara, K | 2 |
| Iwane, N | 2 |
| Hano, T | 2 |
| Ishimitsu, T | 4 |
| Fukuda, H | 1 |
| Uchida, M | 1 |
| Ishibashi, K | 1 |
| Sato, F | 1 |
| Nukui, K | 1 |
| Nagao, M | 1 |
| Kawalec, P | 1 |
| Holko, P | 1 |
| Stawowczyk, E | 1 |
| Borowiec, Ł | 1 |
| van der Merwe, W | 1 |
| van der Merwe, V | 1 |
| Akamine, Y | 1 |
| Uehara, H | 1 |
| Miura, M | 1 |
| Yasui-Furukori, N | 1 |
| Uno, T | 1 |
| Hubert, M | 1 |
| Khodorovich, NA | 2 |
| Arora, A | 1 |
| Jain, S | 1 |
| Khuller, GK | 1 |
| Anthony, EG | 1 |
| Lipkowitz, MS | 3 |
| Bhatnagar, V | 2 |
| Rump, LC | 1 |
| Toyoda, S | 1 |
| Inami, S | 1 |
| Kato, T | 4 |
| Tsukada, K | 1 |
| Nakamoto, A | 1 |
| Kikegawa, Y | 1 |
| Suzuki, A | 1 |
| Anraku, Y | 1 |
| Node, K | 4 |
| Inoue, T | 6 |
| Pesce, RM | 2 |
| Fu, W | 1 |
| Ma, L | 5 |
| Zhu, H | 1 |
| Yang, W | 1 |
| Liu, C | 1 |
| Han, R | 1 |
| Motozato, K | 1 |
| Miura, S | 2 |
| Shiga, Y | 1 |
| Kusumoto, T | 1 |
| Adachi, S | 1 |
| Fujisawa, K | 1 |
| Saku, K | 2 |
| Shirley, M | 1 |
| McCormack, PL | 1 |
| Karpov, YA | 1 |
| Gorbunov, VM | 1 |
| Deev, AD | 4 |
| Machnicki, G | 1 |
| Ong, SH | 1 |
| Wei, ZJ | 1 |
| Kahler, KH | 1 |
| Zapesochnaya, IL | 1 |
| Karakus, E | 1 |
| Halici, Z | 2 |
| Albayrak, A | 1 |
| Bayir, Y | 1 |
| Demirci, E | 1 |
| Aydin, A | 1 |
| Ozturk-Karagoz, B | 1 |
| Cadirci, E | 1 |
| Ayan, AK | 1 |
| Sahin, A | 1 |
| Unal, D | 1 |
| Xu, R | 1 |
| Cai, A | 1 |
| Zheng, D | 1 |
| Qiu, R | 1 |
| Zhou, Y | 1 |
| Feng, Y | 1 |
| Mai, W | 1 |
| Susa, N | 1 |
| Nishida, Y | 2 |
| Yada, Y | 1 |
| Nakayama, T | 1 |
| Asai, S | 2 |
| Takahashi, Y | 2 |
| Tariovskaya, EI | 1 |
| Malchikova, SV | 1 |
| Sirotenko, DV | 2 |
| Prokofieva, EB | 1 |
| Bangalore, S | 3 |
| Holzhauer, B | 3 |
| Zanchetti, A | 15 |
| Setiawati, A | 1 |
| Kalim, H | 1 |
| Abdillah, A | 1 |
| Mohamed, HM | 1 |
| Lamie, NT | 1 |
| Kuznetsova, TE | 1 |
| Borovkova, NY | 1 |
| Borovkova, NJ | 1 |
| Kuznecova, TE | 1 |
| Borovkov, NN | 1 |
| Kovaleva, GV | 1 |
| Alugishvili, MZ | 1 |
| Abesadze, IT | 1 |
| Lohovinina, NL | 1 |
| Korzenewskaya, KV | 1 |
| Titenkov, IV | 1 |
| Kuleshova, EV | 1 |
| Dyplyakov, DV | 1 |
| Hohlunov, SM | 1 |
| Kryukov, AV | 1 |
| Libis, RA | 1 |
| Isayeva, EN | 1 |
| Basyrova, IR | 1 |
| Safonova, DV | 1 |
| He, D | 1 |
| Lin, J | 3 |
| Oh, BH | 5 |
| Kim, BS | 1 |
| Chung, WB | 1 |
| Zhang, ZL | 1 |
| Li, HL | 1 |
| Wen, ZP | 1 |
| Chen, XP | 1 |
| Kondo, K | 1 |
| Toh, R | 1 |
| Ishida, T | 3 |
| Mori, K | 1 |
| Yasuda, T | 1 |
| Hirata, K | 1 |
| Toh, N | 1 |
| Ishii, K | 1 |
| Kihara, H | 1 |
| Iwakura, K | 1 |
| Watanabe, H | 2 |
| Yoshikawa, J | 2 |
| Derevyanchenko, MV | 1 |
| Hu, D | 1 |
| Liao, Y | 1 |
| Huang, J | 5 |
| Zhao, R | 1 |
| Yang, K | 2 |
| Aksnes, TA | 4 |
| Rostrup, M | 6 |
| Mano, T | 2 |
| Eguchi, A | 1 |
| Schetz, D | 1 |
| Foerster, J | 1 |
| Sein Anand, J | 1 |
| Abdelhady, A | 1 |
| Khader, S | 1 |
| Sinnuqrut, S | 1 |
| Albow, A | 1 |
| Pichler, G | 2 |
| Çelik, HT | 1 |
| Akkaya, N | 1 |
| Erdamar, H | 1 |
| Gok, S | 1 |
| Kazanci, F | 1 |
| Demircelik, B | 1 |
| Cakmak, M | 1 |
| Yigitoglu, R | 1 |
| Chong, SJ | 1 |
| Howard, KA | 1 |
| Knox, C | 1 |
| Christopoulou, F | 1 |
| Rizos, EC | 1 |
| Kosta, P | 1 |
| Argyropoulou, MI | 1 |
| Elisaf, M | 1 |
| Lu, J | 2 |
| Du, H | 2 |
| Hao, J | 2 |
| Yang, X | 2 |
| Tanner, RM | 1 |
| Akinyemi, JO | 1 |
| Häckel, A | 1 |
| Einecke, D | 3 |
| Okazaki, O | 1 |
| Noshiro, T | 1 |
| Matsumoto, Y | 1 |
| Levi, M | 1 |
| Pasqua, A | 1 |
| Cricelli, I | 1 |
| Cricelli, C | 1 |
| Piccinni, C | 1 |
| Parretti, D | 1 |
| Lapi, F | 1 |
| Yin, WH | 1 |
| Yeh, HI | 1 |
| Wang, KY | 1 |
| Hung, YJ | 2 |
| Tseng, WK | 1 |
| Wen, MS | 1 |
| Wu, TC | 1 |
| Wu, CC | 2 |
| Cheng, SM | 2 |
| Chen, JW | 1 |
| Hatalova, K | 2 |
| Pella, D | 3 |
| Sidlo, R | 2 |
| Hatala, R | 2 |
| Filippov, EV | 1 |
| Yakushin, SS | 1 |
| Skoczylas, A | 1 |
| Piecha, G | 1 |
| Więcek, A | 1 |
| Vlachopoulos, C | 1 |
| Grammatikou, V | 1 |
| Kallistratos, M | 1 |
| Karagiannis, A | 2 |
| Zhou, HM | 1 |
| Zhong, ML | 1 |
| Wang, RH | 1 |
| Long, CL | 1 |
| Zhang, YF | 1 |
| Cui, WY | 1 |
| Bäurle, A | 1 |
| Saiz Satjes, M | 1 |
| Martinez-Martin, FJ | 5 |
| Vítovec, J | 1 |
| Špinar, J | 1 |
| Lammertz, SE | 1 |
| Stegmann, B | 1 |
| Schruers, KR | 1 |
| Walther, S | 1 |
| Kónyi, A | 1 |
| Sárszegi, Z | 1 |
| Hild, G | 1 |
| Gaszner, B | 1 |
| Michels, G | 1 |
| Pfister, R | 1 |
| Xiao, B | 1 |
| Beard, BL | 1 |
| Marginean, H | 2 |
| Hamilton, BP | 3 |
| Suhan, PS | 1 |
| Nádházi, Z | 1 |
| Alföldi, S | 1 |
| Erdoğan, D | 1 |
| İçli, A | 1 |
| Aksoy, F | 1 |
| Akçay, S | 1 |
| Yücel, H | 1 |
| Ersoy, İ | 1 |
| Özaydın, M | 1 |
| Ahmed, M | 1 |
| Alanbaei, M | 1 |
| El Tamimi, H | 1 |
| Al-Wahshi, Y | 1 |
| Al-Zakwani, I | 1 |
| Al-Ramahi, R | 1 |
| Raddad, AR | 1 |
| Rashed, AO | 1 |
| Bsharat, A | 1 |
| Abu-Ghazaleh, D | 1 |
| Yasin, E | 1 |
| Shehab, O | 1 |
| Zeng, R | 1 |
| Forster, T | 1 |
| Shin, MS | 1 |
| Seo, HS | 3 |
| Shin, ES | 1 |
| Il Kim, D | 1 |
| Konoshita, T | 2 |
| Kaeriyama, S | 1 |
| Urabe, M | 1 |
| Nakaya, T | 1 |
| Yamada, M | 1 |
| Ichikawa, M | 1 |
| Sato, S | 1 |
| Imagawa, M | 1 |
| Fujii, M | 5 |
| Makino, Y | 2 |
| Zenimaru, Y | 1 |
| Wakahara, S | 2 |
| Suzuki, J | 1 |
| Ishizuka, T | 1 |
| Nakamura, H | 3 |
| Komuro, I | 6 |
| Shiki, K | 2 |
| Ugai, H | 1 |
| Taniguchi, A | 2 |
| Ikeda, H | 3 |
| Kuroki, D | 2 |
| Nishimura, S | 2 |
| Ogihara, T | 21 |
| Galappatthy, P | 1 |
| Waniganayake, YC | 1 |
| Sabeer, MI | 1 |
| Wijethunga, TJ | 1 |
| Galappatthy, GK | 1 |
| Ekanayaka, RA | 1 |
| Baysal, SS | 1 |
| Pirat, B | 1 |
| Okyay, K | 1 |
| Bal, UA | 1 |
| Uluçam, MZ | 1 |
| Öztuna, D | 1 |
| Müderrisoğlu, H | 1 |
| Zhong, G | 2 |
| Yang, L | 1 |
| Yao, J | 1 |
| Maida, KD | 1 |
| Vieira, S | 1 |
| Gastaldi, AC | 1 |
| Bezerra, VB | 1 |
| De Araujo, JE | 1 |
| de Souza, HC | 1 |
| Barho, C | 1 |
| Hildemann, S | 1 |
| Bijsmans, ES | 1 |
| Doig, M | 1 |
| Syme, HM | 2 |
| Elliott, J | 2 |
| Pelligand, L | 1 |
| Cerezo, C | 1 |
| Ahn, TH | 2 |
| Yang, JY | 5 |
| Ryu, JG | 1 |
| Hyeon, MS | 1 |
| Tak, SJ | 1 |
| Im, SJ | 1 |
| Pyeon, WB | 1 |
| Jae, JG | 1 |
| Han, GR | 1 |
| Im, SW | 1 |
| Lee, MM | 3 |
| Jayanthi, R | 1 |
| Rajan, PB | 1 |
| Shete, MM | 1 |
| Mendes, M | 1 |
| Dubourg, J | 1 |
| Blanchard, A | 1 |
| Bergerot, D | 1 |
| Courand, PY | 1 |
| Forni, V | 1 |
| Lee, G | 1 |
| Muruganathan, A | 1 |
| Mantzouranis, E | 1 |
| Mani, I | 1 |
| Tousoulis, D | 1 |
| Robles, NR | 1 |
| Calvo, C | 5 |
| Sobrino, J | 1 |
| Espinel, E | 1 |
| Esteban, R | 1 |
| Mateos, L | 1 |
| Macias, JF | 1 |
| Mihalj, M | 1 |
| Tadzic, R | 1 |
| Vcev, A | 1 |
| Rucevic, S | 1 |
| Drenjancevic, I | 1 |
| Huang, Y | 2 |
| Wen, G | 1 |
| Ji, Y | 2 |
| Xing, X | 1 |
| Taniyama, Y | 1 |
| Morishita, R | 1 |
| Saiz-Satjes, M | 2 |
| Roca-Cusachs, A | 3 |
| Rubio-Guerra, AF | 1 |
| Garro-Almendaro, AK | 1 |
| Elizalde-Barrera, CI | 1 |
| Suarez-Cuenca, JA | 1 |
| Duran-Salgado, MB | 1 |
| Ernst, ME | 2 |
| Prineas, RJ | 3 |
| Muntner, PM | 1 |
| Black, HR | 12 |
| Yukisada, K | 1 |
| Sibulo, A | 1 |
| Hafeez, K | 1 |
| Lins, R | 2 |
| Haerden, Y | 1 |
| de Vries, C | 1 |
| Ferket, BS | 1 |
| Hunink, MG | 1 |
| Khanji, M | 1 |
| Agarwal, I | 1 |
| Fleischmann, KE | 1 |
| Petersen, SE | 1 |
| Cohen, BJ | 1 |
| de Leeuw, PW | 3 |
| Fagard, R | 1 |
| Kroon, AA | 3 |
| Shi, R | 1 |
| Liu, K | 1 |
| Shi, D | 1 |
| Sunami, E | 1 |
| Nomura, K | 1 |
| Nishiyama, Y | 1 |
| Katayama, Y | 1 |
| Radchenko, G | 1 |
| Thakkar, J | 1 |
| Bennett, A | 1 |
| Hillis, G | 1 |
| Vo, K | 1 |
| Chou, M | 1 |
| Dehbi, HM | 1 |
| Peiris, D | 1 |
| Krum, H | 1 |
| Woodward, M | 1 |
| Hilmer, S | 1 |
| Moes, AD | 1 |
| Hesselink, DA | 1 |
| Zietse, R | 1 |
| Hoorn, EJ | 1 |
| Gilyarevskiy, SR | 1 |
| Kanorskii, SG | 1 |
| Sereda, AF | 1 |
| Skibitsky, VV | 1 |
| Pyhalova, NE | 1 |
| Glezer On Behalf Of Program Participants, MG | 1 |
| Gridina, SA | 1 |
| Sacco, AP | 1 |
| Dell'Avvocata, F | 1 |
| Ramazzina, E | 1 |
| Cheng, KH | 1 |
| Cheng, KC | 1 |
| Cheng, KY | 1 |
| Yang, YH | 1 |
| Lee, CW | 1 |
| Störset, O | 2 |
| Tepel, M | 3 |
| Hopfenmueller, W | 1 |
| Scholze, A | 1 |
| Maier, A | 1 |
| Ferguson, JM | 1 |
| Minas, J | 1 |
| Siapantas, S | 1 |
| Komesaroff, PA | 1 |
| Sudhir, K | 1 |
| Oleĭnikov, VE | 1 |
| Matrosova, IB | 1 |
| Gerasimova, AS | 1 |
| Tomashevskaia, IuA | 1 |
| Smith, DH | 5 |
| Velazquez, EJ | 6 |
| Gupte, J | 4 |
| Staikos, L | 1 |
| Shi, V | 7 |
| Tuomilehto, J | 2 |
| Ibsen, H | 2 |
| Narkiewicz, K | 2 |
| Hedner, T | 2 |
| Aboutabl, ME | 1 |
| Raafat, M | 1 |
| Maklad, YA | 1 |
| Kenawy, SA | 1 |
| El Din, AG | 1 |
| Aumiller, J | 1 |
| Porthan, K | 1 |
| Viitasalo, M | 2 |
| Vaananen, H | 1 |
| Dabek, J | 1 |
| Suonsyrja, T | 4 |
| Hannila-Handelberg, T | 4 |
| Virolainen, J | 2 |
| Nieminen, MS | 2 |
| Toivonen, L | 2 |
| Kontula, K | 4 |
| Oikarinen, L | 2 |
| Flaa, A | 1 |
| Sevre, K | 4 |
| Mundal, HH | 1 |
| McInnes, GT | 14 |
| Coca, A | 3 |
| Girerd, X | 5 |
| Larochelle, P | 10 |
| Macdonald, T | 1 |
| Anthony Schork, M | 1 |
| Viskoper, R | 3 |
| Widimsky, J | 3 |
| Hughes, AD | 6 |
| Stanton, AV | 3 |
| Jabbar, AS | 1 |
| Chapman, N | 1 |
| Martinez-Perez, ME | 1 |
| McG Thom, SA | 3 |
| Waeber, B | 7 |
| Veeraputhiran, M | 1 |
| Sundermeyer, M | 1 |
| Lin, LC | 1 |
| Voon, WC | 1 |
| Lin, MC | 1 |
| Liu, YB | 1 |
| Su, HM | 1 |
| Chang, PY | 1 |
| Chen, WL | 1 |
| Lin, CS | 1 |
| Nakamura, T | 6 |
| Kawagoe, Y | 3 |
| Ueda, Y | 4 |
| Koide, H | 3 |
| Uno, H | 1 |
| Ishikawa, J | 5 |
| Kabutoya, T | 2 |
| Ishikawa, S | 2 |
| Mehlsen, J | 3 |
| Erdine, S | 5 |
| Ro, YM | 2 |
| Tse, HF | 2 |
| Howes, LG | 1 |
| Aguilar-Salinas, CA | 1 |
| Chaves, H | 1 |
| Guindy, R | 1 |
| Chopra, P | 2 |
| Moller, RA | 1 |
| Schou, IM | 1 |
| Jackson, KC | 1 |
| Sheng, X | 1 |
| Nelson, RE | 1 |
| Keskinaslan, A | 2 |
| Brixner, DI | 1 |
| Kékes, E | 1 |
| Fujimoto, A | 11 |
| Fukiyama, K | 5 |
| Azuma, J | 1 |
| Saruta, T | 21 |
| Kloner, RA | 5 |
| Neutel, J | 3 |
| Weiss, R | 1 |
| Weinberger, MH | 3 |
| Thakker, KM | 1 |
| Schwartz, B | 2 |
| Shi, H | 6 |
| Gregg, AM | 1 |
| Pimenta, E | 2 |
| Patel, BV | 1 |
| Leslie, RS | 1 |
| Thiebaud, P | 1 |
| Nichol, MB | 1 |
| Tang, SS | 2 |
| Solomon, H | 1 |
| Honda, D | 1 |
| Foody, JM | 2 |
| Yao, L | 1 |
| Chen, GP | 1 |
| Zheng, LR | 1 |
| Mou, Y | 1 |
| Hu, SJ | 2 |
| Miranda, RD | 1 |
| Rocha, JC | 2 |
| Kohlmann, O | 4 |
| Gomes, MA | 4 |
| Saraiva, JF | 3 |
| Filho, BL | 1 |
| Shiraishi, H | 1 |
| Shirayama, T | 1 |
| Sakamoto, T | 1 |
| Kuroyanagi, A | 1 |
| Matsubara, H | 3 |
| Grassi, D | 1 |
| O'Flaherty, M | 1 |
| Pellizzari, M | 1 |
| Bendersky, M | 1 |
| Rodriguez, P | 1 |
| Turri, D | 1 |
| Forcada, P | 1 |
| Kotliar, C | 1 |
| Feitosa, AD | 1 |
| Ribeiro, JM | 1 |
| Moriguchi, EH | 1 |
| Précoma, DB | 1 |
| Ribeiro, AB | 4 |
| Brandão, AA | 2 |
| Wedel, H | 8 |
| Beevers, G | 2 |
| Collins, R | 2 |
| Kristinsson, A | 1 |
| Nieminen, M | 2 |
| Chen, HS | 1 |
| Wu, TE | 1 |
| Juan, CC | 1 |
| Lin, HD | 1 |
| Pavlicević, I | 1 |
| Kuzmanić, M | 1 |
| Rumboldt, M | 1 |
| Rumboldt, Z | 1 |
| Saito, I | 2 |
| Fujikawa, K | 1 |
| Fukui, T | 4 |
| Morimoto, S | 6 |
| Maki, K | 3 |
| Aota, Y | 1 |
| Sakuma, T | 1 |
| Iwasaka, T | 3 |
| Preti, P | 18 |
| Corradi, L | 9 |
| Santoro, T | 1 |
| Karpov, IuA | 4 |
| Little, WC | 2 |
| Farber, MA | 2 |
| Levy, D | 2 |
| Massie, BM | 3 |
| Nawaz, S | 1 |
| Yang, D | 2 |
| Cao, T | 2 |
| Feng, X | 2 |
| Luo, Z | 2 |
| Yan, Z | 2 |
| Zhu, Z | 2 |
| Ferrari, R | 1 |
| Martín-Ventura, JL | 4 |
| Muñoz-Garcia, B | 1 |
| Blanco-Colio, LM | 3 |
| Martín-Conejero, A | 1 |
| Madrigal-Matute, J | 1 |
| Vega, M | 1 |
| Ortega, L | 1 |
| Serrano, J | 1 |
| Egido, J | 4 |
| Velasquez, E | 1 |
| Staikos-Byrne, L | 2 |
| Chobanian, AV | 2 |
| Gatlin, M | 3 |
| Nagai, T | 1 |
| Igase, M | 1 |
| Kawajiri, M | 1 |
| Kohara, K | 1 |
| Miki, T | 1 |
| Cohn, JN | 1 |
| Wilson, DJ | 1 |
| Houston, M | 1 |
| Grimm, R | 2 |
| Sun, W | 2 |
| Koh, KK | 3 |
| Quon, MJ | 2 |
| Lee, Y | 4 |
| Koh, Y | 2 |
| Shin, EK | 4 |
| Brommer, P | 2 |
| Miele, C | 2 |
| Minamikawa, J | 1 |
| Honjo, S | 1 |
| Hamamoto, Y | 1 |
| Nabe, K | 1 |
| Koshiyama, H | 1 |
| Belousov, IuB | 2 |
| Shestakova, MV | 1 |
| Belousov, DIu | 1 |
| Preston, RA | 4 |
| Weiss, RJ | 2 |
| Bastien, A | 1 |
| Courtney, DL | 1 |
| Kirchner, K | 1 |
| Louis, GT | 4 |
| Vidt, DG | 4 |
| Zhai, LH | 1 |
| Liang, X | 2 |
| Yang, CY | 1 |
| Zhang, RZ | 1 |
| Wang, ZY | 1 |
| Hu, YH | 1 |
| Carter, BL | 1 |
| Neutel, JM | 20 |
| Bestermann, WH | 1 |
| Dyess, EM | 1 |
| Graff, A | 3 |
| Kursun, A | 3 |
| Praskurnichiĭ, EA | 3 |
| Shevchenko, OP | 4 |
| Savel'eva, SA | 3 |
| Fujiwara, T | 1 |
| Ii, Y | 1 |
| Hatsuzawa, J | 1 |
| Murase, H | 1 |
| Murakami, M | 1 |
| Kimura, N | 1 |
| Buch, J | 3 |
| Flack, JM | 10 |
| Satlin, L | 1 |
| Barbier, M | 2 |
| Hilkert, R | 7 |
| Brunel, P | 2 |
| Sinkiewicz, W | 1 |
| Kavoliuniene, A | 1 |
| Miglinas, M | 1 |
| Prak, H | 1 |
| Wernsing, M | 6 |
| Yen, J | 8 |
| Braun, N | 1 |
| Ulmer, HJ | 2 |
| Ansari, A | 2 |
| Handrock, R | 7 |
| Salvetti, A | 1 |
| Akpinar, E | 1 |
| Keeling, L | 1 |
| Weisskopf, M | 1 |
| Weycker, D | 2 |
| Levy, DG | 1 |
| Edelsberg, J | 2 |
| Kartashov, A | 1 |
| Oster, G | 2 |
| Trenkwalder, P | 2 |
| Schaetzl, R | 1 |
| Borbas, E | 1 |
| Ram, CV | 7 |
| Philipp, T | 3 |
| Pospiech, R | 2 |
| Feihl, F | 1 |
| Han, P | 2 |
| Shen, FM | 3 |
| Xie, HH | 3 |
| Chen, YY | 1 |
| Miao, CY | 3 |
| Mehta, JL | 3 |
| Sassard, J | 1 |
| Su, DF | 5 |
| Cohen, DL | 1 |
| Townsend, RR | 2 |
| Mastorantonakis, S | 1 |
| Chang, CL | 2 |
| Preobrazhenskiĭ, DV | 1 |
| Littlejohn, TW | 6 |
| Hollanders, G | 1 |
| Liao, W | 1 |
| Kaneshiro, Y | 3 |
| Ichihara, A | 3 |
| Sakoda, M | 3 |
| Kurauchi-Mito, A | 1 |
| Kinouchi, K | 1 |
| Maruyama, T | 2 |
| Maruyama, N | 3 |
| Matsumoto, K | 2 |
| Parra, D | 2 |
| Rosenstein, R | 1 |
| Strauss, MH | 1 |
| Weinstein, J | 1 |
| Newton, GE | 1 |
| Escobar, C | 5 |
| Barrios, V | 6 |
| Kotsaftis, P | 1 |
| Savopoulos, C | 1 |
| Agapakis, D | 1 |
| Kiparoglou, R | 1 |
| Hatzitolios, AI | 1 |
| Wallace, EL | 1 |
| Lingle, K | 1 |
| Pierce, D | 1 |
| Satko, S | 1 |
| Majul, CR | 4 |
| Olvera, R | 6 |
| Seeber, M | 5 |
| Kobe, M | 4 |
| Guthrie, R | 2 |
| Eckfeldt, JH | 10 |
| Leiendecker-Foster, C | 5 |
| Lindgren, P | 2 |
| Buxton, M | 2 |
| Kahan, T | 3 |
| Jönsson, B | 2 |
| Liu, P | 1 |
| Mao, G | 1 |
| Wang, B | 1 |
| Na, Y | 1 |
| Liu, Z | 2 |
| Fukuda, M | 3 |
| Masuda, T | 2 |
| Ogura, MN | 2 |
| Moriya, T | 2 |
| Tanaka, K | 1 |
| Ishii, A | 1 |
| Yonezawa, R | 1 |
| Noda, C | 2 |
| Izumi, T | 2 |
| Samuel, R | 9 |
| Purkayastha, D | 16 |
| Choi, SM | 2 |
| Seo, MJ | 1 |
| Kang, KK | 1 |
| Ahn, BO | 2 |
| Yoo, M | 1 |
| Hayashi, K | 4 |
| Rienzo, M | 1 |
| Nogueira, PR | 1 |
| Gomes, EP | 1 |
| Moretti, MA | 1 |
| Ferreira, JF | 1 |
| Armagnajian, D | 1 |
| Mansur, Ade P | 1 |
| Ramires, JA | 1 |
| César, LA | 1 |
| Sanford, M | 1 |
| Keam, SJ | 1 |
| Richard Hobbs, FD | 1 |
| Gensini, G | 2 |
| John Mancini, GB | 1 |
| Bauer, B | 2 |
| Genest, J | 2 |
| Feldman, RD | 1 |
| Harvey, P | 3 |
| Jenssen, TG | 2 |
| da Silva, PM | 3 |
| Alicajić, F | 1 |
| Baguet, JP | 2 |
| Valensi, P | 1 |
| Nisse-Durgeat, S | 2 |
| Mallion, JM | 2 |
| Bahl, VK | 1 |
| Jadhav, UM | 1 |
| Thacker, HP | 2 |
| Tkacheva, ON | 1 |
| Barabashkina, AV | 1 |
| Novikova, IM | 1 |
| Runikhina, NK | 1 |
| Chiang, YT | 3 |
| Devabhaktuni, M | 1 |
| Tsutamoto, T | 5 |
| Tanaka, T | 4 |
| Nishiyama, K | 1 |
| Yamaji, M | 1 |
| Kawahara, C | 1 |
| Yamamoto, T | 3 |
| Horie, M | 2 |
| Calderón, A | 3 |
| Burmistrova, LF | 3 |
| Lokhina, TV | 3 |
| Li, YL | 1 |
| Fang, J | 1 |
| Liu, HP | 1 |
| Qin, XH | 1 |
| Xu, XP | 1 |
| Atkins, N | 1 |
| Dicker, P | 1 |
| Stettler, C | 1 |
| Stanton, A | 2 |
| Witt, N | 1 |
| Tapp, R | 1 |
| Chaturvedi, N | 1 |
| Allemann, S | 1 |
| Mayet, J | 4 |
| Hughes, A | 1 |
| Du, J | 1 |
| Fan, YY | 1 |
| Hitomi, H | 1 |
| Kiyomoto, H | 1 |
| Kimura, S | 1 |
| Kong, CZ | 1 |
| Noma, T | 1 |
| Kohno, M | 1 |
| Nishiyama, A | 1 |
| Nakano, D | 1 |
| Faruqui, AA | 1 |
| Fu, L | 1 |
| Mao, ZX | 1 |
| Zheng, TR | 1 |
| Wang, SL | 1 |
| Martínez Martín, FJ | 1 |
| Meredith, PA | 7 |
| Siragy, HM | 3 |
| Rosendorff, C | 1 |
| Dubiel, R | 3 |
| Xu, J | 2 |
| Chavanu, KJ | 1 |
| Changulani, M | 1 |
| Bradbury, M | 1 |
| Zenios, M | 1 |
| Futai, R | 1 |
| Ito, T | 3 |
| Kawanishi, Y | 1 |
| Terasaki, F | 1 |
| Kitaura, Y | 1 |
| Vivencio, B | 1 |
| Hassanein, A | 1 |
| Desai, A | 1 |
| Verma, A | 1 |
| Izzo, J | 2 |
| Rocha, R | 2 |
| Seifu, Y | 2 |
| Solomon, S | 1 |
| Rosenson, RS | 1 |
| Wilkins, BJ | 1 |
| Lewis, JS | 1 |
| Park, JB | 3 |
| Reichek, N | 2 |
| Rocha, RA | 1 |
| Hall, D | 2 |
| Takei, K | 1 |
| Araki, N | 1 |
| Tamura, N | 1 |
| Furuya, D | 1 |
| Yanagisawa, CT | 1 |
| Shimazu, K | 1 |
| Manisty, CH | 1 |
| Zambanini, A | 2 |
| Parker, KH | 1 |
| Davies, JE | 1 |
| Francis, DP | 1 |
| Manisty, C | 1 |
| Tapp, RJ | 1 |
| Ma, S | 1 |
| Karki, S | 4 |
| Matsumoto, S | 2 |
| Shimodozono, M | 1 |
| Miyata, R | 1 |
| Kawahira, K | 1 |
| Sasaki, H | 1 |
| Saiki, A | 2 |
| Endo, K | 2 |
| Ban, N | 2 |
| Yamaguchi, T | 2 |
| Kawana, H | 2 |
| Nagayama, D | 2 |
| Ohhira, M | 1 |
| Oyama, T | 2 |
| Schunkert, H | 1 |
| Macarie, CE | 1 |
| Vintila, MM | 1 |
| Romanova, J | 1 |
| Dobson, JE | 2 |
| Campbell, NR | 1 |
| Miyauchi, K | 5 |
| Kojima, T | 2 |
| Yokoyama, T | 2 |
| Kurata, T | 3 |
| Kawamura, M | 2 |
| Suwa, S | 3 |
| Okazaki, S | 2 |
| Inoue, K | 2 |
| Fujiwara, Y | 2 |
| Sumiyoshi, M | 2 |
| Tanimoto, K | 2 |
| Nakazato, Y | 2 |
| Yamagami, S | 2 |
| Daida, H | 6 |
| Pavithran, P | 1 |
| Prakash, ES | 1 |
| Dutta, TK | 1 |
| Madanmohan, T | 1 |
| Frampton, JE | 1 |
| Scott, LJ | 1 |
| Kodama, S | 1 |
| Inoue, Y | 1 |
| Sumi, S | 1 |
| Tojyo, H | 1 |
| Ando, C | 1 |
| Niimura, H | 1 |
| Tsuchiya, Y | 1 |
| Mihara, H | 1 |
| Yamanouchi, Y | 1 |
| Ohta, M | 2 |
| Sugawara, S | 1 |
| Kuriyama, C | 1 |
| Hoshino, C | 1 |
| Kikuchi, A | 1 |
| Saunders, E | 3 |
| Victor, R | 2 |
| Watson, K | 2 |
| Jamieson, MJ | 2 |
| Khan, MA | 1 |
| Sattar, MA | 2 |
| Abdullah, NA | 1 |
| Abdulla, MH | 1 |
| Salman, IM | 1 |
| Kazi, RN | 1 |
| Swarup, KR | 1 |
| Rathore, HA | 1 |
| Basri, F | 1 |
| Hussain, NM | 1 |
| Dewa, A | 1 |
| Johns, EJ | 5 |
| Andrushchishina, TB | 1 |
| Nilsson, PM | 2 |
| Hilkert, RJ | 1 |
| Papst, CC | 3 |
| Ferber, P | 3 |
| Ohira, M | 1 |
| Garcia, EP | 1 |
| O'Connor, DT | 1 |
| Brophy, VH | 1 |
| Alcaraz, J | 1 |
| Middleton, JP | 2 |
| Norris, KC | 1 |
| Wright, J | 1 |
| Hiremath, L | 2 |
| Contreras, G | 2 |
| van Onzenoort, HA | 2 |
| Verberk, WJ | 2 |
| Kessels, AG | 2 |
| Neef, C | 2 |
| van der Kuy, PH | 2 |
| Deeks, ED | 2 |
| Grothusen, A | 1 |
| Divchev, D | 1 |
| Luchtefeld, M | 1 |
| Schieffer, B | 1 |
| Nelemans, PJ | 1 |
| Ogunyankin, KO | 1 |
| Day, AG | 1 |
| Ma, LY | 1 |
| Liu, MB | 1 |
| Deng, Q | 3 |
| Zhang, YQ | 1 |
| Li, W | 2 |
| Zhu, DL | 2 |
| Lin, SG | 1 |
| Liu, LS | 1 |
| Crikelair, NA | 1 |
| Hidaka, T | 2 |
| Nakagawa, K | 4 |
| Goto, C | 2 |
| Soga, J | 2 |
| Fujii, Y | 2 |
| Hata, T | 3 |
| Idei, N | 2 |
| Fujimura, N | 2 |
| Chayama, K | 3 |
| Kihara, Y | 2 |
| Higashi, Y | 6 |
| Webb, NJ | 2 |
| Lam, C | 2 |
| Loeys, T | 1 |
| Shahinfar, S | 2 |
| Strehlau, J | 2 |
| Wells, TG | 2 |
| Santoro, E | 1 |
| Manas, D | 1 |
| Gleim, GW | 2 |
| Curran, MP | 1 |
| Ke, YN | 1 |
| Ma, SM | 1 |
| Du, M | 1 |
| Chu, WW | 1 |
| Cheng, XM | 1 |
| Masajtis-Zagajewska, A | 1 |
| Majer, J | 1 |
| Nowicki, M | 1 |
| Miyagawa, K | 1 |
| Dohi, Y | 3 |
| Nakazawa, A | 1 |
| Sugiura, T | 1 |
| Yamashita, S | 1 |
| Sato, K | 1 |
| Kimura, G | 4 |
| Heerspink, HL | 1 |
| de Zeeuw, D | 2 |
| Sarafidis, PA | 1 |
| Malamani, G | 1 |
| Hegde, HV | 1 |
| Puri, GD | 1 |
| Fiehn, A | 1 |
| Lopez, AP | 1 |
| Al Khadra, A | 1 |
| Kanematsu, Y | 1 |
| Kanematsu, M | 1 |
| Kurihara, C | 1 |
| Tsou, TL | 1 |
| Nuki, Y | 1 |
| Liang, EI | 1 |
| Makino, H | 2 |
| Hashimoto, T | 1 |
| Howard, SC | 1 |
| Yamada, H | 1 |
| Suga, N | 1 |
| Kimura, Y | 4 |
| Miura, N | 1 |
| Futenma, A | 1 |
| Imai, H | 1 |
| Takahira, N | 1 |
| Matsumoto, T | 1 |
| Kutsuna, T | 1 |
| Hara, M | 1 |
| Aiba, N | 1 |
| Gridneva, EV | 1 |
| Goto, T | 1 |
| Hirata, M | 1 |
| Hussein, MA | 1 |
| Chapman, RH | 1 |
| Benner, JS | 1 |
| Solomon, HA | 1 |
| Joyce, A | 1 |
| Chan, SH | 1 |
| Wu, KL | 1 |
| Kung, PS | 1 |
| Chan, JY | 1 |
| Boutouyrie, P | 1 |
| Achouba, A | 2 |
| Trunet, P | 1 |
| Destro, M | 5 |
| Cagnoni, F | 1 |
| D'Ospina, A | 1 |
| Ricci, AR | 1 |
| Demichele, E | 1 |
| Peros, E | 1 |
| Zaninelli, A | 1 |
| Carrero, JJ | 1 |
| Sonmez, A | 2 |
| Saglam, M | 1 |
| Yaman, H | 2 |
| Yenicesu, M | 2 |
| Eyileten, T | 2 |
| Moreno, JA | 1 |
| Liu, M | 2 |
| Arif, AF | 1 |
| Kadam, GG | 1 |
| Joshi, C | 1 |
| Ke, Y | 1 |
| Zhu, J | 1 |
| Wang, R | 2 |
| Cardenas, P | 1 |
| Malik, M | 1 |
| Deanfield, JE | 1 |
| Sellier, P | 1 |
| Thaulow, E | 7 |
| Bultas, J | 1 |
| Beckerman, B | 1 |
| Sowers, JR | 10 |
| Jialal, I | 1 |
| Egan, BM | 2 |
| Ofili, EO | 4 |
| Deedwania, PC | 1 |
| Lv, Y | 1 |
| Zou, Z | 1 |
| Chen, GM | 1 |
| Jia, HX | 1 |
| Zhong, J | 1 |
| Fang, WW | 1 |
| Ahrens, K | 1 |
| Punzi, H | 3 |
| Waverczak, WF | 3 |
| Takai, S | 1 |
| Jin, D | 1 |
| Sakonjo, H | 1 |
| Miyazaki, M | 1 |
| Xiang, L | 1 |
| Xie, Y | 1 |
| Xie, Q | 1 |
| Zhang, C | 1 |
| Irvin, MR | 2 |
| Kabagambe, EK | 1 |
| Tiwari, HK | 1 |
| Eaddy, M | 1 |
| Lunacsek, OE | 1 |
| Roberts, C | 1 |
| Kean, AJ | 1 |
| Jackson, JH | 1 |
| Weir, M | 2 |
| Kimura, T | 1 |
| Inoki, I | 1 |
| Miyamori, I | 1 |
| Choi, JW | 1 |
| Lee, SJ | 1 |
| Lim, HE | 1 |
| Hermida, RC | 1 |
| Ayala, DE | 1 |
| Fontao, MJ | 1 |
| Mojón, A | 1 |
| Fernández, JR | 1 |
| Lopatin, IuM | 2 |
| Ferrari, I | 1 |
| Kurata, M | 2 |
| Enomoto, D | 1 |
| Jotoku, M | 1 |
| Desilva, VR | 1 |
| Meng, Y | 1 |
| Zhang, Z | 1 |
| Wu, C | 2 |
| Qi, G | 1 |
| Malesker, MA | 1 |
| Hilleman, DE | 6 |
| Le Jeune, S | 1 |
| Pirollo, A | 1 |
| Mourad, C | 1 |
| Gaudouen, Y | 1 |
| Lopez-Sublet, M | 1 |
| Smith, TR | 3 |
| Koren, MJ | 1 |
| Yilmaz, R | 1 |
| Altun, B | 2 |
| Kahraman, S | 1 |
| Ozer, N | 1 |
| Akinci, D | 1 |
| Turgan, C | 1 |
| Dobson, J | 2 |
| Eldridge, S | 2 |
| Cappuccio, FP | 5 |
| Feder, G | 1 |
| Kasanuki, H | 1 |
| Mori, F | 1 |
| Nagashima, M | 1 |
| Yagi, M | 1 |
| Miwa, Y | 1 |
| Tominaga, M | 1 |
| Sasaguri, T | 1 |
| Ueno, M | 1 |
| Hoshino, A | 1 |
| Abrashkina, ED | 1 |
| Shaalali, N | 1 |
| Pakhrova, OA | 1 |
| Shutemova, EA | 1 |
| Nazarova, OA | 1 |
| Bhad, P | 1 |
| Ayalasomayajula, S | 1 |
| Karan, R | 1 |
| Leon, S | 1 |
| Riviere, GJ | 1 |
| Sunkara, G | 1 |
| Jarugula, V | 1 |
| Ferrario, CM | 2 |
| Smith, RD | 2 |
| Stuhr, T | 2 |
| Erdlenbruch, W | 2 |
| Glazer, R | 4 |
| Mir, O | 1 |
| Coriat, R | 1 |
| Ropert, S | 1 |
| Cabanes, L | 1 |
| Blanchet, B | 1 |
| Camps, S | 1 |
| Billemont, B | 1 |
| Knebelmann, B | 1 |
| Goldwasser, F | 1 |
| Leenen, FH | 8 |
| Coletta, E | 4 |
| Ochoa, JE | 1 |
| Ramos, C | 1 |
| Lonati, L | 1 |
| Koganei, H | 1 |
| Wagatsuma, H | 1 |
| Mitsui, A | 1 |
| Ogawa, T | 3 |
| Konda, T | 2 |
| Narumi, H | 3 |
| Takano, H | 2 |
| Shindo, S | 3 |
| Fujita, M | 4 |
| Mizuma, H | 3 |
| Wasem, J | 1 |
| Ariff, BB | 1 |
| Glor, FP | 1 |
| Crowe, L | 1 |
| Xu, XY | 1 |
| Vennart, W | 1 |
| Firmin, DN | 1 |
| Thom, SM | 2 |
| Richy, FF | 1 |
| Wu, F | 1 |
| Jia, S | 1 |
| Li, H | 1 |
| Cao, B | 1 |
| Giles, T | 1 |
| Yoshida, C | 1 |
| Naito, Y | 2 |
| Nakaboh, A | 1 |
| Matsumoto, M | 3 |
| Ohyanagi, M | 1 |
| Otsuka, Y | 1 |
| Koike, M | 1 |
| Fujita, H | 1 |
| Nagao, K | 1 |
| Mikami, S | 1 |
| Maruhashi, T | 1 |
| Noma, K | 2 |
| Liao, JK | 1 |
| Moen, MD | 1 |
| Say, EA | 1 |
| Shields, CL | 1 |
| Bianciotto, C | 1 |
| Shields, JA | 1 |
| Rodriguez-Rosas, H | 2 |
| Peiro-Martinez, I | 1 |
| Soriano-Perera, P | 2 |
| Pedrianes-Martin, P | 2 |
| Comi-Diaz, C | 2 |
| Schweizer, J | 1 |
| Benduhn, H | 1 |
| Kukushkin, SK | 2 |
| Manoshkina, EM | 2 |
| Ozaki, H | 1 |
| Takayasu, K | 1 |
| Akehi, N | 1 |
| Fukui, S | 1 |
| Sakai, A | 1 |
| Kodama, M | 1 |
| Shimonagata, T | 1 |
| Kobayashi, K | 3 |
| Ota, M | 1 |
| Horiguchi, Y | 1 |
| Ebisuno, S | 1 |
| Katsube, Y | 1 |
| Yamazaki, T | 6 |
| Ohtsu, H | 3 |
| Hori, M | 3 |
| Soma, M | 2 |
| Marketou, ME | 1 |
| Kontaraki, JE | 1 |
| Tsakountakis, NA | 1 |
| Zacharis, EA | 1 |
| Kochiadakis, GE | 1 |
| Arfanakis, DA | 1 |
| Parthenakis, F | 1 |
| Chlouverakis, G | 1 |
| Vardas, PE | 1 |
| Yamashita, T | 4 |
| Inoue, H | 2 |
| Okumura, K | 2 |
| Kodama, I | 2 |
| Aizawa, Y | 2 |
| Atarashi, H | 2 |
| Ohe, T | 2 |
| Kamakura, S | 2 |
| Kumagai, K | 2 |
| Kurachi, Y | 2 |
| Koretsune, Y | 2 |
| Saikawa, T | 2 |
| Sakurai, M | 2 |
| Sugi, K | 2 |
| Nakaya, H | 2 |
| Hirai, M | 2 |
| Fukatani, M | 2 |
| Mitamura, H | 2 |
| Watanabe, E | 2 |
| Ogawa, S | 2 |
| Macias-Batista, A | 1 |
| Bălan, H | 1 |
| Belén Ferro-Rey, M | 1 |
| Sicras-Mainar, A | 1 |
| Alvarez-Martín, C | 1 |
| de Salas-Cansado, M | 1 |
| Lazich, I | 1 |
| Dongre, N | 2 |
| Vigdorchik, AV | 1 |
| Matsuno, Y | 1 |
| Minatoguchi, S | 2 |
| Fujiwara, H | 1 |
| Liu, W | 1 |
| Song, SW | 1 |
| Gu, XF | 1 |
| Ma, XJ | 1 |
| Su, FY | 1 |
| Zhang, H | 1 |
| Liu, AJ | 1 |
| Yoshida, M | 2 |
| Tojo, C | 1 |
| Nakano, A | 1 |
| Oshima, Y | 1 |
| Kojima, Y | 1 |
| Noda, K | 2 |
| Sansanayudh, N | 1 |
| Wongwiwatthananukit, S | 1 |
| Veerayuthvilai, S | 1 |
| Le Bailly De Tilleghem, C | 1 |
| Collier, DJ | 3 |
| Caulfield, MJ | 2 |
| Pavia, A | 2 |
| Al-Khadra, A | 2 |
| He, X | 1 |
| Zhang, HL | 1 |
| Yang, JL | 1 |
| Cheng, G | 1 |
| Sun, L | 1 |
| Li, DL | 1 |
| Jiang, HK | 1 |
| Zhao, Q | 1 |
| Yu, XJ | 1 |
| Zang, WJ | 1 |
| Nemati, F | 1 |
| Rahbar-Roshandel, N | 1 |
| Hosseini, F | 1 |
| Mahmoudian, M | 1 |
| Shafiei, M | 1 |
| Fagard, RH | 2 |
| Pierce, WA | 1 |
| Hederman, AD | 1 |
| Gordon, CJ | 1 |
| Ostrenga, AR | 1 |
| Herrington, B | 1 |
| Dursun, H | 1 |
| Albayrak, F | 1 |
| Uyanik, A | 1 |
| Keleş, NO | 1 |
| Beyzagül, P | 1 |
| Bayram, E | 1 |
| Altunkaynak, ZB | 1 |
| Süleyman, H | 1 |
| Okçu, N | 1 |
| Ünal, B | 1 |
| Makris, T | 2 |
| Maeda, T | 1 |
| Oyama, JI | 1 |
| Sasaki, M | 2 |
| Arima, T | 1 |
| Makino, N | 1 |
| Gosse, P | 1 |
| Queré, S | 1 |
| Goette, A | 1 |
| Giles, TD | 1 |
| Kojima, M | 2 |
| Machida, H | 1 |
| Sugiyama, M | 1 |
| Komada, T | 1 |
| Miyazaki, T | 2 |
| Ninomiya, T | 1 |
| Ichikawa, T | 1 |
| Nakatani, K | 1 |
| Zion, AS | 2 |
| Fan, CM | 2 |
| Yan, LR | 2 |
| Tao, YK | 1 |
| Li, YQ | 1 |
| Gao, MM | 1 |
| Wang, YN | 1 |
| Li, CX | 1 |
| Wang, XW | 1 |
| Lu, XL | 1 |
| Pang, HM | 2 |
| Li, YS | 2 |
| Holtkamp, FA | 1 |
| de Graeff, PA | 4 |
| Laverman, GD | 1 |
| Berl, T | 3 |
| Remuzzi, G | 3 |
| Packham, D | 1 |
| Lewis, JB | 6 |
| Parving, HH | 2 |
| Lambers Heerspink, HJ | 1 |
| Bekki, H | 1 |
| Sone, M | 3 |
| Homma, T | 1 |
| Nakata, M | 1 |
| Nohara, M | 1 |
| Fukami, K | 1 |
| Okuda, S | 1 |
| Yamagishi, S | 2 |
| Sato, E | 1 |
| Fujiwara, N | 1 |
| Takeuchi, M | 1 |
| Uusimaa, P | 2 |
| Peuhkurinen, S | 1 |
| Ylitalo, A | 2 |
| Vuolteenaho, O | 2 |
| Risteli, J | 2 |
| Peuhkurinen, K | 2 |
| Natale, F | 2 |
| Cirillo, C | 1 |
| Granato, C | 1 |
| Concilio, C | 1 |
| Siciliano, A | 1 |
| Credendino, M | 1 |
| Aronne, L | 1 |
| Calabrò, P | 1 |
| Russo, MG | 1 |
| Calabrò, R | 2 |
| Sun, NL | 1 |
| Hao, YM | 1 |
| Tu, Y | 1 |
| Curt, V | 1 |
| Tamura, H | 1 |
| Hiro, T | 1 |
| Komiyama, N | 1 |
| Zeng, J | 1 |
| Jia, M | 1 |
| Ran, H | 1 |
| Tang, H | 2 |
| Kataoka, K | 4 |
| Nako, H | 2 |
| Tokutomi, Y | 4 |
| Dong, YF | 3 |
| Yamamoto, E | 4 |
| Yasuda, O | 1 |
| Sucu, M | 1 |
| Yuce, M | 1 |
| Davutoglu, V | 1 |
| Odili, AN | 2 |
| Richart, T | 1 |
| Kamdem, MK | 1 |
| Aderibigbe, A | 1 |
| Sachson, R | 1 |
| Littlejohn, T | 4 |
| Qian, C | 3 |
| Stoakes, KA | 1 |
| Monti, C | 2 |
| Taranikanti, V | 1 |
| Alriyami, M | 1 |
| Banerjee, Y | 1 |
| Ruggenenti, P | 2 |
| Chan, SS | 1 |
| Rainer, TH | 1 |
| Pool, J | 2 |
| Weitzman, R | 1 |
| Townsend, R | 2 |
| Breitung, K | 1 |
| Remmerbach, TW | 1 |
| Bamias, A | 1 |
| Manios, E | 1 |
| Karadimou, A | 1 |
| Michas, F | 1 |
| Lainakis, G | 1 |
| Constantinidis, C | 1 |
| Deliveliotis, C | 1 |
| Zakopoulos, N | 1 |
| Dimopoulos, MA | 1 |
| Davis, EM | 1 |
| Greene, T | 5 |
| Astor, BC | 1 |
| Toto, R | 1 |
| Pogue, VA | 1 |
| Ghiadoni, L | 1 |
| Funder, JW | 1 |
| Haneda, M | 2 |
| Kishimoto, J | 3 |
| Babazono, T | 1 |
| Hsueh, WA | 2 |
| Nesbitt, SD | 2 |
| Littlejohn, TJ | 1 |
| Jones, CJ | 1 |
| Aerts, A | 1 |
| Coen, N | 1 |
| Hermans, C | 1 |
| MacDonald, K | 1 |
| Brié, H | 1 |
| Lee, C | 1 |
| Shen, YM | 1 |
| Vancayzeele, S | 1 |
| Mecum, N | 1 |
| Abraham, I | 1 |
| Geigy, CA | 1 |
| Schweighauser, A | 1 |
| Doherr, M | 1 |
| Francey, T | 1 |
| Hansel, B | 1 |
| Bonnefont-Rousselot, D | 1 |
| Bittar, R | 1 |
| Chantepie, S | 1 |
| Orsoni, A | 1 |
| Bruckert, E | 1 |
| Chapman, MJ | 1 |
| Kontush, A | 1 |
| Takenaka, T | 2 |
| Uchida, K | 1 |
| Kojima, E | 2 |
| Gen, S | 1 |
| Nodaira, Y | 2 |
| Hoshi, H | 1 |
| Kato, N | 1 |
| Takane, H | 2 |
| Ohno, Y | 2 |
| Suzuki, H | 9 |
| Kuga, K | 1 |
| Xu, DZ | 1 |
| Ohtsuka, M | 1 |
| Aonuma, K | 1 |
| Lau, AH | 1 |
| Ohtsuka, K | 1 |
| Abadoglu, O | 1 |
| Epozturk, K | 1 |
| Atayik, E | 1 |
| Kaptanoglu, E | 1 |
| Campbell, P | 1 |
| Singh, KP | 1 |
| Schuchard, G | 1 |
| Jain, K | 1 |
| Andrews, LM | 1 |
| Ma, J | 2 |
| Morita, T | 1 |
| Kaneda, H | 2 |
| Lang, M | 1 |
| Jones, R | 2 |
| Engholm, M | 1 |
| Eftekhari, A | 2 |
| Chwatko, G | 1 |
| Bald, E | 1 |
| Mulvany, MJ | 2 |
| Ho, D | 1 |
| Abarzúa, P | 1 |
| Dhar, SK | 1 |
| Jia, Z | 1 |
| Pannirselvam, M | 1 |
| Morgans, DJ | 1 |
| Malik, FI | 1 |
| Vatner, SF | 1 |
| Shang, W | 1 |
| Yang, CB | 1 |
| Gu, XW | 1 |
| Xu, LP | 3 |
| Fu, ST | 1 |
| Sridharan, K | 1 |
| Israel, M | 1 |
| Wright, RF | 1 |
| Duprez, D | 3 |
| Oliver, S | 1 |
| Jones, J | 1 |
| Leonard, D | 1 |
| Crabbe, A | 1 |
| Delkhah, Y | 1 |
| Toyama, K | 1 |
| Sueta, D | 1 |
| Koibuchi, N | 1 |
| Drummond, W | 1 |
| Ramos, E | 2 |
| Baek, I | 3 |
| Keefe, DL | 4 |
| Bagmanova, NKh | 1 |
| Fediunina, EIu | 1 |
| Karaulova, IuL | 1 |
| Bentley, RT | 1 |
| March, PA | 1 |
| Nasothimiou, EG | 1 |
| Khan, BV | 1 |
| Guthrie, RM | 2 |
| Fukao, K | 1 |
| Hiki, M | 1 |
| Kiyanagi, T | 1 |
| Hirose, K | 2 |
| Kume, A | 1 |
| Ohsaka, H | 1 |
| Matsumori, R | 1 |
| Rajzer, M | 2 |
| Wojciechowska, W | 1 |
| Kawecka-Jaszcz, K | 3 |
| Undas, A | 1 |
| Edwards, C | 1 |
| Kobayashi, N | 2 |
| Tiryaki, O | 1 |
| Usalan, C | 1 |
| Buyukhatipoglu, H | 1 |
| Sayiner, ZA | 1 |
| Kilisli, H | 1 |
| Hasegawa, H | 1 |
| Tho, LM | 1 |
| Bose, N | 1 |
| Robertson, L | 1 |
| Bhattacharya, S | 1 |
| McClue, L | 1 |
| Anderson, L | 1 |
| Fraser, E | 1 |
| Graham, K | 1 |
| Yosef, H | 1 |
| Lumsden, G | 1 |
| Suárez, C | 1 |
| Kageyama, S | 1 |
| Mochizuki, K | 1 |
| Miyakawa, M | 1 |
| Sugawara, M | 2 |
| Nakayama, M | 1 |
| Ohashi, Y | 1 |
| Li, M | 1 |
| Xu, A | 1 |
| Lam, KS | 1 |
| Cheung, BM | 2 |
| Mal'chikova, SV | 1 |
| Tarlovskaia, EI | 1 |
| Avksent'eva, MV | 1 |
| Ishmurzin, GP | 1 |
| Axthelm, C | 1 |
| Sieder, C | 1 |
| Meister, F | 1 |
| Kaiser, E | 1 |
| Christogiannis, LG | 1 |
| Kostapanos, MS | 1 |
| Tellis, CC | 1 |
| Milionis, HJ | 1 |
| Tselepis, AD | 1 |
| Elisaf, MS | 1 |
| Fukui-Soubou, M | 1 |
| Terashima, H | 1 |
| Kawashima, K | 1 |
| Utsunomiya, O | 1 |
| Terada, T | 1 |
| Youn, JC | 1 |
| Jeong, JW | 2 |
| Jung, JW | 1 |
| Yoon, JH | 3 |
| Kwon, J | 2 |
| Cho, SY | 3 |
| Littlejohn Iii, T | 1 |
| Forker, AD | 1 |
| Bhosekar, V | 1 |
| Yadao, A | 1 |
| Cai, J | 1 |
| Cheng, K | 1 |
| Ye, Q | 1 |
| Ming, Y | 1 |
| Zuo, X | 1 |
| Zhou, P | 2 |
| Palatini, P | 8 |
| Brunner, HR | 5 |
| Schork, MA | 4 |
| Majahalme, S | 2 |
| Koylan, N | 3 |
| Ferdinand, K | 3 |
| Wright, R | 1 |
| Hester, RA | 1 |
| Ichimiya, S | 1 |
| Ohno, M | 1 |
| Sone, T | 1 |
| Ikeda, N | 1 |
| Watarai, M | 1 |
| Tsuji, RL | 1 |
| Silva, GV | 1 |
| Berwanger, O | 1 |
| Mion Júnior, D | 1 |
| Karpov, Y | 1 |
| Vigdorchik, A | 1 |
| Sastravaha, K | 1 |
| Yeh, CM | 2 |
| Thomas, M | 1 |
| Troffa, C | 1 |
| Argiolas, G | 1 |
| Patel, S | 2 |
| Pfeiffer, D | 1 |
| Rennie, N | 1 |
| Sun, H | 1 |
| Devi, P | 1 |
| Xavier, D | 1 |
| Sigamani, A | 1 |
| Pandey, S | 1 |
| Thomas, T | 1 |
| Murthy, S | 1 |
| Sharma, K | 1 |
| Bosco, B | 1 |
| Mehta, K | 1 |
| Joshi, S | 1 |
| Singh, G | 1 |
| Ds, C | 1 |
| Nambiar, A | 1 |
| Pais, P | 1 |
| Terashima, M | 1 |
| Nasu, K | 1 |
| Matsuo, H | 1 |
| Habara, M | 1 |
| Tanaka, N | 1 |
| Rathore, S | 1 |
| Kinoshita, Y | 1 |
| Kimura, M | 2 |
| Ehara, M | 1 |
| Suzuki, Y | 3 |
| Perrone, T | 2 |
| Sharma, AM | 1 |
| Ting, N | 1 |
| Judd, E | 1 |
| Jiang, J | 1 |
| Peng, J | 1 |
| Wu, Q | 1 |
| Papademetriou, V | 8 |
| Ong, ST | 2 |
| Miyata, Y | 1 |
| Sasai, K | 1 |
| Totsuka, N | 1 |
| Wu, SY | 1 |
| Li, HM | 1 |
| Lin, YZ | 1 |
| Zhao, RP | 1 |
| Zhao, W | 1 |
| Baudouin, V | 1 |
| Fakhoury, M | 1 |
| Storme, T | 1 |
| Deschênes, G | 1 |
| Jacqz-Aigrain, E | 1 |
| Defeo, H | 1 |
| Vinisko, R | 1 |
| Yoon, HJ | 1 |
| Wu, ZB | 1 |
| Yu, QG | 1 |
| Sun, CX | 1 |
| Tao, CW | 1 |
| Cutler, JA | 7 |
| Brown, CD | 1 |
| Colon, PJ | 2 |
| Fine, LJ | 1 |
| Baimbridge, C | 3 |
| Henriquez, MA | 2 |
| Ilamaythi, E | 1 |
| Preston, R | 1 |
| Seto, T | 1 |
| Okayama, M | 1 |
| Sueyoshi, K | 1 |
| Kikuta, T | 1 |
| Tajiri, Y | 1 |
| Yamato, H | 1 |
| Ikeda, M | 1 |
| Haku, S | 1 |
| Yanagi, M | 1 |
| Okano, Y | 1 |
| Fujikawa, T | 1 |
| Mizushima, S | 1 |
| Tochikubo, O | 2 |
| Kamdem, MM | 1 |
| Shu, EN | 1 |
| Whaley-Connell, A | 1 |
| Gabieva, NN | 1 |
| Bakhshaliev, AB | 1 |
| Grosso, A | 1 |
| Nakagawa, Y | 2 |
| Vaughan, LK | 1 |
| Aissani, B | 1 |
| Shrestha, S | 1 |
| Kishi, T | 1 |
| Sunagawa, K | 2 |
| Hamada, T | 2 |
| Yamada, K | 1 |
| Mizuta, E | 1 |
| Watanabe, A | 1 |
| Osaki, T | 1 |
| Ishida, K | 1 |
| Hasegawa, A | 1 |
| Sakata, S | 1 |
| Mishima, M | 1 |
| Ogino, K | 1 |
| Nosaka, Y | 1 |
| Miyazaki, S | 1 |
| Ohtahara, A | 2 |
| Ninomiya, H | 1 |
| Kato, M | 2 |
| Yoshida, A | 3 |
| Taniguchi, S | 1 |
| Hisatome, I | 2 |
| Daikuhara, H | 1 |
| Kikuchi, F | 1 |
| Ogura, C | 1 |
| Ono, K | 1 |
| Miyamoto, S | 1 |
| Ikai, A | 1 |
| Mitani, S | 1 |
| Sugimoto, N | 1 |
| Toal, CB | 3 |
| Elliott, HL | 7 |
| Soeki, T | 1 |
| Kitani, M | 1 |
| Kusunose, K | 1 |
| Yagi, S | 1 |
| Taketani, Y | 1 |
| Koshiba, K | 1 |
| Wakatsuki, T | 1 |
| Orino, S | 1 |
| Kawano, K | 1 |
| Sata, M | 1 |
| Lee, IT | 1 |
| Wang, CY | 1 |
| Lee, WJ | 1 |
| Sheu, WH | 1 |
| Watada, H | 2 |
| Tanaka, Y | 2 |
| Kawamori, R | 3 |
| Ikeda, S | 3 |
| Kitagawa, A | 2 |
| Ono, Y | 1 |
| Murayama, F | 1 |
| Choi, JB | 1 |
| Hayashi, D | 2 |
| Ulusoy, S | 2 |
| Ozkan, G | 2 |
| Konca, C | 1 |
| Kaynar, K | 2 |
| Sönmez, M | 1 |
| Karahan, SC | 1 |
| Menteşe, A | 1 |
| Bektaş, O | 1 |
| Mar, GY | 1 |
| Huang, SC | 1 |
| Chen, CS | 1 |
| Hsieh, CM | 1 |
| Huang, LC | 1 |
| Wald, DS | 1 |
| Morris, JK | 1 |
| Wald, NJ | 1 |
| Konis, G | 1 |
| Severin, T | 1 |
| Belenkov, IuN | 1 |
| Danilogorskaia, IuA | 1 |
| Zheleznykh, EA | 1 |
| Shchendrygina, AA | 1 |
| Braun-Dullaeus, RC | 1 |
| Shustov, SB | 1 |
| Alvarez, C | 1 |
| Rogelio, GG | 1 |
| Hristoskova, S | 1 |
| Häring, DA | 1 |
| Rich, MW | 1 |
| Toyama, T | 1 |
| Sato, C | 1 |
| Koyama, K | 1 |
| Kasama, S | 1 |
| Murakami, J | 1 |
| Yamashita, E | 1 |
| Kawaguchi, R | 1 |
| Adachi, H | 1 |
| Hoshizaki, H | 1 |
| Oshima, S | 1 |
| Christian Rump, L | 1 |
| Lago Rivero, N | 1 |
| Arias Santos, I | 1 |
| Paradela Carreiro, A | 1 |
| Inoshita, A | 1 |
| Yoshida, Y | 2 |
| Oh, GC | 1 |
| Zo, JH | 1 |
| Vasey, J | 1 |
| Panjabi, S | 2 |
| Quah, R | 1 |
| Proschan, M | 2 |
| Graumlich, JF | 1 |
| Pavlik, V | 1 |
| Gordon, D | 1 |
| Blumenthal, SS | 1 |
| Castaldo, RS | 1 |
| Chen, SL | 1 |
| Liu, XY | 1 |
| Xu, WM | 1 |
| Mei, WY | 1 |
| Chen, XL | 1 |
| Zhang, BK | 1 |
| Ng, CM | 1 |
| Guo, R | 1 |
| Zhou, YN | 1 |
| Jing, NN | 1 |
| Di, W | 1 |
| Afanas'ev, IuI | 1 |
| Storozhenko, SIu | 1 |
| Grigorova, SIu | 1 |
| Schork, A | 2 |
| Banthia, R | 1 |
| Jain, P | 1 |
| Banthia, P | 1 |
| Belludi, S | 1 |
| Jain, AK | 1 |
| Ohashi, M | 1 |
| Peng, F | 1 |
| Lin, L | 1 |
| Huan, Y | 1 |
| Kumagai, N | 1 |
| Onishi, K | 1 |
| Hoshino, K | 1 |
| Nakamori, S | 1 |
| Kitai, T | 1 |
| Yazu, T | 1 |
| Oota, M | 1 |
| Hiraoka, N | 1 |
| Okamoto, S | 1 |
| Yamada, T | 1 |
| Dohi, K | 1 |
| Nakamura, M | 2 |
| Jones, SW | 1 |
| Hsu, H | 2 |
| Webster, D | 1 |
| Katsiki, N | 1 |
| Athyros, VG | 1 |
| Mikhailidis, DP | 1 |
| Hayoz, D | 1 |
| Meyer, MA | 1 |
| Kandra, A | 4 |
| Joly, MP | 1 |
| Mazzolai, L | 1 |
| Haesler, E | 1 |
| Periard, D | 1 |
| Kunitskaia, NA | 1 |
| Andrianova, MA | 1 |
| Delgado-Montero, A | 1 |
| Zamorano, JL | 1 |
| Unlu, M | 2 |
| Turker, T | 1 |
| Sağlam, K | 2 |
| Paneni, F | 1 |
| Passerini, J | 1 |
| Arslan, Z | 2 |
| Akhan, M | 2 |
| Sarlak, H | 2 |
| Murray, AV | 1 |
| Koenig, W | 1 |
| Garcia-Puig, J | 2 |
| Uddin, A | 1 |
| Chatzikyrkou, C | 1 |
| Menne, J | 1 |
| Mizuno, Y | 1 |
| Yamamoto, H | 1 |
| Goto, SN | 1 |
| Ott, C | 1 |
| Schneider, MP | 2 |
| Raff, U | 1 |
| Ritt, M | 1 |
| Striepe, K | 1 |
| Alberici, M | 2 |
| Seyit Ahmet, AY | 1 |
| Naharci, I | 1 |
| Kocak, N | 1 |
| Zhang, JW | 1 |
| Lu, F | 1 |
| Ma, MM | 1 |
| Wang, JQ | 1 |
| Suo, AQ | 1 |
| Bai, YY | 1 |
| Liu, HQ | 1 |
| Koc, B | 1 |
| Buzinec, P | 1 |
| Swindle, JP | 1 |
| Fedacko, J | 1 |
| Jarcuska, P | 1 |
| Sabol, F | 1 |
| Kmec, J | 1 |
| Lopuchovsky, T | 1 |
| Merkovska, L | 1 |
| Jedlickova, L | 1 |
| Janicko, M | 1 |
| Sajty, M | 1 |
| Aoyama, T | 1 |
| Kawai, N | 1 |
| Iwasa, M | 1 |
| Oda, M | 1 |
| Kida, K | 1 |
| Kojima, S | 1 |
| Goto, N | 1 |
| Goto, M | 1 |
| Sugishita, F | 1 |
| Takai, K | 1 |
| Tanaka, R | 1 |
| Hiei, K | 1 |
| Minagawa, T | 1 |
| Yamamoto, N | 1 |
| Watanabe, I | 1 |
| Yasue, T | 1 |
| Kobayashi, H | 2 |
| Bajnok, L | 1 |
| Dollar, A | 1 |
| Brown, C | 1 |
| Putnam, D | 1 |
| McLaughlin, T | 2 |
| Okamoto, L | 1 |
| Arocho, R | 2 |
| Alizade, IG | 1 |
| Karayeva, NT | 1 |
| Gil-Extremera, B | 1 |
| Maldonato, A | 1 |
| Toutouzas, T | 1 |
| Pessina, AC | 3 |
| On, YK | 3 |
| Park, YB | 2 |
| Chen, J | 2 |
| Gu, Y | 2 |
| Lin, F | 2 |
| Yang, H | 2 |
| Zhu, W | 2 |
| Lin, S | 2 |
| Wheeldon, NM | 1 |
| Sohn, DW | 1 |
| Choi, YS | 1 |
| Blezer, E | 1 |
| Nicolay, K | 1 |
| Goldschmeding, R | 1 |
| Koomans, H | 1 |
| Joles, J | 1 |
| Teive, HA | 1 |
| Germiniani, FM | 1 |
| Werneck, LC | 1 |
| von Vigier, RO | 2 |
| Fossali, E | 2 |
| Edefonti, A | 2 |
| Vogt, B | 1 |
| Bianchetti, MG | 3 |
| Wolfram, RM | 1 |
| Kritz, H | 1 |
| Oguogho, A | 1 |
| Sinzinger, H | 1 |
| Ambrosioni, E | 1 |
| Cybulski, J | 1 |
| Ceremuzyński, L | 1 |
| Gokhale, N | 1 |
| Shahani, S | 1 |
| Pawar, D | 1 |
| Caro, JJ | 1 |
| Agodoa, LY | 3 |
| Charleston, J | 2 |
| Cheek, D | 3 |
| Douglas-Baltimore, JG | 1 |
| Gassman, J | 2 |
| Glassock, R | 1 |
| Hebert, L | 2 |
| Lewis, J | 1 |
| Phillips, RA | 3 |
| Toto, RD | 6 |
| Rostand, SG | 1 |
| Leonetti, G | 5 |
| Magnani, B | 1 |
| Rappelli, A | 1 |
| Grossman, E | 1 |
| Ongtengco, I | 1 |
| Morales, D | 1 |
| Sanderson, J | 1 |
| Lu, ZR | 1 |
| Beilin, LJ | 1 |
| Burke, V | 1 |
| Puddey, IB | 1 |
| Tanomsup, S | 1 |
| Dayi, H | 1 |
| Rahardjo, P | 1 |
| Zambahari, DR | 1 |
| Chen, CY | 1 |
| Soenarta, AA | 1 |
| Buranakitjaroen, P | 1 |
| Tan, C | 1 |
| Soon, TK | 1 |
| Wu, DJ | 1 |
| Rinaldi, A | 6 |
| Pasotti, C | 1 |
| Poletti, L | 1 |
| Marasi, G | 2 |
| Voglini, C | 1 |
| Resnick, LM | 1 |
| Lester, MH | 1 |
| Bernadet-Monrozies, P | 1 |
| Rostaing, L | 1 |
| Kamar, N | 1 |
| Durand, D | 1 |
| Mulatero, P | 1 |
| Rabbia, F | 1 |
| Milan, A | 1 |
| Paglieri, C | 1 |
| Morello, F | 1 |
| Chiandussi, L | 1 |
| Veglio, F | 1 |
| Tomonari, H | 2 |
| Tokudome, G | 1 |
| Horiguchi, M | 1 |
| Hayashi, H | 2 |
| Ishikawa, M | 1 |
| Martynov, AI | 1 |
| Ternovoĭ, SK | 1 |
| Sinitsyn, VE | 1 |
| Pustovitova, TS | 1 |
| Gedgafova, SIu | 1 |
| Sharkova, NE | 1 |
| Sermswan, A | 1 |
| Uboldejpracharak, Y | 1 |
| Suthichaiyakul, T | 1 |
| Sukontasarn, A | 1 |
| Buranakitcharoen, P | 1 |
| Yu, GL | 2 |
| Liang, XQ | 1 |
| Zheng, JQ | 1 |
| Davis, BJ | 1 |
| Cao, Z | 1 |
| de Gasparo, M | 1 |
| Kawachi, H | 1 |
| Cooper, ME | 1 |
| Allen, TJ | 1 |
| Diévart, F | 1 |
| Pasquié, JL | 1 |
| Bernaud, C | 5 |
| Grolleau-Raoux, R | 1 |
| Düsing, R | 1 |
| Pepine, CJ | 1 |
| Koren, M | 1 |
| Bittar, N | 1 |
| Thadani, U | 3 |
| Minkwitz, MC | 1 |
| Michelson, EL | 2 |
| Hutchinson, HG | 1 |
| Zervoudaki, A | 1 |
| Economou, E | 1 |
| Pitsavos, C | 1 |
| Aggeli, C | 1 |
| Vasiliadou, K | 1 |
| Toutouza, M | 1 |
| Toutouzas, P | 1 |
| Xie, XM | 1 |
| He, BR | 1 |
| Nilsson, P | 1 |
| Hernborg, A | 1 |
| Håkansson, J | 1 |
| Werkö, L | 1 |
| Berglund, G | 1 |
| Traynor, K | 1 |
| Usami, T | 1 |
| Malamani, GD | 2 |
| Vanasia, A | 2 |
| Levine, CB | 1 |
| Fahrbach, KR | 1 |
| Frame, D | 1 |
| Connelly, JE | 1 |
| Estok, RP | 1 |
| Stone, LR | 1 |
| Ludensky, V | 1 |
| Wepner, U | 1 |
| Hunsicker, LG | 5 |
| Pfeffer, MA | 1 |
| Porush, JG | 1 |
| Rouleau, JL | 1 |
| Drury, PL | 1 |
| Esmatjes, E | 2 |
| Hricik, D | 1 |
| Parikh, CR | 1 |
| Raz, I | 2 |
| Vanhille, P | 1 |
| Wiegmann, TB | 2 |
| Wolfe, BM | 1 |
| Locatelli, F | 2 |
| Goldhaber, SZ | 1 |
| Lewis, EJ | 7 |
| von Renteln-Kruse, W | 1 |
| Kuramoto, K | 1 |
| Ichikawa, S | 1 |
| Hirai, A | 1 |
| Kanada, S | 1 |
| Nakachi, T | 1 |
| St Hillaire, R | 1 |
| Krause, S | 2 |
| Roniker, B | 2 |
| Kuse-Hamilton, J | 1 |
| Odabas, AR | 1 |
| Cetinkaya, R | 1 |
| Selcuk, Y | 1 |
| Keles, S | 1 |
| Bilen, H | 1 |
| Mounier-Véhier, C | 2 |
| Jaboureck, O | 1 |
| Emeriau, JP | 3 |
| Clerson, P | 1 |
| Carre, A | 2 |
| Tsutsui, T | 3 |
| Hayashi, M | 1 |
| Wada, A | 2 |
| Ohnishi, M | 3 |
| Ishii, C | 2 |
| Vetter, W | 2 |
| Lund-Johansen, P | 7 |
| Stranden, E | 1 |
| Helberg, S | 1 |
| Wessel-Aas, T | 1 |
| Risberg, K | 1 |
| Rønnevik, PK | 1 |
| Istad, H | 1 |
| Madsbu, S | 1 |
| Mashima, K | 1 |
| Nakatsu, T | 1 |
| Murakami, T | 1 |
| Kusachi, S | 1 |
| Tominaga, Y | 1 |
| Yamane, S | 1 |
| Uesugi, T | 1 |
| Mayumi, E | 1 |
| Mitsuda, T | 1 |
| Tsuji, T | 1 |
| Slany, J | 1 |
| Zacharieva, S | 2 |
| Shigarminova, R | 2 |
| Nachev, E | 2 |
| Kamenov, Z | 2 |
| Atanassova, I | 2 |
| Orbetzova, M | 2 |
| Stoynev, A | 2 |
| Doncheva, N | 2 |
| Borissova, AM | 2 |
| Park, HC | 1 |
| Xu, ZG | 1 |
| Choi, S | 1 |
| Goo, YS | 1 |
| Kang, SW | 2 |
| Choi, KH | 1 |
| Ha, SK | 1 |
| Han, DS | 2 |
| Marbury, TC | 2 |
| Robinson, TD | 1 |
| Ko, GT | 2 |
| Chan, HC | 2 |
| Maxwell, SR | 1 |
| Rollins, G | 1 |
| Ishina, TI | 1 |
| Marinin, VF | 1 |
| Fomina, IG | 1 |
| Klocek, M | 1 |
| Kes, S | 1 |
| Caglar, N | 1 |
| Canberk, A | 1 |
| Deger, N | 1 |
| Demirtas, M | 1 |
| Dortlemez, H | 1 |
| Kiliccioglu, B | 1 |
| Kozan, O | 1 |
| Ovunc, K | 1 |
| Turkoglu, C | 1 |
| Scott, I | 1 |
| Stowasser, M | 1 |
| Kungys, G | 1 |
| Naujoks, H | 1 |
| Wanner, C | 1 |
| Brunner, H | 1 |
| Hansson, L | 3 |
| Platt, F | 1 |
| Ekman, S | 4 |
| Laragh, JH | 3 |
| Schork, AM | 1 |
| Smith, B | 3 |
| Felmeden, DC | 2 |
| Blann, AD | 5 |
| Spencer, CG | 3 |
| Beevers, DG | 2 |
| Lip, GY | 5 |
| Sapienza, S | 1 |
| Sacco, P | 1 |
| Floyd, K | 1 |
| DiCesare, J | 1 |
| Doan, QD | 1 |
| Hollenberg, NK | 4 |
| Anderson, R | 2 |
| Akhras, KS | 1 |
| Bittman, RM | 1 |
| Krause, SL | 1 |
| Junren, Z | 1 |
| Maxwell, T | 1 |
| Rodriguez, A | 2 |
| Gamboa, R | 2 |
| Gomez-Fernandez, P | 1 |
| Ortega-Gonzalez, G | 1 |
| Matadamas, N | 1 |
| Rodriguez, F | 1 |
| Dass, B | 1 |
| Kyle, C | 1 |
| Clarysse, L | 1 |
| Bryce, A | 1 |
| Moreno-Heredia, E | 1 |
| Germano, G | 1 |
| Gilles, L | 1 |
| Sanderson, JE | 1 |
| Ohtsuka, S | 1 |
| Yamazaki, A | 1 |
| Oyake, Y | 1 |
| Yamaguchi, I | 1 |
| Kirakozov, DA | 1 |
| Blivin, SJ | 1 |
| Pippins, J | 1 |
| Annis, LG | 1 |
| Lyons, F | 1 |
| Leibovitz, E | 1 |
| Beniashvili, M | 1 |
| Freiman, A | 1 |
| Shargorodsky, M | 1 |
| Gavish, D | 1 |
| Noveck, RJ | 1 |
| Rodby, RA | 6 |
| Chiou, CF | 1 |
| Borenstein, J | 1 |
| Smitten, A | 1 |
| Sengupta, N | 1 |
| Palmer, AJ | 4 |
| Roze, S | 3 |
| Annemans, L | 3 |
| Simon, TA | 1 |
| Chen, RS | 1 |
| Spritzer, PM | 1 |
| Vitola, D | 1 |
| Vilodre, LC | 1 |
| Wender, MC | 1 |
| Reis, FM | 1 |
| Ruschel, S | 1 |
| Castro, I | 1 |
| Tham, TC | 1 |
| Herity, N | 1 |
| Guy, S | 1 |
| Silke, B | 1 |
| Gartenmann, AC | 1 |
| Simonetti, GD | 1 |
| Schmidtko, J | 1 |
| Chanard, J | 1 |
| Toupance, O | 1 |
| Lavaud, S | 1 |
| Hurault de Ligny, B | 1 |
| Moulin, B | 1 |
| Pedrinelli, R | 2 |
| Dell'Omo, G | 2 |
| Nuti, M | 1 |
| Menegato, A | 1 |
| Balbarini, A | 1 |
| Mariani, M | 2 |
| Willenbrock, R | 1 |
| Zannad, F | 8 |
| Kleiman, J | 1 |
| Burns, D | 1 |
| Gaudio, C | 1 |
| Ferri, FM | 1 |
| Pannarale, G | 1 |
| Puddu, PE | 1 |
| Vittore, A | 1 |
| Fera, MS | 1 |
| Vizza, CD | 1 |
| Fedele, F | 1 |
| Manzo, BA | 1 |
| Matalka, MS | 1 |
| Ravnan, SL | 1 |
| Delles, C | 1 |
| Klingbeil, AU | 1 |
| Weidinger, G | 2 |
| Civantos, B | 1 |
| Aleixandre, A | 1 |
| Shigematsu, M | 1 |
| Davidovich, IM | 2 |
| Bloshchinskaia, IA | 1 |
| Petrichko, TA | 2 |
| Samarasinghe, YP | 1 |
| Cox, A | 2 |
| Feher, MD | 1 |
| Rahn, KH | 4 |
| Malacco, E | 7 |
| Varì, N | 2 |
| Capuano, V | 1 |
| Spagnuolo, V | 3 |
| Borgnino, C | 1 |
| Lamotte, M | 2 |
| Ritz, E | 3 |
| Oshima, T | 4 |
| Ono, N | 1 |
| Ozono, R | 1 |
| Ishida, M | 1 |
| Miho, N | 2 |
| Nakashima, H | 1 |
| Kambe, M | 2 |
| Gerzanich, V | 1 |
| Ivanova, S | 1 |
| Simard, JM | 1 |
| Shu, H | 1 |
| Jiang, YY | 2 |
| Hoshide, Y | 1 |
| Morinari, M | 1 |
| Erbagci, Z | 1 |
| Franco, RJ | 1 |
| Goldflus, S | 1 |
| McQuitty, M | 1 |
| Ohbayashi, Y | 1 |
| Sakaguchi, T | 1 |
| Kanamori, T | 1 |
| Yokohama, H | 1 |
| Sichiri, G | 1 |
| Hukai, D | 1 |
| Okabayashi, T | 1 |
| Ozawa, T | 1 |
| Ohno, K | 1 |
| Coyle, D | 1 |
| Jukema, JW | 2 |
| van der Hoorn, JW | 1 |
| Neal, DA | 1 |
| Byrne, CD | 1 |
| Alexander, GJ | 1 |
| Lehfeld, LS | 1 |
| Silveira, LA | 1 |
| Ghini, B | 1 |
| Lopes de Faria, JB | 1 |
| Nobre, F | 2 |
| Santonastaso, M | 3 |
| Ambrosia, GB | 1 |
| Caiazza, A | 1 |
| Libhaber, EN | 1 |
| Libhaber, CD | 1 |
| Candy, GP | 1 |
| Kachope, J | 1 |
| Hlatshwayo, NM | 1 |
| Puane, MO | 1 |
| Woodiwiss, AJ | 1 |
| Norton, GR | 1 |
| Essop, MR | 1 |
| Sareli, P | 2 |
| Bilous, RW | 1 |
| Yamagata, K | 1 |
| Ichinose, S | 1 |
| Tagami, M | 1 |
| Kuwajima, I | 1 |
| Yasunari, K | 1 |
| Asada, A | 1 |
| Nwose, O | 1 |
| Jean-Louis, L | 1 |
| Schofield, L | 2 |
| Baron, M | 1 |
| Sevilla, MA | 1 |
| Voces, F | 1 |
| Carrón, R | 1 |
| Guerrero, EI | 1 |
| Ardanaz, N | 1 |
| San Román, L | 1 |
| Arévalo, MA | 1 |
| Montero, MJ | 1 |
| Terpstra, WF | 2 |
| May, JF | 4 |
| Smit, AJ | 7 |
| Graeff, PA | 1 |
| Meyboom-de Jong, B | 5 |
| Crijns, HJ | 2 |
| Lindholm, LH | 2 |
| Laragh, J | 2 |
| Mitchell, L | 2 |
| Plat, F | 3 |
| Epstein, M | 2 |
| Wimett, L | 1 |
| Laustsen, G | 1 |
| Radauceanu, A | 1 |
| Boivin, JM | 2 |
| Fay, R | 2 |
| Bisognano, J | 1 |
| Roberts, CS | 1 |
| Battleman, D | 1 |
| Garza, D | 1 |
| Tang, S | 1 |
| Zelveian, PA | 1 |
| Oshchepkova, EV | 1 |
| Buniatian, MS | 1 |
| Ueshiba, H | 2 |
| Miyachi, Y | 2 |
| Newburger, JW | 1 |
| Daniels, SR | 1 |
| Sanders, SP | 1 |
| Portman, RJ | 2 |
| Hogg, RJ | 1 |
| Saul, JP | 1 |
| Liebisch, B | 1 |
| Matsumoto, A | 1 |
| Nakajima, T | 1 |
| Iwasawa, K | 1 |
| Takenaka, K | 1 |
| Yamashita, H | 1 |
| Sugiura, S | 1 |
| Hirata, Y | 1 |
| Nagai, R | 2 |
| Sica, DA | 2 |
| Gana, TJ | 1 |
| Bohannon, K | 1 |
| Pascual, LG | 1 |
| Albert, KS | 1 |
| Ganafa, AA | 1 |
| Walton, M | 1 |
| Eatman, D | 1 |
| Abukhalaf, IK | 1 |
| Bayorh, MA | 1 |
| Nadar, SK | 1 |
| McCullough, PA | 2 |
| Poirier, L | 8 |
| de Champlain, J | 6 |
| Lamarre-Cliche, M | 4 |
| Bernobich, E | 1 |
| Cosenzi, A | 1 |
| Campa, C | 1 |
| Zennaro, C | 1 |
| Sasso, F | 1 |
| Paoletti, S | 1 |
| Bellini, G | 1 |
| Tomlinson, B | 1 |
| Woo, J | 1 |
| Thomas, GN | 1 |
| Chau, YM | 1 |
| Critchley, JA | 1 |
| Nadar, S | 1 |
| Berk, BC | 1 |
| Bisognano, JD | 1 |
| Dorigatti, F | 2 |
| Ferrara, R | 1 |
| Bertocchi, F | 5 |
| Basile, J | 3 |
| Alekseenko, SA | 1 |
| Timoshin, SS | 1 |
| Avilova, AA | 1 |
| Fleĭshman, MIu | 1 |
| Lamekhova, VG | 1 |
| El Bardai, S | 1 |
| Lyoussi, B | 1 |
| Wibo, M | 2 |
| Morel, N | 1 |
| Verma, S | 1 |
| Strauss, M | 1 |
| Burgess, E | 1 |
| Himmelmann, A | 1 |
| Jackson, G | 2 |
| Ersoy, C | 1 |
| Imamoğlu, S | 1 |
| Budak, F | 1 |
| Tuncel, E | 1 |
| Ertürk, E | 1 |
| Oral, B | 1 |
| Genov, N | 1 |
| Zingilev, D | 1 |
| Adik-Pathak, L | 1 |
| Pathak, L | 1 |
| Kerkar, PG | 1 |
| Manade, VG | 1 |
| Muda, P | 2 |
| Kampus, P | 2 |
| Zilmer, M | 2 |
| Ristimäe, T | 2 |
| Fischer, K | 2 |
| Zilmer, K | 2 |
| Kairane, C | 1 |
| Teesalu, R | 2 |
| Keck, M | 2 |
| Sauerbrey-Wullkopf, N | 3 |
| Regourd, E | 2 |
| Clemens, A | 2 |
| Ogimoto, A | 1 |
| Mizobuchi, T | 1 |
| Shigematsu, Y | 1 |
| Ohtsuka, T | 1 |
| Fukuoka, T | 2 |
| Brock, CM | 1 |
| Pitcock, J | 1 |
| Atkins, RC | 2 |
| Briganti, EM | 1 |
| Braden, G | 1 |
| Champion de Crespigny, PJ | 1 |
| DeFerrari, G | 2 |
| Drury, P | 1 |
| Karas, M | 5 |
| Imbs, JL | 1 |
| Sener, D | 1 |
| Halil, M | 1 |
| Yavuz, BB | 1 |
| Cankurtaran, M | 1 |
| Arioğul, S | 1 |
| Weder, AB | 1 |
| Papavasiliou, M | 1 |
| Efstathiou, S | 1 |
| Manolis, A | 1 |
| Oron-Herman, M | 1 |
| Sela, BA | 1 |
| Rosenthal, T | 2 |
| Medvedev, IN | 3 |
| Gromnatskiĭ, NI | 2 |
| Dunn, JK | 1 |
| Margolis, KL | 3 |
| Heintz, D | 2 |
| Stolt, P | 2 |
| Khder, Y | 2 |
| Umemoto, S | 1 |
| Tanaka, M | 1 |
| Kawahara, S | 1 |
| Kubo, M | 1 |
| Umeji, K | 1 |
| Hashimoto, R | 1 |
| Matsuzaki, M | 1 |
| Kulschewski, A | 1 |
| Nwachuku, C | 5 |
| Barzilay, J | 4 |
| Batuman, V | 2 |
| Farber, M | 1 |
| Henriquez, M | 2 |
| Kopyt, N | 2 |
| Saklayen, M | 2 |
| Stanford, C | 3 |
| Walworth, C | 2 |
| Ward, H | 2 |
| Wiegmann, T | 2 |
| Bilge, AK | 1 |
| Atilgan, D | 1 |
| Tükek, T | 1 |
| Ozcan, M | 1 |
| Ozben, B | 1 |
| Meriç, M | 1 |
| Ganz, M | 1 |
| Mokabberi, R | 1 |
| Winer, N | 1 |
| Folker, A | 1 |
| Murphy, JA | 1 |
| Hung, E | 1 |
| Bard, M | 1 |
| Perkelvald, A | 1 |
| Knauf, H | 2 |
| Pujadas, JO | 2 |
| Calvo-Gomez, C | 2 |
| Abate, G | 2 |
| Blank, R | 3 |
| LaSalle, J | 1 |
| Reeves, R | 1 |
| Maroni, J | 1 |
| Tarasenko, L | 2 |
| Sun, F | 2 |
| Taylor, BP | 1 |
| Quitkin, FM | 1 |
| McGrath, PJ | 1 |
| Stewart, JW | 1 |
| Gomi, T | 2 |
| Shibuya, Y | 2 |
| Matsuo, K | 1 |
| Kosugi, T | 1 |
| Oku, N | 1 |
| Uetake, Y | 1 |
| Kinugasa, S | 1 |
| Furutera, R | 1 |
| LeBlanc, AR | 2 |
| Nadeau, R | 4 |
| Dubé, B | 2 |
| Florescu, M | 1 |
| Junco, G | 1 |
| Dowie, D | 2 |
| Lash, J | 2 |
| Lipkowitz, M | 2 |
| Ojo, A | 2 |
| Sika, M | 2 |
| Wilkening, B | 1 |
| Zaliūnas, R | 2 |
| Brazdzionyte, J | 2 |
| Zabiela, V | 2 |
| Jurkevicius, R | 1 |
| Chung, N | 1 |
| Krimholtz, MJ | 1 |
| Thomas, S | 1 |
| Bilous, R | 2 |
| Iwai, K | 2 |
| Cowie, MR | 1 |
| Wei, L | 1 |
| Tan, J | 1 |
| Bönner, G | 2 |
| Jurkevicus, R | 1 |
| Yasuda, G | 1 |
| Ando, D | 1 |
| Hirawa, N | 1 |
| Glesby, MJ | 1 |
| Aberg, JA | 1 |
| Kendall, MA | 1 |
| Fichtenbaum, CJ | 1 |
| Hafner, R | 1 |
| Hall, S | 1 |
| Grosskopf, N | 1 |
| Zolopa, AR | 1 |
| Gerber, JG | 1 |
| Nishio, S | 1 |
| Kosuge, K | 1 |
| Ohashi, K | 1 |
| Daley, W | 1 |
| Zelenkofske, S | 1 |
| Koo, BK | 1 |
| Heung-Sun, K | 1 |
| Kang, JH | 1 |
| Woong, CJ | 1 |
| Joon-Han, S | 1 |
| Yoon, J | 1 |
| Jin-Ok, J | 1 |
| Ju, AK | 1 |
| Chong-Yun, R | 1 |
| Yeon, KJ | 1 |
| Park, KM | 1 |
| Lim, DK | 1 |
| Park, SY | 1 |
| Pohl, MA | 2 |
| Blumenthal, S | 1 |
| Cordonnier, DJ | 1 |
| De Alvaro, F | 1 |
| Eisner, G | 1 |
| Gilbert, RE | 1 |
| de Faria, JB | 1 |
| Mangili, R | 1 |
| Moore, J | 1 |
| Schernthaner, G | 1 |
| Spitalewitz, S | 1 |
| Tindall, H | 1 |
| Marín-Iranzo, R | 1 |
| de la Sierra-Iserte, A | 1 |
| Oliván-Martínez, J | 1 |
| Redón-Mas, J | 1 |
| Luque-Otero, M | 2 |
| de la Figuera-von Wichman, M | 1 |
| Pontes-García, C | 1 |
| Delgadillo-Duarte, J | 1 |
| Owecki, M | 1 |
| Sowiński, J | 1 |
| Arslanagic, A | 2 |
| Zulic, I | 1 |
| Bajraktarevic, A | 2 |
| Parke, AL | 1 |
| Raftery, EB | 3 |
| Heber, ME | 2 |
| Brigden, G | 2 |
| Al-Khawaja, I | 2 |
| Mroczek, WJ | 6 |
| Burris, JF | 6 |
| Allenby, KS | 3 |
| Davies, J | 3 |
| Jensen, H | 2 |
| Garsdal, P | 2 |
| Velasco, M | 3 |
| Urbina, A | 2 |
| Silva, H | 1 |
| Fonseca, R | 1 |
| Guevara, J | 2 |
| Hernandez, R | 4 |
| Pieretti, OH | 1 |
| Englert, R | 2 |
| Beressem, P | 2 |
| von Manteuffel, E | 2 |
| Stafunsky, S | 1 |
| Kramar, M | 2 |
| Carvajal, AR | 3 |
| Armas-de Hernande, MJ | 1 |
| Guerrero-Pajuelo, J | 3 |
| Armas-Padilla, MC | 3 |
| Barragan, O | 2 |
| Machado-de Alvarado, I | 2 |
| Vandewoude, MF | 1 |
| Lambert, M | 2 |
| Vryens, R | 1 |
| Varrone, J | 2 |
| Osterloh, IH | 1 |
| Arosio, E | 3 |
| De Marchi, S | 1 |
| Prior, M | 1 |
| Rigoni, A | 1 |
| Lechi, A | 3 |
| White, R | 1 |
| Hobbs, FD | 2 |
| Mancini, GB | 1 |
| Böhler, S | 1 |
| Feldman, R | 1 |
| Metcalfe, M | 1 |
| Matsui, Y | 1 |
| Miki, S | 1 |
| Shimizu, T | 2 |
| Yoshimura, A | 1 |
| Inoue, R | 1 |
| Asayama, J | 1 |
| Ishikawa, K | 2 |
| Silfani, TN | 2 |
| Füessl, HS | 1 |
| de Cavanagh, EM | 1 |
| Toblli, JE | 2 |
| Ferder, L | 1 |
| Piotrkowski, B | 1 |
| Stella, I | 1 |
| Inserra, F | 1 |
| Bertoluci, MC | 1 |
| Uebel, D | 1 |
| Schmidt, A | 1 |
| Thomazelli, FC | 1 |
| Oliveira, FR | 1 |
| Schmid, H | 1 |
| Pascual, J | 1 |
| Goldstein, MR | 1 |
| Formica, RN | 1 |
| Friedman, AL | 1 |
| Lorber, MI | 1 |
| Smith, JD | 1 |
| Eisen, T | 1 |
| Bia, MJ | 1 |
| London, G | 1 |
| Schmieder, R | 1 |
| Franklin, S | 2 |
| Germino, FW | 1 |
| Smith, D | 1 |
| Lacy, PS | 1 |
| Cruickshank, K | 1 |
| Thurston, H | 2 |
| O'Rourke, M | 1 |
| Kim, JE | 1 |
| Kwon, JW | 1 |
| Gómez-Garre, D | 1 |
| Granados, R | 1 |
| Sancho, T | 1 |
| Torres, R | 1 |
| Ruano, M | 1 |
| Salgado, N | 1 |
| Feitosa, GS | 1 |
| Dallaverde, E | 1 |
| Sharman, JE | 1 |
| Lim, R | 1 |
| Marwick, TH | 1 |
| Quan, A | 1 |
| Chavanu, K | 1 |
| Merkel, J | 1 |
| Doggrell, SA | 1 |
| Frei, A | 1 |
| Hess, B | 1 |
| Rodriguez-Iturbe, B | 1 |
| Bremer, T | 1 |
| Man, A | 1 |
| Kask, K | 1 |
| Diamond, C | 1 |
| Furberg, C | 1 |
| Dunn, K | 1 |
| Goff, D | 1 |
| Leenen, F | 1 |
| Mohiuddin, S | 1 |
| Ellsworth, A | 2 |
| Golden, J | 1 |
| Colon, P | 1 |
| Crow, R | 1 |
| Sanjuliani, AF | 1 |
| de Abreu, VG | 1 |
| Francischetti, EA | 1 |
| Miller, MB | 1 |
| Black, H | 2 |
| Okada, M | 1 |
| Lash, JP | 1 |
| Gadegbeku, CA | 1 |
| Hall, Y | 2 |
| Jones, K | 1 |
| Kusek, JW | 1 |
| Unruh, M | 1 |
| Baek, SH | 1 |
| Cho, WH | 1 |
| Jeon, HK | 2 |
| Kyun, J | 1 |
| Maciejewski, S | 1 |
| Mohiuddin, SM | 2 |
| Packard, KA | 1 |
| Mooss, AN | 1 |
| Reyes, AP | 2 |
| Aryana, A | 1 |
| Takemitsu, T | 2 |
| Sakamaki, Y | 1 |
| Sasamura, H | 1 |
| Ikegami, N | 1 |
| Sklerov, JH | 1 |
| Levine, B | 1 |
| Ingwersen, KM | 1 |
| Aronica-Pollack, PA | 1 |
| Fowler, D | 1 |
| Nahata, MC | 2 |
| Mahan, JD | 2 |
| Amerena, J | 1 |
| Balazovjech, I | 1 |
| Cassel, G | 1 |
| Herczeg, B | 1 |
| Magometschnigg, D | 1 |
| Martinez, F | 1 |
| Seabra Gomes, R | 1 |
| Nwachuku, CE | 2 |
| Atlas, SA | 1 |
| Cuyjet, AB | 1 |
| Dart, R | 2 |
| Felicetta, JV | 1 |
| Proschan, MA | 1 |
| Coleman, JJ | 1 |
| Kendall, MJ | 1 |
| Ferrera, D | 1 |
| Houston, MC | 1 |
| Petrella, RJ | 1 |
| Lee, E | 1 |
| Ciccarelli, L | 1 |
| Tedesco, MA | 1 |
| Lai, ZF | 1 |
| Katona, E | 1 |
| Juhász, M | 1 |
| Paragh, G | 1 |
| Kumagai, H | 2 |
| Onami, T | 1 |
| Takimoto, C | 1 |
| Iigaya, K | 1 |
| Shoda, J | 1 |
| Nakamoto, H | 3 |
| Reims, HM | 1 |
| Guptha, S | 1 |
| Moan, A | 1 |
| Os, I | 1 |
| da Silva, CA | 1 |
| Coelho, EB | 1 |
| Salgado, HC | 1 |
| Fazan, R | 1 |
| Mohler, ER | 1 |
| Herrington, D | 1 |
| Ouyang, P | 1 |
| Mangano, C | 1 |
| Ritter, S | 1 |
| Davis, P | 2 |
| Vogel, RA | 1 |
| Dart, AM | 1 |
| Gatzka, CD | 1 |
| Kingwell, B | 1 |
| Nieminen, T | 1 |
| Kähönen, M | 1 |
| Kööbi, T | 1 |
| Cameron, JD | 1 |
| Meredith, IT | 1 |
| Hope, SA | 1 |
| Fournier, A | 1 |
| Ushiyama, M | 1 |
| Kuramochi, T | 1 |
| Katayama, S | 1 |
| Kjeldsen, S | 2 |
| Battegay, E | 3 |
| Calvo-Vargas, C | 1 |
| Cieśliński, A | 1 |
| Degaute, JP | 2 |
| Holwerda, NJ | 1 |
| Kobalava, J | 1 |
| Pedersen, OL | 3 |
| Rudyatmoko, FP | 1 |
| Siamopoulos, KC | 1 |
| Vaidyanathan, S | 1 |
| Valencia, J | 1 |
| Kemp, C | 1 |
| Bizot, MN | 1 |
| Denouel, J | 1 |
| Dieterich, HA | 1 |
| Ikeda, J | 1 |
| Yao, K | 1 |
| Matsubara, M | 1 |
| Sadler, LS | 1 |
| Summerson, J | 1 |
| Cosín-Aguilar, J | 1 |
| Hernándiz-Martínez, A | 1 |
| Arístegui-Urrestarazu, R | 1 |
| Masramón-Morell, X | 1 |
| Aguilar-Llopis, A | 1 |
| Rodríguez-Padial, L | 1 |
| Zamorano-Gómez, JL | 1 |
| Tuñon, J | 1 |
| Duran, MC | 1 |
| Vivanco, F | 1 |
| Sawada, K | 1 |
| Lindqvist, M | 1 |
| Melcher, A | 1 |
| Ekholm, M | 1 |
| Hjemdahl, P | 1 |
| Manabe, S | 1 |
| Murakami, K | 1 |
| Cao, G | 1 |
| Casas, G | 1 |
| Mazza, ON | 1 |
| Rasmussen, S | 1 |
| Borrild, N | 1 |
| Vang Andersen, J | 1 |
| Valcárcel, Y | 1 |
| Jiménez, R | 1 |
| Hernández, V | 1 |
| Arístegui, R | 1 |
| Gil, A | 1 |
| Mahmud, A | 2 |
| Feely, J | 2 |
| De la Figuera von Wichmann, M | 1 |
| Llisterri Caro, JL | 1 |
| Park, JY | 1 |
| Kim, KA | 1 |
| Park, PW | 1 |
| Lee, OJ | 1 |
| Ryu, JH | 1 |
| Lee, GH | 1 |
| Ha, MC | 1 |
| Kim, JS | 1 |
| Lee, KR | 1 |
| Iskendeerov, BG | 1 |
| Berenshteĭn, NV | 1 |
| Abramova, GN | 1 |
| Shibaeva, TM | 1 |
| Okuro, M | 1 |
| Takahashi, T | 2 |
| Okaishi, K | 1 |
| Nakahashi, T | 1 |
| Kanda, T | 1 |
| Tobe, S | 1 |
| Vetrovec, G | 1 |
| Patni, R | 1 |
| Bhatia, V | 1 |
| Mittal, A | 1 |
| Parida, AK | 1 |
| Talwar, R | 1 |
| Kaul, U | 1 |
| Pickering, T | 1 |
| Høegholm, A | 3 |
| Nielsen, ES | 1 |
| Refsgaard, J | 1 |
| Yamagishi, T | 1 |
| Shahzad, G | 1 |
| Korsten, MA | 1 |
| Blatt, C | 1 |
| Motwani, P | 1 |
| Vincze, G | 1 |
| Khan, ZM | 1 |
| Negro, R | 1 |
| Hassan, H | 1 |
| Paavonen, KJ | 2 |
| Miettinen, HE | 2 |
| Strandberg, T | 2 |
| Tikkanen, I | 2 |
| Tilvis, R | 3 |
| Pentikäinen, PJ | 3 |
| Hanyu, H | 1 |
| Hirao, K | 1 |
| Shimizu, S | 1 |
| Iwamoto, T | 1 |
| Koizumi, K | 1 |
| Abe, K | 2 |
| Assouline, L | 1 |
| Shimabukuro, M | 1 |
| Tanaka, H | 2 |
| Shimabukuro, T | 1 |
| Tomiyama, H | 3 |
| Yambe, M | 1 |
| Yamada, J | 1 |
| Motobe, K | 1 |
| Koji, Y | 1 |
| Shiina, K | 1 |
| Yamashina, A | 1 |
| Boye, SW | 1 |
| Le Breton, S | 1 |
| Caglar, K | 1 |
| Acikel, C | 1 |
| Oguz, Y | 1 |
| Yavuz, I | 1 |
| Vural, A | 1 |
| Minami, J | 2 |
| Abe, C | 1 |
| Akashiba, A | 1 |
| Kameda, T | 1 |
| Lefkowitz, M | 3 |
| Massie, B | 1 |
| Ofili, E | 1 |
| Palmieri, V | 1 |
| Pini, R | 1 |
| Chiara Cavallini, M | 1 |
| Poldermans, D | 1 |
| Glazes, R | 1 |
| Kargiannis, S | 1 |
| Kaczor, J | 1 |
| Fomina, I | 1 |
| Vaisse, B | 1 |
| Duguay, D | 1 |
| Pesant, S | 1 |
| Deschepper, CF | 1 |
| deBlois, D | 1 |
| Fabia, MJ | 1 |
| Abdilla, N | 1 |
| Oltra, R | 1 |
| Fernandez, C | 1 |
| Sugimoto, DH | 1 |
| Salko, T | 1 |
| Khan, M | 1 |
| Arora, V | 1 |
| Sugaya, T | 1 |
| Tomizawa, H | 1 |
| Fukuda, T | 1 |
| Numao, T | 1 |
| Prabhakar, H | 1 |
| Rath, GP | 1 |
| Arora, R | 1 |
| Cushman, W | 1 |
| Jin, J | 1 |
| Schneider, H | 1 |
| Varughese, GI | 1 |
| Tahrani, AA | 1 |
| Scarpello, JH | 1 |
| Kearney-Schwartz, A | 1 |
| Virion, JM | 1 |
| Stoltz, JF | 1 |
| Drouin, P | 1 |
| Ozkul, Y | 1 |
| Rahman, A | 1 |
| Schaebel, LH | 1 |
| Chen, H | 1 |
| Rasmussen, CV | 1 |
| Aalkjaer, C | 1 |
| Buus, CL | 1 |
| Davies, RA | 1 |
| Ganeshalingham, A | 1 |
| Wong, W | 1 |
| Balligand, JL | 1 |
| Godfraind, T | 2 |
| Tejada, T | 1 |
| Fornoni, A | 1 |
| Lenz, O | 1 |
| Materson, BJ | 2 |
| Zheng, S | 1 |
| Nath, V | 1 |
| Coyne, DW | 1 |
| Payeras, AC | 1 |
| Sladek, K | 1 |
| Lembo, G | 1 |
| Essalihi, R | 1 |
| Zandvliet, ML | 1 |
| Moreau, S | 1 |
| Gilbert, LA | 1 |
| Bouvet, C | 1 |
| Lenoël, C | 1 |
| Nekka, F | 1 |
| McKee, MD | 1 |
| Moreau, P | 1 |
| Christian, R | 1 |
| Wong, ND | 2 |
| Goff, DC | 2 |
| Naya, M | 1 |
| Tsukamoto, T | 1 |
| Katoh, C | 1 |
| Furumoto, T | 1 |
| Fujii, S | 1 |
| Tamaki, N | 1 |
| Tsutsui, H | 1 |
| Ohmura, C | 1 |
| Sakai, K | 1 |
| Uchino, H | 1 |
| Fujitani, Y | 1 |
| Kanazawa, A | 1 |
| Hirose, T | 1 |
| Iuliano, L | 1 |
| Micheletta, F | 1 |
| Natoli, S | 1 |
| Tramaglino, L | 1 |
| Greco, C | 1 |
| Modesti, PA | 1 |
| Sakai, H | 1 |
| Ryuzaki, M | 2 |
| Nishida, E | 2 |
| Nakajima, S | 1 |
| Yoshimoto, M | 2 |
| Itagaki, K | 2 |
| Shintaku, H | 1 |
| Matsuba, S | 1 |
| Ichijo, H | 1 |
| Lipka, LJ | 1 |
| Ruzicka, M | 1 |
| Murray, LS | 1 |
| Gnehm, P | 1 |
| Keller, DI | 1 |
| Nüesch, R | 1 |
| Zeller, A | 1 |
| Kiss, A | 1 |
| Davis, B | 1 |
| Whelton, P | 1 |
| Wu, J | 1 |
| Wang, MP | 1 |
| Liu, DL | 1 |
| Hu, ZJ | 1 |
| Xu, GY | 1 |
| Cosín Aguilar, J | 1 |
| Hernándiz Martínez, A | 1 |
| Masramón Morell, X | 1 |
| Arístegui Urrestarazu, R | 1 |
| Aguilar Llopis, A | 1 |
| Zamorano Gómez, JL | 1 |
| Armada Peláez, B | 1 |
| Rodríguez Padial, L | 1 |
| Lee, JW | 1 |
| Kim, IJ | 1 |
| Chung, WS | 1 |
| Takagi, T | 1 |
| Terai, M | 1 |
| Tatara, Y | 1 |
| Shiota, A | 1 |
| Gohchi, K | 1 |
| Yatomi, Y | 1 |
| Herfert, O | 1 |
| Dykstra, G | 1 |
| Gillen, D | 1 |
| Kagota, S | 1 |
| Tada, Y | 1 |
| Kubota, Y | 1 |
| Nejime, N | 1 |
| Yamaguchi, Y | 1 |
| Kunitomo, M | 1 |
| Shinozuka, K | 1 |
| Pearse, DD | 1 |
| Puzis, L | 1 |
| Bruschi, P | 1 |
| Ahn, JY | 1 |
| Bagchi, A | 1 |
| Kinagi, SB | 1 |
| Sharma, YK | 1 |
| Baliga, VP | 1 |
| Bollmall, C | 1 |
| Harris-Haywood, S | 1 |
| Bareis, CJ | 1 |
| Scott, CL | 1 |
| Simmons, DL | 1 |
| Heidenreich, PA | 1 |
| Lairson, DR | 1 |
| Shlipak, MG | 1 |
| Goldman, L | 1 |
| Shinozaki, S | 1 |
| Matsuda, N | 1 |
| Plosker, GL | 1 |
| Robinson, DM | 1 |
| Nevzorova, VA | 1 |
| Zakharchuk, NV | 1 |
| Plotnikova, IV | 1 |
| Dickson, M | 1 |
| Plauschinat, CA | 1 |
| McKeage, K | 1 |
| Siddiqui, MA | 1 |
| Umasankar, U | 1 |
| Carroll, TJ | 1 |
| Famuboni, A | 1 |
| Patel, MD | 1 |
| Starke, ID | 1 |
| Tsinamdzgvrishvili, B | 1 |
| Trapaidze, D | 1 |
| Loladze, N | 1 |
| Rekhviashvili, A | 1 |
| Allemann, Y | 1 |
| Fraile, B | 1 |
| Rosa, EC | 1 |
| Zanella, MT | 1 |
| Kohlmann, NE | 1 |
| Ferreira, SR | 1 |
| Plavnik, FL | 1 |
| Pepin, S | 1 |
| Pitha-Rowe, I | 1 |
| de la Figuera, M | 2 |
| Honorato, J | 2 |
| Llisterri, JL | 2 |
| Nakayama, K | 1 |
| Daimon, M | 1 |
| Ge, CJ | 1 |
| Lu, SZ | 1 |
| Chen, YD | 1 |
| Wu, XF | 1 |
| Sugahara-Kobayashi, M | 1 |
| Esnault, VL | 1 |
| Brown, EA | 1 |
| Apetrei, E | 1 |
| Bagon, J | 1 |
| DeChatel, R | 1 |
| Holdaas, H | 2 |
| Krcmery, S | 1 |
| Kara-Perz, H | 1 |
| Kosicka, T | 1 |
| Perz, S | 1 |
| Hirooka, Y | 1 |
| Sagara, Y | 1 |
| Ito, K | 1 |
| Smith, A | 1 |
| DeAngelis, L | 1 |
| Mirenda, V | 1 |
| Botha, J | 1 |
| Busch, M | 1 |
| Franke, S | 1 |
| Wolf, G | 1 |
| Rohde, RD | 1 |
| Stein, G | 1 |
| Takeishi, Y | 1 |
| Hirai, T | 1 |
| Lee, JD | 1 |
| Uzui, H | 1 |
| Senda, S | 1 |
| Miwa, K | 1 |
| Hiraoka, Y | 1 |
| Kinugawa, T | 2 |
| Hosokawa, R | 1 |
| Makarova, SV | 1 |
| Zhukova, VA | 1 |
| Ferri, C | 1 |
| Croce, G | 1 |
| Desideri, G | 1 |
| Rodrigues, SF | 1 |
| Dossantos, RA | 1 |
| de Oliveira, MA | 1 |
| Rastelli, VM | 1 |
| Nucci, Gd | 1 |
| Tostes, Rde C | 1 |
| Nigro, D | 1 |
| Carvalho, MH | 1 |
| Fortes, ZB | 1 |
| Brachmann, J | 1 |
| Mahla, G | 1 |
| Donner, K | 1 |
| Rohatagi, S | 1 |
| Carrothers, TJ | 1 |
| Kshirsagar, S | 1 |
| Khariton, T | 1 |
| Salazar, D | 1 |
| Picado, MJ | 1 |
| Aguilera, MT | 1 |
| Sánchez, M | 1 |
| Lluch, MM | 1 |
| Urbano-Márquez, A | 1 |
| Kanno, Y | 4 |
| Okada, H | 3 |
| Omvik, P | 11 |
| Herland, OB | 5 |
| Eide, I | 6 |
| Midha, R | 5 |
| Turner, RR | 6 |
| Provencher, P | 2 |
| Hosie, J | 3 |
| Bremner, AD | 3 |
| Fell, PJ | 3 |
| James, GV | 1 |
| Saul, PA | 3 |
| Taylor, SH | 4 |
| Abdul Sattar, M | 1 |
| Ayaori, M | 1 |
| Suzukawa, M | 1 |
| Hosoai, H | 1 |
| Nishiwaki, M | 1 |
| Dickerson, JE | 1 |
| Nayler, WG | 4 |
| Agabiti-Rosei, E | 3 |
| Muiesan, ML | 1 |
| Rizzoni, D | 1 |
| Zulli, R | 1 |
| Calebich, S | 1 |
| Castellano, M | 3 |
| Cavaliere, G | 1 |
| Nordio, G | 1 |
| Pasini, F | 1 |
| Zuccato, F | 1 |
| Lombardo, D | 1 |
| Raimondi, F | 1 |
| Bignotti, M | 1 |
| Grandi, AM | 1 |
| Gaudio, G | 1 |
| Guasti, L | 1 |
| Venco, A | 1 |
| Prisant, LM | 4 |
| Adegbile, IA | 1 |
| Alemayehu, D | 1 |
| Lefkowitz, MP | 1 |
| Carr, AA | 1 |
| Ajayi, AA | 2 |
| Akintomide, AO | 1 |
| Sennesael, J | 1 |
| Lamote, J | 1 |
| Violet, I | 1 |
| Tasse, S | 1 |
| Verbeelen, D | 1 |
| Megnien, JL | 1 |
| Levenson, J | 1 |
| Del-Pino, M | 1 |
| Villa, G | 1 |
| Bazil, MK | 1 |
| Webb, RL | 1 |
| Saxenhofer, H | 2 |
| Heynen, G | 3 |
| Anlauf, M | 1 |
| Minuz, P | 2 |
| Pancera, P | 2 |
| Ribul, M | 2 |
| Priante, F | 1 |
| Degan, M | 1 |
| Campedelli, A | 1 |
| Detry, JM | 2 |
| Block, P | 1 |
| De Backer, G | 1 |
| Iimura, O | 1 |
| Imiya, M | 1 |
| Wiinberg, N | 2 |
| Rasmussen, E | 2 |
| Nielsen, PE | 2 |
| Salerno, L | 1 |
| Pepe, S | 1 |
| Gullotti, D | 1 |
| Iacò, V | 1 |
| Why, HJ | 2 |
| Patel, VB | 4 |
| Richardson, PJ | 4 |
| Preedy, VR | 4 |
| Hermans, L | 1 |
| Deblander, A | 1 |
| De Keyser, P | 1 |
| Scheys, I | 1 |
| Lesaffre, E | 1 |
| Westelinck, KJ | 1 |
| van der Schaaf, MR | 1 |
| Hené, RJ | 1 |
| Floor, M | 1 |
| Blankestijn, PJ | 2 |
| Koomans, HA | 3 |
| Santarelli, P | 1 |
| Biscione, F | 1 |
| Natale, A | 1 |
| Manzoli, A | 1 |
| Lanza, GA | 1 |
| Lyons, D | 4 |
| Webster, J | 5 |
| Benjamin, N | 2 |
| Harano, Y | 1 |
| Kageyama, A | 1 |
| Hirose, J | 1 |
| Asakura, Y | 1 |
| Yokota, T | 1 |
| Ikebuchi, M | 1 |
| Suzuki, M | 3 |
| Omae, T | 1 |
| Sempere, AP | 1 |
| Duarte, J | 1 |
| Cabezas, C | 1 |
| Coria, F | 1 |
| Clavería, LE | 1 |
| Ranieri, G | 1 |
| Andriani, A | 1 |
| Lamontanara, G | 1 |
| De Cesaris, R | 2 |
| Ahaneku, JE | 9 |
| Taylor, GO | 4 |
| Agbedana, EO | 4 |
| Walker, O | 5 |
| Salako, LA | 5 |
| Ruvolo, G | 1 |
| Greco, E | 1 |
| Speziale, G | 1 |
| Di Natale, M | 1 |
| Marino, B | 1 |
| Perticone, F | 1 |
| Pugliese, F | 1 |
| Ceravolo, R | 1 |
| Mattioli, PL | 1 |
| Ames, RP | 2 |
| Applegate, WB | 3 |
| Davidov, ME | 2 |
| Ishii, M | 1 |
| Iimura, I | 1 |
| Sowunmi, A | 4 |
| Mengden, T | 1 |
| Binswanger, B | 1 |
| Spühler, T | 1 |
| Zanetti-Elshater, F | 1 |
| Pingitore, R | 1 |
| Beretta-Piccoli, C | 2 |
| Riesen, W | 2 |
| Heinen, G | 2 |
| Rodríguez, N | 1 |
| Domínguez, B | 1 |
| Adolphe, AB | 1 |
| Vlachakis, ND | 2 |
| Rofman, BA | 2 |
| Brescia, D | 1 |
| Zellner, SR | 1 |
| Lorimer, AR | 4 |
| Anderson, JA | 1 |
| Laher, MS | 1 |
| Lazarus, JH | 1 |
| Sanghera, S | 1 |
| Hwang, YS | 1 |
| Yen, HW | 1 |
| Pertusa, S | 1 |
| Marco, MD | 1 |
| Quirce, F | 1 |
| Bueno, JM | 1 |
| Letizia, C | 1 |
| De Ciocchis, A | 1 |
| Cerci, S | 1 |
| Coassin, S | 1 |
| Fisher, H | 1 |
| Tarsitani, P | 1 |
| Scavo, D | 1 |
| Markandu, ND | 4 |
| Singer, DR | 3 |
| MacGregor, GA | 5 |
| Mariani, L | 1 |
| Cosentino, N | 1 |
| Torrisi, G | 1 |
| Arita, M | 1 |
| Horinaka, S | 1 |
| Frohlich, ED | 2 |
| Panuccio, D | 1 |
| Romani, A | 1 |
| Trabatti, MR | 1 |
| Romanelli, R | 1 |
| Nardi, R | 1 |
| Mehmel, HC | 1 |
| Görne, RC | 1 |
| Khokhani, RC | 1 |
| Karnik, ND | 1 |
| Bajan, KD | 1 |
| Ailiani, R | 1 |
| Waknis, SS | 1 |
| Joseph, TA | 1 |
| Chawla, KP | 1 |
| Licata, G | 1 |
| Scaglione, R | 1 |
| Ganguzza, A | 1 |
| Parrinello, G | 1 |
| Costa, R | 1 |
| Merlino, G | 1 |
| Corrao, S | 1 |
| Amato, P | 1 |
| Yasui, K | 1 |
| Tomizawa, T | 1 |
| Sugishita, Y | 1 |
| Abernethy, DR | 4 |
| Burges, R | 1 |
| Moisey, D | 1 |
| Vetrovec, GW | 2 |
| White, W | 4 |
| Frishman, WH | 4 |
| Brobyn, R | 3 |
| Brown, RD | 3 |
| Johnson, BF | 3 |
| Reeves, RL | 3 |
| Wombolt, DG | 3 |
| Maclean, D | 3 |
| Spritzer, N | 1 |
| Neaton, JD | 1 |
| Stamler, J | 1 |
| Grandits, GA | 2 |
| Elmer, PJ | 3 |
| Schoenberger, JA | 1 |
| McDonald, R | 2 |
| de Courten, M | 1 |
| Ferrari, P | 1 |
| Schneider, M | 1 |
| Böhlen, L | 1 |
| Shaw, S | 1 |
| Weidmann, P | 2 |
| Donnelly, R | 1 |
| Miller, SH | 1 |
| Howie, CA | 1 |
| Staessen, J | 1 |
| Amery, A | 1 |
| Crane, M | 1 |
| Carney, C | 1 |
| Gaffney, M | 4 |
| Taylor, C | 1 |
| Cusenza, E | 1 |
| James, IG | 2 |
| Yamanaka, K | 2 |
| Nabata, H | 1 |
| Tachibana, M | 1 |
| Lopez, LM | 2 |
| Gradman, AH | 1 |
| Nash, DT | 1 |
| O'Connell, MT | 1 |
| Garland, WT | 1 |
| Pickering, BI | 1 |
| Beer, NA | 1 |
| Jakubowicz, DJ | 1 |
| Beer, RM | 1 |
| Nestler, JE | 1 |
| Fowler, G | 3 |
| Witte, K | 6 |
| Crichton, WA | 2 |
| Jeffers, TA | 4 |
| Wickham, EA | 2 |
| Sanghera, SS | 2 |
| Cornish, R | 2 |
| Petrie, JC | 5 |
| Grandinetti, O | 1 |
| Feraco, E | 1 |
| Haria, M | 1 |
| Wagstaff, AJ | 1 |
| Ding, YA | 1 |
| Chang, SM | 1 |
| Chou, TC | 1 |
| del Río Fernández, MC | 1 |
| Plagaro Cordero, ME | 1 |
| de Frutos Arribas, JF | 1 |
| del Pozo Román, T | 1 |
| Martín Escudero, JC | 1 |
| Piccirillo, G | 1 |
| Fimognari, FL | 1 |
| Santagada, E | 1 |
| Munizzi, MR | 1 |
| Viola, E | 1 |
| Monteforte, G | 1 |
| Bucca, C | 1 |
| Durante, M | 1 |
| Di Gioacchino, C | 1 |
| Tarantini, S | 1 |
| Lo Verde, A | 1 |
| Cacciafesta, M | 1 |
| Marigliano, V | 1 |
| Velussi, M | 1 |
| Brocco, E | 1 |
| Frigato, F | 1 |
| Zolli, M | 1 |
| Muollo, B | 1 |
| Maioli, M | 1 |
| Carraro, A | 1 |
| Tonolo, G | 1 |
| Fresu, P | 1 |
| Cernigoi, AM | 1 |
| Fioretto, P | 1 |
| Nosadini, R | 1 |
| Paice, AG | 1 |
| Cheng, CP | 1 |
| Elvelin, L | 1 |
| Nordlander, M | 1 |
| Nazzaro, P | 1 |
| Manzari, M | 1 |
| Merlo, M | 1 |
| Triggiani, R | 1 |
| Scarano, AM | 1 |
| Lasciarrea, A | 1 |
| Pirrelli, A | 4 |
| DiBona, GF | 2 |
| Wein, M | 2 |
| Agbedana, OE | 1 |
| Taylor, OG | 1 |
| Lewis, CE | 2 |
| Grandits, A | 1 |
| Flack, J | 1 |
| Skoularigis, J | 1 |
| Strugo, V | 1 |
| Weinberg, J | 1 |
| Chopamba, A | 1 |
| Chautsane, Z | 1 |
| Lee, A | 1 |
| Reddy, K | 1 |
| McMahon, FG | 1 |
| Kupiec, JW | 1 |
| Antonios, TF | 2 |
| Sagnella, GA | 2 |
| Ritter, JM | 1 |
| Brett, SE | 1 |
| Woods, JD | 1 |
| Stratton, PD | 1 |
| Barrow, SE | 1 |
| Zicha, J | 1 |
| Bennett, MA | 1 |
| Hillier, C | 1 |
| Linde, T | 1 |
| Sandhagen, B | 1 |
| Hägg, A | 1 |
| Mörlin, C | 1 |
| Danielson, BG | 1 |
| Monkman, SC | 1 |
| Ellis, JS | 1 |
| Cholerton, S | 1 |
| Thomason, JM | 1 |
| Seymour, RA | 1 |
| Idle, JR | 1 |
| Beltman, FW | 2 |
| Heesen, WF | 2 |
| Kok, RH | 1 |
| Havinga, TK | 3 |
| Schuurman, FH | 3 |
| van der Veur, E | 3 |
| Lie, KI | 2 |
| van Jaarsveld, BC | 1 |
| Derkx, FH | 1 |
| Krijnen, P | 1 |
| Pieterman, H | 1 |
| Man in't Veld, AJ | 1 |
| Woittiez, AJ | 1 |
| Dees, A | 1 |
| Postma, CT | 1 |
| Schalekamp, MA | 1 |
| Pesavento, TE | 1 |
| Jones, PA | 1 |
| Julian, BA | 1 |
| Curtis, JJ | 1 |
| Cicco, G | 2 |
| Dolce, E | 1 |
| Gigante, G | 1 |
| Kokot, F | 2 |
| Witkowicz, J | 1 |
| Kokot, M | 2 |
| Rychlik, G | 1 |
| Raszewska, J | 1 |
| Corea, L | 2 |
| Cardoni, O | 2 |
| Innocenti, P | 2 |
| Porcellati, C | 2 |
| Provvidenza, M | 2 |
| Meilenbrock, S | 1 |
| Sullivan, J | 1 |
| Bodin, F | 1 |
| Lau, CP | 1 |
| Mattana, J | 1 |
| Sankaran, RT | 1 |
| Singhal, PC | 1 |
| Pirante, F | 1 |
| Ikenaga, H | 1 |
| Ishii, N | 1 |
| Ibrahim, MM | 1 |
| el-Boghdadly, B | 1 |
| Zaghloul, SS | 1 |
| Alli, C | 2 |
| Lombardo, M | 2 |
| Zanni, D | 2 |
| Agrati, AM | 1 |
| Cassani, M | 1 |
| Granata, S | 1 |
| Wohler, D | 1 |
| Le Bloch, Y | 1 |
| Lefebvre, J | 2 |
| Archambault, F | 2 |
| Cléroux, J | 2 |
| Boileau, G | 2 |
| Oliván, J | 1 |
| Moreno, R | 1 |
| Hoyos, M | 1 |
| Pizarro, JL | 1 |
| Justo, E | 1 |
| Pérez Cano, R | 1 |
| McDonald, RH | 1 |
| Svendsen, K | 1 |
| Liebson, PR | 1 |
| Iwatsubo, H | 1 |
| Sakai, T | 1 |
| Kumamoto, K | 1 |
| Morita, R | 1 |
| Spratt, KA | 1 |
| Siddiq, T | 1 |
| Sherwood, R | 1 |
| Gorchein, A | 1 |
| Allan, JJ | 1 |
| van Zwieten, PA | 1 |
| Bartel, PR | 1 |
| Loock, M | 1 |
| Becker, P | 1 |
| Robinson, E | 1 |
| van der Meyden, C | 1 |
| Rossouw, S | 1 |
| Kountz, DS | 1 |
| Hrnciar, J | 1 |
| Hrnciarová, M | 1 |
| Jakubíková, K | 1 |
| Viskoper, RJ | 1 |
| Bernink, PJ | 1 |
| Schelling, A | 1 |
| Kantola, IM | 1 |
| Wilkins, MR | 1 |
| Kobrin, I | 3 |
| Wolfer, J | 1 |
| Grahn, BH | 1 |
| Arrington, K | 1 |
| Lusardi, P | 1 |
| Motolese, M | 1 |
| Yajnik, VH | 1 |
| Vatsaraj, DJ | 1 |
| Acharya, HK | 1 |
| Yajnik, NV | 1 |
| Woittiez, A | 1 |
| Charlon, V | 1 |
| Lindberg, E | 1 |
| Pordy, R | 1 |
| Srinivasan, PS | 1 |
| Hakim, ZS | 1 |
| Santani, DD | 1 |
| Goyal, RK | 1 |
| Broccolino, M | 1 |
| Ferrari, S | 1 |
| Montemurro, L | 1 |
| Zaini, G | 1 |
| Cosmi, F | 1 |
| Timio, M | 1 |
| Bentivoglio, M | 1 |
| Wilson, TW | 2 |
| Bolli, P | 1 |
| Myers, M | 1 |
| Handa, SP | 1 |
| Tanner, J | 1 |
| Witkowska, M | 2 |
| Tracz, W | 1 |
| Kubler, G | 1 |
| Negrusz-Kawecka, M | 1 |
| Hlawaty, M | 1 |
| Olszowska, M | 1 |
| Salamon, P | 1 |
| Carney, S | 1 |
| Horwitz, LD | 1 |
| Weinberger, HD | 1 |
| Clegg, L | 1 |
| Videbaek, LM | 1 |
| Jacobsen, IA | 1 |
| Spring, A | 1 |
| Kosmala, W | 1 |
| Jołda-Mydłowska, B | 1 |
| Zou, Y | 1 |
| Kudoh, S | 1 |
| Shiojima, I | 1 |
| Mizuno, T | 1 |
| Hiroi, Y | 1 |
| Yazaki, Y | 1 |
| Mitsuhashi, H | 1 |
| Kinouchi, T | 2 |
| Doba, N | 2 |
| Herzig, S | 1 |
| Khattak, S | 2 |
| Rogan, JW | 2 |
| Saunders, EF | 1 |
| Theis, JG | 1 |
| Arbus, GS | 2 |
| Koren, G | 2 |
| Sasaguri, M | 1 |
| Matsumoto, N | 1 |
| Koga, M | 1 |
| Kinoshita, A | 1 |
| Ideishi, M | 1 |
| Stepien, O | 1 |
| Iouzalen, L | 1 |
| Herembert, T | 1 |
| Marche, P | 1 |
| Stokes, GS | 1 |
| Monaghan, JC | 1 |
| Berman, K | 1 |
| Ryan, M | 1 |
| Campbell, DJ | 1 |
| Pahor, M | 4 |
| Psaty, BM | 1 |
| Witkowicz-Kulhawik, J | 1 |
| Watanabe, M | 1 |
| Kaneda, T | 1 |
| Fujimoto, Y | 1 |
| Shigemasa, C | 1 |
| Watts, RW | 1 |
| Wing, LM | 1 |
| Lacolley, P | 1 |
| Poitevin, P | 1 |
| Koen, R | 1 |
| Levy, BI | 1 |
| Tatti, P | 2 |
| Byington, RP | 1 |
| Di Mauro, P | 1 |
| Guarisco, R | 1 |
| Strollo, G | 1 |
| Strollo, F | 1 |
| Califf, RM | 1 |
| Granger, CB | 1 |
| Levenstein, M | 1 |
| Schnecko, A | 2 |
| Voll, C | 2 |
| Schmidt, T | 2 |
| Lemmer, B | 4 |
| Lequeuche, B | 1 |
| Hotton, JM | 1 |
| Charpentier, JC | 1 |
| Jewell, D | 1 |
| Reed, CV | 1 |
| Yokota, S | 1 |
| Ohara, N | 1 |
| Adachi, T | 1 |
| Narita, H | 1 |
| Isaksson, H | 2 |
| Brodin, U | 1 |
| Schwan, A | 2 |
| Ohman, KP | 2 |
| Rosbotham, JL | 1 |
| Johnson, A | 2 |
| Haque, KN | 1 |
| Holden, CA | 1 |
| Zamorski, MA | 1 |
| Sasaki, S | 4 |
| Nakano, Y | 1 |
| Matsuura, H | 3 |
| Kajiyama, G | 2 |
| Martina, B | 2 |
| Weinbacher, M | 2 |
| Drewe, J | 1 |
| Gasser, P | 1 |
| Rothman, MT | 1 |
| Pfammatter, JP | 1 |
| Clericetti-Affolter, C | 1 |
| Truttmann, AC | 1 |
| Busch, K | 1 |
| Laux-End, R | 1 |
| Nguyen, P | 2 |
| Cartier, P | 2 |
| Wistaff, R | 3 |
| Barnes, CC | 1 |
| Mann, J | 3 |
| Hall, WD | 4 |
| Reed, JW | 1 |
| Preisser, J | 1 |
| Venkat-Raman, G | 1 |
| Feehally, J | 1 |
| Griffin, P | 1 |
| Moore, RJ | 1 |
| Olubodun, JO | 1 |
| Wilkinson, R | 2 |
| Sharifi, AM | 1 |
| Li, JS | 1 |
| Endemann, D | 1 |
| Schiffrin, EL | 2 |
| Ren, D | 1 |
| Schrama, YC | 1 |
| Gong, L | 1 |
| Guo, J | 1 |
| Ye, X | 1 |
| Zhang, G | 1 |
| Phillips, BB | 1 |
| Muller, BA | 1 |
| Beltman, F | 1 |
| Heesen, W | 1 |
| Smit, A | 1 |
| May, J | 1 |
| de Graeff, P | 1 |
| Havinga, T | 1 |
| Schuurman, F | 1 |
| Lie, K | 1 |
| Testa, MA | 1 |
| Simonson, DC | 1 |
| Krafcik, MB | 1 |
| Hartmann, A | 1 |
| Berg, KJ | 1 |
| Lund, K | 1 |
| Fauchald, P | 1 |
| Schaefer, RM | 1 |
| Aldons, PM | 1 |
| Burgess, ED | 1 |
| Singh, GP | 1 |
| Rehn, L | 1 |
| Morgan, TO | 2 |
| Yamreudeewong, W | 1 |
| Halverson, VJ | 1 |
| Lower, DL | 1 |
| Kilpatrick, DM | 1 |
| Enlow, AM | 1 |
| Montopoli, G | 1 |
| Lim, PO | 2 |
| Nys, M | 1 |
| Naas, AA | 1 |
| Osbakken, M | 1 |
| DeQuattro, V | 2 |
| Freestone, S | 1 |
| Allen, MJ | 1 |
| Muirhead, GJ | 1 |
| Bernaud, CM | 1 |
| Lender, D | 1 |
| Arauz-Pacheco, C | 1 |
| Breen, L | 1 |
| Mora-Mora, P | 1 |
| Ramirez, LC | 1 |
| Raskin, P | 1 |
| Hayduk, K | 1 |
| Adamczak, M | 1 |
| Nowitzki, G | 1 |
| Ligtenberg, G | 1 |
| Oey, PL | 1 |
| Klein, IH | 1 |
| Dijkhorst-Oei, LT | 1 |
| Boomsma, F | 1 |
| Wieneke, GH | 1 |
| van Huffelen, AC | 1 |
| Gurm, HS | 1 |
| Farooq, M | 1 |
| Sakata, K | 2 |
| Shirotani, M | 1 |
| Nawada, R | 1 |
| Obayashi, K | 1 |
| Togi, K | 1 |
| Numabe, A | 1 |
| Takishita, S | 1 |
| van der Vleuten, CJ | 1 |
| Trijbels-Smeulders, MA | 1 |
| van de Kerkhof, PC | 1 |
| Hernández-Hernández, R | 1 |
| Armas de Hernández, MJ | 1 |
| Pacheco, B | 1 |
| Yanaka, H | 1 |
| Tojo, A | 1 |
| Ryschon, KL | 1 |
| Wurdeman, RL | 3 |
| Ono, H | 1 |
| Tallian, KB | 1 |
| Turman, MA | 1 |
| Hayes, JR | 1 |
| Mentser, MI | 1 |
| Padley, S | 1 |
| Feher, M | 1 |
| Karasawa, A | 1 |
| Nomura, H | 1 |
| Nito, M | 1 |
| Sonoda, R | 1 |
| Kosaka, N | 1 |
| Yamaguchi, K | 1 |
| Kobayashi, S | 1 |
| Fink, KS | 1 |
| Karam, H | 1 |
| Clozel, JP | 1 |
| Bruneval, P | 1 |
| Gonzalez, MF | 1 |
| Pandita-Gunawardena, ND | 1 |
| Clarke, SE | 1 |
| Cleophas, TJ | 1 |
| van der Meulen, J | 1 |
| van de Luit, L | 1 |
| Zwinderman, AH | 1 |
| Kränzlin, B | 1 |
| Silverstein, DM | 1 |
| Palmer, J | 1 |
| Baluarte, HJ | 1 |
| Brass, C | 1 |
| Conley, SB | 1 |
| Polinsky, MS | 1 |
| Urano, T | 1 |
| Takada, Y | 1 |
| Takada, A | 1 |
| Birkenhäger, WH | 1 |
| Anguita Sánchez, M | 1 |
| Fukuo, K | 1 |
| Niinobu, T | 1 |
| Suhara, T | 1 |
| van der Kleij, AJ | 1 |
| Stingi, GD | 1 |
| Tarallo, MS | 1 |
| Donnan, PT | 1 |
| Cocco, G | 2 |
| Ettlin, T | 1 |
| Baumeler, HR | 1 |
| Melillo, E | 1 |
| Paleev, NR | 1 |
| Chereĭskaia, NK | 1 |
| Raspopina, NA | 1 |
| Pronina, VP | 1 |
| Shuganov, EG | 1 |
| Ecder, T | 2 |
| Brosnahan, GM | 1 |
| Edelstein, CL | 1 |
| Johnson, AM | 1 |
| Schrier, RW | 1 |
| Dieterle, T | 1 |
| Hopper, RV | 1 |
| Zhan, Y | 1 |
| Izumi, Y | 1 |
| Iwao, H | 1 |
| Kraiczi, H | 1 |
| Hedner, J | 1 |
| Peker, Y | 1 |
| Grote, L | 1 |
| Naidu, MU | 1 |
| Usha, PR | 1 |
| Rao, TR | 1 |
| Shobha, JC | 1 |
| Spence, JD | 2 |
| Munoz, C | 1 |
| Huff, MW | 1 |
| Tokmakjian, S | 1 |
| Bishop, JE | 1 |
| Kiernan, LA | 1 |
| Montgomery, HE | 1 |
| Gohlke, P | 1 |
| McEwan, JR | 1 |
| Chaswal, M | 1 |
| Singh, S | 1 |
| Tandon, OP | 1 |
| Shankar, N | 1 |
| Glasser, SP | 2 |
| Frishman, W | 1 |
| Stone, P | 1 |
| Johnson, MF | 1 |
| Mantle, D | 1 |
| Ahmed, S | 1 |
| Rahman, I | 1 |
| MacNee, W | 1 |
| Wassif, WS | 1 |
| Chen, D | 1 |
| Wu, K | 1 |
| Nalbantgil, S | 1 |
| Nalbantgil, I | 1 |
| Onder, R | 1 |
| Yosefy, C | 1 |
| Viskoper, JR | 2 |
| Leshem, Y | 1 |
| Rav-Hon, Y | 1 |
| Rosenberg, GI | 1 |
| Yaskil, E | 1 |
| Jacke, K | 1 |
| Huser, L | 2 |
| Behrends, S | 1 |
| Charchoglian, RA | 1 |
| Anoshin, VV | 1 |
| Mantserova, OA | 1 |
| Sharaev, PI | 1 |
| Kumamaru, H | 1 |
| Clay, DR | 1 |
| Bourg, MP | 1 |
| Lawrence, DB | 1 |
| He, FJ | 1 |
| Lambert, R | 1 |
| Van Nguyen, P | 1 |
| Cusson, J | 1 |
| Beckey, NP | 1 |
| Korman, L | 1 |
| Benetos, A | 1 |
| Consoli, S | 1 |
| Safavian, A | 1 |
| Dubanchet, A | 1 |
| Sheehy, O | 1 |
| LeLorier, J | 1 |
| Smoyer, WE | 1 |
| Bunchman, TE | 1 |
| Lyszkiewicz, DA | 1 |
| Blowey, D | 1 |
| De Luca, N | 1 |
| Fontana, D | 1 |
| Iovino, G | 1 |
| Argenziano, L | 1 |
| Vecchione, C | 1 |
| Mettimano, M | 1 |
| Pichetti, F | 1 |
| Fazzari, L | 1 |
| Migneco, A | 1 |
| Specchia, L | 1 |
| Romano Spica, V | 1 |
| Savi, L | 1 |
| Anderson, A | 1 |
| Bertram, D | 1 |
| Feng, Z | 1 |
| Nakatsuma, A | 1 |
| Kawasaki, H | 1 |
| Kurosaki, Y | 1 |
| Futagami, K | 1 |
| Araki, H | 1 |
| Gomita, Y | 1 |
| Malalamani, GD | 1 |
| Schillaci, G | 1 |
| Knotter, B | 1 |
| Heckmann, M | 1 |
| Schiffer, S | 1 |
| Langdon, C | 1 |
| Abe, A | 1 |
| Kawamura, Y | 1 |
| Whitcomb, C | 1 |
| Enzmann, G | 1 |
| Pershadsingh, HA | 1 |
| Ciuryla, V | 1 |
| Nyström, FH | 1 |
| van den Veur, E | 1 |
| Chastang, C | 1 |
| Shal'nova, SA | 1 |
| Martsevich, SIu | 1 |
| Kutishenko, NP | 1 |
| Alimova, EV | 1 |
| Semenova, IuE | 1 |
| Lebedev, AV | 1 |
| Koniakhina, IP | 1 |
| Zagrebel'nyĭ, AV | 1 |
| Lazareva, ON | 1 |
| Mazur, NA | 2 |
| Pshenitsin, AI | 1 |
| Vikent'ev, VV | 1 |
| Weinberger, M | 1 |
| Pool, JL | 1 |
| Prasad, R | 1 |
| Harris, SM | 1 |
| Zyczynski, TM | 1 |
| Leidy, NK | 1 |
| Doyle, J | 1 |
| Arikian, S | 1 |
| Casciano, J | 1 |
| Casciano, R | 1 |
| Gonzalez, MA | 1 |
| Barber, PJ | 1 |
| Rawlings, JM | 1 |
| Markwell, PJ | 1 |
| Jones, CL | 1 |
| Ciocon, JO | 1 |
| Sweeney, ME | 1 |
| Randall, OS | 2 |
| Faulkner, MA | 1 |
| Andrésdóttir, MB | 1 |
| van Hamersvelt, HW | 1 |
| van Helden, MJ | 1 |
| van de Bosch, WJ | 1 |
| Valk, IM | 1 |
| Huysmans, FT | 1 |
| Tsuboi, K | 1 |
| Siché, JP | 1 |
| Fagret, D | 1 |
| Trémel, F | 1 |
| de Gaudemaris, R | 1 |
| Fujimura, A | 1 |
| Appel, L | 1 |
| Beck, G | 1 |
| Bourgoignie, J | 1 |
| Briggs, JP | 1 |
| Cleveland, W | 1 |
| Douglas, JG | 1 |
| Douglas, M | 1 |
| Faulkner, M | 2 |
| Gabriel, A | 1 |
| Johnson, CJ | 1 |
| Kopple, J | 1 |
| Kusek, J | 1 |
| Lea, J | 1 |
| Massry, S | 1 |
| Middleton, J | 1 |
| Norris, K | 1 |
| O'Connor, D | 1 |
| Pogue, V | 1 |
| Rostand, S | 1 |
| Schulman, G | 1 |
| Smith, W | 1 |
| Thornley-Brown, D | 1 |
| Tisher, CC | 1 |
| Xu, S | 1 |
| Masuo, K | 1 |
| Mikami, H | 1 |
| Tuck, ML | 1 |
| Deray, G | 1 |
| Baumelou, A | 1 |
| Bagnis, C | 1 |
| Kishida, M | 1 |
| Otsuka, F | 1 |
| Ogura, T | 1 |
| Kataoka, H | 1 |
| Yamauchi, T | 1 |
| Yokota, K | 1 |
| Mimura, Y | 1 |
| Macpherson, AK | 1 |
| Neti, S | 1 |
| Macpherson, PA | 1 |
| López, B | 2 |
| Querejeta, R | 2 |
| Varo, N | 1 |
| González, A | 2 |
| Larman, M | 2 |
| Martínez Ubago, JL | 1 |
| Díez, J | 2 |
| Dernellis, J | 1 |
| Kaihlanen, P | 1 |
| Lewis, G | 1 |
| Ginsberg, D | 1 |
| Lefrandt, JD | 3 |
| Gryglas, P | 1 |
| Chan, CH | 1 |
| Pieper, JA | 1 |
| Carretta, R | 3 |
| Bonaduce, D | 1 |
| Condorelli, M | 1 |
| Clarke, WR | 1 |
| Rohde, R | 1 |
| Islim, IF | 1 |
| Watson, RD | 1 |
| Ihenacho, HN | 1 |
| Ebanks, M | 1 |
| Singh, SP | 2 |
| Ebbs, D | 1 |
| Omboni, S | 1 |
| La Commare, P | 1 |
| Yanchick, JK | 1 |
| Hennessy, M | 1 |
| Chapman, JN | 1 |
| Thom, SA | 1 |
| Tokola, H | 1 |
| Ruskoaho, H | 1 |
| Bernardi, L | 1 |
| Angell-James, JE | 1 |
| Sleight, P | 1 |
| Kirby, PL | 1 |
| Caulfield, MC | 1 |
| Griffiths, CG | 1 |
| Hemingway, H | 1 |
| Feder, GS | 1 |
| Boari, L | 1 |
| De Dominicis, E | 1 |
| Giusti, C | 1 |
| Marchesi, M | 1 |
| Marelli, G | 1 |
| Mattarei, M | 1 |
| Mos, L | 1 |
| Novo, S | 1 |
| Santini, M | 1 |
| Semeraro, S | 1 |
| Uslenghi, E | 1 |
| Kilama, MO | 1 |
| Nishikawa, N | 1 |
| Sakata, Y | 1 |
| Miwa, T | 1 |
| Chung, M | 1 |
| Baltodano, NM | 1 |
| Lenz, TL | 1 |
| Heitmann, J | 2 |
| Hausberg, M | 2 |
| Fallon, M | 2 |
| Fluckiger, L | 1 |
| Urbigkeit, A | 2 |
| Murphy, M | 2 |
| de Kam, PJ | 2 |
| van Roon, AM | 1 |
| Kyselovic, J | 1 |
| Maruyama, C | 1 |
| Kuwata, S | 1 |
| Nathisuwan, S | 1 |
| Talbert, RL | 1 |
| Ravassa, S | 1 |
| Fortuño, MA | 1 |
| Franse, LV | 1 |
| Deitcher, SR | 1 |
| Johnson, KC | 1 |
| Shorr, RI | 1 |
| Kottke-Marchant, K | 1 |
| Tracy, RP | 1 |
| Somes, GW | 1 |
| Brosnan, MJ | 1 |
| Hamilton, CA | 1 |
| Graham, D | 1 |
| Lygate, CA | 1 |
| Jardine, E | 1 |
| Elawad, M | 1 |
| Rowen, R | 1 |
| Lewin, A | 1 |
| Ghadanfar, M | 1 |
| Dantas de Medeiros, TM | 1 |
| Nonoyama, K | 1 |
| Barretto, OC | 1 |
| Pu, Q | 1 |
| Shibasaki, Y | 1 |
| Masaki, H | 1 |
| Nishiue, T | 1 |
| Nishikawa, M | 1 |
| Di, SS | 1 |
| Lim, AC | 1 |
| Hart, K | 1 |
| Murrell, D | 1 |
| Deary, AJ | 1 |
| Schumann, AL | 1 |
| Murfet, H | 1 |
| Haydock, SF | 1 |
| Foo, RS | 1 |
| Lai, YM | 1 |
| Su, JZ | 1 |
| Suzuki, R | 1 |
| Ikeda, Y | 1 |
| Tahira, Y | 1 |
| Kanmatsuse, K | 1 |
| Zhu, C | 1 |
| Adigun, AQ | 1 |
| Binggeli, C | 1 |
| Corti, R | 1 |
| Sudano, I | 1 |
| Luscher, TF | 1 |
| Noll, G | 1 |
| Hara, K | 1 |
| Struck, J | 1 |
| Muck, P | 1 |
| Trübger, D | 1 |
| Dendorfer, A | 1 |
| Dodt, C | 1 |
| Mabuchi, N | 1 |
| Kinoshita, M | 1 |
| Nussinovitch, N | 1 |
| Rosenberg, G | 1 |
| Peleg, E | 1 |
| Piazza, S | 1 |
| Di Somma, S | 1 |
| Schrier, R | 1 |
| McFann, K | 1 |
| Chapman, A | 1 |
| Edelstein, C | 1 |
| Brosnahan, G | 1 |
| Tison, L | 1 |
| Adler, S | 1 |
| Huang, H | 1 |
| Gurney, D | 1 |
| Broadhurst, P | 1 |
| Donati, L | 1 |
| Bühler, FR | 2 |
| Kusch, F | 1 |
| Palazzuoli, V | 1 |
| Mondillo, S | 1 |
| Faglia, S | 1 |
| D'Aprile, N | 1 |
| Kristodhullo, A | 1 |
| Oganov, RG | 1 |
| Gratsianskiĭ, NA | 1 |
| Lazebnik, LB | 1 |
| Sidorenko, BA | 1 |
| Ol'binskaia, LI | 1 |
| Vertkin, AL | 1 |
| Habeler, G | 1 |
| Lenzhofer, R | 1 |
| Pall, H | 1 |
| Tomaschek, A | 1 |
| Ziebart-Schroth, A | 1 |
| Zirm, B | 1 |
| Ganzinger, U | 1 |
| Terrachini, V | 1 |
| Canale, C | 1 |
| Lonati, A | 1 |
| Masperone, MA | 1 |
| Bruzzone, F | 1 |
| Malvestiti, FM | 1 |
| Caponnetto, S | 1 |
| Digranes, O | 3 |
| Helland, B | 3 |
| Jordal, O | 3 |
| Stray, T | 3 |
| Borges, ET | 1 |
| Christeler, P | 1 |
| Guillaume-Gentil, M | 1 |
| Hollenstein, U | 1 |
| Mannhart, M | 1 |
| Munehasu, S | 1 |
| Ishiko, J | 1 |
| Buckley, MG | 1 |
| Miller, MA | 1 |
| Höfling, B | 1 |
| Häringer, E | 1 |
| Herrmann, W | 1 |
| Pieske, H | 1 |
| Pieske, R | 1 |
| Philippi, M | 1 |
| Schroeder, P | 1 |
| Erikssen, J | 1 |
| Tyler, HM | 8 |
| Kaplan, NM | 1 |
| Klein, J | 1 |
| Hernández, O | 1 |
| Stafunsky, M | 1 |
| Armas-de Hernández, MJ | 1 |
| Samaniego, V | 1 |
| Moguel, R | 1 |
| Meaney, E | 1 |
| Escudero, J | 1 |
| Hernandez, H | 1 |
| Tettamanti, F | 1 |
| Magenta, M | 1 |
| Rupoli, L | 1 |
| Chianca, R | 1 |
| Catarrasi, C | 1 |
| Ruffilli, MP | 1 |
| Gutkowska, J | 2 |
| Winterbottom, LM | 1 |
| Thorman, AD | 1 |
| Gu, XH | 1 |
| Kiowski, W | 1 |
| Linder, L | 1 |
| de Bruijn, B | 1 |
| Lambert, MD | 1 |
| Robb, OJ | 2 |
| Scott, AK | 2 |
| Frick, MH | 2 |
| McGibney, D | 2 |
| Mitchell, ET | 2 |
| Wilcox, RG | 2 |
| Walker, P | 4 |
| Smedsrud, T | 2 |
| Graves, J | 1 |
| Rofman, B | 1 |
| Koehn, DK | 1 |
| Chrysant, C | 1 |
| Trus, J | 1 |
| Hitchcock, A | 1 |
| Osterloh, I | 1 |
| Reams, GP | 1 |
| Lau, A | 1 |
| Hamory, A | 1 |
| Bauer, JH | 1 |
| Towler, HM | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effect of Amlodipine Versus Bisoprolol on Hypertensive Patients With End-stage Renal Disease on Maintenance Hemodialysis.[NCT04085562] | Phase 4 | 46 participants (Actual) | Interventional | 2019-09-01 | Completed | ||
| A Randomized, Double-Blind, Parallel, Multi-Center, Phase 2 Clinical Trial to Determine the Optimal Dose of AD-209 in Patients With Essential Hypertension[NCT04218552] | Phase 2 | 176 participants (Actual) | Interventional | 2020-02-25 | Completed | ||
| [NCT00000542] | Phase 3 | 0 participants | Interventional | 1993-08-31 | Completed | ||
| Polypill Strategy for Evidence-Based Management of Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention in an Underserved Patient Population[NCT05514938] | Phase 2 | 60 participants (Anticipated) | Interventional | 2022-11-30 | Recruiting | ||
| Developing a Heart Failure Polypill to Improve Outcomes at a Safety Net Hospital: A Pilot Crossover Randomized Controlled Trial[NCT06029712] | Phase 2 | 40 participants (Anticipated) | Interventional | 2024-01-31 | Not yet recruiting | ||
| The SCCS Polypill Pilot Trial[NCT02278471] | Phase 2 | 303 participants (Actual) | Interventional | 2015-12-31 | Completed | ||
| A Multi-center, Randomized, Double-blind, Parallel-group Phase III Clinical Trial to Evaluate the Efficacy and Safety of YHP1701 Fixed Dose Combination in Patients With Dyslipidemia and Hypertension[NCT03103256] | Phase 3 | 106 participants (Actual) | Interventional | 2017-05-17 | Completed | ||
| A Comparative Study for the Effects of Nifedipine GITS and Amlodipine Besylate on Recovery of Blood Pressure Rhythm and Arterial Stiffness in the Young and Middle-aged Subjects With Non-dipper Hypertension[NCT02940548] | Phase 4 | 99 participants (Actual) | Interventional | 2016-12-31 | Terminated (stopped due to The patient recruitment and follow-ups were influenced with the pandemic of COVID-19) | ||
| Levamlodipine Maleate (Xuanning) or Amlodipine Besylate (Norvasc) for Treatment of Hypertension: A Comparative Effectiveness Research[NCT01844570] | 10,000 participants (Anticipated) | Observational | 2013-02-28 | Active, not recruiting | |||
| A Randomized, Double-blind, Active-controlled, Multicenter Phase3 Trial to Evaluate the Efficacy and Safety of Co-administrated Temisartan/Amlodipine and Rosuvastatin in Subjects With Hypertension and Hyperlipidemia[NCT03067688] | Phase 3 | 202 participants (Actual) | Interventional | 2017-04-11 | Completed | ||
| A Muticenter, Randomized, Double-blind, Parallel, Phase 2 Study to Assess Dose-response Relationship of HCP1803 in Patients With Essential Hypertension[NCT03897868] | Phase 2 | 248 participants (Actual) | Interventional | 2019-03-21 | Completed | ||
| A 12 Weeks, Multi-center, Open Label, Randomized, Active Drug Parallel Control Trial to Compare the Effectiveness of Valsartan/Amlodipine and Nifedipine in Treating Chinese Hypertensive Patients Not Respond to Mono Antihypertensive Treatment[NCT01167153] | Phase 4 | 564 participants (Actual) | Interventional | 2010-05-31 | Completed | ||
| Mineralocorticoid Receptor, Coronary Microvascular Function, and Cardiac Efficiency in Hypertension[NCT05593055] | Phase 4 | 75 participants (Anticipated) | Interventional | 2023-08-25 | Recruiting | ||
| Salt Sensitive Hypertension and Striatin[NCT03683069] | Phase 4 | 400 participants (Actual) | Interventional | 2019-01-15 | Active, not recruiting | ||
| A Randomized, Double-blind, Multicenter, Phase 3 Study to Evaluate Efficacy and Safety of HCP1401 for Stage 2 Hypertension Patients Not Controlled by HCP0605[NCT02916602] | Phase 3 | 340 participants (Actual) | Interventional | 2015-04-30 | Completed | ||
| Monotherapy Versus Dual Therapy for Initial Treatment for Hypertension[NCT00994617] | Phase 4 | 600 participants (Anticipated) | Interventional | 2010-01-31 | Recruiting | ||
| A Randomized, Double-blind, Parallel Group Study to Evaluate Metabolic Effects of LCZ696 and Amlodipine in Obese Hypertensive Subjects[NCT01631864] | Phase 2 | 98 participants (Actual) | Interventional | 2012-10-31 | Completed | ||
| Efficacy and Safety of S-amlodipine 2,5 mg and 5 mg in Hypertension Patients: Open-label, Local, Phase IV Study[NCT03038451] | Phase 4 | 43 participants (Actual) | Interventional | 2013-03-20 | Completed | ||
| Evaluation of the Efficacy and Safety of S-amlodipine+Chlorthalidone Combination Therapy and S-amlodipine+Telmisartan Combination Therapy in Hypertensive Patients Inadequately Controlled With Calcium Channel Blocker Monotherapy[NCT03226340] | Phase 4 | 170 participants (Anticipated) | Interventional | 2015-12-02 | Recruiting | ||
| Comparison of Optimal Hypertension Regimens (Part of the Ancestry Informative Markers in Hypertension (AIMHY) Programme - AIMHY-INFORM)[NCT02847338] | Phase 4 | 1,320 participants (Anticipated) | Interventional | 2016-11-30 | Recruiting | ||
| The Precision Hypertension Care Study[NCT02774460] | Phase 4 | 280 participants (Actual) | Interventional | 2017-02-20 | Completed | ||
| A Multi-center, Randomized, Double-blind, Parellel Phase III Clinical Trial to Evaluate the Efficacy and Safety of Triple Therapy of Telmisartan/Amlodipine/Rosuvastatin in Patients With Dyslipidemia and Hypertension[NCT03088254] | Phase 3 | 126 participants (Actual) | Interventional | 2016-09-20 | Completed | ||
| Series of N-of-1 Crossover Trials of Antihypertensive Therapy in Adolescents With Essential Hypertension[NCT02412761] | 42 participants (Actual) | Interventional | 2013-06-30 | Completed | |||
| Comparison of Three Combination Therapies in Lowering Blood Pressure in Black Africans[NCT02742467] | Phase 4 | 702 participants (Actual) | Interventional | 2017-06-07 | Completed | ||
| Randomized, Double-blind, Multi-center Phase III Clinical Trial to Evaluate the Efficacy and Safety of Telmisartan/Amlodipine and Rosuvastatin Co-administration in Hypertensive Patients With Hyperlipidemia[NCT03566316] | Phase 3 | 134 participants (Actual) | Interventional | 2015-11-24 | Completed | ||
| Comparison of Effects Between Calcium Channel Blocker and Diuretics in Combination With Angiotensin II Receptor Blocker on 24-hr Central Blood Pressure and Vascular Hemodynamic Parameters in Hypertensive Patients Multicenter, Double-blind, Active-controll[NCT02294539] | Phase 4 | 231 participants (Actual) | Interventional | 2014-08-31 | Completed | ||
| Short-term Effects of Perindopril-amlodipine Versus Perindopril-indapamide on Blood Pressure Control in Newly Diagnosed Type 2 Diabetes Individuals With Hypertension[NCT03747978] | Phase 4 | 30 participants (Actual) | Interventional | 2016-10-01 | Completed | ||
| A Cluster Randomized Trial On Cardiovascular Risk Factor Management: Caduet Versus Usual Care In Subjects With Hypertension And Additional Cardiovascular Risk Factors In Clinical Practice[NCT00407537] | Phase 4 | 1,531 participants (Actual) | Interventional | 2007-03-31 | Completed | ||
| Study of Independent Role of Continuous Positive Airway Pressure Therapy on Systemic Arterial Pressure in Patients With Sleep Apnea Syndrome and Arterial Hypertension[NCT00801671] | Phase 3 | 50 participants (Actual) | Interventional | 2008-09-30 | Completed | ||
| Pilot Study of Telmisartan (Micardis) For the Prevention of Acute Graft vs. Host Disease Post Allogeneic Hematopoietic Stem Cell Transplantation[NCT02338232] | 32 participants (Actual) | Interventional | 2015-07-07 | Terminated (stopped due to Lack of Accrual) | |||
| An 8-week, Multicenter Study to Evaluate the Efficacy and Safety of the Combination of Valsartan/HCTZ/Amlodipine Compared to Valsartan/HCTZ, Valsartan/Amlodipine, and HCTZ/Amlodipine in Patients With Moderate to Severe Hypertension.[NCT00327587] | Phase 3 | 2,279 participants (Actual) | Interventional | 2006-05-31 | Completed | ||
| Newer vs Older Antihypertensive Agents in African Hypertensive Patients Trial[NCT01030458] | Phase 4 | 183 participants (Actual) | Interventional | 2010-09-30 | Completed | ||
| Pediatric Hypertension and the Renin-Angiotensin SystEm (PHRASE): The Role of Angiotensin-(1-7) in Hypertension and Hypertension-Induced Heart and Kidney Damage[NCT04752293] | 125 participants (Anticipated) | Observational | 2021-05-19 | Recruiting | |||
| A 24-week Study to Evaluate the Effectiveness of Valsartan in Combination With Hydrochlorothiazide Versus Amlodipine on Arterial Compliance in Patients With Hypertension, Type 2 Diabetes and Albuminuria[NCT00171561] | Phase 4 | 144 participants (Actual) | Interventional | 2003-03-31 | Completed | ||
| Evaluation of Hematologic Patients - Training Protocol[NCT00001715] | 898 participants (Actual) | Observational | 1998-04-21 | Completed | |||
| The Novel Antihypertensive Goal Of hYpertension With diAbetes - Hypertensive Events and ARb Treatment (NAGOYA-HEART) Study[NCT00129233] | Phase 4 | 1,150 participants (Actual) | Interventional | 2004-10-31 | Completed | ||
| Cardiovascular Outcomes in Renal Atherosclerotic Lesions (CORAL)[NCT00081731] | Phase 3 | 947 participants (Actual) | Interventional | 2004-04-30 | Completed | ||
| Efficacy of Sevikar® Compared to the Combination of Perindopril/ Amlodipine on Central Arterial Blood Pressure in Patients With Moderate to Severe Hypertension-[NCT01101009] | Phase 4 | 486 participants (Actual) | Interventional | 2010-04-30 | Completed | ||
| Comparison of the Effects of Amlodipine and Losartan on Blood Pressure and Diurnal Variation in Hypertensive Stroke Patients[NCT01830517] | Phase 4 | 84 participants (Actual) | Interventional | 2007-08-31 | Completed | ||
| The Effect of Antihypertensive Agents Over Sleep Apnea: a Randomized Controlled Trial[NCT01896661] | Phase 3 | 53 participants (Actual) | Interventional | 2014-12-31 | Completed | ||
| 8 Week Randomised Double-blind Study to Compare the Efficacy and Safety of Telmisartan 80mg+ Amlodipine 5 mg vs. Amlodipine 5mg Monotherapy in Patients With Hypertension Who Fail to Respond Adequately to Treatment With Amlodipine 5mg Monotherapy[NCT01103960] | Phase 3 | 324 participants (Actual) | Interventional | 2010-07-31 | Completed | ||
| The Study Comparing the Incidence of Cardiovascular Events Between High-dose ARB Monotherapy and Combination Therapy With ARB and Calcium Channel Blocker in Japanese Elderly Hypertensive Patients at High Cardiovascular Risk[NCT00134160] | Phase 4 | 1,000 participants (Anticipated) | Interventional | 2005-08-31 | Completed | ||
| A Randomized Controlled Trial of Aliskiren in the Prevention of Major Cardiovascular Events in Elderly People[NCT01259297] | Phase 3 | 2,336 participants (Actual) | Interventional | 2011-01-31 | Terminated (stopped due to Terminated early in agreement with Health Authorities for feasibility reasons) | ||
| Short - Medium and Long Term Blood Pressure Variability in Essential Hypertensive Patients Treated With Nifedipine GITS or Ramipril - a Randomized Trial[NCT02499822] | Phase 4 | 168 participants (Actual) | Interventional | 2015-10-31 | Completed | ||
| Fixed Combination for Lipid and Blood Pressure Control. Randomized Cross-over Study[NCT03047538] | Phase 4 | 0 participants (Actual) | Interventional | 2017-09-01 | Withdrawn (stopped due to Insufficient funds) | ||
| Randomised, Double-Blind, Parallel-Group Study Evaluating Efficacy and Safety of Co-Administration of Triple Combinations of Olmesartan Medoxomil, Amlodipine Besylate, and Hydrochlorothiazide Compared With Corresponding Olmesartan - Amlodipine Combination[NCT00923091] | Phase 3 | 2,689 participants (Actual) | Interventional | 2009-06-30 | Completed | ||
| A Phase III, Randomized, Active-Comparator Controlled Clinical Trial to Study the Efficacy and Safety of MK-0954E in Japanese Patients With Essential Hypertension Uncontrolled With Losartan and Amlodipine Co-administration[NCT01302691] | Phase 3 | 327 participants (Actual) | Interventional | 2011-01-01 | Completed | ||
| A Phase III, Randomized, Active-Comparator Controlled Clinical Trial to Study the Efficacy and Safety of MK-0954E in Japanese Patients With Essential Hypertension Uncontrolled With MK-954H (L50/H12.5 mg) [PREMINENT®] and an Open-label, Long-term Clinical [NCT01299376] | Phase 3 | 286 participants (Actual) | Interventional | 2011-01-24 | Completed | ||
| A Randomised Double-blind Cross-over Single-centre Study on Molecular Genetics of Drug Responsiveness in Essential Hypertension[NCT03276598] | Phase 4 | 233 participants (Actual) | Interventional | 1999-11-25 | Completed | ||
| Azilsartan Circadian and Sleep Pressure - the 1st Study[NCT01762501] | 957 participants (Actual) | Interventional | 2012-12-31 | Completed | |||
| [NCT01518998] | Phase 2 | 420 participants (Actual) | Interventional | 2011-08-31 | Completed | ||
| Evaluation of Some Emerging Biomarkers of Cardiovascular Risk Stratification in Hypertensive Patients: a 5-years Follow-up[NCT02064218] | 0 participants | Observational | 2007-11-30 | Recruiting | |||
| Comparison Between Losartan and Benazepril in Diabetic Hypertensive Patients With Blood Pressure Not Controlled by Amlodipine: Effects on Echocardiographic Parameters, Vascular Stiffness and Endothelial Function.[NCT01603940] | Phase 4 | 30 participants (Actual) | Interventional | 2012-05-31 | Completed | ||
| A Randomized, Double-blind, Parallel Group Study to Evaluate the Efficacy and Safety of Triple Fixed Dose Combination Therapy With Olmesartan Medoxomil 20mg, Amlodipine 5mg and Hydrochlorothiazide 12.5mg in Patients With Hypertension Not Controlled With D[NCT01838850] | Phase 3 | 344 participants (Actual) | Interventional | 2013-04-30 | Completed | ||
| ARB and CCB Longest Combination Treatment on Ambulatory and Home BP in Hypertension With Atrial Fibrillation -Multicenter Study on Time of Dosing[NCT01748253] | 80 participants (Anticipated) | Interventional | 2012-11-30 | Recruiting | |||
| A Randomized, Double-blind Multicenter, Phase III Study to Evaluate the Efficacy and Safety of Combination of Fimasartan/Amlodipine Versus Fimasartan Monotherapy in Patients With Essential Hypertension Who Fail to Respond Adequately to Fimasartan Monother[NCT02152306] | Phase 3 | 143 participants (Actual) | Interventional | 2014-04-30 | Completed | ||
| A 12 Weeks, Multi-center, Randomized, Open Label, Active Control, Phase IV Clinical Trial to Compare Evaluated Improvement of Edema Index, Safety and Efficacy of Amlodipine Versus S Amlodipine in Patients With Essential Hypertension[NCT04554303] | 80 participants (Anticipated) | Observational | 2020-10-28 | Recruiting | |||
| Management of Resistant Hypertension -Pharmacokinetic Assessment of Different Antihypertensive Regimen -Comparison of Two Treatment Strategies: Increase Sodium Depletion or Combined Blockage of Renin-angiotensin System (RAS)[NCT00224549] | Phase 4 | 180 participants (Actual) | Interventional | 2005-04-30 | Completed | ||
| Thiazide Diuretics for Hypertension in Kidney Transplant Recipients Using Tacrolimus[NCT02644395] | Phase 3 | 49 participants (Actual) | Interventional | 2013-01-18 | Completed | ||
| Pilot Study to Assess Blockade of Calcium Channels and Sodium Chloride Cotransporters for Physiologic Abnormalities in Liver Transplant Associated Hypertension[NCT05275907] | Phase 4 | 0 participants (Actual) | Interventional | 2022-07-12 | Withdrawn (stopped due to Screened participants did not meet inclusion criteria prior to study completion date) | ||
| Influence of Amlodipine on the Mortality of Patients With End-Stage Renal Failure (ADAM [Amlodipine and Dialysis Patients, Action on Mortality])[NCT00124969] | Phase 4 | 356 participants (Actual) | Interventional | 2002-01-31 | Completed | ||
| Relevance of the Interaction Between Antihypertensive and Antirheumatic Drugs in a Family Practice[NCT00631514] | Phase 4 | 88 participants (Actual) | Interventional | 2005-01-31 | Completed | ||
| Candesartan Antihypertensive Survival Evaluation in Japan (CASE-J) Trial of Cardiovascular Events in High-Risk Hypertensive Patients[NCT00125463] | Phase 3 | 3,200 participants | Interventional | 2001-09-30 | Active, not recruiting | ||
| Effect of Combined Antihypertensive Therapy on Blood Pressure and Sexual Function in Patients With Essential Hypertension[NCT01238705] | Phase 4 | 280 participants (Anticipated) | Interventional | 2008-04-30 | Recruiting | ||
| A Prospective, Multinational, Multicenter Trial to Compare the Effects of Amlodipine/Benazepril to Benazepril and Hydrochlorothiazide Combined on the Reduction of Cardiovascular Morbidity and Mortality in Patients With High Risk Hypertension[NCT00170950] | Phase 3 | 11,506 participants (Actual) | Interventional | 2003-10-31 | Terminated (stopped due to The study was terminated early because of significant efficacy results for the primary endpoint in favor of benazepril/amlodipine treatment.) | ||
| MI-Plus: Web-enhanced Guideline Implementation for Post MI CBOC Patients[NCT00126750] | 847 participants (Actual) | Interventional | 2003-09-30 | Completed | |||
| A 12-week, Multicenter Study to Evaluate the Efficacy and Safety of Orally Administered Valsartan/Amlodipine Combo Based Therapy vs Amlodipine Monotherapy in Black Patients With Stage II Hypertension[NCT00353912] | Phase 3 | 571 participants (Actual) | Interventional | 2006-06-30 | Completed | ||
| Valsartan/Amlodipine 160/5 mg or 160/10 mg Versus Valsartan 160 mg Alone for 8 Weeks in Hypertensive Patients Who Are Not Adequately Controlled on Valsartan 160 mg Monotherapy[NCT00170963] | Phase 3 | 1,018 participants (Actual) | Interventional | 2004-10-31 | Completed | ||
| A Double-blind, Randomized, Multicenter, Parallel Group Study to Evaluate the Efficacy, Tolerability, and Safety of Treatment With the Combination of Valsartan/Amlodipine 160/5 mg Compared to Amlodipine 10 mg in Patients With Essential Hypertension Not Ad[NCT00437645] | Phase 3 | 1,183 participants (Actual) | Interventional | 2007-01-31 | Completed | ||
| An Multicenter Study to Evaluate the Efficacy and Safety of a 5 Week Therapy With the Combination of Valsartan 160 mg Plus Amlodipine 10 mg in Hypertensive Patients Not Adequately Responding to a 5 Week Therapy With Ramipril 5 mg and Felodipine 5 mg[NCT00367939] | Phase 3 | 132 participants (Actual) | Interventional | 2005-12-31 | Completed | ||
| A 54-week, Open-label, Multicenter Study to Assess the Long-term Safety and Tolerability of the Combination of Aliskiren 300 mg / Amlodipine 10 mg in Patients With Essential Hypertension[NCT00402103] | Phase 3 | 556 participants (Actual) | Interventional | 2006-11-30 | Completed | ||
| [NCT00693199] | 360 participants (Actual) | Interventional | 2006-07-31 | Completed | |||
| Blood Pressure Lowering Effects of Amosartan Regarding Proviso in Patients With Hypertension: Prospective, Multicenter, Observational Study[NCT03255551] | 50 participants (Actual) | Observational | 2014-01-01 | Completed | |||
| An International, Multicentre, Open Label Study To Assess The Effectiveness Of Amlodipine/Atorvastatin Combination In Subjects With Hypertension And Dyslipidaemia. (The JEWEL II Study)[NCT00174304] | Phase 4 | 1,120 participants | Interventional | 2004-10-31 | Completed | ||
| An International, Multicentre, Open Label Study To Assess The Effectiveness Of Amlodipine -Atorvastatin Combination In Subjects With Hypertension and Dyslipidaemia. (The JEWEL Study)[NCT00330785] | Phase 3 | 1,250 participants | Interventional | 2004-10-31 | Completed | ||
| Efficacy and Safety of Amlodipine Used as add-on Therapy in Moderately to Severely Hypertensive Patients Not Adequately Controlled by Olmesartan Medoxomil 20 mg Monotherapy[NCT00220220] | Phase 3 | 429 participants (Anticipated) | Interventional | 2005-04-30 | Completed | ||
| Treatment of Essential Hypertension With Rasilez. Evaluation of Different Methods of Blood Pressure Measurements - Efficacy and Safety Evaluation[NCT01060865] | Phase 4 | 50 participants (Actual) | Interventional | 2010-03-31 | Terminated (stopped due to The participants signed an old version of the informed consent.) | ||
| Prevalence and Incidence of Dyskalemia in Hypertensive Patients Initiating a Fixed Dose Combination Pill of Telmisartan and Amlodipine[NCT05155436] | Phase 4 | 1,090 participants (Actual) | Interventional | 2022-01-15 | Completed | ||
| Effects of Amlodipine/Benazepril in Reducing Left Ventricular Hypertrophy in Patients With High Risk Hypertension[NCT00139555] | Phase 4 | 125 participants (Actual) | Interventional | 2004-07-31 | Completed | ||
| A Multicenter Trial to Evaluate the Safety and Efficacy of the Combination of Valsartan/Amlodipine 160/10 mg Versus Amlodipine 10 mg Alone for 8 Weeks in Hypertensive Patients Who Are Not Adequately Controlled on Amlodipine 10 mg Monotherapy[NCT00171002] | Phase 3 | 936 participants (Actual) | Interventional | 2004-11-30 | Completed | ||
| A 6-Week Multi-center, Randomized, Double-Blind, Parallel Group Study Comparing the Efficacy of Amlodipine Besylate/Benazepril Versus Amlodipine in the Treatment of Severe Hypertension[NCT00136851] | Phase 4 | 259 participants (Actual) | Interventional | 2004-12-31 | Completed | ||
| A 14 Week Study to Evaluate Effectiveness of a Valsartan Versus an Amlodipine Treatment Strategy in Achieving Blood Pressure Control in Patients With Stage 1 or Stage 2 Hypertension or Uncontrolled on Present Monotherapy[NCT00304226] | Phase 4 | 1,288 participants (Actual) | Interventional | 2006-02-28 | Completed | ||
| Comparison of Diuretic-based With Non-diuretic Based Hypertension Therapy Using Echocardiographic Measures[NCT00229242] | 38 participants (Actual) | Interventional | 2003-11-30 | Completed | |||
| The Effects of Renin Angiotensin System Blockage (RAS), Calcium Channel Blocker and Combine Drugs on TWEAK, PTX3 and FMD Levels in Diabetic Proteinuric Patients With Hypertension[NCT00921570] | Phase 4 | 105 participants (Actual) | Interventional | 2008-02-29 | Completed | ||
| A Multi-national, Multicenter, Double-blind, Double-dummy, Randomized, Active-controlled, Parallel Study Comparing the Efficacy and Safety of Valsartan/Amlodipine 80/5 mg to Amlodipine 5 mg Alone Once Daily in Patients With Mild to Moderate Essential Hype[NCT00413049] | Phase 3 | 698 participants (Actual) | Interventional | 2007-01-31 | Completed | ||
| Double Blind Atorvastatin Amlodipine Study (DUAAL) Effect Of Amlodipine, Atorvastatin And The Combination On Transient Myocardia Ischemia In Coronary Artery Disease.[NCT00159718] | Phase 4 | 360 participants | Interventional | 2001-07-31 | Completed | ||
| A 16-week Double-blind, Randomized, Multicenter, Force-titration Study to Evaluate the Antihypertensive Efficacy of Valsartan/Hydrochlorothiazide (HCTZ) Therapy Compared to HCTZ Based Therapy in Obese, Hypertensive Patients[NCT00439738] | Phase 4 | 412 participants (Actual) | Interventional | 2006-12-31 | Completed | ||
| A Randomized, Double-Blind, Parallel Group Study Evaluating the Efficacy and Safety of Co-Administration of a Triple Combination Therapy of Olmesartan Medoxomil, Amlodipine Besylate and Hydrochlorothiazide in Subjects With Hypertension[NCT00649389] | Phase 3 | 2,500 participants (Actual) | Interventional | 2008-05-31 | Completed | ||
| Manidipine Versus Amlodipine in Patients With Hypertension: Effects on Peripheral Edema Evaluated by Bioimpedance Analysis[NCT03106597] | Phase 4 | 46 participants (Actual) | Interventional | 2015-08-20 | Terminated (stopped due to Difficulty in enrolling subjects) | ||
| A Multicenter, Randomized, Double Blind, Parallel Design Trial to Evaluate the Blood Pressure Lowering Efficacy Comparing Moderate Versus Aggressive Treatment Regimen of Valsartan + Amlodipine in Patients Uncontrolled on ARB Monotherapy[NCT00666536] | Phase 4 | 728 participants (Actual) | Interventional | 2008-03-31 | Completed | ||
| An Open-label, Multicenter Study to Evaluate the Efficacy and Safety of a 4 Week Therapy With Aliskiren 300 mg Plus Hydrochlorothiazide 25 mg in Hypertensive Patients Not Adequately Responding to a 4 Week Therapy With Candesartan 32 mg Plus Hydrochlorothi[NCT00867490] | Phase 3 | 186 participants (Actual) | Interventional | 2009-03-31 | Completed | ||
| A Randomized, 32 Week Double-blind, Parallel-group, Multicenter Study to Compare the Efficacy and Safety of Initiating Treatment With Combination (Aliskiren/Amlodipine) Therapy in Comparison With the Sequential add-on Treatment Strategies in Patients With[NCT00797862] | Phase 3 | 1,254 participants (Actual) | Interventional | 2008-11-30 | Completed | ||
| A Randomized, Double-Blind, Parallel, Placebo or Amlodipine-Controlled Study of the Effects of Losartan on Proteinuria in Pediatric Patients With or Without Hypertension[NCT00568178] | Phase 3 | 306 participants (Actual) | Interventional | 2007-06-01 | Completed | ||
| Azelnidipine and Amlodipine Anti-Coronary Atherosclerotic Trial in Hypertensive Patients Undergoing Coronary Intervention by Serial Volumetric Intravascular Ultrasound Analysis in Junten Medical University (ALPS-J)[NCT00294567] | Phase 4 | 199 participants (Actual) | Interventional | 2005-12-31 | Completed | ||
| An 8 Week Prospective, Multicenter, Randomized, Double-Blind, Active Control, Parallel Group Study to Evaluate the Efficacy and Safety of Aliskiren HCTZ Versus Amlodipine in African American Patients With Stage 2 Hypertension[NCT00739596] | Phase 4 | 332 participants (Actual) | Interventional | 2008-07-31 | Completed | ||
| A 12-week, Randomized, Double-blind, Placebo Controlled, Parallel Group Study Evaluating the Efficacy & Safety of Aliskiren in Patients With Diabetes & Hypertension Not Adequately Responsive to the Combination of Valsartan 160 mg & Hydrochlorothiazide 25 [NCT00219102] | Phase 3 | 336 participants | Interventional | 2005-06-30 | Completed | ||
| A 10-week Multicenter,Forced-titration Study Using 24-hr ABPM to Evaluate the Efficacy of Valsartan/Hydrochlorothiazide (HCTZ) Treatment Regimen vs Conventional Treatment Regimen With Amlodipine and Hydrochlorothiazide (HCTZ) in Patients With Stage 2 Hype[NCT00425997] | Phase 4 | 480 participants (Anticipated) | Interventional | 2006-12-31 | Completed | ||
| A Phase III, 8-week, Multicenter, Randomized, Double-blind Study to Compare the Efficacy and Safety of Amlodipine 5mg+Losartan 50mg Versus Amlodipine 10mg in Patients With Essential Hypertension Not Controlled on Amlodipine Monotherapy[NCT00940667] | Phase 3 | 185 participants (Actual) | Interventional | 2008-05-31 | Completed | ||
| An 8-week, Multicenter, Randomized, Double-blind, Factorial Phase II Study to Evaluate Dose-response Relationship of Amlodipine and Losartan Combination in Patients With Essential Hypertension.[NCT00942344] | Phase 2 | 320 participants (Actual) | Interventional | 2007-05-31 | Completed | ||
| A Randomized, Eight-week Double-blind, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of the Combination of Aliskiren / Amlodipine (300/5 mg and 300/10 mg) in Comparison With Aliskiren 300 mg in Patients With Essential Hypertension [NCT00777946] | Phase 3 | 818 participants (Actual) | Interventional | 2008-10-31 | Completed | ||
| A Randomized, Eight Week Double-blind, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of the Combination of Aliskiren / Amlodipine (150/10 mg and 300/10 mg) in Comparison With Amlodipine 10 mg in Patients With Essential Hypertension[NCT00778921] | Phase 3 | 847 participants (Actual) | Interventional | 2008-10-31 | Completed | ||
| Phase 4 Study of Effects of ARB Compared With Diuretics in Hypertension Patients With High Cardiovascular Risks[NCT01011660] | Phase 4 | 13,542 participants (Anticipated) | Interventional | 2007-10-31 | Recruiting | ||
| A Phase III, 8-week, Multicenter, Randomized, Double-blind Study to Compare the Efficacy and Safety of Amlodipine 5mg+Losartan 100mg Versus Losartan 100mg in Patients With Essential Hypertension Not Controlled on Losartan Monotherapy[NCT00940680] | Phase 3 | 142 participants (Actual) | Interventional | 2008-04-30 | Completed | ||
| Pharmacological Association of the Angiotensin-Converting Enzyme Insertion/Deletion Polymorphism on Blood Pressure and Cardiovascular Risk in Relation to Anti-hypertensive Treatment[NCT00006294] | 37,939 participants (Actual) | Observational | 1999-09-30 | Completed | |||
| Efficacy and Safety of Two Fixed-combination Antihypertensive Regimens, Amtrel® and Co-Diovan® in Type 2 Diabetes Hypertension Patients With Microalbuminuria[NCT01375322] | Phase 4 | 226 participants (Actual) | Interventional | 2007-06-30 | Completed | ||
| Efficacy and Safety of Irbesartan/Amlodipine Fixed Combination Therapy Compared With Irbesartan Monotherapy in Hypertensive Patients Uncontrolled on Irbesartan 150 mg Monotherapy[NCT00957554] | Phase 3 | 435 participants (Actual) | Interventional | 2009-07-31 | Completed | ||
| Efficacy and Safety of Irbesartan/Amlodipine Fixed Combination Therapy Compared With Amlodipine Monotherapy in Hypertensive Patients Uncontrolled on Amlodipine 5 mg Monotherapy[NCT00956644] | Phase 3 | 406 participants (Anticipated) | Interventional | 2009-07-31 | Completed | ||
| A Prospective, Open-Label, Titration Study to Evaluate the Efficacy and Safety Safety of AZOR in Multiple Subgroups of Hypertensive Subjects Who Are Non-Responders to Anti-Hypertensive Monotherapy[NCT00791258] | Phase 4 | 999 participants (Actual) | Interventional | 2008-11-30 | Completed | ||
| A 28 to 54-week, Open-label, Multicenter Study to Assess the Long-term Safety and Tolerability of the Combination of Aliskiren / Amlodipine / Hydrochlorothiazide in Patients With Essential Hypertension[NCT00667719] | Phase 3 | 564 participants (Actual) | Interventional | 2008-06-05 | Completed | ||
| African American Study of Kidney Disease and Hypertension[NCT04364139] | Phase 3 | 1,094 participants (Actual) | Interventional | 1995-02-01 | Completed | ||
| Effect of Renin-angiotensin-system (RAS) Blocker Drugs on Chronic Kidney Disease (CKD) Progression in Elderly Patients With Non Proteinuric Nephropathies (PROERCAN01)[NCT03195023] | Phase 4 | 106 participants (Anticipated) | Interventional | 2015-06-30 | Recruiting | ||
| Evaluation of a Primary Treatment Algorithm Using Fixed Dose Combination Therapy for the Management of Hypertension - Control and Intervention Arms[NCT00129909] | Phase 4 | 2,081 participants (Actual) | Interventional | 2005-05-31 | Completed | ||
| Resistant Hypertension On Treatment - Sequential Nephron Blockade Compared to Dual Blockade of the Renin-angiotensin-aldosterone System Plus Bisoprolol in the Treatment of Resistant Arterial Hypertension: A Randomized Trial (ResHypOT)[NCT02832973] | Phase 4 | 72 participants (Actual) | Interventional | 2015-09-30 | Completed | ||
| A Pivotal Study To Evaluate The Effectiveness of Isometric Handgrip Therapy In Prehypertensive And Hypertensive Patients[NCT04467879] | 146 participants (Actual) | Interventional | 2020-06-01 | Terminated (stopped due to New Protocol and Outcome Measures in Review) | |||
| Clinical and Therapeutic Implications of Fibrosis in Hypertrophic Cardiomyopathy[NCT00879060] | Phase 4 | 53 participants (Actual) | Interventional | 2007-11-30 | Completed | ||
| The Randomized Elimination or Prolongation of Angiotensin Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in Coronavirus Disease 2019[NCT04338009] | 152 participants (Actual) | Interventional | 2020-03-31 | Completed | |||
| A Randomised Open Label, Blinded End Point Trial to Compare the Effects of Spironolactone With Chlortalidone on LV Mass in Stage 3 Chronic Kidney Disease (SPIRO-CKD)[NCT02502981] | Phase 4 | 154 participants (Actual) | Interventional | 2014-06-30 | Active, not recruiting | ||
| Effects of Doxazosin on Ambulatory Blood Pressure and Sympathetic Nervous Activity in Hypertensive Patients With Diabetic Nephropathy[NCT00295555] | Phase 4 | 98 participants (Actual) | Interventional | 2004-01-31 | Completed | ||
| Evaluation of Potential Pharmacokinetic Interactions Between HIV Protease Inhibitors and Calcium Channel Blockers[NCT00039975] | Phase 1 | 32 participants | Interventional | Completed | |||
| Improving Outcomes in Atrial Fibrillation Patients Aided by Implantable Cardiac Monitor: Evaluation of Chronic Beta-blocker Use Versus As-needed Pharmacological Rate Control[NCT05745337] | Phase 1 | 20 participants (Anticipated) | Interventional | 2023-02-06 | Recruiting | ||
| A Randomized, Open-label Study Investigating the Effect of Bilateral Renal Artery Sympathetic Denervation by Catheter-based Radiofrequency Ablation on Blood Pressure and Disease Progression in Autosomal Dominant Polycystic Kidney Disease[NCT01932450] | Phase 2 | 100 participants (Anticipated) | Interventional | 2013-08-31 | Recruiting | ||
| Effect of Pharmacological Heart Rate Reduction on Visco-elastic Properties of the Arterial Wall (BRADYVASC)[NCT02584439] | Phase 3 | 30 participants (Anticipated) | Interventional | 2015-10-31 | Recruiting | ||
| Pulse Wave Velocity as a Predictor for Postoperative Cardiovascular Events[NCT03223441] | 543 participants (Actual) | Observational | 2015-06-30 | Completed | |||
| Comparison of Peripheral and Cerebral Arterial Flow in Acute Ischemic Stroke: Fimasartan vs. Valsartan vs. Atenolol[NCT02403349] | Phase 4 | 105 participants (Actual) | Interventional | 2012-05-31 | Active, not recruiting | ||
| Longitudinal Change of Arterial Stiffness Indices in Relation to Ambulatory Aortic and Branchial Pressure in Long Term Peritoneal Dialysis Patients[NCT03607747] | 40 participants (Anticipated) | Observational | 2018-07-18 | Recruiting | |||
| GenHAT - Genetics of Hypertension Associated Treatments - Ancillary to ALLHAT[NCT00563901] | 37,939 participants (Actual) | Observational | 2000-09-30 | Completed | |||
| Prevention of Hypertension Incidence and Diabetes Italian Assessment Study. Therapeutic Strategies of Prevention of Diabetes and Hypertension in Subjects With Metabolic Syndrome and High-Normal Blood Pressure.[NCT00456963] | Phase 4 | 3,000 participants (Anticipated) | Interventional | 2007-09-30 | Terminated (stopped due to Because of delay in approval of the protocol by a number of Ethics Commitees the trial was terminated on March 4, 2010. No patient had received any study drug.) | ||
| Glucose Optimisation With Angiotensin II Antagonist Losartan in Patients With Hypertension and Other Risk Factors for Metabolic Syndrome (GOAAL)[NCT00237588] | Phase 4 | 25 participants | Interventional | 2004-12-31 | Completed | ||
| A Randomized Controlled Trial of Influenza Vaccine to Prevent Adverse Vascular Events: A Pilot Study[NCT01945268] | Phase 4 | 107 participants (Actual) | Interventional | 2015-04-30 | Completed | ||
| An Open Label, Pharmacogenetic Study of Bisoprolol Treatment in Patients With Uncontrolled Essential Hypertension (BRAVE)[NCT02398929] | Phase 4 | 100 participants (Actual) | Interventional | 2013-01-31 | Completed | ||
| A 12-week Randomized Double-blind Parallel Group Study to Evaluate the Efficacy and Safety of the Combination Aliskiren With HCTZ Compared to Irbesartan or Amlodipine With HCTZ or HCTZ Alone in Hypertensive Patients With BMI ≥ 30 kg/m2 Not Adequately Resp[NCT00219115] | Phase 3 | 493 participants (Actual) | Interventional | 2005-01-31 | Completed | ||
| Valsartan Versus Amlodipine Effect on Left Ventricular Multidirectional Deformation and Adipocytokines Level in Hypertensive Patients: Speckle Tracking Echocardiography[NCT03990480] | Phase 4 | 230 participants (Actual) | Interventional | 2018-12-01 | Completed | ||
| [NCT01652339] | Phase 1 | 40 participants (Actual) | Interventional | 2012-07-31 | Completed | ||
| Improving Equitable Acces and Adherence to Secondary Prevention Therapy With a Fixed-Dose Combination Drug[NCT01321255] | Phase 3 | 2,118 participants (Actual) | Interventional | 2012-01-31 | Completed | ||
| A Double-blind, Randomized, Multicenter Study to Evaluate the Effectiveness of the Combination of Valsartan & Amlodipine in Hypertensive Patients Not Controlled on Monotherapy[NCT00327145] | Phase 3 | 894 participants (Actual) | Interventional | 2006-03-31 | Completed | ||
| An Multicenter Study to Evaluate the Efficacy and Tolerability of a 4-week Therapy With the Combination of Valsartan 160mg + Amlodipine 5mg in Hypertensive Patients Not Adequately Responding to 4-week Treatment With Amlo 5mg or Felodipine 5mg in Monothera[NCT00392262] | Phase 3 | 224 participants (Actual) | Interventional | 2006-08-31 | Completed | ||
| Efficacy and Tolerability of Combination Antihypertensive Drug in Non-Responders to Angiotensin Receptor Blocker(ARB) monoTHerapy Using 24h ABPM.[NCT01713920] | Phase 4 | 68 participants (Actual) | Interventional | 2010-04-30 | Completed | ||
| Fixed-Dose Combination of Perindopril/Amlodipine (Amlessa®) and Fixed-Dose Combination of Perindopril/Indapamide /Amlodipine (Co-Amlessa®) - Contribution to Management in Newly Diagnosed and Uncontrolled Hypertensive Patients[NCT03738761] | Phase 4 | 471 participants (Actual) | Interventional | 2018-02-13 | Completed | ||
| [NCT00000522] | Phase 2 | 0 participants | Interventional | 1985-08-31 | Completed | ||
| Influence of Treatment With the HMG-CoA-Reductase Inhibitor Fluvastatin on Erectile Function in Patients With Cardiovascular Risk-Factors and Erectile Dysfunction[NCT00382161] | Phase 3 | 20 participants (Anticipated) | Interventional | 2006-10-31 | Withdrawn (stopped due to not enough patients meeting inclusion criteria) | ||
| Improving Hypertension Control in Individuals With Diabetes[NCT00743808] | 11,510 participants (Actual) | Observational | 2006-12-31 | Completed | |||
| Comparative Study of Effect of Valsartan 160mg Treatment Versus Continuous Positive Airway Pressure on Arterial Blood Pressure in Patients Who Have an Obstructive Sleep Apnea Syndrome and a Weak or Moderate Hypertension.[NCT00409487] | Phase 4 | 60 participants (Anticipated) | Interventional | 2006-12-31 | Completed | ||
| Molecular Mechanisms of Volume Overload-Aim 1(SCCOR in Cardiac Dysfunction and Disease)[NCT01052428] | Phase 2/Phase 3 | 38 participants (Actual) | Interventional | 2004-08-31 | Completed | ||
| Phase 2/3 Study of Effect of AT1RB Versus ACE Inhibitor in Addition to XO Inhibitor on Progression of LV Remodeling and Dysfunction in Diabetic Patients With Acute MI.[NCT01052272] | Phase 2/Phase 3 | 72 participants (Actual) | Interventional | 2005-07-31 | Completed | ||
| Open, Randomized, Unicenter Study Comparing Metabolic Surgery With Intensive Medical Therapy to Treat Diabetic Kidney Disease[NCT04626323] | Phase 2 | 60 participants (Anticipated) | Interventional | 2021-05-25 | Recruiting | ||
| Determinants of Diabetic Nephropathy in American Indians[NCT01878045] | 141 participants (Actual) | Observational | 2013-11-07 | Suspended (stopped due to This study is on a temporary Administrative Hold pending further discussion for NIDDK and Tribal Leadership.) | |||
| Desferal Administration to Improve the Impaired Reaction to Hypoxia in Diabetes[NCT03085771] | Phase 2 | 30 participants (Anticipated) | Interventional | 2017-01-01 | Recruiting | ||
| Verapamil as Adjunctive Seizure Therapy for Children and Young Adults With Dravet Syndrome[NCT01607073] | Phase 2 | 2 participants (Actual) | Interventional | 2012-04-30 | Completed | ||
| South Danish Hypertension and Diabetes Study[NCT01062763] | Phase 3 | 119 participants (Actual) | Interventional | 2010-03-31 | Completed | ||
| Comparison of Single and Combination Diuretics in Low-Renin Hypertension[NCT02351973] | Phase 4 | 423 participants (Actual) | Interventional | 2009-11-30 | Active, not recruiting | ||
| Optimum Treatment for Drug-Resistant Hypertension[NCT02369081] | Phase 4 | 348 participants (Actual) | Interventional | 2009-05-31 | Active, not recruiting | ||
| Amlodipine Versus Nifedipine ER for the Management of Postpartum Hypertension: A Randomized Controlled Noninferiority Trial[NCT04790279] | Phase 4 | 132 participants (Actual) | Interventional | 2021-04-09 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Polypill versus usual care (NCT02278471)
Timeframe: 12 months
| Intervention | mg/dL (Mean) |
|---|---|
| Usual Care | 109 |
| Polypill | 98 |
polypill versus usual care (NCT02278471)
Timeframe: 2 months
| Intervention | mg/dL (Mean) |
|---|---|
| Usual Care | 108 |
| Polypill | 90 |
polypill-percentage of pills taken, evaluated via pill counts (NCT02278471)
Timeframe: 2 months
| Intervention | percentage of pills taken (Median) |
|---|---|
| Polypill | 98 |
polypill arm-evaluation via pill counts. (NCT02278471)
Timeframe: 12 months
| Intervention | percentage of pills taken (Median) |
|---|---|
| Polypill | 86 |
polypill versus usual care (NCT02278471)
Timeframe: 12 months
| Intervention | mm Hg (Mean) |
|---|---|
| Usual Care | 138 |
| Polypill | 131 |
polypill versus usual care (NCT02278471)
Timeframe: 2 months
| Intervention | mm Hg (Mean) |
|---|---|
| Usual Care | 133 |
| Polypill | 128 |
The sitting blood pressure was trough value (23-26 hours after drug administration) measured by sphygmomanometer. Blood pressure was measured on both arms and the arm with higher msDBP was used at visit 1 and following visits. Measurement of blood pressure was carried out 3 times at each visit on the selected arm. The results and mean value of three sitting blood pressures were recorded for analysis. (NCT01167153)
Timeframe: Baseline, 12 weeks
| Intervention | mm Hg (Mean) |
|---|---|
| Valsartan/Amlodipine | -8.5 |
| Nifedipine | -4.8 |
The sitting blood pressure was trough value (23-26 hours after drug administration) measured by sphygmomanometer. Blood pressure was measured on both arms and the arm with higher mean sitting diastolic blood pressure (MSDBP) was used at visit 1 and following visits. Measurement of blood pressure was carried out 3 times at each visit on the selected arm. The results and mean value of three sitting blood pressures were recorded for analysis. (NCT01167153)
Timeframe: Baseline, 12 weeks
| Intervention | mm Hg (Mean) |
|---|---|
| Valsartan/Amlodipine | -16.8 |
| Nifedipine | -10.6 |
Orthostatic pulse was measured by sphygmomanometer when subject stood for 1 minute at clinic during each visit. (NCT01167153)
Timeframe: Baseline, 12 weeks
| Intervention | beats/min (Mean) |
|---|---|
| Valsartan/Amlodipine | -0.6 |
| Nifedipine | 0.4 |
Sitting pulse was measured by sphygmomanometer after subject sat for 5 minutes at clinic during each visit. (NCT01167153)
Timeframe: Baseline, 12 weeks
| Intervention | beats/min (Mean) |
|---|---|
| Valsartan/Amlodipine | -1.1 |
| Nifedipine | 0.0 |
Blood Pressure (BP) target was defined as mean sitting BP<140/90 mm Hg in non-diabetic patients and<130/80 mm Hg in diabetic patients at 12 weeks. (NCT01167153)
Timeframe: 12 weeks
| Intervention | Percentage of participants (Number) |
|---|---|
| Valsartan/Amlodipine | 79.03 |
| Nifedipine | 57.36 |
The arm with higher sitting blood pressure was selected for all examinations throughout the study. Orthostatic blood pressure was measured when subject stood for 1 minute. Orthostatic blood pressures were measured at screening and each visit. (NCT01167153)
Timeframe: Baseline, 12 weeks
| Intervention | mm Hg (Mean) | |
|---|---|---|
| Orthostatic diastolic blood pressure | Orthostatic systolic blood pressure | |
| Nifedipine | -3.3 | -8.6 |
| Valsartan/Amlodipine | -7.2 | -13.3 |
"Effective SBP control rate was defined as proportion of subjects in whom MSSBP < 140 mmHg or MSSBP reduction ≥ 20 mmHg from baseline.~Effective DBP control rate was defined as proportion of subjects in whom MSDBP < 90 mmHg or MSDBP reduction ≥10 mmHg from baseline." (NCT01167153)
Timeframe: Baseline, 12 weeks
| Intervention | Percentage of participants (Number) | |
|---|---|---|
| Achieving Effective SBP Control | Achieving Effective DBP Control | |
| Nifedipine | 63.40 | 76.98 |
| Valsartan/Amlodipine | 82.40 | 92.88 |
The insulin sensitivity index was assessed by hyperinsulinemic euglycemic clamp (HEGC). A positive change from baseline indicates improvement. (NCT01631864)
Timeframe: baseline, 8 weeks
| Intervention | ug/kg*min/(mmol/L*pmol/L) (Mean) |
|---|---|
| LCZ696 | 0.192 |
| Amlodipine | 0.065 |
Lipolysis was assessed through subcutaneous adipose tissue microdialysis. The actual measure type is adjusted geometric mean. (NCT01631864)
Timeframe: 57 days
| Intervention | micro mol/L (Geometric Mean) |
|---|---|
| LCZ696 | 82.46 |
| Amlodipine | 65.91 |
Oxidative metabolism was assessed by indirect calorimetry. (NCT01631864)
Timeframe: 57 days
| Intervention | carbon dioxide to oxygen ratio (Least Squares Mean) |
|---|---|
| LCZ696 | 0.787 |
| Amlodipine | 0.775 |
Adverse event monitoring was conducted throughout the study. (NCT01631864)
Timeframe: 8 weeks
| Intervention | Participants (Number) | ||
|---|---|---|---|
| Adverse events (serious and non-serious) | Serious adverse events | Deaths | |
| Amlodipine | 37 | 1 | 0 |
| LCZ696 | 30 | 1 | 0 |
For each n-of-1 trial, the preferred drug is defined as that which produces normal ambulatory blood pressure (by pediatric Ambulatory blood pressure monitoring (ABPM) standards), with the greatest magnitude of wake mean systolic BP reduction, and without unacceptable side effects. (NCT02412761)
Timeframe: The outcome of BP control and side effect tolerability will be assessed 2 weeks after starting each drug. Participants will be followed for an average of 10-12 weeks.
| Intervention | Participants (Count of Participants) |
|---|---|
| Lisinopril | 16 |
| Amlodipine | 8 |
| Hydrochlorothiazide | 4 |
(NCT00407537)
Timeframe: Baseline, Month 12
| Intervention | mmHg (Least Squares Mean) |
|---|---|
| Caduet | -10.0128 |
| Usual Care | -6.8429 |
(NCT00407537)
Timeframe: Baseline, Month 4
| Intervention | mmHG (Least Squares Mean) |
|---|---|
| Caduet | -8.3024 |
| Usual Care | -6.6908 |
(NCT00407537)
Timeframe: Baseline, Month 12
| Intervention | mmHg (Least Squares Mean) |
|---|---|
| Caduet | -18.2409 |
| Usual Care | -12.4903 |
(NCT00407537)
Timeframe: Baseline, Month 4
| Intervention | mmHG (Least Squares Mean) |
|---|---|
| Caduet | -15.3088 |
| Usual Care | -12.1619 |
European SCORE: designed to measure cardiovascular disease mortality; computed using age, gender, whether a person lives in a low risk or high risk region, measured total cholesterol, measured HDL cholesterol, systolic blood pressure, and current smoking status. The coefficients were used to derive the score calculated after 4 months of study treatment (Month 4). (NCT00407537)
Timeframe: Baseline, Month 4
| Intervention | percent risk (Mean) |
|---|---|
| Caduet | 3.1 |
| Usual Care | 3.7 |
European SCORE: designed to measure cardiovascular disease mortality; computed using age, gender, whether a person lives in a low risk or high risk region, measured total cholesterol, measured HDL cholesterol, systolic blood pressure, and current smoking status. The coefficients were used to derive the score calculated after 12 months of study treatment (Month 12). (NCT00407537)
Timeframe: Baseline, Month 12
| Intervention | percent risk (Mean) |
|---|---|
| Caduet | 3.0 |
| Usual Care | 3.7 |
"Stroke risk calculated from the Framingham risk for CVD (CHD, stroke, intermittent claudication, congestive heart failure) multiplied by a gender-specific calibration factor for the stroke component risk. Coefficients were used to derive the score calculated at the end of study treatment (Month 12)." (NCT00407537)
Timeframe: Baseline, Month 12
| Intervention | percent risk (Mean) |
|---|---|
| Caduet | 3.7 |
| Usual Care | 4.9 |
"Stroke risk calculated from the Framingham risk for CVD (CHD, stroke, intermittent claudication, congestive heart failure) multiplied by a gender-specific calibration factor for the stroke component risk. Coefficients were used to derive the score calculated at the end of study treatment (Month 12)." (NCT00407537)
Timeframe: Baseline, Month 4
| Intervention | percent risk (Mean) |
|---|---|
| Caduet | 3.7 |
| Usual Care | 4.9 |
Framingham prediction of 10-year risk of CHD: Gender-specific prediction equations formulated to predict CHD risk according to age, diabetes, smoking, blood pressure categories, and total cholesterol and low density lipoprotein (LDL) cholesterol categories. The coefficients were used to derive the score calculated after 4 months of treatment (Month 4). (NCT00407537)
Timeframe: Baseline, Month 4
| Intervention | percent risk (Mean) |
|---|---|
| Caduet | 12.5 |
| Usual Care | 16.3 |
Framingham prediction of 10-year risk of CHD: Gender-specific prediction equations formulated to predict CHD risk according to age, diabetes, smoking, blood pressure categories, and total cholesterol and low density lipoprotein (LDL) cholesterol categories. The coefficients were used to derive the score calculated at the end of study treatment (Month 12). (NCT00407537)
Timeframe: Baseline, Month 12
| Intervention | percent risk (Mean) |
|---|---|
| Caduet | 12.5 |
| Usual Care | 16.3 |
European SCORE: designed to measure cardiovascular disease mortality; computed using age, gender, whether a person lives in a low risk or high risk region, measured total cholesterol, measured HDL cholesterol, systolic blood pressure, and current smoking status. Change from baseline calculated as mean at observation minus mean at Baseline. (NCT00407537)
Timeframe: Baseline, Month 4, Month 12
| Intervention | percent risk (Least Squares Mean) | |
|---|---|---|
| Month 4 | Month 12 | |
| Caduet | -1.8438 | -1.9693 |
| Usual Care | -0.9678 | -0.9963 |
Framingham prediction of 10-year risk of CHD: Gender-specific prediction equations formulated to predict CHD risk according to age, diabetes, smoking, blood pressure categories, and total cholesterol and low density lipoprotein (LDL) cholesterol categories. Change from baseline calculated as mean at observation minus mean at Baseline. (NCT00407537)
Timeframe: Baseline, Month 4, Month 12
| Intervention | percent risk (Least Squares Mean) | |
|---|---|---|
| Month 4 | Month 12 | |
| Caduet | -7.2705 | -7.2374 |
| Usual Care | -2.5155 | -2.5167 |
Mean Total Cholesterol (TC), Low Density Lipoprotein (LDL), High Density Lipoprotein (HDL), and Triglyceride blood concentrations. (NCT00407537)
Timeframe: Baseline, Month 12
| Intervention | mg/dL (Least Squares Mean) | |||
|---|---|---|---|---|
| TC | LDL | HDL | Triglycerides | |
| Caduet | -37.1024 | -33.2420 | -0.4339 | -15.2270 |
| Usual Care | -4.0368 | -3.4168 | -1.0105 | 3.0398 |
Mean Total Cholesterol (TC), Low Density Lipoprotein (LDL), High Density Lipoprotein (HDL), and Triglyceride blood concentrations. Change from baseline measured as mean at Month 4 minus mean at Baseline. (NCT00407537)
Timeframe: Baseline, Month 4
| Intervention | mg/dL (Least Squares Mean) | |||
|---|---|---|---|---|
| TC | LDL | HDL | Triglycerides | |
| Caduet | -42.7542 | -38.2765 | -0.2060 | -20.5645 |
| Usual Care | -3.8144 | -2.9628 | -1.1978 | 3.0828 |
Mean Total Cholesterol (TC), Low Density Lipoprotein (LDL), High Density Lipoprotein (HDL), and Triglyceride blood concentrations. (NCT00407537)
Timeframe: Month 12
| Intervention | mg/dL (Mean) | |||
|---|---|---|---|---|
| TC | LDL | HDL | Triglycerides | |
| Caduet | 163.3 | 87.1 | 47.3 | 151.5 |
| Usual Care | 196.6 | 117.3 | 47.1 | 166.4 |
Mean Total Cholesterol (TC), Low Density Lipoprotein (LDL), High Density Lipoprotein (HDL), and Triglyceride blood concentrations. (NCT00407537)
Timeframe: Month 4
| Intervention | mg/dL (Mean) | |||
|---|---|---|---|---|
| TC | LDL | HDL | Triglycerides | |
| Caduet | 156.0 | 80.9 | 47.6 | 143.5 |
| Usual Care | 195.2 | 116.4 | 46.8 | 164.8 |
(NCT00407537)
Timeframe: Month 12
| Intervention | mmHg (Mean) | |
|---|---|---|
| Systolic | Diastolic | |
| Caduet | 130.6 | 79.2 |
| Usual Care | 134.3 | 81.1 |
(NCT00407537)
Timeframe: Month 4
| Intervention | mmHg (Mean) | |
|---|---|---|
| Systolic | Diastolic | |
| Caduet | 133.5 | 80.7 |
| Usual Care | 134.5 | 81.1 |
Treatments indicative of prescribed medications other than study provided Caduet. (NCT00407537)
Timeframe: Month 4
| Intervention | Participants (Number) | ||||
|---|---|---|---|---|---|
| Increased dose | increased dose of anti-hypertensive medications | increased dose of lipid lowering medications | increase in either medication | increase in both medications | |
| Caduet | 30 | 30 | 0 | 4 | 0 |
| Usual Care | 90 | 88 | 2 | 45 | 0 |
Treatments indicative of prescribed medications other than study provided Caduet. (NCT00407537)
Timeframe: Month 4, Month 12
| Intervention | participants (Number) | |||||||
|---|---|---|---|---|---|---|---|---|
| Month 4: anti-hypertensive and/or lipid lowering | Month 4: anti-hypertensive | Month 4: lipid lowering | Month 4: anti-hypertensive and lipid lowering | Month 12: anti-hypertensive and/or lipid lowering | Month 12: anti-hypertensive | Month 12: lipid lowering | Month 12: anti-hypertensive and lipid lowering | |
| Caduet | 648 | 647 | 45 | 44 | 655 | 654 | 46 | 45 |
| Usual Care | 642 | 637 | 202 | 197 | 642 | 638 | 208 | 204 |
Goals set at <140/90 mmHg according to the seventh Joint National Committee (JNC) on prevention, detection, evaluation, and treatment of high blood pressure and <140/90 mm Hg or <130/80 mm Hg for diabetics ccording to the European Society of Cardiology (ESC) guidelines. (NCT00407537)
Timeframe: Month 4, Month 12
| Intervention | percentage of participants (Number) | |||
|---|---|---|---|---|
| JNC Month 4 | JNC Month 12 | ESC Month 4 | ESC Month 12 | |
| Caduet | 65.2 | 76.1 | 48.6 | 58.2 |
| Usual Care | 62.6 | 60.6 | 46.0 | 47.5 |
Goal set at <100 mg/dL according to the United States (US) National Cholesterol Education Program Adult Treatment Panel 3 and at <80 mg/dL according to the European (EU) Society of Cardiology guidelines. (NCT00407537)
Timeframe: Month 4, Month 12
| Intervention | Percentage of participants (Number) | |||
|---|---|---|---|---|
| US Month 4 | US Month 12 | EU Month 4 | EU Month 12 | |
| Caduet | 77.3 | 71.9 | 52.4 | 46.7 |
| Usual Care | 28.2 | 28.8 | 13.3 | 11.5 |
This variable gives the proportion of patients reaching blood pressure control over time (< 140 mmHg systolic and < 90 mmHg diastolic) (NCT01030458)
Timeframe: 6 months follow-up after randomization
| Intervention | participants (Number) |
|---|---|
| Amlodipine Plus Valsartan | 58 |
| Hydrochlorothiazide Plus Bisoprolol | 40 |
(NCT01030458)
Timeframe: 6 months follow-up after randomization
| Intervention | participants (Number) |
|---|---|
| Amlodipine Plus Valsartan | 1 |
| Hydrochlorothiazide Plus Bisoprolol | 1 |
Blood pressure is measured by means of validated oscillometric OMRON 705IT recorders (OMRON Healthcare Europe BV, Nieuwegein, Netherlands), after the patient has been seated for 5 minutes in a quiet room, according to the ESC/ESH guidelines. Three consecutive blood pressure readings are obtained and the average of these 3 measurements is used as the primary outcome. (NCT01030458)
Timeframe: 6 months follow-up after randomization
| Intervention | mmHg (Mean) |
|---|---|
| Amlodipine Plus Valsartan | 127.2 |
| Hydrochlorothiazide Plus Bisoprolol | 134.1 |
The time (in weeks) after randomisation that will be required to reach and maintain the target, defined as a blood pressure below 140 mmHg systolic and 90 mmHg diastolic. (NCT01030458)
Timeframe: 6 months follow-up after randomization
| Intervention | weeks (Median) |
|---|---|
| Amlodipine Plus Valsartan | 12 |
| Hydrochlorothiazide Plus Bisoprolol | 18 |
(NCT00081731)
Timeframe: Measured at every 3 months for the first year and annually thereafter
| Intervention | participants (Number) |
|---|---|
| Optimal Medical Therapy | 77 |
| Stenting | 68 |
(NCT00081731)
Timeframe: Measured at every 3 months for the first year and annually thereafter
| Intervention | participants (Number) |
|---|---|
| Optimal Medical Therapy | 20 |
| Stenting | 20 |
Only the first event per participant is included in the composite (NCT00081731)
Timeframe: Measured at every 3 months for the first year and annually thereafter
| Intervention | participants (Number) |
|---|---|
| Optimal Medical Therapy | 169 |
| Stenting | 161 |
(NCT00081731)
Timeframe: Measured at every 3 months for the first year and annually thereafter
| Intervention | participants (Number) |
|---|---|
| Optimal Medical Therapy | 26 |
| Stenting | 27 |
(NCT00081731)
Timeframe: Measured at every 3 months for the first year and annually thereafter
| Intervention | participants (Number) |
|---|---|
| Optimal Medical Therapy | 27 |
| Stenting | 30 |
(NCT00081731)
Timeframe: Measured at every 3 months for the first year and annually thereafter
| Intervention | participants (Number) |
|---|---|
| Optimal Medical Therapy | 3 |
| Stenting | 4 |
(NCT00081731)
Timeframe: Measured at every 3 months for the first year and annually thereafter
| Intervention | participants (Number) |
|---|---|
| Optimal Medical Therapy | 16 |
| Stenting | 12 |
Seated trough DBP after 4 weeks. (NCT01103960)
Timeframe: Baseline and 4 weeks
| Intervention | mmHg (Mean) |
|---|---|
| A5 Alone | -7.51 |
| T80/A5 | -9.41 |
Seated trough DBP after 8 weeks or last observation carried forward (LOCF). Analysis will be adjusted for treatment, country, and baseline measurement of endpoint. (NCT01103960)
Timeframe: Baseline and 8 weeks
| Intervention | mmHg (Least Squares Mean) |
|---|---|
| A5 Alone | -10.19 |
| T80/A5 | -12.38 |
Seated trough DBP after 8 weeks or LOCF in Chinese patients. Analysis will be adjusted for treatment and baseline measurement of endpoint. (NCT01103960)
Timeframe: Baseline and 8 weeks
| Intervention | mmHg (Least Squares Mean) |
|---|---|
| A5 Alone | -8.85 |
| T80/A5 | -10.77 |
Seated trough SBP after 4 weeks. (NCT01103960)
Timeframe: Baseline and 4 weeks
| Intervention | mmHg (Mean) |
|---|---|
| A5 Alone | -8.19 |
| T80/A5 | -12.10 |
Seated trough SBP after 8 weeks or LOCF. Analysis will be adjusted for treatment, country, and baseline measurement of endpoint. (NCT01103960)
Timeframe: Baseline and 8 weeks
| Intervention | mmHg (Least Squares Mean) |
|---|---|
| A5 Alone | -11.66 |
| T80/A5 | -16.15 |
Clinically relevant abnormalities for Physical examination, pulse rate, laboratory parameters and ECG. New abnormal findings or worsening of baseline conditions were reported as Adverse Events. (NCT01103960)
Timeframe: From drug administration until end of treatment plus one day
| Intervention | participants (Number) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Atrial fibrilation | Myocardial ischaemia | Blood glucose increased | Protein urine present | Alanine aminotransferase increased | Blood creatinine phosphokinase increased | Blood creatinine increased | Blood glucose abnormal | Heart rate increased | |
| A5 Alone | 0 | 1 | 1 | 2 | 0 | 1 | 0 | 1 | 0 |
| T80/A5 | 1 | 0 | 4 | 1 | 1 | 0 | 1 | 1 | 1 |
DBP control is defined as DBP <90 mmHg or <80 mmHg in patients with diabetes or renal impairment. SBP control is defined as SBP <140 mmHg or <130 mmHg in patients with diabetes or renal impairment. DBP response is defined as DBP <90 mmHg or <80 mmHg in patients with diabetes or renal impairment or a reduction from baseline >=10mmHg. SBP response is defined as SBP<140 mmHg or <130 mmHg in patients with diabetes or renal impairment or a reduction from baseline >=15mmHg. (NCT01103960)
Timeframe: Baseline and 4 weeks
| Intervention | Number of participants (Number) | |||
|---|---|---|---|---|
| DBP control | SBP control | DBP response | SBP response | |
| A5 Alone | 71 | 91 | 87 | 108 |
| T80/A5 | 95 | 103 | 108 | 124 |
DBP control is defined as DBP <90 mmHg or <80 mmHg in patients with diabetes or renal impairment. SBP control is defined as SBP <140 mmHg or <130 mmHg in patients with diabetes or renal impairment. DBP response is defined as DBP <90 mmHg or <80 mmHg in patients with diabetes or renal impairment or a reduction from baseline >=10mmHg. SBP response is defined as SBP<140 mmHg or <130 mmHg in patients with diabetes or renal impairment or a reduction from baseline >=15mmHg. (NCT01103960)
Timeframe: Baseline and 8 weeks
| Intervention | Number of participants (Number) | |||
|---|---|---|---|---|
| DBP control | SBP control | DBP response | SBP response | |
| A5 Alone | 85 | 100 | 101 | 120 |
| T80/A5 | 112 | 119 | 124 | 131 |
BP optimal: SBP <120 mmHg and DBP <80 mmHg, BP normal: SBP <130 mmHg and DBP <85 mmHg but not optimal, BP high-normal: SBP <140 mmHg and DBP <90 mmHg but not normal. Grade 1 hypertension: SBP <160 mmHg and DBP <100 mmHg but not high-normal, Grade 2 hypertension: SBP <180 mmHg and DBP <110 mmHg but not grade 1, Grade 3 hypertension: SBP >=180 mmHg or DBP >=110 mmHg. (NCT01103960)
Timeframe: 4 weeks
| Intervention | Number of participants (Number) | |||||
|---|---|---|---|---|---|---|
| BP optimal | BP normal | BP high-normal | Grade 1 hypertension | Grade 2 hypertension | Grade 3 hypertension | |
| A5 Alone | 1 | 20 | 35 | 81 | 17 | 5 |
| T80/A5 | 7 | 26 | 44 | 62 | 15 | 1 |
BP optimal: SBP <120 mmHg and DBP <80 mmHg, BP normal: SBP <130 mmHg and DBP <85 mmHg but not optimal, BP high-normal: SBP <140 mmHg and DBP <90 mmHg but not normal. Grade 1 hypertension: SBP <160 mmHg and DBP <100 mmHg but not high-normal, Grade 2 hypertension: SBP <180 mmHg and DBP <110 mmHg but not grade 1, Grade 3 hypertension: SBP >=180 mmHg or DBP >=110 mmHg. (NCT01103960)
Timeframe: 8 weeks
| Intervention | Number of participants (Number) | |||||
|---|---|---|---|---|---|---|
| BP optimal | BP normal | BP high-normal | Grade 1 hypertension | Grade 2 hypertension | Grade 3 hypertension | |
| A5 Alone | 7 | 33 | 32 | 69 | 15 | 3 |
| T80/A5 | 11 | 36 | 53 | 48 | 5 | 2 |
The composite CV endpoint is based on the following first adjudicated events: CV death, non-fatal MI,non-fatal stroke, significant heart failure (NCT01259297)
Timeframe: End of study (209 days (median))
| Intervention | participants (Number) |
|---|---|
| Aliskiren Based Regimen | 11 |
| Non-Aliskiren Based Regimen | 14 |
The composite CV endpoint is based on the following first adjudicated events: CV death, non-fatal MI,non-fatal stroke, significant heart failure (NCT01259297)
Timeframe: End of study (209 days (median))
| Intervention | participants (Number) |
|---|---|
| Aliskiren+Amlodipine/HCTZ Group | 2 |
| Placebo | 8 |
The total mortality endpoint was defined as time to death from any cause. Total mortality analysis used the date of last follow-up including the washout period as the censoring date. (NCT01259297)
Timeframe: End of study (209 days (median))
| Intervention | Participants (Number) |
|---|---|
| Aliskiren Based Regimen | 5 |
| Non-Aliskiren Based Regimen | 9 |
Mean sitting diastolic blood pressure (msDBP) is the average of 2 sitting DBP measurements (2 minutes apart). Since each patient had their final follow-up visit at a different time in the trial, these measurements were classified as falling into the 6 week, 6 month, or 12 month measurement period. All available blood pressures were sorted within these periods and the last value within each time range used for analysis. At each timepoint, a patient must have both baseline and postbaseline values to be included in the analysis. (NCT01259297)
Timeframe: Baseline (BL), 6 week, 6 month and 12 month
| Intervention | mmHg (Least Squares Mean) | ||
|---|---|---|---|
| change from Baseline to 6 week (n=821,867) | change from baseline to 6 month (n=730,775) | change from baseline to 12 month (n=397,399) | |
| Aliskiren Based Regimen | -5.6 | -4.9 | -4.3 |
| Non-Aliskiren Based Regimen | -3.6 | -3.5 | -3.9 |
Mean sitting systolic blood pressure (msSBP) is the average of 2 sitting SBP measurements (2 minutes apart). Since each patient had their final follow-up visit at a different time in the trial, these measurements were classified as falling into the 6 week, 6 month, or 12 month measurement period. All available blood pressures were sorted within these periods and the last value within each time range used for analysis. At each timepoint, a patient must have both baseline and postbaseline values to be included in the analysis. (NCT01259297)
Timeframe: Baseline (BL), 6 week, 6 month and 12 month
| Intervention | mmHg (Least Squares Mean) | ||
|---|---|---|---|
| change from Baseline to 6 week (n=821,867) | change from baseline to 6 month (n=730,775) | change from baseline to 12 month (n=397,399) | |
| Aliskiren Based Regimen | -11.9 | -10.1 | -7.7 |
| Non-Aliskiren Based Regimen | -8.02 | -6.8 | -5.8 |
"Decline in ability to perform everyday activities independently was measured primarily by using the Standard Assessment of Global Activities in the Elderly (SAGE) scale. The SAGE comprised of 15 questions, each describing an activity. Patient had to indicate how much difficulty he/she had encountered in performing the activity in last month. Each question's score ranges from 0 (No difficulty) to 3 (difficulty levels were mild (score = 1), moderate (score =2) and severe (score=3)). Part I of SAGE included 4 dimensions:~Community Cognition (maximum of scores of questions 1 to 6);~Instrumental Activities of daily Living (IADL) (maximum of scores of questions 7 to 10);~Mobility (maximum of scores of questions 11 and 12);.~Basic Activities of daily Living (ADL) (maximum of scores of questions 13 to 15) Each dimension's total score ranged from 0 to 3. 0=best, 3=worst A negative change in value from baseline means improvement in the ability to perform everyday activities." (NCT01259297)
Timeframe: Baseline, End of study (209 days [median])
| Intervention | units on a scale (Mean) | |||
|---|---|---|---|---|
| Community Cognition | Instrumental Activities of daily Living (IADL) | Mobility | ADL | |
| Aliskiren Based Regimen | -0.04 | -0.06 | 0.01 | -0.09 |
| Non-Aliskiren Based Regimen | -0.05 | -0.04 | 0.00 | -0.08 |
"The renal dysfunction (composite endpoint) was defined as the first occurrence of either of the following:~End-stage renal disease [ESRD] requiring dialysis or transplantation~Doubling of serum creatinine and reaching an eGFR < 45 ml/min/1.73 m^2." (NCT01259297)
Timeframe: End of study (209 days (median))
| Intervention | participants (Number) | |
|---|---|---|
| ESRD requiring dialysis or transplantation | Doubling of creatinine & eGFR<45 ml/min/1.73 m^2 | |
| Aliskiren Based Regimen | 0 | 7 |
| Non-Aliskiren Based Regimen | 0 | 1 |
"Decline in ability to perform everyday activities independently was measured primarily by using the Standard Assessment of Global Activities in the Elderly (SAGE) scale. The SAGE was comprised of 15 questions, each describing an activity. Patient had to indicate how much difficulty he/she had encountered in performing the activity in the last month. Each question's score ranges from 0 (No difficulty) to 3 (difficulty levels were mild (score = 1), moderate (score =2) and severe (score=3)).~Part II of SAGE included 2 dimensions:~Normal if the scores of all SAGE questions is 0 (i.e., No difficulty)~Mobility Only if scores of both SAGE questions 11 and 12 are 0" (NCT01259297)
Timeframe: End of study (209 days [median])
| Intervention | percentage of participants (Number) | |
|---|---|---|
| Normal | Mobility Only | |
| Aliskiren Based Regimen | 44.2 | 66.8 |
| Non-Aliskiren Based Regimen | 46.5 | 68.6 |
Baseline blood pressure was defined as the average values obtained at the randomization visit and at the visit prior to randomization (NCT00923091)
Timeframe: Baseline to week 10
| Intervention | mm HG (Least Squares Mean) |
|---|---|
| Olmesartan/Amlodipine/Hydrochlorothiazide 20mg/5mg/12.5 mg | -22.5 |
| Olmesartan/Amlodipine/Hydrochlorothiazide 40mg/5mg/12.5mg | -22.5 |
| Olmesartan/Amlodipine/Hydrochlorothiazide 40mg/5mg/25mg | -23.0 |
| Olmesartan/Amlodipine/Hydrochlorothiazide 40mg/10mg/12.5mg | -23.9 |
| Olmesartan/Amlodipine/Hydrochlorothiazide 40mg/10mg/25mg | -23.8 |
| Olmesartan/Amlodipine 20mg/5mg | -20.5 |
| Olmesartan/Amlodipine 40mg/5mg | -21.2 |
| Olmesartan/Amlodipine 40mg/10mg | -22.1 |
(NCT00923091)
Timeframe: Week 18 to week 22
| Intervention | mm Hg (Least Squares Mean) |
|---|---|
| Olmesartan/Amlodipine/Hydrochlorothiazide 20mg/5mg/12.5 mg | -3.3 |
| Olmesartan/Amlodipine/Hydrochlorothiazide 40mg/5mg/12.5mg | -4.1 |
(NCT00923091)
Timeframe: Week 22 to week 26
| Intervention | mm Hg (Least Squares Mean) |
|---|---|
| OLM/AML/HCTZ 40/5/12.5mg Nonresponders Randomized to 40/5/12.5 | -2.7 |
| OLM/AML/HCTZ 40/5/12.5mg Nonresponders Randomized to 40/5/25 | -3.8 |
(NCT00923091)
Timeframe: Week 26 to week 54
| Intervention | mm Hg (Mean) |
|---|---|
| OLM/AML/HCTZ 40/5/25 Titrated to 40/10/25 | -11.9 |
(NCT00923091)
Timeframe: Baseline to week 10
| Intervention | mm Hg (Least Squares Mean) |
|---|---|
| Olmesartan/Amlodipine/Hydrochlorothiazide 20mg/5mg/12.5 mg | -33.2 |
| Olmesartan/Amlodipine/Hydrochlorothiazide 40mg/5mg/12.5mg | -33.7 |
| Olmesartan/Amlodipine/Hydrochlorothiazide 40mg/5mg/25mg | -35.3 |
| Olmesartan/Amlodipine/Hydrochlorothiazide 40mg/10mg/12.5mg | -35.5 |
| Olmesartan/Amlodipine/Hydrochlorothiazide 40mg/10mg/25mg | -36.2 |
| Olmesartan/Amlodipine 20mg/5mg | -29.9 |
| Olmesartan/Amlodipine 40mg/5mg | -30.4 |
| Olmesartan/Amlodipine 40mg/10mg | -32.8 |
(NCT00923091)
Timeframe: Week 18 to week 22
| Intervention | mm Hg (Least Squares Mean) |
|---|---|
| Olmesartan/Amlodipine/Hydrochlorothiazide 20mg/5mg/12.5 mg | -5.7 |
| Olmesartan/Amlodipine/Hydrochlorothiazide 40mg/5mg/12.5mg | -6.5 |
(NCT00923091)
Timeframe: Week 22 to week 26
| Intervention | mm Hg (Least Squares Mean) |
|---|---|
| OLM/AML/HCTZ 40/5/12.5mg Nonresponders Randomized to 40/5/12.5 | -4.5 |
| OLM/AML/HCTZ40/5/12.5mg Nonresponders Randomized to 40/5/25 | -6.7 |
Blood pressure treatment goal was defined as blood pressure <140/90 mmHg or <130/80 mmHg for subjects with diabetes, chronic renal disease, or chronic cardiovascular disease. (NCT00923091)
Timeframe: baseline to week 10
| Intervention | Participants (Number) |
|---|---|
| Olmesartan/Amlodipine/Hydrochlorothiazide 20mg/5mg/12.5 mg | 177 |
| Olmesartan/Amlodipine/Hydrochlorothiazide 40mg/5mg/12.5mg | 176 |
| Olmesartan/Amlodipine/Hydrochlorothiazide 40mg/5mg/25mg | 197 |
| Olmesartan/Amlodipine/Hydrochlorothiazide 40mg/10mg/12.5mg | 190 |
| Olmesartan/Amlodipine/Hydrochlorothiazide 40mg/10mg/25mg | 179 |
| Olmesartan/Amlodipine 20mg/5mg | 144 |
| Olmesartan/Amlodipine 40mg/5mg | 155 |
| Olmesartan/Amlodipine 40mg/10mg | 166 |
Blood pressure treatment goal was defined as blood pressure <140/90 mmHg or <130/80 mmHg for subjects with diabetes, chronic renal disease, or chronic cardiovascular disease. (NCT00923091)
Timeframe: Week 22 to week 26
| Intervention | Participants (Number) |
|---|---|
| OLM/AML/HCTZ 40/5/12.5mg Nonresponders Randomized to 40/5/12.5 | 29 |
| OLM/AML/HCTZ 40/5/12.5mg Nonresponders Randomized to 40/5/25 | 47 |
Blood pressure treatment goal was defined as blood pressure <140/90 mmHg or <130/80 mmHg for subjects with diabetes, chronic renal disease, or chronic cardiovascular disease. (NCT00923091)
Timeframe: Week 18 to week 22
| Intervention | Participants (Number) |
|---|---|
| Olmesartan/Amlodipine/Hydrochlorothiazide 20mg/5mg/12.5 mg | 63 |
| Olmesartan/Amlodipine/Hydrochlorothiazide 40mg/5mg/12.5mg | 137 |
Sitting diastolic blood pressure was measured by automated sphygmomanometer pre-dose on Day 1 (baseline) and at 24 ± 2 hours after the last study drug administration at Week 8. The difference between the baseline and Week 8 assessments was calculated and summarized by treatment arm. (NCT01302691)
Timeframe: Baseline and Week 8
| Intervention | mmHg (Least Squares Mean) |
|---|---|
| L50/H12.5/A5 | -9.1 |
| L50 + A5 | -8.0 |
Sitting systolic blood pressure was measured by automated sphygmomanometer pre-dose on Day 1 (baseline) and at 24 ± 2 hours after the last study drug administration at Week 8. The difference between the baseline and Week 8 assessments was calculated and summarized by treatment arm. (NCT01302691)
Timeframe: Baseline and Week 8
| Intervention | mmHg (Least Squares Mean) |
|---|---|
| L50/H12.5/A5 | -13.4 |
| L50 + A5 | -10.2 |
An AE was defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the product, whether or not considered related to the use of the product. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition which was temporally associated with the use of the product, was also an AE. The percentage of participants who experienced at least 1 AE during the 10-week treatment and follow-up period were summarized by study drug received. (NCT01302691)
Timeframe: up to 14 days after last dose of study drug (up to 10 weeks)
| Intervention | Percentage of Participants (Number) |
|---|---|
| L50/H12.5/A5 | 30.5 |
| L50 + A5 | 28.8 |
An AE was defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the product, whether or not considered related to the use of the product. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition which was temporally associated with the use of the product, was also an AE. Percentage of participants that experienced at least 1 AE that was reported as possibly, probably, or definitely related to the study drug by the investigator during the 10-week treatment and follow-up period were summarized by study drug received. (NCT01302691)
Timeframe: up to 14 days after last dose of study drug (up to 10 weeks)
| Intervention | Percentage of Participants (Number) |
|---|---|
| L50/H12.5/A5 | 11.6 |
| L50 + A5 | 3.7 |
An SAE is any AE occurring at any dose or during any use of Sponsor's product that does the following: results in death; is life threatening; results in persistent or significant disability/incapacity; results in or prolongs an existing inpatient hospitalization; is a congenital anomaly/birth defect; is a cancer; is associated with an overdose; is another important medical event. Percentage of participants that experienced at least 1 SAE that was reported as possibly, probably, or definitely related to the study drug by the investigator during the 10-week treatment and follow-up period were summarized by study drug received (NCT01302691)
Timeframe: up to 14 days after last dose of study drug (up to 10 weeks)
| Intervention | Percentage of Participants (Number) |
|---|---|
| L50/H12.5/A5 | 0.0 |
| L50 + A5 | 0.0 |
An SAE is any AE occurring at any dose or during any use of Sponsor's product that does the following: results in death; is life threatening; results in persistent or significant disability/incapacity; results in or prolongs an existing inpatient hospitalization; is a congenital anomaly/birth defect; is a cancer; is associated with an overdose; is another important medical event. The percentage of participants who experienced at least 1 SAE during the 10-week treatment and follow-up period were summarized by study drug received. (NCT01302691)
Timeframe: up to 14 days after last dose of study drug (up to 10 weeks)
| Intervention | Percentage of Participants (Number) |
|---|---|
| L50/H12.5/A5 | 0.6 |
| L50 + A5 | 0.6 |
An AE was defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the product, whether or not considered related to the use of the product. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition which was temporally associated with the use of the product, was also an AE. The percentage of participants who had study drug stopped during the 8-week treatment period due to an AE regardless of whether or not they completed the study was summarized by treatment arm (NCT01302691)
Timeframe: up to 8 weeks
| Intervention | Percentage of Participants (Number) |
|---|---|
| L50/H12.5/A5 | 1.2 |
| L50 + A5 | 0.0 |
Sitting diastolic blood pressure was measured by automated sphygmomanometer pre-dose on Day 1 (baseline) and at 24 ± 2 hours after the last study drug administration at Week 8. The difference between the baseline and Week 8 assessments was calculated and summarized by treatment arm. (NCT01299376)
Timeframe: Baseline and Week 8
| Intervention | mmHg (Least Squares Mean) |
|---|---|
| L50/H12.5/A5 | -12.1 |
| L50/H12.5 | -6.2 |
Sitting systolic blood pressure was measured by automated sphygmomanometer pre-dose on Day 1 (baseline) and at 24 ± 2 hours after the last study drug administration at Week 8. (NCT01299376)
Timeframe: Baseline and Week 8
| Intervention | mmHg (Least Squares Mean) |
|---|---|
| L50/H12.5/A5 | -17.7 |
| L50/H12.5 | -7.5 |
An AE was defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the product, whether or not considered related to the use of the product. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition which was temporally associated with the use of the product, was also an AE. The percentage of participants who experienced at least 1 AE during the 8-week double-blind treatment period were summarized by study drug received. (NCT01299376)
Timeframe: up to Week 8
| Intervention | Percentage of Participants (Number) |
|---|---|
| L50/H12.5/A5 | 27.0 |
| L50/H12.5 | 29.7 |
An AE was defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the product, whether or not considered related to the use of the product. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition which was temporally associated with the use of the product, was also an AE. The percentage of participants that experienced at least 1 AE during long-term period was summarized. (NCT01299376)
Timeframe: Week 9 up to Week 52 for L50/H12.5→L50/H12.5/A5 arm; Week 1 to Week 52 for L50/H12.5/A5→L50/H12.5/A5
| Intervention | Percentage of Participants (Number) |
|---|---|
| L50/H12.5/A5→L50/H12.5/A5 | 70.9 |
| L50/H12.5→L50/H12.5/A5 | 66.2 |
An AE was defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the product, whether or not considered related to the use of the product. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition which was temporally associated with the use of the product, was also an AE. Percentage of participants that experienced at least 1 AE that was reported as possibly, probably, or definitely related to the study drug by the investigator during the 8-week double-blind treatment period were summarized by study drug received. (NCT01299376)
Timeframe: up to Week 8
| Intervention | Percentage of Participants (Number) |
|---|---|
| L50/H12.5/A5 | 12.1 |
| L50/H12.5 | 14.5 |
An AE was defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the product, whether or not considered related to the use of the product. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition which was temporally associated with the use of the product, was also an AE. Percentage of participants that experienced at least 1 AE that was reported as possibly, probably, or definitely related to the study drug by the investigator during the long-term reporting period was summarized. (NCT01299376)
Timeframe: Week 9 up to Week 52 for L50/H12.5→L50/H12.5/A5 arm; Week 1 to Week 52 for L50/H12.5/A5→L50/H12.5/A5
| Intervention | Percentage of Participants (Number) |
|---|---|
| L50/H12.5/A5→L50/H12.5/A5 | 27.7 |
| L50/H12.5→L50/H12.5/A5 | 14.3 |
An SAE is any AE occurring at any dose or during any use of Sponsor's product that does the following: results in death; is life threatening; results in persistent or significant disability/incapacity; results in or prolongs an existing inpatient hospitalization; is a congenital anomaly/birth defect; is a cancer; is associated with an overdose; is another important medical event. the percentage of participants that experienced an SAE that assessed as possibly, probably, or definitely related to the study drug by the investigator was summarized. (NCT01299376)
Timeframe: Week 9 up to Week 52 for L50/H12.5→L50/H12.5/A5 arm; Week 1 to Week 52 for L50/H12.5/A5→L50/H12.5/A5
| Intervention | Percentage of Participants (Number) |
|---|---|
| L50/H12.5/A5→L50/H12.5/A5 | 0.0 |
| L50/H12.5→L50/H12.5/A5 | 0.8 |
An SAE is any AE occurring at any dose or during any use of Sponsor's product that does the following: results in death; is life threatening; results in persistent or significant disability/incapacity; results in or prolongs an existing inpatient hospitalization; is a congenital anomaly/birth defect; is a cancer; is associated with an overdose; is another important medical event. Percentage of participants that experienced at least 1 SAE that was reported as possibly, probably, or definitely related to the study drug by the investigator during the 8-week double-blind treatment period were summarized by study drug received. (NCT01299376)
Timeframe: up to Week 8
| Intervention | Percentage of Participants (Number) |
|---|---|
| L50/H12.5/A5 | 0.0 |
| L50/H12.5 | 0.0 |
An SAE is any AE occurring at any dose or during any use of Sponsor's product that does the following: results in death; is life threatening; results in persistent or significant disability/incapacity; results in or prolongs an existing inpatient hospitalization; is a congenital anomaly/birth defect; is a cancer; is associated with an overdose; is another important medical event. Those SAEs assessed as possibly, probably, or definitely related to the study drug during the long-term period were summarized. (NCT01299376)
Timeframe: Week 9 up to Week 52 for L50/H12.5→L50/H12.5/A5 arm; Week 1 to Week 52 for L50/H12.5/A5→L50/H12.5/A5
| Intervention | Percentage of Participants (Number) |
|---|---|
| L50/H12.5/A5→L50/H12.5/A5 | 2.1 |
| L50/H12.5→L50/H12.5/A5 | 3.0 |
An SAE is any AE occurring at any dose or during any use of Sponsor's product that does the following: results in death; is life threatening; results in persistent or significant disability/incapacity; results in or prolongs an existing inpatient hospitalization; is a congenital anomaly/birth defect; is a cancer; is associated with an overdose; is another important medical event. The percentage of participants who experienced at least 1 SAE during the 8-week double-blind treatment period were summarized by study drug received. (NCT01299376)
Timeframe: up to Week 8
| Intervention | Percentage of Participants (Number) |
|---|---|
| L50/H12.5/A5 | 0.7 |
| L50/H12.5 | 1.4 |
An AE was defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the product, whether or not considered related to the use of the product. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition which was temporally associated with the use of the product, was also an AE. The percentage of participants who had study drug stopped during the 8-week double-blind treatment period due to an AE regardless of whether or not they completed the study was summarized by treatment arm. (NCT01299376)
Timeframe: up to Week 8
| Intervention | Percentage of Participants (Number) |
|---|---|
| L50/H12.5/A5 | 0.7 |
| L50/H12.5 | 1.4 |
An AE was defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the product, whether or not considered related to the use of the product. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition which was temporally associated with the use of the product, was also an AE. The percentage of participants who had study drug discontinued during the 44 week extension due to an AE regardless of completion status were summarized. (NCT01299376)
Timeframe: Week 9 up to Week 52 for L50/H12.5→L50/H12.5/A5 arm; Week 1 to Week 52 for L50/H12.5/A5→L50/H12.5/A5
| Intervention | Percentage of Participants (Number) |
|---|---|
| L50/H12.5/A5→L50/H12.5/A5 | 2.1 |
| L50/H12.5→L50/H12.5/A5 | 2.3 |
Change from the start of the run-in period (Week -1) at the end of the treatment period (Week 8) (NCT01762501)
Timeframe: Baseline and 8 weeks
| Intervention | mmHg (Mean) |
|---|---|
| Azilsartan | -7.9 |
| Amlodipine | -8.9 |
Change from the start of the run-in period (Week -1) at the end of the treatment period (Week 8) (NCT01762501)
Timeframe: Baseline and 8 weeks
| Intervention | mmHg (Mean) |
|---|---|
| Azilsartan | -14.0 |
| Amlodipine | -17.5 |
Change from the start of the run-in period (Week -1) at the end of the treatment period (Week 8) (NCT01762501)
Timeframe: Baseline and 8 weeks
| Intervention | mmHg (Mean) |
|---|---|
| Azilsartan | -7.1 |
| Amlodipine | -8.9 |
"Change at the end of a treatment period (Week 8) from the beginning point of an observation period~*Nocturnal systolic blood pressure level: the mean value of systolic arterial pressure during night (during sleeping)" (NCT01762501)
Timeframe: Baseline and 8 weeks
| Intervention | mmHg (Mean) |
|---|---|
| Azilsartan | -12.6 |
| Amlodipine | -17.5 |
"Change from the start of the run-in period (Week -1) at the end of the treatment period (Week 8) *The targeted value has been set as the median of the dipping rate, normal type of nocturnal blood pressure variation, rate of nocturnal blood pressure fall (10-20 percent)~** Rate of nocturnal blood pressure fall: calculated as (awake SBP-sleep SBP)/awake SBP" (NCT01762501)
Timeframe: Baseline and 8 weeks
| Intervention | mmHg (Mean) | |||
|---|---|---|---|---|
| riser | non-dipper | dipper | extreme dipper | |
| Amlodipine | -10.1 | -2.1 | 3.1 | -3.1 |
| Azilsartan | -7.3 | -0.7 | 4.5 | -1.9 |
Compare both group effects on diastolic blood pressure. (NCT01603940)
Timeframe: 12 weeks
| Intervention | mmHg (Median) |
|---|---|
| Losartan | 80 |
| Benazepril | 82 |
Access endothelial function by brachial flow-mediated vasodilation (FMD) and compare it between groups (losartan and benazepril) and its relationship to current statin use. (NCT01603940)
Timeframe: 12 weeks
| Intervention | percentage of maximal vasodilation (Median) |
|---|---|
| Losartan | 9.4 |
| Benazepril | 8.8 |
Compare both groups effects on systolic blood pressure. (NCT01603940)
Timeframe: 12 weeks
| Intervention | mmHg (Median) |
|---|---|
| Losartan | 134 |
| Benazepril | 139 |
Access vascular stiffness by pulse wave velocity and compare it between groups (losartan and benazepril). (NCT01603940)
Timeframe: 12 weeks.
| Intervention | m/s (Median) |
|---|---|
| Losartan | 8.5 |
| Benazepril | 8.5 |
Estimate vascular stiffness by measuring augmentation index and compare it between losartan and benazepril groups. (NCT01603940)
Timeframe: 12 weeks
| Intervention | percentage of augmentation pressure (Median) |
|---|---|
| Losartan | 28 |
| Benazepril | 35 |
CV mortality was defined as death due to sudden cardiac death, fatal MI, fatal stroke, coronary intervention, congestive heart failure (CHF), or other CV causes. (NCT00170950)
Timeframe: For each patient, baseline to time of first CV mortality event, MI (non-fatal), or stroke (non-fatal) (or last exposure if no event occurred). (Median duration of exposure was 33.4 months. [25th to 75th percentiles: 21 to 41 months.])
| Intervention | Percentage of Patients with an Event (Number) |
|---|---|
| Benazepril/Amlodipine | 5.0 |
| Benazepril/Hydrochlorothiazide | 6.3 |
Cardiovascular morbidity was defined as including any of the following events: non-fatal MI, non-fatal stroke, hospitalization for unstable angina, resuscitated sudden death, or coronary revascularization procedure (PCI or CABG). (NCT00170950)
Timeframe: For each patient, baseline to time of first CV morbidity event (or last exposure if no event occurred). (Median duration of exposure was 33.4 months. [25th to 75th percentiles: 21 to 41 months.])]
| Intervention | Percentage of Patients with an Event (Number) |
|---|---|
| Benazepril/Amlodipine | 8.6 |
| Benazepril/Hydrochlorothiazide | 10.3 |
CV morbidity was defined as non-fatal myocardial infarction (MI), non-fatal stroke, hospitalization for unstable angina, resuscitated sudden death, or coronary revascularization procedure. CV mortality was defined as death due to MI, stroke, coronary intervention, congestive heart failure (CHF), sudden cardiac death, or other CV causes. (NCT00170950)
Timeframe: For each patient, baseline to time of first CV morbidity or mortality event (or last exposure if no event occurred). (Median duration of exposure was 33.4 months. [25th to 75th percentiles: 21 to 41 months.])
| Intervention | Percentage of Patients with an event (Number) |
|---|---|
| Benazepril/Amlodipine | 9.6 |
| Benazepril/Hydrochlorothiazide | 11.8 |
The investigators used an intent-to-treat approach for our main analysis, basing our outcome measures on provider's eligible patient population in each of the clinics. Performance improvement was calculated at the change (before vs after the intervention) the percentage of provider's patients with each clinical indicator. 1) change in the percentage of patients with improvements in LDL. Improvement defined as LDL-C level < previous 18 mos; 2) Change in the percentage of patients with improvements in A1c. Improvement defined as HbA1c level < previous 18 mos; 3) Change in percentage of patients prescribed Beta Blockers; 4) Change in the percentage of patients prescribed Statins; 5) Change in the percentage of patients prescribed ACEI or ARB; 6) Change in percentage of patients reaching target goal for LDL-C (<100mg/dL); 7) Change in percentage of patients reaching target goal for HbA1c (<8%). (NCT00126750)
Timeframe: 1/1/02 - 12/31/08
| Intervention | percentage of provider's patients (Number) | ||||||
|---|---|---|---|---|---|---|---|
| Change in % of patients w/ improvement in LDL | Change in % of patients w/ improvement in HbA1c | Change in % of patients prescribed B-Blockers | Change in % patients prescribed Statins | Change in % of patients prescribed ACEI or ARB | Change in % of patients reaching target LDL | Change in % of patients reaching target HbA1c | |
| Control | 2.1 | 9.5 | 12.1 | 7.5 | 2.9 | 15.2 | .7 |
| Intervention | 2.8 | 11.5 | 15.5 | 8.5 | 4.9 | 19.9 | 6 |
Blood pressure (BP) was measured at trough (24±3 hours post-dose). The arm in which the highest sitting diastolic BP was found at study entry was used for all subsequent readings. If there was < 0. 5 mmHg difference in BP between the 2 arms, the non-dominant arm was used. At each visit, after the patient was in a sitting position with the back supported and both feet placed on the floor for 5 minutes, systolic and diastolic BP were measured 3 times with an automated BP monitor and appropriate size cuff. Means of the 3 measurements were calculated. A negative change indicates lowered BP. (NCT00437645)
Timeframe: Baseline to Week 8
| Intervention | mmHg (Least Squares Mean) |
|---|---|
| Valsartan/Amlodipine 160/5 mg | -4.65 |
| Amlodipine 10 mg | -4.13 |
Blood pressure (BP) was measured at trough (24±3 hours post-dose). The arm in which the highest sitting diastolic BP was found at study entry was used for all subsequent readings. If there was < 0. 5 mmHg difference in BP between the 2 arms, the non-dominant arm was used. At each visit, after the patient was in a sitting position with the back supported and both feet placed on the floor for 5 minutes, systolic and diastolic BP were measured 3 times with an automated BP monitor and appropriate size cuff. Means of the 3 measurements were calculated. A negative change indicates lowered BP. (NCT00437645)
Timeframe: Baseline to Week 8
| Intervention | mmHg (Least Squares Mean) |
|---|---|
| Valsartan/Amlodipine 160/5 mg | -8.01 |
| Amlodipine 10 mg | -6.30 |
Only occurrences of peripheral edema quantified as a reported adverse event coded as peripheral edema were included in the analysis. If a patient experienced more than one occurrence of peripheral edema between Day 1 and Week 8, it was only counted once in the analysis. (NCT00437645)
Timeframe: Baseline to Week 8
| Intervention | Percentage of patients (Number) |
|---|---|
| Valsartan/Amlodipine 160/5 mg | 6.6 |
| Amlodipine 10 mg | 31.1 |
Blood pressure (BP) was measured at trough (24±3 hours post-dose). The arm in which the highest sitting diastolic BP was found at study entry was used for all subsequent readings. If there was < 0. 5 mmHg difference in BP between the 2 arms, the non-dominant arm was used. At each visit, after the patient was in a sitting position with the back supported and both feet placed on the floor for 5 minutes, systolic and diastolic BP were measured 3 times with an automated BP monitor and appropriate size cuff. Means of the 3 measurements were calculated. A negative change indicates lowered BP. (NCT00437645)
Timeframe: Baseline to Weeks 4, 8, and 12
| Intervention | mmHg (Least Squares Mean) | |||||
|---|---|---|---|---|---|---|
| msSBP: Week 4 (n=576, 535) | msSBP: Week 8 (n=567, 510) | msSBP: Week 12 (n=569, 531) | msDBP: Week 4 (n=576, 535) | msDBP: Week 8 (n=576, 510) | msDBP: Week 12 (n=569, 531) | |
| Amlodipine 10 mg | -6.48 | -6.11 | -7.82 | -4.23 | -3.97 | -4.90 |
| Valsartan/Amlodipine 160/5 mg | -8.40 | -8.15 | -9.08 | -5.05 | -4.68 | -5.50 |
Systolic response was defined as msSBP < 130 mmHg or at least a 20 mmHg reduction from baseline in msSBP at Weeks 4, 8, and 12. Blood pressure (BP) was measured at trough (24±3 hours post-dose). The arm in which the highest sitting diastolic BP was found at study entry was used for all subsequent readings. At each visit, after the patient was in a sitting position with the back supported and both feet placed on the floor for 5 minutes, systolic and diastolic BP were measured 3 times with an automated BP monitor and appropriate size cuff. Means of the 3 measurements were calculated. (NCT00437645)
Timeframe: Baseline to Weeks 4, 8, and 12
| Intervention | Percentage of patients (Number) | ||
|---|---|---|---|
| Week 4 (n=576, 535) | Week 8 (n=567, 510) | Week 12 (n=569, 531) | |
| Amlodipine 10 mg | 25.42 | 25.49 | 31.26 |
| Valsartan/Amlodipine 160/5 mg | 35.07 | 34.22 | 37.96 |
(NCT00402103)
Timeframe: 52 weeks
| Intervention | Percentage of Participants (Number) |
|---|---|
| Aliskiren 150mg/ Amlodipine 5mg Alone | 23.6 |
| Aliskiren 300mg/ Amlodipine 10mg Alone | 71.2 |
| Aliskiren 300mg/ Amlodipine 10mg/ HCTZ | 57.0 |
(NCT00402103)
Timeframe: Baseline, Week 2, Week 4, Week 6, Week 10, Week 14, Week 28, Week 41 and Week 54
| Intervention | mm Hg (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Week 2 (Visit 5) | Week 4 (Visit 6) | Week 6 (Visit 7) | Week 10 (Visit 8) | Week 14 (Visit 9) | Week 28 (Visit 10) | Week 41 (Visit 11) | Week 54 (Visit 12) | Week 54 (Visit 12) (LOCF) | |
| Aliskiren/Amlodipine | -8.7 | -14.0 | -15.7 | -16.3 | -17.1 | -16.7 | -17.0 | -16.3 | -15.7 |
| Aliskiren/Amlodipine/HCTZ | -5.9 | -11.9 | -11.5 | -9.3 | -13.1 | -14.7 | -15.4 | -15.3 | -14.2 |
(NCT00402103)
Timeframe: Baseline, Week 2, Week 10, Week 28 and Week 54
| Intervention | Percentage of patients (Number) | ||||
|---|---|---|---|---|---|
| Week 2 (Visit 5) | Week 10 (Visit 8) | Week 28 (Visit 10) | Week 54 (Visit 12) | Week 54 (Visit 12) (LOCF) | |
| Aliskiren/Amlodipine | 35.3 | 88.0 | 88.2 | 82.0 | 77.3 |
| Aliskiren/Amlodipine/HCTZ | 8.1 | 16.3 | 56.8 | 62.2 | 58.1 |
(NCT00402103)
Timeframe: Baseline, Week 2, Week 10, Week 28 and Week 54
| Intervention | Percentage of patients (Number) | ||||
|---|---|---|---|---|---|
| Week 2 (Visit 5) | Week 10 (Visit 8) | Week 28 (Visit 10) | Week 54 (Visit 12) | Week 54 (Visit 12) (LOCF) | |
| Aliskiren/Amlodipine | 61.2 | 96.8 | 95.9 | 93.2 | 90.6 |
| Aliskiren/Amlodipine/HCTZ | 38.4 | 61.6 | 85.2 | 89.2 | 84.9 |
Blood pressure (BP) was measured with a calibrated aneroid or mercury sphygmomanometer. The arm in which the highest sitting diastolic BP was found at study entry was used for all subsequent readings. At each visit, after the patient was in a sitting position for five minutes, systolic/diastolic BP was measured 3 times at 1-2-minute intervals. The mean of the 3 measurements was calculated. A negative change score indicates lowered BP. (NCT00413049)
Timeframe: Baseline to end of study (Week 8)
| Intervention | mmHg (Least Squares Mean) |
|---|---|
| Valsartan/Amlodipine 80/5 mg | -9.7 |
| Amlodipine 5 mg | -7.1 |
Blood pressure (BP) was measured with a calibrated aneroid or mercury sphygmomanometer. The arm in which the highest sitting diastolic BP was found at study entry was used for all subsequent readings. At each visit, after the patient was in a sitting position for five minutes, systolic/diastolic BP was measured 3 times at 1-2-minute intervals. The mean of the 3 measurements was calculated. A negative change score indicates lowered BP. (NCT00413049)
Timeframe: Baseline to end of study (Week 8)
| Intervention | mmHg (Least Squares Mean) |
|---|---|
| Valsartan/Amlodipine 80/5 mg | -11.4 |
| Amlodipine 5 mg | -7.4 |
A patient achieved a diastolic response if their msDBP < 90 mmHg at Week 8 or they had a ≥ 10 mmHg decrease in msDBP compared to baseline at the end of the study (Week 8). Blood pressure (BP) was measured with a calibrated aneroid or mercury sphygmomanometer. The arm in which the highest sitting diastolic BP was found at study entry was used for all subsequent readings. At each visit, after the patient was in a sitting position for five minutes, systolic/diastolic BP was measured 3 times at 1-2-minute intervals. The mean of the 3 measurements was calculated. (NCT00413049)
Timeframe: Baseline to end of study (Week 8)
| Intervention | Percentage of patients (Number) |
|---|---|
| Valsartan/Amlodipine 80/5 mg | 79.3 |
| Amlodipine 5 mg | 66.8 |
A patient achieved diastolic control if their msDBP < 90 mmHg at the end of the study (Week 8). Blood pressure (BP) was measured with a calibrated aneroid or mercury sphygmomanometer. The arm in which the highest sitting diastolic BP was found at study entry was used for all subsequent readings. At each visit, after the patient was in a sitting position for five minutes, systolic/diastolic BP was measured 3 times at 1-2-minute intervals. The mean of the 3 measurements was calculated. (NCT00413049)
Timeframe: Baseline to end of study (Week 8)
| Intervention | Percentage of patients (Number) |
|---|---|
| Valsartan/Amlodipine 80/5 mg | 75.5 |
| Amlodipine 5 mg | 64.5 |
A patient achieved overall control if the msSBP/msDBP < 140/90 mmHg at the end of the study (Week 8). Blood pressure (BP) was measured with a calibrated aneroid or mercury sphygmomanometer. The arm in which the highest sitting diastolic BP was found at study entry was used for all subsequent readings. At each visit, after the patient was in a sitting position for five minutes, systolic/diastolic BP was measured 3 times at 1-2-minute intervals. The mean of the 3 measurements was calculated. (NCT00413049)
Timeframe: Baseline to end of study (Week 8)
| Intervention | Percentage of patients (Number) |
|---|---|
| Valsartan/Amlodipine 80/5 mg | 69.2 |
| Amlodipine 5 mg | 57.6 |
Two 24 hour ambulatory blood pressure monitoring (ABPM) evaluations were performed, one at baseline prior to randomization and one at Week 8 (end of study), in a subset of the intent-to-treat population of patients. For each evaluation, the ABPM device was attached to the non-dominant arm of the patient. A correlation was made between the ABPM device readings and measurements taken with a mercury sphygmomanometer and stethoscope. Following the correlation procedure, BP was measured at study specified intervals. A negative change score indicates lowered BP. (NCT00413049)
Timeframe: Baseline to end of study (Week 8)
| Intervention | mmHg (Mean) | |
|---|---|---|
| Diastolic BP | Systolic BP | |
| Amlodipine 5 mg | 0.3 | -0.2 |
| Valsartan/Amlodipine 80/5 mg | -6.3 | -7.3 |
After a 75 gram anhydrous glucose challenge 2 hours after an oral glucose tolerance test (NCT00439738)
Timeframe: Week 16
| Intervention | mg/dL (Mean) | |||||
|---|---|---|---|---|---|---|
| Baseline visit (0 minutes) | Week 16 (0 minutes) | Change from baseline to week 16 (0 minutes) | Baseline visit (120 minutes) | Week 16 (120 minutes) | Change from baseline to week 16 (120 minutes) | |
| HCTZ +Amlodipine | 99.4 | 102.8 | 3.4 | 127.7 | 146.5 | 18.9 |
| Valsartan/HCTZ (Hydrochlorothiazide) | 98.0 | 98.1 | -0.5 | 123.9 | 126.3 | 2.1 |
After a 75 gram anhydrous glucose challenge 2 hours after an oral glucose tolerance test (NCT00439738)
Timeframe: Week 16
| Intervention | mg/dL (Mean) | |||||
|---|---|---|---|---|---|---|
| Baseline visit (0 minutes) | Week 16 (0 minutes) | Change from baseline to week 16 (0 minutes) | Baseline visit (120 minutes) | Week 16 (120 minutes) | Change from baseline to week 16 (120 minute) | |
| HCTZ +Amlodipine | 20.37 | 23.62 | 3.67 | 95.95 | 120.01 | 28.07 |
| Valsartan/HCTZ (Hydrochlorothiazide) | 19.66 | 23.45 | 3.41 | 92.04 | 116.04 | 24.68 |
After a 75 gram anhydrous glucose challenge 2 hours after an oral glucose tolerance test (NCT00439738)
Timeframe: Week 16
| Intervention | mg/dL (Mean) | |||||
|---|---|---|---|---|---|---|
| Baseline visit (0 minutes) | Week 16 (0 minutes) | Change from baseline to week 16 (0 minutes) | Baseline visit (120 minutes) | Week 16 (120 minutes) | Change from baseline to week 16 (120 minutes) | |
| HCTZ +Amlodipine | 0.47 | 0.47 | 0.00 | 0.10 | 0.10 | -0.01 |
| Valsartan/HCTZ (Hydrochlorothiazide) | 0.45 | 0.46 | 0.01 | 0.11 | 0.10 | -0.01 |
(NCT00439738)
Timeframe: Baseline to Weeks 4, 8, 12 and 16
| Intervention | mm Hg (Mean) | |||||
|---|---|---|---|---|---|---|
| Baseline | Week 4 | Week 8 | Week 12 | Week 16 | Change from baseline to week 16 | |
| HCTZ +Amlodipine | 93.6 | 87.6 | 85.1 | 82.8 | 80.9 | -12.7 |
| Valsartan/HCTZ (Hydrochlorothiazide) | 94.9 | 85.7 | 81.9 | 81.1 | 80.8 | -14.0 |
(NCT00439738)
Timeframe: Baseline to Week 8
| Intervention | mm Hg (Mean) | ||
|---|---|---|---|
| Baseline | Week 8 | Change from baseline | |
| HCTZ +Amlodipine | 159.0 | 137.5 | -21.5 |
| Valsartan/HCTZ (Hydrochlorothiazide) | 159.7 | 131.2 | -28.6 |
Mean sitting systolic blood pressure/mean sitting diastolic blood pressure < 140/90 mm Hg (NCT00439738)
Timeframe: Weeks 4, 8, 12 16 and End of Study (for patients that did not complete the last visit at week 16)
| Intervention | participants (Number) | ||||
|---|---|---|---|---|---|
| Week 4 | Week 8 | Week 12 | Week 16 | End of study | |
| HCTZ +Amlodipine | 69 | 102 | 112 | 140 | 146 |
| Valsartan/HCTZ (Hydrochlorothiazide) | 91 | 123 | 122 | 124 | 133 |
Mean sitting systolic blood pressure/mean sitting diastolic blood pressure < 130/80 mm Hg (NCT00439738)
Timeframe: Week 4, 8, 12, 16, End of Study (for patients that did not complete the last visit at week 16)
| Intervention | participants (Number) | ||||
|---|---|---|---|---|---|
| Week 4 | Week 8 | Week 12 | Week 16 | End of Study | |
| HCTZ +Amlodipine | 18 | 23 | 46 | 65 | 68 |
| Valsartan/HCTZ (Hydrochlorothiazide) | 33 | 59 | 57 | 62 | 68 |
(NCT00649389)
Timeframe: baseline to 12 weeks
| Intervention | mm Hg (Mean) |
|---|---|
| OM40/AML10 | -17.8 |
| OM40/HCTZ25 | -16.5 |
| AML10/HCTZ25 | -14.8 |
| OM40/AML10/HCTZ25 | -21.5 |
(NCT00649389)
Timeframe: Baseline to week 12
| Intervention | mm Hg (Mean) |
|---|---|
| OM40/AML10 | -31.1 |
| OM40/HCTZ25 | -31.2 |
| AML10/HCTZ25 | -28.9 |
| OM40/AML10/HCTZ25 | -38.1 |
(NCT00649389)
Timeframe: Baseline to 12 weeks
| Intervention | Percentage of subjects (Number) |
|---|---|
| OM40/AML10 | 46.0 |
| OM40/HCTZ25 | 46.6 |
| AML10/HCTZ25 | 34.9 |
| OM40/AML10/HCTZ25 | 64.3 |
(NCT00649389)
Timeframe: Baseline to 12 weeks or early termination
| Intervention | mm Hg (Mean) | |
|---|---|---|
| Diastolic blood pressure | Systolic blood pressure | |
| AML10/HCTZ25 | -10.7 | -18.5 |
| OM40/AML10 | -13.9 | -23.5 |
| OM40/AML10/HCTZ25 | -18.0 | -30.3 |
| OM40/HCTZ25 | -14.5 | -23.9 |
(NCT00666536)
Timeframe: Baseline and Week 4
| Intervention | mmHg (Mean) | ||
|---|---|---|---|
| Baseline MSDBP | Week 4 MSDBP | Change From Baseline to Week 4 in MSDBP | |
| Aggressive Treatment Regimen (5/320 mg to 10/320 mg) | 95.5 | 84.8 | -10.7 |
| Moderate Treatment Regimen (5/160 mg) | 95.0 | 86.2 | -8.8 |
(NCT00666536)
Timeframe: Baseline and Week 4
| Intervention | mmHg (Mean) | ||
|---|---|---|---|
| Baseline MSSBP | Week 4 MSSBP | Change From Baseline to Week 4 in MSSBP | |
| Aggressive Treatment Regimen (5/320 mg to 10/320 mg) | 163.9 | 140.9 | -23.0 |
| Moderate Treatment Regimen (5/160 mg) | 163.3 | 144.4 | -18.9 |
(NCT00666536)
Timeframe: Baseline and Weeks 2, 8 and 12
| Intervention | mmHg (Mean) | ||||||
|---|---|---|---|---|---|---|---|
| Baseline MSDBP | Week 2 MSDBP | Change From Baseline to Week 2 in MSDBP | Week 8 MSDBP | Change From Baseline to Week 8 in MSDBP | Week 12 MSDBP | Change From Baseline to Week 12 in MSDBP | |
| Aggressive Treatment Regimen (5/320 mg to 10/320 mg) | 95.5 | 88.2 | -7.3 | 81.6 | -13.9 | 81.5 | -14.0 |
| Moderate Treatment Regimen (5/160 mg) | 95.0 | 87.1 | -7.9 | 84.0 | -11.0 | 83.8 | -11.2 |
(NCT00666536)
Timeframe: Baseline and Weeks 2, 8 and 12
| Intervention | mmHg (Mean) | ||||||
|---|---|---|---|---|---|---|---|
| Baseline MSSBP | Week 2 MSSBP | Change From Baseline to Week 2 in MSSBP | Week 8 MSSBP | Change From Baseline to Week 8 in MSSBP | Week 12 MSSBP | Change From Baseline to Week 12 in MSSBP | |
| Aggressive Treatment Regimen (5/320 mg to 10/320 mg) | 163.9 | 147.0 | -16.9 | 136.0 | -27.9 | 135.7 | -28.1 |
| Moderate Treatment Regimen (5/160 mg) | 163.3 | 146.0 | -17.3 | 140.5 | -22.8 | 139.2 | -24.1 |
(NCT00666536)
Timeframe: Weeks 2, 4, 8 and 12
| Intervention | Percentage of Patients (Number) | |||
|---|---|---|---|---|
| Week 2 | Week 4 | Week 8 | Week 12 | |
| Aggressive Treatment Regimen (5/320 mg to 10/320 mg) | 31.1 | 49.2 | 66.1 | 62.8 |
| Moderate Treatment Regimen (5/160 mg) | 32.5 | 37.5 | 49.6 | 55.7 |
(NCT00666536)
Timeframe: Weeks 2, 4, 8 and 12
| Intervention | Percentage of Patients (Number) | |||
|---|---|---|---|---|
| Week 2 | Week 4 | Week 8 | Week 12 | |
| Aggressive Treatment Regimen (5/320 mg to 10/320 mg) | 25.1 | 43.7 | 61.7 | 59.8 |
| Moderate Treatment Regimen (5/160 mg) | 25.8 | 31.1 | 46.2 | 50.7 |
The arm in which the highest sitting diastolic pressures were found at study entry was the arm used for all subsequent readings. A calibrated sphygmomanometer and appropriate size cuff were used to measure arterial sitting blood pressure (BP) at trough with the arm supported at the level of the heart. At each study visit, after having the patient in a sitting position for at least 5 minutes, systolic/diastolic blood pressure were measured 3 times at 1-2 minute intervals. A mean was calculated from the 3 measurements. A negative change indicates improvement. (NCT00867490)
Timeframe: Baseline Phase 2 to end of Phase 2
| Intervention | mmHg (Mean) |
|---|---|
| Phase 2 - Aliskiren+HCTZ | -3.12 |
The arm in which the highest sitting diastolic pressures were found at study entry was the arm used for all subsequent readings. A calibrated sphygmomanometer and appropriate size cuff were used to measure arterial sitting blood pressure (BP) at trough with the arm supported at the level of the heart. At each study visit, after having the patient in a sitting position for at least 5 minutes, systolic/diastolic blood pressure were measured 3 times at 1-2 minute intervals. A mean was calculated from the 3 measurements. A negative change indicates improvement. (NCT00867490)
Timeframe: Baseline Phase 3 to end of Phase 3
| Intervention | mmHg (Mean) |
|---|---|
| Phase III - Aliskiren+HCTZ+Amlodipine | -5.87 |
The arm in which the highest sitting diastolic pressures were found at study entry was the arm used for all subsequent readings. A calibrated sphygmomanometer and appropriate size cuff were used to measure arterial sitting blood pressure (BP) at trough with the arm supported at the level of the heart. At each study visit, after having the patient in a sitting position for at least 5 minutes, systolic/diastolic blood pressure were measured 3 times at 1-2 minute intervals. A mean was calculated from the 3 measurements. A negative change indicates improvement. (NCT00867490)
Timeframe: Baseline Phase 2 to end of Phase 2
| Intervention | mmHg (Mean) |
|---|---|
| Phase 2 - Aliskiren+HCTZ | -2.81 |
The arm in which the highest sitting diastolic pressures were found at study entry was the arm used for all subsequent readings. A calibrated sphygmomanometer and appropriate size cuff were used to measure arterial sitting blood pressure (BP) at trough with the arm supported at the level of the heart. At each study visit, after having the patient in a sitting position for at least 5 minutes, systolic/diastolic blood pressure were measured 3 times at 1-2 minute intervals. A mean was calculated from the 3 measurements. A negative change indicates improvement. (NCT00867490)
Timeframe: Baseline Phase 3 to end of Phase 3
| Intervention | mmHg (Mean) |
|---|---|
| Phase III - Aliskiren+HCTZ+Amlodipine | -9.20 |
Pulse pressure is systolic pressure (SP) minus diastolic pressure (DP). The arm in which the highest sitting DPs were found at study entry was the arm used for all subsequent readings. A calibrated sphygmomanometer and appropriate size cuff were used to measure arterial sitting blood pressure (BP) at trough with the arm supported at the level of the heart. At each study visit, after having the patient in a sitting position for at least 5 minutes, SP and DP were measured 3 times at 1-2 minute intervals. A mean was calculated from the 3 measurements. A negative change indicates improvement. (NCT00867490)
Timeframe: Baseline Phase 2 to end of Phase 2
| Intervention | mmHg (Mean) |
|---|---|
| Phase 2 - Aliskiren+HCTZ | 0.31 |
Pulse pressure is systolic pressure (SP) minus diastolic pressure (DP). The arm in which the highest sitting DPs were found at study entry was the arm used for all subsequent readings. A calibrated sphygmomanometer and appropriate size cuff were used to measure arterial sitting blood pressure (BP) at trough with the arm supported at the level of the heart. At each study visit, after having the patient in a sitting position for at least 5 minutes, SP and DP were measured 3 times at 1-2 minute intervals. A mean was calculated from the 3 measurements. A negative change indicates improvement. (NCT00867490)
Timeframe: Baseline Phase 3 to end of Phase 3
| Intervention | mmHg (Mean) |
|---|---|
| Phase III - Aliskiren+HCTZ+Amlodipine | -3.33 |
Pulse rate was measured once for 30 seconds just prior to blood pressure measurements in the sitting position. (NCT00867490)
Timeframe: Baseline Phase 2 to end of Phase 2
| Intervention | BPM (beats per minute) (Mean) |
|---|---|
| Phase 2 - Aliskiren+HCTZ | 0.27 |
Pulse rate was measured once for 30 seconds just prior to blood pressure measurements in the sitting position. (NCT00867490)
Timeframe: Baseline Phase 3 to end of Phase 3
| Intervention | BPM (beats per minute) (Mean) |
|---|---|
| Phase III - Aliskiren+HCTZ+Amlodipine | 0.03 |
Blood pressure response was defined as msSBP < 140 mmHg or a 20 mmHg decrease in msSBP at the end of Phase 2 compared to Baseline in Phase 2 or a msDBP < 90 mmHg or a 10 mmHg decrease in msDBP at the end of Phase 2 compared to Baseline in Phase 2. (NCT00867490)
Timeframe: Baseline Phase 2 to end of Phase 2
| Intervention | Percentage of patients (Number) | |
|---|---|---|
| msSBP response | msDBP response | |
| Phase 2 - Aliskiren+HCTZ | 37.4 | 34.1 |
Blood pressure response was defined as msSBP < 140 mmHg or a 20 mmHg decrease in msSBP at the end of Phase 2 compared to Baseline in Phase 2 or a msDBP < 90 mmHg or a 10 mmHg decrease in msDBP at the end of Phase 2 compared to Baseline in Phase 2. (NCT00867490)
Timeframe: Baseline Phase 3 to end of Phase 3
| Intervention | Percentage of patients (Number) | |
|---|---|---|
| msSBP response | msDBP response | |
| Phase III - Aliskiren+HCTZ+Amlodipine | 54.1 | 47.5 |
Normalized blood pressure was defined as a msSBP < 140 mmHg and/or a msDBP < 90 mmHg. (NCT00867490)
Timeframe: Baseline Phase 2 to end of Phase 2
| Intervention | Percentage of patients (Number) | |
|---|---|---|
| msSBP < 140 mmHg | msDBP < 90 mmHg | |
| Phase 2 - Aliskiren+HCTZ | 37.4 | 33.3 |
Normalized was defined as a msSBP < 140 mm Hg and/or a msDBP < 90 mm Hg. (NCT00867490)
Timeframe: Baseline Phase 3 to end of Phase 3
| Intervention | Percentage of patients (Number) | |
|---|---|---|
| msSBP < 140 mmHg | msDBP < 90 mmHg | |
| Phase III - Aliskiren+HCTZ+Amlodipine | 54.1 | 44.3 |
Diastolic Blood pressure was measured in a sitting position using a validated automated blood pressure monitor (the Omron device) according to Guidelines of the British Hypertension Society, at Baseline and 24 weeks of study treatment. Analysis used a repeated measures ANCOVA model with treatment, visit and region, as factors, treatment by visit interaction and baseline msDBP as a covariate. (NCT00797862)
Timeframe: Baseline to 24 weeks
| Intervention | mmHg (Least Squares Mean) |
|---|---|
| Aliskiren+Amlodipine | -13.64 |
| Aliskiren Start-Amlodipine Add On | -13.22 |
| Amlodipine Start-Aliskiren Add On | -12.25 |
Diastolic Blood Pressure was measured in a sitting position using a validated automated blood pressure monitor (the Omron device) according to Guidelines of the British Hypertension Society, at Baseline and 32 weeks of study treatment. Change at Week 32 used a separate repeated measures ANCOVA model containing Week 8, 16, 24 and 32 data. Treatment, visit and region were factors in the model, treatment by visit interaction and baseline msDBP a covariate. (NCT00797862)
Timeframe: Baseline to 32 weeks
| Intervention | mmHg (Least Squares Mean) |
|---|---|
| Aliskiren+Amlodipine | -12.96 |
| Aliskiren Start-Amlodipine Add On | -12.96 |
| Amlodipine Start-Aliskiren Add On | -11.62 |
Systolic Blood pressure was measured in a sitting position using a validated automated blood pressure monitor (the Omron device) according to Guidelines of the British Hypertension Society, at Baseline and 24 weeks of study treatment. Analysis used a repeated measures ANCOVA model with treatment, visit and region as factors, treatment by visit interaction and baseline msSBP as a covariate. (NCT00797862)
Timeframe: Baseline to 24 weeks
| Intervention | mmHg (Least Squares Mean) |
|---|---|
| Aliskiren+Amlodipine | -27.37 |
| Aliskiren Start-Amlodipine Add On | -26.34 |
| Amlodipine Start-Aliskiren Add On | -25.52 |
Systolic Blood pressure was measured in a sitting position using a validated automated blood pressure monitor (the Omron device) according to Guidelines of the British Hypertension Society, at Baseline and 32 weeks of study treatment. Change at week 32 used a separate repeated measures ANCOVA model containing Week 8, 16, 24 & 32 data. Treatment, visit and region were factors in the model, treatment by visit interaction and baseline msSBP was a covariate. (NCT00797862)
Timeframe: Baseline to 32 weeks
| Intervention | mmHg (Least Squares Mean) |
|---|---|
| Aliskiren+Amlodipine | -26.42 |
| Aliskiren Start-Amlodipine Add On | -25.75 |
| Amlodipine Start-Aliskiren Add On | -24.32 |
Diastolic Blood pressure was measured in a sitting position using a validated automated blood pressure monitor (the Omron device) according to Guidelines of the British Hypertension Society, at Baseline and over 8, 16 and 24 weeks of study treatment. The overall mean change in msDBP from baseline was estimated over three time points: Week 8, Week 16, and Week 24. Analysis used a repeated measures ANCOVA model with treatment, visit and regions as factors, treatment by visit interaction and baseline msDBP as a covariate. (NCT00797862)
Timeframe: Baseline, 8 weeks, 16 weeks and 24 weeks
| Intervention | mmHg (Least Squares Mean) |
|---|---|
| Aliskiren+Amlodipine | -12.39 |
| Aliskiren Start-Amlodipine Add On | -8.37 |
| Amlodipine Start-Aliskiren Add On | -9.02 |
Systolic Blood Pressure was measured in a sitting position using a validated automated blood pressure monitor (the Omron device) according to Guidelines of the British Hypertension Society, at Baseline and over 8, 16 and 24 weeks of study treatment. The overall mean change in msSBP from baseline was estimated over three time points: Week 8, Week 16, and Week 24. Analysis used a repeated measures Analysis of Covariance (ANCOVA) model with treatment, visit, and region as factors, treatment by visit interaction and baseline msSBP as a covariate. (NCT00797862)
Timeframe: Baseline, 8 weeks, 16 weeks, and 24 weeks
| Intervention | mmHg (Least Squares Mean) |
|---|---|
| Aliskiren+Amlodipine | -25.34 |
| Aliskiren Start-Amlodipine Add On | -17.94 |
| Amlodipine Start-Aliskiren Add On | -19.81 |
Systolic & Diastolic Blood Pressure were measured in a sitting position using a validated automated blood pressure monitor (the Omron device) according to Guidelines of the British Hypertension Society, at Baseline and after 8, 16 , 24 and 32 weeks. Outcome is reported as percentage of participants achieving overall blood pressure control (msSBP <140 mmHg and msDBP <90 mmHg) at weeks 8, 16, 24 & 32 endpoints. (NCT00797862)
Timeframe: Baseline to week 8, 16, 24 and 32 endpoints
| Intervention | Percentage of Participants (Number) | |||
|---|---|---|---|---|
| Week 8 endpoint | Week 16 endpoint | Week 24 endpoint | Week 32 endpoint | |
| Aliskiren Start-Amlodipine Add On | 22.8 | 33.3 | 62.8 | 59.0 |
| Aliskiren+Amlodipine | 46.5 | 65.9 | 63.4 | 61.6 |
| Amlodipine Start-Aliskiren Add On | 25.2 | 40.9 | 57.8 | 53.4 |
(NCT00568178)
Timeframe: Baseline and Week 12
| Intervention | mm Hg (Least Squares Mean) |
|---|---|
| Losartan-Hypertensive Participants | -3.8 |
| Amlodipine-Hypertensive Participants | 0.8 |
(NCT00568178)
Timeframe: Baseline and Week 12
| Intervention | mm Hg (Least Squares Mean) |
|---|---|
| Losartan-Hypertensive Participants | -5.5 |
| Amlodipine-Hypertensive Participants | -0.1 |
"Change in urinary protein excretion, determined as urinary Pr/Cr ratio compared to baseline*, after approximately twelve weeks of treatment.~Baseline is defined as values obtained at Visit 3, Week (-1) during the Single Blind Run-in period." (NCT00568178)
Timeframe: Baseline and Week 12
| Intervention | Percent Change in Pr/Cr (Geometric Mean) |
|---|---|
| Losartan | -35.80 |
| Amlodipine/Placebo | 1.37 |
"The outcome measure of glomerular filtration rate was based on mL/min/1.73m^2, as determined by the Schwartz formula:~GFR = _____0.55 x height (cm)_______ divided by serum creatinine (mg/dL)~GFR values were compared to the baseline GFR measure.~[Note: For male participants, ages 13 to 17 years, 0.70 was used as~the multiplier in place of 0.55]~Baseline in regard to the extension is defined as the last value obtained in the double-blind treatment phase." (NCT00568178)
Timeframe: Baseline and Month 36
| Intervention | Change in GFR mL/min1.73m^2 (Least Squares Mean) |
|---|---|
| Losartan Open Label Extension | 3.3 |
| Enalapril Open Label Extension | 7.0 |
"Change in urinary protein excretion, determined as urinary Pr/Cr ratio compared to baseline*, after approximately three years of treatment.~*The baseline for efficacy data in the extension was defined as the last value obtained in the double-blind treatment phase." (NCT00568178)
Timeframe: Baseline and Month 36
| Intervention | Percent Change in Pr/Cr (Geometric Mean) |
|---|---|
| Losartan Open Label Extension | -30.01 |
| Enalapril Open Label Extension | -40.45 |
To compare the percentage of patients achieving BP control (<140/90 mm Hg) after 8 weeks of treatment with an aliskiren HCTZ-based treatment regimen (aliskiren HCTZ 150/12.5 mg, 300/25 mg) versus an amlodipine-based treatment regimen (amlodipine 5 mg, 10 mg) in African American patients with stage 2 hypertension. (NCT00739596)
Timeframe: 8 weeks
| Intervention | Cumulative percentage of participants (Number) |
|---|---|
| Aliskiren HCTZ | 63.6 |
| Amlodipine | 62.3 |
To compare the percentage of responders after 8 weeks of treatment with an aliskiren HCTZ based treatment regimen (aliskiren HCTZ 150/12.5 mg, 300/25 mg) versus an amlodipine-based treatment regimen (amlodipine 5 mg, 10 mg) in African American patients with stage 2 hypertension: [ Responders were defined as patients with MSSBP < 140 mm Hg or a decrease from baseline ≥ 20 mm Hg at 1st response. A response was counted when a patient first achieved MSSBP < 140 mm Hg or a decrease from baseline ≥ 20 mm Hg.] (NCT00739596)
Timeframe: 8 weeks
| Intervention | Cumulative percentage of responders (Number) |
|---|---|
| Aliskiren HCTZ | 84.6 |
| Amlodipine | 90.7 |
To assess the change from baseline in mean sitting diastolic blood pressure (MSDBP) after 8 weeks of treatment with an aliskiren HCTZ-based treatment regimen (aliskiren HCTZ 150/12.5 mg, 300/25 mg) versus an amlodipine-based treatment regimen (amlodipine 5 mg, 10 mg) in African American patients with stage 2 hypertension. (NCT00739596)
Timeframe: Baseline and 8 weeks
| Intervention | mm Hg (Mean) | ||
|---|---|---|---|
| Baseline | Week 8 | Change from Baseline to Week 8 | |
| Aliskiren HCTZ | 96.0 | 86.0 | -10.0 |
| Amlodipine | 95.0 | 84.0 | -11.0 |
To compare the change from baseline in mean sitting pulse pressure (MSPP) after 8 weeks of treatment with an aliskiren HCTZ-based treatment regimen (aliskiren HCTZ 150/12.5 mg, 300/25 mg) versus an amlodipine-based treatment regimen (amlodipine 5 mg, 10 mg) in African American patients with stage 2 hypertension. (NCT00739596)
Timeframe: Baseline and 8 weeks
| Intervention | mm Hg (Mean) | ||
|---|---|---|---|
| Baseline | Week 8 | Change from Baseline to Week 8 | |
| Aliskiren HCTZ | 72.2 | 52.7 | -19.4 |
| Amlodipine | 73.1 | 55.1 | -18.0 |
To assess the change from baseline in MSSBP after 8 weeks of treatment with an aliskiren HCTZ-based treatment regimen (aliskiren HCTZ 150/12.5 mg, 300/25 mg) versus an amlodipine-based treatment regimen (amlodipine 5 mg, 10 mg) in African American patients with stage 2 hypertension. (NCT00739596)
Timeframe: Baseline and 8 weeks
| Intervention | mm Hg (Mean) | ||
|---|---|---|---|
| Baseline | Week 8 | Change from baseline to Week 8 | |
| Aliskiren HCTZ | 168.2 | 138.8 | -29.4 |
| Amlodipine | 168.1 | 139.1 | -29.0 |
After the patient had been sitting for 5 minutes, systolic and diastolic blood pressures were measured 3 times using the automatic Blood Pressure monitor and appropriate size cuff. The repeat sitting measurements were made at 1-2 minute intervals and the mean of these 3 sitting blood pressure measurements was used as the average sitting blood pressure for that visit. The difference of the msDBP at baseline from the msDBP at 8 weeks was calculated using an Analysis of Covariance (ANCOVA) model with baseline as a covariate and treatment and region as two factors. (NCT00777946)
Timeframe: Baseline, End of Study (Week 8)
| Intervention | mm Hg (Least Squares Mean) |
|---|---|
| Aliskiren 300 mg/Amlodipine 10 mg | -13.07 |
| Aliskiren 300 mg/Amlodipine 5 mg | -10.54 |
| Aliskiren 300 mg | -5.84 |
After the patient had been sitting for 5 minutes, systolic and diastolic blood pressures were measured 3 times using the automatic Blood Pressure monitor and appropriate size cuff. The repeat sitting measurements were made at 1-2 minute intervals and the mean of these 3 sitting blood pressure measurements was used as the average sitting blood pressure for that visit. The difference of the msSBP at baseline from the msSBP at 8 weeks was calculated using an ANCOVA model with baseline as a covariate and treatment and region as two factors. (NCT00777946)
Timeframe: Baseline, End of Study (Week 8)
| Intervention | mm Hg (Least Squares Mean) |
|---|---|
| Aliskiren 300 mg/Amlodipine 10 mg | -18.04 |
| Aliskiren 300 mg/Amlodipine 5 mg | -14.43 |
| Aliskiren 300 mg | -6.42 |
"After the patient had been sitting for 5 minutes, with the back supported and both feet placed on the floor, systolic and diastolic blood pressures were measured 3 times using the automatic Blood Pressure monitor and appropriate size cuff. The repeat sitting measurements were made at 1-2 minute intervals and the mean of these 3 sitting blood pressure measurements was used as the average sitting blood pressure for that visit.~A Diastolic Blood Pressure Response was defined as a mean sitting Diastolic Blood Pressure (msDBP) <90 mmHg or a ≥ 10 mmHg reduction in msDBP from baseline." (NCT00777946)
Timeframe: 8 weeks
| Intervention | Percentage of participants (Number) |
|---|---|
| Aliskiren 300 mg/Amlodipine 10 mg | 83.6 |
| Aliskiren 300 mg/Amlodipine 5 mg | 77.7 |
| Aliskiren 300 mg | 51.5 |
"After the patient had been sitting for 5 minutes, with the back supported and both feet placed on the floor, systolic and diastolic blood pressures were measured 3 times using the automatic Blood Pressure monitor and appropriate size cuff. The repeat sitting measurements were made at 1-2 minute intervals and the mean of these 3 sitting blood pressure measurements was used as the average sitting blood pressure for that visit.~A Systolic Blood Pressure Response was defined as a mean sitting Systolic Blood Pressure (msSBP) <140 mmHg or a ≥ 20 mmHg reduction in msSBP from baseline." (NCT00777946)
Timeframe: 8 weeks
| Intervention | Percentage of participants (Number) |
|---|---|
| Aliskiren 300 mg/Amlodipine 10 mg | 77.2 |
| Aliskiren 300 mg/Amlodipine 5 mg | 69.7 |
| Aliskiren 300 mg | 43.8 |
"After the patient had been sitting for 5 minutes, with the back supported and both feet placed on the floor, systolic and diastolic blood pressures were measured 3 times using the automatic Blood Pressure monitor and appropriate size cuff. The repeat sitting measurements were made at 1-2 minute intervals and the mean of these 3 sitting blood pressure measurements was used as the average sitting blood pressure for that visit.~Blood Pressure control was defined as having a mean sitting Diastolic Blood Pressure <90 and a mean sitting Systolic Blood Pressure <140." (NCT00777946)
Timeframe: 8 weeks
| Intervention | Percentage of participants (Number) |
|---|---|
| Aliskiren 300 mg/Amlodipine 10 mg | 65.5 |
| Aliskiren 300 mg/Amlodipine 5 mg | 56.5 |
| Aliskiren 300 mg | 31.5 |
"The number of participants with any Serious Adverse Event and the number of participants with Adverse Events in any system organ class.~Additional information about Adverse Events can be found in the Adverse Event Section." (NCT00777946)
Timeframe: 8 weeks
| Intervention | participants (Number) | |
|---|---|---|
| Serious Adverse Events | Adverse Events | |
| Aliskiren 300 mg | 1 | 59 |
| Aliskiren 300 mg/Amlodipine 10 mg | 3 | 85 |
| Aliskiren 300 mg/Amlodipine 5 mg | 4 | 80 |
(NCT00778921)
Timeframe: Baseline and Week 8
| Intervention | mm Hg (Least Squares Mean) |
|---|---|
| Aliskiren/Amlodipine 300/10 mg | -10.99 |
| Aliskiren/Amlodipine 150/10 mg | -8.95 |
| Amlodipine 10 mg | -7.23 |
(NCT00778921)
Timeframe: Baseline and Week 8
| Intervention | mm Hg (Least Squares Mean) |
|---|---|
| Aliskiren/Amlodipine 300/10 mg | -14.42 |
| Aliskiren/Amlodipine 150/10 mg | -11.01 |
| Amlodipine 10 mg | -8.20 |
(NCT00778921)
Timeframe: 8 weeks
| Intervention | Participants (Number) |
|---|---|
| Aliskiren/Amlodipine 300/10 mg | 87 |
| Aliskiren/Amlodipine 150/10 mg | 99 |
| Amlodipine 10 mg | 92 |
(NCT00791258)
Timeframe: baseline to 12 weeks
| Intervention | Percentage of participants (Number) |
|---|---|
| Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide | 75.8 |
(NCT00791258)
Timeframe: baseline to 12 weeks
| Intervention | Percentage of participants (Number) |
|---|---|
| Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide | 84.3 |
Once the Ambulatory Blood Pressure Monitor (ABPM) has been applied, the dose of medication was taken and the subject wore the ABPM for a period of 24 hours. Daytime is defined as 8 a.m. to 4 p.m. Nighttime is defined as 10 p.m. to 6 a.m. (NCT00791258)
Timeframe: Baseline to 12 weeks
| Intervention | mm Hg (Mean) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 24-hour mean systolic blood pressure | Mean daytime systolic blood pressure | Mean nighttime systolic blood pressure | Systolic blood pressure - last 2 hours of dose | Systolic blood pressure - last 4 hours of dose | Systolic blood pressure - last 6 hours of dose | 24-hour mean diastolic blood pressure | Mean daytime diastolic blood pressure | Mean nighttime diastolic blood pressure | Diastolic blood pressure - last 2 hours of dose | Diastolic blood pressure - last 4 hours of dose | Diastolic blood pressure - last 6 hours of dose | |
| Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide | -14.8 | -16.3 | -12.5 | -13.6 | -13.0 | -12.6 | -9.4 | -10.6 | -7.6 | -8.6 | -8.0 | -7.7 |
Once the Ambulatory Blood Pressure Monitor (ABPM) has been applied, the dose of medication was taken and the subject wore the ABPM for a period of 24 hours. Daytime is defined as 8 a.m. to 4 p.m. Nighttime is defined as 10 p.m. to 6 a.m. (NCT00791258)
Timeframe: Baseline to 20 weeks
| Intervention | mm Hg (Mean) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 24-hour mean systolic blood pressure | Mean daytime systolic blood pressure | Mean nighttime systolic blood pressure | Systolic blood pressure - last 2 hours of dose | Systolic blood pressure - last 4 hours of dose | Systolic blood pressure - last 6 hours of dose | 24-hour mean diastolic blood pressure | Mean daytime diastolic blood pressure | Mean nighttime diastolic blood pressure | Diastolic blood pressure - last 2 hours of dose | Diastolic blood pressure - last 4 hours of dose | Diastolic blood pressure - last 6 hours of dose | |
| Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide | -21.0 | -23.2 | -17.5 | -19.6 | -18.2 | -17.9 | -13.3 | -15.0 | -11.1 | -12.3 | -11.6 | -11.3 |
(NCT00791258)
Timeframe: Baseline to 4, 8, 12, 16, 20 weeks
| Intervention | mm Hg (Mean) | ||||
|---|---|---|---|---|---|
| 4 weeks, N=975 | 8 weeks, N=929 | 12 weeks, N=865 | 16 weeks, N=797 | 20 weeks, N=745 | |
| Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide | -8.1 | -9.1 | -11.9 | -14.6 | -14.5 |
(NCT00791258)
Timeframe: Baseline to 4, 8, 12, 16, 20 weeks
| Intervention | mm Hg (Mean) | ||||
|---|---|---|---|---|---|
| 4 weeks, N=975 | 8 weeks, N=929 | 12 weeks, N=865 | 16 weeks, N=797 | 20 weeks, N=745 | |
| Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide | -14.6 | -16.6 | -21.8 | -26.0 | -26.8 |
(NCT00791258)
Timeframe: Baseline to 4, 8, 12, 16, 20 weeks
| Intervention | Percentage of Participants (Number) | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 4 weeks: <140/90 mm Hg, N=230 | 4 weeks: <135/80 mm Hg, N=230 | 4 weeks: <130/80 mm Hg, N=230 | 4 weeks: <120/80 mm Hg, N=230 | 8 weeks: <140/90 mm Hg, N=231 | 8 weeks: <135/80 mm Hg, N=231 | 8 weeks: <130/80 mm Hg, N=232 | 8 weeks: <120/80 mm Hg, N=232 | 12 weeks: <140/90mm Hg, N=232 | 12 weeks: <135/80 mm Hg, N=232 | 12 weeks: <130/80 mm Hg, N=232 | 12 weeks: <120/80 mm Hg, N=232 | 16 weeks: <140/90 mm Hg, N=232 | 16 weeks: <135/80 mm Hg, N=232 | 16 weeks: <130/80 mm Hg, N=232 | 16 weeks: <120/80 mm Hg, N=232 | 20 weeks: <140/90 mm Hg, N=232 | 20 weeks: <135/80 mm Hg, N=232 | 20 weeks: <130/80 mm Hg, N=232 | 20 weeks: <120/80 mm Hg, N=232 | |
| Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide | 45.7 | 14.8 | 10.4 | 3.9 | 55.0 | 23.8 | 20.8 | 10.4 | 68.5 | 38.4 | 35.8 | 16.4 | 80.6 | 49.1 | 47.4 | 30.6 | 86.6 | 57.8 | 55.2 | 39.7 |
(NCT00791258)
Timeframe: Baseline to 4, 8, 12, 16, 20 weeks
| Intervention | Percentage of Participants (Number) | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 4 weeks: <90 mm Hg, N=230 | 4 weeks: <85 mm Hg, N=230 | 4 weeks: <80 mm Hg, N=230 | 8 weeks: <90 mm Hg, N=231 | 8 weeks: <85 mm Hg, N=231 | 8 weeks: <80 mm Hg, N=231 | 12 weeks: <90 mm Hg, N=232 | 12 weeks: <85 mm Hg, N=232 | 12 weeks: <80 mm Hg, N=232 | 16 weeks: <90 mm Hg, N=232 | 16 weeks: <85 mm Hg, N=232 | 16 weeks: <80 mm Hg, N=232 | 20 weeks: <90 mm Hg, N=232 | 20 weeks: <85 mm Hg, N=232 | 20 weeks: <80 mm Hg, N=232 | |
| Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide | 60.9 | 42.2 | 19.6 | 71.9 | 53.7 | 30.3 | 82.3 | 66.0 | 45.3 | 92.2 | 76.3 | 55.2 | 94.8 | 80.6 | 61.2 |
(NCT00791258)
Timeframe: Baseline to 4, 8, 12, 16, 20 weeks
| Intervention | Percentage of Participants (Number) | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 4 weeks: ≤ 10 mm Hg, N=230 | 4 weeks: >10 and ≤ 15 mm Hg, N=230 | 4 weeks: >15 and ≤ 20 mm Hg, N=230 | 4 weeks: >20 mm Hg, N=230 | 8 weeks: ≤ 10 mm Hg, N=220 | 8 weeks: >10 and ≤ 15 mm Hg, N=220 | 8 weeks: >15 and ≤ 20 mm Hg, N=220 | 8 weeks: >20 mm Hg, N=220 | 12 weeks: ≤ 10 mm Hg, N=208 | 12 weeks: >10 and ≤15 mm Hg, N=208 | 12 weeks: >15 and ≤ 20 mm Hg, N=208 | 12 weeks: >20 mm Hg, N=208 | 16 weeks: ≤ 10 mm Hg, N=199 | 16 weeks: >10 and ≤ 15 mm Hg, N=199 | 16 weeks: >15 and ≤ 20 mm Hg, N=199 | 16 weeks: >20 mm Hg, N=199 | 20 weeks: ≤ 10 mm Hg, N=189 | 20 weeks: >10 and ≤ 15 mm Hg, N=189 | 20 weeks: >15 and ≤ 20 mm Hg, N=189 | 20 weeks: >20 mm Hg, N=189 | |
| Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide | 70.0 | 17.8 | 7.9 | 4.4 | 66.8 | 15.0 | 10.9 | 7.3 | 54.8 | 21.2 | 12.0 | 12.0 | 38.7 | 19.6 | 23.1 | 18.6 | 36.0 | 19.6 | 20.6 | 23.8 |
(NCT00791258)
Timeframe: Baseline to 4, 8, 12, 16, 20 weeks
| Intervention | Percentage of Participants (Number) | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 4 weeks: <140 mm Hg, N=230 | 4 weeks: <135 mm Hg, N=230 | 4 weeks: <130 mm Hg, N=230 | 4 weeks: <120 mm Hg, N=230 | 8 weeks: <140 mm Hg, N=231 | 8 weeks: <135 mm Hg, N=231 | 8 weeks: <130 mm Hg, N=231 | 8 weeks: <120 mm Hg, N=231 | 12 weeks: <140 mm Hg, N=232 | 12 weeks: <135 mm Hg, N=232 | 12 weeks: <130 mm Hg, N=232 | 12 weeks: <120 mm Hg, N=232 | 16 weeks: <140 mm Hg, N=232 | 16 weeks: <135 mm Hg, N=232 | 16 weeks: <130 mm Hg, N=232 | 16 weeks: <120 mm Hg, N=232 | 20 weeks: <140 mm Hg, N=232 | 20 weeks: <135 mm Hg, N=232 | 20 weeks: <130 mm Hg, N=232 | 20 weeks: <120 mm Hg, N=232 | |
| Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide | 51.7 | 34.4 | 19.6 | 5.7 | 62.3 | 44.6 | 33.8 | 13.0 | 76.3 | 59.1 | 47.0 | 19.8 | 84.9 | 71.1 | 61.2 | 34.1 | 91.0 | 80.6 | 71.1 | 44.4 |
(NCT00791258)
Timeframe: Baseline to 4, 8, 12, 16, 20 weeks
| Intervention | Percentage of Participants (Number) | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 4 weeks: ≤ 15 mm Hg, N=230 | 4 weeks: >15 and ≤ 30 mm Hg, N=230 | 4 weeks: >30 and ≤ 45 mm Hg, N=230 | 4 weeks: >45 mm Hg, N=230 | 8 weeks: ≤ 15 mm Hg, N=220 | 8 weeks: >15 and ≤ 30 mm Hg, N=220 | 8 weeks: >30 and ≤ 45 mm Hg, N=220 | 8 weeks: >45 mm Hg, N=220 | 12 weeks: ≤ 15 mm Hg, N=208 | 12 weeks: >15 and ≤ 30 mm Hg, N=208 | 12 weeks: >30 and ≤ 45 mm Hg, N=208 | 12 weeks: >45 mm Hg, N=208 | 16 weeks: ≤ 15 mm Hg, N=199 | 16 weeks: >15 and ≤ 30 mm Hg, N=199 | 16 weeks: >30 and ≤ 45 mm Hg, N=199 | 16 weeks: >45 mm Hg, N=199 | 20 weeks: ≤ 15 mm Hg, N=189 | 20 weeks: >15 and ≤ 30 mm Hg, N=189 | 20 weeks: >30 and ≤ 45 mm Hg, N=189 | 20 weeks: >45 mm Hg, N=189 | |
| Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide | 60.0 | 32.2 | 7.4 | 0.4 | 53.6 | 38.2 | 7.3 | 0.9 | 38.9 | 41.8 | 16.4 | 2.9 | 30.7 | 37.2 | 25.1 | 7.0 | 24.3 | 37.6 | 29.6 | 8.5 |
(NCT00791258)
Timeframe: Baseline to 4, 8, 12, 16, 20 weeks
| Intervention | Percentage of Participants (Number) | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 4 weeks: <90 mm Hg, N=128 | 4 weeks: <85 mm Hg, N=128 | 4 weeks: <80 mm Hg, N=128 | 8 weeks: <90 mm Hg, N=128 | 8 weeks: <85 mm Hg, N=128 | 8 weeks: <80 mm Hg, N=128 | 12 weeks: <90 mm Hg, N=128 | 12 weeks: <85 mm Hg, N=128 | 12 weeks: <80 mm Hg, N=128 | 16 weeks: <90 mm Hg, N=128 | 16 weeks: <85 mm Hg, N=128 | 16 weeks: <80 mm Hg, N=128 | 20 weeks: <90 mm Hg, N=128 | 20 weeks: <85 mm Hg, N=128 | 20 weeks: <80 mm Hg, N=128 | |
| Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide | 83.6 | 69.5 | 45.3 | 89.1 | 79.7 | 60.2 | 95.3 | 87.5 | 71.1 | 96.9 | 93.0 | 82.0 | 96.9 | 93.0 | 85.2 |
(NCT00791258)
Timeframe: Baseline to 4, 8, 12, 16, 20 weeks
| Intervention | Percentage of Participants (Number) | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 4 weeks: ≤ 10 mm Hg, N=126 | 4 weeks: >10 and ≤ 15 mm Hg, N=126 | 4 weeks: >15 and ≤ 20 mm Hg, N=126 | 4 weeks: >20 mm Hg, N=126 | 8 weeks: ≤ 10 mm Hg, N=123 | 8 weeks: >10 and ≤ 15 mm Hg, N=123 | 8 weeks: >15 and ≤ 20 mm Hg, N=123 | 8 weeks: >20 mm Hg, N=123 | 12 weeks: ≤ 10 mm Hg, N=120 | 12 weeks: >10 and ≤15 mm Hg, N=120 | 12 weeks: >15 and ≤ 20 mm Hg, N=120 | 12 weeks: >20 mm Hg, N=120 | 16 weeks: ≤ 10 mm Hg, N=112 | 16 weeks: >10 and ≤ 15 mm Hg, N=112 | 16 weeks: >15 and ≤ 20 mm Hg, N=112 | 16 weeks: >20 mm Hg, N=112 | 20 weeks: ≤ 10 mm Hg, N=105 | 20 weeks: >10 and ≤ 15 mm Hg, N=105 | 20 weeks: >15 and ≤ 20 mm Hg, N=105 | 20 weeks: >20 mm Hg, N=105 | |
| Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide | 47.6 | 26.2 | 13.5 | 12.7 | 38.2 | 24.4 | 22.0 | 15.5 | 33.3 | 25.8 | 19.2 | 21.7 | 27.7 | 17.0 | 20.5 | 34.8 | 36.2 | 16.2 | 18.1 | 29.5 |
(NCT00791258)
Timeframe: Baseline to 4, 8, 12, 16, 20 weeks
| Intervention | Percentage of Participants (Number) | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 4 weeks: <140 mm Hg, N=128 | 4 weeks: <135 mm Hg, N=128 | 4 weeks: <130 mm Hg, N=128 | 4 weeks: <120 mm Hg, N=128 | 8 weeks: <140 mm Hg, N=128 | 8 weeks: <135 mm Hg, N=128 | 8 weeks: <130 mm Hg, N=128 | 8 weeks: <120 mm Hg, N=128 | 12 weeks: <140 mm Hg, N=128 | 12 weeks: <135 mm Hg, N=128 | 12 weeks: <130 mm Hg, N=128 | 12 weeks: <120 mm Hg, N=128 | 16 weeks: <140 mm Hg, N=128 | 16 weeks: <135 mm Hg, N=128 | 16 weeks: <130 mm Hg, N=128 | 16 weeks: <120 mm Hg, N=128 | 20 weeks: <140 mm Hg, N=128 | 20 weeks: <135 mm Hg, N=128 | 20 weeks: <130 mm Hg, N=128 | 20 weeks: <120 mm Hg, N=128 | |
| Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide | 64.8 | 51.6 | 35.2 | 11.7 | 76.6 | 67.2 | 51.6 | 25.0 | 89.1 | 78.9 | 66.4 | 38.3 | 95.3 | 89.8 | 81.3 | 47.7 | 97.7 | 93.0 | 85.9 | 51.6 |
(NCT00791258)
Timeframe: Baseline to 4, 8, 12, 16, 20 weeks
| Intervention | Percentage of Participants (Number) | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 4 weeks: ≤ 15 mm Hg, N=126 | 4 weeks: >15 and ≤ 30 mm Hg, N=126 | 4 weeks: >30 and ≤ 45 mm Hg, N=126 | 4 weeks: >45 mm Hg, N=126 | 8 weeks: ≤ 15 mm Hg, N=123 | 8 weeks: >15 and ≤ 30 mm Hg, N=123 | 8 weeks: >30 and ≤ 45 mm Hg, N=123 | 8 weeks: >45 mm Hg, N=123 | 12 weeks: ≤ 15 mm Hg, N=120 | 12 weeks: >15 and ≤ 30 mm Hg, N=120 | 12 weeks: >30 and ≤ 45 mm Hg, N=120 | 12 weeks: >45 mm Hg, N=120 | 16 weeks: ≤ 15 mm Hg, N=112 | 16 weeks: >15 and ≤ 30 mm Hg, N=112 | 16 weeks: >30 and ≤ 45 mm Hg, N=112 | 16 weeks: >45 mm Hg, N=112 | 20 weeks: ≤ 15 mm Hg, N=105 | 20 weeks: >15 and ≤ 30 mm Hg, N=105 | 20 weeks: >30 and ≤ 45 mm Hg, N=105 | 20 weeks: >45 mm Hg, N=105 | |
| Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide | 43.7 | 38.1 | 15.9 | 2.4 | 40.7 | 35.8 | 22.0 | 1.6 | 28.3 | 39.2 | 27.5 | 5.0 | 20.5 | 36.6 | 31.3 | 11.6 | 29.5 | 28.6 | 33.3 | 8.6 |
(NCT00791258)
Timeframe: Baseline to 4, 8, 12, 16, 20 weeks
| Intervention | Percentage of Participants (Number) | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 4 weeks: <90 mm Hg, N=227 | 4 weeks: <85 mm Hg, N=227 | 4 weeks: <80 mm Hg, N=227 | 8 weeks: <90 mm Hg, N=227 | 8 weeks: <85 mm Hg, N=227 | 8 weeks: <80 mm Hg, N=227 | 12 weeks: <90 mm Hg, N=227 | 12 weeks: <85 mm Hg, N=227 | 12 weeks: <80 mm Hg, N=227 | 16 weeks: <90 mm Hg, N=227 | 16 weeks: <85 mm Hg, N=227 | 16 weeks: <80 mm Hg, N=227 | 20 weeks: <90 mm Hg, N=227 | 20 weeks: <85 mm Hg, N=227 | 20 weeks: <80 mm Hg, N=227 | |
| Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide | 88.1 | 76.7 | 58.2 | 92.1 | 83.7 | 71.8 | 97.4 | 92.1 | 80.2 | 98.7 | 94.3 | 88.6 | 98.7 | 95.2 | 90.3 |
(NCT00791258)
Timeframe: Baseline to 4, 8, 12, 16, 20 weeks
| Intervention | Percentage of Participants (Number) | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 4 weeks: ≤ 10 mm Hg, N=224 | 4 weeks: >10 and ≤ 15 mm Hg, N=224 | 4 weeks: >15 and ≤ 20 mm Hg, N=224 | 4 weeks: >20 mm Hg, N=224 | 8 weeks: ≤ 10 mm Hg, N=217 | 8 weeks: >10 and ≤ 15 mm Hg, N=217 | 8 weeks: >15 and ≤ 20 mm Hg, N=217 | 8 weeks: >20 mm Hg, N=217 | 12 weeks: ≤ 10 mm Hg, N=199 | 12 weeks: >10 and ≤15 mm Hg, N=199 | 12 weeks: >15 and ≤ 20 mm Hg, N=199 | 12 weeks: >20 mm Hg, N=199 | 16 weeks: ≤ 10 mm Hg, N=179 | 16 weeks: >10 and ≤ 15 mm Hg, N=179 | 16 weeks: >15 and ≤ 20 mm Hg, N=179 | 16 weeks: >20 mm Hg, N=179 | 20 weeks: ≤ 10 mm Hg, N=166 | 20 weeks: >10 and ≤ 15 mm Hg, N=166 | 20 weeks: >15 and ≤ 20 mm Hg, N=166 | 20 weeks: >20 mm Hg, N=166 | |
| Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide | 63.8 | 20.5 | 9.4 | 6.3 | 57.1 | 19.8 | 14.3 | 8.8 | 45.2 | 25.1 | 15.6 | 14.1 | 27.4 | 25.1 | 22.9 | 24.6 | 34.9 | 20.5 | 24.1 | 20.5 |
(NCT00791258)
Timeframe: Baseline to 4, 8, 12, 16, 20 weeks
| Intervention | Percentage of Participants (Number) | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 4 weeks: <140 mm Hg, N=227 | 4 weeks: <135 mm Hg, N=227 | 4 weeks: <130 mm Hg, N=227 | 4 weeks: <120 mm Hg, N=227 | 8 weeks: <140 mm Hg, N=227 | 8 weeks: <135 mm Hg, N=227 | 8 weeks: <130 mm Hg, N=227 | 8 weeks: <120 mm Hg, N=227 | 12 weeks: <140 mm Hg, N=227 | 12 weeks: <135 mm Hg, N=227 | 12 weeks: <130 mm Hg, N=227 | 12 weeks: <120 mm Hg, N=227 | 16 weeks: <140 mm Hg, N=227 | 16 weeks: <135 mm Hg, N=227 | 16 weeks: <130 mm Hg, N=227 | 16 weeks: <120 mm Hg, N=227 | 20 weeks: <140 mm Hg, N=227 | 20 weeks: <135 mm Hg, N=227 | 20 weeks: <130 mm Hg, N=227 | 20 weeks: <120 mm Hg, N=227 | |
| Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide | 52.0 | 37.9 | 23.4 | 9.7 | 67.0 | 57.7 | 43.6 | 18.1 | 80.6 | 70.0 | 56.8 | 28.6 | 87.7 | 79.7 | 70.9 | 43.6 | 91.6 | 85.9 | 78.9 | 50.7 |
(NCT00791258)
Timeframe: Baseline to 4, 8, 12, 16, 20 weeks
| Intervention | Percentage of Participants (Number) | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 4 weeks: ≤ 15 mm Hg, N=224 | 4 weeks: >15 and ≤ 30 mm Hg, N=224 | 4 weeks: >30 and ≤ 45 mm Hg, N=224 | 4 weeks: >45 mm Hg, N=224 | 8 weeks: ≤ 15 mm Hg, N=217 | 8 weeks: >15 and ≤ 30 mm Hg, N=217 | 8 weeks: >30 and ≤ 45 mm Hg, N=217 | 8 weeks: >45 mm Hg, N=217 | 12 weeks: ≤ 15 mm Hg, N=199 | 12 weeks: >15 and ≤ 30 mm Hg, N=199 | 12 weeks: >30 and ≤ 45 mm Hg, N=199 | 12 weeks: >45 mm Hg, N=199 | 16 weeks: ≤ 15 mm Hg, N=179 | 16 weeks: >15 and ≤ 30 mm Hg, N=179 | 16 weeks: >30 and ≤ 45 mm Hg, N=179 | 16 weeks: >45 mm Hg, N=179 | 20 weeks: ≤ 15 mm Hg, N=166 | 20 weeks: >15 and ≤ 30 mm Hg, N=166 | 20 weeks: >30 and ≤ 45 mm Hg, N=166 | 20 weeks: >45 mm Hg, N=166 | |
| Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide | 47.3 | 40.2 | 11.2 | 1.3 | 42.9 | 37.8 | 16.6 | 2.8 | 26.6 | 46.7 | 24.6 | 2.0 | 17.9 | 32.4 | 39.7 | 10.1 | 14.5 | 37.4 | 38.0 | 10.2 |
(NCT00791258)
Timeframe: Baseline to 4, 8, 12, 16, 20 weeks
| Intervention | Percentage of Participants (Number) | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 4 weeks: <90 mm Hg, N=98 | 4 weeks: <85 mm Hg, N=98 | 4 weeks: <80 mm Hg, N=98 | 8 weeks: <90 mm Hg, N=100 | 8 weeks: <85 mm Hg, N=100 | 8 weeks: <80 mm Hg, N=100 | 12 weeks: <90 mm Hg, N=100 | 12 weeks: <85 mm Hg, N=100 | 12 weeks: <80 mm Hg, N=100 | 16 weeks: <90 mm Hg, N=100 | 16 weeks: <85 mm Hg, N=100 | 16 weeks: <80 mm Hg, N=100 | 20 weeks: <90 mm Hg, N=100 | 20 weeks: <85 mm Hg, N=100 | 20 weeks: <80 mm Hg, N=100 | |
| Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide | 66.3 | 53.1 | 34.7 | 85.0 | 70.0 | 48.0 | 92.0 | 78.0 | 62.0 | 96.0 | 90.0 | 75.0 | 96.0 | 90.0 | 75.0 |
(NCT00791258)
Timeframe: Baseline to 4, 8, 12, 16, 20 weeks
| Intervention | Percentage of Participants (Number) | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 4 weeks: ≤ 10 mm Hg, N=98 | 4 weeks: >10 and ≤ 15 mm Hg, N=98 | 4 weeks: >15 and ≤ 20 mm Hg, N=98 | 4 weeks: >20 mm Hg, N=98 | 8 weeks: ≤ 10 mm Hg, N=91 | 8 weeks: >10 and ≤ 15 mm Hg, N=91 | 8 weeks: >15 and ≤ 20 mm Hg, N=91 | 8 weeks: >20 mm Hg, N=91 | 12 weeks: ≤ 10 mm Hg, N=83 | 12 weeks: >10 and ≤15 mm Hg, N=83 | 12 weeks: >15 and ≤ 20 mm Hg, N=83 | 12 weeks: >20 mm Hg, N=83 | 16 weeks: ≤ 10 mm Hg, N=75 | 16 weeks: >10 and ≤ 15 mm Hg, N=75 | 16 weeks: >15 and ≤ 20 mm Hg, N=75 | 16 weeks: >20 mm Hg, N=75 | 20 weeks: ≤ 10 mm Hg, N=71 | 20 weeks: >10 and ≤ 15 mm Hg, N=71 | 20 weeks: >15 and ≤ 20 mm Hg, N=71 | 20 weeks: >20 mm Hg, N=71 | |
| Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide | 65.3 | 16.3 | 8.2 | 10.2 | 52.8 | 18.7 | 14.3 | 14.3 | 41.0 | 20.5 | 14.5 | 24.1 | 30.7 | 25.3 | 16.0 | 28.0 | 31.0 | 12.7 | 26.8 | 29.6 |
(NCT00791258)
Timeframe: Baseline to 4, 8, 12, 16, 20 weeks
| Intervention | Percentage of Participants (Number) | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 4 weeks: <140 mm Hg, N=98 | 4 weeks: <135 mm Hg, N=98 | 4 weeks: <130 mm Hg, N=98 | 4 weeks: <120 mm Hg, N=98 | 8 weeks: <140 mm Hg, N=100 | 8 weeks: <135 mm Hg, N=100 | 8 weeks: <130 mm Hg, N=100 | 8 weeks: <120 mm Hg, N=100 | 12 weeks: <140 mm Hg, N=100 | 12 weeks: <135 mm Hg, N=100 | 12 weeks: <130 mm Hg, N=100 | 12 weeks: <120 mm Hg, N=100 | 16 weeks: <140 mm Hg, N=100 | 16 weeks: <135 mm Hg, N=100 | 16 weeks: <130 mm Hg, N=100 | 16 weeks: <120 mm Hg, N=100 | 20 weeks: <140 mm Hg, N=100 | 20 weeks: <135 mm Hg, N=100 | 20 weeks: <130 mm Hg, N=100 | 20 weeks: <120 mm Hg, N=100 | |
| Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide | 55.1 | 39.8 | 31.6 | 10.2 | 64.0 | 51.0 | 41.0 | 15.0 | 77.0 | 67.0 | 54.0 | 30.0 | 84.0 | 77.0 | 66.0 | 37.0 | 88.0 | 83.0 | 72.0 | 41.0 |
(NCT00791258)
Timeframe: Baseline to 4, 8, 12, 16, 20 weeks
| Intervention | Percentage of Participants (Number) | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 4 weeks: ≤ 15 mm Hg, N=98 | 4 weeks: >15 and ≤ 30 mm Hg, N=98 | 4 weeks: >30 and ≤ 45 mm Hg, N=98 | 4 weeks: >45 mm Hg, N=98 | 8 weeks: ≤ 15 mm Hg, N=91 | 8 weeks: >15 and ≤ 30 mm Hg, N=91 | 8 weeks: >30 and ≤ 45 mm Hg, N=91 | 8 weeks: >45 mm Hg, N=91 | 12 weeks: ≤ 15 mm Hg, N=83 | 12 weeks: >15 and ≤ 30 mm Hg, N=83 | 12 weeks: >30 and ≤ 45 mm Hg, N=83 | 12 weeks: >45 mm Hg, N=83 | 16 weeks: ≤ 15 mm Hg, N=75 | 16 weeks: >15 and ≤ 30 mm Hg, N=75 | 16 weeks: >30 and ≤ 45 mm Hg, N=75 | 16 weeks: >45 mm Hg, N=75 | 20 weeks: ≤ 15 mm Hg, N=71 | 20 weeks: >15 and ≤ 30 mm Hg, N=71 | 20 weeks: >30 and ≤ 45 mm Hg, N=71 | 20 weeks: >45 mm Hg, N=71 | |
| Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide | 50.0 | 37.8 | 7.1 | 5.1 | 42.9 | 44.0 | 9.9 | 3.3 | 31.3 | 36.1 | 25.3 | 7.2 | 22.7 | 36.0 | 34.7 | 6.7 | 23.9 | 33.8 | 33.8 | 8.5 |
(NCT00791258)
Timeframe: Baseline to 4, 8, 12, 16, 20 weeks
| Intervention | Percentage of Participants (Number) | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 4 weeks: <90 mm Hg, N=497 | 4 weeks: <85 mm Hg, N=497 | 4 weeks: <80 mm Hg, N=497 | 8 weeks: <90 mm Hg, N=497 | 8 weeks: <85 mm Hg, N=500 | 8 weeks: <80 mm Hg, N=500 | 12 weeks: <90 mm Hg, N=500 | 12 weeks: <85 mm Hg, N=500 | 12 weeks: <80 mm Hg, N=500 | 16 weeks: <90 mm Hg, N=500 | 16 weeks: <85 mm Hg, N=500 | 16 weeks: <80 mm Hg, N=500 | 20 weeks: <90 mm Hg, N=500 | 20 weeks: <85 mm Hg, N=500 | 20 weeks: <80 mm Hg, N=500 | |
| Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide | 63.2 | 46.3 | 26.0 | 77.2 | 59.4 | 38.8 | 86.6 | 69.8 | 48.4 | 93.2 | 80.4 | 60.4 | 94.6 | 83.8 | 67.6 |
(NCT00791258)
Timeframe: Baseline to 4, 8, 12, 16, 20 weeks
| Intervention | Percentage of Participants (Number) | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 4 weeks: ≤ 10 mm Hg, N=495 | 4 weeks: >10 and ≤ 15 mm Hg, N=495 | 4 weeks: >15 and ≤ 20 mm Hg, N=495 | 4 weeks: >20 mm Hg, N=495 | 8 weeks: ≤ 10 mm Hg, N=468 | 8 weeks: >10 and ≤ 15 mm Hg, N=468 | 8 weeks: >15 and ≤ 20 mm Hg, N=468 | 8 weeks: >20 mm Hg, N=468 | 12 weeks: ≤ 10 mm Hg, N=436 | 12 weeks: >10 and ≤15 mm Hg, N=436 | 12 weeks: >15 and ≤ 20 mm Hg, N=436 | 12 weeks: >20 mm Hg, N=436 | 16 weeks: ≤ 10 mm Hg, N=400 | 16 weeks: >10 and ≤ 15 mm Hg, N=400 | 16 weeks: >15 and ≤ 20 mm Hg, N=400 | 16 weeks: >20 mm Hg, N=400 | 20 weeks: ≤ 10 mm Hg, N=379 | 20 weeks: >10 and ≤ 15 mm Hg, N=379 | 20 weeks: >15 and ≤ 20 mm Hg, N=379 | 20 weeks: >20 mm Hg, N=379 | |
| Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide | 67.5 | 17.8 | 8.5 | 6.3 | 59.4 | 19.9 | 13.0 | 7.7 | 48.9 | 22.5 | 16.1 | 12.6 | 33.3 | 23.0 | 19.0 | 24.8 | 31.9 | 18.7 | 22.4 | 26.9 |
(NCT00791258)
Timeframe: Baseline to 4, 8, 12, 16, 20 weeks
| Intervention | Percentage of Participants (Number) | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 4 weeks: <140 mm Hg, N=497 | 4 weeks: <135 mm Hg, N=497 | 4 weeks: <130 mm Hg, N=497 | 4 weeks: <120 mm Hg, N=497 | 8 weeks: <140 mm Hg, N=500 | 8 weeks: <135 mm Hg, N=500 | 8 weeks: <130 mm Hg, N=500 | 8 weeks: <120 mm Hg, N=500 | 12 weeks: <140 mm Hg, N=500 | 12 weeks: <135 mm Hg, N=500 | 12 weeks: <130 mm Hg, N=500 | 12 weeks: <120 mm Hg, N=500 | 16 weeks: <140 mm Hg, N=500 | 16 weeks: <135 mm Hg, N=500 | 16 weeks: <130 mm Hg, N=500 | 16 weeks: <120 mm Hg, N=500 | 20 weeks: <140 mm Hg, N=500 | 20 weeks: <135 mm Hg, N=500 | 20 weeks: <130 mm Hg, N=500 | 20 weeks: <120 mm Hg, N=500 | |
| Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide | 51.3 | 37.2 | 23.3 | 7.9 | 63.2 | 49.2 | 37.0 | 13.8 | 76.6 | 61.6 | 49.2 | 23.2 | 85.8 | 75.6 | 63.6 | 34.6 | 90.2 | 82.6 | 72.2 | 43.0 |
(NCT00791258)
Timeframe: Baseline to 4, 8, 12, 16, 20 weeks
| Intervention | Percentage of Participants (Number) | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 4 weeks: ≤ 15 mm Hg, N=495 | 4 weeks: >15 and ≤ 30 mm Hg, N=495 | 4 weeks: >30 and ≤ 45 mm Hg, N=495 | 4 weeks: >45 mm Hg, N=495 | 8 weeks: ≤ 15 mm Hg, N=468 | 8 weeks: >15 and ≤ 30 mm Hg, N=468 | 8 weeks: >30 and ≤ 45 mm Hg, N=468 | 8 weeks: >45 mm Hg, N=468 | 12 weeks: ≤ 15 mm Hg, N=436 | 12 weeks: >15 and ≤ 30 mm Hg, N=436 | 12 weeks: >30 and ≤ 45 mm Hg, N=436 | 12 weeks: >45 mm Hg, N=436 | 16 weeks: ≤ 15 mm Hg, N=400 | 16 weeks: >15 and ≤ 30 mm Hg, N=400 | 16 weeks: >30 and ≤ 45 mm Hg, N=400 | 16 weeks: >45 mm Hg, N=400 | 20 weeks: ≤ 15 mm Hg, N=379 | 20 weeks: >15 and ≤ 30 mm Hg, N=379 | 20 weeks: >30 and ≤ 45 mm Hg, N=379 | 20 weeks: >45 mm Hg, N=379 | |
| Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide | 56.0 | 35.2 | 8.5 | 0.4 | 52.4 | 35.9 | 10.3 | 1.5 | 37.8 | 42.4 | 17.4 | 2.5 | 27.8 | 36.0 | 27.5 | 8.8 | 20.6 | 37.5 | 33.3 | 8.7 |
Once the Ambulatory Blood Pressure Monitor (ABPM) has been applied, the dose of medication was taken and the subject wore the ABPM for a period of 24 hours. (NCT00791258)
Timeframe: Baseline to 12 weeks
| Intervention | Percentage of participants (Number) | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 24-hour mean systolic blood pressure <140 mmHg | 24-hour mean systolic blood pressure <135 mmHg | 24-hour mean systolic blood pressure <130 mmHg | 24-hour mean systolic blood pressure <120 mmHg | 24-hour mean diastolic blood pressure <90 mmHg | 24-hour mean diastolic blood pressure <85 mmHg | 24-hour mean diastolic blood pressure <80 mmHg | 24-hour mean blood pressure <140/90 mmHg | 24-hour mean blood pressure <135/95 mmHg | 24-hour mean blood pressure <135/80 mmHg | 24-hour mean blood pressure <130/80 mmHg | 24-hour mean blood pressure <125/75 mmHg | 24-hour mean blood pressure <120/80 mmHg | 24-hour mean blood pressure <120/70 mmHg | |
| Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide | 95.6 | 90.4 | 79.9 | 47.2 | 98.7 | 96.1 | 84.7 | 94.3 | 89.1 | 80.3 | 73.4 | 52.4 | 45.9 | 27.5 |
Once the Ambulatory Blood Pressure Monitor (ABPM) has been applied, the dose of medication was taken and the subject wore the ABPM for a period of 24 hours. (NCT00791258)
Timeframe: Baseline to 20 weeks
| Intervention | Percentage of participants (Number) | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 24-hour mean systolic blood pressure <140 mmHg | 24-hour mean systolic blood pressure <135 mmHg | 24-hour mean systolic blood pressure <130 mmHg | 24-hour mean systolic blood pressure <120 mmHg | 24-hour mean diastolic blood pressure <90 mmHg | 24-hour mean diastolic blood pressure <85 mmHg | 24-hour mean diastolic blood pressure <80 mmHg | 24-hour mean blood pressure <140/90 mmHg | 24-hour mean blood pressure <135/95 mmHg | 24-hour mean blood pressure <135/80 mmHg | 24-hour mean blood pressure <130/80 mmHg | 24-hour mean blood pressure <125/75 mmHg | 24-hour mean blood pressure <120/80 mmHg | 24-hour mean blood pressure <120/70 mmHg | |
| Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide | 99.5 | 97.5 | 94.5 | 70.4 | 100.0 | 97.5 | 93.0 | 99.5 | 96.0 | 92.5 | 90.5 | 75.4 | 70.4 | 55.3 |
Once the Ambulatory Blood Pressure Monitor (ABPM) has been applied, the dose of medication was taken and the subject wore the ABPM for a period of 24 hours. Daytime is defined as 8AM - 4PM. (NCT00791258)
Timeframe: Baseline to 12 weeks
| Intervention | Percentage of participants (Number) | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Daytime mean systolic blood pressure <140 mmHg | Daytime mean systolic blood pressure <135 mmHg | Daytime mean systolic blood pressure <130 mmHg | Daytime mean systolic blood pressure <120 mmHg | Daytime mean diastolic blood pressure <90 mmHg | Daytime mean diastolic blood pressure <85 mmHg | Daytime mean diastolic blood pressure <80 mmHg | Daytime mean blood pressure <140/90 mmHg | Daytime mean blood pressure <135/95 mmHg | Daytime mean blood pressure <135/80 mmHg | Daytime mean blood pressure <130/80 mmHg | Daytime mean blood pressure <125/75 mmHg | Daytime mean blood pressure <120/80 mmHg | Daytime mean blood pressure <120/70 mmHg | |
| Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide | 88.2 | 79.9 | 66.4 | 28.8 | 95.6 | 83.0 | 65.5 | 86.9 | 72.9 | 61.1 | 53.3 | 31.9 | 27.9 | 13.1 |
Once the Ambulatory Blood Pressure Monitor (ABPM) has been applied, the dose of medication was taken and the subject wore the ABPM for a period of 24 hours. Daytime is defined as 8AM - 4PM. (NCT00791258)
Timeframe: Baseline to 20 weeks
| Intervention | Percentage of participants (Number) | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Daytime mean systolic blood pressure <140 mmHg | Daytime mean systolic blood pressure <135 mmHg | Daytime mean systolic blood pressure <130 mmHg | Daytime mean systolic blood pressure <120 mmHg | Daytime mean diastolic blood pressure <90 mmHg | Daytime mean diastolic blood pressure <85 mmHg | Daytime mean diastolic blood pressure <80 mmHg | Daytime mean blood pressure <140/90 mmHg | Daytime mean blood pressure <135/95 mmHg | Daytime mean blood pressure <135/80 mmHg | Daytime mean blood pressure <130/80 mmHg | Daytime mean blood pressure <125/75 mmHg | Daytime mean blood pressure <120/80 mmHg | Daytime mean blood pressure <120/70 mmHg | |
| Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide | 96.5 | 93.5 | 83.9 | 51.8 | 98.5 | 92.5 | 83.9 | 95.0 | 88.4 | 81.9 | 77.4 | 56.8 | 51.3 | 33.2 |
Once the Ambulatory Blood Pressure Monitor (ABPM) has been applied, the dose of medication was taken and the subject wore the ABPM for a period of 24 hours. Nighttime is defined as 10p.m. - 6 a.m. (NCT00791258)
Timeframe: Baseline to 12 weeks
| Intervention | Percentage of participants (Number) | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Nighttime mean systolic blood pressure <140 mmHg | Nighttime mean systolic blood pressure <135 mmHg | Nighttime mean systolic blood pressure <130 mmHg | Nighttime mean systolic blood pressure <120 mmHg | Nighttime mean diastolic blood pressure <90 mmHg | Nighttime mean diastolic blood pressure <85 mmHg | Nighttime mean diastolic blood pressure <80 mmHg | Nighttime mean blood pressure <140/90 mmHg | Nighttime mean blood pressure <135/95 mmHg | Nighttime mean blood pressure <135/80 mmHg | Nighttime mean blood pressure <130/80 mmHg | Nighttime mean blood pressure <125/75 mmHg | Nighttime mean blood pressure <120/80 mmHg | Nighttime mean blood pressure <120/70 mmHg | |
| Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide | 97.8 | 94.3 | 92.6 | 74.7 | 99.6 | 98.3 | 94.8 | 97.4 | 93.4 | 90.8 | 89.1 | 77.7 | 74.2 | 62.0 |
Once the Ambulatory Blood Pressure Monitor (ABPM) has been applied, the dose of medication was taken and the subject wore the ABPM for a period of 24 hours. Nighttime is defined as 10 p.m. - 6 a.m. (NCT00791258)
Timeframe: Baseline to 20 weeks
| Intervention | Percentage of participants (Number) | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Nighttime mean systolic blood pressure <140 mmHg | Nighttime mean systolic blood pressure <135 mmHg | Nighttime mean systolic blood pressure <130 mmHg | Nighttime mean systolic blood pressure <120 mmHg | Nighttime mean diastolic blood pressure <90 mmHg | Nighttime mean diastolic blood pressure <85 mmHg | Nighttime mean diastolic blood pressure <80 mmHg | Nighttime mean blood pressure <140/90 mmHg | Nighttime mean blood pressure <135/95 mmHg | Nighttime mean blood pressure <135/80 mmHg | Nighttime mean blood pressure <130/80 mmHg | Nighttime mean blood pressure <125/75 mmHg | Nighttime mean blood pressure <120/80 mmHg | Nighttime mean blood pressure <120/70 mmHg | |
| Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide | 99.5 | 99.5 | 97.5 | 86.4 | 99.5 | 98.5 | 96.0 | 99.0 | 98.5 | 96.0 | 95.0 | 88.9 | 85.9 | 78.9 |
(NCT00791258)
Timeframe: Baseline to 12 weeks
| Intervention | Percentage of participants (Number) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Systolic blood pressure <140 mmHg | Systolic blood pressure <135 mmHg | Systolic blood pressure <130 mmHg | Systolic blood pressure <120 mmHg | Diastolic blood pressure <90 mmHg | Diastolic blood pressure <85 mmHg | Diastolic blood pressure <80 mmHg | Blood pressure <140/90 mmHg | Blood pressure <135/80 mmHg | Blood pressure <130/80 mmHg | Blood pressure <120/80 mmHg | |
| Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide | 88.5 | 75.2 | 62.0 | 33.6 | 94.7 | 83.2 | 61.1 | 86.7 | 55.8 | 49.6 | 29.2 |
(NCT00791258)
Timeframe: Baseline to 20 weeks
| Intervention | Percentage of participants (Number) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Systolic blood pressure <140 mmHg | Systolic blood pressure <135 mmHg | Systolic blood pressure <130 mmHg | Systolic blood pressure <120 mmHg | Diastolic blood pressure <90 mmHg | Diastolic blood pressure <85 mmHg | Diastolic blood pressure <80 mmHg | Blood pressure <140/90 mmHg | Blood pressure <135/80 mmHg | Blood pressure <130/80 mmHg | Blood pressure <120/80 mmHg | |
| Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide | 93.8 | 87.6 | 79.7 | 47.8 | 98.2 | 89.4 | 77.0 | 92.9 | 74.3 | 69.9 | 43.4 |
(NCT00791258)
Timeframe: Baseline to 12 weeks
| Intervention | Percentage of participants (Number) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Systolic blood pressure <140 mmHg | Systolic blood pressure <135 mmHg | Systolic blood pressure <130 mmHg | Systolic blood pressure <120 mmHg | Diastolic blood pressure <90 mmHg | Diastolic blood pressure <85 mmHg | Diastolic blood pressure <80 mmHg | Blood pressure <140/90 mmHg | Blood pressure <135/80 mmHg | Blood pressure <130/80 mmHg | Blood pressure <120/80 mmHg | |
| Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide | 73.5 | 59.0 | 47.9 | 18.8 | 86.3 | 72.7 | 48.7 | 68.4 | 40.2 | 34.2 | 16.2 |
(NCT00791258)
Timeframe: Baseline to 20 weeks
| Intervention | Percentage of participants (Number) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Systolic blood pressure <140 mmHg | Systolic blood pressure <135 mmHg | Systolic blood pressure <130 mmHg | Systolic blood pressure <120 mmHg | Diastolic blood pressure <90 mmHg | Diastolic blood pressure <85 mmHg | Diastolic blood pressure <80 mmHg | Blood pressure <140/90 mmHg | Blood pressure <135/80 mmHg | Blood pressure <130/80 mmHg | Blood pressure <120/80 mmHg | |
| Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide | 89.7 | 83.8 | 69.2 | 41.0 | 91.5 | 85.5 | 69.2 | 85.5 | 64.1 | 59.8 | 36.8 |
(NCT00791258)
Timeframe: Baseline to 12 weeks
| Intervention | Percentage of participants (Number) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Systolic blood pressure <140 mmHg | Systolic blood pressure <135 mmHg | Systolic blood pressure <130 mmHg | Systolic blood pressure <120 mmHg | Diastolic blood pressure <90 mmHg | Diastolic blood pressure <85 mmHg | Diastolic blood pressure <80 mmHg | Blood pressure <140/90 mmHg | Blood pressure <135/80 mmHg | Blood pressure <130/80 mmHg | Blood pressure <120/80 mmHg | |
| Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide | 92.8 | 82.5 | 78.3 | 51.2 | 94.6 | 86.8 | 71.7 | 88.6 | 67.5 | 65.1 | 48.2 |
(NCT00791258)
Timeframe: Baseline to 20 weeks
| Intervention | Percentage of participants (Number) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Systolic blood pressure <140 mmHg | Systolic blood pressure <135 mmHg | Systolic blood pressure <130 mmHg | Systolic blood pressure <120 mmHg | Diastolic blood pressure <90 mmHg | Diastolic blood pressure <85 mmHg | Diastolic blood pressure <80 mmHg | Blood pressure <140/90 mmHg | Blood pressure <135/80 mmHg | Blood pressure <130/80 mmHg | Blood pressure <120/80 mmHg | |
| Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide | 92.8 | 82.5 | 78.3 | 51.2 | 94.6 | 86.8 | 71.7 | 88.6 | 67.5 | 65.1 | 48.2 |
(NCT00791258)
Timeframe: Baseline to 12 weeks
| Intervention | Percentage of participants (Number) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Systolic blood pressure <140 mmHg | Systolic blood pressure <135 mmHg | Systolic blood pressure <130 mmHg | Systolic blood pressure <120 mmHg | Diastolic blood pressure <90 mmHg | Diastolic blood pressure <85 mmHg | Diastolic blood pressure <80 mmHg | Blood pressure <140/90 mmHg | Blood pressure <135/80 mmHg | Blood pressure <130/80 mmHg | Blood pressure <120/80 mmHg | |
| Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide | 100.0 | 90.0 | 75.0 | 25.0 | 100.0 | 95.0 | 75.0 | 100.0 | 70.0 | 65.0 | 20.0 |
(NCT00791258)
Timeframe: Baseline to 20 weeks
| Intervention | Percentage of participants (Number) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Systolic blood pressure <140 mmHg | Systolic blood pressure <135 mmHg | Systolic blood pressure <130 mmHg | Systolic blood pressure <120 mmHg | Diastolic blood pressure <90 mmHg | Diastolic blood pressure <85 mmHg | Diastolic blood pressure <80 mmHg | Blood pressure <140/90 mmHg | Blood pressure <135/80 mmHg | Blood pressure <130/80 mmHg | Blood pressure <120/80 mmHg | |
| Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide | 100.0 | 100.0 | 95.0 | 45.0 | 100.0 | 95.0 | 95.0 | 100.0 | 95.0 | 95.0 | 40.0 |
(NCT00791258)
Timeframe: Baseline to 12 weeks
| Intervention | Percentage of participants (Number) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Systolic blood pressure <140 mmHg | Systolic blood pressure <135 mmHg | Systolic blood pressure <130 mmHg | Systolic blood pressure <120 mmHg | Diastolic blood pressure <90 mmHg | Diastolic blood pressure <85 mmHg | Diastolic blood pressure <80 mmHg | Blood pressure <140/90 mmHg | Blood pressure <135/80 mmHg | Blood pressure <130/80 mmHg | Blood pressure <120/80 mmHg | |
| Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide | 81.3 | 69.3 | 53.0 | 31.5 | 94.4 | 80.6 | 64.3 | 78.5 | 52.7 | 43.5 | 27.9 |
(NCT00791258)
Timeframe: Baseline to 20 weeks
| Intervention | Percentage of participants (Number) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Systolic blood pressure <140 mmHg | Systolic blood pressure <135 mmHg | Systolic blood pressure <130 mmHg | Systolic blood pressure <120 mmHg | Diastolic blood pressure <90 mmHg | Diastolic blood pressure <85 mmHg | Diastolic blood pressure <80 mmHg | Blood pressure <140/90 mmHg | Blood pressure <135/80 mmHg | Blood pressure <130/80 mmHg | Blood pressure <120/80 mmHg | |
| Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide | 91.5 | 84.5 | 71.4 | 47.4 | 98.2 | 89.8 | 78.5 | 90.5 | 71.0 | 61.5 | 44.5 |
(NCT00791258)
Timeframe: Baseline to 12 weeks
| Intervention | Percentage of participants (Number) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Systolic blood pressure <140 mmHg | Systolic blood pressure <135 mmHg | Systolic blood pressure <130 mmHg | Systolic blood pressure <120 mmHg | Diastolic blood pressure <90 mmHg | Diastolic blood pressure <85 mmHg | Diastolic blood pressure <80 mmHg | Blood pressure <140/90 mmHg | Blood pressure <135/80 mmHg | Blood pressure <130/80 mmHg | Blood pressure <120/80 mmHg | |
| Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide | 80.8 | 69.2 | 56.0 | 26.1 | 89.7 | 76.9 | 59.0 | 76.1 | 52.6 | 46.2 | 23.1 |
(NCT00791258)
Timeframe: Baseline to 20 weeks
| Intervention | Percentage of participants (Number) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Systolic blood pressure <140 mmHg | Systolic blood pressure <135 mmHg | Systolic blood pressure <130 mmHg | Systolic blood pressure <120 mmHg | Diastolic blood pressure <90 mmHg | Diastolic blood pressure <85 mmHg | Diastolic blood pressure <80 mmHg | Blood pressure <140/90 mmHg | Blood pressure <135/80 mmHg | Blood pressure <130/80 mmHg | Blood pressure <120/80 mmHg | |
| Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide | 92.3 | 87.2 | 79.5 | 47.4 | 96.6 | 89.3 | 74.8 | 90.6 | 70.1 | 65.0 | 44.0 |
(NCT00791258)
Timeframe: Baseline to 4, 8, 12, 16, 20 weeks
| Intervention | Percentage of Participants (Number) | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 4 weeks: <140/90 mm Hg, N=975 | 4 weeks: <135/80 mm Hg, N=975 | 4 weeks: <130/80 mm Hg, N=975 | 4 weeks: <120/80 mm Hg, N=975 | 8 weeks: <140/90 mm Hg, N=929 | 8 weeks: <135/80 mm Hg, N=929 | 8 weeks: <130/80 mm Hg, N=929 | 8 weeks: <120/80 mm Hg, N=929 | 12 weeks: <140/90 mm Hg, N=865 | 12 weeks: <135/80 mm Hg, N=865 | 12 weeks: <130/80 mm Hg, N=865 | 12 weeks: <120/80 mm Hg, N=865 | 16 weeks: <140/90mm Hg, N=797 | 16 weeks: <135/80mm Hg, N=797 | 16 weeks: <130/80mm Hg, N=797 | 16 weeks: <120/80mm Hg, N=797 | 20 weeks: <140/90 mm Hg, N=745 | 20 weeks: <135/80 mm Hg, N=745 | 20 weeks: <130/80 mm Hg, N=745 | 20 weeks: <120/80 mm Hg, N=745 | |
| Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide | 49.1 | 23.0 | 17.3 | 7.8 | 52.4 | 29.8 | 24.8 | 11.2 | 68.1 | 40.0 | 34.3 | 17.6 | 77.8 | 51.3 | 46.2 | 28.7 | 81.3 | 55.6 | 50.1 | 28.2 |
(NCT00791258)
Timeframe: Baseline to 4, 8, 12, 16, 20 weeks
| Intervention | Percentage of participants (Number) | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 4 weeks: <90 mm Hg, N=975 | 4weeks: <85 mm Hg, N=975 | 4 weeks: <80 mm Hg, N=975 | 8 weeks: <90 mm Hg, N=929 | 8 weeks: <85 mm Hg, N=929 | 8 weeks: <80 mm Hg, N=929 | 12 weeks: <90 mm Hg, N=865 | 12 weeks: <85 mm Hg, N=865 | 12 weeks: <80 mm Hg, N=865 | 16 weeks: <90 mm Hg, N=797 | 16 weeks: <85 mm Hg, N=797 | 16 weeks: <80 mm Hg, N=797 | 20 weeks: <90 mm Hg, N=745 | 20 weeks: <85 mm Hg, N=745 | 20 weeks: <80 mm Hg, N=745 | |
| Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide | 71.3 | 55.2 | 34.2 | 75.1 | 57.1 | 40.2 | 84.3 | 68.7 | 49.5 | 90.2 | 76.9 | 59.6 | 89.7 | 79.5 | 62.0 |
(NCT00791258)
Timeframe: Baseline to 4, 8, 12, 16, 20 weeks
| Intervention | Percentage of Participants (Number) | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 4 weeks: ≤ 10 mm Hg, N=975 | 4 weeks: >10 and ≤ 15 mm Hg, N=975 | 4 weeks: >15 and ≤ 20 mm Hg, N=975 | 4 weeks: >20 mm Hg, N=975 | 8 weeks: ≤ 10 mm Hg, N=929 | 8 weeks: >10 and ≤ 15 mm Hg, N=929 | 8 weeks: >15 and ≤ 20 mm Hg, N=929 | 8 weeks: >20 mm Hg, N=929 | 12 weeks: ≤ 10 mm Hg, N=865 | 12 weeks: >10 and ≤ 15 mm Hg, N=865 | 12 weeks: >15 and ≤ 20 mm Hg, N=865 | 12 weeks: >20 mm Hg, N=865 | 16 weeks: ≤ 10 mm Hg, N=797 | 16 weeks: >10 and ≤ 15 mm Hg, N=797 | 16 weeks: >15 and ≤ 20 mm Hg, N=797 | 16 weeks: >20 mm Hg, N=797 | 20 weeks: ≤ 10 mm Hg, N=745 | 20 weeks: >10 and ≤ 15 mm Hg, N=745 | 20 weeks: >15 and ≤ 20 mm Hg, N=745 | 20 weeks: >20 mm Hg, N=745 | |
| Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide | 61.3 | 21.0 | 10.5 | 7.2 | 54.7 | 20.7 | 14.1 | 10.6 | 43.8 | 24.1 | 15.8 | 16.3 | 30.4 | 22.8 | 21.5 | 25.4 | 31.4 | 19.9 | 22.6 | 26.2 |
(NCT00791258)
Timeframe: Baseline to 4, 8, 12, 16, 20 weeks
| Intervention | Percentage of Participants (Number) | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 4 weeks: <140 mm Hg, N=975 | 4 weeks: <135 mm Hg, N=975 | 4 weeks: <130 mm Hg, N=975 | 4 weeks: <120 mm Hg, N=975 | 8 weeks: <140 mm Hg, N=929 | 8 weeks: <135 mm Hg, N=929 | 8 weeks: <130 mm Hg, N=929 | 8 weeks: <120 mm Hg, N=929 | 12 weeks: <140 mm Hg, N=865 | 12 weeks: <135 mm Hg, N=865 | 12 weeks: <130 mm Hg, N=865 | 12 weeks: <120 mm Hg, N=865 | 16 weeks: <140 mm Hg, N=797 | 16 weeks: <135 mm Hg, N=797 | 16 weeks: <130 mm Hg, N=797 | 16 weeks: <120 mm Hg, N=797 | 20 weeks: <140 mm Hg, N=745 | 20 weeks: <135 mm Hg, N=745 | 20 weeks: <130 mm Hg, N=745 | 20 weeks: <120 mm Hg, N=745 | |
| Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide | 54.2 | 39.8 | 25.3 | 8.9 | 57.2 | 45.9 | 35.0 | 12.9 | 72.6 | 59.0 | 45.3 | 19.4 | 80.9 | 70.3 | 58.9 | 30.9 | 84.3 | 75.2 | 64.2 | 31.5 |
(NCT00791258)
Timeframe: Baseline to 4, 8, 12, 16, 20 weeks
| Intervention | Percentage of Participants (Number) | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 4 weeks: ≤ 15 mm Hg, N=975 | 4 weeks: >15 and ≤ 30 mm Hg, N=975 | 4 weeks: >30 and ≤ 45 mm Hg, N=975 | 4 weeks: >45 mm Hg, N=975 | 8 weeks: ≤ 15 mm Hg, N=929 | 8 weeks: >15 and ≤ 30 mm Hg, N=929 | 8 weeks: >30 and ≤ 45 mm Hg, N=929 | 8 weeks: >45 mm Hg, N=929 | 12 weeks: ≤ 15 mm Hg, N=865 | 12 weeks: >15 and ≤ 30 mm Hg, N=865 | 12 weeks: >30 and ≤ 45 mm Hg, N=865 | 12 weeks: >45 mm Hg, N=865 | 16 weeks: ≤ 15 mm Hg, N=797 | 16 weeks: >15 and ≤ 30 mm Hg, N=797 | 16 weeks: >30 and ≤ 45 mm Hg, N=797 | 16 weeks: >45 mm Hg, N=797 | 20 weeks: ≤ 15 mm Hg, N=745 | 20 weeks: >15 and ≤ 30 mm Hg, N=745 | 20 weeks: >30 and ≤ 45 mm Hg, N=745 | 20 weeks: >45 mm Hg, N=745 | |
| Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide | 51.4 | 36.6 | 10.5 | 1.5 | 45.8 | 37.7 | 14.3 | 2.3 | 30.5 | 43.1 | 22.4 | 3.9 | 23.2 | 35.9 | 32.0 | 8.9 | 20.4 | 36.2 | 34.0 | 9.4 |
(NCT00791258)
Timeframe: Baseline to 4, 8, 12, 16, 20 weeks
| Intervention | Percentage of Participants (Number) | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 4 weeks: <90 mm Hg, N=454 | 4 weeks: <85 mm Hg, N=454 | 4 weeks: <80 mm Hg, N=454 | 8 weeks: <90 mm Hg, N=457 | 8 weeks: <85 mm Hg, N=457 | 8 weeks: <80 mm Hg, N=457 | 12 weeks: <90 mm Hg, N=457 | 12 weeks: <85 mm Hg, N=457 | 12 weeks: <80 mm Hg, N=457 | 16 weeks: <90 mm Hg, N=457 | 16 weeks: <85 mm Hg, N=457 | 16 weeks: <80 mm Hg, N=457 | 20 weeks: <90 mm Hg, N=457 | 20 weeks: <85 mm Hg, N=457 | 20 weeks: <80 mm Hg, N=457 | |
| Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide | 69.6 | 53.5 | 31.9 | 82.1 | 66.1 | 43.5 | 90.4 | 76.6 | 56.5 | 94.8 | 83.2 | 65.9 | 95.4 | 86.2 | 72.0 |
(NCT00791258)
Timeframe: Baseline to 4, 8, 12, 16, 20 weeks
| Intervention | Percentage of Participants (Number) | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 4 weeks: ≤ 10 mm Hg, N=453 | 4 weeks: >10 and ≤ 15 mm Hg, N=453 | 4 weeks: >15 and ≤ 20 mm Hg, N=453 | 4 weeks: >20 mm Hg, N=453 | 8 weeks: ≤ 10 mm Hg, N=431 | 8 weeks: >10 and ≤ 15 mm Hg, N=431 | 8 weeks: >15 and ≤ 20 mm Hg, N=431 | 8 weeks: >20 mm Hg, N=431 | 12 weeks: ≤ 10 mm Hg, N=402 | 12 weeks: >10 and ≤15 mm Hg, N=402 | 12 weeks: >15 and ≤ 20 mm Hg, N=402 | 12 weeks: >20 mm Hg, N=402 | 16 weeks: ≤ 10 mm Hg, N=371 | 16 weeks: >10 and ≤ 15 mm Hg, N=371 | 16 weeks: >15 and ≤ 20 mm Hg, N=371 | 16 weeks: >20 mm Hg, N=371 | 20 weeks: ≤ 10 mm Hg, N=356 | 20 weeks: >10 and ≤ 15 mm Hg, N=356 | 20 weeks: >15 and ≤ 20 mm Hg, N=356 | 20 weeks: >20 mm Hg, N=356 | |
| Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide | 62.7 | 22.3 | 8.6 | 6.4 | 56.6 | 19.7 | 15.3 | 8.4 | 44.3 | 22.1 | 17.4 | 16.2 | 32.4 | 24.0 | 21.0 | 22.6 | 33.2 | 19.4 | 22.5 | 25.0 |
(NCT00791258)
Timeframe: Baseline to 4, 8, 12, 16, 20 weeks
| Intervention | Percentage of Participants (Number) | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 4 weeks: <140 mm Hg, N=454 | 4 weeks: <135 mm Hg, N=454 | 4 weeks: <130 mm Hg, N=454 | 4 weeks: <120 mm Hg, N=454 | 8 weeks: <140 mm Hg, N=457 | 8 weeks: <135 mm Hg, N=457 | 8 weeks: <130 mm Hg, N=457 | 8 weeks: <120 mm Hg, N=457 | 12 weeks: <140 mm Hg, N=457 | 12 weeks: <135 mm Hg, N=457 | 12 weeks: <130 mm Hg, N=457 | 12 weeks: <120 mm Hg, N=457 | 16 weeks: <140 mm Hg, N=457 | 16 weeks: <135 mm Hg, N=457 | 16 weeks: <130 mm Hg, N=457 | 16 weeks: <120 mm Hg, N=457 | 20 weeks: <140 mm Hg, N=457 | 20 weeks: <135 mm Hg, N=457 | 20 weeks: <130 mm Hg, N=457 | 20 weeks: <120 mm Hg, N=457 | |
| Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide | 56.4 | 41.4 | 27.1 | 7.9 | 67.6 | 54.3 | 40.9 | 16.2 | 81.4 | 67.2 | 54.1 | 27.6 | 88.8 | 80.3 | 67.0 | 39.0 | 91.5 | 85.6 | 74.8 | 47.1 |
(NCT00791258)
Timeframe: Baseline to 4, 8, 12, 16, 20 weeks
| Intervention | Percentage of Participants (Number) | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 4 weeks: ≤ 15 mm Hg, N=453 | 4 weeks: >15 and ≤ 30 mm Hg, N=453 | 4 weeks: >30 and ≤ 45 mm Hg, N=453 | 4 weeks: >45 mm Hg, N=453 | 8 weeks: ≤ 15 mm Hg, N=431 | 8 weeks: >15 and ≤ 30 mm Hg, N=431 | 8 weeks: >30 and ≤ 45 mm Hg, N=431 | 8 weeks: >45 mm Hg, N=431 | 12 weeks: ≤ 15 mm Hg, N=402 | 12 weeks: >15 and ≤ 30 mm Hg, N=402 | 12 weeks: >30 and ≤ 45 mm Hg, N=402 | 12 weeks: >45 mm Hg, N=402 | 16 weeks: ≤ 15 mm Hg, N=371 | 16 weeks: >15 and ≤ 30 mm Hg, N=371 | 16 weeks: >30 and ≤ 45 mm Hg, N=371 | 16 weeks: >45 mm Hg, N=371 | 20 weeks: ≤ 15 mm Hg, N=356 | 20 weeks: >15 and ≤ 30 mm Hg, N=356 | 20 weeks: >30 and ≤ 45 mm Hg, N=356 | 20 weeks: >45 mm Hg, N=356 | |
| Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide | 49.5 | 38.4 | 11.5 | 0.7 | 48.0 | 35.5 | 14.4 | 2.1 | 30.4 | 43.8 | 22.6 | 3.2 | 24.0 | 37.7 | 29.1 | 9.2 | 19.7 | 36.5 | 36.0 | 7.9 |
(NCT00791258)
Timeframe: Baseline to 4, 8, 12, 16, 20 weeks
| Intervention | Percentage of Participants (Number) | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 4 weeks: <90 mm Hg, N=190 | 4 weeks: <85 mm Hg, N=190 | 4 weeks: <80 mm Hg, N=190 | 8 weeks: <90 mm Hg, N=190 | 8 weeks: <85 mm Hg, N=190 | 8 weeks: <80 mm Hg, N=190 | 12 weeks: <90 mm Hg, N=190 | 12 weeks: <85 mm Hg, N=190 | 12 weeks: <80 mm Hg, N=190 | 16 weeks: <90 mm Hg, N=190 | 16 weeks: <85 mm Hg, N=190 | 16 weeks: <80 mm Hg, N=190 | 20 weeks: <90 mm Hg, N=190 | 20 weeks: <85 mm Hg, N=190 | 20 weeks: <80 mm Hg, N=190 | |
| Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide | 75.8 | 64.2 | 39.0 | 85.8 | 72.6 | 51.1 | 94.2 | 83.2 | 63.7 | 97.9 | 89.0 | 70.5 | 99.0 | 90.5 | 76.8 |
(NCT00791258)
Timeframe: Baseline to 4, 8, 12, 16, 20 weeks
| Intervention | Percentage of Participants (Number) | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 4 weeks: ≤ 10 mm Hg, N=189 | 4 weeks: >10 and ≤ 15 mm Hg, N=189 | 4 weeks: >15 and ≤ 20 mm Hg, N=189 | 4 weeks: >20 mm Hg, N=189 | 8 weeks: ≤ 10 mm Hg, N=181 | 8 weeks: >10 and ≤ 15 mm Hg, N=181 | 8 weeks: >15 and ≤ 20 mm Hg, N=181 | 8 weeks: >20 mm Hg, N=181 | 12 weeks: ≤ 10 mm Hg, N=170 | 12 weeks: >10 and ≤15 mm Hg, N=170 | 12 weeks: >15 and ≤ 20 mm Hg, N=170 | 12 weeks: >20 mm Hg, N=170 | 16 weeks: ≤ 10 mm Hg, N=156 | 16 weeks: >10 and ≤ 15 mm Hg, N=156 | 16 weeks: >15 and ≤ 20 mm Hg, N=156 | 16 weeks: >20 mm Hg, N=156 | 20 weeks: ≤ 10 mm Hg, N=150 | 20 weeks: >10 and ≤ 15 mm Hg, N=150 | 20 weeks: >15 and ≤ 20 mm Hg, N=150 | 20 weeks: >20 mm Hg, N=150 | |
| Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide | 67.7 | 16.9 | 11.6 | 3.7 | 60.8 | 20.4 | 14.9 | 3.9 | 41.2 | 32.4 | 12.9 | 13.5 | 32.7 | 26.9 | 21.8 | 18.6 | 37.3 | 18.0 | 26.0 | 18.7 |
(NCT00791258)
Timeframe: Baseline to 4, 8, 12, 16, 20 weeks
| Intervention | Percentage of Participants (Number) | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 4 weeks: <140 mm Hg, N=190 | 4 weeks: <135 mm Hg, N=190 | 4 weeks: <130 mm Hg, N=190 | 4 weeks: <120 mm Hg, N=190 | 8 weeks: <140 mm Hg, N=190 | 8 weeks: <135 mm Hg, N=190 | 8 weeks: <130 mm Hg, N=190 | 8 weeks: <120 mm Hg, N=190 | 12 weeks: <140 mm Hg, N=190 | 12 weeks: <135 mm Hg, N=190 | 12 weeks: <130 mm Hg, N=190 | 12 weeks: <120 mm Hg, N=190 | 16 weeks: <140 mm Hg, N=190 | 16 weeks: <135 mm Hg, N=190 | 16 weeks: <130 mm Hg, N=190 | 16 weeks: <120 mm Hg, N=190 | 20 weeks: <140 mm Hg, N=190 | 20 weeks: <135 mm Hg, N=190 | 20 weeks: <130 mm Hg, N=190 | 20 weeks: <120 mm Hg, N=190 | |
| Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide | 54.7 | 41.1 | 26.3 | 10.0 | 69.0 | 56.3 | 42.6 | 15.8 | 81.6 | 69.5 | 57.9 | 30.0 | 87.9 | 79.0 | 69.0 | 39.5 | 91.1 | 84.2 | 75.3 | 48.4 |
(NCT00791258)
Timeframe: Baseline to 4, 8, 12, 16, 20 weeks
| Intervention | Percentage of Participants (Number) | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 4 weeks: ≤ 15 mm Hg, N=189 | 4 weeks: >15 and ≤ 30 mm Hg, N=189 | 4 weeks: >30 and ≤ 45 mm Hg, N=189 | 4 weeks: >45 mm Hg, N=189 | 8 weeks: ≤ 15 mm Hg, N=181 | 8 weeks: >15 and ≤ 30 mm Hg, N=181 | 8 weeks: >30 and ≤ 45 mm Hg, N=181 | 8 weeks: >45 mm Hg, N=181 | 12 weeks: ≤ 15 mm Hg, N=170 | 12 weeks: >15 and ≤ 30 mm Hg, N=170 | 12 weeks: >30 and ≤ 45 mm Hg, N=170 | 12 weeks: >45 mm Hg, N=170 | 16 weeks: ≤ 15 mm Hg, N=156 | 16 weeks: >15 and ≤ 30 mm Hg, N=156 | 16 weeks: >30 and ≤ 45 mm Hg, N=156 | 16 weeks: >45 mm Hg, N=156 | 20 weeks: ≤ 15 mm Hg, N=150 | 20 weeks: >15 and ≤ 30 mm Hg, N=150 | 20 weeks: >30 and ≤ 45 mm Hg, N=150 | 20 weeks: >45 mm Hg, N=150 | |
| Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide | 56.1 | 36.0 | 7.9 | 0.0 | 54.1 | 34.3 | 11.6 | 0.0 | 35.3 | 38.2 | 22.9 | 3.5 | 28.2 | 40.4 | 26.3 | 5.1 | 26.0 | 40.0 | 26.7 | 7.3 |
(NCT00791258)
Timeframe: Baseline to 12 and 20 weeks
| Intervention | Percentage of participants (Number) | |
|---|---|---|
| 12 weeks | 20 weeks | |
| Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide | 71.3 | 84.8 |
The arm in which the highest sitting diastolic pressures were found at study entry was the arm used for all subsequent readings. A calibrated sphygmomanometer and appropriate size cuff were used to measure arterial sitting blood pressure (BP) at trough with the arm supported at the level of the heart. At each study visit, after having the participant in a sitting position for five minutes, systolic/diastolic blood pressure were measured 3 times at 1-2 minute intervals. A mean was calculated from the 3 measurements. A negative change indicates improvement. Week 28 Endpoint was the last non-missing post-baseline measurement value on or before Week 28, and Week 54 Endpoint was the last non-missing measurement value after Week 28. (NCT00667719)
Timeframe: Baseline, Weeks 28 and 54 endpoint
| Intervention | mmHg (Mean) | ||
|---|---|---|---|
| Baseline | Change from Baseline to Week 28 Endpoint | Change from Baseline to Week 54 Endpoint | |
| Aliskiren/Amlodipine/Hydrochlorothiazide | 101.8 | -20.3 | -21.8 |
The arm in which the highest sitting diastolic pressures were found at study entry was the arm used for all subsequent readings. A calibrated sphygmomanometer and appropriate size cuff were used to measure arterial sitting blood pressure (BP) at trough with the arm supported at the level of the heart. At each study visit, after having the participant in a sitting position for five minutes, systolic/diastolic blood pressure were measured 3 times at 1-2 minute intervals. A mean was calculated from the 3 measurements. A negative change indicates improvement. Week 28 Endpoint was the last non-missing post-baseline measurement value on or before Week 28, and Week 54 Endpoint was the last non-missing measurement value after Week 28. (NCT00667719)
Timeframe: Baseline, Weeks 28 and 54 endpoints
| Intervention | millimeters of mercury (Mean) | ||
|---|---|---|---|
| Baseline | Change from baseline to Week 28 Endpoint | Change from Baseline to Week 54 Endpoint | |
| Aliskiren/Amlodipine/Hydrochlorothiazide | 166.1 | -34.2 | -37.3 |
An AE was defined as the appearance or worsening of any undesirable sign, symptom, or medical condition occurring after starting the study drug, even if the event is not considered to be related to study drug. An SAE was defined as an event which was fatal or life-threatening, resulted in persistent or significant disability/incapacity, constituted a congenital anomaly/birth defect, required inpatient hospitalization or prolongation of existing hospitalization, was medically significant, i.e. defined as an event that jeopardizes the participant or may require medical or surgical intervention to prevent one of the outcomes listed above. (NCT00667719)
Timeframe: 54 weeks
| Intervention | Participants (Count of Participants) | ||
|---|---|---|---|
| Any Adverse Events | Serious Adverse Events | Death | |
| Aliskiren/Amlodipine/Hydrochlorothiazide 300/10/25 mg | 255 | 14 | 0 |
| Aliskiren/Amlodipine/Hydrochlorothiazide 300/5/12.5 mg | 54 | 1 | 0 |
| Aliskiren/Hydrochlorothiazide 300/12.5 mg | 57 | 0 | 0 |
Blood pressure control was defined as having a mean sitting diastolic blood pressure <90 mmHg and a mean sitting systolic blood pressure <140 mmHg. Percentage of participants achieving the blood pressure control of < 140/90 mmHg were reported. Week 28 Endpoint was the last non-missing post-baseline measurement value on or before Week 28 and Week 54 Endpoint was the last non-missing measurement value after Week 28. (NCT00667719)
Timeframe: Weeks 28 and 54 endpoints
| Intervention | percentage of participants (Number) | |
|---|---|---|
| Week 28 Endpoint | Week 54 Endpoint | |
| Aliskiren/Amlodipine/Hydrochlorothiazide | 69.1 | 77.1 |
Diastolic Blood pressure response was defined as a mean sitting diastolic blood pressure <90 mmHg or a >=10 mmHg reduction from baseline value. Week 28 Endpoint was the last non-missing post-baseline measurement value on or before Week 28, and Week 54 Endpoint was the last non-missing measurement value after Week 28. (NCT00667719)
Timeframe: Weeks 28 and 54 endpoints
| Intervention | percentage of participants (Number) | |
|---|---|---|
| Week 28 Endpoint | Week 54 Endpoint | |
| Aliskiren/Amlodipine/Hydrochlorothiazide | 91.8 | 96.6 |
Systolic blood pressure response was defined as a mean sitting systolic blood pressure <140 mmHg or a >=20 mmHg reduction from baseline value. Week 28 Endpoint was the last non-missing post-baseline measurement value on or before Week 28, and Week 54 Endpoint was the last non-missing measurement value after Week 28. (NCT00667719)
Timeframe: Weeks 28 and 54 endpoints
| Intervention | percentage of participants (Number) | |
|---|---|---|
| Week 28 Endpoint | Week 54 Endpoint | |
| Aliskiren/Amlodipine/Hydrochlorothiazide | 90.2 | 93.7 |
Specific variables of collagen turnover markers that will be evaluated include markers of collagen synthesis (PINP, PIIINP), and marker of collagen degradation (ICTP). A two-sample t-test was used to compare the differences between these collagen turnover markers at baseline and the absolute differences in change from baseline to 12 months of follow-up. (NCT00879060)
Timeframe: The time points measured were at Baseline and at 12 Months (Follow-Up).
| Intervention | micrograms/L (Mean) | |||||
|---|---|---|---|---|---|---|
| Baseline (PINP) | 12 Months (PINP) | Baseline (PIIINP) | 12 Months (PIIINP) | Baseline (ICTP) | 12 Months (ICTP) | |
| Placebo Control | 2.1 | 0.6 | 4.5 | 1.6 | 2.5 | -2.3 |
| Spironolactone | 2.1 | 0.7 | 4.7 | 2.0 | 2.2 | 2.7 |
CMR will be utilized as it has superior reproducibility (as compared to 2-D echocardiography). Late Gadolinium Enhancement (LGE) Assessment of myocardial fibrosis by CMR will be expressed as a percentage of left ventricular mass (%LV), maximum left ventricular wall thickness (in mm), left ventricular end-diastolic cavity size (in mm/m^2), and left atrial dimension (in mm). (NCT00879060)
Timeframe: The time points measured were at Baseline and at 12 Months (Follow-Up)
| Intervention | millimeters (Mean) | |
|---|---|---|
| Left Atrial Dimension (Baseline) | Left Atrial Dimension (12-Month Follow-Up) | |
| Placebo Control | 41 | 40 |
| Spironolactone | 40 | 40 |
CMR will be utilized as it has superior reproducibility (as compared to 2-D echocardiography). Late Gadolinium Enhancement (LGE) Assessment of myocardial fibrosis by CMR will be expressed as a percentage of left ventricular mass (%LV), maximum left ventricular wall thickness (in mm), left ventricular end-diastolic (LVED) cavity size (in mm/m^2), and left atrial dimension (in mm). (NCT00879060)
Timeframe: The time points measured were at Baseline and at 12 Months (Follow-Up)
| Intervention | mm/m^2 (Mean) | |
|---|---|---|
| LVED Cavity Size (Baseline) | LVED Cavity Size (12-Month Follow-Up) | |
| Placebo Control | 145 | 146 |
| Spironolactone | 133 | 129 |
CMR will be utilized as it has superior reproducibility (as compared to 2-D echocardiography). Late Gadolinium Enhancement (LGE) Assessment of myocardial fibrosis by CMR will be expressed as a percentage of left ventricular mass (%LV), maximum left ventricular wall thickness (in mm), left ventricular end-diastolic cavity size (in mm/m^2), and left atrial dimension (in mm). (NCT00879060)
Timeframe: The time points measured were at Baseline and at 12 Months (Follow-Up).
| Intervention | millimeters (Mean) | |
|---|---|---|
| Maximum Left Ventricular Wall Thickness (Baseline) | Maximum Left Ventricular Wall Thickness (12-Month Follow-Up) | |
| Placebo Control | 21 | 19 |
| Spironolactone | 22 | 22 |
CMR will be utilized as it has superior reproducibility (as compared to 2-D echocardiography). Late Gadolinium Enhancement (LGE) Assessment of myocardial fibrosis by CMR will be expressed as a percentage of left ventricular mass (%LV), maximum left ventricular wall thickness (in mm), left ventricular end-diastolic cavity size (in mm/m^2), and left atrial dimension (in mm). (NCT00879060)
Timeframe: The time points measured were at Baseline and at 12 Months (Follow-Up).
| Intervention | Percentage of Total LV Mass (Mean) | |
|---|---|---|
| LGE Assessment of Myocardial Fibrosis (Baseline) | LGE Assessment of Myocardial Fibrosis (12-Month Follow-Up) | |
| Placebo Control | 2.5 | 2.8 |
| Spironolactone | 1.1 | 1.8 |
This data was collected at baseline, prior to drug administration, and again at 12-months of follow-up to determine if spironolactone improves a subject's functional capacity during exercise (peak oxygen consumption levels/peak VO2). Peak VO2 levels were measured in ml/kg/min. (NCT00879060)
Timeframe: The time points measured were at Baseline and at 12 Months (Follow-Up).
| Intervention | ml/kg/min (Mean) | |
|---|---|---|
| Peak VO2 (Baseline) | Peak VO2 (12-Month Follow-Up) | |
| Placebo Control | 28 | 29 |
| Spironolactone | 30 | 29 |
This data was collected at baseline, prior to drug administration, and again at 12-months of follow-up to assess heart failure symptoms according to the New York Heart Association (NYHA) functional class, which is an estimate of a patients functional ability. The NYHA functional classes include: Class I (no limitation of physical activity), Class II (slight limitation of physical activity), Class III (marked limitation of physical activity), and Class IV (unable to carry out any physical acitivity without discomfort). (NCT00879060)
Timeframe: Time points were measured at Baseline and again at 12 months (follow-up)
| Intervention | score on a scale (Mean) | |
|---|---|---|
| NYHA Class (Baseline) | NYHA Class (12-Month Follow Up) | |
| Placebo Control | 1.5 | 1.6 |
| Spironolactone | 1.6 | 1.7 |
This data was collected at baseline, prior to drug administration, and again at 12-months of follow-up to measure indices of diastolic function by Tissue Doppler Echocardiography using the Septal E/e' ratio. (NCT00879060)
Timeframe: The time points measured were at Baseline and at 12 Months (Follow-Up).
| Intervention | Ratio (Mean) | |
|---|---|---|
| Diastolic Function (Baseline) | Diastolic Function (12-month Follow-Up) | |
| Placebo Control | 15 | 13 |
| Spironolactone | 14 | 13 |
(NCT04338009)
Timeframe: Up to 28 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Discontinuation Arm | 10 |
| Continuation Arm | 11 |
"The Area Under the Curve of the modified SOFA (AUC SOFA) from daily measurements, weighted to account for the shorter observation period among patients who die in-hospital.~How to interpret the AUC SOFA?: a higher area indicates more severe disease and/or longer hospitalization.The range is 0.1 to 377.3." (NCT04338009)
Timeframe: Up to 28 days
| Intervention | units on a scale (SOFA x days) (Median) |
|---|---|
| Discontinuation Arm | 7 |
| Continuation Arm | 12 |
"The primary endpoint of the trial will be a global rank based on patient outcomes according to four factors: (1) time to death, (2) the number of days supported by invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO), (3) the number of days supported by renal replacement therapy or pressor/inotropic therapy, and (4) a modified sequential Organ Failure Assessment (SOFA) score. The modified SOFA score will include the cardiac, respiratory, renal and coagulation domains of the SOFA score.~How to interpret the rank?: patients are ranked from worst to best outcomes, such that patients with bad outcomes are ranked at the top and patients who have the best outcomes are ranked at the bottom." (NCT04338009)
Timeframe: Up to 28 days
| Intervention | score on a scale (range 1 to 152) (Median) |
|---|---|
| Discontinuation Arm | 81 |
| Continuation Arm | 73 |
Hypotension Requiring Vasopressors, inotropes or mechanical hemodynamic support (ventricular assist device or intra-aortic balloon pump). (NCT04338009)
Timeframe: Up to 28 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Discontinuation Arm | 8 |
| Continuation Arm | 9 |
Need to be transferred to an intensive care unit or to supported by a breathing machine (NCT04338009)
Timeframe: Up to 28 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Discontinuation Arm | 14 |
| Continuation Arm | 16 |
This outcome measurement looked at the median length of hospitalization. (NCT04338009)
Timeframe: Up to 28 days
| Intervention | days (Median) |
|---|---|
| Discontinuation Arm | 5 |
| Continuation Arm | 6 |
(NCT04338009)
Timeframe: Up to 28 days
| Intervention | days (Median) |
|---|---|
| Discontinuation Arm | 15 |
| Continuation Arm | 13 |
Left Ventricular Ejection Fraction Is a calculation of heart pump function determined from the volume after complete filling minus the volume after complete contraction divided by the volume after complete filling. A value of 55% or greater is normal. (NCT01052428)
Timeframe: 5 visits per Participant over 2 years (about every 6 months)
| Intervention | percent (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Month 0 (n=19,19) | Month 3 (n=1,0) | Month 6 (n=17,19) | Month 9 (n=1,1) | Month 12 (n=14,15) | Month 15 (n=3,2) | Month 18 (n=14,18) | Month 21 (n=5,0) | Month 24 (n=16,18) | |
| Placebo | 62.62 | 63.90 | 63.80 | 41.90 | 61.70 | 44.70 | 60.95 | 53.79 | 59.95 |
| Toprol XL | 62.09 | NA | 61.29 | 54.81 | 62.77 | 68.47 | 62.05 | NA | 63.02 |
Left Ventricular End Diastolic Volume Indexed to Body Surface Area: As an indicator of heart size, the blood volume of the heart is related to the body size. The end diastolic volume is the blood volume of the heart at the end of filling, just before contraction. The relation of heart blood volume to body size is more accurate in determining pathology because larger people require a larger heart blood volume. The values that are too high or too low indicate a diseased myocardium. (NCT01052428)
Timeframe: 5 visits per Participant over 2 years (about every 6 months)
| Intervention | ml/m^2 (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Month 0 (n=19,19) | Month 3 (n=1,0) | Month 6 (n=17,19) | Month 9 (n=1,0) | Month 12 (n=14,15) | Month 15 (n=3,2) | Month 18 (n=14,18) | Month 21 (n=5,0) | Month 24 (n=16,18) | |
| Placebo | 91.66 | 90.93 | 90.84 | 70.56 | 88.99 | 82.73 | 90.16 | 85.75 | 87.31 |
| Toprol XL | 95.74 | NA | 95.24 | NA | 95.71 | 98.16 | 97.6 | NA | 95.16 |
Left Ventricular End Systolic Volume Indexed to Body Surface Area As an indicator of heart size, the blood volume of the heart is related to the body size. The end systolic volume is the blood volume of the heart at the end of contraction and is an index of the pump function of the heart. This relation to body size is more accurate in determining pathology because larger people require a larger heart blood volume. The values that are too high or too low indicate a diseased myocardium. (NCT01052428)
Timeframe: 5 visits per Participant over 2 years (about every 6 months)
| Intervention | ml/m^2 (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Month 0 (n=19,19) | Month 3 (n=1,0) | Month 6 (n=17,19) | Month 9 (n=1,0) | Month 12 (n=14,15) | Month 15 (n=3,2) | Month 18 (n=14,18) | Month 21 (n=5,0) | Month 24 (n=16,18) | |
| Placebo | 34.01 | 32.83 | 32.53 | 40.99 | 33.70 | 47.25 | 34.99 | 39.97 | 34.47 |
| Toprol XL | 35.98 | NA | 36.53 | NA | 35.89 | 30.97 | 36.72 | NA | 35.13 |
Left Ventricular End-diastolic Mass Indexed to Left Ventricular End-diastolic Volume As an indicator of heart muscle mass and heart blood volume, the mass indexed to end diastolic volume determines whether there is an adequate amount of heart muscle to pump the heart blood volume obtained from a three-dimensional analysis. The values that are too high or too low indicate a diseased myocardium. (NCT01052428)
Timeframe: 5 visits per Participant over 2 years (about every 6 months)
| Intervention | g/ml (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Month 0 (n=19,19) | Month 3 (n=1,0) | Month 6 (n=17,19) | Month 9 (n=1,1) | Month 12 (n=14,15) | Month 15 (n=3,2) | Month 18 (n=14,18) | Month 21 (n=5,0) | Month 24 (n=16,18) | |
| Placebo | 0.61 | 0.53 | 0.62 | 0.67 | 0.65 | 0.65 | 0.65 | 0.61 | 0.64 |
| Toprol XL | 0.61 | NA | 0.6 | 0.53 | 0.60 | 0.55 | 0.59 | NA | 0.62 |
Left Ventricular End-Diastolic Radius to Wall Thickness As an indicator of heart muscle mass and heart volume chamber diameter, the end-diastolic radius indexed to end diastolic wall thickness determines whether there is an adequate amount of heart muscle to pump the heart blood volume obtained from a two-dimensional analysis. The values that are too high or too low indicate a diseased myocardium. (NCT01052428)
Timeframe: 5 visits per Participant over 2 years (about every 6 months)
| Intervention | unitless (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Month 0 (n=19,19) | Month 3 (n=1,0) | Month 6 (n=17,19) | Month 9 (n=1,1) | Month 12 (n=14,15) | Month 15 (n=3,2) | Month 18 (n=14,18) | Month 21 (n=5,0) | Month 24 (n=16,18) | |
| Placebo | 4.76 | 5.02 | 4.51 | 4.15 | 4.46 | 4.61 | 4.43 | 4.72 | 4.52 |
| Toprol XL | 4.69 | NA | 4.85 | 5.74 | 4.79 | 5.02 | 4.77 | NA | 4.59 |
Peak Early Filling Rate The peak early filling rate of change is calculated from the slope of the volume during the early filling of the heart with respect to time. The higher values indicate a very healthy heart muscle and lower values are indicative of a very stiff muscle. (NCT01052428)
Timeframe: 5 visits per Participant over 2 years (about every 6 months)
| Intervention | EDV/sec (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Month 0 (n=19,19) | Month 3 (n=1,0) | Month 6 (n=17,19) | Month 9 (n=1,0) | Month 12 (n=14,15) | Month 15 (n=3,2) | Month 18 (n=14,18) | Month 21 (n=5,0) | Month 24 (n=16,18) | |
| Placebo | 2.27 | 2.58 | 2.38 | 1.56 | 2.26 | 1.83 | 1.95 | 1.73 | 2.17 |
| Toprol XL | 2.12 | NA | 2.08 | NA | 2.24 | 2.28 | 2.26 | NA | 2.25 |
Systolic Longitudinal Strain. By identifying two points on the heart, the strain is the difference between the distance between these two points at the end of filling of the heart and the end of contraction divided by the length at the end of filling. Thus, the measure is like the ejection fraction, however the strain is more localized to a specified segment in the heart muscle. The higher values indicate a healthy heart. (NCT01052428)
Timeframe: 5 visits per Participant over 2 years (about every 6 months)
| Intervention | percent/%Systolic interval (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Month 0 (n=19,19) | Month 3 (n=1,0) | Month 6 (n=17,19) | Month 9 (n=1,0) | Month 12 (n=14,15) | Month 15 (n=3,2) | Month 18 (n=14,18) | Month 21 (n=5,0) | Month 24 (n=16,18) | |
| Placebo | 87.94 | 115.07 | 45.90 | 37.2 | 87.85 | 52.95 | 88.11 | 67.53 | 79.94 |
| Toprol XL | 82.55 | NA | 78.68 | NA | 80.04 | 88.34 | 79.29 | NA | 85.18 |
LVEF is a calculation of heart pump function determined from the volume after complete filling minus the volume after complete contraction divided by the volume after complete filling. A value of 55% or greater is normal. This is a measure of LV Systolic Function. Since some visits did not occur at the scheduled 6 month intervals, the results have been divided into 3-month visit intervals for reporting purposes (NCT01052272)
Timeframe: 5 visits per Participant over 2 years (about every 6 months)
| Intervention | percent (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Month 0 (n=17,17,18,18) | Month 6(n=14,11,11,12) | Month 9(n=1,2,0,0) | Month 12(n=12,11,11,11) | Month 15(n=3,2,1,1) | Month 18(n=10,12,8,8) | Month 21(n=3,0,0,1) | Month 24 (n=11,9,8,10) | Month 27 (n=1,1,0,1) | |
| Candesartan Cilexetil | 56.36 | 56.82 | 42.62 | 52.37 | 39.88 | 56.33 | NA | 51.70 | 54.17 |
| Candesartan Cilexetil and Allopurinol | 52.68 | 57.28 | NA | 56.11 | 54.46 | 57.82 | 56.17 | 55.79 | 54.40 |
| Ramipril | 52.19 | 54.20 | 64.98 | 52.76 | 52.13 | 55.02 | 51.27 | 57.18 | 50.73 |
| Ramipril and Allopurinol | 53.37 | 52.80 | NA | 51.74 | 34.89 | 54.05 | NA | 55.59 | NA |
LVEDV/BSA: As an indicator of heart size, the blood volume of the heart is related to the body size. The relation of heart blood volume to body size is more accurate in determining pathology because larger people require a larger heart blood volume. The values that are too high or too low indicate a diseased myocardium. This is a measure of LV Diastolic Function. Since some visits did not occur at the scheduled 6 month intervals, the results have been divided into 3-month visit intervals. (NCT01052272)
Timeframe: 5 visits per Participant over 2 years (about every 6 months)
| Intervention | ml/m^2 (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Month 0 (n=17,17,18,18) | Month 6(n=14,11,11,12) | Month 9(n=1,2,0,0) | Month12(n=12,11,11,11) | Month 15(n=3,2,1,1) | Month 18(n=10,12,8,8) | Month 21(n=3,0,0,1) | Month 24 (n=11,9,8,10) | Month 27 (n=1,1,0,1) | |
| Candesartan Cilexetil | 78.06 | 78.60 | 93.57 | 85.44 | 90.20 | 82.74 | NA | 84.28 | 76.65 |
| Candesartan Cilexetil and Allopurinol | 79.03 | 78.01 | NA | 79.75 | 63.1 | 84.95 | 75.27 | 79.72 | 75.05 |
| Ramipril | 73.03 | 74.10 | 73.23 | 75.34 | 81.19 | 75.28 | 71.99 | 70.46 | 48.68 |
| Ramipril and Allopurinol | 78.52 | 86.13 | NA | 83.95 | 108.25 | 67.96 | NA | 71.63 | NA |
LVESV/BSA: The end systolic volume is the blood volume of the heart at the end of contraction and is an index of the pump function of the heart. This relation to body size is more accurate in determining pathology because larger people require a larger heart blood volume. The values that are too high or too low indicate a diseased myocardium. This is a measure of LV Systolic Function. Since some visits did not occur at the scheduled 6 month intervals, the results have been divided into 3-month visit intervals. (NCT01052272)
Timeframe: 5 visits per Participant over 2 years (about every 6 months)
| Intervention | ml/m^2 (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Month 0 (n=17,17,18,18) | Month 6(n=14,11,11,12) | Month 9(n=1,2,0,0) | Month 12(n=12,11,11,11) | Month 15(n=3,2,1,1) | Month 18(n=10,12,8,8) | Month 21(n=3,0,0,1) | Month 24 (n=11,9,8,10) | Month 27 (n=1,1,0,1) | |
| Candesartan Cilexetil | 35.26 | 35.26 | 53.87 | 42.27 | 54.04 | 37.76 | NA | 41.72 | 35.13 |
| Candesartan Cilexetil and Allopurinol | 39.49 | 34.15 | NA | 36.07 | 28.74 | 37.18 | 32.99 | 35.99 | 34.22 |
| Ramipril | 36.20 | 34.77 | 25.64 | 36.82 | 39.42 | 35.30 | 35.23 | 31.17 | 23.98 |
| Ramipril and Allopurinol | 37.91 | 42.88 | NA | 42.34 | 70.48 | 30.39 | NA | 31.56 | NA |
LVED Mass/LVEDV: As an indicator of heart muscle mass and heart blood volume, the mass indexed to end diastolic volume determines whether there is an adequate amount of heart muscle to pump the heart blood volume obtained from a three-dimensional analysis. The values that are too high or too low indicate a diseased myocardium. This is a measure of LV Geometry. Since some visits did not occur at the scheduled 6 month intervals, the results have been divided into 3-month visit intervals for reporting purposes. (NCT01052272)
Timeframe: 5 visits per Participant over 2 years (about every 6 months)
| Intervention | g/ml (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Month 0 (n=17,17,18,18) | Month 6(n=14,11,11,12) | Month 9(n=1,2,0,0) | Month 12(n=12,11,11,11) | Month 15(n=3,2,1,1) | Month 18(n=10,12,8,8) | Month 21(n=3,0,0,1) | Month 24 (n=11,9,8,10) | Month 27 (n=1,1,0,1) | |
| Candesartan Cilexetil | 0.95 | 0.83 | 0.67 | 0.78 | 0.70 | 0.79 | NA | 0.80 | 0.64 |
| Candesartan Cilexetil and Allopurinol | 0.87 | 0.82 | NA | 0.86 | 0.68 | 0.80 | 0.69 | 0.82 | 0.69 |
| Ramipril | 0.92 | 0.87 | 0.75 | 0.84 | 0.81 | 0.79 | 0.95 | 0.84 | 0.93 |
| Ramipril and Allopurinol | 0.86 | 0.71 | NA | 0.72 | 0.57 | 0.83 | NA | 0.80 | NA |
LVED Radius/Wall thickness As an indicator of heart muscle mass and heart volume chamber diameter, the end-diastolic radius indexed to end diastolic wall thickness determines whether there is an adequate amount of heart muscle to pump the heart blood volume obtained from a two-dimensional analysis. The values that are too high or too low indicate a diseased myocardium. This is a measure of LV Geometry. Since some visits did not occur at the scheduled 6 month intervals, the results have been divided into 3-month visit intervals for reporting purposes. (NCT01052272)
Timeframe: 5 visits per Participant over 2 years (about every 6 months)
| Intervention | unitless (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Month 0 (n=17,17,18,18) | Month 6(n=14,11,11,12) | Month 9(n=1,2,0,0) | Month 12(n=12,11,11,11) | Month 15(n=3,2,1,1) | Month 18(n=10,12,8,8) | Month 21(n=3,0,0,1) | Month 24 (n=11,9,8,10) | Month 27 (n=1,1,0,1) | |
| Candesartan Cilexetil | 3.14 | 3.39 | 4.14 | 3.68 | 4.10 | 3.71 | NA | 3.58 | 4.04 |
| Candesartan Cilexetil and Allopurinol | 3.45 | 3.63 | NA | 3.42 | 3.90 | 3.56 | 4.24 | 3.56 | 4.29 |
| Ramipril | 3.23 | 3.32 | 3.42 | 3.43 | 3.44 | 3.60 | 2.92 | 3.46 | 3.12 |
| Ramipril and Allopurinol | 3.57 | 4.04 | NA | 4.01 | 4.57 | 3.60 | NA | 3.61 | NA |
By identifying three points in three different planes in the heart muscle, the maximum shortening is the average of the difference between the distance between these three points at the end of filling of the heart and the end of contraction divided by the length at the end of filling times 100. The maximum shortening is a three dimensional analysis. The higher values indicate a healthy heart. This is a measure of LV Systolic Function. Since some visits did not occur at the scheduled 6 month intervals, the results have been divided into 3-month visit intervals for reporting purposes. (NCT01052272)
Timeframe: 5 visits per Participant over 2 years (about every 6 months)
| Intervention | percent of length at end of filling (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Month 0 (n=17,17,17,18) | Month 6(n=14,11,10,12) | Month 9(n=1,2,0,0) | Month 12(n=11,11,10,10) | Month 15(n=3,2,1,1) | Month 18(n=10,12,7,8) | Month 21(n=3,0,0,1) | Month 24 (n=11,9,8,10) | Month 27 (n=1,1,0,1) | |
| Candesartan Cilexetil | 16.68 | 17.50 | 19.08 | 17.13 | 16.28 | 17.55 | NA | 16.62 | 20.38 |
| Candesartan Cilexetil and Allopurinol | 16.00 | 18.50 | NA | 18.51 | 16.36 | 17.52 | 17.89 | 17.85 | 16.59 |
| Ramipril | 15.81 | 16.88 | 18.43 | 14.57 | 17.06 | 17.26 | 16.68 | 15.67 | 13.70 |
| Ramipril and Allopurinol | 15.84 | 18.72 | NA | 17.96 | 14.22 | 17.46 | NA | 17.52 | NA |
The Peak Early Filling Rate Normalized to EDV is calculated from the slope of the volume during the early filling of the heart with respect to time. The higher values indicate a very healthy heart muscle and lower values are indicative of a very stiff muscle. This is a measure of LV Diastolic Function. Since some visits did not occur at the scheduled 6 month intervals, the results have been divided into 3-month visit intervals for reporting purposes. (NCT01052272)
Timeframe: 5 visits per Participant over 2 years (about every 6 months)
| Intervention | 1/sec (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Month 0 (n=17,17,18,18) | Month 6(n=14,11,11,12) | Month 9(n=1,2,0,0) | Month 12(n=12,11,11,11) | Month 15(n=3,2,1,1) | Month 18(n=10,12,8,8) | Month 21(n=3,0,0,1) | Month 24 (n=11,9,8,10) | Month 27 (n=1,1,0,1) | |
| Candesartan Cilexetil | 2.01 | 2.02 | 1.13 | 1.90 | 1.48 | 1.93 | NA | 1.65 | 1.10 |
| Candesartan Cilexetil and Allopurinol | 2.0 | 1.98 | NA | 1.77 | 2.28 | 2.05 | 2.50 | 1.82 | 2.15 |
| Ramipril | 1.93 | 1.74 | 2.50 | 1.80 | 2.02 | 1.91 | 1.69 | 2.05 | 1.34 |
| Ramipril and Allopurinol | 2.11 | 2.03 | NA | 1.93 | 1.56 | 1.89 | NA | 1.88 | NA |
The secondary outcome measure is the change in number of absence seizures from Week 8 (Baseline) to Week 12 (NCT01607073)
Timeframe: Week 8 to Week 12
| Intervention | Abscence seizures (Number) |
|---|---|
| Week 8 Baseline | 165 |
| Week 12 Verapamil 4mg/kg/Day | 101 |
The primary study endpoint is the change in number of seizures from baseline. Since we only had one participant finish the study, the endpoint was changed to Week 12 visit. Participants were on verapamil for 4 weeks at Week 12. (NCT01607073)
Timeframe: Week 8 (baseline) to Week 12
| Intervention | General tonic-clonic seizures (Number) |
|---|---|
| Week 8 Baseline | 39 |
| Week 12 Verapamil 4mg/kg/Day | 14 |
The secondary outcome is the change in number of myoclonic seizures between baseline Week 8 visit and Week 12 visit. (NCT01607073)
Timeframe: Week 8 (baseline) to Week 12
| Intervention | Myoclonic seizures (Number) |
|---|---|
| Week 8 Baseline | 116 |
| Week 12 Verapamil 4mg/kg/Day | 175 |
(NCT01062763)
Timeframe: 4 months
| Intervention | participants (Number) |
|---|---|
| Addition of Spironolactone | 4 |
| Placebo | 0 |
Change of diastolic blood pressure from baseline to study end at four months. (NCT01062763)
Timeframe: 4 months
| Intervention | mm Hg (Mean) |
|---|---|
| Addition of Spironolactone | -3.9 |
| Placebo | -0.3 |
Change of systolic blood pressure from baseline to study end at four months. (NCT01062763)
Timeframe: 4 months
| Intervention | mm Hg (Mean) |
|---|---|
| Addition of Spironolactone | -9.6 |
| Placebo | -0.7 |
198 reviews available for amlodipine and Hypertension
| Article | Year |
|---|---|
Effect of amlodipine on ventricular hypertrophy in hypertension patients: a systematic review and meta-analysis.
Topics: Amlodipine; Blood Pressure; Calcium Channel Blockers; Female; Humans; Hypertension; Hypertrophy, Lef | 2021 |
Initial combination therapy for hypertension in patients of African ancestry: a systematic review and meta-analysis.
Topics: Adult; Amlodipine; Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Drug Therapy, | 2022 |
Perindopril/Indapamide/Amlodipine in Hypertension: A Profile of Its Use.
Topics: Amlodipine; Antihypertensive Agents; Blood Pressure; Drug Combinations; Humans; Hypertension; Indapa | 2022 |
Nifedipine or amlodipine? The choice for hypertension during pregnancy: a systematic review and meta-analysis.
Topics: Amlodipine; Female; Humans; Hypertension; Infant, Newborn; Nifedipine; Obstetric Labor, Premature; P | 2022 |
Efficacy of Single-Pill, Triple Antihypertensive Therapy in Patients with Uncontrolled Hypertension: A Systematic Review and Meta-analysis.
Topics: Adult; Amlodipine; Antihypertensive Agents; Blood Pressure; Blood Pressure Monitoring, Ambulatory; D | 2022 |
A growing evidence base for the fixed-dose combination of bisoprolol and amlodipine to manage hypertension.
Topics: Amlodipine; Antihypertensive Agents; Bisoprolol; Blood Pressure; Drug Combinations; Humans; Hyperten | 2022 |
Evaluation of the Safety and Efficacy of Dual Therapy Perindopril/Amlodipine in the Management of Hypertension. A Systematic Review and Meta-Analysis.
Topics: Amlodipine; Antihypertensive Agents; Blood Pressure; Drug Combinations; Humans; Hypertension; Perind | 2022 |
Single-Pill Combination with Three Antihypertensive Agents to Improve Blood Pressure Control in Hypertension: Focus on Olmesartan-Based Combinations.
Topics: Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Drug Therapy, Combination; Humans; Hydroc | 2023 |
Topics: Amlodipine; Ankle; Calcium Channel Blockers; Drug-Related Side Effects and Adverse Reactions; Edema; | 2023 |
Efficacy of single-pill combination in uncontrolled essential hypertension: A systematic review and network meta-analysis.
Topics: Amlodipine; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihyperten | 2023 |
Amlodipine in the current management of hypertension.
Topics: Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Humans; Hyperte | 2023 |
Efficacy and Safety of Azelnidipine as an Antihypertensive Compared to Amlodipine: A Systematic Review and Meta-analysis.
Topics: Amlodipine; Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Dihydropyridines; Hum | 2023 |
A Reappraisal of the Effects of L-type Ca
Topics: Amlodipine; Antihypertensive Agents; Calcium; Calcium Channel Blockers; Dihydropyridines; Fura-2; He | 2023 |
[Antihypertensive combination therapy as single pill - useful or only expensive?]
Topics: Amlodipine; Antihypertensive Agents; Blood Pressure; Combined Modality Therapy; Drug Combinations; D | 2023 |
ACE-inhibitor/calcium antagonist combination: is this the first-choice therapy in arterial hypertension?
Topics: Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Calcium Channel Block | 2019 |
Comparative efficacy and safety of oral antihypertensive agents in pregnant women with chronic hypertension: a network metaanalysis.
Topics: Abruptio Placentae; Amlodipine; Antihypertensive Agents; Atenolol; Cesarean Section; Chronic Disease | 2020 |
Analytical and Bioanalytical Techniques for the Quantification of the Calcium Channel Blocker - Amlodipine: A Critical Review.
Topics: Amlodipine; Blood Pressure; Calcium Channel Blockers; Humans; Hypertension; Pharmaceutical Preparati | 2021 |
Amlodipine Compared with Benidipine in the Management of Hypertension: A Systematic Review and Meta-Analysis.
Topics: Aged; Aged, 80 and over; Amlodipine; Antihypertensive Agents; Blood Pressure; Calcium Channel Blocke | 2020 |
Plasma Trough Concentrations of Antihypertensive Drugs for the Assessment of Treatment Adherence: A Meta-Analysis.
Topics: Amlodipine; Antihypertensive Agents; Humans; Hydrochlorothiazide; Hypertension; Treatment Adherence | 2021 |
Angiotensin Receptor Blocker and Calcium Channel Blocker Preventing Atrial Fibrillation Recurrence in Patients with Hypertension and Atrial Fibrillation: A Meta-analysis.
Topics: Amlodipine; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Atrial Fibri | 2021 |
Feline comorbidities: The intermingled relationship between chronic kidney disease and hypertension.
Topics: Amlodipine; Animals; Antihypertensive Agents; Blood Pressure; Cat Diseases; Cats; Comorbidity; Hyper | 2021 |
Blood Pressure Variability in Patients with Diabetes Mellitus with Hypertension: Treatment Recommendations and Role of Amlodipine.
Topics: Amlodipine; Blood Pressure; Calcium Channel Blockers; Diabetes Complications; Diabetes Mellitus; Hum | 2017 |
[Fixed-Drug Combination Amlodipine, Indapamide and Perindopril: New Horizons of Antihypertensive Therapy].
Topics: Amlodipine; Antihypertensive Agents; Blood Pressure; Drug Combinations; Drug Therapy, Combination; D | 2017 |
Noncholestatic acute hepatocellular injury following candesartan administration.
Topics: Adult; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; | 2018 |
[Lipertance® The ASCOT single-pill combination has finally arrived].
Topics: Amlodipine; Atorvastatin; Cardiovascular Diseases; Clinical Trials as Topic; Drug Combinations; Huma | 2017 |
Treating Visit-to-Visit Blood Pressure Variability to Improve Prognosis: Is Amlodipine the Drug of Choice?
Topics: Amlodipine; Antihypertensive Agents; Blood Pressure; Humans; Hypertension; Prognosis; Treatment Outc | 2017 |
[Clinical Features of Arterial Hypertension in the Elderly and Senile Age and the Rationale for Using the Combination of Amlodipine/Indapamide-retard].
Topics: Age Factors; Aged; Aged, 80 and over; Amlodipine; Antihypertensive Agents; Blood Pressure; Drug Ther | 2017 |
Perindopril arginine and amlodipine besylate for hypertension: a safety evaluation.
Topics: Amlodipine; Antihypertensive Agents; Blood Pressure; Cough; Dose-Response Relationship, Drug; Drug C | 2018 |
Effects of Long- and Intermediate-Acting Dihydropyridine Calcium Channel Blockers in Hypertension: A Systematic Review and Meta-Analysis of 18 Prospective, Randomized, Actively Controlled Trials.
Topics: Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Dihydropyridine | 2018 |
Fixed-Dose Combination Amlodipine/Celecoxib (Consensi) for Hypertension and Osteoarthritis.
Topics: Amlodipine; Anti-Inflammatory Agents, Non-Steroidal; Antihypertensive Agents; Celecoxib; Humans; Hyp | 2019 |
Amlodipine in the Era of New Generation Calcium Channel Blockers.
Topics: Albuminuria; Amlodipine; Atherosclerosis; Calcium Channel Blockers; Diabetes Complications; Diabetic | 2018 |
Amlodipine and celecoxib for treatment of hypertension and osteoarthritis pain.
Topics: Amlodipine; Anti-Inflammatory Agents, Non-Steroidal; Antihypertensive Agents; Celecoxib; Drug Combin | 2018 |
Pharmacogenomics of amlodipine and hydrochlorothiazide therapy and the quest for improved control of hypertension: a mini review.
Topics: Adult; Amlodipine; Antihypertensive Agents; Female; Genome-Wide Association Study; Genome, Human; Hu | 2019 |
Peripheral edema and headache associated with amlodipine treatment: a meta-analysis of randomized, placebo-controlled trials.
Topics: Amlodipine; Antihypertensive Agents; Calcium Channel Blockers; Edema; Headache; Humans; Hypertension | 2019 |
Anti-hypertensive efficacy of amlodipine dosing during morning versus evening: A meta-analysis.
Topics: Amlodipine; Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Drug Chronotherapy; H | 2019 |
Irbesartan/amlodipine: a review of its use in adult patients with essential hypertension not adequately controlled with monotherapy.
Topics: Adult; Amlodipine; Antihypertensive Agents; Biphenyl Compounds; Blood Pressure; Drug Therapy, Combin | 2013 |
Long-term safety and efficacy of telmisartan/amlodipine single pill combination in the treatment of hypertension.
Topics: Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; Benzoa | 2013 |
Meta-analysis of three observational studies of amlodipine/valsartan in hypertensive patients with additional risk factors.
Topics: Amlodipine; Antihypertensive Agents; Blood Pressure; Clinical Trials as Topic; Diabetes Complication | 2013 |
A review of the efficacy and tolerability of combination amlodipine/valsartan in non-white patients with hypertension.
Topics: Amlodipine; Amlodipine, Valsartan Drug Combination; Antihypertensive Agents; Asian People; Black or | 2013 |
Pharmacological and clinical properties of AIMIX® combination tablets LD&HD, fixed-dose combination of irbesartan and amlodipine besilate.
Topics: Amlodipine; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Biphenyl Comp | 2013 |
CYP3A5 polymorphism, amlodipine and hypertension.
Topics: Amlodipine; Antihypertensive Agents; Cytochrome P-450 CYP3A; Genotype; Humans; Hypertension; Polymor | 2014 |
Aliskiren and amlodipine in the management of essential hypertension: meta-analysis of randomized controlled trials.
Topics: Amides; Amlodipine; Antihypertensive Agents; Blood Pressure; Fumarates; Humans; Hypertension; Obesit | 2013 |
Early combination therapy with telmisartan plus amlodipine for rapid achievement of blood pressure goals.
Topics: Aged; Amlodipine; Antihypertensive Agents; Benzimidazoles; Benzoates; Blood Pressure; Double-Blind M | 2013 |
Photodistributed telangiectasia induced by calcium channel blockers: case report and review of the literature.
Topics: Amlodipine; Calcium Channel Blockers; Erythema; Female; Humans; Hypertension; Middle Aged; Photosens | 2013 |
Renal protection with calcium antagonists: the role of lercanidipine.
Topics: Amlodipine; Calcium Channel Blockers; Dihydropyridines; Female; Humans; Hypertension; Kidney Failure | 2013 |
Effectiveness of the fixed-dose combination of olmesartan/amlodipine/hydrochlorothiazide for the treatment of hypertension in patients stratified by age, race and diabetes, CKD and chronic CVD.
Topics: Age Factors; Amlodipine; Cardiovascular Diseases; Diabetes Complications; Drug Therapy, Combination; | 2013 |
A review of the benefits of early treatment initiation with single-pill combinations of telmisartan with amlodipine or hydrochlorothiazide.
Topics: Administration, Oral; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; | 2013 |
[Advantages of ramipril/amlodipin fixed combination therapy. When should we use it?].
Topics: Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Pressure; Calci | 2013 |
Aliskiren/amlodipine vs. aliskiren/hydrochlorothiazide in hypertension: indirect meta-analysis of trials comparing the two combinations vs. monotherapy.
Topics: Amides; Amlodipine; Antihypertensive Agents; Blood Pressure; Drug Therapy, Combination; Female; Fuma | 2014 |
Blood pressure variability over 24 h: prognostic implications and treatment perspectives. An assessment using the smoothness index with telmisartan-amlodipine monotherapy and combination.
Topics: Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; Benzoa | 2014 |
Indirect treatment comparison between fixed-dose-combinations of amlodipine/losartan and amlodipine/valsartan in blood pressure control.
Topics: Aged; Amlodipine; Amlodipine, Valsartan Drug Combination; Antihypertensive Agents; Blood Pressure; D | 2014 |
The contribution of the ACCOMPLISH trial to the treatment of stage 2 hypertension.
Topics: Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Benzazepines; Calcium | 2014 |
Effects of amlodipine and other classes of antihypertensive drugs on long-term blood pressure variability: evidence from randomized controlled trials.
Topics: Amlodipine; Antihypertensive Agents; Atenolol; Blood Pressure; Cardiovascular Diseases; Chlorthalido | 2014 |
Amlodipine and cardiovascular outcomes in hypertensive patients: meta-analysis comparing amlodipine-based versus other antihypertensive therapy.
Topics: Amlodipine; Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Chi-Square Distributi | 2014 |
Evaluation of blood pressure reduction response and responder characteristics to fixed-dose combination treatment of amlodipine and losartan: a post hoc analysis of pooled clinical trials.
Topics: Adult; Amlodipine; Angiotensin Receptor Antagonists; Antihypertensive Agents; Blood Pressure; Calciu | 2014 |
Uptitrating amlodipine significantly reduces blood pressure in diabetic patients with hypertension: a retrospective, pooled analysis.
Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Comorbid | 2014 |
Combination therapy in the extended cardiovascular continuum: a focus on perindopril and amlodipine.
Topics: Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Calcium Channel Block | 2015 |
Prestalia--another combination for hypertension.
Topics: Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Calcium Chan | 2015 |
Perindopril/amlodipine (Prestalia(®)): a review in hypertension.
Topics: Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Pressure; Calci | 2015 |
Treatment of hypertensive patients with diabetes: beyond blood pressure control and focus on manidipine.
Topics: Amlodipine; Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Diabetes Mellitus; Di | 2016 |
[What are the effects of fixed-dose combination of candesartan and amlodipine].
Topics: Amlodipine; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Drug Combinations; Humans; | 2016 |
The Results of ACES (Antihypertensive Combinations' Long Term Efficacy Comparing Study): Analysis of Metabolic Effects of Antihypertensive Combination Therapies.
Topics: Adult; Aged; Aged, 80 and over; Amlodipine; Antihypertensive Agents; Blood Pressure; Calcium Channel | 2016 |
Quarter-dose quadruple combination therapy for initial treatment of hypertension: placebo-controlled, crossover, randomised trial and systematic review.
Topics: Administration, Oral; Amlodipine; Antihypertensive Agents; Atenolol; Biphenyl Compounds; Blood Press | 2017 |
[The Role of the Three-Drug Combination Antihypertensive in Improving the Treatment of Arterial Hypertension].
Topics: Amlodipine; Antihypertensive Agents; Drug Therapy, Combination; Humans; Hypertension; Indapamide; Pe | 2017 |
Comparison of angiotensin II type 1 receptor antagonists in the treatment of essential hypertension.
Topics: Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Calcium Channel Blocke | 2008 |
Amlodipine/ARB fixed-dose combinations for the treatment of hypertension: focus on amlodipine/olmesartan combination.
Topics: Aged; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Calcium Channel | 2008 |
[Combined antihypertensive and antilipemic therapy as one of the pillars in the poly-pharmacologic preventive strategy for patients with high cardiovascular risk].
Topics: Adult; Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Atorvast | 2008 |
Fixed combinations in the management of hypertension: patient perspectives and rationale for development and utility of the olmesartan-amlodipine combination.
Topics: Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Blood Pressure; Calciu | 2008 |
Optimizing the treatment of hypertension and stable coronary artery disease: clinical evidence for fixed-combination perindopril/amlodipine.
Topics: Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Calcium Channel Blockers; Clinical Trials as T | 2008 |
Olmesartan/Amlodipine: combination therapy for the treatment of hypertension [corrected].
Topics: Amlodipine; Angiotensin II Type 1 Receptor Blockers; Blood Pressure; Calcium Channel Blockers; Clini | 2009 |
Mitigation of calcium channel blocker-related oedema in hypertension by antagonists of the renin-angiotensin system.
Topics: Amlodipine; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antih | 2009 |
Antihypertensive efficacy of olmesartan medoxomil or valsartan in combination with amlodipine: a review of factorial-design studies.
Topics: Amlodipine; Antihypertensive Agents; Double-Blind Method; Drug Therapy, Combination; Humans; Hyperte | 2009 |
Complementary mechanisms of angiotensin receptor blockers and calcium channel blockers in managing hypertension.
Topics: Amlodipine; Angiotensin II Type 1 Receptor Blockers; Calcium Channel Blockers; Drug Combinations; Dr | 2009 |
[The combination of an ACE inhibitor and a calcium channel blocker is an optimal combination for the treatment of hypertension].
Topics: Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Calcium Channel Block | 2009 |
Olmesartan medoxomil/amlodipine.
Topics: Amlodipine; Antihypertensive Agents; Drug Combinations; Humans; Hypertension; Imidazoles; Olmesartan | 2009 |
Amlodipine and valsartan as components of a rational and effective fixed-dose combination.
Topics: Age Factors; Aged; Amlodipine; Amlodipine, Valsartan Drug Combination; Angiotensin II Type 1 Recepto | 2009 |
Fixed combination of amlodipine and atorvastatin in cardiovascular risk management: patient perspectives.
Topics: Amlodipine; Antihypertensive Agents; Atorvastatin; Calcium Channel Blockers; Cardiovascular Diseases | 2009 |
Potential concerns about generic substitution: bioequivalence versus therapeutic equivalence of different amlodipine salt forms.
Topics: Amlodipine; Antihypertensive Agents; Dissent and Disputes; Dosage Forms; Drug Compounding; Drugs, Ge | 2009 |
Single-pill combination of amlodipine and valsartan in the management of hypertension.
Topics: Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Blood Pressure; Calciu | 2009 |
Non-functional parathyroid carcinoma: a review of the literature and report of a case requiring extensive surgery.
Topics: Amlodipine; Antihypertensive Agents; Deglutition Disorders; Diabetes Mellitus, Type 2; Esophagectomy | 2009 |
Amlodipine/valsartan single-pill combination: a review of its use in the management of hypertension.
Topics: Adult; Aged; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Calcium C | 2009 |
Improving vascular function in hypertension: potential benefits of combination therapy with amlodipine and renin-angiotensin-aldosterone system blockers.
Topics: Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Blood Vessels; Drug Th | 2010 |
Hypertension and diabetes: should we treat early surrogates? What are the cons?
Topics: Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Cardiovascular Diseas | 2009 |
Angiotensin II type 1 receptor blockade: high hopes sent back to reality?
Topics: Amlodipine; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antih | 2009 |
Amlodipine/Atorvastatin: a review of its use in the treatment of hypertension and dyslipidaemia and the prevention of cardiovascular disease.
Topics: Amlodipine; Anticholesteremic Agents; Antihypertensive Agents; Blood Pressure; Cardiovascular Diseas | 2010 |
Amlodipine and angiotensin-converting enzyme inhibitor combination versus amlodipine monotherapy in hypertension: a meta-analysis of randomized controlled trials.
Topics: Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Calcium Channel Block | 2010 |
Importance of a fixed combination of telmisartan and amlodipine for the treatment of hypertension.
Topics: Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; Benzoa | 2010 |
Effects of amlodipine plus atorvastatin association in hypertensive hypercholesterolemic patients.
Topics: Amlodipine; Antihypertensive Agents; Atorvastatin; Biomarkers; Blood Pressure; Cardiovascular Diseas | 2010 |
Efficacy of fixed-dose combination therapy in the treatment of patients with hypertension: focus on amlodipine/valsartan.
Topics: Amlodipine; Amlodipine, Valsartan Drug Combination; Angiotensin II Type 1 Receptor Blockers; Antihyp | 2010 |
Combinations of inhibitors of the renin-angiotensin system with calcium channel blockers for the treatment of hypertension: focus on perindopril/amlodipine.
Topics: Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Calcium Channel Block | 2010 |
Role of olmesartan in combination therapy in blood pressure control and vascular function.
Topics: Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Blood Pressure; Blood | 2010 |
Efficacy and tolerability of olmesartan/amlodipine combination therapy in patients with mild-to-severe hypertension: focus on 24-h blood pressure control.
Topics: Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Blood Pressure; Circad | 2010 |
Efficacy and safety profiles of manidipine compared with amlodipine: a meta-analysis of head-to-head trials.
Topics: Adult; Amlodipine; Ankle; Antihypertensive Agents; Blood Pressure; Dihydropyridines; Edema; Humans; | 2011 |
Telmisartan/amlodipine: single-pill combination in hypertension.
Topics: Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; Benzoa | 2010 |
Combination of telmisartan plus amlodipine in the treatment of hypertension: review of results.
Topics: Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; Benzoa | 2010 |
Valsartan-amlodipine-hydrochlorothiazide: the definitive fixed combination?
Topics: Amlodipine; Antihypertensive Agents; Blood Pressure; Diuretics; Drug Combinations; Humans; Hydrochlo | 2010 |
[Amlodipine in contemporary therapy of cardiovascular diseases].
Topics: Amlodipine; Biotransformation; Blood Pressure; Calcium Channel Blockers; Humans; Hypertension; Hyper | 2010 |
Olmesartan medoxomil, amlodipine besylate and hydrochlorothiazide triple combination for hypertension.
Topics: Amlodipine; Antihypertensive Agents; Drug Combinations; Drug Therapy, Combination; Humans; Hydrochlo | 2011 |
Olmesartan medoxomil/amlodipine/hydrochlorothiazide: fixed-dose combination in hypertension.
Topics: Amlodipine; Antihypertensive Agents; Drug Combinations; Humans; Hydrochlorothiazide; Hypertension; I | 2011 |
Combination therapy with aliskiren and amlodipine in hypertension: treatment rationale and clinical results.
Topics: Amides; Amlodipine; Antihypertensive Agents; Drug Therapy, Combination; Fumarates; Humans; Hypertens | 2011 |
Albuminuria and blood pressure, independent targets for cardioprotective therapy in patients with diabetes and nephropathy: a post hoc analysis of the combined RENAAL and IDNT trials.
Topics: Aged; Albuminuria; Amlodipine; Angiotensin Receptor Antagonists; Biphenyl Compounds; Blood Pressure; | 2011 |
In brief: Another three-drug combination for hypertension.
Topics: Amides; Amlodipine; Animals; Drug Approval; Drug Combinations; Fumarates; Humans; Hydrochlorothiazid | 2011 |
Olmesartan/amlodipine: a review of its use in the management of hypertension.
Topics: Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Blood Pressure; Calciu | 2011 |
Triple-drug, fixed-dose combinations for the treatment of hypertension: focus on olmesartan/amlodipine/hydrochlorothiazide combination.
Topics: Amlodipine; Antihypertensive Agents; Clinical Trials as Topic; Drug Therapy, Combination; Humans; Hy | 2011 |
Perindopril for the treatment of hypertension.
Topics: Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Pressure; Cardi | 2011 |
Combined aliskiren-amlodipine treatment for hypertension in African Americans: clinical science and management issues.
Topics: Amides; Amlodipine; Antihypertensive Agents; Black or African American; Blood Pressure; Calcium Chan | 2011 |
Angiotensin II receptor blocker combinations: from guidelines to clinical practice.
Topics: Amlodipine; Angiotensin Receptor Antagonists; Antineoplastic Agents; Drug Therapy, Combination; Huma | 2012 |
The effect of amlodipine besylate, losartan potassium, olmesartan medoxomil, and other antihypertensives on central aortic blood pressure and biomarkers of vascular function.
Topics: Amlodipine; Animals; Antihypertensive Agents; Biomarkers; Blood Pressure; Drug Therapy, Combination; | 2011 |
Revisiting evidence of blood pressure-dependent and independent effects of amlodipine on the risk of stroke.
Topics: Amlodipine; Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Humans; Hypertension; | 2011 |
Single-pill telmisartan and amlodipine: a rational combination for the treatment of hypertension.
Topics: Amlodipine; Antihypertensive Agents; Benzimidazoles; Benzoates; Clinical Trials as Topic; Drug Combi | 2011 |
Single-pill triple-combination therapy: an alternative to multiple-drug treatment of hypertension.
Topics: Amides; Amlodipine; Antihypertensive Agents; Drug Combinations; Drug Design; Fumarates; Humans; Hydr | 2011 |
Review: a single-pill combination of telmisartan plus amlodipine for the treatment of hypertension.
Topics: Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; Benzoa | 2011 |
Which patients benefit the most from the perindopril/amlodipine combination.
Topics: Amlodipine; Antihypertensive Agents; Clinical Trials as Topic; Coronary Artery Disease; Humans; Hype | 2011 |
Olmesartan/amlodipine: blood pressure lowering and beyond in special populations.
Topics: Amlodipine; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Blood Pressur | 2012 |
Aliskiren, amlodipine and hydrochlorothiazide triple combination for hypertension.
Topics: Amides; Amlodipine; Antihypertensive Agents; Blood Pressure; Drug Therapy, Combination; Fumarates; H | 2012 |
Efficacy and safety of angiotensin II type 1 receptor blocker/calcium channel blocker combination therapy for hypertension: focus on a single-pill fixed-dose combination of valsartan and amlodipine.
Topics: Amlodipine; Amlodipine, Valsartan Drug Combination; Angiotensin II Type 1 Receptor Blockers; Calcium | 2012 |
Blood pressure control with angiotensin receptor blocker-based three-drug combinations: key trials.
Topics: Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Blood Pressure; Calciu | 2012 |
Fixed-dose combination therapy of candesartan cilexetil and amlodipine besilate for the treatment of hypertension in Japan.
Topics: Administration, Oral; Amlodipine; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Blood | 2012 |
Long-acting dihydropyridine calcium-channel blockers and sympathetic nervous system activity in hypertension: a literature review comparing amlodipine and nifedipine GITS.
Topics: Amlodipine; Calcium Channel Blockers; Female; Humans; Hypertension; Male; Nifedipine; Sympathetic Ne | 2012 |
[Remodeling of vascular bed in patients with arterial hypertension: possibilities of diagnostics and correction].
Topics: Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Biological Availability; Blood Vessels; | 2012 |
The single pill triple combination of aliskiren, amlodipine, and hydrochlorothiazide in the treatment of hypertension.
Topics: Amides; Amlodipine; Antihypertensive Agents; Drug Combinations; Fumarates; Humans; Hydrochlorothiazi | 2012 |
Atorvastatin calcium plus amlodipine for the treatment of hypertension.
Topics: Amlodipine; Antihypertensive Agents; Atorvastatin; Calcium Channel Blockers; Drug Combinations; Dysl | 2012 |
Telmisartan plus amlodipine single-pill combination for the management of hypertensive patients with a metabolic risk profile (added-risk patients).
Topics: Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Benzimidazoles; Benzo | 2013 |
Triple combination therapy to improve blood pressure control: experience with olmesartan-amlodipine-hydrochlorothiazide therapy.
Topics: Amlodipine; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Calcium Chann | 2012 |
Effects of telmisartan therapy on interleukin-6 and tumor necrosis factor-alpha levels: a meta-analysis of randomized controlled trials.
Topics: Amlodipine; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Benzoates; Blood Pressure; Calc | 2013 |
[Lessons from the novel renoprotective studies with antihypertensive drugs].
Topics: Amlodipine; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihyperten | 2013 |
[The effect of angiotensin-converting enzyme inhibitors on the progression of chronic renal failure].
Topics: Amlodipine; Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibito | 2002 |
Evolution of calcium antagonists: past, present, and future.
Topics: Amlodipine; Calcium Channel Blockers; Diabetic Angiopathies; Edema; Humans; Hypertension; Hypertroph | 2003 |
Effect of amlodipine on systolic blood pressure.
Topics: Age Factors; Amlodipine; Antihypertensive Agents; Blood Pressure; Diabetes Complications; Dose-Respo | 2003 |
[Amlodipin in the treatment of cardiovascular diseases].
Topics: Amlodipine; Calcium Channel Blockers; Humans; Hypertension | 2003 |
Treatment of diabetic nephropathy with angiotensin II receptor antagonist.
Topics: Amlodipine; Angiotensin Receptor Antagonists; Antihypertensive Agents; Biphenyl Compounds; Creatinin | 2003 |
Recommendations for the management of special populations: racial and ethnic populations.
Topics: Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Black or African Amer | 2003 |
[Recent intervention studies with antihypertensive drugs and their influence on guidelines].
Topics: Adrenergic beta-Antagonists; Aged; Amlodipine; Angiotensin Receptor Antagonists; Angiotensin-Convert | 2003 |
Amlodipine and atorvastatin in atherosclerosis: a review of the potential of combination therapy.
Topics: Amlodipine; Animals; Arteriosclerosis; Atorvastatin; Calcium Channel Blockers; Combined Modality The | 2004 |
[ALLHAT trial--antithesis to the overuse of vasodilating antihypertensive drugs].
Topics: Adrenergic alpha-Antagonists; Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypert | 2004 |
The VALUE trial: a commentary.
Topics: Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Calcium Channel Blocke | 2004 |
The role of existing and newer calcium channel blockers in the treatment of hypertension.
Topics: Amlodipine; Antihypertensive Agents; Calcium Channel Blockers; Humans; Hypertension; Nifedipine; Nit | 2004 |
Eplerenone in hypertension.
Topics: Amlodipine; Antihypertensive Agents; Blood Pressure; Clinical Trials as Topic; Enalapril; Eplerenone | 2004 |
A closer look at Caduet. The new generation of combination treatment.
Topics: Amlodipine; Drug Combinations; Drug Costs; Heptanoic Acids; Humans; Hyperlipidemias; Hypertension; P | 2005 |
[Old or new antihypertensives--which are better?].
Topics: Adrenergic beta-Antagonists; Amlodipine; Angiotensin I; Angiotensin Receptor Antagonists; Angiotensi | 2005 |
[Treatment of hypertension in elderly patients with coronary heart disease].
Topics: Adrenergic beta-Antagonists; Aged; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Angiotensin- | 2005 |
Simultaneous treatment of hypertension and dyslipidaemia may help to reduce overall cardiovascular risk: focus on amlodipine/atorvastatin single-pill therapy.
Topics: Amlodipine; Anticholesteremic Agents; Antihypertensive Agents; Atorvastatin; Cardiovascular Diseases | 2005 |
An update on the safety of amlodipine.
Topics: Amlodipine; Antihypertensive Agents; Calcium Channel Blockers; Drug Therapy, Combination; Humans; Hy | 1991 |
[Ischemic heart disease combined with hypertension: peculiarities of course and selection of therapy].
Topics: Adrenergic beta-Antagonists; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive | 2005 |
[Recent multi-center clinical studies about calcium blockade and cardiovascular diseases].
Topics: Adult; Aged; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhi | 2006 |
Will ASCOT change the form of anti-hypertensive therapy?
Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Atenolol; Blood Pressure; Cardiovascular Diseases; | 2006 |
Hypertension control in the elderly with amlodipine.
Topics: Age Factors; Aged; Amlodipine; Antihypertensive Agents; Calcium Channel Blockers; Humans; Hypertensi | 2000 |
A review of the efficacy of fixed-dose combinations olmesartan medoxomil/hydrochlorothiazide and amlodipine besylate/benazepril in factorial design studies.
Topics: Amlodipine; Antihypertensive Agents; Benzazepines; Blood Pressure; Drug Therapy, Combination; Factor | 2006 |
Is amlodipine the best initial monotherapy for hypertension?
Topics: Amlodipine; Humans; Hypertension; Multicenter Studies as Topic; Randomized Controlled Trials as Topi | 2006 |
A single-pill combination of amlodipine besylate and atorvastatin calcium.
Topics: Amlodipine; Anticholesteremic Agents; Antihypertensive Agents; Atorvastatin; Calcium Channel Blocker | 2006 |
The Anglo-Scandinavian Cardiac Outcomes Trial-- blood pressure lowering arm.
Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Atenolol; Blood Pressure; Calcium Channel Blockers | 2006 |
Amlodipine better than lisinopril? How one randomized clinical trial ended fallacies from observational studies.
Topics: Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Calcium Channel Blockers; Coronary Disease; Hu | 2006 |
Lessons from the African-American Study of Kidney Disease and Hypertension: an update.
Topics: Adrenergic beta-Antagonists; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive | 2006 |
[Prevention of target organ damage with modern antihypertensive agents].
Topics: Amlodipine; Antihypertensive Agents; Drug Combinations; Drug Synergism; Drug Therapy, Combination; H | 2006 |
[VALUE].
Topics: Aged; Aged, 80 and over; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agent | 2006 |
[CASE-J].
Topics: Adult; Aged; Aged, 80 and over; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensiv | 2006 |
[Novel actions of calcium channel blockers].
Topics: Amlodipine; Animals; Azetidinecarboxylic Acid; Calcium Channel Blockers; Depression; Dihydropyridine | 2006 |
[HOSP study].
Topics: Adult; Aged; Aged, 80 and over; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensiv | 2006 |
Vascular protection of dual therapy (atorvastatin-amlodipine) in hypertensive patients.
Topics: Amlodipine; Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Calcium Channel Blockers; Drug | 2006 |
[Overview of cardiovascular risk factors].
Topics: Age Factors; Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; As | 2006 |
A single-pill combination of amlodipine besylate and atorvastatin calcium (update).
Topics: Amlodipine; Antihypertensive Agents; Clinical Trials as Topic; Drug Combinations; Heptanoic Acids; H | 2007 |
Prevention of stroke and myocardial infarction by amlodipine and Angiotensin receptor blockers: a quantitative overview.
Topics: Aged; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Coronary Artery | 2007 |
[J-ELAN study (effect of losartan and amlodipine on left ventricular diastolic function in patients with mild-to-moderate hypertension)].
Topics: Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Calcium Channel Blocke | 2007 |
Antihypertensive activity of angiotensin II AT1 receptor antagonists: a systematic review of studies with 24 h ambulatory blood pressure monitoring.
Topics: Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Blood Pressure Monitor | 2007 |
Combination therapy with renin-angiotensin system blockers: will amlodipine replace hydrochlorothiazide?
Topics: Amlodipine; Antihypertensive Agents; Calcium Channel Blockers; Diuretics; Drug Therapy, Combination; | 2007 |
[A first drug combination for the treatment of arterial hypertension with a calcium channel antagonist (amlodipine besylate) and an angiotensin receptor blocker (valsartan): Exforge].
Topics: Amlodipine; Angiotensin II Type 1 Receptor Blockers; Calcium Channel Blockers; Drug Combinations; Hu | 2007 |
Amlodipine/Valsartan: fixed-dose combination in hypertension.
Topics: Amlodipine; Amlodipine, Valsartan Drug Combination; Angiotensin II Type 1 Receptor Blockers; Calcium | 2008 |
Amlodipine/atorvastatin fixed-dose combination: a review of its use in the prevention of cardiovascular disease and in the treatment of hypertension and dyslipidemia.
Topics: Amlodipine; Anticholesteremic Agents; Atorvastatin; Calcium Channel Blockers; Cardiovascular Disease | 2008 |
Role of combination therapy in the treatment of hypertension: focus on valsartan plus amlodipine.
Topics: Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Calcium Channel Block | 2008 |
Amlodipine; clinical relevance of a unique pharmacokinetic profile.
Topics: Amlodipine; Antihypertensive Agents; Blood Pressure; Half-Life; Humans; Hypertension; Metabolic Clea | 1993 |
Unique pharmacologic properties of amlodipine.
Topics: Amlodipine; Animals; Aorta; Calcium Channel Blockers; Delayed-Action Preparations; Dogs; Hypertensio | 1994 |
Amlodipine. A reappraisal of its pharmacological properties and therapeutic use in cardiovascular disease.
Topics: Amlodipine; Angina Pectoris; Cardiovascular Diseases; Hemodynamics; Humans; Hypertension | 1995 |
Vascular selective calcium entry blockers in the treatment of cardiovascular disorders: focus on felodipine.
Topics: Amlodipine; Calcium Channel Blockers; Coronary Disease; Felodipine; Heart Failure; Hemodynamics; Hum | 1995 |
Amlodipine: an overview of its pharmacodynamic and pharmacokinetic properties.
Topics: Amlodipine; Angina Pectoris; Animals; Humans; Hypertension; In Vitro Techniques | 1994 |
Patterns of compliance with once versus twice daily antihypertensive drug therapy in primary care: a randomized clinical trial using electronic monitoring.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amlodipine; Antihypertensive Agents; Canada; Diltiazem; | 1997 |
Renoprotection and renin-angiotensin system blockade in diabetes mellitus.
Topics: Amlodipine; Angiotensin Receptor Antagonists; Antihypertensive Agents; Biphenyl Compounds; Diabetic | 1997 |
Safety of long-acting dihydropyridine calcium channel blockers in hypertensive patients.
Topics: Amlodipine; Calcium Channel Blockers; Cause of Death; Cerebrovascular Disorders; Clinical Trials as | 1998 |
Interactions of cyclosporin A and amlodipine: blood cyclosporin A levels, hypertension and kidney function.
Topics: Amlodipine; Animals; Calcium Channel Blockers; Cyclosporine; Drug Interactions; Humans; Hypertension | 1998 |
Calcium antagonists and cardiovascular risk in diabetes.
Topics: Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Calcium Channel Block | 1998 |
Long-term morbidity and mortality trials with amlodipine.
Topics: Amlodipine; Antihypertensive Agents; Calcium Channel Blockers; Clinical Trials as Topic; Humans; Hyp | 1999 |
Safety and efficacy of angiotensin II receptor antagonists.
Topics: Amlodipine; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Blood Pressu | 1999 |
Fixed-dose combination vs monotherapy in hypertension: a meta-analysis evaluation.
Topics: Amlodipine; Antihypertensive Agents; Benzazepines; Drug Combinations; Humans; Hypertension; Lisinopr | 1999 |
Long-term potential of angiotensin receptor blockade for cardiovascular protection in hypertension: the VALUE trial. Valsartan Antihypertensive Long-term Use Evaluation.
Topics: Amlodipine; Animals; Antihypertensive Agents; Calcium Channel Blockers; Cardiovascular Diseases; Cli | 1999 |
Dihydropyridine calcium-channel blockers for the treatment of hypertensive diabetic patients.
Topics: Amlodipine; Calcium Channel Blockers; Diabetic Angiopathies; Dihydropyridines; Enalapril; Fosinopril | 2000 |
Circadian heart rate response to chronotherapy versus conventional therapy in patients with hypertension and myocardial ischemia.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Amlodipine; Atenolol; Blood Pressure; C | 2000 |
Amlodipine/benazepril: fixed dose combination therapy for hypertension.
Topics: Amlodipine; Antihypertensive Agents; Benzazepines; Blood Pressure; Clinical Trials as Topic; Drug Co | 2001 |
Management of coronary heart disease risk factors and progression with calcium channel blockers.
Topics: Amlodipine; Antihypertensive Agents; Calcium Channel Blockers; Clinical Trials as Topic; Coronary Ar | 2001 |
A review of vasopeptidase inhibitors: a new modality in the treatment of hypertension and chronic heart failure.
Topics: Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Animals; Atrial Natriuretic Factor; Dose-Respo | 2002 |
A granuloma annulare-like eruption associated with the use of amlodipine.
Topics: Amlodipine; Biopsy, Needle; Calcium Channel Blockers; Female; Granuloma Annulare; Hand Dermatoses; H | 2002 |
Amlodipine--a new calcium-channel blocker.
Topics: Amlodipine; Angina Pectoris; Angina Pectoris, Variant; Humans; Hypertension | 1992 |
Clinical pharmacokinetics of amlodipine.
Topics: Absorption; Amlodipine; Angina Pectoris; Biological Availability; Calcium Channel Blockers; Drug Int | 1992 |
[Amlodipine].
Topics: Amlodipine; Angina Pectoris; Calcium Channel Blockers; Humans; Hypertension; Nifedipine | 1991 |
[Amlodipin (Norvasc). A new calcium antagonist with long half-life].
Topics: Amlodipine; Angina Pectoris; Calcium Channel Blockers; Half-Life; Humans; Hypertension; Nifedipine | 1991 |
New drugs for hypertension--variations on old themes.
Topics: Amlodipine; Antihypertensive Agents; Delayed-Action Preparations; Dihydropyridines; Doxazosin; Human | 1991 |
Amlodipine: an effective once-daily antihypertensive agent.
Topics: Amlodipine; Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Drug Administration S | 1991 |
The clinical consequences of the absorption, distribution, metabolism and excretion of amlodipine.
Topics: Amlodipine; Blood Pressure; Calcium Channel Blockers; Humans; Hypertension; Nifedipine | 1991 |
Amlodipine in the treatment of hypertension.
Topics: Amlodipine; Blood Pressure Determination; Calcium Channel Blockers; Clinical Trials as Topic; Dose-R | 1991 |
Amlodipine in hypertension: an overview of the clinical dossier.
Topics: Amlodipine; Calcium Channel Blockers; Humans; Hypertension; Nifedipine | 1988 |
1056 trials available for amlodipine and Hypertension
| Article | Year |
|---|---|
Initial treatment with a single pill containing quadruple combination of quarter doses of blood pressure medicines versus standard dose monotherapy in patients with hypertension (QUARTET): a phase 3, randomised, double-blind, active-controlled trial.
Topics: Amlodipine; Antihypertensive Agents; Australia; Bisoprolol; Blood Pressure; Double-Blind Method; Dru | 2021 |
Serum uric acid change in relation to antihypertensive therapy with the dihydropyridine calcium channel blockers.
Topics: Amlodipine; Antihypertensive Agents; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Calcium | 2021 |
Risk of hospitalized and non-hospitalized gastrointestinal bleeding in ALLHAT trial participants receiving diuretic, ACE-inhibitor, or calcium-channel blocker.
Topics: Aged; Aged, 80 and over; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agen | 2021 |
Evaluation of Danzhi Xiaoyao powder and amlodipine sustained-release tablets in follow-up treatment of the hypertensive crisis and the interleukin-6 gene expression.
Topics: Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Delayed-Action Preparations; Double-Blind | 2021 |
Fixed-dose Combination of Metoprolol, Telmisartan, and Chlorthalidone for Essential Hypertension in Adults with Stable Coronary Artery Disease: Phase III Study.
Topics: Adult; Amlodipine; Antihypertensive Agents; Blood Pressure; Chlorthalidone; Coronary Artery Disease; | 2022 |
Effect of amlodipine versus bisoprolol in hypertensive patients on maintenance hemodialysis: A randomized controlled trial.
Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Bisoprolol; Blood Pressure; Female; Humans; Hypert | 2021 |
An anchored simulated treatment comparison of uptitration of amlodipine compared with a low-dose combination treatment with amlodipine 5 mg/bisoprolol 5 mg for patients with hypertension suboptimally controlled by amlodipine 5 mg monotherapy.
Topics: Amlodipine; Antihypertensive Agents; Bisoprolol; Blood Pressure; Drug Combinations; Humans; Hyperten | 2022 |
A Randomized Open-Label Parallel-Group Study Comparing the Efficacy and Safety of Cilnidipine and Amlodipine in Hypertensive Adults.
Topics: Adult; Amlodipine; Calcium Channel Blockers; Dihydropyridines; Humans; Hypertension; India | 2022 |
Effects of individualized administration of folic acid on prothrombotic state and vascular endothelial function with H-type hypertension: A double-blinded, randomized clinical cohort study.
Topics: Amlodipine; Cohort Studies; Double-Blind Method; Drug-Related Side Effects and Adverse Reactions; Fe | 2022 |
Achieving the Latest American Heart Association and American College of Cardiology Therapeutic Goals for Hypertension With Combination Therapy and Its Effects on Blood Pressure and Central Hemodynamic Parameters.
Topics: American Heart Association; Amlodipine; Angiotensin Receptor Antagonists; Antihypertensive Agents; B | 2022 |
A Differential Response to Antihypertensive Therapy in African Men and Women: Insights From the CREOLE Trial.
Topics: Amlodipine; Antihypertensive Agents; Black People; Blood Pressure; Double-Blind Method; Drug Combina | 2022 |
Efficacy and safety of Tengfu Jiangya tablet combined with valsartan/amlodipine in the treatment of stage 2 hypertension: study protocol for a randomized controlled trial.
Topics: Amlodipine; Antihypertensive Agents; Blood Pressure; Double-Blind Method; Drug Therapy, Combination; | 2022 |
Association of Low-Dose Triple Combination Therapy vs Usual Care With Time at Target Blood Pressure: A Secondary Analysis of the TRIUMPH Randomized Clinical Trial.
Topics: Adult; Amlodipine; Antihypertensive Agents; Blood Pressure; Chlorthalidone; Female; Humans; Hyperten | 2022 |
Effect of 3, 2-Drug Combinations of Antihypertensive Therapies on Blood Pressure Variability in Black African Patients: Secondary Analyses of the CREOLE Trial.
Topics: Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Pressure; Blood | 2022 |
Effects of high-intensity statin combined with telmisartan versus amlodipine on glucose metabolism in hypertensive atherosclerotic cardiovascular disease patients with impaired fasting glucose: A randomized multicenter trial.
Topics: Amlodipine; Atherosclerosis; Cardiovascular Diseases; Fasting; Glucose; Heart Diseases; Humans; Hydr | 2022 |
Efficacy and safety of low-dose antihypertensive combination of amlodipine, telmisartan, and chlorthalidone: A randomized, double-blind, parallel, phase II trial.
Topics: Amlodipine; Antihypertensive Agents; Blood Pressure; Chlorthalidone; Double-Blind Method; Drug Combi | 2022 |
Reduced efficacy of blood pressure lowering drugs in the presence of diabetes mellitus-results from the TRIUMPH randomised controlled trial.
Topics: Amlodipine; Antihypertensive Agents; Blood Pressure; Chlorthalidone; Diabetes Mellitus; Drug Combina | 2023 |
The Efficacy of Rosuvastatin, Amlodipine, and Aspirin in the Treatment of Hypertension with Coronary Heart Disease and Its Effect on Platelet Aggregation.
Topics: Amlodipine; Antihypertensive Agents; Aspirin; Coronary Disease; Humans; Hypertension; Lipids; Platel | 2022 |
Effects of olmesartan and amlodipine on blood pressure, endothelial function, and vascular inflammation.
Topics: Aged; Amlodipine; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihy | 2023 |
Effects of amlodipine combined with atorvastatin on Th17/Treg imbalance and vascular microcirculation in hypertensive patients with atherosclerosis: A double-blind, single-center randomized controlled trial.
Topics: Amlodipine; Atherosclerosis; Atorvastatin; Carotid Artery Diseases; Humans; Hypertension; Microcircu | 2023 |
Heterogeneity in Blood Pressure Response to 4 Antihypertensive Drugs: A Randomized Clinical Trial.
Topics: Amlodipine; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihyperten | 2023 |
Comparison of efficacy and safety between third-dose triple and third-dose dual antihypertensive combination therapies in patients with hypertension.
Topics: Amlodipine; Antihypertensive Agents; Blood Pressure; Chlorthalidone; Double-Blind Method; Drug Thera | 2023 |
Initial treatment with a single capsule containing half-dose quadruple therapy vs standard-dose dual therapy in hypertensive patients (QUADUAL): Study protocol for a randomized, blinded, crossover trial.
Topics: Amlodipine; Antihypertensive Agents; Blood Pressure; Cross-Over Studies; Double-Blind Method; Drug T | 2023 |
Efficacy of Allisartan Isoproxil in the Treatment of Mild-to-Moderate Essential Hypertension.
Topics: Amlodipine; Antihypertensive Agents; Blood Pressure; Double-Blind Method; Essential Hypertension; Hu | 2023 |
A Randomized, Multicenter, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of a Quadruple Combination of Amlodipine, Losartan, Rosuvastatin, and Ezetimibe in Patients with Concomitant Essential Hypertension and Dyslipidemia.
Topics: Amlodipine; Antihypertensive Agents; Blood Pressure; Cholesterol, LDL; Double-Blind Method; Dyslipid | 2023 |
Combined use of amlodipine and folic acid are significantly more efficacious than amlodipine alone in lowering plasma homocysteine and blood pressure among hypertensive patients with hyperhomocysteinemia and intolerance to ACEI: A multicenter, randomized,
Topics: Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Blood Pressure; Double-Blind Method; Folic Aci | 2023 |
Effects of chlorthalidone plus amiloride compared with amlodipine on short-term blood pressure variability in individuals with hypertension and obstructive sleep apnea: a randomized controlled trial.
Topics: Adult; Amiloride; Amlodipine; Antihypertensive Agents; Blood Pressure; Blood Pressure Monitoring, Am | 2023 |
Randomized, multicenter, parallel, open, phase 4 study to compare the efficacy and safety of rosuvastatin/amlodipine polypill versus atorvastatin/amlodipine polypill in hypertension patient with dyslipidemia.
Topics: Amlodipine; Atorvastatin; Cholesterol, LDL; Double-Blind Method; Dyslipidemias; Humans; Hypertension | 2023 |
Efficacy and safety of standard dose triple combination of telmisartan 80 mg/amlodipine 5 mg/chlorthalidone 25 mg in primary hypertension: A randomized, double-blind, active-controlled, multicenter phase 3 trial.
Topics: Aged; Amlodipine; Chlorthalidone; Essential Hypertension; Female; Humans; Hypertension; Leukemia, My | 2023 |
Polypill for Cardiovascular Disease Prevention in an Underserved Population.
Topics: Adult; Alabama; Amlodipine; Antihypertensive Agents; Atorvastatin; Cholesterol, LDL; Community Healt | 2019 |
Polypill for Cardiovascular Disease Prevention in an Underserved Population.
Topics: Adult; Alabama; Amlodipine; Antihypertensive Agents; Atorvastatin; Cholesterol, LDL; Community Healt | 2019 |
Polypill for Cardiovascular Disease Prevention in an Underserved Population.
Topics: Adult; Alabama; Amlodipine; Antihypertensive Agents; Atorvastatin; Cholesterol, LDL; Community Healt | 2019 |
Polypill for Cardiovascular Disease Prevention in an Underserved Population.
Topics: Adult; Alabama; Amlodipine; Antihypertensive Agents; Atorvastatin; Cholesterol, LDL; Community Healt | 2019 |
Polypill for Cardiovascular Disease Prevention in an Underserved Population.
Topics: Adult; Alabama; Amlodipine; Antihypertensive Agents; Atorvastatin; Cholesterol, LDL; Community Healt | 2019 |
Polypill for Cardiovascular Disease Prevention in an Underserved Population.
Topics: Adult; Alabama; Amlodipine; Antihypertensive Agents; Atorvastatin; Cholesterol, LDL; Community Healt | 2019 |
Polypill for Cardiovascular Disease Prevention in an Underserved Population.
Topics: Adult; Alabama; Amlodipine; Antihypertensive Agents; Atorvastatin; Cholesterol, LDL; Community Healt | 2019 |
Polypill for Cardiovascular Disease Prevention in an Underserved Population.
Topics: Adult; Alabama; Amlodipine; Antihypertensive Agents; Atorvastatin; Cholesterol, LDL; Community Healt | 2019 |
Polypill for Cardiovascular Disease Prevention in an Underserved Population.
Topics: Adult; Alabama; Amlodipine; Antihypertensive Agents; Atorvastatin; Cholesterol, LDL; Community Healt | 2019 |
Long-term effect of the perindopril/indapamide/amlodipine single-pill combination on left ventricular hypertrophy in outpatient hypertensive subjects.
Topics: Amlodipine; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Drug Combinations; Female; Follow | 2019 |
Circulating microparticles and central blood pressure according to antihypertensive strategy.
Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Cell-Derived Microparticles; Drug Therapy, Combina | 2019 |
Comparative effects of 2.5mg levamlodipine and 5mg amlodipine on vascular endothelial function and atherosclerosis.
Topics: Aged; Aged, 80 and over; Amlodipine; Antihypertensive Agents; Atherosclerosis; Endothelium, Vascular | 2019 |
A randomized, double-blind clinical trial to evaluate the efficacy and safety of a fixed-dose combination of amlodipine/rosuvastatin in patients with dyslipidemia and hypertension.
Topics: Amlodipine; Antihypertensive Agents; Blood Pressure; Double-Blind Method; Drug Therapy, Combination; | 2020 |
Use of amlodipine oral solution for the treatment of hypertension in children.
Topics: Administration, Oral; Amlodipine; Antihypertensive Agents; Body Weight; Child; Child, Preschool; Fem | 2020 |
Valsartan Versus Amlodipine Effect on Left Ventricular Multidirectional Deformation and Adipocytokines Levels in Hypertensive Patients: Speckle Tracking Echocardiography.
Topics: Adipokines; Adiponectin; Adult; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensiv | 2020 |
Association of Low-Dose Triple Combination Therapy With Therapeutic Inertia and Prescribing Patterns in Patients With Hypertension: A Secondary Analysis of the TRIUMPH Trial.
Topics: Amlodipine; Antihypertensive Agents; Blood Pressure; Chlorthalidone; Dose-Response Relationship, Dru | 2020 |
A comparative study for the effects of nifedipine GITS and amlodipine besylate administrated in daytime or at nighttime on recovery of blood pressure rhythm and arterial stiffness in the young and middle-aged subjects with non-dipper hypertension (NARRAS)
Topics: Adult; Amlodipine; Antihypertensive Agents; Blood Pressure; Blood Pressure Monitoring, Ambulatory; H | 2020 |
Assessment of suitable antihypertensive therapies: Combination with high-dose amlodipine/irbesartan vs triple combination with amlodipine/irbesartan/indapamide (ASAHI-AI study).
Topics: Amlodipine; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihyperten | 2020 |
Effectiveness of Levoamlodipine Maleate for Hypertension Compared with Amlodipine Besylate: a Pragmatic Comparative Effectiveness Study.
Topics: Aged; Amlodipine; Antihypertensive Agents; Calcium Channel Blockers; Cardiovascular Diseases; China; | 2021 |
Efficacy and safety of co-administered telmisartan/amlodipine and rosuvastatin in subjects with hypertension and dyslipidemia.
Topics: Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Double-Blind Method; Drug Combinations; D | 2020 |
Blood-pressure Lowering Efficacy and Safety of Perindopril / Indapamide / Amlodipine Single-pill Combination in Hypertensive Patients: Phase III Trial in India.
Topics: Amlodipine; Antihypertensive Agents; Blood Pressure; Drug Combinations; Humans; Hypertension; Indapa | 2020 |
Amlodipine/valsartan fixed-dose combination treatment in the management of hypertension: A double-blind, randomized trial.
Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Double-Blind Method; Drug Combinat | 2020 |
Ultra-low-dose quadruple combination blood pressure-lowering therapy in patients with hypertension: The QUARTET randomized controlled trial protocol.
Topics: Adrenergic beta-Antagonists; Amlodipine; Antihypertensive Agents; Bisoprolol; Calcium Channel Blocke | 2021 |
Low-Dose Triple Antihypertensive Combination Therapy in Patients with Hypertension: A Randomized, Double-Blind, Phase II Study.
Topics: Aged; Amlodipine; Antihypertensive Agents; Chlorthalidone; Dose-Response Relationship, Drug; Double- | 2020 |
Adherence to triple-component antihypertensive regimens is higher with single-pill than equivalent two-pill regimens: A randomized controlled trial.
Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Drug Combinations; Drug Therapy, C | 2021 |
Comparison of losartan and amlodipine effects on the outcomes of patient with COVID-19 and primary hypertension: A randomised clinical trial.
Topics: Aged; Aged, 80 and over; Amlodipine; Antihypertensive Agents; Blood Pressure; COVID-19; Double-Blind | 2021 |
Effects of the valsartan/amlodipine combination and nifedipine gastrointestinal therapeutic system monotherapy on brachial pulse pressure and radial augmentation index in hypertensive patients.
Topics: Amlodipine; Antihypertensive Agents; Blood Pressure; Humans; Hypertension; Nifedipine; Tetrazoles; T | 2021 |
Striatin genotype-based, mineralocorticoid receptor antagonist-driven clinical trial: study rationale and design.
Topics: Adolescent; Adult; Aged; Aldosterone; Alleles; Amlodipine; Animals; Blood Pressure; Calmodulin-Bindi | 2021 |
Striatin genotype-based, mineralocorticoid receptor antagonist-driven clinical trial: study rationale and design.
Topics: Adolescent; Adult; Aged; Aldosterone; Alleles; Amlodipine; Animals; Blood Pressure; Calmodulin-Bindi | 2021 |
Striatin genotype-based, mineralocorticoid receptor antagonist-driven clinical trial: study rationale and design.
Topics: Adolescent; Adult; Aged; Aldosterone; Alleles; Amlodipine; Animals; Blood Pressure; Calmodulin-Bindi | 2021 |
Striatin genotype-based, mineralocorticoid receptor antagonist-driven clinical trial: study rationale and design.
Topics: Adolescent; Adult; Aged; Aldosterone; Alleles; Amlodipine; Animals; Blood Pressure; Calmodulin-Bindi | 2021 |
Monotherapy treatment with chlorthalidone or amlodipine in the systolic blood pressure intervention trial (SPRINT).
Topics: Amlodipine; Antihypertensive Agents; Blood Pressure; Chlorthalidone; Humans; Hypertension; Treatment | 2021 |
Effects of Renin-Angiotensin-Aldosterone Inhibitors on Early Outcomes of Hypertensive COVID-19 Patients: A Randomized Triple-Blind Clinical Trial.
Topics: Aldosterone; Amlodipine; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; | 2021 |
Differential effects of eplerenone versus amlodipine on muscle metaboreflex function in hypertensive humans.
Topics: Amlodipine; Animals; Blood Pressure; Cross-Over Studies; Eplerenone; Hand Strength; Humans; Hyperten | 2021 |
Comparative Effects of an Angiotensin II Receptor Blocker (ARB)/Diuretic vs. ARB/Calcium-Channel Blocker Combination on Uncontrolled Nocturnal Hypertension Evaluated by Information and Communication Technology-Based Nocturnal Home Blood Pressure Monitorin
Topics: Aged; Amlodipine; Angiotensin Receptor Antagonists; Biphenyl Compounds; Blood Pressure Monitoring, A | 2017 |
Electrocardiographic Left Ventricular Hypertrophy Predicts Cardiovascular Morbidity and Mortality in Hypertensive Patients: The ALLHAT Study.
Topics: Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Cause of Death; Chlorthalidone; Disease P | 2017 |
The effects of increasing calcium channel blocker dose vs. adding a diuretic to treatment regimens for patients with uncontrolled hypertension.
Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Biphenyl Compounds; Blood Pressure; Calcium Channe | 2017 |
Effects of valsartan and amlodipine on oxidative stress in type 2 diabetic patients with hypertension: a randomized, multicenter study.
Topics: Amlodipine; Antihypertensive Agents; Diabetes Mellitus, Type 2; Female; Humans; Hypertension; Male; | 2017 |
Comparison of ambulatory blood pressure-lowering effects of higher doses of different calcium antagonists in uncontrolled hypertension: the Calcium Antagonist Controlled-Release High-Dose Therapy in Uncontrolled Refractory Hypertensive Patients (CARILLON)
Topics: Aged; Aged, 80 and over; Amlodipine; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Bl | 2017 |
Heterogeneity in Early Responses in ALLHAT (Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial).
Topics: Aged; Amlodipine; Analysis of Variance; Antihypertensive Agents; Blood Pressure; Cardiovascular Dise | 2017 |
Efficacy and tolerability of initial high vs low doses of S-(-)-amlodipine in hypertension.
Topics: Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Ca | 2017 |
Evaluation of the effect of time dependent dosing on pharmacokinetic and pharmacodynamics of amlodipine in normotensive and hypertensive human subjects.
Topics: Adult; Amlodipine; Antihypertensive Agents; Blood Pressure; Blood Pressure Monitoring, Ambulatory; C | 2017 |
Systemic and tissue-specific effects of aliskiren on the RAAS and carbohydrate/lipid metabolism in obese patients with hypertension.
Topics: Adipose Tissue; Adult; Amides; Amlodipine; Angiotensin II; Antihypertensive Agents; Blood Glucose; D | 2017 |
Blood pressure-lowering efficacy of indapamide SR/amlodipine combination in older patients with hypertension: A post hoc analysis of the NESTOR trial (Natrilix SR vs Enalapril in Hypertensive Type 2 Diabetics With Microalbuminuria).
Topics: Aged; Aged, 80 and over; Albuminuria; Amlodipine; Antihypertensive Agents; Blood Pressure; Diabetes | 2017 |
Reduction in microalbuminuria by calcium channel blockers in patients with type 2 diabetes mellitus and hypertension-A randomized, open-label, active-controlled, superiority, parallel-group clinical trial.
Topics: Adult; Aged; Albuminuria; Amlodipine; Calcium Channel Blockers; Diabetes Mellitus, Type 2; Dihydropy | 2017 |
Comparison of Fixed-dose Combinations of Amlodipine/Losartan Potassium/Chlorthalidone and Amlodipine/Losartan Potassium in Patients With Stage 2 Hypertension Inadequately Controlled With Amlodipine/Losartan Potassium: A Randomized, Double-blind, Multicent
Topics: Adult; Aged; Aged, 80 and over; Amlodipine; Antihypertensive Agents; Blood Pressure; Chlorthalidone; | 2017 |
Monotherapy with amlodipine or hydrochlorothiazide in patients with mild to moderate hypertension: Comparison of their efficacy and effects on electrolytes.
Topics: Adult; Amlodipine; Antihypertensive Agents; Blood Pressure; Blood Pressure Determination; Dose-Respo | 2017 |
Relationship Between Visit-to-Visit Blood Pressure Variability (BPV) and Kidney Function in Patients with Hypertension.
Topics: Aged; Amlodipine; Analysis of Variance; Blood Pressure; Blood Pressure Determination; Female; Glomer | 2017 |
Combination Therapy Is Superior to Sequential Monotherapy for the Initial Treatment of Hypertension: A Double-Blind Randomized Controlled Trial.
Topics: Adolescent; Adult; Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Dose-Response Relation | 2017 |
Effect of Sacubitril/Valsartan on Exercise-Induced Lipid Metabolism in Patients With Obesity and Hypertension.
Topics: Adipose Tissue; Aminobutyrates; Amlodipine; Angiotensin Receptor Antagonists; Biphenyl Compounds; Bl | 2018 |
Pharmacologic Prevention of Incident Atrial Fibrillation: Long-Term Results From the ALLHAT (Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial).
Topics: Amlodipine; Antihypertensive Agents; Atrial Fibrillation; Atrial Flutter; Chlorthalidone; Double-Bli | 2017 |
The effects of angiotensin receptor neprilysin inhibition by sacubitril/valsartan on adipose tissue transcriptome and protein expression in obese hypertensive patients.
Topics: Adipose Tissue; Adult; Aminobutyrates; Amlodipine; Angiotensin Receptor Antagonists; Biphenyl Compou | 2018 |
Efficacy and Safety of S-Amlodipine 2.5 and 5 mg/d in Hypertensive Patients Who Were Treatment-Naive or Previously Received Antihypertensive Monotherapy.
Topics: Adult; Amlodipine; Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Drug Substitut | 2018 |
Rationale and design of the comparison of 3 combination therapies in lowering blood pressure in black Africans (CREOLE study): 2 × 3 factorial randomized single-blind multicenter trial.
Topics: Adult; Africa South of the Sahara; Aged; Amlodipine; Antihypertensive Agents; Black People; Drug Com | 2018 |
S-amlodipine plus chlorthalidone vs. S-amlodipine plus telmisartan in hypertensive patients unresponsive to amlodipine monotherapy: study protocol for a randomized controlled trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Ant | 2018 |
Metoprolol has a similar therapeutic effect as amlodipine on BP lowering in hypertensive patients with obstructive sleep apnea.
Topics: Administration, Oral; Adult; Aged; Amlodipine; Blood Pressure; Blood Pressure Monitoring, Ambulatory | 2019 |
A randomized controlled crossover trial evaluating differential responses to antihypertensive drugs (used as mono- or dual therapy) on the basis of ethnicity: The comparIsoN oF Optimal Hypertension RegiMens; part of the Ancestry Informative Markers in HYp
Topics: Adolescent; Adult; Aged; Amlodipine; Antihypertensive Agents; Asian People; Black People; Chlorthali | 2018 |
Fixed Low-Dose Triple Combination Antihypertensive Medication vs Usual Care for Blood Pressure Control in Patients With Mild to Moderate Hypertension in Sri Lanka: A Randomized Clinical Trial.
Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Benzimidazoles; Benzoates; Blood Pressure; Chlorth | 2018 |
Risk Factors Influencing Outcomes of Atrial Fibrillation in ALLHAT.
Topics: Aged; Aged, 80 and over; Amlodipine; Antihypertensive Agents; Atrial Fibrillation; Atrial Flutter; C | 2018 |
Long-term mortality after blood pressure-lowering and lipid-lowering treatment in patients with hypertension in the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT) Legacy study: 16-year follow-up results of a randomised factorial trial.
Topics: Adult; Aged; Amlodipine; Anticholesteremic Agents; Antihypertensive Agents; Atenolol; Atorvastatin; | 2018 |
The Precision HYpertenSIon Care (PHYSIC) study: a double-blind, randomized, repeated cross-over study.
Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Benzimidazoles; Biomarkers; Biphenyl Compounds; Bl | 2019 |
Hypertension Treatment Effects on Orthostatic Hypotension and Its Relationship With Cardiovascular Disease.
Topics: Amlodipine; Antihypertensive Agents; Blood Pressure; Blood Pressure Determination; Cardiovascular Di | 2018 |
The Interaction of a Diabetes Gene Risk Score With 3 Different Antihypertensive Medications for Incident Glucose-level Elevation.
Topics: Alkadienes; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Blood Glucose; Calcium Channel Blo | 2019 |
Efficacy and Safety of Triple Therapy With Telmisartan, Amlodipine, and Rosuvastatin in Patients With Dyslipidemia and Hypertension: The Jeil Telmisartan, Amlodipine, and Rosuvastatin Randomized Clinical Trial.
Topics: Aged; Amlodipine; Anticholesteremic Agents; Antihypertensive Agents; Blood Pressure; Double-Blind Me | 2019 |
Effect of amlodipine besylate combined with acupoint application of traditional Chinese medicine nursing on the treatment of renal failure and hypertension by the PI3K/AKT pathway.
Topics: Acupuncture Points; Amlodipine; Animals; Blood Pressure; Female; Humans; Hypertension; Kidney; Male; | 2019 |
Treating Hypertension in Children With
Topics: Academic Medical Centers; Adolescent; Amlodipine; Antihypertensive Agents; Bayes Theorem; Blood Pres | 2019 |
Comparison of Dual Therapies for Lowering Blood Pressure in Black Africans.
Topics: Adult; Africa South of the Sahara; Aged; Amlodipine; Antihypertensive Agents; Black People; Blood Pr | 2019 |
Efficacy and Tolerability of Telmisartan/Amlodipine and Rosuvastatin Coadministration in Hypertensive Patients with Hyperlipidemia: A Phase III, Multicenter, Randomized, Double-blind Study.
Topics: Aged; Amlodipine; Anticholesteremic Agents; Antihypertensive Agents; Double-Blind Method; Drug Combi | 2019 |
Efficacy and Safety of Incremental Dosing of a New Single-Pill Formulation of Perindopril and Amlodipine in the Management of Hypertension.
Topics: Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Pressure; | 2019 |
Prevention of Heart Failure in Hypertension-Disentangling the Role of Evolving Left Ventricular Hypertrophy and Blood Pressure Lowering: The ALLHAT Study.
Topics: Aged; Amlodipine; Antihypertensive Agents; Causality; Chlorthalidone; Doxazosin; Electrocardiography | 2019 |
Prevention of Heart Failure in Hypertension-Disentangling the Role of Evolving Left Ventricular Hypertrophy and Blood Pressure Lowering: The ALLHAT Study.
Topics: Aged; Amlodipine; Antihypertensive Agents; Causality; Chlorthalidone; Doxazosin; Electrocardiography | 2019 |
Prevention of Heart Failure in Hypertension-Disentangling the Role of Evolving Left Ventricular Hypertrophy and Blood Pressure Lowering: The ALLHAT Study.
Topics: Aged; Amlodipine; Antihypertensive Agents; Causality; Chlorthalidone; Doxazosin; Electrocardiography | 2019 |
Prevention of Heart Failure in Hypertension-Disentangling the Role of Evolving Left Ventricular Hypertrophy and Blood Pressure Lowering: The ALLHAT Study.
Topics: Aged; Amlodipine; Antihypertensive Agents; Causality; Chlorthalidone; Doxazosin; Electrocardiography | 2019 |
A randomized controlled trial on the blood pressure-lowering effect of amlodipine and nifedipine-GITS in sustained hypertension.
Topics: Amlodipine; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Calcium Channel Blockers; Case-Co | 2019 |
Comparison of 24-Hour Ambulatory Central Blood Pressure Reduction Efficacy Between Fixed Amlodipine or Up-Titrated Hydrochlorothiazide Plus Losartan: The K-Central Study.
Topics: Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Do | 2019 |
Pharmacokinetic Drug Interactions Between Amlodipine, Valsartan, and Rosuvastatin in Healthy Volunteers.
Topics: Adult; Amlodipine; Cross-Over Studies; Dose-Response Relationship, Drug; Drug Interactions; Drug Mon | 2019 |
Short-term effects of perindopril-amlodipine vs perindopril-indapamide on blood pressure control in sub-Saharan type 2 diabetic individuals newly diagnosed for hypertension: A double-blinded randomized controlled trial.
Topics: Africa South of the Sahara; Amlodipine; Antihypertensive Agents; Blood Pressure; Blood Pressure Moni | 2019 |
The association of smoothness index of central blood pressure with ambulatory carotid femoral pulse wave velocity after 20-week treatment with losartan in combination with amlodipine versus hydrochlorothiazide.
Topics: Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Carotid-Femoral Pulse Wave Velocity; Fema | 2019 |
Effect of tablets with a combination of telmisartan and amlodipine on patients with hypertension: the Cotalo study.
Topics: Aged; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; | 2013 |
Low-grade inflammation and ambulatory blood pressure response to antihypertensive treatment: the ALPHABET study.
Topics: Amlodipine; Antihypertensive Agents; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Dose-Res | 2013 |
Post hoc analysis of the Cluster Randomized Usual Care versus Caduet Investigation Assessing Long-term risk (CRUCIAL) trial.
Topics: Amlodipine; Antihypertensive Agents; Atorvastatin; Blood Pressure; Coronary Disease; Drug Combinatio | 2013 |
A comparative pharmacokinetic study of a fixed dose combination for essential hypertensive patients: a randomized crossover study in healthy human volunteers.
Topics: Adolescent; Adult; Amlodipine; Benzimidazoles; Benzoates; Cross-Over Studies; Drug Therapy, Combinat | 2013 |
Combination of antihypertensive therapy in the elderly, multicenter investigation (CAMUI) trial: results after 1 year.
Topics: Aged; Aged, 80 and over; Amlodipine; Angiotensin Receptor Antagonists; Antihypertensive Agents; Calc | 2013 |
Efficacy of initiating therapy with amlodipine and hydrochlorothiazide or their combination in hypertensive Nigerians.
Topics: Adult; Aged; Aged, 80 and over; Amlodipine; Antihypertensive Agents; Drug Therapy, Combination; Fema | 2013 |
Mortality and morbidity during and after Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial: results by sex.
Topics: Aged; Aged, 80 and over; Amlodipine; Antihypertensive Agents; Calcium Channel Blockers; Chlorthalido | 2013 |
Control of home blood pressure with an amlodipine- or losartan-based regimen and progression of carotid artery intima-media thickness in hypertensive patients: the HOSP substudy.
Topics: Aged; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Blood Pressure; | 2013 |
Combined olmesartan, amlodipine, and hydrochlorothiazide therapy in randomized patients with hypertension: a subgroup analysis of the TRINITY study by age.
Topics: Adolescent; Adult; Age Factors; Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Double-Bl | 2013 |
Efficacy/safety of a fixed-dose amlodipine/olmesartan medoxomil-based treatment regimen in hypertensive blacks and non-blacks with uncontrolled BP on prior antihypertensive monotherapy.
Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Dose-Response Relationship, Drug; | 2013 |
Comparison of benazepril plus amlodipine or hydrochlorothiazide in high-risk patients with hypertension and coronary artery disease.
Topics: Aged; Amlodipine; Antihypertensive Agents; Benzazepines; Coronary Artery Disease; Double-Blind Metho | 2013 |
Efficacy and tolerability between an olmesartan/amlodipine fixed-dose combination and an amlodipine double dose in mild to moderate hypertension.
Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Drug Therapy, Combination; Edema; | 2013 |
Antihypertensive response to combination of olmesartan and amlodipine does not depend on method and time of drug administration.
Topics: Amlodipine; Analysis of Variance; Angiotensin II Type 1 Receptor Blockers; Blood Pressure; Blood Pre | 2013 |
Effects of aerobic exercise and drug therapy on blood pressure and antihypertensive drugs: a randomized controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Amiloride; Amlodipine; Antihypertensive Agents; Blood Pressure; Diur | 2013 |
Azelnidipine plus olmesartan versus amlodipine plus olmesartan on arterial stiffness and cardiac function in hypertensive patients: a randomized trial.
Topics: Aged; Amlodipine; Azetidinecarboxylic Acid; Diastole; Dihydropyridines; Drug Therapy, Combination; F | 2013 |
Effects of CPAP on "vascular" risk factors in patients with obstructive sleep apnea and arterial hypertension.
Topics: Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Arterial Pressure; Blo | 2013 |
Effects of demographics on the antihypertensive efficacy of triple therapy with amlodipine, valsartan, and hydrochlorothiazide for moderate to severe hypertension.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amlodipine; Antihypertensive Agents; Blood Pressure; Dem | 2013 |
Effects of antihypertensive drugs on central blood pressure in humans: a preliminary observation.
Topics: Aged; Amlodipine; Antihypertensive Agents; Aorta; Arterial Pressure; Benzimidazoles; Biphenyl Compou | 2013 |
Efficacy of the combination of amlodipine and candesartan in hypertensive patients with coronary artery disease: a subanalysis of the HIJ-CREATE study.
Topics: Aged; Amlodipine; Angiotensin Receptor Antagonists; Benzimidazoles; Biphenyl Compounds; Calcium Chan | 2013 |
Efficacy of newer versus older antihypertensive drugs in black patients living in sub-Saharan Africa.
Topics: Adult; Africa South of the Sahara; Amlodipine; Antihypertensive Agents; Bisoprolol; Black People; Dr | 2013 |
Evaluation of safety and efficacy of a fixed olmesartan/amlodipine combination therapy compared to single monotherapies.
Topics: Adipokines; Amlodipine; Blood Glucose; Blood Pressure; Body Mass Index; Body Weight; Double-Blind Me | 2013 |
Efficacy of amlodipine/olmesartan medoxomil ± hydrochlorothiazide in patients aged ≥ 65 or < 65 years with uncontrolled hypertension on prior monotherapy.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Amlodipine; Antihypertensive Agents; Blood | 2013 |
[Effect of a fixed-dose perindopril and amlodipine combination on intrarenal hemodynamic and kidney functional parameters in patients with essential hypertension].
Topics: Adult; Amlodipine; Antihypertensive Agents; Drug Combinations; Female; Glomerular Filtration Rate; H | 2013 |
The efficacy and safety of fixed-dose combination of amlodipine/benazepril in Chinese essential hypertensive patients not adequately controlled with benazepril monotherapy: a multicenter, randomized, double-blind, double-dummy, parallel-group clinical tri
Topics: Adolescent; Adult; Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Benzazepines; Blood P | 2014 |
Olmesartan/amlodipine/hydrochlorothiazide in obese participants with hypertension: a TRINITY subanalysis.
Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Body Mass Index; Double-Blind Meth | 2013 |
[The effectiveness and safety of L-amlodipine besylate for blood pressure control in patients with mild to moderate essential hypertension].
Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Essential Hypertension; Female; Humans; Hypertensi | 2013 |
Efficacy and safety of valsartan and amlodipine single-pill combination in hypertensive patients (PEAK study).
Topics: Administration, Oral; Aged; Amlodipine; Antihypertensive Agents; Drug Combinations; Female; Humans; | 2013 |
Effect of renin-angiotensin system blockade on soluble Klotho in patients with type 2 diabetes, systolic hypertension, and albuminuria.
Topics: Aged; Albuminuria; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Biomarkers; Blood Pressure; | 2013 |
Effect of renin-angiotensin system blockade on soluble Klotho in patients with type 2 diabetes, systolic hypertension, and albuminuria.
Topics: Aged; Albuminuria; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Biomarkers; Blood Pressure; | 2013 |
Effect of renin-angiotensin system blockade on soluble Klotho in patients with type 2 diabetes, systolic hypertension, and albuminuria.
Topics: Aged; Albuminuria; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Biomarkers; Blood Pressure; | 2013 |
Effect of renin-angiotensin system blockade on soluble Klotho in patients with type 2 diabetes, systolic hypertension, and albuminuria.
Topics: Aged; Albuminuria; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Biomarkers; Blood Pressure; | 2013 |
Effect of renin-angiotensin system blockade on soluble Klotho in patients with type 2 diabetes, systolic hypertension, and albuminuria.
Topics: Aged; Albuminuria; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Biomarkers; Blood Pressure; | 2013 |
Effect of renin-angiotensin system blockade on soluble Klotho in patients with type 2 diabetes, systolic hypertension, and albuminuria.
Topics: Aged; Albuminuria; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Biomarkers; Blood Pressure; | 2013 |
Effect of renin-angiotensin system blockade on soluble Klotho in patients with type 2 diabetes, systolic hypertension, and albuminuria.
Topics: Aged; Albuminuria; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Biomarkers; Blood Pressure; | 2013 |
Effect of renin-angiotensin system blockade on soluble Klotho in patients with type 2 diabetes, systolic hypertension, and albuminuria.
Topics: Aged; Albuminuria; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Biomarkers; Blood Pressure; | 2013 |
Effect of renin-angiotensin system blockade on soluble Klotho in patients with type 2 diabetes, systolic hypertension, and albuminuria.
Topics: Aged; Albuminuria; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Biomarkers; Blood Pressure; | 2013 |
Comparison of the antialbuminuric effects of L-/N-type and L-type calcium channel blockers in hypertensive patients with diabetes and microalbuminuria: the study of assessment for kidney function by urinary microalbumin in randomized (SAKURA) trial.
Topics: Aged; Albuminuria; Amlodipine; Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Ca | 2013 |
[Combined therapy of arterial hypertension with the fixed combination of perindopril arginine / amlodipine in real clinical practice: the organization and the main results of the program CONSTANTA].
Topics: Adult; Aged; Aged, 80 and over; Amlodipine; Antihypertensive Agents; Blood Pressure; Blood Pressure | 2013 |
The effects of amlodipine and S(-)-amlodipine on vascular endothelial function in patients with hypertension.
Topics: Amlodipine; Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Cells, Cultured; Chin | 2014 |
Valsartan/amlodipine compared to nifedipine GITS in patients with hypertension inadequately controlled by monotherapy.
Topics: Adult; Amlodipine; Amlodipine, Valsartan Drug Combination; Antihypertensive Agents; Asian People; De | 2013 |
Effects of dividing amlodipine daily doses on trough drug concentrations and blood pressure control over a 24-hour period.
Topics: Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Cr | 2013 |
Results from a 12 months, randomized, clinical trial comparing an olmesartan/amlodipine single pill combination to olmesartan and amlodipine monotherapies on blood pressure and inflammation.
Topics: Amlodipine; Antihypertensive Agents; Blood Glucose; Blood Pressure; Body Mass Index; Body Weight; Do | 2014 |
Differential effects of aliskiren/amlodipine combination and high-dose amlodipine monotherapy on endothelial function in elderly hypertensive patients.
Topics: Aged; Aged, 80 and over; Amides; Amlodipine; Antihypertensive Agents; Blood Pressure; Calcium Channe | 2014 |
Different aspects of sartan + calcium antagonist association compared to the single therapy on inflammation and metabolic parameters in hypertensive patients.
Topics: Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Blood Pressure; Body M | 2014 |
Effects of valsartan versus amlodipine in diabetic hypertensive patients with or without previous cardiovascular disease.
Topics: Aged; Amlodipine; Antihypertensive Agents; Cardiovascular Diseases; Case-Control Studies; Death, Sud | 2013 |
Long-term effects of irbesartan on plasma aldosterone concentration and left atrial volume in hypertensive patients.
Topics: Aged; Aldosterone; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Atrial Remodeling; Biphenyl | 2014 |
Echocardiographic changes and treatment goal rates after a 6-month combined treatment with amlodipine and losartan: a validation study in Andean countries (METAL study).
Topics: Aged; Albuminuria; Amlodipine; Antihypertensive Agents; Blood Pressure; Dose-Response Relationship, | 2013 |
Daytime systolic ambulatory blood pressure with a direct switch between candesartan monotherapy and the fixed-dose combination olmesartan/amlodipine in patients with uncontrolled essential hypertension (SEVICONTROL-1).
Topics: Aged; Amlodipine; Angiotensin Receptor Antagonists; Antihypertensive Agents; Benzimidazoles; Bipheny | 2013 |
Comparative effects of telmisartan and valsartan as add-on agents for hypertensive patients with morning blood pressure insufficiently controlled by amlodipine monotherapy.
Topics: Adult; Aged; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimida | 2014 |
Comparative effectiveness of a fixed-dose combination of losartan + HCTZ versus bisoprolol + HCTZ in patients with moderate-to-severe hypertension: results of the 6-month ELIZA trial.
Topics: Adrenergic beta-1 Receptor Antagonists; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihyp | 2013 |
[Blood pressure lowering efficacy of telmisartan and amlodipine taking on the morning or at bedtime: ABPM results].
Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Benzimidazoles; Benzoates; Blood Pressure Monitori | 2013 |
Genetic algorithm guided population pharmacokinetic model development for simvastatin, concurrently or non-concurrently co-administered with amlodipine.
Topics: Adult; Aged; Algorithms; Amlodipine; Drug Interactions; Drug Therapy, Combination; Female; Humans; H | 2014 |
Stenting and medical therapy for atherosclerotic renal-artery stenosis.
Topics: Aged; Amlodipine; Angioplasty, Balloon; Angiotensin II Type 1 Receptor Blockers; Anticholesteremic A | 2014 |
Effect of aliskiren in chronic kidney disease patients with refractory hypertension undergoing hemodialysis: a randomized controlled multicenter study.
Topics: Aged; Amides; Amlodipine; Antihypertensive Agents; Calcium Channel Blockers; Female; Fumarates; Huma | 2014 |
Amlodipine reduces blood pressure during dynamic resistance exercise in hypertensive patients.
Topics: Adult; Amlodipine; Arterial Pressure; Calcium Channel Blockers; Cross-Over Studies; Double-Blind Met | 2015 |
[Endothelial dysfunction is a target for combination antihypertensive therapy in hypertensive patients with type 2 diabetes mellitus].
Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Comorbidity; Diabetes Mellitus, Type 2; Drug Combi | 2013 |
Risk of hospitalized gastrointestinal bleeding in persons randomized to diuretic, ACE-inhibitor, or calcium-channel blocker in ALLHAT.
Topics: Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Calcium Channel | 2013 |
The fixed-dose combination of olmesartan/amlodipine was superior in central aortic blood pressure reduction compared with perindopril/amlodipine: a randomized, double-blind trial in patients with hypertension.
Topics: Adult; Aged; Amlodipine; Confidence Intervals; Dose-Response Relationship, Drug; Double-Blind Method | 2013 |
Comparison of the effects of amlodipine and losartan on blood pressure and diurnal variation in hypertensive stroke patients: a prospective, randomized, double-blind, comparative parallel study.
Topics: Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Ci | 2013 |
The effect of antihypertensive agents on sleep apnea: protocol for a randomized controlled trial.
Topics: Adult; Amlodipine; Antihypertensive Agents; Blood Pressure; Blood Pressure Monitoring, Ambulatory; C | 2014 |
A randomized, double-blind study to evaluate the efficacy and safety of a single-pill combination of telmisartan 80 mg/amlodipine 5 mg versus amlodipine 5 mg in hypertensive Asian patients.
Topics: Aged; Amlodipine; Antihypertensive Agents; Benzimidazoles; Benzoates; Blood Pressure; Double-Blind M | 2014 |
Comparative effect of canrenone or hydrochlorothiazide addition to valsartan/amlodipine combination on urinary albumin excretion in well-controlled type 2 diabetic hypertensive patients with microalbuminuria.
Topics: Adult; Aged; Albuminuria; Amlodipine; Amlodipine, Valsartan Drug Combination; Antihypertensive Agent | 2014 |
Daytime systolic ambulatory blood pressure with a two-step switch from candesartan to olmesartan monotherapy and the fixed-dose combination of olmesartan/amlodipine in patients with uncontrolled essential hypertension (SEVICONTROL-2).
Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Blood Pressure | 2014 |
[Possibilities of rational combination antihypertensive therapy: results of HEMERA international clinical trial].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amlodipine; Antihypertensive Agents; Blood Pressure; Diu | 2013 |
TRIple pill vs Usual care Management for Patients with mild-to-moderate Hypertension (TRIUMPH): Study protocol.
Topics: Adult; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Benzoates; Blood Pressur | 2014 |
Effects of combining azilsartan medoxomil with amlodipine in patients with stage 2 hypertension.
Topics: Aged; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; | 2014 |
The effect of aliskiren versus ramipril-based treatment on the Ambulatory Arterial Stiffness Index in hypertensive patients.
Topics: Adult; Aged; Amides; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; | 2014 |
Efficacy and safety of olmesartan/amlodipine/hydrochlorothiazide in patients with hypertension not at goal with mono, dual or triple drug therapy: results of the CHAMPiOn study.
Topics: Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Dr | 2014 |
ABCB1 polymorphism and gender affect the pharmacokinetics of amlodipine in Chinese patients with essential hypertension: a population analysis.
Topics: Adult; Aged; Amlodipine; Asian People; ATP Binding Cassette Transporter, Subfamily B; Blood Pressure | 2014 |
Sex differences in response to angiotensin II receptor blocker-based therapy in elderly, high-risk, hypertensive Japanese patients: a subanalysis of the OSCAR study.
Topics: Age Factors; Aged; Aged, 80 and over; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Asian Peo | 2014 |
Aliskiren alone or with other antihypertensives in the elderly with borderline and stage 1 hypertension: the APOLLO trial.
Topics: Aged; Amides; Amlodipine; Antihypertensive Agents; Blood Pressure; Double-Blind Method; Drug Therapy | 2014 |
Triple-combination treatment with olmesartan medoxomil/amlodipine/ hydrochlorothiazide in Hispanic/Latino patients with hypertension: the TRINITY study.
Topics: Aged; Amlodipine; Antihypertensive Agents; Double-Blind Method; Female; Hispanic or Latino; Humans; | 2014 |
[Impact of combination antihypertensive therapy on heart rate variability parameters and target organ status in patients with arterial hypertension and type 2 diabetes mellitus].
Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Comorbidity; Diabetes Mellitus, Type 2; Drug Thera | 2013 |
[Organoprotective and metabolic effects of S-amlodipine in patients with arterial hypertension].
Topics: Adult; Amlodipine; Blood Pressure; Calcium Channel Blockers; Female; Follow-Up Studies; Humans; Hype | 2013 |
Impact of azelnidipine and amlodipine on left ventricular mass and longitudinal function in hypertensive patients with left ventricular hypertrophy.
Topics: Adult; Aged; Amlodipine; Analysis of Variance; Azetidinecarboxylic Acid; Calcium Channel Blockers; D | 2014 |
The efficacy and safety of arotinolol combined with a different calcium channel blocker in the treatment of Chinese patients with essential hypertension: a one-year follow-up study.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Amlodipine; Anti | 2014 |
Reduction in cardiovascular risk using a proactive multifactorial intervention is consistent among patients residing in Pacific Asian and non-Pacific Asian regions: a CRUCIAL trial subanalysis.
Topics: Aged; Amlodipine; Antihypertensive Agents; Asia; Calcium Channel Blockers; Cardiovascular Diseases; | 2014 |
Blood pressure control with a single-pill combination of indapamide sustained-release and amlodipine in patients with hypertension: the EFFICIENT study.
Topics: Adult; Amlodipine; Antihypertensive Agents; Blood Pressure; Delayed-Action Preparations; Drug Combin | 2014 |
Effect of chlorthalidone, amlodipine, and lisinopril on visit-to-visit variability of blood pressure: results from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial.
Topics: Acute Coronary Syndrome; Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensiv | 2014 |
Evaluation of the efficacy and tolerability of fixed-dose combination therapy of azilsartan and amlodipine besylate in Japanese patients with grade I to II essential hypertension.
Topics: Aged; Amlodipine; Antihypertensive Agents; Asian People; Benzimidazoles; Dose-Response Relationship, | 2014 |
Open-label study assessing the long-term efficacy and safety of triple olmesartan/amlodipine/hydrochlorothiazide combination therapy for hypertension.
Topics: Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Do | 2014 |
Blood pressure control and cardiovascular outcomes in normal-weight, overweight, and obese hypertensive patients treated with three different antihypertensives in ALLHAT.
Topics: Aged; Aged, 80 and over; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agen | 2014 |
Efficacy of olmesartan/amlodipine combination therapy in reducing ambulatory blood pressure in moderate-to-severe hypertensive patients not controlled by amlodipine alone.
Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Blood Pressure Monitoring, Ambulat | 2014 |
Differential effects of azelnidipine and amlodipine on sympathetic nerve activity in patients with primary hypertension.
Topics: Amlodipine; Antihypertensive Agents; Azetidinecarboxylic Acid; Baroreflex; Blood Pressure; Calcium C | 2014 |
Greater efficacy of aldosterone blockade and diuretic reinforcement vs. dual renin-angiotensin blockade for left ventricular mass regression in patients with resistant hypertension.
Topics: Adolescent; Adult; Aged; Aldosterone; Amiloride; Amlodipine; Angiotensin II Type 1 Receptor Blockers | 2014 |
Characteristics and long-term follow-up of participants with peripheral arterial disease during ALLHAT.
Topics: Aged; Amlodipine; Antihypertensive Agents; Chlorthalidone; Double-Blind Method; Female; Follow-Up St | 2014 |
Comparison of the antialbuminuric effects of benidipine and hydrochlorothiazide in Renin-Angiotensin System (RAS) inhibitor-treated hypertensive patients with albuminuria: the COSMO-CKD (COmbination Strategy on Renal Function of Benidipine or Diuretics Tr
Topics: Adult; Aged; Albuminuria; Amlodipine; Blood Pressure; Dihydropyridines; Female; Glomerular Filtratio | 2014 |
Functional vascular study in hypertensive subjects with type 2 diabetes using losartan or amlodipine.
Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Blood Pressure Monitoring, Ambulat | 2014 |
The effects of calcium channel blockers on nephropathy and pigment epithelium-derived factor in the treatment of hypertensive patients with type 2 diabetes mellitus.
Topics: Aged; Albuminuria; Amlodipine; Blood Pressure; Calcium Channel Blockers; Creatinine; Diabetes Mellit | 2015 |
Efficacy and safety of olmesartan medoxomil/amlodipine fixed-dose combination for hypertensive patients uncontrolled with monotherapy.
Topics: Adolescent; Adult; Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; China; Double-Blind Me | 2014 |
[The influence of citoflavin on molecular mechanisms of hypertensive encephalopathy development in patients with systolic arterial hypertension].
Topics: Aged; Aged, 80 and over; Amlodipine; Aspirin; Atorvastatin; Blood Pressure; Blood Proteins; Drug Com | 2014 |
Efficacy and tolerability of amlodipine camsylate/losartan 5/100-mg versus losartan/hydrochlorothiazide 100/12.5-mg fixed-dose combination in hypertensive patients nonresponsive to losartan 100-mg monotherapy.
Topics: Adult; Amlodipine; Antihypertensive Agents; Blood Pressure; Double-Blind Method; Drug Combinations; | 2014 |
[Optimization of arterial hypertension management by the use of two- and three-drugs fixed dose combinations at the daily stay department].
Topics: Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Da | 2014 |
[Fixed irbesartan/amlodipine combination: efficacy and safety of the use of four dosing regimens in patients with arterial hypertension].
Topics: Aged; Amlodipine; Antihypertensive Agents; Biphenyl Compounds; Blood Pressure; Dose-Response Relatio | 2014 |
[Postregistration study of comparative assessment efficacy of the use of fixed combination of nebivolol and amlodipine for the treatment of patients with moderate and high degree of arterial hypertension].
Topics: Adult; Amlodipine; Antihypertensive Agents; Benzopyrans; Blood Pressure; Blood Pressure Monitoring, | 2014 |
Efficacy and safety of the dual L- and T-type calcium channel blocker, ACT-280778: a proof-of-concept study in patients with mild-to-moderate essential hypertension.
Topics: Administration, Oral; Adult; Aged; Amlodipine; Antihypertensive Agents; Benzimidazoles; Blood Pressu | 2015 |
Efficacy and tolerability of triple-combination therapy with olmesartan, amlodipine, and hydrochlorothiazide: a subgroup analysis of patients stratified by hypertension severity, age, sex, and obesity.
Topics: Adult; Age Factors; Aged; Amlodipine; Blood Pressure; Body Mass Index; Dose-Response Relationship, D | 2014 |
Effects of different antihypertensive drugs on blood pressure variability in patients with ischemic stroke.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Amlodipine; Antihypertensive Agents; Blood Pre | 2014 |
Aortic remodelling following the treatment and regression of hypertensive left ventricular hypertrophy: a cardiovascular magnetic resonance study.
Topics: Adult; Aged; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Aorta, Th | 2015 |
Efficacy and safety of fixed-dose losartan/hydrochlorothiazide/amlodipine combination versus losartan/hydrochlorothiazide combination in Japanese patients with essential hypertension.
Topics: Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Drug Combinations; Drug Monitoring; Essen | 2015 |
Efficacy and safety of fixed-dose losartan/hydrochlorothiazide/amlodipine combination versus losartan/hydrochlorothiazide combination in Japanese patients with essential hypertension.
Topics: Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Drug Combinations; Drug Monitoring; Essen | 2015 |
Efficacy and safety of fixed-dose losartan/hydrochlorothiazide/amlodipine combination versus losartan/hydrochlorothiazide combination in Japanese patients with essential hypertension.
Topics: Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Drug Combinations; Drug Monitoring; Essen | 2015 |
Efficacy and safety of fixed-dose losartan/hydrochlorothiazide/amlodipine combination versus losartan/hydrochlorothiazide combination in Japanese patients with essential hypertension.
Topics: Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Drug Combinations; Drug Monitoring; Essen | 2015 |
[Correction of endothelial dysfunction in hypertensive patients with type 2 diabetes mellitus during combined antihypertensive therapy].
Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Blood Flow Velocity; Blood Glucose; Blood Pressure | 2014 |
Evening versus morning dosing of antihypertensive drugs in hypertensive patients with sleep apnoea: a cross-over study.
Topics: Adult; Amlodipine; Antihypertensive Agents; Blood Pressure; Blood Pressure Monitoring, Ambulatory; C | 2015 |
Fixed-dose combination of losartan and hydrochlorothiazide significantly improves endothelial function in uncontrolled hypertension by low-dose amlodipine: a randomized study.
Topics: Aged; Amlodipine; Antihypertensive Agents; Brachial Artery; Drug Therapy, Combination; Endothelium, | 2014 |
Comparison of single-pill strategies first line in hypertension: perindopril/amlodipine versus valsartan/amlodipine.
Topics: Adult; Aged; Amlodipine; Amlodipine, Valsartan Drug Combination; Antihypertensive Agents; Blood Pres | 2015 |
Endocan, a novel marker of endothelial dysfunction in patients with essential hypertension: comparative effects of amlodipine and valsartan.
Topics: Adult; Amlodipine; Antihypertensive Agents; Blood Pressure; C-Reactive Protein; Endothelium, Vascula | 2015 |
Effects of lercanidipine versus amlodipine in hypertensive patients with cerebral ischemic stroke.
Topics: Aged; Amlodipine; Antihypertensive Agents; Blood Pressure Monitoring, Ambulatory; Brain Ischemia; Di | 2015 |
Stroke outcomes among participants randomized to chlorthalidone, amlodipine or lisinopril in ALLHAT.
Topics: Age Factors; Aged; Amlodipine; Cause of Death; Chlorthalidone; Confidence Intervals; Dose-Response R | 2014 |
Randomized evaluation of a novel, fixed-dose combination of perindopril 3.5 mg/amlodipine 2.5 mg as a first-step treatment in hypertension.
Topics: Adolescent; Adult; Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Double-Blind Method; D | 2015 |
[A fixed-dose lisinopril and amlodipine combination in conjunction with rosuvastatin in patients with hypertensive disease and coronary heart disease].
Topics: Amlodipine; Antihypertensive Agents; Blood Pressure; Coronary Disease; Dose-Response Relationship, D | 2014 |
Amlodipine+benazepril is superior to hydrochlorothiazide+benazepril irrespective of baseline pulse pressure: subanalysis of the ACCOMPLISH trial.
Topics: Aged; Amlodipine; Antihypertensive Agents; Benzazepines; Blood Pressure; Double-Blind Method; Drug T | 2015 |
Pharmacogenomics of hypertension: a genome‐wide, placebo‐controlled cross‐over study, using four classes of antihypertensive drugs.
Topics: Adult; Aldehyde Oxidoreductases; Amlodipine; Antihypertensive Agents; Benzimidazoles; Biphenyl Compo | 2015 |
Treatment of Hypertensive Patients With Diabetes and Microalbuminuria With Combination Indapamide SR/Amlodipine: Retrospective Analysis of NESTOR.
Topics: Aged; Albuminuria; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Ca | 2015 |
Age-related difference in the sleep pressure-lowering effect between an angiotensin II receptor blocker and a calcium channel blocker in Asian hypertensives: the ACS1 Study.
Topics: Administration, Oral; Aged; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Blo | 2015 |
[Effectiveness and safety of losartan and its combination with amlodipine in therapy of arterial hypertension].
Topics: Aged; Amlodipine; Antihypertensive Agents; Drug Therapy, Combination; Female; Humans; Hypertension; | 2013 |
Add-on effect of hydrochlorothiazide 12.5 mg in Japanese subjects with essential hypertension uncontrolled with losartan 50 mg and amlodipine 5 mg.
Topics: Adult; Aged; Aged, 80 and over; Amlodipine; Antihypertensive Agents; Blood Pressure; Double-Blind Me | 2015 |
[The influence of combined therapy with calcium antagonist and angiotensin-converting enzyme inhibitor on the circadian profile of arterial pressure in patients with arterial hypertension in the Far North].
Topics: Adult; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Blood Pressure; Calcium Channel Blocker | 2014 |
Curative effect of amlodipine combined with enalapril in curing hypertension of the aged.
Topics: Age Factors; Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Bl | 2015 |
[Changes of twenty-four-hour profile blood pressure and its correction of patients with arterial hypertension on the background of combined antihypertensive therapy application].
Topics: Amlodipine; Antihypertensive Agents; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Drug Com | 2014 |
[Amlodipine and bisoprolol application in patients with arterial hypertension].
Topics: Amlodipine; Antihypertensive Agents; Bisoprolol; Blood Pressure; Blood Pressure Monitoring, Ambulato | 2014 |
Efficacy and safety of perindopril arginine + amlodipine in hypertension.
Topics: Amlodipine; Antihypertensive Agents; Diabetes Mellitus; Double-Blind Method; Drug Therapy, Combinati | 2015 |
A multicenter, non-comparative study to evaluate the efficacy and safety of fixed-dose olmesartan/amlodipine in Korean patients with hypertension who are naïve or non-responders to anti-hypertensive monotherapy (ACE-HY study).
Topics: Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Pressure; | 2015 |
A Randomized, Multicenter, Double-blind, Placebo-controlled, 3 × 3 Factorial Design, Phase II Study to Evaluate the Efficacy and Safety of the Combination of Fimasartan/Amlodipine in Patients With Essential Hypertension.
Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Biphenyl Compounds; Blood Pressure; Double-Blind M | 2015 |
Visit-to-visit variability and seasonal variation in blood pressure: Combination of Antihypertensive Therapy in the Elderly, Multicenter Investigation (CAMUI) Trial subanalysis.
Topics: Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Drug Therapy, Combination; Female; Humans | 2015 |
Health-related quality of life impact of a triple combination of olmesartan medoxomil, amlodipine besylate and hydrochlorotiazide in subjects with hypertension.
Topics: Adult; Aged; Amlodipine; Analysis of Variance; Antihypertensive Agents; Drug Combinations; Female; H | 2015 |
Association of the ADRB2 (rs2053044) polymorphism and angiotensin-converting enzyme-inhibitor blood pressure response in the African American Study of Kidney Disease and Hypertension.
Topics: 5' Untranslated Regions; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Black or African Amer | 2015 |
Differing Effects of Aliskiren/Amlodipine Combination and High-Dose Amlodipine Monotherapy on Ambulatory Blood Pressure and Target Organ Protection.
Topics: Aged; Aged, 80 and over; Amides; Amlodipine; Antihypertensive Agents; Blood Pressure; Blood Pressure | 2016 |
Adding Hydrochlorothiazide to Olmesartan/Amlodipine Increases Efficacy in Patients With Inadequate Blood Pressure Control on Dual-Combination Therapy.
Topics: Adult; Aged; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Blood Pressure; Blood Pressure Mon | 2016 |
Choice of Antihypertensive Combination Therapy Based on Daily Salt Intake.
Topics: Aged; Amlodipine; Amlodipine, Valsartan Drug Combination; Antihypertensive Agents; Blood Pressure; D | 2015 |
A study about the relevance of adding acetylsalicylic acid in primary prevention in subjects with type 2 diabetes mellitus: effects on some new emerging biomarkers of cardiovascular risk.
Topics: Aged; Amlodipine; Antihypertensive Agents; Aspirin; Biomarkers; Calcium Channel Blockers; Cardiovasc | 2015 |
Antidepressant medication can improve hypertension in elderly patients with depression.
Topics: Aged; Aged, 80 and over; Amlodipine; Antidepressive Agents; Antihypertensive Agents; Citalopram; Dep | 2015 |
Efficacy and safety of two single-pill fixed-dose combinations of angiotensin II receptor blockers/calcium channel blockers in hypertensive patients (EXAMINER study).
Topics: Aged; Amlodipine; Antihypertensive Agents; Biphenyl Compounds; Blood Pressure; Dose-Response Relatio | 2016 |
Fixed-Combination Olmesartan/Amlodipine Was Superior to Perindopril + Amlodipine in Reducing Central Systolic Blood Pressure in Hypertensive Patients With Diabetes.
Topics: Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Diabetes Mellitus, Type 2; Double-Blind M | 2016 |
Renin-Angiotensin System Blockade Associated with Statin Improves Endothelial Function in Diabetics.
Topics: Amino Acids; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Benzazep | 2015 |
[Pharmacoeconomic Efficacy of a Fixed Combination of Bisoprolol and Amlodipine].
Topics: Aged; Amlodipine; Antihypertensive Agents; Aorta; Bisoprolol; Blood Pressure; Costs and Cost Analysi | 2015 |
No evidence for a J-shaped curve in treated hypertensive patients with increased cardiovascular risk: The VALUE trial.
Topics: Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Blood Pressure Determination; Coronary Ar | 2016 |
Age- and Sex-Related Differences in Efficacy With an Angiotensin II Receptor Blocker and a Calcium Channel Blocker in Asian Hypertensive Patients.
Topics: Age Factors; Aged; Amlodipine; Angiotensin Receptor Antagonists; Asian People; Benzimidazoles; Calci | 2016 |
[The Antihypertensive Effect of the Fixed Combination of Lisinopril and Amlodipine in Patients With Coronary Heart Disease After Coronary Artery Bypass Grafting].
Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Coronary Artery Bypass; Coronary A | 2015 |
Efficacy and Safety Study of Olmesartan Medoxomil, Amlodipine, and Hydrochlorothiazide Combination Therapy in Patients with Hypertension Not Controlled with Olmesartan Medoxomil and Hydrochlorothiazide Combination Therapy: Results of a Randomized, Double-
Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Double-Blind Method; Drug Therapy, | 2016 |
Comparison of telmisartan/amlodipine and telmisartan/hydrochlorothiazide in the treatment of Japanese patients with uncontrolled hypertension: the TAT-Kobe study.
Topics: Aged; Aged, 80 and over; Amlodipine; Benzimidazoles; Benzoates; Drug Therapy, Combination; Female; H | 2016 |
Effect of Diuretic or Calcium-Channel Blocker Plus Angiotensin-Receptor Blocker on Diastolic Function in Hypertensive Patients.
Topics: Adult; Aged; Aged, 80 and over; Amlodipine; Angiotensin Receptor Antagonists; Blood Pressure; Calciu | 2016 |
[Cardio-Nephroprotection--the Most Important Goal of Antihypertensive Therapy in Patients With Type 2 Diabetes].
Topics: Adult; Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Blood Pressure; Calcium Channel B | 2015 |
Efficacy and Safety of Fixed-Dose Perindopril Arginine/Amlodipine in Hypertensive Patients Not Adequately Controlled with Amlodipine 5 mg or Perindopril tert-Butylamine 4 mg Monotherapy.
Topics: Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Double-Blind Method; Drug Combinations; D | 2016 |
Predictors of cardiac morbidity in diabetic, new-onset diabetic and non-diabetic high-risk hypertensive patients: The Valsartan Antihypertensive Long-term Use Evaluation (VALUE) trial.
Topics: Amlodipine; Antihypertensive Agents; Blood Pressure; Diabetes Complications; Female; Heart Failure; | 2016 |
Long-term effects of L- and N-type calcium channel blocker on uric acid levels and left atrial volume in hypertensive patients.
Topics: Amlodipine; Atrial Function, Left; Atrial Remodeling; Biomarkers; Blood Pressure; Calcium Channel Bl | 2016 |
Comparative study of the efficacy of olmesartan/amlodipine vs. perindopril/amlodipine in peripheral blood pressure after missed dose in type 2 diabetes.
Topics: Adult; Aged; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhi | 2016 |
The Effects of Valsartan and Amlodipine on the Levels of Irisin, Adropin, and Perilipin.
Topics: Adult; Amlodipine; Antihypertensive Agents; Blood Proteins; Calcium; Carrier Proteins; Female; Fibro | 2015 |
Effects of aerobic dance training on blood pressure in individuals with uncontrolled hypertension on two antihypertensive drugs: a randomized clinical trial.
Topics: Adult; Aged; Amiloride; Amlodipine; Antihypertensive Agents; Blood Pressure Determination; Combined | 2016 |
[New drug combination for initial therapy].
Topics: Amlodipine; Dose-Response Relationship, Drug; Drug Combinations; Europe; Humans; Hypertension; Perin | 2016 |
Dose Timing of an Angiotensin II Receptor Blocker/Calcium Channel Blocker Combination in Hypertensive Patients With Paroxysmal Atrial Fibrillation.
Topics: Amlodipine; Angiotensin II Type 1 Receptor Blockers; Atrial Fibrillation; Benzimidazoles; Benzoates; | 2016 |
Combination With Low-dose Dextromethorphan Improves the Effect of Amlodipine Monotherapy in Clinical Hypertension: A First-in-human, Concept-proven, Prospective, Dose-escalation, Multicenter Study.
Topics: Amlodipine; Antihypertensive Agents; Dextromethorphan; Drug Therapy, Combination; Female; Humans; Hy | 2016 |
Olmesartan Combined With Amlodipine on Oxidative Stress Parameters in Type 2 Diabetics, Compared With Single Therapies: A Randomized, Controlled, Clinical Trial.
Topics: Adult; Amlodipine; Antihypertensive Agents; Aryldialkylphosphatase; Blood Pressure; Body Mass Index; | 2016 |
Benefits of Fixed Dose Combination of Ramipril/Amlodipine in Hypertensive Diabetic Patients: A Subgroup Analysis of RAMONA Trial.
Topics: Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Pressure; | 2016 |
Comparative Study of the Efficacy of Olmesartan/Amlodipine vs. Perindopril/Amlodipine in Peripheral and Central Blood Pressure Parameters After Missed Dose in Type 2 Diabetes.
Topics: Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Diabetes Mellitus, Type 2; Female; Humans | 2016 |
Clinical and demographic correlates of medication and visit adherence in a large randomized controlled trial.
Topics: Aged; Amlodipine; Antihypertensive Agents; Appointments and Schedules; Black People; Chlorthalidone; | 2016 |
Short-Term Cardioprotective Effects of the Original Perindopril/Amlodipine Fixed-Dose Combination in Patients with Stable Coronary Artery Disease: Results of the PAPA-CAD Study.
Topics: Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Ca | 2016 |
A Randomized, Double-blind, Multicenter, Phase III Study to Evaluate the Efficacy and Safety of Fimasartan/Amlodipine Combined Therapy Versus Fimasartan Monotherapy in Patients With Essential Hypertension Unresponsive to Fimasartan Monotherapy.
Topics: Aged; Amlodipine; Antihypertensive Agents; Biphenyl Compounds; Blood Pressure; Double-Blind Method; | 2016 |
The efficacy and long-term safety of a triple combination of 80 mg telmisartan, 5 mg amlodipine and 12.5 mg hydrochlorothiazide in Japanese patients with essential hypertension: a randomized, double-blind study with open-label extension.
Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Benzimidazoles; Benzoates; Blood Pressure; Double- | 2017 |
Leg edema with (S)-amlodipine vs conventional amlodipine given in triple therapy for hypertension: a randomized double blind controlled clinical trial.
Topics: Adult; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Pressure | 2016 |
Treatment-associated change in apelin concentration in patients with hypertension and its relationship with left ventricular diastolic function.
Topics: Amlodipine; Antihypertensive Agents; Apelin; Biomarkers; Case-Control Studies; Echocardiography; Fem | 2017 |
Comparison of the Efficacy and Safety of Fixed-dose S-Amlodipine/Telmisartan and Telmisartan in Hypertensive Patients Inadequately Controlled with Telmisartan: A Randomized, Double-blind, Multicenter Study.
Topics: Amlodipine; Antihypertensive Agents; Benzimidazoles; Benzoates; Blood Pressure; Double-Blind Method; | 2016 |
Effect of hydrochlorothiazide in addition to telmisartan/amlodipine combination for treating hypertensive patients uncontrolled with telmisartan/amlodipine: a randomized, double-blind study.
Topics: Adult; Aged; Aged, 80 and over; Amlodipine; Antihypertensive Agents; Benzimidazoles; Benzoates; Doub | 2017 |
Differential effects of lercanidipine/enalapril versus amlodipine/enalapril and hydrochlorothiazide/enalapril on target organ damage and sympathetic activation in non-obese essential hypertensive subjects.
Topics: Adult; Amlodipine; Antihypertensive Agents; Blood Pressure; Blood Pressure Monitoring, Ambulatory; D | 2016 |
Lercanidipine valuable effect on urine protein losses: the RED LEVEL study.
Topics: Aged; Albuminuria; Amlodipine; Antihypertensive Agents; Blood Pressure; Dihydropyridines; Double-Bli | 2016 |
Factors associated with the reduction of albumin excretion in diabetic hypertensive patients: differential effect of manidipine versus amlodipine.
Topics: Adult; Aged; Albumins; Albuminuria; Amlodipine; Antihypertensive Agents; Blood Pressure; Diabetes Me | 2017 |
Effect of losartan combined with amlodipine or with a thiazide on uric acid levels in hypertensive patients.
Topics: Amlodipine; Antihypertensive Agents; Biomarkers; Blood Pressure; Dose-Response Relationship, Drug; D | 2017 |
Electrocardiographic measures of left ventricular hypertrophy in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial.
Topics: Aged; Amlodipine; Antihypertensive Agents; Chlorthalidone; Electrocardiography; Female; Humans; Hype | 2016 |
Treatment-Resistant Hypertension and Outcomes Based on Randomized Treatment Group in ALLHAT.
Topics: Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Cardiovascular Diseases; Chlorthalidone; | 2017 |
Efficacy and safety of sacubitril/valsartan (LCZ696) add-on to amlodipine in Asian patients with systolic hypertension uncontrolled with amlodipine monotherapy.
Topics: Aged; Aminobutyrates; Amlodipine; Angiotensin Receptor Antagonists; Antihypertensive Agents; Asian P | 2017 |
The effects of missed doses of amlodipine and losartan on blood pressure in older hypertensive patients.
Topics: Aged; Aged, 80 and over; Amlodipine; Antihypertensive Agents; Blood Pressure; Double-Blind Method; F | 2017 |
Effects of Amlodipine and Valsartan on Blood Pressure Variability and Pulse Wave Velocity in Hypertensive Patients.
Topics: Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Drug Therapy, Combination; Essential Hype | 2017 |
Quarter-dose quadruple combination therapy for initial treatment of hypertension: placebo-controlled, crossover, randomised trial and systematic review.
Topics: Administration, Oral; Amlodipine; Antihypertensive Agents; Atenolol; Biphenyl Compounds; Blood Press | 2017 |
Chlorthalidone Versus Amlodipine for Hypertension in Kidney Transplant Recipients Treated With Tacrolimus: A Randomized Crossover Trial.
Topics: Aged; Amlodipine; Antihypertensive Agents; Blood Pressure Monitoring, Ambulatory; Chlorthalidone; Cr | 2017 |
Chlorthalidone Versus Amlodipine for Hypertension in Kidney Transplant Recipients Treated With Tacrolimus: A Randomized Crossover Trial.
Topics: Aged; Amlodipine; Antihypertensive Agents; Blood Pressure Monitoring, Ambulatory; Chlorthalidone; Cr | 2017 |
Chlorthalidone Versus Amlodipine for Hypertension in Kidney Transplant Recipients Treated With Tacrolimus: A Randomized Crossover Trial.
Topics: Aged; Amlodipine; Antihypertensive Agents; Blood Pressure Monitoring, Ambulatory; Chlorthalidone; Cr | 2017 |
Chlorthalidone Versus Amlodipine for Hypertension in Kidney Transplant Recipients Treated With Tacrolimus: A Randomized Crossover Trial.
Topics: Aged; Amlodipine; Antihypertensive Agents; Blood Pressure Monitoring, Ambulatory; Chlorthalidone; Cr | 2017 |
Fixed-Dose Triple Combination of Antihypertensive Drugs Improves Blood Pressure Control: From Clinical Trials to Clinical Practice.
Topics: Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Ca | 2017 |
Predictors of new-onset diabetes mellitus in hypertensive patients: the VALUE trial.
Topics: Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Blood Glucose; Blood P | 2008 |
Effect of amlodipine on cardiovascular events in hypertensive haemodialysis patients.
Topics: Aged; Amlodipine; Blood Pressure; Calcium Channel Blockers; Cardiovascular Diseases; Chronic Disease | 2008 |
Effects of a fixed-dose ACE inhibitor-diuretic combination on ambulatory blood pressure and arterial properties in isolated systolic hypertension.
Topics: Aged; Aged, 80 and over; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Blood Pressure; Calci | 2008 |
[Efficacy and organoprotective action of amlodipine in patients with arterial hypertension with metabolic derangements].
Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Female; Follow-Up Studies; Humans; | 2008 |
Predictors of blood pressure response to intensified and fixed combination treatment of hypertension: the ACCOMPLISH study.
Topics: Aged; Amlodipine; Antihypertensive Agents; Benzazepines; Blood Pressure; Dose-Response Relationship, | 2008 |
Short-term electrophysiological effects of losartan, bisoprolol, amlodipine, and hydrochlorothiazide in hypertensive men.
Topics: Action Potentials; Amlodipine; Antihypertensive Agents; Bisoprolol; Blood Pressure; Cross-Over Studi | 2009 |
Effects on plasma noradrenaline may explain some of the improved insulin sensitivity seen by AT-1 receptor blockade.
Topics: Aged; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Blood Pressure; Cross-Over Studies; Doubl | 2008 |
Progressive effects of valsartan compared with amlodipine in prevention of diabetes according to categories of diabetogenic risk in hypertensive patients: the VALUE trial.
Topics: Aged; Amlodipine; Antihypertensive Agents; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Me | 2008 |
Effect of antihypertensive treatment on retinal microvascular changes in hypertension.
Topics: Adult; Amlodipine; Antihypertensive Agents; Blood Pressure; Female; Humans; Hypertension; Lisinopril | 2008 |
An eight-week, multicenter, randomized, double-blind study to evaluate the efficacy and tolerability of fixed-dose amlodipine/benazepril combination in comparison with amlodipine as first-line therapy in chinese patients with mild to moderate hypertension
Topics: Adult; Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Benzazep | 2008 |
Comparison of renal and vascular protective effects between telmisartan and amlodipine in hypertensive patients with chronic kidney disease with mild renal insufficiency.
Topics: Adult; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Benzoates; Blood Pressu | 2008 |
Effects of strict blood pressure control by a long-acting calcium channel blocker on brain natriuretic peptide and urinary albumin excretion rate in Japanese hypertensive patients.
Topics: Albuminuria; Amlodipine; Biomarkers; Blood Pressure; Blood Pressure Monitoring, Ambulatory; C-Reacti | 2008 |
Single-pill amlodipine/atorvastatin helps patients of diverse ethnicity attain recommended goals for blood pressure and lipids (the Gemini-AALA study).
Topics: Administration, Oral; Aged; Amlodipine; Antihypertensive Agents; Atorvastatin; Blood Pressure; Cardi | 2009 |
[Combined antihypertensive and antilipemic therapy as one of the pillars in the poly-pharmacologic preventive strategy for patients with high cardiovascular risk].
Topics: Adult; Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Atorvast | 2008 |
Blood pressure control with amlodipine add-on therapy in patients with hypertension and diabetes: results of the Amlodipine Diabetic Hypertension Efficacy Response Evaluation Trial.
Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Diabetes Mellitus, Type 2; Double-Blind Method; Dr | 2008 |
An 18-week, prospective, randomized, double-blind, multicenter study of amlodipine/ramipril combination versus amlodipine monotherapy in the treatment of hypertension: the assessment of combination therapy of amlodipine/ramipril (ATAR) study.
Topics: Adult; Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Pr | 2008 |
Losartan decreased premature ventricular contractions in patients with hypertension.
Topics: Aged; Amlodipine; Anti-Arrhythmia Agents; Enalapril; Humans; Hypertension; Losartan; Middle Aged; Ve | 2009 |
Hypertensive urgencies in the emergency department: evaluating blood pressure response to rest and to antihypertensive drugs with different profiles.
Topics: Amlodipine; Antihypertensive Agents; Blood Pressure; Combined Modality Therapy; Emergencies; Emergen | 2008 |
The Anglo-Scandinavian Cardiac Outcomes Trial: blood pressure-lowering limb: effects in patients with type II diabetes.
Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Atenolol; Blood Pressure; Cardiovascular Diseases; | 2008 |
ARB candesartan and CCB amlodipine in hypertensive patients: the CASE-J trial.
Topics: Aged; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; | 2008 |
Interaction between antihypertensives and NSAIDs in primary care: a controlled trial.
Topics: Acetaminophen; Aged; Amlodipine; Anti-Inflammatory Agents, Non-Steroidal; Antihypertensive Agents; B | 2008 |
Beneficial effects of combination therapy with angiotensin II receptor blocker and angiotensin-converting enzyme inhibitor on vascular endothelial function.
Topics: Aged; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; | 2008 |
Effect of valsartan addition to amlodipine on insulin sensitivity in overweight-obese hypertensive patients.
Topics: Adult; Aged; Amlodipine; Cross-Over Studies; Drug Therapy, Combination; Female; Humans; Hypertension | 2008 |
[Russian clinical studies: KARDINAL - Cardilopin. The efficacy and quality of life in patients with arterial hypertension].
Topics: Adult; Aged; Amlodipine; Calcium Channel Blockers; Female; Humans; Hypertension; Male; Middle Aged; | 2008 |
Heart failure with preserved and reduced left ventricular ejection fraction in the antihypertensive and lipid-lowering treatment to prevent heart attack trial.
Topics: Adrenergic alpha-Antagonists; Aged; Amlodipine; Antihypertensive Agents; Coronary Disease; Double-Bl | 2008 |
Add-on manidipine versus amlodipine in diabetic patients with hypertension and microalbuminuria: the AMANDHA study.
Topics: Adult; Aged; Albuminuria; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Convertin | 2008 |
Treatment with amlodipine and atorvastatin has additive effect on blood and plaque inflammation in hypertensive patients with carotid atherosclerosis.
Topics: Aged; Amlodipine; Anticholesteremic Agents; Atorvastatin; Blood Pressure; Calcium Channel Blockers; | 2008 |
The diabetes subgroup baseline characteristics of the Avoiding Cardiovascular Events Through Combination Therapy in Patients Living With Systolic Hypertension (ACCOMPLISH) trial.
Topics: Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Benzazepines; Blood Glucose; Blood Press | 2008 |
Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients.
Topics: Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Benzazepines; B | 2008 |
Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients.
Topics: Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Benzazepines; B | 2008 |
Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients.
Topics: Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Benzazepines; B | 2008 |
Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients.
Topics: Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Benzazepines; B | 2008 |
Coadministered amlodipine and atorvastatin produces early improvements in arterial wall compliance in hypertensive patients with dyslipidemia.
Topics: Adult; Aged; Amlodipine; Arteries; Atorvastatin; Compliance; Drug Therapy, Combination; Dyslipidemia | 2009 |
Distinct vascular and metabolic effects of different classes of anti-hypertensive drugs.
Topics: Adipokines; Adiponectin; Adult; Aged; Amlodipine; Antihypertensive Agents; Atenolol; Benzimidazoles; | 2010 |
Efficacy and tolerability of olmesartan medoxomil combined with amlodipine in patients with moderate to severe hypertension after amlodipine monotherapy: a randomized, double-blind, parallel-group, multicentre study.
Topics: Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Calcium Channel Blocke | 2009 |
Comparison of effects of amlodipine and angiotensin receptor blockers on the intima-media thickness of carotid arterial wall (AAA study: amlodipine vs. ARB in atherosclerosis study).
Topics: Aged; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Calcium Channel Blockers; Carotid Arterie | 2009 |
[Economics of nephroprotection in arterial hypertension and type 2 diabetes mellitus].
Topics: Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Biphenyl Compounds; Co | 2008 |
Blood pressure control by drug group in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
Topics: Aged; Aged, 80 and over; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agen | 2008 |
The use of a single-pill calcium channel blocker/statin combination in the management of hypertension and dyslipidemia: a randomized, placebo-controlled, multicenter study.
Topics: Amlodipine; Analysis of Variance; Atorvastatin; Calcium Channel Blockers; Double-Blind Method; Drug | 2009 |
[Effects of amlodipine on blood pressure. Results of cardiovascular tests and heart rate variability in patients with metabolic syndrome].
Topics: Adult; Aged; Amlodipine; Blood Pressure Monitoring, Ambulatory; Calcium Channel Blockers; Female; He | 2008 |
The Phase III, double-blind, parallel-group controlled study of amlodipine 10 mg once daily in Japanese patients with essential hypertension who insufficiently responded to amlodipine 5 mg once daily.
Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Dose-Res | 2009 |
Efficacy and safety of initial combination therapy with amlodipine/valsartan compared with amlodipine monotherapy in black patients with stage 2 hypertension: the EX-STAND study.
Topics: Adult; Aged; Amlodipine; Amlodipine, Valsartan Drug Combination; Antihypertensive Agents; Black Peop | 2009 |
Efficacy and tolerability of amlodipine/valsartan combination therapy in hypertensive patients not adequately controlled on valsartan monotherapy.
Topics: Amlodipine; Antihypertensive Agents; Double-Blind Method; Drug Therapy, Combination; Female; Humans; | 2009 |
Efficacy and safety of the single pill combination of amlodipine 10 mg plus valsartan 160 mg in hypertensive patients not controlled by amlodipine 10 mg plus olmesartan 20 mg in free combination.
Topics: Adult; Aged; Aged, 80 and over; Amlodipine; Cohort Studies; Drug Combinations; Female; Humans; Hyper | 2009 |
The combination of amlodipine/valsartan 5/160 mg produces less peripheral oedema than amlodipine 10 mg in hypertensive patients not adequately controlled with amlodipine 5 mg.
Topics: Aged; Amlodipine; Antihypertensive Agents; Drug Combinations; Edema; Female; Humans; Hypertension; M | 2009 |
Combination of amlodipine 10 mg and valsartan 160 mg lowers blood pressure in patients with hypertension not controlled by an ACE inhibitor/CCB combination.
Topics: Aged; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; | 2008 |
Long-term tolerability and efficacy of the combination of amlodipine/valsartan in hypertensive patients: a 54-week, open-label extension study.
Topics: Amlodipine; Antihypertensive Agents; Double-Blind Method; Drug Therapy, Combination; Female; Humans; | 2009 |
Coronary heart disease benefits from blood pressure and lipid-lowering.
Topics: Amlodipine; Anticholesteremic Agents; Antihypertensive Agents; Atenolol; Atorvastatin; Blood Pressur | 2009 |
[Is the combination of benazepril and amlodipine more effective in hypertension than the combination of benazepril and hydrochlorothiazide? Results of the ACCOMPLISH trial].
Topics: Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Benzazepines; Blood Pressure; Calcium Ch | 2009 |
Add-on benefits of amlodipine and thiazide in nondiabetic chronic kidney disease stage 1/2 patients treated with valsartan.
Topics: Adult; Albuminuria; Amlodipine; Antihypertensive Agents; Blood Pressure; Blood Pressure Monitoring, | 2009 |
Comparison of the antiproteinuric effects of the calcium channel blockers benidipine and amlodipine administered in combination with angiotensin receptor blockers to hypertensive patients with stage 3-5 chronic kidney disease.
Topics: Aged; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Calcium Channel Blockers; Dihydropyridine | 2009 |
Telmisartan plus amlodipine in patients with moderate or severe hypertension: results from a subgroup analysis of a randomized, placebo-controlled, parallel-group, 4 x 4 factorial study.
Topics: Amlodipine; Analysis of Variance; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Benzoates | 2009 |
Antihypertensive pharmacogenetic effect of fibrinogen-beta variant -455G>A on cardiovascular disease, end-stage renal disease, and mortality: the GenHAT study.
Topics: Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Calcium Channel | 2009 |
Efficacy of combined amlodipine/terazosin therapy in male hypertensive patients with lower urinary tract symptoms: a randomized, double-blind clinical trial.
Topics: Adrenergic alpha-Antagonists; Amlodipine; Antihypertensive Agents; Double-Blind Method; Drug Therapy | 2009 |
Influence of nifedipine coat-core and amlodipine on systemic arterial stiffness modulated by sympathetic and parasympathetic activity in hypertensive patients.
Topics: Adult; Aged; Amlodipine; Arteries; Blood Pressure; Calcium Channel Blockers; Female; Heart; Heart Ra | 2009 |
Effects of force-titrated valsartan/hydrochlorothiazide versus amlodipine/hydrochlorothiazide on ambulatory blood pressure in patients with stage 2 hypertension: the EVALUATE study.
Topics: Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Di | 2009 |
Effects of candesartan and amlodipine on cardiovascular events in hypertensive patients with chronic kidney disease: subanalysis of the CASE-J Study.
Topics: Aged; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds; Blood | 2009 |
Combination of amlodipine and enalapril in hypertensive patients with coronary disease.
Topics: Amlodipine; Antihypertensive Agents; Blood Pressure; Coronary Disease; Drug Therapy, Combination; Ed | 2009 |
International open-label studies to assess the efficacy and safety of single-pill amlodipine/atorvastatin in attaining blood pressure and lipid targets recommended by country-specific guidelines: the JEWEL programme.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amlodipine; Anticholesteremic Agents; Antihypertensive A | 2009 |
International open-label studies to assess the efficacy and safety of single-pill amlodipine/atorvastatin in attaining blood pressure and lipid targets recommended by country-specific guidelines: the JEWEL programme.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amlodipine; Anticholesteremic Agents; Antihypertensive A | 2009 |
International open-label studies to assess the efficacy and safety of single-pill amlodipine/atorvastatin in attaining blood pressure and lipid targets recommended by country-specific guidelines: the JEWEL programme.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amlodipine; Anticholesteremic Agents; Antihypertensive A | 2009 |
International open-label studies to assess the efficacy and safety of single-pill amlodipine/atorvastatin in attaining blood pressure and lipid targets recommended by country-specific guidelines: the JEWEL programme.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amlodipine; Anticholesteremic Agents; Antihypertensive A | 2009 |
Efficacy and safety of a stepped-care regimen using olmesartan medoxomil, amlodipine and hydrochlorothiazide in patients with moderate-to-severe hypertension: an open-label, long-term study.
Topics: Adult; Aged; Aged, 80 and over; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Calcium Channel | 2009 |
Effects of candesartan cilexetil on carotid remodeling in hypertensive diabetic patients: the MITEC study.
Topics: Aged; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; | 2009 |
Management of hypertension with the fixed combination of perindopril and amlodipine in daily clinical practice: results from the STRONG prospective, observational, multicenter study.
Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Clinical Medicine; Drug Combinatio | 2009 |
[The study of effects of ramipril and amlodipine combination in patients with arterial hypertension and type 2 diabetes mellitus].
Topics: Adult; Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Blood Pressure; Blood Pressure Mo | 2009 |
Triple antihypertensive therapy with amlodipine, valsartan, and hydrochlorothiazide: a randomized clinical trial.
Topics: Adult; Amlodipine; Antihypertensive Agents; Blood Pressure; Diastole; Double-Blind Method; Drug Ther | 2009 |
Long-term effect of efonidipine therapy on plasma aldosterone and left ventricular mass index in patients with essential hypertension.
Topics: Aged; Aldosterone; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzym | 2009 |
Olmesartan medoxomil plus amlodipine increases efficacy in patients with moderate-to-severe hypertension after monotherapy: a randomized, double-blind, parallel-group, multicentre study.
Topics: Amlodipine; Angiotensin II Type 1 Receptor Blockers; Blood Pressure; Calcium Channel Blockers; Doubl | 2009 |
[Efficacy of calcium antagonists depending on the functional state of parathyroid glands in patients with hypertensive disease].
Topics: Adult; Amlodipine; Blood Pressure; Calcium; Calcium Channel Blockers; Echocardiography, Doppler; Fem | 2009 |
[Amlodipine combined with terazosin reduces postvoid residual and the risk of acute urinary retention].
Topics: Adrenergic alpha-Antagonists; Aged; Amlodipine; Antihypertensive Agents; Double-Blind Method; Drug T | 2009 |
Ambulatory blood pressure monitoring predicts cardiovascular events in treated hypertensive patients--an Anglo-Scandinavian cardiac outcomes trial substudy.
Topics: Aged; Amlodipine; Atenolol; Blood Pressure Monitoring, Ambulatory; Drug Therapy, Combination; Female | 2009 |
Differential effects of antihypertensive treatment on the retinal microcirculation: an anglo-scandinavian cardiac outcomes trial substudy.
Topics: Aged; Amlodipine; Antihypertensive Agents; Atenolol; Cardiovascular Diseases; Dose-Response Relation | 2009 |
[Effects of Songling Xuemaikang Capsule on ambulatory blood pressure in treatment of essential hypertension: a single-blind randomized controlled trial].
Topics: Adult; Aged; Aged, 80 and over; Amlodipine; Antineoplastic Agents; Benzimidazoles; Benzoates; Blood | 2009 |
Manidipine in hypertensive patients with metabolic syndrome: the MARIMBA study.
Topics: Adiponectin; Adult; Aged; Aged, 80 and over; Albuminuria; Amlodipine; Antihypertensive Agents; Blood | 2009 |
ACCOMPLISH the goal: hypertension and beyond.
Topics: Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Benzazepines; Calcium | 2009 |
Results of treatment with telmisartan-amlodipine in hypertensive patients.
Topics: Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; Benzoa | 2009 |
Comparison of olmesartan medoxomil versus amlodipine besylate on regression of ventricular and vascular hypertrophy.
Topics: Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Diastole; Female; Humans; Hypertension; H | 2009 |
Olmesartan ameliorates myocardial function independent of blood pressure control in patients with mild-to-moderate hypertension.
Topics: Aged; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Biomarkers; Blood Pressure; C-Reactive Pr | 2009 |
EXCEED: Exforge-intensive control of hypertension to evaluate efficacy in diastolic dysfunction: study rationale, design, and participant characteristics.
Topics: Aged; Amlodipine; Amlodipine, Valsartan Drug Combination; Antihypertensive Agents; Blood Pressure; D | 2009 |
Treatment of hypertension in metabolic syndrome subjects with amlodipine and olmesartan-effects on oxidized non-esterified free fatty acids and cytokine production.
Topics: Adult; Aged; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Cell Adhe | 2009 |
Additive beneficial effects of atorvastatin combined with amlodipine in patients with mild-to-moderate hypertension.
Topics: Amlodipine; Antihypertensive Agents; Atorvastatin; Cross-Over Studies; Drug Synergism; Drug Therapy, | 2011 |
Magnetic resonance imaging left ventricular mass reduction with fixed-dose angiotensin-converting enzyme inhibitor-based regimens in patients with high-risk hypertension.
Topics: Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Benzazepines; Calcium Channel Blockers; | 2009 |
Comparison of the anti-hypertensive effects of the L/N-type calcium channel antagonist cilnidipine, and the L-type calcium channel antagonist amlodipine in hypertensive patients with cerebrovascular disease.
Topics: Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Calcium Channel | 2009 |
Differences in the magnitude of wave reflection account for differential effects of amlodipine- versus atenolol-based regimens on central blood pressure: an Anglo-Scandinavian Cardiac Outcome Trial substudy.
Topics: Aged; Amlodipine; Antihypertensive Agents; Atenolol; Blood Flow Velocity; Blood Pressure; Brachial A | 2009 |
Atorvastatin treatment is associated with less augmentation of the carotid pressure waveform in hypertension: a substudy of the Anglo-Scandinavian Cardiac Outcome Trial (ASCOT).
Topics: Aged; Amlodipine; Ankle Brachial Index; Anticholesteremic Agents; Antihypertensive Agents; Atorvasta | 2009 |
Subgroup analyses of an efficacy and safety study of concomitant administration of amlodipine besylate and olmesartan medoxomil: evaluation by baseline hypertension stage and prior antihypertensive medication use.
Topics: Amlodipine; Antihypertensive Agents; Blood Pressure; Double-Blind Method; Drug Administration Schedu | 2009 |
Benefits of the angiotensin II receptor antagonist olmesartan in controlling hypertension and cerebral hemodynamics after stroke.
Topics: Acetazolamide; Adult; Aged; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Ag | 2009 |
Protective effects of efonidipine, a T- and L-type calcium channel blocker, on renal function and arterial stiffness in type 2 diabetic patients with hypertension and nephropathy.
Topics: 8-Hydroxy-2'-Deoxyguanosine; Aged; Aldosterone; Amlodipine; Arteries; Calcium Channel Blockers; Calc | 2009 |
Efficacy and tolerability of amlodipine/valsartan combination therapy in hypertensive patients not adequately controlled on amlodipine monotherapy.
Topics: Adult; Aged; Aged, 80 and over; Algorithms; Amlodipine; Antihypertensive Agents; Blood Pressure; Dou | 2009 |
Baseline heart rate, antihypertensive treatment, and prevention of cardiovascular outcomes in ASCOT (Anglo-Scandinavian Cardiac Outcomes Trial).
Topics: Aged; Amlodipine; Antihypertensive Agents; Atenolol; Bendroflumethiazide; Coronary Disease; Europe; | 2009 |
Azelnidipine and amlodipine anti-coronary atherosclerosis trial in hypertensive patients undergoing coronary intervention by serial volumetric intravascular ultrasound analysis in Juntendo university (ALPS-J).
Topics: Adult; Aged; Amlodipine; Azetidinecarboxylic Acid; Calcium Channel Blockers; Coronary Artery Disease | 2009 |
Additive antihypertensive and antihypertrophic effects of long-acting Ca blockers in uncontrolled hypertensive patients with angiotensin-receptor blocker based treatment.
Topics: Aged; Amlodipine; Benzimidazoles; Biphenyl Compounds; Calcium Channel Blockers; Drug Therapy, Combin | 2009 |
[An experience of the use of a fixed atenolol amlodipine combination in real clinical practice: results of multicenter Russian study].
Topics: Administration, Oral; Adolescent; Adult; Amlodipine; Atenolol; Blood Pressure; Dose-Response Relatio | 2009 |
Comparative efficacy and safety of amlodipine/benazepril combination therapy and amlodipine monotherapy in severe hypertension.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amlodipine; Antihypertensive Agents; Benzazepines; Chron | 2010 |
Randomized study to compare valsartan +/- HCTZ versus amlodipine +/- HCTZ strategies to maximize blood pressure control.
Topics: Adult; Aged; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Blood Pre | 2009 |
Effects of olmesartan, an angiotensin II receptor blocker, and amlodipine, a calcium channel blocker, on Cardio-Ankle Vascular Index (CAVI) in type 2 diabetic patients with hypertension.
Topics: 8-Hydroxy-2'-Deoxyguanosine; Aged; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Ankle; Antih | 2009 |
CYP3A4 and CYP3A5 polymorphisms and blood pressure response to amlodipine among African-American men and women with early hypertensive renal disease.
Topics: Aged; Alleles; Amlodipine; Black or African American; Blood Pressure; Cytochrome P-450 CYP3A; Female | 2010 |
Assessing medication adherence simultaneously by electronic monitoring and pill count in patients with mild-to-moderate hypertension.
Topics: Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Blood Pressure Determination; Double-Blin | 2010 |
Effect of self-measurement of blood pressure on adherence to treatment in patients with mild-to-moderate hypertension.
Topics: Amlodipine; Antihypertensive Agents; Blood Pressure; Double-Blind Method; Humans; Hydrochlorothiazid | 2010 |
Successful treatment of hypertension accounts for improvements in markers of diastolic function - a pilot study comparing hydrochlorothiazide-based and amlodipine-based treatment strategies.
Topics: Amlodipine; Antihypertensive Agents; Blood Pressure; Drug Therapy, Combination; Female; Humans; Hydr | 2009 |
[Effects of amlodipine plus telmisartan or amlodipine plus amiloride regimen on blood pressure control in hypertensive patients: preliminary report of Chinese Hypertension Intervention Efficacy (CHIEF) trial].
Topics: Aged; Amlodipine; Antihypertensive Agents; Benzimidazoles; Benzoates; Blood Pressure; Drug Therapy, | 2009 |
Amlodipine/valsartan/hydrochlorothiazide triple combination therapy in moderate/severe hypertension: Secondary analyses evaluating efficacy and safety.
Topics: Adolescent; Adult; Amlodipine; Antihypertensive Agents; Blood Pressure; Double-Blind Method; Drug Co | 2009 |
Randomized, double-blind, controlled study of losartan in children with proteinuria.
Topics: Adolescent; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Biomarkers | 2010 |
[Efficacy and safety of the single pill combination of valsartan 80 mg plus amlodipine 5 mg in mild to moderate essential hypertensive patients without adequate blood pressure control by monotherapy].
Topics: Adult; Amlodipine; Antihypertensive Agents; Blood Pressure; Double-Blind Method; Drug Therapy, Combi | 2009 |
[Perindopril, amlodipine and telmisartan improve arterial stiffness in patients with hypertension].
Topics: Aged; Amlodipine; Antihypertensive Agents; Benzimidazoles; Benzoates; Blood Pressure; Brachial Arter | 2009 |
Effect of moxonidine and amlodipine on serum YKL-40, plasma lipids and insulin sensitivity in insulin-resistant hypertensive patients-a randomized, crossover trial.
Topics: Adipokines; Adult; Amlodipine; Antihypertensive Agents; Biomarkers; Blood Pressure; Body Size; Chiti | 2010 |
Renoprotective effect of calcium channel blockers in combination with an angiotensin receptor blocker in elderly patients with hypertension. A randomized crossover trial between benidipine and amlodipine.
Topics: Aged; Aged, 80 and over; Albuminuria; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihyper | 2010 |
Efficacy and tolerability of amlodipine plus olmesartan medoxomil in patients with difficult-to-treat hypertension.
Topics: Age Factors; Aged; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Bla | 2010 |
Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial.
Topics: Aged; Albuminuria; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Be | 2010 |
Effect of valsartan or olmesartan addition to amlodipine on ankle edema in hypertensive patients.
Topics: Adult; Aged; Amlodipine; Ankle Joint; Antihypertensive Agents; Blood Pressure; Cross-Over Studies; D | 2010 |
Long-term efficacy of a combination of amlodipine and olmesartan medoxomil ± hydrochlorothiazide in patients with hypertension stratified by age, race and diabetes status: a substudy of the COACH trial.
Topics: Age Factors; Aged; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Blo | 2010 |
Design and rationale of a real-life study to compare treatment strategies for cardiovascular risk factors: the CRUCIAL study.
Topics: Adult; Aged; Aged, 80 and over; Amlodipine; Anticholesteremic Agents; Antihypertensive Agents; Atorv | 2010 |
Effects of beta blockers and calcium-channel blockers on within-individual variability in blood pressure and risk of stroke.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Amlodipine; Antihypertensive Agents; Atenolol; Blood Press | 2010 |
Valsartan addition to amlodipine is more effective than losartan addition in hypertensive patients inadequately controlled by amlodipine.
Topics: Adult; Aged; Amlodipine; Anthracenes; Antihypertensive Agents; Blood Pressure; Cross-Over Studies; D | 2010 |
[Comparative efficiency of indapamide combinations with various derivaties of calcium antagonists in patients with arterial hypertension].
Topics: Adult; Aged; Amlodipine; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Calcium Channel Bloc | 2010 |
Amlodipine-valsartan combination decreases central systolic blood pressure more effectively than the amlodipine-atenolol combination: the EXPLOR study.
Topics: Administration, Oral; Adolescent; Adult; Aged; Amlodipine; Antihypertensive Agents; Atenolol; Blood | 2010 |
Rationale and design of the NAGOYA HEART Study: comparison between valsartan and amlodipine regarding morbidity and mortality in patients with hypertension and glucose intolerance.
Topics: Adult; Aged; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Calcium C | 2010 |
Combined therapy with renin-angiotensin system and calcium channel blockers in type 2 diabetic hypertensive patients with proteinuria: effects on soluble TWEAK, PTX3, and flow-mediated dilation.
Topics: Adult; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; C-Reactive Prot | 2010 |
The combination of amlodipine and angiotensin receptor blocker or diuretics in high-risk hypertensive patients: rationale, design and baseline characteristics.
Topics: Aged; Amiloride; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzi | 2011 |
Treatment of hypertension: postmarketing surveillance study results of telmisartan monotherapy, fixed dose combination of telmisartan + hydrochlorothiazide/amlodipine.
Topics: Amlodipine; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Benzoates; Drug Combinations; F | 2009 |
Efficacy and safety of a single-pill combination of amlodipine/valsartan in Asian hypertensive patients inadequately controlled with amlodipine monotherapy.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Algorithms; Amlodipine; Antihypertensive Agents; Asian P | 2010 |
Simultaneous treatment to attain blood pressure and lipid goals and reduced CV risk burden using amlodipine/atorvastatin single-pill therapy in treated hypertensive participants in a randomized controlled trial.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Amlodipine; Antihypertensive Agents; Biomarker | 2010 |
Potent anti-ischaemic effects of statins in chronic stable angina: incremental benefit beyond lipid lowering?
Topics: Aged, 80 and over; Amlodipine; Angina, Stable; Antihypertensive Agents; Atorvastatin; Chronic Diseas | 2010 |
Angiotensin receptor blocker/diuretic combination preserves insulin responses in obese hypertensives.
Topics: Aged; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Blood Glucose; Blood Pressure; Body Mass | 2010 |
Efficacy of amlodipine and olmesartan medoxomil in patients with hypertension: the AZOR Trial Evaluating Blood Pressure Reductions and Control (AZTEC) study.
Topics: Adult; Aged; Aged, 80 and over; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensiv | 2010 |
[Clinical efficacy study on calming liver and restraining Yang formula in treating patients with mild or moderate degree of essential hypertension].
Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Anxiety; Blood Pressure; Cholesterol; Cholesterol, | 2010 |
Pharmacogenetic association of hypertension candidate genes with fasting glucose in the GenHAT Study.
Topics: Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Glucose; | 2010 |
24-hour ambulatory blood pressure in the ACCOMPLISH trial.
Topics: Amlodipine; Analysis of Variance; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; | 2010 |
Blood pressure and medication during long-term antihypertensive therapy based on morning home SBP in hypertensive patients: Hypertension Control Based on Home Systolic Pressure (HOSP) substudy.
Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Blood Pressure Monitoring, Ambulat | 2010 |
Effects of telmisartan and amlodipine in combination on ambulatory blood pressure in stages 1-2 hypertension.
Topics: Adult; Aged; Aged, 80 and over; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensiv | 2010 |
Cardiovascular events during differing hypertension therapies in patients with diabetes.
Topics: Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Benzazepines; B | 2010 |
A new-generation N/L-type calcium channel blocker leads to less activation of the renin-angiotensin system compared with conventional L type calcium channel blocker.
Topics: Aged; Albuminuria; Aldosterone; Amlodipine; Angiotensin I; Angiotensin II; Blood Pressure; Calcium C | 2010 |
Non-concurrent dosing attenuates the pharmacokinetic interaction between amlodipine and simvastatin.
Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Area Under Curve; Drug Administration Schedule; Dr | 2010 |
Chronotherapy with valsartan/amlodipine fixed combination: improved blood pressure control of essential hypertension with bedtime dosing.
Topics: Adult; Aged; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Blood Pre | 2010 |
Time to achieve blood pressure goal with a combination versus a conventional monotherapy approach in hypertensive patients with metabolic syndrome.
Topics: Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Comorbidity; Dose-Response Relationship, | 2010 |
Angiotensin II receptor blockade with valsartan decreases plasma osteopontin levels in patients with essential hypertension.
Topics: Aged; Amlodipine; Angiotensin II Type 1 Receptor Blockers; C-Reactive Protein; Female; Humans; Hyper | 2011 |
Effects of combination therapy with amlodipine and fosinopril administered at different times on blood pressure and circadian blood pressure pattern in patients with essential hypertension.
Topics: Amlodipine; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Chi-Square Distribution; Circadia | 2010 |
Triple therapy with olmesartan medoxomil, amlodipine besylate, and hydrochlorothiazide in adult patients with hypertension: The TRINITY multicenter, randomized, double-blind, 12-week, parallel-group study.
Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Double-Blind Method; Drug Combinat | 2010 |
Efficacy and safety of olmesartan medoxomil plus amlodipine in age, gender and hypertension severity defined subgroups of hypertensive patients.
Topics: Age Factors; Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Double-Blind Method; Drug Th | 2011 |
Combination therapy with amlodipine/valsartan in essential hypertension: a 52-week, randomised, open-label, extension study.
Topics: Adolescent; Adult; Aged; Amlodipine; Amlodipine, Valsartan Drug Combination; Antihypertensive Agents | 2010 |
Impact of amlodipine or ramipril treatment on left ventricular mass and carotid intima-media thickness in nondiabetic hemodialysis patients.
Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Atherosclerosis; Carotid Arteries; Female; Heart V | 2010 |
Effect of amlodipine + candesartan on cardiovascular events in hypertensive patients with coronary artery disease (from The Heart Institute of Japan Candesartan Randomized Trial for Evaluation in Coronary Artery Disease [HIJ-CREATE] Study).
Topics: Adult; Aged; Aged, 80 and over; Amlodipine; Angina, Unstable; Angiotensin II Type 1 Receptor Blocker | 2010 |
Antiproteinuric effect of cilnidipine in hypertensive Japanese treated with renin-angiotensin-system inhibitors - a multicenter, open, randomized trial using 24-hour urine collection.
Topics: Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Calcium Channel Blockers; Dihydropyridines; Fe | 2010 |
The bedtime administration ameliorates blood pressure variability and reduces urinary albumin excretion in amlodipine-olmesartan combination therapy.
Topics: Adult; Aged; Aged, 80 and over; Albumins; Amlodipine; Antihypertensive Agents; Blood Pressure; Blood | 2010 |
Evaluation of pharmacokinetic interactions between amlodipine, valsartan, and hydrochlorothiazide in patients with hypertension.
Topics: Adolescent; Adult; Amlodipine; Amlodipine, Valsartan Drug Combination; Antihypertensive Agents; Dose | 2011 |
Effectiveness and tolerability of a fixed-dose combination of olmesartan and amlodipine in clinical practice.
Topics: Aged; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Blood Pressure; | 2010 |
Triple combination therapy with amlodipine, valsartan, and hydrochlorothiazide vs dual combination therapy with amlodipine and hydrochlorothiazide for stage 2 hypertensive patients.
Topics: Aged; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Blood Pressure; | 2010 |
Pharmacokinetic and antihypertensive profile of amlodipine and felodipine-ER in younger versus older patients with hypertension.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Amlodipine; Antihypertensive Agents; Blood Pressure; De | 2010 |
Effects of valsartan and amlodipine on cardiorenal protection in Japanese hypertensive patients: the Valsartan Amlodipine Randomized Trial.
Topics: Aged; Amlodipine; Antihypertensive Agents; Asian People; Blood Pressure; Cardiovascular Diseases; Fe | 2011 |
Carotid artery hemodynamics: observing patient-specific changes with amlodipine and lisinopril by using MR imaging computation fluid dynamics.
Topics: Adult; Amlodipine; Analysis of Variance; Angiotensin-Converting Enzyme Inhibitors; Blood Flow Veloci | 2010 |
Azelnidipine and amlodipine: a comparison of their effects and safety in a randomized double-blinded clinical trial in Chinese essential hypertensive patients.
Topics: Adolescent; Adult; Aged; Amlodipine; Antihypertensive Agents; Azetidinecarboxylic Acid; Blood Pressu | 2010 |
Moderate versus intensive treatment of hypertension with amlodipine/valsartan for patients uncontrolled on angiotensin receptor blocker monotherapy.
Topics: Amlodipine; Angiotensin Receptor Antagonists; Double-Blind Method; Drug Therapy, Combination; Female | 2011 |
Role of plasma aldosterone concentration in regression of left-ventricular mass following antihypertensive medication.
Topics: Adult; Aged; Aldosterone; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agen | 2011 |
24-Hour ambulatory blood pressure response to combination valsartan/hydrochlorothiazide and amlodipine/hydrochlorothiazide in stage 2 hypertension by ethnicity: the EVALUATE study.
Topics: Aged; Aged, 80 and over; Amlodipine; Antihypertensive Agents; Blood Pressure; Blood Pressure Monitor | 2010 |
Calcium channel blocker and Rho-associated kinase activity in patients with hypertension.
Topics: Adult; Aged; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Calcium C | 2011 |
Olmesartan/amlodipine vs olmesartan/hydrochlorothiazide in hypertensive patients with metabolic syndrome: the OLAS study.
Topics: Adiponectin; Adult; Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; C-Reactive Protein; C | 2011 |
Efficacy and tolerability of aliskiren 300 mg/hydrochlorothiazide 25 mg (± amlodipine 5 mg) in hypertensive patients not controlled by candesartan 32 mg plus HCT 25 mg.
Topics: Adult; Aged; Algorithms; Amides; Amlodipine; Antihypertensive Agents; Benzimidazoles; Biphenyl Compo | 2011 |
The effect of losartan and amlodipine on left ventricular diastolic function and atherosclerosis in Japanese patients with mild-to-moderate hypertension (J-ELAN) study.
Topics: Adrenergic alpha-Antagonists; Aged; Amlodipine; Angiotensin II Type 2 Receptor Blockers; Antihyperte | 2011 |
Benidipine reduces albuminuria and plasma aldosterone in mild-to-moderate stage chronic kidney disease with albuminuria.
Topics: Aged; Albuminuria; Aldosterone; Amlodipine; Angiotensin Receptor Antagonists; Blood Pressure; Calciu | 2011 |
Differential effect of telmisartan and amlodipine on monocyte chemoattractant protein-1 and peroxisome proliferator-activated receptor-gamma gene expression in peripheral monocytes in patients with essential hypertension.
Topics: Amlodipine; Antihypertensive Agents; Benzimidazoles; Benzoates; Chemokine CCL2; Female; Gene Express | 2011 |
Randomized trial of angiotensin II-receptor blocker vs. dihydropiridine calcium channel blocker in the treatment of paroxysmal atrial fibrillation with hypertension (J-RHYTHM II study).
Topics: Aged; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Atrial Fibrillation; Benzimidazoles; Biph | 2011 |
Effects of manidipine and its combination with an ACE inhibitor on insulin sensitivity and metabolic, inflammatory and prothrombotic markers in hypertensive patients with metabolic syndrome: the MARCADOR study.
Topics: Adult; Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Benzimid | 2011 |
Bedtime versus at awakening administration of BP lowering drugs--is it the way to success?
Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Cohort Studies; Drug Chronotherapy; Female; Humans | 2009 |
Aliskiren and the calcium channel blocker amlodipine combination as an initial treatment strategy for hypertension control (ACCELERATE): a randomised, parallel-group trial.
Topics: Amides; Amlodipine; Antihypertensive Agents; Calcium Channel Blockers; Diastole; Double-Blind Method | 2011 |
Real-life safety and effectiveness of amlodipine/valsartan combination in the treatment of hypertension.
Topics: Administration, Oral; Amlodipine; Antihypertensive Agents; Bangladesh; Blood Pressure; Blood Pressur | 2011 |
Effects of candesartan versus amlodipine on home-measured blood pressure, QT dispersion and left ventricular hypertrophy in high-risk hypertensive patients.
Topics: Aged; Amlodipine; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Blood | 2011 |
24-Hour ambulatory blood pressure control with triple-therapy amlodipine, valsartan and hydrochlorothiazide in patients with moderate to severe hypertension.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amlodipine; Antihypertensive Agents; Blood Pressure Moni | 2011 |
Comparison of changes of body water measured by using bioelectrical impedance analysis between lercanidipine and amlodipine therapy in hypertensive outpatients.
Topics: Aged; Aged, 80 and over; Amlodipine; Antihypertensive Agents; Body Composition; Body Water; Dihydrop | 2010 |
Efficacy and safety of losartan in children with Alport syndrome--results from a subgroup analysis of a prospective, randomized, placebo- or amlodipine-controlled trial.
Topics: Adolescent; Adult; Amlodipine; Antihypertensive Agents; Blood Pressure; Child; Child, Preschool; Dou | 2011 |
Impact of amlodipine-based therapy among older and younger patients in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA).
Topics: Adult; Age Factors; Aged; Amlodipine; Antihypertensive Agents; Atenolol; Double-Blind Method; Drug T | 2011 |
Proactive multiple cardiovascular risk factor management compared with usual care in patients with hypertension and additional risk factors: the CRUCIAL trial.
Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Atorvastatin; Cardiovascular Diseases; Drug Combin | 2011 |
Efficacy of morning and evening dosing of amlodipine/valsartan combination in hypertensive patients uncontrolled by 5 mg of amlodipine.
Topics: Aged; Amlodipine; Amlodipine, Valsartan Drug Combination; Antihypertensive Agents; Blood Pressure; B | 2011 |
The role of ambulatory blood pressure monitoring compared with clinic and home blood pressure measures in evaluating moderate versus intensive treatment of hypertension with amlodipine/valsartan for patients uncontrolled on angiotensin receptor blocker mo
Topics: Adult; Aged; Amlodipine; Amlodipine, Valsartan Drug Combination; Angiotensin Receptor Antagonists; A | 2011 |
Effects of up-titration of candesartan versus candesartan plus amlodipine on kidney function in type 2 diabetic patients with albuminuria.
Topics: Aged; Albuminuria; Amlodipine; Angiotensin Receptor Antagonists; Antihypertensive Agents; Benzimidaz | 2012 |
[Comparison of benazepril monotherapy to amlodipine plus benazepril in the treatment of patients with mild and moderate hypertension: a multicentre, randomized, double-blind, parallel-controlled study].
Topics: Adult; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Benzazepines; | 2011 |
Beneficial cardiometabolic actions of telmisartan plus amlodipine therapy in elderly patients with poorly controlled hypertension.
Topics: Adiponectin; Age Factors; Aged; Aged, 80 and over; Amlodipine; Angiotensin II Type 1 Receptor Blocke | 2011 |
Calcium channel blocker inhibition of AGE and RAGE axis limits renal injury in nondiabetic patients with stage I or II chronic kidney disease.
Topics: Adult; Amlodipine; Analysis of Variance; Angiotensin II Type 1 Receptor Blockers; Antihypertensive A | 2011 |
Natriuretic peptides and collagen biomarkers in patients with medical treatment for hypertension.
Topics: Amlodipine; Antihypertensive Agents; Atenolol; Atrial Natriuretic Factor; Biomarkers; Collagen; Coll | 2011 |
Efficacy and tolerability of a single-pill combination of amlodipine/valsartan in Asian hypertensive patients not adequately controlled with valsartan monotherapy.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Ant | 2011 |
Azelnidipine and amlodipine anti-coronary atherosclerosis trial in hypertensive patients undergoing coronary intervention by serial volumetric intravascular ultrasound analysis in Juntendo University (ALPS-J).
Topics: Amlodipine; Azetidinecarboxylic Acid; Blood Pressure; Calcium Channel Blockers; Coronary Artery Dise | 2011 |
Fixed-combination of amlodipine and diuretic chronotherapy in the treatment of essential hypertension: improved blood pressure control with bedtime dosing-a multicenter, open-label randomized study.
Topics: Aged; Amlodipine; Blood Pressure; Calcium Channel Blockers; Diuretics; Drug Therapy, Combination; Fe | 2011 |
Rationale and design of the Newer Versus Older Antihypertensive Agents in African Hypertensive Patients (NOAAH) trial.
Topics: Adult; Africa South of the Sahara; Aged; Amlodipine; Antihypertensive Agents; Bisoprolol; Black Peop | 2011 |
Management of hypertension in patients with diabetes using an amlodipine-, olmesartan medoxomil-, and hydrochlorothiazide-based titration regimen.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amlodipine; Antihypertensive Agents; Diabetes Mellitus, | 2011 |
Effect of aliskiren addition to amlodipine on ankle edema in hypertensive patients: a three-way crossover study.
Topics: Amides; Amlodipine; Ankle; Ankle Joint; Antihypertensive Agents; Blood Pressure; Calcium Channel Blo | 2011 |
Peripheral and central blood pressure responses of combination aliskiren/hydrochlorothiazide and amlodipine monotherapy in African American patients with stage 2 hypertension: the ATLAAST trial.
Topics: Adult; Amides; Amlodipine; Antihypertensive Agents; Black or African American; Blood Pressure; Brach | 2011 |
Limitations of analyses based on achieved blood pressure: lessons from the African American study of kidney disease and hypertension trial.
Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Black or African American; Blood Pressure; Female; | 2011 |
Design and rationale of Japanese evaluation between Formula of Azelnidipine and amlodipine add on olmesartan to Get antialbuminuric effect study (J-FLAG) : evaluation of the antialbuminuric effects between calcium channel blocker with sympatholytic action
Topics: Adult; Aged; Albuminuria; Amlodipine; Azetidinecarboxylic Acid; Calcium Channel Blockers; Diabetic N | 2011 |
Design and rationale of the study of assessment for kidney function by urinary microalbumin in randomized (SAKURA) trial.
Topics: Aged; Albuminuria; Amlodipine; Calcium Channel Blockers; Calcium Channels, L-Type; Calcium Channels, | 2011 |
A titrate-to-goal study of switching patients uncontrolled on antihypertensive monotherapy to fixed-dose combinations of amlodipine and olmesartan medoxomil ± hydrochlorothiazide.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Algorithms; Amlodipine; Angiotensin II Type 1 Receptor B | 2011 |
Blood pressure-lowering response to amlodipine as a determinant of the antioxidative activity of small, dense HDL3.
Topics: Aged; Amlodipine; Antihypertensive Agents; Antioxidants; Blood Pressure; Body Mass Index; Calcium Ch | 2011 |
[Candesartan Antihypertensive Survival Evaluation in Japan (CASE-J) trial].
Topics: Amlodipine; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Humans; Hypertension; Tetra | 2011 |
Effect of antihypertensive agents on blood pressure variability: the Natrilix SR versus candesartan and amlodipine in the reduction of systolic blood pressure in hypertensive patients (X-CELLENT) study.
Topics: Aged; Amlodipine; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Blood | 2011 |
Telmisartan and amlodipine single-pill combinations vs amlodipine monotherapy for superior blood pressure lowering and improved tolerability in patients with uncontrolled hypertension: results of the TEAMSTA-5 study.
Topics: Adult; Amlodipine; Antihypertensive Agents; Benzimidazoles; Benzoates; Blood Pressure; Blood Pressur | 2011 |
Losartan and amlodipine on myocardial structure and function: a prospective, randomized, clinical trial.
Topics: Amlodipine; Antihypertensive Agents; Blood Pressure; Diabetes Mellitus, Type 2; Diabetic Angiopathie | 2012 |
Effects of Azelnidipine plus OlmesaRTAn versus amlodipine plus olmesartan on central blood pressure and left ventricular mass index: the AORTA study.
Topics: Adult; Aged; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Azetidine | 2011 |
Comparative efficacy and safety of combination aliskiren/amlodipine and amlodipine monotherapy in African Americans with stage 2 hypertension.
Topics: Adult; Amides; Amlodipine; Black or African American; Blood Pressure; Blood Pressure Monitoring, Amb | 2011 |
Combination angiotensin-receptor blocker (ARB)/calcium channel blocker with HCTZ vs the maximal recommended dose of an ARB with HCTZ in patients with stage 2 hypertension: the exforge as compared to losartan treatment in stage 2 systolic hypertension (EXA
Topics: Amlodipine; Angiotensin Receptor Antagonists; Blood Pressure; Calcium Channel Blockers; Dose-Respons | 2011 |
Improving adherence with amlodipine/atorvastatin therapy: IMPACT study.
Topics: Amlodipine; Anticholesteremic Agents; Antihypertensive Agents; Atorvastatin; Black or African Americ | 2011 |
Predictors of systolic BP <140 mmHg and systolic BP level by randomly assigned treatment group (benazepril plus amlodipine or hydrochlorothiazide) in the ACCOMPLISH Study.
Topics: Amlodipine; Antihypertensive Agents; Benzazepines; Drug Therapy, Combination; Electrocardiography; F | 2012 |
Long-term effects of candesartan and amlodipine on cardiovascular morbidity and mortality in Japanese high-risk hypertensive patients: the Candesartan Antihypertensive Survival Evaluation in Japan Extension Study (CASE-J Ex).
Topics: Aged; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; | 2011 |
Aliskiren as add-on therapy in the treatment of hypertensive diabetic patients inadequately controlled with valsartan/HCT combination: a placebo-controlled study.
Topics: Aged; Amides; Amlodipine; Antihypertensive Agents; Blood Pressure; Diabetes Mellitus, Type 1; Diabet | 2011 |
[Efficacy of fixed combination amlodipine/valsartan in hospitalized patients with hypertensive disease].
Topics: Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Dr | 2011 |
Baseline predictors of resistant hypertension in the Anglo-Scandinavian Cardiac Outcome Trial (ASCOT): a risk score to identify those at high-risk.
Topics: Aged; Algorithms; Amlodipine; Antihypertensive Agents; Atenolol; Bendroflumethiazide; Diuretics; Dru | 2011 |
Efficacy and tolerability of telmisartan plus amlodipine in added-risk hypertensive patients.
Topics: Adult; Age Factors; Aged; Amlodipine; Antihypertensive Agents; Benzimidazoles; Benzoates; Blood Pres | 2011 |
Effects of calcium channel blockers on glucose tolerance, inflammatory state, and circulating progenitor cells in non-diabetic patients with essential hypertension: a comparative study between azelnidipine and amlodipine on glucose tolerance and endotheli
Topics: Adult; Aged; Amlodipine; Azetidinecarboxylic Acid; Blood Glucose; Calcium Channel Blockers; Cross-Ov | 2011 |
Plasma fibrin clot properties in arterial hypertension and their modification by antihypertensive medication.
Topics: Adult; Amlodipine; Antihypertensive Agents; Bisoprolol; Blood Coagulation; Female; Fibrin; Humans; H | 2012 |
Switching patients with uncontrolled hypertension on amlodipine 10 mg to single-pill combinations of telmisartan and amlodipine: results of the TEAMSTA-10 study.
Topics: Aged; Amlodipine; Antihypertensive Agents; Benzimidazoles; Benzoates; Blood Pressure; Calcium Channe | 2011 |
Effect of telmisartan addition to amlodipine on ankle edema development in treating hypertensive patients.
Topics: Adult; Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Ankle; Antihypertensive Agents; B | 2011 |
Office and ambulatory blood pressure-lowering effects of combination valsartan/hydrochlorothiazide vs. hydrochlorothiazide-based therapy in obese, hypertensive patients.
Topics: Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Co | 2011 |
Effects of valsartan and amlodipine on home blood pressure and cardiovascular events in Japanese hypertensive patients: a subanalysis of the VART.
Topics: Aged; Albuminuria; Amlodipine; Angina Pectoris; Antihypertensive Agents; Asian People; Blood Pressur | 2012 |
Effects of aliskiren on QT duration and dispersion in hypertensive patients with type 2 diabetes mellitus.
Topics: Aged; Amides; Amlodipine; Antihypertensive Agents; Blood Pressure; Diabetes Mellitus, Type 2; Diabet | 2012 |
Effects of losartan and amlodipine alone or combined with simvastatin in hypertensive patients with nonalcoholic hepatic steatosis.
Topics: Aged; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Blood Pressure; | 2012 |
Optimal Combination of Effective ANtihypertensives (OCEAN) study: a prospective, randomized, open-label, blinded endpoint trial--rationale, design and results of a pilot study in Japan.
Topics: Adrenergic beta-Antagonists; Aged; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Angiotensin- | 2012 |
Impact of combination therapy with amlodipine and atorvastatin on plasma adiponectin levels in hypertensive patients with coronary artery disease: combination therapy and adiponectin.
Topics: Adiponectin; Aged; Aged, 80 and over; Amlodipine; Anticholesteremic Agents; Antihypertensive Agents; | 2011 |
Efficacy and tolerability of the single-pill combination of aliskiren 300 mg/amlodipine 10 mg in hypertensive patients not controlled by olmesartan 40 mg/amlodipine 10 mg.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amides; Amlodipine; Antihypertensive Agents; Drug Combin | 2012 |
Distinct effects of fixed combinations of valsartan with either amlodipine or hydrochlorothiazide on lipoprotein subfraction profile in patients with hypertension.
Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Cholesterol; Female; Humans; Hydrochlorothiazide; | 2013 |
Comparative efficacy and safety profile of amlodipine 5 mg/losartan 50 mg fixed-dose combination and amlodipine 10 mg monotherapy in hypertensive patients who respond poorly to amlodipine 5 mg monotherapy: an 8-week, multicenter, randomized, double-blind
Topics: Adult; Amlodipine; Analysis of Variance; Angiotensin II Type 1 Receptor Blockers; Antihypertensive A | 2011 |
24-hour efficacy and safety of Triple-Combination Therapy With Olmesartan, Amlodipine, and Hydrochlorothiazide: the TRINITY ambulatory blood pressure substudy.
Topics: Amlodipine; Antihypertensive Agents; Blood Pressure Monitoring, Ambulatory; Double-Blind Method; Dru | 2011 |
Comparison of aliskiren/hydrochlorothiazide combination therapy and amlodipine monotherapy in patients with stage 2 systolic hypertension and type 2 diabetes mellitus.
Topics: Amides; Amlodipine; Analysis of Variance; Antihypertensive Agents; Blood Pressure; Diabetes Mellitus | 2011 |
Comparing antihypertensive effect and plasma ciclosporin concentration between amlodipine and valsartan regimens in hypertensive renal transplant patients receiving ciclosporin therapy.
Topics: Adult; Amlodipine; Antihypertensive Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Bindi | 2011 |
Usefulness of heart rate to predict cardiac events in treated patients with high-risk systemic hypertension.
Topics: Aged; Amlodipine; Amlodipine, Valsartan Drug Combination; Antihypertensive Agents; Blood Pressure; D | 2012 |
Ambulatory blood pressure response to triple therapy with an angiotensin-receptor blocker (ARB), calcium-channel blocker (CCB), and HCTZ versus dual therapy with an ARB and HCTZ.
Topics: Amlodipine; Angiotensin Receptor Antagonists; Antihypertensive Agents; Blood Pressure; Blood Pressur | 2011 |
Renal outcomes in hypertensive Black patients at high cardiovascular risk.
Topics: Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Benzazepines; B | 2012 |
Evaluation of the dose-response relationship of amlodipine and losartan combination in patients with essential hypertension: an 8-week, randomized, double-blind, factorial, phase II, multicenter study.
Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Double-Blind Method; Drug Combinat | 2012 |
Comparison between valsartan and amlodipine regarding cardiovascular morbidity and mortality in hypertensive patients with glucose intolerance: NAGOYA HEART Study.
Topics: Amlodipine; Antihypertensive Agents; Blood Glucose; Blood Pressure; Diabetes Mellitus, Type 2; Femal | 2012 |
Antihypertensive and metabolic effects of Angiotensin receptor blocker/diuretic combination therapy in obese, hypertensive African American and white patients.
Topics: Adult; Aged; Aged, 80 and over; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensiv | 2013 |
Aliskiren penetrates adipose and skeletal muscle tissue and reduces renin-angiotensin system activity in obese hypertensive patients.
Topics: Adipose Tissue; Adult; Amides; Amlodipine; Antihypertensive Agents; Calcium Channel Blockers; Extrac | 2012 |
Antihypertensive efficacy and tolerability of aliskiren/amlodipine single- pill combinations in patients with an inadequate response to aliskiren monotherapy.
Topics: Administration, Oral; Adult; Aged; Amides; Amlodipine; Antihypertensive Agents; Blood Pressure; Calc | 2012 |
Efficacy and tolerability of aliskiren/amlodipine single-pill combinations in patients who did not respond fully to amlodipine monotherapy¥.
Topics: Administration, Oral; Adult; Aged; Amides; Amlodipine; Antihypertensive Agents; Argentina; Blood Pre | 2012 |
Combination of amlodipine plus angiotensin receptor blocker or diuretics in high-risk hypertensive patients: a 96-week efficacy and safety study.
Topics: Aged; Amiloride; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzi | 2012 |
Effect of fixed dose combinations of metoprolol and amlodipine in essential hypertension: MARS--a randomized controlled trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amlodipine; Blood Pressure; Dose-Response Relationship, | 2011 |
Protective effect of telmisartan against endothelial dysfunction after coronary drug-eluting stent implantation in hypertensive patients.
Topics: Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Benzimidazoles; | 2012 |
Effects of valsartan versus olmesartan addition to amlodipine/hydrochlorothiazide combination in treating stage 2 hypertensive patients.
Topics: Adult; Aged; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Blood Pre | 2012 |
Long-term efficacy and safety of triple-combination therapy with olmesartan medoxomil and amlodipine besylate and hydrochlorothiazide for hypertension.
Topics: Aged; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Blood Pressure; | 2012 |
Single-pill combination of telmisartan/amlodipine versus amlodipine monotherapy in diabetic hypertensive patients: an 8-week randomized, parallel-group, double-blind trial.
Topics: Aged; Amlodipine; Antihypertensive Agents; Benzimidazoles; Benzoates; Blood Pressure; Body Mass Inde | 2012 |
Gene panels to help identify subgroups at high and low risk of coronary heart disease among those randomized to antihypertensive treatment: the GenHAT study.
Topics: Aged; Amlodipine; Antihypertensive Agents; Chlorthalidone; Coronary Disease; Doxazosin; Female; Foll | 2012 |
Clinical significance of incident hypokalemia and hyperkalemia in treated hypertensive patients in the antihypertensive and lipid-lowering treatment to prevent heart attack trial.
Topics: Aged; Amlodipine; Antihypertensive Agents; Blood Chemical Analysis; Cardiovascular Diseases; Chlorth | 2012 |
Evaluation of the efficacy and tolerability of combination therapy with candesartan cilexetil and amlodipine besilate compared with candesartan cilexetil monotherapy and amlodipine besilate monotherapy in Japanese patients with mild-to-moderate essential
Topics: Aged; Amlodipine; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Double-Blind Method; | 2012 |
Efficacy and safety of aranidipine enteric-coated tablets compared with amlodipine in Chinese patients with mild to moderate essential hypertension: a multicenter, randomized, double-blind, parallel-controlled clinical trial.
Topics: Adult; Amlodipine; Antihypertensive Agents; Blood Pressure; Blood Pressure Monitoring, Ambulatory; D | 2012 |
Single-pill combination of telmisartan/amlodipine in patients with severe hypertension: results from the TEAMSTA severe HTN study.
Topics: Aged; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; | 2012 |
Comparison of the efficacy and safety of fixed-dose amlodipine/losartan and losartan in hypertensive patients inadequately controlled with losartan: a randomized, double-blind, multicenter study.
Topics: Adult; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Blood Pressure; | 2012 |
Pharmacogenetic association of NOS3 variants with cardiovascular disease in patients with hypertension: the GenHAT study.
Topics: Aged; Alleles; Amlodipine; Antihypertensive Agents; Cardiovascular Diseases; Chlorthalidone; Double- | 2012 |
Pharmacogenetic association of NOS3 variants with cardiovascular disease in patients with hypertension: the GenHAT study.
Topics: Aged; Alleles; Amlodipine; Antihypertensive Agents; Cardiovascular Diseases; Chlorthalidone; Double- | 2012 |
Pharmacogenetic association of NOS3 variants with cardiovascular disease in patients with hypertension: the GenHAT study.
Topics: Aged; Alleles; Amlodipine; Antihypertensive Agents; Cardiovascular Diseases; Chlorthalidone; Double- | 2012 |
Pharmacogenetic association of NOS3 variants with cardiovascular disease in patients with hypertension: the GenHAT study.
Topics: Aged; Alleles; Amlodipine; Antihypertensive Agents; Cardiovascular Diseases; Chlorthalidone; Double- | 2012 |
[Effects of valsartan combined with amlodipine or hydrochlorothiazide regimen on blood pressure variation in elderly hypertensive patients].
Topics: Aged; Amlodipine; Blood Pressure; Drug Therapy, Combination; Female; Humans; Hydrochlorothiazide; Hy | 2012 |
Long-term renal and cardiovascular outcomes in Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) participants by baseline estimated GFR.
Topics: Amlodipine; Antihypertensive Agents; Canada; Chlorthalidone; Chronic Disease; Coronary Disease; Doub | 2012 |
Angiotensin II receptor blocker-based therapy in Japanese elderly, high-risk, hypertensive patients.
Topics: Aged; Aged, 80 and over; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Azetidinecarboxylic Ac | 2012 |
[Clinical implications from the results of the CASE-J extension].
Topics: Amlodipine; Angiotensin Receptor Antagonists; Benzimidazoles; Biphenyl Compounds; Calcium Channel Bl | 2012 |
Effects of valsartan or ramipril addition to amlodipine/hydrochlorothiazide combination on left ventricular mass in diabetic hypertensive patients with left ventricular hypertrophy.
Topics: Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Diabetes Mellitus, Type 2; Double-Blind M | 2012 |
Long-term effects of calcium antagonists on augmentation index in hypertensive patients with chronic kidney disease: a randomized controlled study.
Topics: Aged; Amlodipine; Antihypertensive Agents; Azetidinecarboxylic Acid; Blood Pressure; Calcium Channel | 2012 |
Effect of telmisartan on paroxysmal atrial fibrillation recurrence in hypertensive patients with normal or increased left atrial size.
Topics: Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Atrial Fibrilla | 2012 |
Effects of exercise therapy alone and in combination with a calcium channel blocker or an angiotensin receptor blocker in hypertensive patients.
Topics: Adult; Aged; Amlodipine; Angiotensin Receptor Antagonists; Antihypertensive Agents; Blood Pressure; | 2012 |
Blood pressure effects of high-dose amlodipine-benazepril combination in Black and White hypertensive patients not controlled on monotherapy.
Topics: Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Benzazepines; Black P | 2012 |
Combination therapy of angiotensin II receptor blocker and calcium channel blocker exerts pleiotropic therapeutic effects in addition to blood pressure lowering: amlodipine and candesartan trial in Yokohama (ACTY).
Topics: Aged; Albuminuria; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Ben | 2012 |
Progress report on the first sub-Saharan Africa trial of newer versus older antihypertensive drugs in native black patients.
Topics: Administration, Oral; Adult; Africa South of the Sahara; Aged; Amlodipine; Amlodipine, Valsartan Dru | 2012 |
Change in high-sensitive cardiac troponin T on hypertensive treatment.
Topics: Aged; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Biomarkers; Bloo | 2013 |
Amlodipine/valsartan 5/160 mg versus valsartan 160 mg in Chinese hypertensives.
Topics: Adult; Aged; Amlodipine; Amlodipine, Valsartan Drug Combination; Antihypertensive Agents; Asian Peop | 2013 |
The combination of OLmesartan and a CAlcium channel blocker (azelnidipine) or candesartan and a calcium channel blocker (amlodipine) in type 2 diabetic hypertensive patients: the OLCA study.
Topics: Aged; Albuminuria; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Aze | 2012 |
L/T-type and L/N-type calcium-channel blockers attenuate cardiac sympathetic nerve activity in patients with hypertension.
Topics: Aged; Amlodipine; Antihypertensive Agents; Calcium Channel Blockers; Calcium Channels, L-Type; Calci | 2012 |
Renoprotective and antioxidant effects of cilnidipine in hypertensive patients.
Topics: 8-Hydroxy-2'-Deoxyguanosine; Aged; Albuminuria; Amlodipine; Antihypertensive Agents; Antioxidants; B | 2012 |
Efficacy of amlodipine/olmesartan ± hydrochlorothiazide in patients uncontrolled on prior calcium channel blocker or angiotensin II receptor blocker monotherapy.
Topics: Adult; Aged; Aged, 80 and over; Amlodipine; Angiotensin Receptor Antagonists; Antihypertensive Agent | 2012 |
Comparison of the efficacy and safety profiles of two fixed-dose combinations of antihypertensive agents, amlodipine/benazepril versus valsartan/hydrochlorothiazide, in patients with type 2 diabetes mellitus and hypertension: a 16-week, multicenter, rando
Topics: Aged; Albuminuria; Amlodipine; Analysis of Variance; Angiotensin II Type 1 Receptor Blockers; Angiot | 2012 |
Management of home blood pressure by amlodipine combined with angiotensin II receptor blocker in type 2 diabetes.
Topics: Aged; Amlodipine; Angiotensin Receptor Antagonists; Antihypertensive Agents; Blood Pressure; Diabete | 2012 |
[Uncontrolled arterial hypertension--new possibilities in solving problems of increasing the effectiveness of treatment].
Topics: Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Blood Pressure Monitoring, Ambulatory; Calcium | 2012 |
Triple-Combination therapy with olmesartan, amlodipine, and hydrochlorothiazide in black and non-black study participants with hypertension: the TRINITY randomized, double-blind, 12-week, parallel-group study.
Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Black People; Double-Blind Method; Drug Therapy, C | 2012 |
Post-marketing surveillance study of valsartan/amlodipine combination in Taiwanese hypertensive patients.
Topics: Aged; Amlodipine; Antihypertensive Agents; Asian People; Blood Pressure; Female; Humans; Hypertensio | 2012 |
Randomized Polypill crossover trial in people aged 50 and over.
Topics: Aged; Amlodipine; Anticholesteremic Agents; Antihypertensive Agents; Blood Pressure; Cardiovascular | 2012 |
Clinic and ambulatory blood pressure lowering effect of aliskiren/amlodipine/hydrochlorothiazide combination in patients with moderate-to-severe hypertension: a randomized active-controlled trial.
Topics: Aged; Amides; Amlodipine; Antihypertensive Agents; Double-Blind Method; Drug Therapy, Combination; F | 2012 |
I-ADD study: assessment of efficacy and safety profile of irbesartan/amlodipine fixed-dose combination therapy compared with irbesartan monotherapy in hypertensive patients uncontrolled with irbesartan 150 mg monotherapy: a multicenter, phase III, prospec
Topics: Adult; Africa, Northern; Aged; Aged, 80 and over; Amlodipine; Analysis of Variance; Angiotensin II T | 2012 |
I-COMBINE study: assessment of efficacy and safety profile of irbesartan/amlodipine fixed-dose combination therapy compared with amlodipine monotherapy in hypertensive patients uncontrolled with amlodipine 5 mg monotherapy: a multicenter, phase III, prosp
Topics: Adult; Africa, Northern; Aged; Aged, 80 and over; Amlodipine; Analysis of Variance; Angiotensin II T | 2012 |
Optimization of blood pressure treatment with fixed-combination perindopril/amlodipine in patients with arterial hypertension.
Topics: Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Calcium Channel Blockers; Drug Combinati | 2012 |
Treatment with aliskiren/amlodipine combination in patients with moderate-to-severe hypertension: a randomised, double-blind, active comparator trial.
Topics: Aged; Amides; Amlodipine; Antihypertensive Agents; Double-Blind Method; Drug Combinations; Female; F | 2012 |
Olmesartan improves coronary flow reserve of hypertensive patients using coronary magnetic resonance imaging compared with amlodipine.
Topics: Adenosine; Adult; Aged; Amlodipine; Antihypertensive Agents; Coronary Circulation; Echocardiography; | 2012 |
Efficacy and safety of triple antihypertensive therapy with the olmesartan/amlodipine/hydrochlorothiazide combination.
Topics: Adult; Aged; Aging; Amlodipine; Antihypertensive Agents; Double-Blind Method; Drug Therapy, Combinat | 2012 |
Proactive cardiovascular risk management versus usual care in patients with and without diabetes mellitus: CRUCIAL trial subanalysis.
Topics: Adult; Aged; Amlodipine; Blood Pressure; Diabetes Complications; Diabetes Mellitus; Drug Combination | 2012 |
L/N-type calcium channel blocker cilnidipine reduces plasma aldosterone, albuminuria, and urinary liver-type fatty acid binding protein in patients with chronic kidney disease.
Topics: Aged; Albuminuria; Aldosterone; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensiv | 2013 |
Quantification of pedal edema during treatment with S(-)-amlodipine nicotinate versus amlodipine besylate in female Korean patients with mild to moderate hypertension: a 12-week, multicenter, randomized, double-blind, active-controlled, phase IV clinical
Topics: Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Dose-Response R | 2012 |
Olmesartan/amlodipine combination versus olmesartan or amlodipine monotherapies on blood pressure and insulin resistance in a sample of hypertensive patients.
Topics: Amlodipine; Antihypertensive Agents; Blood Pressure; Body Mass Index; Body Weight; Double-Blind Meth | 2013 |
Clinical study of western medicine combined with Chinese medicine based on syndrome differentiation in the patients with polarized hypertension.
Topics: Aged; Amlodipine; Antihypertensive Agents; Biphenyl Compounds; Blood Pressure; Diastole; Drugs, Chin | 2012 |
[Modeling and simulation activities to design sampling scheme for population pharmacokinetic study on amlodipine].
Topics: Adult; Age Factors; Alanine Transaminase; Amlodipine; Antihypertensive Agents; Bayes Theorem; Body W | 2012 |
Cardiovascular outcomes in hypertensive patients: comparing single-agent therapy with combination therapy.
Topics: Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Cardiovascular Diseases; Double-Blind Met | 2012 |
Titration of telmisartan, but not addition of amlodipine, reduces urine albumin in diabetic patients treated with telmisartan-diuretic.
Topics: Adult; Aged; Albuminuria; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Benzo | 2013 |
Efficacy of amlodipine/olmesartan medoxomil ± HCTZ in obese patients uncontrolled on antihypertensive monotherapy.
Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Drug Therapy, Combination; Female; Humans; Hydroch | 2012 |
Efficacy and safety of aliskiren and amlodipine combination therapy in patients with hypertension: a randomized, double-blind, multifactorial study.
Topics: Adult; Aged; Amides; Amlodipine; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Calcium Chan | 2013 |
The effects of telmisartan and amlodipine in treatment-naïve and previously treated hypertensive patients: a subanalysis from a 4 × 4 factorial design study.
Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Benzimidazoles; Benzoates; Blood Pressure; Dose-Re | 2013 |
Olmesartan/amlodipine/hydrochlorothiazide in participants with hypertension and diabetes, chronic kidney disease, or chronic cardiovascular disease: a subanalysis of the multicenter, randomized, double-blind, parallel-group TRINITY study.
Topics: Aged; Amlodipine; Antihypertensive Agents; Cardiovascular Diseases; Diabetes Complications; Double-B | 2012 |
Changes in aortic pulse wave velocity in hypertensive postmenopausal women: comparison between a calcium channel blocker vs angiotensin receptor blocker regimen.
Topics: Aged; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Blood Pressure; Calcium Channel Blockers; | 2012 |
[Possibilities of pharmacological correction of the arterial hypertension in elderly patients with gout].
Topics: Aged; Amlodipine; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Calcium Channel Blockers; C | 2012 |
The comparative effects of valsartan and amlodipine on vascular microinflammation in newly diagnosed hypertensive patients.
Topics: Adult; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Blood Pressure; | 2013 |
An additional LDL-lowering effect of amlodipine; not only an antihypertensive?
Topics: Adult; Aged; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Calcium C | 2013 |
Safety and efficacy of aliskiren/amlodipine/hydrochlorothiazide triple combination in patients with moderate to severe hypertension: a 54-week, open-label study.
Topics: Adult; Aged; Amides; Amlodipine; Antihypertensive Agents; Biological Availability; Blood Pressure; D | 2012 |
[Azelnidipine and amlodipine anti-coronary atherosclerosis trial in hypertensive patients undergoing coronary intervention by serial volumetric intravascular ultrasound analysis in Juntendo Medical University].
Topics: Aged; Amlodipine; Azetidinecarboxylic Acid; Blood Pressure; Calcium Channel Blockers; Coronary Arter | 2012 |
Effects of an olmesartan/amlodipine fixed dose on blood pressure control, some adipocytokines and interleukins levels compared with olmesartan or amlodipine monotherapies.
Topics: Adipokines; Amlodipine; Antihypertensive Agents; Blood Pressure; Double-Blind Method; Drug Combinati | 2013 |
Effects of body size and hypertension treatments on cardiovascular event rates: subanalysis of the ACCOMPLISH randomised controlled trial.
Topics: Aged; Amlodipine; Antihypertensive Agents; Benzazepines; Body Mass Index; Body Size; Body Weight; Ca | 2013 |
Effects of manidipine vs. amlodipine on intrarenal haemodynamics in patients with arterial hypertension.
Topics: Adult; Aged; Albuminuria; Amlodipine; Creatinine; Dihydropyridines; Double-Blind Method; Female; Hem | 2013 |
Efficacy of an amlodipine/olmesartan treatment algorithm in patients with or without type 2 diabetes and hypertension (a secondary analysis of the BP-CRUSH study).
Topics: Adult; Aged; Algorithms; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agent | 2013 |
The comparative effects of valsartan and amlodipine on vWf levels and N/L ratio in patients with newly diagnosed hypertension.
Topics: Adult; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Biomarkers; Blo | 2013 |
[Effects of telmisartan on the level of Aβ1-42, interleukin-1β, tumor necrosis factor α and cognition in hypertensive patients with Alzheimer's disease].
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Amlodipine; Amyloid beta-Peptides; Antihypertensive Agen | 2012 |
Amlodipine seems to be superior to valsartan in decreasing microalbuminuria in newly diagnosed hypertensive patients: a novel effect to be explained with hyperfiltration?
Topics: Adult; Albuminuria; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Calcium Channel Blockers; F | 2013 |
Slovak trial on cardiovascular risk reduction following national guidelines with CaDUET® (the STRONG DUET study).
Topics: Aged; Amlodipine; Antihypertensive Agents; Cardiovascular Diseases; Drug Combinations; Female; Hepta | 2013 |
Comparative effect of candesartan and amlodipine, and effect of switching from valsartan, losartan, telmisartan and olmesartan to candesartan, on early morning hypertension and heart rate.
Topics: Aged; Amlodipine; Antihypertensive Agents; Benzimidazoles; Benzoates; Biphenyl Compounds; Drug Subst | 2013 |
The effects of amlodipine on cerebral circulatory values in patients with essential hypertension.
Topics: Adult; Amlodipine; Blood Pressure; Calcium Channel Blockers; Case-Control Studies; Cerebral Arteries | 2001 |
Nebivolol vs amlodipine as first-line treatment of essential arterial hypertension in the elderly.
Topics: Aged; Aged, 80 and over; Amlodipine; Antihypertensive Agents; Benzopyrans; Blood Pressure; Double-Bl | 2002 |
Differential effects of a long-acting angiotensin converting enzyme inhibitor (temocapril) and a long-acting calcium antagonist (amlodipine) on ventricular ectopic beats in older hypertensive patients.
Topics: Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Blood Pressure; Calcium Channel Blockers | 2002 |
Effects of angiotensin converting enzyme inhibitor and calcium antagonist on endothelial function in patients with essential hypertension.
Topics: Adult; Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Ascorbic Acid; Calcium Channel Bl | 2002 |
Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect.
Topics: Adult; Aged; Albuminuria; Amlodipine; Angiotensin Receptor Antagonists; Antihypertensive Agents; Blo | 2002 |
Improvement of endothelial function by amlodipine and vitamin C in essential hypertension.
Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Ascorbic Acid; Calcium Channel Blockers; Endotheli | 2002 |
[Arterial hypertension in elderly individuals].
Topics: Age Factors; Aged; Aged, 80 and over; Amlodipine; Antihypertensive Agents; Calcium Channel Blockers; | 2002 |
Efficacy and safety of losartan-amplodipine combination--an Indian postmarketing surveillance experience.
Topics: Adult; Aged; Amlodipine; Blood Pressure Determination; Dose-Response Relationship, Drug; Drug Admini | 2002 |
Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Anti | 2002 |
Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Anti | 2002 |
Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Anti | 2002 |
Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Anti | 2002 |
Tolerability of long-term treatment with lercanidipine versus amlodipine and lacidipine in elderly hypertensives.
Topics: Aged; Amlodipine; Calcium Channel Blockers; Dihydropyridines; Double-Blind Method; Drug Therapy, Com | 2002 |
Persistence of the antihypertensive efficacy of amlodipine and nifedipine GITS after two 'missed doses': a randomised, double-blind comparative trial in Asian patients.
Topics: Amlodipine; Antihypertensive Agents; Asia, Southeastern; Blood Pressure Monitoring, Ambulatory; Dose | 2002 |
Effects of amlodipine fosinopril combination on microalbuminuria in hypertensive type 2 diabetic patients.
Topics: Aged; Albuminuria; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Ca | 2002 |
Drug effects on aldosterone/plasma renin activity ratio in primary aldosteronism.
Topics: Aldosterone; Amlodipine; Antihypertensive Agents; Atenolol; Biphenyl Compounds; Confounding Factors, | 2002 |
Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
Topics: Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Calcium Channel | 2002 |
Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
Topics: Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Calcium Channel | 2002 |
Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
Topics: Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Calcium Channel | 2002 |
Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
Topics: Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Calcium Channel | 2002 |
Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
Topics: Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Calcium Channel | 2002 |
Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
Topics: Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Calcium Channel | 2002 |
Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
Topics: Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Calcium Channel | 2002 |
Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
Topics: Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Calcium Channel | 2002 |
Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
Topics: Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Calcium Channel | 2002 |
Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
Topics: Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Calcium Channel | 2002 |
Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
Topics: Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Calcium Channel | 2002 |
Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
Topics: Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Calcium Channel | 2002 |
Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
Topics: Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Calcium Channel | 2002 |
Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
Topics: Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Calcium Channel | 2002 |
Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
Topics: Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Calcium Channel | 2002 |
Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
Topics: Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Calcium Channel | 2002 |
Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
Topics: Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Calcium Channel | 2002 |
Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
Topics: Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Calcium Channel | 2002 |
Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
Topics: Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Calcium Channel | 2002 |
Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
Topics: Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Calcium Channel | 2002 |
Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
Topics: Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Calcium Channel | 2002 |
Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
Topics: Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Calcium Channel | 2002 |
Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
Topics: Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Calcium Channel | 2002 |
Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
Topics: Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Calcium Channel | 2002 |
Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
Topics: Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Calcium Channel | 2002 |
Antiproteinuric effects of combined antihypertensive therapies in patients with overt type 2 diabetic nephropathy.
Topics: Aged; Amlodipine; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihy | 2002 |
[Validation of the therapeutic role of amlodipine in 31,946 French hypertensive patients].
Topics: Aged; Amlodipine; Antihypertensive Agents; Female; France; Heart Rate; Humans; Hypertension; Male; M | 2000 |
Comparison of effects of nisoldipine-extended release and amlodipine in patients with systemic hypertension and chronic stable angina pectoris.
Topics: Amlodipine; Angina Pectoris; Calcium Channel Blockers; Delayed-Action Preparations; Double-Blind Met | 2003 |
[Effect of losartan and amilodipine on the platelet activation and renal function in patients with mild and moderate hypertension].
Topics: Amlodipine; Antihypertensive Agents; Female; Humans; Hypertension; Kidney; Kidney Function Tests; Lo | 2002 |
[CEA comprehensive evaluation for Western and traditional Chinese hypotensive drugs].
Topics: Adult; Aged; Aged, 80 and over; Amlodipine; Antihypertensive Agents; Benzazepines; Cost-Benefit Anal | 2001 |
Effect of benazepril addition to amlodipine on ankle oedema and subcutaneous tissue pressure in hypertensive patients.
Topics: Adult; Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Ankle; Benzazepines; Calcium Chan | 2003 |
[Control of systolic blood pressure in the VALUE trial after 12 months].
Topics: Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Cardiovascular Diseases; Double-Blind Met | 2003 |
Cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial of patients with type 2 diabetes and overt nephropathy.
Topics: Amlodipine; Angiotensin II; Angiotensin Receptor Antagonists; Antihypertensive Agents; Biphenyl Comp | 2003 |
Azelnidipine and amlodipine: a comparison of their pharmacokinetics and effects on ambulatory blood pressure.
Topics: Amlodipine; Antihypertensive Agents; Azetidinecarboxylic Acid; Blood Pressure; Blood Pressure Monito | 2003 |
The ALLHAT Trial. Diuretics are still the preferred initial drugs for high blood pressure.
Topics: Aged; Amlodipine; Antihypertensive Agents; Blood Pressure Determination; Chlorthalidone; Diuretics; | 2003 |
Effects of the selective aldosterone blocker eplerenone versus the calcium antagonist amlodipine in systolic hypertension.
Topics: Aged; Albuminuria; Amlodipine; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Calcium Channe | 2003 |
The effect of high dose losartan on erythropoietin resistance in patients undergoing haemodialysis.
Topics: Adult; Amlodipine; Anemia; Angiotensin Receptor Antagonists; Antihypertensive Agents; Dose-Response | 2003 |
Randomized, comparative, double-blind study of amlodipine vs. nicardipine as a treatment of isolated systolic hypertension in the elderly.
Topics: Aged; Aged, 80 and over; Amlodipine; Antihypertensive Agents; Blood Pressure; Blood Pressure Monitor | 2002 |
Quantification of leg oedema in postmenopausal hypertensive patients treated with lercanidipine or amlodipine.
Topics: Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Blood Volume; Calcium Channel Blockers; D | 2003 |
Effect of amlodipine and hormone replacement therapy on blood pressure and bone markers in menopause.
Topics: Amlodipine; Antihypertensive Agents; Blood Pressure; Estrogen Replacement Therapy; Female; Heart Rat | 2003 |
Effect of losartan and amlodipine on proteinuria and transforming growth factor-beta1 in patients with IgA nephropathy.
Topics: Adult; Amlodipine; Antihypertensive Agents; Blood Pressure; Female; Glomerulonephritis, IGA; Humans; | 2003 |
Antihypertensive efficacy and safety of olmesartan medoxomil compared with amlodipine for mild-to-moderate hypertension.
Topics: Amlodipine; Antihypertensive Agents; Blood Pressure Monitoring, Ambulatory; Circadian Rhythm; Double | 2003 |
Restoration of nocturnal dip in blood pressure is associated with improvement in left ventricular ejection fraction. A 1-year clinical study comparing the effects of amlodipine and nifedipine retard on ambulatory blood pressure and left ventricular systol
Topics: Aged; Amlodipine; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Calcium Channel Blockers; C | 2003 |
Effect of amlodipine, quinapril, and losartan on pulse wave velocity and plasma collagen markers in patients with mild-to-moderate arterial hypertension.
Topics: Adult; Aldosterone; Amlodipine; Antihypertensive Agents; Biomarkers; Blood Flow Velocity; Blood Pres | 2003 |
Treatment of mild-to-moderate hypertension with calcium channel blockers: a multicentre comparison of once-daily nifedipine GITS with once-daily amlodipine.
Topics: Adult; Aged; Amlodipine; Blood Pressure; Calcium Channel Blockers; Drug Administration Schedule; Dru | 2003 |
Are thiazide diuretics preferred as first-line therapy for hypertension? An appraisal of The Antihypertensive and Lipid-lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
Topics: Aged; Amlodipine; Benzothiadiazines; Blood Chemical Analysis; Chlorthalidone; Diuretics; Dose-Respon | 2003 |
Effect of benazepril amlodipine combination on fibrinolysis in hypertensive diabetic patients.
Topics: Adult; Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Benzazepines; Blood Pressure; Cal | 2003 |
Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitors or calcium channel blocker vs diuretic. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
Topics: Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Calcium Channel Blockers; Chlorthalidone | 2003 |
Pharmacokinetics of amlodipine in hypertensive patients undergoing haemodialysis.
Topics: Adult; Aged; Amlodipine; Area Under Curve; Calcium Channel Blockers; Female; Hemodialysis Solutions; | 2003 |
VALUE trial: Long-term blood pressure trends in 13,449 patients with hypertension and high cardiovascular risk.
Topics: Algorithms; Amlodipine; Antihypertensive Agents; Blood Pressure; Cardiovascular Diseases; Cohort Stu | 2003 |
A comparison of flow-mediated dilatation and von Willebrand factor as markers of endothelial cell function in health and in hypertension: relationship to cardiovascular risk and effects of treatment: a substudy of the Anglo-Scandinavian Cardiac Outcomes T
Topics: Aged; Amlodipine; Anticholesteremic Agents; Antihypertensive Agents; Atenolol; Brachial Artery; Card | 2003 |
Results of a pilot pharmacotherapy quality improvement program using fixed-dose, combination amlodipine/benazepril antihypertensive therapy in a long-term care setting.
Topics: Aged; Aged, 80 and over; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Benzazepines; Calcium | 2003 |
Symptoms and the distress they cause: comparison of an aldosterone antagonist and a calcium channel blocking agent in patients with systolic hypertension.
Topics: Aged; Amlodipine; Analysis of Variance; Calcium Channel Blockers; Eplerenone; Female; Humans; Hypert | 2003 |
Comparison of the blood pressure-lowering effects and tolerability of Losartan- and Amlodipine-based regimens in patients with isolated systolic hypertension.
Topics: Adult; Aged; Aged, 80 and over; Amlodipine; Antihypertensive Agents; Blood Pressure; Double-Blind Me | 2003 |
Amlodipine improves vascular function in patients with moderate to severe hypertension.
Topics: Acetylcholine; Adult; Amlodipine; Blood Pressure; Calcium Channel Blockers; Female; Forearm; Heart R | 2003 |
Comparative efficacy and safety of nisoldipine extended-release (ER) and amlodipine (CESNA-III study) in African American patients with hypertension.
Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Black or African American; Blood Pressure; Blood P | 2003 |
One year follow-up of hormone replacement therapy with percutaneous estradiol and low-dose vaginal natural progesterone in women with mild to moderate hypertension.
Topics: Administration, Cutaneous; Administration, Intravaginal; Aldosterone; Amlodipine; Antihypertensive A | 2003 |
Haemodynamic comparison of amlodipine and atenolol in essential hypertension using the quantascope.
Topics: Amlodipine; Antihypertensive Agents; Atenolol; Blood Pressure; Double-Blind Method; Heart Rate; Hemo | 1993 |
Better renoprotective effect of angiotensin II antagonist compared to dihydropyridine calcium channel blocker in childhood.
Topics: Adolescent; Albuminuria; Amlodipine; Angiotensin II; Antihypertensive Agents; Biphenyl Compounds; Bl | 2003 |
Amlodipine reduces cyclosporin-induced hyperuricaemia in hypertensive renal transplant recipients.
Topics: Adult; Amlodipine; Cyclosporine; Double-Blind Method; Female; Follow-Up Studies; Graft Rejection; Gr | 2003 |
Heterogeneous effect of calcium antagonists on leg oedema: a comparison of amlodipine versus lercanidipine in hypertensive patients.
Topics: Adult; Amlodipine; Blood Pressure; Calcium Channel Blockers; Cross-Over Studies; Dihydropyridines; E | 2003 |
Effects of eplerenone, enalapril, and eplerenone/enalapril in patients with essential hypertension and left ventricular hypertrophy: the 4E-left ventricular hypertrophy study.
Topics: Adult; Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Double-B | 2003 |
Effects of eplerenone, enalapril, and eplerenone/enalapril in patients with essential hypertension and left ventricular hypertrophy: the 4E-left ventricular hypertrophy study.
Topics: Adult; Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Double-B | 2003 |
Effects of eplerenone, enalapril, and eplerenone/enalapril in patients with essential hypertension and left ventricular hypertrophy: the 4E-left ventricular hypertrophy study.
Topics: Adult; Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Double-B | 2003 |
Effects of eplerenone, enalapril, and eplerenone/enalapril in patients with essential hypertension and left ventricular hypertrophy: the 4E-left ventricular hypertrophy study.
Topics: Adult; Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Double-B | 2003 |
Comparative effects of irbesartan versus amlodipine on left ventricular mass index in hypertensive patients with left ventricular hypertrophy.
Topics: Adult; Aged; Amlodipine; Analysis of Variance; Biphenyl Compounds; Blood Pressure; Female; Heart Rat | 2003 |
Direct comparison of the effects of valsartan and amlodipine on renal hemodynamics in human essential hypertension.
Topics: Amlodipine; Antihypertensive Agents; Double-Blind Method; Glomerular Filtration Rate; Humans; Hypert | 2003 |
Effects of calcium channel antagonists on left ventricular hypertrophy and diastolic function in patients with essential hypertension.
Topics: Amlodipine; Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Diastole; Dihydropyri | 2003 |
A randomized, double-blind, active-controlled, parallel-group comparison of valsartan and amlodipine in the treatment of isolated systolic hypertension in elderly patients: the Val-Syst study.
Topics: Aged; Aged, 80 and over; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Calcium Channel Blocke | 2003 |
Effect of antihypertensive monotherapy and combination therapy on arterial distensibility and left ventricular mass.
Topics: Adult; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Benzazepines; Calcium Channel Blockers; | 2004 |
Comparison of valsartan and amlodipine on ambulatory and morning blood pressure in hypertensive patients.
Topics: Aged; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Blood Pressure; | 2004 |
Efficacy and tolerability of the combination valsartan/hydrochlorothiazide compared with amlodipine in a mild-to-moderately hypertensive Brazilian population.
Topics: Aged; Amlodipine; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Brazil; Double-Blind Method | 2003 |
Effect of an angiotensin II type 1 receptor blocker, valsartan, on neurohumoral factors in patients with hypertension: comparison with a long-acting calcium channel antagonist, amlodipine.
Topics: Aged; Aldosterone; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Calcium Channel Blockers; Co | 2003 |
Hemodynamic effects of amlodipine, bisoprolol, and lisinopril in hypertensive patients after liver transplantation.
Topics: Adult; Aged; Aldosterone; Amlodipine; Antihypertensive Agents; Bisoprolol; Cross-Over Studies; Femal | 2004 |
Amlodipine 2.5 mg once daily in older hypertensives: a Brazilian multi-centre study.
Topics: Aged; Amlodipine; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Brazil; Circadian Rhythm; F | 2004 |
Comparison of the effects on 24-h ambulatory blood pressure of valsartan and amlodipine, alone or in combination with a low-dose diuretic, in elderly patients with isolated systolic hypertension (Val-syst Study).
Topics: Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Ci | 2004 |
Effect of slow-release indapamide and perindopril compared with amlodipine on 24-hour blood pressure and left ventricular mass in hypertensive patients of African ancestry.
Topics: Adult; Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Black Pe | 2004 |
An economic evaluation of the Irbesartan in Diabetic Nephropathy Trial (IDNT) in a UK setting.
Topics: Amlodipine; Antihypertensive Agents; Biphenyl Compounds; Cohort Studies; Cost-Benefit Analysis; Diab | 2004 |
Comparative effects of valsartan versus amlodipine on left ventricular mass and reactive oxygen species formation by monocytes in hypertensive patients with left ventricular hypertrophy.
Topics: Amlodipine; Antihypertensive Agents; Cross-Sectional Studies; Double-Blind Method; Echocardiography; | 2004 |
Initial angiotensin-converting enzyme inhibitor/calcium channel blocker combination therapy achieves superior blood pressure control compared with calcium channel blocker monotherapy in patients with stage 2 hypertension.
Topics: Adult; Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Benzazep | 2004 |
Effects of amlodipine and lisinopril on intima-media thickness in previously untreated, elderly hypertensive patients (the ELVERA trial).
Topics: Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Calcium Channel | 2004 |
Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial.
Topics: Aged; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Blood Pressure; | 2004 |
Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial.
Topics: Aged; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Blood Pressure; | 2004 |
Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial.
Topics: Aged; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Blood Pressure; | 2004 |
Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial.
Topics: Aged; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Blood Pressure; | 2004 |
Amlodipine/benazepril combination therapy for hypertensive patients nonresponsive to benazepril monotherapy.
Topics: Adult; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Benzazepines; | 2004 |
Differential time effect profiles of amlodipine, as compared to valsartan, revealed by ambulatory blood pressure monitoring, self blood pressure measurements and dose omission protocol.
Topics: Amlodipine; Antihypertensive Agents; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Double-B | 2004 |
Effects of the long-acting calcium channel blockers, amlodipine, manidipine and cilnidipine on steroid hormones and insulin resistance in hypertensive obese patients.
Topics: Aged; Amlodipine; Analysis of Variance; Body Mass Index; Calcium Channel Blockers; Dehydroepiandrost | 2004 |
A randomized, placebo-controlled trial of amlodipine in children with hypertension.
Topics: Adolescent; Amlodipine; Blood Pressure; Calcium Channel Blockers; Child; Double-Blind Method; Drug A | 2004 |
Amlodipine increases nitric oxide production in exhaled air during exercise in patients with essential hypertension.
Topics: Adult; Amlodipine; Antihypertensive Agents; Blood Pressure; Breath Tests; Exercise; Heart Rate; Huma | 2004 |
Antihypertensive efficacy of night-time graded-release diltiazem versus morning amlodipine in African Americans.
Topics: Adolescent; Adult; Aged; Amlodipine; Antihypertensive Agents; Black or African American; Blood Press | 2004 |
Effect of amlodipine-atorvastatin combination on fibrinolysis in hypertensive hypercholesterolemic patients with insulin resistance.
Topics: Adult; Aged; Amlodipine; Anticholesteremic Agents; Antihypertensive Agents; Atorvastatin; Drug Thera | 2004 |
Rationale and design of a study comparing two fixed-dose combination regimens to reduce albuminuria in patients with type II diabetes and hypertension.
Topics: Adult; Aged; Aged, 80 and over; Albuminuria; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; A | 2005 |
A comparison of the efficacy and duration of action of telmisartan, amlodipine and ramipril in patients with confirmed ambulatory hypertension.
Topics: Aged; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; | 2004 |
Randomized, controlled, parallel-group comparison of ambulatory and clinic blood pressure responses to amlodipine or enalapril during and after treatment in adult chinese patients with hypertension.
Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Asian People; Blood Pressure; Blood Pressure Monit | 2004 |
Platelet morphology and plasma indices of platelet activation in essential hypertension: effects of amlodipine-based antihypertensive therapy.
Topics: Amlodipine; Antihypertensive Agents; Blood Platelets; Cross-Sectional Studies; Female; Humans; Hyper | 2004 |
Ambulatory versus clinic blood pressure for the assessment of anti hypertensive efficacy in clinical trials: insights from the Val-Syst Study.
Topics: Aged; Aged, 80 and over; Ambulatory Care Facilities; Amlodipine; Antihypertensive Agents; Blood Pres | 2004 |
Ambulatory blood pressure monitoring and active renin in menopausal women treated with amlodipine and hormone replacement therapy.
Topics: Amlodipine; Antihypertensive Agents; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Choleste | 2004 |
Multicentric, clinical trial of S-Amlodipine 2.5 mg versus Amlodipine 5 mg in the treatment of mild to moderate hypertension--a randomized, double-blind clinical trial.
Topics: Amlodipine; Blood Pressure; Double-Blind Method; Female; Humans; Hypertension; Male; Middle Aged; St | 2004 |
Effect of antihypertensive treatment with candesartan or amlodipine on glutathione and its redox status, homocysteine and vitamin concentrations in patients with essential hypertension.
Topics: Amlodipine; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Female; Fol | 2005 |
Proteinuria reduction and progression to renal failure in patients with type 2 diabetes mellitus and overt nephropathy.
Topics: Adult; Aged; Amlodipine; Biphenyl Compounds; Blood Pressure; Diabetes Mellitus, Type 2; Diabetic Nep | 2005 |
Effects of circadian rhythms, posture, and medication on renin-aldosterone interrelations in essential hypertensives.
Topics: Adult; Aged; Aldosterone; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Convertin | 2005 |
Efficacy and tolerability of candesartan cilexetil vs. amlodipine as assessed by home blood pressure in hypertensive patients.
Topics: Adolescent; Adult; Aged; Amlodipine; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Bl | 2005 |
Comparison of antihypertensive effects of an angiotensin-converting enzyme inhibitor, a calcium antagonist and a diuretic in patients with hypertension not controlled by angiotensin receptor blocker monotherapy.
Topics: Adolescent; Adult; Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agen | 2005 |
[Effect of amlodipine on intravascular thrombocyte activity in patients with arterial hypertension and metabolic syndrome].
Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Biomarkers; Blood Platelets; Humans; Hypertension; | 2005 |
24-hour ambulatory blood-pressure effects of valsartan and hydrochlorothiazide combinations compared with amlodipine in hypertensive patients at increased cardiovascular risk: a VAST sub-study.
Topics: Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Ci | 2005 |
Renal outcomes in high-risk hypertensive patients treated with an angiotensin-converting enzyme inhibitor or a calcium channel blocker vs a diuretic: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
Topics: Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Blood Pressure; Calcium Channel Blockers | 2005 |
Renal outcomes in high-risk hypertensive patients treated with an angiotensin-converting enzyme inhibitor or a calcium channel blocker vs a diuretic: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
Topics: Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Blood Pressure; Calcium Channel Blockers | 2005 |
Renal outcomes in high-risk hypertensive patients treated with an angiotensin-converting enzyme inhibitor or a calcium channel blocker vs a diuretic: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
Topics: Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Blood Pressure; Calcium Channel Blockers | 2005 |
Renal outcomes in high-risk hypertensive patients treated with an angiotensin-converting enzyme inhibitor or a calcium channel blocker vs a diuretic: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
Topics: Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Blood Pressure; Calcium Channel Blockers | 2005 |
Effects of amlodipine and fosinopril on heart rate variability and left ventricular mass in mild-to-moderate essential hypertension.
Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Electrocardiography; Female; Fosinopril; Heart Rat | 2005 |
Comparison of blood pressure control with amlodipine and controlled-release isradipine: an open-label, drug substitution study.
Topics: Amlodipine; Analysis of Variance; Blood Pressure Determination; Calcium Channel Blockers; Delayed-Ac | 2005 |
Effect of fixed-dose ACE-inhibitor/calcium channel blocker combination therapy vs. ACE-inhibitor monotherapy on arterial compliance in hypertensive patients with type 2 diabetes.
Topics: Albuminuria; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Benzazep | 2005 |
Evaluation of long-term efficacy and acceptability of indapamide SR in elderly hypertensive patients.
Topics: Aged; Aged, 80 and over; Amlodipine; Analysis of Variance; Antihypertensive Agents; Double-Blind Met | 2005 |
Single-pill therapy in the treatment of concomitant hypertension and dyslipidemia (the amlodipine/atorvastatin gemini study).
Topics: Adult; Aged; Aged, 80 and over; Amlodipine; Antihypertensive Agents; Atorvastatin; Drug Combinations | 2005 |
Effect of the renin-angiotensin system or calcium channel blockade on the circadian variation of heart rate variability, blood pressure and circulating catecholamines in hypertensive patients.
Topics: Aged; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; | 2005 |
Blood pressure control, drug therapy, and kidney disease.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Anti | 2005 |
Effects of amlodipine and lacidipine on heart rate variability in hypertensive patients with stable angina pectoris and isolated left ventricular diastolic dysfunction.
Topics: Adult; Aged; Amlodipine; Angina Pectoris; Blood Pressure; Calcium Channel Blockers; Circadian Rhythm | 2005 |
Results of a multicenter, 8-week, parallel-group, randomized,double-blind, double-dummy, Phase III clinical trial to evaluate the efficacy and tolerability of amlodipine maleate versus amlodipine besylate in Korean patients with mild to moderate hypertens
Topics: Adult; Aged; Amlodipine; Blood Pressure; Calcium Channel Blockers; Double-Blind Method; Female; Huma | 2005 |
Targeting albumin excretion rate in the treatment of the hypertensive diabetic patient with renal disease.
Topics: Adult; Aged; Albuminuria; Amlodipine; Benzimidazoles; Biphenyl Compounds; Cross-Over Studies; Diabet | 2005 |
Effects of nilvadipine and amlodipine in patients with mild to moderate essential hypertension: a double blind, prospective, randomised clinical trial.
Topics: Adolescent; Adult; Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Calcium Channel Blocke | 2005 |
Clinical observation on Breviscapine in treating hypertension patients complicated with micro-albuminuria of renal impairment.
Topics: Adult; Aged; Albuminuria; Amlodipine; Antihypertensive Agents; beta 2-Microglobulin; Blood Pressure; | 2005 |
Efficacy and tolerability of combination therapy with valsartan plus hydrochlorothiazide compared with amlodipine monotherapy in hypertensive patients with other cardiovascular risk factors: the VAST study.
Topics: Age Factors; Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Cerebrovascular Disorders; D | 2005 |
Effect of amlodipine and lacidipine on left ventricular diastolic and long axis functions in arterial hypertension and stable angina pectoris.
Topics: Aged; Amlodipine; Angina Pectoris; Calcium Channel Blockers; Coronary Angiography; Coronary Disease; | 2005 |
Effects of losartan and amlodipine on urinary albumin excretion and ambulatory blood pressure in hypertensive type 2 diabetic patients with overt nephropathy.
Topics: Adult; Albuminuria; Amlodipine; Antihypertensive Agents; Blood Pressure; Blood Pressure Monitoring, | 2005 |
[Normodipin in correction of platelet rheology in hypertensive patients with metabolic syndrome].
Topics: Amlodipine; Blood Platelets; Female; Humans; Hypertension; Lipid Peroxidation; Lipids; Male; Metabol | 2005 |
Pharmacokinetic interactions between indinavir plus ritonavir and calcium channel blockers.
Topics: Adolescent; Adult; Amlodipine; Calcium Channel Blockers; Diltiazem; Drug Interactions; Drug Therapy, | 2005 |
Interaction between amlodipine and simvastatin in patients with hypercholesterolemia and hypertension.
Topics: Administration, Oral; Aged; Amlodipine; Antihypertensive Agents; Drug Interactions; Female; Humans; | 2005 |
A noninferiority comparison of valsartan/hydrochlorothiazide combination versus amlodipine in black hypertensives.
Topics: Adult; Aged; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Black People; Blood Pressure; Calc | 2005 |
Clinic blood pressure responses to two amlodipine salt formulations, adipate and besylate, in adult Korean patients with mild to moderate hypertension: a multicenter, randomized, double-blind, parallel-group, 8-week comparison.
Topics: Adipates; Adult; Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Capsules; Double-Blind M | 2005 |
Independent and additive impact of blood pressure control and angiotensin II receptor blockade on renal outcomes in the irbesartan diabetic nephropathy trial: clinical implications and limitations.
Topics: Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Biphenyl Compounds; Di | 2005 |
[Double blind study of the efficacy and safety of the fixed dose combination of enalapril 10 mg/nitrendipine 20 mg versus the increase of amlopidine dose in essential hypertensive patients not controlled with amlodipine 5 mg].
Topics: Amlodipine; Antihypertensive Agents; Double-Blind Method; Drug Therapy, Combination; Enalapril; Fema | 2005 |
Clinical study on safety and efficacy of the administration of amlodipine in a combination with lisinopril in hypertensive patients.
Topics: Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Pressure; Calci | 2005 |
Efficacy of combination therapy for systolic blood pressure in patients with severe systolic hypertension: the Systolic Evaluation of Lotrel Efficacy and Comparative Therapies (SELECT) study.
Topics: Aged; Amlodipine; Analysis of Variance; Antihypertensive Agents; Benzazepines; Blood Pressure Monito | 2005 |
24-hour blood pressure control with the once-daily calcium antagonist amlodipine.
Topics: Adolescent; Adult; Aged; Amlodipine; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Calcium | 1991 |
Effect of amlodipine on 24-hour ambulatory blood pressure in hypertensive patients.
Topics: Aged; Amlodipine; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Calcium Channel Blockers; D | 1991 |
A double-blind comparison of amlodipine and placebo added to open enalapril in patients with moderate to severe essential hypertension.
Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Double-Blind Method; Drug Therapy, | 1991 |
A double-blind, parallel, comparative evaluation of amlodipine vs. captopril in the monotherapeutic treatment of mild and moderate essential hypertension.
Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Captopril; Double-Blind Method; Dr | 1991 |
An open, parallel, comparative evaluation of amlodipine and nitrendipine in the monotherapeutic treatment of mild and moderate essential hypertension.
Topics: Amlodipine; Antihypertensive Agents; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Drug Adm | 1991 |
Amlodipine in hypertension: its effects on platelet aggregation and dynamic exercise.
Topics: Amlodipine; Blood Pressure; Calcium Channel Blockers; Drug Administration Schedule; Exercise; Female | 1991 |
Open evaluation of amlodipine in the monotherapeutic treatment of systolic hypertension in the elderly.
Topics: Aged; Aged, 80 and over; Amlodipine; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Calcium | 1991 |
The efficacy and safety of amlodipine in the treatment of mild and moderate essential hypertension in general practice.
Topics: Adult; Aged; Aged, 80 and over; Amlodipine; Blood Pressure; Calcium Channel Blockers; Dose-Response | 1991 |
Haemodynamic effects of AT1 inhibition and Ca2+-channel blockade in hypertensive patients during isometric stress.
Topics: Amlodipine; Analysis of Variance; Antihypertensive Agents; Calcium Channel Blockers; Cross-Over Stud | 2006 |
Sympatho-excitatory responses to once-daily dihydropyridines in young versus older hypertensive patients: amlodipine versus felodipine extended release.
Topics: Adult; Aged; Aged, 80 and over; Aging; Amlodipine; Antihypertensive Agents; Blood Pressure; Body Wei | 2006 |
Effect of losartan and amlodipine on left ventricular diastolic function in patients with mild-to-moderate hypertension (J-ELAN): rationale and design.
Topics: Adult; Amlodipine; Antihypertensive Agents; Blood Pressure; Diastole; Female; Humans; Hypertension; | 2006 |
Effects of a structured treatment algorithm on blood pressure goal rates in both stage 1 and stage 2 hypertension.
Topics: Adult; Aged; Aged, 80 and over; Algorithms; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Blo | 2006 |
Urinary TGF-beta1 reduction related to a decrease of systolic blood pressure in patients with type 2 diabetes and clinical diabetic nephropathy.
Topics: Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Atenolol; Blood Gluco | 2006 |
Losartan and prevention of atrial fibrillation recurrence in hypertensive patients.
Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Atrial Fibrillation; Double-Blind Method; Female; | 2006 |
A randomized trial comparing losartan with amlodipine as initial therapy for hypertension in the early post-transplant period.
Topics: Adult; Aged; Amlodipine; Blood Pressure Determination; Chi-Square Distribution; Dose-Response Relati | 2006 |
Indapamide SR versus candesartan and amlodipine in hypertension: the X-CELLENT Study.
Topics: Adult; Aged; Aged, 80 and over; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensiv | 2006 |
Cardiovascular outcomes in high-risk hypertensive patients stratified by baseline glomerular filtration rate.
Topics: Aged; Amlodipine; Antihypertensive Agents; Cardiovascular Diseases; Chlorthalidone; Chronic Disease; | 2006 |
Comparison of monotherapy with irbesartan 150 mg or amlodipine 5 mg for treatment of mild-to-moderate hypertension.
Topics: Adolescent; Adult; Aged; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agent | 2005 |
Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study.
Topics: Age Distribution; Amlodipine; Antihypertensive Agents; Aorta; Atenolol; Blood Pressure; Brachial Art | 2006 |
Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study.
Topics: Age Distribution; Amlodipine; Antihypertensive Agents; Aorta; Atenolol; Blood Pressure; Brachial Art | 2006 |
Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study.
Topics: Age Distribution; Amlodipine; Antihypertensive Agents; Aorta; Atenolol; Blood Pressure; Brachial Art | 2006 |
Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study.
Topics: Age Distribution; Amlodipine; Antihypertensive Agents; Aorta; Atenolol; Blood Pressure; Brachial Art | 2006 |
Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study.
Topics: Age Distribution; Amlodipine; Antihypertensive Agents; Aorta; Atenolol; Blood Pressure; Brachial Art | 2006 |
Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study.
Topics: Age Distribution; Amlodipine; Antihypertensive Agents; Aorta; Atenolol; Blood Pressure; Brachial Art | 2006 |
Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study.
Topics: Age Distribution; Amlodipine; Antihypertensive Agents; Aorta; Atenolol; Blood Pressure; Brachial Art | 2006 |
Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study.
Topics: Age Distribution; Amlodipine; Antihypertensive Agents; Aorta; Atenolol; Blood Pressure; Brachial Art | 2006 |
Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study.
Topics: Age Distribution; Amlodipine; Antihypertensive Agents; Aorta; Atenolol; Blood Pressure; Brachial Art | 2006 |
Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study.
Topics: Age Distribution; Amlodipine; Antihypertensive Agents; Aorta; Atenolol; Blood Pressure; Brachial Art | 2006 |
Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study.
Topics: Age Distribution; Amlodipine; Antihypertensive Agents; Aorta; Atenolol; Blood Pressure; Brachial Art | 2006 |
Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study.
Topics: Age Distribution; Amlodipine; Antihypertensive Agents; Aorta; Atenolol; Blood Pressure; Brachial Art | 2006 |
Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study.
Topics: Age Distribution; Amlodipine; Antihypertensive Agents; Aorta; Atenolol; Blood Pressure; Brachial Art | 2006 |
Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study.
Topics: Age Distribution; Amlodipine; Antihypertensive Agents; Aorta; Atenolol; Blood Pressure; Brachial Art | 2006 |
Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study.
Topics: Age Distribution; Amlodipine; Antihypertensive Agents; Aorta; Atenolol; Blood Pressure; Brachial Art | 2006 |
Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study.
Topics: Age Distribution; Amlodipine; Antihypertensive Agents; Aorta; Atenolol; Blood Pressure; Brachial Art | 2006 |
Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study.
Topics: Age Distribution; Amlodipine; Antihypertensive Agents; Aorta; Atenolol; Blood Pressure; Brachial Art | 2006 |
Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study.
Topics: Age Distribution; Amlodipine; Antihypertensive Agents; Aorta; Atenolol; Blood Pressure; Brachial Art | 2006 |
Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study.
Topics: Age Distribution; Amlodipine; Antihypertensive Agents; Aorta; Atenolol; Blood Pressure; Brachial Art | 2006 |
Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study.
Topics: Age Distribution; Amlodipine; Antihypertensive Agents; Aorta; Atenolol; Blood Pressure; Brachial Art | 2006 |
Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study.
Topics: Age Distribution; Amlodipine; Antihypertensive Agents; Aorta; Atenolol; Blood Pressure; Brachial Art | 2006 |
Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study.
Topics: Age Distribution; Amlodipine; Antihypertensive Agents; Aorta; Atenolol; Blood Pressure; Brachial Art | 2006 |
Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study.
Topics: Age Distribution; Amlodipine; Antihypertensive Agents; Aorta; Atenolol; Blood Pressure; Brachial Art | 2006 |
Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study.
Topics: Age Distribution; Amlodipine; Antihypertensive Agents; Aorta; Atenolol; Blood Pressure; Brachial Art | 2006 |
Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study.
Topics: Age Distribution; Amlodipine; Antihypertensive Agents; Aorta; Atenolol; Blood Pressure; Brachial Art | 2006 |
Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study.
Topics: Age Distribution; Amlodipine; Antihypertensive Agents; Aorta; Atenolol; Blood Pressure; Brachial Art | 2006 |
Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study.
Topics: Age Distribution; Amlodipine; Antihypertensive Agents; Aorta; Atenolol; Blood Pressure; Brachial Art | 2006 |
Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study.
Topics: Age Distribution; Amlodipine; Antihypertensive Agents; Aorta; Atenolol; Blood Pressure; Brachial Art | 2006 |
Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study.
Topics: Age Distribution; Amlodipine; Antihypertensive Agents; Aorta; Atenolol; Blood Pressure; Brachial Art | 2006 |
Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study.
Topics: Age Distribution; Amlodipine; Antihypertensive Agents; Aorta; Atenolol; Blood Pressure; Brachial Art | 2006 |
Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study.
Topics: Age Distribution; Amlodipine; Antihypertensive Agents; Aorta; Atenolol; Blood Pressure; Brachial Art | 2006 |
Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study.
Topics: Age Distribution; Amlodipine; Antihypertensive Agents; Aorta; Atenolol; Blood Pressure; Brachial Art | 2006 |
Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study.
Topics: Age Distribution; Amlodipine; Antihypertensive Agents; Aorta; Atenolol; Blood Pressure; Brachial Art | 2006 |
Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study.
Topics: Age Distribution; Amlodipine; Antihypertensive Agents; Aorta; Atenolol; Blood Pressure; Brachial Art | 2006 |
Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study.
Topics: Age Distribution; Amlodipine; Antihypertensive Agents; Aorta; Atenolol; Blood Pressure; Brachial Art | 2006 |
Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study.
Topics: Age Distribution; Amlodipine; Antihypertensive Agents; Aorta; Atenolol; Blood Pressure; Brachial Art | 2006 |
Losartan improves resistance artery lesions and prevents CTGF and TGF-beta production in mild hypertensive patients.
Topics: Adult; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Arteries; Conn | 2006 |
[The "LOTHAR" study: evaluation of efficacy and tolerability of the fixed combination of amlodipine and losartan in the treatment of essential hypertension].
Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Blood Pressure Monitoring, Ambulatory; Chi-Square | 2006 |
Role of diuretics in the prevention of heart failure: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial.
Topics: Adrenergic beta-Antagonists; Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihyperte | 2006 |
Comparison of the effects of cilnidipine and amlodipine on ambulatory blood pressure.
Topics: Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Ca | 2005 |
Selective imidazoline agonist moxonidine in obese hypertensive patients.
Topics: Adult; Amlodipine; Anthropometry; Antihypertensive Agents; Female; Hemodynamics; Humans; Hypertensio | 2006 |
Use of 24-h ambulatory blood pressure monitoring to assess blood pressure control: a comparison of olmesartan medoxomil and amlodipine besylate.
Topics: Amlodipine; Antihypertensive Agents; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Female; | 2006 |
Antihypertensive therapy, the alpha-adducin polymorphism, and cardiovascular disease in high-risk hypertensive persons: the Genetics of Hypertension-Associated Treatment Study.
Topics: Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Calmodulin-Binding Proteins; Chlorthalido | 2007 |
Regression of cardiac hypertrophy in type 2 diabetes with hypertension by candesartan.
Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Blood Pressure | 2006 |
Quality of life in the African American Study of Kidney Disease and Hypertension: effects of blood pressure management.
Topics: Adolescent; Adult; Aged; Amlodipine; Antihypertensive Agents; Black or African American; Blood Press | 2006 |
Comparison of efficacy and tolerability of amlodipine orotate versus amlodipine besylate in adult patients with mild to moderate hypertension: a multicenter, randomized, double-blind, placebo-controlled, parallel-group, 8-week follow-up, noninferiority tr
Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Double-Blind Method; Female; Follo | 2006 |
Effects of valsartan compared to amlodipine on preventing type 2 diabetes in high-risk hypertensive patients: the VALUE trial.
Topics: Aged; Amlodipine; Antihypertensive Agents; Diabetes Mellitus, Type 2; Double-Blind Method; Female; H | 2006 |
Randomized, double-blind, crossover comparison of amlodipine and valsartan in african-americans with hypertension using 24-hour ambulatory blood pressure monitoring.
Topics: Adult; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Black or Africa | 2006 |
Effects of amlodipine and valsartan on vascular damage and ambulatory blood pressure in untreated hypertensive patients.
Topics: Amlodipine; Antihypertensive Agents; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Carotid | 2006 |
Population pharmacokinetics of amlodipine in hypertensive children and adolescents.
Topics: Adolescent; Amlodipine; Antihypertensive Agents; Child; Child, Preschool; Female; Humans; Hypertensi | 2006 |
The Valsartan Antihypertensive Long-Term Use Evaluation (VALUE) trial: outcomes in patients receiving monotherapy.
Topics: Aged; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Blood Pressure; | 2006 |
Clinical events in high-risk hypertensive patients randomly assigned to calcium channel blocker versus angiotensin-converting enzyme inhibitor in the antihypertensive and lipid-lowering treatment to prevent heart attack trial.
Topics: Amlodipine; Angioedema; Angiotensin-Converting Enzyme Inhibitors; Black People; Blood Glucose; Blood | 2006 |
[Combined therapy with amlodipin and lisinopril in arterial hypertension: efficacy of a low-dose combination].
Topics: Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Calcium Channel Blockers; Cost-Benefit Analysi | 2006 |
Efficacy and safety of coadministered amlodipine and atorvastatin in patients with hypertension and dyslipidemia: results of the AVALON trial.
Topics: Adolescent; Adult; Aged; Amlodipine; Atorvastatin; Blood Pressure; Calcium Channel Blockers; Cholest | 2006 |
Effects of amlodipine-atorvastatin combination on inflammation markers and insulin sensitivity in normocholesterolemic obese hypertensive patients.
Topics: Adult; Aged; Amlodipine; Atorvastatin; Biomarkers; Blood Glucose; Body Mass Index; Calcium Channel B | 2006 |
Effects of monotherapy and combination therapy on blood pressure control and target organ damage: a randomized prospective intervention study in a large population of hypertensive patients.
Topics: Adult; Aged; Aged, 80 and over; Amlodipine; Antihypertensive Agents; Blood Pressure; Blood Pressure | 2006 |
Incidence and predictors of angioedema in elderly hypertensive patients at high risk for cardiovascular disease: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
Topics: Aged; Aged, 80 and over; Amlodipine; Angioedema; Angiotensin-Converting Enzyme Inhibitors; Antihyper | 2006 |
The newly developed calcium antagonist, azelnidipine, increases drain volume in continuous ambulatory peritoneal dialysis patients.
Topics: Amlodipine; Antihypertensive Agents; Azetidinecarboxylic Acid; Blood Pressure; Calcium Channel Block | 2006 |
Targeting hypertension with valsartan: Lessons learned from the Valsartan/HCTZ versus Amlodipine in stage II hypertensive patients (VASt) trial.
Topics: Amlodipine; C-Reactive Protein; Drug Combinations; Humans; Hydrochlorothiazide; Hypertension; Interl | 2006 |
Improved insulin sensitivity with the angiotensin II-receptor blocker losartan in patients with hypertension and other cardiovascular risk factors.
Topics: Aged; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Biomarkers; Bloo | 2006 |
Randomized study of angiotensin II type 1 receptor blocker vs dihydropiridine calcium antagonist for the treatment of paroxysmal atrial fibrillation in patients with hypertension.
Topics: Amlodipine; Angiotensin II Type 1 Receptor Blockers; Atrial Fibrillation; Benzimidazoles; Biphenyl C | 2006 |
A randomized, double-blind trial comparing the effects of amlodipine besylate/benazepril HCl vs amlodipine on endothelial function and blood pressure.
Topics: Aged; Amlodipine; Analysis of Variance; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive A | 2006 |
Amlodipine versus angiotensin II receptor blocker; control of blood pressure evaluation trial in diabetics (ADVANCED-J).
Topics: Adult; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Blood Pressure; | 2006 |
Outcomes in subgroups of hypertensive patients treated with regimens based on valsartan and amlodipine: An analysis of findings from the VALUE trial.
Topics: Aged; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Calcium Channel Blockers; Female; Heart A | 2006 |
Fasting glucose levels and incident diabetes mellitus in older nondiabetic adults randomized to receive 3 different classes of antihypertensive treatment: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHA
Topics: Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Glucose; | 2006 |
Renal and vascular protective effects of telmisartan in patients with essential hypertension.
Topics: Amlodipine; Angiotensin II Type 1 Receptor Blockers; Arteriosclerosis; Benzimidazoles; Benzoates; Bl | 2006 |
Long-term calcium antagonist treatment of human hypertension with mibefradil or amlodipine increases sympathetic nerve activity.
Topics: Aged; Aged, 80 and over; Amlodipine; Antihypertensive Agents; Blood Pressure; Calcium Channel Blocke | 2007 |
The effect of losartan and amlodipine on serum adiponectin in Japanese adults with essential hypertension.
Topics: Adiponectin; Adult; Aged; Amlodipine; Antihypertensive Agents; Drug Therapy, Combination; Female; Hu | 2006 |
Efficacy and safety of 24 weeks of therapy with bendroflumethiazide 1.25 mg/day or 2.5 mg/day and potassium chloride compared with enalapril 10 mg/day and amlodipine 5 mg/day in patients with mild to moderate primary hypertension : a multicentre, randomis
Topics: Adult; Aged; Amlodipine; Bendroflumethiazide; Enalapril; Female; Humans; Hypertension; Male; Middle | 2006 |
Low-dose quadruple antihypertensive combination: more efficacious than individual agents--a preliminary report.
Topics: Adrenergic beta-Antagonists; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive | 2007 |
Pharmacokinetic and pharmacodynamic characteristics of a new S-amlodipine formulation in healthy Korean male subjects: a randomized, open-label, two-period, comparative, crossover study.
Topics: Adult; Amlodipine; Angina Pectoris; Asian People; Blood Pressure; Calcium Channel Blockers; Cross-Ov | 2006 |
Effect of valsartan addition to amlodipine on ankle oedema and subcutaneous tissue pressure in hypertensive patients.
Topics: Adult; Age Factors; Aged; Amlodipine; Ankle; Blood Pressure; Cross-Over Studies; Drug Therapy, Combi | 2007 |
[Evaluation of hypotensive and antiischemic effects of a combination of dihydropyridine and non-dihydropyridine calcium antagonists in patients suffering from coronary artery disease with arterial hypertension].
Topics: Adult; Aged; Amlodipine; Blood Pressure; Calcium Channel Blockers; Coronary Circulation; Drug Therap | 2006 |
Angiotensin I-converting enzyme inhibitor improves reactive hyperemia in elderly hypertensives with arteriosclerosis obliterans.
Topics: Aged; Aged, 80 and over; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Arteriosclerosis Obli | 2006 |
Amlodipine added to quinapril vs quinapril alone for the treatment of hypertension in diabetes: the Amlodipine in Diabetes (ANDI) trial.
Topics: Amlodipine; Antihypertensive Agents; Blood Pressure Determination; Calcium Channel Blockers; Diabete | 2007 |
Ambulatory blood pressure monitoring after 1 year on valsartan or amlodipine-based treatment: a VALUE substudy.
Topics: Age Factors; Aged; Amlodipine; Antihypertensive Agents; Blood Pressure Monitoring, Ambulatory; Circa | 2007 |
Efficacy of azelnidipine on home blood pressure and pulse rate in patients with essential hypertension: comparison with amlodipine.
Topics: Aged; Amlodipine; Azetidinecarboxylic Acid; Blood Pressure; Blood Pressure Monitoring, Ambulatory; C | 2006 |
The effects of telmisartan and amlodipine on metabolic parameters and blood pressure in type 2 diabetic, hypertensive patients.
Topics: Aged; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Benzoates; Blood Pressure | 2006 |
Predictors of antihypertensive drug responses: initial data from a placebo-controlled, randomized, cross-over study with four antihypertensive drugs (The GENRES Study).
Topics: Adrenergic beta-Antagonists; Adult; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihyperte | 2007 |
Predictors of antihypertensive drug responses: initial data from a placebo-controlled, randomized, cross-over study with four antihypertensive drugs (The GENRES Study).
Topics: Adrenergic beta-Antagonists; Adult; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihyperte | 2007 |
Predictors of antihypertensive drug responses: initial data from a placebo-controlled, randomized, cross-over study with four antihypertensive drugs (The GENRES Study).
Topics: Adrenergic beta-Antagonists; Adult; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihyperte | 2007 |
Predictors of antihypertensive drug responses: initial data from a placebo-controlled, randomized, cross-over study with four antihypertensive drugs (The GENRES Study).
Topics: Adrenergic beta-Antagonists; Adult; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihyperte | 2007 |
Favourable effects of nilvadipine on cognitive function and regional cerebral blood flow on SPECT in hypertensive patients with mild cognitive impairment.
Topics: Aged; Amlodipine; Antihypertensive Agents; Brain; Cerebrovascular Circulation; Cognition Disorders; | 2007 |
Effects of valsartan or amlodipine alone or in combination on plasma catecholamine levels at rest and during standing in hypertensive patients.
Topics: Adolescent; Adult; Aged; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agent | 2007 |
Effects of telmisartan on fat distribution in individuals with the metabolic syndrome.
Topics: Adipose Tissue, White; Adult; Aged; Amlodipine; Analysis of Variance; Angiotensin II Type 1 Receptor | 2007 |
Discrepancy between improvement of insulin sensitivity and that of arterial endothelial function in patients receiving antihypertensive medication.
Topics: Aged; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; | 2007 |
Direct Renin inhibition with aliskiren in obese patients with arterial hypertension.
Topics: Administration, Oral; Adult; Aged; Amides; Amlodipine; Antihypertensive Agents; Biphenyl Compounds; | 2007 |
Direct Renin inhibition with aliskiren in obese patients with arterial hypertension.
Topics: Administration, Oral; Adult; Aged; Amides; Amlodipine; Antihypertensive Agents; Biphenyl Compounds; | 2007 |
Direct Renin inhibition with aliskiren in obese patients with arterial hypertension.
Topics: Administration, Oral; Adult; Aged; Amides; Amlodipine; Antihypertensive Agents; Biphenyl Compounds; | 2007 |
Direct Renin inhibition with aliskiren in obese patients with arterial hypertension.
Topics: Administration, Oral; Adult; Aged; Amides; Amlodipine; Antihypertensive Agents; Biphenyl Compounds; | 2007 |
Effect of antihypertensive agents on plasma adiponectin levels in hypertensive patients with metabolic syndrome.
Topics: Adiponectin; Adrenergic beta-Antagonists; Adult; Amlodipine; Angiotensin II Type 1 Receptor Blockers | 2007 |
Effects of amlodipine and candesartan on oxidized LDL level in patients with mild to moderate essential hypertension.
Topics: Alkenes; Amlodipine; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Double-Blind Method; Female | 2006 |
Effect of telmisartan-amlodipine combination at different doses on urinary albumin excretion in hypertensive diabetic patients with microalbuminuria.
Topics: Adult; Aged; Albuminuria; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Benzo | 2007 |
Long-term efficacy of combination therapy with losartan and low-dose hydrochlorothiazide in patients with uncontrolled hypertension.
Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Drug Administr | 2007 |
Add-on amlodipine improves arterial function and structure in hypertensive patients treated with an angiotensin receptor blocker.
Topics: Albuminuria; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Blood Pre | 2007 |
Baseline characteristics in the Avoiding Cardiovascular events through Combination therapy in Patients Living with Systolic Hypertension (ACCOMPLISH) trial: a hypertensive population at high cardiovascular risk.
Topics: Aged; Amlodipine; Antihypertensive Agents; Benzazepines; Body Mass Index; Diabetes Mellitus, Type 2; | 2007 |
Tolerability and blood pressure-lowering efficacy of the combination of amlodipine plus valsartan compared with lisinopril plus hydrochlorothiazide in adult patients with stage 2 hypertension.
Topics: Amlodipine; Antihypertensive Agents; Blood Pressure; Dose-Response Relationship, Drug; Double-Blind | 2007 |
Amlodipine and valsartan combined and as monotherapy in stage 2, elderly, and black hypertensive patients: subgroup analyses of 2 randomized, placebo-controlled studies.
Topics: Age Factors; Aged; Amlodipine; Antihypertensive Agents; Black People; Blood Pressure; Dose-Response | 2007 |
Effects of "newer" and "older" antihypertensive drugs on hemorrheological, platelet, and endothelial factors. A substudy of the Anglo-Scandinavian Cardiac Outcomes Trial.
Topics: Adrenergic beta-Antagonists; Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihyperte | 2007 |
The effects of high-dose amlodipine/benazepril combination therapies on blood pressure reduction in patients not adequately controlled with amlodipine monotherapy.
Topics: Adult; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Benzazepines; Blood Pressure; Blood Pre | 2007 |
Azelnidipine reduces urinary protein excretion and urinary liver-type fatty acid binding protein in patients with hypertensive chronic kidney disease.
Topics: 8-Hydroxy-2'-Deoxyguanosine; Adult; Amlodipine; Antioxidants; Azetidinecarboxylic Acid; Blood Pressu | 2007 |
Effects of new calcium channel blocker, azelnidipine, and amlodipine on baroreflex sensitivity and ambulatory blood pressure.
Topics: Adult; Aged; Aged, 80 and over; Amlodipine; Azetidinecarboxylic Acid; Baroreflex; Blood Pressure; Bl | 2007 |
Exceptional early blood pressure control rates: the ACCOMPLISH trial.
Topics: Amlodipine; Antihypertensive Agents; Benzazepines; Blood Pressure; Double-Blind Method; Drug Therapy | 2007 |
Two multicenter, 8-week, randomized, double-blind, placebo-controlled, parallel-group studies evaluating the efficacy and tolerability of amlodipine and valsartan in combination and as monotherapy in adult patients with mild to moderate essential hyperten
Topics: Amlodipine; Angiotensin II Type 1 Receptor Blockers; Calcium Channel Blockers; Double-Blind Method; | 2007 |
Haemorheological disturbances in hypertensive type 2 diabetic patients--influence of antihypertensive therapy.
Topics: Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Flow Velocity; | 2007 |
Prevention of renal dysfunction and hypertension by amlodipine after heart transplant.
Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Creatini | 2007 |
Antihypertensive efficacy and safety of manidipine versus amlodipine in elderly subjects with isolated systolic hypertension: MAISH study.
Topics: Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Cardiovascular | 2007 |
Blood pressure control in Hispanics in the antihypertensive and lipid-lowering treatment to prevent heart attack trial.
Topics: Aged; Amlodipine; Antihypertensive Agents; Atenolol; Black People; Blood Pressure; Canada; Chlorthal | 2007 |
Renal and vascular protective effects of cilnidipine in patients with essential hypertension.
Topics: Albuminuria; Amlodipine; Antihypertensive Agents; Arteries; Calcium Channel Blockers; Dihydropyridin | 2007 |
Calcium channel blocker, azelnidipine, reduces lipid hydroperoxides in patients with type 2 diabetes independent of blood pressure.
Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Ascorbic Acid; Azetidinecarboxylic Acid; Blood Pre | 2007 |
Efficacy and tolerability of candesartan cilexetil/hydrochlorothiazide and amlodipine in patients with poorly controlled mild-to-moderate essential hypertension.
Topics: Adult; Aged; Aged, 80 and over; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; | 2007 |
Economic evaluation of ASCOT-BPLA: antihypertensive treatment with an amlodipine-based regimen is cost effective compared with an atenolol-based regimen.
Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Atenolol; Cost-Benefit Analysis; Diabetes Mellitus | 2008 |
Comparison of the effects of efonidipine and amlodipine on aldosterone in patients with hypertension.
Topics: Aged; Aged, 80 and over; Aldosterone; Amlodipine; Blood Pressure; Calcium Channel Blockers; Calcium | 2007 |
Crossover study of amlodipine versus nifedipine CR with home blood pressure monitoring via cellular phone: internet-mediated open-label crossover trial of calcium channel blockers for hypertension (i-TECHO trial).
Topics: Adult; Aged; Amlodipine; Blood Pressure Determination; Calcium Channel Blockers; Cell Phone; Cross-O | 2007 |
Efficacy and safety of olmesartan medoxomil and hydrochlorothiazide compared with benazepril and amlodipine besylate.
Topics: Amlodipine; Antihypertensive Agents; Benzazepines; Blood Pressure; Diastole; Drug-Related Side Effec | 2007 |
Does blockade of the renin angiotensin system affect sympathetic and blood pressure responses to amlodipine in young hypertensive patients?
Topics: Adult; Amlodipine; Angiotensin I; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Antihyper | 2007 |
[Effect of atorvastatin on carotid intima-medial of thickness of primary hypertension patients of Han nationality in China].
Topics: Aged; Amlodipine; Anticholesteremic Agents; Antihypertensive Agents; Atorvastatin; Benzazepines; Car | 2007 |
Results of a phase III, 8-week, multicenter, prospective, randomized, double-blind, parallel-group clinical trial to assess the effects of amlodipine camsylate versus amlodipine besylate in Korean adults with mild to moderate hypertension.
Topics: Adolescent; Adult; Aged; Amlodipine; Analysis of Variance; Antihypertensive Agents; Blood Pressure; | 2007 |
Renal-protective effect of T-and L-type calcium channel blockers in hypertensive patients: an Amlodipine-to-Benidipine Changeover (ABC) study.
Topics: Aged; Amlodipine; Calcium Channel Blockers; Dihydropyridines; Female; Guideline Adherence; Humans; H | 2007 |
Effectiveness of add-on low-dose diuretics in combination therapy for hypertension: losartan/hydrochlorothiazide vs. candesartan/amlodipine.
Topics: Aged; Amlodipine; Antihypertensive Agents; Asian People; Benzimidazoles; Biphenyl Compounds; Diureti | 2007 |
Blood pressure control and response rates with zofenopril compared with amlodipine in hypertensive patients.
Topics: Adult; Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Blood Pressure; Calcium Channel B | 2007 |
A randomized, placebo-controlled trial to evaluate the efficacy, safety, and pharmacodynamic interaction of coadministered amlodipine and atorvastatin in 1660 patients with concomitant hypertension and dyslipidemia: the respond trial.
Topics: Alanine Transaminase; Alkaline Phosphatase; Amlodipine; Anticholesteremic Agents; Antihypertensive A | 2007 |
Effects of candesartan compared with amlodipine in hypertensive patients with high cardiovascular risks: candesartan antihypertensive survival evaluation in Japan trial.
Topics: Aged; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds; Blood | 2008 |
[The effect of lisinopril and amlodipine treatment on left ventricular hypertrophy in hypertensive patients].
Topics: Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Pressure; Calci | 2006 |
Improved attainment of blood pressure and cholesterol goals using single-pill amlodipine/atorvastatin in African Americans: the CAPABLE trial.
Topics: Adult; Aged; Amlodipine; Anticholesteremic Agents; Antihypertensive Agents; Atorvastatin; Black or A | 2008 |
Amlodipine improves endothelial function and metabolic parameters in patients with hypertension.
Topics: Adiponectin; Amlodipine; Antihypertensive Agents; Biomarkers; Cholesterol, HDL; Double-Blind Method; | 2009 |
Results of a comparative, phase III, 12-week, multicenter, prospective, randomized, double-blind assessment of the efficacy and tolerability of a fixed-dose combination of telmisartan and amlodipine versus amlodipine monotherapy in Indian adults with stag
Topics: Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Benzimidazoles; Benzo | 2007 |
Clinical outcomes by race in hypertensive patients with and without the metabolic syndrome: Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
Topics: Aged; Aged, 80 and over; Amlodipine; Antihypertensive Agents; Black People; Chlorthalidone; Double-B | 2008 |
Cost-effectiveness of chlorthalidone, amlodipine, and lisinopril as first-step treatment for patients with hypertension: an analysis of the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
Topics: Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Calcium Channel Blockers; Chlorthalidone; Cost | 2008 |
Determinants of new-onset diabetes among 19,257 hypertensive patients randomized in the Anglo-Scandinavian Cardiac Outcomes Trial--Blood Pressure Lowering Arm and the relative influence of antihypertensive medication.
Topics: Aged; Amlodipine; Antihypertensive Agents; Atenolol; Calcium Channel Blockers; Diabetic Angiopathies | 2008 |
Reduced incidence of new-onset atrial fibrillation with angiotensin II receptor blockade: the VALUE trial.
Topics: Aged; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Atrial Fibrillat | 2008 |
[Efficacy of adipin and normodipin (generic drugs of amlodipine) vs norvsc in treatment of essential hypertension].
Topics: Amlodipine; Calcium Channel Blockers; Cross-Over Studies; Drugs, Generic; Female; Humans; Hypertensi | 2008 |
Efficacy of the combination of amlodipine and valsartan in patients with hypertension uncontrolled with previous monotherapy: the Exforge in Failure after Single Therapy (EX-FAST) study.
Topics: Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Blood Pressure; Calciu | 2008 |
Blood pressure and cardiorenal responses to antihypertensive therapy in obese women.
Topics: Adult; Amlodipine; Analysis of Variance; Antihypertensive Agents; Blood Pressure; Blood Pressure Mon | 2008 |
Effects of different ACE inhibitor combinations on albuminuria: results of the GUARD study.
Topics: Adult; Aged; Aged, 80 and over; Albuminuria; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; A | 2008 |
High doses of lercanidipine are better tolerated than other dihydropyridines in hypertensive patients with metabolic syndrome: results from the TOLERANCE study.
Topics: Adolescent; Adult; Aged; Amlodipine; Antihypertensive Agents; Calcium Channel Blockers; Cross-Sectio | 2008 |
Comparative evaluation of effect of valsartan/amlodipine and atenolol/amlodipine combinations on atrial fibrillation recurrence in hypertensive patients with type 2 diabetes mellitus.
Topics: Aged; Amlodipine; Anti-Arrhythmia Agents; Antihypertensive Agents; Atenolol; Atrial Fibrillation; Bl | 2008 |
Valsartan Amlodipine Randomized Trial (VART): design, methods, and preliminary results.
Topics: 3-Iodobenzylguanidine; Aged; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive A | 2008 |
Synergistic effect of amlodipine and atorvastatin on blood pressure, left ventricular remodeling, and C-reactive protein in hypertensive patients with primary hypercholesterolemia.
Topics: Aged; Amlodipine; Antihypertensive Agents; Atorvastatin; Blood Pressure; C-Reactive Protein; Drug Sy | 2008 |
The effects of amlodipine and enalapril on renal function in adults with hypertension and nondiabetic nephropathies: a 3-year, randomized, multicenter, double-blind, placebo-controlled study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amlodipine; Antihypertensive Agents; Blood Pressure; Coh | 2008 |
Effects of valsartan or amlodipine on endothelial function and oxidative stress after one year follow-up in patients with essential hypertension.
Topics: 8-Hydroxy-2'-Deoxyguanosine; Adult; Aged; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Asian | 2008 |
Valsartan improves arterial stiffness in type 2 diabetes independently of blood pressure lowering.
Topics: Adult; Aged; Aged, 80 and over; Albuminuria; Amlodipine; Angiotensin II Type 1 Receptor Blockers; An | 2008 |
Serum levels of the advanced glycation end products Nepsilon-carboxymethyllysine and pentosidine are not influenced by treatment with the angiotensin receptor II type 1 blocker irbesartan in patients with type 2 diabetic nephropathy and hypertension.
Topics: Aged; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Arginine; Biphen | 2008 |
Comparative effects of amlodipine monotherapy and combination therapy with betaxolol on cardiac autonomic nervous activity and health-related quality of life in patients with poorly controlled hypertension.
Topics: Aged; Amlodipine; Antihypertensive Agents; Autonomic Nervous System; Betaxolol; Blood Pressure; Calc | 2008 |
[Effect of antihypertensive drugs of various pharmacological groups on reaction of arterial pressure under conditions of stree testing. Part II. Value of various strategies of potentiation of systemic vasodilatation].
Topics: Acrylates; Adrenergic beta-Antagonists; Adult; Amlodipine; Angiotensin II Type 1 Receptor Blockers; | 2008 |
Effective and safe reduction of blood pressure with the combination of amlodipine 5 mg and valsartan 160 mg in hypertensive patients not controlled by calcium channel blocker monotherapy.
Topics: Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Blood Pressure; Calciu | 2008 |
Tolerability of high doses of lercanidipine versus high doses of other dihydropyridines in daily clinical practice: the TOLERANCE Study.
Topics: Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Cross-Sectional | 2008 |
Laboratory tests as predictors of the antihypertensive effects of amlodipine, bisoprolol, hydrochlorothiazide and losartan in men: results from the randomized, double-blind, crossover GENRES Study.
Topics: Adult; Amlodipine; Antihypertensive Agents; Bisoprolol; Blood Pressure; Calcium; Cross-Over Studies; | 2008 |
Evaluation of population pharmacokinetics and exposure-response relationship with coadministration of amlodipine besylate and olmesartan medoxomil.
Topics: Adult; Age Factors; Amlodipine; Antihypertensive Agents; Drug Therapy, Combination; Female; Humans; | 2008 |
[Efficacy of combined antihypertensive treatment with amlodipine and lisinopril in metabolic syndrome].
Topics: Adult; Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Blood Glucose; Blood Pressure; Bl | 2008 |
The combination of olmesartan medoxomil and amlodipine besylate in controlling high blood pressure: COACH, a randomized, double-blind, placebo-controlled, 8-week factorial efficacy and safety study.
Topics: Aged; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Blood Pressure; Blood Pressure Monitoring | 2008 |
Comparative evaluation of the antihypertensive efficacy of once-daily amlodipine versus nitrendipine with 24-hour ambulatory blood pressure monitoring in essential hypertension.
Topics: Adult; Aged; Amlodipine; Blood Pressure; Double-Blind Method; Drug Administration Schedule; Female; | 1993 |
A double-blind, long-term, comparative study on quality of life, safety, and efficacy during treatment with amlodipine or enalapril in mild or moderate hypertensive patients: a multicenter study.
Topics: Adult; Aged; Amlodipine; Blood Pressure; Double-Blind Method; Enalapril; Female; Humans; Hypertensio | 1993 |
Comparison of amlodipine and captopril in hypertension based on 24-hour ambulatory monitoring.
Topics: Adult; Aged; Ambulatory Care; Amlodipine; Blood Pressure; Blood Pressure Determination; Captopril; D | 1993 |
Side effects of dihydropyridine therapy: comparison of amlodipine and nifedipine retard.
Topics: Adult; Aged; Aged, 80 and over; Amlodipine; Blood Pressure; Delayed-Action Preparations; Drug Admini | 1993 |
Alpha-blockade and calcium antagonism: an effective and well-tolerated combination for the treatment of resistant hypertension.
Topics: Adrenergic alpha-Antagonists; Adult; Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Blo | 1995 |
Cardiovascular structural changes and calcium antagonist therapy in patients with hypertension.
Topics: Adult; Amlodipine; Analysis of Variance; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Card | 1994 |
Efficacy and safety evaluation of lacidipine compared with amlodipine in mild-to-moderate hypertensive patients.
Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Dihydrop | 1994 |
Low-dose drug combination therapy: an alternative first-line approach to hypertension treatment.
Topics: Adult; Aged; Amlodipine; Analysis of Variance; Bisoprolol; Blood Pressure; Double-Blind Method; Drug | 1995 |
The efficacy and tolerability of amlodipine and hydrochlorothiazide in Nigerians with essential hypertension.
Topics: Amlodipine; Blood Pressure; Drug Tolerance; Female; Heart Rate; Humans; Hydrochlorothiazide; Hyperte | 1995 |
Comparison of perindopril and amlodipine in cyclosporine-treated renal allograft recipients.
Topics: Adult; Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Blood Pressure; Cross-Over Studie | 1995 |
Amlodipine induces a flow and pressure-independent vasoactive effect on the brachial artery in hypertension.
Topics: Adult; Amlodipine; Analysis of Variance; Blood Flow Velocity; Blood Pressure; Brachial Artery; Compl | 1995 |
Effects of different antihypertensive drugs on plasma fibrinogen in hypertensive patients.
Topics: Adolescent; Adult; Aged; Amlodipine; Antihypertensive Agents; Atenolol; Blood Glucose; Blood Pressur | 1995 |
Use of drugs with more than a twenty-four-hour duration of action.
Topics: Aged; Amlodipine; Cross-Over Studies; Drug Administration Schedule; Female; Humans; Hypertension; Ma | 1994 |
Amlodipine and haemodynamic effects of cyclo-oxygenase inhibition.
Topics: 6-Ketoprostaglandin F1 alpha; Adult; Aldosterone; Amlodipine; Biomarkers; Blood Pressure; Creatinine | 1995 |
Patient compliance and therapeutic coverage: comparison of amlodipine and slow release nifedipine in the treatment of hypertension. The Belgian Collaborative Study Group.
Topics: Amlodipine; Cross-Over Studies; Delayed-Action Preparations; Female; Humans; Hypertension; Male; Mid | 1995 |
Renal effects of amlodipine.
Topics: Adult; Aged; Amlodipine; Animals; Blood Pressure; Blood Urea Nitrogen; Creatinine; Enalapril; Female | 1995 |
Evaluation and quality-of-life assessment of amlodipine and enalapril in patients with hypertension.
Topics: Adult; Aged; Amlodipine; Blood Pressure; Double-Blind Method; Enalapril; Female; Follow-Up Studies; | 1995 |
Comparative effects of amlodipine and felodipine ER on office and ambulatory blood pressure in patients with mild to moderate hypertension. Danish Multicentre Group.
Topics: Adult; Aged; Amlodipine; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Double-Blind Method; | 1995 |
At equipotent doses, isradipine is better tolerated than amlodipine in patients with mild-to-moderate hypertension: a double-blind, randomized, parallel-group study.
Topics: Adult; Aged; Amlodipine; Ankle; Belgium; Blood Pressure; Delayed-Action Preparations; Double-Blind M | 1994 |
Hypertension after renal transplantation. Calcium channel or converting enzyme blockade?
Topics: Adult; Amlodipine; Blood Pressure; Cross-Over Studies; Cyclosporine; Double-Blind Method; Humans; Hy | 1995 |
Electrophysiologic effects of amlodipine vs. diltiazem in patients with coronary artery disease and beta-blocking therapy.
Topics: Adult; Aged; Amlodipine; Atenolol; Coronary Disease; Diltiazem; Drug Therapy, Combination; Electroph | 1994 |
The effect of antihypertensive therapy on responsiveness to local intra-arterial NG-monomethyl-L-arginine in patients with essential hypertension.
Topics: Amlodipine; Arginine; Blood Pressure; Double-Blind Method; Enalapril; Female; Forearm; Humans; Hyper | 1994 |
Effects of lisinopril and amlodipine on microalbuminuria and renal function in patients with hypertension.
Topics: Adult; Aged; Albuminuria; Amlodipine; Female; Hemodynamics; Humans; Hypertension; Kidney; Lisinopril | 1994 |
Changes in lipid and lipoprotein values during a cross-over treatment of doxazosin, moduretic and amlodipine in hypertensive patients.
Topics: Adult; Aged; Amiloride; Amlodipine; Antihypertensive Agents; Cross-Over Studies; Double-Blind Method | 1994 |
[Time of drug intake in hypertension and angina pectoris. A controlled monitoring study].
Topics: Aged; Amlodipine; Angina Pectoris; Confidence Intervals; Cross-Over Studies; Female; Humans; Hyperte | 1994 |
Amlodipine versus ramipril in the treatment of mild to moderate hypertension: evaluation by 24-hour ambulatory blood pressure monitoring.
Topics: Adult; Amlodipine; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Double-Blind Method; Femal | 1994 |
Double-blind comparison of amlodipine and hydrochlorothiazide in patients with mild to moderate hypertension.
Topics: Adolescent; Adult; Aged; Amlodipine; Atenolol; Blood Pressure; Cholesterol; Cholesterol, HDL; Choles | 1994 |
A long-term, double-blind, comparative study on quality of life during treatment with amlodipine or enalapril in mild or moderate hypertensive patients: a multicentre study.
Topics: Adult; Aged; Amlodipine; Double-Blind Method; Enalapril; Female; Humans; Hypertension; Male; Middle | 1994 |
Efficacy and safety of amlodipine in hypertensive patients with renal dysfunction.
Topics: Adult; Aged; Amlodipine; Female; Humans; Hypertension; Japan; Kidney Diseases; Male; Middle Aged; Tr | 1994 |
The use of self-measured blood pressure determinations in assessing dynamics of drug compliance in a study with amlodipine once a day, morning versus evening.
Topics: Adult; Aged; Aged, 80 and over; Amlodipine; Blood Pressure; Blood Pressure Determination; Drug Admin | 1993 |
Calcium antagonists for treatment of diabetes-associated hypertension. Metabolic and renal effects of amlodipine.
Topics: Adult; Aged; Albuminuria; Amlodipine; Blood Glucose; Blood Pressure; Calcium Channel Blockers; Diabe | 1994 |
Long-term open evaluation of amlodipine vs hydrochlorothiazide in patients with essential hypertension.
Topics: Adolescent; Adult; Aged; Amlodipine; Blood Pressure; Drug Therapy, Combination; Female; Humans; Hydr | 1993 |
Double-blind comparison of amlodipine and nifedipine retard in the treatment of mild to moderate hypertension.
Topics: Adult; Aged; Aging; Amlodipine; Blood Pressure; Double-Blind Method; Drug Administration Schedule; F | 1994 |
Amlodipine in ambulatory hypertensive patients: humoral and haemodynamic effects.
Topics: Adult; Aged; Aged, 80 and over; Albuminuria; Aldosterone; Amlodipine; Blood Pressure; Cholesterol; F | 1993 |
Amlodipine and lisinopril in combination for the treatment of essential hypertension: efficacy and predictors of response.
Topics: Adult; Amlodipine; Blood Pressure; Double-Blind Method; Drug Combinations; Female; Forecasting; Horm | 1993 |
[Amlodipine in isolated systolic hypertension in the aged].
Topics: Age Factors; Aged; Amlodipine; Body Weight; Calcium Channel Blockers; Drug Evaluation; Female; Human | 1993 |
[Monotherapy of mild to moderate hypertension. Double-blind comparative study: amlodipine versus enalapril].
Topics: Adult; Aged; Amlodipine; Blood Pressure; Dose-Response Relationship, Drug; Double-Blind Method; Drug | 1993 |
Amlodipine in mild and moderate hypertension: initial Indian experience.
Topics: Adult; Aged; Amlodipine; Blood Pressure; Female; Humans; Hypertension; Male; Middle Aged; Single-Bli | 1993 |
Effects of amlodipine on renal haemodynamics in mild to moderate hypertensive patients. A randomized controlled study versus placebo.
Topics: Adult; Amlodipine; Double-Blind Method; Female; Glomerular Filtration Rate; Humans; Hypertension; Ma | 1993 |
The effect of amlodipine on ambulatory blood pressure in hypertensive patients.
Topics: Adolescent; Adult; Aged; Amlodipine; Blood Pressure; Blood Pressure Monitors; Double-Blind Method; D | 1994 |
Amlodipine versus atenolol in essential hypertension.
Topics: Adolescent; Adult; Aged; Amlodipine; Atenolol; Blood Pressure; Double-Blind Method; Drug Administrat | 1994 |
Combination therapy with amlodipine and captopril for resistant systemic hypertension.
Topics: Adolescent; Adult; Aged; Amlodipine; Blood Pressure; Captopril; Double-Blind Method; Drug Administra | 1994 |
[Circadian rhythm of arterial pressure and use of amlodipine in primary hypertension].
Topics: Adult; Aged; Amlodipine; Blood Pressure; Circadian Rhythm; Female; Humans; Hypertension; Male; Middl | 1993 |
Treatment of Mild Hypertension Study. Final results. Treatment of Mild Hypertension Study Research Group.
Topics: Acebutolol; Aged; Amlodipine; Antihypertensive Agents; Chlorthalidone; Diastole; Double-Blind Method | 1993 |
Treatment of Mild Hypertension Study. Final results. Treatment of Mild Hypertension Study Research Group.
Topics: Acebutolol; Aged; Amlodipine; Antihypertensive Agents; Chlorthalidone; Diastole; Double-Blind Method | 1993 |
Treatment of Mild Hypertension Study. Final results. Treatment of Mild Hypertension Study Research Group.
Topics: Acebutolol; Aged; Amlodipine; Antihypertensive Agents; Chlorthalidone; Diastole; Double-Blind Method | 1993 |
Treatment of Mild Hypertension Study. Final results. Treatment of Mild Hypertension Study Research Group.
Topics: Acebutolol; Aged; Amlodipine; Antihypertensive Agents; Chlorthalidone; Diastole; Double-Blind Method | 1993 |
[Does antihypertensive treatment with amlodipine or enalapril affect quality of life? A multicenter study in general practice].
Topics: Adult; Aged; Amlodipine; Enalapril; Family Practice; Female; Humans; Hypertension; Male; Middle Aged | 1993 |
Pharmacodynamic modeling of the antihypertensive response to amlodipine.
Topics: Adult; Amlodipine; Analysis of Variance; Blood Pressure; Dose-Response Relationship, Drug; Double-Bl | 1993 |
Double-blind, parallel, comparative study on quality of life during treatment with amlodipine or enalapril in mild or moderate hypertensive patients: a multicentre study.
Topics: Adaptation, Psychological; Adult; Aged; Amlodipine; Attitude to Health; Blood Pressure; Cholesterol; | 1993 |
APTH--a trial on ambulatory blood pressure monitoring and treatment of hypertension: objectives and protocol.
Topics: Amlodipine; Antihypertensive Agents; Blood Pressure Determination; Blood Pressure Monitors; Dipeptid | 1993 |
Double-blind comparison between nifedipine and amlodipine for the treatment of essential hypertension.
Topics: Adult; Aged; Amlodipine; Blood Pressure; Double-Blind Method; Female; Hormones; Humans; Hypertension | 1993 |
Harmonic regression analysis of the effect of drug treatment on the diurnal rhythm of blood pressure and angina.
Topics: Amlodipine; Angina Pectoris; Blood Pressure; Circadian Rhythm; Double-Blind Method; Humans; Hyperten | 1993 |
Early side-effects of antihypertensive therapy: comparison of amlodipine and nifedipine retard.
Topics: Adult; Aged; Amlodipine; Delayed-Action Preparations; Dizziness; Double-Blind Method; Edema; Female; | 1993 |
Double-blind evaluation of the dose-response relationship of amlodipine in essential hypertension.
Topics: Adolescent; Adult; Aged; Amlodipine; Blood Pressure; Dose-Response Relationship, Drug; Double-Blind | 1993 |
The calcium channel blocker amlodipine raises serum dehydroepiandrosterone sulfate and androstenedione, but lowers serum cortisol, in insulin-resistant obese and hypertensive men.
Topics: Adult; Amlodipine; Androgens; Androstenedione; Calcium Channel Blockers; Dehydroepiandrosterone; Deh | 1993 |
A comparison of amlodipine with enalapril in the treatment of moderate/severe hypertension.
Topics: Adult; Aged; Amlodipine; Blood Pressure; Enalapril; Female; Heart Rate; Humans; Hypertension; Male; | 1993 |
A comparison of amlodipine with enalapril in the treatment of isolated systolic hypertension.
Topics: Aged; Amlodipine; Blood Pressure; Enalapril; Female; Heart Rate; Humans; Hypertension; Male; Middle | 1993 |
Middle term evaluation of amlodipine vs nitrendipine: efficacy, safety and metabolic effects in elderly hypertensive patients.
Topics: Aged; Aging; Ambulatory Care; Amlodipine; Blood Pressure; Blood Pressure Determination; Female; Huma | 1993 |
Office and ambulatory blood pressure: a comparison between amlodipine and felodipine ER. Danish Multicentre Group.
Topics: Adult; Aged; Amlodipine; Blood Pressure Monitoring, Ambulatory; Calcium Channel Blockers; Delayed-Ac | 1995 |
Comparison of amlodipine and quinapril on ambulatory blood pressure and platelet function in hypertension.
Topics: Adult; Aged; Aldosterone; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Age | 1995 |
Power spectral analysis of heart rate in elderly hypertensive subjects with or without silent coronary disease.
Topics: Aged; Algorithms; Amlodipine; Antihypertensive Agents; Case-Control Studies; Coronary Disease; Doubl | 1996 |
Effects of cilazapril and amlodipine on kidney function in hypertensive NIDDM patients.
Topics: Adult; Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Pr | 1996 |
Antihypertensive treatment with verapamil and amlodipine. Their effect on the functional autonomic and cardiovascular stress responses.
Topics: Adult; Amlodipine; Antihypertensive Agents; Calcium Channel Blockers; Hemodynamics; Humans; Hyperten | 1995 |
Effect of amlodipine on left ventricular mass in the Amlodipine Cardiovascular Community Trial.
Topics: Adult; Aged; Aged, 80 and over; Amlodipine; Analysis of Variance; Black People; Blood Pressure; Calc | 1995 |
Relationship between body mass index (BMI) and changes in plasma total and HDL-cholesterol levels during treatment of hypertension in African patients.
Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Black People; Body Mass Index; Cholesterol; Choles | 1995 |
Efficacy and tolerance of antihypertensive treatment in men and women with stage 1 diastolic hypertension. Results of the Treatment of Mild Hypertension Study.
Topics: Acebutolol; Aged; Amlodipine; Antihypertensive Agents; Chlorthalidone; Doxazosin; Enalapril; Female; | 1996 |
Comparison of amlodipine and benazepril monotherapy to amlodipine plus benazepril in patients with systemic hypertension: a randomized, double-blind, placebo-controlled, parallel-group study. The Benazepril/Amlodipine Study Group.
Topics: Adult; Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Benzazep | 1995 |
A diuretic is more effective than a beta-blocker in hypertensive patients not controlled on amlodipine and lisinopril.
Topics: Adrenergic beta-Antagonists; Adult; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypert | 1996 |
Prostacyclin biosynthesis in essential hypertension before and during treatment.
Topics: 6-Ketoprostaglandin F1 alpha; Adult; Aged; Amlodipine; Antihypertensive Agents; Bendroflumethiazide; | 1996 |
Sex- and age-related antihypertensive effects of amlodipine. The Amlodipine Cardiovascular Community Trial Study Group.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Amlodipine; Antihypertensive Agents; Black People; Bloo | 1996 |
[Personal clinical experience in the treatment of arterial hypertension using amlodipine].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amlodipine; Antihypertensive Agents; Blood Pressure; Hum | 1996 |
Decreased blood viscosity and serum levels of erythropoietin after anti-hypertensive treatment with amlodipine or metoprolol: results of a cross-over study.
Topics: Adult; Aged; Amlodipine; Blood Cell Count; Blood Chemical Analysis; Blood Viscosity; Cross-Over Stud | 1996 |
'Hypertension resistant to two-drug treatment' is a useful criterion to select patients for angiography: the 'Dutch Renal Artery Stenosis Intervention Cooperative' (DRASTIC) study.
Topics: Adolescent; Adult; Aged; Amlodipine; Angiography; Antihypertensive Agents; Atenolol; Drug Resistance | 1996 |
Amlodipine increases cyclosporine levels in hypertensive renal transplant patients: results of a prospective study.
Topics: Adult; Amlodipine; Cross-Over Studies; Cyclosporine; Female; Humans; Hypertension; Kidney Transplant | 1996 |
-Efficacy and safety of using amlodipine in treatment of mild and moderate essential hypertension-.
Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Dizziness; Drug Administration Schedule; Edema; Fe | 1995 |
Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: a comparative study of the efficacy and safety against amlodipine.
Topics: Adult; Aged; Amlodipine; Angiotensin II; Angiotensin Receptor Antagonists; Antihypertensive Agents; | 1996 |
Relative efficacy and tolerability of lacidipine and amlodipine in patients with mild-to-moderate hypertension: a randomized double-blind study.
Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Dihydropyridines; Double-Blind Met | 1996 |
Changes in peripheral hemodynamics and vasodilating prostaglandins after high-dose short-term ibuprofen in chronically treated hypertensive patients.
Topics: 6-Ketoprostaglandin F1 alpha; Amlodipine; Anti-Inflammatory Agents, Non-Steroidal; Blood Pressure; C | 1996 |
Albuminuria and transferrinuria in essential hypertension. Effects of antihypertensive therapy.
Topics: Adult; Albuminuria; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; B | 1996 |
Blood pressure and blood glucose levels during a cross-over treatment of doxazosin, moduretic and amlodipine in hypertensive patients.
Topics: Adult; Aged; Amiloride; Amlodipine; Antihypertensive Agents; Blood Glucose; Blood Pressure; Cross-Ov | 1996 |
Biochemical changes during a cross-over treatment of doxazosin, moduretic and amlodipine in hypertensive patients.
Topics: Adult; Aged; Amiloride; Amlodipine; Antihypertensive Agents; Blood Proteins; Calcium; Creatinine; Cr | 1996 |
Antihypertensive effects of amlodipine and hydrochlorothiazide in elderly patients with ambulatory hypertension.
Topics: Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Ci | 1995 |
[The first clinical experience in Italy with angiotensin II receptor antagonists: results of a multicenter study on the efficacy and tolerance in arterial hypertension].
Topics: Adult; Aged; Amlodipine; Angiotensin II; Angiotensin Receptor Antagonists; Antihypertensive Agents; | 1995 |
[Effect of the treatment with amlodipine on left ventricular hypertrophy in hypertensive patients].
Topics: Amlodipine; Antihypertensive Agents; Echocardiography; Female; Humans; Hypertension; Hypertrophy, Le | 1996 |
Long-term effects on sexual function of five antihypertensive drugs and nutritional hygienic treatment in hypertensive men and women. Treatment of Mild Hypertension Study (TOMHS)
Topics: Acebutolol; Aged; Amlodipine; Antihypertensive Agents; Chlorthalidone; Double-Blind Method; Doxazosi | 1997 |
Long-term effects on sexual function of five antihypertensive drugs and nutritional hygienic treatment in hypertensive men and women. Treatment of Mild Hypertension Study (TOMHS)
Topics: Acebutolol; Aged; Amlodipine; Antihypertensive Agents; Chlorthalidone; Double-Blind Method; Doxazosi | 1997 |
Long-term effects on sexual function of five antihypertensive drugs and nutritional hygienic treatment in hypertensive men and women. Treatment of Mild Hypertension Study (TOMHS)
Topics: Acebutolol; Aged; Amlodipine; Antihypertensive Agents; Chlorthalidone; Double-Blind Method; Doxazosi | 1997 |
Long-term effects on sexual function of five antihypertensive drugs and nutritional hygienic treatment in hypertensive men and women. Treatment of Mild Hypertension Study (TOMHS)
Topics: Acebutolol; Aged; Amlodipine; Antihypertensive Agents; Chlorthalidone; Double-Blind Method; Doxazosi | 1997 |
Long-term effects on sexual function of five antihypertensive drugs and nutritional hygienic treatment in hypertensive men and women. Treatment of Mild Hypertension Study (TOMHS)
Topics: Acebutolol; Aged; Amlodipine; Antihypertensive Agents; Chlorthalidone; Double-Blind Method; Doxazosi | 1997 |
Long-term effects on sexual function of five antihypertensive drugs and nutritional hygienic treatment in hypertensive men and women. Treatment of Mild Hypertension Study (TOMHS)
Topics: Acebutolol; Aged; Amlodipine; Antihypertensive Agents; Chlorthalidone; Double-Blind Method; Doxazosi | 1997 |
Long-term effects on sexual function of five antihypertensive drugs and nutritional hygienic treatment in hypertensive men and women. Treatment of Mild Hypertension Study (TOMHS)
Topics: Acebutolol; Aged; Amlodipine; Antihypertensive Agents; Chlorthalidone; Double-Blind Method; Doxazosi | 1997 |
Long-term effects on sexual function of five antihypertensive drugs and nutritional hygienic treatment in hypertensive men and women. Treatment of Mild Hypertension Study (TOMHS)
Topics: Acebutolol; Aged; Amlodipine; Antihypertensive Agents; Chlorthalidone; Double-Blind Method; Doxazosi | 1997 |
Long-term effects on sexual function of five antihypertensive drugs and nutritional hygienic treatment in hypertensive men and women. Treatment of Mild Hypertension Study (TOMHS)
Topics: Acebutolol; Aged; Amlodipine; Antihypertensive Agents; Chlorthalidone; Double-Blind Method; Doxazosi | 1997 |
Differential effects of amlodipine on ambulatory blood pressure in elderly hypertensive patients with different nocturnal reductions in blood pressure.
Topics: Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Ca | 1997 |
Patient compliance and therapeutic coverage: amlodipine versus nifedipine SR in the treatment of hypertension and angina: interim results. Steering Committee and Cardiologists and General Practitioners involved in the Belgium Multicentre Study on Patient
Topics: Amlodipine; Angina Pectoris; Female; Humans; Hypertension; Male; Middle Aged; Nifedipine; Patient Co | 1994 |
Short-term antihypertensive medication does not exacerbate sleep-disordered breathing in newly diagnosed hypertensive patients.
Topics: Amlodipine; Antihypertensive Agents; Cross-Over Studies; Double-Blind Method; Humans; Hypertension; | 1997 |
[The role of calcium inhibitors in the treatment of arterial hypertension].
Topics: Adult; Aged; Amlodipine; Calcium Channel Blockers; Female; Humans; Hypertension; Male; Middle Aged | 1997 |
A randomised, double-blind trial comparing mibefradil and amlodipine: two long-acting calcium antagonists with similar efficacy but different tolerability profiles. Mibefradil International Study Group.
Topics: Adult; Aged; Amlodipine; Benzimidazoles; Calcium Channel Blockers; Double-Blind Method; Female; Huma | 1997 |
Fixed combination of benazepril and low-dose amlodipine in the treatment of mild to moderate essential hypertension: evaluation by 24-hour noninvasive ambulatory blood pressure monitoring.
Topics: Adult; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Benzazepines; | 1997 |
Mibefradil in the treatment of systemic hypertension: comparative studies with other calcium antagonists.
Topics: Adult; Aged; Amlodipine; Benzimidazoles; Calcium Channel Blockers; Diltiazem; Double-Blind Method; E | 1997 |
Safety of mibefradil, a new once-a-day, selective T-type calcium channel antagonist.
Topics: Aged; Amlodipine; Angina Pectoris; Benzimidazoles; Calcium Channel Blockers; Chronic Disease; Drug A | 1997 |
Physical performance is preserved after regression of left ventricular hypertrophy.
Topics: Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Double-Blind Method; Drug Therapy, Combin | 1997 |
Long-term effects of angiotensin-converting enzyme inhibitors and calcium antagonists on the right and left ventricles in essential hypertension.
Topics: Adult; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Pressure | 1997 |
Combined therapy with benazepril and amlodipine in the treatment of hypertension inadequately controlled by an ACE inhibitor alone.
Topics: Adolescent; Adult; Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agen | 1997 |
Patterns of compliance with once versus twice daily antihypertensive drug therapy in primary care: a randomized clinical trial using electronic monitoring.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amlodipine; Antihypertensive Agents; Canada; Diltiazem; | 1997 |
[Comparative study to assess the efficacy and adverse effects of amlodipine and nifedipine retard in patients with stable exertional angina and hypertension].
Topics: Aged; Amlodipine; Angina Pectoris; Blood Pressure; Calcium Channel Blockers; Drug Administration Sch | 1997 |
Main results of the losartan versus amlodipine (LOA) study on drug tolerability and psychological general well-being. LOA Study Group.
Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Double-Blind Method; Female; Heart | 1997 |
Comparison of amlodipine and long-acting diltiazem in the treatment of mild or moderate hypertension.
Topics: Adult; Aged; Aged, 80 and over; Amlodipine; Antihypertensive Agents; Blood Pressure; Blood Pressure | 1997 |
Crossover comparison of the pharmacokinetics of amlodipine and felodipine ER in hypertensive patients.
Topics: Adult; Amlodipine; Antihypertensive Agents; Area Under Curve; Blood Pressure; Cross-Over Studies; De | 1997 |
[The effect of amlodipine on structure and function of the heart and exercise tolerance in patients with hypertension].
Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Diastole; Exercise Test; Exercise Tolerance; Femal | 1997 |
Renoprotection and renin-angiotensin system blockade in diabetes mellitus.
Topics: Amlodipine; Angiotensin Receptor Antagonists; Antihypertensive Agents; Biphenyl Compounds; Diabetic | 1997 |
Double-blind crossover study of the interaction between perindopril and amlodipine on blood pressure and hormones related to fluid and electrolyte balance in patients with essential hypertension.
Topics: Adult; Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Blood Pressure; Calcium Channel B | 1998 |
[Effect of 12-week treatment with amlodipine on plasma renin activity and adrenal cortex function in patients with essential hypertension].
Topics: Adult; Aldosterone; Amlodipine; Antihypertensive Agents; Female; Humans; Hydrocortisone; Hypertensio | 1997 |
Evaluation of changes in sympathetic nerve activity and heart rate in essential hypertensive patients induced by amlodipine and nifedipine.
Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Circadia | 1998 |
A placebo-controlled comparison of diltiazem and amlodipine monotherapy in essential hypertension using 24-h ambulatory monitoring.
Topics: Adolescent; Adult; Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Calcium Channel Blocke | 1998 |
Outcome results of the Fosinopril Versus Amlodipine Cardiovascular Events Randomized Trial (FACET) in patients with hypertension and NIDDM.
Topics: Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Glucose; Blood | 1998 |
Hypertension and diabetes and the Fosinopril versus Amlodipine Cardiovascular Events Trial (FACET). More ammunition against surrogate end points.
Topics: Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Calcium Channel Block | 1998 |
Compliance and antihypertensive efficacy of amlodipine compared with nifedipine slow-release.
Topics: Adolescent; Adult; Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Blood Pressure Monitor | 1998 |
Comparative effects of felodipine ER, amlodipine and nifedipine GITS on 24 h blood pressure control and trough to peak ratios in mild to moderate ambulatory hypertension: a forced titration study.
Topics: Adult; Aged; Amlodipine; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Calcium Channel Bloc | 1998 |
Efficacy of low-dose combination of bisoprolol/hydrochlorothiazide compared with amlodipine and enalapril in men and women with essential hypertension.
Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Bisoprolol; Blood Pressure; Dose-Response Relation | 1998 |
Effects of amlodipine and lisinopril on left ventricular mass and diastolic function in previously untreated patients with mild to moderate diastolic hypertension.
Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Female; | 1998 |
Effect of amlodipine versus felodipine extended release on 24-hour ambulatory blood pressure in hypertension.
Topics: Amlodipine; Antihypertensive Agents; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Calcium | 1998 |
CCBs vs ACE inhibitors in patients with diabetes.
Topics: Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Calcium Channel Block | 1998 |
Angiotensin-converting enzyme inhibition, but not calcium antagonism, improves a response of the renal vasculature to L-arginine in patients with essential hypertension.
Topics: Adult; Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Arginine | 1998 |
Effects of losartan titrated to losartan/hydrochlorothiazide and amlodipine on blood pressure and peripheral capillary microcirculation in patients with mild-to-moderate hypertension.
Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Blood Flow Velocity; Blood Pressure; Capillaries; | 1998 |
Differences between amlodipine and lisinopril in control of clinic and twenty-four hour ambulatory blood pressures.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amlodipine; Antihypertensive Agents; Blood Pressure; Blo | 1998 |
Different effects of nifedipine and amlodipine on circulating catecholamine levels in essential hypertensive patients.
Topics: Adult; Amlodipine; Antihypertensive Agents; Blood Pressure; Drug Administration Schedule; Epinephrin | 1998 |
The antihypertensive efficacy of losartan and amlodipine assessed with office and ambulatory blood pressure monitoring. Canadian Cozaar Hyzaar Amlodipine Trial Study Group.
Topics: Adolescent; Adult; Aged; Amlodipine; Antihypertensive Agents; Blood Pressure Monitoring, Ambulatory; | 1998 |
The Valsartan Antihypertensive Long-term Use Evaluation (VALUE) trial of cardiovascular events in hypertension. Rationale and design.
Topics: Aged; Amlodipine; Angiotensin II; Antihypertensive Agents; Calcium Channel Blockers; Cardiovascular | 1998 |
Comparison of the efficacy of dihydropyridine calcium channel blockers in African American patients with hypertension. ISHIB Investigators Group. International Society on Hypertension in Blacks.
Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Black People; Blood Pressure; Body Weight; Calcium | 1998 |
Renal and haemodynamic effects of amlodipine and nifedipine in hypertensive renal transplant recipients.
Topics: Adolescent; Adult; Aged; Amlodipine; Blood Pressure; Calcium Channel Blockers; Cross-Over Studies; C | 1998 |
Parallel comparative trial of amlodipine and nitrendipine monotherapy in patients with essential hypertension.
Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Blood Pressure Monitoring, Ambulat | 1998 |
Comorbidity of hypertension and diabetes: the fosinopril versus amlodipine cardiovascular events trial (FACET)
Topics: Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Calcium Channel Block | 1998 |
Different effects of nifedipine and amlodipine on circulating catecholamine levels in essential hypertensive patients.
Topics: Adult; Amlodipine; Antihypertensive Agents; Blood Pressure; Diastole; Drug Administration Schedule; | 1998 |
Two-year follow-up study to evaluate the reduction of left ventricular mass and diastolic function in mild to moderate diastolic hypertensive patients.
Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Blood Flow Velocity; Blood Pressure; Blood Pressur | 1998 |
Renal effects of losartan and amlodipine in hypertensive patients with non-diabetic nephropathy.
Topics: Adult; Aged; Albuminuria; Amlodipine; Antihypertensive Agents; Biomarkers; Blood Pressure; Cross-Ove | 1998 |
Improved tolerability of felodipine compared with amlodipine in elderly hypertensives: a randomised, double-blind study in 535 patients, focusing on vasodilatory adverse events. The International Study Group.
Topics: Aged; Amlodipine; Antihypertensive Agents; Delayed-Action Preparations; Dizziness; Double-Blind Meth | 1998 |
A perspective on the calcium antagonists in blacks (CAB) trial.
Topics: Amlodipine; Antihypertensive Agents; Black or African American; Blood Pressure; Blood Pressure Monit | 1998 |
Evaluation of amlodipine dosing for conversion of nifedipine extended-release to amlodipine in the treatment of hypertension.
Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Calcium Channel Blockers; Delayed-Action Preparati | 1999 |
Irbesartan reduces QT dispersion in hypertensive individuals.
Topics: Aged; Amlodipine; Angiotensin Receptor Antagonists; Antihypertensive Agents; Biphenyl Compounds; Dou | 1999 |
Low-dose combination therapy as first-line hypertension treatment for blacks and nonblacks.
Topics: Aged; Amlodipine; Analysis of Variance; Antihypertensive Agents; Bisoprolol; Black People; Chi-Squar | 1999 |
Sildenafil citrate and blood-pressure-lowering drugs: results of drug interaction studies with an organic nitrate and a calcium antagonist.
Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Cross-Over Studies; Double-Blind M | 1999 |
The Fosinopril versus Amlodipine Cardiovascular Events Trial (FACET) and combination therapies.
Topics: Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Calcium Channel Block | 1999 |
Low-dose combination treatment for hypertension versus single-drug treatment-bisoprolol/hydrochlorothiazide versus amlodipine, enalapril, and placebo: combined analysis of comparative studies.
Topics: Amlodipine; Bisoprolol; Double-Blind Method; Drug Therapy, Combination; Enalapril; Humans; Hydrochlo | 1998 |
Double-blind, randomized, multicentre comparison of the effects of amlodipine and perindopril on 24 h therapeutic coverage and beyond in patients with mild to moderate hypertension. General Physicians Investigators' Group.
Topics: Adolescent; Adult; Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Blood Pressure Monitor | 1999 |
A double blind comparison of the effects of amlodipine and enalapril on insulin sensitivity in hypertensive patients.
Topics: Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Glucose; Calciu | 1999 |
Is initial dose titration of amlodipine worthwhile in patients with mild to moderate hypertension?
Topics: Amlodipine; Analysis of Variance; Blood Pressure; Calcium Channel Blockers; Dose-Response Relationsh | 1999 |
Reduction of sympathetic hyperactivity by enalapril in patients with chronic renal failure.
Topics: Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Baroreflex; Calcium Channel Blockers; Enalapri | 1999 |
Effects of amlodipine and cilnidipine on cardiac sympathetic nervous system and neurohormonal status in essential hypertension.
Topics: Adult; Aged; Amlodipine; Blood Pressure; Calcium Channel Blockers; Dihydropyridines; Female; Heart; | 1999 |
Amlodipine, a long-acting calcium channel blocker, attenuates morning blood pressure rise in hypertensive patients.
Topics: Amlodipine; Blood Pressure; Calcium Channel Blockers; Circadian Rhythm; Cross-Over Studies; Female; | 1999 |
Ambulatory 24-h blood pressure assessment of the felodipine-metoprolol combination versus amlodipine in mild to moderate hypertension. Lorraine General Physician Investigators Group.
Topics: Amlodipine; Antihypertensive Agents; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Drug The | 1999 |
Effects of amlodipine and enalapril on platelet function in patients with mild to moderate hypertension.
Topics: Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Calcium Channel Blockers; Double-Blind Method; | 1999 |
Long-term potential of angiotensin receptor blockade for cardiovascular protection in hypertension: the VALUE trial. Valsartan Antihypertensive Long-term Use Evaluation.
Topics: Amlodipine; Animals; Antihypertensive Agents; Calcium Channel Blockers; Cardiovascular Diseases; Cli | 1999 |
Efficacy of amlodipine in pediatric patients with hypertension.
Topics: Administration, Oral; Adolescent; Amlodipine; Antihypertensive Agents; Blood Pressure; Child; Female | 1999 |
Amlodipine as monotherapy in hypertensive Africans: clinical efficacy and safety studies.
Topics: Aged; Amlodipine; Antihypertensive Agents; Black People; Blood Pressure; Calcium Channel Blockers; D | 1996 |
Amlodipine lowers blood pressure without affecting cerebral blood flow as measured by single photon emission computed tomography in elderly hypertensive subjects.
Topics: Aged; Aged, 80 and over; Amlodipine; Antihypertensive Agents; Blood Pressure; Blood Pressure Monitor | 1999 |
Daytime-selective antihypertensive activity of celiprolol.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Adult; Amlodipine; Angiotensin-Converting Enzyme | 1999 |
Use of calcium-channel blockers in pediatric renal transplant recipients.
Topics: Adolescent; Amlodipine; Blood Pressure; Calcium Channel Blockers; Cross-Over Studies; Drug Therapy, | 1999 |
Does the Dundee Step Test predict outcome in treated hypertension? A sub-study protocol for the ASCOT trial. Anglo-Scandinavian Cardiac Outcome Trial.
Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Atenolol; Bendroflumethiazide; Blood Pressure; Diu | 2000 |
The effect of amlodipine and enalapril on blood pressure and neurohumoral activation in hypertensive patients with Ribbing's disease (multiple epiphysal dystrophy).
Topics: Adolescent; Adult; Aged; Amlodipine; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Calci | 2000 |
Amlodipine, enalapril, and dependent leg edema in essential hypertension.
Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Diastole; Dose-Response Relationsh | 2000 |
Effect of antihypertensive therapy on renal function and urinary albumin excretion in hypertensive patients with autosomal dominant polycystic kidney disease.
Topics: Adult; Albuminuria; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Blood Pressure; Calcium Ch | 2000 |
Effects of losartan titrated to Losartan/Hydrochlorothiazide and amlodipine on left ventricular mass in patients with mild-to-moderate hypertension. A double-blind randomized controlled study.
Topics: Adult; Aged; Amlodipine; Angiotensin Receptor Antagonists; Antihypertensive Agents; Blood Pressure; | 1999 |
Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). ALLHAT Collaborative Research Group.
Topics: Adrenergic alpha-Antagonists; Aged; Amlodipine; Anticholesteremic Agents; Antihypertensive Agents; C | 2000 |
Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). ALLHAT Collaborative Research Group.
Topics: Adrenergic alpha-Antagonists; Aged; Amlodipine; Anticholesteremic Agents; Antihypertensive Agents; C | 2000 |
Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). ALLHAT Collaborative Research Group.
Topics: Adrenergic alpha-Antagonists; Aged; Amlodipine; Anticholesteremic Agents; Antihypertensive Agents; C | 2000 |
Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). ALLHAT Collaborative Research Group.
Topics: Adrenergic alpha-Antagonists; Aged; Amlodipine; Anticholesteremic Agents; Antihypertensive Agents; C | 2000 |
Comparison of atenolol, amlodipine, enalapril, hydrochlorothiazide, and losartan for antihypertensive treatment in patients with obstructive sleep apnea.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Anti | 2000 |
Evaluation of amlodipine, lisinopril, and a combination in the treatment of essential hypertension.
Topics: Adult; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Calcium Channel Blockers; Cross-Over St | 2000 |
Effect of amlodipine on hemodynamic and endocrine responses to mental stress.
Topics: Adolescent; Adult; Aged; Amlodipine; Biomarkers; Calcium Channel Blockers; Chromatography, High Pres | 2000 |
Medical therapy, symptoms, and the distress the cause: relation to quality of life in patients with angina pectoris and/or hypertension.
Topics: Adult; Adverse Drug Reaction Reporting Systems; Aged; Aged, 80 and over; Amlodipine; Angina Pectoris | 2000 |
[The effect of amlodipine, nifedipine and perindopril on insulin sensitivity and blood lipid of patients with essential hypertension].
Topics: Amlodipine; Antihypertensive Agents; Calcium Channel Blockers; Female; Humans; Hypertension; Insulin | 1998 |
Clinically additive effect between doxazosin and amlodipine in the treatment of essential hypertension.
Topics: Adult; Amlodipine; Antihypertensive Agents; Cross-Over Studies; Double-Blind Method; Doxazosin; Drug | 2000 |
[Multicenter community-based trial of amlodipine in hypertension in Israel].
Topics: Adult; Aged; Aged, 80 and over; Amlodipine; Antihypertensive Agents; Blood Pressure; Female; Heart R | 1999 |
Amlodipine is comparable to angiotensin-converting enzyme inhibitor for long-term renoprotection in hypertensive patients with renal dysfunction: a one-year, prospective, randomized study.
Topics: Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Calcium Channel Blockers; Captopril; Chr | 2000 |
Efficacy of candesartan cilexetil alone or in combination with amlodipine and hydrochlorothiazide in moderate-to-severe hypertension. UK and Israel Candesartan Investigators.
Topics: Aldosterone; Amlodipine; Analysis of Variance; Antihypertensive Agents; Benzimidazoles; Biphenyl Com | 2000 |
[Calcium channel blocking agents and albuminuria in diabetic and hypertensive patients. A pilot study].
Topics: Absorption; Aged; Albuminuria; Amlodipine; Antihypertensive Agents; Calcium Channel Blockers; Creati | 2000 |
Efficacy, safety, and effects on quality of life of bisoprolol/hydrochlorothiazide versus amlodipine in elderly patients with systolic hypertension.
Topics: Adrenergic beta-Antagonists; Aged; Amlodipine; Bisoprolol; Blood Pressure; Blood Pressure Monitoring | 2000 |
Patterns of amlodipine and felodipine use in an elderly Quebec population.
Topics: Aged; Amlodipine; Antihypertensive Agents; Felodipine; Female; Humans; Hypertension; Male; Patient C | 2000 |
A randomized prospective crossover trial of amlodipine in pediatric hypertension.
Topics: Adolescent; Amlodipine; Antihypertensive Agents; Blood Pressure; Blood Pressure Monitoring, Ambulato | 2000 |
Haemodynamic and metabolic effects of rilmenidine in hypertensive patients with metabolic syndrome X. A double-blind parallel study versus amlodipine.
Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Blood Glucose; Body Weight; Double-Blind Method; F | 2000 |
Combination therapy with beta-adrenergic blockade and amlodipine as second line treatment in essential hypertension.
Topics: Adrenergic beta-Antagonists; Adult; Amlodipine; Atenolol; Calcium Channel Blockers; Double-Blind Met | 2000 |
Effect of indomethacin on blood pressure in elderly people with essential hypertension well controlled on amlodipine or enalapril.
Topics: Abdominal Pain; Adult; Aged; Aged, 80 and over; Amlodipine; Anti-Inflammatory Agents, Non-Steroidal; | 2000 |
Comparison of efficacy and side effects of combination therapy of angiotensin-converting enzyme inhibitor (benazepril) with calcium antagonist (either nifedipine or amlodipine) versus high-dose calcium antagonist monotherapy for systemic hypertension.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Be | 2000 |
Blood pressure reduction associated with preservation of renal function in hypertensive patients with IgA nephropathy: a 3-year follow-up.
Topics: Adult; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Benzazepines; Calcium Channel Blockers; | 2000 |
Effects of different dihydropyridine calcium antagonists on plasma norepinephrine in essential hypertension.
Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Dihydrop | 2000 |
Treatment of hypertension in patients > or =65 years of age: experience with amlodipine.
Topics: Aged; Amlodipine; Antihypertensive Agents; Calcium Channel Blockers; Humans; Hypertension | 2000 |
[Ambulatory blood pressure monitoring in hypertensive CAPD patients].
Topics: Adrenergic alpha-Antagonists; Aged; Amlodipine; Blood Pressure; Blood Pressure Monitoring, Ambulator | 2000 |
A comparison of nisoldipine ER and amlodipine for the treatment of mild to moderate hypertension.
Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Blood Pressure Determination; Delayed-Action Prepa | 2000 |
Less difference between office and ambulatory blood pressure in women than in men both before and during antihypertensive treatment.
Topics: Adult; Amlodipine; Antihypertensive Agents; Blood Pressure Determination; Blood Pressure Monitoring, | 2000 |
Long-term effects of amlodipine and lisinopril on left ventricular mass and diastolic function in elderly, previously untreated hypertensive patients: the ELVERA trial.
Topics: Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Calcium Channel Blockers; Diastole; Doub | 2001 |
A comparison of indapamide SR 1.5 mg with both amlodipine 5 mg and hydrochlorothiazide 25 mg in elderly hypertensive patients: a randomized double-blind controlled study.
Topics: Aged; Aged, 80 and over; Amlodipine; Antihypertensive Agents; Double-Blind Method; Female; Humans; H | 2001 |
[Comparative study of spirapril (quadropril) and amlodipine efficacy. Results of randomized trial in patients with mild to moderate arterial hypertension].
Topics: Administration, Oral; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Blood Pressure; Blood Pr | 2000 |
Comparative effects of candesartan cilexetil and amlodipine in patients with mild systemic hypertension. Comparison of Candesartan and Amlodipine for Safety, Tolerability and Efficacy (CASTLE) Study Investigators.
Topics: Amlodipine; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Calcium Cha | 2001 |
A retrospective analysis comparing the costs and cost effectiveness of amlodipine and enalapril in the treatment of hypertension.
Topics: Amlodipine; Antihypertensive Agents; Cost of Illness; Cost-Benefit Analysis; Drug Costs; Drug Therap | 2001 |
Baseline characteristics of the diabetic participants in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
Topics: Adrenergic alpha-Antagonists; Adult; Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Ant | 2001 |
Ankle edema formation during treatment with the calcium channel blockers lacidipine and amlodipine: a single-centre study.
Topics: Adolescent; Adult; Aged; Amlodipine; Ankle; Blood Pressure; Calcium Channel Blockers; Dihydropyridin | 2000 |
Effects of amlodipine on baroreflex and sympathetic nervous system activity in mild-to-moderate hypertension.
Topics: Adolescent; Adult; Aged; Amlodipine; Antihypertensive Agents; Baroreflex; Blood Pressure; Catecholam | 2001 |
Influence of diltiazem on the pharmacokinetics of amlodipine in elderly hypertensive patients.
Topics: Aged; Aged, 80 and over; Amlodipine; Antihypertensive Agents; Diltiazem; Humans; Hypertension | 2001 |
Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Anti | 2001 |
Usefulness of serum carboxy-terminal propeptide of procollagen type I in assessment of the cardioreparative ability of antihypertensive treatment in hypertensive patients.
Topics: Adult; Aged; Amlodipine; Angiotensin Receptor Antagonists; Antihypertensive Agents; Biopsy; Blood Pr | 2001 |
Usefulness of serum carboxy-terminal propeptide of procollagen type I in assessment of the cardioreparative ability of antihypertensive treatment in hypertensive patients.
Topics: Adult; Aged; Amlodipine; Angiotensin Receptor Antagonists; Antihypertensive Agents; Biopsy; Blood Pr | 2001 |
Usefulness of serum carboxy-terminal propeptide of procollagen type I in assessment of the cardioreparative ability of antihypertensive treatment in hypertensive patients.
Topics: Adult; Aged; Amlodipine; Angiotensin Receptor Antagonists; Antihypertensive Agents; Biopsy; Blood Pr | 2001 |
Usefulness of serum carboxy-terminal propeptide of procollagen type I in assessment of the cardioreparative ability of antihypertensive treatment in hypertensive patients.
Topics: Adult; Aged; Amlodipine; Angiotensin Receptor Antagonists; Antihypertensive Agents; Biopsy; Blood Pr | 2001 |
Once-daily treatment of patients with hypertension: a placebo-controlled study of amlodipine and benazepril vs amlodipine or benazepril alone.
Topics: Adult; Aged; Aged, 80 and over; Amlodipine; Antihypertensive Agents; Benzazepines; Double-Blind Meth | 2001 |
Less adrenergic response to mental task during verapamil compared to amlodipine treatment in hypertensive subjects.
Topics: Adrenergic Agents; Adult; Aged; Amlodipine; Antihypertensive Agents; Baroreflex; Blood Pressure; Cal | 2001 |
[The comparison of hypotensive efficiency and tolerability of amlodipine and enalapril in patients with essential hypertension].
Topics: Aged; Amlodipine; Calcium Channel Blockers; Enalapril; Female; Humans; Hypertension; Male; Middle Ag | 2001 |
Blood pressure reduction and tolerability of amlodipine versus nifedipine retard in Chinese patients with type 2 diabetes mellitus and hypertension: a randomized 1-year clinical trial.
Topics: Administration, Oral; Aged; Amlodipine; Blood Pressure; Calcium Channel Blockers; Diabetes Mellitus, | 2001 |
Effects of long-acting ACE inhibitor (temocapril) and long-acting Ca channel blocker (amlodipine) on 24-h ambulatory BP in elderly hypertensive patients.
Topics: Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Blood Pressure; Blood Pressure Monitorin | 2001 |
Clinical trials report. The effect of Ramipril versus Amlodipine on renal outcomes in hypertension nephrosclerosis.
Topics: Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Creatinine; Humans; H | 2001 |
A multicenter, randomized double-blind study of valsartan/hydrochlorothiazide combination versus amlodipine in patients with mild to moderate hypertension.
Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Double-Blind Method; Drug Combinat | 2001 |
Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes.
Topics: Adult; Aged; Amlodipine; Angiotensin Receptor Antagonists; Antihypertensive Agents; Biphenyl Compoun | 2001 |
Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes.
Topics: Adult; Aged; Amlodipine; Angiotensin Receptor Antagonists; Antihypertensive Agents; Biphenyl Compoun | 2001 |
Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes.
Topics: Adult; Aged; Amlodipine; Angiotensin Receptor Antagonists; Antihypertensive Agents; Biphenyl Compoun | 2001 |
Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes.
Topics: Adult; Aged; Amlodipine; Angiotensin Receptor Antagonists; Antihypertensive Agents; Biphenyl Compoun | 2001 |
Amlodipine: effective for treatment of mild to moderate essential hypertension and left ventricular hypertrophy.
Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Echocardiography; Female; Heart Ra | 2001 |
A comparison of selected antihypertensives and the use of conventional vs ambulatory blood pressure in the detection and treatment of hypertension.
Topics: Adult; Aged; Amlodipine; Analysis of Variance; Antihypertensive Agents; Bendroflumethiazide; Blood P | 2001 |
A clinical trial in type 2 diabetic nephropathy.
Topics: Adult; Aged; Amlodipine; Angiotensin Receptor Antagonists; Biphenyl Compounds; Calcium Channel Block | 2001 |
Efficacy, tolerability, and impact on quality of life of long-term treatment with manidipine or amlodipine in patients with essential hypertension.
Topics: Adult; Aged; Amlodipine; Analysis of Variance; Antihypertensive Agents; Blood Pressure; Chi-Square D | 2001 |
Effect of sildenafil on blood pressure and arterial wave reflection in treated hypertensive men.
Topics: Aged; Amlodipine; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihy | 2001 |
Effects of blood pressure lowering with amlodipine or lisinopril on vascular structure of the common carotid artery.
Topics: Adult; Aged; Aged, 80 and over; Amlodipine; Analysis of Variance; Antihypertensive Agents; Carotid A | 2001 |
Efficacy, tolerability and influence on "quality of life" of nifedipine GITS versus amlodipine in elderly patients with mild-moderate hypertension.
Topics: Aged; Aged, 80 and over; Amlodipine; Blood Pressure; Calcium Channel Blockers; Double-Blind Method; | 2001 |
Comparative pharmacokinetics and pharmacodynamics of amlodipine in hypertensive patients with and without type II diabetes mellitus.
Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Area Under Curve; Blood Pressure; Diabetes Mellitu | 2001 |
Comparison of 24-hour blood pressure profiles in patients with hypertension who were switched from amlodipine to nisoldipine.
Topics: Adult; Aged; Amlodipine; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Calcium Channel Bloc | 2001 |
The effects of dihydropyridine and phenylalkylamine calcium antagonist classes on autonomic function in hypertension: the VAMPHYRE study.
Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Autonomic Nervous System; Baroreflex; Blood Pressu | 2001 |
Contrasting effects of verapamil and amlodipine on cardiovascular stress responses in hypertension.
Topics: Adult; Aged; Amlodipine; Blood Pressure; Calcium Channel Blockers; Cross-Over Studies; Double-Blind | 2001 |
Cilnidipine more highly attenuates cold pressor stress-induced platelet activation in hypertension than does amlodipine.
Topics: Amlodipine; beta-Thromboglobulin; Blood Pressure; Calcium Channel Blockers; Cold Temperature; Cross- | 2001 |
Stimulation of cardiac apoptosis in essential hypertension: potential role of angiotensin II.
Topics: Adult; Aged; Amlodipine; Angiotensin II; Angiotensin Receptor Antagonists; Antihypertensive Agents; | 2002 |
Fosinopril versus amlodipine comparative treatments study: a randomized trial to assess effects on plasminogen activator inhibitor-1.
Topics: Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Biomarkers; Blood Pressure; Calcium Channel Bl | 2002 |
Persistence of antihypertensive efficacy after missed doses: comparison of amlodipine and nifedipine gastrointestinal therapeutic system.
Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Circadian Rhythm; Cross-Over Studi | 2002 |
Amlodipine versus chlorthalidone versus placebo in the treatment of stage I isolated systolic hypertension.
Topics: Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Chlorthalidone; Double-Blind Method; Fema | 2002 |
Effect of amlodipine compared to atenolol on small arteries of previously untreated essential hypertensive patients.
Topics: Acetylcholine; Adrenergic beta-Antagonists; Adult; Amlodipine; Antihypertensive Agents; Arteries; At | 2002 |
Angiotensin II type 1 receptor antagonist, losartan, causes regression of left ventricular hypertrophy in end-stage renal disease.
Topics: Adult; Aged; Aged, 80 and over; Amlodipine; Angiotensin II; Angiotensin Receptor Antagonists; Antihy | 2002 |
Trough:peak ratio and smoothness index in the evaluation of 24-h blood pressure control in hypertension: a comparative study between valsartan/hydrochlorothiazide combination and amlodipine.
Topics: Adult; Amlodipine; Antihypertensive Agents; Blood Pressure; Blood Pressure Monitoring, Ambulatory; D | 2002 |
Double-blind, placebo-controlled crossover comparison of five classes of antihypertensive drugs.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Adult; Amlodipine; Angiotensin-Converting | 2002 |
Double-blind, placebo-controlled crossover comparison of five classes of antihypertensive drugs.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Adult; Amlodipine; Angiotensin-Converting | 2002 |
Double-blind, placebo-controlled crossover comparison of five classes of antihypertensive drugs.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Adult; Amlodipine; Angiotensin-Converting | 2002 |
Double-blind, placebo-controlled crossover comparison of five classes of antihypertensive drugs.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Adult; Amlodipine; Angiotensin-Converting | 2002 |
Effects of chronic calcium channel blockade on sympathetic nerve activity in hypertension.
Topics: Amlodipine; Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Delayed-Action Prepar | 2002 |
Severity of hypertension affects improved resistance artery endothelial function by angiotensin-converting enzyme inhibition.
Topics: Adult; Amlodipine; Analysis of Variance; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive | 2002 |
Effect of ramipril versus amlodipine on renal outcomes in hypertensive nephrosclerosis.
Topics: Adolescent; Adult; Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agen | 2002 |
Effects of selective angiotensin II receptor blockade on sympathetic nerve activity in primary hypertensive subjects.
Topics: Amlodipine; Angiotensin Receptor Antagonists; Antihypertensive Agents; Blood Pressure; Cross-Over St | 2002 |
Combination therapy of amlodipine/benazepril versus monotherapy of amlodipine in a practice-based setting.
Topics: Adult; Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Benzazepines; Calcium Channel Blo | 2002 |
A comparative crossover evaluation of amlodipine and nifedipine GITS before and after a missed dose: 48-h blood pressure profiles.
Topics: Amlodipine; Antihypertensive Agents; Blood Pressure; Circadian Rhythm; Cross-Over Studies; Digestive | 2002 |
Comparison of benazepril-amlodipine and captopril-thiazide combinations in the management of mild-to-moderate hypertension.
Topics: Administration, Oral; Aged; Amlodipine; Antihypertensive Agents; Benzazepines; Captopril; Double-Bli | 2002 |
Cardiac and renal effects of standard versus rigorous blood pressure control in autosomal-dominant polycystic kidney disease: results of a seven-year prospective randomized study.
Topics: Adult; Amlodipine; Antihypertensive Agents; Blood Pressure; Creatinine; Echocardiography; Enalapril; | 2002 |
Von Willebrand factor, soluble P-selectin, and target organ damage in hypertension: a substudy of the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT).
Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Atenolol; Bendroflumethiazide; Blood Pressure; Cro | 2002 |
Comparison of the effects of amlodipine and captopril on clinic and ambulatory blood pressure.
Topics: Adult; Ambulatory Care; Amlodipine; Blood Pressure; Captopril; Circadian Rhythm; Clinical Protocols; | 1992 |
Intra-arterial monitoring of the antihypertensive effects of once-daily amlodipine.
Topics: Amlodipine; Antihypertensive Agents; Blood Pressure; Blood Pressure Determination; Blood Pressure Mo | 1992 |
Amlodipine--a new calcium-channel blocker.
Topics: Amlodipine; Angina Pectoris; Angina Pectoris, Variant; Humans; Hypertension | 1992 |
A randomized, placebo-controlled, double-blind comparison of amlodipine and atenolol in patients with essential hypertension.
Topics: Adolescent; Adult; Aged; Amlodipine; Atenolol; Blood Pressure; Double-Blind Method; Female; Humans; | 1992 |
[Effectiveness and tolerance of amlodipine in treatment of patients with mild to moderate hypertension. Results of a long-term study with a new calcium antagonist].
Topics: Adult; Aged; Amlodipine; Blood Pressure; Calcium Channel Blockers; Drug Evaluation; Female; Humans; | 1992 |
[A comparison between amlodipine and nifedipine retard in patients with essential arterial hypertension].
Topics: Adult; Aged; Amlodipine; Analysis of Variance; Calcium Channel Blockers; Delayed-Action Preparations | 1992 |
Amlodipine compared to nitrendipine in hypertensive patients: the effects on toleration in relationship to the onset of action.
Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Female; | 1992 |
Comparison of early side effects with amlodipine and nifedipine retard in hypertension.
Topics: Adolescent; Adult; Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Calcium Channel Blocke | 1992 |
A double-blind crossover study of the effect of concomitant diuretic therapy in hypertensive patients treated with amlodipine.
Topics: Adult; Amlodipine; Bendroflumethiazide; Blood Pressure; Calcium Channel Blockers; Double-Blind Metho | 1991 |
[Therapy of mild to moderate hypertension. Efficacy and tolerance of Amlodipine in comparison with the combination nifedipine/mefruside].
Topics: Adult; Aged; Amlodipine; Calcium Channel Blockers; Drug Combinations; Female; Humans; Hypertension; | 1991 |
Amlodipine: an effective once-daily antihypertensive agent.
Topics: Amlodipine; Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Drug Administration S | 1991 |
A double-blind evaluation of the effect of amlodipine on ambulatory blood pressure.
Topics: Adolescent; Adult; Aged; Amlodipine; Blood Pressure; Blood Pressure Determination; Calcium Channel B | 1991 |
A study of the efficacy and safety of amlodipine for the treatment of hypertension in general practice.
Topics: Adult; Aged; Aged, 80 and over; Amlodipine; Calcium Channel Blockers; Edema; Female; Headache; Human | 1991 |
A double-blind, parallel, comparative evaluation of amlodipine against captopril in the monotherapeutic treatment of mild and moderate essential hypertension: interim results.
Topics: Amlodipine; Blood Pressure; Calcium Channel Blockers; Captopril; Double-Blind Method; Drug Administr | 1991 |
Amlodipine compared to nitrendipine for the treatment of mild-to-moderate hypertension.
Topics: Amlodipine; Calcium Channel Blockers; Female; Heart Rate; Humans; Hypertension; Male; Middle Aged; N | 1991 |
Efficacy and tolerability of amlodipine in patients with mild-to-moderate hypertension.
Topics: Adult; Aged; Amlodipine; Blood Pressure; Calcium Channel Blockers; Heart Rate; Humans; Hypertension; | 1991 |
Clinical evaluation of amlodipine, a new long-acting calcium antagonist, in mild and moderate hypertension.
Topics: Adult; Aged; Amlodipine; Blood Pressure; Calcium Channel Blockers; Delayed-Action Preparations; Hear | 1991 |
Twenty-four-hour blood pressure control using once daily treatment with a calcium antagonist or an angiotensin converting enzyme inhibitor.
Topics: Amlodipine; Blood Pressure; Calcium Channel Blockers; Enalapril; Female; Humans; Hypertension; Male; | 1991 |
Long-term haemodynamic effects of amlodipine at rest and during exercise in essential hypertension.
Topics: Amlodipine; Blood Pressure; Blood Pressure Monitors; Calcium Channel Blockers; Exercise; Female; Hem | 1990 |
Effects of amlodipine on blood pressure, heart rate, catecholamines, lipids and responses to adrenergic stimulus.
Topics: Amlodipine; Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Catecholamines; Doubl | 1990 |
Arterial vasodilator effects of the dihydropyridine calcium antagonist amlodipine alone and in combination with verapamil in systemic hypertension.
Topics: Amlodipine; Calcium Channel Blockers; Drug Therapy, Combination; Female; Forearm; Humans; Hypertensi | 1990 |
Amlodipine with enalapril therapy in moderate-severe essential hypertension.
Topics: Adult; Aged; Amlodipine; Blood Pressure; Calcium Channel Blockers; Double-Blind Method; Drug Therapy | 1990 |
Multicenter placebo-controlled comparison of amlodipine and atenolol in mild to moderate hypertension.
Topics: Adult; Aged; Amlodipine; Atenolol; Blood Pressure; Calcium Channel Blockers; Clinical Trials as Topi | 1988 |
A randomized placebo-controlled comparison of amlodipine and atenolol in mild to moderate systemic hypertension.
Topics: Adolescent; Adult; Aged; Amlodipine; Atenolol; Blood Pressure; Calcium Channel Blockers; Clinical Tr | 1988 |
Once-daily amlodipine in the treatment of mild to moderate hypertension.
Topics: Adult; Amlodipine; Blood Pressure; Calcium Channel Blockers; Double-Blind Method; Female; Heart Rate | 1988 |
A double-blind evaluation of the effect of amlodipine on ambulatory blood pressure in hypertensive patients.
Topics: Amlodipine; Blood Pressure; Calcium Channel Blockers; Clinical Trials as Topic; Double-Blind Method; | 1988 |
Amlodipine: a double-blind evaluation of the dose-response relationship in mild to moderate hypertension.
Topics: Adult; Aged; Amlodipine; Blood Pressure; Calcium Channel Blockers; Clinical Trials as Topic; Dose-Re | 1988 |
A double-blind crossover comparison of amlodipine and placebo added to captopril in moderate to severe hypertension.
Topics: Adolescent; Adult; Aged; Amlodipine; Calcium Channel Blockers; Captopril; Clinical Trials as Topic; | 1988 |
Comparison of amlodipine and verapamil in the treatment of mild to moderate hypertension.
Topics: Adolescent; Adult; Aged; Amlodipine; Blood Pressure; Calcium Channel Blockers; Clinical Trials as To | 1988 |
Long-term open evaluation of amlodipine versus hydrochlorothiazide in patients with essential hypertension.
Topics: Adolescent; Adult; Aged; Amlodipine; Blood Pressure; Calcium Channel Blockers; Female; Humans; Hydro | 1988 |
Double-blind comparison of amlodipine and hydrochlorothiazide in patients with mild to moderate hypertension.
Topics: Adolescent; Adult; Aged; Amlodipine; Blood Pressure; Calcium Channel Blockers; Clinical Trials as To | 1988 |
Safety and efficacy of amlodipine added to hydrochlorothiazide therapy in essential hypertension.
Topics: Adult; Aged; Amlodipine; Blood Pressure; Calcium Channel Blockers; Double-Blind Method; Drug Therapy | 1989 |
A dose-response study of amlodipine in mild to moderate hypertension.
Topics: Adult; Aged; Amlodipine; Blood Pressure; Calcium Channel Blockers; Clinical Trials as Topic; Dose-Re | 1989 |
Antihypertensive effectiveness of amlodipine in combination with hydrochlorothiazide.
Topics: Alanine Transaminase; Amlodipine; Aspartate Aminotransferases; Calcium Channel Blockers; Cholesterol | 1989 |
A comparison of amlodipine, verapamil and placebo in the treatment of mild to moderate hypertension. Amlodipine Study Group.
Topics: Adult; Aged; Amlodipine; Blood Pressure; Calcium Channel Blockers; Double-Blind Method; Female; Huma | 1989 |
The safety of amlodipine.
Topics: Adrenergic beta-Antagonists; Aged; Amlodipine; Calcium Channel Blockers; Clinical Trials as Topic; D | 1989 |
Once daily amlodipine in the treatment of mild to moderate hypertension.
Topics: Adult; Amlodipine; Blood Pressure; Calcium Channel Blockers; Clinical Trials as Topic; Double-Blind | 1987 |
842 other studies available for amlodipine and Hypertension
| Article | Year |
|---|---|
Dihydropyrimidine calcium channel blockers. 4. Basic 3-substituted-4-aryl-1,4-dihydropyrimidine-5-carboxylic acid esters. Potent antihypertensive agents.
Topics: Amlodipine; Animals; Antihypertensive Agents; Calcium Channel Blockers; Crystallization; Hypertensio | 1992 |
Renin secreting tumour: a rare cause of secondary hypertension.
Topics: Adult; Amlodipine; Antihypertensive Agents; Female; Humans; Hypertension; Kidney Neoplasms; Labetalo | 2021 |
Galangin alleviates vascular dysfunction and remodelling through modulation of the TNF-R1, p-NF-κB and VCAM-1 pathways in hypertensive rats.
Topics: Amlodipine; Animals; Anti-Inflammatory Agents, Non-Steroidal; Antihypertensive Agents; Antioxidants; | 2021 |
[Vasoprotective effects hypotensive therapy in patients with coronary heart disease combined with chronic kidney disease stage 2-3 after coronary stenting].
Topics: Amlodipine; Antihypertensive Agents; Blood Pressure; Coronary Disease; Drug Combinations; Humans; Hy | 2021 |
Expanding role for single-pill combination drug therapy in the initial treatment of hypertension?
Topics: Amlodipine; Antihypertensive Agents; Drug Therapy, Combination; Humans; Hypertension | 2021 |
Clinical effectiveness and safety of amlodipine/losartan-based single-pill combination therapy in patients with hypertension: Findings from real-world, multicenter observational databases.
Topics: Amlodipine; Antihypertensive Agents; Humans; Hypertension; Losartan; Treatment Outcome; Uric Acid | 2021 |
Dose-dependent atorvastatin associated with angioedema.
Topics: Aged; Amlodipine; Angioedema; Antihypertensive Agents; Atorvastatin; Calcium Channel Blockers; Femal | 2022 |
Amlodipine Induced Gingival Hyperplasia.
Topics: Amlodipine; Calcium Channel Blockers; Gingival Hyperplasia; Humans; Hypertension | 2021 |
Borderline and Hypertension.
Topics: Adolescent; Amlodipine; Antihypertensive Agents; Humans; Hypertension; Male; Treatment Outcome | 2022 |
Effect of Blood Pressure Reduction on Intraocular Pressure and Ophthalmic Artery Blood Flow Velocity in Hypertension.
Topics: Amlodipine; Atenolol; Blood Flow Velocity; Blood Pressure; Humans; Hypertension; Intraocular Pressur | 2022 |
Comment on 'Comparison of losartan and amlodipine effects on the outcomes of patient with COVID-19 and primary hypertension: A randomised clinical trial'.
Topics: Amlodipine; Antihypertensive Agents; COVID-19; Humans; Hypertension; Losartan; SARS-CoV-2 | 2021 |
In hypertension, a quadpill containing quarter doses of 4 BP drugs reduced BP at 12 wk vs. standard-dose monotherapy.
Topics: Amlodipine; Antihypertensive Agents; Blood Pressure; Double-Blind Method; Drug Therapy, Combination; | 2022 |
Cancer Risk of Angiotensin II Receptor Blocker Valsartan: A Population-based Study.
Topics: Amlodipine; Angiotensin Receptor Antagonists; Antihypertensive Agents; Blood Pressure; Calcium Chann | 2022 |
Management of American Heart Association/American College of Cardiology-Defined Stage 2 Hypertension by Cardiologists in India.
Topics: American Heart Association; Amlodipine; Antihypertensive Agents; Blood Pressure; Cardiologists; Card | 2022 |
Unusual case of pleural effusion caused by amlodipine in a dog with systemic hypertension.
Topics: Acute Disease; Amlodipine; Animals; Dog Diseases; Dogs; Exudates and Transudates; Humans; Hypertensi | 2022 |
Ambulatory blood pressure response to S-amlodipine in Korean adult patients with uncontrolled essential hypertension: A prospective, observational study.
Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Blood Pressure Monitoring, Ambulat | 2022 |
Effectiveness of indapamide/amlodipine single-pill combination in patients with isolated systolic hypertension: post-hoc analysis of the ARBALET study.
Topics: Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Drug Combinations; Female; Humans; Hypert | 2022 |
Circulating renin-angiotensin-aldosterone system activity in cats with systemic hypertension or cardiomyopathy.
Topics: Aldosterone; Amlodipine; Animals; Biomarkers; Cardiomyopathies; Cat Diseases; Cats; Furosemide; Hype | 2022 |
Blood pressure response to commonly administered antihypertensives for severe inpatient hypertension.
Topics: Adult; Amlodipine; Antihypertensive Agents; Blood Pressure; Carvedilol; Cohort Studies; Humans; Hydr | 2022 |
Use of Perindopril Arginine/Indapamide/Amlodipine in the Management of Hypertension in Two Sub-Saharan African Island Countries of Madagascar and Mauritius.
Topics: Amlodipine; Antihypertensive Agents; Arginine; Blood Pressure; Blood Pressure Monitoring, Ambulatory | 2022 |
Use of single pill combinations in the treatment of arterial hypertension in Poland: The current practice and guidelines, the impact on reimbursement spending and patient co-payment.
Topics: Amlodipine; Antihypertensive Agents; Drug Combinations; Humans; Hypertension; Poland | 2022 |
Gingival enlargement improvement following medication change from amlodipine to benidipine and periodontal therapy.
Topics: Amlodipine; Antihypertensive Agents; Calcium Channel Blockers; Dihydropyridines; Female; Gingival Hy | 2022 |
Brain-penetrant calcium channel blockers are associated with a reduced incidence of neuropsychiatric disorders.
Topics: Amlodipine; Brain; Calcium Channel Blockers; Dementia; Depressive Disorder, Major; Female; Humans; H | 2022 |
Comparative efficacy of generic nifedipine versus brand-name amlodipine for hypertension management in Taiwan.
Topics: Amlodipine; Calcium Channel Blockers; Drugs, Generic; Heart Failure; Humans; Hypertension; Ischemic | 2022 |
Different Approaches in Manipulating Ratio Spectra for Analyzing Amlodipine Besylate and Irbesartan Combination.
Topics: Amlodipine; Antihypertensive Agents; Humans; Hypertension; Irbesartan; Spectrophotometry; Tetrazoles | 2022 |
Antihypertensive drug prescription trends for pregnant women with hypertension in acute hospitals in Japan.
Topics: Amlodipine; Antihypertensive Agents; Calcium Channel Blockers; Drug Prescriptions; Female; Hospitals | 2022 |
Eco-friendly spectrophotometric evaluation of triple-combination therapies in the treatment strategy of patients suffering from hypertension during coronavirus pandemic - Spectralprint recognition study.
Topics: Amlodipine; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihyperten | 2022 |
Evaluation of presentation, treatment and outcome in hypertensive emergency in dogs and cats: 15 cases (2003-2019).
Topics: Amlodipine; Animals; Antihypertensive Agents; Blindness; Cat Diseases; Cats; Dog Diseases; Dogs; Eme | 2022 |
Impact of simultaneous management of hypertension and hypercholesterolemia with ACE inhibitors and statins on cardiovascular outcomes in the Brisighella Heart Study: A 8-year follow-up.
Topics: Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Atorvastatin; Blood P | 2022 |
RP-HPLC method development and validation for simultaneous estimation of telmisartan, rosuvastatin calcium, and amlodipine besylate in combination.
Topics: Amlodipine; Antihypertensive Agents; Chromatography, High Pressure Liquid; Humans; Hypertension; Ros | 2022 |
Choice of antihypertensive agent in isolated systolic hypertension and isolated diastolic hypertension: A secondary analysis of the ALLHAT trial.
Topics: Amlodipine; Antihypertensive Agents; Chlorthalidone; Humans; Hypertension; Isolated Systolic Hyperte | 2022 |
The India Hypertension Control Initiative-early outcomes in 26 districts across five states of India, 2018-2020.
Topics: Amlodipine; Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Humans; Hydrochloroth | 2023 |
Antihypertensive medicine use differs between Ghana and Nigeria.
Topics: Amlodipine; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihyperten | 2022 |
INDICATORS OF ENDOTHELIAL DYSFUNCTION, MARKERS OF INFLAMMATION AND LIPID METABOLISM IN PATIENTS WITH HYPERTENSION WITH THE ADMINISTRATION OF QUERCETIN.
Topics: Adult; Amlodipine; Antihypertensive Agents; Blood Pressure; Female; Humans; Hypertension; Inflammati | 2022 |
Single Nucleotide Polymorphisms in Amlodipine-Associated Genes and Their Correlation with Blood Pressure Control among South African Adults with Hypertension.
Topics: Adult; Amlodipine; Blood Pressure; Female; Humans; Hypertension; Male; Polymorphism, Single Nucleoti | 2022 |
Benefits of Valsartan and Amlodipine in Lipolysis through PU.1 Inhibition in Fructose-Induced Adiposity.
Topics: Activating Transcription Factor 3; Adiposity; Amlodipine; Angiotensin Receptor Antagonists; Antihype | 2022 |
Antihypertensive treatment improves glycemic control in patients with newly diagnosed type 2 diabetes mellitus: A prospective cohort study.
Topics: Amlodipine; Antihypertensive Agents; Diabetes Mellitus, Type 2; Glucose; Glycated Hemoglobin; Glycem | 2022 |
Relationship Between Calcium Channel Blockers Therapy and Cognitive Function Improvement in Cognitive Decline Patients with Cerebrovascular Disease.
Topics: Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Cerebrovascular | 2022 |
Financial implications of protocol-based hypertension treatment: an insight into medication costs in public and private health sectors in India.
Topics: Amlodipine; Chlorthalidone; Humans; Hypertension; India; Private Sector; Telmisartan | 2023 |
Delayed Decline of Cognitive Function by Antihypertensive Agents: A Cohort Study Linked with Genotype Data.
Topics: Adrenergic Antagonists; Adult; Aged; Amlodipine; Antihypertensive Agents; Apolipoprotein E4; Calcium | 2022 |
EFFECTIVENESS OF LISINOPRIL AND AMLODIPINE COMBINATION AT HYPERTENSION WITH COMORBIDITY OF ARTERIOSCLEROSIS OBLITERANS IN GENERAL PRACTICE.
Topics: Amlodipine; Antihypertensive Agents; Arteriosclerosis Obliterans; Blood Pressure; Comorbidity; Gener | 2022 |
EFFECTIVENESS OF LISINOPRIL AND AMLODIPINE COMBINATION AT HYPERTENSION WITH COMORBIDITY OF ARTERIOSCLEROSIS OBLITERANS IN GENERAL PRACTICE.
Topics: Amlodipine; Antihypertensive Agents; Arteriosclerosis Obliterans; Blood Pressure; Comorbidity; Gener | 2022 |
EFFECTIVENESS OF LISINOPRIL AND AMLODIPINE COMBINATION AT HYPERTENSION WITH COMORBIDITY OF ARTERIOSCLEROSIS OBLITERANS IN GENERAL PRACTICE.
Topics: Amlodipine; Antihypertensive Agents; Arteriosclerosis Obliterans; Blood Pressure; Comorbidity; Gener | 2022 |
EFFECTIVENESS OF LISINOPRIL AND AMLODIPINE COMBINATION AT HYPERTENSION WITH COMORBIDITY OF ARTERIOSCLEROSIS OBLITERANS IN GENERAL PRACTICE.
Topics: Amlodipine; Antihypertensive Agents; Arteriosclerosis Obliterans; Blood Pressure; Comorbidity; Gener | 2022 |
Efficacy and safety of single pill combination of amlodipine and valsartan in hypertensive Saudi patients.
Topics: Amlodipine; Antihypertensive Agents; Blood Pressure; Drug Combinations; Drug Therapy, Combination; H | 2023 |
Adherence to Triple Single-Pill Combination of Perindopril/Indapamide/Amlodipine: Findings from Real-World Analysis in Italy.
Topics: Adult; Amlodipine; Antihypertensive Agents; Blood Pressure; Drug Combinations; Humans; Hypertension; | 2023 |
Effect of long-term antihypertensive treatment on cerebrovascular structure and function in hypertensive rats.
Topics: Amlodipine; Animals; Antihypertensive Agents; Atenolol; Carotid Artery, Common; Hypertension; Hypote | 2023 |
Improved Persistence to Medication, Decreased Cardiovascular Events and Reduced All-Cause Mortality in Hypertensive Patients With Use of Single-Pill Combinations: Results From the START-Study.
Topics: Amlodipine; Antihypertensive Agents; Blood Pressure; Drug Combinations; Humans; Hypertension; Medica | 2023 |
Effect of Fixed-dose Combination Amlodipine/Valsartan in Comparison to Two Drug Combination Nebivolol/Valsartan on 24-Hour Ambulatory Blood Pressure.
Topics: Amlodipine; Antihypertensive Agents; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Drug Com | 2023 |
Efficacy of Antihypertensive Drugs of Different Classes After Renal Denervation in Spontaneously Hypertensive Rats.
Topics: Aldosterone; Amlodipine; Animals; Antihypertensive Agents; Bisoprolol; Blood Pressure; Cardiomyopath | 2023 |
An Expert Opinion on the Role of the Rosuvastatin/Amlodipine Single Pill Fixed Dose Combination in Cardiovascular Prevention.
Topics: Amlodipine; Antihypertensive Agents; Cardiovascular Diseases; Drug Combinations; Expert Testimony; H | 2023 |
Effects of Valsartan and Amlodipine Tablets Combined with α-Lipoic Acid on T-AOC, IL-6 and β2-MG Levels in Patients with Diabetic Nephropathy.
Topics: Amlodipine; Antihypertensive Agents; Antioxidants; Diabetes Mellitus, Type 2; Diabetic Nephropathies | 2023 |
5-Aminolevulinic acid hydrochloride enhances bupivacaine-induced hypotension in spontaneously hypertensive rats.
Topics: Aminolevulinic Acid; Amlodipine; Animals; Antihypertensive Agents; Blood Pressure; Bupivacaine; Hype | 2023 |
Amlodipine limits microglia activation and cognitive dysfunction in aged hypertensive mice.
Topics: Amlodipine; Animals; Antihypertensive Agents; Blood Pressure; Calcium; Calcium Channel Blockers; Dem | 2023 |
Folic acid enhances the cardiovascular protective effect of amlodipine in renal hypertensive rats with elevated homocysteine.
Topics: Amlodipine; Animals; Endothelial Cells; Folic Acid; Homocysteine; Hyperhomocysteinemia; Hypertension | 2023 |
Effects of 5-fluorouracil Co-administration on Blood Pressure in Patients Maintained on Antihypertensives: a Retrospective Case Series.
Topics: Amlodipine; Antihypertensive Agents; Antineoplastic Agents; Blood Pressure; Cytochrome P-450 CYP3A; | 2023 |
Amlodipine fatality trends.
Topics: Amlodipine; Antihypertensive Agents; Calcium Channel Blockers; Humans; Hypertension | 2023 |
Impact of bisoprolol and amlodipine on cardiopulmonary responses and symptoms during exercise in patients with chronic obstructive pulmonary disease.
Topics: Adrenergic beta-Antagonists; Amlodipine; Bisoprolol; Exercise Test; Humans; Hypertension; Pulmonary | 2023 |
[Swelling of the labial gingiva of the teeth].
Topics: Amlodipine; Child; Gingiva; Humans; Hypertension; Male; Renal Insufficiency, Chronic | 2023 |
Adherence and related cardiovascular outcomes to single pill vs. separate pill administration of antihypertensive triple-combination therapy.
Topics: Adult; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Calcium Channe | 2023 |
In the prevention of dementia, the focus should be on early and consistent treatment of hypertension.
Topics: Amlodipine; Antihypertensive Agents; Blood Pressure; Dementia; Drug Combinations; Humans; Hypertensi | 2023 |
Concurrent disorders of cats with diabetes mellitus and arterial systolic hypertension.
Topics: Aldosterone; Amlodipine; Animals; Antihypertensive Agents; Cat Diseases; Cats; Diabetes Mellitus; Hy | 2023 |
Effect of Initial Treatment With a Single Pill Containing Quadruple Combination of Quarter Doses of Blood Pressure Medicines Versus Standard Dose Monotherapy in Patients With Hypertension on Ambulatory Blood Pressure Indices: Results From the QUARTET Stud
Topics: Amlodipine; Antihypertensive Agents; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Double-B | 2023 |
Improvement in hemodynamics of amlodipine besylate combined with metoprolol in patients with hypertension complicated by heart failure.
Topics: Amlodipine; Heart Failure; Hemodynamics; Humans; Hypertension; Metoprolol | 2023 |
Hordeum vulgare ethanolic extract mitigates high salt-induced cerebellum damage via attenuation of oxidative stress, neuroinflammation, and neurochemical alterations in hypertensive rats.
Topics: Amlodipine; Animals; Cerebellum; Ethanol; Hordeum; Hypertension; Neuroinflammatory Diseases; Oxidati | 2023 |
Real-World Effectiveness and Safety of a Single-Pill Combination of Olmesartan/Amlodipine/Hydrochlorothiazide in Korean Patients with Hypertension and Cardiovascular Risk Factors.
Topics: Amlodipine; Antihypertensive Agents; Blood Pressure; Cardiovascular Diseases; Drug Combinations; Fem | 2023 |
A real-world analysis of outcomes and healthcare costs of patients on perindopril/indapamide/amlodipine single-pill vs. multiple-pill combination in Italy.
Topics: Adult; Amlodipine; Antihypertensive Agents; Drug Combinations; Health Care Costs; Humans; Hypertensi | 2024 |
Treatment with Free Triple Combination Therapy of Atorvastatin, Perindopril, Amlodipine in Hypertensive Patients: A Real-World Population Study in Italy.
Topics: Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Atorvastatin; B | 2019 |
Effects of Antihypertensive Class on Falls, Syncope, and Orthostatic Hypotension in Older Adults: The ALLHAT Trial.
Topics: Accidental Falls; Aged; Aged, 80 and over; Amlodipine; Antihypertensive Agents; Atenolol; Chlorthali | 2019 |
[Effects of changing the appearance of medications in safety and adherence in chronic patients over 65 years of age in primary care. CAMBIMED Study].
Topics: Aged; Aged, 80 and over; Amlodipine; Antihypertensive Agents; Chronic Disease; Drug Labeling; Drug P | 2020 |
Relationships between endogenous CYP3A markers and plasma amlodipine exposure and metabolism in early postpartum and non-peripartum women with hypertension.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Amlodipine; Antihypertensive Agents; Biomarker | 2019 |
Chronic thrombotic microangiopathy secondary to antiphospholipid syndrome, presenting with severe hypertension and chronic renal impairment.
Topics: Adult; Amlodipine; Anticoagulants; Antihypertensive Agents; Antiphospholipid Syndrome; Diagnosis, Di | 2019 |
Rare cause of severe hypertension in an adolescent boy presenting with short stature: Questions.
Topics: Adolescent; Amlodipine; Antihypertensive Agents; Body Height; Developmental Disabilities; Humans; Hy | 2020 |
[Antihypertensive Effect of Switching to a Fixed Perindopril/Amlodipine Combination in Patients Ineffectively Treated by Free Sartan-Containing Combinations. Results of the AVANGARD Study].
Topics: Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Blood Pressure; Drug C | 2019 |
Comparative effectiveness of combination treatment for hypertension in black Africans.
Topics: Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Black People; Calcium | 2020 |
Uncertain Etiology of Left Ventricular Hypertrophy in a Young Subject With Hypertension Treated With Dexamphetamine.
Topics: Adult; Amlodipine; Antihypertensive Agents; Cardiomyopathies; Deprescriptions; Dextroamphetamine; Ec | 2020 |
Synergistic therapeutic effects of Duzhong Jiangya Tablets and amlodipine besylate combination in spontaneously hypertensive rats using
Topics: Amlodipine; Animals; Antihypertensive Agents; Blood Pressure; Drug Synergism; Drugs, Chinese Herbal; | 2020 |
Efficacy and safety of a combination antihypertensive drug (olmesartan plus azelnidipine): "Issues with hypertension studies in real-world practice".
Topics: Amlodipine; Antihypertensive Agents; Azetidinecarboxylic Acid; Blood Pressure; Blood Pressure Monito | 2020 |
The hypertensive child.
Topics: Abdominal Pain; Adrenocorticotropic Hormone; Aldosterone; Amlodipine; Antihypertensive Agents; Catec | 2019 |
PK/PD modeling based on NO-ET homeostasis for improving management of sunitinib-induced hypertension in rats.
Topics: Administration, Oral; Amlodipine; Animals; Antihypertensive Agents; Biomarkers; Blood Pressure; Endo | 2020 |
Detection of significant left renal artery stenosis caused by fibromuscular dysplasia with selective angiography.
Topics: Amlodipine; Angioplasty, Balloon; Antihypertensive Agents; Computed Tomography Angiography; Drug Com | 2020 |
The effects of antihypertensive class on gout in older adults: secondary analysis of the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial.
Topics: Aged; Amlodipine; Antihypertensive Agents; Atenolol; Blood Pressure; Chlorthalidone; Female; Gout; H | 2020 |
Fixed-dose combinations of lipid-lowering and antihypertensive agents: The way forward?
Topics: Amlodipine; Antihypertensive Agents; Blood Pressure; Double-Blind Method; Dyslipidemias; Humans; Hyp | 2020 |
Importance of fixed-dose combinations in cardiovascular prevention: the possibility of treating two diagnoses with a single pill.
Topics: Amlodipine; Antihypertensive Agents; Atorvastatin; Blood Pressure; Cardiovascular Diseases; Drug Com | 2020 |
The impact of manual quality control review on the feasibility of central ambulatory blood pressure monitoring.
Topics: Amlodipine; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Feasibility Studies; Humans; Hype | 2020 |
Single-pill combination of cilnidipine, an L-/N-type calcium channel blocker, and valsartan effectively reduces home pulse pressure in patients with uncontrolled hypertension and sympathetic hyperactivity: The HOPE-Combi survey.
Topics: Amlodipine; Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Calcium Channels, L-T | 2020 |
Comparison of effects of L/N-type and L-type calcium channel blockers on post-infarct cardiac remodelling in spontaneously hypertensive rats.
Topics: Amlodipine; Animals; Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Calcium Chan | 2020 |
Pharmacokinetic and pharmacodynamic evaluation of nano-fixed dose combination for hypertension.
Topics: Amlodipine; Animals; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Disease Models, An | 2020 |
[Antihypertensive and Vasoprotective Effects of Combined Pharmacotherapy in Patients with Arterial Hypertension and Prediabetes].
Topics: Amlodipine; Antihypertensive Agents; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Drug Com | 2020 |
Effect of Nigella sativa and Fenugreek on the Pharmacokinetics and Pharmacodynamics of Amlodipine in Hypertensive Rats.
Topics: Amlodipine; Animals; Antihypertensive Agents; Blood Pressure; Herb-Drug Interactions; Hypertension; | 2020 |
The comparison of side effects of methyldopa, amlodipine, and metoprolol in pregnant women with chronic hypertension.
Topics: Adult; Amlodipine; Antihypertensive Agents; Blood Pressure; Female; Humans; Hypertension; Incidence; | 2020 |
Hemolytic Anemia and Thrombocytopenia: How to Treat?
Topics: Amlodipine; Anemia, Hemolytic; Carvedilol; Cocaine; Humans; Hypertension; Male; Medication Adherence | 2020 |
[Therapeutic approaches to the Rational Use of trip-le combination therapy with a fixed combination of amlodipine, indapamide and perindopril arginine (TRIPLE COMBINATION) in patients with hypertension who do not control blood pressure on conventional tre
Topics: Aged; Amlodipine; Antihypertensive Agents; Arginine; Blood Pressure; Blood Pressure Monitoring, Ambu | 2020 |
Consensi --a fixed dose combination of amlodipine and celecoxib.
Topics: Amlodipine; Antihypertensive Agents; Calcium Channel Blockers; Celecoxib; Cyclooxygenase 2 Inhibitor | 2020 |
Amlodipine-induced gingival hypertrophy.
Topics: Amlodipine; Antihypertensive Agents; Calcium Channel Blockers; Gingival Hypertrophy; Humans; Hyperte | 2020 |
Calcium channel blockers, survival and ischaemic stroke in patients with dementia: a Swedish registry study.
Topics: Alzheimer Disease; Amlodipine; Brain Ischemia; Calcium Channel Blockers; Humans; Hypertension; Ische | 2021 |
Fixed-dose combination of amlodipine and atorvastatin improves clinical outcomes in patients with concomitant hypertension and dyslipidemia.
Topics: Amlodipine; Antihypertensive Agents; Atorvastatin; Drug Combinations; Drug Therapy, Combination; Dys | 2020 |
Acute idiopathic polyradiculoneuritis with secondary arterial hypertension in a 5-year-old male Siberian Husky.
Topics: Amlodipine; Animals; Antihypertensive Agents; Dog Diseases; Dogs; Hypertension; Male; Polyradiculone | 2020 |
Resistant hypertension during antituberculosis treatment: how is rifampicin implicated?
Topics: Aged; Amlodipine; Antibiotics, Antitubercular; Antihypertensive Agents; Drug Interactions; Drug Ther | 2020 |
Antihypertensive therapy and short-term blood pressure variability.
Topics: Amlodipine; Antihypertensive Agents; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Calcium | 2021 |
Telmisartan Plus S-Amlodipine Single-Pill Combination Therapy is Safe and Effective in Patients with Hypertension from Large-Scale Nationwide Surveillance Data in Korea (NOVEL) Study.
Topics: Amlodipine; Antihypertensive Agents; Benzoates; Blood Pressure; Drug Combinations; Drug Therapy, Com | 2021 |
Worsening Kidney Function Is the Major Mechanism of Heart Failure in Hypertension: The ALLHAT Study.
Topics: Aged; Amlodipine; Antihypertensive Agents; Double-Blind Method; Female; Heart Failure; Humans; Hyper | 2021 |
[Comorbidity of arterial hyperten-sion and tension-type headache].
Topics: Amlodipine; Antihypertensive Agents; Blood Pressure; Comorbidity; Drug Combinations; Humans; Hyperte | 2020 |
Amlodipine Induced Massive Ascites, a Rare Clinical Case.
Topics: Adult; Amlodipine; Ascites; Calcium Channel Blockers; Edema; Humans; Hypertension; Male | 2020 |
Treatment of calcium channel blocker-induced gingival overgrowth without modifying medication.
Topics: Aged; Amlodipine; Calcium Channel Blockers; Diabetes Mellitus, Type 2; Gingival Overgrowth; Humans; | 2021 |
Single-pill combination of cilnidipine, an l-/n-type calcium channel blocker, and valsartan reduces the day-by-day variability of morning home systolic blood pressure in patients with treated hypertension: A sub-analysis of the HOPE-combi survey.
Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Calcium | 2021 |
Ocular fundus abnormalities in cats affected by systemic hypertension: Prevalence, characterization, and outcome of treatment.
Topics: Amlodipine; Animals; Antihypertensive Agents; Cat Diseases; Cats; Female; Fundus Oculi; Hypertension | 2021 |
[Fixed combination atorvastatin-perindopril (Lipercosyl®) for substitution treatment of cardiovascular risk management].
Topics: Amlodipine; Antihypertensive Agents; Atorvastatin; Blood Pressure; Cardiovascular Diseases; Drug Com | 2021 |
Expression of Cyr61 in ApoE
Topics: Amides; Amlodipine; Angiotensin II; Animals; Antihypertensive Agents; Apolipoproteins E; Blood Press | 2021 |
Assessing Adherence to Antihypertensive Medication by Means of Dose-Dependent Reference Plasma Concentration Ranges and Ultra-High Performance Liquid Chromatography-Ion Trap Mass Spectrometry Analysis.
Topics: Amlodipine; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Body Fluids; Chromatography | 2021 |
Psychological Continuum of Elderly Patients Suffering from Arterial Hypertension with Metabolic Syndrome, Against the Background of Chronotherapy with a Fixed Combination of Amlodipine, Lisinopril and Rosuvastatin.
Topics: Aged; Amlodipine; Antihypertensive Agents; Anxiety; Blood Pressure; Chronotherapy; Humans; Hypertens | 2021 |
Fixed-dose combination amlodipine-celecoxib for treatment of hypertension and osteoarthritis pain: an up-to-date evaluation.
Topics: Amlodipine; Antihypertensive Agents; Blood Pressure; Celecoxib; Drug Combinations; Humans; Hypertens | 2021 |
[REMODELING OF THE LEFT VENTRICLE, SUBCLINICAL MANIFESTATIONS OF ATHEROSCLEROSIS IN PATIENTS WITH HYPERTONIC DISEASE WITH RHEUMATOID ARTHRITIS BY THE INFLUENCE OF DIFFERENT TREATMENT SCHEMES].
Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Arthritis, Rheumatoid; Atherosclerosis; Blood Pres | 2021 |
Combination of atorvastatin or hydrochlorothiazide/amlodipine with
Topics: Amlodipine; Atherosclerosis; Atorvastatin; Drugs, Chinese Herbal; Humans; Hydrochlorothiazide; Hyper | 2021 |
A Big Headache: An Unusual Case of Hypertensive Urgency in an Adolescent.
Topics: Adolescent; Amlodipine; Antihypertensive Agents; Aorta, Abdominal; Aortic Valve Stenosis; Computed T | 2021 |
More Than Meets the Eye: A Patient with Hand Swelling and Newly Diagnosed Diabetes Mellitus.
Topics: Aged; Amlodipine; Anemia; Antihypertensive Agents; Blood Sedimentation; C-Reactive Protein; Diabetes | 2021 |
Long-acting tunable release of amlodipine loaded PEG-PCL micelles for tailored treatment of chronic hypertension.
Topics: Amlodipine; Animals; Calcium Channel Blockers; Calcium Channels; Cell Line; Cell Survival; Chronic D | 2021 |
Long-Term Incidence of Stroke and Dementia in ASCOT.
Topics: Aged; Amlodipine; Anticholesteremic Agents; Antihypertensive Agents; Atenolol; Atorvastatin; Cholest | 2021 |
Platelet Dysfunction Because of Amlodipine in Bone Marrow Transplant Recipient.
Topics: Amlodipine; Bone Marrow Transplantation; Child; Cyclophosphamide; Graft vs Host Disease; Hematopoiet | 2022 |
Assessment of a strategy combining ambulatory blood pressure, adherence monitoring and a standardised triple therapy in resistant hypertension.
Topics: Adult; Amlodipine; Antihypertensive Agents; Blood Pressure; Blood Pressure Monitoring, Ambulatory; F | 2021 |
Use of Amlodipine in Psittacine Birds: 5 Cases (2010-2018).
Topics: Amlodipine; Animals; Birds; Hypertension; Prospective Studies; Psittaciformes; Retrospective Studies | 2021 |
Differential restoration of functional hyperemia by antihypertensive drug classes in hypertension-related cerebral small vessel disease.
Topics: Amlodipine; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Cerebral Smal | 2021 |
Effect of Hibiscus sabdariffa and Zingiber officinale on pharmacokinetics and pharmacodynamics of amlodipine.
Topics: Amlodipine; Animals; Antihypertensive Agents; Area Under Curve; Blood Pressure; Drug Therapy, Combin | 2021 |
[What do we Mean by "Ideal" Blood Pressure Control?]
Topics: Amlodipine; Antihypertensive Agents; Blood Pressure; Drug Combinations; Heart Failure; Humans; Hyper | 2021 |
Effect of Co-Administration of Curcumin with Amlodipine in Hypertension.
Topics: Amlodipine; Animals; Antihypertensive Agents; Blood Pressure; Curcumin; Drug Therapy, Combination; H | 2021 |
Amlodipine: The double edged sword.
Topics: Age Factors; Amlodipine; Blood Pressure Determination; Calcium Channel Blockers; Child; Child, Presc | 2017 |
Combination of anti-hypertensive drugs: a molecular dynamics simulation study.
Topics: Amlodipine; Antihypertensive Agents; Atenolol; Dimyristoylphosphatidylcholine; Humans; Hydrogen Bond | 2017 |
Efficacy of olmesartan amlodipine in Colombian hypertensive patients (soat study).
Topics: Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Co | 2017 |
Case of Asymptomatic Carotid Artery Stenosis in a Hypertensive Patient.
Topics: Aged; Amlodipine; Antihypertensive Agents; Carotid Stenosis; Diuretics; Echocardiography, Doppler; H | 2017 |
Adherence to Treatment, Safety, Tolerance, and Effectiveness of Perindopril/Amlodipine Fixed-Dose Combination in Greek Patients with Hypertension and Stable Coronary Artery Disease: A Pan-Hellenic Prospective Observational Study of Daily Clinical Practice
Topics: Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Pressure; | 2017 |
Oxidative stress: link between hypertension and diabetes.
Topics: Amlodipine; Diabetes Mellitus, Type 2; Humans; Hypertension; Oxidative Stress; Valsartan | 2017 |
Effects of carvedilol or amlodipine on target organ damage in L-NAME hypertensive rats: their relationship with blood pressure variability.
Topics: Amlodipine; Animals; Antihypertensive Agents; Aorta; Biomarkers; Blood Pressure; Blood Pressure Dete | 2017 |
Predictors of visit-to-visit blood pressure variability in patients with hypertension: an analysis of trials with an amlodipine treatment arm.
Topics: Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Blood Pressure Determination; Clinical Tr | 2017 |
The Antihypertensive Efficacy of the Triple Fixed Combination of Perindopril, Indapamide, and Amlodipine: The Results of the PETRA Study.
Topics: Adult; Amlodipine; Antihypertensive Agents; Blood Pressure; Blood Pressure Monitoring, Ambulatory; D | 2017 |
mRNA levels of circadian clock components Bmal1 and Per2 alter independently from dosing time-dependent efficacy of combination treatment with valsartan and amlodipine in spontaneously hypertensive rats.
Topics: Amlodipine; Animals; Antihypertensive Agents; Aorta; ARNTL Transcription Factors; Blood Pressure; Ci | 2017 |
Prospective direct comparison of antihypertensive effect and safety between high-dose amlodipine or indapamide in hypertensive patients uncontrolled by standard doses of angiotensin receptor blockers and amlodipine.
Topics: Aged; Aged, 80 and over; Amlodipine; Angiotensin Receptor Antagonists; Antihypertensive Agents; Biph | 2018 |
Teaching Neuro
Topics: Amlodipine; Antihypertensive Agents; Female; Humans; Hypertension; Magnetic Resonance Imaging; Middl | 2017 |
[Optimization of BP Control and Arterial Elasticity With Fixed Combination Therapy Perindopril and Amlodipine In Patients With Arterial Hypertension and Increased Pulse Wave Velocity].
Topics: Adult; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Pressure | 2017 |
Visit-to-visit variability of blood pressure.
Topics: Amlodipine; Arm; Blood Pressure; Blood Pressure Determination; Humans; Hypertension | 2017 |
Long-term persistence with single-pill, fixed-dose combination therapy versus two pills of amlodipine and perindopril for hypertension: Australian experience.
Topics: Aged; Amlodipine; Antihypertensive Agents; Australia; Drug Combinations; Drug Therapy, Combination; | 2017 |
Drug utilization among hypertensive patients in the outpatient department of medicine in a tertiary care hospital: A cross-sectional study.
Topics: Amlodipine; Antihypertensive Agents; Atenolol; Cross-Sectional Studies; Drug Prescriptions; Drug Uti | 2018 |
Single-Pill Triple Fixed Dose Combination Therapy with Single Component Drug Monitoring in Treatment-Resistant Hypertension: A Pilot Study.
Topics: Administration, Oral; Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Blood Pressure Moni | 2018 |
[One year persistence of free and fixed dose combinations of perindopril/amlodipine].
Topics: Amlodipine; Antihypertensive Agents; Drug Administration Schedule; Drug Combinations; Drug Prescript | 2017 |
Study on the Effect of Irbesartan on Atrial Fibrillation Recurrence in Kumamoto: Atrial Fibrillation Suppression Trial (SILK study).
Topics: Aged; Amlodipine; Angiotensin Receptor Antagonists; Atrial Fibrillation; Biphenyl Compounds; Blood P | 2018 |
Does a fixed-dose combination of amlodipine and atorvastatin improve persistence with therapy in the Australian population?
Topics: Aged; Amlodipine; Antihypertensive Agents; Atorvastatin; Australia; Cohort Studies; Drug Combination | 2018 |
Validated LC-MS/MS Method for the Simultaneous Determination of Amlodipine and Its Major Metabolites in Human Plasma of Hypertensive Patients.
Topics: Amlodipine; Antihypertensive Agents; Chromatography, Liquid; Humans; Hypertension; Molecular Structu | 2017 |
[One year adherence of ramipril versus ramipril/amlodipine fixed dose combination therapy in hypertension].
Topics: Amlodipine; Antihypertensive Agents; Drug Combinations; Female; Humans; Hungary; Hypertension; Male; | 2017 |
Who benefits from fixed-dose combinations? Two-year statin adherence trajectories in initiators of combined amlodipine/atorvastatin therapy.
Topics: Aged; Amlodipine; Anticholesteremic Agents; Antihypertensive Agents; Australia; Blood Pressure; Drug | 2017 |
[Pharmacogenetic approaches to predicting the efficiency and safety of amlodipine in patients with arterial hypertension].
Topics: Amlodipine; ATP Binding Cassette Transporter, Subfamily B; Blood Pressure; Genotype; Humans; Hyperte | 2017 |
Ischemic Optic Neuropathy in a Dog with Acute Bilateral Blindness and Primary Systemic Hypertension.
Topics: Amlodipine; Animals; Anti-Inflammatory Agents; Antihypertensive Agents; Blindness; Dog Diseases; Dog | 2018 |
Amlodipine Corrects Changes in Blood Pressure and Baroreceptor Reflex Sensitivity in Sprague Dawley Rats Fed a High Salt Diet.
Topics: Amlodipine; Animals; Baroreflex; Blood Pressure; Calcium Channel Blockers; Calcium, Dietary; Diet; H | 2017 |
Initial Single-Pill Blood Pressure-Lowering Therapy: Should It Be for Most People?
Topics: Amlodipine; Antihypertensive Agents; Blood Pressure; Double-Blind Method; Humans; Hypertension | 2017 |
Endothelial transcriptomics reveals activation of fibrosis-related pathways in hypertension.
Topics: Amlodipine; Animals; Blood Pressure; Calcium Channel Blockers; Disease Models, Animal; Fibrosis; Hea | 2018 |
Alteration of serum immunoglobins, C-reactive protein, vitamin D, and electrolyte by atenolol and amlodipine in stress-induced hypertensive rats.
Topics: Amlodipine; Angiotensin II; Animals; Antihypertensive Agents; Atenolol; C-Reactive Protein; Calcium; | 2018 |
[Blood Pressure Variability. Visit-to-Visit Blood Pressure Variability].
Topics: Amlodipine; Antihypertensive Agents; Blood Pressure; Blood Pressure Determination; Drug Combinations | 2017 |
[Indapamide SR/Amlodipine Fixed Dose Combination: Novel Approach to Effective Control of Systolic Arterial Pressure].
Topics: Amlodipine; Antihypertensive Agents; Arterial Pressure; Diuretics; Drug Combinations; Humans; Hypert | 2017 |
[Lisinopril, Amlodipine, Rosuvastatin as a Novel Fixed Combination in the Fight Against Cardiovascular Disease].
Topics: Amlodipine; Antihypertensive Agents; Blood Pressure; Cardiovascular Diseases; Drug Combinations; Hum | 2017 |
Prior Medications and the Cardiovascular Benefits From Combination Angiotensin-Converting Enzyme Inhibition Plus Calcium Channel Blockade Among High-Risk Hypertensive Patients.
Topics: Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Benzazepines; B | 2018 |
Blood pressure variability and risk of cardiovascular events and death in patients with hypertension and different baseline risks.
Topics: Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Female; Heart Failure; Humans; Hypertensi | 2018 |
Modifications in drug adherence after switch to fixed-dose combination of perindopril/amlodipine in clinical practice. Results of a large-scale Italian experience. The amlodipine-perindopril in real settings (AMPERES) study.
Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Drug Combinations; Drug Substituti | 2018 |
Comparison between L-type and N/L-type calcium channel blockers in the regulation of home blood-pressure variability in elderly hypertensive patients.
Topics: Aged; Amlodipine; Ankle Brachial Index; Antihypertensive Agents; Blood Pressure; Calcium Channel Blo | 2018 |
Fixed-dose vs free-dose combinations for the management of hypertension-An analysis of 81 958 patients.
Topics: Age Factors; Aged; Aged, 80 and over; Amlodipine; Antihypertensive Agents; Benzimidazoles; Biphenyl | 2018 |
[24‑Hour Arterial Pressure Variability: Prognostic Significance, Methods of Evaluation, Effect of Antihypertensive Therapy].
Topics: Amlodipine; Antihypertensive Agents; Arterial Pressure; Drug Combinations; Humans; Hypertension; Per | 2017 |
Effectiveness of a Fixed-Dose, Single-Pill Combination of Perindopril and Amlodipine in Patients with Hypertension: A Non-Interventional Study.
Topics: Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Dr | 2018 |
Fimasartan increases glucose-stimulated insulin secretion in patients with type 2 diabetes and hypertension compared with amlodipine.
Topics: Aged; Amlodipine; Angiotensin Receptor Antagonists; Antihypertensive Agents; Biphenyl Compounds; Cro | 2018 |
Antihypertensive drug use in resistant and nonresistant hypertension and in controlled and uncontrolled resistant hypertension.
Topics: Amlodipine; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihyperten | 2018 |
Visual outcome in cats with hypertensive chorioretinopathy.
Topics: Amlodipine; Animals; Antihypertensive Agents; Benzazepines; Blindness; Cat Diseases; Cats; Choroid D | 2019 |
Influence of 3 calcium channel blockers on gingival overgrowth in a population of severe refractory hypertensive patients.
Topics: Adult; Aged; Amlodipine; Brazil; Calcium Channel Blockers; Felodipine; Female; Gingival Overgrowth; | 2018 |
Amlodipine toxicity complicated by concurrent medications.
Topics: Amlodipine; Antidepressive Agents; Antihypertensive Agents; Bradycardia; Cardiovascular Agents; Drug | 2018 |
Long-term effects of antihypertensive therapy on cardiovascular events and new-onset diabetes mellitus in high-risk hypertensive patients in Japan.
Topics: Aged; Amlodipine; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Cardi | 2018 |
Comparison of real-world effectiveness between valsartan and non-RAS inhibitor monotherapy on the incidence of new diabetes in Chinese hypertensive patients: An electronic health recording system based study.
Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Aged; Amlodipine; Angiotensin II Type 1 Receptor Blo | 2019 |
[Assessment of Efficacy of Combined Pharmacotherapy With Fixed Perindopril/Amlodipine Combination in Patients With Combined Cardiovascular Pathology in Outpatient Practice].
Topics: Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Pressure; | 2018 |
[Influence of Therapy With Fixed Combination of Perindopril and Amlodipine on Parameters of Elasticity of Main Vessels and Microcirculation in Patients With Arterial Hypertension and Type 2 Diabetes Mellitus].
Topics: Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Diabetes Mellitus, Type 2; Drug Combinati | 2018 |
Comparison of amlodipine versus other calcium channel blockers on blood pressure variability in hypertensive patients in China: a retrospective propensity score-matched analysis.
Topics: Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; China; Cohort S | 2018 |
Effects of Amlodipine on Bone Metabolism in Orchidectomised Spontaneously Hypertensive Rats.
Topics: Amlodipine; Animals; Biomarkers; Biomechanical Phenomena; Body Composition; Bone and Bones; Bone Den | 2018 |
A retrospective study evaluating the tolerability and effectiveness of adjunctive antihypertensive drugs in patients with inadequate response to initial treatment.
Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Drug-Related Side Effects and Adverse Reactions; F | 2018 |
[The influence of benazepril and amlodipine on the expression of secretin and somatostatin in spontaneously hypertensive rats].
Topics: Amlodipine; Animals; Antihypertensive Agents; Benzazepines; Blood Pressure; Hypertension; Male; Rand | 2018 |
Perindopril 3.5 mg/amlodipine 2.5 mg versus renin-angiotensin system inhibitor monotherapy as first-line treatment in hypertension: a combined analysis.
Topics: Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Drug Combinations; Female; Humans; Hypert | 2018 |
Successful management of proteinuria and systemic hypertension in a dog with renal cell carcinoma with surgery, telmisartan, and amlodipine.
Topics: Amlodipine; Animals; Antihypertensive Agents; Carcinoma, Renal Cell; Dog Diseases; Dogs; Hypertensio | 2018 |
How to Treat Hypertension in Venlafaxine-Medicated Patients-Pharmacokinetic Considerations in Prescribing Amlodipine and Ramipril.
Topics: Amlodipine; Antihypertensive Agents; Cytochrome P-450 CYP2D6 Inhibitors; Databases, Factual; Drug In | 2018 |
[Day-by Day Blood Pressure Variability: Methodological Aspects, Prognostic Value, Effects of Antihypertensive Therapy].
Topics: Amlodipine; Antihypertensive Agents; Blood Pressure; Drug Combinations; Humans; Hypertension; Perind | 2018 |
Diffuse vesiculobullous eruption with systemic findings.
Topics: Amlodipine; Anti-Inflammatory Agents, Non-Steroidal; Antihypertensive Agents; Arthralgia; Drug Hyper | 2018 |
Low Levels of Amlodipine in Breast Milk and Plasma.
Topics: Adult; Amlodipine; Antihypertensive Agents; Breast Feeding; Chromatography; Female; Humans; Hyperten | 2018 |
Without Warning: Scleroderma Renal Crisis.
Topics: Acute Kidney Injury; Amlodipine; Antihypertensive Agents; Humans; Hypertension; Labetalol; Lisinopri | 2019 |
[Combined Therapy of Arterial Hypertension With Triple Fixed-Dose Combination of Amlodipine/Indapamide/Perindopril Arginine in Real Clinical Practice: the Organization and the Main Results of the DOKAZATEL'STVO (Proof) Study].
Topics: Academic Medical Centers; Aged; Amlodipine; Antihypertensive Agents; Arginine; Blood Pressure; Blood | 2018 |
[THE COMBINED THERAPY IN HYPERTENSIVE PATIENTS WITH DYSLIPIDEMIA].
Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Drug Combinations; Drug Therapy, Combination; Dysl | 2018 |
Reliable and easy-to-use LC-MS/MS-method for simultaneous determination of the antihypertensives metoprolol, amlodipine, canrenone and hydrochlorothiazide in patients with therapy-refractory arterial hypertension.
Topics: Amlodipine; Antihypertensive Agents; Canrenone; Carbon Isotopes; Chromatography, High Pressure Liqui | 2019 |
Measuring Central or Peripheral Blood Pressure Levels? That is the Question in the Modern Clinical Practice of Hypertension.
Topics: Amlodipine; Blood Pressure; Blood Pressure Determination; Humans; Hypertension; Nebivolol; Valsartan | 2018 |
Low-dose combination therapy to control sustained ambulatory hypertension-Basic principles and future directions.
Topics: Amlodipine; Antihypertensive Agents; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Humans; | 2019 |
Successful re-administration of Pazopanib in a patient with metastatic renal cell carcinoma and a history of Pazopanib-induced nephrotic syndrome: a case report.
Topics: Aged; Amlodipine; Angiogenesis Inhibitors; Antihypertensive Agents; Antineoplastic Agents; Carcinoma | 2019 |
Topics: Amlodipine; Antihypertensive Agents; Blood Pressure; Drug Combinations; Female; Humans; Hypertension | 2018 |
Topics: Amlodipine; Antihypertensive Agents; Blood Pressure; Drug Combinations; Humans; Hypertension; Myocar | 2019 |
Effectiveness and Adherence to Treatment with Perindopril/Indapamide/Amlodipine Single-Pill Combination in a Greek Population with Hypertension.
Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Drug Combinations; Female; Greece; | 2019 |
Consensi: Is it a conscientious combination?
Topics: Amlodipine; Antihypertensive Agents; Arthralgia; Blood Pressure; Celecoxib; Clinical Trials as Topic | 2019 |
S-amlodipine improves endothelial dysfunction via the RANK/RANKL/OPG system by regulating microRNA-155 in hypertension.
Topics: Amlodipine; Animals; Cell Line; Female; Human Umbilical Vein Endothelial Cells; Humans; Hypertension | 2019 |
EFFICACY AND SAFETY OF A SINGLE-PILL COMBINATION OF ATORVASTATIN/AMLODIPINE IN PATIENTS WITH ARTERIAL HYPERTENSION AND DYSLIPIDEMIA.
Topics: Aged; Amlodipine; Anticholesteremic Agents; Antihypertensive Agents; Blood Pressure; Cholesterol; Ch | 2018 |
Utility of fixed-dose single tablet antihypertensive drug combinations in Cameroonians with type 2 diabetes and newly diagnosed hypertension.
Topics: Africa South of the Sahara; Amlodipine; Antihypertensive Agents; Blood Pressure; Diabetes Mellitus, | 2019 |
Treatment of Hypertensive and Hypercholesterolaemic Patients with the Triple Fixed Combination of Atorvastatin, Perindopril and Amlodipine: The Results of the CORAL Study.
Topics: Adult; Aged; Aged, 80 and over; Amlodipine; Animals; Anticholesteremic Agents; Antihypertensive Agen | 2019 |
In black Africans with hypertension, amlodipine-based therapy vs perindopril-hydrochlorothiazide improved BP control.
Topics: Amlodipine; Antihypertensive Agents; Black People; Blood Pressure; Humans; Hydrochlorothiazide; Hype | 2019 |
Feasibility of 24-h central blood pressure monitoring: experience from multinational clinical trial assessing the efficacy of perindopril/indapamide/amlodipine.
Topics: Amlodipine; Antihypertensive Agents; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Drug Com | 2019 |
Safety of Amlodipine in Early Pregnancy.
Topics: Abnormalities, Drug-Induced; Aged; Amlodipine; Antihypertensive Agents; Chronic Disease; Female; Fol | 2019 |
Safety of Antihypertensive Medications in Pregnancy: Living With Uncertainty.
Topics: Amlodipine; Antihypertensive Agents; Female; Humans; Hypertension; Pregnancy; Uncertainty | 2019 |
Lessons from a patient with Turner syndrome.
Topics: Amlodipine; Blood Pressure; Chlorthalidone; Estrogens; Female; Hormone Replacement Therapy; Humans; | 2013 |
[Telangiectasia during amlodipine therapy].
Topics: Amlodipine; Antihypertensive Agents; Bisoprolol; Calcium Channel Blockers; Drug Substitution; Drug T | 2013 |
Amlodipine-induced gingival hyperplasia in chronic renal failure: a case report.
Topics: Adult; Amlodipine; Calcium Channel Blockers; Gingival Hyperplasia; Humans; Hypertension; Kidney Fail | 2012 |
Pill burden in hypertensive patients treated with single-pill combination therapy--an observational study.
Topics: Aged; Aged, 80 and over; Amlodipine; Antihypertensive Agents; Cost of Illness; Drug Combinations; Dr | 2013 |
Voltage-dependent N-type Ca2+ channels in endothelial cells contribute to oxidative stress-related endothelial dysfunction induced by angiotensin II in mice.
Topics: Amlodipine; Angiotensin II; Animals; Aorta, Thoracic; Biomarkers; Blood Pressure; Calcium; Calcium C | 2013 |
Associations between visit-to-visit variability in blood pressure measured in the office and antihypertensive drugs: the J-HOME-Morning study.
Topics: Aged; Amlodipine; Analysis of Variance; Antihypertensive Agents; Blood Pressure; Calcium Channel Blo | 2013 |
Amlodipine increases vitamin D levels more than valsartan in newly diagnosed hypertensive patients: pointing to an additional effect on bone metabolism or a novel marker of inflammation?
Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Biomarkers; Bone Remodeling; Female; Humans; Hyper | 2013 |
Twenty-four-hour ambulatory blood pressure reduction with a perindopril/amlodipine fixed-dose combination.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amlodipine; Antihypertensive Agents; Blood Pressure; Dru | 2013 |
[Hypertension. Goal: achieving target blood pressure with only 1 pill daily].
Topics: Amlodipine; Antihypertensive Agents; Drug Combinations; Germany; Humans; Hydrochlorothiazide; Hypert | 2013 |
Telmisartan exerts pleiotropic effects in endothelial cells and promotes endothelial cell quiescence and survival.
Topics: Amlodipine; Angiotensin II Type 1 Receptor Blockers; Apoptosis; Benzimidazoles; Benzoates; Blood Pro | 2013 |
Fixed combination of amlodipine/atorvastatin: from mechanisms to trials.
Topics: Amlodipine; Anticholesteremic Agents; Calcium Channel Blockers; Cardiovascular Diseases; Drug Combin | 2013 |
Generalised peripheral oedema associated with amlodipine therapy in two dogs.
Topics: Amlodipine; Animals; Antihypertensive Agents; Dog Diseases; Dogs; Edema; Female; Hypertension | 2013 |
Lower, faster, better: the delusions of surrogate markers in hypertension.
Topics: Amlodipine; Antihypertensive Agents; Benzimidazoles; Benzoates; Drug Combinations; Female; Humans; H | 2013 |
[The effect of amlodipine, bisoprolol on the myocardial ultrastructure of the hypertensive rats].
Topics: Amlodipine; Animals; Antihypertensive Agents; Bisoprolol; Blood Pressure; Capillaries; Drug Combinat | 2013 |
Concerns for the heart failure reduction in the NAGOYA HEART Study based on meta-regression from the evidence.
Topics: Amlodipine; Blood Glucose; Diabetes Mellitus, Type 2; Female; Glucose Intolerance; Humans; Hypertens | 2013 |
Differential effects of antihypertensive treatments on apoptosis, oxidative stress, and expression of angiotensin receptors in the cerebral cortex from the onset of prehypertension and hypertension in stroke-prone spontaneous hypertensive rats.
Topics: Amlodipine; Animals; Antihypertensive Agents; Apoptosis; Blotting, Western; Cerebral Cortex; Hyperte | 2013 |
Young woman with idiopathic supradiaphragmatic mid-aortic syndrome and hypertension successfully controlled with a beta-blocker-calcium antagonist fixed-dose combination.
Topics: Adrenergic beta-1 Receptor Antagonists; Amlodipine; Aorta, Abdominal; Aortic Arch Syndromes; Bisopro | 2013 |
The prevalence of ocular lesions associated with hypertension in a population of geriatric cats in Auckland, New Zealand.
Topics: Aging; Amlodipine; Animals; Antihypertensive Agents; Cat Diseases; Cats; Eye Diseases; Hypertension; | 2014 |
Amlodipine increased endothelial nitric oxide and decreased nitroxidative stress disproportionately to blood pressure changes.
Topics: Amlodipine; Animals; Antihypertensive Agents; Aorta; Blood Pressure; Disease Models, Animal; Endothe | 2014 |
Tardive dystonic syndrome induced by the calcium-channel blocker amlodipine.
Topics: Aged; Amlodipine; Antihypertensive Agents; Female; Humans; Hypertension; Male; Movement Disorders | 2014 |
Titration of amlodipine to higher doses: a comparison of Asian and Western experience.
Topics: Aged; Amlodipine; Antihypertensive Agents; Asia; Asian People; Blood Pressure; Calcium Channel Block | 2013 |
[On the way to achieve hypertension treatment goals: results of the open observational program AESCULAP (exforge--clinical safety and efficiency of using a double combination of antihypertensive drugs in patients with uncontrolled blood pressure)].
Topics: Aged; Amlodipine; Amlodipine, Valsartan Drug Combination; Angiotensin-Converting Enzyme Inhibitors; | 2013 |
Commentary in support of a highly effective hypertension treatment algorithm.
Topics: Adult; Algorithms; Amlodipine; Antihypertensive Agents; Blood Pressure; Drug Combinations; Drug Ther | 2013 |
Long-term prehypertension treatment with losartan effectively prevents brain damage and stroke in stroke-prone spontaneously hypertensive rats.
Topics: Aldosterone; Amlodipine; Angiotensin II; Animals; Apoptosis; Blood Pressure; Brain; Hypertension; Lo | 2014 |
Combination therapy of amlodipine and atorvastatin has more beneficial vascular effects than monotherapy in salt-sensitive hypertension.
Topics: Amlodipine; Animals; Antihypertensive Agents; Aorta; Atorvastatin; Blood Pressure; C-Reactive Protei | 2014 |
Chronic blockade of angiotensin AT₁ receptors improves cardinal symptoms of metabolic syndrome in diet-induced obesity in rats.
Topics: Amlodipine; Angiotensin II Type 1 Receptor Blockers; Animals; Anti-Obesity Agents; Antihypertensive | 2014 |
ARB-based single-pill platform to guide a practical therapeutic approach to hypertensive patients.
Topics: Administration, Oral; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; | 2014 |
Hydralazine associated pauci-immune glomerulonephritis.
Topics: Aged; Aged, 80 and over; Amlodipine; Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Ant | 2014 |
Real-life effectiveness, safety, and tolerability of amlodipine/valsartan or amlodipine/valsartan/hydrochlorothiazide single-pill combination in patients with hypertension from Pakistan.
Topics: Adult; Aged; Amlodipine; Amlodipine, Valsartan Drug Combination; Antihypertensive Agents; Blood Pres | 2014 |
Antihypertensive efficacy of triple combination perindopril/indapamide plus amlodipine in high-risk hypertensives: results of the PIANIST study (Perindopril-Indapamide plus AmlodipiNe in high rISk hyperTensive patients).
Topics: Adult; Aged; Aged, 80 and over; Amlodipine; Antihypertensive Agents; Blood Pressure; Blood Pressure | 2014 |
Short-term amlodipine induced liver injury : an extremely rare acute complication.
Topics: Amlodipine; Calcium Channel Blockers; Chemical and Drug Induced Liver Injury; Diagnosis, Differentia | 2013 |
Hypokalaemia in a hyperthyroid domestic shorthair cat with adrenal hyperplasia.
Topics: Adrenal Glands; Adrenocortical Hyperfunction; Aldosterone; Amlodipine; Animals; Carbimazole; Cat Dis | 2014 |
Clinical impact of patient adherence to a fixed-dose combination of olmesartan, amlodipine and hydrochlorothiazide.
Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Drug Combinations; Essential Hyper | 2014 |
Impact of antihypertensive combination and monotreatments on blood pressure variability: assessment by old and new indices. Data from a large ambulatory blood pressure monitoring database.
Topics: Adult; Aged; Algorithms; Amlodipine; Antihypertensive Agents; Benzimidazoles; Benzoates; Blood Press | 2014 |
Effects of single pill-based combination therapy of amlodipine and atorvastatin on within-visit blood pressure variability and parameters of renal and vascular function in hypertensive patients with chronic kidney disease.
Topics: Aged; Amlodipine; Antihypertensive Agents; Atorvastatin; Biomarkers; Blood Pressure; Capsules; Drug | 2014 |
Is amlodipine more cardioprotective than other antihypertensive drug classes?
Topics: Amlodipine; Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Heart Failure; Humans | 2014 |
[Effect of fixed-dose combination of perindopril A/amlodipine on inter visit-to-visit and inter visit blood pressure and heart rate variability in real clinical practice in the Russian observation program KONSTANTA].
Topics: Adult; Aged; Aged, 80 and over; Ambulatory Care; Amlodipine; Blood Pressure; Blood Pressure Determin | 2014 |
Efficacy and safety of valsartan/amlodipine single-pill combination in patients with essential hypertension (PEAK LOW).
Topics: Administration, Oral; Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Drug Administration | 2014 |
[Hypertension. Guidelines recommend fixed combinations].
Topics: Amlodipine; Antihypertensive Agents; Diabetes Mellitus, Type 2; Drug Combinations; Guideline Adheren | 2014 |
Critical blood pressure threshold dependence of hypertensive injury and repair in a malignant nephrosclerosis model.
Topics: Amlodipine; Animals; Antihypertensive Agents; Blood Pressure; Disease Models, Animal; Drug Therapy, | 2014 |
Drug effects on the CVS in conscious rats: separating cardiac output into heart rate and stroke volume using PKPD modelling.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Amiloride; Amlodipine; Animals; Atropine; Enalapril; | 2014 |
Real-world clinical experience of amlodipine/valsartan and amlodipine/valsartan/hydrochlorothiazide in hypertension: the EXCITE study.
Topics: Adult; Aged; Amlodipine; Amlodipine, Valsartan Drug Combination; Antihypertensive Agents; Asia; Bloo | 2014 |
A calcified left ventricular mass.
Topics: Aged, 80 and over; Aging; Amlodipine; Anticholesteremic Agents; Antihypertensive Agents; Aspirin; At | 2014 |
Discovering the sympathomodulatory properties of new calcium channel blockers: an exciting but still snaky journey.
Topics: Amlodipine; Antihypertensive Agents; Azetidinecarboxylic Acid; Baroreflex; Calcium Channel Blockers; | 2014 |
[Results of the Russian EKSPERT program: post-marketing supervision over efficacy and influence of the preparation Ekvator on quality of life at out-patients with arterial hypertension].
Topics: Aged; Ambulatory Care; Amlodipine; Antihypertensive Agents; Blood Pressure; Blood Pressure Monitorin | 2014 |
If I had resistant hypertension.
Topics: Amlodipine; Antihypertensive Agents; Atorvastatin; Blood Pressure; Dose-Response Relationship, Drug; | 2014 |
Blood pressure control and satisfaction of hypertensive patients following a switch to combined drugs of an angiotensin receptor blocker and a calcium channel blocker in clinical practice of nephrology.
Topics: Aged; Amlodipine; Angiotensin Receptor Antagonists; Azetidinecarboxylic Acid; Benzimidazoles; Benzoa | 2015 |
Additional information regarding the SEVITENSION study.
Topics: Amlodipine; Female; Humans; Hypertension; Imidazoles; Male; Perindopril; Tetrazoles | 2014 |
Treatment of hypertension and renal injury induced by the angiogenesis inhibitor sunitinib: preclinical study.
Topics: Acute Kidney Injury; Amlodipine; Angiogenesis Inhibitors; Animals; Blood Pressure; Disease Models, A | 2014 |
Comparative effects of valsartan in combination with cilnidipine or amlodipine on cardiac remodeling and diastolic dysfunction in Dahl salt-sensitive rats.
Topics: Amlodipine; Animals; Antihypertensive Agents; Dihydropyridines; Drug Evaluation, Preclinical; Drug T | 2015 |
Triple combination therapy in hypertension: the antihypertensive efficacy of treatment with perindopril, amlodipine, and indapamide SR.
Topics: Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Blood Pressure Monitoring, Ambulatory; De | 2014 |
A medication adherence and persistence comparison of hypertensive patients treated with single-, double- and triple-pill combination therapy.
Topics: Adult; Aged; Amlodipine; Amlodipine, Valsartan Drug Combination; Antihypertensive Agents; Drug Combi | 2014 |
Possible amlodipine-induced hepatotoxicity after stem cell transplant.
Topics: Aged; Alanine Transaminase; Amlodipine; Antihypertensive Agents; Aspartate Aminotransferases; Chemic | 2015 |
No pharmacokinetic interaction between raltegravir and amlodipine: importance for co-prescribing in ageing HIV-infected individuals.
Topics: Adult; Amlodipine; Anti-HIV Agents; Antihypertensive Agents; Chromatography, Liquid; Cross-Over Stud | 2014 |
TRPC1, CaN and NFATC3 signaling pathway in the pathogenesis and progression of left ventricular hypertrophy in spontaneously hypertensive rats.
Topics: Amlodipine; Animals; Antihypertensive Agents; Benzimidazoles; Benzoates; Disease Models, Animal; Dis | 2015 |
Pharmacokinetic drug-drug interaction of calcium channel blockers with cyclosporine in hematopoietic stem cell transplant children.
Topics: Adolescent; Amlodipine; Calcium Channel Blockers; Child; Child, Preschool; Cyclosporine; Dihydropyri | 2014 |
[Myopathy and rhabdomyolysis after treatment with simvastatin, amlodipine, and roxithromycin].
Topics: Aged; Amlodipine; Anti-Bacterial Agents; Antihypertensive Agents; Drug Interactions; Humans; Hyperte | 2014 |
Negligible pharmacokinetic interaction of red ginseng and antihypertensive agent amlodipine in Sprague-Dawley rats.
Topics: Administration, Oral; Amlodipine; Animals; Antihypertensive Agents; Chromatography, High Pressure Li | 2014 |
Simvastatin prescribing patterns before and after FDA dosing restrictions: a retrospective analysis of a large healthcare claims database.
Topics: Amlodipine; Calcium Channel Blockers; Comorbidity; Drug Interactions; Drug Labeling; Drug Prescripti | 2015 |
[Medication adherence with the fixed combination of ramipril and amlodipine].
Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Databases, Factual; Drug Administration Schedule; | 2014 |
Ramipril/amlodipine single pill - effectiveness, tolerance and patient satisfaction with antihypertensive therapy in relation to nutritional status.
Topics: Amlodipine; Antihypertensive Agents; Blood Pressure; Drug Combinations; Humans; Hypertension; Medica | 2014 |
Clinical outcomes and healthcare costs in hypertensive patients treated with a fixed-dose combination of amlodipine/valsartan.
Topics: Aged; Amlodipine; Amlodipine, Valsartan Drug Combination; Angiotensin Receptor Antagonists; Antihype | 2015 |
Single-pill combination therapy in the initial treatment of marked hypertension: a propensity-matched analysis.
Topics: Amlodipine; Antihypertensive Agents; Benzimidazoles; Benzoates; Blood Pressure; Dihydropyridines; Do | 2015 |
Long-term use of angiotensin II receptor antagonists and calcium-channel antagonists in Algerian hypertensive patients: effects on metabolic and oxidative parameters.
Topics: Algeria; Amlodipine; Angiotensin Receptor Antagonists; Benzimidazoles; Benzoates; Calcium Channel Bl | 2015 |
Safety and effectiveness of a fixed-dose combination of olmesartan, amlodipine, and hydrochlorothiazide in clinical practice.
Topics: Adult; Aged; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Austria; | 2015 |
Real-world effectiveness of amlodipine/valsartan and amlodipine/valsartan/hydrochlorothiazide in high-risk patients and other subgroups.
Topics: Administration, Oral; Adult; Aged; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihyperten | 2015 |
Angiotensin II receptor blockers decrease serum concentration of fatty acid-binding protein 4 in patients with hypertension.
Topics: 3T3 Cells; Adrenergic beta-Agonists; Amlodipine; Angiotensin II Type 2 Receptor Blockers; Animals; A | 2015 |
[24-Hour blood pressure profiles in brachial artery and the aorta: correlation and effects of fixed combination of amlodipine and lisinopril].
Topics: Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Arterial Pressure; Blood Pressure Determinatio | 2014 |
[Evaluating the effectiveness of a fixed combination of amlodipine and bisoprolol in ambulatory patients with arterial hypertension and ischemic heart disease].
Topics: Adrenergic beta-1 Receptor Antagonists; Aged; Amlodipine; Bisoprolol; Blood Pressure; Calcium Channe | 2014 |
[Organoprotective effects of the combination of perindopril and amlodipine depending on the renal functional state in patients with arterial hypertension].
Topics: Amlodipine; Antihypertensive Agents; Drug Combinations; Female; Hemodynamics; Humans; Hypertension; | 2013 |
Efficacy, safety, and tolerability of antihypertensive therapy with aliskiren/amlodipine in clinical practice in Austria. The RALLY (Rasilamlo long lasting efficacy) study.
Topics: Aged; Aged, 80 and over; Amides; Amlodipine; Antihypertensive Agents; Austria; Drug Combinations; Fe | 2015 |
[Optimizing antihypertensive therapy].
Topics: Amlodipine; Antihypertensive Agents; Drug Combinations; Humans; Hydrochlorothiazide; Hypertension; I | 2015 |
Benefits of a fixed-dose combination of bisoprolol and amlodipine in the treatment of hypertension in daily practice: results of more than 4000 patients.
Topics: Adult; Aged; Aged, 80 and over; Amlodipine; Antihypertensive Agents; Bisoprolol; Blood Pressure; Dru | 2015 |
[Fixed dose combination perindopril-indapamide-amlodipine (Triplixam) for the treatment of arterial hypertension].
Topics: Amlodipine; Antihypertensive Agents; Blood Pressure; Drug Combinations; Drug Synergism; Humans; Hype | 2014 |
[Efficacy of a fixed-dose combination of perindopril and amlodipine in the treatment of hypertensive patients. A clinical case].
Topics: Amlodipine; Antihypertensive Agents; Drug Combinations; Humans; Hypertension; Male; Middle Aged; Per | 2014 |
The effect of calcium channel blockers on prevention of preeclampsia in pregnant women with chronic hypertension.
Topics: Adult; Amlodipine; Aspirin; Birth Weight; Blood Pressure; Calcium Channel Blockers; China; Female; H | 2015 |
[Hypertensive patients' adherence, motivation, and awareness during fixed-dose perindopril A and amlodipine combination treatment (results of the CONSTANTA trial)].
Topics: Aged; Amlodipine; Antihypertensive Agents; Clinical Trials as Topic; Drug Combinations; Female; Huma | 2015 |
[Effect of combination antihypertensive therapy on circadian blood pressure and metabolic parameters in patients with type 2 diabetes mellitus].
Topics: Amlodipine; Antihypertensive Agents; Biological Availability; Blood Glucose; Blood Pressure; Blood P | 2014 |
Comparison of single-pill strategies first line in hypertension: perindopril/amlodipine versus valsartan/amlodipine.
Topics: Amlodipine; Amlodipine, Valsartan Drug Combination; Antihypertensive Agents; Female; Humans; Hyperte | 2015 |
Comparison of single-pill strategies first line in hypertension: perindopril/amlodipine versus valsartan/amlodipine.
Topics: Amlodipine; Amlodipine, Valsartan Drug Combination; Antihypertensive Agents; Female; Humans; Hyperte | 2015 |
Cilnidipine but not amlodipine suppresses sympathetic activation elicited by isometric exercise in hypertensive patients.
Topics: Aged; Amlodipine; Autonomic Nervous System; Calcium Channel Blockers; Dihydropyridines; Exercise; Fe | 2015 |
The therapeutic advantage of combination antihypertensive drug therapy using amlodipine and irbesartan in hypertensive patients: Analysis of the post-marketing survey data from PARTNER (Practical combination therapy of Amlodin and angiotensin II Receptor
Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Biphenyl Compounds; Blood Pressure; Blood Pressure | 2015 |
Economic evaluation of single-pill combination of indapamide and amlodipine in the treatment of arterial hypertension in the Polish setting.
Topics: Adult; Aged; Aged, 80 and over; Amlodipine; Antihypertensive Agents; Calcium Channel Blockers; Cost- | 2015 |
Difficult Hypertension Clinic Utilizing a Nurse Specialist: A Cost-Efficient Model for the Modern Era?
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Ambulatory Care Facilities; Amlodipine; Antihypertensive | 2015 |
Multiple inductive effects of carbamazepine on combined therapy with paliperidone and amlodipine.
Topics: Amlodipine; Antipsychotic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Blood Pre | 2015 |
[Sleep apnea: RR lowering drugs need to be administered in the evening].
Topics: Amlodipine; Blood Pressure; Cross-Over Studies; Drug Chronotherapy; Drug Therapy, Combination; Human | 2015 |
[Fixed combination improves compliance].
Topics: Amlodipine; Amlodipine, Valsartan Drug Combination; Drug Combinations; Humans; Hydrochlorothiazide; | 2015 |
[Optimization of treatment in hypertensive patients in real clinical practice: Role of a fixed-dose perindopril A and amlodipine combination (Results of the Russian observational CONSTANTA trial].
Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Drug Combinations; Female; Heart R | 2015 |
Development of Sustained Release "NanoFDC (Fixed Dose Combination)" for Hypertension - An Experimental Study.
Topics: Amlodipine; Animals; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Calcium Channel Bl | 2015 |
[The Fixed Combination of Perindopril A/Amlodipine--a Rational Choice to Improve the Control of Hypertension in Clinical Practice (Results of the Program KONSTANT observational program)].
Topics: Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Blood Pressure; Calcium Channel Blockers; Dose | 2015 |
Perindopril arginine + amlodipine for the treatment of hypertension in the USA.
Topics: Amlodipine; Antihypertensive Agents; Blood Pressure; Drug Combinations; Humans; Hypertension; Perind | 2015 |
Effectiveness of Fixed-Dose Perindopril/Amlodipine on Clinic, Ambulatory and Self-Monitored Blood Pressure and Blood Pressure Variability: An Open-Label, Non Comparative Study in the General Practice.
Topics: Adult; Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Pr | 2015 |
Comparison of amlodipine/valsartan/hydrochlorothiazide single pill combination and free combination: adherence, persistence, healthcare utilization and costs.
Topics: Aged; Aged, 80 and over; Amlodipine; Antihypertensive Agents; Cohort Studies; Drug Combinations; Fem | 2015 |
[DYNAMICS OF THE CIRCADIAN BLOOD PRESSURE PROFILE DURING COMBINED AMLODIPINE-VALSARTAN THERAPY IN FAR NORTH RESIDENTS].
Topics: Adult; Amlodipine; Amlodipine, Valsartan Drug Combination; Antihypertensive Agents; Arctic Regions; | 2015 |
Effects of Administration of Amlodipine and Lacidipine on Inflammation-Induced Bone Loss in the Ovariectomized Rat.
Topics: Amlodipine; Animals; Bone Density; Calcium Channel Blockers; Collagen Type I; Collagen Type I, alpha | 2016 |
Amlodipine suppresses Ang-II-induced endothelium dysfunction by diminishing ROCK1 expression.
Topics: Amlodipine; Angiotensin II; Apoptosis; bcl-2-Associated X Protein; Calcium Channel Blockers; Endothe | 2016 |
Comparative effect of fixed-dose combination tablets of candesartan cilexetil/amlodipine versus olmesartan medoxomil/azelnidipine on laboratory parameters in patients with hypertension: a retrospective cohort study.
Topics: Aged; Alanine Transaminase; Amlodipine; Antihypertensive Agents; Aspartate Aminotransferases; Azetid | 2016 |
[Stiffness of the Arterial Wall and Central Hemodynamics During Long-Term Combination Antihypertensive Therapy].
Topics: Aged; Amlodipine; Antihypertensive Agents; Aorta; Blood Pressure; Drug Combinations; Essential Hyper | 2015 |
Clinical Effectiveness, Safety and Tolerability of Amlodipine/Valsartan in Hypertensive Patients: the Indonesian Subset of the EXCITE Study.
Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Cough; Drug Combinations; Drug Sub | 2015 |
Application and validation of superior spectrophotometric methods for simultaneous determination of ternary mixture used for hypertension management.
Topics: Amlodipine; Antihypertensive Agents; Benzimidazoles; Benzoates; Drug Combinations; Hydrochlorothiazi | 2016 |
[EFFECTIVENESS OF FIXED COMBINATION OF PERINDOPRILARGININE AND AMLODIPINE FOR THE TREATMENT OF ARTERIAL HYPERTENSION WITH CONCOMITANT CHRONIC CARDIAC INSUFFICIENCY AND SIGNS OF CHRONIC KIDNEY DISEASE].
Topics: Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Drug Combinations; Drug Monitoring; Femal | 2015 |
[Therapy of Arterial Hypertension in Patients With Chronic Heart Failure and Signs of Chronic Kidney Disease With Fixed Perindopril/Amlodipine Combination].
Topics: Amlodipine; Antihypertensive Agents; Blood Pressure; Dose-Response Relationship, Drug; Drug Combinat | 2015 |
Prehypertensive treatment with losartan, however not amlodipine, leads to long-term effects on blood pressure and reduces the risk of stroke in spontaneously hypertensive stroke-prone rats.
Topics: Amlodipine; Animals; Blood Pressure; Gene Expression Regulation; Humans; Hypertension; Losartan; Mal | 2016 |
Treating hypertension in cats.
Topics: Amlodipine; Animals; Antihypertensive Agents; Cat Diseases; Cats; Hypertension; Medication Errors; T | 2015 |
[Ramipril plus amlodipine and lisinopril plus amlodipine fixed dose combinations and patient's adherence].
Topics: Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Pressure; Calci | 2016 |
Influence of G-protein β-Polypeptide 3 C825T Polymorphism on Antihypertensive Response to Telmisartan and Amlodipine in Chinese Patients.
Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Benzimidazoles; Benzoates; Blood Pressure; Essenti | 2016 |
[Drug interaction in 63-year-old male sportsman--a case report].
Topics: Amlodipine; Confusion; Dizziness; Drug Interactions; Exercise; Humans; Hyperlipidemias; Hypertension | 2015 |
The Efficacy of Perindopril/Amlodipine in Reaching Blood Pressure Targets: Results of the CONTROL Study.
Topics: Adult; Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Pr | 2016 |
Hypokalaemia and drinking green tea: a literature review and report of 2 cases.
Topics: Aged; Amlodipine; Antihypertensive Agents; Bendroflumethiazide; Drinking Behavior; Female; Humans; H | 2016 |
Does this patient have hypertensive encephalopathy?
Topics: Amlodipine; Antihypertensive Agents; Biphenyl Compounds; Brain; Carbazoles; Carvedilol; Computed Tom | 2016 |
Amlodipine and atorvastatin improved hypertensive cardiac hypertrophy through regulation of receptor activator of nuclear factor kappa B ligand/receptor activator of nuclear factor kappa B/osteoprotegerin system in spontaneous hypertension rats.
Topics: Administration, Oral; Amlodipine; Animals; Antihypertensive Agents; Atorvastatin; Cardiomegaly; Cros | 2016 |
Visit-to-Visit Variability of BP and CKD Outcomes: Results from the ALLHAT.
Topics: Aged; Amlodipine; Antihyperkalemic Agents; Blood Pressure; Blood Pressure Determination; Chlorthalid | 2016 |
[One year persistence of atorvastatin and amlodipine fixed dose combination versus atorvastatin therapy].
Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Atorvastatin; Blood Pressure; Cholesterol, LDL; Dr | 2016 |
[New fixed dose combination for initial control of hypertension].
Topics: Amlodipine; Antihypertensive Agents; Blood Pressure; Delayed-Action Preparations; Dose-Response Rela | 2016 |
Patient Adherence to Olmesartan/Amlodipine Combinations: Fixed Versus Extemporaneous Combinations.
Topics: Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Drug Therapy, Combination; Female; Humans | 2016 |
Switching from a Free Association of Perindopril/Amlodipine to a Fixed-Dose Combination: Increased Antihypertensive Efficacy and Tolerability.
Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Cohort Studies; Diabetes Mellitus, | 2016 |
[The Possibilities of Pharmacological Correction of Endothelial Dysfunction in Patients With Arterial Hypertension].
Topics: Amlodipine; Antihypertensive Agents; Blood Pressure; Drug Combinations; Female; Humans; Hypertension | 2015 |
Effects of antihypertensive treatment on plasma apelin, resistin, and visfatin concentrations.
Topics: Adrenergic beta-1 Receptor Antagonists; Adult; Amlodipine; Angiotensin II Type 1 Receptor Blockers; | 2016 |
Effectiveness of perindopril/amlodipine fixed dose combination in everyday clinical practice: results from the EMERALD study.
Topics: Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Drug Combinations; Female; Humans; Hypert | 2016 |
Synergisms of cardiovascular effects between iptakalim and amlodipine, hydrochlorothiazide or propranolol in anesthetized rats.
Topics: Amlodipine; Animals; Antihypertensive Agents; Blood Pressure; Drug Synergism; Heart Rate; Hydrochlor | 2015 |
[Effective blood pressure control with a fixed combination].
Topics: Amlodipine; Antihypertensive Agents; Drug Combinations; Humans; Hydrochlorothiazide; Hypertension; M | 2016 |
Pharmacokinetic considerations in the treatment of hypertension in risperidone-medicated patients - thinking of clinically relevant CYP2D6 interactions.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amlodipine; Antihypertensive Agents; Antipsychotic Agent | 2016 |
Safety and effectiveness of combined antihypertensive and cholesterol-lowering therapy in high-/very high-risk patients.
Topics: Amlodipine; Anticholesteremic Agents; Antihypertensive Agents; Cholesterol; Humans; Hypercholesterol | 2016 |
[71-year old woman with arterial hypertension and oral finding].
Topics: Aged; Amlodipine; Diagnosis, Differential; Drug Substitution; Female; Gingival Hyperplasia; Humans; | 2016 |
Amlodipine and Atorvastatin Improved Hypertensive Cardiac Remodeling through Regulation of MMPs/TIMPs in SHR Rats.
Topics: Amlodipine; Animals; Anticholesteremic Agents; Antihypertensive Agents; Atorvastatin; Blotting, West | 2016 |
Ramipril + amlodipine and ramipril + hydrochlorothiazide fixed-dose combinations in relation to patient adherence.
Topics: Amlodipine; Antihypertensive Agents; Drug Therapy, Combination; Humans; Hungary; Hydrochlorothiazide | 2016 |
Effects of azelnidipine and amlodipine on exercise-induced sympathoexcitation assessed by pupillometry in hypertensive patients.
Topics: Amlodipine; Antihypertensive Agents; Autonomic Nervous System; Azetidinecarboxylic Acid; Blood Press | 2016 |
The effect of fixed-dose combination of valsartan and amlodipine on nighttime blood pressure in patients with non-dipper hypertension.
Topics: Adult; Amlodipine; Antihypertensive Agents; Blood Pressure; Blood Pressure Monitoring, Ambulatory; C | 2016 |
Efficacy and Safety Assessment of Hypertension Management with Coveram (Perindopril/Amlodipine Fixed Combination) in Patients with Previous Angiotensin Receptor Blocker (ARB) Treatment: Arabian Gulf STRONG Study.
Topics: Adult; Aged; Aged, 80 and over; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Con | 2016 |
Evaluation of potential drug- drug interactions among Palestinian hemodialysis patients.
Topics: Adult; Aged; Aged, 80 and over; Amlodipine; Arabs; Aspirin; Calcium Carbonate; Comorbidity; Diabetes | 2016 |
Is Time an Important Problem in Management of Hypertension and Hypercholesterolemia by Using an Amlodipine-Atorvastatin Single Pill Combination?
Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Atorvastatin; Blood Pressure; Case-Control Studies | 2016 |
On the top of ARB N/L type Ca channel blocker leads to less elevation of aldosterone.
Topics: Aged; Aldosterone; Amlodipine; Angiotensin Receptor Antagonists; Blood Pressure; Calcium Channel Blo | 2016 |
[Association between gene polymorphism of calcium/calmodulin-dependent kinase 4 and efficacy of amlodipine in the treatment of hypertension in Chinese Han nationality].
Topics: Alleles; Amlodipine; Asian People; Blood Pressure; Calcium-Calmodulin-Dependent Protein Kinase Type | 2016 |
Amlodipine and enalapril promote distinct effects on cardiovascular autonomic control in spontaneously hypertensive rats: the role of aerobic physical training.
Topics: Adaptation, Physiological; Amlodipine; Animals; Antihypertensive Agents; Arterial Pressure; Autonomi | 2016 |
Management of Hypertension With a Fixed-Dose (Single-Pill) Combination of Bisoprolol and Amlodipine.
Topics: Amlodipine; Antihypertensive Agents; Bisoprolol; Clinical Trials as Topic; Drug Combinations; Humans | 2017 |
Factors Influencing the Relationship Between the Dose of Amlodipine Required for Blood Pressure Control and Change in Blood Pressure in Hypertensive Cats.
Topics: Amlodipine; Animals; Antihypertensive Agents; Blood Pressure; Cat Diseases; Cats; Cross-Sectional St | 2016 |
Effect of visit-to-visit blood pressure variability on cardiovascular events in patients with coronary artery disease and well-controlled blood pressure.
Topics: Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Blood Pressure Determination; Cardiovascu | 2016 |
Amlodipine-Induced Gingival Overgrowth.
Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Calcium Channel Blockers; Female; Gingival Overgro | 2016 |
Cilnidipine: Next Generation Calcium Channel Blocker.
Topics: Adult; Amlodipine; Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Calcium Channe | 2016 |
Copeptin is increased in resistant hypertension.
Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Biomarkers; Biphenyl Compounds; Blood Pressure; Co | 2016 |
Significance of BP Control in Reducing Stroke Events: Role of Amlodipine in an Indian Perspective.
Topics: Amlodipine; Antihypertensive Agents; Drug Therapy, Combination; Humans; Hypertension; India; Stroke | 2016 |
Blood Pressure Reduction is Associated With the Changes in Oxidative Stress and Endothelial Activation in Hypertension, Regardless of Antihypertensive Therapy.
Topics: Adult; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Blood Pressure; | 2016 |
CYP3A4*1G and CYP3A5*3 genetic polymorphisms alter the antihypertensive efficacy of amlodipine in patients with hypertension following renal transplantation
.
Topics: Adult; Amlodipine; Antihypertensive Agents; ATP Binding Cassette Transporter, Subfamily B; Blood Pre | 2017 |
Are diuretic additives fit for uncontrolled hypertensive patients receiving telmisartan and amlodipine treatment?
Topics: Amlodipine; Antihypertensive Agents; Benzimidazoles; Benzoates; Blood Pressure; Diuretics; Drug Comb | 2017 |
Replacement of Amlodipine and Lercanidipine by Barnidipine: Tolerability and Effectiveness in a Real-Life Study.
Topics: Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Dihydropyridine | 2017 |
Cost-effectiveness of the polypill versus risk assessment for prevention of cardiovascular disease.
Topics: Administration, Oral; Adult; Aged; Amlodipine; Antihypertensive Agents; Cardiovascular Diseases; Com | 2017 |
A Fixed-Dose Combination of Bisoprolol and Amlodipine for Hypertension: A Potential Benefit to Selected Patients.
Topics: Amlodipine; Antihypertensive Agents; Bisoprolol; Humans; Hypertension | 2017 |
Effects of Candesartan Cilexetil Compared with Amlodipine on Serum Asymmetric Dimethylarginine Levels in the Chronic Stage of Cerebral Infarction: A Preliminary Study.
Topics: Aged; Aged, 80 and over; Amlodipine; Antihypertensive Agents; Arginine; Benzimidazoles; Biomarkers; | 2016 |
Impact of Statin Therapy on the Blood Pressure-Lowering Efficacy of a Single-Pill Perindopril/Amlodipine Combination in Hypertensive Patients with Hypercholesterolemia.
Topics: Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Biomarkers; Blood Pressure; Calcium Channel Bl | 2017 |
[Comparison of Verapamil and Amlodipine for Treatment of Chronic Heart Failure With Preserved Left Ventricular Ejection Fraction in Patients With Hypertensive Disease].
Topics: Aged; Amlodipine; Antihypertensive Agents; Echocardiography; Exercise Tolerance; Female; Heart Failu | 2016 |
[Effects of Amlodipine/Lisinopril Fixed-Dose Combination on Severity of Left Ventricular Hypertrophy and Parameters of Myocardial Stiffness in Patients With Hypertension].
Topics: Aged; Amlodipine; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Drug Therapy, Combination; | 2016 |
[Efficacy and Safety of a Fixed Combination of Perindopril Arginine and Amlodipine in Patients With Hypertension Uncontrolled by Treatment With Angiotensin II Receptor Blockers in Real Clinical Practice. Results of the PREVOSHODSTVO (SUPERIORITY) Program]
Topics: Aged; Amlodipine; Angiotensin Receptor Antagonists; Antihypertensive Agents; Arginine; Blood Pressur | 2017 |
[The Effectiveness of Combination Antihypertensive Therapy in Women With Hypothyroidism and the Metabolic Syndrome].
Topics: Amlodipine; Antihypertensive Agents; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Dihydrop | 2016 |
[The Fixed Combination of Amlodipine and Bisoprolol Eliminates the Effect of -Blockers on Central Pulse Wave in Patients With Arterial Hypertension].
Topics: Amlodipine; Antihypertensive Agents; Bisoprolol; Blood Pressure; Blood Pressure Determination; Drug | 2015 |
[The Use of Fixed Perindopril A/Amlodipine Combination Provides High Compliance to Therapy, Effective and Safe Arterial Pressure Lowering in Patients With Previous Inefferctive Therapy. The POTENTIAL Program].
Topics: Amlodipine; Antihypertensive Agents; Arterial Pressure; Drug Combinations; Female; Humans; Hypertens | 2015 |
[Comparative Assessment of Effects of Free and Fixed Combinations of Hypotensive Drugs on Quality of Life of Patients With Arterial Hypertension of High and Very High Risk].
Topics: Amlodipine; Antihypertensive Agents; Bisoprolol; Blood Pressure; Female; Humans; Hypertension; Indap | 2016 |
Long-term outcomes of lercanidipine versus other calcium channel blockers in newly diagnosed hypertension: a nationwide cohort study.
Topics: Adolescent; Adult; Aged; Amlodipine; Blood Pressure; Calcium Channel Blockers; Cohort Studies; Dihyd | 2017 |
[Amlodipine is the better partner].
Topics: Aged; Amlodipine; Antihypertensive Agents; Benzazepines; Blood Pressure; Drug Therapy, Combination; | 2008 |
A stunning day in hypertension research - Results of ONTARGET, ACCOMPLISH and HYVET.
Topics: Amlodipine; Antihypertensive Agents; Benzazepines; Benzimidazoles; Benzoates; Clinical Trials as Top | 2008 |
Sildenafil augments the beneficial hemodynamic and histopathological effects of amlodipine in nitric oxide-deficient hypertensive rats: role of nitric oxide-cyclic GMP pathway.
Topics: Amlodipine; Animals; Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Cyclic GMP; | 2008 |
[Unexpected study data for treatment of hypertension. Combination therapy with a diuretic not imperative].
Topics: Amlodipine; Antihypertensive Agents; Benzazepines; Cardiovascular Diseases; Cause of Death; Drug Com | 2008 |
Application in the STRATHE trial of a score system to compare the efficacy and the tolerability of different therapeutic strategies in the management of hypertension.
Topics: Amlodipine; Antihypertensive Agents; Atenolol; Double-Blind Method; Drug Therapy, Combination; Franc | 2008 |
Rhabdomyolysis resulting from pharmacologic interaction between erlotinib and simvastatin.
Topics: Aged; Amlodipine; Anti-Inflammatory Agents, Non-Steroidal; Anticholesteremic Agents; Antihypertensiv | 2008 |
[Hypertension--does it matter how blood pressure is lowered?].
Topics: Amlodipine; Anticholesteremic Agents; Antihypertensive Agents; Atenolol; Atorvastatin; Bendroflumeth | 2008 |
Adherence with multiple-combination antihypertensive pharmacotherapies in a US managed care database.
Topics: Adolescent; Adult; Age Factors; Aged; Amlodipine; Antihypertensive Agents; Drug Combinations; Drug T | 2008 |
Long-term effects of candesartan and amlodipine on cardiovascular mortality and morbidity in Japanese high-risk hypertensive patients: rationale, design, and characteristics of candesartan antihypertensive survival evaluation in Japan extension (CASE-J Ex
Topics: Amlodipine; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds; Blood Press | 2009 |
Adherence with single-pill amlodipine/atorvastatin vs a two-pill regimen.
Topics: Aged; Amlodipine; Atorvastatin; Calcium Channel Blockers; Drug Combinations; Female; Heptanoic Acids | 2008 |
Aliskiren for hypertension in adults.
Topics: Adult; Amides; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Drug C | 2008 |
Effects of atorvastatin on calcium-regulating proteins: a possible mechanism to repair cardiac dysfunction in spontaneously hypertensive rats.
Topics: Amlodipine; Animals; Antihypertensive Agents; Atorvastatin; Blood Pressure; Blotting, Western; Calci | 2009 |
Based treatment algorithm for essencial hypertension with olmesartan medoxomil.
Topics: Adult; Aged; Algorithms; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agent | 2008 |
Myocardial heat shock protein 60 expression in insulin-resistant and diabetic rats.
Topics: Amlodipine; Animals; Antihypertensive Agents; Chaperonin 60; Diabetes Mellitus, Experimental; Diseas | 2009 |
Cost-effectiveness analysis: controlled-release nifedipine and valsartan combination therapy in patients with essential hypertension: the adalat CR and valsartan cost-effectiveness combination (ADVANCE-Combi) study.
Topics: Amlodipine; Cost-Benefit Analysis; Delayed-Action Preparations; Double-Blind Method; Drug Therapy, C | 2008 |
The optimal target blood pressure for antihypertensive treatment in Japanese elderly patients with high-risk hypertension: a subanalysis of the Candesartan Antihypertensive Survival Evaluation in Japan (CASE-J) trial.
Topics: Aged; Aged, 80 and over; Amlodipine; Antihypertensive Agents; Asian People; Benzimidazoles; Biphenyl | 2008 |
Hypertension, heart failure, and ejection fraction.
Topics: Amlodipine; Calcium Channel Blockers; Heart Failure; Humans; Hypertension; Hypolipidemic Agents; Myo | 2008 |
Increased transient receptor potential canonical type 3 channels in vasculature from hypertensive rats.
Topics: Amlodipine; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Animals; Aorta, Thoracic; Benz | 2009 |
Does it matter how hypertension is controlled?
Topics: Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Benzazepines; Calcium | 2008 |
[Migraine improved by amlodipine medication in a case with hypertension].
Topics: Amlodipine; Antihypertensive Agents; Female; Humans; Hypertension; Middle Aged; Migraine Disorders | 2008 |
[The relationship between the effect of amlodipine on carotid intimal-medial thickness and angiotensin converting enzyme genotypes in elderly hypertensive patients].
Topics: Aged; Aged, 80 and over; Amlodipine; Carotid Artery Diseases; Female; Gene Frequency; Genotype; Huma | 2008 |
All thiazide-like diuretics are not chlorthalidone: putting the ACCOMPLISH study into perspective.
Topics: Amlodipine; Antihypertensive Agents; Benzazepines; Chlorthalidone; Diuretics; Humans; Hydrochlorothi | 2009 |
Effectiveness of add-on therapy with amlodipine in hypertensive patients receiving valsartan.
Topics: Adolescent; Adult; Aged; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agent | 2008 |
[The ACCOMPLISH trial: are results really unexpected?].
Topics: Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Benzazepines; Calcium Channel Blockers; Diuret | 2009 |
The combination of atenolol and amlodipine is better than their monotherapy for preventing end-organ damage in different types of hypertension in rats.
Topics: Amlodipine; Animals; Atenolol; Blood Pressure; Drug Therapy, Combination; Hemodynamics; Hypertension | 2009 |
Will the results of the ACCOMPLISH trial affect the recommendations of JNC 8?
Topics: Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Benzazepines; Calcium Channel Blockers; Diuret | 2009 |
Long-term safety, tolerability and efficacy of combination therapy with aliskiren and amlodipine in patients with hypertension.
Topics: Adult; Aged; Amides; Amlodipine; Antihypertensive Agents; Blood Pressure; Diastole; Drug Therapy, Co | 2009 |
Benazepril plus amlodipine or hydrochlorothiazide for hypertension.
Topics: Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Benzazepines; Calcium | 2009 |
Effects of cardiac complications on cardiovascular events in Japanese high-risk hypertensive patients: subanalysis of the CASE-J trial.
Topics: Adrenergic Antagonists; Aged; Amlodipine; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Calciu | 2009 |
Benazepril plus amlodipine or hydrochlorothiazide for hypertension.
Topics: Adrenergic beta-Antagonists; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive | 2009 |
Benazepril plus amlodipine or hydrochlorothiazide for hypertension.
Topics: Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Benzazepines; Blood P | 2009 |
Diabetes and hypertension: which is the best approach?
Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Atenolol; Blood Pressure; Cardiovascular Diseases; | 2009 |
Hypertension associated with rhabdomyolysis may also be caused by unilateral adrenal hyperplasia.
Topics: Adrenal Gland Neoplasms; Adrenalectomy; Adrenocortical Hyperfunction; Aged; Amlodipine; Follow-Up St | 2009 |
Amlodipine-induced myoclonus.
Topics: Aged; Amlodipine; Antihypertensive Agents; Calcium Channel Blockers; Clonidine; Diuretics; Humans; H | 2009 |
The lifetime cost effectiveness of amlodipine-based therapy plus atorvastatin compared with atenolol plus atorvastatin, amlodipine-based therapy alone and atenolol-based therapy alone: results from ASCOT1.
Topics: Adrenergic beta-Antagonists; Amlodipine; Antihypertensive Agents; Atenolol; Atorvastatin; Calcium Ch | 2009 |
[Clinical study of the month. The ACCOMPLISH study: challenging the choice of antihypertensive medications in systolic hypertensive patients with high cardiovascular risk].
Topics: Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Benzazepines; Cardiov | 2009 |
Beneficial effects of the combination of amlodipine and losartan for lowering blood pressure in spontaneously hypertensive rats.
Topics: Acetylcholine; Administration, Oral; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Animals; A | 2009 |
[Comparative evaluation of the antihypertensive efficacy of amlodipine versus enalapril].
Topics: Adult; Aged; Aged, 80 and over; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensi | 2009 |
Triple fixed-dose combination therapy: back to the past.
Topics: Amlodipine; Antihypertensive Agents; Blood Pressure; Diastole; Drug Therapy, Combination; Humans; Hy | 2009 |
[Fixed combination perindopril-amlodipine (Coveram) in the treatment of hypertension and coronary heart disease].
Topics: Administration, Oral; Amlodipine; Antihypertensive Agents; Coronary Disease; Drug Combinations; Huma | 2009 |
Exforge HCT.
Topics: Amlodipine; Amlodipine, Valsartan Drug Combination; Angiotensin II Type 1 Receptor Blockers; Antihyp | 2009 |
Mineralocorticoid receptor blockade and calcium channel blockade have different renoprotective effects on glomerular and interstitial injury in rats.
Topics: Amlodipine; Animals; Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Cell Hypoxia | 2009 |
Evaluation of safety and efficacy of telmisartan-amlodipine combination in treating hypertension.
Topics: Amlodipine; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antih | 2008 |
Effect of switching from amlodipine to combination therapy with telmisartan and low-dose hydrochlorothiazide.
Topics: Aged; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; | 2009 |
Hypertension as a complication of Taylor spatial frame.
Topics: Adolescent; Amlodipine; Antihypertensive Agents; Bone Lengthening; Equipment Design; External Fixato | 2009 |
Re: Efficacy and safety of the single pill combination of amlodipine 10 mg plus valsartan 160 mg in hypertensive patients not controlled by amlodipine 10 mg plus olmesartan 20 mg in free combination.
Topics: Amlodipine; Antihypertensive Agents; Clinical Trials as Topic; Dosage Forms; Dose-Response Relations | 2009 |
Amlodipine besylate/olmesartan medoximil fixed combination for the treatment of hypertension.
Topics: Aged; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Blood Pressure; | 2009 |
Increased rhythmicity in hypertensive arterial smooth muscle is linked to transient receptor potential canonical channels.
Topics: Amlodipine; Angiotensin II Type 1 Receptor Blockers; Animals; Arterioles; Benzimidazoles; Benzoates; | 2010 |
Effect of antihypertensive drug therapy on short-term heart rate variability in newly diagnosed essential hypertension.
Topics: Adult; Amlodipine; Antihypertensive Agents; Arrhythmia, Sinus; Atenolol; Enalapril; Female; Heart Ra | 2010 |
Effects of benidipine, a long-acting T-type calcium channel blocker, on home blood pressure and renal function in patients with essential hypertension: a retrospective, 'real-world' comparison with amlodipine.
Topics: Adult; Aged; Albuminuria; Amlodipine; Blood Pressure; Calcium Channel Blockers; Calcium Channels, T- | 2009 |
Amlodipine/Atorvastatin single-pill therapy for blood pressure and lipid goals in African Americans: influence of the metabolic syndrome and type 2 diabetes mellitus.
Topics: Adult; Aged; Amlodipine; Anticholesteremic Agents; Atorvastatin; Black or African American; Blood Pr | 2009 |
Functional subtypes of renal alpha1-adrenoceptor in spontaneously hypertensive rats with streptozotocin-induced experimental diabetic nephropathy.
Topics: Adrenergic Antagonists; Amlodipine; Animals; Diabetes Mellitus, Experimental; Diabetic Nephropathies | 2009 |
Amlodipine/valsartan/hydrochlorothiazide: fixed-dose combination in hypertension.
Topics: Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Calcium Channel Blocke | 2009 |
[Sevikar or Forzaten: olmesartan medoxomil and amlodipine besylate fixed combination in the treatment of hypertension].
Topics: Amlodipine; Antihypertensive Agents; Drug Combinations; Humans; Hypertension; Imidazoles; Olmesartan | 2009 |
Pioglitazone improves endothelium-dependent vasodilation in hypertensive patients with impaired glucose tolerance in part through a decrease in oxidative stress.
Topics: Acetylcholine; Aged; Amlodipine; Case-Control Studies; Endothelium, Vascular; Female; Glucose; Gluco | 2010 |
New drug information: Twynsta 40 mg/5mg.
Topics: Amlodipine; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Benzoates; Drug Combinations; H | 2010 |
Composite renal endpoints: was ACCOMPLISH accomplished?
Topics: Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Benzazepines; Calcium | 2010 |
An unusual phenomenon with entropy during induction of general anaesthesia.
Topics: Adrenergic beta-Antagonists; Amlodipine; Anesthesia, General; Anesthetics, Intravenous; Antihyperten | 2010 |
A third amlodipine/ARB combination (Twynsta) for hypertension.
Topics: Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; Benzoa | 2010 |
Pharmacologically induced thoracic and abdominal aortic aneurysms in mice.
Topics: Aminopropionitrile; Amlodipine; Angiotensin II; Animals; Antihypertensive Agents; Aortic Aneurysm, A | 2010 |
Effects of combination therapy with angiotensin II type I receptor blockers and calcium channel blockers on renal function in hypertensive patients/a retrospective, "real-world" comparative study.
Topics: Aged; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Calcium Channel Blockers; Creatinine; Dih | 2010 |
Beneficial effects of L- and N-type calcium channel blocker on glucose and lipid metabolism and renal function in patients with hypertension and type II diabetes mellitus.
Topics: Adult; Aged; Amlodipine; Calcium Channel Blockers; Calcium Channels, L-Type; Calcium Channels, N-Typ | 2011 |
Effects of antihypertensive drugs in the prevention of new-onset diabetes mellitus in patients with hypertension at high-risk of cardiovascular events in relation to aging.
Topics: Age Distribution; Age Factors; Aged; Amlodipine; Antihypertensive Agents; Benzimidazoles; Biphenyl C | 2010 |
Effects of ingestion of grapefruit juice or grapefruit on the hypotensive effect and plasma concentrations of dihydropyridine calcium antagonists (amlodipine and nifedipine): a case study.
Topics: Amlodipine; Beverages; Blood Pressure; Calcium Channel Blockers; Citrus paradisi; Cytochrome P-450 C | 2010 |
Role of diabetes and obesity in outcomes of the candesartan antihypertensive survival evaluation in Japan (CASE-J) trial.
Topics: Aged; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; | 2010 |
Does a single-pill antihypertensive/lipid-lowering regimen improve adherence in US managed care enrolees? A non-randomized, observational, retrospective study.
Topics: Adult; Aged; Amlodipine; Atorvastatin; Calcium Channel Blockers; Drug Therapy, Combination; Female; | 2010 |
Oral intake of rosiglitazone promotes a central antihypertensive effect via upregulation of peroxisome proliferator-activated receptor-gamma and alleviation of oxidative stress in rostral ventrolateral medulla of spontaneously hypertensive rats.
Topics: Administration, Oral; Amlodipine; Analysis of Variance; Animals; Blood Pressure; Disease Models, Ani | 2010 |
Role of valsartan, amlodipine and hydrochlorothiazide fixed combination in blood pressure control: an update.
Topics: Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Pressure; Calci | 2010 |
Hypertension: antihypertensive class matters for combination therapy.
Topics: Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Benzazepines; Blood P | 2010 |
Combination therapy with irbesartan and efonidipine for attenuation of proteinuria in Dahl salt-sensitive rats.
Topics: Amlodipine; Angiotensin II Type 1 Receptor Blockers; Animals; Biphenyl Compounds; Blood Pressure; Ca | 2010 |
Predicted coronary heart disease risk reduction and dual blood pressure/cholesterol goal attainment in patients with hypertension treated in real-world clinical practice.
Topics: Amlodipine; Anticholesteremic Agents; Antihypertensive Agents; Atorvastatin; Blood Pressure; Calcium | 2010 |
[How to increase the adherence to treatment of patients with arterial hypertension and dyslipidemia: focus on fixed combination of amlodipine and atorvastatin].
Topics: Adrenergic beta-Antagonists; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Anticholesteremic | 2010 |
Comparison of amlodipine/valsartan fixed-dose combination therapy and conventional therapy.
Topics: Aged; Amlodipine; Antihypertensive Agents; Drug Combinations; Female; Health Services; Humans; Hyper | 2010 |
Ethnic differences in blood pressure response to first and second-line antihypertensive therapies in patients randomized in the ASCOT Trial.
Topics: Age Factors; Amlodipine; Antihypertensive Agents; Atenolol; Blood Pressure; Confounding Factors, Epi | 2010 |
Tribenzor for hypertension.
Topics: Amlodipine; Antihypertensive Agents; Blood Pressure; Clinical Trials as Topic; Drug Combinations; Dr | 2010 |
[Effect of atorvastatin on hemorheological parameters in patients with arterial hypertension with dyslipidemia].
Topics: Adult; Amlodipine; Anticholesteremic Agents; Antihypertensive Agents; Atorvastatin; Blood Viscosity; | 2010 |
Treatment of bevacizumab-induced hypertension by amlodipine.
Topics: Adult; Aged; Amlodipine; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antihypertensiv | 2012 |
The N-type and L-type calcium channel blocker cilnidipine suppresses renal injury in Dahl rats fed a high-salt diet.
Topics: Albuminuria; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; | 2010 |
Improving quality of life in hypertension management using a fixed-dose combination of olmesartan and amlodipine in primary care.
Topics: Aged; Amlodipine; Antihypertensive Agents; Diastole; Drug Combinations; Female; Heart Rate; Humans; | 2010 |
Strengthening diuretics' role in hypertension.
Topics: Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Calcium Channel Block | 2010 |
Amlodipine suppressed cardiac gene expression of brain natriuretic peptide, transforming growth factor-β₁ and fibronectin mediated by aldosterone in male stroke-prone spontaneously hypertensive rats.
Topics: Aldosterone; Amlodipine; Angiotensin II; Animals; Antihypertensive Agents; Blood Pressure; Calcium C | 2010 |
What your blood pressure isn't revealing.
Topics: Adrenergic beta-Antagonists; American Heart Association; Amlodipine; Anti-Arrhythmia Agents; Antihyp | 2010 |
Chronic conjunctival chemosis from amlodipine besylate (Norvasc).
Topics: Aged; Amlodipine; Antihypertensive Agents; Chronic Disease; Conjunctival Diseases; Edema; Foot Disea | 2011 |
Aliskiren/amlodipine (Tekamlo): another combination tablet for hypertension.
Topics: Amides; Amlodipine; Antihypertensive Agents; Calcium Channel Blockers; Drug Combinations; Drug Inter | 2010 |
[Fixed combination of telmisartan and amlodipine. Lowering blood pressure with dual power].
Topics: Amlodipine; Antihypertensive Agents; Benzimidazoles; Benzoates; Blood Pressure; Blood Pressure Monit | 2010 |
[Fixed drug combinations in hypertension: a budget impact analysis for the Spanish Health System on the marketing of a fixed combination of olmesartan/amlodipine].
Topics: Aged; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Costs and Cost A | 2011 |
Age-related differences in the effects of antihypertensive therapy on left ventricular hypertrophy in high-risk patients with hypertension-candesartan antihypertensive survival evaluation in Japan subanalysis.
Topics: Age Factors; Aged; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Com | 2011 |
Initial combination antihypertensives: let's ACCELERATE.
Topics: Amides; Amlodipine; Antihypertensive Agents; Calcium Channel Blockers; Drug Therapy, Combination; Fu | 2011 |
Synergism of telmisartan and amlodipine on blood pressure reduction and cardiorenal protection in hypertensive rats.
Topics: Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Benzimidazol | 2011 |
L/N-type calcium channel blocker cilnidipine ameliorates proteinuria and inhibits the renal renin-angiotensin-aldosterone system in deoxycorticosterone acetate-salt hypertensive rats.
Topics: Amlodipine; Animals; Calcium Channel Blockers; Calcium Channels, L-Type; Calcium Channels, N-Type; C | 2011 |
Amlodipine ameliorates endothelial dysfunction in mesenteric arteries from spontaneously hypertensive rats.
Topics: Acetylcholine; Amlodipine; Animals; Antihypertensive Agents; Ascorbic Acid; Blood Pressure; Endothel | 2011 |
Anti-inflammatory effects of anti-hypertensive agents: influence on interleukin-1β secretion by peripheral blood polymorphonuclear leukocytes from patients with essential hypertension.
Topics: Adult; Amlodipine; Anti-Inflammatory Agents, Non-Steroidal; Antihypertensive Agents; Atenolol; Capto | 2011 |
Blood pressure lowering therapy in older and younger hypertensive patients.
Topics: Adult; Age Factors; Aged; Amlodipine; Calcium Channel Blockers; Clinical Trials as Topic; Drug Thera | 2011 |
Angioedema associated with dihydropyridine calcium-channel blockers in a child with Burkitt lymphoma.
Topics: Amlodipine; Angioedema; Burkitt Lymphoma; Calcium Channel Blockers; Child; Humans; Hypertension; Mac | 2011 |
Effects of hypertension and ovariectomy on rat hepatocytes. Are amlodipine and lacidipine protective? (A stereological and histological study).
Topics: Amlodipine; Animals; Calcium Channel Blockers; Cytoprotection; Dihydropyridines; Female; Hepatocytes | 2010 |
The 'pyrrhic victory' of amlodipine over hydrochlorothiazide in the OLAS Study.
Topics: Amlodipine; Antihypertensive Agents; Blood Pressure; Body Mass Index; Comorbidity; Drug Therapy, Com | 2011 |
The correlation between the clinical laboratory data and the telomere length in peripheral blood leukocytes of Japanese female patients with hypertension.
Topics: Adult; Aged; Aged, 80 and over; Aging; Amlodipine; Antihypertensive Agents; Blotting, Southern; Crea | 2011 |
The vanishing story of angiotensin II receptor blockers in the treatment of atrial fibrillation.
Topics: Amlodipine; Angiotensin II Type 1 Receptor Blockers; Atrial Fibrillation; Benzimidazoles; Biphenyl C | 2011 |
The effect of antihypertensive agents in people at high risk of cardiovascular disease and diabetes: a view through smoke and mirrors.
Topics: Amlodipine; Antihypertensive Agents; Blood Pressure; Cardiovascular Diseases; Comorbidity; Diabetes | 2011 |
Worsening of rosacea in patients treated with dihydropyridine calcium channel blockers: a clinical observation.
Topics: Amlodipine; Calcium Channel Blockers; Female; Humans; Hypertension; Middle Aged; Rosacea | 2011 |
Eplerenone potentiates protective effects of amlodipine against cardiovascular injury in salt-sensitive hypertensive rats.
Topics: Aldosterone; Amlodipine; Animals; Antihypertensive Agents; Blood Pressure; Carotid Arteries; Drug Th | 2011 |
Amlodipine-induced massive gingival hypertrophy.
Topics: Adolescent; Amlodipine; Calcium Channel Blockers; Gingival Hypertrophy; Humans; Hypertension; Male | 2011 |
Initial combination therapy for treatment of hypertension.
Topics: Amides; Amlodipine; Antihypertensive Agents; Drug Therapy, Combination; Fumarates; Humans; Hypertens | 2011 |
Initial combination therapy for treatment of hypertension.
Topics: Amides; Amlodipine; Antihypertensive Agents; Blood Pressure; Drug Therapy, Combination; Fumarates; H | 2011 |
Initial combination therapy for treatment of hypertension.
Topics: Amides; Amlodipine; Antihypertensive Agents; Blood Pressure; Drug Therapy, Combination; Fumarates; H | 2011 |
[Gingival hyperplasia as side effect of the calcium channel blocker amlodipine].
Topics: Aged, 80 and over; Amlodipine; Antihypertensive Agents; Calcium Channel Blockers; Female; Gingival H | 2010 |
The use of 24-h ambulatory blood pressure monitoring (ABPM) during the first cycle of sunitinib improves the diagnostic accuracy and management of hypertension in patients with advanced renal cancer.
Topics: Adult; Aged; Aged, 80 and over; Amlodipine; Antihypertensive Agents; Antineoplastic Agents; Benzopyr | 2011 |
Mixed messages on blood pressure goals.
Topics: Amlodipine; Antihypertensive Agents; Black or African American; Blood Pressure; Glomerular Filtratio | 2011 |
Efficacy of Sevikar® compared to the combination of perindopril plus amlodipine on central arterial blood pressure in patients with moderate-to-severe hypertension: Rationale and design of the SEVITENSION study.
Topics: Aged; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; | 2011 |
[A powerful duo: antihypertensives aliskiren and amlodipine in one tablet. Combination tablet for hypertensive patients with diabetes and overweight].
Topics: Amides; Amlodipine; Antihypertensive Agents; Diabetes Mellitus, Type 2; Dose-Response Relationship, | 2011 |
Eplerenone, amlodipine and experimental hypertension: one plus one equals three.
Topics: Amlodipine; Animals; Antihypertensive Agents; Eplerenone; Heart; Hypertension; Male; Mineralocortico | 2011 |
[Selection of rational combinations of indapamide with various of calcium antagonists in patients with arterial hypertension].
Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Blood Pressure Monitoring, Ambulat | 2011 |
[Combination of perindopril and amlodipine as optimal basis for realization of desirable clinical effects in the treatment of arterial hypertension with fixed drug combination].
Topics: Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Blood Pressure; Calcium Channel Blockers; Card | 2011 |
Blood pressure-dependent and independent effects of amlodipine and angiotensin receptor blockers on the risk of stroke.
Topics: Amlodipine; Angiotensin II Type 1 Receptor Blockers; Blood Pressure; Calcium Channel Blockers; Human | 2011 |
Amlodipine + valsartan + hydrochlorothiazide. A 3-drug fixed-dose combination for hypertension: too many drawbacks.
Topics: Amlodipine; Antihypertensive Agents; Drug Combinations; Drug Packaging; Humans; Hydrochlorothiazide; | 2011 |
Efficacy of amlodipine and olmesartan medoxomil in hypertensive patients with diabetes and obesity.
Topics: Adult; Aged; Aged, 80 and over; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensiv | 2011 |
Effectiveness of amlodipine-valsartan single-pill combinations: hierarchical modeling of blood pressure and total cardiovascular disease risk outcomes (the EXCELLENT study).
Topics: Aged; Amlodipine; Amlodipine, Valsartan Drug Combination; Antihypertensive Agents; Blood Pressure; C | 2011 |
Occurrence of systemic hypertension in dogs with acute kidney injury and treatment with amlodipine besylate.
Topics: Acute Kidney Injury; Amlodipine; Animals; Antihypertensive Agents; Dog Diseases; Dogs; Female; Hyper | 2011 |
Aliskiren/amlodipine combination for the treatment of hypertension.
Topics: Amides; Amlodipine; Antihypertensive Agents; Clinical Trials as Topic; Drug Combinations; Drug Inter | 2011 |
Amlodipine and loop diuretics as the second anti-hypertensive medication for the treatment of hypertension with chronic kidney diseases.
Topics: Aged; Amlodipine; Angiotensin II Type 2 Receptor Blockers; Antihypertensive Agents; Blood Pressure; | 2011 |
Comparison of daily anti-hypertensive effects of amlodipine and nifedipine coat-core using ambulatory blood pressure monitoring - utility of "hypobaric curve" and "hypobaric area".
Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Blood Pressure Monitoring, Ambulat | 2011 |
Successful rapid rituximab desensitization for hypersensitivity reactions to monoclonal antibodies in a patient with rheumatoid arthritis: a remarkable option.
Topics: Adalimumab; Adult; Amlodipine; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies | 2011 |
Severe circadian hypertension in a young man.
Topics: Amlodipine; Angioplasty, Balloon; Antihypertensive Agents; Blood Pressure Monitoring, Ambulatory; Ci | 2011 |
Comparison of real-world adherence, healthcare resource utilization and costs for newly initiated valsartan/amlodipine single-pill combination versus angiotensin receptor blocker/calcium channel blocker free-combination therapy.
Topics: Amlodipine; Angiotensin Receptor Antagonists; Antihypertensive Agents; Calcium Channel Blockers; Dru | 2011 |
Intravascular ultrasound parameters in non-inferiority trial.
Topics: Amlodipine; Azetidinecarboxylic Acid; Coronary Artery Disease; Dihydropyridines; Humans; Hypertensio | 2011 |
Influence of coronary risk factors on coronary events in Japanese high-risk hypertensive patients. - Primary and secondary prevention of ischemic heart disease in a subanalysis of the Candesartan Antihypertensive Survival Evaluation in Japan (CASE-J) tria
Topics: Aged; Amlodipine; Antihypertensive Agents; Asian People; Benzimidazoles; Biphenyl Compounds; Coronar | 2011 |
Effect of cystamine on blood pressure and vascular characteristics in spontaneously hypertensive rats.
Topics: Adaptation, Physiological; Amlodipine; Animals; Antihypertensive Agents; Blood Pressure; Cystamine; | 2011 |
Inhibition of smooth muscle myosin as a novel therapeutic target for hypertension.
Topics: Amlodipine; Animals; Antihypertensive Agents; Blood Pressure; Cardiac Output; Dogs; Female; Hemodyna | 2011 |
Synergism of irbesartan and amlodipine on hemodynamic amelioration and organ protection in spontaneously hypertensive rats.
Topics: Amlodipine; Animals; Antihypertensive Agents; Baroreflex; Biphenyl Compounds; Blood Pressure; Drug S | 2011 |
Beneficial effects of combination of valsartan and amlodipine on salt-induced brain injury in hypertensive rats.
Topics: Amlodipine; Angiotensin II Type 1 Receptor Blockers; Animals; Blood Pressure; Brain; Calcium Channel | 2011 |
Recurrent vestibular paroxysms associated with systemic hypertension in a dog.
Topics: Amlodipine; Animals; Antihypertensive Agents; Ataxia; Dog Diseases; Dogs; Enalapril; Female; Hyperte | 2011 |
[Antihypertensive therapy in routine practice: fixed or free combination? Fixed combination scores with better prognosis].
Topics: Amlodipine; Amlodipine, Valsartan Drug Combination; Antihypertensive Agents; Drug Combinations; Huma | 2011 |
Assessment on antihypertensive effect and safety of nifedipine controlled-release tablet administered at 80 mg/day in practical clinic.
Topics: Adult; Age Factors; Aged; Ambulatory Care Facilities; Amlodipine; Antihypertensive Agents; Blood Pre | 2012 |
Effects of lisinopril, irbesartan, and amlodipine on the thrombogenic variables in the early and late stages of the treatment in hypertensive patients.
Topics: Adult; Aged; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhi | 2012 |
STK39 variation predicts the ambulatory blood pressure response to losartan in hypertensive men.
Topics: Adult; Alleles; Amlodipine; Antihypertensive Agents; Bisoprolol; Blood Pressure; Blood Pressure Moni | 2012 |
Trastuzumab-related palmar plantar erythrodysaesthesia.
Topics: Aged; Amlodipine; Antibodies, Monoclonal, Humanized; Anticholesteremic Agents; Antihypertensive Agen | 2012 |
[Pharmaco-economical aspects of treatment of patients with arterial hypertension with fixed perindopril/amlodipine combination].
Topics: Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Co | 2011 |
[Estimation of antihypertension efficiency and use of fixed combination perindopril+amlodipin by uncontrollable hypertension patients within the limits of routine treatment].
Topics: Adult; Aged; Aged, 80 and over; Amlodipine; Biological Availability; Blood Pressure Monitoring, Ambu | 2011 |
Efficacy, safety, and palatability of RACTAB(®) formulation amlodipine orally disintegrating tablets.
Topics: Administration, Oral; Adolescent; Adult; Aged; Amlodipine; Blood Pressure; Drug Stability; Female; H | 2011 |
A new dimension in hypertension management with the amlodipine/perindopril combination.
Topics: Amlodipine; Antihypertensive Agents; Humans; Hypertension; Perindopril; Randomized Controlled Trials | 2011 |
An economic evaluation of antihypertensive therapies based on clinical trials.
Topics: Amlodipine; Antihypertensive Agents; Atenolol; Blood Pressure; Drug Costs; Drug Therapy, Combination | 2012 |
Amlodipine/valsartan single-pill combination: a prospective, observational evaluation of the real-life safety and effectiveness in the routine treatment of hypertension.
Topics: Adult; Aged; Aged, 80 and over; Amlodipine; Amlodipine, Valsartan Drug Combination; Antihypertensive | 2012 |
Impaired sodium excretion and salt-sensitive hypertension in corin-deficient mice.
Topics: Aldosterone; Amiloride; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensi | 2012 |
Pharmacokinetic interaction between tacrolimus and amlodipine in a renal transplant child.
Topics: Amlodipine; Antihypertensive Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cass | 2012 |
Initial choice of antihypertensive on long-term cardiovascular outcomes in CKD.
Topics: Amlodipine; Antihypertensive Agents; Chlorthalidone; Female; Glomerular Filtration Rate; Humans; Hyp | 2012 |
[Hypertension: improved therapy adherence after switch to a fixed drug combinations].
Topics: Amlodipine; Antihypertensive Agents; Controlled Clinical Trials as Topic; Dose-Response Relationship | 2012 |
[Antihypertensive efficacy of a low-dose combination of amlodipine and lisinopril in the treatment of arterial hypertension in postmenopausal women].
Topics: Amlodipine; Antihypertensive Agents; Dose-Response Relationship, Drug; Drug Combinations; Female; Hu | 2012 |
RYR3 gene polymorphisms and cardiovascular disease outcomes in the context of antihypertensive treatment.
Topics: Adult; Amlodipine; Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Cardiovascular | 2013 |
Combination therapy of atorvastatin and amlodipine inhibits sympathetic nervous system activation and improves cognitive function in hypertensive rats.
Topics: Amlodipine; Animals; Anticholesteremic Agents; Antihypertensive Agents; Antioxidants; Atorvastatin; | 2012 |
Effects of cilnidipine on serum uric acid level and urinary nitrogen monoxide excretion in patients with hypertension.
Topics: Aged; Aged, 80 and over; Amlodipine; Calcium Channel Blockers; Dihydropyridines; Female; Humans; Hyp | 2012 |
A comparison of the effects of fixed dose vs. single-agent combinations on 24-h blood pressure variability.
Topics: Aged; Amlodipine; Amlodipine, Valsartan Drug Combination; Angiotensin II Type 1 Receptor Blockers; A | 2012 |
Thrombin activatable fibrinolysis inhibitor (TAFI) levels in hypertensive patients and a comparison of the effects of amlodipine and ramipril on TAFI levels.
Topics: Adult; Amlodipine; Antihypertensive Agents; Carboxypeptidase B2; Female; Fibrinolysis; Humans; Hyper | 2013 |
Amlodidine + aliskiren.
Topics: Amides; Amlodipine; Drug Combinations; Fumarates; Humans; Hypertension | 2012 |
Efficacy and tolerability of fixed-dose amlodipine/olmesartan medoxomil with or without hydrochlorothiazide in Hispanic and non-Hispanic patients whose blood pressure is uncontrolled on antihypertensive monotherapy.
Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Blood Pressure Monitoring, Ambulat | 2012 |
Hypertension in older adults: progress and limitations.
Topics: Amlodipine; Angiotensin II Type 1 Receptor Blockers; Azetidinecarboxylic Acid; Calcium Channel Block | 2012 |
Amlodipine in pediatric patient with uncontrolled multifactorial hypertension. Formulation of amlodipine oral suspension.
Topics: Administration, Oral; Amlodipine; Calcium Channel Blockers; Child, Preschool; Female; Humans; Hypert | 2012 |
Comparative effectiveness analysis of amlodipine/renin-angiotensin system blocker combinations.
Topics: Adolescent; Adult; Aged; Amlodipine; Angiotensin Receptor Antagonists; Blood Pressure; Calcium Chann | 2012 |
How much effect of different antihypertensive medications on cardiovascular outcomes is attributable to their effects on blood pressure?
Topics: Amlodipine; Antihypertensive Agents; Biostatistics; Blood Pressure; Cardiovascular Diseases; Chlorth | 2013 |
[Potentialities of medicinal correction of cerebrovascular disturbances in patients with arterial hypertension].
Topics: Amlodipine; Antihypertensive Agents; Bisoprolol; Cerebrovascular Disorders; Drug Therapy, Combinatio | 2012 |
Additive effects of cilnidipine and angiotensin II receptor blocker in preventing the progression of diabetic nephropathy in diabetic spontaneously hypertensive rats.
Topics: Amlodipine; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Biomarkers; B | 2013 |
I take three different blood pressure medications-six pills total-every day. They are isosorbide mononitrate, amlodipine, and atenolol. They seem to do a good job bringing down my blood pressure, but before my 6 p.m. atenolol and then later before my 10 p
Topics: Amlodipine; Atenolol; Blood Pressure; Blood Pressure Determination; Circadian Rhythm; Drug Administr | 2011 |
Amlodipine- induced gingival overgrowth: a case report.
Topics: Adult; Amlodipine; Antihypertensive Agents; Calcium Channel Blockers; Female; Gingival Overgrowth; H | 2012 |
Transient prehypertensive treatment in spontaneously hypertensive rats: a comparison of losartan and amlodipine regarding long-term blood pressure, cardiac and renal protection.
Topics: Aldosterone; Amlodipine; Angiotensin II; Animals; Antihypertensive Agents; Blood Pressure; Cardioton | 2012 |
Improving drug adherence using fixed combinations caused beneficial treatment outcomes and decreased health-care costs in patients with hypertension.
Topics: Aged; Aged, 80 and over; Amlodipine; Angiotensin Receptor Antagonists; Benzimidazoles; Benzoates; Bi | 2013 |
Editorial: aliskiren/amlodipine single-pill combinations: more evidence in favour of combination formulations for the treatment of hypertension.
Topics: Amides; Amlodipine; Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Female; Fumar | 2012 |
Targeting albuminuria in arterial hypertension and diabetes: how is it best achieved and what is its clinical relevance?
Topics: Albuminuria; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Benzoates; Blood P | 2013 |
[Modern hypertension treatment. More than effective blood pressure reduction].
Topics: Amlodipine; Antihypertensive Agents; Drug Combinations; Humans; Hypertension; Imidazoles; Randomized | 2012 |
Amlodipine-induced gingival enlargement--a clinical report.
Topics: Amlodipine; Antihypertensive Agents; Calcium Channel Blockers; Female; Gingival Overgrowth; Humans; | 2012 |
Exfoliative esophagitis in a patient with metastatic renal cell carcinoma during sunitinib treatment.
Topics: Amlodipine; Antihypertensive Agents; Antineoplastic Agents; Aspirin; Carcinoma, Renal Cell; Cyclooxy | 2013 |
Clinical and economic outcomes associated with amlodipine/renin-angiotensin system blocker combinations.
Topics: Adult; Aged; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Calcium Channel Blockers; Drug The | 2013 |
Olmesartan-based therapies: an effective way to improve blood pressure control and cardiovascular protection.
Topics: Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Blood Pressure; Cardio | 2013 |
A retrospective electronic chart review of blood pressure changes in elderly patients treated with amlodipine or an angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker.
Topics: Aged; Amlodipine; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihy | 2002 |
Endothelin receptor antagonist combined with a calcium channel blocker attenuates renal injury in spontaneous hypertensive rats with diabetes.
Topics: Amlodipine; Angiotensin II; Animals; Bosentan; Calcium Channel Blockers; Collagen Type IV; Diabetic | 2002 |
Reduction of cerebral injury in stroke-prone spontaneously hypertensive rats by amlodipine.
Topics: Amlodipine; Animals; Antihypertensive Agents; Blood Pressure; Brain Edema; Hypertension; Male; Rats; | 2002 |
Parkinsonian syndrome induced by amlodipine: case report.
Topics: Aged; Aged, 80 and over; Amlodipine; Female; Humans; Hypertension; Neurologic Examination; Parkinson | 2002 |
[Pulse pressure indicates risk. Systolic hypertension is especially dangerous].
Topics: Amlodipine; Blood Pressure; Humans; Hypertension; Risk Factors; Systole | 2002 |
Cyclosporin enhances the tendency towards oedema and flushing noted on dihydropyridine calcium channel blockers.
Topics: Adolescent; Adult; Amlodipine; Calcium Channel Blockers; Child; Child, Preschool; Cyclosporine; Dihy | 2002 |
Antiplatelet activity of semotiadil fumarate.
Topics: Adenosine Diphosphate; Adult; Amlodipine; Calcium Channel Blockers; Case-Control Studies; Collagen; | 2002 |
[Hypertension and metabolic syndrome in population of one company. Monotherapy with amlodipine and doxazosin].
Topics: Adult; Amlodipine; Anticholesteremic Agents; Antihypertensive Agents; Blood Pressure; Doxazosin; Fem | 2002 |
[A megatrial of ARB in Japan--CASE-J].
Topics: Adult; Aged; Aged, 80 and over; Amlodipine; Angiotensin Receptor Antagonists; Benzimidazoles; Biphen | 2002 |
Efficacy and safety of a therapeutic interchange from high-dose calcium channel blockers to a fixed-dose combination of amlodipine/benazepril in patients with moderate-to-severe hypertension.
Topics: Amlodipine; Antihypertensive Agents; Benzazepines; Calcium Channel Blockers; Dose-Response Relations | 2002 |
Pedal edema--not all dihydropyridine calcium antagonists are created equal.
Topics: Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Calcium Channel Blockers; Edema; Humans; Hyper | 2002 |
Differential effects of antihypertensive drug therapy on arterial compliance.
Topics: Adrenergic beta-Antagonists; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive | 2002 |
[Changes of distensibility of the aorta in elderly patients during long-term therapy with various classes of hypotensive drugs (magnetic resonance tomography data)].
Topics: Adrenergic beta-Antagonists; Age Factors; Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors | 2002 |
Blood pressure response to antihypertensive agents related to baseline blood pressure.
Topics: Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Female; Humans; Hypertension; Male; Mibef | 2002 |
[Calcium antagonist against hypertension. Arteriosclerosis controlled].
Topics: Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Arteriosclerosis; Calcium Channel Blockers; Cl | 2002 |
[Contrast of losartan, fosinopril and amlodipine on cardiomyocyte apoptosis and left ventricular remolding in hypertensive rats].
Topics: Amlodipine; Animals; Antihypertensive Agents; Apoptosis; Cardiotonic Agents; Female; Fosinopril; Hyp | 2001 |
Disparate effects of angiotensin II antagonists and calcium channel blockers on albuminuria in experimental diabetes and hypertension: potential role of nephrin.
Topics: Albuminuria; Amlodipine; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Blood P | 2003 |
[Old or new antihypertensive drugs? Consequences from ALLHAT. Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial].
Topics: Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Calcium Channel | 2003 |
Plasma levels of active extracellular matrix metalloproteinases 2 and 9 in patients with essential hypertension before and after antihypertensive treatment.
Topics: Adult; Amlodipine; Antihypertensive Agents; Drug Administration Schedule; Echocardiography; Female; | 2003 |
[ALLHAT--the most comprehensive antihypertensive treatment trial in the world. The significance of thiazide diuretics for patients older than 55 years is confirmed].
Topics: Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Benzothiadiazin | 2003 |
[Consequences of ALLHAT: Thiazides rehabilitated--time to change prescription patterns].
Topics: Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Benzothiadiazin | 2003 |
ALLHAT finds diuretics best for initial hypertension therapy.
Topics: Amlodipine; Antihypertensive Agents; Chlorthalidone; Clinical Trials as Topic; Diuretics; Humans; Hy | 2003 |
Antihypertensive drugs and renal protection.
Topics: Adrenergic beta-Antagonists; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive | 2003 |
Diuretics: first choice for treating high BP.
Topics: Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Calcium Channel Blockers; Chlorthalidone | 2003 |
[Established blood pressure drug wins out in a comparative study. In hypertension, a diuretic first!].
Topics: Adrenergic alpha-Antagonists; Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypert | 2003 |
Hats off to an old blood pressure drug. For treating high blood pressure, an old--and inexpensive--medication is a great place to start or a good one to add.
Topics: Amlodipine; Antihypertensive Agents; Chlorthalidone; Clinical Trials as Topic; Diuretics; Humans; Hy | 2003 |
Summaries for patients. Effects of blood pressure drugs in patients with diabetes and kidney disease.
Topics: Amlodipine; Angiotensin II; Angiotensin Receptor Antagonists; Antihypertensive Agents; Biphenyl Comp | 2003 |
Life-style and medication compliance in elderly patients.
Topics: Adult; Age Factors; Aged; Amlodipine; Antihypertensive Agents; Drug Administration Schedule; Humans; | 1998 |
Effects of long-acting calcium channel antagonists on neurohumoral factors: comparison of nifedipine coat-core with amlodipine.
Topics: Aged; Aged, 80 and over; Aldosterone; Amlodipine; Blood Pressure; Calcium Channel Blockers; Chemistr | 2003 |
[What are the sequelae of the ALLHAT Study?].
Topics: Amlodipine; Antihypertensive Agents; Blood Pressure; Chlorthalidone; Critical Pathways; Humans; Hype | 2003 |
Diuretics: older, cheaper, better.
Topics: Adrenergic beta-Antagonists; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Benzothiadiazines | 2003 |
Exponential-exponential cosine fitting of blood pressure decay induced by a long-acting calcium blocker, amlodipine, using home blood pressure measurement.
Topics: Aged; Amlodipine; Blood Pressure; Blood Pressure Determination; Calcium Channel Blockers; Female; Hu | 2003 |
[ALLHAT: Old Hat Hits All? On selection of the optimal antihypertensive drug].
Topics: Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Cause of Death; Chlorthalidone; Dose-Resp | 2003 |
Journals should select drug advertisements more carefully.
Topics: Advertising; Amlodipine; Antihypertensive Agents; Drug Costs; Drug Industry; Humans; Hypertension; P | 2003 |
Diuretics are better first-line antihypertensive therapy than calcium channel blockers and ACE inhibitors.
Topics: Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Calcium Channel Block | 2003 |
A cheaper way to control high blood pressure.
Topics: Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Calcium Channel Blockers; Chlorthalidone; Clin | 2003 |
[Heart rate variability in patients with hypertension and type 2 diabetes treated with long acting calcium antagonists].
Topics: Aged; Amlodipine; Antihypertensive Agents; Blood Pressure Monitoring, Ambulatory; Calcium Channel Bl | 2003 |
A comparative analysis of amlodipine and felodipine in a military outpatient population: efficacy, outcomes, and cost considerations.
Topics: Amlodipine; Analysis of Variance; Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; | 2003 |
Treatment with amlodipine and atorvastatin have additive effect in improvement of arterial compliance in hypertensive hyperlipidemic patients.
Topics: Aged; Amlodipine; Anticholesteremic Agents; Antihypertensive Agents; Arteries; Atorvastatin; Biomark | 2003 |
The cost-effectiveness of irbesartan in the treatment of hypertensive patients with type 2 diabetic nephropathy.
Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Biphenyl Compounds; Cost-Benefit Analysis; Diabete | 2003 |
Evaluation of a therapeutic conversion from amlodipine to felodipine.
Topics: Aged; Amlodipine; Blood Pressure; Data Collection; Drug Evaluation; Felodipine; Heart Rate; Humans; | 2003 |
Effect of dietary calcium supplements and amlodipine on growth, arterial blood pressure, and cardiac hypertrophy of spontaneously hypertensive rats.
Topics: Amlodipine; Animals; Blood Pressure; Body Weight; Calcium Channel Blockers; Calcium, Dietary; Cardio | 2003 |
[Gestational arterial hypertension. Mechanisms of formation. Treatment with normodipin].
Topics: Adolescent; Adult; Amlodipine; Antihypertensive Agents; Arm; Arteries; Blood Flow Velocity; Endothel | 2003 |
Calcium channel blocker induced gum hypertrophy: no class distinction.
Topics: Amlodipine; Antihypertensive Agents; Calcium Channel Blockers; Gingival Hypertrophy; Humans; Hyperte | 2004 |
[Health economic consequences of the use of irbesartan in patients in Germany with type 2 diabetes, nephropathy and hypertension].
Topics: Amlodipine; Antihypertensive Agents; Biphenyl Compounds; Computer Simulation; Creatinine; Diabetes M | 2004 |
Effect of amlodipine and cilazapril treatment on platelet Ca2+ handling in spontaneously hypertensive rats.
Topics: Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Blood Platel | 2003 |
Early pathophysiological changes in cerebral vessels predisposing to stroke.
Topics: Amlodipine; Angiotensin II; Animals; Arterioles; Benzylamines; Brain; Calcium Channel Blockers; Calc | 2003 |
Synergism of atenolol and amlodipine on lowering and stabilizing blood pressure in spontaneously hypertensive rats.
Topics: Adrenergic beta-Antagonists; Amlodipine; Animals; Antihypertensive Agents; Atenolol; Blood Pressure; | 2004 |
Inhibition of oxidative stress and improvement of endothelial function by amlodipine in angiotensin II-infused rats.
Topics: Amlodipine; Angiotensin II; Animals; Blood Pressure; Calcium Channel Blockers; Endothelium-Dependent | 2004 |
Amlodipine associated hyperpigmentation.
Topics: Amlodipine; Biopsy, Needle; Calcium Channel Blockers; Humans; Hyperpigmentation; Hypertension; Immun | 2004 |
Two useful methods for evaluating antihypertensive drugs in conscious freely moving rats.
Topics: Amlodipine; Animals; Antihypertensive Agents; Atenolol; Blood Pressure; Drug Evaluation, Preclinical | 2004 |
Economic evaluation of the use of irbesartan and amlodipine in the treatment of diabetic nephropathy in patients with hypertension in Canada.
Topics: Adult; Aged; Amlodipine; Biphenyl Compounds; Cohort Studies; Cost-Benefit Analysis; Diabetic Nephrop | 2004 |
Early blood pressure normalization independent of the class of antihypertensive agent prevents augmented renal fibronectin and albuminuria in experimental diabetic nephropathy.
Topics: Albuminuria; Amlodipine; Animals; Antihypertensive Agents; Blood Glucose; Blood Pressure; Body Weigh | 2004 |
Amlodipine and carvedilol prevent cytotoxicity in cortical neurons isolated from stroke-prone spontaneously hypertensive rats.
Topics: Amlodipine; Animals; Antioxidants; Carbazoles; Carvedilol; Cell Death; Cell Hypoxia; Cells, Cultured | 2004 |
Amlodipine decreases fibrosis and cardiac hypertrophy in spontaneously hypertensive rats: persistent effects after withdrawal.
Topics: Amlodipine; Animals; Antihypertensive Agents; Blood Pressure; Disease Models, Animal; Dose-Response | 2004 |
Valsartan treatment of hypertension--does VALUE add value?
Topics: Aged; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; | 2004 |
Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE Trial.
Topics: Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Blood Pressure; Calciu | 2004 |
Effects of the angiotensin-1 receptor blocker valsartan compared with amlodipine on renal hemodynamics.
Topics: Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Calcium Channel Blocke | 2004 |
Amlodipine/atorvastatin (Caduet).
Topics: Amlodipine; Angina Pectoris; Atorvastatin; Clinical Trials as Topic; Dose-Response Relationship, Dru | 2004 |
Caduet treats two cardiovascular conditions at once.
Topics: Amlodipine; Clinical Trials as Topic; Double-Blind Method; Drug Combinations; Heptanoic Acids; Human | 2004 |
[The value of VALUE--a hypertension study which compared valsartan with amlodipine. New data support early, optimal blood pressure control for high-risk patients].
Topics: Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Blood Pressure; Calciu | 2004 |
Incremental effectiveness of amlodipine besylate in the treatment of hypertension with single and multiple medication regimens.
Topics: Aged; Aged, 80 and over; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting | 2004 |
[Characteristics of hypotensive effect in patients with arterial hypertension and desaturation signs of obstructive sleep apnea syndrome during sleep].
Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Blood Gas Monitoring, Transcutaneous; Blood Pressu | 2004 |
[Case report: hypertension after stroke].
Topics: Aged; Aged, 80 and over; Amlodipine; Antihypertensive Agents; Basal Ganglia Cerebrovascular Disease; | 2004 |
Amlodipine attenuates oxidative stress-induced hypertension.
Topics: Amlodipine; Animals; Antihypertensive Agents; Aorta; Blood Pressure; Cyclic AMP; Cyclic GMP; Dinopro | 2004 |
Plasma and platelet-derived vascular endothelial growth factor and angiopoietin-1 in hypertension: effects of antihypertensive therapy.
Topics: Amlodipine; Angiopoietin-1; Antihypertensive Agents; Blood Platelets; Blood Pressure; Calcium Channe | 2004 |
ALLHAT: what has it taught us so far?
Topics: Amlodipine; Antihypertensive Agents; Chlorthalidone; Humans; Hypertension; Lisinopril; Myocardial In | 2004 |
Antihypertensive treatment and renal damage: amlodipine exerts protective effect through the polyol pathway.
Topics: Administration, Oral; Amlodipine; Animals; Blood Glucose; Blood Pressure; Body Weight; Collagen Type | 2004 |
[Preventing end-organ damage in hypertension. What is the significance of the VALUE Study for general practice?].
Topics: Amlodipine; Angiotensin II Type 1 Receptor Blockers; Calcium Channel Blockers; Cardiovascular Diseas | 2004 |
VALUE in hypertension treatment.
Topics: Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Cardiovascular Disease | 2004 |
[AT1 blocker or calcium antagonist in treatment of hypertension. What protects the heart better?].
Topics: Amlodipine; Angiotensin II Type 1 Receptor Blockers; Cardiovascular Diseases; Clinical Trials as Top | 2004 |
[VALUE study underscores the significance of reaching aimed blood pressure values for minimizing cardiovascular risks].
Topics: Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Cardiovascular | 2004 |
[Effect of enalapril, lisinopril, and amlodipine on the course of chronic gastrititis in patients with arterial hypertension].
Topics: Adult; Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Calcium | 2004 |
Comparative study of the antihypertensive activity of Marrubium vulgare and of the dihydropyridine calcium antagonist amlodipine in spontaneously hypertensive rat.
Topics: Amlodipine; Animals; Antihypertensive Agents; Aorta; Calcium Channel Blockers; Hypertension; In Vitr | 2004 |
Angiotensin receptor blockers and myocardial infarction.
Topics: Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; Biphen | 2004 |
Valuable lessons from VALUE.
Topics: Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Blood Pressure; Calciu | 2004 |
The value of VALUE: the importance of lowering blood pressure quickly.
Topics: Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Humans; Hypertension; Middle Aged; Risk F | 2004 |
Effect of amlodipine on insulin resistance & tumor necrosis factor-alpha levels in hypertensive obese type 2 diabetic patients.
Topics: Adolescent; Adult; Aged; Amlodipine; Calcium Channel Blockers; Diabetes Mellitus, Type 2; Female; Ho | 2004 |
Chiral molecules in hypertension: focus on S-amlodipine.
Topics: Amlodipine; Blood Pressure; Calcium Channel Blockers; Humans; Hypertension; Stereoisomerism | 2004 |
[Safety and antihypertensive efficacy of the dihydropyridine calcium antagonist Amlodipine besylate--results from an observational study in 9,672 patients].
Topics: Adolescent; Adult; Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Calcium Channel Blocke | 2004 |
Exercise-related syncope induced by vasodilator therapy in an elderly hypertensive patient.
Topics: Aged; Amlodipine; Exercise; Female; Humans; Hypertension; Hypertrophy, Left Ventricular; Syncope; Va | 2005 |
[Hypertension therapy in practice test. Calcium antagonist receives good marks].
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Amlodipine; Angiotensin Receptor Antagoni | 2005 |
Anasarca edema with amlodipine treatment.
Topics: Aged; Amlodipine; Edema; Female; Humans; Hypertension | 2005 |
Adult hypertension: reducing cardiovascular morbidity and mortality.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Alcohol Drinking | 2005 |
The Avoiding Cardiovascular events through COMbination therapy in Patients Living with Systolic Hypertension (ACCOMPLISH) trial: a comparison of first-line combination therapies.
Topics: Amlodipine; Antihypertensive Agents; Benzazepines; Cardiovascular Diseases; Drug Therapy, Combinatio | 2005 |
Is there more to life than blood pressure?
Topics: Amlodipine; Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Humans; Hypertension; | 2005 |
Risk reduction therapy for syndrome X: comparison of several treatments.
Topics: Amlodipine; Animals; Antihypertensive Agents; Bezafibrate; Blood Pressure; Body Weight; Captopril; F | 2005 |
Outcomes in hypertensive black and nonblack patients treated with chlorthalidone, amlodipine, and lisinopril.
Topics: Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Black People; C | 2005 |
Outcomes in hypertensive black and nonblack patients treated with chlorthalidone, amlodipine, and lisinopril.
Topics: Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Black People; C | 2005 |
Outcomes in hypertensive black and nonblack patients treated with chlorthalidone, amlodipine, and lisinopril.
Topics: Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Black People; C | 2005 |
Outcomes in hypertensive black and nonblack patients treated with chlorthalidone, amlodipine, and lisinopril.
Topics: Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Black People; C | 2005 |
Outcomes in hypertensive black and nonblack patients treated with chlorthalidone, amlodipine, and lisinopril.
Topics: Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Black People; C | 2005 |
Outcomes in hypertensive black and nonblack patients treated with chlorthalidone, amlodipine, and lisinopril.
Topics: Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Black People; C | 2005 |
Outcomes in hypertensive black and nonblack patients treated with chlorthalidone, amlodipine, and lisinopril.
Topics: Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Black People; C | 2005 |
Outcomes in hypertensive black and nonblack patients treated with chlorthalidone, amlodipine, and lisinopril.
Topics: Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Black People; C | 2005 |
Outcomes in hypertensive black and nonblack patients treated with chlorthalidone, amlodipine, and lisinopril.
Topics: Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Black People; C | 2005 |
Calcium antagonist reduces oxidative stress by upregulating Cu/Zn superoxide dismutase in stroke-prone spontaneously hypertensive rats.
Topics: Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Animals; Calcium Channel Blockers; Coronary Ve | 2004 |
Do antihypertensives make tranylcypromine safer? Three case reports.
Topics: Amlodipine; Antihypertensive Agents; Calcium Channel Blockers; Depressive Disorder; Drug Therapy, Co | 2005 |
Morning rise in blood pressure is a predictor of left ventricular hypertrophy in treated hypertensive patients.
Topics: Activity Cycles; Aged; Amlodipine; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Calcium Ch | 2004 |
Blood pressure and cardiovascular risk reduction--new targets, new challenges.
Topics: Amlodipine; Antihypertensive Agents; Blood Pressure; Cardiovascular Diseases; Enalapril; Humans; Hyp | 2005 |
[Calcium antagonists: first choice antihypertensive drugs].
Topics: Amlodipine; Antihypertensive Agents; Calcium Channel Blockers; Clinical Trials as Topic; Follow-Up S | 2005 |
[Successful pharmacological treatment of hyperinsulinemic hypoglycemia with verapamil and amlodipine--case report].
Topics: Aged, 80 and over; Amlodipine; Calcium Channel Blockers; Female; Humans; Hyperinsulinism; Hypertensi | 2005 |
[ASCOT-BPLA Study raises new questions regarding: which is the best initial antihypertensive drug?].
Topics: Adrenergic beta-Antagonists; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive | 2005 |
Acute pain in the tip of the index finger.
Topics: Acute Disease; Amlodipine; Arterial Occlusive Diseases; Aspirin; Cyanosis; Diagnostic Errors; Female | 2005 |
Can combining different risk interventions into a single formulation contribute to improved cardiovascular disease risk reduction? Rationale and design for an international, open-label program to assess the effectiveness of a single pill (amlodipine/atorv
Topics: Amlodipine; Anticholesteremic Agents; Antihypertensive Agents; Atorvastatin; Blood Pressure; Cardiov | 2006 |
Smoking and antihypertensive medication: interaction between blood pressure reduction and arterial stiffness.
Topics: Aged; Amlodipine; Antihypertensive Agents; Arteries; Arteriosclerosis; Blood Pressure; Blood Pressur | 2005 |
Calcium channel blockades exhibit anti-inflammatory and antioxidative effects by augmentation of endothelial nitric oxide synthase and the inhibition of angiotensin converting enzyme in the N(G)-nitro-L-arginine methyl ester-induced hypertensive rat aorta
Topics: Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Animals; Anti-Inflammatory Agents; Antihyperte | 2005 |
[ASCOT Study of optimal hypertension therapy. New study results against the "diuretics first" recommendation].
Topics: Adrenergic beta-Antagonists; Adult; Aged; Amlodipine; Antihypertensive Agents; Cardiovascular Diseas | 2005 |
[Antihypertensive therapy: campaign of the giants].
Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Atenolol; Bendroflumethiazide; Coronary Disease; D | 2005 |
Renal mitochondrial dysfunction in spontaneously hypertensive rats is attenuated by losartan but not by amlodipine.
Topics: Actins; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Animals; Blood Pressure; Calcium Channe | 2006 |
ASCOT-BPLA.
Topics: Amlodipine; Calcium Channel Blockers; Humans; Hypertension; Neoplasms; Randomized Controlled Trials | 2006 |
The X-cellent Study.
Topics: Adult; Aged; Aged, 80 and over; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Animals; Antihy | 2006 |
Summaries for patients. Do the effects of blood pressure drugs differ by kidney function?
Topics: Aged; Amlodipine; Antihypertensive Agents; Cardiovascular Diseases; Chlorthalidone; Chronic Disease; | 2006 |
Omission of drug dose information.
Topics: Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Calcium Channel Block | 2006 |
Effects of amlodipine orotate on hypertension-related complications in spontaneously hypertensive rats.
Topics: Amlodipine; Animals; Antihypertensive Agents; Blood Pressure; Body Weight; Calcium; Cardiomegaly; Ce | 2006 |
Cardiac syndrome X: relevance of arterial pressure waveform analysis to patients with chest pain and normal coronary arteries.
Topics: Aged; Amlodipine; Antihypertensive Agents; Chest Pain; Coronary Angiography; Coronary Circulation; E | 2006 |
[Health economic consequences of the use of irbesartan in patients with type 2 diabetes, hypertension and nephropathy in Switzerland].
Topics: Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Biphenyl Compounds; Ca | 2006 |
Arteriolar remodeling in essential hypertension: are connective tissue growth factor and transforming growth factor involved?
Topics: Amlodipine; Antihypertensive Agents; Arterioles; Connective Tissue Growth Factor; Humans; Hypertensi | 2006 |
CACNA1C polymorphisms are associated with the efficacy of calcium channel blockers in the treatment of hypertension.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amlodipine; Antihypertensive Agents; Calcium Channel Blo | 2006 |
[The most recent study into blood pressure lowering by amlodipine: the beginning of the end for the beta-blockers].
Topics: Adrenergic beta-Antagonists; Amlodipine; Antihypertensive Agents; Blood Pressure; Cardiovascular Dis | 2006 |
Results of the ASCOT-BPLA trial: no practical implications for treatment of hypertension.
Topics: Amlodipine; Atenolol; Cardiovascular Diseases; Clinical Trials as Topic; Drug Therapy, Combination; | 2006 |
Comparison of health costs associated with treatment of hypertension with a calcium channel blocker and angiotensin-converting enzyme inhibitor in the United States and Japan.
Topics: Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Calcium Channel Blockers; Cardiovascular Disea | 2006 |
Two cases of fatal amlodipine overdose.
Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Calcium Channel Blockers; Drug Overdose; Female; G | 2006 |
Benazepril combined with either amlodipine or hydrochlorothiazide is more effective than monotherapy for blood pressure control and prevention of end-organ injury in hypertensive Dahl rats.
Topics: Acetylcholine; Administration, Oral; Amlodipine; Animals; Antihypertensive Agents; Benzazepines; Blo | 2006 |
What blood-pressure level provides greatest renoprotection in patients with diabetic nephropathy and hypertension?
Topics: Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Biphenyl Compounds; Di | 2006 |
Enhancement of cardiac oxidative stress by tachycardia and its critical role in cardiac hypertrophy and fibrosis.
Topics: Amlodipine; Animals; Azetidinecarboxylic Acid; Cardiomegaly; Dihydropyridines; Endomyocardial Fibros | 2006 |
Antihypertensive agents have different ability to modulate arterial pressure and heart rate variability in 2K1C rats.
Topics: Amlodipine; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Atenolol; Aut | 2006 |
Letter by Dart et al regarding article, "Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study".
Topics: Adrenergic beta-Antagonists; Amlodipine; Antihypertensive Agents; Aorta; Atenolol; Blood Pressure; E | 2006 |
Letter by Nieminen et al regarding article, "Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study".
Topics: Adrenergic beta-Antagonists; Amlodipine; Antihypertensive Agents; Aorta; Atenolol; Blood Pressure; H | 2006 |
Letter by Cameron et al regarding article, "Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study".
Topics: Adrenergic beta-Antagonists; Amlodipine; Antihypertensive Agents; Aorta; Atenolol; Blood Pressure; H | 2006 |
Letter by Safar and Fournier regarding article, "Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study".
Topics: Adrenergic beta-Antagonists; Amlodipine; Antihypertensive Agents; Aorta; Atenolol; Blood Pressure; H | 2006 |
Treatment with hypotensive agents affects the impaired relaxation of the penile corpus cavernosum in hypertensive rats.
Topics: Amlodipine; Animals; Antihypertensive Agents; Blood Pressure; Carbon Monoxide; Cyclic GMP; Electric | 2006 |
Lack of pharmacokinetic interactions of aliskiren, a novel direct renin inhibitor for the treatment of hypertension, with the antihypertensives amlodipine, valsartan, hydrochlorothiazide (HCTZ) and ramipril in healthy volunteers.
Topics: Adolescent; Adult; Amides; Amlodipine; Antihypertensive Agents; Drug Interactions; Drug Therapy, Com | 2006 |
Effects of benidipine, a long-lasting dihydropyridine-Ca2+ channel blocker, on cerebral blood flow autoregulation in spontaneously hypertensive rats.
Topics: Administration, Oral; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; | 2006 |
[Coronary disease risk and prevalence of heart disease in primary care patients with hypertension and renal disease].
Topics: Adult; Age Factors; Aged; Amlodipine; Antihypertensive Agents; Clinical Trials as Topic; Coronary Di | 2006 |
In vivo and in vitro effects of nebivolol on penile structures in hypertensive rats.
Topics: Acetylcholine; Actins; Adrenergic beta-Antagonists; Amlodipine; Animals; Antihypertensive Agents; Ar | 2006 |
Efficacy and safety of amlodipine: a comparative study of hypertensive patients treated at primary- and specialised-care centres.
Topics: Adult; Aged; Amlodipine; Calcium Channel Blockers; Diastole; Drug Therapy, Combination; Female; Huma | 2006 |
The Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) Heart Failure Validation Study: diagnosis and prognosis.
Topics: Adrenergic alpha-Antagonists; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive | 2007 |
Amlodipine induced gingival hyperplasia: a rare entity.
Topics: Amlodipine; Gingival Hyperplasia; Humans; Hypertension; Male; Middle Aged; Oral Hygiene | 2007 |
Angiotensin-converting enzyme (ACE) inhibitor-associated angioedema of the stomach and small intestine: a case report.
Topics: Amlodipine; Angioedema; Angiotensin-Converting Enzyme Inhibitors; Benzazepines; Calcium Channel Bloc | 2006 |
Risk of diabetes in a real-world setting among patients initiating antihypertensive therapy with valsartan or amlodipine.
Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Databases, Factual; Diabetes Mellitus; Diabetes Me | 2007 |
Pulsology reloaded: commentary on similar effects of treatment on central and brachial blood pressure in older hypertensive subjects.
Topics: Aged; Aged, 80 and over; Aging; Amlodipine; Antihypertensive Agents; Atenolol; Blood Pressure; Brach | 2007 |
[Correction of primary hemostasis in patients suffering from arterial hypertension with metabolic syndrome].
Topics: Adult; Amlodipine; Antihypertensive Agents; Antioxidants; Benzopyrans; Ethanolamines; Female; Hemost | 2007 |
Fibroblast apoptosis precedes cardiomyocyte mass reduction during left ventricular remodeling in hypertensive rats treated with amlodipine.
Topics: Amlodipine; Animals; Antihypertensive Agents; Apoptosis; Fibroblasts; Heart; Hypertension; Male; Mus | 2007 |
Sudden cardiac standstill during skin flap elevation in a patient undergoing craniotomy.
Topics: Aged; Amlodipine; Anesthesia, General; Anti-Arrhythmia Agents; Antihypertensive Agents; Atropine; Bl | 2007 |
The putative link between glycemic control and cardiac arrhythmias.
Topics: Amlodipine; Antihypertensive Agents; Arrhythmias, Cardiac; Blood Glucose; Chlorthalidone; Diabetes M | 2007 |
Influence of calcium channel blocker drugs in neuromuscular transmission.
Topics: Adult; Amlodipine; Calcium Channel Blockers; Electromyography; Female; Fingers; Humans; Hypertension | 2007 |
Chronic cystamine treatment inhibits small artery remodelling in rats.
Topics: Amlodipine; Animals; Antihypertensive Agents; Blood Pressure; Collagen; Cystamine; Disease Models, A | 2007 |
Amlodipine-induced bilateral upper extremity edema.
Topics: Amlodipine; Antihypertensive Agents; Child; Edema; Female; Humans; Hypertension; Upper Extremity; Va | 2007 |
[Treating essential hypertension. Are beta blockers still first choice?].
Topics: Adrenergic beta-Antagonists; Amlodipine; Antihypertensive Agents; Atenolol; Bendroflumethiazide; Cor | 2007 |
Amlodipine and stroke prevention.
Topics: Amlodipine; Blood Pressure; Calcium Channel Blockers; Circadian Rhythm; Humans; Hypertension; Myocar | 2007 |
ACE inhibitor-based, directly observed therapy for hypertension in hemodialysis patients.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Anti | 2007 |
Distinct effects of amlodipine treatment on vascular elastocalcinosis and stiffness in a rat model of isolated systolic hypertension.
Topics: Amlodipine; Animals; Calcinosis; Calcium; Calcium Channel Blockers; Collagen; Compliance; Hypertensi | 2007 |
S-amlodipine--the 2007 clinical review.
Topics: Amlodipine; Angina Pectoris; Antihypertensive Agents; Humans; Hypertension; Molecular Conformation; | 2007 |
Olmesartan, but not amlodipine, improves endothelium-dependent coronary dilation in hypertensive patients.
Topics: Adult; Amlodipine; Blood Chemical Analysis; Cohort Studies; Coronary Circulation; Coronary Stenosis; | 2007 |
Aortic coarctation in the elderly: how many errors lie behind an unexpected diagnosis?
Topics: Age Factors; Aged; Amlodipine; Antihypertensive Agents; Aortic Coarctation; Diagnostic Errors; Enala | 2007 |
Novel mechanism and role of angiotensin II induced vascular endothelial injury in hypertensive diastolic heart failure.
Topics: Acetophenones; Amlodipine; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Antihyp | 2007 |
The relationships between initial blood pressure and the response to different antihypertensive agents.
Topics: Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Blood Pressure; Blood | 2007 |
[Therapy-refractory arterial hypertension in a young patient].
Topics: Adult; Amlodipine; Antihypertensive Agents; Calcium Channel Blockers; Drug Therapy, Combination; Hum | 2007 |
Metabolic and clinical outcomes in nondiabetic individuals with the metabolic syndrome assigned to chlorthalidone, amlodipine, or lisinopril as initial treatment for hypertension: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent
Topics: Aged; Amlodipine; Antihypertensive Agents; Atherosclerosis; Blood Pressure; Chlorthalidone; Cohort S | 2008 |
[Overweight and obesity in hypertensive Spanish patients. The CORONARIA study].
Topics: Amlodipine; Analysis of Variance; Antihypertensive Agents; Body Mass Index; Calcium Channel Blockers | 2007 |
[Hypertension therapy for type 2 diabetics].
Topics: Amlodipine; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antih | 2007 |
[Risk oriented therapy of hypertension. Lowering blood pressure and risk].
Topics: Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Blood Pressure; Cardio | 2007 |
Two amlodipine/ARB combinations for hypertension.
Topics: Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Calcium Channel Blocke | 2007 |
Peroxynitrite is Involved in the dysfunction of vasorelaxation in SHR/NDmcr-cp rats, spontaneously hypertensive obese rats.
Topics: Acetylcholine; Amlodipine; Animals; Aorta, Thoracic; Blood Glucose; Blood Pressure; Blotting, Wester | 2007 |
Upregulation of cortical COX-2 in salt-sensitive hypertension: role of angiotensin II and reactive oxygen species.
Topics: Amlodipine; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agent | 2008 |
Pharmacogenetic association of the NPPA T2238C genetic variant with cardiovascular disease outcomes in patients with hypertension.
Topics: Aged; Amlodipine; Antihypertensive Agents; Atrial Natriuretic Factor; Blood Pressure; Cardiovascular | 2008 |
Effect of telmisartan and amlodipine on home blood pressure by monitoring newly developed telemedicine system: monitoring test by using telemedicine. Telmisartan's effect on home blood pressure (TelTelbosu).
Topics: Amlodipine; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Benzoates; Blood Pressure; Calc | 2008 |
Add-on effect of bedtime dosing of the alpha(1)-adrenergic receptor antagonist doxazosin on morning hypertension and left ventricular hypertrophy in patients undergoing long-term amlodipine monotherapy.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Adult; Aged; Amlodipine; Bloo | 2007 |
[The state of cerebral blood flow in hypertensive crises and possibilities of its correction].
Topics: Amlodipine; Antihypertensive Agents; Blood Flow Velocity; Blood Pressure; Cerebrovascular Circulatio | 2007 |
My diastolic blood pressure reading consistently registers 65 to 75, but my systolic registers 125 to 135. My doctor says that because that diastolic is well controlled (I'm 72 and take amlodipine), that there's no need to try to lower the systolic. Wha
Topics: Aged; Amlodipine; Antihypertensive Agents; Diastole; Humans; Hypertension; Male; Reference Values; S | 2007 |
Compliance with antihypertensive therapy in the elderly: a comparison of fixed-dose combination amlodipine/benazepril versus component-based free-combination therapy.
Topics: Age Factors; Aged; Aged, 80 and over; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihype | 2008 |
Vertebral artery dissection: not a rare cause of stroke in the young.
Topics: Adult; Amlodipine; Anticoagulants; Antihypertensive Agents; Aspirin; Craniocerebral Trauma; Female; | 2008 |
Stepwise decline in visual field after serial sildenafil use.
Topics: Amlodipine; Antihypertensive Agents; Disease Progression; Dose-Response Relationship, Drug; Drug Int | 2008 |
Decreased expression of angiotensin II type 1 and type 2 receptors in the brain after long-term administration of antihypertensive drugs in stroke-prone spontaneously hypertensive rat.
Topics: Amlodipine; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Anima | 2008 |
[Is hypotensive effectiveness of amlodipine therapy in smokers connected with endothelin-1 (ET-1) concentration?].
Topics: Aged; Amlodipine; Antihypertensive Agents; Endothelin-1; Female; Humans; Hypertension; Male; Middle | 2007 |
Amlodipine reduces the antimigratory effect of diclofenac in spontaneously hypertensive rats.
Topics: Amlodipine; Animals; Anti-Inflammatory Agents, Non-Steroidal; Antihypertensive Agents; Blood Pressur | 2008 |
Evidence for an alpha 1-adrenoceptor subtype mediating adrenergic vasoconstriction in Wistar normotensive and stroke-prone spontaneously hypertensive rat kidney.
Topics: Adrenergic alpha-Antagonists; Amlodipine; Animals; Cerebrovascular Disorders; Clonidine; Dose-Respon | 1994 |
Renal protective effects of amlodipine on partially nephrectomized spontaneously hypertensive rats fed a high-salt diet.
Topics: Amlodipine; Animals; Blood Pressure; Body Weight; Hypertension; Kidney; Kidney Diseases; Nephrectomy | 1994 |
Alpha 1-adrenoceptor subtypes mediating adrenergic vasoconstriction in kidney, one-clip Goldblatt and deoxycorticosterone acetate-salt hypertensive rats.
Topics: Adrenergic alpha-Antagonists; Amlodipine; Animals; Clonidine; Desoxycorticosterone; Disease Models, | 1994 |
Effects of Ca-antagonists on oxidative susceptibility of low density lipoprotein (LDL).
Topics: Adult; Amlodipine; Apolipoproteins; Calcium Channel Blockers; Electrophoresis, Agar Gel; Fatty Acids | 1995 |
End-organ involvement and calcium antagonist therapy: animal studies.
Topics: Administration, Oral; Amlodipine; Animals; Aorta, Thoracic; Arteriosclerosis; Binding Sites; Blood P | 1994 |
One-year antihypertensive treatment with amlodipine: effects on 24-hour blood pressure and left ventricular anatomy and function.
Topics: Adult; Amlodipine; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Diastole; Echocardiography | 1995 |
Hemodynamic effects of amlodipine and benazeprilat in spontaneously hypertensive rats.
Topics: Amlodipine; Angiotensin I; Angiotensin-Converting Enzyme Inhibitors; Animals; Benzazepines; Blood Pr | 1993 |
[Amlodipine in long-term treatment of mild and moderate hypertension. A multicenter study].
Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Dose-Response Relationship, Drug; | 1995 |
Calcium channel blockade: is lowering office blood pressure enough? Introduction.
Topics: Amlodipine; Blood Pressure; Humans; Hypertension | 1995 |
Gastrointestinal bleeding induced by amlodipine.
Topics: Aged; Aged, 80 and over; Amlodipine; Gastrointestinal Hemorrhage; Humans; Hypertension; Male; Middle | 1995 |
[Gingival hyperplasia induced by amlodipine].
Topics: Adult; Amlodipine; Calcium Channel Blockers; Gingival Hyperplasia; Humans; Hypertension; Male; Nifed | 1995 |
Effects of angiotensin converting enzyme inhibition on cardiac collagen in hypertensive and normotensive rats.
Topics: Amlodipine; Animals; Blood Pressure; Collagen; Heart; Hydroxyproline; Hypertension; Lisinopril; Male | 1994 |
Improvement of insulin sensitivity for glucose metabolism with the long-acting Ca-channel blocker amlodipine in essential hypertensive subjects.
Topics: Amlodipine; Blood Glucose; Catecholamines; Female; Glucose Tolerance Test; Homeostasis; Humans; Hype | 1995 |
Parkinsonism induced by amlodipine.
Topics: Aged; Amlodipine; Female; Follow-Up Studies; Humans; Hypertension; Parkinson Disease, Secondary | 1995 |
[The effect on left ventricular mass of treatment with amlodipine and diet therapy in obese patients with arterial hypertension].
Topics: Amlodipine; Combined Modality Therapy; Diet, Reducing; Evaluation Studies as Topic; Female; Heart Ve | 1994 |
Biochemical changes during amlodipine treatment in hypertensive patients.
Topics: Amlodipine; Black People; Blood Chemical Analysis; Blood Pressure; Female; Humans; Hypertension; Mal | 1994 |
[Experience with amlodipine (Norvasc) in the management of arterial hypertension].
Topics: Adult; Aged; Amlodipine; Blood Pressure; Chronic Disease; Drug Evaluation; Female; Humans; Hypertens | 1993 |
Amlodipine--once-daily monotherapy in systemic hypertension.
Topics: Adult; Amlodipine; Blood Pressure; Blood Pressure Monitors; Circadian Rhythm; Diastole; Female; Hear | 1994 |
[Sexual dysfunction due to captopril and amlodipine].
Topics: Aged; Amlodipine; Captopril; Erectile Dysfunction; Humans; Hypertension; Male | 1994 |
Biochemical components and myocardial performance after reversal of left ventricular hypertrophy in spontaneously hypertensive rats.
Topics: Amlodipine; Animals; Benzazepines; Collagen; Drug Combinations; Hemodynamics; Hypertension; Hypertro | 1993 |
[The assessment of glucose tolerance in hypertensive subjects treated with amlodipine].
Topics: Amlodipine; Blood Glucose; Drug Evaluation; Female; Glucose Tolerance Test; Humans; Hypertension; In | 1993 |
Safety and efficacy of amlodipine. A new once-daily calcium antagonist in non-hypertensive patients with coronary artery disease.
Topics: Amlodipine; Blood Pressure; Blood Pressure Monitors; Circadian Rhythm; Coronary Disease; Drug Admini | 1993 |
An overview of the pharmacokinetics and pharmacodynamics of amlodipine in elderly persons with systemic hypertension.
Topics: Administration, Oral; Adult; Aged; Amlodipine; Atrial Natriuretic Factor; Biological Availability; B | 1994 |
Hemodynamic and electrophysiologic effects of first- and second-generation calcium antagonists.
Topics: Amlodipine; Calcium Channel Blockers; Cardiac Output; Dihydropyridines; Electrophysiology; Female; H | 1994 |
Measurement of long-term hemodynamic changes and the use of 24-hour blood pressure monitoring to evaluate treatment.
Topics: Adult; Amlodipine; Blood Pressure; Blood Pressure Monitors; Cardiac Output; Circadian Rhythm; Exerci | 1994 |
Lack of effect of long-term amlodipine on insulin sensitivity and plasma insulin in obese patients with essential hypertension.
Topics: Amlodipine; Blood Pressure; Female; Humans; Hypertension; Insulin; Insulin Resistance; Male; Middle | 1993 |
Long-term hemodynamic effects at rest and during exercise of newer antihypertensive agents and salt restriction in essential hypertension: review of epanolol, doxazosin, amlodipine, felodipine, diltiazem, lisinopril, dilevalol, carvedilol, and ketanserin.
Topics: Adult; Amlodipine; Antihypertensive Agents; Benzeneacetamides; Carbazoles; Carvedilol; Diet, Sodium- | 1993 |
Amlodipine approved for hypertension, angina therapy.
Topics: Amlodipine; Angina Pectoris; Drug Approval; Humans; Hypertension; United States; United States Food | 1993 |
Long term effects of amlodipine on organ damage, stroke and life span in stroke prone spontaneously hypertensive rats.
Topics: Amlodipine; Animals; Cerebrovascular Disorders; Heart; Hypertension; Kidney; Longevity; Male; Myocar | 1993 |
[Leukocytoclastic vasculitis in relation to amlodipine administration].
Topics: Adult; Amlodipine; Antihypertensive Agents; Calcium Channel Blockers; Chronic Disease; Humans; Hyper | 1995 |
The chronic treatment of amlodipine in regressing hypertrophy.
Topics: Amlodipine; Animals; Blood Pressure; Calcium Channel Blockers; DNA; Heart Ventricles; Hypertension; | 1995 |
Effects of amlodipine on 24-hour ambulatory blood pressure profiles, electrocardiographic monitoring, and left ventricular mass and function in black patients with very severe hypertension.
Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Black People; Blood Pressure; Blood Pressure Monit | 1995 |
Endothelium-dependent relaxation in resistance arteries from spontaneously hypertensive rats: effect of long-term treatment with perindopril, quinapril, hydralazine or amlodipine.
Topics: Acetylcholine; Amlodipine; Animals; Antihypertensive Agents; Arginine; Bradykinin; Dose-Response Rel | 1996 |
Automated gas chromatographic assay for amlodipine in plasma and gingival crevicular fluid.
Topics: Amlodipine; Angina Pectoris; Autoanalysis; Chromatography, Gas; Gingival Crevicular Fluid; Gingival | 1996 |
Blood glucose levels in hypertensive patients during treatment with different antihypertensive agents.
Topics: Amlodipine; Antihypertensive Agents; Blood Glucose; Doxazosin; Female; Humans; Hypertension; Male; M | 1996 |
Predictive value of ambulatory blood pressure shortly after withdrawal of antihypertensive drugs in primary care patients.
Topics: Adult; Amlodipine; Antihypertensive Agents; Blood Pressure; Blood Pressure Monitoring, Ambulatory; F | 1996 |
[Transcutaneous oximetry in smokers with moderate hypertension and peripheral arterial disease treated with amlodipine and defibrotide, also with total smoking cessation].
Topics: Amlodipine; Antihypertensive Agents; Blood Gas Monitoring, Transcutaneous; Blood Viscosity; Calcium | 1995 |
Increased applied pressure enhances the uptake of IgG complexes by macrophages.
Topics: Amlodipine; Antigen-Antibody Complex; Calcium; Cell Line; Cinnarizine; Humans; Hypertension; Immunog | 1996 |
Does combined therapy of Ca-channel blocker and angiotensin converting enzyme inhibitor exceed monotherapy in renal protection against hypertensive injury in rats?
Topics: Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Animals; Blood Pressure; Body Weight; Calcium | 1996 |
Hemodynamic and 24-h blood pressure profile of amlodipine monotherapy.
Topics: Adult; Amlodipine; Antihypertensive Agents; Blood Pressure; Blood Pressure Determination; Blood Pres | 1996 |
Albuminuria in diabetes mellitus: relation to ambulatory versus office blood pressure and effects of cilazapril.
Topics: Adolescent; Adult; Aged; Albuminuria; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Blood Pr | 1996 |
[Avoiding compliance problems. Selection of the right drugs is important].
Topics: Amlodipine; Antihypertensive Agents; Dose-Response Relationship, Drug; Humans; Hypertension; Treatme | 1996 |
Converting enzyme inhibitor improves forearm reactive hyperemia in essential hypertension.
Topics: Aged; Aged, 80 and over; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Blood Pressure; Calci | 1997 |
Sex- and age-related antihypertensive effects of amlodipine.
Topics: Aged; Aging; Amlodipine; Antihypertensive Agents; Edema; Female; Humans; Hypertension; Male; Middle | 1997 |
Effects of the dihydropyridine calcium channel blocker amlodipine on ventricular and atrial protein synthesis in an aortic constriction model of hypertension and, following chronic treatment, in the left ventricle of SHR rats.
Topics: Amlodipine; Animals; Antihypertensive Agents; Calcium Channel Blockers; Contractile Proteins; Diseas | 1997 |
Drug treatment of hypertension in acute intermittent porphyria: doxazosin and amlodipine.
Topics: Amlodipine; Antihypertensive Agents; Doxazosin; Drug Monitoring; Female; Humans; Hypertension; Middl | 1997 |
Amlodipine in chronic heart failure.
Topics: Amlodipine; Angina Pectoris; Angiotensin-Converting Enzyme Inhibitors; Calcium Channel Blockers; Dru | 1997 |
Cost containment for treating hypertension in African Americans: impact of a combined ACE inhibitor-calcium channel blocker.
Topics: Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Benzazepines; Black P | 1997 |
Diagnostic ophthalmology. Hypertensive retinopathy.
Topics: Amlodipine; Animals; Antihypertensive Agents; Blood Pressure; Blood Urea Nitrogen; Body Temperature; | 1997 |
Evaluation of amlodipine in mild to moderate hypertension--a clinical report.
Topics: Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Constipation; Diastole; Electrocardiograp | 1995 |
Effects of chronic treatment with amlodipine in streptozotocin-diabetic and spontaneously hypertensive rats.
Topics: Amlodipine; Animals; Blood Glucose; Blood Pressure; Calcium Channel Blockers; Diabetes Mellitus, Exp | 1997 |
Efficient inhibition of the development of cardiac remodeling by a long-acting calcium antagonist amlodipine.
Topics: Amlodipine; Animals; Antihypertensive Agents; Calcium Channel Blockers; Cardiomegaly; Collagen; Hear | 1998 |
Relationship between endothelial function and fibrinolysis in early hypertension.
Topics: Adult; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Benzazepines; Blood Pressure; Brachial | 1998 |
[Amlodipine].
Topics: Amlodipine; Angina Pectoris; Antihypertensive Agents; Calcium Channel Blockers; Coronary Disease; He | 1998 |
Efficacy of amlodipine in pediatric bone marrow transplant patients.
Topics: Adolescent; Age Factors; Amlodipine; Bone Marrow Transplantation; Child; Child, Preschool; Cohort St | 1998 |
Amlodipine lowers blood pressure without increasing sympathetic activity or activating the renin-angiotensin system in patients with essential hypertension.
Topics: Aged; Amlodipine; Blood Pressure; Calcium Channel Blockers; Female; Humans; Hypertension; Male; Midd | 1997 |
Amlodipine and vascular hypertrophy.
Topics: Amlodipine; Animals; Calcium Channel Blockers; Cell Count; Cell Cycle; Cell Division; Cells, Culture | 1997 |
Treatment of hypertensive patients with diabetes.
Topics: Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Calcium Channel Block | 1998 |
Different effects of calcium antagonists on fluid filtration of large arteries and albumin permeability in spontaneously hypertensive rats.
Topics: Amlodipine; Animals; Benzimidazoles; Blood Pressure; Calcium Channel Blockers; Capillary Permeabilit | 1998 |
Effects of amlodipine once or twice daily on circadian blood pressure profile, myocardial hypertrophy, and beta-adrenergic signaling in transgenic hypertensive TGR(mREN2)27 rats.
Topics: Adenylyl Cyclases; Amlodipine; Animals; Animals, Genetically Modified; Antihypertensive Agents; Bloo | 1998 |
Cardioprotective effects of an angiotensin-converting-enzyme inhibitor, imidapril, and Ca2+ channel antagonist, amlodipine, in spontaneously hypertensive rats at established stage of hypertension.
Topics: Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Animals; Blood Pressure; Calcium Channel Block | 1998 |
Painful subcutaneous fat necrosis of the newborn associated with intra-partum use of a calcium channel blocker.
Topics: Amlodipine; Calcium Channel Blockers; Fat Necrosis; Female; Humans; Hypertension; Infant, Newborn; M | 1998 |
Amlodipine once-daily in systemic hypertension.
Topics: Adolescent; Adult; Amlodipine; Antihypertensive Agents; Calcium Channel Blockers; Child; Child, Pres | 1998 |
Influence of baseline values on lipids and lipoprotein changes during amlodipine treatment of hypertension.
Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Female; Humans; Hypertension; Lipids; Lipoproteins | 1998 |
Effects of enalapril and amlodipine on small-artery structure and composition, and on endothelial dysfunction in spontaneously hypertensive rats.
Topics: Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Arteries; Ca | 1998 |
Effect of amlodipine on the growth of vascular smooth muscle cells of spontaneously hypertensive rats.
Topics: Amlodipine; Animals; Aorta, Thoracic; Calcium Channel Blockers; Cell Division; Cells, Cultured; Hype | 1997 |
Severe neuromuscular complications possibly associated with amlodipine.
Topics: Amlodipine; Antihypertensive Agents; Arthralgia; Female; Humans; Hypertension; Middle Aged; Neuromus | 1998 |
Quality of life and calcium channel blockade with nifedipine GITS versus amlodipine in hypertensive patients in Spain. Gastrointestinal Therapeutic System.
Topics: Adolescent; Adult; Aged; Amlodipine; Antihypertensive Agents; Calcium Channel Blockers; Double-Blind | 1998 |
Key features of candesartan cilexetil and a comparison with other angiotensin II receptor antagonists.
Topics: Amlodipine; Angiotensin Receptor Antagonists; Antihypertensive Agents; Benzimidazoles; Biphenyl Comp | 1999 |
Calcium channel blockers and benign hypertension.
Topics: Amlodipine; Antihypertensive Agents; Calcium Channel Blockers; Female; Humans; Hypertension; Intracr | 1999 |
Telangiectasia and gingival hyperplasia as side-effects of amlodipine (Norvasc) in a 3-year-old girl.
Topics: Amlodipine; Antihypertensive Agents; Child, Preschool; Female; Gingival Hyperplasia; Humans; Hyperte | 1999 |
Effects of amlodipine on nitric oxide synthase mRNA expression and coronary microcirculation in prolonged nitric oxide blockade-induced hypertensive rats.
Topics: Amlodipine; Animals; Calcium Channel Blockers; Coronary Circulation; Hemodynamics; Hypertension; Mal | 1999 |
Differential effects of T- and L-type calcium antagonists on glomerular dynamics in spontaneously hypertensive rats.
Topics: Amlodipine; Animals; Antihypertensive Agents; Benzimidazoles; Calcium Channel Blockers; Calcium Chan | 1999 |
Achilles tendonitis: an unusual complication of amlodipine therapy.
Topics: Achilles Tendon; Amlodipine; Ankle; Antihypertensive Agents; Calcium Channel Blockers; Edema; Humans | 1999 |
[Effects of benidipine hydrochloride (Coniel) on blood pressure, heart rate and plasma norepinephrine concentration in spontaneously hypertensive rats].
Topics: Amlodipine; Animals; Blood Pressure; Calcium Channel Blockers; Dihydropyridines; Heart Rate; Hyperte | 1999 |
Antihypertensive treatment and CHD in the elderly.
Topics: Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Pressure; | 1999 |
Contrasting effects of selective T- and L-type calcium channel blockade on glomerular damage in DOCA hypertensive rats.
Topics: Amlodipine; Analysis of Variance; Animals; Blood Pressure; Body Weight; Calcium Channel Blockers; Ca | 1999 |
Cardiovascular risk, renal hypertensive damage, and effects of amlodipine treatment in transgenic TGR(mREN2)27 rats.
Topics: Albumins; Amlodipine; Animals; Animals, Genetically Modified; Blood Pressure; Calcium; Calcium Chann | 1999 |
Influence of baseline values on lipids, lipoproteins and fibrinolytic parameters during amlodipine treatment of hypertension in Japanese patients.
Topics: Aged; Amlodipine; Antihypertensive Agents; Calcium Channel Blockers; Female; Fibrinolysis; Humans; H | 2000 |
[Arterial hypertension and systolic left ventricular dysfunction: therapeutic approach].
Topics: Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Calcium Channel Block | 1999 |
Pranidipine enhances the action of nitric oxide released from endothelial cells.
Topics: Amlodipine; Animals; Aorta, Thoracic; Calcium Channel Blockers; Cells, Cultured; Coculture Technique | 2000 |
Laser-assisted optical rotational red cell analyzer (LORCA) in clinical practice. Hemorheological kinetics and tissue oxygenation.
Topics: Amlodipine; Anticholesteremic Agents; Antihypertensive Agents; Calcium Channel Blockers; Erythrocyte | 1999 |
[Treatment of arterial hypertension in patients with bronchial asthma].
Topics: Adult; Aged; Amlodipine; Asthma; Blood Pressure; Bronchoconstriction; Calcium Channel Blockers; Fema | 1999 |
Calcium-channel blockade can mask the diagnosis of Conn's syndrome.
Topics: Adult; Amlodipine; Biomarkers; Calcium Channel Blockers; Electrolytes; Female; Humans; Hyperaldoster | 1999 |
Cardiovascular effects of combination of perindopril, candesartan, and amlodipine in hypertensive rats.
Topics: Adrenergic beta-Antagonists; Amlodipine; Angiotensin Receptor Antagonists; Angiotensin-Converting En | 2000 |
Raised blood pressure, not renin-angiotensin systems, causes cardiac fibrosis in TGR m(Ren2)27 rats.
Topics: Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Animals; Animals, Genetically Modified; Antihy | 2000 |
A study of pulmonary profile of hypertensive patients--comparison of atenolol vs amlodipine.
Topics: Amlodipine; Antihypertensive Agents; Atenolol; Humans; Hypertension; Total Lung Capacity; Vital Capa | 1998 |
Effects of lisinopril and amlodipine on antioxidant status in experimental hypertension.
Topics: Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Animals; Antioxidants; Blood Urea Nitrogen; Ca | 2000 |
Contribution of the renin-angiotensin system to subsensitivity of soluble guanylyl cyclase in TGR(mREN2)27 rats.
Topics: Aging; Amlodipine; Analysis of Variance; Animals; Animals, Genetically Modified; Aorta, Thoracic; Bl | 2000 |
[Amlodipine effects on central hemodynamics and arterial pressure in hypertensive patients].
Topics: Adult; Aged; Amlodipine; Blood Pressure; Calcium Channel Blockers; Echocardiography, Doppler; Female | 2000 |
Outcomes of an amlodipine-to-felodipine therapeutic interchange program.
Topics: Aged; Amlodipine; Antihypertensive Agents; Chi-Square Distribution; Confidence Intervals; Felodipine | 2000 |
Retrospective evaluation of the conversion of amlodipine to alternative calcium channel blockers.
Topics: Amlodipine; Blood Pressure; Calcium Channel Blockers; Diltiazem; Felodipine; Female; Humans; Hyperte | 2000 |
Treatment of hypertensive children with amlodipine.
Topics: Adolescent; Adult; Aging; Amlodipine; Antihypertensive Agents; Blood Pressure; Child; Child, Prescho | 2000 |
Effects of long-term treatment with calcium antagonists on periarterial nerve function in the mesenteric artery of spontaneously hypertensive rats.
Topics: Amlodipine; Animals; Blood Pressure; Calcium Channel Blockers; Dihydropyridines; Drug Interactions; | 2000 |
[Are all antihypertensive agents equal? Cardiovascular events in hypertensive patients randomized to treatment with doxazosin or chlorthalidone. The ALLHAT study].
Topics: Adrenergic alpha-Antagonists; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive | 2000 |
Normalisation of blood pressure in hypertensive TGR(mREN2)27 rats by amlodipine vs. enalapril: effects on cardiac hypertrophy and signal transduction pathways.
Topics: Adenylyl Cyclases; Amlodipine; Analysis of Variance; Angiotensin-Converting Enzyme Inhibitors; Anima | 2001 |
[Comparative effects of amlodipine (stamlo) and enalapril (enam) on arterial pressure, painless myocardial ischemia and diastolic function of left ventricle in patients with arterial hypertension].
Topics: Adult; Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Blood Pressure; Calcium Channel B | 2000 |
Hypertensive African Americans with kidney disease should seek advice from doctor about blood pressure medication.
Topics: Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Black or African Amer | 2001 |
Feline hypertension: clinical findings and response to antihypertensive treatment in 30 cases.
Topics: Amlodipine; Animals; Antihypertensive Agents; Blood Pressure; Cat Diseases; Cats; Disease-Free Survi | 2001 |
Effects of amlodipine on serum levels of adrenal androgens and insulin in hypertensive men with obesity.
Topics: Adult; Aged; Amlodipine; Calcium Channel Blockers; Dehydroepiandrosterone; Dehydroepiandrosterone Su | 2001 |
Weight reduction and pharmacologic treatment in obese hypertensives.
Topics: Adult; Amlodipine; Analysis of Variance; Angiotensin-Converting Enzyme Inhibitors; Blood Pressure; C | 2001 |
Amlodipine and long-term renoprotection in hypertensive patients with renal dysfunction.
Topics: Amlodipine; Calcium Channel Blockers; Humans; Hypertension; Kidney | 2001 |
Chronic treatment with amlodipine modulates adrenocortical angiotensin II receptors in spontaneously hypertensive rats.
Topics: Adrenal Cortex; Aldosterone; Amlodipine; Animals; Antihypertensive Agents; Hypertension; Male; Rats; | 2001 |
A rapid procedure for initial drug evaluation.
Topics: Amlodipine; Antihypertensive Agents; Arterioles; Calcium Channels; Computer Simulation; Dose-Respons | 2001 |
Right atrial function in hypertensive patients: effects of antihypertensive therapy.
Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Atrial Function, Right; Echocardiography, Doppler; | 2001 |
Efficacy and safety of a therapeutic interchange from high-dose calcium channel blockers to a fixed-dose combination of amlodipine/benazepril in patients with moderate-to-severe hypertension.
Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Benzazepines; Blood Pressure; Calcium Channel Bloc | 2001 |
Effect of indomethacin on blood pressure in elderly people with essential hypertension well controlled on amlodipine or enalapril.
Topics: Amlodipine; Anti-Inflammatory Agents, Non-Steroidal; Antihypertensive Agents; Blood Pressure; Enalap | 2001 |
Pharmacist-managed hypertension therapy conversion.
Topics: Amlodipine; Analysis of Variance; Antihypertensive Agents; Calcium Channel Blockers; Drug Costs; Fem | 2001 |
Anglo-Scandinavian Cardiac Outcomes Trial: a brief history, rationale and outline protocol.
Topics: Amlodipine; Antihypertensive Agents; Atenolol; Benzothiadiazines; Coronary Disease; Diuretics; Human | 2001 |
Vasoactive peptides and procollagen propeptides in patients with hypertension in relation to cardiac hypertrophy and diastolic heart failure: design of the study and patient characteristics.
Topics: Amlodipine; Antihypertensive Agents; Atenolol; Atrial Natriuretic Factor; Bendroflumethiazide; Cardi | 2001 |
Comparative effects of atenolol-based and amlodipine-based antihypertensive therapy on QT dispersion in hypertensive subjects.
Topics: Amlodipine; Antihypertensive Agents; Atenolol; Electrocardiography; Humans; Hypertension; Hypertroph | 2001 |
Baroreflex sensitivity and heart rate variability as predictors of cardiovascular outcome in hypertensive patients with multiple risk factors for coronary disease.
Topics: Adrenergic beta-Antagonists; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive | 2001 |
Differential response to amlodipine and atenolol mono-therapy for hypertension by ethnic group.
Topics: Adrenergic beta-Antagonists; Adult; Amlodipine; Atenolol; Black or African American; Blood Pressure | 2001 |
Long-term administration of amlodipine prevents decompensation to diastolic heart failure in hypertensive rats.
Topics: Amlodipine; Analysis of Variance; Animals; Antihypertensive Agents; Calcium Channel Blockers; Collag | 2001 |
Effect of the angiotensin-converting enzyme inhibitor imidapril on reactive hyperemia in patients with essential hypertension: relationship between treatment periods and resistance artery endothelial function.
Topics: Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Endothelium, Vascular; Female; Forearm; | 2001 |
Effects of amlodipine and lacidipine on cardiac remodelling and renin production in salt-loaded stroke-prone hypertensive rats.
Topics: Actins; Amlodipine; Animals; Atrial Natriuretic Factor; Blood Pressure; Calcium Channel Blockers; Co | 2001 |
Irbesartan lowers superoxide levels and increases nitric oxide bioavailability in blood vessels from spontaneously hypertensive stroke-prone rats.
Topics: Amlodipine; Angiotensin II; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Aort | 2002 |
[Innovation, step innovation, Me too. Are calcium antagonists interchangeable?].
Topics: Aged; Amlodipine; Calcium Channel Blockers; Delayed-Action Preparations; Heart Failure; Humans; Hype | 2001 |
Normal erythrocyte calpain I activity on membrane proteins under near-physiological conditions in patients with essential hypertension.
Topics: Adult; Amlodipine; Ankyrins; Calcium-Binding Proteins; Calpain; Captopril; Case-Control Studies; Ele | 2002 |
[Diabetic patient with hypertension takes A-I I blocker. Less likely dialysis].
Topics: Albuminuria; Amlodipine; Angiotensin II; Angiotensin Receptor Antagonists; Antihypertensive Agents; | 2002 |
Novel mechanisms of the antiproliferative effects of amlodipine in vascular smooth muscle cells from spontaneously hypertensive rats.
Topics: Amlodipine; Animals; Calcium Channel Blockers; Cell Division; Cells, Cultured; Growth Substances; Hy | 2002 |
[The effects of endothelin blockade on renal expression of angiotensin II type 1 receptor in diabetic hypertensive rats].
Topics: Amlodipine; Animals; Antihypertensive Agents; Bosentan; Cilazapril; Diabetes Complications; Diabetes | 2002 |
Syncope following oral chloroquine administration in a hypertensive patient controlled on amlodipine.
Topics: Administration, Oral; Amlodipine; Chloroquine; Drug Synergism; Humans; Hypertension; Malaria; Male; | 2002 |
[Comparative effects of losartan and amlodipine on activities of sympathetic nerve, renin-angiotensin-aldosterone system and brain natriuretic peptide in the elderly hypertensive patients].
Topics: Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Heart Rate; Hum | 2002 |
Impaired regulation of renal oxygen consumption in spontaneously hypertensive rats.
Topics: Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Animals; Bradykinin; Cyclic N-Oxides; Enalapri | 2002 |
Antihypertensive mechanism of amlodipine in essential hypertension: role of pressor reactivity to norepinephrine and angiotensin II.
Topics: Adult; Amlodipine; Angiotensin II; Antihypertensive Agents; Blood Pressure; Body Weight; Dose-Respon | 1992 |
[The association of amlodipine with isosorbide-5-mononitrate in the treatment of ischemic-hypertensive cardiopathy].
Topics: Adult; Amlodipine; Antihypertensive Agents; Calcium Channel Blockers; Coronary Disease; Drug Evaluat | 1992 |
[Circadian rhythm in the clinical course of cardiovascular diseases. Clinical experience using Norvasc (amlodipine) in the treatment of patients with ischemic heart disease and arterial hypertension].
Topics: Amlodipine; Circadian Rhythm; Coronary Disease; Humans; Hypertension | 1992 |
Effects of amlodipine on plasma lipid and lipoprotein levels in hypertensive patients.
Topics: Adult; Amlodipine; Female; Humans; Hypertension; Lipids; Lipoproteins; Middle Aged | 1992 |
[24-hour protection and control: a new era of calcium antagonists. Amlodipine provides 24 hours of efficacy and safety].
Topics: Amlodipine; Calcium Channel Blockers; Circadian Rhythm; Coronary Disease; Humans; Hypertension; Nife | 1992 |
Pharmacokinetics and pharmacodynamics of amlodipine.
Topics: Amlodipine; Antihypertensive Agents; Calcium Channel Blockers; Half-Life; Humans; Hypertension; Nife | 1992 |
Long-term haemodynamic effects of amlodipine at rest and during exercise in essential hypertension.
Topics: Adult; Amlodipine; Antihypertensive Agents; Blood Pressure; Blood Pressure Monitors; Calcium Channel | 1992 |
Vascular injury: mechanisms and manifestations.
Topics: Amlodipine; Animals; Aorta, Thoracic; Arteriosclerosis; Calcium; Calcium Channel Blockers; Cardiomeg | 1991 |
[Antihypertensive effects of amlodipine, a new calcium antagonist].
Topics: Administration, Oral; Amlodipine; Animals; Calcium Channel Blockers; Dogs; Dose-Response Relationshi | 1991 |
Long-term haemodynamic effects of amlodipine at rest and during exercise in essential hypertension.
Topics: Adult; Amlodipine; Calcium Channel Blockers; Drug Administration Schedule; Female; Heart; Heart Rate | 1991 |
The effects of the calcium antagonist amlodipine on blood pressure and platelet aggregation in hypertensive patients.
Topics: Amlodipine; Calcium Channel Blockers; Drug Administration Schedule; Exercise Test; Female; Heart Rat | 1991 |
Circadian variation in blood pressure: considerations for therapy.
Topics: Amlodipine; Antihypertensive Agents; Blood Pressure; Blood Pressure Determination; Calcium Channel B | 1991 |
Acute, chronic and postwithdrawal antihypertensive and renal effects of amlodipine in hypertensive patients.
Topics: Amlodipine; Blood Pressure; Calcium Channel Blockers; Glomerular Filtration Rate; Heart Rate; Humans | 1991 |
Effects of amlodipine, a long-acting dihydropyridine calcium antagonist in aging hypertension: pharmacodynamics in relation to disposition.
Topics: Administration, Oral; Adult; Aged; Aging; Amlodipine; Atrial Natriuretic Factor; Blood Pressure; Cal | 1990 |
Protecting the vasculature: an eye toward the future.
Topics: Amlodipine; Animals; Arteries; Arteriosclerosis; Blood Pressure; Calcium Channel Blockers; Cerebrova | 1990 |
The effect of amlodipine on hypertension-induced cardiac hypertrophy and reperfusion-induced calcium overload.
Topics: Aging; Amlodipine; Animals; Blood Pressure; Calcium; Calcium Channel Blockers; Cardiomegaly; Coronar | 1988 |
Amlodipine in elderly hypertensive patients: pharmacokinetics and pharmacodynamics.
Topics: Adult; Aged; Aging; Amlodipine; Blood Pressure; Calcium Channel Blockers; Female; Half-Life; Hormone | 1988 |
Amlodipine therapy corrects renal abnormalities encountered in the hypertensive state.
Topics: Adult; Aged; Amlodipine; Blood Pressure; Body Fluids; Calcium Channel Blockers; Drug Evaluation; Glo | 1987 |
A study of the action of amlodipine on adrenergically regulated sodium handling by the kidney in normotensive and hypertensive rats.
Topics: Amlodipine; Animals; Calcium Channel Blockers; Hypertension; Kidney; Kidney Concentrating Ability; K | 1988 |
A study of the renal actions of amlodipine in the normotensive and spontaneously hypertensive rat.
Topics: Amlodipine; Animals; Calcium Channel Blockers; Hypertension; Kidney Tubules; Kidney Tubules, Proxima | 1988 |
Amlodipine and captopril in moderate-severe essential hypertension.
Topics: Adolescent; Adult; Aged; Amlodipine; Calcium Channel Blockers; Captopril; Double-Blind Method; Drug | 1988 |